FN Thomson Reuters Web of Science™ VR 1.0 PT J AU Hazlett, EA Blair, NJ Fernandez, N Mascitelli, K Perez-Rodriguez, MM New, AS Goetz, RR Goodman, M AF Hazlett, Erin A. Blair, Nicholas J. Fernandez, Nicolas Mascitelli, Kathryn Perez-Rodriguez, M. Mercedes New, Antonia S. Goetz, Raymond R. Goodman, Marianne TI Startle amplitude during unpleasant pictures is greater in veterans with a history of multiple-suicide attempts and predicts a future suicide attempt SO PSYCHOPHYSIOLOGY LA English DT Article DE Suicide; Affective startle modulation; Amygdala; Columbia Suicide Severity Rating Scale; Emotion; Veteran ID BORDERLINE PERSONALITY-DISORDER; FEAR-POTENTIATED STARTLE; AFFECT-MODULATED STARTLE; INTERNALIZING PSYCHOPATHOLOGY; EMOTION REGULATION; AMYGDALA; SCALE; DEPRESSION; BEHAVIOR; REFLEX AB Recent studies demonstrate that veterans exhibit higher suicide risk compared with the general U.S. population. A prior suicide attempt is a well-documented predictor of suicide death. Despite increased attention to clinical risk factors of suicide and efforts to develop psychosocial interventions to reduce suicide risk, the underlying biological factors that confer this risk are not well understood. This study examined affect-modulated startle (AMS) during a series of intermixed unpleasant, neutral, and pleasant pictures in a sample of 108 demographically-matched veterans at low (passive ideators: n=26) and high risk (active ideators: n=29; single attempters: n=28; and multiple attempters: n=25) for suicide based on the Columbia Suicide Severity Rating Scale. An exploratory aim involved a longitudinal component in a subset of the high-risk sample that went on to participate in a randomized 6-month clinical trial. We investigated whether baseline AMS predicts a subsequent suicide attempt at 12-month follow-up. Compared with the other three groups, multiple attempters showed greater startle potentiation during unpleasant pictures and deficient overall startle habituation from early to later trials. The groups did not differ in startle during neutral or pleasant pictures, or self-reported picture valence. Greater startle during unpleasant pictures was associated with greater emotion dysregulation as measured by the Difficulties in Emotion Regulation Scale and a future suicide attempt assessed prospectively at 12-month follow-up. These findings suggest that startle potentiation during unpleasant pictures in multiple-suicide attempters is a promising psychophysiological biomarker of suicide risk and underscore the clinical importance of targeting emotion dysregulation in the treatment of patients at-risk for suicide. C1 [Hazlett, Erin A.; Perez-Rodriguez, M. Mercedes; New, Antonia S.; Goodman, Marianne] Icahn Sch Med Mt Sinai, Dept Psychiat, New York, NY 10029 USA. [Hazlett, Erin A.] Icahn Sch Med Mt Sinai, Dept Neurosci, New York, NY 10029 USA. [Hazlett, Erin A.; Blair, Nicholas J.; Fernandez, Nicolas; Mascitelli, Kathryn; Goodman, Marianne] James J Peters Vet Affairs Med Ctr, Mental Illness Res Educ & Clin Ctr MIRECC VISN So, Bronx, NY USA. [Hazlett, Erin A.; Blair, Nicholas J.; Fernandez, Nicolas; Mascitelli, Kathryn] James J Peters Vet Affairs Med Ctr, Res & Dev, Bronx, NY USA. [Goetz, Raymond R.] New York State Psychiat Inst & Hosp, Div Clin Phenomenol, New York, NY 10032 USA. [Goetz, Raymond R.] Columbia Univ, Coll Phys & Surg, New York, NY USA. RP Hazlett, EA (reprint author), James J Peters VA Med Ctr, Mental Illness Res Educ & Clin Ctr, 130 West Kingsbridge Rd,Room 6A-44, Bronx, NY 10468 USA. EM erin.hazlett@mssm.edu FU Department of Defense [W81XWH0910722]; VA Merit Award [I01CX00026]; VISN 2 South Mental Illness, Research, Education, and Clinical Center (MIRECC) at the JJPVAMC FX This research was supported by a grant from the Department of Defense (W81XWH0910722-supplement to EAH and MG; MPIs), a VA Merit Award (I01CX00026 to EAH), and the VISN 2 South Mental Illness, Research, Education, and Clinical Center (MIRECC) at the JJPVAMC. NR 50 TC 1 Z9 1 U1 3 U2 3 PU WILEY-BLACKWELL PI HOBOKEN PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA SN 0048-5772 EI 1469-8986 J9 PSYCHOPHYSIOLOGY JI Psychophysiology PD OCT PY 2016 VL 53 IS 10 BP 1524 EP 1534 DI 10.1111/psyp.12698 PG 11 WC Psychology, Biological; Neurosciences; Physiology; Psychology; Psychology, Experimental SC Psychology; Neurosciences & Neurology; Physiology GA DX5WK UT WOS:000384453200007 PM 27378071 ER PT J AU Painter, JM Gray, K McGinn, MM Mostoufi, S Hoerster, KD AF Painter, Janelle M. Gray, Kristen McGinn, Meghan M. Mostoufi, Sheeva Hoerster, Katherine D. TI The relationships of posttraumatic stress disorder and depression symptoms with health-related quality of life and the role of social support among Veterans SO QUALITY OF LIFE RESEARCH LA English DT Article DE PTSD; Depression; Health-related quality of life; Physical health; Mental health; Social support ID MENTAL-HEALTH; ANXIETY DISORDERS; PHYSICAL-ACTIVITY; CLINICAL-SAMPLE; VALIDITY; PTSD; ASSOCIATIONS; METAANALYSIS; INDIVIDUALS; COMORBIDITY AB The presence of posttraumatic stress disorder (PTSD) or depression symptoms is associated with poor quality of life. Social support buffers against developing symptoms of PTSD and depression and is associated with greater quality of life. We examined the relationships between PTSD and depression symptom severity with physical (PCS) and mental (MCS) health-related quality of life (HRQoL), and whether social support moderated these relationships. Randomly selected Veterans with at least one Primary Care or PTSD Clinical Team visit received a mailed survey including self-report measures of health and wellness. Among the 717 respondents, we examined the association between symptom severity and HRQoL using linear regression. We included interaction terms between symptom severity and social support to examine whether social support moderated these associations. Social support did not moderate the association between symptom severity and mental HRQoL. Higher PTSD and depression symptom severity were associated with lower MCS scores, whereas higher social support was associated with higher MCS scores. When examining physical HRQoL, social support moderated the association with PTSD and depression symptom severity. Among individuals with high social support, there was a negative association between symptom severity and PCS scores, whereas there was no association among those with low social support. Although there are contexts in which social support is helpful, in some cases it may interfere with HRQoL among those with mental health conditions. Thus, it is important to educate support providers about behaviors that enhance the benefits and minimize the costs of social support. C1 [Painter, Janelle M.; McGinn, Meghan M.; Mostoufi, Sheeva] VA Puget Sound Hlth Care Syst, Mental Hlth Serv, Seattle Div, 1660 S Columbian Way S-116, Seattle, WA 98108 USA. [Painter, Janelle M.] Univ Calif Berkeley, Dept Psychol, 3210 Tolman Hall, Berkeley, CA 94720 USA. [Gray, Kristen; Hoerster, Katherine D.] VA Puget Sound Hlth Care Syst, Hlth Serv Res & Dev Serv, Seattle Div, Seattle, WA USA. [Gray, Kristen] Univ Washington, Dept Hlth Serv, Seattle, WA 98195 USA. [McGinn, Meghan M.; Hoerster, Katherine D.] Univ Washington, Dept Psychiat & Behav Sci, Seattle, WA 98195 USA. RP Painter, JM (reprint author), VA Puget Sound Hlth Care Syst, Mental Hlth Serv, Seattle Div, 1660 S Columbian Way S-116, Seattle, WA 98108 USA.; Painter, JM (reprint author), Univ Calif Berkeley, Dept Psychol, 3210 Tolman Hall, Berkeley, CA 94720 USA. EM janelle.painter@va.gov FU VA Puget Sound, Seattle Division Mental Illness Research Education and Clinical Center; VA Puget Sound, Seattle Division Health Services Research and Development Center of Excellence; VA Career Development Award [HSRD CDA 12-263] FX This material is the result of work supported by resources from VA Puget Sound Healthcare System. Funding for the study was provided by the VA Puget Sound, Seattle Division Mental Illness Research Education and Clinical Center and the VA Puget Sound, Seattle Division Health Services Research and Development Center of Excellence. Dr. Hoerster is supported by a VA Career Development Award (HSR&D CDA 12-263). NR 56 TC 0 Z9 0 U1 10 U2 16 PU SPRINGER PI DORDRECHT PA VAN GODEWIJCKSTRAAT 30, 3311 GZ DORDRECHT, NETHERLANDS SN 0962-9343 EI 1573-2649 J9 QUAL LIFE RES JI Qual. Life Res. PD OCT PY 2016 VL 25 IS 10 BP 2657 EP 2667 DI 10.1007/s11136-016-1295-5 PG 11 WC Health Care Sciences & Services; Health Policy & Services; Public, Environmental & Occupational Health SC Health Care Sciences & Services; Public, Environmental & Occupational Health GA DV5TQ UT WOS:000382993000023 PM 27085339 ER PT J AU Rodrigo-Troyano, A Suarez-Cuartin, G Peiro, M Barril, S Castillo, D Sanchez-Reus, F Plaza, V Restrepo, MI Chalmers, JD Sibila, O AF Rodrigo-Troyano, Ana Suarez-Cuartin, Guillermo Peiro, Meritxell Barril, Silvia Castillo, Diego Sanchez-Reus, Ferran Plaza, Vicente Restrepo, Marcos I. Chalmers, James D. Sibila, Oriol TI Pseudomonas aeruginosa resistance patterns and clinical outcomes in hospitalized exacerbations of COPD SO RESPIROLOGY LA English DT Article DE COPD; exacerbation; Pseudomonas aeruginosa ID OBSTRUCTIVE PULMONARY-DISEASE; RISK-FACTORS; CYSTIC-FIBROSIS; ANTIMICROBIAL RESISTANCE; ANTIBIOTIC-RESISTANCE; MULTIDRUG-RESISTANCE; BACTERIAL-INFECTIONS; MORTALITY; AIRWAY; BRONCHIECTASIS AB Background and objectiveAcute exacerbations of chronic obstructive pulmonary disease (AECOPD) due to Pseudomonas aeruginosa (PA) are associated with worse outcomes. PA antibiotic resistance is important to determine treatment and may influence clinical outcomes. The aim was to study clinical characteristics and outcomes in patients with AECOPD associated with PA based on their antibiotic resistance. MethodsThis was a prospective observational study including all patients with AECOPD and positive PA sputum culture admitted in a respiratory ward in a tertiary hospital in Barcelona during 2013-2014. PA was defined as resistant (PA-R) when the antibiogram showed 1 resistance. ResultsFour hundred one patients with AECOPD were evaluated. Of them, 54 (13%) had a positive PA sputum culture. Eighty-two per cent were men, median age was 77 (SD 7) years old and FEV1 was less than 36% (SD 17) of predicted value. PA-R was isolated in 35 patients (66%), and PA-sensitive (PA-S) was isolated in 18 (34%) patients. No differences were found in demographics, lung function and comorbidities among groups. PA-R patients were more likely exposed to prior oral corticosteroids (77% vs 44%, P=0.03) and antibiotics (77% vs 31%, P=0.01), respectively. AECOPD patients associated with PA-S were more likely to die at 30 days (odds ratio 13.53, 95% confidence interval: 1.14-69.56, P=0.03) and 90 days (odds ratio 7.09, 95% confidence interval: 1.33-37.89, P=0.02), respectively. ConclusionPseudomonas aeruginosa-resistant affects patients with severe AECOPD and previous use of corticosteroids and antibiotics. The presence of PA-S is associated with higher mortality. These results may suggest increased virulence in PA-S strains causing acute infections. Pseudomonas aeruginosa (PA) plays an important role in AECOPD. However, the impact of PA resistance patterns on clinical outcomes is not clear. Our study demonstrates that the presence of PA-sensitive is associated with higher mortality. C1 [Rodrigo-Troyano, Ana; Suarez-Cuartin, Guillermo; Peiro, Meritxell; Barril, Silvia; Castillo, Diego; Plaza, Vicente; Sibila, Oriol] Autonomous Univ Barcelona UAB, Hosp Santa Creu & St Pau, Resp Dept, Barcelona, Spain. [Rodrigo-Troyano, Ana; Suarez-Cuartin, Guillermo; Peiro, Meritxell; Barril, Silvia; Castillo, Diego; Sanchez-Reus, Ferran; Plaza, Vicente; Sibila, Oriol] Biomed Res Inst St Pau IIB St Pau, Barcelona, Spain. [Sanchez-Reus, Ferran] Hosp Santa Creu & Sant Pau, Dept Microbiol, Barcelona, Spain. [Restrepo, Marcos I.] South Texas Vet Hlth Care Syst, San Antonio, TX USA. [Restrepo, Marcos I.] Univ Texas Hlth Sci Ctr San Antonio, San Antonio, TX 78229 USA. [Chalmers, James D.] Univ Dundee, Tayside Resp Res Grp, Dundee, Scotland. RP Sibila, O (reprint author), Hosp Santa Creu & Sant Pau, Serv Pneumol, C St Antoni M Claret 167, Barcelona 08025, Spain. EM osibila@santpau.cat NR 40 TC 3 Z9 3 U1 1 U2 3 PU WILEY-BLACKWELL PI HOBOKEN PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA SN 1323-7799 EI 1440-1843 J9 RESPIROLOGY JI Respirology PD OCT PY 2016 VL 21 IS 7 BP 1235 EP 1242 DI 10.1111/resp.12825 PG 8 WC Respiratory System SC Respiratory System GA DX5RQ UT WOS:000384439800014 PM 27325555 ER PT J AU Leng, Y Blackwell, T Stone, KL Hoang, TD Redline, S Yaffe, K AF Leng, Yue Blackwell, Terri Stone, Katie L. Hoang, Tina D. Redline, Susan Yaffe, Kristine TI Periodic Limb Movements in Sleep are Associated with Greater Cognitive Decline in Older Men without Dementia SO SLEEP LA English DT Article DE cognition; cognitive decline; periodic limb movements; PLMS; polysomnography ID OSTEOPOROTIC FRACTURES; PARKINSONS-DISEASE; EXECUTIVE FUNCTION; LEG MOVEMENTS; MROS; DISORDER; RISK AB Study Objectives: To examine the association between periodic limb movements in sleep (PLMS) and change in selected aspects of cognition in community-dwelling older men. Methods: We studied 2,636 older men without dementia who underwent in-home polysomnography with measurement of the periodic limb movement index (PLMI) and periodic limb movement arousal index (PLMAI) using piezoelectric sensors. Random-effects models and logistic regression were used to examine the association between PLMI, PLMAI, and 3- to 4-y change in cognition. Results: After multivariable adjustment, men with a high PLMI had greater decline on the Trail Making Test - Part B (P trend = 0.02); those with a PLMI >= 30 were 48% more likely (odds ratio = 1.48, 95% confidence interval = 1.05-2.07) to experience the development of significant cognitive impairment (>= 1 SD above mean change). Further adjustment for sleep efficiency, nocturnal hypoxemia, or dopaminergic medication use and analysis among men without Parkinson disease (n = 2,607) showed similar findings. No significant association was found for PLMAI or for Modified Mini-Mental State Examination scores. Conclusions: Among older men without dementia, higher PLMS frequency was associated with greater decline in cognition, particularly in executive function. C1 [Leng, Yue] Univ Calif San Francisco, Dept Psychiat, San Francisco, CA USA. [Blackwell, Terri; Stone, Katie L.] Calif Pacific Med Ctr, Res Inst, San Francisco, CA USA. [Hoang, Tina D.] Northern Calif Inst Res & Educ, San Francisco, CA USA. [Redline, Susan] Brigham & Womens Hosp, Dept Med, 75 Francis St, Boston, MA 02115 USA. [Redline, Susan] Harvard Med Sch, Beth Israel Deaconess Med Ctr, Dept Med, Boston, MA USA. [Yaffe, Kristine] Univ Calif San Francisco, Dept Psychiat, San Francisco VA Med Ctr, San Francisco, CA USA. [Yaffe, Kristine] Univ Calif San Francisco, Dept Neurol, San Francisco VA Med Ctr, San Francisco, CA USA. [Yaffe, Kristine] Univ Calif San Francisco, Dept Epidemiol, San Francisco VA Med Ctr, San Francisco, CA 94143 USA. RP Yaffe, K (reprint author), Univ Calif San Francisco, Box 181,4150 Clement St, San Francisco, CA 94121 USA. EM kristine.yaffe@ucsf.edu FU National Institutes of Health; National Institute on Aging (NIA); National Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS); National Center for Advancing Translational Sciences (NCATS); NIH Roadmap for Medical Research [U01 AG027810, U01 AG042124, U01 AG042139, U01 AG042140, U01 AG042143, U01 AG042145, U01 AG042168, U01 AR066160, UL1 TR000128]; National Heart, Lung, and Blood Institute (NHLBI) [R01 HL071194, R01 HL070848, R01 HL070847, R01 HL070842, R01 HL070841, R01 HL070837, R01 HL070838, R01 HL070839]; K24 grant [AG031155]; NIH; PCORU; Jazz Pharmaceuticals FX This was not an industry supported study. The Osteoporotic Fractures in Men (MrOS) Study is supported by National Institutes of Health funding. The following institutes provide support: the National Institute on Aging (NIA), the National Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS), the National Center for Advancing Translational Sciences (NCATS), and NIH Roadmap for Medical Research under the following grant numbers: U01 AG027810, U01 AG042124, U01 AG042139, U01 AG042140, U01 AG042143, U01 AG042145, U01 AG042168, U01 AR066160, and UL1 TR000128. The National Heart, Lung, and Blood Institute (NHLBI) provides funding for the MrOS Sleep ancillary study "Outcomes of Sleep Disorders in Older Men" under the following grant numbers: R01 HL071194, R01 HL070848, R01 HL070847, R01 HL070842, R01 HL070841, R01 HL070837, R01 HL070838, and R01 HL070839. Dr Yaffe received funding from K24 grant AG031155. The funding sources had no role in the design and conduction of the study; collection, management, analysis, and interpretation of the data; the decision to submit the manuscript for publication; preparation or approval of the manuscript. Terri Blackwell, Dr. Yaffe, Dr. Redline, and Dr. Stone have received grant support from the NIH grant and supporting agencies as listed above. Dr. Redline's institution receives grant support from NIH and PCORU and has received grant funding from Jazz Pharmaceuticals. The other authors have indicated no financial conflicts of interest. Analysis was performed at California Pacific Medical Center, Research Institute. NR 27 TC 0 Z9 0 U1 2 U2 4 PU AMER ACAD SLEEP MEDICINE PI WESTCHESTER PA ONE WESTBROOK CORPORATE CTR, STE 920, WESTCHESTER, IL 60154 USA SN 0161-8105 EI 1550-9109 J9 SLEEP JI Sleep PD OCT 1 PY 2016 VL 39 IS 10 BP 1807 EP 1810 DI 10.5665/sleep.6158 PG 4 WC Clinical Neurology; Neurosciences SC Neurosciences & Neurology GA DX4ET UT WOS:000384334700005 PM 27568800 ER PT J AU Perlis, ML Grandner, MA Chakravorty, S Bernert, RA Brown, GK Thase, ME AF Perlis, Michael L. Grandner, Michael A. Chakravorty, Subhajit Bernert, Rebecca A. Brown, Gregory K. Thase, Michael E. TI Suicide and sleep: Is it a bad thing to be awake when reason sleeps? SO SLEEP MEDICINE REVIEWS LA English DT Review DE Sleep disturbance; Suicide; Circadian patterning; Hypofrontality; Executive function ID HOSPITALIZED DEPRESSED-PATIENTS; NEUROBEHAVIORAL PERFORMANCE; COGNITIVE PERFORMANCE; CIRCADIAN-RHYTHMS; HEALTHY CONTROLS; DEPRIVATION; TIME; MODULATION; IDEATION; INSOMNIA AB Suicide is the second leading cause of death, worldwide, for those between the ages of 24 and 44 y old. In 2013, more than 41,000 suicides occurred in the United States. These statistics underscore the need to 1) understand why people die by suicide and 2) identify risk factors that are potentially modifiable. While it has been posited that sleep disturbance may represent one such factor, systematic research in this arena did not begin until the 2000s. Since that time, sleep disturbance has been reliably identified as a risk factor for suicidal ideation, suicide attempts, and suicide. While insomnia, nightmares, and other sleep disorders have each been found to contribute to the risk for suicidal ideation and behavior, it is also possible that these factors share some common variance. One possibility is that sleep disturbance results in being awake at night, and being awake at night also confers risk. The hypothesis proffered here is that being awake when one is not biologically prepared to be so results in "hypofrontality" and diminished executive function, and that this represents a common pathway to suicidal ideation and behavior. Such a proposition is highly testable under a variety of possible protocols. The current review summarizes the extant literature on suicide rates by time-of-day, and discusses circadian, psychosocial, and neurocognitive explanations of risk. Such a focus promises to enhance our understanding of how sleep disturbance may confer risk, allows for the identification of future lines of research, and further justifies the need for interventions that promote good sleep continuity among at-risk individuals. (C) 2015 Elsevier Ltd. All rights reserved. C1 [Perlis, Michael L.; Chakravorty, Subhajit] Univ Penn, Behav Sleep Med Program, Dept Psychiat, Philadelphia, PA 19104 USA. [Perlis, Michael L.] Univ Penn, Ctr Sleep & Circadian Neurobiol, Philadelphia, PA 19104 USA. [Perlis, Michael L.] Univ Penn, Sch Nursing, Philadelphia, PA 19104 USA. [Grandner, Michael A.] Univ Arizona, Dept Psychiat, Tucson, AZ 85721 USA. [Chakravorty, Subhajit] Philadelphia Vet Affairs Med Ctr, Mental Illness Res Educ & Clin Ctr, Philadelphia, PA USA. [Bernert, Rebecca A.] Stanford Univ, Dept Psychiat & Behav Sci, Sch Med, Stanford, CA 94305 USA. [Brown, Gregory K.] Univ Penn, Ctr Prevent Suicide, Dept Psychiat, Philadelphia, PA 19104 USA. [Thase, Michael E.] Univ Penn, Mood & Anxiety Disorders Treatment & Res Program, Dept Psychiat, Philadelphia, PA 19104 USA. RP Perlis, ML (reprint author), Univ Penn, Dept Psychiat, Upenn Behav Sleep Med Program, 3535 Market St,Suite 670, Philadelphia, PA 19104 USA. EM mperlis@upenn.edu FU [R01AG041783]; [R01AT003332]; [R01MH077900]; [R21ES022931]; [K23HL110216]; [R01MH086572]; [NCC-958]; [IK2CX000855]; [R01MH082794]; [R01NR004281] FX The empirical work regarding the circadian patterning of suicide has been ongoing since 2013 and includes the efforts and talents of a larger group of investigators than those that contributed to the present theoretical review including: David Dinges, Mathias Basner, Ruben Gur, David Roalf, Knashawn Morales, Phil Gehrman, and Ninad Chaudhary. The following are in receipt of grants as follows: Michael Perlis (R01AG041783, R01AT003332, R01MH077900); Michael Grandner (R21ES022931, K23HL110216); Gregory Brown (R01MH086572); Mathias Basner (National Space Biomedical Research Institute through NASA NCC-958); Subhajit Chakravorty (IK2CX000855); Michael Thase (R01MH082794); and David Dinges (R01NR004281). NR 50 TC 3 Z9 3 U1 7 U2 9 PU W B SAUNDERS CO LTD PI LONDON PA 32 JAMESTOWN RD, LONDON NW1 7BY, ENGLAND SN 1087-0792 EI 1532-2955 J9 SLEEP MED REV JI Sleep Med. Rev. PD OCT PY 2016 VL 29 BP 101 EP 107 DI 10.1016/j.smrv.2015.10.003 PG 7 WC Clinical Neurology; Neurosciences SC Neurosciences & Neurology GA DV5ZN UT WOS:000383009300009 PM 26706755 ER PT J AU Liachko, NF Saxton, AD McMillan, PJ Strovas, TJ Currey, HN Taylor, LM Wheeler, JM Oblak, AL Ghetti, B Montine, TJ Keene, CD Raskind, MA Bird, TD Kraemer, BC AF Liachko, Nicole F. Saxton, Aleen D. McMillan, Pamela J. Strovas, Timothy J. Currey, Heather N. Taylor, Laura M. Wheeler, Jeanna M. Oblak, Adrian L. Ghetti, Bernardino Montine, Thomas J. Keene, C. Dirk Raskind, Murray A. Bird, Thomas D. Kraemer, Brian C. TI The phosphatase calcineurin regulates pathological TDP-43 phosphorylation SO ACTA NEUROPATHOLOGICA LA English DT Article DE Calcineurin; TDP-43; TARDBP; Amyotrophic lateral sclerosis; Frontotemporal lobar degeneration; FK506; Tacrolimus; pTDP ID AMYOTROPHIC-LATERAL-SCLEROSIS; FRONTOTEMPORAL LOBAR DEGENERATION; DEPENDENT PROTEIN PHOSPHATASE; ALZHEIMERS ASSOCIATION GUIDELINES; TAR-DNA-BINDING; CAENORHABDITIS-ELEGANS; NEUROPATHOLOGIC ASSESSMENT; CYTOPLASMIC INCLUSIONS; NATIONAL INSTITUTE; DISEASE AB Detergent insoluble inclusions of TDP-43 protein are hallmarks of the neuropathology in over 90 % of amyotrophic lateral sclerosis (ALS) cases and approximately half of frontotemporal dementia (FTLD-TDP) cases. In TDP-43 proteinopathy disorders, lesions containing aggregated TDP-43 protein are extensively post-translationally modified, with phosphorylated TDP-43 (pTDP) being the most consistent and robust marker of pathological TDP-43 deposition. Abnormally phosphorylated TDP-43 has been hypothesized to mediate TDP-43 toxicity in many neurodegenerative disease models. To date, several different kinases have been implicated in the genesis of pTDP, but no phosphatases have been shown to reverse pathological TDP-43 phosphorylation. We have identified the phosphatase calcineurin as an enzyme binding to and catalyzing the removal of pathological C-terminal phosphorylation of TDP-43 in vitro. In C. elegans models of TDP-43 proteinopathy, genetic elimination of calcineurin results in accumulation of excess pTDP, exacerbated motor dysfunction, and accelerated neurodegenerative changes. In cultured human cells, treatment with FK506 (tacrolimus), a calcineurin inhibitor, results in accumulation of pTDP species. Lastly, calcineurin co-localizes with pTDP in degenerating areas of the central nervous system in subjects with FTLD-TDP and ALS. Taken together, these findings suggest calcineurin acts on pTDP as a phosphatase in neurons. Furthermore, patient treatment with calcineurin inhibitors may have unappreciated adverse neuropathological consequences. C1 [Liachko, Nicole F.; Saxton, Aleen D.; McMillan, Pamela J.; Strovas, Timothy J.; Currey, Heather N.; Wheeler, Jeanna M.; Bird, Thomas D.; Kraemer, Brian C.] Vet Affairs Puget Sound Hlth Care Syst, Geriatr Res Educ & Clin Ctr, Seattle, WA 98108 USA. [Liachko, Nicole F.; Taylor, Laura M.; Kraemer, Brian C.] Univ Washington, Dept Med, Div Gerontol & Geriatr Med, Seattle, WA 98104 USA. [McMillan, Pamela J.; Raskind, Murray A.] Vet Affairs Puget Sound Hlth Care Syst, Mental Illness Res Educ Ctr, Seattle, WA 98108 USA. [McMillan, Pamela J.; Raskind, Murray A.] Vet Affairs Puget Sound Hlth Care Syst, Mental Illness Res Clin Ctr, Seattle, WA 98108 USA. [McMillan, Pamela J.; Raskind, Murray A.; Kraemer, Brian C.] Univ Washington, Dept Psychiat & Behav Sci, Seattle, WA 98195 USA. [Oblak, Adrian L.; Ghetti, Bernardino] Indiana Univ Sch Med, Dept Pathol & Lab Med, Indianapolis, IN 46202 USA. [Montine, Thomas J.; Keene, C. Dirk; Kraemer, Brian C.] Univ Washington, Dept Pathol, Seattle, WA 98195 USA. [Bird, Thomas D.] Univ Washington, Dept Neurol, Seattle, WA 98195 USA. [Bird, Thomas D.] Univ Washington, Dept Med, Div Med Genet, Seattle, WA 98104 USA. [Montine, Thomas J.] Stanford Univ, Sch Med, Dept Pathol, Palo Alto, CA 94305 USA. RP Kraemer, BC (reprint author), Vet Affairs Puget Sound Hlth Care Syst, Geriatr Res Educ & Clin Ctr, Seattle, WA 98108 USA.; Kraemer, BC (reprint author), Univ Washington, Dept Med, Div Gerontol & Geriatr Med, Seattle, WA 98104 USA.; Kraemer, BC (reprint author), Univ Washington, Dept Psychiat & Behav Sci, Seattle, WA 98195 USA.; Kraemer, BC (reprint author), Univ Washington, Dept Pathol, Seattle, WA 98195 USA. EM kraemerb@u.washington.edu FU NIH Office of Research Infrastructure Programs [P40 OD010440]; Department of Veterans Affairs [I01BX002619, I01BX007080]; National Institutes of Health [R01NS064131, P50AG05136] FX We thank the reviewers for helpful comments and suggestions. We thank Michael Gitcho for constructive discussion about calcineurin and TDP-43. We thank Elaine Loomis, John Kushleika, Kaili Chickering, Susan Danner, and Samantha Rice for outstanding technical assistance and Allison Beller for outstanding administrative support. We thank Virginia Lee and Manuela Neumann for antibodies and the Developmental Studies Hybridoma Bank (NICHD) for the beta-tubulin antibody E7. We thank WormBase (WS251) for C. elegans genetic information. Some strains were provided by the CGC, which is funded by NIH Office of Research Infrastructure Programs (P40 OD010440), and other strains were provided by the National Bioresource Project (Japan). This work was supported by Grants from the Department of Veterans Affairs [Merit Review Grant #I01BX002619 to B. K., Career Development Award 2 #I01BX007080 to N. L.] and National Institutes of Health [R01NS064131 to B. K and P50AG05136 for T. J. M. and C. D. K. for the UW ADRC for A. L. O and B. G.]. NR 62 TC 2 Z9 2 U1 0 U2 4 PU SPRINGER PI NEW YORK PA 233 SPRING ST, NEW YORK, NY 10013 USA SN 0001-6322 EI 1432-0533 J9 ACTA NEUROPATHOL JI Acta Neuropathol. PD OCT PY 2016 VL 132 IS 4 BP 545 EP 561 DI 10.1007/s00401-016-1600-y PG 17 WC Clinical Neurology; Neurosciences; Pathology SC Neurosciences & Neurology; Pathology GA DW2HL UT WOS:000383463400006 PM 27473149 ER PT J AU Dang, BN Westbrook, RA Hartman, CM Giordano, TP AF Dang, Bich N. Westbrook, Robert A. Hartman, Christine M. Giordano, Thomas P. TI Retaining HIV Patients in Care: The Role of Initial Patient Care Experiences SO AIDS AND BEHAVIOR LA English DT Article DE Patient satisfaction; Patient experience; HIV infection; Retention in care; Prospective studies ID SELF-EFFICACY SCALE; SOCIAL SUPPORT; SATISFACTION; VALIDATION; PREDICTORS; ADHERENCE; QUALITY AB Cross-sectional studies have shown an association between better patient experiences and health outcomes. However, the direction of causality remains unclear. Our prospective study seeks to determine whether better initial patient experiences predict subsequent retention in HIV care. We enrolled patients new to an HIV clinic in Houston, Texas, from August 26, 2013 to November 18, 2013. The patients' overall experience with the HIV provider was based on six items; overall experience with the HIV clinic was based on five items. We measured subsequent retention over the first 6 months and entire first year of HIV care. Analyses included 140 patients. Sixty-one percent were non-Hispanic black, 41 % were diagnosed with HIV within the last 3 months, and 36 % had a CD4 cell count < 200. Thirty three percent were totally satisfied with their initial HIV provider experience and 32 % were totally satisfied with their initial HIV clinic experience. Retention was 68 % over the first 6 months and 51 % over the first year. Satisfaction with the HIV provider at the initial visit significantly predicted 6-month retention in care (aOR = 3.56, p = 0.006). Similar results were found for satisfaction with the HIV clinic (aOR = 4.67, p = 0.002). Neither of the patient experience measures at the initial visit predicted 12-month retention. Patients with better initial care experiences have significantly greater retention in HIV care. The effect of better initial care experiences was limited in duration. Consistently improving patient care experiences, not only at baseline but also on subsequent visits, may be a way to increase retention in HIV care. C1 [Dang, Bich N.; Hartman, Christine M.; Giordano, Thomas P.] VA Ctr Innovat Qual Effectiveness & Safety IQuESt, Houston, TX 77030 USA. [Dang, Bich N.; Hartman, Christine M.; Giordano, Thomas P.] Michael E DeBakey Vet Affairs Med Ctr 152, 2002 Holcombe Blvd, Houston, TX 77030 USA. [Dang, Bich N.; Hartman, Christine M.; Giordano, Thomas P.] Baylor Coll Med, Dept Med, Houston, TX 77030 USA. [Dang, Bich N.; Giordano, Thomas P.] Harris Hlth Syst, Houston, TX 77030 USA. [Westbrook, Robert A.] Rice Univ, Jesse H Jones Grad Sch Business, Houston, TX USA. RP Dang, BN (reprint author), VA Ctr Innovat Qual Effectiveness & Safety IQuESt, Houston, TX 77030 USA.; Dang, BN (reprint author), Michael E DeBakey Vet Affairs Med Ctr 152, 2002 Holcombe Blvd, Houston, TX 77030 USA.; Dang, BN (reprint author), Baylor Coll Med, Dept Med, Houston, TX 77030 USA.; Dang, BN (reprint author), Harris Hlth Syst, Houston, TX 77030 USA. EM bndang@bcm.edu FU National Institutes of Health [P30AI036211]; supplemental funds to the District of Columbia Developmental Center for AIDS Research [5P30AI087714] FX We thank Drs. Daniel M. Musher and Richard L. Street for their critical review of an earlier draft of this manuscript. This study was supported by a supplement to the National Institutes of Health-funded Baylor College of Medicine-University of Texas Houston Center for AIDS Research (Grant Number P30AI036211), supplemental funds to the District of Columbia Developmental Center for AIDS Research (Grant Number 5P30AI087714), the facilities and resources of the Houston VA Center for Innovations in Quality, Effectiveness and Safety (HFP90-020), and the facilities and resources of Harris Health System. NR 29 TC 2 Z9 2 U1 0 U2 0 PU SPRINGER/PLENUM PUBLISHERS PI NEW YORK PA 233 SPRING ST, NEW YORK, NY 10013 USA SN 1090-7165 EI 1573-3254 J9 AIDS BEHAV JI AIDS Behav. PD OCT PY 2016 VL 20 IS 10 BP 2477 EP 2487 DI 10.1007/s10461-016-1340-y PG 11 WC Public, Environmental & Occupational Health; Social Sciences, Biomedical SC Public, Environmental & Occupational Health; Biomedical Social Sciences GA DV7GG UT WOS:000383103800028 PM 26910339 ER PT J AU Weisbord, SD Palevsky, PM AF Weisbord, Steven D. Palevsky, Paul M. TI Prevention of Contrast-Associated Acute Kidney Injury: What Should We Do? SO AMERICAN JOURNAL OF KIDNEY DISEASES LA English DT Editorial Material ID RANDOMIZED CONTROLLED-TRIALS; INDUCED NEPHROPATHY; ISO-OSMOLAR; METAANALYSIS; MEDIA; NEPHROTOXICITY; ANGIOGRAPHY; IODIXANOL; CORONARY; OUTCOMES C1 [Weisbord, Steven D.; Palevsky, Paul M.] Univ Pittsburgh, Sch Med, VA Pittsburgh Healthcare Syst, Pittsburgh, PA USA. RP Palevsky, PM (reprint author), VA Pittsburgh Healthcare Syst, Rm 7E123,111F-U,Univ Dr, Pittsburgh, PA 15240 USA. EM palevsky@pitt.edu OI Palevsky, Paul/0000-0002-7334-5400 NR 17 TC 1 Z9 1 U1 3 U2 3 PU W B SAUNDERS CO-ELSEVIER INC PI PHILADELPHIA PA 1600 JOHN F KENNEDY BOULEVARD, STE 1800, PHILADELPHIA, PA 19103-2899 USA SN 0272-6386 EI 1523-6838 J9 AM J KIDNEY DIS JI Am. J. Kidney Dis. PD OCT PY 2016 VL 68 IS 4 BP 518 EP 521 DI 10.1053/j.ajkd.2016.05.005 PG 4 WC Urology & Nephrology SC Urology & Nephrology GA DW8GF UT WOS:000383892200012 PM 27233380 ER PT J AU Jotwani, V Scherzer, R Estrella, MM Jacobson, LP Witt, MD Palella, FJ Macatangay, B Bennett, M Parikh, CR Ix, JH Shlipak, MG AF Jotwani, Vasantha Scherzer, Rebecca Estrella, Michelle M. Jacobson, Lisa P. Witt, Mallory D. Palella, Frank J., Jr. Macatangay, Bernard Bennett, Michael Parikh, Chirag R. Ix, Joachim H. Shlipak, Michael G. TI HIV Infection, Tenofovir, and Urine alpha(1)-Microglobulin: A Cross-sectional Analysis in the Multicenter AIDS Cohort Study SO AMERICAN JOURNAL OF KIDNEY DISEASES LA English DT Article DE Tenofovir disoproxil fumarate (TDF); nephrotoxicity; HIV infection; proximal tubular dysfunction; tubular toxicity; biomarker; urine alpha(1)-microglobulin (A1M); kidney damage; antiretroviral (ARV) medication; Multicenter AIDS Cohort Study (MACS) ID CHRONIC KIDNEY-DISEASE; LOW-MOLECULAR-WEIGHT; DISOPROXIL FUMARATE; PROTEASE INHIBITORS; GLOMERULAR FUNCTION; FUNCTION DECLINE; P-GLYCOPROTEIN; APOL1 GENOTYPE; RENAL-FUNCTION; RISK-FACTORS AB Background: Tenofovir disoproxil fumarate (TDF) can cause proximal tubular damage and chronic kidney disease in human immunodeficiency virus (HIV)-infected individuals. Urine alpha(1)-microglobulin (A1M), a low-molecular-weight protein indicative of proximal tubular dysfunction, may enable earlier detection of TDF-associated tubular toxicity. Study Design: Cross-sectional. Setting & Participants: 883 HIV-infected and 350 -uninfectedmen enrolled in the Multicenter AIDS Cohort Study. Predictors: HIV infection and TDF exposure. Outcome: Urine A1M level. Results: Urine A1M was detectable in 737 (83%) HIV-infected and 202 (58%) -uninfected men (P < 0.001). Among HIV-infected participants, 573 (65%) were current TDF users and 112 (13%) were past TDF users. After multivariable adjustment including demographics, traditional kidney disease risk factors, and estimated glomerular filtration rate, HIV infection was associated with 136% (95% CI, 104%-173%) higher urine A1M levels and 1.5-fold (95% CI, 1.3- to 1.6-fold) prevalence of detectable A1M. When participants were stratified by TDF exposure, HIV infection was associated with higher adjusted A1M levels, by 164% (95% CI, 127%-208%) among current users, 124% (95% CI, 78%-183%) among past users, and 76% (95% CI, 45%-115%) among never users. Among HIV-infected participants, each year of cumulative TDF exposure was associated with 7.6% (95% CI, 5.4%-9.9%) higher A1M levels in fully adjusted models, a 4-fold effect size relative to advancing age (1.8% [95% CI, 0.9%-2.7%] per year). Each year since TDF treatment discontinuation was associated with 4.9% (95% CI, 29.4%-20.2%) lower A1M levels among past users. Limitations: Results may not be generalizable to women. Conclusions: HIV-infected men had higher urine A1M levels compared with HIV-uninfected men. Among HIV-infected men, cumulative TDF exposure was associated with incrementally higher A1M levels, whereas time since TDF treatment discontinuation was associated with progressively lower A1M levels. Urine A1M appears to be a promising biomarker for detecting and monitoring TDF-associated tubular toxicity. (C) 2016 by the National Kidney Foundation, Inc. Published by Elsevier Inc. All rights reserved. C1 [Jotwani, Vasantha; Scherzer, Rebecca; Shlipak, Michael G.] San Francisco VA Med Ctr, Dept Med, San Francisco, CA USA. [Jotwani, Vasantha; Scherzer, Rebecca] Univ Calif San Francisco, Dept Epidemiol & Biostat, San Francisco, CA 94143 USA. [Estrella, Michelle M.] Johns Hopkins Sch Med, Dept Med, Baltimore, MD USA. [Jacobson, Lisa P.] Johns Hopkins Bloomberg Sch Publ Hlth, Dept Epidemiol, Baltimore, MD USA. [Witt, Mallory D.] Harbor UCLA Med Ctr, Dept Med, Div HIV Med, Torrance, CA 90509 USA. [Witt, Mallory D.] Harbor UCLA, Los Angeles Biomed Res Inst, Torrance, CA USA. [Palella, Frank J., Jr.] Northwestern Univ, Dept Med, Div Infect Dis, Chicago, IL 60611 USA. [Macatangay, Bernard] Univ Pittsburgh, Div Infect Dis, Dept Med, Pittsburgh, PA USA. [Bennett, Michael] Cincinnati Childrens Hosp Med Ctr, Div Nephrol & Hypertens, Cincinnati, OH 45229 USA. [Parikh, Chirag R.] Yale Univ, Dept Med, Nephrol Sect, New Haven, CT 06520 USA. [Parikh, Chirag R.] Yale Univ, Program Appl Translat Res, New Haven, CT USA. [Ix, Joachim H.] Univ Calif San Diego, Dept Med, Div Nephrol Hypertens, San Diego, CA 92103 USA. [Ix, Joachim H.] Vet Affairs San Diego Healthcare Syst, Nephrol Sect, San Diego, CA USA. [Shlipak, Michael G.] San Francisco VA Med Ctr, Kidney Hlth Res Collaborat, San Francisco, CA USA. [Shlipak, Michael G.] Univ Calif San Francisco, San Francisco, CA 94143 USA. RP Jotwani, V (reprint author), San Francisco VA Med Ctr, 4150 Clement St,Box 111A1, San Francisco, CA 94121 USA. EM vasantha.jotwani@ucsf.edu FU National Institute of Allergy and Infectious Diseases; National Cancer Institute; National Institute on Drug Abuse; National Institute of Mental Health; National Heart, Lung and Blood Institute; National Institute on Deafness and Communication Disorders; National Center for Advancing Translational Sciences a component of the National Institutes of Health (NIH) [UL1-TR001079]; NIH Roadmap for Medical Research; [R01-AG034853-01A2] FX Support: MACS Kidney Study is funded by grant R01-AG034853-01A2 (Principal Investigator [PI], Dr Shlipak), which was administered by the Northern California Institute for Research and Education, and with resources of the Veterans Affairs Medical Center, San Francisco, CA. Data in this manuscript were collected by the MACS with centers at Baltimore (U01-AI35042): The Johns Hopkins University Bloomberg School of Public Health: Joseph B. Margolick (PI), Jay Bream, Todd Brown, Barbara Crain, Adrian Dobs, Richard Elion, Michelle Estrella, Lisette Johnson-Hill, Sean Leng, Anne Monroe, Cynthia Munro, Michael W. Plankey, Wendy Post, Ned Sacktor, Jennifer Schrack, Chloe Thio; Chicago (U01-AI35039): Feinberg School of Medicine, Northwestern University, and Cook County Bureau of Health Services: Steven M. Wolinsky (PI), John P. Phair, Sheila Badri, Dana Gabuzda, Frank J. Palella Jr, Sudhir Penugonda, Susheel Reddy, Matthew Stephens, Linda Teplin; Los Angeles (U01-AI35040): University of California, UCLA Schools of Public Health and Medicine: Roger Detels (PI), Otoniel Martinez-Maza (Co-PI), Aaron Aronow, Peter Anton, Robert Bolan, Elizabeth Breen, Anthony Butch, Shehnaz Hussain, Beth Jamieson, Eric N. Miller, John Oishi, Harry Vinters, Dorothy Wiley, Mallory Witt, Otto Yang, Stephen Young, Zuo Feng Zhang; Pittsburgh (U01-AI35041): University of Pittsburgh, Graduate School of Public Health: Charles R. Rinaldo (PI), Lawrence A. Kingsley (Co-PI), James T. Becker, Phalguni Gupta, Kenneth Ho, Susan Koletar, Jeremy J. Martinson, John W. Mellors, Anthony J. Silvestre, Ronald D. Stall; Data Coordinating Center (UM1-AI35043): The Johns Hopkins University Bloomberg School of Public Health: Lisa P. Jacobson (PI), Gypsyamber D'Souza (Co-PI), Alison Abraham, Keri Althoff, Jennifer Deal, Priya Duggal, Sabina Haberlen, Alvaro Muoz, Derek Ng, Janet Schollenberger, Eric C. Seaberg, Sol Su, Pamela Surkan. Institute of Allergy and Infectious Diseases: Robin E. Huebner; National Cancer Institute: Geraldina Dominguez. The MACS is funded primarily by the National Institute of Allergy and Infectious Diseases, with additional co-funding from the National Cancer Institute, the National Institute on Drug Abuse, and the National Institute of Mental Health. Targeted supplemental funding for specific projects was also provided by the National Heart, Lung and Blood Institute, and the National Institute on Deafness and Communication Disorders. MACS data collection is also supported by UL1-TR001079 (Johns Hopkins University Institute for Clinical and Translational Research) from the National Center for Advancing Translational Sciences a component of the National Institutes of Health (NIH), and NIH Roadmap for Medical Research. The contents of this publication are solely the responsibility of the authors and do not represent the official views of the NIH, Johns Hopkins Institute for Clinical and Translational Research, or the National Center for Advancing Translational Sciences. The funders of this study had no role in study design; collection, analysis or interpretation of data; manuscript preparation; or the decision to submit the report for publication. The MACS website is located at https://statepi.jhsph.edu/macs/macs.html NR 52 TC 1 Z9 1 U1 0 U2 1 PU W B SAUNDERS CO-ELSEVIER INC PI PHILADELPHIA PA 1600 JOHN F KENNEDY BOULEVARD, STE 1800, PHILADELPHIA, PA 19103-2899 USA SN 0272-6386 EI 1523-6838 J9 AM J KIDNEY DIS JI Am. J. Kidney Dis. PD OCT PY 2016 VL 68 IS 4 BP 571 EP 581 DI 10.1053/j.ajkd.2016.03.430 PG 11 WC Urology & Nephrology SC Urology & Nephrology GA DW8GF UT WOS:000383892200018 PM 27287300 ER PT J AU Troxel, AB Asch, DA Volpp, KG AF Troxel, Andrea B. Asch, David A. Volpp, Kevin G. TI Statistical issues in pragmatic trials of behavioral economic interventions SO CLINICAL TRIALS LA English DT Article; Proceedings Paper CT 8th Annual Symposium on Statistical Issues in Clinical Trials CY APR, 2015 CL Univ Penn, Philadelphia, PA HO Univ Penn DE Effectiveness; generalizability; innovation; opt-out consent ID CONVERTING ENZYME-INHIBITORS; ACUTE MYOCARDIAL-INFARCTION; ACUTE CORONARY SYNDROMES; BLOOD-PRESSURE CONTROL; LONG-TERM ADHERENCE; ELDERLY PATIENTS; STATIN THERAPY; BETA-BLOCKERS; DISCONTINUATION; PERSISTENCE AB Background: Randomized clinical trials provide gold-standard evidence for the efficacy of interventions, but have limitations, including highly selected populations that make inference on effectiveness difficult and a lack of ability to adapt and change midstream. Methods: We propose two innovations for pragmatic trial design. Results: Evidence-based evolutionary testing, a framework that allows adaptation of interventions and rapid-cycle innovation, preserves the power of randomization while acknowledging the need for adaptation and learning. An opt-out consent framework increases the fraction of the target population who participate in trials, but may lead to dampening of effect sizes. Conclusion: Pragmatic trials offer numerous advantages in the evaluation of behavioral interventions in health. Statistical innovations, including evidence-based evolutionary testing and opt-out framing of consent and enrollment processes, can enhance the power of pragmatic trials and lead to more rapid progress. C1 [Troxel, Andrea B.] Univ Penn, Perelman Sch Med, Dept Biostat & Epidemiol, 622 Blockley Hall,423 Guardian Dr, Philadelphia, PA 19104 USA. [Asch, David A.; Volpp, Kevin G.] Univ Penn, Dept Med, Perelman Sch Med, Philadelphia, PA 19104 USA. [Asch, David A.; Volpp, Kevin G.] US Dept Vet Affairs, Philadelphia, PA USA. RP Troxel, AB (reprint author), Univ Penn, Perelman Sch Med, Dept Biostat & Epidemiol, 622 Blockley Hall,423 Guardian Dr, Philadelphia, PA 19104 USA. EM atroxel@mail.med.upenn.edu OI Troxel, Andrea/0000-0002-1393-3075 FU NCI NIH HHS [P30 CA016520]; NIA NIH HHS [P30 AG034546] NR 28 TC 0 Z9 0 U1 5 U2 5 PU SAGE PUBLICATIONS LTD PI LONDON PA 1 OLIVERS YARD, 55 CITY ROAD, LONDON EC1Y 1SP, ENGLAND SN 1740-7745 EI 1740-7753 J9 CLIN TRIALS JI Clin. Trials PD OCT PY 2016 VL 13 IS 5 BP 478 EP 483 DI 10.1177/1740774516654862 PG 6 WC Medicine, Research & Experimental SC Research & Experimental Medicine GA DW1GZ UT WOS:000383392600003 PM 27365015 ER PT J AU Lash, DB Jolliff, J Munoz, A Heidari, A AF Lash, D. Benjamin Jolliff, J. Munoz, A. Heidari, A. TI Cross-reactivity between voriconazole, fluconazole and itraconazole SO JOURNAL OF CLINICAL PHARMACY AND THERAPEUTICS LA English DT Article DE allergy; fluconazole; voriconazole; itraconazole ID FIXED DRUG ERUPTION AB What is known and objectiveHypersensitivity to triazoles is a rare occurrence and cross-reactivity between agents is unknown. We present a successful voriconazole challenge in a patient allergic to fluconazole and itraconazole. Case summaryA 41-year-old immunocompetent male with coccidioidomycosis developed fever, eosinophilia and maculopapular rash from fluconazole. Switching to itraconazole resulted in worsening of the rash and skin sloughing over 25% of his body. He was given an oral-graded challenge of voriconazole which he tolerated without incident. What is new and conclusionThis is the first report of a lack of cross-reactivity between itraconazole and voriconazole. A 41 year old immunocompetent male with coccidioidomycosis developed fever, eosinophilia, and maculopapular rash from fluconazole. Switching to itraconazole resulted in worsening of the rash and skin sloughing over 25% of his body, while an oral-graded-challenge of voriconazole was tolerated without incident. This is the first report of a lack of cross-reactivity between itraconazole and voriconazole. C1 [Lash, D. Benjamin] Western Univ Hlth Sci, Pomona, CA 91766 USA. [Lash, D. Benjamin] VA Greater Los Angeles Healthcare Syst, Los Angeles, CA USA. [Jolliff, J.] Kern Med, Dept Pharm, Bakersfield, CA USA. [Munoz, A.; Heidari, A.] Kern Med, Dept Med, Bakersfield, CA USA. RP Lash, DB (reprint author), Western Univ Hlth Sci, Coll Pharm, 309 E Second St, Pomona, CA 91766 USA. EM DLash@WesternU.edu NR 7 TC 0 Z9 0 U1 0 U2 0 PU WILEY-BLACKWELL PI HOBOKEN PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA SN 0269-4727 EI 1365-2710 J9 J CLIN PHARM THER JI J. Clin. Pharm. Ther. PD OCT PY 2016 VL 41 IS 5 BP 566 EP 567 DI 10.1111/jcpt.12417 PG 2 WC Pharmacology & Pharmacy SC Pharmacology & Pharmacy GA DW0YD UT WOS:000383368300018 ER PT J AU Polnaszek, B Gilmore-Bykovskyi, A Hovanes, M Roiland, R Ferguson, P Brown, R Kind, AJH AF Polnaszek, Brock Gilmore-Bykovskyi, Andrea Hovanes, Melissa Roiland, Rachel Ferguson, Patrick Brown, Roger Kind, Amy J. H. TI Overcoming the Challenges of Unstructured Data in Multisite, Electronic Medical Record-based Abstraction SO MEDICAL CARE LA English DT Article DE unstructured data; medical record abstraction; communication documents ID INTERRATER RELIABILITY; HIGH AGREEMENT; DISCHARGE SUMMARIES; HOSPITAL DISCHARGE; LOW KAPPA; CARE; QUALITY; INFORMATION; CONCORDANCE; PHYSICIANS AB Background: Unstructured data encountered during retrospective electronic medical record (EMR) abstraction has routinely been identified as challenging to reliably abstract, as these data are often recorded as free text, without limitations to format or structure. There is increased interest in reliably abstracting this type of data given its prominent role in care coordination and communication, yet limited methodological guidance exists. Objectives: As standard abstraction approaches resulted in substandard data reliability for unstructured data elements collected as part of a multisite, retrospective EMR study of hospital discharge communication quality, our goal was to develop, apply and examine the utility of a phase-based approach to reliably abstract unstructured data. This approach is examined using the specific example of discharge communication for warfarin management. Research Design: We adopted a "fit-for-use" framework to guide the development and evaluation of abstraction methods using a 4-step, phase-based approach including (1) team building; (2) identification of challenges; (3) adaptation of abstraction methods; and (4) systematic data quality monitoring. Measures: Unstructured data elements were the focus of this study, including elements communicating steps in warfarin management (eg, warfarin initiation) and medical follow-up (eg, timeframe for follow-up). Results: After implementation of the phase-based approach, interrater reliability for all unstructured data elements demonstrated kappa's of >= 0.89-an average increase of +0.25 for each unstructured data element. Conclusions: As compared with standard abstraction methodologies, this phase-based approach was more time intensive, but did markedly increase abstraction reliability for unstructured data elements within multisite EMR documentation. C1 [Polnaszek, Brock; Gilmore-Bykovskyi, Andrea; Hovanes, Melissa; Kind, Amy J. H.] Univ Wisconsin, Sch Med & Publ Hlth, Dept Med, Div Geriatr, Madison, WI USA. [Polnaszek, Brock; Roiland, Rachel; Kind, Amy J. H.] William S Middleton Hosp, US Dept Vet Affairs, GRECC, Madison, WI 53705 USA. [Gilmore-Bykovskyi, Andrea; Brown, Roger] Univ Wisconsin, Sch Nursing, Madison, WI USA. [Ferguson, Patrick] Univ Wisconsin, Dept Populat Hlth Sci, Madison, WI USA. RP Kind, AJH (reprint author), William S Middleton Hosp, US Dept Vet Affairs, GRECC, Madison, WI 53705 USA. EM ajk@medicine.wisc.edu FU National Institute on Aging Paul B. Beeson Patient-Oriented Research Career Development Award [K23AG034551]; American Federation for Aging Research; John A. Hartford Foundation; Atlantic Philanthropies; Starr Foundation; Madison VA Geriatric Research, Education and Clinical Center [2013-19]; University of Wisconsin School of Medicine and Public Health's Health Innovation Program; Community-Academic Partnerships core of the University of Wisconsin Institute for Clinical and Translational Research; Clinical and Translational Science Award program of the National Center for Research Resources, National Institutes of Health [1UL1RR025011] FX Supported by National Institute on Aging Paul B. Beeson Patient-Oriented Research Career Development Award (K23AG034551 [PI Kind]), in partnership with the American Federation for Aging Research, the John A. Hartford Foundation, the Atlantic Philanthropies, and the Starr Foundation and the Madison VA Geriatric Research, Education and Clinical Center (GRECC-Manuscript #2013-19). Additional support was provided by the University of Wisconsin School of Medicine and Public Health's Health Innovation Program; the Community-Academic Partnerships core of the University of Wisconsin Institute for Clinical and Translational Research; and the Clinical and Translational Science Award program of the National Center for Research Resources, National Institutes of Health (1UL1RR025011). NR 39 TC 0 Z9 0 U1 0 U2 0 PU LIPPINCOTT WILLIAMS & WILKINS PI PHILADELPHIA PA TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA SN 0025-7079 EI 1537-1948 J9 MED CARE JI Med. Care PD OCT PY 2016 VL 54 IS 10 BP E65 EP E72 PG 8 WC Health Care Sciences & Services; Health Policy & Services; Public, Environmental & Occupational Health SC Health Care Sciences & Services; Public, Environmental & Occupational Health GA DW9RO UT WOS:000383999900001 PM 27624585 ER PT J AU Bowles, DW Deutsch, E Raben, D AF Bowles, Daniel W. Deutsch, Eric Raben, David TI Successes and Failures of Combined Modality Therapies in Head and Neck Cancer SO SEMINARS IN RADIATION ONCOLOGY LA English DT Article ID SQUAMOUS-CELL CARCINOMA; GROWTH-FACTOR RECEPTOR; LOCALLY ADVANCED HEAD; MODULATED RADIATION-THERAPY; PHOSPHATIDYLINOSITOL 3-KINASE INHIBITOR; RANDOMIZED PHASE-II; INDUCTION CHEMOTHERAPY; HUMAN-PAPILLOMAVIRUS; FACTOR-BETA; IN-VIVO AB The paradigms for treating head and neck squamous cell carcinoma are changing as new subgroups are defined. The technical successes of improved radiation therapy are many; however, the success of novel combined therapies are few. With the emergence of human papillomavirus and the development of immunooncology agents, such as checkpoint inhibitors, are we ready to reevaluate how we use radiation and chemotherapy for locally advanced and metastatic disease-will we remain the fire or become the fire starter? (C) 2016 Published by Elsevier Inc. C1 [Bowles, Daniel W.] Univ Colorado, Sch Med, Div Med Oncol, Aurora, CO USA. [Bowles, Daniel W.] Denver Vet Affairs Med Ctr, Dept Med, Denver, CO USA. [Deutsch, Eric] Univ Paris Saclay, Univ Paris 11, Dept Radiotherapy, INSERM Mol Radiotherapy 1030, St Aubin, France. [Raben, David] Univ Colorado, Sch Med, Dept Radiat Oncol, Aurora, CO USA. RP Raben, D (reprint author), Univ Colorado Hlth, Dept Radiat Oncol, Mail Stop F706,1665 Aurora Court,Suite 1032, Aurora, CO 80045 USA. EM david.raben@ucdenver.edu NR 86 TC 0 Z9 0 U1 1 U2 1 PU W B SAUNDERS CO-ELSEVIER INC PI PHILADELPHIA PA 1600 JOHN F KENNEDY BOULEVARD, STE 1800, PHILADELPHIA, PA 19103-2899 USA SN 1053-4296 EI 1532-9461 J9 SEMIN RADIAT ONCOL JI Semin. Radiat. Oncol. PD OCT PY 2016 VL 26 IS 4 BP 299 EP 306 DI 10.1016/j.semradonc.2016.05.004 PG 8 WC Oncology; Radiology, Nuclear Medicine & Medical Imaging SC Oncology; Radiology, Nuclear Medicine & Medical Imaging GA DW4UY UT WOS:000383639700006 PM 27619251 ER PT J AU Debrey, SM Leehey, MA Klepitskaya, O Filley, CM Shah, RC Kluger, B Berry-Kravis, E Spector, E Tassone, F Hall, DA AF Debrey, Sarah M. Leehey, Maureen A. Klepitskaya, Olga Filley, Christopher M. Shah, Raj C. Kluger, Benzi Berry-Kravis, Elizabeth Spector, Elaine Tassone, Flora Hall, Deborah A. TI Clinical Phenotype of Adult Fragile X Gray Zone Allele Carriers: a Case Series SO CEREBELLUM LA English DT Article DE Fragile X-associated tremor/ataxia syndrome; Trinucleotide repeat expansion; Ataxia; Parkinsonism; Movement disorders ID TREMOR/ATAXIA SYNDROME FXTAS; COMORBIDITY SURVEY REPLICATION; FMR1 MESSENGER-RNA; PREMUTATION CARRIERS; CGG-REPEAT; ALZHEIMERS-DISEASE; PARKINSON-DISEASE; NEEDS POPULATION; EXPANDED ALLELES; RATING-SCALE AB Considerable research has focused on patients with trinucleotide (CGG) repeat expansions in the fragile X mental retardation 1 (FMR1) gene that fall within either the full mutation (> 200 repeats) or premutation range (55-200 repeats). Recent interest in individuals with gray zone expansions (41-54 CGG repeats) has grown due to reported phenotypes that are similar to those observed in premutation carriers, including neurological, molecular, and cognitive signs. The purpose of this manuscript is to describe a series of adults with FMR1 alleles in the gray zone presenting with movement disorders or memory loss. Gray zone carriers ascertained in large FMR1 screening studies were identified and their clinical phenotypes studied. Thirty-one gray zone allele carriers were included, with mean age of symptom onset of 53 years in patients with movement disorders and 57 years in those with memory loss. Four patients were chosen for illustrative case reports and had the following diagnoses: early-onset Parkinson disease (PD), atypical parkinsonism, dementia, and atypical essential tremor. Some gray zone carriers presenting with parkinsonism had typical features, including bradykinesia, rigidity, and a positive response to dopaminergic medication. These patients had a higher prevalence of peripheral neuropathy and psychiatric complaints than would be expected. The patients seen in memory clinics had standard presentations of cognitive impairment with no apparent differences. Further studies are necessary to determine the associations between FMR1 expansions in the gray zone and various phenotypes of neurological dysfunction. C1 [Debrey, Sarah M.] Emory Univ, Dept Psychiat, Atlanta, GA 30322 USA. [Leehey, Maureen A.; Klepitskaya, Olga; Filley, Christopher M.; Kluger, Benzi] Univ Colorado, Sch Med, Dept Neurol, Aurora, CO USA. [Filley, Christopher M.; Kluger, Benzi] Univ Colorado, Sch Med, Dept Psychiat, Aurora, CO USA. [Filley, Christopher M.] Denver Vet Affairs Med Ctr, Denver, CO USA. [Shah, Raj C.] Rush Univ, Rush Alzheimers Dis Ctr, Chicago, IL 60612 USA. [Berry-Kravis, Elizabeth] Rush Univ, Dept Pediat, Chicago, IL 60612 USA. [Berry-Kravis, Elizabeth] Rush Univ, Dept Biochem, Chicago, IL 60612 USA. [Berry-Kravis, Elizabeth; Hall, Deborah A.] Rush Univ, Dept Neurol Sci, 1725 West Harrison St,Suite 755, Chicago, IL 60612 USA. [Spector, Elaine] Univ Colorado Denver, Dept Pediat, Childrens Hosp Colorado, Denver Genet DNA Diagnost Lab, Aurora, CO USA. [Tassone, Flora] Univ Calif Davis, Sch Med, Dept Biochem & Mol Med, Davis, CA 95616 USA. [Tassone, Flora] Univ Calif Davis, Med Ctr, MIND Inst, Sacramento, CA 95817 USA. RP Hall, DA (reprint author), Rush Univ, Dept Neurol Sci, 1725 West Harrison St,Suite 755, Chicago, IL 60612 USA. EM Deborah_A_Hall@rush.edu FU [R01NS052487] FX This work was funded by R01NS052487 (DAH). We thank the patients who participated in these studies. NR 66 TC 1 Z9 1 U1 3 U2 3 PU SPRINGER PI NEW YORK PA 233 SPRING ST, NEW YORK, NY 10013 USA SN 1473-4222 EI 1473-4230 J9 CEREBELLUM JI Cerebellum PD OCT PY 2016 VL 15 IS 5 SI SI BP 623 EP 631 DI 10.1007/s12311-016-0809-6 PG 9 WC Neurosciences SC Neurosciences & Neurology GA DV4XL UT WOS:000382928900011 PM 27372099 ER PT J AU Mundinger, TO Taborsky, GJ AF Mundinger, Thomas O. Taborsky, Gerald J., Jr. TI Early sympathetic islet neuropathy in autoimmune diabetes: lessons learned and opportunities for investigation SO DIABETOLOGIA LA English DT Review DE Autoimmunity; Diabetes; Glucagon; Human; Insulin-induced hypoglycaemia; Islet; Neuropathy; Neurotrophins; Review; Rodent; Sympathetic nerves ID INSULIN-INDUCED HYPOGLYCEMIA; P75 NEUROTROPHIN RECEPTOR; VESICULAR MONOAMINE TRANSPORTER; PERIPHERAL-NERVE REGENERATION; INCREASED GLUCAGON-SECRETION; PANCREATIC BETA-CELLS; MITOCHONDRIAL BIOENERGETICS; AUTONOMIC NEUROPATHY; NEURITE OUTGROWTH; IMPAIRED GLUCAGON AB This review outlines the current state of knowledge regarding a unique neural defect of the pancreatic islet in autoimmune diabetes, one that we have termed early sympathetic islet neuropathy (eSIN). We begin with the findings that a majority of islet sympathetic nerves are lost near the onset of type 1, but not type 2, diabetes and that this nerve loss is restricted to the islet. We discuss later work demonstrating that while the loss of islet sympathetic nerves and the loss of islet beta cells in type 1 diabetes both require infiltration of the islet by lymphocytes, their respective mechanisms of tissue destruction differ. Uniquely, eSIN requires the activation of a specific neurotrophin receptor and we propose two possible pathways for activation of this receptor during the immune attack on the islet. We also outline what is known about the functional consequences of eSIN, focusing on impairment of sympathetically mediated glucagon secretion and its application to the clinical problem of insulin-induced hypoglycaemia. Finally, we offer our view on the important remaining questions regarding this unique neural defect. C1 [Mundinger, Thomas O.; Taborsky, Gerald J., Jr.] Univ Washington, Div Metab Endocrinol & Nutr, Dept Med, Seattle, WA 98105 USA. [Mundinger, Thomas O.; Taborsky, Gerald J., Jr.] Vet Affairs Puget Sound Hlth Care Syst, 1660 S Columbian Way, Seattle, WA 98108 USA. RP Mundinger, TO (reprint author), Univ Washington, Div Metab Endocrinol & Nutr, Dept Med, Seattle, WA 98105 USA. EM mundin@u.washington.edu FU NIH [P30-DK-017047]; Biomedical Laboratory R&D Service of the US Department of Veterans Affairs; US National Institute of Health [R01-DK-050154] FX The studies to determine basal islet expression of BDNF and NGF were performed in part at the Cell Function Analysis Core of the University of Washington's Diabetes Research Center, which is supported by NIH grant no. P30-DK-017047. This work was supported by a Merit Review from the Biomedical Laboratory R&D Service of the US Department of Veterans Affairs and by US National Institute of Health grant no. R01-DK-050154. NR 83 TC 0 Z9 0 U1 3 U2 6 PU SPRINGER PI NEW YORK PA 233 SPRING ST, NEW YORK, NY 10013 USA SN 0012-186X EI 1432-0428 J9 DIABETOLOGIA JI Diabetologia PD OCT PY 2016 VL 59 IS 10 BP 2058 EP 2067 DI 10.1007/s00125-016-4026-0 PG 10 WC Endocrinology & Metabolism SC Endocrinology & Metabolism GA DV7NI UT WOS:000383122800003 PM 27342407 ER PT J AU Meier, DT Entrup, L Templin, AT Hogan, MF Mellati, M Zraika, S Hull, RL Kahn, SE AF Meier, Daniel T. Entrup, Leon Templin, Andrew T. Hogan, Meghan F. Mellati, Mahnaz Zraika, Sakeneh Hull, Rebecca L. Kahn, Steven E. TI The S20G substitution in hIAPP is more amyloidogenic and cytotoxic than wild-type hIAPP in mouse islets SO DIABETOLOGIA LA English DT Article DE Amylin; Amyloid; Beta cell; Insulin secretion; Islet; Islet amyloid polypeptide; Toxicity; Type 2 diabetes ID BETA-CELL APOPTOSIS; AMYLIN GENE; POLYPEPTIDE; MUTATION; JAPANESE AB Aims/hypothesis The S20G human islet amyloid polypeptide (hIAPP) substitution is associated with an earlier onset of type 2 diabetes in humans. Studies of synthetic S20G hIAPP in cell-free systems and immortalised beta cells have suggested that this may be due to increased hIAPP amyloidogenicity and cytotoxicity. Thus, using primary islets from mice with endogenous S20G hIAPP expression, we sought to determine whether the S20G gene mutation leads to increased amyloid-induced toxicity, beta cell loss and reduced beta cell function. Methods Islets from mice in which mouse Iapp was replaced with human wild-type or S20G hIAPP were isolated and cultured in vitro under amyloid-forming conditions. Levels of insulin and hIAPP mRNA and protein, amyloid deposition and beta cell apoptosis and area, as well as glucose-stimulated insulin and hIAPP secretion, were quantified. Results Islets expressing S20G hIAPP cultured in 16.7 mmol/l glucose demonstrated increased amyloid deposition and beta cell apoptosis, reduced beta cell area, decreased insulin content and diminished glucose-stimulated insulin secretion, compared with islets expressing wild-type hIAPP. Amyloid deposition and beta cell apoptosis were also increased when S20G islets were cultured in 11.1 mmol/l glucose (the concentration that is thought to be physiological for mouse islets). Conclusions/interpretation S20G hIAPP reduces beta cell number and function, thereby possibly explaining the earlier onset of type 2 diabetes in individuals carrying this gene mutation. C1 [Meier, Daniel T.; Entrup, Leon; Templin, Andrew T.; Hogan, Meghan F.; Mellati, Mahnaz; Zraika, Sakeneh; Hull, Rebecca L.; Kahn, Steven E.] VA Puget Sound Hlth Care Syst, 1660 S Columbian Way, Seattle, WA 98108 USA. [Meier, Daniel T.; Entrup, Leon; Templin, Andrew T.; Hogan, Meghan F.; Mellati, Mahnaz; Zraika, Sakeneh; Hull, Rebecca L.; Kahn, Steven E.] Univ Washington, Seattle, WA 98195 USA. RP Kahn, SE (reprint author), VA Puget Sound Hlth Care Syst, 1660 S Columbian Way, Seattle, WA 98108 USA.; Kahn, SE (reprint author), Univ Washington, Seattle, WA 98195 USA. EM skahn@uw.edu OI Kahn, Steven/0000-0001-7307-9002 FU Department of Veterans Affairs [BX001060]; NIH [DK-017047, DK-007247, DK-080945, DK-088082, DK-098506, DK-107022, HL-007028]; Swiss National Foundation Fellowship; Dick and Julia McAbee Endowed Fellowship in Diabetes from the University of Washington; American Diabetes Association Mentor-Based Fellowship FX This work was supported by the Department of Veterans Affairs grant BX001060 and NIH grants DK-017047, DK-007247, DK-080945, DK-088082, DK-098506, DK-107022 and HL-007028. DTM was supported by a Swiss National Foundation Fellowship and the Dick and Julia McAbee Endowed Fellowship in Diabetes from the University of Washington. ATT was supported by an American Diabetes Association Mentor-Based Fellowship. NR 17 TC 1 Z9 1 U1 1 U2 2 PU SPRINGER PI NEW YORK PA 233 SPRING ST, NEW YORK, NY 10013 USA SN 0012-186X EI 1432-0428 J9 DIABETOLOGIA JI Diabetologia PD OCT PY 2016 VL 59 IS 10 BP 2166 EP 2171 DI 10.1007/s00125-016-4045-x PG 6 WC Endocrinology & Metabolism SC Endocrinology & Metabolism GA DV7NI UT WOS:000383122800015 PM 27393137 ER PT J AU Rogus-Pulia, NM Larson, C Mittal, BB Pierce, M Zecker, S Kennelty, K Kind, A Connor, NP AF Rogus-Pulia, Nicole M. Larson, Charles Mittal, Bharat B. Pierce, Marge Zecker, Steven Kennelty, Korey Kind, Amy Connor, Nadine P. TI Effects of Change in Tongue Pressure and Salivary Flow Rate on Swallow Efficiency Following Chemoradiation Treatment for Head and Neck Cancer SO DYSPHAGIA LA English DT Article DE Deglutition; Deglutition disorders; Tongue strength; Saliva; Hyposalivation; Head and neck cancer; Chemoradiation ID NASOPHARYNGEAL CARCINOMA; RANDOMIZED-TRIAL; ORAL-CANCER; DRY MOUTH; XEROSTOMIA; RADIOTHERAPY; STRENGTH; PERFORMANCE; PERCEPTION; RADIATION AB Patients treated with chemoradiation for head and neck cancer frequently develop dysphagia. Tissue damage to the oral tongue causing weakness along with decreases in saliva production may contribute to dysphagia. Yet, effects of these variables on swallowing-related measures are unclear. The purpose of this study was (1) to determine effects of chemoradiation on tongue pressures, as a surrogate for strength, and salivary flow rates and (2) to elucidate relationships among tongue pressures, saliva production, and swallowing efficiency by bolus type. Twenty-one patients with head and neck cancer treated with chemoradiation were assessed before and after treatment and matched with 21 healthy control participants who did not receive chemoradiation. Each participant was given a questionnaire to rate dysphagia symptoms. Videofluoroscopic Evaluation of Swallowing (VFES) was used to determine swallowing efficiency; the Saxon test measured salivary flow rate; and the Iowa Oral Performance Instrument (IOPI) was used for oral tongue maximum and endurance measures. Results revealed significantly lower tongue endurance measures for patients post-treatment as compared to controls (p = .012). Salivary flow rates also were lower compared to pre-treatment (p = .000) and controls (p = .000). Simple linear regression analyses showed that change in salivary flow rate was predictive of change in swallow efficiency measures from pre- to post-treatment for 1 mL thin liquid (p = .017), 3 mL nectar-thick liquid (p = .026), and 3 mL standard barium pudding (p = .011) boluses. Based on these findings, it appears that chemoradiation treatment affects tongue endurance and salivary flow rate, and these changes may impact swallow efficiency. These factors should be considered when planning treatment for dysphagia. C1 [Rogus-Pulia, Nicole M.; Kennelty, Korey; Kind, Amy] William S Middleton Mem Vet Adm Med Ctr, Geriatr Res Educ & Clin Ctr, 2500 Overlook Terrace,Madison GRECC 11G, Madison, WI 53705 USA. [Rogus-Pulia, Nicole M.; Kind, Amy] Univ Wisconsin, Sch Med & Publ Hlth, Dept Med, Madison, WI 53705 USA. [Larson, Charles; Zecker, Steven] Northwestern Univ, Dept Commun Sci & Disorders, Frances Searle Bldg, Evanston, IL 60208 USA. [Mittal, Bharat B.] Northwestern Univ, Dept Radiat Oncol, Feinberg Sch Med, Chicago, IL 60611 USA. [Pierce, Marge] Northwestern Mem Hosp, Radiat Oncol, Chicago, IL 60611 USA. [Kennelty, Korey] Univ Wisconsin, Sch Pharm, Madison, WI 53706 USA. [Connor, Nadine P.] Univ Wisconsin, Sch Med & Publ Hlth, Dept Surg, Madison, WI 53706 USA. [Connor, Nadine P.] Univ Wisconsin, Dept Commun Sci & Disorders, Madison, WI 53706 USA. RP Rogus-Pulia, NM (reprint author), William S Middleton Mem Vet Adm Med Ctr, Geriatr Res Educ & Clin Ctr, 2500 Overlook Terrace,Madison GRECC 11G, Madison, WI 53705 USA.; Rogus-Pulia, NM (reprint author), Univ Wisconsin, Sch Med & Publ Hlth, Dept Med, Madison, WI 53705 USA. EM npulia@wisc.edu FU NIA NIH HHS [K23 AG034551] NR 50 TC 0 Z9 0 U1 1 U2 1 PU SPRINGER PI NEW YORK PA 233 SPRING ST, NEW YORK, NY 10013 USA SN 0179-051X EI 1432-0460 J9 DYSPHAGIA JI Dysphagia PD OCT PY 2016 VL 31 IS 5 BP 687 EP 696 DI 10.1007/s00455-016-9733-7 PG 10 WC Otorhinolaryngology SC Otorhinolaryngology GA DV4ZB UT WOS:000382933400012 PM 27492408 ER PT J AU Rachakonda, G Vu, T Jin, L Samanta, D Datta, PK AF Rachakonda, Girish Vu, Trung Jin, Lin Samanta, Debangshu Datta, Pran K. TI Role of TGF-beta-induced Claudin-4 expression through c-Jun signaling in non-small cell lung cancer SO CELLULAR SIGNALLING LA English DT Article DE Claudin-4; TGF-beta; c-jun; Smad; Migration; Tumorigenicity ID OVARIAN-CANCER; GASTRIC-CARCINOMA; PANCREATIC-CANCER; BARRIER FUNCTION; PROTEINS; OCCLUDIN; IDENTIFICATION; TRANSCRIPTION; PERMEABILITY; METASTASIS AB Claudia-4 has been identified as an integral member of tight junctions and has been found to be upregulated in various types of cancers especially in metastatic cancers. However, the molecular mechanism of the upregulation of Claudin-4 and its role in lung tumorigenesis are unknown. The aim of the present study is to investigate the role of Claudin-4 on migration and tumorigenicity of lung cancer cells and to examine the regulatory effects of TGF-beta on Claudin-4 expression. We have observed that TGF-beta induces the expression of Claudin-4 dramatically in lung cell lines in a time dependent manner. TGF-beta-induced Smad signaling is important for enhancing Claudin-4mRNA level through inducing its promoter activity. Treatment with curcumin, a c-Jun inhibitor, or stable knockdown of c-Jun abrogates TGF-beta-induced Claudin-4 expression suggesting an involvement of the c-Jun pathway. Notably, TGF-beta-induced Claudin-4 expression through c-Jun pathway plays a role in TGF-beta-mediated motility and tumorigenicity of these cells. In support of these observations, we have uncovered that Claudin-4 is upregulated in 14 of 24 (58%) lung tumors when compared with normal lung tissue. This is the first study to show how TGF-beta regulates the expression of Claudin-4 through c-Jun signaling and how this pathway contributes to the migratory and tumorigenic phenotype of lung tumor cells. (C) 2016 Published by Elsevier Inc. C1 [Rachakonda, Girish; Jin, Lin; Samanta, Debangshu; Datta, Pran K.] Vanderbilt Univ, Med Ctr, Dept Surg, Nashville, TN USA. [Vu, Trung; Jin, Lin; Datta, Pran K.] Univ Alabama Birmingham, Dept Med, Div Hematol & Oncol, UAB Comprehens Canc Ctr, Birmingham, AL 35294 USA. [Jin, Lin; Datta, Pran K.] Birmingham Vet Affairs Med Ctr, Birmingham, AL USA. [Rachakonda, Girish] Meharry Med Coll, Dept Microbiol & Immunol, Nashville, TN 37208 USA. [Samanta, Debangshu] Johns Hopkins Univ, Sch Med, McKusick Nathans Inst Genet Med, Baltimore, MD USA. RP Datta, PK (reprint author), Univ Alabama Birmingham, Dept Med, Div Hematol & Oncol, 1824 6th Ave South,WTI 520C, Birmingham, AL 35294 USA. EM prandatta@uabmc.edu FU Department of Veterans Affairs Merit Review Award [R01 CA95195]; Faculty Development Award from UAB Comprehensive Cancer Center [P30 CA013148] FX This work was supported by R01 CA95195, Department of Veterans Affairs Merit Review Award, and a Faculty Development Award from UAB Comprehensive Cancer Center, P30 CA013148 (to P.K.D.). NR 32 TC 0 Z9 0 U1 4 U2 4 PU ELSEVIER SCIENCE INC PI NEW YORK PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA SN 0898-6568 EI 1873-3913 J9 CELL SIGNAL JI Cell. Signal. PD OCT PY 2016 VL 28 IS 10 BP 1537 EP 1544 DI 10.1016/j.cellsig.2016.07.006 PG 8 WC Cell Biology SC Cell Biology GA DU6UW UT WOS:000382351100010 PM 27424491 ER PT J AU Melrose, RJ Brommelhoff, JA Narvaez, T Natta, L Jones, HHR Sakhai, S Wong, L Curtis, S Horning, SM AF Melrose, Rebecca J. Brommelhoff, Jessica A. Narvaez, Theresa Natta, Laura Jones, Hannah H. Riskin Sakhai, Sherwin Wong, Lawrence Curtis, Stacey Horning, Sheena M. TI The use of Information and Communication technology when completing instrumental activities of daily living SO COMPUTERS IN HUMAN BEHAVIOR LA English DT Article DE ICT; Technology; Activities of daily living; Aging; Memory ID MILD COGNITIVE IMPAIRMENT; ACQUIRED BRAIN-INJURY; EVERYDAY TECHNOLOGY; OLDER-ADULTS; ALZHEIMERS-DISEASE; COMPUTER USE; QUESTIONNAIRE; DIFFICULTIES; DISABILITIES; ASSOCIATION AB Purpose of the study: An important aspect of cognitive assessment is inquiry of the patient's ability to manage instrumental activities of daily living (IADLs), including finances, medication, and transportation. Information and Communication technology (ICT, e.g. smartphones, computers) has become increasingly prevalent in American culture. We aimed to characterize what IADLs were being completed with ICI, and what factors predict ICT use to manage IADLs. Design and methods: We administered a self-report survey to 505 Veterans seeking care at the VA Greater Los Angeles Healthcare System. Results: Seventy percent reported regular ICI use. Of ICT users, 76% reported use for finances, 86% for shopping, 72% for health management, 75% for transportation, and 97% for communication. Logistic regression was used to identify predictors of high ICT use. Longer duration of computer use was significant in all models. Younger age, higher education, and better self-reported memory were associated with greater use for a subset of IADLs. Veterans with more health problems were more likely to use ICT to manage their healthcare. Implications: These findings suggest that Veterans are using ICT to support IADLs. It appears appropriate for clinicians to incorporate questions about ICT use into IADLs assessment, which may assist in detecting subtle changes to day to day functioning and improve the accurate diagnosis of cognitive disorders. Published by Elsevier Ltd. C1 [Melrose, Rebecca J.; Brommelhoff, Jessica A.; Narvaez, Theresa; Natta, Laura; Jones, Hannah H. Riskin; Sakhai, Sherwin; Wong, Lawrence; Curtis, Stacey; Horning, Sheena M.] West LA VA, VA Greater Los Angeles Healthcare Syst, 11301 Wilshire Blvd 116AE, Los Angeles, CA USA. [Melrose, Rebecca J.; Brommelhoff, Jessica A.] Univ Calif Los Angeles, David Geffen Sch Med, Dept Psychiat & Biobehav Sci, Los Angeles, CA 90095 USA. [Horning, Sheena M.] Univ Cincinnati, Coll Med, Dept Neurol, Cincinnati, OH USA. RP Melrose, RJ (reprint author), West LA VA, VA Greater Los Angeles Healthcare Syst, 11301 Wilshire Blvd 116AE, Los Angeles, CA USA. EM Rebecca.Melrose@va.gov; Jbrommelhoff@gmail.com; Theresa.Narvaez@va.gov; Lnatta@altamirarecovery.com; Hannah.Riskin-Jones@va.gov; Ssakhai@paloaltou.edu; Lawrence.Wong@va.gov; Stacey.Curtis@va.gov; SheenaHorning@gmail.com OI Horning, Sheena/0000-0002-9704-0070 FU VA Career Development Award FX R. Melrose was supported by a VA Career Development Award. NR 38 TC 0 Z9 0 U1 8 U2 8 PU PERGAMON-ELSEVIER SCIENCE LTD PI OXFORD PA THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, ENGLAND SN 0747-5632 EI 1873-7692 J9 COMPUT HUM BEHAV JI Comput. Hum. Behav. PD OCT PY 2016 VL 63 BP 471 EP 479 DI 10.1016/j.chb.2016.05.045 PG 9 WC Psychology, Multidisciplinary; Psychology, Experimental SC Psychology GA DU6QP UT WOS:000382340000051 ER PT J AU Ford, J Palzes, V Roach, BJ Fryer, SL Mathalon, DH AF Ford, Judith Palzes, Vanessa Roach, Brian J. Fryer, Susanna L. Mathalon, Daniel H. TI Action-based predictive coding is abnormal in psychotic patients SO INTERNATIONAL JOURNAL OF PSYCHOPHYSIOLOGY LA English DT Meeting Abstract CT 18th World Congress of Psychophysiology of the International Organization of Psychophysiology (IOP) CY AUG 31-SEP 04, 2016 CL Havana, CUBA SP Int Org Psychophysiol C1 [Ford, Judith; Roach, Brian J.; Fryer, Susanna L.; Mathalon, Daniel H.] UCSF, San Francisco, CA USA. [Ford, Judith; Palzes, Vanessa; Roach, Brian J.; Fryer, Susanna L.; Mathalon, Daniel H.] San Francisco VA Med Ctr, San Francisco, CA USA. NR 0 TC 0 Z9 0 U1 1 U2 1 PU ELSEVIER SCIENCE BV PI AMSTERDAM PA PO BOX 211, 1000 AE AMSTERDAM, NETHERLANDS SN 0167-8760 EI 1872-7697 J9 INT J PSYCHOPHYSIOL JI Int. J. Psychophysiol. PD OCT PY 2016 VL 108 SI SI MA 463 BP 13 EP 13 DI 10.1016/j.ijpsycho.2016.07.045 PG 1 WC Psychology, Biological; Neurosciences; Physiology; Psychology; Psychology, Experimental SC Psychology; Neurosciences & Neurology; Physiology GA DU7QC UT WOS:000382408700044 ER PT J AU Mathalon, DH Hamilton, H Bachman, P Belger, A Carrion, R Duncan, E Johannesen, J Niznikiewicz, M Cadenhead, K AF Mathalon, Daniel H. Hamilton, Holly Bachman, Peter Belger, Aysenil Carrion, Ricardo Duncan, Erica Johannesen, Jason Niznikiewicz, Margaret Cadenhead, Kristin CA Consortium NAPLS TI Mismatch Negativity and Repetition Positivity Predict Transition to Psychosis in Clinical High Risk Individuals SO INTERNATIONAL JOURNAL OF PSYCHOPHYSIOLOGY LA English DT Meeting Abstract CT 18th World Congress of Psychophysiology of the International Organization of Psychophysiology (IOP) CY AUG 31-SEP 04, 2016 CL Havana, CUBA SP Int Org Psychophysiol C1 [Mathalon, Daniel H.; Hamilton, Holly] Univ CA San Francisco, San Francisco, CA 94117 USA. [Mathalon, Daniel H.; Hamilton, Holly] San Francisco VA Med Ctr, San Francisco, CA 94121 USA. [Bachman, Peter] Univ Pittsburgh, Pittsburgh, PA 15213 USA. [Belger, Aysenil] Univ N Carolina, Chapel Hill, NC 27599 USA. [Carrion, Ricardo] Hillside Hosp, Glen Oaks, NY 11004 USA. [Duncan, Erica] Emory Univ, Atlanta, GA 30322 USA. [Johannesen, Jason] Yale Univ, New Haven, CT 06520 USA. [Niznikiewicz, Margaret] Harvard Univ, Boston, MA 02115 USA. [Cadenhead, Kristin; Consortium NAPLS] Univ CA San Diego, San Diego, CA 92093 USA. NR 0 TC 0 Z9 0 U1 3 U2 3 PU ELSEVIER SCIENCE BV PI AMSTERDAM PA PO BOX 211, 1000 AE AMSTERDAM, NETHERLANDS SN 0167-8760 EI 1872-7697 J9 INT J PSYCHOPHYSIOL JI Int. J. Psychophysiol. PD OCT PY 2016 VL 108 SI SI MA 471 BP 37 EP 37 DI 10.1016/j.ijpsycho.2016.07.122 PG 1 WC Psychology, Biological; Neurosciences; Physiology; Psychology; Psychology, Experimental SC Psychology; Neurosciences & Neurology; Physiology GA DU7QC UT WOS:000382408700122 ER PT J AU Ho, ECY Truccolo, W AF Ho, E. C. Y. Truccolo, Wilson TI Interaction between synaptic inhibition and glial-potassium dynamics leads to diverse seizure transition modes in biophysical models of human focal seizures SO JOURNAL OF COMPUTATIONAL NEUROSCIENCE LA English DT Article DE Focal epilepsy; Seizure dynamics; Spike-wave discharges; Gamma oscillations ID SINGLE-NEURON DYNAMICS; GAMMA-OSCILLATIONS; SPREADING DEPRESSION; EPILEPTIC CORTEX; NETWORK MODEL; FIRE NEURONS; SYNCHRONY; FLUCTUATIONS; PROPAGATION; INTERNEURON AB How focal seizures initiate and evolve in human neocortex remains a fundamental problem in neuroscience. Here, we use biophysical neuronal network models of neocortical patches to study how the interaction between inhibition and extracellular potassium ([K (+)] (o) ) dynamics may contribute to different types of focal seizures. Three main types of propagated focal seizures observed in recent intracortical microelectrode recordings in humans were modelled: seizures characterized by sustained (similar to 30-60 Hz) gamma local field potential (LFP) oscillations; seizures where the onset in the propagated site consisted of LFP spikes that later evolved into rhythmic (similar to 2-3 Hz) spike-wave complexes (SWCs); and seizures where a brief stage of low-amplitude fast-oscillation (similar to 10-20 Hz) LFPs preceded the SWC activity. Our findings are fourfold: (1) The interaction between elevated [K (+)] (o) (due to abnormal potassium buffering by glial cells) and the strength of synaptic inhibition plays a predominant role in shaping these three types of seizures. (2) Strengthening of inhibition leads to the onset of sustained narrowband gamma seizures. (3) Transition into SWC seizures is obtained either by the weakening of inhibitory synapses, or by a transient strengthening followed by an inhibitory breakdown (e.g. GABA depletion). This reduction or breakdown of inhibition among fast-spiking (FS) inhibitory interneurons increases their spiking activity and leads them eventually into depolarization block. Ictal spike-wave discharges in the model are then sustained solely by pyramidal neurons. (4) FS cell dynamics are also critical for seizures where the evolution into SWC activity is preceded by low-amplitude fast oscillations. Different levels of elevated [K (+)] (o) were important for transitions into and maintenance of sustained gamma oscillations and SWC discharges. Overall, our modelling study predicts that the interaction between inhibitory interneurons and [K (+)] (o) glial buffering under abnormal conditions may explain different types of ictal transitions and dynamics during propagated seizures in human focal epilepsy. C1 [Ho, E. C. Y.; Truccolo, Wilson] Brown Univ, Dept Neurosci, Providence, RI 02912 USA. [Ho, E. C. Y.; Truccolo, Wilson] Brown Univ, Inst Brain Sci, Providence, RI 02912 USA. [Truccolo, Wilson] US Dept Vet Affairs, Ctr Neurorestorat & Neurotechnol, Providence, RI 02903 USA. RP Ho, ECY; Truccolo, W (reprint author), Brown Univ, Dept Neurosci, Providence, RI 02912 USA.; Ho, ECY; Truccolo, W (reprint author), Brown Univ, Inst Brain Sci, Providence, RI 02912 USA.; Truccolo, W (reprint author), US Dept Vet Affairs, Ctr Neurorestorat & Neurotechnol, Providence, RI 02903 USA. EM ernest_ho@brown.edu; wilson_truccolo@brown.edu FU National Institute of Neurological Disorders and Stroke (NINDS) [R01NS079533]; U.S. Department of Veterans Affairs, Merit Review Award [I01RX000668]; Pablo J. Salame '88 Goldman Sachs endowed Assistant Professorship of Computational Neuroscience FX This research was supported by: the National Institute of Neurological Disorders and Stroke (NINDS), grant R01NS079533; the U.S. Department of Veterans Affairs, Merit Review Award I01RX000668; and the Pablo J. Salame '88 Goldman Sachs endowed Assistant Professorship of Computational Neuroscience. The contents do not represent the views of the U.S. Department of Veterans Affairs or the United States Government. NR 66 TC 1 Z9 1 U1 5 U2 9 PU SPRINGER PI DORDRECHT PA VAN GODEWIJCKSTRAAT 30, 3311 GZ DORDRECHT, NETHERLANDS SN 0929-5313 EI 1573-6873 J9 J COMPUT NEUROSCI JI J. Comput. Neurosci. PD OCT PY 2016 VL 41 IS 2 BP 225 EP 244 DI 10.1007/s10827-016-0615-7 PG 20 WC Mathematical & Computational Biology; Neurosciences SC Mathematical & Computational Biology; Neurosciences & Neurology GA DU7ON UT WOS:000382404600007 ER PT J AU Hill, J Shields, J Passero, V AF Hill, Jordan Shields, Jenna Passero, Vida TI Tyrosine kinase inhibitor-associated syndrome of inappropriate secretion of anti-diuretic hormone SO JOURNAL OF ONCOLOGY PHARMACY PRACTICE LA English DT Article DE Dasatinib; tyrosine kinase inhibitor; syndrome of inappropriate secretion of anti-diuretic hormone; hyponatremia ID MANAGEMENT; IMATINIB AB Hyponatremia is a common complication among cancer patients. Certain antineoplastic agents have been associated with syndrome of inappropriate secretion of anti-diuretic hormone-induced hyponatremia. The most common agents associated with secretion of anti-diuretic hormone are vinca alkaloids, platinum compounds, and alkylating agents. We report a case of secretion of anti-diuretic hormone associated with tyrosine kinase inhibitors. C1 [Hill, Jordan; Shields, Jenna; Passero, Vida] Vet Affairs Pittsburgh Healthcare Syst, Dept Clin Pharm, Pittsburgh, PA USA. RP Shields, J (reprint author), Vet Affairs Pittsburgh Healthcare Syst, Dept Pharm, Univ Dr, Pittsburgh, PA 15240 USA. EM Jenna.Shields@va.gov NR 7 TC 0 Z9 0 U1 0 U2 2 PU SAGE PUBLICATIONS LTD PI LONDON PA 1 OLIVERS YARD, 55 CITY ROAD, LONDON EC1Y 1SP, ENGLAND SN 1078-1552 EI 1477-092X J9 J ONCOL PHARM PRACT JI J. Oncol. Pharm. Pract. PD OCT PY 2016 VL 22 IS 5 BP 729 EP 732 DI 10.1177/1078155215592023 PG 4 WC Oncology; Pharmacology & Pharmacy SC Oncology; Pharmacology & Pharmacy GA DU7SM UT WOS:000382414900010 PM 26089312 ER PT J AU Zhao, W Ho, L Wang, J Bi, WN Yemul, S Ward, L Freire, D Mazzola, P Brathwaite, J Mezei, M Sanchez, R Elder, GA Pasinetti, GM AF Zhao, Wei Ho, Lap Wang, Jun Bi, Weina Yemul, Shrishailam Ward, Libby Freire, Daniel Mazzola, Paolo Brathwaite, Justin Mezei, Mihaly Sanchez, Roberto Elder, Gregory A. Pasinetti, Giulio Maria TI In Silico Modeling of Novel Drug Ligands for Treatment of Concussion Associated Tauopathy SO JOURNAL OF CELLULAR BIOCHEMISTRY LA English DT Article DE CONCUSSION; OLFACTORY RECEPTOR; G PROTEIN-COUPLED RECEPTORS; IN SILICO SCREENING; TAU PHOSPHORYLATION ID TRAUMATIC BRAIN-INJURY; PROTEIN STRUCTURES; TRANSGENIC MICE; PREDICTION; RECEPTORS; EXPOSURE; DISEASE; SITES; TOOLS AB The objective of this study was to develop an in silico screening model for characterization of potential novel ligands from commercial drug libraries able to functionally activate certain olfactory receptors (ORs), which are members of the class A rhodopsin-like family of G protein couple receptors (GPCRs), in the brain of murine models of concussion. We previously found that concussions may significantly influence expression of certain ORs, for example, OR4M1 in subjects with a history of concussion/traumatic brain injury (TBI). In this study, we built a 3-D OR4M1 model and used it in in silico screening of potential novel ligands from commercial drug libraries. We report that in vitro activation of OR4M1 with the commercially available ZINC library compound 10915775 led to a significant attenuation of abnormal tau phosphorylation in embryonic cortico-hippocampal neuronal cultures derived from NSE-OR4M1 transgenic mice, possibly through modulation of the JNK signaling pathway. The attenuation of abnormal tau phosphorylation was rather selective since ZINC10915775 significantly decreased tau phosphorylation on tau Ser202/T205 (AT8 epitope) and tau Thr212/Ser214 (AT100 epitope), but not on tau Ser396/404 (PHF-1 epitope). Moreover, no response of ZINC10915775 was found in control hippocampal neuronal cultures derived from wild type littermates. Our in silico model provides novel means to pharmacologically modulate select ubiquitously expressed ORs in the brain through high affinity ligand activation to prevent and eventually to treat concussion induced down regulation of ORs and subsequent cascade of tau pathology. J. Cell. Biochem. 117: 2241-2248, 2016. (c) 2016 Wiley Periodicals, Inc. C1 [Zhao, Wei; Ho, Lap; Wang, Jun; Bi, Weina; Yemul, Shrishailam; Ward, Libby; Freire, Daniel; Mazzola, Paolo; Brathwaite, Justin; Elder, Gregory A.; Pasinetti, Giulio Maria] Icahn Sch Med Mt Sinai, Dept Neurol, 1 Gustave L Levy Pl,Box 1137, New York, NY 10029 USA. [Zhao, Wei; Wang, Jun; Pasinetti, Giulio Maria] James J Peters VA Med Ctr, Geriatr Res Educ Clin Ctr, Bronx, NY USA. [Mazzola, Paolo] Univ Milano Bicocca, Sch Med & Surg, Monza, Italy. [Mezei, Mihaly; Sanchez, Roberto] Icahn Sch Med Mt Sinai, Dept Struct & Chem Biol, New York, NY 10029 USA. [Mezei, Mihaly; Sanchez, Roberto] Icahn Sch Med Mt Sinai, Expt Therapeut Inst, New York, NY 10029 USA. [Elder, Gregory A.; Pasinetti, Giulio Maria] Icahn Sch Med Mt Sinai, Dept Psychiat, New York, NY 10029 USA. RP Pasinetti, GM (reprint author), Icahn Sch Med Mt Sinai, Dept Neurol, 1 Gustave L Levy Pl,Box 1137, New York, NY 10029 USA. EM giulio.pasinetti@mssm.edu FU Department of Defense [W81XWH-12-1-0582]; Veterans Affairs [Merit 1I01RX000996-01] FX This study was supported by the Department of Defense (Grant W81XWH-12-1-0582) to GMP and by the Veterans Affairs (Merit 1I01RX000996-01) to GAE. This material is also the result of work supported in part with resources and the use of facilities at the James J. Peters Veterans Affairs Medical Center, Bronx, NY. In addition, Dr. Pasinetti holds a Career Scientist Award in the Research and Development unit and is the Director of the Basic and Biomedical Research and Training Program, GRECC, James J. Peters Veterans Affairs Medical Center. We also acknowledge that the contents of this manuscript do not represent the views of the U.S. Department of Veterans Affairs or the United States Government. NR 23 TC 0 Z9 0 U1 4 U2 4 PU WILEY-BLACKWELL PI HOBOKEN PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA SN 0730-2312 EI 1097-4644 J9 J CELL BIOCHEM JI J. Cell. Biochem. PD OCT PY 2016 VL 117 IS 10 BP 2241 EP 2248 DI 10.1002/jcb.25521 PG 8 WC Biochemistry & Molecular Biology; Cell Biology SC Biochemistry & Molecular Biology; Cell Biology GA DS6LE UT WOS:000380892500006 PM 26910498 ER PT J AU Peterson, RL Galaleldeen, A Villarreal, J Taylor, AB Cabelli, DE Hart, PJ Culotta, VC AF Peterson, Ryan L. Galaleldeen, Ahmad Villarreal, Johanna Taylor, Alexander B. Cabelli, Diane E. Hart, P. John Culotta, Valeria C. TI The Phylogeny and Active Site Design of Eukaryotic Copper-only Superoxide Dismutases SO JOURNAL OF BIOLOGICAL CHEMISTRY LA English DT Article ID AMYOTROPHIC-LATERAL-SCLEROSIS; CANDIDA-ALBICANS; ZINC; BINDING; SOD1; GENE; PH; EVOLUTION; ERYTHROCUPREIN; MECHANISM AB In eukaryotes the bimetallic Cu/Zn superoxide dismutase (SOD) enzymes play important roles in the biology of reactive oxygen species by disproportionating superoxide anion. Recently, we reported that the fungal pathogen Candida albicans expresses a novel copper-only SOD, known as SOD5, that lacks the zinc cofactor and electrostatic loop (ESL) domain of Cu/Zn-SODs for substrate guidance. Despite these abnormalities, C. albicans SOD5 can disproportionate superoxide at rates limited only by diffusion. Here we demonstrate that this curious copper-only SOD occurs throughout the fungal kingdom as well as in phylogenetically distant oomycetes or "pseudofungi" species. It is the only form of extracellular SOD in fungi and oomycetes, in stark contrast to the extracellular Cu/Zn-SODs of plants and animals. Through structural biology and biochemical approaches we demonstrate that these copper-only SODs have evolved with a specialized active site consisting of two highly conserved residues equivalent to SOD5 Glu-110 and Asp-113. The equivalent positions are zinc binding ligands in Cu/ZnSODs and have evolved in copper-only SODs to control catalysis and copper binding in lieu of zinc and the ESL. Similar to the zinc ion in Cu/Zn-SODs, SOD5 Glu-110 helps orient a key copper-coordinating histidine and extends the pH range of enzyme catalysis. SOD5 Asp-113 connects to the active site in a manner similar to that of the ESL in Cu/Zn-SODs and assists in copper cofactor binding. Copper-only SODs are virulence factors for certain fungal pathogens; thus this unique active site may be a target for future anti-fungal strategies. C1 [Peterson, Ryan L.; Culotta, Valeria C.] Johns Hopkins Univ, Bloomberg Sch Publ Hlth, Dept Biochem & Mol Biol, Baltimore, MD 21205 USA. [Galaleldeen, Ahmad; Villarreal, Johanna] St Marys Univ, Dept Biol Sci, San Antonio, TX 78228 USA. [Galaleldeen, Ahmad; Taylor, Alexander B.; Hart, P. John] Univ Texas Hlth Sci Ctr San Antonio, Dept Biochem, San Antonio, TX 78229 USA. [Cabelli, Diane E.] Brookhaven Natl Labs, Dept Chem, Upton, NY 11973 USA. [Hart, P. John] South Texas Vet Hlth Care Syst, Dept Vet Affairs, Geriatr Res Educ & Clin Ctr, San Antonio, TX 78229 USA. RP Culotta, VC (reprint author), Johns Hopkins Univ, Bloomberg Sch Publ Hlth, Dept Biochem & Mol Biol, Baltimore, MD 21205 USA. EM vculott1@jhu.edu FU National Institutes of Health [P41 GM103403, P30 CA054174]; United States Department of Energy [DE-AC02-06CH11357]; Office of the Vice President for Research; United States Department of Energy, Office of Science, Office of Basic Energy Sciences [DE-AC02-98-CH10886] FX We thank Drs. Julie Gleason and Brian Learn for helpful discussions and Professor Jiou Wang for assistance with protein purification. Support for Northeastern Collaborative Access Team beamline 24-ID-E was provided by National Institutes of Health Grant P41 GM103403 and United States Department of Energy Grant DE-AC02-06CH11357. The X-Ray Crystallography Core Laboratory at the University of Texas Health Science Center at San Antonio is supported in part by the Office of the Vice President for Research and by National Institutes of Health Grant P30 CA054174 (Cancer Therapy and Research Center). Pulse radiolysis studies were carried out using the Van de Graaff facilities of the BNL Accelerator Center for Energy Research, which is supported by United States Department of Energy, Office of Science, Office of Basic Energy Sciences through Grant DE-AC02-98-CH10886. NR 58 TC 0 Z9 0 U1 6 U2 6 PU AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC PI BETHESDA PA 9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA SN 0021-9258 EI 1083-351X J9 J BIOL CHEM JI J. Biol. Chem. PD SEP 30 PY 2016 VL 291 IS 40 BP 20911 EP 20923 PG 13 WC Biochemistry & Molecular Biology SC Biochemistry & Molecular Biology GA DY8UG UT WOS:000385406200010 PM 27535222 ER PT J AU Sippel, LM Mota, NP Kachadourian, LK Krystal, JH Southwick, SM Harpaz-Rotem, I Pietrzak, RH AF Sippel, Lauren M. Mota, Natalie P. Kachadourian, Lorig K. Krystal, John H. Southwick, Steven M. Harpaz-Rotem, Ilan Pietrzak, Robert H. TI The burden of hostility in US Veterans: Results from the National Health and Resilience in Veterans Study SO PSYCHIATRY RESEARCH LA English DT Article DE Risk factors; Protective factors; Anger; Aggression; Veterans ID POSTTRAUMATIC-STRESS-DISORDER; RISK-FACTORS; VIETNAM VETERANS; ALCOHOL-CONSUMPTION; MILITARY PERSONNEL; BEHAVIORAL RISK; SOCIAL SUPPORT; AUDIT-C; VIOLENCE; VALIDATION AB Hostility is associated with substantial mental and physical health consequences. Population-based data regarding the nature and longitudinal course of hostility in U.S. veterans are scarce. We analyzed data from 2157 U.S. veterans who participated in the National Health and Resilience in Veterans Study, a nationally representative, prospective cohort study of U.S. veterans. We identified the prevalence of longitudinal courses of hostility (chronic, increasing, decreasing, or no hostility). We then evaluated relationships between sociodemographic, risk, and protective correlates measured at baseline and longitudinal courses of two aspects of hostility-aggressive urges and difficulties controlling anger. The majority of veterans (61.2%) reported experiencing difficulties controlling anger and a sizable minority of veterans (23.9%) reported experiencing aggressive urges over a two-year period. Protective psychosocial characteristics (e.g., optimism) and aspects of social connectedness (e.g., secure attachment style) were negatively associated with hostility. Psychological distress predicted all symptomatic hostility courses, while alcohol misuse predicted chronic aggressive urges and all symptomatic courses of difficulties controlling anger. These findings provide the first known population-based evaluation of the prevalence, course, and risk and protective correlates of hostility in U.S. veterans, and suggest targets for prevention and treatment efforts that can help mitigate risk for hostility in this population. Published by Elsevier Ireland Ltd. C1 [Sippel, Lauren M.; Mota, Natalie P.; Kachadourian, Lorig K.; Krystal, John H.; Southwick, Steven M.; Harpaz-Rotem, Ilan; Pietrzak, Robert H.] US Dept Vet Affairs, Natl Ctr PTSD, VA Connecticut Healthcare Syst, 950 Campbell Ave 15W, West Haven, CT USA. [Sippel, Lauren M.; Mota, Natalie P.; Kachadourian, Lorig K.; Krystal, John H.; Southwick, Steven M.; Harpaz-Rotem, Ilan; Pietrzak, Robert H.] Yale Univ, Sch Med, Dept Psychiat, 333 Cedar St, New Haven, CT USA. [Mota, Natalie P.] Univ Manitoba, Dept Clin Hlth Psychol, Winnipeg, MB, Canada. RP Sippel, LM (reprint author), VA Connecticut Healthcare Syst, Natl Ctr PTSD, 950 Campbell Ave 151D, West Haven, CT 06516 USA. EM lauren.sippel@yale.edu FU Office of Academic Affiliations, Advanced Fellowship Program in Mental Illness Research and Treatment, Department of Veterans Affairs; U. S. Department of Veterans Affairs National Center for Posttraumatic Stress Disorder FX Preparation of this manuscript was supported by the Office of Academic Affiliations, Advanced Fellowship Program in Mental Illness Research and Treatment, Department of Veterans Affairs (regarding the authors Lauren M. Sippel and Lorig K. Kachadourian). The National Health and Resilience in Veterans Study was supported by the U. S. Department of Veterans Affairs National Center for Posttraumatic Stress Disorder and a private donation. The views and opinions expressed in this report are those of the authors and should not be construed to represent the U. S. government. The funding source had no role in study design; in the collection, analysis and interpretation of data; in the writing of the report; or in the decision to submit the paper for publication. NR 55 TC 1 Z9 1 U1 9 U2 9 PU ELSEVIER IRELAND LTD PI CLARE PA ELSEVIER HOUSE, BROOKVALE PLAZA, EAST PARK SHANNON, CO, CLARE, 00000, IRELAND SN 0165-1781 J9 PSYCHIAT RES JI Psychiatry Res. PD SEP 30 PY 2016 VL 243 BP 421 EP 430 DI 10.1016/j.psychres.2016.06.040 PG 10 WC Psychiatry SC Psychiatry GA DW7EA UT WOS:000383812800066 PM 27450745 ER PT J AU Hough, CM Luks, TL Lai, KR Vigil, O Guillory, S Nongpiur, A Fekri, SM Kupferman, E Mathalon, DH Mathews, CA AF Hough, Christina M. Luks, Tracy L. Lai, Karen Vigil, Ofilio Guillory, Sylvia Nongpiur, Arvind Fekri, Shiva M. Kupferman, Eve Mathalon, Daniel H. Mathews, Carol A. TI Comparison of brain activation patterns during executive function tasks in hoarding disorder and non-hoarding OCD SO PSYCHIATRY RESEARCH-NEUROIMAGING LA English DT Article DE Neuroimaging; fMRI; Stroop; Go/No-go; Conflict monitoring; Response inhibition; Hoarding disorder ID OBSESSIVE-COMPULSIVE DISORDER; ANTERIOR CINGULATE CORTEX; VOXEL-BASED MORPHOMETRY; RESPONSE-INHIBITION; COGNITIVE CONTROL; SYMPTOM DIMENSIONS; ERROR-DETECTION; NEURAL MECHANISMS; DECISION-MAKING; GO/NOGO TASK AB We examined differences in regional brain activation during tests of executive function in individuals with Hoarding Disorder (HD), Obsessive Compulsive Disorder (OCD), and healthy controls (HC) using functional magnetic resonance imaging (fMRI). Participants completed computerized versions of the Stroop and Go/No-Go task. We found that during the conflict monitoring and response inhibition condition in the Go/No-Go task, individuals with HD had significantly greater activity than controls in the anterior cingulate cortex (ACC) and right dorsolateral prefrontal cortex (DLPFC). HD also exhibited significantly greater right DLPFC activity than OCD. We also observed significant differences in activity between HD and HC and between HD and OCD in regions (ACC, anterior insula, orbitofrontal cortex, and striatum) involved in evaluating stimulus-response-reward associations, or the personal and task-relevant value of stimuli and behavioral responses to stimuli. These results support the hypothesis that individuals with HD have difficulty deciding on the value or task relevance of stimuli, and may perceive an abnormally high risk of negative feedback for difficult or erroneous cognitive behavior. (C) 2016 Elsevier Ireland Ltd. All rights reserved. C1 [Hough, Christina M.; Lai, Karen; Vigil, Ofilio; Guillory, Sylvia; Fekri, Shiva M.; Kupferman, Eve; Mathalon, Daniel H.; Mathews, Carol A.] Univ Calif San Francisco, Dept Psychiat, UCSF Weill Inst Neurosci, San Francisco, CA USA. [Luks, Tracy L.] Univ Calif San Francisco, Dept Radiol & Biomed Imaging, San Francisco, CA 94143 USA. [Guillory, Sylvia; Mathalon, Daniel H.] San Francisco VA Med Ctr, Dept Psychiat, San Francisco, CA USA. [Nongpiur, Arvind; Mathews, Carol A.] Univ Florida, Dept Psychiat, Gainesville, FL 32611 USA. [Nongpiur, Arvind] North Eastern Indira Gandhi Reg Inst Hlth & Med S, Dept Psychiat, Shillong, Meghalaya, India. [Lai, Karen] Univ Calif Los Angeles, Dept Psychiat & Biobehav Sci, Los Angeles, CA 90024 USA. [Vigil, Ofilio] Univ Calif Davis, Davis, CA 95616 USA. [Guillory, Sylvia] Univ Massachusetts, Dept Psychol, Boston, MA 02125 USA. [Fekri, Shiva M.] Univ Colorado, Dept Psychol, Denver, CO 80202 USA. RP Mathews, CA (reprint author), Univ Florida, Coll Med, 100 S Newell Dr L4-100, Gainesville, FL 32610 USA. EM carolmathews@ufl.edu FU NIMH [R21 MH087748, K08 MH081065, R01 0977669]; Fogarty International Training Program in Chronic Non-Communicable Diseases and Disorders at the University of Florida [1D43TW009120] FX This research was supported by NIMH Grants R21 MH087748, K08 MH081065 and R01 0977669, and a gift from the Althea Foundation. Post-Doctoral support to AN is by the Fogarty International Training Program in Chronic Non-Communicable Diseases and Disorders at the University of Florida, Grant # 1D43TW009120 (Cottler PI). NR 71 TC 0 Z9 0 U1 8 U2 13 PU ELSEVIER IRELAND LTD PI CLARE PA ELSEVIER HOUSE, BROOKVALE PLAZA, EAST PARK SHANNON, CO, CLARE, 00000, IRELAND SN 0925-4927 EI 1872-7506 J9 PSYCHIAT RES-NEUROIM JI Psychiatry Res. Neuroimaging PD SEP 30 PY 2016 VL 255 BP 50 EP 59 DI 10.1016/j.pscychresns.2016.07.007 PG 10 WC Clinical Neurology; Neuroimaging; Psychiatry SC Neurosciences & Neurology; Psychiatry GA DW8VY UT WOS:000383934800007 PM 27522332 ER PT J AU Darcq, E Morisot, N Phamluong, K Warnault, V Jeanblanc, J Longo, FM Massa, SM Ron, D AF Darcq, Emmanuel Morisot, Nadege Phamluong, Khanhky Warnault, Vincent Jeanblanc, Jerome Longo, Frank M. Massa, Stephen M. Ron, Dorit TI The Neurotrophic Factor Receptor p75 in the Rat Dorsolateral Striatum Drives Excessive Alcohol Drinking SO JOURNAL OF NEUROSCIENCE LA English DT Article DE addiction; alcohol; BDNF; dorsal striatum; neurotrophic factor; p75NTR ID NERVE GROWTH-FACTOR; ETHANOL-CONSUMPTION; CORTICOSTRIATAL BDNF; HOMEOSTATIC PATHWAY; GENE POLYMORPHISM; PROTEIN-SYNTHESIS; RNA INTERFERENCE; SERUM-LEVELS; P75(NTR); ACTIVATION AB Brain-derived neurotrophic factor (BDNF) signaling in the dorsolateral striatum (DLS) keeps alcohol intake in moderation. For example, activation of the BDNF receptor tropomyosin receptor kinase B (TrkB) in the DLS reduces intake in rats that consume moderate amounts of alcohol. Here, we tested whether long-term excessive consumption of alcohol produces neuroadaptations in BDNF signaling in the rat DLS. We found that BDNF was no longer able to gate alcohol self-administration after a history of repeated cycles of binge alcohol drinking and withdrawal. We then elucidated the possible neuroadaptations that could block the ability of BDNF to keep consumption of alcohol in moderation. We report that intermittent access to 20% alcohol in a two-bottle choice paradigm that models excessive alcohol drinking produces a mobilization of DLS p75 neurotrophin receptor (p75NTR), whose activities oppose those of the Trk receptors, including TrkB. These neuroadaptations were not observed in the DLS of rats exposed to continuous access to 10% alcohol or in rats consuming sucrose. Furthermore, short hairpin RNA (shRNA)-mediated knockdown of the p75NTR gene in the DLS, as well as intra-DLS infusion or systemic administration of the p75NTR modulator, LM11A-31, significantly reduced binge drinking of alcohol. Together, our results suggest that excessive alcohol consumption produces a change in BDNF signaling in the DLS, which is mediated by the recruitment of p75NTR. Our data also imply that modulators of p75NTR signaling could be developed as medications for alcohol abuse disorders. C1 [Darcq, Emmanuel; Morisot, Nadege; Phamluong, Khanhky; Warnault, Vincent; Jeanblanc, Jerome; Ron, Dorit] Univ Calif San Francisco, Dept Neurol, 675 Nelson Rising Lane,Box 0663, San Francisco, CA 94143 USA. [Longo, Frank M.] Stanford Univ, Dept Neurol & Neurol Sci, Stanford, CA 94305 USA. [Massa, Stephen M.] San Francisco VA Med Ctr, Lab Computat Neurochem & Drug Discovery, San Francisco, CA 94121 USA. [Darcq, Emmanuel] McGill Univ, Douglas Res Ctr, Montreal, PQ H4H 1R3, Canada. [Jeanblanc, Jerome] Univ Picardie Jules Verne, Res Grp Alcohol & Pharmacodependences, INSERM ERI 24, F-80000 Amiens, France. [Warnault, Vincent] Univ Popeu Fabra, Neurobiol Behav Res Grp, Barcelona 08002, Spain. RP Ron, D (reprint author), Univ Calif San Francisco, Dept Neurol, 675 Nelson Rising Lane,Box 0663, San Francisco, CA 94143 USA. EM dorit.ron@ucsf.edu RI warnault, vincent/M-8195-2015 OI warnault, vincent/0000-0002-9812-3791 FU NIAAA [R01 AA016848, R37 AA01684, P50 AA017072]; Jean Perkins Foundation; VA Merit Grant [I01BX000267] FX This work was supported by NIAAA Grants R01 AA016848, R37 AA01684, and P50 AA017072 (D.R.), the Jean Perkins Foundation (F.L.), and VA Merit Grant I01BX000267 (S.M.M.). We thank Samuel Sakhai for reading this manuscript. NR 70 TC 0 Z9 0 U1 3 U2 3 PU SOC NEUROSCIENCE PI WASHINGTON PA 11 DUPONT CIRCLE, NW, STE 500, WASHINGTON, DC 20036 USA SN 0270-6474 J9 J NEUROSCI JI J. Neurosci. PD SEP 28 PY 2016 VL 36 IS 39 BP 10116 EP 10127 DI 10.1523/JNEUROSCI.4597-14.2016 PG 12 WC Neurosciences SC Neurosciences & Neurology GA EC8BB UT WOS:000388363800012 PM 27683907 ER PT J AU Latif, R Realubit, RB Karan, C Mezei, M Davies, TF AF Latif, Rauf Realubit, Ronald B. Karan, Charles Mezei, Mihaly Davies, Terry F. TI TSH Receptor Signaling Abrogation by a Novel Small Molecule SO FRONTIERS IN ENDOCRINOLOGY LA English DT Article DE TSH receptor; small molecule; antagonist ID STIMULATING HORMONE-RECEPTOR; PROTEIN-COUPLED RECEPTOR; HUMAN THYROTROPIN RECEPTOR; CRYSTAL-STRUCTURE; GRAVES-DISEASE; TRANSMEMBRANE DOMAIN; THYROID-FUNCTION; AGONISTS; LOOP; ANTAGONIST AB Pathological activation of the thyroid-stimulating hormone receptor (TSHR) is caused by thyroid-stimulating antibodies in patients with Graves' disease (GD) or by somatic and rare genomic mutations that enhance constitutive activation of the receptor influencing both G protein and non-G protein signaling. Potential selective small molecule antagonists represent novel therapeutic compounds for abrogation of such abnormal TSHR signaling. In this study, we describe the identification and in vitro characterization of a novel small molecule antagonist by high-throughput screening (HTS). The identification of the TSHR antagonist was performed using a transcription-based TSH-inhibition bioassay. TSHR-expressing CHO cells, which also expressed a luciferase-tagged CRE response element, were optimized using bovine TSH as the activator, in a 384 well plate format, which had a Z score of 0.3-0.6. Using this HTS assay, we screened a diverse library of similar to 80,000 compounds at a final concentration of 16.7 mu M. The selection criteria for a positive hit were based on a mean signal threshold of >= 50% inhibition of control TSH stimulation. The screening resulted in 450 positive hits giving a hit ratio of 0.56%. A secondary confirmation screen against TSH and forskolin - a post receptor activator of adenylyl cyclase - confirmed one TSHR-specific candidate antagonist molecule (named VA-K-14). This lead molecule had an IC50 of 12.3 mu M and a unique chemical structure. A parallel analysis for cell viability indicated that the lead inhibitor was non-cytotoxic at its effective concentrations. In silico docking studies performed using a TSHR transmembrane model showed the hydrophobic contact locations and the possible mode of inhibition of TSHR signaling. Furthermore, this molecule was capable of inhibiting TSHR stimulation by GD patient sera and monoclonal-stimulating TSHR antibodies. In conclusion, we report the identification of a novel small molecule TSHR inhibitor, which has the potential to be developed as a therapeutic antagonist for abrogation of TSHR signaling by TSHR autoantibodies in GD. C1 [Latif, Rauf; Davies, Terry F.] Icahn Sch Med Mt Sinai, Thyroid Res Unit, James J Peters VA Med Ctr, New York, NY 10029 USA. [Realubit, Ronald B.; Karan, Charles] Columbia Univ, Sulzberger Columbia Genome Ctr, New York, NY USA. [Mezei, Mihaly] Icahn Sch Med Mt Sinai, Dept Pharmacol Sci, New York, NY 10029 USA. RP Latif, R (reprint author), Icahn Sch Med Mt Sinai, Thyroid Res Unit, James J Peters VA Med Ctr, New York, NY 10029 USA. EM rauf.latif@mssm.edu FU NIH [DK069713]; VA Merit Award [BX000800] FX The authors thank Drs. R. Baliram, Risheng Ma, and Syed A Morshed for critical reading of the manuscript and their comments. The authors also wish to thank Miss Xhensila Hyka from Sulzberger Columbia Genome Center, Columbia University for her technical assistance. This work was supported in part by NIH grant DK069713 & the VA Merit Award BX000800 (to TD). NR 50 TC 0 Z9 0 U1 1 U2 3 PU FRONTIERS MEDIA SA PI LAUSANNE PA PO BOX 110, EPFL INNOVATION PARK, BUILDING I, LAUSANNE, 1015, SWITZERLAND SN 1664-2392 J9 FRONT ENDOCRINOL JI Front. Endocrinol. PD SEP 27 PY 2016 VL 7 AR 130 DI 10.3389/fendo.2016.00130 PG 10 WC Endocrinology & Metabolism SC Endocrinology & Metabolism GA DY8EP UT WOS:000385361900001 PM 27729899 ER PT J AU Krishnasamy, Y Ramshesh, VK Gooz, M Schnellmann, RG Lemasters, JJ Zhong, Z AF Krishnasamy, Yasodha Ramshesh, Venkat K. Gooz, Monika Schnellmann, Rick G. Lemasters, John J. Zhong, Zhi TI Ethanol and High Cholesterol Diet Causes Severe Steatohepatitisand Early Liver Fibrosis in Mice SO PLOS ONE LA English DT Article ID ENDOPLASMIC-RETICULUM STRESS; HEPATIC STELLATE CELLS; MITOCHONDRIAL PERMEABILITY TRANSITION; PROTEIN-CALORIE MALNUTRITION; CYTOCHROME-C-OXIDASE; ALCOHOLIC LIVER; NONALCOHOLIC STEATOHEPATITIS; OXIDATIVE STRESS; UNITED-STATES; UP-REGULATION AB Background and Aim Because ethanol consumption is commonly associated with a high cholesterol diet, we examined whether combined consumption of ethanol and high cholesterol increases liver injury and fibrosis. Methods Male C57BL/6J mice were fed diets containing: 1) 35% of calories from corn oil (CTR), 2) CTR plus 0.5% (w/v) cholesterol (Chol), 3) CTR plus ethanol (27% of calories) (EtOH), or 4) EtOH+Chol for 3 months. Results In mice fed Chol or EtOH alone, ALT increased to similar to 160 U/L, moderate hepatic steatosis occurred, and leukocyte infiltration, necrosis, and apoptosis increased modestly, but no observable fibrosis developed. By contrast in mice fed EtOH+Chol, ALT increased to similar to 270 U/L, steatosis was more extensive and mostly macrovesicular, and expression of proinflammatory molecules (HMGB-1, TLR4, TNF alpha, ICAM-1) and leukocyte infiltration increased substantially. Necrosis and apoptosis also increased. Trichrome staining and second harmonic generation microscopy revealed hepatic fibrosis. Fibrosis was mostly sinusoidal and/or perivenular, but in some mice bridging fibrosis occurred. Expression of smooth muscle alpha-actin and TGF-beta 1 increased slightly by Chol, moderately by EtOH, and markedly by EtOH+Chol. TGF-beta pseudoreceptor BAMBI increased slightly by Chol, remained unchanged by EtOH and decreased by EtOH+Chol. MicroRNA-33a, which enhances TGF-beta fibrotic effects, and phospho-Smad2/3, the down-stream signal of TGF-beta, also increased more greatly by EtOH+Chol than Chol or EtOH. Metalloproteinase-2 and -9 were decreased only by EtOH+Chol. Conclusion High dietary cholesterol and chronic ethanol consumption synergistically increase liver injury, inflammation, and profibrotic responses and suppress antifibrotic responses, leading to severe steatohepatitis and early fibrosis in mice. C1 [Krishnasamy, Yasodha; Ramshesh, Venkat K.; Gooz, Monika; Schnellmann, Rick G.; Lemasters, John J.; Zhong, Zhi] Med Univ South Carolina, Dept Drug Discovery & Biomed Sci, Charleston, SC 29425 USA. [Schnellmann, Rick G.] Ralph H Johnson Vet Affairs Med Ctr, Charleston, SC USA. [Lemasters, John J.] Med Univ South Carolina, Dept Biochem & Mol Biol, Charleston, SC 29425 USA. [Lemasters, John J.] Russian Acad Sci, Inst Theoret & Expt Biophys, Pushchino, Moscow Region, Russia. RP Zhong, Z (reprint author), Med Univ South Carolina, Dept Drug Discovery & Biomed Sci, Charleston, SC 29425 USA. EM Zhong@musc.edu FU National Institutes of Health [AA017756, DK073336, DK037034]; NIH [1P30 CA138313, S10 OD018113, C06 RR015455] FX This work was supported, in part, by Grants AA017756, DK073336 and DK037034 from the National Institutes of Health. The Cell & Molecular Imaging Core of the Hollings Cancer Center at the Medical University of South Carolina supported by NIH Grant 1P30 CA138313 and the Shared Instrumentation Grant S10 OD018113 provided instrumentation and assistance for SHG microscopy. Animals were housed in the Animal Resources at Medical University of South Carolina supported by NIH Grant C06 RR015455. The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript. NR 71 TC 0 Z9 0 U1 4 U2 6 PU PUBLIC LIBRARY SCIENCE PI SAN FRANCISCO PA 1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA SN 1932-6203 J9 PLOS ONE JI PLoS One PD SEP 27 PY 2016 VL 11 IS 9 AR e0163342 DI 10.1371/journal.pone.0163342 PG 20 WC Multidisciplinary Sciences SC Science & Technology - Other Topics GA DX2AT UT WOS:000384169900017 PM 27676640 ER PT J AU Ibrahim, SA Kim, H McConnell, KJ AF Ibrahim, Said A. Kim, Hyunjee McConnell, K. John TI The CMS Comprehensive Care Model and Racial Disparity in Joint Replacement SO JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION LA English DT Editorial Material ID KNEE; ARTHROPLASTY; RACE; HIP C1 [Ibrahim, Said A.] Univ Penn, Perelman Sch Med, Philadelphia, PA 19104 USA. [Ibrahim, Said A.] Philadelphia VA Med Ctr, Ctr Hlth Equ Res & Promot, Philadelphia, PA USA. [Kim, Hyunjee; McConnell, K. John] Oregon Hlth & Sci Univ, Ctr Hlth Syst Effectiveness, Portland, OR 97201 USA. RP Ibrahim, SA (reprint author), Univ Penn, Perelman Sch Med, Ctr Hlth Equ Res & Promot, Philadelphia VA Med Ctr Annex, 3900 Woodland Ave, Philadelphia, PA 19104 USA. EM said.ibrahim2@va.gov FU NIAMS NIH HHS [K24 AR055259] NR 9 TC 0 Z9 0 U1 0 U2 0 PU AMER MEDICAL ASSOC PI CHICAGO PA 330 N WABASH AVE, STE 39300, CHICAGO, IL 60611-5885 USA SN 0098-7484 EI 1538-3598 J9 JAMA-J AM MED ASSOC JI JAMA-J. Am. Med. Assoc. PD SEP 27 PY 2016 VL 316 IS 12 BP 1258 EP 1259 DI 10.1001/jama.2016.12330 PG 2 WC Medicine, General & Internal SC General & Internal Medicine GA DW9EW UT WOS:000383959800014 PM 27653166 ER PT J AU Wizeman, JW Nicholas, AP Ishigami, A Mohan, R AF Wizeman, John W. Nicholas, Anthony P. Ishigami, Akihito Mohan, Royce TI Citrullination of glial intermediate filaments is an early response in retinal injury SO MOLECULAR VISION LA English DT Article ID FIBRILLARY ACIDIC PROTEIN; PEPTIDYLARGININE DEIMINASE; ALZHEIMERS-DISEASE; MULLER CELLS; MACULAR DEGENERATION; MULTIPLE-SCLEROSIS; VIMENTIN; PROLIFERATION; EXPRESSION; ACTIVATION AB Purpose: A hallmark of retinal gliosis is the increased detection and modification of the type III intermediate filament (IF) proteins vimentin and glial fibrillary acidic protein (GFAP). Here, we investigated vimentin and GFAP in Muller glia in a mouse model of alkali injury, focusing on the posttranslational modification of citrullination. Methods: Mice were injured by corneal exposure to 1.0 N NaOH, and eyes were enucleated at different time points following injury. The levels of soluble and cytoskeletal forms of IF proteins and citrullination were measured using western blot analysis. Citrullinated GFAP was identified by immunoprecipitation followed by two-dimensional (2D) isoelectric focusing-polyacrylamide gel electrophoresis (IEF-PAGE) western blotting using a specific antibody that recognizes citrullinated GFAP. Vimentin, GFAP, and citrullinated proteins were localized in the retina by immunohistochemistry (IHC). Drug treatments were investigated in retinal explant cultures of posterior eyecups obtained from mouse eyes that were injured in vivo. Results: Detection of GFAP in injured retinas increased over a period of 1 to 7 days, showing increased levels in both soluble and cytoskeletal forms of this IF protein. The global level of citrullinated proteins was also induced over this period, with low-salt buffer extraction showing the most abundant early changes in citrullination. Using IHC, we found that GFAP filaments assembled at Muller glial end feet, growing in size with time through the inner layers of the retina at 1-3 h postinjury. Interestingly, over this early time period, levels of soluble citrullinated proteins also increased within the retina, as detected by western blotting, coincident with the localization of the citrullinated epitopes on growing GFAP filaments and existing vimentin filaments by 3 h after injury. Taking advantage of the in vivo injury model to promote a robust gliotic response, posterior eyecups from 7-day postinjured eyes were treated in explant cultures with the peptidyl arginine deiminase inhibitor Cl-amidine, which was found to reduce global citrullination. Surprisingly, the detection of injury-induced high-molecular-weight GFAP species containing citrullinated epitopes was also reduced by Cl-amidine treatment. Using a low dose of the potent type III IF drug withaferin A (WFA), we showed that Cl-amidine treatment in combination with WFA reduced global protein citrullination further, suggesting that GFAP may be a key component of pathological citrullinated targets. Conclusions: Our findings illuminate citrullination as a potential novel target for trauma-induced retinal gliosis. We also propose that strategies for combining drugs targeting type III IFs and citrullination may potentiate tissue repair, which is an idea that needs to be validated in vivo. C1 [Wizeman, John W.; Mohan, Royce] Univ Connecticut, Ctr Hlth, Dept Neurosci, 263 Farmington Ave, Farmington, CT 06030 USA. [Nicholas, Anthony P.] Univ Alabama Birmingham, Dept Neurol, UAB Stn, Birmingham, AL 35294 USA. [Nicholas, Anthony P.] Birmingham VA Med Ctr, Birmingham, AL USA. [Ishigami, Akihito] Tokyo Metropolitan Inst Gerontol, Mol Regulat Aging, Tokyo, Japan. RP Mohan, R (reprint author), Univ Connecticut, Ctr Hlth, Dept Neurosci, 263 Farmington Ave, Farmington, CT 06030 USA. EM mohan@uchc.edu FU National Eye Institute/NIH grant [R01EY016782]; John A. and Florence Mattern Solomon Endowed Chair in Vision Biology and Eye Diseases FX This work was supported in part by funding from the National Eye Institute/NIH grant R01EY016782 and from the John A. and Florence Mattern Solomon Endowed Chair in Vision Biology and Eye Diseases. Conflicts of Interest: The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript. Royce Mohan is one of the inventors on US Patent 8,283,323. NR 57 TC 0 Z9 0 U1 1 U2 1 PU MOLECULAR VISION PI ATLANTA PA C/O JEFF BOATRIGHT, LAB B, 5500 EMORY EYE CENTER, 1327 CLIFTON RD, N E, ATLANTA, GA 30322 USA SN 1090-0535 J9 MOL VIS JI Mol. Vis. PD SEP 26 PY 2016 VL 22 BP 1137 EP 1155 PG 19 WC Biochemistry & Molecular Biology; Ophthalmology SC Biochemistry & Molecular Biology; Ophthalmology GA DX7OB UT WOS:000384576500001 PM 27703308 ER PT J AU Johnson, SD Young, MRI AF Johnson, Sara D. Young, M. Rita I. TI Indomethacin Treatment of Mice with Premalignant Oral Lesions Sustains Cytokins Production and Slows Progression to Cancer SO FRONTIERS IN IMMUNOLOGY LA English DT Article DE head and neck cancer; HNSCC; immune; premalignant oral lesions; cytokines; T cell ID SQUAMOUS-CELL CARCINOMA; NECK-CANCER; DENDRITIC CELLS; T-CELLS; CYCLOOXYGENASE-2 EXPRESSION; PROGNOSTIC-SIGNIFICANCE; SUPPRESSOR-CELLS; HEAD; INHIBITION; CELECOXIB AB Current treatment options for head and neck squamous cell carcinoma (HNSCC) patients are often ineffective due to tumor-localized and systemic immunosuppression. Using the 4-NQO mouse model of oral carcinogenesis, this study showed that premalignant oral lesion cells produce higher levels of the immune modulator, PGE2, compared to HNSCC cells. Inhibiting prostaglandin production of premalignant lesion cells with the pan-cyclooxygenase inhibitor indomethacin stimulated their induction of spleen cell cytokine production. In contrast, inhibiting HNSCC prostaglandin production did not stimulate their induction of spleen cell cytokine production. Treatment of mice bearing premalignant oral lesions with indomethacin slowed progression of premalignant oral lesions to HNSCC. Flow cytometric analysis of T cells in the regional lymph nodes of lesion-bearing mice receiving indomethacin treatment showed an increase in lymph node cellularity and in the absolute number of CD8(+) T cells expressing IFN-gamma compared to levels in lesion-bearing mice receiving diluent control treatment. The cytokine-stimulatory effect of indomethacin treatment was not localized to regional lymph nodes but was also seen in the spleen of mice with premalignant oral lesions. Together, these data suggest that inhibiting prostaglandin production at the premalignant lesion stage boosts immune capability and improves clinical outcomes. C1 [Johnson, Sara D.; Young, M. Rita I.] Ralph H Johnson VA Med Ctr, Res Serv, Charleston, SC 29401 USA. [Johnson, Sara D.] Med Univ South Carolina, Dept Pathol & Lab Med, Charleston, SC 29425 USA. [Young, M. Rita I.] Med Univ South Carolina, Dept Otolaryngol Head & Neck Surg, Charleston, SC 29425 USA. RP Young, MRI (reprint author), Ralph H Johnson VA Med Ctr, Res Serv, Charleston, SC 29401 USA.; Young, MRI (reprint author), Med Univ South Carolina, Dept Otolaryngol Head & Neck Surg, Charleston, SC 29425 USA. EM youngmr@musc.edu FU Clinical Sciences Research and Development Program of the Department of Veterans Affairs [I01-CX000851]; National Institutes of Health [RO1-CA128837] FX This work was supported by the Clinical Sciences Research and Development Program (I01-CX000851) of the Department of Veterans Affairs and by grants from the National Institutes of Health (RO1-CA128837) (MY). NR 43 TC 1 Z9 1 U1 2 U2 2 PU FRONTIERS MEDIA SA PI LAUSANNE PA PO BOX 110, EPFL INNOVATION PARK, BUILDING I, LAUSANNE, 1015, SWITZERLAND SN 1664-3224 J9 FRONT IMMUNOL JI Front. Immunol. PD SEP 22 PY 2016 VL 7 AR UNSP 379 DI 10.3389/fimmu.2016.00379 PG 12 WC Immunology SC Immunology GA DW5KM UT WOS:000383683600002 PM 27713748 ER PT J AU Singh, JA Yu, SH AF Singh, Jasvinder A. Yu, Shaohua TI Allopurinol reduces the risk of myocardial infarction (MI) in the elderly: a study of Medicare claims SO ARTHRITIS RESEARCH & THERAPY LA English DT Article DE Allopurinol; Myocardial infarction; MI; Risk factor; Pharmacoepidemiology; Elderly; Predictor; Coronary artery disease; CAD ID IMPROVES ENDOTHELIAL FUNCTION; CHRONIC KIDNEY-DISEASE; CHRONIC HEART-FAILURE; LEFT-VENTRICULAR MASS; XANTHINE-OXIDASE INHIBITION; FREE-RADICAL GENERATION; TERM-FOLLOW-UP; BLOOD-PRESSURE; URIC-ACID; SYSTEMATIC ANALYSIS AB Background: Previous observational studies that have examined the association of allopurinol with myocardial infarction (MI) have provided contradictory results. One study showed that allopurinol reduced the risk, while another study showed an increased risk with allopurinol. Therefore, our objective was to assess whether allopurinol use is associated with a reduction in the risk of MI in the elderly. Method: We used the 2006-2012 5 % random sample of Medicare beneficiaries to study the association of new allopurinol initiation and the risk of incident MI in a cohort study. Multivariable-adjusted Cox regression models adjusted for age, gender, race, and Charlson index, in addition to various cardio-protective medications (beta-blockers, angiotensin-converting enzyme (ACE) inhibitors, diuretics, statins). We calculated hazard ratios (HRs) with 95 % confidence intervals (CIs). Sensitivity analyses adjusted for coronary artery disease (CAD) risk factors, including hypertension, hyperlipidemia, diabetes, and smoking. Results: Of the 29,298 episodes of incident allopurinol use, 1544 were associated with incident MI (5.3 % episodes). Allopurinol use was associated with reduced hazards of MI, with a HR of 0.85 (95 % CI, 0.77 to 0.95). Compared to no allopurinol use, longer durations of allopurinol use were associated with a lower HR of MI: 1-180 days, 0.98 (95 % CI, 0.84 to 1.14); 181 days to 2 years, 0.83 (95 % CI, 0.72 to 0.95); and >2 years, 0.70 (95 % CI, 0.56 to 0.88). Other factors associated with a higher hazard of MI were: age 75 to <85 years and >= 85 years, male gender, higher Charlson index score, and the use of an ACE inhibitor. Adjustment for CAD risk factors confirmed these findings. Conclusion: Incident allopurinol use was associated with a reduction in the risk of incident MI in the elderly. Longer durations of allopurinol use reduced the risk of incident MI incrementally. Future studies should assess the underlying mechanisms for MI prevention and assess the risk-benefit ratio for allopurinol use. C1 [Singh, Jasvinder A.] Birmingham VA Med Ctr, Med Serv, Birmingham, AL 35233 USA. [Singh, Jasvinder A.; Yu, Shaohua] Univ Alabama Birmingham, Sch Med, Dept Med, Fac Off Tower 805B,510 20th St S, Birmingham, AL 35294 USA. [Singh, Jasvinder A.; Yu, Shaohua] Univ Alabama Birmingham, Div Epidemiol, Sch Publ Hlth, Fac Off Tower 805B,510 20th St S, Birmingham, AL 35294 USA. [Singh, Jasvinder A.] Mayo Clin, Coll Med, Dept Orthoped Surg, Rochester, MN USA. RP Singh, JA (reprint author), Birmingham VA Med Ctr, Med Serv, Birmingham, AL 35233 USA.; Singh, JA (reprint author), Univ Alabama Birmingham, Sch Med, Dept Med, Fac Off Tower 805B,510 20th St S, Birmingham, AL 35294 USA.; Singh, JA (reprint author), Univ Alabama Birmingham, Div Epidemiol, Sch Publ Hlth, Fac Off Tower 805B,510 20th St S, Birmingham, AL 35294 USA. EM Jasvinder.md@gmail.com FU UAB Division of Rheumatology FX This material is the result of work supported by research funds from UAB Division of Rheumatology and the resources and use of facilities at the Birmingham VA Medical Center. NR 56 TC 1 Z9 1 U1 2 U2 2 PU BIOMED CENTRAL LTD PI LONDON PA 236 GRAYS INN RD, FLOOR 6, LONDON WC1X 8HL, ENGLAND SN 1478-6354 EI 1478-6362 J9 ARTHRITIS RES THER JI Arthritis Res. Ther. PD SEP 22 PY 2016 VL 18 AR 209 DI 10.1186/s13075-016-1111-1 PG 11 WC Rheumatology SC Rheumatology GA DX3SC UT WOS:000384292200001 ER PT J AU Mirkheshti, N Park, S Jiang, S Cropper, J Werner, SL Song, CS Chatterjee, B AF Mirkheshti, Nooshin Park, Sulgi Jiang, Shoulei Cropper, Jodie Werner, Sherry L. Song, Chung S. Chatterjee, Bandana TI Dual targeting of androgen receptor and mTORC1 by salinomycin in prostate cancer SO ONCOTARGET LA English DT Article DE androgen receptor; CYP17A1; HSD3 beta 1; mTORC1; AMPK ID SERINE 81 PHOSPHORYLATION; CELL-DEATH; INCREASED SURVIVAL; IN-VIVO; AUTOPHAGY; ACTIVATION; GROWTH; AMPK; CASTRATION; PATHWAY AB Androgen receptor (AR) and PI3K/AKT/mTORC1 are major survival signals that drive prostate cancer to a lethal disease. Reciprocal activation of these oncogenic pathways from negative cross talks contributes to low/limited success of pathway-selective inhibitors in curbing prostate cancer progression. We report that the antibiotic salinomycin, a cancer stem cell blocker, is a dual-acting AR and mTORC1 inhibitor, inhibiting PTEN-deficient castration-sensitive and castration-resistant prostate cancer in culture and xenograft tumors. AR expression, its transcriptional activity, and androgen biosynthesis regulating enzymes CYP17A1, HSD3 beta 1 were reduced by sub-micro molar salinomycin. Estrogen receptor-a expression was unchanged. Loss of phosphorylated AR at serine-81, which is an index for nuclear AR activity, preceded total AR reduction. Rapamycin enhanced the AR protein level without altering phosphoAR-Ser81 and CYP17A1. Inactivation of mTORC1, evident from reduced phosphorylation of mTOR and downstream effectors, as well as AMPK activation led to robust autophagy induction. Apoptosis increased modestly, albeit significantly, by sub-micro molar salinomycin. Enhanced stimulatory TSC2 phosphorylation at Ser-1387 by AMPK, and reduced inhibitory TSC2 phosphorylation at Ser-939/Thr-1462 catalyzed by AKT augmented TSC2/TSC1 activity, which led to mTORC1 inhibition. AMPK-mediated raptor phosphorylation further reduced mTOR's kinase function and mTORC1 activity. Our novel finding on dual inhibition of AR and mTORC1 suggests that salinomycin is potentially active as monotherapy against advanced prostate cancer. C1 [Mirkheshti, Nooshin; Park, Sulgi; Jiang, Shoulei; Cropper, Jodie; Song, Chung S.; Chatterjee, Bandana] Univ Texas Hlth Sci Ctr San Antonio, Dept Mol Med, San Antonio, TX 78245 USA. [Werner, Sherry L.] Univ Texas Hlth Sci Ctr San Antonio, Dept Pathol, San Antonio, TX 78245 USA. [Chatterjee, Bandana] South Texas Vet Hlth Care Syst, San Antonio, TX 78229 USA. RP Chatterjee, B (reprint author), Univ Texas Hlth Sci Ctr San Antonio, Dept Mol Med, San Antonio, TX 78245 USA.; Chatterjee, B (reprint author), South Texas Vet Hlth Care Syst, San Antonio, TX 78229 USA. EM chatterjee@uthscsa.edu FU VA Merit-review grant [1I01BX000280]; Research Career Scientist Award from VA; DOD IDEA grant [W81XWH-14-1-0606]; Morrison Trust Foundation [P30-CA054174] FX The study was supported by VA Merit-review grant (1I01BX000280), Research Career Scientist Award from VA (to BC), DOD IDEA grant (W81XWH-14-1-0606) and Morrison Trust Foundation. P30-CA054174 (NIH), awarded to Cancer Therapy & Research Center at UTHSCSA, provided Pathology & FACS Core Services. NR 54 TC 0 Z9 0 U1 1 U2 1 PU IMPACT JOURNALS LLC PI ALBANY PA 6211 TIPTON HOUSE, STE 6, ALBANY, NY 12203 USA SN 1949-2553 J9 ONCOTARGET JI Oncotarget PD SEP 20 PY 2016 VL 7 IS 38 BP 62240 EP 62254 DI 10.18632/oncotarget.11404 PG 15 WC Oncology; Cell Biology SC Oncology; Cell Biology GA EB2CN UT WOS:000387164700107 PM 27557496 ER PT J AU Ahmad, S Varagic, J VonCannon, JL Groban, L Collawn, JF Dell'Italia, LJ Ferrario, CM AF Ahmad, Sarfaraz Varagic, Jasmina VonCannon, Jessica L. Groban, Leanne Collawn, James F. Dell'Italia, Louis J. Ferrario, Carlos M. TI Primacy of cardiac chymase over angiotensin converting enzyme as an angiotensin-(1-12) metabolizing enzyme SO BIOCHEMICAL AND BIOPHYSICAL RESEARCH COMMUNICATIONS LA English DT Article DE Rat cardiac chymase; Angiotensin-converting enzyme; Angiotensin-(1-12); Angiotensin I; Angiotensin II; Renin-angiotensin system ID BLOOD-PRESSURE; II GENERATION; HIGH-GLUCOSE; SYSTEM; HEART; RATS; PROANGIOTENSIN-12; RECEPTOR; PEPTIDE; LOCALIZATION AB We showed previously that rat angiotensin-(1-12) [Ang-(1-12)] is metabolized by chymase and angiotensin converting enzyme (ACE) to generate Angiotensin II (Ang II). Here, we investigated the affinity of cardiac chymase and ACE enzymes for Ang-(1-12) and Angiotensin I (Ang I) substrates. Native plasma membranes (PMs) isolated from heart and lung tissues of adult spontaneously hypertensive rats (SHR) were incubated with radiolabeled I-125-Ang-(1-12) or I-125-Ang I, in the absence or presence of a chymase or ACE inhibitor (chymostatin and lisinopril, respectively). Products were quantitated by HPLC connected to an in-line flow-through gamma detector. The rate of I-125-Ang II formation from I-125-Ang-(1-12) by chymase was significantly higher (heart: 7.0 +/- 0.6 fmol/min/mg; lung: 33 +/- 1.2 fmol/min/mg, P < 0.001) when compared to I-125-Ang I substrate (heart: 0.8 +/- 0.1 fmol/min/mg; lung: 2.1 +/- 0.1 fmol/min/mg). Substrate affinity of I-125-Ang-(1-12) for rat cardiac chymase was also confirmed using excess unlabeled Ang-(1-12) or Ang I (0-250 mu M). The rate of I-125-Ang II formation was significantly lower using unlabeled Ang-(1-12) compared to unlabeled Ang I substrate. Kinetic data showed that rat chymase has a lower K-m (64 +/- 63 mu M vs 142 +/- 17 mu M), higher V-max (132 +/- 1.3 mu M/min/mg vs 1.9 +/- 0.2 mu M/min/mg) and more than 15-fold higher catalytic efficiency (ratio of V-max/K-m) for Ang-(1-12) compared to Ang I substrate, respectively. We also investigated ACE mediated hydrolysis of I-125-Ang-(1-12) and I-125-Ang I in solubilized membrane fractions of the SHR heart and lung. Interestingly, no significant difference in I-125-Ang II formation by ACE was detected using either substrate, I-125-Ang-(1-12) or I-125-Ang I, both in the heart (1.8 +/- 0.2 fmol/min/mg and 1.8 +/- 0.3 fmol/min/mg, respectively) and in the lungs (239 +/- 25 fmol/min/mg and 248 +/- 34 fmol/min/mg, respectively). Compared to chymase, ACE-mediated Ang-(1-12) metabolism in the heart was several fold lower. Overall our findings suggest that Ang-(1-12), not Ang I, is the better substrate for Ang II formation by chymase in adult rats. In addition, this confirms our previous observation that chymase (rather than ACE) is the main hydrolyzing enzyme responsible for Ang II generation from Ang-(1-12) in the adult rat heart. (C) 2016 Elsevier Inc. All rights reserved. C1 [Ahmad, Sarfaraz; Varagic, Jasmina; Ferrario, Carlos M.] Wake Forest Univ, Sch Med, Gen Surg, Winston Salem, NC 27109 USA. [Varagic, Jasmina; VonCannon, Jessica L.; Groban, Leanne] Wake Forest Univ, Sch Med, Hypertens & Vasc Res Ctr, Winston Salem, NC 27109 USA. [Groban, Leanne] Wake Forest Univ, Sch Med, Anesthesiol, Winston Salem, NC 27109 USA. [Groban, Leanne] Wake Forest Univ, Sch Med, Internal Med Mol Med, Winston Salem, NC 27109 USA. [Ferrario, Carlos M.] Wake Forest Univ, Sch Med, Internal Med Nephrol, Winston Salem, NC 27109 USA. [Ferrario, Carlos M.] Wake Forest Univ, Sch Med, Internal Med Cardiovasc Med, Winston Salem, NC 27109 USA. [Collawn, James F.] Univ Alabama Birmingham, Dept Cell Dev & Integrat Biol, Birmingham, AL USA. [Dell'Italia, Louis J.] Univ Alabama Birmingham, Dept Med, Div Cardiovasc Dis, Birmingham VA Med Ctr, Birmingham, AL 35294 USA. RP Ahmad, S (reprint author), Wake Forest Sch Med, Dept Surg, Med Ctr Blvd, Winston Salem, NC 27157 USA. EM sahmad@wakehealth.edu OI Ferrario, Carlos M/0000-0003-0792-6239 FU National Heart, Blood, Lung Institute of the NIH [P01 HL-051952] FX This work was supported by grant from the National Heart, Blood, Lung Institute of the NIH (P01 HL-051952 to CMF). NR 42 TC 1 Z9 1 U1 0 U2 0 PU ACADEMIC PRESS INC ELSEVIER SCIENCE PI SAN DIEGO PA 525 B ST, STE 1900, SAN DIEGO, CA 92101-4495 USA SN 0006-291X EI 1090-2104 J9 BIOCHEM BIOPH RES CO JI Biochem. Biophys. Res. Commun. PD SEP 16 PY 2016 VL 478 IS 2 BP 559 EP 564 DI 10.1016/j.bbrc.2016.07.100 PG 6 WC Biochemistry & Molecular Biology; Biophysics SC Biochemistry & Molecular Biology; Biophysics GA DW3FX UT WOS:000383528600009 PM 27465904 ER PT J AU Zhang, BY Kwon, OJ Henry, G Malewska, A Wei, X Zhang, L Brinkley, W Zhang, YQ Castro, PD Titus, M Chen, R Sayeeduddin, M Raj, GV Mauck, R Roehrborn, C Creighton, CJ Strand, DW Ittmann, MM Xin, L AF Zhang, Boyu Kwon, Oh-Joon Henry, Gervaise Malewska, Alicia Wei, Xing Zhang, Li Brinkley, William Zhang, Yiqun Castro, Patricia D. Titus, Mark Chen, Rui Sayeeduddin, Mohammad Raj, Ganesh V. Mauck, Ryan Roehrborn, Claus Creighton, Chad J. Strand, Douglas W. Ittmann, Michael M. Xin, Li TI Non-Cell-Autonomous Regulation of Prostate Epithelial Homeostasis by Androgen Receptor SO MOLECULAR CELL LA English DT Article ID HYPERPLASIA; INFLAMMATION; CANCER; EXPRESSION; THERAPY; PROLIFERATION; TUMORIGENESIS; FINASTERIDE; METASTASIS; GROWTH AB Prostate inflammation has been suggested as an etiology for benign prostatic hyperplasia (BPH). We show that decreased expression of the androgen receptor (AR) in luminal cells of human BPH specimens correlates with a higher degree of regional prostatic inflammation. However, the cause-and-effect relationship between the two events remains unclear. We investigated specifically whether attenuating AR activity in prostate luminal cells induces inflammation. Disrupting luminal cell AR signaling in mouse models promotes cytokine production cell-autonomously, impairs epithelial barrier function, and induces immune cell infiltration, which further augments local production of cytokines and chemokines including Il-1 and Ccl2. This inflammatory microenvironment promotes AR-independent prostatic epithelial proliferation, which can be abolished by ablating IL-1 signaling or depleting its major cellular source, the macrophages. This study demonstrates that disrupting luminal AR signaling promotes prostate inflammation, which may serve as a mechanism for resistance to androgen-targeted therapy for prostate-related diseases. C1 [Zhang, Boyu; Kwon, Oh-Joon; Wei, Xing; Zhang, Li; Brinkley, William; Xin, Li] Baylor Coll Med, Dept Mol & Cellular Biol, Houston, TX 77030 USA. [Henry, Gervaise; Malewska, Alicia; Raj, Ganesh V.; Mauck, Ryan; Roehrborn, Claus; Strand, Douglas W.] Univ Texas Southwestern Med Ctr Dallas, Dept Urol, Dallas, TX 75390 USA. [Brinkley, William; Zhang, Yiqun; Creighton, Chad J.; Ittmann, Michael M.; Xin, Li] Baylor Coll Med, Dan L Duncan Canc Ctr, Houston, TX 77030 USA. [Castro, Patricia D.; Sayeeduddin, Mohammad; Ittmann, Michael M.; Xin, Li] Baylor Coll Med, Dept Pathol & Immunol, Houston, TX 77030 USA. [Titus, Mark] UT MD Anderson Canc Ctr, Dept Genitourinary Med Oncol, Houston, TX 77030 USA. [Chen, Rui] Baylor Coll Med, Dept Mol & Human Genet, Houston, TX 77030 USA. [Creighton, Chad J.] Baylor Coll Med, Dept Med, Houston, TX 77030 USA. [Ittmann, Michael M.] Michael E DeBakey Dept Vet Affairs Med Ctr, Houston, TX 77030 USA. RP Xin, L (reprint author), Baylor Coll Med, Dept Mol & Cellular Biol, Houston, TX 77030 USA.; Xin, L (reprint author), Baylor Coll Med, Dan L Duncan Canc Ctr, Houston, TX 77030 USA.; Xin, L (reprint author), Baylor Coll Med, Dept Pathol & Immunol, Houston, TX 77030 USA. EM xin@bcm.edu FU NIH [AI036211, CA125123, RR024574, P30 CA125123]; [R01DK092202]; [R01DK107436]; [K01DK098277]; [P20DK097775] FX We thank Ms. Debra Townley and Dr. Vijay Yechoor for help with transmission electron microscopic analysis, Dr. Paul Labhart at Active Motif for helping to analyze AR ChIP-seq results, and Drs. Guido Verhoeven and Karel De Gendt for the AR conditional mice. We thank the technical support from the Cytometry and Cell Sorting Core at Baylor College of Medicine (NIH grants AI036211, CA125123, and RR024574) and the expert assistance of Joel M. Sederstrom. This work is supported by grants R01DK092202 and R01DK107436 (to L.X.), K01DK098277 (to D.S.), P20DK097775 (to M.M.I.), and NIH P30 CA125123 (the Cancer Center Shared Resources Grant). NR 41 TC 1 Z9 1 U1 0 U2 0 PU CELL PRESS PI CAMBRIDGE PA 600 TECHNOLOGY SQUARE, 5TH FLOOR, CAMBRIDGE, MA 02139 USA SN 1097-2765 EI 1097-4164 J9 MOL CELL JI Mol. Cell PD SEP 15 PY 2016 VL 63 IS 6 BP 976 EP 989 DI 10.1016/j.molcel.2016.07.025 PG 14 WC Biochemistry & Molecular Biology; Cell Biology SC Biochemistry & Molecular Biology; Cell Biology GA EE3RN UT WOS:000389514700008 PM 27594448 ER PT J AU Robertson, HT Swenson, ER AF Robertson, H. Thomas Swenson, Erik R. TI True and True, but Not Causally Related SO AMERICAN JOURNAL OF RESPIRATORY AND CRITICAL CARE MEDICINE LA English DT Letter ID HEART-FAILURE; DEAD SPACE; VENTILATION; EXERCISE C1 [Robertson, H. Thomas] Univ Washington, Seattle, WA 98195 USA. [Swenson, Erik R.] Vet Affairs Puget Sound Hlth Care Syst, Seattle, WA USA. RP Robertson, HT (reprint author), Univ Washington, Seattle, WA 98195 USA. NR 6 TC 0 Z9 0 U1 1 U2 1 PU AMER THORACIC SOC PI NEW YORK PA 25 BROADWAY, 18 FL, NEW YORK, NY 10004 USA SN 1073-449X EI 1535-4970 J9 AM J RESP CRIT CARE JI Am. J. Respir. Crit. Care Med. PD SEP 15 PY 2016 VL 194 IS 6 BP 774 EP 775 PG 2 WC Critical Care Medicine; Respiratory System SC General & Internal Medicine; Respiratory System GA DV8WC UT WOS:000383216400026 PM 27628083 ER PT J AU George, MS AF George, Mark S. TI Is Functional Magnetic Resonance Imaging-Inspired Electroencephalogram Feedback the Next New Treatment in Psychiatry? SO BIOLOGICAL PSYCHIATRY LA English DT Editorial Material ID REAL-TIME FMRI C1 [George, Mark S.] Med Univ South Carolina, Dept Psychiat, Brain Stimulat Div, 502N,67 President St, Charleston, SC 29425 USA. [George, Mark S.] Ralph H Johnson Vet Affairs Med Ctr, Charleston, SC USA. RP George, MS (reprint author), Med Univ South Carolina, Dept Psychiat, Brain Stimulat Div, 502N,67 President St, Charleston, SC 29425 USA. EM mgeorge2@mac.com NR 7 TC 0 Z9 0 U1 2 U2 3 PU ELSEVIER SCIENCE INC PI NEW YORK PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA SN 0006-3223 EI 1873-2402 J9 BIOL PSYCHIAT JI Biol. Psychiatry PD SEP 15 PY 2016 VL 80 IS 6 BP 422 EP 423 DI 10.1016/j.biopsych.2016.07.009 PG 2 WC Neurosciences; Psychiatry SC Neurosciences & Neurology; Psychiatry GA DU5OG UT WOS:000382260500007 PM 27565542 ER PT J AU Bryan, CJ Rudd, MD Peterson, AL Young-McCaughan, S Wertenberger, EG AF Bryan, Craig J. Rudd, M. David Peterson, Alan L. Young-McCaughan, Stacey Wertenberger, Evelyn G. TI The ebb and flow of the wish to live and the wish to die among suicidal military personnel SO JOURNAL OF AFFECTIVE DISORDERS LA English DT Article DE Suicide; Military; Brief cognitive behavioral therapy; Suicidal ambivalence ID RANDOMIZED CONTROLLED-TRIAL; BEHAVIORAL THERAPY BCBT; FOLLOW-UP; DEATH AB Background: The relative balance between the wish to live and the wish to die (i.e., suicidal ambivalence) is a robust predictor of suicidal behavior and may be a mechanism underlying the effectiveness of treatments that reduce suicidal behaviors. To date, however, few studies have explored possible mechanisms of action in these treatments. Method: Active duty Soldiers (N=152) with a recent suicide attempt and/or active suicide ideation were randomized to receive brief cognitive behavioral therapy (BCBT) or treatment as usual (TAU). The Suicide Attempt Self-Injury Inventory (Linehan et al., 2006a) was used to assess the incidence of suicide attempts during the 2-year follow-up. The wish to live and the wish to die were assessed with items 1 and 2, respectively, of the Beck Scale for Suicide Ideation (Beck and Steer, 1991). Results: Across both treatments, the wish to live was significantly weaker among patients who attempted suicide but the wish to die was stronger only among patients who attempted suicide in TAU. Among nonattempters, the wish to die stabilized the wish to live, but among attempters the wish to live and the wish to die were not associated with each other. In BCBT the wish to live destabilized the wish to die among nonattempters. Limitations: Self-report methodology, predominantly male sample. Conclusions: The emergence of suicidal behavior is driven primarily by the absence of the wish to live. BCBT is associated with a unique coupling of an ambivalent wish to live and wish to die, which may suggest an underlying mechanism of action. (C) 2016 Elsevier B.V. All rights reserved. C1 [Bryan, Craig J.] Univ Utah, Natl Ctr Vet Studies, 260 S Cent Campus Dr,Room 205, Salt Lake City, UT 84112 USA. [Rudd, M. David] Univ Memphis, Natl Ctr Vet Studies, Memphis, TN 38152 USA. [Peterson, Alan L.] Univ Texas Hlth Sci Ctr San Antonio, South Texas Vet Hlth Care Syst, San Antonio, TX 78229 USA. [Young-McCaughan, Stacey] Univ Texas Hlth Sci Ctr San Antonio, San Antonio, TX 78229 USA. [Wertenberger, Evelyn G.] US Army, MEDDAC, Ft Carson, CO USA. RP Bryan, CJ (reprint author), Univ Utah, Natl Ctr Vet Studies, 260 S Cent Campus Dr,Room 205, Salt Lake City, UT 84112 USA. EM craig.bryan@utah.edu OI Bryan, Craig/0000-0002-9714-0733 FU Department of Defense [W81XWH-09-1-0569] FX This project was supported in part through research funding by the Department of Defense award #W81XWH-09-1-0569 (M. david Rudd, Principal Investigator). The views expressed in this article are solely those of the authors and do not represent the official position or policy of the U.S. Army, the Department of Defense, or the United States Government. NR 23 TC 3 Z9 3 U1 1 U2 6 PU ELSEVIER SCIENCE BV PI AMSTERDAM PA PO BOX 211, 1000 AE AMSTERDAM, NETHERLANDS SN 0165-0327 EI 1573-2517 J9 J AFFECT DISORDERS JI J. Affect. Disord. PD SEP 15 PY 2016 VL 202 BP 58 EP 66 DI 10.1016/j.jad.2016.05.049 PG 9 WC Clinical Neurology; Psychiatry SC Neurosciences & Neurology; Psychiatry GA DS2EH UT WOS:000380555400009 PM 27253218 ER PT J AU Cohen, JR Adams, ZW Menon, SV Youngstrom, EA Bunnell, BE Acierno, R Ruggiero, KJ Danielson, CK AF Cohen, Joseph R. Adams, Zachary W. Menon, Suvarna V. Youngstrom, Eric A. Bunnell, Brian E. Acierno, Ron Ruggiero, Kenneth J. Danielson, Carla Kmett TI How should we screen for depression following a natural disaster? An ROC approach to post-disaster screening in adolescents and adults SO JOURNAL OF AFFECTIVE DISORDERS LA English DT Article DE Depression; Natural disasters; Adolescents; Empirically-based assessment ID POSTTRAUMATIC-STRESS-DISORDER; LATENT PROFILE ANALYSIS; SOCIAL SUPPORT; RISK-FACTORS; GENERAL-POPULATION; NATIONAL SAMPLE; TRAUMATIC EVENT; SYMPTOMS; COMORBIDITY; PTSD AB Background: The present study's aim was to provide the foundation for an efficient, empirically based protocol for depression screening following a natural disaster. Utilizing a Receiver Operating Characteristic (ROC) analytic approach, the study tested a) what specific disaster-related stressors (i.e., property damage, loss of basic services) and individual-related constructs (i.e., PTSD symptoms, trauma history, social support) conveyed the greatest risk for post-natural disaster depression, b) specific cutoff scores across these measures, and c) whether the significance or cutoff scores for each construct varied between adolescents and adults. Methods: Structured phone-based clinical interviews were conducted with 2000 adolescents who lived through a tornado and 1543 adults who survived a hurricane. Results: Findings suggested that in both adolescents and adults, individual-related constructs forecasted greater risk for depressive symptoms following a natural disaster compared to disaster-related stressors. Furthermore, trauma history and PTSD symptoms were particularly strong indicators for adolescent depressive symptoms compared to adult depressive symptoms. Adolescents and adults who reported vulnerable scores for social support, trauma history, and lifetime PTSD symptoms were approximately twice as likely to present as depressed following the natural disaster. Limitations: Findings from the present study were limited to post-disaster assessments and based on self-reported functioning 6-12 months following the natural disaster. Conclusions: The present study synthesizes the extensive body of research on post-disaster functioning by providing a clear framework for which questions may be most important to ask when screening for depression following a natural disaster. (C) 2016 Elsevier B.V. All rights reserved. C1 [Cohen, Joseph R.; Menon, Suvarna V.] Univ Illinois, Dept Psychol, 603 E Daniel St, Champaign, IL 61820 USA. [Adams, Zachary W.; Danielson, Carla Kmett] Med Univ South Carolina, Natl Crime Victims Res & Treatment Ctr, Charleston, SC USA. [Youngstrom, Eric A.] Univ N Carolina, Dept Psychol, Chapel Hill, NC USA. [Bunnell, Brian E.; Acierno, Ron; Ruggiero, Kenneth J.] Med Univ South Carolina, Coll Nursing, Charleston, SC USA. [Acierno, Ron; Ruggiero, Kenneth J.] Ralph H Johnson Vet Adm Med Ctr, Charleston, SC USA. RP Cohen, JR (reprint author), Univ Illinois, Dept Psychol, 603 E Daniel St, Champaign, IL 61820 USA. EM cohenj@illinois.edu FU National Institute of Mental Health [R01MH081056, R21MH086313, MH05220-01A2, T32MH188869]; National Institute of Drug Abuse (NIDA) [R01DA31285, K12-DA031794] FX The National Institute of Mental Health supported this study and the team of collaborators: data collection occurred via Grants R01MH081056 to KJR, R21MH086313 to CKD, and MH05220-01A2 to RA. The National Institute of Drug Abuse (NIDA) sponsored R01DA31285 and K12-DA031794, while the National Institute of Mental Health sponsored T32MH188869. The authors have no conflicts of interest to report. NR 59 TC 0 Z9 0 U1 3 U2 7 PU ELSEVIER SCIENCE BV PI AMSTERDAM PA PO BOX 211, 1000 AE AMSTERDAM, NETHERLANDS SN 0165-0327 EI 1573-2517 J9 J AFFECT DISORDERS JI J. Affect. Disord. PD SEP 15 PY 2016 VL 202 BP 102 EP 109 DI 10.1016/j.jad.2016.05.034 PG 8 WC Clinical Neurology; Psychiatry SC Neurosciences & Neurology; Psychiatry GA DS2EH UT WOS:000380555400014 PM 27259082 ER PT J AU Mufson, EJ Ikonomovic, MD Counts, SE Perez, SE Malek-Ahmadi, M Scheff, SW Ginsberg, SD AF Mufson, Elliott J. Ikonomovic, Milos D. Counts, Scott E. Perez, Sylvia E. Malek-Ahmadi, Michael Scheff, Stephen W. Ginsberg, Stephen D. TI Molecular and cellular pathophysiology of preclinical Alzheimer's disease SO BEHAVIOURAL BRAIN RESEARCH LA English DT Review ID MILD COGNITIVE IMPAIRMENT; POSITRON-EMISSION-TOMOGRAPHY; PITTSBURGH COMPOUND-B; AMYLOID CASCADE HYPOTHESIS; BASAL FOREBRAIN NEURONS; FLORBETAPIR F 18; IN-VIVO; A-BETA; ENTORHINAL CORTEX; FRONTAL-CORTEX AB Although the two pathological hallmarks of Alzheimer's disease (AD), senile plaques composed of amyloid-beta (A beta) peptides and neurofibrillary tangles (NFTs) consisting of hyperphosphorylated tau, have been studied extensively in postmortem AD and relevant animal and cellular models, the pathogenesis of AD remains unknown, particularly in the early stages of the disease where therapies presumably would be most effective. We and others have demonstrated that A beta plaques and NFTs are present in varying degrees before the onset and throughout the progression of dementia. In this regard, aged people with no cognitive impairment (NCI), mild cognitive impairment (MCI, a presumed prodromal AD transitional state, and AD all present at autopsy with varying levels of pathological hallmarks. Cognitive decline, a requisite for the clinical diagnosis of dementia associated with AD, generally correlates better with NFTs than A beta plaques. However, correlations are even higher between cognitive decline and synaptic loss. In this review, we illustrate relevant clinical pathological research in preclinical AD and throughout the progression of dementia in several areas including A beta and tau pathobiology, single population expression profiling of vulnerable hippocampal and basal forebrain neurons, neuroplasticity, neuroimaging, cerebrospinal fluid (CSF) biomarker studies and their correlation with antemortem cognitive endpoints. In each of these areas, we provide evidence for the importance of studying the pathological hallmarks of AD not in isolation, but rather in conjunction with other molecular, cellular, and imaging markers to provide a more systematic and comprehensive assessment of the multiple changes that occur during the transition from NCI to MCI to frank AD. (C) 2016 Elsevier B.V. All rights reserved. C1 [Mufson, Elliott J.; Perez, Sylvia E.] Barrow Neurol Inst, Dept Neurobiol, Phoenix, AZ 85013 USA. [Mufson, Elliott J.; Perez, Sylvia E.] Barrow Neurol Inst, Dept Neurol, Phoenix, AZ 85013 USA. [Ikonomovic, Milos D.] Univ Pittsburgh, Dept Neurol, Pittsburgh, PA 15260 USA. [Ikonomovic, Milos D.] Univ Pittsburgh, Dept Psychiat, Pittsburgh, PA USA. [Ikonomovic, Milos D.] VA Pittsburgh Healthcare Syst, Geriatr Res Educ & Clin Ctr, Pittsburgh, PA USA. [Counts, Scott E.] Mercy Hlth St Marys Hosp, Hauenstien Neurosci Inst, Dept Family Med, Dept Translat Sci & Mol Med, Grand Rapids, MI USA. [Malek-Ahmadi, Michael] Banner Alzheimers Inst, Phoenix, AZ USA. [Scheff, Stephen W.] Univ Kentucky, Sanders Brown Ctr Aging, Lexington, KY 40536 USA. [Ginsberg, Stephen D.] NYU, Langone Med Ctr, Dept Neurosci & Physiol, Ctr Dementia Res,Nathan Kline Inst,Dept Psychiat, Orangeburg, NY USA. RP Mufson, EJ (reprint author), Barrow Neurol Inst, Dept Neurobiol, Phoenix, AZ 85013 USA. EM Elliott.Mufson@dignityhealth.org OI Ginsberg, Stephen /0000-0002-1797-4288; Malek-Ahmadi, Michael/0000-0001-9901-3650 FU NIH [PO1AG14449, RO1AG043375, P30AG010161, PO1 AG107617, R21AG026032, R21AG042146]; Barrow Neurological Institute Barrow and Beyond FX This study was supported by NIH grants PO1AG14449, RO1AG043375, P30AG010161, PO1 AG107617, R21AG026032, R21AG042146, and Barrow Neurological Institute Barrow and Beyond. NR 182 TC 11 Z9 11 U1 25 U2 87 PU ELSEVIER SCIENCE BV PI AMSTERDAM PA PO BOX 211, 1000 AE AMSTERDAM, NETHERLANDS SN 0166-4328 EI 1872-7549 J9 BEHAV BRAIN RES JI Behav. Brain Res. PD SEP 15 PY 2016 VL 311 BP 54 EP 69 DI 10.1016/j.bbr.2016.05.030 PG 16 WC Behavioral Sciences; Neurosciences SC Behavioral Sciences; Neurosciences & Neurology GA DS1XJ UT WOS:000380418200007 PM 27185734 ER PT J AU Tostanoski, LH Chiu, YC Gammon, JM Simon, T Andorko, JI Bromberg, JS Jewell, CM AF Tostanoski, Lisa H. Chiu, Yu-Chieh Gammon, Joshua M. Simon, Thomas Andorko, James I. Bromberg, Jonathan S. Jewell, Christopher M. TI Reprogramming the Local Lymph Node Microenvironment Promotes Tolerance that Is Systemic and Antigen Specific SO CELL REPORTS LA English DT Article ID EXPERIMENTAL AUTOIMMUNE ENCEPHALOMYELITIS; REGULATORY T-CELLS; MULTIPLE-SCLEROSIS; IMMUNE TOLERANCE; DISEASE; CNS; IMMUNOTHERAPY; TRAFFICKING; INDUCTION; DELIVERY AB Many experimental therapies for autoimmune diseases, such as multiple sclerosis (MS), aim to bias T cells toward tolerogenic phenotypes without broad suppression. However, the link between local signal integration in lymph nodes (LNs) and the specificity of systemic tolerance is not well understood. We used intra-LN injection of polymer particles to study tolerance as a function of signals in the LN micro-environment. In a mouse MS model, intra-LN introduction of encapsulated myelin self-antigen and a regulatory signal (rapamycin) permanently reversed paralysis after one treatment during peak disease. Therapeutic effects were myelin specific, required antigen encapsulation, and were less potent without rapamycin. This efficacy was accompanied by local LN reorganization, reduced inflammation, systemic expansion of regulatory T cells, and reduced T cell infiltration to the CNS. Our findings suggest that local control over signaling in distinct LNs can promote cell types and functions that drive tolerance that is systemic but antigen specific. C1 [Tostanoski, Lisa H.; Chiu, Yu-Chieh; Gammon, Joshua M.; Andorko, James I.; Jewell, Christopher M.] Univ Maryland, Fischell Dept Bioengn, 8228 Paint Branch Dr, College Pk, MD 20742 USA. [Simon, Thomas; Bromberg, Jonathan S.] Univ Maryland, Sch Med, Dept Surg, 29 South Greene St, Baltimore, MD 21201 USA. [Simon, Thomas; Bromberg, Jonathan S.] Univ Maryland, Sch Med, Ctr Vasc & Inflammatory Dis, 800 West Baltimore St, Baltimore, MD 21201 USA. [Bromberg, Jonathan S.; Jewell, Christopher M.] Univ Maryland, Sch Med, Dept Microbiol & Immunol, 685 West Baltimore St, Baltimore, MD 21201 USA. [Bromberg, Jonathan S.; Jewell, Christopher M.] Marlene & Stewart Greenebaum Canc Ctr, 22 South Greene St, Baltimore, MD 21201 USA. [Jewell, Christopher M.] US Dept Vet Affairs, 10 North Greene St, Baltimore, MD 21201 USA. RP Jewell, CM (reprint author), Univ Maryland, Fischell Dept Bioengn, 8228 Paint Branch Dr, College Pk, MD 20742 USA.; Jewell, CM (reprint author), Univ Maryland, Sch Med, Dept Microbiol & Immunol, 685 West Baltimore St, Baltimore, MD 21201 USA.; Jewell, CM (reprint author), Marlene & Stewart Greenebaum Canc Ctr, 22 South Greene St, Baltimore, MD 21201 USA.; Jewell, CM (reprint author), US Dept Vet Affairs, 10 North Greene St, Baltimore, MD 21201 USA. EM cmjewell@umd.edu FU National Multiple Sclerosis Society [RG-1501-02968, PP2103]; National Science Foundation (NSF) CAREER Award [1351688]; Maryland Innovation Initiative; NIH [1 R01AI114496-01, T32 CA154274, T32 AI089621]; Alex's Lemonade Stand Foundation; Damon Runyon Foundation [DRR3415]; Young Investigator of the Alliance for Cancer Gene Therapy [15051543]; Melanoma Research Alliance [348963] FX We thank A. Beaven at the University of Maryland Imaging Core Facility. This work was supported in part by the National Multiple Sclerosis Society Award RG-1501-02968 and PP2103, National Science Foundation (NSF) CAREER Award 1351688, the Maryland Innovation Initiative, and NIH 1 R01AI114496-01. L.H.T. is an NSF Graduate Fellow (DGE1322106). Y.-C.C. is a trainee on NIH grant T32 CA154274. J.M.G. is a POST awardee from Alex's Lemonade Stand Foundation. J.I.A. is a trainee on NIH grant T32 AI089621 and a Graduate Fellow of the American Association of Pharmaceutical Scientists. C.M.J. is a Damon Runyon-Rachleff Innovator supported by the Damon Runyon Foundation (DRR3415) and a Young Investigator of the Alliance for Cancer Gene Therapy (15051543) and the Melanoma Research Alliance (348963). NR 36 TC 4 Z9 4 U1 7 U2 7 PU CELL PRESS PI CAMBRIDGE PA 600 TECHNOLOGY SQUARE, 5TH FLOOR, CAMBRIDGE, MA 02139 USA SN 2211-1247 J9 CELL REP JI Cell Reports PD SEP 13 PY 2016 VL 16 IS 11 BP 2940 EP 2952 DI 10.1016/j.celrep.2016.08.033 PG 13 WC Cell Biology SC Cell Biology GA DW8CZ UT WOS:000383882300015 PM 27626664 ER PT J AU Akgun, KM Tate, JP Oursler, KK Crystal, S Leaf, DA Womack, JA Brown, TT Justice, AC Crothers, K AF Akgun, Kathleen M. Tate, Janet P. Oursler, Krisann K. Crystal, Stephen Leaf, David A. Womack, Julie A. Brown, Todd T. Justice, Amy C. Crothers, Kristina TI Association of chronic obstructive pulmonary disease with frailty measurements in HIV-infected and uninfected Veterans SO AIDS LA English DT Article DE adapted frailty-related phenotype; chronic obstructive pulmonary disease; frail; HIV; physical activity ID ANTIRETROVIRAL THERAPY; ELDERLY-PEOPLE; AGING COHORT; RISK-FACTORS; MORTALITY; ADULTS; INDEX; INDIVIDUALS; PHENOTYPE; HEALTH AB Objective: Chronic obstructive pulmonary disease (COPD) prevalence is increasing among aging HIV-infected individuals. We determined the association between COPD and self-reported measures of frailty [adapted frailty-related phenotype (aFRP)] and physical limitation, and a clinical biomarker of physiologic frailty [Veterans Aging Cohort Study (VACS) Index] in HIV-infected compared with uninfected individuals. Design: Cross-sectional study of VACS participants between 2002 and 2012. Methods: Prefrail/aFRP was obtained from self-reported surveys. Prefrail was defined as 1-2 domains of physical shrinking, exhaustion, slowness and low physical activity; aFRP was defined as at least 3 domains. Physical limitation scale was determined from 12 self-reported survey items assessing limitations performing physical activities. VACS index includes age and laboratory measurements. We used regression models to test for associations between COPD and outcomes in models stratified by HIV status. Results: The sample included 3538 HIV-infected and 3606 uninfected participants; 67 and 63% were black (P = 0.0003), 97 and 92% were men (P < 0.0001) and 4 and 5% had COPD (P = 0.2). In unadjusted analyses, COPD was associated with all three outcomes (P < 0.0001). In adjusted analyses, COPD was associated with increased prefrail and aFRP in HIV-infected and uninfected participants (P = 0.01 for all comparisons). COPD was associated with physical limitation in both groups (P < 0.0001). There was an interaction between COPD and physical limitation by HIV status with increased physical limitation among HIV-infected participants (P = 0.04). COPD was not associated with VACS index. Conclusion: COPD was strongly associated with aFRP and physical limitations. COPD management may mediate frailty through functional limitations rather than physiologic biomarkers, especially in HIV-infected individuals. Copyright (C) 2016 Wolters Kluwer Health, Inc. All rights reserved. C1 [Akgun, Kathleen M.; Tate, Janet P.; Justice, Amy C.] VA Connecticut Healthcare Syst, Dept Internal Med, West Haven, CT USA. [Akgun, Kathleen M.; Tate, Janet P.; Justice, Amy C.] Yale Univ, Sch Med, Dept Internal Med, New Haven, CT 06510 USA. [Oursler, Krisann K.] Salem VA Med Ctr, Dept Med, Salem, VA USA. [Oursler, Krisann K.] Virginia Tech Caril SOM, Salem, VA USA. [Crystal, Stephen] Rutgers State Univ, Inst Hlth Healthcare Policy & Aging Res, New Brunswick, NJ USA. [Leaf, David A.] Univ Calif Los Angeles, Sch Med, Dept Med, VA Greater Los Angeles Healthcare Syst, Los Angeles, CA 90024 USA. [Womack, Julie A.] Yale Sch Nursing, New Haven, CT USA. [Womack, Julie A.] VA Connecticut Healthcare Syst, West Haven, CT USA. [Brown, Todd T.] Johns Hopkins Univ, Div Endocrinol Diabet & Metab, Baltimore, MD USA. [Crothers, Kristina] Univ Washington, Sch Med, Dept Med, Seattle, WA 98195 USA. RP Akgun, KM (reprint author), Dept Internal Med, Sect Pulm Crit Care & Sleep Med, 950 Campbell Ave MS11 ACSLG, West Haven, CT 06516 USA. EM kathleen.akgun@yale.edu OI Crothers, Kristina/0000-0001-9702-0371 FU VHA HSRD VISN1 [V1CDA2012-20]; Association of Subspecialty Physicians; CHEST Foundation of the American College of Chest Physicians T. Franklin Williams Award; National Institute on Alcohol Abuse and Alcoholism [5U01AA013566-05]; Agency for Healthcare Research and Quality (AHRQ) [U19HS021112]; National Institutes of Health [R01 HL095136, VHA I01 RX000667]; National Institutes of Health, National Heart, Lung, and Blood Institute [R01 HL090342] FX VHA HSR&D VISN1 Career Development Award V1CDA2012-20 (KMA); Association of Subspecialty Physicians and CHEST Foundation of the American College of Chest Physicians T. Franklin Williams Award (KMA); National Institute on Alcohol Abuse and Alcoholism 5U01AA013566-05 (ACJ); Agency for Healthcare Research and Quality (AHRQ) U19HS021112 (SC); National Institutes of Health, R01 HL095136 and VHA I01 RX000667 (KAO), National Institutes of Health, National Heart, Lung, and Blood Institute R01 HL090342 (K.C.). NR 44 TC 2 Z9 2 U1 2 U2 2 PU LIPPINCOTT WILLIAMS & WILKINS PI PHILADELPHIA PA TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA SN 0269-9370 EI 1473-5571 J9 AIDS JI Aids PD SEP 10 PY 2016 VL 30 IS 14 BP 2185 EP 2193 DI 10.1097/QAD.0000000000001162 PG 9 WC Immunology; Infectious Diseases; Virology SC Immunology; Infectious Diseases; Virology GA DW4FE UT WOS:000383597100007 PM 27191979 ER PT J AU Singh, JA Yu, SH AF Singh, Jasvinder A. Yu, Shaohua TI Allopurinol and the risk of stroke in older adults receiving medicare SO BMC NEUROLOGY LA English DT Article DE Allopurinol; Stroke; Elderly; Medicare; Ischemic stroke; Urate-lowering therapy; Hyperuricemia; Age; Race; Gender ID LEFT-VENTRICULAR MASS; QUALITY-OF-LIFE; IMPROVES ENDOTHELIAL FUNCTION; CHRONIC KIDNEY-DISEASE; CHRONIC HEART-FAILURE; ADMINISTRATIVE DATA; ISCHEMIC-STROKE; DYSFUNCTION; PREVENTION; ADHERENCE AB Background: Previous studies of allopurinol and stroke risk have provided contradictory findings, ranging from a protective effect to an increased risk. Our objective was to assess whether allopurinol use is associated with the risk of stroke in the elderly. Methods: We used the 5 % random sample of Medicare beneficiaries from 2006-2012 to study the association of new allopurinol initiation and incident stroke. We used multivariable-adjusted Cox regression models adjusted for age, gender, race, Charlson index, and cardio-protective medications (beta-blockers, ACE inhibitors, diuretics, statins) to calculate hazards ratio (HR) with 95 % confidence intervals (CI). Sensitivity analyses adjusted for coronary artery disease (CAD) risk factors including hypertension, hyperlipidemia, diabetes, and smoking instead of Charlson index. Results: Among 28,488 eligible episodes of incident allopurinol, 2,177 ended in incident stroke (7.6 % episodes). In multivariable-adjusted analyses, allopurinol use was associated with 9 % lower hazard ratio for stoke, 0.91 (95 % CI, 0.83 to 0.99). Compared to no allopurinol use, allopurinol use durations of 181 days to 2 years, 0.88 (95 % CI, 0.78 to 0.99) and > 2 years, 0.79 (95 % CI, 0.65 to 0.96) were significantly associated with lower multivariable-adjusted hazard of stroke. Sensitivity analyses adjusted for CAD risk factors confirmed these findings. In subgroup analyses, significant associations were noted between allopurinol use and the risk of ischemic stroke, 0.89 (95 % CI, 0.81 to 0.98); associations were not significant for hemorrhagic stroke, 1.01 (95 % CI, 0.79 to 1.29). Conclusions: Allopurinol use is associated with lower risk of stroke overall, more specifically ischemic stroke. This association is evident after 6-months of allopurinol use, and the hazard reduction increases with longer duration of use. Future studies need to examine underlying mechanisms. C1 [Singh, Jasvinder A.] Birmingham VA Med Ctr, Med Serv, Birmingham, AL USA. [Singh, Jasvinder A.; Yu, Shaohua] Univ Alabama Birmingham UAB, Sch Med, Dept Med, Birmingham, AL 35294 USA. [Singh, Jasvinder A.] Univ Alabama Birmingham UAB, Sch Publ Hlth, Div Epidemiol, Birmingham, AL 35294 USA. [Singh, Jasvinder A.] Mayo Clin, Dept Orthoped Surg, Coll Med, Rochester, MN 55905 USA. [Singh, Jasvinder A.] Univ Alabama Birmingham, Fac Off Tower 805B,510 20th St S, Birmingham, AL 35294 USA. RP Singh, JA (reprint author), Birmingham VA Med Ctr, Med Serv, Birmingham, AL USA.; Singh, JA (reprint author), Univ Alabama Birmingham UAB, Sch Med, Dept Med, Birmingham, AL 35294 USA.; Singh, JA (reprint author), Univ Alabama Birmingham UAB, Sch Publ Hlth, Div Epidemiol, Birmingham, AL 35294 USA.; Singh, JA (reprint author), Mayo Clin, Dept Orthoped Surg, Coll Med, Rochester, MN 55905 USA.; Singh, JA (reprint author), Univ Alabama Birmingham, Fac Off Tower 805B,510 20th St S, Birmingham, AL 35294 USA. EM Jasvinder.md@gmail.com FU Division of Rheumatology at the University of Alabama at Birmingham FX This material is the result of work supported by research funds from the Division of Rheumatology at the University of Alabama at Birmingham and the resources and use of facilities at the Birmingham VA Medical Center, Birmingham, Alabama, USA. The funding body did not play any role in design, in the collection, analysis, and interpretation of data; in the writing of the manuscript; and in the decision to submit the manuscript for publication. NR 40 TC 2 Z9 2 U1 2 U2 2 PU BIOMED CENTRAL LTD PI LONDON PA 236 GRAYS INN RD, FLOOR 6, LONDON WC1X 8HL, ENGLAND SN 1471-2377 J9 BMC NEUROL JI BMC Neurol. PD SEP 7 PY 2016 VL 16 AR 164 DI 10.1186/s12883-016-0692-2 PG 9 WC Clinical Neurology SC Neurosciences & Neurology GA DX6KB UT WOS:000384491500001 PM 27604082 ER PT J AU Vistamehr, A Kautz, SA Bowden, MG Neptune, RR AF Vistamehr, Arian Kautz, Steven A. Bowden, Mark G. Neptune, Richard R. TI Correlations between measures of dynamic balance in individuals with post-stroke hemiparesis (vol 49, pg 396, 2016) SO JOURNAL OF BIOMECHANICS LA English DT Correction C1 [Vistamehr, Arian] Brooks Rehabil Hosp, Mot Anal Ctr, Jacksonville, FL USA. [Kautz, Steven A.; Bowden, Mark G.] Ralph H Johnson VA Med Ctr, Charleston, SC USA. [Kautz, Steven A.; Bowden, Mark G.] Med Univ South Carolina, Dept Hlth Sci & Res, Charleston, SC USA. [Kautz, Steven A.; Bowden, Mark G.] Med Univ South Carolina, Div Phys Therapy, Charleston, SC USA. [Neptune, Richard R.] Univ Texas Austin, Dept Mech Engn, 204 E Dean Keeton St,Stop C2200, Austin, TX 78712 USA. RP Neptune, RR (reprint author), Univ Texas Austin, Dept Mech Engn, 204 E Dean Keeton St,Stop C2200, Austin, TX 78712 USA. EM rneptune@mail.utexas.edu NR 1 TC 0 Z9 0 U1 0 U2 0 PU ELSEVIER SCI LTD PI OXFORD PA THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, OXON, ENGLAND SN 0021-9290 EI 1873-2380 J9 J BIOMECH JI J. Biomech. PD SEP 6 PY 2016 VL 49 IS 13 BP 3127 EP 3127 DI 10.1016/j.jbiomech.2016.08.001 PG 1 WC Biophysics; Engineering, Biomedical SC Biophysics; Engineering GA DY9RH UT WOS:000385472300082 PM 27515439 ER PT J AU Cusi, K Orsak, B Bril, F Lomonaco, R Hecht, J Ortiz-Lopez, C Tio, F Hardies, J Darland, C Musi, N Webb, A Portillo-Sanchez, P AF Cusi, Kenneth Orsak, Beverly Bril, Fernando Lomonaco, Romina Hecht, Joan Ortiz-Lopez, Carolina Tio, Fermin Hardies, Jean Darland, Celia Musi, Nicolas Webb, Amy Portillo-Sanchez, Paola TI Long-Term Pioglitazone Treatment for Patients With Nonalcoholic Steatohepatitis and Prediabetes or Type 2 Diabetes Mellitus A Randomized Trial SO ANNALS OF INTERNAL MEDICINE LA English DT Article ID FATTY LIVER-DISEASE; PLACEBO-CONTROLLED TRIAL; INSULIN-RESISTANCE; BLADDER-CANCER; AMINOTRANSFERASE LEVELS; HEPATIC STEATOSIS; NATURAL-HISTORY; RISK; PREVALENCE; NAFLD AB Background: The metabolic defects of nonalcoholic steatohepatitis (NASH) and prediabetes or type 2 diabetes mellitus (T2DM) seem to be specifically targeted by pioglitazone. However, information about its long-term use in this population is limited. Objective: To determine the efficacy and safety of long-term pioglitazone treatment in patients with NASH and prediabetes or T2DM. Design: Randomized, double-blind, placebo-controlled trial. (ClinicalTrials. gov: NCT00994682) Setting: University hospital. Participants: Patients (n = 101) with prediabetes or T2DM and biopsy-proven NASH were recruited from the general population and outpatient clinics. Intervention: All patients were prescribed a hypocaloric diet (500-kcal/d deficit from weight-maintaining caloric intake) and then randomly assigned to pioglitazone, 45 mg/d, or placebo for 18 months, followed by an 18-month open-label phase with pioglitazone treatment. Measurements: The primary outcome was a reduction of at least 2 points in the nonalcoholic fatty liver disease activity score in 2 histologic categories without worsening of fibrosis. Secondary outcomes included other histologic outcomes, hepatic triglyceride content measured by magnetic resonance and proton spectroscopy, and metabolic parameters. Results: Among patients randomly assigned to pioglitazone, 58% achieved the primary outcome (treatment difference, 41 percentage points [95% CI, 23 to 59 percentage points]) and 51% had resolution of NASH (treatment difference, 32 percentage points [CI, 13 to 51 percentage points]) (P < 0.001 for each). Pioglitazone treatment also was associated with improvement in individual histologic scores, including the fibrosis score (treatment difference, -0.5 [CI, -0.9 to 0.0]; P = 0.039); reduced hepatic triglyceride content from 19% to 7% (treatment difference, -7 percentage points [CI, -10 to -4 percentage points]; P < 0.001); and improved adipose tissue, hepatic, and muscle insulin sensitivity (P < 0.001 vs. placebo for all). All 18-month metabolic and histologic improvements persisted over 36 months of therapy. The overall rate of adverse events did not differ between groups, although weight gain was greater with pioglitazone (2.5 kg vs. placebo). Limitation: Single-center study. Conclusion: Long-term pioglitazone treatment is safe and effective in patients with prediabetes or T2DM and NASH. C1 [Cusi, Kenneth; Bril, Fernando; Lomonaco, Romina; Portillo-Sanchez, Paola] Univ Florida, 1600 SW Archer Rd,Room H-2, Gainesville, FL 32610 USA. Malcom Randall Vet Affairs Med Ctr, Gainesville, FL USA. [Orsak, Beverly; Hecht, Joan; Ortiz-Lopez, Carolina; Tio, Fermin; Hardies, Jean; Darland, Celia; Musi, Nicolas; Webb, Amy] Univ Texas Hlth Sci Ctr San Antonio, 7703 Floyd Curl Dr,DTL Room 3-380S, San Antonio, TX 78229 USA. Audie L Murphy Vet Adm Med Ctr, San Antonio, TX USA. RP Cusi, K (reprint author), Univ Florida, 1600 SW Archer Rd,Room H-2, Gainesville, FL 32610 USA.; Cusi, K (reprint author), Univ Florida, Div Endocrinol Diabet & Metab, Med, 1600 SW Archer Rd,Room H-2, Gainesville, FL 32610 USA. EM Kenneth.Cusi@medicine.ufl.edu FU Burroughs Wellcome Fund [1006762.01]; American Diabetes Association [1-08-CR-08]; National Center for Research Resources [MO1-RR-01346]; UTHSCSA Clinical Research Center and Research Imaging Center; Veterans Affairs Medical Research Fund FX By the Burroughs Wellcome Fund (1006762.01 [Dr. Cusi]) and the American Diabetes Association (1-08-CR-08 [Dr. Cusi]). Additional support was provided by the National Center for Research Resources (MO1-RR-01346), the UTHSCSA Clinical Research Center and Research Imaging Center, and the Veterans Affairs Medical Research Fund. NR 56 TC 26 Z9 26 U1 6 U2 8 PU AMER COLL PHYSICIANS PI PHILADELPHIA PA INDEPENDENCE MALL WEST 6TH AND RACE ST, PHILADELPHIA, PA 19106-1572 USA SN 0003-4819 EI 1539-3704 J9 ANN INTERN MED JI Ann. Intern. Med. PD SEP 6 PY 2016 VL 165 IS 5 BP 305 EP + DI 10.7326/M15-1774 PG 20 WC Medicine, General & Internal SC General & Internal Medicine GA DV3BC UT WOS:000382795000001 PM 27322798 ER PT J AU Dooley, DP Brown, TM AF Dooley, David P. Brown, Thomas M. TI Alcohol Use SO ANNALS OF INTERNAL MEDICINE LA English DT Letter C1 [Dooley, David P.; Brown, Thomas M.] Univ Texas Hlth Sci Ctr San Antonio, San Antonio, TX 78229 USA. [Dooley, David P.; Brown, Thomas M.] Audie L Murphy Vet Affairs Med Ctr, San Antonio, TX USA. RP Dooley, DP (reprint author), Univ Texas Hlth Sci Ctr San Antonio, San Antonio, TX 78229 USA. NR 3 TC 0 Z9 0 U1 0 U2 0 PU AMER COLL PHYSICIANS PI PHILADELPHIA PA INDEPENDENCE MALL WEST 6TH AND RACE ST, PHILADELPHIA, PA 19106-1572 USA SN 0003-4819 EI 1539-3704 J9 ANN INTERN MED JI Ann. Intern. Med. PD SEP 6 PY 2016 VL 165 IS 5 BP 379 EP 379 DI 10.7326/L16-0108 PG 1 WC Medicine, General & Internal SC General & Internal Medicine GA DV3BC UT WOS:000382795000015 PM 27595224 ER PT J AU Bates, ER Tamis-Holland, JE Bittl, JA O'Gara, PT Levine, GN AF Bates, Eric R. Tamis-Holland, Jacqueline E. Bittl, John A. O'Gara, Patrick T. Levine, Glenn N. TI PCI Strategies in Patients With ST-Segment Elevation Myocardial Infarction and Multivessel Coronary Artery Disease SO JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY LA English DT Review DE myocardial ischemia; myocardial revascularization; outcome assessment ID MULTI-VESSEL DISEASE; IMMEDIATE COMPLETE REVASCULARIZATION; CULPRIT-ONLY REVASCULARIZATION; RANDOMIZED CONTROLLED-TRIALS; 2013 ACCF/AHA GUIDELINE; PRIMARY ANGIOPLASTY; CLINICAL-OUTCOMES; INTERVENTION STRATEGIES; NONCULPRIT ARTERIES; STEMI PATIENTS AB Recent randomized controlled trials have suggested that patients with ST-segment elevation myocardial infarction and multivessel coronary artery disease may benefit more from multivessel percutaneous coronary intervention (PCI) compared with culprit vessel-only primary PCI. The American College of Cardiology, American Heart Association, and Society for Cardiovascular Angiography and Interventions recently published an updated recommendation on this topic. The purpose of this State-of-the-Art Review is to accurately document existing published reports, describe their limitations, and establish a base for future studies. (C) 2016 by the American College of Cardiology Foundation. C1 [Bates, Eric R.] Univ Michigan, Med Ctr, Dept Internal Med, Div Cardiovasc Dis, Ann Arbor, MI 48109 USA. [Tamis-Holland, Jacqueline E.] Mt Sinai St Lukes Hosp, Dept Internal Med, Div Cardiol, New York, NY USA. [Bittl, John A.] Munroe Reg Med Ctr, Munroe Heart & Vasc Inst, Ocala, FL USA. [O'Gara, Patrick T.] Brigham & Womens Hosp, Dept Internal Med, Div Cardiovasc, 75 Francis St, Boston, MA 02115 USA. [Levine, Glenn N.] Baylor Coll Med, Michael E DeBakey Med Ctr, Cardiol Sect, Houston, TX 77030 USA. RP Bates, ER (reprint author), CVC Cardiovasc Med, 1500 East Med Ctr Dr, Ann Arbor, MI 48109 USA. EM ebates@umich.edu NR 100 TC 2 Z9 2 U1 2 U2 2 PU ELSEVIER SCIENCE INC PI NEW YORK PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA SN 0735-1097 EI 1558-3597 J9 J AM COLL CARDIOL JI J. Am. Coll. Cardiol. PD SEP 6 PY 2016 VL 68 IS 10 BP 1066 EP 1081 DI 10.1016/j.jacc.2016.05.086 PG 16 WC Cardiac & Cardiovascular Systems SC Cardiovascular System & Cardiology GA DU6GX UT WOS:000382313500012 PM 27585512 ER PT J AU Levitan, EB Graham, LA Valle, JA Richman, JS Hollis, R Holcomb, CN Maddox, TM Hawn, MT AF Levitan, Emily B. Graham, Laura A. Valle, Javier A. Richman, Joshua S. Hollis, Robert Holcomb, Carla N. Maddox, Thomas M. Hawn, Mary T. TI Pre-operative echocardiography among patients with coronary artery disease in the United States Veterans Affairs healthcare system: A retrospective cohort study SO BMC CARDIOVASCULAR DISORDERS LA English DT Article DE Echocardiography; Surgery; Major adverse cardiac events ID NONCARDIAC SURGERY; ASSOCIATION; POPULATION; RISK AB Background: Echocardiography is not recommended for routine pre-surgical evaluation but may have value for patients at high risk of major adverse cardiovascular events (MACE). The objective of this study was to evaluate whether pre-operative echocardiography is associated with lower risk of post-operative MACE among patients with coronary artery disease. Methods: Using administrative and registry data, we examined associations of echocardiography within 3 months prior to surgery with postoperative MACE (myocardial infarction, revascularization, or death within 30 days) among patients with coronary artery disease undergoing elective, non-cardiac surgeries in the United States Veterans Affairs healthcare system in 2000-2012. Results: Echocardiography preceded 4,378 (16.4 %) of 26,641 surgeries. MACE occurred within 30 days following 944 (3.5 %) surgeries. A 10 % higher case-mix adjusted rate of pre-operative echocardiography assessed at the hospital level was associated with a hospital-level risk of MACE that was 1.0 % (95 % confidence interval [CI] 0.1 %, 2.0 %) higher overall and 1.7 % (95 % CI 0.2 %, 3.2 %) higher among patients with recent myocardial infarction, valvular heart disease, or heart failure. At the patient level, pre-operative echocardiography was associated with an odds ratio for MACE of 1.9 (95 % CI 1.7, 2.2) overall and 1.8 (95 % CI 1.5, 2.2) among patients with recent myocardial infarction, valvular heart disease, or heart failure adjusting for MACE risk factors. Conclusions: Pre-operative echocardiography was not associated with lower risk of post-operative MACE, even in a high risk population. Future guidelines should encourage pre-operative echocardiography only in specific patients with cardiovascular disease among whom findings can be translated into effective changes in care. C1 [Levitan, Emily B.; Graham, Laura A.] Univ Alabama Birmingham, Dept Epidemiol, Birmingham, AL 35294 USA. [Levitan, Emily B.; Graham, Laura A.; Richman, Joshua S.; Hollis, Robert; Holcomb, Carla N.; Hawn, Mary T.] Birmingham Vet Affairs Med Ctr, Birmingham, AL 35233 USA. [Valle, Javier A.; Maddox, Thomas M.] Univ Colorado, Div Cardiol, Denver, CO 80202 USA. [Richman, Joshua S.; Hollis, Robert; Holcomb, Carla N.] Univ Alabama Birmingham, Dept Surg, Birmingham, AL 35294 USA. [Maddox, Thomas M.] Vet Affairs Eastern Colorado Hlth Care Syst, Denver, CO USA. [Hawn, Mary T.] Stanford Univ, Dept Surg, Stanford, CA 94305 USA. RP Levitan, EB (reprint author), Univ Alabama Birmingham, Dept Epidemiol, Birmingham, AL 35294 USA.; Levitan, EB (reprint author), Birmingham Vet Affairs Med Ctr, Birmingham, AL 35233 USA. EM elevitan@uab.edu FU United States VA Health Services Research & Development grant [IIR 09-347]; VA Career Development Awards FX This study was supported by a United States VA Health Services Research & Development grant (No. IIR 09-347). In addition, Drs Maddox and Richman are supported by VA Career Development Awards. The funding agency did not have a role in the design of the study and collection, analysis, and interpretation of data or in writing the manuscript. NR 18 TC 0 Z9 0 U1 2 U2 2 PU BIOMED CENTRAL LTD PI LONDON PA 236 GRAYS INN RD, FLOOR 6, LONDON WC1X 8HL, ENGLAND SN 1471-2261 J9 BMC CARDIOVASC DISOR JI BMC Cardiovasc. Disord. PD SEP 5 PY 2016 VL 16 AR 173 DI 10.1186/s12872-016-0357-5 PG 9 WC Cardiac & Cardiovascular Systems SC Cardiovascular System & Cardiology GA DV8SR UT WOS:000383207500001 PM 27596717 ER PT J AU Makarov, DV Sedlander, E Braithwaite, RS Sherman, SE Zeliadt, S Gross, CP Curnyn, C Shedlin, M AF Makarov, Danil V. Sedlander, Erica Braithwaite, R. Scott Sherman, Scott E. Zeliadt, Steven Gross, Cary P. Curnyn, Caitlin Shedlin, Michele TI A qualitative study to understand guideline-discordant use of imaging to stage incident prostate cancer SO IMPLEMENTATION SCIENCE LA English DT Article DE Theoretical domains framework; Prostate cancer; Imaging; Guideline; Qualitative; Semi-structured interviews ID THEORETICAL DOMAINS FRAMEWORK; PRIMARY-CARE; BONE-SCAN; TRENDS; IMPLEMENTATION; APPROPRIATE; RECOMMENDATIONS; STRATEGIES; MANAGEMENT; ADHERENCE AB Background: Approximately half of veterans with low-risk prostate cancer receive guideline-discordant imaging. Our objective was to identify and describe (1) physician knowledge, attitudes, and practices related to the use of imaging to stage prostate cancer, (2) patient attitudes and behaviors related to use of imaging, and (3) to compare responses across three VA medical centers (VAMCs). Methods: A qualitative approach was used to explore patient and provider knowledge and behaviors relating to the use of imaging. We conducted 39 semi-structured interviews total-including 22 interviews with patients with newly diagnosed with prostate cancer and 17 interviews with physicians caring for them-between September 2014 and July 2015 at three VAMCs representing a spectrum of inappropriate imaging rates. After core theoretical concepts were identified, the Theoretical Domains Framework (TDF) was selected to explore linkages between themes within the dataset and existing domains within the framework. Interviews were audio-recorded, transcribed verbatim, and then coded and analyzed using Nvivo software. Results: Themes from patient interviews were categorized within four TDF domains. Patients reported little interest in staging as compared to disease treatment (goals), and many could not remember if they had imaging at all (knowledge). Patients tended to trust their doctor to make decisions about appropriate tests (beliefs about capabilities). Some patients expressed a minor concern for radiation exposure, but anxiety about cancer outcomes outweighed these fears (emotion). Themes from physician interviews were categorized within five TDF domains. Most physicians self-reported that they know and trust imaging guidelines (knowledge) yet some were still likely to follow their own intuition, whether due to clinical suspicion or years of experience (beliefs about capabilities). Additionally, physicians reported that medico-legal concerns, fear of missing associated diagnoses (beliefs about consequences), influence from colleagues who image frequently (social influences), and the facility where they practice influences rates of imaging (environmental context). Conclusions: Interviews with patients and physicians suggest that physicians are the primary (and in some cases only) decision-makers regarding staging imaging for prostate cancer. This finding suggests a physician-targeted intervention may be the most effective strategy to improve guideline-concordant prostate cancer imaging. C1 [Makarov, Danil V.; Sherman, Scott E.] VA New York Harbor Healthcare Syst, 423 E 23rd St, New York, NY 10010 USA. [Makarov, Danil V.; Sedlander, Erica; Curnyn, Caitlin] NYU, Langone Med Ctr, Dept Urol, 150 E 32nd St, New York, NY 10016 USA. [Makarov, Danil V.; Sedlander, Erica; Braithwaite, R. Scott; Sherman, Scott E.; Curnyn, Caitlin] NYU, Langone Med Ctr, Dept Populat Hlth, 550 First Ave, New York, NY USA. [Zeliadt, Steven] VA Puget Sound Healthcare Syst, 1600 S Columbian Way, Seattle, WA USA. [Gross, Cary P.] Yale Sch Med, Dept Internal Med, ES Harkness Mem Hall,367 Cedar St, New Haven, CT USA. [Shedlin, Michele] NYU, Coll Nursing, 433 First Ave, New York, NY USA. RP Makarov, DV (reprint author), VA New York Harbor Healthcare Syst, 423 E 23rd St, New York, NY 10010 USA.; Makarov, DV (reprint author), NYU, Langone Med Ctr, Dept Urol, 150 E 32nd St, New York, NY 10016 USA. EM Danil.Makarov@nyumc.org OI Makarov, Danil/0000-0002-0565-9272; Sherman, Scott/0000-0003-1752-7303 FU United States Department of Veterans Affairs; Veterans Health Administration; Health Services Research and Development Service FX Funding for this study was provided by the United States Department of Veterans Affairs, Veterans Health Administration, and Health Services Research and Development Service. NR 55 TC 0 Z9 0 U1 1 U2 1 PU BIOMED CENTRAL LTD PI LONDON PA 236 GRAYS INN RD, FLOOR 6, LONDON WC1X 8HL, ENGLAND SN 1748-5908 J9 IMPLEMENT SCI JI Implement. Sci. PD SEP 2 PY 2016 VL 11 AR 118 DI 10.1186/s13012-016-0484-5 PG 12 WC Health Care Sciences & Services; Health Policy & Services SC Health Care Sciences & Services GA DV4SS UT WOS:000382916000001 PM 27590603 ER PT J AU Miller, MR Davidson, EH Wang, EW Yu, JY Fernandez-Miranda, JC Wang, DJ Schuman, JS Washington, KM AF Miller, Maxine R. Davidson, Edward H. Wang, Eric W. Yu, Jenny Ying Fernandez-Miranda, Juan C. Wang, Dawn J. Schuman, Joel S. Washington, Kia M. TI Total Human Eye Allotransplantation (THEA): Preclincal Cadaveric Studies SO INVESTIGATIVE OPHTHALMOLOGY & VISUAL SCIENCE LA English DT Meeting Abstract CT Annual Meeting of the Association-for-Research-in-Vision-and-Ophthalmology (ARVO) CY MAY 01-05, 2016 CL Seattle, WA SP Assoc Res Vis & Ophthalmol C1 [Miller, Maxine R.; Davidson, Edward H.; Wang, Dawn J.; Washington, Kia M.] Univ Pittsburgh, Dept Plast Surg, Pittsburgh, PA USA. [Miller, Maxine R.; Yu, Jenny Ying; Schuman, Joel S.] Univ Pittsburgh, Dept Ophthalmol, Pittsburgh, PA 15260 USA. [Wang, Eric W.] Univ Pittsburgh, Dept Otolaryngol, Pittsburgh, PA 15260 USA. [Fernandez-Miranda, Juan C.] Univ Pittsburgh, Dept Neurosurg, Pittsburgh, PA USA. [Schuman, Joel S.] Univ Pittsburgh, Swanson Sch Engn, Dept Bioengn, Pittsburgh, PA USA. [Washington, Kia M.] VA Pittsburgh Healtcare Syst, Pittsburgh, PA USA. FU [5T32 EY017271-07] FX 5T32 EY017271-07 NR 0 TC 0 Z9 0 U1 0 U2 0 PU ASSOC RESEARCH VISION OPHTHALMOLOGY INC PI ROCKVILLE PA 12300 TWINBROOK PARKWAY, ROCKVILLE, MD 20852-1606 USA SN 0146-0404 EI 1552-5783 J9 INVEST OPHTH VIS SCI JI Invest. Ophthalmol. Vis. Sci. PD SEP PY 2016 VL 57 IS 12 MA 707 PG 3 WC Ophthalmology SC Ophthalmology GA EK8LA UT WOS:000394174002127 ER PT J AU Rohrer, B Parsons, N Schnabolk, G Tomlinson, S AF Rohrer, Baerbel Parsons, Nate Schnabolk, Gloriane Tomlinson, Steven TI The complement system is dual-hatted, acting in both damage and repair processes in the murine model of choroidal neovascularization. SO INVESTIGATIVE OPHTHALMOLOGY & VISUAL SCIENCE LA English DT Meeting Abstract CT Annual Meeting of the Association-for-Research-in-Vision-and-Ophthalmology (ARVO) CY MAY 01-05, 2016 CL Seattle, WA SP Assoc Res Vis & Ophthalmol C1 [Rohrer, Baerbel; Parsons, Nate; Schnabolk, Gloriane; Tomlinson, Steven] Med Univ South Carolina, Charleston, SC USA. [Rohrer, Baerbel; Parsons, Nate; Schnabolk, Gloriane; Tomlinson, Steven] Ralph H Johnson VA Med Ctr, Charleston, SC USA. FU Department of Veterans Affairs [RX000444]; National Institutes of Health [EY019320]; Feldberg Endowment; Research to Prevent Blindness (RPB), New York, NY FX Support This work was sponsored in part by a Department of Veterans Affairs merit award RX000444, a National Institutes of Health grant EY019320, the Feldberg Endowment as well as an unrestricted grant to MUSC from Research to Prevent Blindness (RPB), New York, NY. NR 0 TC 0 Z9 0 U1 0 U2 0 PU ASSOC RESEARCH VISION OPHTHALMOLOGY INC PI ROCKVILLE PA 12300 TWINBROOK PARKWAY, ROCKVILLE, MD 20852-1606 USA SN 0146-0404 EI 1552-5783 J9 INVEST OPHTH VIS SCI JI Invest. Ophthalmol. Vis. Sci. PD SEP PY 2016 VL 57 IS 12 MA 2123 PG 2 WC Ophthalmology SC Ophthalmology GA EK8LA UT WOS:000394174005031 ER PT J AU Schnabolk, G Coughlin, B Joseph, K Raikwar, H Kunchithapautham, K Johnson, K Moore, K Wang, Y Rohrer, B AF Schnabolk, Gloriane Coughlin, Beth Joseph, Kusumam Raikwar, Himanshu Kunchithapautham, Kannan Johnson, Krista Moore, Kristi Wang, Yi Rohrer, Baerbel TI Connecting the innate and adaptive immune responses in mouse choroidal neovascularization via the anaphylatoxin C5a and gamma delta T-cells. SO INVESTIGATIVE OPHTHALMOLOGY & VISUAL SCIENCE LA English DT Meeting Abstract CT Annual Meeting of the Association-for-Research-in-Vision-and-Ophthalmology (ARVO) CY MAY 01-05, 2016 CL Seattle, WA SP Assoc Res Vis & Ophthalmol C1 [Schnabolk, Gloriane; Rohrer, Baerbel] Ralph H Johnson VA Med Ctr, Res, Charleston, SC USA. [Coughlin, Beth; Joseph, Kusumam; Raikwar, Himanshu; Kunchithapautham, Kannan; Rohrer, Baerbel] Med Univ South Carolina, Charleston, SC USA. [Johnson, Krista; Moore, Kristi; Wang, Yi] Alex Pharmaceut, Cheshire, CT USA. FU [VA1I01RX000444-05] FX VA1I01RX000444-05 NR 0 TC 0 Z9 0 U1 0 U2 0 PU ASSOC RESEARCH VISION OPHTHALMOLOGY INC PI ROCKVILLE PA 12300 TWINBROOK PARKWAY, ROCKVILLE, MD 20852-1606 USA SN 0146-0404 EI 1552-5783 J9 INVEST OPHTH VIS SCI JI Invest. Ophthalmol. Vis. Sci. PD SEP PY 2016 VL 57 IS 12 MA 478 PG 3 WC Ophthalmology SC Ophthalmology GA EK8LA UT WOS:000394174001311 ER PT J AU Thomas, AS Redd, T Campbell, JP Suhler, EB Rosenbaum, JT Lin, P AF Thomas, Akshay S. Redd, Travis Campbell, J. Peter Suhler, Eric B. Rosenbaum, James T. Lin, Phoebe TI The Impact and Implication of Peripheral Vascular Leakage on Ultra Widefield Fluorescein Angiography in Uveitis SO INVESTIGATIVE OPHTHALMOLOGY & VISUAL SCIENCE LA English DT Meeting Abstract CT Annual Meeting of the Association-for-Research-in-Vision-and-Ophthalmology (ARVO) CY MAY 01-05, 2016 CL Seattle, WA SP Assoc Res Vis & Ophthalmol C1 [Thomas, Akshay S.; Redd, Travis; Campbell, J. Peter; Suhler, Eric B.; Rosenbaum, James T.; Lin, Phoebe] Oregon Hlth & Sci Univ, Casey Eye Inst, Wilsonville, OR USA. [Suhler, Eric B.] Portland VA Med Ctr, Portland, OR USA. [Rosenbaum, James T.] Devers Eye Inst, Portland, OR USA. FU Research to Prevent Blindness FX Unrestricted Institutional Grant from Research to Prevent Blindness NR 0 TC 0 Z9 0 U1 0 U2 0 PU ASSOC RESEARCH VISION OPHTHALMOLOGY INC PI ROCKVILLE PA 12300 TWINBROOK PARKWAY, ROCKVILLE, MD 20852-1606 USA SN 0146-0404 EI 1552-5783 J9 INVEST OPHTH VIS SCI JI Invest. Ophthalmol. Vis. Sci. PD SEP PY 2016 VL 57 IS 12 MA 1648 PG 2 WC Ophthalmology SC Ophthalmology GA EK8LA UT WOS:000394174004042 ER PT J AU Dansingani, KK Gilani, F Phasukkijwatana, N Novais, EA Querques, L Sarraf, D Waheed, NK Duker, JS Querques, G Yannuzzi, LA Freund, KB AF Dansingani, Kunal K. Gilani, Fatimah Phasukkijwatana, Nopasak Novais, Eduardo Amorim Querques, Lea Sarraf, David Waheed, Nadia K. Duker, Jay S. Querques, Giuseppe Yannuzzi, Lawrence A. Freund, K. Bailey TI Angiographic optical coherence tomography (OCT) of subretinal hyperreflective material (SHRM) SO INVESTIGATIVE OPHTHALMOLOGY & VISUAL SCIENCE LA English DT Meeting Abstract CT Annual Meeting of the Association-for-Research-in-Vision-and-Ophthalmology (ARVO) CY MAY 01-05, 2016 CL Seattle, WA SP Assoc Res Vis & Ophthalmol C1 [Dansingani, Kunal K.; Gilani, Fatimah; Yannuzzi, Lawrence A.; Freund, K. Bailey] Vitreous Retina Macula Consultants New York, New York, NY USA. [Dansingani, Kunal K.; Gilani, Fatimah; Yannuzzi, Lawrence A.; Freund, K. Bailey] LuEsther T Mertz Retinal Res Ctr, New York, NY USA. [Phasukkijwatana, Nopasak; Sarraf, David] Univ Calif Los Angeles, Stein Eye Instutute, Los Angeles, CA USA. [Phasukkijwatana, Nopasak] Mahidol Univ, Siriraj Hosp, Dept Ophthalmol, Fac Med, Bangkok, Thailand. [Novais, Eduardo Amorim; Waheed, Nadia K.; Duker, Jay S.] Tufts Univ, Sch Med, New England Eye Ctr, Boston, MA 02111 USA. [Querques, Lea; Querques, Giuseppe] Univ Vita Salute San Raffaele, IRCCS Osped San Raffaele, Milan, Italy. [Sarraf, David] Greater Los Angeles VA Hlth Ctr, Stein Eye Inst, Los Angeles, CA USA. NR 0 TC 0 Z9 0 U1 0 U2 0 PU ASSOC RESEARCH VISION OPHTHALMOLOGY INC PI ROCKVILLE PA 12300 TWINBROOK PARKWAY, ROCKVILLE, MD 20852-1606 USA SN 0146-0404 EI 1552-5783 J9 INVEST OPHTH VIS SCI JI Invest. Ophthalmol. Vis. Sci. PD SEP PY 2016 VL 57 IS 12 PG 3 WC Ophthalmology SC Ophthalmology GA EK8YM UT WOS:000394210604030 ER PT J AU Ishii, M Rohrer, B AF Ishii, Masaaki Rohrer, Baerbel TI Partial Bystander Effect Elicited by single cell photo-oxidative blue light stimulation and apoptotic cell death radiation mediated by ROS and Calcium Signaling. SO INVESTIGATIVE OPHTHALMOLOGY & VISUAL SCIENCE LA English DT Meeting Abstract CT Annual Meeting of the Association-for-Research-in-Vision-and-Ophthalmology (ARVO) CY MAY 01-05, 2016 CL Seattle, WA SP Assoc Res Vis & Ophthalmol C1 [Ishii, Masaaki; Rohrer, Baerbel] Med Univ South Carolina, Ophthalmol, Charleston, SC USA. [Rohrer, Baerbel] Ralph H Johnson VA Med Ctr, Div Res, Charleston, SC USA. FU NH [EY019320]; Veterans Affairs merit award [RX000444] FX Support NH Grant EY019320, Veterans Affairs merit award RX000444 NR 0 TC 0 Z9 0 U1 0 U2 0 PU ASSOC RESEARCH VISION OPHTHALMOLOGY INC PI ROCKVILLE PA 12300 TWINBROOK PARKWAY, ROCKVILLE, MD 20852-1606 USA SN 0146-0404 EI 1552-5783 J9 INVEST OPHTH VIS SCI JI Invest. Ophthalmol. Vis. Sci. PD SEP PY 2016 VL 57 IS 12 MA 2708 PG 2 WC Ophthalmology SC Ophthalmology GA EK8YI UT WOS:000394210201081 ER PT J AU Jung, JJ Hoang, QV Rofagha, S Sarraf, D Freund, KB AF Jung, Jesse J. Hoang, Quan V. Rofagha, Soraya Sarraf, David Freund, K. Bailey TI Ultra-widefield Indocyanine Green Angiography in Central Serous Chorioretinopathy and Pachychoroid Pigment Epitheliopathy SO INVESTIGATIVE OPHTHALMOLOGY & VISUAL SCIENCE LA English DT Meeting Abstract CT Annual Meeting of the Association-for-Research-in-Vision-and-Ophthalmology (ARVO) CY MAY 01-05, 2016 CL Seattle, WA SP Assoc Res Vis & Ophthalmol C1 [Jung, Jesse J.; Rofagha, Soraya] Eadt Bay Retina Consultants Inc, Oakland, CA USA. [Hoang, Quan V.] Columbia Coll Phys & Surg, Edward S Harkness Eye Inst, Dept Ophthalmol, New York, NY USA. [Rofagha, Soraya] Univ Calif San Francisco, Dept Ophthalmol, San Francisco, CA USA. [Sarraf, David] Univ Calif Los Angeles, Stein Eye Inst, Retinal Disorders & Ophthalm Genet Div, Los Angeles, CA USA. [Sarraf, David] Greater Los Angeles VA Healthcare Ctr, Dept Ophthalmol, Los Angeles, CA USA. [Freund, K. Bailey] Vitreous Retina Macula Consultants New York, New York, NY USA. [Freund, K. Bailey] NYU, Sch Med, Dept Ophthalmol, New York, NY USA. NR 0 TC 0 Z9 0 U1 1 U2 1 PU ASSOC RESEARCH VISION OPHTHALMOLOGY INC PI ROCKVILLE PA 12300 TWINBROOK PARKWAY, ROCKVILLE, MD 20852-1606 USA SN 0146-0404 EI 1552-5783 J9 INVEST OPHTH VIS SCI JI Invest. Ophthalmol. Vis. Sci. PD SEP PY 2016 VL 57 IS 12 MA 5353 PG 2 WC Ophthalmology SC Ophthalmology GA EK8YM UT WOS:000394210601032 ER PT J AU Liu, L Rebecca, S Jia, Y Zhang, XB Tan, O Huang, D AF Liu, Liang Rebecca, Spain Jia, Yali Zhang, Xinbo Tan, Ou Huang, David TI Optic Nerve Head Perfusion and Retinal Structural Measurement by Optical Coherence Tomography in Multiple Sclerosis SO INVESTIGATIVE OPHTHALMOLOGY & VISUAL SCIENCE LA English DT Meeting Abstract CT Annual Meeting of the Association-for-Research-in-Vision-and-Ophthalmology (ARVO) CY MAY 01-05, 2016 CL Seattle, WA SP Assoc Res Vis & Ophthalmol C1 [Liu, Liang; Jia, Yali; Zhang, Xinbo; Tan, Ou; Huang, David] Oregon Hlth & Sci Univ, Casey Eye Inst, Portland, OR 97201 USA. [Rebecca, Spain] Oregon Hlth & Sci Univ, Portland VA Med Ctr, Dept Neurol, Portland, OR 97201 USA. FU Research to Prevent Blindness; [R01 EY023285 03]; [DP3 DK104397 01]; [R01 EY024544 02]; [P30 EY010572 21] FX Support R01 EY023285 03; DP3 DK104397 01; R01 EY024544 02; P30 EY010572 21; Unrestricted grant from Research to Prevent Blindness NR 0 TC 0 Z9 0 U1 0 U2 0 PU ASSOC RESEARCH VISION OPHTHALMOLOGY INC PI ROCKVILLE PA 12300 TWINBROOK PARKWAY, ROCKVILLE, MD 20852-1606 USA SN 0146-0404 EI 1552-5783 J9 INVEST OPHTH VIS SCI JI Invest. Ophthalmol. Vis. Sci. PD SEP PY 2016 VL 57 IS 12 MA 4218 PG 2 WC Ophthalmology SC Ophthalmology GA EK8YI UT WOS:000394210204067 ER PT J AU Obert, E Gourdie, R Ghatnekar, G Rohrer, B AF Obert, Elisabeth Gourdie, Robert Ghatnekar, Gautam Rohrer, Baerbel TI Targeting the tight junction protein, zonula occludens-1, with the connexin 43 mimetic peptide, alpha CT1, reduces VEGF-dependent RPE pathophysiology SO INVESTIGATIVE OPHTHALMOLOGY & VISUAL SCIENCE LA English DT Meeting Abstract CT Annual Meeting of the Association-for-Research-in-Vision-and-Ophthalmology (ARVO) CY MAY 01-05, 2016 CL Seattle, WA SP Assoc Res Vis & Ophthalmol C1 [Obert, Elisabeth; Rohrer, Baerbel] Med Univ South Carolina, Charlestobn, SC USA. [Gourdie, Robert] Virginia Tech, Caril Res Inst, Roanoke, VA USA. [Ghatnekar, Gautam] First String Therapeut, Mt Pleasant, SC USA. [Rohrer, Baerbel] Ralph H Johnson VA Med Ctr, Charleston, SC USA. NR 0 TC 0 Z9 0 U1 0 U2 0 PU ASSOC RESEARCH VISION OPHTHALMOLOGY INC PI ROCKVILLE PA 12300 TWINBROOK PARKWAY, ROCKVILLE, MD 20852-1606 USA SN 0146-0404 EI 1552-5783 J9 INVEST OPHTH VIS SCI JI Invest. Ophthalmol. Vis. Sci. PD SEP PY 2016 VL 57 IS 12 MA 4993 PG 2 WC Ophthalmology SC Ophthalmology GA EK8YI UT WOS:000394210205261 ER PT J AU Radhakrishnan, K Raghunandan, S Vyas, RJ Vu, AC Bryant, D Duan, YQ Knecht, BE Chalam, KV Grant, MB Parsons-Wingerter, PA AF Radhakrishnan, Krishnan Raghunandan, Sneha Vyas, Ruchi J. Vu, Amanda C. Bryant, Douglas Duan, Yaqian Knecht, Brenda E. Chalam, K. V. Grant, Maria B. Parsons-Wingerter, Patricia A. TI Association between Increased Vascular Density and Loss of Protective RAS in Early-Stage NPDR SO INVESTIGATIVE OPHTHALMOLOGY & VISUAL SCIENCE LA English DT Meeting Abstract CT Annual Meeting of the Association-for-Research-in-Vision-and-Ophthalmology (ARVO) CY MAY 01-05, 2016 CL Seattle, WA SP Assoc Res Vis & Ophthalmol C1 [Radhakrishnan, Krishnan] US Dept Vet Affairs, Clin Epidemiol Res Ctr, CT Healthcare Syst, West Haven, CT USA. [Radhakrishnan, Krishnan] Univ Kentucky, Coll Med, Dept Internal Med, Lexington, KY USA. [Raghunandan, Sneha; Vyas, Ruchi J.; Parsons-Wingerter, Patricia A.] NASA, Space Life Sci Res Branch, Ames Res Ctr, Moffett Field, CA USA. [Vu, Amanda C.] Univ Berkeley, Dept Biomed Engn, NASA SLSTP Summer Internship Program, Berkeley, CA USA. [Bryant, Douglas; Duan, Yaqian; Knecht, Brenda E.; Grant, Maria B.] Indiana Univ, Eugene & Marilyn Glick Eye Inst, Dept Ophthalmol, Indianapolis, IN 46204 USA. [Chalam, K. V.] Univ Florida, Dept Ophthalmol, Jacksonville, FL USA. [Grant, Maria B.] Indiana Univ Sch Med, Dept Integrat & Cellular Physiol, Indianapolis, IN 46202 USA. FU NHLBI [R01HL110170]; NASA Human Research Program FX NHLBI R01HL110170 to M Grant and P Parsons. NASA Human Research Program to P Parsons. NR 0 TC 0 Z9 0 U1 0 U2 0 PU ASSOC RESEARCH VISION OPHTHALMOLOGY INC PI ROCKVILLE PA 12300 TWINBROOK PARKWAY, ROCKVILLE, MD 20852-1606 USA SN 0146-0404 EI 1552-5783 J9 INVEST OPHTH VIS SCI JI Invest. Ophthalmol. Vis. Sci. PD SEP PY 2016 VL 57 IS 12 MA 5035 PG 3 WC Ophthalmology SC Ophthalmology GA EK8YI UT WOS:000394210205302 ER PT J AU Rosenzweig, HL Brown, B Snow, P Vance, E Silver, P Caspi, RR Lee, EJ AF Rosenzweig, Holly Lallman Brown, Brieanna Snow, Paige Vance, Emily Silver, Phyllis Caspi, Rachel R. Lee, Ellen J. TI Mincle activation and Syk/Card9 signaling axis are central to development of autoimmune disease of the eye SO INVESTIGATIVE OPHTHALMOLOGY & VISUAL SCIENCE LA English DT Meeting Abstract CT Annual Meeting of the Association-for-Research-in-Vision-and-Ophthalmology (ARVO) CY MAY 01-05, 2016 CL Seattle, WA SP Assoc Res Vis & Ophthalmol C1 [Rosenzweig, Holly Lallman; Brown, Brieanna; Snow, Paige; Vance, Emily; Lee, Ellen J.] Portland VA Med Ctr, Portland, OR USA. [Rosenzweig, Holly Lallman; Vance, Emily; Lee, Ellen J.] Oregon Hlth & Sci Univ, Mol Microbiol & Immunol, Portland, OR 97201 USA. [Silver, Phyllis; Caspi, Rachel R.] NEI, Immunol Lab, Bldg 10, Bethesda, MD 20892 USA. FU NIH/NEI [EY025250]; Department of Veterans Affairs Biomedical Laboratory [I01 BX002180]; NEI [EY00184] FX NIH/NEI (grant EY025250), the Department of Veterans Affairs Biomedical Laboratory (I01 BX002180), and NEI intramural support (Project # EY00184). NR 0 TC 0 Z9 0 U1 0 U2 0 PU ASSOC RESEARCH VISION OPHTHALMOLOGY INC PI ROCKVILLE PA 12300 TWINBROOK PARKWAY, ROCKVILLE, MD 20852-1606 USA SN 0146-0404 EI 1552-5783 J9 INVEST OPHTH VIS SCI JI Invest. Ophthalmol. Vis. Sci. PD SEP PY 2016 VL 57 IS 12 PG 2 WC Ophthalmology SC Ophthalmology GA EK8YM UT WOS:000394210605301 ER PT J AU Sarraf, D Hill, L Lu, N Gune, S Tuomi, L AF Sarraf, David Hill, Lauren Lu, Na Gune, Shamika Tuomi, Lisa TI Efficacy of ranibizumab therapy in eyes with neovascular AMD and pigment epithelial detachment (PED): a HARBOR subanalysis study SO INVESTIGATIVE OPHTHALMOLOGY & VISUAL SCIENCE LA English DT Meeting Abstract CT Annual Meeting of the Association-for-Research-in-Vision-and-Ophthalmology (ARVO) CY MAY 01-05, 2016 CL Seattle, WA SP Assoc Res Vis & Ophthalmol C1 [Sarraf, David] Univ Calif Los Angeles, Stein Eye Inst, Dept Ophthalmol, Los Angeles, CA USA. [Sarraf, David] Greater Los Angeles VA Healthcare Ctr, Los Angeles, CA USA. [Hill, Lauren; Lu, Na; Gune, Shamika; Tuomi, Lisa] Genentech Inc, San Francisco, CA 94080 USA. FU Genentech, Inc., South San Francisco, CA FX Genentech, Inc., South San Francisco, CA, provided support for the study and participated in the study design; conducting the study; and data collection, management, and interpretation NR 0 TC 0 Z9 0 U1 0 U2 0 PU ASSOC RESEARCH VISION OPHTHALMOLOGY INC PI ROCKVILLE PA 12300 TWINBROOK PARKWAY, ROCKVILLE, MD 20852-1606 USA SN 0146-0404 EI 1552-5783 J9 INVEST OPHTH VIS SCI JI Invest. Ophthalmol. Vis. Sci. PD SEP PY 2016 VL 57 IS 12 PG 2 WC Ophthalmology SC Ophthalmology GA EK8YM UT WOS:000394210604136 ER PT J AU Washington, KM Li, Y Komatsu, C Miller, MR van der Merwe, Y Wollstein, G Fu, VLN Gorantla, VS Chan, KC Schuman, JS AF Washington, Kia M. Li, Yang Komatsu, Chiaki Miller, Maxine R. van der Merwe, Yolandi Wollstein, Gadi Fu, Valeria L. N. Gorantla, Vijay S. Chan, Kevin C. Schuman, Joel S. TI Studies of Structure and Function in Whole Eye Transplantation SO INVESTIGATIVE OPHTHALMOLOGY & VISUAL SCIENCE LA English DT Meeting Abstract CT Annual Meeting of the Association-for-Research-in-Vision-and-Ophthalmology (ARVO) CY MAY 01-05, 2016 CL Seattle, WA SP Assoc Res Vis & Ophthalmol C1 [Washington, Kia M.; Komatsu, Chiaki; Miller, Maxine R.; Gorantla, Vijay S.] Univ Pittsburgh, Dept Plast Surg, Pittsburgh, PA USA. [Washington, Kia M.] VA Pittsburgh Healthcare Syst, Pittsburgh, PA USA. [Li, Yang] Fourth Mil Med Univ, Xijing Hosp, Dept Plast & Reconstruct Surg, Xian, Peoples R China. [Miller, Maxine R.; van der Merwe, Yolandi; Wollstein, Gadi; Fu, Valeria L. N.; Chan, Kevin C.; Schuman, Joel S.] Univ Pittsburgh, Dept Ophthalmol, Pittsburgh, PA 15260 USA. [van der Merwe, Yolandi; Wollstein, Gadi; Chan, Kevin C.; Schuman, Joel S.] Univ Pittsburgh, Dept Bioengn, Swanson Sch Engn, Pittsburgh, PA USA. FU Office of the Assistant Secretary of Defense for Health Affairs [W81XWH-14-1-0421] FX Office of the Assistant Secretary of Defense for Health Affairs under Award No. W81XWH-14-1-0421 NR 0 TC 0 Z9 0 U1 0 U2 0 PU ASSOC RESEARCH VISION OPHTHALMOLOGY INC PI ROCKVILLE PA 12300 TWINBROOK PARKWAY, ROCKVILLE, MD 20852-1606 USA SN 0146-0404 EI 1552-5783 J9 INVEST OPHTH VIS SCI JI Invest. Ophthalmol. Vis. Sci. PD SEP PY 2016 VL 57 IS 12 PG 3 WC Ophthalmology SC Ophthalmology GA EK8YM UT WOS:000394210603340 ER PT J AU Hugos, C Chen, Z Chen, Y Cameron, M Wick, K Turner, A Haselkorn, J Sloan, A Chiara, T Mc Coy, S Bever, C Kunce, A Bourdette, D AF Hugos, C. Chen, Z. Chen, Y. Cameron, M. Wick, K. Turner, A. Haselkorn, J. Sloan, A. Chiara, T. Mc Coy, S. Bever, C. Kunce, A. Bourdette, D. TI A multicenter randomized controlled trial of two group programs in multiple sclerosis: effects on fatigue and self-efficacy SO MULTIPLE SCLEROSIS JOURNAL LA English DT Meeting Abstract CT 32nd Congress of the European-Committee-for-Treatment-and-Research-in-Multiple-Sclerosis (ECTRIMS) CY SEP 14-17, 2016 CL London, ENGLAND SP European Comm Treatment & Res Multiple Sclerosis C1 [Hugos, C.; Cameron, M.; Wick, K.; Bourdette, D.] VA Portland Hlth Care Syst, Portland, OR USA. [Chen, Z.; Chen, Y.; Bourdette, D.] Oregon Hlth & Sci Univ, Portland, OR 97201 USA. [Turner, A.; Haselkorn, J.; Sloan, A.] VA Puget Sound Hlth Care Syst, Seattle, WA USA. [Chiara, T.; Mc Coy, S.] North Florida South Georgia Vet Hlth Syst, Gainesville, FL USA. [Bever, C.; Kunce, A.] VA Maryland Hlth Care Syst, Baltimore, MD USA. FU VA RRD [F7777-R]; OCTRI NCATS [UL1TR000128] FX VA RR&D F7777-R and OCTRI NCATS-funded CTSA grant (UL1TR000128 NR 0 TC 0 Z9 0 U1 0 U2 0 PU SAGE PUBLICATIONS LTD PI LONDON PA 1 OLIVERS YARD, 55 CITY ROAD, LONDON EC1Y 1SP, ENGLAND SN 1352-4585 EI 1477-0970 J9 MULT SCLER J JI Mult. Scler. J. PD SEP PY 2016 VL 22 SU 3 MA P759 BP 378 EP 378 PG 1 WC Clinical Neurology; Neurosciences SC Neurosciences & Neurology GA DV9NJ UT WOS:000383267201498 ER PT J AU Rinker, JR Meador, W Sung, V Nicholas, A Cutter, G AF Rinker, J. R. Meador, W. Sung, V. Nicholas, A. Cutter, G. TI Results of a pilot trial of lithium in progressive multiple sclerosis SO MULTIPLE SCLEROSIS JOURNAL LA English DT Meeting Abstract CT 32nd Congress of the European-Committee-for-Treatment-and-Research-in-Multiple-Sclerosis (ECTRIMS) CY SEP 14-17, 2016 CL London, ENGLAND SP European Comm Treatment & Res Multiple Sclerosis C1 [Rinker, J. R.; Meador, W.; Sung, V.; Nicholas, A.] Univ Alabama Birmingham, Neurol, Birmingham, AL USA. [Rinker, J. R.; Sung, V.; Nicholas, A.] Birmingham VA Med Ctr, Neurol, Birmingham, AL USA. [Cutter, G.] Univ Alabama Birmingham, Biostat, Birmingham, AL USA. FU Department of Veterans Affairs [CDA2-003-10S] FX Funding for the trial was provided through the Department of Veterans Affairs, CDA2-003-10S. NR 0 TC 0 Z9 0 U1 0 U2 0 PU SAGE PUBLICATIONS LTD PI LONDON PA 1 OLIVERS YARD, 55 CITY ROAD, LONDON EC1Y 1SP, ENGLAND SN 1352-4585 EI 1477-0970 J9 MULT SCLER J JI Mult. Scler. J. PD SEP PY 2016 VL 22 SU 3 MA P1282 BP 678 EP 679 PG 2 WC Clinical Neurology; Neurosciences SC Neurosciences & Neurology GA DV9NJ UT WOS:000383267202481 ER PT J AU Hazlett, E Blair, N Fernandez, N Mascitelli, K Banthin, D Goodman, M AF Hazlett, Erin Blair, Nicholas Fernandez, Nicolas Mascitelli, Kathryn Banthin, David Goodman, Marianne TI AFFECTIVE STARTLE DURING UNPLEASANT PICTURES PREDICTS A FUTURE SUICIDE ATTEMPT IN VETERANS SO PSYCHOPHYSIOLOGY LA English DT Meeting Abstract DE startle eyeblink; emotion; depression; suicide C1 Icahn Sch Med Mt Sinai, New York, NY 10029 USA. James J Peters VA Med Ctr, New York, NY USA. FU Department of Defense [W81XWH0910722]; VA Merit Award [I01CX00026]; VISN 2 South Mental Illness, Research, Education, and Clinical Center (MIRECC) at the James J. Peters VA Medical Center FX This research was supported by a Department of Defense grant (W81XWH0910722) to EAH and MG; MPIs), a VA Merit Award (I01CX00026) to EAH, and the VISN 2 South Mental Illness, Research, Education, and Clinical Center (MIRECC) at the James J. Peters VA Medical Center. NR 0 TC 0 Z9 0 U1 0 U2 0 PU WILEY-BLACKWELL PI HOBOKEN PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA SN 0048-5772 EI 1469-8986 J9 PSYCHOPHYSIOLOGY JI Psychophysiology PD SEP PY 2016 VL 53 SU 1 SI SI MA 1-12 BP S19 EP S19 PG 1 WC Psychology, Biological; Neurosciences; Physiology; Psychology; Psychology, Experimental SC Psychology; Neurosciences & Neurology; Physiology GA EK1FX UT WOS:000393672300076 ER PT J AU McCleery, A Wynn, JK Polon, N Szewczyk, W Roach, BJ Mathalon, DH Green, MF AF McCleery, Amanda Wynn, Jonathan K. Polon, Nora Szewczyk, Warren Roach, Brian J. Mathalon, Daniel H. Green, Michael F. TI DIMINISHED CORTICAL PLASTICITY IN CHRONIC PHASE SCHIZOPHRENIA: AN ELECTROPHYSIOLOGICAL STUDY SO PSYCHOPHYSIOLOGY LA English DT Meeting Abstract C1 [McCleery, Amanda; Wynn, Jonathan K.; Polon, Nora; Szewczyk, Warren; Green, Michael F.] Univ Calif Los Angeles, Los Angeles, CA USA. [McCleery, Amanda; Wynn, Jonathan K.; Green, Michael F.] VA Greater Los Angeles, Los Angeles, CA USA. [Roach, Brian J.; Mathalon, Daniel H.] Univ Calif San Francisco, San Francisco, CA 94143 USA. [Roach, Brian J.; Mathalon, Daniel H.] San Francisco VA Hlth Care Syst, San Francisco, CA USA. FU VA Greater Los Angeles VISN 22 Mental Illness Research, Education, and Clinical Center (MIRECC) Pala Grant FX VA Greater Los Angeles VISN 22 Mental Illness Research, Education, and Clinical Center (MIRECC) Pala Grant (PI: McCleery). NR 0 TC 0 Z9 0 U1 0 U2 0 PU WILEY-BLACKWELL PI HOBOKEN PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA SN 0048-5772 EI 1469-8986 J9 PSYCHOPHYSIOLOGY JI Psychophysiology PD SEP PY 2016 VL 53 SU 1 SI SI MA 1-23 BP S22 EP S22 PG 1 WC Psychology, Biological; Neurosciences; Physiology; Psychology; Psychology, Experimental SC Psychology; Neurosciences & Neurology; Physiology GA EK1FX UT WOS:000393672300086 ER PT J AU McCullough, MB AF McCullough, Megan B. TI Fat-Talk Nation: The Human Costs of America's War on Fat SO ANTHROPOLOGICAL QUARTERLY LA English DT Book Review ID OBESITY C1 [McCullough, Megan B.] US Dept Vet Affairs, Washington, DC 20420 USA. RP McCullough, MB (reprint author), US Dept Vet Affairs, Washington, DC 20420 USA. NR 23 TC 0 Z9 0 U1 1 U2 1 PU GEORGE WASHINGTON UNIV INST ETHNOGRAPHIC RESEARCH PI WASHINGTON PA GEORGE WASHINGTON UNIV, 2110 G ST, N W, WASHINGTON, DC 20052 USA SN 0003-5491 EI 1534-1518 J9 ANTHROPOL QUART JI Anthropol. Q. PD FAL PY 2016 VL 89 IS 4 BP 1285 EP 1291 PG 7 WC Anthropology SC Anthropology GA EJ3BY UT WOS:000393087500016 ER PT J AU Hill-Burns, EM Ross, OA Wissemann, WT Soto-Ortolaza, AI Zareparsi, S Siuda, J Lynch, T Wszolek, ZK Silburn, PA Mellick, GD Ritz, B Scherzer, CR Zabetian, CP Factor, SA Breheny, PJ Payami, H AF Hill-Burns, Erin M. Ross, Owen A. Wissemann, William T. Soto-Ortolaza, Alexandra I. Zareparsi, Sepideh Siuda, Joanna Lynch, Timothy Wszolek, Zbigniew K. Silburn, Peter A. Mellick, George D. Ritz, Beate Scherzer, Clemens R. Zabetian, Cyrus P. Factor, Stewart A. Breheny, Patrick J. Payami, Haydeh TI Identification of genetic modifiers of age-at-onset for familial Parkinson's disease SO HUMAN MOLECULAR GENETICS LA English DT Article ID GENOME-WIDE ASSOCIATION; RECESSIVE JUVENILE PARKINSONISM; SEGREGATION ANALYSIS; TUMOR-SUPPRESSOR; RISK-FACTORS; MUTATIONS; COMMON; VISUALIZATION; EXPRESSION; VARIANTS AB Parkinson's disease (PD) is the most common cause of neurodegenerative movement disorder and the second most common cause of dementia. Genes are thought to have a stronger effect on age-at-onset of PD than on risk, yet there has been a phenomenal success in identifying risk loci but not age-at-onset modifiers. We conducted a genome-wide study for age-at-onset. We analysed familial and non-familial PD separately, per prior evidence for strong genetic effect on age-at-onset in familial PD. GWAS was conducted in 431 unrelated PD individuals with at least one affected relative (familial PD) and 1544 non-familial PD from the NeuroGenetics Research Consortium (NGRC); an additional 737 familial PD and 2363 non-familial PD were used for replication. In familial PD, two signals were detected and replicated robustly: one mapped to LHFPL2 on 5q14.1 (P-NGRC = 3E-8, P-Replication = 2E-5, PNGRC+Replication = 1E-11), the second mapped to TPM1 on 15q22.2 (P-NGRC = 8E-9, P-Replication = 2E-4, PNGRC+Replication-9E-11). The variants that were associated with accelerated onset had low frequencies (<0.02). The LHFPL2 variant was associated with earlier onset by 12.33 [95% CI: 6.2; 18.45] years in NGRC, 8.03 [2.95; 13.11] years in replication, and 9.79 [5.88; 13.70] years in the combined data. The TPM1 variant was associated with earlier onset by 15.30 [8.10; 22.49] years in NGRC, 9.29 [1.79; 16.79] years in replication, and 12.42 [7.23; 17.61] years in the combined data. Neither LHFPL2 nor TPM1 was associated with age-at-onset in non-familial PD. LHFPL2 ( function unknown) is overexpressed in brain tumours. TPM1 encodes a highly conserved protein that regulates muscle contraction, and is a tumour-suppressor gene. C1 [Hill-Burns, Erin M.; Wissemann, William T.; Payami, Haydeh] Univ Alabama Birmingham, Dept Neurol, UAB Stn, Birmingham, AL 35294 USA. [Ross, Owen A.; Soto-Ortolaza, Alexandra I.] Mayo Clin Jacksonville, Dept Neurosci, 4500 San Pablo Rd, Jacksonville, FL 32224 USA. [Zareparsi, Sepideh] Oregon Hlth & Sci Univ, Dept Mol & Med Genet, Portland, OR 97201 USA. [Siuda, Joanna] Med Univ Silesia, Dept Neurol, Katowice, Poland. [Lynch, Timothy] Univ Coll Dublin, Mater Misericordiae Univ Hosp, Conway Inst Biomol & Biomed Res, Dublin Neurol Inst, Dublin, Ireland. [Wszolek, Zbigniew K.] Mayo Clin Jacksonville, Dept Neurol, 4500 San Pablo Rd, Jacksonville, FL 32224 USA. [Silburn, Peter A.; Mellick, George D.] Griffith Univ, Eskitis Inst Drug Discovery, Nathan, Qld, Australia. [Ritz, Beate] Univ Calif Los Angeles, Geffen Sch Med, Fielding Sch Publ Hlth & Neurol, Dept Epidemiol, Los Angeles, CA USA. [Scherzer, Clemens R.] Harvard Med Sch, Neurogen Lab, Cambridge, MA USA. [Scherzer, Clemens R.] Brigham & Womens Hosp, Cambridge, MA USA. [Zabetian, Cyrus P.] VA Puget Sound Hlth Care Syst, Seattle, WA USA. [Zabetian, Cyrus P.] Univ Washington, Dept Neurol, Seattle, WA 98195 USA. [Factor, Stewart A.] Emory Univ, Sch Med, Dept Neurol, Atlanta, GA 30322 USA. [Breheny, Patrick J.] Univ Iowa, Dept Biostat, Iowa City, IA USA. [Payami, Haydeh] HudsonAlpha Inst Biotechnol, Ctr Genom Med, Huntsville, AL USA. RP Payami, H (reprint author), MCLM 401,1918 Univ Blvd, Birmingham, AL 35233 USA. EM haydehpayami@uabmc.edu FU National Institute of Neurological Disorders And Stroke [R01NS036960]; National Institutes of Health [P30AG08017, HHSN268200782096C, U01NS082157, P50AG005134, R01ES010544, U54ES012078, R01NS078086, P50NS72187]; Department of Veterans Affairs [1I01BX000531]; Office of Research & Development, Clinical Sciences Research & Development Service, Department of Veteran Affairs; Close to the Cure Foundation; American Parkinson's Disease Association; Stowarzyszenie na Rzecz Rozwoju Neurologii Wieku Podeszlego grant; Harvard NeuroDiscovery Center (HNDC); Parkinson's Disease Biomarkers Program (PDBP); U.S. Department of Defense; M.E.M.O. Hoffman Foundation; University of Alabama at Birmingham FX This work was supported by a grant from the National Institute of Neurological Disorders And Stroke [grant number R01NS036960]. Additional support was provided by National Institutes of Health [grant number P30AG08017]; a Merit Review Award from the Department of Veterans Affairs [grant number 1I01BX000531]; Office of Research & Development, Clinical Sciences Research & Development Service, Department of Veteran Affairs; and the Close to the Cure Foundation. Genomewide array genotyping was conducted by the Center for Inherited Disease Research, which is funded by the National Institutes of Health [grant number HHSN268200782096C]. Studies providing samples and data for replication were supported by National Institutes of Health [grant numbers U01NS082157, P50AG005134, R01ES010544, U54ES012078, R01NS078086 and P50NS72187]; a gift from Carl Edward Bolch, Jr. and Susan Bass Bolch; the American Parkinson's Disease Association; the Stowarzyszenie na Rzecz Rozwoju Neurologii Wieku Podeszlego grant; the Harvard NeuroDiscovery Center (HNDC); the Parkinson's Disease Biomarkers Program (PDBP); the U.S. Department of Defense; and the M.E.M.O. Hoffman Foundation. The content is solely the responsibility of the authors and does not necessarily represent the official views of the funding agencies. The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript. Funding to pay the Open Access publication charges for this article was provided by the University of Alabama at Birmingham. NR 66 TC 1 Z9 1 U1 0 U2 0 PU OXFORD UNIV PRESS PI OXFORD PA GREAT CLARENDON ST, OXFORD OX2 6DP, ENGLAND SN 0964-6906 EI 1460-2083 J9 HUM MOL GENET JI Hum. Mol. Genet. PD SEP 1 PY 2016 VL 25 IS 17 BP 3849 EP 3862 DI 10.1093/hmg/ddw206 PG 14 WC Biochemistry & Molecular Biology; Genetics & Heredity SC Biochemistry & Molecular Biology; Genetics & Heredity GA EJ4IW UT WOS:000393181300016 PM 27402877 ER PT J AU Phasukkijwatana, N Rahimi, M Iafe, N Sarraf, D AF Phasukkijwatana, Nopasak Rahimi, Mansour Iafe, Nicholas Sarraf, David TI Central Retinal Vein Occlusion and Paracentral Acute Middle Maculopathy Diagnosed With En Face Optical Coherence Tomography SO OPHTHALMIC SURGERY LASERS & IMAGING RETINA LA English DT Article ID CAPILLARY ISCHEMIA AB A 21-year-old healthy female presented with acute-onset vision loss in the left eye. Multimodal imaging, including fundus photography and fluorescein angiography, was unremarkable. En face optical coherence tomography (OCT) demonstrated paracentral acute middle maculopathy (PAMM) lesions in a perivenular fern-like pattern leading to the diagnosis of central retinal vein occlusion (CRVO). En face OCT can be an important modality to identify the distribution of abnormalities of the middle retina such as PAMM. The distribution of PAMM lesions in the posterior pole will be a critical element in the determination of the etiologic disorder. C1 [Phasukkijwatana, Nopasak; Rahimi, Mansour; Iafe, Nicholas; Sarraf, David] Univ Calif Los Angeles, David Geffen Sch Med, Stein Eye Inst, Los Angeles, CA 90095 USA. [Phasukkijwatana, Nopasak] Mahidol Univ, Siriraj Hosp, Fac Med, Dept Ophthalmol, Bangkok, Thailand. [Sarraf, David] Greater Los Angeles VA Healthcare Ctr, Los Angeles, CA USA. RP Sarraf, D (reprint author), Univ Calif Los Angeles, David Geffen Sch Med, Stein Eye Inst, Retinal Disorders & Ophthalm Genet Div, Los Angeles, CA 90095 USA. EM dsarraf@ucla.edu FU Genentech; Optovue; Regeneron FX Dr. Sarraf receives research support from Genentech, Optovue, and Regeneron; none of these disclosures have any role in the conduct of the study. The remaining authors report no relevant financial disclosures. NR 6 TC 0 Z9 0 U1 1 U2 1 PU SLACK INC PI THOROFARE PA 6900 GROVE RD, THOROFARE, NJ 08086 USA SN 2325-8160 EI 2325-8179 J9 OSLI RETINA JI Ophthalmic Surg. Lasers Imag. Retin. PD SEP PY 2016 VL 47 IS 9 BP 862 EP 864 DI 10.3928/23258160-20160901-10 PG 3 WC Ophthalmology; Surgery SC Ophthalmology; Surgery GA EJ3HM UT WOS:000393103200010 PM 27631483 ER PT J AU Lee, J Capra, G Klobucar, T AF Lee, Jennifer Capra, Gina Klobucar, Thomas TI Forging New Paths to Integrate Rural Veterans' Care Nationwide SO JOURNAL OF RURAL HEALTH LA English DT Editorial Material DE access to care; community care; integrated health care; rural; veteran C1 [Lee, Jennifer] US Dept Vet Affairs, Secretary Hlth Policy & Serv, Washington, DC USA. [Capra, Gina; Klobucar, Thomas] US Dept Vet Affairs, Off Rural Hlth, Washington, DC USA. RP Klobucar, T (reprint author), VA Off Rural Hlth, 810 Vermont Ave NW, Washington, DC 20420 USA. EM Thomas.Klobucar@va.gov FU US Department of Veterans Affairs FX All authors are funded by the US Department of Veterans Affairs. NR 1 TC 0 Z9 0 U1 0 U2 0 PU WILEY-BLACKWELL PI HOBOKEN PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA SN 0890-765X EI 1748-0361 J9 J RURAL HEALTH JI J. Rural Health PD FAL PY 2016 VL 32 IS 4 SI SI BP 374 EP 376 DI 10.1111/jrh.12214 PG 3 WC Health Care Sciences & Services; Health Policy & Services; Public, Environmental & Occupational Health SC Health Care Sciences & Services; Public, Environmental & Occupational Health GA EI4BP UT WOS:000392438200004 PM 27627732 ER PT J AU Wong, ES Rinne, ST Hebert, PL Cook, MA Liu, CF AF Wong, Edwin S. Rinne, Seppo T. Hebert, Paul L. Cook, Meredith A. Liu, Chuan-Fen TI Hospital Distance and Readmissions Among VA-Medicare Dual-Enrolled Veterans SO JOURNAL OF RURAL HEALTH LA English DT Article DE access to care; econometrics; Medicare; utilization of health services; veterans ID OBSTRUCTIVE PULMONARY-DISEASE; AFFAIRS HEALTH-CARE; SERVICES; RISK; SELECTION; DEMAND; ACCESS; DEATH; MODEL AB Purpose: Geographic access to inpatient care at the Veterans Affairs (VA) Health Care System is challenging for many veterans with chronic obstructive pulmonary disease (COPD) given relatively few VA hospitals nationwide. Veterans with lengthy travel distances may obtain non-VA care, particularly those dually enrolled in Medicare. Our primary objective was to assess whether distance from VA patients' residence to the nearest VA and non-VA hospitals was associated with 30-day all-cause readmission and the system where patients were readmitted (VA or Medicare). Methods: Using VA and Medicare administrative data, we identified 21,273 patients hospitalized for COPD between October 2008 and September 2011 and dually enrolled in VA and fee-for-service Medicare. Outcome variables were dichotomous measures denoting readmission for any cause within 30 days following discharge and whether the readmission occurred in a non-VA hospital through Medicare. Distance to the nearest hospital was defined as the number of miles between patients' residence ZIP code and the ZIP code of the nearest VA and non-VA hospital accepting Medicare, respectively. Probit models with sample selection were applied to examine the relationship between hospital distance and outcome measures. Findings: Respective distances to the nearest VA and non-VA hospital were not associated with 30-day all-cause readmission. Greater distance to the nearest VA hospital was associated with a greater conditional probability of choosing non-VA hospitals for readmission. Conclusions: COPD patients with poor geographic access to VA hospitals did not forgo subsequent inpatient care following their index hospitalization, but they were more likely to seek non-VA substitutes. C1 [Wong, Edwin S.; Hebert, Paul L.; Cook, Meredith A.; Liu, Chuan-Fen] VA Puget Sound Hlth Care Syst, Ctr Innovat Vet Ctr & Value Driven Care, 1660 S Columbian Way,HSR&MS S-152, Seattle, WA 98108 USA. [Wong, Edwin S.; Hebert, Paul L.; Liu, Chuan-Fen] Univ Washington, Dept Hlth Serv, Seattle, WA 98195 USA. [Rinne, Seppo T.] VA Connecticut Hlth Care Syst, Dept Vet Affairs, West Haven, CT USA. [Rinne, Seppo T.] Yale Univ, Dept Internal Med, Sect Pulm & Crit Care, New Haven, CT USA. RP Wong, ES (reprint author), VA Puget Sound Hlth Care Syst, Ctr Innovat Vet Ctr & Value Driven Care, 1660 S Columbian Way,HSR&MS S-152, Seattle, WA 98108 USA. EM edwin.wong@va.gov FU Health Services Research and Development (HSR&D) Service, Office of Research and Development, Department of Veterans Affairs (VA) [IIR 09-354]; VA HSR&D Career Development Award [CDA 13-024] FX This research was supported by the Health Services Research and Development (HSR&D) Service, Office of Research and Development, Department of Veterans Affairs (VA), IIR 09-354. Dr. Wong is supported by a VA HSR&D Career Development Award (CDA 13-024). The views expressed are those of the authors and do not necessarily reflect the views of the United States Government, the Department of Veterans Affairs, the University of Washington, and Yale University. NR 28 TC 0 Z9 0 U1 1 U2 1 PU WILEY-BLACKWELL PI HOBOKEN PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA SN 0890-765X EI 1748-0361 J9 J RURAL HEALTH JI J. Rural Health PD FAL PY 2016 VL 32 IS 4 SI SI BP 377 EP 386 DI 10.1111/jrh.12191 PG 10 WC Health Care Sciences & Services; Health Policy & Services; Public, Environmental & Occupational Health SC Health Care Sciences & Services; Public, Environmental & Occupational Health GA EI4BP UT WOS:000392438200005 PM 27424850 ER PT J AU Cordasco, KM Mengeling, MA Yano, EM Washington, DL AF Cordasco, Kristina M. Mengeling, Michelle A. Yano, Elizabeth M. Washington, Donna L. TI Health and Health Care Access of Rural Women Veterans: Findings From the National Survey of Women Veterans SO JOURNAL OF RURAL HEALTH LA English DT Article DE access to care; health-related quality of life; utilization of health services; veterans; women ID QUALITY-OF-LIFE; SHORT SCREENING SCALE; MOS SHORT-FORM; URBAN DISPARITIES; PATIENT POPULATION; AMBULATORY-CARE; FEMALE VETERANS; UNITED-STATES; VA; DISEASE AB Purpose: Disparities in health and health care access between rural and urban Americans are well documented. There is evidence that these disparities are mirrored within the US veteran population. However, there are few studies assessing this issue among women veterans (WVs). Methods: Using the 2008-2009 National Survey of Women Veterans, a population-based cross-sectional national telephone survey, we examined rural WVs' health and health care access compared to urban WVs. We measured health using the Medical Outcomes Study Short-Form (SF-12); access using measures of regular source of care (RSOC), health care utilization, and unmet needs; and barriers to getting needed care. Findings: Rural WVs have significantly worse physical health functioning compared to urban WVs (mean physical component score of 43.6 for rural WVs versus 47.2 for urban WVs; P = .007). Rural WVs were more likely to have a VA RSOC (16.4% versus 10.6%; P = .009) and use VA health care (21.7% versus 12.9%; P < .001), and had fewer non-VA health care visits compared with urban WVs (mean 4.2 versus 5.9; P = .021). They had similar overall numbers of health care visits (mean 5.8 versus 7.1; P = .11). Access barriers were affordability for rural WVs and work release time for urbanWVs. Rural WVs additionally reported that transportation was a major factor affecting health care decisions. Conclusions: Our findings demonstrate VA's crucial role in addressing disparities in health and health care access for rural WVs. As VA continues to strive to optimally meet the needs of all WVs, innovative care models need to account for their high health care needs and persistent barriers to care. C1 [Cordasco, Kristina M.; Yano, Elizabeth M.; Washington, Donna L.] VA HSR&D Ctr Study Healthcare Innovat Implementat, Los Angeles, CA USA. [Cordasco, Kristina M.; Washington, Donna L.] VA Greater Los Angeles Healthcare Syst, Dept Med, Los Angeles, CA USA. [Cordasco, Kristina M.; Washington, Donna L.] Univ Calif Los Angeles, Dept Med, Geffen Sch Med, Los Angeles, CA 90024 USA. [Mengeling, Michelle A.] VA Ctr Comprehens Access & Delivery Res & Evaluat, Iowa City, IA USA. [Mengeling, Michelle A.] Vet Rural Hlth Resource Ctr, Iowa City, IA USA. [Mengeling, Michelle A.] Univ Iowa, Carver Coll Med, Dept Internal Med, Iowa City, IA USA. [Yano, Elizabeth M.] Univ Calif Los Angeles, Fielding Sch Publ Hlth, Dept Hlth Policy & Management, Los Angeles, CA USA. RP Cordasco, KM (reprint author), 11301 Wilshire Blvd 111G, Los Angeles, CA 90073 USA. EM kristina.cordasco@va.gov FU Department of Veterans Affairs (VA) Women's Health Services, Office of Patient Care Services; VA Health Services Research and Development (HSRD) Service [SDR-08-270]; VA HSR&D Senior Research Career Scientist Award [RCS 05-195]; VA Women's Health Research Network (SDR) [10-012] FX This study was funded by the Department of Veterans Affairs (VA) Women's Health Services, Office of Patient Care Services, and the VA Health Services Research and Development (HSR&D) Service (#SDR-08-270). Dr. Yano's time was supported by a VA HSR&D Senior Research Career Scientist Award (#RCS 05-195), with additional support from the VA Women's Health Research Network (SDR #10-012). NR 51 TC 0 Z9 0 U1 1 U2 1 PU WILEY-BLACKWELL PI HOBOKEN PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA SN 0890-765X EI 1748-0361 J9 J RURAL HEALTH JI J. Rural Health PD FAL PY 2016 VL 32 IS 4 SI SI BP 397 EP 406 DI 10.1111/jrh.12197 PG 10 WC Health Care Sciences & Services; Health Policy & Services; Public, Environmental & Occupational Health SC Health Care Sciences & Services; Public, Environmental & Occupational Health GA EI4BP UT WOS:000392438200007 PM 27466970 ER PT J AU Fischer, EP McSweeney, JC Wright, P Cheney, A Curran, GM Henderson, K Fortney, JC AF Fischer, Ellen P. McSweeney, Jean C. Wright, Patricia Cheney, Ann Curran, Geoffrey M. Henderson, Kathy Fortney, John C. TI Overcoming Barriers to Sustained Engagement in Mental Health Care: Perspectives of Rural Veterans and Providers SO JOURNAL OF RURAL HEALTH LA English DT Article DE mental health care; peer support; self-reliance; trust; veterans ID POSTTRAUMATIC-STRESS-DISORDER; HELP-SEEKING; SERVICES; TRUST; PSYCHOTHERAPY; MILITARY; BELIEFS; CULTURE; ILLNESS AB Purpose: To better understand the attitudes, beliefs, and values that influence use of mental health care among rural veterans. Methods: In-depth, semistructured interviews were conducted with 25 rural veterans and 11 rural mental health care providers in 4 states. Experienced qualitative interviewers asked participants about the attitudinal factors they thought most influenced rural veterans' decisions to seek and sustain mental health care. Verbatim transcriptions were analyzed using content analysis and constant comparison. Findings: Rural veterans and their mental health care providers reported the same major attitudinal barriers to veterans' mental health treatment-seeking. Pre-eminent among those barriers was the importance rural veterans place on independence and self-reliance. The centrality of self-reliance was attributed variously to rural, military, religious, and/or gender-based belief systems. Stoicism, the stigma associated with mental illness and health care, and a lack of trust in the VA as a caring organization were also frequently mentioned. Perceived need for care and the support of other veterans were critical to overcoming attitudinal barriers to initial treatment-seeking, whereas critical facilitators of ongoing service use included "warm handoffs" from medical to mental health care providers, perceived respect and caring from providers, as well as provider accessibility and continuity. Conclusions: Attitudes and values, like self-reliance, commonly associated with rural culture may play an important role in underutilization of needed mental health services. System support for peer and provider behaviors that generate trust and demonstrate caring may help overcome attitudinal barriers to treatment-seeking and sustained engagement in mental health care among rural veterans. C1 [Fischer, Ellen P.; Curran, Geoffrey M.; Henderson, Kathy] Cent Arkansas Vet Healthcare Syst, Ctr Mental Healthcare & Outcomes Res, 2200 Ft Roots Dr,Bldg 58,NLR 152, North Little Rock, AR 72114 USA. [Fischer, Ellen P.; Curran, Geoffrey M.] Univ Arkansas Med Sci, Coll Med, Dept Psychiat, Little Rock, AR 72205 USA. [McSweeney, Jean C.; Wright, Patricia] Univ Arkansas Med Sci, Coll Nursing, Little Rock, AR 72205 USA. [Cheney, Ann] Univ Calif Riverside, Sch Med, Dept Social Med & Populat Hlth, Riverside, CA 92521 USA. [Curran, Geoffrey M.] Univ Arkansas Med Sci, Coll Pharm, Dept Pharm Practice, Little Rock, AR 72205 USA. [Fortney, John C.] VA Puget Sound Hlth Care Syst, Ctr Innovat Vet Ctr & Value Driven Care, Seattle, WA USA. [Fortney, John C.] Univ Washington, Sch Med, Dept Psychiat, Seattle, WA USA. RP Fischer, EP (reprint author), Cent Arkansas Vet Healthcare Syst, Ctr Mental Healthcare & Outcomes Res, 2200 Ft Roots Dr,Bldg 58,NLR 152, North Little Rock, AR 72114 USA. EM FischerEllenP@uams.edu FU US Department of Veterans Affairs, Veterans Health Administration, Health Services Research & Development Service award [IIR 11-290]; VA South Central Mental Illness Research, Education, and Clinical Center FX The research reported here was funded by the US Department of Veterans Affairs, Veterans Health Administration, Health Services Research & Development Service award IIR 11-290, and by the VA South Central Mental Illness Research, Education, and Clinical Center. The views expressed in this report are those of the authors and do not necessarily represent the views of the Department of Veterans Affairs. NR 38 TC 0 Z9 0 U1 3 U2 3 PU WILEY-BLACKWELL PI HOBOKEN PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA SN 0890-765X EI 1748-0361 J9 J RURAL HEALTH JI J. Rural Health PD FAL PY 2016 VL 32 IS 4 SI SI BP 429 EP 438 DI 10.1111/jrh.12203 PG 10 WC Health Care Sciences & Services; Health Policy & Services; Public, Environmental & Occupational Health SC Health Care Sciences & Services; Public, Environmental & Occupational Health GA EI4BP UT WOS:000392438200010 PM 27557334 ER PT J AU Hariri, BM Cohen, NA AF Hariri, Benjamin M. Cohen, Noam A. TI New insights into upper airway innate immunity SO AMERICAN JOURNAL OF RHINOLOGY & ALLERGY LA English DT Article ID TASTE RECEPTOR T2R38; MUCOID PSEUDOMONAS-AERUGINOSA; UPPER RESPIRATORY-INFECTION; NASAL EPITHELIAL-CELLS; NITRIC-OXIDE SYNTHASE; CHRONIC RHINOSINUSITIS; CYSTIC-FIBROSIS; VITAMIN-D; IN-VITRO; HUMAN BETA-DEFENSIN-2 AB Background: Protecting the upper airway from microbial infection is an important function of the immune system. Proper detection of these pathogens is paramount for sinonasal epithelial cells to be able to prepare a defensive response. Toll-like receptors and, more recently, bitter taste receptors and sweet taste receptors have been implicated as sensors able to detect the presence of these pathogens and certain compounds that they secrete. Activation of these receptors also triggers innate immune responses to prevent or counteract infection, including mucociliary clearance and the production and secretion of antimicrobial compounds (e.g., defensins). Objective: To provide an overview of the current knowledge of the role of innate immunity in the upper airway, the mechanisms by which it is carried out, and its clinical relevance. Methods: A literature review of the existing knowledge of the role of innate immunity in the human sinonasal cavity was performed. Results: Clinical and basic science studies have shown that the physical epithelial cell barrier, mucociliary clearance, and antimicrobial compound secretion play pivotal innate immune roles in defending the sinonasal cavity from infection. Clinical findings have also linked dysfunction of these defense mechanisms with diseases, such as chronic rhinosinusitis and cystic fibrosis. Recent discoveries have elucidated the significance of bitter and sweet taste receptors in modulating immune responses in the upper airway. Conclusion: Numerous innate immune mechanisms seem to work in a concerted fashion to keep the sinonasal cavity free of infection. Understanding sinonasal innate immune function and dysfunction in health and disease has important implications for patients with respiratory ailments, such as chronic rhinosinusitis and cystic fibrosis. C1 [Hariri, Benjamin M.; Cohen, Noam A.] Univ Penn, Dept Otorhinolaryngol Head & Neck Surg, Ravdin Bldg,5th Floor,3400 Spruce St, Philadelphia, PA 19104 USA. [Cohen, Noam A.] Philadelphia VA Med Ctr, Surg Serv, Philadelphia, PA USA. [Cohen, Noam A.] Monell Chem Senses Ctr, Philadelphia, PA USA. RP Cohen, NA (reprint author), Univ Penn, Dept Otorhinolaryngol Head & Neck Surg, Ravdin Bldg,5th Floor,3400 Spruce St, Philadelphia, PA 19104 USA. EM noam.cohen@uphs.upenn.edu OI Cohen, Noam/0000-0002-9462-3932 FU NIH [R01DC013588, R21DC013886] FX Funding source NIH R01DC013588 and NIH R21DC013886 to N.A.C. NR 85 TC 0 Z9 0 U1 1 U2 1 PU OCEAN SIDE PUBLICATIONS INC PI PROVIDENCE PA 95 PITMAN ST, PROVIDENCE, RI 02906 USA SN 1945-8924 EI 1945-8932 J9 AM J RHINOL ALLERGY JI Am. J. Rhinol. Allergy PD SEP-OCT PY 2016 VL 30 IS 5 BP 319 EP 323 DI 10.2500/ajra.2016.30.4360 PG 5 WC Otorhinolaryngology SC Otorhinolaryngology GA EG2EA UT WOS:000390854700009 ER PT J AU Juttukonda, LJ Chazin, WJ Skaar, EP AF Juttukonda, Lillian J. Chazin, Walter J. Skaar, Eric P. TI Acinetobacter baumannii Coordinates Urea Metabolism with Metal Import To Resist Host-Mediated Metal Limitation SO MBIO LA English DT Article ID GRAM-NEGATIVE BACTERIA; ESCHERICHIA-COLI; STAPHYLOCOCCUS-AUREUS; ALLOPHANATE HYDROLASE; HUMAN CALPROTECTIN; DEFENSE PROTEIN; MANGANESE; TRANSPORTER; INFECTIONS; AMIDOLYASE AB During infection, bacterial pathogens must adapt to a nutrient metal-limited environment that is imposed by the host. The innate immune protein calprotectin inhibits bacterial growth in vitro by chelating the divalent metal ions zinc (Zn2+, Zn) and manganese (Mn2+, Mn), but pathogenic bacteria are able to cause disease in the presence of this antimicrobial protein in vivo. One such pathogen is Acinetobacter baumannii, a Gram-negative bacterium that causes pneumonia and bloodstream infections that can be complicated by resistance to multiple antibiotics. A. baumannii inhibition by calprotectin is dependent on calprotectin Mn binding, but the mechanisms employed by A. baumannii to overcome Mn limitation have not been identified. This work demonstrates that A. baumannii coordinates transcription of an NRAMP family Mn transporter and a urea carboxylase to resist the antimicrobial activities of calprotectin. This NRAMP family transporter facilitates Mn accumulation and growth of A. baumannii in the presence of calprotectin. A. baumannii is found to utilize urea as a sole nitrogen source, and urea utilization requires the urea carboxylase encoded in an operon with the NRAMP family transporter. Moreover, urea carboxylase activity is essential for calprotectin resistance in A. baumannii. Finally, evidence is provided that this system combats calprotectin in vivo, as deletion of the transporter impairs A. baumannii fitness in a mouse model of pneumonia, and this fitness defect is modulated by the presence of calprotectin. These findings reveal that A. baumannii has evolved mechanisms to subvert host-mediated metal sequestration and they uncover a connection between metal starvation and metabolic stress. IMPORTANCE Acinetobacter baumannii is a bacterium that causes bloodstream, wound, urinary tract, and pneumonia infections, with a high disease burden in intensive care units. Treatment of A. baumannii infection is complicated by resistance to most antibiotics in use today, and resistance to last-resort therapies has become commonplace. New treatments for A. baumannii infection are desperately needed, but our current understanding of the bacterial factors required to cause infection is limited. We previously found that the abundant innate immune protein calprotectin inhibits the growth of A. baumannii by withholding essential metals. Despite this, A. baumannii is still able to infect wild-type mice, which produce calprotectin during infection. Here, we identify factors employed by A. baumannii during infection to overcome calprotectin-mediated metal sequestration. Moreover, we expose a connection between metal starvation and metabolism that may be a "chink in the armor" of A. baumannii and lead to new treatment options. C1 [Juttukonda, Lillian J.; Skaar, Eric P.] Vanderbilt Univ, Sch Med, Dept Pathol Microbiol & Immunol, Nashville, TN 37212 USA. [Chazin, Walter J.] Vanderbilt Univ, Dept Biochem, Nashville, TN 37232 USA. [Chazin, Walter J.] Vanderbilt Univ, Dept Chem, Nashville, TN USA. [Chazin, Walter J.] Vanderbilt Univ, Struct Biol Ctr, 221 Kirkland Hall, Nashville, TN 37235 USA. [Skaar, Eric P.] Tennessee Valley Healthcare Syst, US Dept Vet Affairs, Nashville, TN 37212 USA. RP Skaar, EP (reprint author), Vanderbilt Univ, Sch Med, Dept Pathol Microbiol & Immunol, Nashville, TN 37212 USA.; Skaar, EP (reprint author), Tennessee Valley Healthcare Syst, US Dept Vet Affairs, Nashville, TN 37212 USA. EM eric.skaar@vanderbilt.edu FU HHS \ National Institutes of Health (NIH) [AI101171, T32 GM07347]; U.S. Department of Veterans Affairs (VA) [INFB-024-13F]; American Heart Association (AHA) [15PRE25060007] FX This work, including the efforts of Lillian Johnson Juttukonda, was funded by HHS vertical bar National Institutes of Health (NIH) (AI101171 and T32 GM07347). This work, including the efforts of Eric P. Skaar, was funded by U.S. Department of Veterans Affairs (VA) (INFB-024-13F). This work, including the efforts of Lillian Johnson Juttukonda, was funded by American Heart Association (AHA) (15PRE25060007). NR 53 TC 1 Z9 1 U1 4 U2 4 PU AMER SOC MICROBIOLOGY PI WASHINGTON PA 1752 N ST NW, WASHINGTON, DC 20036-2904 USA SN 2150-7511 J9 MBIO JI mBio PD SEP-OCT PY 2016 VL 7 IS 5 AR e01475-16 DI 10.1128/mBio.01475-16 PG 11 WC Microbiology SC Microbiology GA EF2CU UT WOS:000390132900031 ER PT J AU Aiken, ARA Borrero, S Callegari, LS Dehlendorf, C AF Aiken, Abigail R. A. Borrero, Sonya Callegari, Lisa S. Dehlendorf, Christine TI Rethinking the Pregnancy Planning Paradigm: Unintended Conceptions or Unrepresentative Concepts? SO PERSPECTIVES ON SEXUAL AND REPRODUCTIVE HEALTH LA English DT Editorial Material ID UNITED-STATES; CONTRACEPTIVE USE; YOUNG-ADULTS; WOMEN; AMBIVALENT; FERTILITY; HAPPINESS; HEALTH; RISK; WANTEDNESS C1 [Aiken, Abigail R. A.] Univ Texas Austin, LBJ Sch Publ Affairs, Austin, TX 78712 USA. [Aiken, Abigail R. A.] Univ Texas Austin, Populat Res Ctr, Austin, TX 78712 USA. [Borrero, Sonya] Univ Pittsburgh, Dept Med, Ctr Res Hlth Care, Pittsburgh, PA 15260 USA. [Borrero, Sonya] VA Pittsburgh Healthcare System, VA Ctr Hlth Equity Res & Promot, VA Adv Fellowship Program Womens Hlth, Pittsburgh, PA USA. [Callegari, Lisa S.] Univ Washington, Sch Med, Dept Obstet & Gynecol, Seattle, WA 98195 USA. [Callegari, Lisa S.] Dept Vet Affairs, Puget Sound Hlth Care Syst, Hlth Serv Res & Dev, Seattle, WA USA. [Dehlendorf, Christine] Univ Calif San Francisco, Dept Family & Community Med, San Francisco, CA 94143 USA. [Dehlendorf, Christine] Univ Calif San Francisco, Dept Obstet Gynecol & Reprod Sci, San Francisco, CA USA. [Dehlendorf, Christine] Univ Calif San Francisco, Dept Epidemiol & Biostat, San Francisco, CA 94143 USA. RP Aiken, ARA (reprint author), Univ Texas Austin, LBJ Sch Publ Affairs, Austin, TX 78712 USA.; Aiken, ARA (reprint author), Univ Texas Austin, Populat Res Ctr, Austin, TX 78712 USA. EM araa2@utexas.edu FU NICHD NIH HHS [P2C HD047879, R21 HD076327, R24 HD042849]; NIMHD NIH HHS [P60 MD006902] NR 29 TC 3 Z9 3 U1 6 U2 7 PU WILEY-BLACKWELL PI HOBOKEN PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA SN 1538-6341 EI 1931-2393 J9 PERSPECT SEX REPRO H JI Perspect. Sex Reprod. Health PD SEP PY 2016 VL 48 IS 3 BP 147 EP 151 DI 10.1363/48e10316 PG 5 WC Demography; Family Studies SC Demography; Family Studies GA ED9IK UT WOS:000389183200005 PM 27513444 ER PT J AU Wiederhold, NP Kovanda, L Najvar, LK Bocanegra, R Olivo, M Kirkpatrick, WR Patterson, TF AF Wiederhold, Nathan P. Kovanda, Laura Najvar, Laura K. Bocanegra, Rosie Olivo, Marcos Kirkpatrick, William R. Patterson, Thomas F. TI Isavuconazole Is Effective for the Treatment of Experimental Cryptococcal Meningitis SO ANTIMICROBIAL AGENTS AND CHEMOTHERAPY LA English DT Article ID PHARMACODYNAMIC TARGET DETERMINATION; ANTIFUNGAL TRIAZOLE BAL4815; MURINE MODEL; DOSE PHARMACOKINETICS; ASPERGILLUS-FUMIGATUS; HEALTHY-VOLUNTEERS; GATTII; FLUCONAZOLE; NEOFORMANS; MENINGOENCEPHALITIS AB We evaluated the efficacy of isavuconazole against cryptococcal meningitis. Treatment with either oral isavuconazole (120 mg/kg and 240 mg/kg twice a day [BID]) or fluconazole as the positive control significantly improved survival in mice infected intracranially with either Cryptococcus neoformans USC1597 or H99 and significantly reduced brain fungal burdens for both isolates. Concentrations of isavuconazole in plasma and brain tissue also demonstrated that the greatest improvements in survival and fungal burden were associated with elevated exposures. C1 [Wiederhold, Nathan P.; Najvar, Laura K.; Bocanegra, Rosie; Olivo, Marcos; Kirkpatrick, William R.; Patterson, Thomas F.] Univ Texas Hlth Sci Ctr San Antonio, San Antonio, TX 78229 USA. [Kovanda, Laura] Astellas Pharma Global Dev Inc, Northbrook, IL USA. [Najvar, Laura K.; Bocanegra, Rosie; Olivo, Marcos; Kirkpatrick, William R.; Patterson, Thomas F.] South Texas Vet Hlth Care Syst, San Antonio, TX USA. RP Wiederhold, NP (reprint author), Univ Texas Hlth Sci Ctr San Antonio, San Antonio, TX 78229 USA. EM wiederholdn@uthscsa.edu FU Astellas Pharma US (Astellas) FX This work, including the efforts of Nathan P. Wiederhold and Thomas F. Patterson, was funded by Astellas Pharma US (Astellas). NR 22 TC 0 Z9 0 U1 1 U2 1 PU AMER SOC MICROBIOLOGY PI WASHINGTON PA 1752 N ST NW, WASHINGTON, DC 20036-2904 USA SN 0066-4804 EI 1098-6596 J9 ANTIMICROB AGENTS CH JI Antimicrob. Agents Chemother. PD SEP PY 2016 VL 60 IS 9 BP 5600 EP 5603 DI 10.1128/AAC.00229-16 PG 4 WC Microbiology; Pharmacology & Pharmacy SC Microbiology; Pharmacology & Pharmacy GA ED7OH UT WOS:000389055400061 PM 27324761 ER PT J AU Spetz, J Dudley, N Trupin, L Rogers, M Meier, DE Dumanovsky, T AF Spetz, Joanne Dudley, Nancy Trupin, Laura Rogers, Maggie Meier, Diane E. Dumanovsky, Tamara TI Few Hospital Palliative Care Programs Meet National Staffing Recommendations SO HEALTH AFFAIRS LA English DT Article ID CANCER-PATIENTS; US HOSPITALS; CONSULTATION; COST; EDUCATION; ACCESS; TEAMS; CONFIDENCE; RESILIENCY; CLINICIAN AB The predominant model for palliative care delivery, outside of hospice care, is the hospital-based consultative team. Although a majority of US hospitals offer palliative care services, there has been little research on the staffing of their program teams and whether those teams meet national guidelines, such as the Joint Commission's standard of including at least one physician, an advanced practice or other registered nurse, a social worker, and a chaplain. Data from the 2012-13 annual surveys of the National Palliative Care Registry indicate that only 25 percent of participating programs met that standard based on funded positions, and even when unfunded positions were included, only 39 percent of programs met the standard. Larger palliative care programs were more likely than smaller ones to include a funded physician position, while smaller programs were more reliant upon advanced practice and registered nurses. To meet current and future palliative care needs, expanded and enhanced education, as well as supportive financing mechanisms for consultations, are needed. C1 [Spetz, Joanne] Univ Calif San Francisco, Philip R Lee Inst Hlth Policy Studies, Econ, San Francisco, CA 94143 USA. [Spetz, Joanne] Univ Calif San Francisco, Healthforce Ctr, San Francisco, CA 94143 USA. [Dudley, Nancy] UCSF Dept Geriatr, San Francisco, CA USA. [Dudley, Nancy] San Francisco VA Med Ctr, San Francisco, CA USA. [Trupin, Laura] UCSF, Philip R Lee Inst Hlth Policy Studies, San Francisco, CA USA. [Rogers, Maggie; Meier, Diane E.] Ctr Adv Palliat Care, New York, NY USA. [Meier, Diane E.] Icahn Sch Med Mt Sinai, Brookdale Dept Geriatr & Palliat Med, New York, NY 10029 USA. [Dumanovsky, Tamara] Ctr Adv Palliat Care, Res & Analyt, New York, NY USA. RP Spetz, J (reprint author), Univ Calif San Francisco, Philip R Lee Inst Hlth Policy Studies, Econ, San Francisco, CA 94143 USA.; Spetz, J (reprint author), Univ Calif San Francisco, Healthforce Ctr, San Francisco, CA 94143 USA. EM joanne.spetz@ucsf.edu FU Health Resources and Services Administration (HRSA) of the Department of Health and Human Services (HHS) under Cooperative Agreement for a Regional Center for Health Workforce Studies [U81HP26494]; Center to Advance Palliative Care; National Palliative Care Research Center; Patty and Jay Baker National Palliative Care Center FX This study was supported by the Health Resources and Services Administration (HRSA) of the Department of Health and Human Services (HHS) under the Cooperative Agreement for a Regional Center for Health Workforce Studies (Grant No. U81HP26494). The information in or content and conclusions of this article are those of the authors and should not be construed as the official position or policy of, nor should any endorsements be inferred by, HRSA, HHS, or the US government. The National Palliative Care Registry is supported by the Center to Advance Palliative Care, the National Palliative Care Research Center, and the Patty and Jay Baker National Palliative Care Center. R. Sean Morrison provided helpful suggestions in the interpretation of the National Registry data and editorial suggestions. NR 35 TC 0 Z9 0 U1 1 U2 2 PU PROJECT HOPE PI BETHESDA PA 7500 OLD GEORGETOWN RD, STE 600, BETHESDA, MD 20814-6133 USA SN 0278-2715 J9 HEALTH AFFAIR JI Health Aff. PD SEP PY 2016 VL 35 IS 9 BP 1690 EP 1697 DI 10.1377/hlthaff.2016.0113 PG 8 WC Health Care Sciences & Services; Health Policy & Services SC Health Care Sciences & Services GA EB1LT UT WOS:000387114300021 PM 27605652 ER PT J AU Clary-Muronda, V Pope, C AF Clary-Muronda, Valerie Pope, Charlene TI Integrative Review of Instruments to Measure Team Performance During Neonatal Resuscitation Simulations in the Birthing Room SO JOGNN-JOURNAL OF OBSTETRIC GYNECOLOGIC AND NEONATAL NURSING LA English DT Article DE birthing room; interprofessional; measurement; neonatal; resuscitation; simulation; social ecological model ID IN-SITU SIMULATION; PATIENT SAFETY; HEALTH-CARE; BEHAVIOR; SKILLS; COLLABORATION; COMMUNICATION; SATISFACTION; READINESS; EDUCATION AB Objective: To identify instruments appropriate to measure interprofessional team performance in neonatal resuscitation (NR), describe the validity and reliability of extant NR instruments, and determine instruments for use in interprofessional birthing room NR simulations. Data Sources: The Cumulative Index to Nursing and Allied Health Literature, Ovid MEDLINE, Proquest, ScienceDirect, PubMed, and Scopus databases were searched. Study Selection: We used inclusion and exclusion criteria and screened 641 abstracts from January 2000 through December 2014 for relevance to the research question. We reviewed 78 full-text primary research publications in English and excluded 37 publications not specific to pediatrics or neonatology. After in-depth review of the 41 studies that remained, we excluded additional studies if they did not have an interprofessional focus, include psychometric information, or include a measurement instrument. Ten publications met the inclusion criteria. Data Extraction and Synthesis: Studies were reviewed, categorized, and scored to identify instruments to measure interprofessional team performance in simulations of birthing room NR. A social ecological model was used as a guide framework to identify multiple influencing factors at various levels that affect team performance. Ten instruments with documentation of validity and reliability for technical competence and team processes in interprofessional birthing room NR teams were identified. Conclusion: Extant instruments rarely address the multiple factors that may impede interprofessional team performance in birthing room NR. It is necessary for researchers to engage in rigorous psychometric testing of measurement instruments to ensure their validity and reliability for interprofessional NR teams and consider tests or updates (if necessary) of extant instruments rather than the development of new instruments. C1 [Clary-Muronda, Valerie] Thomas Jefferson Univ, Coll Nursing, 130 S 9th St,Ste 762,Edison Bldg, Philadelphia, PA 19107 USA. [Clary-Muronda, Valerie; Pope, Charlene] Med Univ South Carolina, Coll Nursing, Charleston, SC USA. [Pope, Charlene] Ralph H Johnson VA Med Ctr, Res, Charleston, SC USA. RP Clary-Muronda, V (reprint author), Thomas Jefferson Univ, Coll Nursing, 130 S 9th St,Ste 762,Edison Bldg, Philadelphia, PA 19107 USA. EM vclarymuronda@gmail.com NR 50 TC 0 Z9 0 U1 3 U2 3 PU ELSEVIER SCIENCE INC PI NEW YORK PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA SN 0884-2175 EI 1552-6909 J9 JOGNN-J OBST GYN NEO JI JOGNN PD SEP-OCT PY 2016 VL 45 IS 5 BP 684 EP 698 DI 10.1016/j.jogn.2016.04.007 PG 15 WC Nursing; Obstetrics & Gynecology SC Nursing; Obstetrics & Gynecology GA ED4TN UT WOS:000388844600015 PM 27470178 ER PT J AU Chao, LL Abadjian, LR Esparza, IL Reeb, R AF Chao, Linda L. Abadjian, Linda R. Esparza, Iva L. Reeb, Rosemary TI Insomnia Severity, Subjective Sleep Quality, and Risk for Obstructive Sleep Apnea in Veterans With Gulf War Illness SO MILITARY MEDICINE LA English DT Article ID COGNITIVE-BEHAVIORAL THERAPY; ORGANOPHOSPHATE PESTICIDES; IMMUNE FUNCTION; SHEEP FARMERS; FIBROMYALGIA; DEPRESSION; SYMPTOMS; EXPOSURE; HEALTH; INDEX AB Despite the fact that sleep disturbances are common in veterans with Gulf War Illness (GWI), there has been a paucity of published sleep studies in this veteran population to date. Therefore, the present study examined subjective sleep quality (assessed with the Pittsburgh Sleep Quality Index), insomnia severity (assessed with the Insomnia Severity Index), and risk for obstructive sleep apnea (assessed with the STOP questionnaire) in 98 Gulf War veterans. Veterans with GWI, defined either by the Kansas or Centers for Disease Control and Prevention criteria, had greater risk for obstructive sleep apnea (i.e., higher STOP scores) than veterans without GWI. This difference persisted even after accounting for potentially confounding demographic (e.g., age, gender) and clinical variables. Veterans with GWI, defined by either the Kansas or Centers for Disease Control and Prevention criteria, also had significantly greater insomnia severity and poorer sleep quality than veterans without GWI (p < 0.05), even after accounting for potentially confounding variables. Furthermore, there were significant, positive correlations between insomnia severity, subjective sleep quality, and GWI symptom severity (p <= 0.01). In stepwise linear regression models, insomnia severity significantly predicted GWI status over and above demographic and clinical variables. Together these findings provide good rationale for treating sleep disturbances in the management of GWI. C1 [Chao, Linda L.; Abadjian, Linda R.; Esparza, Iva L.; Reeb, Rosemary] San Francisco VA Med Ctr, Ctr Imaging Neurodegenerat Dis, 4150 Clement St 114M, San Francisco, CA 94121 USA. [Chao, Linda L.; Reeb, Rosemary] Univ Calif San Francisco, Dept Radiol & Biomed Imaging, 505 Parnassus Ave, San Francisco, CA 94143 USA. [Chao, Linda L.] Univ Calif San Francisco, Dept Psychiat, 401 Parnassus Ave, San Francisco, CA 94143 USA. RP Chao, LL (reprint author), San Francisco VA Med Ctr, Ctr Imaging Neurodegenerat Dis, 4150 Clement St 114M, San Francisco, CA 94121 USA.; Chao, LL (reprint author), Univ Calif San Francisco, Dept Radiol & Biomed Imaging, 505 Parnassus Ave, San Francisco, CA 94143 USA.; Chao, LL (reprint author), Univ Calif San Francisco, Dept Psychiat, 401 Parnassus Ave, San Francisco, CA 94143 USA. FU Department of Veterans Affairs Merit grant [I01BX007080]; San Francisco Veterans Affairs Medical Center FX Support for this work was provided by a Department of Veterans Affairs Merit grant No. I01BX007080 entitled "Longitudinal Assessment of Gulf War Veterans with Suspected Sarin Exposure" as well as resources and the use of facilities at the San Francisco Veterans Affairs Medical Center. The authors would like to thank all the GW veterans who participated in this study. NR 61 TC 0 Z9 0 U1 3 U2 3 PU ASSOC MILITARY SURG US PI BETHESDA PA 9320 OLD GEORGETOWN RD, BETHESDA, MD 20814 USA SN 0026-4075 EI 1930-613X J9 MIL MED JI Milit. Med. PD SEP PY 2016 VL 181 IS 9 BP 1127 EP 1134 DI 10.7205/MILMED-D-15-00474 PG 8 WC Medicine, General & Internal SC General & Internal Medicine GA DW5MV UT WOS:000383690500037 PM 27612364 ER PT J AU Ward, L Pasinetti, GM AF Ward, Libby Pasinetti, Giulio Maria TI Recommendations for Development of Botanical Polyphenols as "Natural Drugs'' for Promotion of Resilience Against Stress-Induced Depression and Cognitive Impairment SO NEUROMOLECULAR MEDICINE LA English DT Review DE Polyphenols; Botanicals; Resilience; Stress-induced depression; Sleep deprivation-induced cognitive impairment; Microbiome ID ALZHEIMERS-DISEASE; DIETARY POLYPHENOLS; MAJOR DEPRESSION; COLONIC METABOLISM; SLEEP-DEPRIVATION; ANXIETY DISORDERS; GUT MICROBIOTA; BRAIN; SEED; HEALTH AB E xtensive evidence has demonstrated that psychological stress has detrimental effects on psychological health, cognitive function, and ultimately well-being. While stressful events are a significant cause of psychopathology, most individuals exposed to adversity maintain normal psychological functioning. The mechanisms underlying such resilience are poorly understood, and there is an urgent need to identify and target these mechanisms to promote resilience under stressful events. Botanicals have been used throughout history to treat various medical conditions; however, the development of botanical compounds into potential preventative and therapeutic agents in studies promoting brain health is hindered by the fact that most orally consumed botanicals are extensively metabolized during absorption and/or by postabsorptive xenobiotic metabolism. Therefore, the primary objective of this review article is to provide recommendations for developing natural compounds as novel therapeutic strategies to promote resilience in susceptible subjects. The development of botanical polyphenols to ultimately attenuate mood disorders and cognitive impairment will rely on understanding (1) the absorption and bioavailability of botanical polyphenols with emphasis on flavan-3-ols, (2) the characterization of tissue-specific accumulation of biologically available polyphenols and their mechanisms of action in the brain, and eventually (3) the characterization of biologically available polyphenol metabolites in mechanisms associated with the promotion of resilience against mood disorders and cognitive impairment in response to stress. We also summarize exciting new lines of investigation about the role of botanicals such as polyphenols in the promotion of cognitive and psychological resilience. This information will provide a strategical framework for the future development of botanicals as therapeutic agents to promote resilience, ultimately preventing and/or therapeutically treating cognitive impairment and psychological dysfunction. C1 [Ward, Libby; Pasinetti, Giulio Maria] Icahn Sch Med Mt Sinai, Dept Neurol, New York, NY 10029 USA. [Pasinetti, Giulio Maria] James J Peters Vet Affairs Med Ctr, Geriatr Res Educ & Clin Ctr, Bronx, NY 10468 USA. RP Pasinetti, GM (reprint author), Icahn Sch Med Mt Sinai, Dept Neurol, New York, NY 10029 USA.; Pasinetti, GM (reprint author), James J Peters Vet Affairs Med Ctr, Geriatr Res Educ & Clin Ctr, Bronx, NY 10468 USA. EM Giulio.Pasinetti@mssm.edu FU National Center for Complementary and Integrative Health (NCCIH) [P50 AT008661-01]; Office of Dietary Supplements (ODS); Career Scientist Award in the Research and Development unit FX This publication was supported by Grant Number P50 AT008661-01, titled "Dietary Botanicals in the Preservation of Cognitive and Psychological Resilience," from the National Center for Complementary and Integrative Health (NCCIH) and the Office of Dietary Supplements (ODS). In addition, Dr. Pasinetti holds a Career Scientist Award in the Research and Development unit and is the Director of the Basic and Biomedical Research and Training Program, GRECC, James J. Peters Veterans Affairs Medical Center. We acknowledge that the contents of this manuscript do not represent the views of the NCCIH, ODS, National Institutes of Health, U.S. Department of Veterans Affairs, or the United States Government. NR 61 TC 1 Z9 1 U1 5 U2 6 PU HUMANA PRESS INC PI TOTOWA PA 999 RIVERVIEW DRIVE SUITE 208, TOTOWA, NJ 07512 USA SN 1535-1084 EI 1559-1174 J9 NEUROMOL MED JI Neuromol. Med. PD SEP PY 2016 VL 18 IS 3 BP 487 EP 495 DI 10.1007/s12017-016-8418-6 PG 9 WC Neurosciences SC Neurosciences & Neurology GA EC1GA UT WOS:000387851700021 PM 27342633 ER PT J AU Soto-Pina, AE Franklin, C Rani, CSS Gottlieb, H Hinojosa-Laborde, C Strong, R AF Soto-Pina, Alexandra E. Franklin, Cynthia Rani, C. S. Sheela Gottlieb, Helmut Hinojosa-Laborde, Carmen Strong, Randy TI A Novel Model of Dexamethasone-Induced Hypertension: Use in Investigating the Role of Tyrosine Hydroxylase SO JOURNAL OF PHARMACOLOGY AND EXPERIMENTAL THERAPEUTICS LA English DT Article ID CATECHOLAMINE BIOSYNTHETIC-ENZYMES; ADRENAL-MEDULLA; GENE-EXPRESSION; RHEUMATOID-ARTHRITIS; BLOOD-PRESSURE; XANTHINE-OXIDASE; UP-REGULATION; RAT; GLUCOCORTICOIDS; STRESS AB Our objective was to study hypertension induced by chronic administration of synthetic glucocorticoid, dexamethasone (DEX), under nonstressful conditions and examine the role of catecholamine biosynthesis. To achieve this, we did the following: 1) used radiotelemetry to record mean arterial pressure (MAP) and heart rate (HR) in freely moving rats, and 2) administered different doses of DEX in drinking water. To evaluate the involvement of tyrosine hydroxylase (TH), the rate-limiting step in catecholamine biosynthesis, we treated rats with the TH inhibitor, alpha-methyl-paratyrosine (alpha-MPT), for 3 days prior to administration of DEX and assessed TH mRNA and protein expression by quantitative realtime polymerase chain reaction and Western blot in the adrenal medulla. We observed a dose-dependent elevation in blood pressure with a DEX dose of 0.3 mg/kg administered for 10 days, significantly increasing MAP by +15.0 +/- 1.1 mm Hg, while concomitantly reducing HR. Although this DEX treatment also significantly decreased body weight, pair-fed animals that showed similar decreases in body weight due to lowered food intake were not hypertensive, suggesting that body weight changes may not account for DEX-induced hypertension. Chronic DEX treatment significantly increased the TH mRNA and protein levels in the adrenal medulla, and alpha-MPT administration not only reduced DEX pressor effects, but also inhibited TH (serine(40)) phosphorylation. Our study thus validates a novel model to study hypertension induced by chronic intake of DEX in freely moving rats not subject to the confounding factors of previous models and establishes its dependence on concomitant activation of peripheral catecholamine biosynthesis. C1 [Soto-Pina, Alexandra E.] Univ Autonoma Estado Mexico, Fac Med, Toluca, Mexico. [Rani, C. S. Sheela; Hinojosa-Laborde, Carmen; Strong, Randy] Univ Texas Hlth Sci Ctr San Antonio, Dept Pharmacol, San Antonio, TX 78229 USA. [Franklin, Cynthia; Gottlieb, Helmut] Univ Incarnate Word, Feik Sch Pharm, San Antonio, TX USA. [Strong, Randy] South Texas Vet Hlth Care Syst, Audie L Murphy Div, San Antonio, TX USA. RP Soto-Pina, AE (reprint author), Paseo Tollocan Esq Jesus Carranza, Toluca 50180, Estado De Mexic, Mexico. EM aesotop@uaemex.mx FU Department of Veteran Affairs; Consejo Nacional de Ciencia y Technologia; American Heart Association FX This work was supported by the Department of Veteran Affairs (to R.S.), Consejo Nacional de Ciencia y Technologia (to A.E.S.-P.), and a predoctoral award from the American Heart Association (to A.E.S.-P.). NR 71 TC 0 Z9 0 U1 1 U2 1 PU AMER SOC PHARMACOLOGY EXPERIMENTAL THERAPEUTICS PI BETHESDA PA 9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3995 USA SN 0022-3565 EI 1521-0103 J9 J PHARMACOL EXP THER JI J. Pharmacol. Exp. Ther. PD SEP 1 PY 2016 VL 358 IS 3 BP 528 EP 536 DI 10.1124/jpet.116.234005 PG 9 WC Pharmacology & Pharmacy SC Pharmacology & Pharmacy GA ED7RA UT WOS:000389065700019 PM 27405316 ER PT J AU Zuschlag, ZD Lalich, CJ Short, EB Hamner, M Kahn, DA AF Zuschlag, Zachary D. Lalich, Callie J. Short, Edward B. Hamner, Mark Kahn, David A. TI Pyrotherapy for the Treatment of Psychosis in the 21st Century: A Case Report and Literature Review SO JOURNAL OF PSYCHIATRIC PRACTICE LA English DT Review DE pyrotherapy; pyretotherapy; schizophrenia; schizoaffective disorder; psychosis; fever; Wagner-Jauregg; heat shock response; sulforaphane ID INSULIN COMA; THERAPY; FEVER; SULFORAPHANE; PARALYSIS; MALARIA AB The concept that fevers can improve the condition of patients with certain medical and psychiatric diseases dates back to Hippocrates. Over the centuries, it has been observed that fevers and infectious agents have been beneficial for a broad spectrum of diseases, including neurologic conditions such as epilepsy and psychiatric illnesses including melancholy and psychosis. Interest in the concept of fever as a treatment for disease, termed pyrotherapy or pyretotherapy, peaked in the late 1800s and early 1900s thanks to the Nobel Prize winning work of Julius Wagner-Jauregg for his studies with malaria therapy for general paralysis of the insane, now more commonly referred to as neurosyphilis. The use of inoculations of infectious agents for their fever-inducing effects in the treatment of neurosyphilis quickly spread throughout the world, and, by the 1920s, it was considered by many to be the treatment of choice for neurosyphilis as well as other psychotic disorders. However, with the discovery of penicillin for the treatment of syphilis, which coincided with the advent of convulsion-oriented practices including electroconvulsive therapy and insulin coma for the treatment of psychotic disorders, pyrotherapy soon lost favor among psychiatrists and, since the 1950s, it has largely been overlooked by the scientific community. In this article, the authors provide a brief literature review of the history of pyrotherapy and present a case report of a woman with schizoaffective disorder and severe psychotic symptoms who experienced a remarkable resolution of psychotic symptoms following an episode of bacteremia with high fever. C1 [Zuschlag, Zachary D.; Lalich, Callie J.; Short, Edward B.; Hamner, Mark] Med Univ South Carolina, Dept Psychiat & Behav Sci, Charleston, SC USA. [Hamner, Mark] Ralph H Johnson Vet Adm, Charleston, SC USA. [Kahn, David A.] Columbia Univ Coll Phys & Surg, 630 W 168th St, New York, NY 10032 USA. RP Zuschlag, ZD (reprint author), 102 Doughty St, Charleston, SC 29425 USA. EM zuschlagzd@gmail.com NR 51 TC 0 Z9 0 U1 0 U2 0 PU LIPPINCOTT WILLIAMS & WILKINS PI PHILADELPHIA PA TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA SN 1527-4160 EI 1538-1145 J9 J PSYCHIATR PRACT JI J. Psychiatr. Pract. PD SEP PY 2016 VL 22 IS 5 BP 410 EP 415 DI 10.1097/PRA.0000000000000181 PG 6 WC Psychiatry SC Psychiatry GA EC5AY UT WOS:000388146700008 PM 27648506 ER PT J AU Gonzalez, S Gupta, J Villa, E Mallawaarachchi, I Rodriguez, M Ramirez, M Zavala, J Armas, R Dassori, A Contreras, J Flores, D Jerez, A Ontiveros, A Nicolini, H Escamilla, M AF Gonzalez, Suzanne Gupta, Jayanta Villa, Erika Mallawaarachchi, Indika Rodriguez, Marco Ramirez, Mercedes Zavala, Juan Armas, Regina Dassori, Albana Contreras, Javier Flores, Deborah Jerez, Alvaro Ontiveros, Alfonso Nicolini, Humberto Escamilla, Michael TI Replication of genome-wide association study (GWAS) susceptibility loci in a Latino bipolar disorder cohort SO BIPOLAR DISORDERS LA English DT Article DE bipolar disorder; Central American; family studies; genetics; lysosomal associated membrane protein 3 (LAMP3); Latinos; Mexican; Mexican-American; nuclear factor kappa B subunit 1 (NFKB1); serologically defined colon cancer antigen 8 (SDCCAG8) ID FAMILY-BASED ASSOCIATION; COMMON VARIANTS; JEWISH POPULATION; CANDIDATE GENES; SCHIZOPHRENIA; HAPLOTYPE; DEPRESSION; DISEASE; LINKAGE; RISK AB Objectives: Recent genome-wide association studies (GWASs) have identified numerous putative genetic polymorphisms associated with bipolar disorder (BD) and/or schizophrenia (SC). We hypothesized that a portion of these polymorphisms would also be associated with BD in the Latino American population. To identify such regions, we tested previously identified genetic variants associated with BD and/or SC and ancestral haploblocks containing these single nucleotide polymorphisms (SNPs) in a sample of Latino subjects with BD. Methods: A total of 2254 Latino individuals were genotyped for 91 SNPs identified in previous BD and/or SC GWASs, along with selected SNPs in strong linkage disequilibrium with these markers. Family-based single marker and haplotype association testing was performed using the PBAT software package. Empirical P-values were derived from 10 000 permutations. Results: Associations of eight a priori GWAS SNPs with BD were replicated with nominal (P <=.05) levels of significance. These included SNPs within nuclear factor I A (NFIA), serologically defined colon cancer antigen 8 (SDCCAG8), lysosomal associated membrane protein 3 (LAMP3), nuclear factor kappa B subunit 1 (NFKB1), major histocompatibility complex, class I, B (HLA-B) and 5'-nucleotidase, cytosolic II (NT5C2) and SNPs within intragenic regions microRNA 6828 (MIR6828)-solute carrier family 7 member 14 (SLC7A14) and sonic hedgehog (SHH)-long intergenic non-protein coding RNA 1006 (LINC01006). Of the 76 ancestral haploblocks that were tested for associations with BD, our top associated haploblock was located in LAMP3; however, the association did not meet statistical thresholds of significance following Bonferroni correction. Conclusions: These results indicate that some of the gene variants found to be associated with BD or SC in other populations are also associated with BD risk in Latinos. Variants in six genes and two intragenic regions were associated with BD in our Latino sample and provide additional evidence for overlap in genetic risk between SC and BD. C1 [Gonzalez, Suzanne; Villa, Erika; Rodriguez, Marco; Ramirez, Mercedes; Zavala, Juan; Escamilla, Michael] Texas Tech Univ, Hlth Sci Ctr, Paul L Foster Sch Med, Ctr Excellence Neurosci,Dept Biomed Sci, El Paso, TX 79430 USA. [Gupta, Jayanta] Florida Gulf Coast Univ, Dept Hlth Sci, Coll Hlth Profess & Social Work, Ft Myers, FL USA. [Mallawaarachchi, Indika] Texas Tech Univ, Hlth Sci Ctr, Paul L Foster Sch Med, Biostat & Epidemiol Consulting Lab, El Paso, TX USA. [Ramirez, Mercedes; Zavala, Juan; Escamilla, Michael] Texas Tech Univ, Paul L Foster Sch Med, Dept Psychiat, Hlth Sci Ctr, El Paso, TX USA. [Armas, Regina] Univ Calif San Francisco, Langley Porter Psychiat Inst, San Francisco, CA 94143 USA. [Dassori, Albana] Univ Texas Hlth Sci Ctr San Antonio, Dept Psychiat, San Antonio, TX 78229 USA. [Dassori, Albana] South Texas Vet Hlth Care Syst, San Antonio, TX USA. [Contreras, Javier] Univ Costa Rica, Ctr Invest Biol Celular & Mol, San Jose, Costa Rica. [Contreras, Javier] Univ Costa Rica, Escuela Biol, San Jose, Costa Rica. [Flores, Deborah] Univ Calif Los Angeles, Med Ctr, Los Angeles Biomed Res Ctr Harbor, Torrance, CA 90509 USA. [Jerez, Alvaro] Ctr Int Trastornos Afect & Conducta Adict, Guatemala City, Guatemala. [Ontiveros, Alfonso] Inst Informac & Invest Salud Mental AC, Monterrey, Nuevo Leon, Mexico. [Nicolini, Humberto] Grp Estudios Med & Familiares Carracci SC, Mexico City, DF, Mexico. RP Gonzalez, S (reprint author), Texas Tech Univ, Hlth Sci Ctr, Paul L Foster Sch Med, Ctr Excellence Neurosci,Dept Biomed Sci, El Paso, TX 79430 USA. EM suzanne.gonzalez@ttuhsc.edu OI Jerez Magana, Alvaro Antonio/0000-0002-1208-3769 NR 62 TC 0 Z9 0 U1 1 U2 1 PU WILEY-BLACKWELL PI HOBOKEN PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA SN 1398-5647 EI 1399-5618 J9 BIPOLAR DISORD JI Bipolar Disord. PD SEP PY 2016 VL 18 IS 6 BP 520 EP 527 DI 10.1111/bdi.12438 PG 8 WC Clinical Neurology; Neurosciences; Psychiatry SC Neurosciences & Neurology; Psychiatry GA EC7HS UT WOS:000388308400006 PM 27759212 ER PT J AU Ospina, LH Russo, M Nitzburg, GC Cuesta-Diaz, A Shanahan, M Perez-Rodriguez, MM Mcgrath, M Levine, H Mulaimovic, S Burdick, KE AF Ospina, Luz H. Russo, Manuela Nitzburg, George C. Cuesta-Diaz, Armando Shanahan, Megan Perez-Rodriguez, Mercedes M. Mcgrath, Meaghan Levine, Hannah Mulaimovic, Sandra Burdick, Katherine E. TI The effects of cigarette smoking behavior and psychosis history on general and social cognition in bipolar disorder SO BIPOLAR DISORDERS LA English DT Article DE bipolar disorder; neurocognition; psychosis; smoking; social cognition ID SERIOUS MENTAL-ILLNESS; RATING-SCALE; TOBACCO SMOKING; WORKING-MEMORY; SCREENING-TEST; AUDIT-C; SCHIZOPHRENIA; NICOTINE; DEPRESSION; DEFICITS AB Objectives: Several studies have documented the prevalence and effects of cigarette smoking on cognition in psychotic disorders; fewer have focused on bipolar disorder (BD). Cognitive and social dysfunction are common in BD, and the severity of these deficits may be related both to illness features (e.g., current symptoms, psychosis history) and health-related behaviors (e.g.,smoking, alcohol use). The current study assessed the influence of cigarette smoking on general and social cognition in a BD cohort, accounting for illness features with a focus on psychosis history. Methods: We assessed smoking status in 105 euthymic patients with BD, who completed a comprehensive battery including social (facial affect recognition, emotional problem-solving, and theory of mind) and general (the MATRICS Consensus Cognitive Battery and executive functioning) cognitive measures. We compared smokers vs nonsmokers on cognitive performance and tested for the effects of psychosis history, premorbid intellectual functioning, substance use, and current affective symptoms. Results: Within the nonpsychotic subgroup with BD (n=45), smokers generally outperformed nonsmokers; by contrast, for subjects with BD with a history of psychosis (n=41), nonsmokers outperformed smokers. This pattern was noted more globally using a general composite cognitive score and on social/affective measures assessing patients' ability to identify emotions of facial stimuli and solve emotional problems. Conclusions: Cigarette smoking differentially affects performance on both general and social cognition in patients with BD as a function of psychosis history. These results suggest that there may be at least partially divergent underlying neurobiological causes for cognitive dysfunction in patients with BD with and without psychosis. C1 [Ospina, Luz H.; Russo, Manuela; Nitzburg, George C.; Cuesta-Diaz, Armando; Shanahan, Megan; Perez-Rodriguez, Mercedes M.; Mcgrath, Meaghan; Levine, Hannah; Mulaimovic, Sandra; Burdick, Katherine E.] Icahn Sch Med Mt Sinai, Dept Psychiat, New York, NY 10029 USA. [Ospina, Luz H.; Russo, Manuela; Nitzburg, George C.; Cuesta-Diaz, Armando; Shanahan, Megan; Perez-Rodriguez, Mercedes M.; Mcgrath, Meaghan; Levine, Hannah; Mulaimovic, Sandra; Burdick, Katherine E.] Icahn Sch Med Mt Sinai, Dept Neurosci, New York, NY 10029 USA. [Burdick, Katherine E.] James J Peters VA Med Ctr, Bronx, NY USA. RP Burdick, KE (reprint author), Icahn Sch Med Mt Sinai, Dept Psychiat, New York, NY 10029 USA.; Burdick, KE (reprint author), Icahn Sch Med Mt Sinai, Dept Neurosci, New York, NY 10029 USA. EM katherine.burdick@mssm.edu FU NIMH NIH HHS [R01 MH100125] NR 79 TC 0 Z9 0 U1 4 U2 4 PU WILEY-BLACKWELL PI HOBOKEN PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA SN 1398-5647 EI 1399-5618 J9 BIPOLAR DISORD JI Bipolar Disord. PD SEP PY 2016 VL 18 IS 6 BP 528 EP 538 DI 10.1111/bdi.12420 PG 11 WC Clinical Neurology; Neurosciences; Psychiatry SC Neurosciences & Neurology; Psychiatry GA EC7HS UT WOS:000388308400007 PM 27650399 ER PT J AU Dodson, JA Matlock, DD Forman, DE AF Dodson, John A. Matlock, Daniel D. Forman, Daniel E. TI Geriatric Cardiology: An Emerging Discipline SO CANADIAN JOURNAL OF CARDIOLOGY LA English DT Review ID AORTIC-VALVE-REPLACEMENT; ACUTE MYOCARDIAL-INFARCTION; CARDIOVASCULAR-DISEASE ENTERPRISES; OLDER-ADULTS; HEART-FAILURE; ELDERLY-PATIENTS; COGNITIVE IMPAIRMENT; MAJOR SHAREHOLDERS; DECISION-MAKING; UNITED-STATES AB Given changing demographics, patients with cardiovascular (CV) disease in developed countries are now older and more complex than even a decade ago. This trend is expected to continue into the foreseeable future; accordingly, cardiologists are encountering patients with a greater number of comorbid illnesses as well as "geriatric conditions," such as cognitive impairment and frailty, which complicate management and influence outcomes. Simultaneously, technological advances have widened the therapeutic options available for patients, including those with the most advanced CV disease. In the setting of these changes, geriatric cardiology has recently emerged as a discipline that aims to adapt principles from geriatric medicine to everyday cardiology practice. Accordingly, the tasks of a "geriatric cardiologist" may include both traditional evidence-based CV management plus comprehensive geriatric assessment, medication reduction, team-based coordination of care, and explicit incorporation of patient goals into management. Given that the field is still in its relative infancy, the training pathways and structure of clinical programs in geriatric cardiology are still being delineated. In this review, we highlight the rationale behind geriatric cardiology as a discipline, several current approaches by geriatric cardiology programs, and future directions for the field. C1 [Dodson, John A.] NYU, Sch Med, Leon H Charney Div Cardiol, New York, NY USA. [Dodson, John A.] NYU, Sch Med, Dept Med, New York, NY USA. [Dodson, John A.] NYU, Sch Med, Dept Populat Hlth, New York, NY USA. [Matlock, Daniel D.] Univ Colorado, Sch Med, Dept Med, Div Geriatr, Aurora, CO USA. [Forman, Daniel E.] Univ Pittsburgh, Med Ctr, Dept Med, Sect Geriatr Cardiol, Pittsburgh, PA USA. [Forman, Daniel E.] Univ Pittsburgh, VA Pittsburgh Healthcare Syst, Geriatr Res Educ & Clin Ctr, Pittsburgh, PA USA. RP Dodson, JA (reprint author), NYU, Sch Med, 227 E 30th St, New York, NY 10016 USA. EM john.dodson@nyumc.org FU American Heart Association; Peter A. Lefkow, MD Lead Charitable Trust; NIA grant [P30 AG024827]; VA Office of Rehabilitation Research and Development grant [F0834-R]; National Institutes on Aging [K23AG040696] FX J.A.D. is supported in part by a Mentored Clinical and Population Research Award from the American Heart Association and by the Peter A. Lefkow, MD Lead Charitable Trust. D.E.F. is supported in part by NIA grant P30 AG024827 and VA Office of Rehabilitation Research and Development grant F0834-R. D.D.M. is supported by a career development award from the National Institutes on Aging (K23AG040696). NR 75 TC 1 Z9 1 U1 3 U2 3 PU ELSEVIER SCIENCE INC PI NEW YORK PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA SN 0828-282X EI 1916-7075 J9 CAN J CARDIOL JI Can. J. Cardiol. PD SEP PY 2016 VL 32 IS 9 BP 1056 EP 1064 DI 10.1016/j.cjca.2016.03.019 PG 9 WC Cardiac & Cardiovascular Systems SC Cardiovascular System & Cardiology GA EC7DU UT WOS:000388296800005 PM 27476988 ER PT J AU Forman, DE Alexander, KP AF Forman, Daniel E. Alexander, Karen P. TI Frailty: A Vital Sign for Older Adults With Cardiovascular Disease SO CANADIAN JOURNAL OF CARDIOLOGY LA English DT Review ID AORTIC-VALVE-REPLACEMENT; CORONARY-ARTERY-DISEASE; ALL-CAUSE MORTALITY; GAIT SPEED; PHYSICAL PERFORMANCE; ELDERLY-PATIENTS; CARDIAC-SURGERY; HEART-FAILURE; EYEBALL TEST; RISK AB Mechanisms of aging predispose to cardiovascular disease (CVD), as well as to aggregate health challenges. For older adults, CVD is likely to exist in combination with comorbid conditions, disability, polypharmacy, falling risks, and body composition changes. These other dimensions of health result in cumulative weakening with greater clinical complexity that confound basic precepts of CVD presentation, prognosis, and treatments. A convenient operational tool is needed to gauge this age-related vulnerability such that it can be integrated in the evaluation and treatment of CVD. Frailty is a concept that is neither disease-nor age-specific, but is used to characterize the reserve that a person has available to tolerate stresses associated with aging, disease, and even therapy. Frailty arises from specific biological mechanisms in association with cumulative physiological decrements, psychosocial stresses, and physical impairments. Performance-based and survey tools have been developed and tested to measure frailty. Although different frailty tools vary in practicality, measured domains, and precise applications, all are useful in identifying risks that commonly accrue with age. Although comparisons between frailty tools are ongoing and sometimes even controversial, the rationale to integrate routine use of frailty screening as part of routine care is relatively straightforward and easy to envision. Frailty assessment applied as a vital sign (for standard maintenance and evaluation of new symptoms) enhances perspectives of risk, decision-making, and opportunities for tailored CVD management. C1 [Forman, Daniel E.] Univ Pittsburgh, Med Ctr, Geriatr Cardiol Sect, Pittsburgh, PA USA. [Forman, Daniel E.] Univ Pittsburgh, VA Pittsburgh Healthcare Syst, Geriatr Res Educ & Clin Ctr, Pittsburgh, PA USA. [Alexander, Karen P.] Duke Univ, Med Ctr, Duke Clin Res Inst, Durham, NC USA. [Alexander, Karen P.] Duke Univ, Med Ctr, Div Cardiol, Durham, NC 27710 USA. RP Forman, DE (reprint author), Univ Pittsburgh, Med Ctr, Sect Geriatr Cardiol, Div Cardiol, 3471 Fifth Ave,Suite 500, Pittsburgh, PA 15213 USA.; Forman, DE (reprint author), Univ Pittsburgh, Med Ctr, Div Geriatr, 3471 Fifth Ave,Suite 500, Pittsburgh, PA 15213 USA. EM formand@pitt.edu FU NIA grant [P30 AG024827]; VA Office of Rehabilitation Research and Development grant [F0834-R] FX Dr Forman is supported in part by NIA grant P30 AG024827 and VA Office of Rehabilitation Research and Development grant F0834-R. NR 73 TC 3 Z9 3 U1 5 U2 5 PU ELSEVIER SCIENCE INC PI NEW YORK PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA SN 0828-282X EI 1916-7075 J9 CAN J CARDIOL JI Can. J. Cardiol. PD SEP PY 2016 VL 32 IS 9 BP 1082 EP 1087 DI 10.1016/j.cjca.2016.05.015 PG 6 WC Cardiac & Cardiovascular Systems SC Cardiovascular System & Cardiology GA EC7DU UT WOS:000388296800008 PM 27476987 ER PT J AU Schopfer, DW Forman, DE AF Schopfer, David W. Forman, Daniel E. TI Cardiac Rehabilitation in Older Adults SO CANADIAN JOURNAL OF CARDIOLOGY LA English DT Review ID AMERICAN-HEART-ASSOCIATION; RANDOMIZED CONTROLLED-TRIALS; ARTERY-DISEASE PATIENTS; FRAIL ELDERLY-PATIENTS; QUALITY-OF-LIFE; PHYSICAL-ACTIVITY; MYOCARDIAL-INFARCTION; PULMONARY-REHABILITATION; CARDIOVASCULAR EVENTS; SCIENTIFIC STATEMENT AB The biology of aging and the pathophysiology of cardiovascular disease (CVD) overlap, with the effect that CVD is endemic in the growing population of older adults. Moreover, CVD in older adults is usually complicated by age-related complexities, including multimorbidity, polypharmacy, frailty, and other intricacies that add to the risks of ambiguous symptoms, deconditioning, iatrogenesis, falls, disability, and other challenges. Cardiac rehabilitation (CR) is a comprehensive lifestyle program that can have particular benefit for older patients with cardiovascular conditions. Although CR was originally designed primarily as an exercise training program for younger adults after a myocardial infarction or coronary artery bypass surgery, it has evolved as a comprehensive lifestyle program (promoting physical activity as well as education, diet, risk reduction, and adherence) for a broader range of CVD (coronary heart disease, heart failure, and valvular heart disease). It provides a valuable opportunity to address and moderate many of the challenges pertinent for the large and growing population of older adults with CVD. Cardiac rehabilitation promotes physical function (cardiorespiratory fitness as well as strength and balance) that helps overcome disease and deconditioning as well as related vulnerabilities such as disability, frailty, and falls. Similarly, CR facilitates education, monitoring, and guidance to reduce iatrogenesis and promote adherence. Furthermore, CR fosters cognition, socialization, and independence in older patients. Yet despite all its conceptual benefits, CR is significantly underused in older populations. This review discusses benefits and the paradoxical underuse of CR, as well as evolving models of care that may achieve greater application and efficacy. C1 [Schopfer, David W.] Univ Calif San Francisco, Dept Med, San Francisco, CA USA. [Schopfer, David W.] San Francisco VA Med Ctr, Dept Med, San Francisco, CA USA. [Forman, Daniel E.] Univ Pittsburgh, Med Ctr, Geriatr Cardiol Sect, Pittsburgh, PA USA. [Forman, Daniel E.] VA Pittsburgh Healthcare Syst, Geriatr Res & Clin Ctr, Pittsburgh, PA USA. [Forman, Daniel E.] Univ Pittsburgh, Dept Med, Pittsburgh, PA USA. RP Forman, DE (reprint author), Div Geriatr, Sect Geriatr Cardiol, 3471 Fifth Ave, Pittsburgh, PA 15213 USA.; Forman, DE (reprint author), Div Cardiol, 3471 Fifth Ave, Pittsburgh, PA 15213 USA. EM formand@pitt.edu OI Schopfer, David/0000-0002-7244-9857 FU National Center for Advancing Translational Sciences of the NIH [KL2TR000143]; NIA grant [P30 AG024827]; VA Office of Rehabilitation Research and Development grant [F0834-R] FX D.W.S. is supported by the National Center for Advancing Translational Sciences of the NIH under Award Number KL2TR000143. D.E.F. is supported in part by NIA grant P30 AG024827 and VA Office of Rehabilitation Research and Development grant F0834-R. NR 77 TC 2 Z9 2 U1 9 U2 11 PU ELSEVIER SCIENCE INC PI NEW YORK PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA SN 0828-282X EI 1916-7075 J9 CAN J CARDIOL JI Can. J. Cardiol. PD SEP PY 2016 VL 32 IS 9 BP 1088 EP 1096 DI 10.1016/j.cjca.2016.03.003 PG 9 WC Cardiac & Cardiovascular Systems SC Cardiovascular System & Cardiology GA EC7DU UT WOS:000388296800009 PM 27297002 ER PT J AU Lipworth, B Wedzicha, J Devereux, G Vestbo, J Dransfield, MT AF Lipworth, Brian Wedzicha, Jadwiga Devereux, Graham Vestbo, Jorgen Dransfield, Mark T. TI Beta-blockers in COPD: time for reappraisal SO EUROPEAN RESPIRATORY JOURNAL LA English DT Article ID OBSTRUCTIVE PULMONARY-DISEASE; CHRONIC HEART-FAILURE; LEFT-VENTRICULAR HYPERTROPHY; RANDOMIZED CONTROLLED-TRIAL; MYOCARDIAL-INFARCTION; REGRESSION-ANALYSIS; EXERCISE CAPACITY; PERSISTENT ASTHMA; CLINICAL-OUTCOMES; EJECTION FRACTION AB The combined effects on the heart of smoking and hypoxaemia may contribute to an increased cardiovascular burden in chronic obstructive pulmonary disease (COPD). The use of beta-blockers in COPD has been proposed because of their known cardioprotective effects as well as reducing heart rate and improving systolic function. Despite the proven cardiac benefits of beta-blockers post-myocardial infarction and in heart failure they remain underused due to concerns regarding potential bronchoconstriction, even with cardioselective drugs. Initiating treatment with beta-blockers requires dose titration and monitoring over a period of weeks, and beta-blockers may be less well tolerated in older patients with COPD who have other comorbidities. Medium-term prospective placebo-controlled safety studies in COPD are warranted to reassure prescribers regarding the pulmonary and cardiac tolerability of beta-blockers as well as evaluating their potential interaction with concomitant inhaled long-acting bronchodilator therapy. Several retrospective observational studies have shown impressive reductions in mortality and exacerbations conferred by beta-blockers in COPD. However, this requires confirmation from long-term prospective placebo-controlled randomised controlled trials. The real challenge is to establish whether beta-blockers confer benefits on mortality and exacerbations in all patients with COPD, including those with silent cardiovascular disease where the situation is less clear. C1 [Lipworth, Brian] Univ Dundee, Ninewells Hosp & Med Sch, Scottish Ctr Resp Res, Dundee DD1 9SY, Scotland. [Wedzicha, Jadwiga] Imperial Coll London, Natl Heart & Lung Inst, Airways Dis Sect, London, England. [Devereux, Graham] Univ Aberdeen, Appl Hlth Sci, Aberdeen, Scotland. [Vestbo, Jorgen] Univ Manchester, Univ Hosp South Manchester NHS Fdn Trust, Ctr Resp Med & Allergy, Manchester, Lancs, England. [Dransfield, Mark T.] Univ Alabama Birmingham, Div Pulm Allergy & Crit Care Med, Lung Hlth Ctr, Birmingham, AL USA. [Dransfield, Mark T.] Birmingham VA Med Ctr, Birmingham, AL USA. RP Lipworth, B (reprint author), Univ Dundee, Ninewells Hosp & Med Sch, Scottish Ctr Resp Res, Dundee DD1 9SY, Scotland. EM b.j.lipworth@dundee.ac.uk FU Medical Research Council [G0800570, G1001365, G1001372] NR 79 TC 5 Z9 5 U1 4 U2 4 PU EUROPEAN RESPIRATORY SOC JOURNALS LTD PI SHEFFIELD PA 442 GLOSSOP RD, SHEFFIELD S10 2PX, ENGLAND SN 0903-1936 EI 1399-3003 J9 EUR RESPIR J JI Eur. Resp. J. PD SEP PY 2016 VL 48 IS 3 BP 880 EP 888 DI 10.1183/13993003.01847-2015 PG 9 WC Respiratory System SC Respiratory System GA EC7GL UT WOS:000388304800036 PM 27390282 ER PT J AU Liao, JM Emanuel, EJ Navathe, AS AF Liao, Joshua M. Emanuel, Ezekiel J. Navathe, Amol S. TI Six health care trends that will reshape the patient-provider dynamic SO HEALTHCARE-THE JOURNAL OF DELIVERY SCIENCE AND INNOVATION LA English DT Article ID PHYSICIAN; MEDICINE AB Six trends - movement towards value-based payment, rapid adoption of digital health technology, care delivery in non-traditional settings, development of individualized clinical guidelines, increased transparency, and growing cultural awareness about the harms of medical overuse are driving the US health care system towards a future defined by quality- and patient-centric care. Health care organizations are responding to these changes by implementing provider and workforce changes, pursuing stronger payer provider integration, and accelerating the use of digital technology and data. While these efforts can also improve the clinical relationship and create positive system redesign among health care organizations, they require alignment between organizational and physician incentives that can inadvertently harm the dynamic between patients and providers. Organizations can utilize several strategies to preserve the patient-physician relationship and advance the positive benefits of new organizational strategies while guarding against unintended consequences. (C) 2016 Elsevier Inc. All rights reserved. C1 [Liao, Joshua M.; Emanuel, Ezekiel J.; Navathe, Amol S.] Univ Penn, Sch Med, Div Gen Internal Med, Philadelphia, PA 19104 USA. [Emanuel, Ezekiel J.; Navathe, Amol S.] Univ Penn, Dept Med Eth & Hlth Policy, Philadelphia, PA 19104 USA. [Navathe, Amol S.] Philadelphia VA Med Ctr, Philadelphia, PA USA. RP Liao, JM (reprint author), Div Gen Internal Med, 1205 Blockley,423 Guardian Dr, Philadelphia, PA 19104 USA. NR 17 TC 0 Z9 0 U1 4 U2 4 PU ELSEVIER SCIENCE BV PI AMSTERDAM PA PO BOX 211, 1000 AE AMSTERDAM, NETHERLANDS SN 2213-0764 EI 2213-0772 J9 HEALTHCARE JI HealthCare PD SEP PY 2016 VL 4 IS 3 BP 148 EP 150 DI 10.1016/j.hjdsi.2016.06.008 PG 3 WC Health Care Sciences & Services SC Health Care Sciences & Services GA EC4NE UT WOS:000388107800008 PM 27396533 ER PT J AU Neuman, MD Passarella, MR Werner, RM AF Neuman, Mark D. Passarella, Molly R. Werner, Rachel M. TI The relationship between historical risk-adjusted 30-day mortality and subsequent hip fracture outcomes: Retrospective cohort study SO HEALTHCARE-THE JOURNAL OF DELIVERY SCIENCE AND INNOVATION LA English DT Article DE Hip fracture; Quality measurement; Aging/geriatrics; Surgical outcomes ID MINIMUM DATA SET; NURSING-HOME RESIDENTS; QUALITY-OF-CARE; FUNCTIONAL STATUS; PSYCHOMETRIC CHARACTERISTICS; SURGICAL MORTALITY; OLDER-ADULTS; SURGERY; MDS; COMORBIDITIES AB Background: While 30-day risk-adjusted mortality is a performance measure for hip fracture care, it has not been shown to predict long-term outcomes. We assessed whether hospital rankings based on historical 30-day mortality predicted subsequent hip fracture outcomes. Methods: Using national Medicare data, we calculated annual hospital performance rankings based on standardized 30-day hip fracture mortality ratios. We used logistic regression to measure the association of patients' survival at 180 days with their hospital's ranking for the year prior to admission. Subgroup analyses assessed whether associations between hospital performance and 180-day outcomes were similar for community-dwelling patients as well as those living in nursing homes prior to fracture. Results: Out of 378,077 patients hospitalized with hip fractures between January 1, 2007 and June 30, 2009, 81,653 (21.6%) died by 180 days. Worse historical hospital performance was associated with a greater adjusted odds of 30 day mortality (odds ratio (OR), fourth vs. first quartile: 1.24, 95% confidence interval (CI): 1.18,1.29, P< 0.001) and 180 day mortality (OR, fourth vs. first quartile: 1.15, 95% CI 1.11,1.18, P< 0.001). Past hospital performance was associated with death or new nursing home placement among community dwellers (OR, fourth vs. first quartile: 1.09, 95% CI 1.05, 1.13, P < 0.001), but was not associated with death or new dependence in locomotion among nursing home residents (OR 1.05, 95% CI 0.97, 1.15, P=0.229). Conclusions: Better historical hospital hip fracture mortality predicts modest decreases in mortality at 180 days for subsequent patients, but is inconsistently associated with changes in functional outcomes. Level of evidence: Level 3 (Non-randomized controlled cohort study). (C) 2015 Elsevier Inc. All rights reserved. C1 [Neuman, Mark D.] Univ Penn, Perelman Sch Med, Dept Anesthesiol & Crit Care, 423 Guardian Dr,1119A Blockley Hall, Philadelphia, PA 19104 USA. [Neuman, Mark D.; Werner, Rachel M.] Univ Penn, Leonard Davis Inst Hlth Econ, Philadelphia, PA 19104 USA. [Neuman, Mark D.] Univ Penn, Perelman Sch Med, Dept Internal Med, Div Geriatr Med, Philadelphia, PA 19104 USA. [Passarella, Molly R.] Childrens Hosp Philadelphia, Ctr Outcomes Res, Philadelphia, PA 19104 USA. [Werner, Rachel M.] Univ Penn, Perelman Sch Med, Dept Internal Med, Div Gen Internal Med, Philadelphia, PA 19104 USA. [Werner, Rachel M.] Philadelphia VA Med Ctr, Ctr Hlth Equ Res & Promot, Philadelphia, PA USA. RP Neuman, MD (reprint author), Univ Penn, Perelman Sch Med, Dept Anesthesiol & Crit Care, 423 Guardian Dr,1119A Blockley Hall, Philadelphia, PA 19104 USA. EM neumanm@mail.med.upenn.edu FU NIA NIH HHS [K08 AG043548, K24 AG047908] NR 51 TC 1 Z9 1 U1 2 U2 2 PU ELSEVIER SCIENCE BV PI AMSTERDAM PA PO BOX 211, 1000 AE AMSTERDAM, NETHERLANDS SN 2213-0764 EI 2213-0772 J9 HEALTHCARE JI HealthCare PD SEP PY 2016 VL 4 IS 3 BP 192 EP 199 DI 10.1016/j.hjdsi.2015.10.008 PG 8 WC Health Care Sciences & Services SC Health Care Sciences & Services GA EC4NE UT WOS:000388107800016 PM 27637826 ER PT J AU Ray, SK Samntaray, S Banik, NL AF Ray, Swapan K. Samntaray, Supriti Banik, Naren L. TI Future directions for using estrogen receptor agonists in the treatment of acute and chronic spinal cord injury SO NEURAL REGENERATION RESEARCH LA English DT Editorial Material ID VSC4.1 MOTONEURONS; DOSE ESTROGEN; NEUROPROTECTION C1 [Ray, Swapan K.] Univ South Carolina, Sch Med, Dept Pathol Microbiol & Immunol, Columbia, SC 29208 USA. [Samntaray, Supriti] Med Univ South Carolina, Dept Neurosci, Charleston, SC USA. [Banik, Naren L.] Med Univ South Carolina, Dept Neurol & Neurosurg, Charleston, SC USA. [Banik, Naren L.] Ralph H Johnson Vet Adm Med Ctr, Charleston, SC USA. RP Ray, SK (reprint author), Univ South Carolina, Sch Med, Dept Pathol Microbiol & Immunol, Columbia, SC 29208 USA. EM swapan.ray@uscmed.sc.edu NR 10 TC 2 Z9 2 U1 0 U2 0 PU MEDKNOW PUBLICATIONS & MEDIA PVT LTD PI MUMBAI PA B-9, KANARA BUSINESS CENTRE, OFF LINK RD, GHAKTOPAR-E, MUMBAI, 400075, INDIA SN 1673-5374 EI 1876-7958 J9 NEURAL REGEN RES JI Neural Regen. Res. PD SEP PY 2016 VL 11 IS 9 BP 1418 EP 1419 DI 10.4103/1673-5374.191212 PG 2 WC Cell Biology; Neurosciences SC Cell Biology; Neurosciences & Neurology GA EC0DP UT WOS:000387768400020 PM 27857741 ER PT J AU Pownall, HJ Schwartz, AV Bray, GA Berkowitz, RI Lewis, CE Boyko, EJ Jakicic, JM Chen, HY Heshka, S Gregg, EW Johnson, KC AF Pownall, Henry J. Schwartz, Anne V. Bray, George A. Berkowitz, Robert I. Lewis, Cora E. Boyko, Edward J. Jakicic, John M. Chen, Haiying Heshka, Stanley Gregg, Edward W. Johnson, Karen C. CA Look AHEAD Res Grp TI Changes in Regional Body Composition over 8 Years in a Randomized Lifestyle Trial: The Look AHEAD Study SO OBESITY LA English DT Article ID MUSCLE STRENGTH; OLDER-ADULTS; OBESITY; INTERVENTION; WOMEN; MASS; MEN AB Objective: To test the hypothesis that an 8-year intensive lifestyle intervention (ILI) suppresses aging-dependent changes in regional lean mass (LM) and fat mass (FM) among people with overweight/obesity and type 2 diabetes. Methods: Regional body composition was measured by dual-energy X-ray absorptiometry within a subset of 1,019 volunteers (45-75 years old) in the Look AHEAD study randomized to ILI or diabetes support and education (DSE). The ILI goal was to achieve and maintain >= 7% weight loss through increased physical activity and reduced caloric intake. Results: Over 8 years, the DSE group exhibited a linear loss of LM and FM. During year 1, the ILI group lost LM and FM. Between years 1 and 8, the ILI group regained most FM in all regions; regional LM converged with that of the DSE group; the percent of LM loss was greater for the leg than for the trunk. Among both groups, regional LM and FM change was proportional to the size of the region, trunk>leg>arm. Conclusions: Aging-dependent LM losses, particularly in the leg region, were not suppressed by ILI. The long-term consequences of rapid LM and FM loss and subsequent regain mostly as fat are unknown. C1 [Pownall, Henry J.] Houston Methodist Res Inst, Dept Cardiol, Houston, TX 77030 USA. [Pownall, Henry J.] Baylor Coll Med, Houston, TX 77030 USA. [Schwartz, Anne V.] Univ Calif San Francisco, Dept Epidemiol & Biostat, San Francisco, CA 94143 USA. [Bray, George A.] LSU, Dept Clin Obes & Metab, Pennington Biomed Res Ctr, Baton Rouge, LA USA. [Berkowitz, Robert I.] Univ Penn, Sch Med, Dept Child & Adolescent Psychiat & Behav Sci, Philadelphia, PA 19104 USA. [Lewis, Cora E.] Univ Alabama Birmingham, Div Prevent Med, Birmingham, AL USA. [Boyko, Edward J.] VA Puget Sound Hlth Care Syst, Dept Internal Med, Seattle, WA USA. [Boyko, Edward J.] Univ Washington, Seattle, WA 98195 USA. [Jakicic, John M.] Univ Pittsburgh, Dept Hlth & Phys Act, Pittsburgh, PA USA. [Chen, Haiying] Wake Forest Sch Med, Dept Biostat, Winston Salem, NC USA. [Heshka, Stanley] St Lukes Roosevelt Hosp, Inst Human Nutr, New York, NY 10025 USA. [Gregg, Edward W.] Ctr Dis Control & Prevent, Div Diabet Translat, Atlanta, GA USA. [Johnson, Karen C.] Univ Tennessee, Dept Prevent Med, Memphis, TN USA. RP Pownall, HJ (reprint author), Houston Methodist Res Inst, Dept Cardiol, Houston, TX 77030 USA.; Pownall, HJ (reprint author), Baylor Coll Med, Houston, TX 77030 USA. EM hjpownall@houstonmethodist.org OI Boyko, Edward/0000-0002-3695-192X FU NIH; NIDDK [DK57136, DK57149, DK56990, DK57177, DK57171, DK57151, DK57182, DK57131, DK57002, DK57078, DK57154, DK57178, DK57219, DK57008, DK57135, DK56992]; NHLBI; National Institute of Nursing Research; National Center on Minority Health and Health Disparities; NIH Office of Research on Women's Health; Centers for Disease Control and Prevention; NIDDK; Johns Hopkins Bayview General Clinical Research Center (GCRC) [M01RR02719]; Massachusetts General Hospital Mallinckrodt GCRC; Massachusetts Institute of Technology GCRC [M01RR01066]; University of Colorado Health Sciences GCRC [M01RR00051]; Clinical Nutrition Research Unit [P30 DK48520]; University of Tennessee at Memphis GCRC [M01RR0021140]; University of Pittsburgh GCRC [M01RR000056]; Clinical Translational Research Center [UL1 RR 024153]; NIH [DK 046204]; VA Puget Sound Health Care System Medical Research Service, Department of Veterans Affairs; Frederic C. Bartter GCRC [M01RR01346] FX NIH cooperative agreements with NIDDK: DK57136, DK57149, DK56990, DK57177, DK57171, DK57151, DK57182, DK57131, DK57002, DK57078, DK57154, DK57178, DK57219, DK57008, DK57135, and DK56992 and by NHLBI; National Institute of Nursing Research; National Center on Minority Health and Health Disparities; NIH Office of Research on Women's Health; and Centers for Disease Control and Prevention. Other support was from the Intramural Research Program of NIDDK. Other support was from Johns Hopkins Bayview General Clinical Research Center (GCRC; M01RR02719); Massachusetts General Hospital Mallinckrodt GCRC and Massachusetts Institute of Technology GCRC (M01RR01066); University of Colorado Health Sciences GCRC (M01RR00051) and Clinical Nutrition Research Unit (P30 DK48520); University of Tennessee at Memphis GCRC (M01RR0021140); University of Pittsburgh GCRC (M01RR000056), the Clinical Translational Research Center (UL1 RR 024153), and NIH grant (DK 046204); VA Puget Sound Health Care System Medical Research Service, Department of Veterans Affairs; and Frederic C. Bartter GCRC (M01RR01346). Contributions to Look AHEAD were from FedEx Corporation; Health Management Resources; LifeScan, Inc., a Johnson & Johnson Company; OPTIFAST (R) (Nestle HealthCare Nutrition) Inc.; Hoffmann-La Roche Inc.; Abbott Nutrition; and Slim-Fast Brand (Unilever North America). NR 29 TC 0 Z9 0 U1 2 U2 2 PU WILEY-BLACKWELL PI HOBOKEN PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA SN 1930-7381 EI 1930-739X J9 OBESITY JI Obesity PD SEP PY 2016 VL 24 IS 9 BP 1899 EP 1905 DI 10.1002/oby.21577 PG 7 WC Endocrinology & Metabolism; Nutrition & Dietetics SC Endocrinology & Metabolism; Nutrition & Dietetics GA EC6VW UT WOS:000388275800013 PM 27465756 ER PT J AU Baumel, A Correll, CU Hauser, M Brunette, M Rotondi, A Ben-Zeev, D Gottlieb, JD Mueser, KT Achtyes, ED Schooler, NR Robinson, DG Gingerich, S Marcy, P Meyer-Kalos, P Kane, JM AF Baumel, Amit Correll, Christoph U. Hauser, Marta Brunette, Mary Rotondi, Armando Ben-Zeev, Dror Gottlieb, Jennifer D. Mueser, Kim T. Achtyes, Eric D. Schooler, Nina R. Robinson, Delbert G. Gingerich, Susan Marcy, Patricia Meyer-Kalos, Piper Kane, John M. TI Health Technology Intervention After Hospitalization for Schizophrenia: Service Utilization and User Satisfaction SO PSYCHIATRIC SERVICES LA English DT Article ID PSYCHOSIS; MODEL AB Objective: The authors examined patients' acceptance of the Health Technology Program (HTP), an integrative approach to relapse prevention after hospitalization of adults with schizophrenia or related disorders. The program combines use of digital tools with support from a mental health technology coach (MHTC). Methods: Patients with schizophrenia spectrum disorders received six months of treatment that began within 60 days of a psychiatric hospitalization and included the development of a personalized relapse prevention plan, three digital tools, and contacts with MHTCs. Results: A total of 200 patients (mean +/- SDage=34.6 +/- 10.6 years) had 28.2 +/- 2.0 contacts with the MHTC that lasted 38.3 +/- 14.2 minutes. The most discussed topic was case management (52%), and digital tools were discussed in 45% of meetings. Altogether, 87% of patients used at least one of the digital tools, with 96% of patients rating the HTP as satisfying to at least some extent. Conclusions: These data suggest very high acceptance of the HTP, a program that integrates available human support with digital tools. C1 [Baumel, Amit; Correll, Christoph U.; Hauser, Marta; Schooler, Nina R.; Robinson, Delbert G.; Marcy, Patricia; Kane, John M.] Northwell Hlth, Zucker Hillside Hosp, Dept Psychiat Res, Glen Oaks, NY 11004 USA. [Baumel, Amit; Correll, Christoph U.; Robinson, Delbert G.; Kane, John M.] Hofstra Northwell Sch Med, Hempstead, NY USA. [Hauser, Marta; Marcy, Patricia] Feinstein Inst Med Res, Ctr Psychiat Neurosci, Manhasset, NY USA. [Schooler, Nina R.] Suny Downstate Med Ctr, Dept Psychiat & Behav Sci, Brooklyn, NY 11203 USA. [Brunette, Mary; Ben-Zeev, Dror] Dartmouth Coll, Geisel Sch Med, Dartmouth Psychiat Res Ctr, Ctr Technol & Behav Hlth, 1 Med Ctr Dr, Lebanon, NH 03756 USA. [Rotondi, Armando] Clin & Translat Sci Inst, Dept Crit Care Med, Pittsburgh, PA USA. [Rotondi, Armando] US Dept Vet Affairs, Mental Illness Res Educ & Clin Ctr, Med Ctr, Pittsburgh, PA USA. [Gottlieb, Jennifer D.; Mueser, Kim T.] Boston Univ, Ctr Psychiat Rehabil, Boston, MA 02215 USA. [Achtyes, Eric D.] Cherry Hlth, E Lansing, MI USA. [Achtyes, Eric D.] Michigan State Univ, Coll Human Med, E Lansing, MI 48824 USA. [Meyer-Kalos, Piper] Minnesota Ctr Chem & Mental Hlth, Dept Social Work, St Paul, MN USA. RP Baumel, A (reprint author), Northwell Hlth, Zucker Hillside Hosp, Dept Psychiat Res, Glen Oaks, NY 11004 USA. OI Achtyes, Eric/0000-0001-8939-1535 FU Centers for Medicare and Medicaid Services, Department of Health and Human Services [1C1CMS331052-01-00]; AssurEx; Avanir; CMMS; Janssen; Network180; Novartis; Otsuka; Pfizer; Pine Rest Foundation; Priority Health; Vanguard Research Group; Bristol-Myers Squibb; Lundbeck; Takeda; Genentech; Neurocrine FX The project described was made possible by grant 1C1CMS331052-01-00 from the Centers for Medicare and Medicaid Services, Department of Health and Human Services. The contents of this report are solely the responsibility of the authors and do not necessarily represent the official views of the U.S. Department of Health and Human Services or any of its agencies.; Dr. Correll has been a consultant or advisor to or has received honoraria from AbbVie, Acadia, Actavis, Alkermes, Eli Lilly, Forum, Genentech, Gerson Lehrman Group, IntraCellular Therapies, Janssen, Johnson and Johnson, Lundbeck, MedAvante, Medscape, Otsuka, Pfizer, ProPhase, Reviva, Roche, Sunovion, Supernus, Takeda, and Teva. He has received grant support from Bristol-Myers Squibb, Lundbeck, Otsuka, and Takeda. Dr. Hauser has been a consultant to Otsuka. Dr. Brunette holds a research contract with Alkermes. Dr. Ben-Zeev has an intervention content licensing agreement with Pear Therapeutics. Dr. Achtyes has received research support from AssurEx, Avanir, CMMS, Janssen, Network180, Novartis, Otsuka, Pfizer, Pine Rest Foundation, Priority Health, and Vanguard Research Group, and he has been an advisor to Roche. Dr. Schooler has served on advisory boards or as a consultant for Abbott, Alkermes, Amgen, Eli Lilly, Forum (formerly EnVivo), Janssen Psychiatry, Roche, and Sunovion. She has received grant or research support from Genentech, Neurocrine, and Otsuka. She served on a Data Monitoring Board for Shire and on the faculty of the Lundbeck International Neuroscience Foundation. Dr. Robinson has been a consultant to Asubio, Costello, Innovative Science Solutions, and Shire, and he has received grants from Bristol-Myers Squibb, Janssen, and Otsuka. Ms. Marcy is a shareholder in Pfizer. Dr. Kane has been a consultant for Alkermes, Eli Lilly, EnVivo Pharmaceuticals (Forum), Forest, Genentech, Intracellular Therapeutics, Janssen Pharmaceutica, Johnson and Johnson, Lundbeck, Otsuka, Reviva, Roche, Sunovion, and Teva. He has received lecture honoraria from Genentech, Janssen, Lundbeck, and Otsuka. He is a shareholder in MedAvante Inc., LB Pharmaceuticals, and Vanguard Research Group. Dr. Baumel, Dr. Rotondi, Dr. Gottlieb, Dr. Mueser, Ms. Gingerich, and Dr. Meyer-Kalos report no financial relationships with commercial interests. NR 13 TC 0 Z9 0 U1 2 U2 2 PU AMER PSYCHIATRIC PUBLISHING, INC PI ARLINGTON PA 1000 WILSON BOULEVARD, STE 1825, ARLINGTON, VA 22209-3901 USA SN 1075-2730 EI 1557-9700 J9 PSYCHIAT SERV JI Psychiatr. Serv. PD SEP 1 PY 2016 VL 67 IS 9 BP 1035 EP 1038 DI 10.1176/appi.ps.201500317 PG 4 WC Health Policy & Services; Public, Environmental & Occupational Health; Psychiatry SC Health Care Sciences & Services; Public, Environmental & Occupational Health; Psychiatry GA EC6SS UT WOS:000388267600018 PM 27247171 ER PT J AU Reid, MW May, FP Martinez, B Cohen, S Wang, H Williams, DL Spiegel, BMR AF Reid, Mark W. May, Folasade P. Martinez, Bibiana Cohen, Samuel Wang, Hank Williams, Demetrius L., Jr. Spiegel, Brennan M. R. TI Preventing Endoscopy Clinic No-Shows: Prospective Validation of a Predictive Overbooking Model SO AMERICAN JOURNAL OF GASTROENTEROLOGY LA English DT Article ID NON-ATTENDANCE; SCREENING COLONOSCOPY; OUTPATIENT ENDOSCOPY; PATIENT ABSENTEEISM; GENERAL-PRACTICE; PRIMARY-CARE; HEALTH-CARE; APPOINTMENTS; ACCESS; NONATTENDANCE AB OBJECTIVES: Patient absenteeism for scheduled visits and procedures ("no-show") occurs frequently in healthcare systems worldwide, resulting in treatment delays and financial loss. To address this problem, we validated a predictive overbooking system that identifies patients at high risk for missing scheduled gastrointestinal endoscopy procedures ("no-shows" and cancellations), and offers their appointments to other patients on short notice. METHODS: We prospectively tested a predictive overbooking system at a Veterans Administration outpatient endoscopy clinic over a 34-week period, alternating between traditional booking and predictive overbooking methods. For the latter, we assigned a no-show risk score to each scheduled patient, utilizing a previously developed logistic regression model built with electronic health record data. To compare booking methods, we measured service utilization-defined as the percentage of daily total clinic capacity occupied by patients-and length of clinic workday. RESULTS: Compared to typical booking, predictive overbooking resulted in nearly all appointment slots being filled-2.5 slots available during control weeks vs. 0.35 slots during intervention weeks, t(161)=4.10, P=0.0001. Service utilization increased from 86% during control weeks to 100% during intervention weeks, allowing 111 additional patients to undergo procedures. Physician and staff overages were more common during intervention weeks, but less than anticipated (workday length of 7.84h (control) vs. 8.31h (intervention), t(161)=2.28, P=0.02). CONCLUSIONS: Predictive overbooking may be used to maximize endoscopy scheduling. Future research should focus on adapting the model for use in primary care and specialty clinics. C1 [Reid, Mark W.; May, Folasade P.; Cohen, Samuel; Williams, Demetrius L., Jr.] VA Greater Los Angeles Healthcare Syst, Dept Gastroenterol, Los Angeles, CA USA. [Reid, Mark W.; Martinez, Bibiana; Williams, Demetrius L., Jr.] CS CORE, Los Angeles, CA USA. [May, Folasade P.] Univ Calif Los Angeles, David Geffen Sch Med, Div Digest Dis, Los Angeles, CA 90095 USA. [Wang, Hank] Kaiser Permanente Northern Calif, Oakland, CA USA. Univ Calif Los Angeles, Fielding Sch Publ Hlth, Dept Hlth Policy & Management, Los Angeles, CA USA. Cedars Sinai Med Ctr, Dept Med, Los Angeles, CA 90048 USA. Pacific Theatre Bldg,116 North Robertson Blvd, Los Angeles, CA 90048 USA. RP Spiegel, BMR (reprint author), Cedars Sinai Med Ctr, Dept Med, Los Angeles, CA 90048 USA. EM brennan.spiegel@cshs.org FU VA Health Services Research and Development (HSRD) Merit Award [IIR 12-055] FX This study was funded by a VA Health Services Research and Development (HSR&D) Merit Award (IIR 12-055). The study funder approved the study design, but did not contribute to this manuscript. NR 43 TC 1 Z9 1 U1 2 U2 2 PU NATURE PUBLISHING GROUP PI NEW YORK PA 75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA SN 0002-9270 EI 1572-0241 J9 AM J GASTROENTEROL JI Am. J. Gastroenterol. PD SEP PY 2016 VL 111 IS 9 BP 1267 EP 1273 DI 10.1038/ajg.2016.269 PG 7 WC Gastroenterology & Hepatology SC Gastroenterology & Hepatology GA EB1YX UT WOS:000387154000014 PM 27377518 ER PT J AU Yang, J Zhao, YF Zhang, P Li, YH Yang, Y Yang, Y Zhu, JJ Song, X Jiang, GN Fan, J AF Yang, Jie Zhao, Yanfeng Zhang, Peng Li, Yuehua Yang, Yong Yang, Yang Zhu, Junjie Song, Xiao Jiang, Gening Fan, Jie TI Hemorrhagic shock primes for lung vascular endothelial cell pyroptosis: role in pulmonary inflammation following LPS SO CELL DEATH & DISEASE LA English DT Article ID NLRP3 INFLAMMASOME; INTRACELLULAR LPS; MACROPHAGE DEATH; ENDOTOXIC-SHOCK; INNATE IMMUNITY; GASDERMIN D; CASPASE 1; ACTIVATION; INJURY; MECHANISMS AB Hemorrhagic shock (HS) often renders patients more susceptible to lung injury by priming for an exaggerated response to a second infectious stimulus. Acute lung injury (ALI) is a major component of multiple organ dysfunction syndrome following HS and regularly serves as a major cause of patient mortality. The lung vascular endothelium is an active organ that has a central role in the development of ALI through synthesizing and releasing of a number of inflammatory mediators. Cell pyroptosis is a caspase-1-dependent regulated cell death, which features rapid plasma membrane rupture and release of proinflammatory intracellular contents. In this study, we demonstrated an important role of HS in priming for LPS-induced lung endothelial cell (EC) pyroptosis. We showed that LPS through TLR4 activates Nlrp3 (NACHT, LRR, and PYD domains containing protein 3) inflammasome in mouse lung vascular EC, and subsequently induces caspase-1 activation. However, HS induced release of high-mobility group box 1 (HMGB1), which acting through the receptor for advanced glycation end products initiates EC endocytosis of HMGB1, and subsequently triggers a cascade of molecular events, including cathepsin B release from ruptured lysosomes followed by pyroptosome formation and caspase-1 activation. These HS-induced events enhance LPS-induced EC pyroptosis. We further showed that lung vascular EC pyroptosis significantly exaggerates lung inflammation and injury. The present study explores a novel mechanism underlying HS-primed ALI and thus presents a potential therapeutic target for post-HS ALI. C1 [Yang, Jie; Zhao, Yanfeng; Zhang, Peng; Yang, Yong; Yang, Yang; Zhu, Junjie; Song, Xiao; Jiang, Gening; Fan, Jie] Tongji Univ, Sch Med, Shanghai Pulm Hosp, Dept Thorac Surg, 507 Zhengmin Rd, Shanghai 200433, Peoples R China. [Yang, Jie; Li, Yuehua; Yang, Yong; Fan, Jie] Univ Pittsburgh, Sch Med, Dept Surg, Pittsburgh, PA 15213 USA. [Li, Yuehua; Fan, Jie] Vet Affairs Pittsburgh Healthcare Syst, Res & Dev, Pittsburgh, PA 15240 USA. [Fan, Jie] Univ Pittsburgh, McGowan Inst Regenerat Med, Pittsburgh, PA 15219 USA. RP Jiang, GN; Fan, J (reprint author), Tongji Univ, Sch Med, Shanghai Pulm Hosp, Dept Thorac Surg, 507 Zhengmin Rd, Shanghai 200433, Peoples R China.; Fan, J (reprint author), Univ Pittsburgh, Sch Med, Dept Surg, VAPHS, Bldg 1,1W142,151U,Univ Dr, Pittsburgh, PA 15213 USA. EM jgnwp@aliyun.com; jif7@pitt.edu FU National Institutes of Health [HL-079669, HL-123882, HL076179]; VA Merit Award [1I01BX002729]; National Natural Science Foundation of China [81470262, 81400056]; Shanghai Rising-Star Program [14QA1403200]; Shanghai Medical New Excellent Youth [XYQ2013115] FX This work was supported by the National Institutes of Health Grant HL-079669 (JF), National Institutes of Health Grant HL-123882 (JF), National Institutes of Health Grant HL076179 (JF), VA Merit Award 1I01BX002729 (JF), National Natural Science Foundation of China 81470262 (JF), National Natural Science Foundation of China 81400056 (YZ), Shanghai Rising-Star Program 14QA1403200 (PZ), and Shanghai Medical New Excellent Youth XYQ2013115 (PZ). NR 55 TC 1 Z9 1 U1 5 U2 5 PU NATURE PUBLISHING GROUP PI LONDON PA MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND SN 2041-4889 J9 CELL DEATH DIS JI Cell Death Dis. PD SEP PY 2016 VL 7 AR e2363 DI 10.1038/cddis.2016.274 PG 16 WC Cell Biology SC Cell Biology GA EC2QF UT WOS:000387968100014 PM 27607578 ER PT J AU Wilder, E Fernandez, MP Krejci-Manwaring, J AF Wilder, Elizabeth Fernandez, Martin P. Krejci-Manwaring, Jennifer TI Mucous Membrane Pemphigoid Involving the Trachea and Bronchi: An Extremely Rare and Life-Threatening Presentation SO CUTIS LA English DT Letter ID MEDICAL-TREATMENT; INVOLVEMENT C1 [Wilder, Elizabeth] Baylor Univ, Med Ctr, Dallas, TX USA. [Fernandez, Martin P.] Scott & White Mem Hosp & Clin, Sect Dermatopathol, Temple, TX 76508 USA. [Krejci-Manwaring, Jennifer] Univ Texas Hlth Sci Ctr San Antonio, Div Dermatol & Cutaneous Surg, San Antonio, TX 78229 USA. [Krejci-Manwaring, Jennifer] Audie Murphy Vet Hosp, San Antonio, TX USA. RP Krejci-Manwaring, J (reprint author), 7400 Merton Minter Blvd, San Antonio, TX 78229 USA. EM KrejciManwar@uthscsa.edu NR 14 TC 0 Z9 0 U1 0 U2 0 PU QUADRANT HEALTHCOM INC PI PARSIPPANY PA 7 CENTURY DRIVE, STE 302, PARSIPPANY, NJ 07054-4603 USA SN 0011-4162 EI 2326-6929 J9 CUTIS JI Cutis PD SEP PY 2016 VL 98 IS 3 BP E24 EP E27 PG 4 WC Dermatology SC Dermatology GA EC3IV UT WOS:000388020700008 PM 27814419 ER PT J AU Chapman, MA Meza, R Lieber, RL AF Chapman, Mark A. Meza, Rachel Lieber, Richard L. TI Skeletal muscle fibroblasts in health and disease SO DIFFERENTIATION LA English DT Review ID DUCHENNE MUSCULAR-DYSTROPHY; CONNECTIVE-TISSUE FIBROBLASTS; COLLAGEN GENE-EXPRESSION; NORMAL MYOGENIC CELLS; EXTRACELLULAR-MATRIX; ROTATOR CUFF; REGENERATIVE CAPACITY; MECHANICAL-PROPERTIES; FORCE TRANSMISSION; MODULATED CELLS AB As the primary producer of extracellular matrix (ECM) proteins in skeletal muscle, fibroblasts play an important role providing structural support to muscle. Skeletal muscle ECM is vital for force transduction from muscle cells to tendons and bones to create movement It is these ECM connections that allow the movement created in muscle to be transmitted to our skeleton. This review discusses how fibroblasts participate in maintaining this healthy ECM within skeletal muscle. Additionally, from a basic science perspective, we discuss current methods to identify and study skeletal muscle fibroblasts, as this is critical to bettering our understanding of these important cells. Finally, skeletal muscle fibrosis is discussed, which is a devastating clinical condition characterized by an overproduction of ECM within skeletal muscle. We discuss the role that fibroblasts and other cells play in muscle fibrosis as well as the implications of this work. Published by Elsevier B.V. on behalf of International Society of Differentiation C1 [Chapman, Mark A.; Lieber, Richard L.] Univ Calif San Diego, Dept Bioengn, 9500 Gilman Dr, La Jolla, CA 92093 USA. [Meza, Rachel] Univ Calif San Diego, Dept Biol, 9500 Gilman Dr, La Jolla, CA 92093 USA. [Lieber, Richard L.] Univ Calif San Diego, Dept Orthopaed Surg, 9500 Gilman Dr, La Jolla, CA 92093 USA. [Lieber, Richard L.] US Dept Vet Affairs, 9500 Gilman Dr, La Jolla, CA 92093 USA. [Lieber, Richard L.] Rehabil Inst Chicago, 345 East Super St, Chicago, IL 60611 USA. RP Lieber, RL (reprint author), Northwestern Univ, Rehabil Inst Chicago, Sch Med, 345 East Super Dr, Chicago, IL 60611 USA. EM rlieber@ric.org FU NIAMS NIH HHS [P30 AR061303] NR 83 TC 2 Z9 2 U1 2 U2 2 PU ELSEVIER SCI LTD PI OXFORD PA THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, OXON, ENGLAND SN 0301-4681 EI 1432-0436 J9 DIFFERENTIATION JI Differentiation PD SEP PY 2016 VL 92 IS 3 SI SI BP 108 EP 115 DI 10.1016/j.diff.2016.05.007 PG 8 WC Cell Biology; Developmental Biology SC Cell Biology; Developmental Biology GA EC3WI UT WOS:000388057400006 PM 27282924 ER PT J AU Niquet, J Baldwin, R Norman, K Suchomelova, L Lumley, L Wasterlain, CG AF Niquet, Jerome Baldwin, Roger Norman, Keith Suchomelova, Lucie Lumley, Lucille Wasterlain, Claude G. TI Midazolam-ketamine dual therapy stops cholinergic status epilepticus and reduces Morris water maze deficits SO EPILEPSIA LA English DT Article DE Refractory status epilepticus; Cholinergic seizures; Neuronal injury; Hippocampal sclerosis; Spatial memory; Epileptogenesis ID REFRACTORY STATUS EPILEPTICUS; CONVULSIVE STATUS EPILEPTICUS; SOMAN-INDUCED SEIZURES; GABA(A) RECEPTORS; HIPPOCAMPAL-NEURONS; PILOCARPINE MODEL; GUINEA-PIGS; EPILEPSY; RATS; ACCUMULATION AB Objective: Pharmacoresistance remains an unsolved therapeutic challenge in status epilepticus (SE) and in cholinergic SE induced by nerve agent intoxication. SE triggers a rapid internalization of synaptic c-aminobutyric acid A (GABA(A)) receptors and externalization of N-methyl-D-aspartate (NMDA) receptors that may explain the loss of potency of standard antiepileptic drugs (AEDs). We hypothesized that a drug combination aimed at correcting the consequences of receptor trafficking would reduce SE severity and its long-term consequences. Methods: A severe model of SE was induced in adult Sprague-Dawley rats with a high dose of lithium and pilocarpine. The GABA(A) receptor agonist midazolam, the NMDA receptor antagonist ketamine, and/or the AED valproate were injected 40 min after SE onset in combination or as monotherapy. Measures of SE severity were the primary outcome. Secondary outcomes were acute neuronal injury, spontaneous recurrent seizures (SRS), and Morris water maze (MWM) deficits. Results: Midazolam-ketamine dual therapy was more efficient than double-dose midazolam or ketamine monotherapy or than valproate-midazolam or valproate-ketamine dual therapy in reducing several parameters of SE severity, suggesting a synergistic mechanism. In addition, midazolam-ketamine dual therapy reduced SE-induced acute neuronal injury, epileptogenesis, and MWM deficits. Significance: This study showed that a treatment aimed at correcting maladaptive GABA(A) receptor and NMDA receptor trafficking can stop SE and reduce its long-term consequences. Early midazolam-ketamine dual therapy may be superior to monotherapy in the treatment of benzodiazepine-refractory SE. C1 [Niquet, Jerome; Wasterlain, Claude G.] Univ Calif Los Angeles, David Geffen Sch Med, Dept Neurol, Los Angeles, CA 90095 USA. [Niquet, Jerome; Baldwin, Roger; Norman, Keith; Suchomelova, Lucie; Wasterlain, Claude G.] Vet Affairs Greater Los Angeles Healthcare Syst, Epilepsy Res Lab 151, Los Angeles, CA USA. [Lumley, Lucille] USAMRICD, Aberdeen Proving Ground, MD USA. [Wasterlain, Claude G.] Univ Calif Los Angeles, David Geffen Sch Med, Brain Res Inst, Los Angeles, CA 90095 USA. RP Niquet, J (reprint author), VA Greater Los Angeles Healthcare Syst, Epilepsy Res Lab, 11301 Wilshire Blvd,Bldg 114,Room 139, Los Angeles, CA 90073 USA. EM jniquet@ucla.edu FU U.S. Department of Veterans Affairs (Biomedical Laboratory Research and Development Service) [I01 BX000273-07]; National Institute of Neurological Diseases and Stroke (NINDS) [UO1 NS074926] FX This work was supported in part by Merit Review Award #I01 BX000273-07 from the U.S. Department of Veterans Affairs (Biomedical Laboratory Research and Development Service) and National Institute of Neurological Diseases and Stroke (NINDS; grant UO1 NS074926; CW). NR 35 TC 1 Z9 1 U1 2 U2 2 PU WILEY PI HOBOKEN PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA SN 0013-9580 EI 1528-1167 J9 EPILEPSIA JI Epilepsia PD SEP PY 2016 VL 57 IS 9 BP 1406 EP 1415 DI 10.1111/epi.13480 PG 10 WC Clinical Neurology SC Neurosciences & Neurology GA EB8QJ UT WOS:000387655600014 PM 27500978 ER PT J AU Polsunas, PJ Sowa, G Fritz, JM Gentili, A Morone, NE Raja, SN Rodriguez, E Schmader, K Scholten, JD Weiner, DK AF Polsunas, Patrick J. Sowa, Gwendolyn Fritz, Julie M. Gentili, Angela Morone, Natalia E. Raja, Srinivasa Naga Rodriguez, Eric Schmader, Kenneth Scholten, Joel D. Weiner, Debra K. TI Deconstructing Chronic Low Back Pain in the Older Adult-Step by Step Evidence and Expert-Based Recommendations for Evaluation and Treatment: Part X: Sacroiliac Joint Syndrome SO PAIN MEDICINE LA English DT Article DE Chronic Low Back Pain; Sacroiliac Joint Pain; Older Adults ID INJECTION ARTHROGRAPHY TECHNIQUE; PROVOCATION TESTS; SELF-MANAGEMENT; REFERRAL MAPS; LUMBAR DISC; DIAGNOSIS; PREVALENCE; VALIDITY; DISEASE AB Objective. To present an algorithm of sequential treatment options for managing sacroiliac joint ( SIJ) pain in the setting of chronic low back pain ( CLBP) in the older adult. This is the tenth part in a series, and includes an illustrative clinical case. Methods. The stepped care drug table and evaluation and treatment algorithm were created following a thorough literature review of approaches and subsequent analysis through a modified Delphi process. The principal investigator developed the initial draft, which was refined for content by an interdisciplinary panel of five experts. The refined materials were then assessed for the feasibility of implementation and validity of recommendations for older adults in a primary care setting by a panel of nine primary care providers. While not exclusive to Veteran's Health Administration (VHA) facilities, an emphasis was made to include resources and medications available to providers in the VHA. Results. The algorithm and drug table developed to systematically identify and address SIJ pain in the older adult is presented here. The process should begin with recognizing the presenting symptoms of CLBP stemming from the SI region, and supporting physical exam testing using the compression test and thigh thrust maneuver. Identification of the SIJ as a pain generator is followed by assessment and treatment of contributory factors. SIJ pain treatment should begin with education and self-management including exercise, and may escalate to include interventional procedures and/or referral to a pain rehabilitation program. Conclusions. Pain originating from the SIJ is often under-recognized, but a structured and consistent approach can help identify older patients who would benefit from treatment of this contributor to CLBP. Key Words. Chronic Low Back Pain; Sacroiliac Joint Pain; Older Adults. C1 [Polsunas, Patrick J.] Univ Pittsburgh, Sch Med, Pittsburgh, PA USA. [Sowa, Gwendolyn] Univ Pittsburgh, Dept Phys Med & Rehabil, Pittsburgh, PA USA. [Sowa, Gwendolyn] Univ Pittsburgh, Dept Orthopaed Surg, Pittsburgh, PA USA. Univ Pittsburgh, Dept Bioengn, Pittsburgh, PA USA. [Fritz, Julie M.] Univ Utah, Coll Hlth, Dept Phys Therapy, Salt Lake City, UT USA. [Gentili, Angela] Hunter Holmes McGuire VA Med Ctr, Richmond, VA USA. [Gentili, Angela] Virginia Commonwealth Univ Hlth Syst, Richmond, VA USA. [Morone, Natalia E.; Weiner, Debra K.] Vet Affairs Pittsburgh Healthcare Syst, Ctr Geriatr Res Educ & Clin, Pittsburgh, PA USA. [Morone, Natalia E.] Univ Pittsburgh, Sch Med, Div Gen Internal Med, Ctr Res Hlth Care, Pittsburgh, PA USA. [Morone, Natalia E.; Weiner, Debra K.] Univ Pittsburgh, Sch Med, Clin & Translat Sci Inst, Pittsburgh, PA USA. [Sowa, Gwendolyn; Raja, Srinivasa Naga] Johns Hopkins Univ, Sch Med, Dept Anesthesiol, Baltimore, MD USA. [Raja, Srinivasa Naga] Johns Hopkins Univ, Sch Med, Crit Care Med, Baltimore, MD USA. [Raja, Srinivasa Naga] Johns Hopkins Univ, Sch Med, Div Pain Med, Baltimore, MD USA. [Rodriguez, Eric] Univ Pittsburgh, Sch Med, Div Geriatr Med, Pittsburgh, PA USA. [Schmader, Kenneth] GRECC, Durham VA Med Ctr, Durham, NC USA. [Schmader, Kenneth] Duke Univ, Med Ctr, Dept Med, Div Geriatr, Durham, NC 27710 USA. [Scholten, Joel D.] Washington DC VA Med Ctr, Washington, DC USA. [Scholten, Joel D.] Vet Hlth Adm, Rehabil Serv, Washington, DC USA. [Scholten, Joel D.] Vet Hlth Adm, Prosthet Serv, Washington, DC USA. [Weiner, Debra K.] Univ Pittsburgh, Dept Psychiat, Pittsburgh, PA USA. [Weiner, Debra K.] Univ Pittsburgh, Dept Anesthesiol, Pittsburgh, PA USA. [Weiner, Debra K.] Dept Med, Div Geriatr Med, Pittsburgh, PA USA. RP Weiner, DK (reprint author), VA Pittsburgh Healthcare Syst, Univ Dr,Bldg 30,00GR, Pittsburgh, PA 15240 USA. EM debra.weiner@va.gov FU Department of Veterans Affairs, Veterans Health Administration, Office of Research and Development, Rehabilitation Research and Development Service FX This material is based on work supported by the Department of Veterans Affairs, Veterans Health Administration, Office of Research and Development, Rehabilitation Research and Development Service. The contents of this report do not represent the views of the Department of Veterans Affairs or the United States government. NR 32 TC 2 Z9 2 U1 3 U2 3 PU OXFORD UNIV PRESS PI OXFORD PA GREAT CLARENDON ST, OXFORD OX2 6DP, ENGLAND SN 1526-2375 EI 1526-4637 J9 PAIN MED JI Pain Med. PD SEP PY 2016 VL 17 IS 9 BP 1638 EP 1647 DI 10.1093/pm/pnw151 PG 10 WC Medicine, General & Internal SC General & Internal Medicine GA EC3IZ UT WOS:000388021100007 PM 27605679 ER PT J AU Harris, JA Herrel, LA Healy, MA Wancata, LM Perumalswami, CR AF Harris, John A. Herrel, Lindsey A. Healy, Mark A. Wancata, Lauren M. Perumalswami, Chithra R. TI Milestones for the Final Mile: Interspecialty Distinctions in Primary Palliative Care Skills Training SO JOURNAL OF PAIN AND SYMPTOM MANAGEMENT LA English DT Article DE Primary palliative care; graduate medical education; Accreditation Council for Graduate Medical Education; milestones; content analysis; residency ID OF-LIFE CARE; NATIONAL-SURVEY; MEDICAL-STUDENTS; CURRICULUM; RESIDENTS; EDUCATION; HOSPICE; FELLOWS; ISSUES AB Context. Primary palliative care (PPC) skills are useful in a wide variety of medical and surgical specialties, and the expectations of PPC skill training are unknown across graduate medical education. Objectives. We characterized the variation and quality of PPC skills in residency outcomes-based Accreditation Council for Graduate Medical Education (ACGME) milestones. Methods. We performed a content analysis with structured implicit review of 2015 ACGME milestone documents from 14 medical and surgical specialties chosen for their exposure to clinical situations requiring PPC. For each specialty milestone document, we characterized the variation and quality of PPC skills in residency outcomes-based ACGME milestones. Results. We identified 959 occurrences of 29 palliative search terms within 14 specialty milestone documents. Within these milestone documents, implicit review characterized 104 milestones with direct saliency to PPC skills and 196 milestones with indirect saliency. Initial interrater agreement of the saliency rating among the primary reviewers was 89%. Specialty milestone documents varied widely in their incorporation of PPC skills within milestone documents. PPC milestones were most commonly found in milestone documents for Anesthesiology, Pediatrics, Urology, and Physical Medicine and Rehabilitation. PPC-relevant milestones were most commonly found in the Interpersonal and Communication Skills core competency with 108 (36%) relevant milestones classified under this core competency. Conclusions. Future revisions of specialty-specific ACGME milestone documents should focus on currently underrepresented, but important PPC skills. (C) 2016 The Authors. Published by Elsevier Inc. C1 [Harris, John A.] Univ Michigan, Inst Healthcare Policy & Innovat, Robert Wood Johnson Fdn Clin Scholars Program, Ann Arbor, MI 48109 USA. [Harris, John A.] Univ Michigan, Dept Obstet & Gynecol, Ann Arbor, MI 48109 USA. [Herrel, Lindsey A.] Univ Michigan, Dow Div Urol Hlth Serv Res, Dept Urol, Ann Arbor, MI 48109 USA. [Herrel, Lindsey A.] Univ Michigan, Inst Healthcare Policy & Innovat, Ann Arbor, MI 48109 USA. [Healy, Mark A.; Wancata, Lauren M.] Univ Michigan, Dept Surg, Ann Arbor, MI 48109 USA. [Healy, Mark A.] Univ Michigan, Ctr Healthcare Outcomes & Policy, Ann Arbor, MI 48109 USA. [Perumalswami, Chithra R.] Univ Michigan, Robert Wood Johnson Fdn Clin Scholars Program, US Dept Vet Affairs, Inst Healthcare Policy & Innovat, Ann Arbor, MI 48109 USA. [Perumalswami, Chithra R.] Univ Michigan, Dept Internal Med, Div Geriatr & Palliat Med, Ann Arbor, MI 48109 USA. RP Harris, JA (reprint author), 2800 Plymouth Rd,Bldg 14,Room G100, Ann Arbor, MI 48109 USA. EM harrja@med.umich.edu OI Harris, John/0000-0002-7907-8139 FU Robert Wood Johnson Foundation Clinical Scholars Program; U.S. Department of Veterans Affairs [N018080]; NIH T32 grant [CA009672, F025681] FX Dr. Harris is a Robert Wood Johnson Foundation Clinical Scholar at the University of Michigan. Dr. Perumalswami is a Robert Wood Johnson Foundation and Veterans Affairs Clinical Scholar at the University of Michigan. Support for the publication was provided by the Robert Wood Johnson Foundation Clinical Scholars Program and the U.S. Department of Veterans Affairs (N018080). The Robert Wood Johnson Foundation and the Department of Veterans Affairs were not directly involved in study design, data acquisition and interpretation, article preparation or review. Any opinions expressed herein do not necessarily reflect the opinions of the Robert Wood Johnson Foundation or the Department of Veterans Affairs. Drs. Wancata and Healy are supported by NIH T32 grant CA009672. Dr. Herrel is funded by NIH T32 grant F025681. The authors have no pertinent conflicts of interest to disclose. NR 23 TC 0 Z9 0 U1 4 U2 4 PU ELSEVIER SCIENCE INC PI NEW YORK PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA SN 0885-3924 EI 1873-6513 J9 J PAIN SYMPTOM MANAG JI J. Pain Symptom Manage. PD SEP PY 2016 VL 52 IS 3 BP 345 EP + DI 10.1016/j.jpainsymman.2016.03.007 PG 13 WC Health Care Sciences & Services; Medicine, General & Internal; Clinical Neurology SC Health Care Sciences & Services; General & Internal Medicine; Neurosciences & Neurology GA EA7RV UT WOS:000386830500007 PM 27260828 ER PT J AU Garrido, MM Dowd, B Hebert, PL Maciejewski, ML AF Garrido, Melissa M. Dowd, Bryan Hebert, Paul L. Maciejewski, Matthew L. TI Understanding Treatment Effect Terminology in Pain and Symptom Management Research SO JOURNAL OF PAIN AND SYMPTOM MANAGEMENT LA English DT Article DE Treatment effect; randomized controlled trial; health services research; terminology; observational study; treatment assignment; selection bias ID HEALTH-SERVICES RESEARCH; INSTRUMENTAL VARIABLES; RANDOMIZED-TRIALS; SUBGROUP ANALYSIS; HETEROGENEITY; STATEMENT; MODELS; CANCER; CARE; GUIDELINES AB Within health services and medical research, there is a wide variety of terminology related to treatment effects. Understanding differences in types of treatment effects is especially important in pain and symptom management research where nonexperimental and quasiexperimental observational data analysis is common. We use the example of a palliative care consultation team leader considering implementation of a medication reconciliation program and a care-coordination intervention reported in the literature to illustrate population-level and conditional treatment effects and to highlight the sensitivity of values of treatment effects to sample selection and treatment assignment. Our goal is to facilitate appropriate reporting and interpretation of study results and to help investigators understand what information a decision maker needs when deciding whether to implement a treatment. Greater awareness of the reasons why treatment effects may differ across studies of the same patients in the same treatment settings can help policy makers and clinicians understand to whom a study's results may be generalized. Published by Elsevier Inc. C1 [Garrido, Melissa M.] James J Peters VA Med Ctr, Bronx, NY USA. [Garrido, Melissa M.] Icahn Sch Med Mt Sinai, New York, NY 10029 USA. [Dowd, Bryan] Univ Minnesota, Sch Publ Hlth, Minneapolis, MN USA. [Hebert, Paul L.] VA Puget Sound, Seattle, WA USA. [Hebert, Paul L.] Univ Washington, Sch Publ Hlth, Seattle, WA 98195 USA. [Maciejewski, Matthew L.] Durham VA Med Ctr, Durham, NC USA. [Maciejewski, Matthew L.] Duke Univ, Sch Med, Durham, NC USA. RP Garrido, MM (reprint author), 4A-17,130 West Kingsbridge Rd, Bronx, NY 10468 USA. EM melissa.garrido@va.gov OI Garrido, Melissa/0000-0002-8986-3536 FU Department of Veterans Affairs, Veterans Health Administration, Office of Research and Development, Health Services Research, and Development Service [CDA 11-201/CDP 12-255, RCS 10-391] FX Dr. Garrido (CDA 11-201/CDP 12-255) and Dr. Maciejewski (RCS 10-391) receive support from the Department of Veterans Affairs, Veterans Health Administration, Office of Research and Development, Health Services Research, and Development Service. The views expressed in this article are those of the authors and do not necessarily reflect the position or policy of the Department of Veterans Affairs or the United States government. The authors declare no conflicts of interest. NR 29 TC 0 Z9 0 U1 2 U2 2 PU ELSEVIER SCIENCE INC PI NEW YORK PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA SN 0885-3924 EI 1873-6513 J9 J PAIN SYMPTOM MANAG JI J. Pain Symptom Manage. PD SEP PY 2016 VL 52 IS 3 BP 446 EP 452 DI 10.1016/j.jpainsymman.2016.01.016 PG 7 WC Health Care Sciences & Services; Medicine, General & Internal; Clinical Neurology SC Health Care Sciences & Services; General & Internal Medicine; Neurosciences & Neurology GA EA7RV UT WOS:000386830500019 PM 27220944 ER PT J AU Yoshikawa, TT Ouslander, JG Applegate, WB AF Yoshikawa, Thomas T. Ouslander, Joseph G. Applegate, William B. TI Influence of Studies Published by the Journal of the American Geriatrics Society: Top 20 Articles from 2000-2015 SO JOURNAL OF THE AMERICAN GERIATRICS SOCIETY LA English DT Letter ID OLDER-ADULTS; CONTROLLED-TRIAL; HIP FRACTURE; FRAILTY; CARE; IMPAIRMENT; EXERCISE; DELIRIUM C1 [Yoshikawa, Thomas T.] Dept Vet Affairs Greater Los Angeles Healthcare S, Los Angeles, CA USA. [Yoshikawa, Thomas T.] Univ Calif Los Angeles, Los Angeles, CA USA. [Ouslander, Joseph G.] Charles E Schmidt Coll Biomed Sci, Dept Integrated Med Sci, Boca Raton, FL USA. [Applegate, William B.] Wake Forest Univ, Bowman Gray Sch Med, Sticht Ctr Aging, Sect Gerontol & Geriatr Med,Dept Med, Winston Salem, NC USA. RP Yoshikawa, TT (reprint author), VA Greater Los Angeles Healthcare Syst, 11301 Wilshire Blvd,Bldg 158, Los Angeles, CA 90073 USA. EM toyoshikawa@cdrewu.edu FU American Geriatrics Society FX All three authors receive a stipend from the American Geriatrics Society in their role as editors of JAGS. The authors have no other conflicts of interest to disclose relevant to this article. NR 20 TC 1 Z9 1 U1 3 U2 3 PU WILEY-BLACKWELL PI HOBOKEN PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA SN 0002-8614 EI 1532-5415 J9 J AM GERIATR SOC JI J. Am. Geriatr. Soc. PD SEP PY 2016 VL 64 IS 9 BP 1763 EP 1768 DI 10.1111/jgs.14492 PG 6 WC Geriatrics & Gerontology; Gerontology SC Geriatrics & Gerontology GA EB0FC UT WOS:000387017800031 PM 27553684 ER PT J AU Thorpe, CT Fowler, NR Harrigan, K Zhao, XH Kang, YH Hanlon, JT Gellad, WF Schleiden, LJ Thorpe, JM AF Thorpe, Carolyn T. Fowler, Nicole R. Harrigan, Katherine Zhao, Xinhua Kang, Yihuang Hanlon, Joseph T. Gellad, Walid F. Schleiden, Loren J. Thorpe, Joshua M. TI Racial and Ethnic Differences in Initiation and Discontinuation of Antidementia Drugs by Medicare Beneficiaries SO JOURNAL OF THE AMERICAN GERIATRICS SOCIETY LA English DT Article DE dementia; health disparities; antidementia medications; Medicare; medication discontinuation ID CHOLINESTERASE INHIBITOR THERAPY; CLINICAL-PRACTICE GUIDELINE; SEVERE ALZHEIMERS-DISEASE; PHARMACOLOGICAL-TREATMENT; DEMENTIA; DONEPEZIL; CARE; DISPARITIES; MEMANTINE; PRESCRIPTION AB OBJECTIVES: To examine racial and ethnic differences in initiation and time to discontinuation of antidementia medication in Medicare beneficiaries. DESIGN: Retrospective cohort study. SETTING: Secondary analysis of 2009-10 enrollment, claims, and Part D prescription data for a 10% national sample of U.S. Medicare fee-for-service beneficiaries. PARTICIPANTS: Beneficiaries aged 65 and older with Alzheimer's disease or related dementia (ADRD) before 2009 and no fills for antidementia medications in the first half of 2009 (N = 84,043). MEASUREMENTS: Initiation was defined as having one or more fills for antidementia medication in the second half of 2009 and discontinuation as a gap in coverage of 30 days or more during the year after initiation. The Andersen Behavioral Model was used to guide covariate selection. RESULTS: Overall, 3,481 (4.1%) of previous nonusers initiated antidementia medication in the second half of 2009. Of those initiating one drug class (acetylcholinesterase inhibitors (AChEIs) or memantine), 9% later added the other class, and 2% switched classes. Of initiators, 23% discontinued within 1 month, and 62% discontinued within 1 year. Hispanic beneficiaries were more likely than white beneficiaries to initiate (adjusted odds ratio = 1.25, 95% confidence interval (CI) = 1.10-.41). Black and white beneficiaries did not differ in likelihood of initiation. Hispanic (adjusted hazard ratio (aHR) = 1.56, 95% CI = 1.34-1.82) and black (aHR = 1.25, 95% CI = 1.08-1.44) beneficiaries discontinued at a faster rate than white beneficiaries. CONCLUSION: Initiation of antidementia medications was no different in black and white beneficiaries and more likely in Hispanic beneficiaries; black and Hispanic beneficiaries discontinued at a faster rate. More research into reasons explaining these differences is needed. C1 [Thorpe, Carolyn T.; Harrigan, Katherine; Zhao, Xinhua; Hanlon, Joseph T.; Schleiden, Loren J.; Thorpe, Joshua M.] Univ Pittsburgh, Sch Pharm, Dept Pharm & Therapeut, 919 Salk Hall,3501 Terrace St, Pittsburgh, PA 15261 USA. [Thorpe, Carolyn T.; Zhao, Xinhua; Hanlon, Joseph T.; Gellad, Walid F.; Schleiden, Loren J.; Thorpe, Joshua M.] Vet Affairs Pittsburgh Healthcare Syst, Ctr Hlth Equ Res & Promot, Pittsburgh, PA USA. [Fowler, Nicole R.] Indiana Univ, Sch Med, Indianapolis, IN USA. [Fowler, Nicole R.] Indiana Univ, Ctr Aging Res, Indianapolis, IN 46204 USA. [Fowler, Nicole R.] Regenstrief Inst Inc, Ctr Hlth Innovat & Implementat, Indianapolis, IN USA. [Zhao, Xinhua; Kang, Yihuang; Hanlon, Joseph T.] Univ Pittsburgh, Dept Med, Div Geriatr Med, Pittsburgh, PA USA. [Gellad, Walid F.] Univ Pittsburgh, Dept Med, Div Gen Internal Med, Pittsburgh, PA USA. RP Thorpe, CT (reprint author), Univ Pittsburgh, Sch Pharm, Dept Pharm & Therapeut, 919 Salk Hall,3501 Terrace St, Pittsburgh, PA 15261 USA. EM ctthorpe@pitt.edu FU RAND-University of Pittsburgh Health Institute; Pittsburgh Claude D. Pepper Older Americans Independence Center [NIA P30 AG024827]; University of Pittsburgh School of Pharmacy FX The RAND-University of Pittsburgh Health Institute, the Pittsburgh Claude D. Pepper Older Americans Independence Center (NIA P30 AG024827), and the University of Pittsburgh School of Pharmacy provided funding for this study. NR 48 TC 0 Z9 0 U1 1 U2 1 PU WILEY-BLACKWELL PI HOBOKEN PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA SN 0002-8614 EI 1532-5415 J9 J AM GERIATR SOC JI J. Am. Geriatr. Soc. PD SEP PY 2016 VL 64 IS 9 BP 1806 EP 1814 DI 10.1111/jgs.14403 PG 9 WC Geriatrics & Gerontology; Gerontology SC Geriatrics & Gerontology GA EB0FC UT WOS:000387017800038 PM 27549029 ER PT J AU Alessi, C Martin, JL Fiorentino, L Fung, CH Dzierzewski, JM Tapia, JCR Song, Y Josephson, K Jouldjian, S Mitchell, MN AF Alessi, Cathy Martin, Jennifer L. Fiorentino, Lavinia Fung, Constance H. Dzierzewski, Joseph M. Tapia, Juan C. Rodriguez Song, Yeonsu Josephson, Karen Jouldjian, Stella Mitchell, Michael N. TI Cognitive Behavioral Therapy for Insomnia in Older Veterans Using Nonclinician Sleep Coaches: Randomized Controlled Trial SO JOURNAL OF THE AMERICAN GERIATRICS SOCIETY LA English DT Article DE insomnia; sleep; cognitive behavioral therapy; aged; randomized controlled trial ID PRACTICE PARAMETERS; ADULTS; RISK; METAANALYSIS; DISORDERS; UPDATE; DISTURBANCES; SYMPTOMS; EFFICACY; VALIDITY AB OBJECTIVES: To test a new cognitive behavioral therapy for insomnia (CBT-I) program designed for use by nonclinicians. DESIGN: Randomized controlled trial. SETTING: Department of Veterans Affairs healthcare system. PARTICIPANTS: Community-dwelling veterans aged 60 and older who met diagnostic criteria for insomnia of 3 months duration or longer (N = 159). INTERVENTION: Nonclinician "sleep coaches" delivered a five-session manual-based CBT-I program including stimulus control, sleep restriction, sleep hygiene, and cognitive therapy (individually or in small groups), with weekly telephone behavioral sleep medicine supervision. Controls received five sessions of general sleep education. MEASUREMENTS: Primary outcomes, including self-reported (7-day sleep diary) sleep onset latency (SOL-D), wake after sleep onset (WASO-D), total wake time (TWT-D), and sleep efficiency (SE-D); Pittsburgh Sleep Quality Index (PSQI); and objective sleep efficiency (7-day wrist actigraphy, SE-A) were measured at baseline, at the post-treatment assessment, and at 6- and 12-month follow-up. Additional measures included the Insomnia Severity Index (ISI), depressive symptoms (Patient Health Questionnaire-9 (PHQ-9)), and quality of life (Medical Outcomes Study 12-item Short-form Survey version 2 (SF-12v2)). RESULTS: Intervention subjects had greater improvement than controls between the baseline and posttreatment assessments, the baseline and 6-month assessments, and the baseline and 12-month assessments in SOL-D (-23.4, -15.8, and -17.3 minutes, respectively), TWT-D (-68.4, -37.0, and -30.9 minutes, respectively), SE-D (10.5%, 6.7%, and 5.4%, respectively), PSQI (-3.4, -2.4, and -2.1 in total score, respectively), and ISI (-4.5, -3.9, and -2.8 in total score, respectively) (all P < .05). There were no significant differences in SE-A, PHQ-9, or SF-12v2. CONCLUSION: Manual-based CBT-I delivered by nonclinician sleep coaches improves sleep in older adults with chronic insomnia. C1 [Alessi, Cathy; Martin, Jennifer L.; Fung, Constance H.; Dzierzewski, Joseph M.; Song, Yeonsu; Josephson, Karen; Jouldjian, Stella; Mitchell, Michael N.] Vet Affairs Greater Los Angeles Healthcare Syst, Geriatr Res Educ & Clin Ctr, Los Angeles, CA USA. [Alessi, Cathy; Martin, Jennifer L.; Fung, Constance H.; Dzierzewski, Joseph M.; Tapia, Juan C. Rodriguez; Song, Yeonsu] Univ Calif Los Angeles, David Geffen Sch Med, Dept Med, Los Angeles, CA 90095 USA. [Fiorentino, Lavinia] Univ Calif San Diego, Dept Psychiat, San Diego, CA 92103 USA. [Tapia, Juan C. Rodriguez] Pontificia Univ Catolica Chile, Dept Med, Santiago, Chile. RP Alessi, C (reprint author), 16111 Plummer St 11E, North Hills, CA 91343 USA. EM cathy.alessi@va.gov FU VA Health Services Research and Development [Alessi IIR 08-295]; VA Greater Los Angeles Geriatric Research, Education and Clinical Center FX Funded by VA Health Services Research and Development (Alessi IIR 08-295) and the VA Greater Los Angeles Geriatric Research, Education and Clinical Center. NR 43 TC 0 Z9 0 U1 7 U2 7 PU WILEY-BLACKWELL PI HOBOKEN PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA SN 0002-8614 EI 1532-5415 J9 J AM GERIATR SOC JI J. Am. Geriatr. Soc. PD SEP PY 2016 VL 64 IS 9 BP 1830 EP 1838 DI 10.1111/jgs.14304 PG 9 WC Geriatrics & Gerontology; Gerontology SC Geriatrics & Gerontology GA EB0FC UT WOS:000387017800041 PM 27550552 ER PT J AU Cenzer, IS Tang, V Boscardin, WJ Smith, AK Ritchie, C Wallhagen, MI Espaldon, R Covinsky, KE AF Cenzer, Irena S. Tang, Victoria Boscardin, W. John Smith, Alexander K. Ritchie, Christine Wallhagen, Margaret I. Espaldon, Roxanne Covinsky, Kenneth E. TI One-Year Mortality After Hip Fracture: Development and Validation of a Prognostic Index SO JOURNAL OF THE AMERICAN GERIATRICS SOCIETY LA English DT Article DE hip fracture; prediction; mortality ID OLDER-ADULTS; LOGISTIC-REGRESSION; UNITED-STATES; RISK-FACTORS; OUTCOMES; HOSPITALIZATION; MODELS; RACE AB OBJECTIVES: To develop a prediction index for 1-year mortality after hip fracture in older adults that includes predictors from a wide range of domains. DESIGN: Retrospective cohort study. SETTINGS: Health and Retirement Study (HRS). PARTICIPANTS: HRS participants who experienced hip fracture between 1992 and 2010 as identified according to Medicare claims data (N = 857). MEASUREMENTS: Outcome measure was death within 1 year of hip fracture. Predictor measures were participant demographic characteristics, socioeconomic status, social support, health, geriatric symptoms, and function. Variables independently associated with 1-year mortality were identified, and best-subsets regression was used to identify the final model. The selected variables were weighted to create a risk index. The index was internally validated using bootstrapping to estimate model optimism. RESULTS: Mean age at time of hip fracture was 84, and 76% of the participants were women. There were 235 deaths (27%) during the 1-year follow up. Five predictors of mortality were included in the final model: aged 90 and older (2 points), male sex (2 points), congestive heart failure (2 points), difficulty preparing meals (2 points), and not being able to drive (1 point). The point scores of the index were associated with 1-year mortality, with 0 points predicting 10% risk and 7 to 9 points predicting 66% risk. The c-statistic for the final model was 0.73, with an estimated optimism penalty of 0.01, indicating very little evidence of overfitting. CONCLUSION: The prognostic index combines demographic, comorbidity, and function variables and can be used to differentiate between individuals at low and high risk of 1-year mortality after hip fracture. C1 [Cenzer, Irena S.; Tang, Victoria; Boscardin, W. John; Smith, Alexander K.; Ritchie, Christine; Espaldon, Roxanne; Covinsky, Kenneth E.] Univ Calif San Francisco, Sch Nursing, Div Geriatr, San Francisco, CA 94143 USA. [Wallhagen, Margaret I.] Univ Calif San Francisco, Sch Nursing, Dept Physiol Nursing, San Francisco, CA 94143 USA. [Boscardin, W. John] Univ Calif San Francisco, Dept Epidemiol & Biostat, San Francisco, CA 94143 USA. [Cenzer, Irena S.; Tang, Victoria; Boscardin, W. John; Smith, Alexander K.; Ritchie, Christine; Espaldon, Roxanne; Covinsky, Kenneth E.] San Francisco VA Med Ctr, San Francisco, CA USA. [Ritchie, Christine] Jewish Home San Francisco, San Francisco, CA USA. RP Cenzer, IS (reprint author), 4150 Clement St,181G, San Francisco, CA 94121 USA. EM irena.stijacic@ucsf.edu FU National Institutes of Health; National Institute of Nursing Research [R01 NR013347]; National Institute on Aging [K24AG029812, P30AG04428, K23AG040772]; American Federation for Aging Research; John A. Hartford Foundation FX Supported by the National Institutes of Health and National Institute of Nursing Research (R01 NR013347; PI: Covinsky; Co-I: Ritchie). Dr. Covinsky was supported in part by grants from the National Institute on Aging (K24AG029812 and P30AG04428). Dr. Smith was supported in part by a Paul Beeson career development award from the National Institute on Aging (K23AG040772) and the American Federation for Aging Research. Dr. Wallhagen was supported in part by the John A. Hartford Foundation. NR 27 TC 0 Z9 0 U1 1 U2 1 PU WILEY-BLACKWELL PI HOBOKEN PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA SN 0002-8614 EI 1532-5415 J9 J AM GERIATR SOC JI J. Am. Geriatr. Soc. PD SEP PY 2016 VL 64 IS 9 BP 1863 EP 1868 DI 10.1111/jgs.14237 PG 6 WC Geriatrics & Gerontology; Gerontology SC Geriatrics & Gerontology GA EB0FC UT WOS:000387017800046 PM 27295578 ER PT J AU Cui, J Cai, YH Hu, Y Huang, ZH Luo, YX Kaz, AM Yang, ZH Chen, DK Fan, XJ Grady, WM Wang, JP AF Cui, Ji Cai, Yonghua Hu, Ying Huang, Zenghong Luo, Yanxin Kaz, Andrew M. Yang, Zihuan Chen, Dianke Fan, Xinjuan Grady, William M. Wang, Jianping TI Epigenetic silencing of TPM2 contributes to colorectal cancer progression upon RhoA activation SO TUMOR BIOLOGY LA English DT Article DE Colorectal cancer; DNA methylation; TPM2 ID BETA-TROPOMYOSIN EXPRESSION; IDENTIFICATION; TRANSFORMATION; METHYLATION; SUPPRESSOR; PROTEOMICS; PROTEINS; PATHWAY AB Beta-tropomyosin (beta-tropomyosin, TPM2) has been found to be downregulated in colorectal cancer (CRC) in previous studies. In this study, we aimed to investigate the mechanisms and potential biological consequences of the downregulation of TPM2 in colorectal cancer. TPM2 expression in colorectal cancer was assessed by qRT-PCR and immunostaining. The biological functions of TPM2 were assessed in cell lines either overexpressing or underexpressingTPM2. Aberrant DNA methylation in the promoter region is associated with suppression of TPM2 expression in primary colorectal cancer tissue samples. Treatment with the demethylation agent 5-AZA can induceTPM2 expression in colorectal cancer cell lines. Reconstitution of TPM2 suppresses cell proliferation and migration in colorectal cancer cell lines, whereas the loss of TPM2 expression is associated with increased tumor proliferation and migration in vitro, which was accompanied by RhoA activation. In summary, our findings indicate that TPM2 appears to be commonly silenced by aberrant DNA methylation in colon cancer. TPM2 loss is associated with RhoA activation and tumor proliferation. C1 [Cui, Ji] Sun Yat Sen Univ, Affiliated Hosp 1, Dept Gastrointestinal Surg, Guangzhou, Guangdong, Peoples R China. [Cai, Yonghua; Huang, Zenghong; Luo, Yanxin; Wang, Jianping] Sun Yat Sen Univ, Dept Colorectal Surg, Affilated Hosp 6, Guangzhou 56055, Guangdong, Peoples R China. [Cai, Yonghua; Huang, Zenghong; Luo, Yanxin; Yang, Zihuan; Chen, Dianke; Wang, Jianping] Sun Yat Sen Univ, Gastrointestinal Inst, Guangzhou, Guangdong, Peoples R China. [Hu, Ying] Sun Yat Sen Univ, Affiliated Hosp 1, Dept Med 2, Guangzhou, Guangdong, Peoples R China. [Chen, Dianke] Sun Yat Sen Univ, Dept Oncol, Affilated Hosp 6, Guangzhou, Guangdong, Peoples R China. [Fan, Xinjuan] Sun Yat Sen Univ, Dept Pathol, Affilated Hosp 6, Guangzhou, Guangdong, Peoples R China. [Luo, Yanxin; Kaz, Andrew M.; Grady, William M.] Fred Hutchinson Canc Res Ctr, Div Clin Res, 1100 Fairview Ave N D4-100, Seattle, WA 98109 USA. [Kaz, Andrew M.; Grady, William M.] Univ Washington, Sch Med, Dept Med, Seattle, WA 98195 USA. [Kaz, Andrew M.] VA Puget Sound Hlth Care Syst, Res & Dev Serv, Seattle, WA USA. RP Wang, JP (reprint author), Sun Yat Sen Univ, Dept Colorectal Surg, Affilated Hosp 6, Guangzhou 56055, Guangdong, Peoples R China.; Wang, JP (reprint author), Sun Yat Sen Univ, Gastrointestinal Inst, Guangzhou, Guangdong, Peoples R China.; Grady, WM (reprint author), Fred Hutchinson Canc Res Ctr, Div Clin Res, 1100 Fairview Ave N D4-100, Seattle, WA 98109 USA.; Grady, WM (reprint author), Univ Washington, Sch Med, Dept Med, Seattle, WA 98195 USA. EM cuiji168@163.com; yonghua.cai@163.com; 974552048@qq.com; huangznh@mail2.sysu.edu.cn; luoyx25@mail.sysu.edu.cn; akaz@fhcrc.org; yzhuan@mail.sysu.edu.cn; chendianke@163.com; juanjuanfan@163.com; wgrady@fhcrc.org; wjp@mail.sysu.edu.cn FU National Basic Research Program of China (973 Program) [2015CB554001]; Program of Introducing Talents of Discipline to Universities of China [B12003]; International Science & Technology Cooperation Program of China [2011DFA32570]; Science and Technology Program of Guangzhou [201506010099, 2014Y2-00160]; National Natural Science Foundation of China [81172040, 81201920, 81472257]; Guangdong Natural Science Funds for Distinguished Young Scholars [2016A030306002]; Fundamental Research Funds for the Central Universities (Sun Yat-sen University) [2015ykzd10, 13ykpy37] FX Support for these studies was provided by a National Basic Research Program of China (973 Program) (No. 2015CB554001, JW), Program of Introducing Talents of Discipline to Universities of China (B12003, JW) and International Science & Technology Cooperation Program of China (2011DFA32570, JW), the Science and Technology Program of Guangzhou (No. 201506010099, YL; No. 2014Y2-00160, JW), National Natural Science Foundation of China (81172040 JW; 81201920 and 81472257, YL), the Guangdong Natural Science Funds for Distinguished Young Scholars (2016A030306002, YL), and the Fundamental Research Funds for the Central Universities (Sun Yat-sen University) (No. 2015ykzd10, YL; No. 13ykpy37, YL). NR 18 TC 0 Z9 0 U1 0 U2 0 PU SPRINGER PI DORDRECHT PA VAN GODEWIJCKSTRAAT 30, 3311 GZ DORDRECHT, NETHERLANDS SN 1010-4283 EI 1423-0380 J9 TUMOR BIOL JI Tumor Biol. PD SEP PY 2016 VL 37 IS 9 BP 12477 EP 12483 DI 10.1007/s13277-016-5103-1 PG 7 WC Oncology SC Oncology GA EB0ZJ UT WOS:000387075400087 PM 27333992 ER PT J AU Gopal, R Prochazka, A AF Gopal, Ravi Prochazka, Allan TI Measuring Medical Student Well-being: Questions About a Recent Study SO ACADEMIC MEDICINE LA English DT Letter C1 [Gopal, Ravi; Prochazka, Allan] Denver Vet Affairs Med Ctr, Denver, CO 80220 USA. RP Gopal, R (reprint author), Denver Vet Affairs Med Ctr, Denver, CO 80220 USA. EM ravi.gopal@va.gov NR 3 TC 0 Z9 0 U1 0 U2 0 PU LIPPINCOTT WILLIAMS & WILKINS PI PHILADELPHIA PA TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA SN 1040-2446 EI 1938-808X J9 ACAD MED JI Acad. Med. PD SEP PY 2016 VL 91 IS 9 BP 1189 EP 1189 PG 1 WC Education, Scientific Disciplines; Health Care Sciences & Services SC Education & Educational Research; Health Care Sciences & Services GA EA5PX UT WOS:000386674800002 PM 27576029 ER PT J AU Naidu, SS Aronow, HD Box, LC Duffy, PL Kolansky, DM Kupfer, JM Latif, F Mulukutla, SR Rao, SV Swaminathan, RV Blankenship, JC AF Naidu, Srihari S. Aronow, Herbert D. Box, Lyndon C. Duffy, Peter L. Kolansky, Daniel M. Kupfer, Joel M. Latif, Faisal Mulukutla, Suresh R. Rao, Sunil V. Swaminathan, Rajesh V. Blankenship, James C. TI SCAI Expert Consensus Statement: 2016 Best Practices in the Cardiac Catheterization Laboratory: (Endorsed by the Cardiological Society of India, and Sociedad Latino Americana de Cardiologia Intervencionista; Affirmation of Value by the Canadian Association of Interventional Cardiology-Association Canadienne de Cardiologie d'intervention) SO CATHETERIZATION AND CARDIOVASCULAR INTERVENTIONS LA English DT Article ID PERCUTANEOUS CORONARY INTERVENTION; RADIOGRAPHIC CONTRAST-MEDIA; CARDIOVASCULAR ANGIOGRAPHY; TASK-FORCE; HEART-ASSOCIATION; FEMORAL-ARTERY; INFORMED-CONSENT; MYOCARDIAL-INFARCTION; PRACTICE GUIDELINES; INDUCED NEPHROPATHY C1 [Naidu, Srihari S.] Winthrop Univ Hosp, Div Cardiol, Mineola, NY 11501 USA. [Aronow, Herbert D.] Brown Univ, Warren Alpert Med Sch, Cardiovasc Inst, Providence, RI 02912 USA. [Box, Lyndon C.] West Valley Med Ctr, Caldwell, ID USA. [Duffy, Peter L.] FirstHealth Carolinas, Pinehurst, NC USA. [Kolansky, Daniel M.] Univ Penn, Perelman Sch Med, Cardiovasc Med Div, Philadelphia, PA 19104 USA. [Kupfer, Joel M.] Univ Illinois, Sch Med Peoria, Peoria, IL USA. [Latif, Faisal] Univ Oklahoma, Oklahoma City, OK USA. [Latif, Faisal] VA Med Ctr, Oklahoma City, OK USA. [Mulukutla, Suresh R.] Univ Pittsburgh, Pittsburgh, PA USA. [Mulukutla, Suresh R.] VA Pittsburgh Healthcare Syst, Pittsburgh, PA USA. [Rao, Sunil V.] Duke Univ, Med Ctr, Durham, NC USA. [Swaminathan, Rajesh V.] New York Presbyterian Hosp, Weill Cornell Med Coll, Greenberg Div Cardiol, New York, NY USA. [Blankenship, James C.] Geisinger Med Ctr, Danville, PA 17822 USA. RP Naidu, SS (reprint author), 120 Mineola Blvd,Suite 500, Mineola, NY 11501 USA. EM ssnaidu@winthrop.org NR 74 TC 0 Z9 0 U1 0 U2 0 PU WILEY-BLACKWELL PI HOBOKEN PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA SN 1522-1946 EI 1522-726X J9 CATHETER CARDIO INTE JI Catheter. Cardiovasc. Interv. PD SEP PY 2016 VL 88 IS 3 BP 407 EP 423 DI 10.1002/ccd.26551 PG 17 WC Cardiac & Cardiovascular Systems SC Cardiovascular System & Cardiology GA EA7GX UT WOS:000386799900021 PM 27137680 ER PT J AU Clapp, JD Kemp, JJ Cox, KS Tuerk, PW AF Clapp, Joshua D. Kemp, Joshua J. Cox, Keith S. Tuerk, Peter W. TI PATTERNS OF CHANGE IN RESPONSE TO PROLONGED EXPOSURE: IMPLICATIONS FOR TREATMENT OUTCOME SO DEPRESSION AND ANXIETY LA English DT Article DE Posttraumatic stress disorder; combat disorder; veteran; psychotherapies; treatment outcome; clinical psychology ID POSTTRAUMATIC-STRESS-DISORDER; COGNITIVE PROCESSING THERAPY; MENTAL-HEALTH PROBLEMS; PSYCHOLOGICAL TREATMENTS; SUDDEN GAINS; PSYCHOMETRIC PROPERTIES; BEHAVIORAL THERAPY; IMAGINAL EXPOSURE; SUICIDAL IDEATION; VIETNAM VETERANS AB BackgroundAssessment of response to Prolonged Exposure (PE) suggests some patients may experience discontinuous change involving sudden symptom reductions and/or temporary exacerbations. The current study looked to (1) isolate profiles of PE response among treatment-seeking veterans and (2) identify factors associated with unique patterns of change. MethodsArchival records were examined for veterans receiving PE through a specialty Veterans Affairs Medical Center (VAMC) clinic (N = 109). Latent profile analysis was used to extract response trajectories defined by change in weekly PTSD Checklist (PCL) scores. Associations with provider status (staff vs. intern), setting (in-person vs. telehealth), initial severity (PTSD; depression), and eventual treatment gains were examined. ResultsThree profiles were observed. Rapid Responders (18.3%) evidenced sharp reductions at Week 2 and again between Weeks 5 and 6. Linear Responders (40.4%) demonstrated gradual reductions throughout the 10-week assessment window. Delayed Responder (41.3%) scores were relatively stable over the evaluation period although final session outcomes indicated reliable change (PCL>10) in 40% of patients. Profiles were similar with respect to provider status, treatment setting, and initial symptom severity. Rapid Responders evidenced lower final session scores relative to Linear (g = 1.13) and Delayed (g = 1.85) groups, with Linear Responders reporting lower end scores than Delayed Responders (g= 1.02). ConclusionsAnticipating patterns of recovery and their association with therapeutic outcome is of immense clinical value. Sudden gains emerged as a strong predictor of enhanced response. Data also suggest potential benefits of extending standard intervention for patients who fail to demonstrate an immediate response to PE. C1 [Clapp, Joshua D.; Kemp, Joshua J.] Univ Wyoming, Dept Psychol, 1000 E Univ Ave, Laramie, WY 82071 USA. [Cox, Keith S.] Univ North Carolina Asheville, Dept Psychol, Asheville, NC USA. [Tuerk, Peter W.] Ralph H Johnson VA Med Ctr, Charleston, SC 29401 USA. [Tuerk, Peter W.] Med Univ South Carolina, Dept Psychiat & Behav Sci, Charleston, SC USA. RP Clapp, JD (reprint author), Univ Wyoming, Dept Psychol, 1000 E Univ Ave, Laramie, WY 82071 USA. EM jclapp@uwyo.edu NR 66 TC 2 Z9 2 U1 14 U2 14 PU WILEY-BLACKWELL PI HOBOKEN PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA SN 1091-4269 EI 1520-6394 J9 DEPRESS ANXIETY JI Depress. Anxiety PD SEP PY 2016 VL 33 IS 9 BP 807 EP 815 DI 10.1002/da.22534 PG 9 WC Psychology, Clinical; Psychiatry; Psychology SC Psychology; Psychiatry GA DW5SR UT WOS:000383707700004 PM 27321062 ER PT J AU Anderson, BJ Wahlquist, AE Hill, EG Marshall, DT Kimchi, ET O'Carroll, KFS Camp, ER AF Anderson, Brandon J. Wahlquist, Amy E. Hill, Elizabeth G. Marshall, David T. Kimchi, Eric T. O'Carroll, Kevin F. Staveley Camp, E. Ramsay TI The impact of metabolic syndrome on outcome and response to neoadjuvant chemoradiation in locally advanced rectal cancer patients SO INTERNATIONAL JOURNAL OF SURGERY LA English DT Article DE Metabolic syndrome; Rectal cancer; Neoadjuvant; Chemoradiation; Hypertension; Diabetes; Obesity ID HYPERTENSION; RISK; CHEMORADIOTHERAPY AB Background and objectives: Metabolic syndrome (MetS) is a constellation of cardiovascular risk factors shown to increase the risk of developing various malignancies, as well as diminish tumor response to conventional therapies. The effects of MetS and its individual components on therapeutic response and treatment-related outcomes were examined in patients with locally advanced rectal cancer (LARC). Methods: Data was retrospectively collected on LARC patients treated with neoadjuvant chemoradiation (nCRT) and surgery. Medical records were reviewed for patient characteristics, staging, treatment plan, and outcomes. Results: One hundred two patients were included in the study. Patients with HTN had a significantly decreased nCRT response and were four times more likely to experience a poor response to treatment compared to patients without HTN. Additionally, HTN was found to significantly increase the rate of surgical complications. Neither DM nor obesity exhibited any significant effect on therapeutic response or complication rates, either individually or in combination with another risk factor. Conclusion: This study demonstrates the importance of considering underlying MetS risk factors, especially HTN, when predicting tumor response in LARC patients undergoing nCRT followed by radical surgery. The results provide support for an increased focus on pre-treatment risk factor control to optimize cancer therapy outcomes. (C) 2016 IJS Publishing Group Ltd. Published by Elsevier Ltd. All rights reserved. C1 [Anderson, Brandon J.; Kimchi, Eric T.; O'Carroll, Kevin F. Staveley; Camp, E. Ramsay] Med Univ South Carolina, Dept Surg, 25 Courtenay Dr,Room 7018,MSC 295, Charleston, SC 29425 USA. [Wahlquist, Amy E.; Hill, Elizabeth G.] Dept Publ Hlth Sci, Charleston, SC 29425 USA. [Wahlquist, Amy E.; Hill, Elizabeth G.; Kimchi, Eric T.; O'Carroll, Kevin F. Staveley; Camp, E. Ramsay] Hollings Canc Ctr, Charleston, SC 29425 USA. [Marshall, David T.] Dept Radiat Oncol, Charleston, SC 29425 USA. [Kimchi, Eric T.; O'Carroll, Kevin F. Staveley; Camp, E. Ramsay] Ralph H Johnson VA Med Ctr, Charleston, SC 29425 USA. RP Camp, ER (reprint author), Med Univ South Carolina, Dept Surg, 25 Courtenay Dr,Room 7018,MSC 295, Charleston, SC 29425 USA. EM campe@musc.edu FU Cancer Center Support Grant [P30 CA138313] FX Cancer Center Support Grant P30 CA138313. NR 18 TC 0 Z9 0 U1 0 U2 0 PU ELSEVIER SCIENCE BV PI AMSTERDAM PA PO BOX 211, 1000 AE AMSTERDAM, NETHERLANDS SN 1743-9191 EI 1743-9159 J9 INT J SURG JI Int. J. Surg. PD SEP PY 2016 VL 33 BP 8 EP 12 DI 10.1016/j.ijsu.2016.07.011 PN A PG 5 WC Surgery SC Surgery GA EA8NM UT WOS:000386892400002 PM 27432024 ER PT J AU Filley, CM AF Filley, Christopher M. TI White Matter Dementia: Origin, Development, Progress, and Prospects SO JOURNAL OF NEUROPSYCHIATRY AND CLINICAL NEUROSCIENCES LA English DT Article ID TRAUMATIC BRAIN-INJURY; CENTRAL-NERVOUS-SYSTEM; ALZHEIMERS-DISEASE; MULTIPLE-SCLEROSIS; VASCULAR DEMENTIA; RISK-FACTOR; STRUCTURAL CONNECTIVITY; MEDITERRANEAN DIET; METABOLIC SYNDROME; SERUM-CHOLESTEROL AB The term white matter dementia (WMD) was introduced in 1988 to highlight the role of white matter in the development of dementia. As the concept has been refined with new insights into the structure and function of normal and abnormal white matter, research has expanded to consider normal cognition, network connectivity, novel treatment ideas, and the etiopath-ogenesis of neurodegenerative dementia. Emerging data are also identifying new opportunities for dementia prevention by avoidance of acquired vascular and traumatic white matter insults. The idea of WMD promises to continue as a useful construct informing the study of dementia and the understanding of brain-behavior relationships. C1 [Filley, Christopher M.] Univ Colorado, Sch Med, Behav Neurol Sect, Aurora, CO 80045 USA. [Filley, Christopher M.] Denver Vet Affairs Med Ctr, Denver, CO 80220 USA. RP Filley, CM (reprint author), Univ Colorado, Sch Med, Behav Neurol Sect, Aurora, CO 80045 USA.; Filley, CM (reprint author), Denver Vet Affairs Med Ctr, Denver, CO 80220 USA. EM christopher.filley@ucdenver.edu NR 110 TC 0 Z9 0 U1 2 U2 2 PU AMER PSYCHIATRIC PUBLISHING, INC PI ARLINGTON PA 1000 WILSON BOULEVARD, STE 1825, ARLINGTON, VA 22209-3901 USA SN 0895-0172 EI 1545-7222 J9 J NEUROPSYCH CLIN N JI J. Neuropsychiatr. Clin. Neurosci. PD FAL PY 2016 VL 28 IS 4 BP 262 EP 272 DI 10.1176/appi.neuropsych.16010003 PG 11 WC Clinical Neurology; Neurosciences; Psychiatry SC Neurosciences & Neurology; Psychiatry GA EA3NO UT WOS:000386510100002 ER PT J AU Eckerlin, DM Kovalesky, A Jakupcak, M AF Eckerlin, Denise M. Kovalesky, Andrea Jakupcak, Matthew TI Military Sexual Trauma in Male Service Members SO AMERICAN JOURNAL OF NURSING LA English DT Article DE military; military sexual trauma; posttraumatic stress disorder; sexual assault; sexual trauma ID POSTTRAUMATIC-STRESS-DISORDER; COGNITIVE PROCESSING THERAPY; GENDER-DIFFERENCES; MALE VETERANS; HEALTH; AFGHANISTAN; ASSAULT; IRAQ; MEN; PREVALENCE AB The experience of military sexual trauma (MST), which can result from assault, battery, or harassment of a sexual nature, may jeopardize the mental health of service members as well as that of their family members, colleagues, and community members. Although a greater proportion of female than male service members are subjected to MST, the Department of Defense estimates that the absolute numbers of affected men and women, across all ranks and branches of military service, are nearly equal because roughly 85% of military members are men. Little research has explored the effects of MST on men. This article discusses the unique ways in which men may experience MST, and examines how social stereotypes of masculinity, myths surrounding sexual assault, and military culture and structure often influence a man's interpretation of an attack and his likelihood of reporting the incident or seeking treatment. It describes current treatments for MST-related mental health conditions and addresses implications for nurses and other health care professionals. C1 [Eckerlin, Denise M.] Univ Washington, Med Ctr, RN Resource Team, Seattle, WA 98195 USA. [Eckerlin, Denise M.] Univ Washington, Med Ctr, Resource Team Unit Practice Council, Seattle, WA 98195 USA. [Kovalesky, Andrea] Univ Washington Bothell, Sch Nursing & Hlth Studies, Bothell, WA USA. [Jakupcak, Matthew] VA Puget Sound Hlth Care Syst, Northwest Mental Illness Res Educ & Clin Ctr, Seattle, WA USA. [Jakupcak, Matthew] VA Puget Sound Hlth Care Syst, Seattle, WA USA. RP Eckerlin, DM (reprint author), Univ Washington, Med Ctr, RN Resource Team, Seattle, WA 98195 USA.; Eckerlin, DM (reprint author), Univ Washington, Med Ctr, Resource Team Unit Practice Council, Seattle, WA 98195 USA. EM deck@u.washington.edu NR 44 TC 0 Z9 0 U1 6 U2 6 PU LIPPINCOTT WILLIAMS & WILKINS PI PHILADELPHIA PA TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA SN 0002-936X EI 1538-7488 J9 AM J NURS JI Am. J. Nurs. PD SEP PY 2016 VL 116 IS 9 BP 34 EP 43 PG 10 WC Nursing SC Nursing GA DZ8IO UT WOS:000386114300015 PM 27513073 ER PT J AU Dansingani, KK Tan, ACS Gilani, F Phasukkijwatana, N Novais, E Querques, L Waheed, NK Duker, JS Querques, G Yannuzzi, LA Sarraf, D Freund, KB AF Dansingani, Kunal K. Tan, Anna C. S. Gilani, Fatimah Phasukkijwatana, Nopasak Novais, Eduardo Querques, Lea Waheed, Nadia K. Duker, Jay S. Querques, Giuseppe Yannuzzi, Lawrence A. Sarraf, David Freund, K. Bailey TI Subretinal Hyperreflective Material Imaged With Optical Coherence Tomography Angiography SO AMERICAN JOURNAL OF OPHTHALMOLOGY LA English DT Article ID MACULAR DEGENERATION; CHOROIDAL NEOVASCULARIZATION; OCT ANGIOGRAPHY; RANIBIZUMAB AB PURPOSE: The range of subretinal hyperreflective material (SHRM) seen in macular disease includes type 2 macular neovascularization, fibrosis, exudation, vitelliform material, and hemorrhage. The prognostic significance of SHRM has been evaluated retrospectively in clinical trials, but discriminating SHRM subtypes traditionally requires multiple imaging modalities. The purpose of this study is to describe optical coherence tomography angiography (OCTA) flow characteristics and artifacts that might help to distinguish SHRM subtypes. DESIGN: Validity analysis. METHODS: Patients with age-related macular degeneration (AMD), myopia, pachychoroid disease, and macular dystrophy, manifesting SHRM on optical coherence tomography (OCT), were recruited. Clinical chart review and multimodal imaging established the SHRM subtype. All patients underwent OCTA. OCT and OCTA images were examined together for (1) intrinsic flow, (2) retinal projection onto the anterior SHRM surface (strong, weak, absent), (3) retinal projection through SHRM onto retinal pigment epithelium (RPE), and (4) masking of choriocapillaris flow. RESULTS: Thirty-three eyes of 25 patients were included (type 2 neovascularization x3; fibrosis x4; exudation x10; hemorrhage x5; vitelliform x17). Mean age per eye was 76 years (standard deviation: 12). Intrinsic flow was strongest in type 2 neovascularization. Subretinal fibrosis showed limited flow in residual large-caliber vessels and branches. Flow was not detected within foci of exudation, hemorrhage, or vitelliform lesions. Retina-SHRM surface projection was strongest onto smooth-surfaced SHRM and weaker onto exudation. Retinal projection was weakest on the surface of vitelliform lesions. Retina-RPE projection was masked by dense hemorrhage and vitelliform material. In compound SHRM, OCTA distinguished between vascular and avascular components. CONCLUSION: Optical coherence tomography angiography can distinguish vascular from avascular SHRM components. OCTA artifacts may distinguish certain avascular SHRM components. (C) 2016 Elsevier Inc. All rights reserved. C1 [Dansingani, Kunal K.; Tan, Anna C. S.; Gilani, Fatimah; Yannuzzi, Lawrence A.; Freund, K. Bailey] Vitreous Retina Macula Consultants New York, 460 Pk Ave, New York, NY 10022 USA. [Dansingani, Kunal K.; Tan, Anna C. S.; Gilani, Fatimah; Yannuzzi, Lawrence A.; Freund, K. Bailey] Manhattan Eye Ear & Throat Hosp, LuEsther T Mertz Retinal Res Ctr, New York, NY 10021 USA. [Dansingani, Kunal K.] Univ Nebraska Med Ctr, Truhlsen Eye Inst, Omaha, NE USA. [Dansingani, Kunal K.] Moorfields Eye Hosp, London, England. [Tan, Anna C. S.] Singapore Eye Res Inst, Singapore Natl Eye Ctr, Singapore, Singapore. [Phasukkijwatana, Nopasak; Sarraf, David] Univ Calif Los Angeles, Stein Eye Inst, Los Angeles, CA USA. [Phasukkijwatana, Nopasak] Mahidol Univ, Siriraj Hosp, Dept Ophthalmol, Fac Med, Bangkok, Thailand. [Novais, Eduardo; Waheed, Nadia K.; Duker, Jay S.] Tufts Univ, Sch Med, New England Eye Ctr, Boston, MA 02111 USA. [Novais, Eduardo] Univ Sao Paulo, Sch Med, Sao Paulo, Brazil. [Querques, Lea; Querques, Giuseppe] Univ Vita Salute San Raffaele, IRCCS Osped San Raffaele, Milan, Italy. [Yannuzzi, Lawrence A.; Freund, K. Bailey] NYU, Dept Ophthalmol, Sch Med, 550 1St Ave, New York, NY 10016 USA. [Sarraf, David] Greater Los Angeles VA Healthcare Ctr, Los Angeles, CA USA. RP Freund, KB (reprint author), Vitreous Retina Macula Consultants New York, 460 Pk Ave, New York, NY 10022 USA. EM kbfnyf@aol.com OI Novais, Eduardo/0000-0001-6790-4627; Freund, K. Bailey/0000-0002-7888-9773 FU LUESTHER T. MERTZ RETINAL RESEARCH CENTER; Macula Foundation, Inc, New York, New York FX FUNDING/SUPPORT: FUNDING SUPPORT WAS RECEIVED FROM THE LUESTHER T. MERTZ RETINAL RESEARCH CENTER AND THE Macula Foundation, Inc, New York, New York. The funding bodies supported this research but had no role in the design, conduct, or decision to publish. NR 17 TC 1 Z9 1 U1 1 U2 2 PU ELSEVIER SCIENCE INC PI NEW YORK PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA SN 0002-9394 EI 1879-1891 J9 AM J OPHTHALMOL JI Am. J. Ophthalmol. PD SEP PY 2016 VL 169 BP 235 EP 248 DI 10.1016/j.ajo.2016.06.031 PG 14 WC Ophthalmology SC Ophthalmology GA DW4UA UT WOS:000383637300025 PM 27349411 ER PT J AU Melzer, AC Feemster, LC Crothers, K Carson, SS Gillespie, SE Henderson, AG Krishnan, JA Lindenauer, PK McBurnie, MA Mularski, RA Naureckas, ET Pickard, AS Au, DH AF Melzer, Anne C. Feemster, Laura C. Crothers, Kristina Carson, Shannon S. Gillespie, Suzanne E. Henderson, Ashley G. Krishnan, Jerry A. Lindenauer, Peter K. McBurnie, Mary Ann Mularski, Richard A. Naureckas, Edward T. Pickard, A. Simon Au, David H. CA COPD Outcomes-Based Network Cl TI Respiratory and Bronchitic Symptoms Predict Intention to Quit Smoking among Current Smokers with, and at Risk for, Chronic Obstructive Pulmonary Disease SO ANNALS OF THE AMERICAN THORACIC SOCIETY LA English DT Article AB Rationale: Smoking cessation is the most important intervention for patients with chronic obstructive pulmonary disease (COPD). What leads smokers with COPD to quit smoking remains unknown. Objectives: We sought to examine the association between respiratory symptoms and other markers of COPD severity with intention to quit smoking among a cohort of patients with probable COPD. Methods: We conducted a cross-sectional study of subjects with COPD or fixed airflow obstruction clinically diagnosed on the basis of pulmonary function testing. The subjects were identified in the COPD Outcomes-based Network for Clinical Effectiveness and Research Translation multicenter registry. The primary outcome was the intention to quit smoking within the next 30 days (yes or no), which was examined using model building with multivariable logistic regression, clustered by study site. Measurements and Main Results: We identified 338 current smokers with COPD via the registry. Of these subjects, 57.4% (n = 194) had confirmed airflow obstruction based on pulmonary function testing. Nearly one-third (29.2%; n = 99) intended to quit smoking in the next 30 days. In adjusted analyses, compared with subjects without airflow obstruction based on pulmonary function testing, subjects with Global Initiative for Chronic Obstructive Lung Disease stage I/II COPD were more likely to be motivated to quit (odds ratio [OR], 1.85; 95% confidence interval [CI], 1.37-2.49), with no association found for subjects with Global Initiative for Chronic Obstructive Lung Disease stage III/IV disease. Among the entire cohort, frequent phlegm (OR, 2.10; 95% CI, 1.22-3.64), cough (OR, 1.74; 95% CI, 1.01-2.99), wheeze (OR, 1.73; 95% CI, 1.09-3.18), and higher modified Medical Research Council dyspnea score (OR, 1.26 per point; 95% CI, 1.13-1.41) were associated with increased odds of intending to quit smoking. Low self-reported health was associated with decreased odds of intending to quit (OR, 0.75; 95% CI, 0.62-0.92). Conclusions: Frequent cough, phlegm, wheeze, and shortness of breath were associated with intention to quit smoking in the next 30 days, with a less clear relationship for severity of illness graded by pulmonary function testing and self-rated health. These findings can be used to inform the content of tobacco cessation interventions to provide a more tailored approach for patients with respiratory diseases such as COPD. C1 [Melzer, Anne C.; Feemster, Laura C.; Crothers, Kristina; Au, David H.] Univ Washington, Div Pulm & Crit Care, Seattle, WA 98195 USA. [Melzer, Anne C.; Feemster, Laura C.; Au, David H.] VA Puget Sound, Ctr Innovat Vet, Ctr & Value Driven Care, Seattle, WA USA. [Carson, Shannon S.; Henderson, Ashley G.] Univ N Carolina, Chapel Hill, NC USA. [Gillespie, Suzanne E.; McBurnie, Mary Ann; Mularski, Richard A.] Kaiser Permanente Northwest, Ctr Hlth Res, Portland, OR USA. [Krishnan, Jerry A.] Univ Illinois Hosp & Hlth Sci Syst, Populat Hlth Sci Program, Chicago, IL USA. [Lindenauer, Peter K.] Tufts Univ, Sch Med, Dept Med, Ctr Qual Care Res,Baystate Med Ctr, Springfield, MA 01199 USA. [Naureckas, Edward T.] Univ Chicago, Dept Med, 5841 S Maryland Ave, Chicago, IL 60637 USA. [Pickard, A. Simon] Univ Illinois, Coll Pharm, Dept Pharm Syst Outcomes & Policy, Chicago, IL USA. [Pickard, A. Simon] Univ Illinois, Coll Pharm, Ctr Pharmacoepidemiol & Pharmacoecon, Chicago, IL USA. RP Melzer, AC (reprint author), Minneapolis VA Med Ctr, 1 Vet Way, Minneapolis, MN 55417 USA. EM acmelzer@uw.edu OI Crothers, Kristina/0000-0001-9702-0371 FU Department of Veterans Affairs, Health Services Research and Development Service FX This material is based upon work supported by the Department of Veterans Affairs, Health Services Research and Development Service, which provided access to data, office space, and programming and data management. The views expressed in this article are those of the authors and do not necessarily reflect the position or policy of the Department of Veterans Affairs. The authors acknowledge the other member sites of the CONCERT Consortium, without which this project could not have been completed. D.H.A. has personally reviewed the data, understands the statistical methods employed for efficacy analysis, and confirms an understanding of this analysis, that the methods are clearly described and that they are a fair way to report the results. NR 0 TC 0 Z9 0 U1 0 U2 0 PU AMER THORACIC SOC PI NEW YORK PA 25 BROADWAY, 18 FL, NEW YORK, NY 10004 USA SN 1546-3222 EI 2325-6621 J9 ANN AM THORAC SOC JI Ann. Am. Thoracic Society PD SEP PY 2016 VL 13 IS 9 BP 1490 EP 1496 DI 10.1513/AnnalsATS.201601-075OC PG 7 WC Respiratory System SC Respiratory System GA DZ8KB UT WOS:000386118200014 PM 27268422 ER PT J AU Balekian, AA Tanner, NT Fisher, JM Silvestri, GA Gould, MK AF Balekian, Alex A. Tanner, Nichole T. Fisher, Joshua M. Silvestri, Gerard A. Gould, Michael K. TI Factors Associated with a Positive Baseline Screening Exam Result in the National Lung Screening Trial SO ANNALS OF THE AMERICAN THORACIC SOCIETY LA English DT Article AB Rationale: Lung cancer screening with low-dose computed tomography (LDCT) has been shown to decrease mortality in eligible high-risk patients. However, this mortality benefit comes with a high rate of false-positive findings, which require further evaluation. Objectives: To identify patient-and center-specific factors associated with having a pulmonary nodule on baseline LDCT, and to develop a prediction rule to help in shared decision making. Methods: We identified individuals who underwent baseline LDCT screening as part of the National Lung Screening Trial. A positive screen was defined as a nodule 4 mm or greater in largest dimension. Using multiple logistic regression, we identified variables independently associated with having a positive screen. Measurements and Main Results: Among the 26,004 patients with complete data who underwent baseline LDCT, 7,123 patients (27%) had a positive screen. In a multivariate analysis, older age (odds ratio [OR] = 1.03 per 1-year increase, 95% confidence interval [CI] = 1.03-1.04), female sex (OR = 1.08, 95% CI = 1.01-1.14), white race (OR = 1.39, 95% CI = 1.25-1.55), heavier smoking history (OR = 1.02 per 5 pack-years smoked over 30, 95% CI = 1.00-1.04), history of chronic obstructive pulmonary disease (OR = 1.08, 95% CI = 1.01-1.17), being married (OR = 1.08, 95% CI = 1.02-1.15), hard rock mining (OR = 1.40, 95% CI = 1.04-1.89), and farm work (OR = 1.13, 95% CI = 1.03-1.23) were independently associated with having a positive screen, whereas having a college degree (OR = 0.94, 95% CI = 0.86-1.00) and abstinence from smoking (OR = 0.98 per year, 95% CI = 0.98-0.99) were associated with not having a positive screen. Patients enrolled at a site in an area highly endemic for histoplasma were 30% more likely to have a positive baseline LDCT screen (OR = 1.30, 95% CI = 1.21-1.40). The area under the receiver operator characteristic curve for the full model was 0.57 (0.56-0.58); including enrollment center as a random effect increased the area under the receiver operator characteristic curve to 0.65. Conclusions: In the National Lung Screening Trial, both patientand center-specific factors were associated with having a positive baseline screen. Although the model does not have sufficient accuracy to provide personalized risk estimates to guide shared decision making on an individual basis, it can nonetheless inform screening centers of the likelihood of further follow-up testing for their populations at large when allocating resources. Data collected from centers as broad-based screening is implemented can be used to improve model accuracy further. C1 [Balekian, Alex A.; Fisher, Joshua M.] Univ Southern Calif, Keck Sch Med, Div Pulm Crit Care & Sleep Med, Los Angeles, CA USA. [Tanner, Nichole T.] Ralph H Johnson Vet Affairs Hosp, Hlth Equ & Rural Outreach Innovat Ctr, Charleston, SC USA. [Tanner, Nichole T.; Silvestri, Gerard A.] Med Univ South Carolina, Div Pulm & Crit Care Med, Charleston, SC USA. [Gould, Michael K.] Kaiser Permanente Southern Calif, Dept Res & Evaluat, Pasadena, CA USA. RP Balekian, AA (reprint author), Univ Southern Calif, Keck Sch Med, 2020 Zonal Ave,IRD 723, Los Angeles, CA 90033 USA. EM alex.balekian@med.usc.edu NR 0 TC 1 Z9 1 U1 1 U2 1 PU AMER THORACIC SOC PI NEW YORK PA 25 BROADWAY, 18 FL, NEW YORK, NY 10004 USA SN 1546-3222 EI 2325-6621 J9 ANN AM THORAC SOC JI Ann. Am. Thoracic Society PD SEP PY 2016 VL 13 IS 9 BP 1568 EP 1574 DI 10.1513/AnnalsATS.201602-091OC PG 7 WC Respiratory System SC Respiratory System GA DZ8KB UT WOS:000386118200024 PM 27387658 ER PT J AU Courtright, KR Madden, V Gabler, NB Cooney, E Small, DS Troxel, A Casarett, D Ersek, M Cassel, JB Nicholas, LH Escobar, G Hill, SH O'Brien, D Vogel, M Halpern, SD AF Courtright, Katherine R. Madden, Vanessa Gabler, Nicole B. Cooney, Elizabeth Small, Dylan S. Troxel, Andrea Casarett, David Ersek, Mary Cassel, J. Brian Nicholas, Lauren Hersch Escobar, Gabriel Hill, Sarah H. O'Brien, Dan Vogel, Mark Halpern, Scott D. TI Rationale and Design of the Randomized Evaluation of Default Access to Palliative Services (REDAPS) Trial SO ANNALS OF THE AMERICAN THORACIC SOCIETY LA English DT Article AB The substantial nationwide investment in inpatient palliative care services stems from their great promise to improve patient-centered outcomes and reduce costs. However, robust experimental evidence of these benefits is lacking. The Randomized Evaluation of Default Access to Palliative Services (REDAPS) study is a pragmatic, stepped-wedge, cluster randomized trial designed to test the efficacy and costs of specialized palliative care consultative services for hospitalized patients with advanced chronic obstructive pulmonary disease, dementia, or end-stage renal disease, as well as the overall effectiveness of ordering such services by default. Additional aims are to identify the types of services that are most beneficial and the types of patients most likely to benefit, including comparisons between ward and intensive care unit patients. We hypothesize that patient-centered outcomes can be improved without increasing costs by simply changing the default option for palliative care consultation from opt-in to opt-out for patients with life-limiting illnesses. Patients aged 65 years or older are enrolled at 11 hospitals using an integrated electronic health record. As a pragmatic trial designed to enroll between 12,000 and 15,000 patients, eligibility is determined using a validated, electronic health record-based algorithm, and all outcomes are captured via the electronic health record and billing systems data. The time at which each hospital transitions from control, opt-in palliative care consultation to intervention, opt-out consultation is randomly assigned. The primary outcome is a composite measure of in-hospital mortality and length of stay. Secondary outcomes include palliative care process measures and clinical and economic outcomes. C1 [Courtright, Katherine R.; Halpern, Scott D.] Univ Penn, Dept Med, Pulm Allergy & Crit Care Med Div, Philadelphia, PA 19104 USA. [Courtright, Katherine R.; Madden, Vanessa; Gabler, Nicole B.; Cooney, Elizabeth; Troxel, Andrea; Halpern, Scott D.] Univ Penn, Ctr Hlth Incent & Behav Econ, Philadelphia, PA 19104 USA. [Courtright, Katherine R.; Madden, Vanessa; Gabler, Nicole B.; Cooney, Elizabeth; Halpern, Scott D.] Univ Penn, Fostering Improvements End Of Life Decis Sci Prog, Philadelphia, PA 19104 USA. [Madden, Vanessa; Gabler, Nicole B.; Cooney, Elizabeth; Small, Dylan S.; Troxel, Andrea; Halpern, Scott D.] Univ Penn, Ctr Clin Epidemiol & Biostat, Philadelphia, PA 19104 USA. [Small, Dylan S.] Univ Penn, Wharton Sch, Dept Stat, Philadelphia, PA 19104 USA. [Casarett, David; Halpern, Scott D.] Univ Penn, Dept Med Eth & Hlth Policy, Philadelphia, PA 19104 USA. [Casarett, David] Univ Penn, Dept Med, Philadelphia, PA 19104 USA. [Ersek, Mary] Univ Penn, Sch Nursing, Philadelphia, PA 19104 USA. [Ersek, Mary] US Dept Vet Affairs, Philadelphia, PA USA. [Cassel, J. Brian] Virginia Commonwealth Univ, Div Hematol Oncol, Richmond, VA USA. [Nicholas, Lauren Hersch] Johns Hopkins Univ, Dept Hlth Policy & Management, Baltimore, MD 21218 USA. [Escobar, Gabriel] Kaiser Permanente Northern Calif, Div Res, Oakland, CA USA. [Hill, Sarah H.; O'Brien, Dan; Vogel, Mark] Ascens Hlth, St Louis, MO USA. [Vogel, Mark] Michigan State Univ, Dept Family Med, E Lansing, MI 48824 USA. RP Halpern, SD (reprint author), Univ Penn, Div Pulm Allergy & Crit Care, Perelman Sch Med, 726 Blockley Hall,423 Guardian Dr, Philadelphia, PA 19104 USA. EM shalpern@exchange.upenn.edu OI Troxel, Andrea/0000-0002-1393-3075 FU National Institute of Aging [UH3 AG050311] FX Supported by the National Institute of Aging grant UH3 AG050311 (S.D.H.). NR 0 TC 1 Z9 1 U1 0 U2 0 PU AMER THORACIC SOC PI NEW YORK PA 25 BROADWAY, 18 FL, NEW YORK, NY 10004 USA SN 1546-3222 EI 2325-6621 J9 ANN AM THORAC SOC JI Ann. Am. Thoracic Society PD SEP PY 2016 VL 13 IS 9 BP 1629 EP 1639 DI 10.1513/AnnalsATS.201604-308OT PG 11 WC Respiratory System SC Respiratory System GA DZ8KB UT WOS:000386118200032 PM 27348271 ER PT J AU Erickson, M Braun, K List, R Utech, A Moore, C White, DL Garcia, JM AF Erickson, Megan Braun, Katie List, Riesa Utech, Anne Moore, Carolyn White, Donna L. Garcia, Jose M. TI Evaluation of US Veterans Nutrition Education for Diabetes Prevention SO JOURNAL OF NUTRITION EDUCATION AND BEHAVIOR LA English DT Article DE diabetes; prediabetes; nutrition education; veterans ID MANAGEMENT; INTERVENTION; REDUCTION; THERAPY AB Objective: Evaluate the effectiveness of nutrition education interventions for diabetes prevention. Design: Retrospective cohort design. Setting: Tertiary-care US Veterans' Hospital, July 2007 to July 2012, using pre-existing database. Participants: Prediabetic, adult veterans (n = 372), mostly men (94.4%, n = 351). Interventions: Visits with existing nutrition education classes were collected. Main Outcome Measures: Primary outcome: diabetes status; predictors: visits/encounters, age, body mass index, weight change, and hemoglobin A1c. Analysis: Cox proportional hazards method, chi(2) test, and logistic regression. Results: In this sample, prediabetic veterans who received nutrition education were less likely to develop diabetes when compared with prediabetic veterans who did not receive nutrition education (hazard ratio, 0.71; 95% confidence interval, 0.55-0.92; P < .01). This difference remained significant after adjusting for body mass index and weight change. Conclusions and Implications: Nutrition education was significantly associated with preventing the progression from prediabetes to diabetes in US Veterans participating in a nutrition education intervention at the Michael E. DeBakey Veterans Affairs Medical Center. C1 [Erickson, Megan; Braun, Katie; Moore, Carolyn] Texas Womans Univ, Houston, TX USA. [Braun, Katie; Utech, Anne; Garcia, Jose M.] Michael E DeBakey VA Med Ctr, 2002 Holcombe Blvd,Rm 3B-243, Houston, TX 77030 USA. [List, Riesa] Dept Vet Affairs, Nutr & Food Serv, Houston, TX USA. [List, Riesa] Dept Vet Affairs, Nutr & Food Serv, Hines, IL USA. [White, Donna L.] Michael E DeBakey VA Med Ctr, Sect Gastroenterol & Hepatol, Houston, TX USA. [White, Donna L.] Baylor Coll Med, Houston, TX 77030 USA. [White, Donna L.] Michael E DeBakey VA Med Ctr, Sect Hlth Serv Res IQuESt, Clin Epidemiol & Comparat Effectiveness Program, Houston, TX USA. [White, Donna L.] Texas Med Ctr, Ctr Digest Dis, Houston, TX USA. [White, Donna L.; Garcia, Jose M.] Baylor Coll Med, Dan L Duncan Canc Ctr, Houston, TX 77030 USA. [White, Donna L.; Garcia, Jose M.] Michael E DeBakey VA Med Ctr, CTRID, Houston, TX USA. [Garcia, Jose M.] Michael E DeBakey VA Med Ctr, Ctr Translat Res Inflammatory Dis, VA Puget Sound Hlth Care Syst, Geriatr Res Educ & Clin Ctr, Seattle, WA USA. [Garcia, Jose M.] Univ Washington, Sch Med, Seattle, WA USA. [Garcia, Jose M.] Baylor Coll Med, Dept Mol & Cell Biol, Houston, TX 77030 USA. [Garcia, Jose M.] Baylor Coll Med, Huffington Ctr Aging, Houston, TX 77030 USA. RP Erickson, M (reprint author), Michael E DeBakey VA Med Ctr, 2002 Holcombe Blvd,Rm 3B-243, Houston, TX 77030 USA. EM Megan.Erickson@sdstate.edu FU Department of Veterans Affairs (MERIT) [I01-BX000507, I01 CX000174]; NIA [T32AG000183, AG040583]; National Institute of Diabetes Digestive and Kidney Diseases [DK095082]; Center for Innovations the in Quality, Effectiveness, and Safety [CIN 13-413]; Michael E. DeBakey VA Medical Center, Houston, TX FX Dr Garcia received research support from the Department of Veterans Affairs (MERIT grants: I01-BX000507 and I01 CX000174 and the NIA T32AG000183 and AG040583). The content is solely the responsibility of the authors and does not necessarily represent the official view of the funding agencies. Dr White's effort was supported in part by the National Institute of Diabetes Digestive and Kidney Diseases (DK095082, PI: White) and the Center for Innovations the in Quality, Effectiveness, and Safety (No. CIN 13-413), Michael E. DeBakey VA Medical Center, Houston, TX. The views expressed in this article are those of the authors and do not necessarily represent the views of the Department of Veterans Affairs or the National Institutes of Health. The authors would also like to acknowledge the following individuals for their technical and written contributions to the original works in which this project stems: Dr Charles Wright, Karen Moreland, Caroline Nelson, Rose Bush, John Radcliffe, Mary Watson, and Shanil Juma. The Institutional Review Boards at Baylor College of Medicine, The Michael E. DeBakey VA Medical Center, and Texas Woman's University approved both protocols. NR 17 TC 0 Z9 0 U1 2 U2 2 PU ELSEVIER SCIENCE INC PI NEW YORK PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA SN 1499-4046 EI 1878-2620 J9 J NUTR EDUC BEHAV JI J. Nutr. Educ. Behav. PD SEP PY 2016 VL 48 IS 8 BP 538 EP + DI 10.1016/j.jneb.2016.06.007 PG 7 WC Education, Scientific Disciplines; Nutrition & Dietetics SC Education & Educational Research; Nutrition & Dietetics GA EA1IW UT WOS:000386346700004 PM 27614279 ER PT J AU Million, M Larauche, M AF Million, M. Larauche, M. TI Stress, sex, and the enteric nervous system SO NEUROGASTROENTEROLOGY AND MOTILITY LA English DT Review DE development; early life adversity; enteric nervous system; sex differences; stress ID GONADOTROPIN-RELEASING-HORMONE; IRRITABLE-BOWEL-SYNDROME; ESTROGEN-RECEPTOR-ALPHA; GASTROINTESTINAL-TRACT; MYENTERIC NEURONS; GENE-EXPRESSION; SMALL-INTESTINE; EMERGING ROLES; GNRH RECEPTORS; ANIMAL-MODELS AB Made up of millions of enteric neurons and glial cells, the enteric nervous system (ENS) is in a key position to modulate the secretomotor function and visceral pain of the gastrointestinal tract. The early life developmental period, through which most of the ENS development occurs, is highly susceptible to microenvironmental perturbation. Over the past decade, accumulating evidence has shown the impact of stress and early life adversity (ELA) on host gastrointestinal pathophysiology. While most of the focus has been on alterations in brain structure and function, limited experimental work in rodents suggest that the enteric nervous system can also be directly affected, as shown by changes in the number, phenotype, and reactivity of enteric nerves. The work of Medland et al. in the current issue of this journal demonstrates that such alterations also occur in pigs, a larger mammalian species with high translational value to human. This work also highlights a sex-differential susceptibility of the ENS to the effect of ELA, which could contribute to the higher prevalence of GI disorders in women. In this mini-review, we will discuss the development and composition of the ENS and related gastrointestinal sensory motor and secretory functions. We will then focus on the influence of stress on the enteric nervous system, with a particular emphasis on neurodevelopmental changes. Finally, we will discuss the influence of sex on those parameters. C1 [Million, M.; Larauche, M.] UCLA, David Geffen Sch Med, Dept Med, Div Digest Dis,CURE Digest Dis Res Ctr, Los Angeles, CA USA. [Million, M.; Larauche, M.] Oppenheimer Family Ctr Neurobiol Stress & Resilie, Los Angeles, CA USA. [Million, M.; Larauche, M.] VA Greater Angeles Healthcare Syst, Los Angeles, CA USA. RP Larauche, M (reprint author), West Los Angeles VA Med Ctr, CURE Digest Dis Res Ctr, 11301 Wilshire Blvd,Bldg 115 Rm 111, Los Angeles, CA 90073 USA. EM mlarauche@mednet.ucla.edu FU NIDDK NIH HHS [K01 DK088937, P30 DK041301, P50 DK064539, R01 DK078676] NR 60 TC 1 Z9 1 U1 6 U2 6 PU WILEY-BLACKWELL PI HOBOKEN PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA SN 1350-1925 EI 1365-2982 J9 NEUROGASTROENT MOTIL JI Neurogastroenterol. Motil. PD SEP PY 2016 VL 28 IS 9 BP 1283 EP 1289 DI 10.1111/nmo.12937 PG 7 WC Gastroenterology & Hepatology; Clinical Neurology; Neurosciences SC Gastroenterology & Hepatology; Neurosciences & Neurology GA DY8HL UT WOS:000385370000001 PM 27561694 ER PT J AU Taylor, AM Phillips, K Patel, KV Turk, DC Dworkin, RH Beaton, D Clauw, DJ Gignac, MAM Markman, JD Williams, DA Bujanover, S Burke, LB Carr, DB Choy, EH Conaghan, PG Cowan, P Farrar, JT Freeman, R Gewandter, J Gilron, I Goli, V Gover, TD Haddox, JD Kerns, RD Kopecky, EA Lee, DA Malamut, R Mease, P Rappaport, BA Simon, LS Singh, JA Smith, SM Strand, V Tugwell, P Vanhove, GF Veasley, C Walco, GA Wasan, AD Witter, J AF Taylor, Ann M. Phillips, Kristine Patel, Kushang V. Turk, Dennis C. Dworkin, Robert H. Beaton, Dorcas Clauw, Daniel J. Gignac, Monique A. M. Markman, John D. Williams, David A. Bujanover, Shay Burke, Laurie B. Carr, Daniel B. Choy, Ernest H. Conaghan, Philip G. Cowan, Penney Farrar, John T. Freeman, Roy Gewandter, Jennifer Gilron, Ian Goli, Veeraindar Gover, Tony D. Haddox, J. David Kerns, Robert D. Kopecky, Ernest A. Lee, David A. Malamut, Richard Mease, Philip Rappaport, Bob A. Simon, Lee S. Singh, Jasvinder A. Smith, Shannon M. Strand, Vibeke Tugwell, Peter Vanhove, Gertrude F. Veasley, Christin Walco, Gary A. Wasan, Ajay D. Witter, James TI Assessment of physical function and participation in chronic pain clinical trials: IMMPACT/OMERACT recommendations SO PAIN LA English DT Review DE OMERACT; IMMPACT; Pain; Physical performance measures; Patient-reported outcomes; Physical functioning; Physical activity; Accelerometer; Work; Employment; HRQOL; Social participation; Caregiver burden; Clinical trials ID PATIENT-REPORTED OUTCOMES; LOW-BACK-PAIN; EARLY RHEUMATOID-ARTHRITIS; QUALITY-OF-LIFE; COMMUNITY INTEGRATION QUESTIONNAIRE; HEALTH-ASSESSMENT QUESTIONNAIRE; WORK LIMITATIONS QUESTIONNAIRE; SICKNESS IMPACT PROFILE; TASK-FORCE REPORT; PSYCHOMETRIC PROPERTIES AB Although pain reduction is commonly the primary outcome in chronic pain clinical trials, physical functioning is also important. A challenge in designing chronic pain trials to determine efficacy and effectiveness of therapies is obtaining appropriate information about the impact of an intervention on physical function. The Initiative on Methods, Measurement, and Pain Assessment in Clinical Trials (IMMPACT) and Outcome Measures in Rheumatology (OMERACT) convened a meeting to consider assessment of physical functioning and participation in research on chronic pain. The primary purpose of this article is to synthesize evidence on the scope of physical functioning to inform work on refining physical function outcome measurement. We address issues in assessing this broad construct and provide examples of frequently used measures of relevant concepts. Investigators can assess physical functioning using patient-reported outcome (PRO), performance-based, and objective measures of activity. This article aims to provide support for the use of these measures, covering broad aspects of functioning, including work participation, social participation, and caregiver burden, which researchers should consider when designing chronic pain clinical trials. Investigators should consider the inclusion of both PROs and performance-based measures as they provide different but also important complementary information. The development and use of reliable and valid PROs and performance-based measures of physical functioning may expedite development of treatments, and standardization of these measures has the potential to facilitate comparison across studies. We provide recommendations regarding important domains to stimulate research to develop tools that are more robust, address consistency and standardization, and engage patients early in tool development. C1 [Taylor, Ann M.] Cardiff Univ, Sch Med, Ctr Med Educ, Cardiff, S Glam, Wales. [Phillips, Kristine] Univ Michigan, Dept Internal Med, Ann Arbor, MI 48109 USA. [Patel, Kushang V.; Turk, Dennis C.; Walco, Gary A.] Univ Washington, Dept Anesthesiol & Pain Med, Box 356540, Seattle, WA 98195 USA. [Dworkin, Robert H.; Gewandter, Jennifer; Smith, Shannon M.] Univ Rochester, Sch Med & Dent, Dept Anesthesiol, Rochester, NY USA. [Beaton, Dorcas] Univ Toronto, Dept Occupat Sci & Occupat Therapy, Toronto, ON M5S 1A1, Canada. [Beaton, Dorcas; Gignac, Monique A. M.] Univ Toronto, Inst Work & Hlth, Toronto, ON M5S 1A1, Canada. [Clauw, Daniel J.; Williams, David A.] Univ Michigan, Dept Anesthesiol, Ann Arbor, MI 48109 USA. [Markman, John D.] Univ Rochester, Dept Neurol, Rochester, NY USA. [Bujanover, Shay] Depomed, Newark, CA USA. [Burke, Laurie B.] LORAGroup LLC, Royal Oak, MD USA. [Burke, Laurie B.] Univ Maryland, Dept Hlth Serv Res, Baltimore, MD 21201 USA. [Carr, Daniel B.] Tufts Univ, Sch Med, Publ Hlth & Community Med, Boston, MA 02111 USA. [Choy, Ernest H.] Cardiff Univ, Div Infect & Immun, Cardiff, S Glam, Wales. [Conaghan, Philip G.] Univ Leeds, NIHR Leeds Musculoskeletal Biomed Res Unit, Leeds, W Yorkshire, England. [Conaghan, Philip G.] Univ Leeds, Inst Rheumat & Musculoskeletal Med, Leeds, W Yorkshire, England. [Cowan, Penney] Amer Chron Pain Assoc, Rocklin, CA USA. [Farrar, John T.] Univ Penn, Dept Clin Epidemiol & Biostat, Philadelphia, PA 19104 USA. [Freeman, Roy] Harvard Univ, Dept Neurol, Cambridge, MA 02138 USA. [Gilron, Ian] Queens Univ, Dept Anesthesiol, Ottawa, ON, Canada. [Goli, Veeraindar] Duke Univ, Med Ctr, Dept Psychiat, Durham, NC 27710 USA. [Goli, Veeraindar] Pfizer Inc, Durham, NC USA. [Gover, Tony D.] US Army Med Res & Mat Command, Clin & Rehabil Med Res Program, Ft Detrick, MD USA. [Haddox, J. David] Purdue Pharma LP, Stamford, CT USA. [Kerns, Robert D.] Vet Affairs Connecticut Healthcare Syst, Dept Vet Affairs, West Haven, CT USA. [Kerns, Robert D.] Yale Univ, Dept Psychiat & Psychol, New Haven, CT USA. [Kopecky, Ernest A.] Collegium Pharmaceut Inc, Canton, MA USA. [Lee, David A.] Chadds Ford, Pennsylvania, PA USA. [Malamut, Richard] Teva Pharmaceut, N Wales, PA USA. [Mease, Philip] Swedish Med Ctr, Rheumatol Clin Res Div, Seattle, WA USA. [Mease, Philip] Univ Washington, Sch Med, Seattle, WA USA. [Mease, Philip] Stanford Univ, Div Immunol Rheumatol, Palo Alto, CA 94304 USA. [Rappaport, Bob A.] Analges Concepts LLC, Arlington, VA USA. [Simon, Lee S.] SDG Consulting LLC, Cambridge, MA USA. [Singh, Jasvinder A.] Birmingham Vet Affairs Med Ctr, Med Serv, Birmingham, AL USA. [Singh, Jasvinder A.] Mayo Clin, Coll Med, Dept Orthoped Surg, Rochester, MN USA. [Strand, Vibeke] Stanford Univ, Sch Med, Div Immunol Rheumatol, Palo Alto, CA 94304 USA. [Tugwell, Peter] Univ Ottawa, Fac Med, Ctr Global Hlth, Ottawa, ON, Canada. [Vanhove, Gertrude F.] Jazz Pharmaceut, Palo Alto, CA USA. [Veasley, Christin] Chron Pain Res Alliance, Washington, DC USA. [Wasan, Ajay D.] Univ Pittsburgh, Sch Med, Dept Anesthesiol, Pittsburgh, PA USA. [Witter, James] NIH, Bldg 10, Bethesda, MD 20892 USA. RP Turk, DC (reprint author), Univ Washington, Dept Anesthesiol & Pain Med, Box 356540, Seattle, WA 98195 USA. EM turkdc@uw.edu OI Tugwell, Peter/0000-0001-5062-0556 FU Analgesic; Anesthetic; Addiction Clinical Trial Translations, Innovations, Opportunities, and Networks (ACTTION); FDA FX The views expressed in this article are those of the authors. The reader should infer no official endorsement by the US Department of Veterans Affairs, US FDA, or the US National Institutes of Health. Support for the meeting was provided by the Analgesic, Anesthetic, and Addiction Clinical Trial Translations, Innovations, Opportunities, and Networks (ACTTION) public-private partnership with the FDA, which has received grants, contracts, and other revenue for its activities from the FDA, multiple pharmaceutical and device companies, and other sources. NR 210 TC 1 Z9 1 U1 13 U2 13 PU LIPPINCOTT WILLIAMS & WILKINS PI PHILADELPHIA PA TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA SN 0304-3959 EI 1872-6623 J9 PAIN JI Pain PD SEP PY 2016 VL 157 IS 9 BP 1836 EP 1850 DI 10.1097/j.pain.0000000000000577 PG 15 WC Anesthesiology; Clinical Neurology; Neurosciences SC Anesthesiology; Neurosciences & Neurology GA DZ7AH UT WOS:000386014700002 PM 27058676 ER PT J AU Azar, SS Larson, EA Recht, M Taylor, JA AF Azar, Sharl S. Larson, Emily A. Recht, Michael Taylor, Jason A. TI EVALUATION OF THE CYTOKINE PROFILE OF HUMAN DERIVED FACTOR VIII (FVIII) PRODUCTS SO AMERICAN JOURNAL OF HEMATOLOGY LA English DT Meeting Abstract C1 [Azar, Sharl S.; Recht, Michael; Taylor, Jason A.] Oregon Hlth & Sci Univ, Hemophilia Ctr, Portland, OR 97201 USA. [Azar, Sharl S.; Larson, Emily A.; Taylor, Jason A.] Portland VA Med Ctr, Portland, OR USA. NR 0 TC 0 Z9 0 U1 0 U2 0 PU WILEY-BLACKWELL PI HOBOKEN PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA SN 0361-8609 EI 1096-8652 J9 AM J HEMATOL JI Am. J. Hematol. PD SEP PY 2016 VL 91 IS 9 MA F30 BP E409 EP E410 PG 2 WC Hematology SC Hematology GA DY6LT UT WOS:000385237100108 ER PT J AU Gay, ND Azar, SS Salomon, O Taylor, JA AF Gay, Nathan D. Azar, Sharl S. Salomon, Ophira Taylor, Jason A. TI MANAGEMENT OF A PATIENT WITH FACTOR XI DEFICIENCY WITH INHIBITORS UNDERGOING CARDIAC SURGERY: A CASE REPORT AND REVIEW OF THE LITERATURE SO AMERICAN JOURNAL OF HEMATOLOGY LA English DT Meeting Abstract C1 [Gay, Nathan D.; Azar, Sharl S.; Taylor, Jason A.] Oregon Hlth & Sci Univ, Dept Med, Div Hematol & Med Oncol, Portland, OR 97201 USA. [Azar, Sharl S.; Taylor, Jason A.] Oregon Hlth & Sci Univ, Hemophilia Ctr, Portland, OR 97201 USA. [Azar, Sharl S.; Taylor, Jason A.] Portland VA Med Ctr, Portland, OR USA. [Salomon, Ophira] Chaim Sheba Med Ctr, Amalia Biron Res Inst Thrombosis & Hemostasis, Tel Hashomer, Israel. [Salomon, Ophira] Tel Aviv Univ, Sackler Fac Med, Tel Aviv, Israel. NR 0 TC 0 Z9 0 U1 0 U2 0 PU WILEY-BLACKWELL PI HOBOKEN PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA SN 0361-8609 EI 1096-8652 J9 AM J HEMATOL JI Am. J. Hematol. PD SEP PY 2016 VL 91 IS 9 MA F37 BP E413 EP E413 PG 1 WC Hematology SC Hematology GA DY6LT UT WOS:000385237100115 ER PT J AU Porter, AL Staresinic, CE Margolis, AR Ray, CA Schoen, RR Fletcher, CD AF Porter, Andrea L. Staresinic, Carla E. Margolis, Amanda R. Ray, Cheryl A. Schoen, Rebecca R. Fletcher, Christopher D. TI BASELINE CHARACTERISTICS OF PATIENTS ON AN EXTENDED INTERVAL OF INTERNATIONAL NORMALIZED RATIO FOLLOW-UP PROTOCOL IN AN ANTICOAGULATION CLINIC SO AMERICAN JOURNAL OF HEMATOLOGY LA English DT Meeting Abstract C1 [Porter, Andrea L.; Staresinic, Carla E.; Margolis, Amanda R.; Ray, Cheryl A.; Schoen, Rebecca R.; Fletcher, Christopher D.] William S Middleton Mem Vet Adm Med Ctr, Madison, WI USA. [Porter, Andrea L.; Margolis, Amanda R.] Univ Wisconsin, Sch Pharm, 425 N Charter St, Madison, WI 53706 USA. [Fletcher, Christopher D.] Univ Wisconsin, Sch Med & Publ Hlth, Madison, WI USA. NR 0 TC 0 Z9 0 U1 0 U2 0 PU WILEY-BLACKWELL PI HOBOKEN PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA SN 0361-8609 EI 1096-8652 J9 AM J HEMATOL JI Am. J. Hematol. PD SEP PY 2016 VL 91 IS 9 MA T2 BP E363 EP E363 PG 1 WC Hematology SC Hematology GA DY6LT UT WOS:000385237100014 ER PT J AU Navathe, AS Sen, AP Rosenthal, MB Pearl, RM Ubel, PA Emanuel, EJ Volpp, KG AF Navathe, Amol S. Sen, Aditi P. Rosenthal, Meredith B. Pearl, Robert M. Ubel, Peter A. Emanuel, Ezekiel J. Volpp, Kevin G. TI New Strategies for Aligning Physicians With Health System Incentives SO AMERICAN JOURNAL OF MANAGED CARE LA English DT Editorial Material C1 [Navathe, Amol S.; Emanuel, Ezekiel J.; Volpp, Kevin G.] Univ Penn, Dept Med Eth & Hlth Policy, Perelman Sch Med, Philadelphia, PA 19104 USA. [Navathe, Amol S.; Volpp, Kevin G.] Univ Penn, Dept Med, Perelman Sch Med, Philadelphia, PA 19104 USA. [Navathe, Amol S.; Sen, Aditi P.; Emanuel, Ezekiel J.; Volpp, Kevin G.] Leonard Davis Inst Ctr Hlth Incentives & Behav Ec, Philadelphia, PA USA. [Navathe, Amol S.; Volpp, Kevin G.] Philadelphia Vet Affairs Med Ctr, Ctr Hlth Equ Res & Promot, Philadelphia, PA USA. [Sen, Aditi P.; Emanuel, Ezekiel J.; Volpp, Kevin G.] Univ Penn, Wharton Sch, Dept Hlth Care Management, Philadelphia, PA 19104 USA. [Rosenthal, Meredith B.] Harvard Sch Publ Hlth, Dept Hlth Policy & Management, Boston, MA USA. [Pearl, Robert M.] Permanente Med Grp Inc, Oakland, CA USA. [Ubel, Peter A.] Duke Univ, Fuqua Sch Business, Durham, NC 27706 USA. [Ubel, Peter A.] Duke Univ, Sanford Sch Publ Policy, Durham, NC USA. RP Navathe, AS (reprint author), Univ Penn, Dept Med Eth & Hlth Policy, Hlth Policy & Med, 1108 Blockley Hall, Philadelphia, PA 19104 USA. EM amol@wharton.upenn.edu FU Commonwealth Fund FX This work has been partially supported by a grant from the Commonwealth Fund. The funding source reviewed the manuscript but did not make any fundamental alterations. NR 7 TC 0 Z9 0 U1 0 U2 0 PU MANAGED CARE & HEALTHCARE COMMUNICATIONS LLC PI PLAINSBORO PA 666 PLAINSBORO RD, STE 300, PLAINSBORO, NJ 08536 USA SN 1088-0224 J9 AM J MANAG CARE JI Am. J. Manag. Care PD SEP PY 2016 VL 22 IS 9 BP 610 EP 612 PG 3 WC Health Care Sciences & Services; Health Policy & Services; Medicine, General & Internal SC Health Care Sciences & Services; General & Internal Medicine GA DX9UC UT WOS:000384740300010 PM 27662223 ER PT J AU Langevin, JP Chen, JWY Koek, RJ Sultzer, DL Mandelkern, MA Schwartz, HN Krahl, SE AF Langevin, Jean-Philippe Chen, James W. Y. Koek, Ralph J. Sultzer, David L. Mandelkern, Mark A. Schwartz, Holly N. Krahl, Scott E. TI Deep Brain Stimulation of the Basolateral Amygdala: Targeting Technique and Electrodiagnostic Findings SO BRAIN SCIENCES LA English DT Article DE amygdala; basolateral nucleus; deep brain stimulation; microelectrode recording; PTSD; targeting technique ID POSTTRAUMATIC-STRESS-DISORDER; CIRCUIT; CORTEX; FEAR AB The amygdala plays a critical role in emotion regulation. It could prove to be an effective neuromodulation target in the treatment of psychiatric conditions characterized by failure of extinction. We aim to describe our targeting technique, and intra-operative and post-operative electrodiagnostic findings associated with the placement of deep brain stimulation (DBS) electrodes in the amygdala. We used a transfrontal approach to implant DBS electrodes in the basolateral nucleus of the amygdala (BLn) of a patient suffering from severe post-traumatic stress disorder. We used microelectrode recording (MER) and awake intra-operative neurostimulation to assist with the placement. Post-operatively, the patient underwent monthly surveillance electroencephalograms (EEG). MER predicted the trajectory of the electrode through the amygdala. The right BLn showed a higher spike frequency than the left BLn. Intra-operative neurostimulation of the BLn elicited pleasant memories. The monthly EEG showed the presence of more sleep patterns over time with DBS. BLn DBS electrodes can be placed using a transfrontal approach. MER can predict the trajectory of the electrode in the amygdala and it may reflect the BLn neuronal activity underlying post-traumatic stress disorder PTSD. The EEG findings may underscore the reduction in anxiety. C1 [Langevin, Jean-Philippe] VA Greater Los Angeles Healthcare Syst, Neurosurg Serv, Los Angeles, CA 90073 USA. [Chen, James W. Y.] VA Greater Los Angeles Healthcare Syst, Neurol Serv, Los Angeles, CA 90073 USA. [Koek, Ralph J.; Sultzer, David L.; Schwartz, Holly N.] VA Greater Los Angeles Healthcare Syst, Psychiat & Mental Hlth Serv, Los Angeles, CA 90073 USA. [Mandelkern, Mark A.] VA Greater Los Angeles Healthcare Syst, Nucl Med, Serv Radiol, Los Angeles, CA 90073 USA. [Krahl, Scott E.] VA Greater Los Angeles Healthcare Syst, Res & Dev Serv, Los Angeles, CA 90073 USA. RP Langevin, JP (reprint author), VA Greater Los Angeles Healthcare Syst, Neurosurg Serv, Los Angeles, CA 90073 USA. EM jean-philippe.langevin@va.gov; james.chen1@va.gov; ralph.koek@va.gov; david.sultzer@va.gov; mark.mandelkern@va.gov; holly.schwartz@va.gov; scott.krahl@va.gov NR 20 TC 0 Z9 0 U1 3 U2 3 PU MDPI AG PI BASEL PA ST ALBAN-ANLAGE 66, CH-4052 BASEL, SWITZERLAND SN 2076-3425 EI 2976-3425 J9 BRAIN SCI JI Brain Sci. PD SEP PY 2016 VL 6 IS 3 AR 28 DI 10.3390/brainsci6030028 PG 9 WC Neurosciences SC Neurosciences & Neurology GA DY9XH UT WOS:000385488600009 ER PT J AU Grunfeld, C Dankner, R AF Grunfeld, Carl Dankner, Rachel TI Diabetes in HIV-infected persons in Cameroon? SO DIABETES-METABOLISM RESEARCH AND REVIEWS LA English DT Editorial Material DE diabetes; HIV-infected patients; protease inhibitors AB In the past, the increased prevalence of diabetes in HIV infection has been attributed to antiretroviral drugs. In this study, Cameroonians with HIV infection were shown in a paper in this issue of the Journal to be more likely to have diabetes if they were not on therapy. Future research should examine if the diabetes is related to the host response to infection or to socioeconomic factors that might both contribute to not being on anti-retroviral therapy and predispose to diabetes. Copyright (C) 2016 John Wiley & Sons, Ltd. C1 [Grunfeld, Carl] San Francisco VA Med Ctr, San Francisco, CA 94121 USA. [Grunfeld, Carl] Univ Calif San Francisco, Dept Med, Div Endocrinol & Metab, San Francisco, CA USA. [Grunfeld, Carl] Northern Calif Inst Res & Educ, San Francisco, CA USA. [Dankner, Rachel] Tel Aviv Univ, Dept Epidemiol & Prevent Med, Sch Publ Hlth, IL-69978 Tel Aviv, Israel. [Dankner, Rachel] Feinstein Inst Med Res, Patient Oriented Res, Manhasset, NY USA. RP Grunfeld, C (reprint author), San Francisco VA Med Ctr, San Francisco, CA 94121 USA. EM carl.grunfeld@ucsf.edu NR 2 TC 0 Z9 0 U1 0 U2 0 PU WILEY-BLACKWELL PI HOBOKEN PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA SN 1520-7560 J9 DIABETES-METAB RES JI Diabetes-Metab. Res. Rev. PD SEP PY 2016 VL 32 IS 6 BP 512 EP 513 DI 10.1002/dmrr.2796 PG 2 WC Endocrinology & Metabolism SC Endocrinology & Metabolism GA DZ2ZR UT WOS:000385712700005 PM 26936763 ER PT J AU Gattoni-Celli, S Young, MRI AF Gattoni-Celli, Sebastiano Young, M. Rita I. TI Restoration of Immune Responsiveness to Glioma by Vaccination of Mice with Established Brain Gliomas with a Semi-Allogeneic Vaccine SO INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES LA English DT Article DE cytokines; glioblastoma; immune activation; vaccination ID GLIOBLASTOMA; CANCER AB Prior studies had shown the clinical efficacy of a semi-allogeneic glioma vaccine in mice with lethal GL261 gliomas. This was confirmed in the present study. As subcutaneous vaccination resulted in protection against tumor in the brain, the present study assessed the impact of this vaccination of mice bearing established GL261 brain gliomas on their cytokine production upon in vitro exposure to tumor-derived products. Mice with established GL261 brain gliomas were vaccinated subcutaneously with H-2(b) GL261 glioma cells fused with H-2(d) RAG-neo cells or with a mock vaccine of phosphate-buffered saline. The results of these analyses show that the presence of GL261 tumor-conditioned medium resulted in increased production of Th1, inflammatory and inhibitory cytokines by spleen cells from control mice and from vaccinated glioma-bearing mice. In contrast, spleen cells of tumor-bearing, mock-vaccinated mice produced lower levels of cytokines in the presence of tumor-conditioned media. However, these results also show that there was not a heightened level of cytokine production in the presence of tumor-conditioned medium by spleen cells of vaccinated mice over the production by spleen cells of control mice. Overall, these results show that vaccination slows growth of the GL261 tumors to the point where GL261-vaccinated mice do not show the signs of morbidly or splenic dysfunction exhibited by unvaccinated, late stage glioma-bearing mice. C1 [Gattoni-Celli, Sebastiano; Young, M. Rita I.] Ralph H Johnson Vet Affairs Med Ctr, Res Serv 151, 109 Bee St, Charleston, SC 29401 USA. [Gattoni-Celli, Sebastiano] Med Univ South Carolina, Dept Radiat Oncol, 173 Ashley Ave, Charleston, SC 29425 USA. [Young, M. Rita I.] Med Univ South Carolina, Dept Otolaryngol Head & Neck Surg, 173 Ashley Ave, Charleston, SC 29425 USA. RP Young, MRI (reprint author), Ralph H Johnson Vet Affairs Med Ctr, Res Serv 151, 109 Bee St, Charleston, SC 29401 USA.; Young, MRI (reprint author), Med Univ South Carolina, Dept Otolaryngol Head & Neck Surg, 173 Ashley Ave, Charleston, SC 29425 USA. EM gattonis@musc.edu; rita.young@va.gov FU Department of Veterans Affairs CSR D Merit Awards [I01-CX000851, I01-CX000753] FX This research was funded in part by the Department of Veterans Affairs CSR & D Merit Awards I01-CX000851 (M. Rita I. Young) and I01-CX000753 (Sebastiano Gattoni-Celli). M. Rita I. Young is a Senior Research Career Scientist at the Ralph H. Johnson VA Medical Center (VAMC) and a Professor of Otolaryngology at the Medical University of South Carolina (MUSC) in Charleston, SC, USA. Sebastiano Gattoni-Celli is a Professor of Radiation Oncology at MUSC and a Research Health Scientist at the Ralph H. Johnson VAMC in Charleston, SC, USA. NR 18 TC 1 Z9 1 U1 1 U2 1 PU MDPI AG PI BASEL PA ST ALBAN-ANLAGE 66, CH-4052 BASEL, SWITZERLAND SN 1422-0067 J9 INT J MOL SCI JI Int. J. Mol. Sci. PD SEP PY 2016 VL 17 IS 9 AR 1465 DI 10.3390/ijms17091465 PG 9 WC Biochemistry & Molecular Biology; Chemistry, Multidisciplinary SC Biochemistry & Molecular Biology; Chemistry GA DZ0JU UT WOS:000385525500091 ER PT J AU Lemanske, RF Kakumanu, S Shanovich, K Antos, N Cloutier, MM Mazyck, D Phipatanakul, W Schantz, S Szefler, S Vandlik, R Williams, P AF Lemanske, Robert F., Jr. Kakumanu, Sujani Shanovich, Kathleen Antos, Nicholas Cloutier, Michelle M. Mazyck, Donna Phipatanakul, Wanda Schantz, Shirley Szefler, Stanley Vandlik, Renee Williams, Paul TI Creation and implementation of SAMPRO (TM): A school-based asthma management program SO JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY LA English DT Article DE Asthma; school; school nurse; children; asthma action plan; education; environment; triggers ID ACTION PLANS; CHILDHOOD ASTHMA; HEALTH CENTERS; CARE; CHILDREN; IMPACT; OUTCOMES; BURDEN; NURSES AB Clinicians who care for children with asthma have an obligation to coordinate asthma care with the schools. Aside from routine clinical care of asthmatic children, providers must educate the family and child about the need for an asthma treatment plan in school and support the school nurse meeting the needs of the student requiring school-based asthma care. The following article was developed by multiple stakeholders to address this need. It describes the 4 components of the School-based Asthma Management Program (SAMPRO (TM)). SAMPRO (TM) details elements necessary for the education of children, families, clinicians, and school-based personnel based on a "circle of support'' that would enhance multidirectional communication and promote better care for children with asthma within the school setting. C1 [Lemanske, Robert F., Jr.] Univ Wisconsin, Sch Med & Publ Hlth, Dept Pediat & Med, Madison, WI 53706 USA. [Shanovich, Kathleen] Univ Wisconsin, Sch Med & Publ Hlth, Dept Pediat, Madison, WI 53706 USA. [Antos, Nicholas] Med Coll Wisconsin, Childrens Hosp Wisconsin, Dept Pediat, Milwaukee, WI 53226 USA. [Cloutier, Michelle M.] Univ Connecticut, Hlth Ctr Farmington, Dept Pediat, Hartford, CT 06112 USA. [Cloutier, Michelle M.] CT Childrens Med Ctr, Asthma Ctr, Hartford, CT USA. [Kakumanu, Sujani] Univ Wisconsin, Sch Med & Publ Hlth, Madison, WI 53706 USA. [Kakumanu, Sujani] William S Middleton Mem Vet Adm Med Ctr, Madison, WI USA. [Mazyck, Donna; Schantz, Shirley] Natl Assoc Sch Nurses, Silver Spring, MD USA. [Phipatanakul, Wanda] Harvard Med Sch, Boston Childrens Hosp, Div Allergy & Immunol, Boston, MA USA. [Szefler, Stanley] Univ Colorado, Sch Med, Childrens Hosp Colorado, Breathing Inst, Aurora, CO USA. [Szefler, Stanley] Univ Colorado, Sch Med, Dept Pediat, Aurora, CO USA. [Vandlik, Renee] Amer Acad Allergy Asthma & Immunol, Milwaukee, WI USA. [Williams, Paul] Univ Washington, Sch Med, Allergist NW Asthma & Allergy Ctr, Dept Pediat, Seattle, WA 98195 USA. RP Lemanske, RF (reprint author), 750 Highland Ave 4235 HSLC, Madison, WI 53705 USA. EM rfl@medicine.wisc.edu FU American Academy of Allergy, Asthma Immunology; National Association of School Nurses FX Supported by funds provided by the American Academy of Allergy, Asthma & Immunology and the National Association of School Nurses. NR 35 TC 3 Z9 3 U1 0 U2 0 PU MOSBY-ELSEVIER PI NEW YORK PA 360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA SN 0091-6749 EI 1097-6825 J9 J ALLERGY CLIN IMMUN JI J. Allergy Clin. Immunol. PD SEP PY 2016 VL 138 IS 3 BP 711 EP 723 DI 10.1016/j.jaci.2016.06.015 PG 13 WC Allergy; Immunology SC Allergy; Immunology GA DY9ZM UT WOS:000385496000006 PM 27596707 ER PT J AU Okai, D Askey-Jones, S Mack, J Martin, A Chaudhuri, KR Samuel, M David, AS Brown, RG AF Okai, David Askey-Jones, Sally Mack, Joel Martin, Anne Chaudhuri, Kallol Ray Samuel, Michael David, Anthony S. Brown, Richard G. TI Parkinson's Impulse-Control Scale for the Severity Rating of Impulse-Control Behaviors in Parkinson's Disease: A Semistructured Clinical Assessment Tool SO MOVEMENT DISORDERS CLINICAL PRACTICE LA English DT Article DE impulse-control disorder; Parkinson's disease; severity; rating; carer ID QUALITY-OF-LIFE; CONTROL DISORDERS; DOPAMINE DYSREGULATION; COMPULSIVE DISORDERS; QUESTIONNAIRE AB BackgroundImpulse-control behaviors (ICBs) are increasingly recognized in Parkinson's disease (PD) as drug-related effects of dopaminergic mediation that occur in 15% to 35% of patients with PD. The authors describe the design and evaluation of a new, clinician-rated severity scale for the assessment of syndromal and subsyndromal forms of impulse-control disorders (ICDs), simple (punding) and complex (hobbyism) repetitive behaviors, and compulsive overuse of medication (dopamine dysregulation syndrome). MethodsThe Parkinson's Impulse-Control Scale (PICS), the first PD-specific, semistructured interview to cover the full range of PD-related ICBs, is described along with initial evidence on its clinimetric properties including interrater reliability, discriminant validity and sensitivity to change. A convenience sample of PD patients with ICBs and those without were administered a semistructured interview (n = 92). ResultsThe scale distinguished between those with and without clinically detected ICBs and between patients with syndromal ICD and subsyndromal ICB (receiver operating characteristic areas under the curve, 92%-95%). Cutoff values were suggested, and substantial agreement was reported on weighted kappa () values for clinician-clinician rating of severity ( = 0.92). Significant improvements were detected on the scale after a randomized controlled trial of cognitive-behavioral therapy and medication adjustment (t[22] = 5.47; P < 0.001). ConclusionsThe PICS appears to be a reliable measure of the full range of PD ICBs with good levels of interrater reliability. It may provide a useful measure to assess the severity of ICBs and monitor change in clinical and research settings; although, given the specialized centers used for recruitment of this sample, further psychometric evaluation is required. C1 [Okai, David; Askey-Jones, Sally; David, Anthony S.] Kings Coll London, Inst Psychiat Psychol & Neurosci, Sect Cognit Neuropsychiat, London, England. [Okai, David] Oxford Univ Hosp NHS Trust, Dept Psychol Med, Oxford, England. [Askey-Jones, Sally] Newcastle Univ, Sch Psychol, Newcastle Upon Tyne, Tyne & Wear, England. [Mack, Joel] Portland VA Med Ctr, Portland, OR USA. [Martin, Anne; Chaudhuri, Kallol Ray; Samuel, Michael] Kings Coll Hosp NHS Trust, Kings Hlth Partners, London, England. [Brown, Richard G.] Kings Coll London, Inst Psychiat Psychol & Neurosci, Dept Psychol, PO77, London SE5 8AF, England. RP Brown, RG (reprint author), Kings Coll London, Inst Psychiat Psychol & Neurosci, Dept Psychol, PO77, London SE5 8AF, England. EM richard.g.brown@kcl.ac.uk RI David, Anthony/C-1315-2011 OI David, Anthony/0000-0003-0967-774X NR 21 TC 0 Z9 0 U1 3 U2 3 PU WILEY-BLACKWELL PI HOBOKEN PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA SN 2330-1619 J9 MOV DISORD CLIN PRAC JI MOV. DISORD. CLIN. PRACT. PD SEP-OCT PY 2016 VL 3 IS 5 BP 494 EP 499 DI 10.1002/mdc3.12316 PG 6 WC Clinical Neurology SC Neurosciences & Neurology GA DY9BD UT WOS:000385426200010 PM 27774496 ER PT J AU Dong, TK Ona, K Scandurra, AE Demetriou, SK Oh, DH AF Dong, Tiffany K. Ona, Katherine Scandurra, Amy E. Demetriou, Stephanie K. Oh, Dennis H. TI Deficient Nucleotide Excision Repair in Squamous Cell Carcinoma Cells SO PHOTOCHEMISTRY AND PHOTOBIOLOGY LA English DT Article ID NONMELANOMA SKIN-CANCER; CYCLOBUTANE PYRIMIDINE DIMERS; COMPARATIVE GENOMIC HYBRIDIZATION; XERODERMA-PIGMENTOSUM; HUMAN KERATINOCYTES; DNA-DAMAGE; CHROMOSOMAL-ABERRATIONS; P53; LINES; TUMORS AB Squamous cell carcinomas (SCCs) are associated with ultraviolet radiation and multiple genetic changes, but the mechanisms leading to genetic instability are unclear. SCC cell lines were compared to normal keratinocytes for sensitivity to ultraviolet radiation, DNA repair kinetics and DNA repair protein expression. Relative to normal keratinocytes, four SCC cell lines were all variably sensitive to ultraviolet radiation and, except for the SCC25 cell line, were deficient in global repair of cyclobutane pyrimidine dimers, although not 6-4 photoproducts. Impaired DNA repair of cyclobutane pyrimidine dimers was associated with reduced mRNA expression from XPC but not DDB2 genes which each encode key DNA damage recognition proteins. However, levels of XPC or DDB2 proteins or both were variably reduced in repair-deficient SCC cell lines. p53 levels did not correlate with DNA repair activity or with XPC and DDB2 levels, but p63 levels were deficient in cell lines with reduced global repair. Repair-proficient SCC25 cells depleted of p63 lost XPC expression, early global DNA repair activity and UV resistance. These results demonstrate that some SCC cell lines are deficient in global nucleotide excision repair and support a role for p63 as a regulator of nucleotide excision repair in SCCs. C1 [Dong, Tiffany K.; Ona, Katherine; Scandurra, Amy E.; Demetriou, Stephanie K.; Oh, Dennis H.] San Francisco VA Med Ctr, Dermatol Res Unit, San Francisco, CA 94121 USA. [Dong, Tiffany K.; Demetriou, Stephanie K.; Oh, Dennis H.] Univ Calif San Francisco, Dept Dermatol, San Francisco, CA 94143 USA. RP Oh, DH (reprint author), San Francisco VA Med Ctr, Dermatol Res Unit, San Francisco, CA 94121 USA.; Oh, DH (reprint author), Univ Calif San Francisco, Dept Dermatol, San Francisco, CA 94143 USA. EM ohd@derm.ucsf.edu FU Department of Veterans Affairs, Office of Research and Development, Biomedical Laboratory Research and Development; NIH [R01 CA105958] FX We thank J. Cleaver for helpful discussions. Work was supported by a Merit Review Award from the Department of Veterans Affairs, Office of Research and Development, Biomedical Laboratory Research and Development (to D.H.O.) and in part by NIH grant R01 CA105958 (to D.H.O.). NR 43 TC 0 Z9 0 U1 9 U2 9 PU WILEY-BLACKWELL PI HOBOKEN PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA SN 0031-8655 EI 1751-1097 J9 PHOTOCHEM PHOTOBIOL JI Photochem. Photobiol. PD SEP-OCT PY 2016 VL 92 IS 5 BP 760 EP 766 DI 10.1111/php.12625 PG 7 WC Biochemistry & Molecular Biology; Biophysics SC Biochemistry & Molecular Biology; Biophysics GA DW4FG UT WOS:000383597300014 PM 27499003 ER PT J AU Hirsch, JA Cuesta, GM Jordan, BD Fonzetti, P Levin, L AF Hirsch, Joseph A. Cuesta, George M. Jordan, Barry D. Fonzetti, Pasquale Levin, Leann TI The Auditory Naming Test Improves Diagnosis of Naming Deficits in Dementia SO SAGE OPEN LA English DT Article DE assessment of cognitive disorders; dementia; Alzheimer's disease; naming; anomia; neuropsychology ID MENTAL-STATE-EXAMINATION; ALZHEIMERS-DISEASE; FRONTOTEMPORAL DEMENTIA; VASCULAR DEMENTIA; IMPAIRMENT; SCORES; AGE; PERFORMANCE; POPULATION; EDUCATION AB Many patients with presumptive Alzheimer's disease (AD) or other dementias may show minimal impairment on the Boston Naming Test (BNT), a visual confrontation naming measure. We sought to determine whether a semantic naming test, the Auditory Naming Test (ANT), would improve accuracy for identifying naming deficits in patients diagnosed with dementia (N = 458) at an outpatient memory disorders clinic. Factor analysis revealed that both tests measured the same broad construct. Frequency of naming impairment with the ANT was significantly greater than with the BNT for patients with AD, regardless of dementia severity or levels of education (p < .01). Effect size was moderate (phi = 0.45). BNT but not ANT performance declined with age in patients with AD. Sex differences were found for the BNT, but not the ANT, in the AD population. Accuracy rate of naming impairment diagnosis with the ANT in patients with AD was good (72%). Specificity (81%) and positive predictive value (PPV) (89%) with the ANT in AD were excellent, whereas sensitivity (69%) and negative predictive value (NPV) (58%) were modest. Receiver operating characteristic with area under the curve (ROC AUC) was excellent (0.958). A similar pattern was seen in patients with vascular dementia (VaD) or mixed AD/VaD. There was no significant effect in patients with amnestic mild cognitive impairment (aMCI). It is concluded that the ANT substantially improves the ability to diagnose naming impairment in patients with AD, VaD, and mixed AD/VaD dementia, and should be included in a neuropsychological battery administered to elderly patients with suspected dementia. C1 [Hirsch, Joseph A.; Jordan, Barry D.; Fonzetti, Pasquale; Levin, Leann] Burke Rehabil Ctr, Cornell Univ, Weill Med Coll, White Plains, NY USA. [Cuesta, George M.] US Dept Vet Affairs, New York, NY USA. RP Hirsch, JA (reprint author), Burke Rehabil Hosp, Memory Evaluat & Treatment Serv, 785 Mamaroneck Ave, White Plains, NY 10605 USA. EM jhirsch@burke.org NR 41 TC 0 Z9 0 U1 5 U2 5 PU SAGE PUBLICATIONS INC PI THOUSAND OAKS PA 2455 TELLER RD, THOUSAND OAKS, CA 91320 USA SN 2158-2440 J9 SAGE OPEN JI SAGE Open PD SEP PY 2016 VL 6 IS 3 AR 2158244016665693 DI 10.1177/2158244016665693 PG 10 WC Social Sciences, Interdisciplinary SC Social Sciences - Other Topics GA DY9ZK UT WOS:000385495800059 ER PT J AU Ritchie, CS Houston, TK Richman, JS Sobko, HJ Berner, ES Taylor, BB Salanitro, AH Locher, JL AF Ritchie, Christine S. Houston, Thomas K. Richman, Joshua S. Sobko, Heather J. Berner, Eta S. Taylor, Benjamin B. Salanitro, Amanda H. Locher, Julie L. TI The E-Coach technology-assisted care transition system: a pragmatic randomized trial SO TRANSLATIONAL BEHAVIORAL MEDICINE LA English DT Article DE Care transitions; Telehealth; Self-management ID INTERACTIVE VOICE RESPONSE; HEART-FAILURE; IDENTIFY PATIENTS; ELDERLY-PATIENTS; HEALTH-CARE; INTERVENTION; QUALITY; HOSPITALIZATION; READMISSION; VALIDATION AB Care transitions from the hospital to home remain a vulnerable time for many patients, especially for those with heart failure (CHF) and chronic obstructive pulmonary disease (COPD). Despite regular use in chronic disease management, it remains unclear how technology can best support patients during their transition from the hospital. We sought to evaluate the impact of a technology-supported care transition support program on hospitalizations, days out of the community and mortality. Using a pragmatic randomized trial, we enrolled patients (511 enrolled, 478 analyzed) hospitalized with CHF/COPD to "E-Coach," an intervention with condition specific customization and in-hospital and post discharge support by a care transition nurse (CTN), interactive voice response post-discharge calls, and CTN follow-up versus usual post-discharge care (UC). The primary outcome was 30-day rehospitalization. Secondary outcomes included (1) rehospitalization and death and (2) days in the hospital and out of the community. E Coach and UC groups were similar at baseline except for gender imbalance (p= 0.02). After adjustment for gender, our primary outcome, 30-day rehospitalization rates did not differ between the E-Coach and UC groups (15.0 vs. 16.3 %, adjusted hazard ratio [95 % confidence interval]: 0.94 [0.60, 1.49]). However, in the COPD subgroup, E Coach was associated with significantly fewer days in the hospital (0.5 vs. 1.6, p= 0.03). E-Coach, an IVRaugmented care transition intervention did not reduce rehospitalization. The positive impact on our secondary outcome (days in hospital) among COPD patients, but not in CHF, may suggest that E-Coach may be more beneficial among patients with COPD. C1 [Ritchie, Christine S.] Univ Alabama Birmingham, Div Gerontol Geriatr & Palliat Care, Birmingham, AL USA. [Ritchie, Christine S.] Univ Calif San Francisco, Div Geriatr, San Francisco, CA 94143 USA. [Houston, Thomas K.] Bedford VAMC, eHlth Qual Enhancement Res Initiat, Bedford, MA 01730 USA. [Houston, Thomas K.] Univ Massachusetts, Sch Med, Div Hlth Informat & Implementat Sci, 368 Plantat St, Worcester, MA 01605 USA. [Richman, Joshua S.] Birmingham VA Med Ctr, Birmingham, AL USA. [Sobko, Heather J.] Southern Res Inst, Birmingham, AL 35255 USA. [Berner, Eta S.] UAB, Dept Hlth Serv Adm, Hlth Informat, Sch Hlth Profess, Birmingham, AL USA. [Taylor, Benjamin B.] UAB, Dept Med, Div Gen Internal Med, Birmingham, AL USA. [Salanitro, Amanda H.] Vanderbilt Univ, VA Tennessee & Valley Healthcare Syst, Geriatr Res Educ & Clin Ctr, 221 Kirkland Hall, Nashville, TN 37235 USA. [Salanitro, Amanda H.] Vanderbilt Univ, Sect Hosp Med, Geriatr Res Educ & Clin Ctr, 221 Kirkland Hall, Nashville, TN 37235 USA. [Locher, Julie L.] UAB, Sch Publ Hlth, Birmingham, AL USA. RP Houston, TK (reprint author), Bedford VAMC, eHlth Qual Enhancement Res Initiat, Bedford, MA 01730 USA.; Houston, TK (reprint author), Univ Massachusetts, Sch Med, Div Hlth Informat & Implementat Sci, 368 Plantat St, Worcester, MA 01605 USA. EM Thomas.Houston@umassmed.edu FU Agency for Healthcare Research and Quality of Care of Complex Patients [R18-HS017786-02] FX This study was in part supported by the Agency for Healthcare Research and Quality of Care of Complex Patients grant (R18-HS017786-02). NR 42 TC 0 Z9 0 U1 6 U2 6 PU SPRINGER INTERNATIONAL PUBLISHING AG PI CHAM PA GEWERBESTRASSE 11, CHAM, CH-6330, SWITZERLAND SN 1869-6716 EI 1613-9860 J9 TRANSL BEHAV MED JI Transl. Behav. Med. PD SEP PY 2016 VL 6 IS 3 BP 428 EP 437 DI 10.1007/s13142-016-0422-8 PG 10 WC Public, Environmental & Occupational Health SC Public, Environmental & Occupational Health GA DY6TP UT WOS:000385261500011 PM 27339715 ER PT J AU Graves, MC Harris, JR Hannon, PA Hammerback, K Parrish, AT Ahmed, F Zhou, C Allen, CL AF Graves, Meredith C. Harris, Jeffrey R. Hannon, Peggy A. Hammerback, Kristen Parrish, Amanda T. Ahmed, Faruque Zhou, Chuan Allen, Claire L. TI Promoting Influenza Vaccination to Restaurant Employees SO AMERICAN JOURNAL OF HEALTH PROMOTION LA English DT Article DE Influenza; Vaccination; Immunization; Workplace; Employee; Promotion; Prevention Research AB Purpose. To evaluate an evidence-based workplace approach to increasing adult influenza vaccination levels applied in the restaurant setting Design. We implemented an intervention and conducted a pre/post analysis to determine effect on vaccination. Setting. Eleven Seattle-area restaurants. Subjects. Restaurants with 25+ employees speaking English or Spanish and over 18 years. Intervention. Restaurants received influenza vaccination promotion materials, assistance arranging on-site vaccination events, and free influenza vaccinations for employees. Measures. Pre/post employee surveys of vaccination status with direct observation and employer interviews to evaluate implementation. Analysis. We conducted descriptive analysis of employee survey data and performed qualitative analysis of implementation data. To assess intervention effect, we used a mixed-effects logistic regression model with a restaurant-specific random effect. Results. Vaccination levels increased from 26% to 46% (adjusted odds ratio 2.33, 95% confidence interval 1.69, 3.22), with 428 employees surveyed pre intervention, 305 surveyed postintervention, and response rates of 73% and 55%, respectively. The intervention was effective across subgroups, but there were restaurant-level differences. Conclusion. An access-based workplace intervention can increase influenza vaccination levels in restaurant employees, but restaurant-level factors may influence success. C1 [Graves, Meredith C.] VA Puget Sound Hlth Care Syst, Seattle, WA USA. [Harris, Jeffrey R.; Hannon, Peggy A.; Hammerback, Kristen; Parrish, Amanda T.; Zhou, Chuan; Allen, Claire L.] Univ Washington, Sch Publ Hlth, Dept Hlth Serv, Seattle, WA 98195 USA. [Harris, Jeffrey R.; Hannon, Peggy A.; Hammerback, Kristen; Parrish, Amanda T.; Allen, Claire L.] Hlth Promot Res Ctr, 1107 45th Ave NE,Suite 200, Seattle, WA 98105 USA. [Ahmed, Faruque] Ctr Dis Control & Prevent, Immunizat Serv Div, Atlanta, GA USA. [Zhou, Chuan] Seattle Childrens Res Inst, Seattle, WA USA. RP Harris, JR (reprint author), Hlth Promot Res Ctr, 1107 45th Ave NE,Suite 200, Seattle, WA 98105 USA. EM jh7@uw.edu NR 7 TC 0 Z9 0 U1 1 U2 1 PU SAGE PUBLICATIONS INC PI THOUSAND OAKS PA 2455 TELLER RD, THOUSAND OAKS, CA 91320 USA SN 0890-1171 EI 2168-6602 J9 AM J HEALTH PROMOT JI Am. J. Health Promot. PD SEP PY 2016 VL 30 IS 7 BP 498 EP 500 DI 10.4278/ajhp.131216-ARB-643 PG 3 WC Public, Environmental & Occupational Health SC Public, Environmental & Occupational Health GA DY0VG UT WOS:000384813700002 PM 26305606 ER PT J AU Arora, V Rozet, I AF Arora, Vivek Rozet, Irene TI Tarlov Cysts Incidental Finding during Subarachnoid Drain Placement SO ANESTHESIOLOGY LA English DT Editorial Material C1 [Arora, Vivek] VA Puget Sound Hlth Care Syst, Seattle, WA 98108 USA. Univ Washington, Dept Anesthesiol & Pain Med, Seattle, WA 98195 USA. RP Arora, V (reprint author), VA Puget Sound Hlth Care Syst, Seattle, WA 98108 USA. EM varora2@uw.edu NR 3 TC 0 Z9 0 U1 0 U2 0 PU LIPPINCOTT WILLIAMS & WILKINS PI PHILADELPHIA PA TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA SN 0003-3022 EI 1528-1175 J9 ANESTHESIOLOGY JI Anesthesiology PD SEP PY 2016 VL 125 IS 3 BP 598 EP 598 DI 10.1097/ALN.0000000000001118 PG 1 WC Anesthesiology SC Anesthesiology GA DY3VQ UT WOS:000385024100028 PM 27035856 ER PT J AU Zhu, W Carney, KE Pigott, VM Falgoust, LM Clark, PA Kuo, JS Sun, DD AF Zhu, Wen Carney, Karen E. Pigott, Victoria M. Falgoust, Lindsay M. Clark, Paul A. Kuo, John S. Sun, Dandan TI Glioma-mediated microglial activation promotes glioma proliferation and migration: roles of Na+/H+ exchanger isoform 1 SO CARCINOGENESIS LA English DT Article ID MT1-MMP EXPRESSION; GLIOBLASTOMA CELLS; MYELOID CELLS; TUMOR-CELLS; NHE1; INVASION; POLARIZATION; MACROPHAGES; METASTASIS; SURVIVAL AB Microglia play important roles in extracellular matrix remodeling, tumor invasion, angiogenesis, and suppression of adaptive immunity in glioma. Na+/H+ exchanger isoform 1 (NHE1) regulates microglial activation and migration. However, little is known about the roles of NHE1 in intratumoral microglial activation and microglia-glioma interactions. Our study revealed up-regulation of NHE1 protein expression in both glioma cells and tumor-associated Iba1(+) microglia in glioma xenografts and glioblastoma multiforme microarrays. Moreover, we observed positive correlation of NHE1 expression with Iba1 intensity in microglia/macrophages. Glioma cells, via conditioned medium or non-contact glioma-microglia co-cultures, concurrently upregulated microglial expression of NHE1 protein and other microglial activation markers (iNOS, arginase-1, TGF-beta, IL-6, IL-10 and the matrix metalloproteinases MT1-MMP and MMP9). Interestingly, glioma-stimulated microglia reciprocally enhanced glioma proliferation and migration. Most importantly, inhibition of microglial NHE1 activity via small interfering RNA (siRNA) knockdown or the potent NHE1-specific inhibitor HOE642 significantly attenuated microglial activation and abolished microglia-stimulated glioma migration and proliferation. Taken together, our findings provide the first evidence that NHE1 function plays an important role in glioma-microglia interactions, enhancing glioma proliferation and invasion by stimulating microglial release of soluble factors. NHE1 upregulation is a novel marker of the glioma-associated microglial activation phenotype. Inhibition of NHE1 represents a novel glioma therapeutic strategy by targeting tumor-induced microglial activation. C1 [Zhu, Wen; Carney, Karen E.; Pigott, Victoria M.; Falgoust, Lindsay M.; Sun, Dandan] Univ Pittsburgh, Dept Neurol, Pittsburgh, PA 15213 USA. [Clark, Paul A.; Kuo, John S.] Univ Wisconsin, Sch Med & Publ Hlth, Dept Neurol Surg, Madison, WI 53792 USA. [Clark, Paul A.; Kuo, John S.] Univ Wisconsin, Sch Med & Publ Hlth, Carbone Canc Ctr, Madison, WI 53792 USA. [Sun, Dandan] Vet Affairs Pittsburgh Hlth Care Syst, Geriatr Res Educ & Clin Ctr, Pittsburgh, PA 15261 USA. RP Sun, DD (reprint author), Univ Pittsburgh, Dept Neurol, Pittsburgh, PA 15213 USA.; Sun, DD (reprint author), Vet Affairs Pittsburgh Hlth Care Syst, Geriatr Res Educ & Clin Ctr, Pittsburgh, PA 15261 USA. EM sund@upmc.edu FU National Institutes of Health [R01NS075995, R01NS048216]; HEADRUSH Brain Tumor Research Professorship; Roger Loff Memorial GBM Research Fund; Department of Neurological Surgery [R01CA158800] FX National Institutes of Health (partial support, R01NS075995 and R01NS048216 to D.S. and J.S.K.); HEADRUSH Brain Tumor Research Professorship, Roger Loff Memorial GBM Research Fund, and Department of Neurological Surgery (partial support, R01CA158800 to J.S.K.). NR 56 TC 2 Z9 2 U1 2 U2 2 PU OXFORD UNIV PRESS PI OXFORD PA GREAT CLARENDON ST, OXFORD OX2 6DP, ENGLAND SN 0143-3334 EI 1460-2180 J9 CARCINOGENESIS JI Carcinogenesis PD SEP PY 2016 VL 37 IS 9 BP 839 EP 851 DI 10.1093/carcin/bgw068 PG 13 WC Oncology SC Oncology GA DY5IV UT WOS:000385133900002 PM 27287871 ER PT J AU Padua, D Mahurkar-Joshi, S Law, IKM Polytarchou, C Vu, JP Pisegna, JR Shih, D Iliopoulos, D Pothoulakis, C AF Padua, David Mahurkar-Joshi, Swapna Law, Ivy Ka Man Polytarchou, Christos Vu, John P. Pisegna, Joseph R. Shih, David Iliopoulos, Dimitrios Pothoulakis, Charalabos TI A long noncoding RNA signature for ulcerative colitis identifies IFNG-AS1 as an enhancer of inflammation SO AMERICAN JOURNAL OF PHYSIOLOGY-GASTROINTESTINAL AND LIVER PHYSIOLOGY LA English DT Article DE inflammatory bowel disease; ulcerative colitis; lncRNA; inflammation; interferon gamma ID BOWEL-DISEASE; PROSTATE-CANCER; CROHNS-DISEASE; TH1 CELLS; EXPRESSION; INTERFERON; TMEVPG1; PROGRESSION; ACTIVATION; THERAPY AB High-throughput technologies revealed new categories of genes, including the long noncoding RNAs (lncRNAs), involved in the pathogenesis of human disease; however, the role of lncRNAs in the ulcerative colitis (UC) has not been evaluated. Gene expression profiling was used to develop lncRNA signatures in UC samples. Jurkat T cells were activated by PMA/ionomycin subsequently interferon-gamma (IFNG) and tumor necrosis factor (TNF)-gamma protein levels were assessed by ELISA. Anti-sense molecules were designed to block IFNG-AS1 expression. A unique set of lncRNAs was differentially expressed between UC and control samples. Of these, IFNG-AS1 was among the highest statistically significant lncRNAs (fold change: 5.27, P value: 7.07E-06). Bioinformatic analysis showed that IFNG-AS1 was associated with the IBD susceptibility loci SNP rs7134599 and its genomic location is adjacent to the inflammatory cytokine IFNG. In mouse models of colitis, active colitis samples had increased colonic expression of this lncRNA. Utilizing the Jurkat T cell model, we found IFNG-AS1 to positively regulate IFNG expression. Novel lncRNA signatures differentiate UC patients with active disease, patients in remission, and control subjects. A subset of these lncRNAs was found to be associated with the clinically validated IBD susceptibility loci. IFNG-AS1 was one of these differentially expressed lncRNAs in UC patients and found to regulate the key inflammatory cytokine, IFNG, in CD4 T cells. Taking these findings together, our study revealed novel lncRNA signatures deregulated in UC and identified IFNG-AS1 as a novel regulator of IFNG inflammatory responses, suggesting the potential importance of noncoding RNA mechanisms on regulation of inflammatory bowel disease-related inflammatory responses. C1 [Padua, David; Mahurkar-Joshi, Swapna; Law, Ivy Ka Man; Iliopoulos, Dimitrios; Pothoulakis, Charalabos] Univ Calif Los Angeles, David Geffen Sch Med, Div Digest Dis, Los Angeles, CA 90095 USA. [Polytarchou, Christos; Iliopoulos, Dimitrios] Univ Calif Los Angeles, David Geffen Sch Med, Ctr Syst Biomed, Los Angeles, CA 90095 USA. [Polytarchou, Christos] Nottingham Trent Univ, Sch Sci & Technol, Nottingham, England. [Vu, John P.; Pisegna, Joseph R.] VA Greater Los Angeles Healthcare Syst, Div Gastroenterol Hepatol & Parenteral Nutr, Los Angeles, CA USA. [Vu, John P.; Pisegna, Joseph R.] Univ Calif Los Angeles, David Geffen Sch Med, Dept Med, Los Angeles, CA 90095 USA. [Shih, David] Cedars Sinai Med Ctr, Inflammatory Bowel & Immunobiol Res Inst, Los Angeles, CA 90048 USA. RP Pothoulakis, C (reprint author), 675 Charles E Young Dr South,MRL RM 1240, Los Angeles, CA 90095 USA. EM cpothoulakis@mednet.ucla.edu FU NIH/NIDDK [T32 DK007180-41, R01 DK060729, P30 DK 41301] FX This research was supported by NIH/NIDDK T32 DK007180-41 grant (D. Padua), and R01 DK060729 (C. Pothoulakis). Support was also provided by NIH/NIDDK P30 DK 41301 Center Grant (D. Iliopoulos and C. Pothoulakis). NR 40 TC 0 Z9 0 U1 3 U2 3 PU AMER PHYSIOLOGICAL SOC PI BETHESDA PA 9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA SN 0193-1857 EI 1522-1547 J9 AM J PHYSIOL-GASTR L JI Am. J. Physiol.-Gastroint. Liver Physiol. PD SEP 1 PY 2016 VL 311 IS 3 BP G446 EP G457 DI 10.1152/ajpgi.00212.2016 PG 12 WC Gastroenterology & Hepatology; Physiology SC Gastroenterology & Hepatology; Physiology GA DY0FL UT WOS:000384772600011 PM 27492330 ER PT J AU Rickard, JP Kish, T AF Rickard, Joshua P. Kish, Troy TI Systemic Intravenous Lidocaine for the Treatment of Complex Regional Pain Syndrome: A Case Report and Literature Review SO AMERICAN JOURNAL OF THERAPEUTICS LA English DT Review DE intravenous lidocaine; complex regional pain syndrome; pain; causalgia; aglodystrophy; reflex sympathetic dystrophy ID SYNDROME TYPE-I; MANAGEMENT; INFUSIONS; EFFICACY AB Complex regional pain syndrome (CRPS) was described in 1864 by Mitchell et al as a condition characterized by many unique symptoms. Although symptoms may differ from patient to patient, the most common complaints are painful swelling in upper or lower extremities or changes in the skin. CRPS has been given many different names since it was first mentioned in the literature in 1851. The most common alternative names include causalgia, aglodystrophy, and sympathetic dystrophy syndrome. This condition is generally diagnosed in older adults because of trauma, nerve damage, and coronary artery disease; however, there are cases of CRPS affecting the pediatric and young adult population. The fourth edition of the diagnostic and treatment guidelines of CRPS published by Harden et al in 2013 suggest many different pharmacologic treatment options for these patients. Intravenous lidocaine is used to block the sodium channels in neuronal membranes, thus stopping initiation and conduction of impulses associated with neuropathic and inflammatory pain. The use of regional intravenous lidocaine (by applying a tourniquet on the affected extremity) has been well-documented in the literature with a successful decrease in pain symptoms. A unique case of the use of systemic intravenous lidocaine will be presented. C1 [Rickard, Joshua P.] James J Peters VA Med Ctr, Bronx, NY 10468 USA. [Kish, Troy] Long Isl Univ, Arnold & Marie Schwartz Coll Pharm & Hlth Sci, Brooklyn, NY USA. RP Rickard, JP (reprint author), James J Peters VA Med Ctr, Bronx, NY 10468 USA. EM josh.rickard90@gmail.com OI Rickard, Joshua/0000-0002-4447-1096 FU James J. Peters VA Medical Center, Bronx, NY FX Supported by the resources and by the use of facilities at the James J. Peters VA Medical Center, Bronx, NY. NR 10 TC 0 Z9 0 U1 6 U2 8 PU LIPPINCOTT WILLIAMS & WILKINS PI PHILADELPHIA PA TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA SN 1075-2765 EI 1536-3686 J9 AM J THER JI Am. J. Ther. PD SEP-OCT PY 2016 VL 23 IS 5 BP E1266 EP E1269 DI 10.1097/MJT.0000000000000345 PG 4 WC Pharmacology & Pharmacy SC Pharmacology & Pharmacy GA DX5TY UT WOS:000384446400028 PM 26398854 ER PT J AU Greene, SJ Hernandez, AF Sun, JL Metra, M Butler, J Ambrosy, AP Ezekowitz, JA Starling, RC Teerlink, JR Schulte, PJ Voors, AA Armstrong, PW O'Connor, CM Mentz, RJ AF Greene, Stephen J. Hernandez, Adrian F. Sun, Jie-Lena Metra, Marco Butler, Javed Ambrosy, Andrew P. Ezekowitz, Justin A. Starling, Randall C. Teerlink, John R. Schulte, Phillip J. Voors, Adriaan A. Armstrong, Paul W. O'Connor, Christopher M. Mentz, Robert J. TI Influence of Clinical Trial Site Enrollment on Patient Characteristics, Protocol Completion, and End Points: Insights From the ASCEND-HF Trial (Acute Study of Clinical Effectiveness of Nesiritide in Decompensated Heart Failure) SO CIRCULATION-HEART FAILURE LA English DT Article DE clinical trial; heart failure; patient discharge; quality of life ID OUTCOMES; DYSPNEA; CONDUCT; PREDICTORS; MANAGEMENT; TOLVAPTAN; PROPOSAL AB Background Most international acute heart failure trials have failed to show benefit with respect to key end points. The impact of site enrollment and protocol execution on trial performance is unclear. Methods and Results We assessed the impact of varying site enrollment volume among all 7141 acute heart failure patients from the ASCEND-HF trial (Acute Study of Clinical Effectiveness of Nesiritide in Decompensated Heart Failure). Overall, 398 sites enrolled 1 patient, and median enrollment was 12 patients (interquartile range, 5-23). Patients from high enrolling sites (>60 patients/site) tended to have lower ejection fraction, worse New York Heart Association functional class, and lower utilization of guideline-directed medical therapy but fewer comorbidities and lower B-type natriuretic peptide level. Every 10 patient increase (up to 100 patients) in site enrollment correlated with lower likelihood of protocol noncompletion (odds ratio, 0.93; 95% confidence interval [CI], 0.89-0.98). After adjustment, increasing site enrollment predicted higher risk of persistent dyspnea at 6 hours (per 10 patient increase: odds ratio 1.02; 95% CI, 1.01-1.03) but not at 24 hours (odds ratio, 0.99; 95% CI, 0.98-1.00). Higher site enrollment was independently associated with lower risk of 30-day death or rehospitalization (per 10 patient increase: odds ratio, 0.98, 95% CI, 0.96-0.99) but not 180-day mortality (hazard ratio, 0.99; 95% CI, 0.98-1.01). The influence of increasing site enrollment on clinical end points varied across geographic regions with strongest associations in Latin America and Asia-Pacific (all interaction P<0.01). Conclusions In this large, acute heart failure trial, site enrollment correlated with protocol completion and was independently associated with trial end points. Individual and regional site performance present challenges to be considered in design of future acute heart failure trials. Clinical Trial Registration URL: http://www.clinicaltrials.gov. Unique identifier: NCT00475852. C1 [Greene, Stephen J.; Hernandez, Adrian F.; Ambrosy, Andrew P.; O'Connor, Christopher M.; Mentz, Robert J.] Duke Univ, Med Ctr, Div Cardiol, 2301 Erwin Rd,Suite 7400, Durham, NC 27705 USA. [Hernandez, Adrian F.; Sun, Jie-Lena; Ambrosy, Andrew P.; Schulte, Phillip J.; O'Connor, Christopher M.; Mentz, Robert J.] Duke Clin Res Inst, Durham, NC USA. [Metra, Marco] Univ Brescia, Cardiol, I-25121 Brescia, Italy. [Butler, Javed] SUNY Stony Brook, Div Cardiol, Stony Brook, NY 11794 USA. [Ezekowitz, Justin A.; Armstrong, Paul W.] Univ Alberta, Canadian VIGOUR Ctr, Edmonton, AB, Canada. [Starling, Randall C.] Cleveland Clin, Cleveland, OH 44106 USA. [Teerlink, John R.] Univ Calif San Francisco, Sch Med, San Francisco Vet Affairs Med Ctr, Cardiol Sect, San Francisco, CA 94143 USA. [Voors, Adriaan A.] Univ Groningen, Univ Med Ctr Groningen, Dept Cardiol, Groningen, Netherlands. RP Greene, SJ (reprint author), Duke Univ, Med Ctr, Div Cardiol, 2301 Erwin Rd,Suite 7400, Durham, NC 27705 USA. EM stephen.greene@duke.edu FU Scios Inc. (Mountain View, CA) FX Scios Inc. (Mountain View, CA) provided financial and material support for the ASCEND-HF trial. Database management and statistical analysis was performed by the Duke Clinical Research Institute. NR 23 TC 1 Z9 1 U1 1 U2 1 PU LIPPINCOTT WILLIAMS & WILKINS PI PHILADELPHIA PA TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA SN 1941-3289 EI 1941-3297 J9 CIRC-HEART FAIL JI Circ.-Heart Fail. PD SEP PY 2016 VL 9 IS 9 AR UNSP e002986 DI 10.1161/CIRCHEARTFAILURE.116.002986 PG 10 WC Cardiac & Cardiovascular Systems SC Cardiovascular System & Cardiology GA DX5ZG UT WOS:000384460800003 ER PT J AU Goldenberg, A Mousdicas, N Silverberg, N Powell, D Pelletier, JL Silverberg, JI Zippin, J Fonacier, L Tosti, A Lawley, L Chang, MW Scheman, A Kleiner, G Williams, J Watsky, K Dunnick, CA Frederickson, R Matiz, C Chaney, K Estes, TS Botto, N Draper, M Kircik, L Lugo-Somolinos, A Machler, B Jacob, SE AF Goldenberg, Alina Mousdicas, Nico Silverberg, Nanette Powell, Douglas Pelletier, Janice L. Silverberg, Jonathan I. Zippin, Jonathan Fonacier, Luz Tosti, Antonella Lawley, Leslie Chang, Mary Wu Scheman, Andrew Kleiner, Gary Williams, Judith Watsky, Kalman Dunnick, Cory A. Frederickson, Rachel Matiz, Catalina Chaney, Keri Estes, Tracy S. Botto, Nina Draper, Michelle Kircik, Leon Lugo-Somolinos, Aida Machler, Brian Jacob, Sharon E. TI Pediatric Contact Dermatitis Registry Inaugural Case Data SO DERMATITIS LA English DT Article AB Background: Little is known about the epidemiology of allergic contact dermatitis (ACD) in US children. More widespread diagnostic confirmation through epicutaneous patch testing is needed. Objective: The aim was to quantify patch test results from providers evaluating US children. Methods: The study is a retrospective analysis of deidentified patch test results of children aged 18 years or younger, entered by participating providers in the Pediatric Contact Dermatitis Registry, during the first year of data collection (2015-2016). Results: One thousand one hundred forty-two cases from 34 US states, entered by 84 providers, were analyzed. Sixty-five percent of cases had one or more positive patch test (PPT), with 48% of cases having 1 or more relevant positive patch test (RPPT). The most common PPT allergens were nickel (22%), fragrance mix I (11%), cobalt (9.1%), balsam of Peru (8.4%), neomycin (7.2%), propylene glycol (6.8%), cocamidopropyl betaine (6.4%), bacitracin (6.2%), formaldehyde (5.7%), and gold (5.7%). Conclusions: This US database provides multidisciplinary information on pediatric ACD, rates of PPT, and relevant RPPT reactions, validating the high rates of pediatric ACD previously reported in the literature. The registry database is the largest comprehensive collection of US-only pediatric patch test cases on which future research can be built. Continued collaboration between patients, health care providers, manufacturers, and policy makers is needed to decrease the most common allergens in pediatric consumer products. C1 [Goldenberg, Alina] Univ Calif San Diego, Dept Dermatol, La Jolla, CA 92093 USA. [Mousdicas, Nico] Indiana Univ Hlth, Dept Dermatol, Indianapolis, IN USA. [Silverberg, Nanette] Icahn Sch Med Mt Sinai, New York, NY 10029 USA. [Powell, Douglas] Univ Utah, Dept Dermatol, Salt Lake City, UT USA. [Pelletier, Janice L.] Eastern Maine Med Ctr, Dept Pediat, Bangor, ME USA. [Pelletier, Janice L.] Univ Vermont, Coll Med, Burlington, VT USA. [Silverberg, Jonathan I.] Northwestern Univ, Feinberg Sch Med, Dept Dermatol Prevent Med & Med Social Sci, Chicago, IL 60611 USA. [Zippin, Jonathan] Cornell Univ, Weill Med Coll, New York, NY 10021 USA. [Fonacier, Luz] SUNY Stony Brook, Dept Med, Stony Brook, NY 11794 USA. [Fonacier, Luz] Winthrop Univ Hosp, Allergy & Immunol Training Program, Mineola, NY 11501 USA. [Tosti, Antonella] Univ Miami, Dept Dermatology& Cutaneous Surg, Coral Gables, FL USA. [Lawley, Leslie] Emory Univ, Sch Med, Dept Dermatol & Pediat, Atlanta, GA USA. [Chang, Mary Wu] Univ Connecticut, Sch Med, Dept Dermatol & Pediat, Farmington, CT USA. [Scheman, Andrew] Northwestern Univ, Dermatol Clin, Chicago, IL USA. [Kleiner, Gary] Univ Miami, Miller Sch Med, Dept Pediat, Miami, FL 33136 USA. [Williams, Judith] Eastern Virginia Med Sch, Dept Pediat & Dermatol, Childrens Specialty Grp, Norfolk, VA 23501 USA. [Watsky, Kalman] Yale Univ, Sch Med, Dept Dermatol, New Haven, CT 06510 USA. [Dunnick, Cory A.] Univ Colorado Denver, Dept Dermatol, Denver, CO USA. [Dunnick, Cory A.] Denver VAMC, Denver, CO USA. [Frederickson, Rachel] Vanguard Skin Specialists, Colorado Springs, CO USA. [Matiz, Catalina] Univ Calif San Diego, Dept Dermatol, San Diego, CA 92103 USA. [Chaney, Keri] Med Coll Wisconsin, Dept Dermatol, Milwaukee, WI 53226 USA. [Estes, Tracy S.] Asthma & Allergy Care Delaware, Newark, DE USA. [Botto, Nina] Univ Calif San Francisco, Dept Dermatol, San Francisco, CA 94143 USA. [Draper, Michelle] Everett Clin, Dept Dermatol, Everett, WA USA. [Kircik, Leon] Phys Skin Care PLLC, Louisville, KY USA. [Kircik, Leon] DermResearch PLLC, Louisville, KY USA. [Kircik, Leon] KY, New York, NY USA. [Kircik, Leon] Icahn Sch Med Mt Sinai, New York, NY 10029 USA. [Lugo-Somolinos, Aida] Univ N Carolina, Dept Dermatol, Chapel Hill, NC USA. [Machler, Brian] NYU Ronald O Perelman Sch Med, Dept Dermatol, New York, NY USA. [Jacob, Sharon E.] Loma Linda Univ, Dept Dermatol, Loma Linda, CA 92350 USA. RP Jacob, SE (reprint author), Loma Linda Univ, Dept Dermatol, Fac Med Off, 11370 Anderson St,Suite 2600, Loma Linda, CA 92350 USA. EM sjacob@contactderm.net FU Society of Pediatric Dermatology Pilot Project Grant FX The provider registry component portion of this study was funded in part by a Society of Pediatric Dermatology Pilot Project Grant. S.E.J. and A.G. were directly involved in the design, data collection and analysis, conduction of the study, and IRB approvals and preliminary manuscript preparation. The other authors were directly involved in self-reporting their deidentified patch test results and in the preparation and final review of the manuscript. Coauthorship was granted to the investigators who entered more than 15 cases within 1 year of data collection. NR 13 TC 2 Z9 2 U1 2 U2 2 PU LIPPINCOTT WILLIAMS & WILKINS PI PHILADELPHIA PA TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA SN 1710-3568 EI 2162-5220 J9 DERMATITIS JI Dermatitis PD SEP-OCT PY 2016 VL 27 IS 5 BP 293 EP 302 DI 10.1097/DER.0000000000000214 PG 10 WC Dermatology SC Dermatology GA DX7OM UT WOS:000384577700010 PM 27649353 ER PT J AU Livorsi, D Knobloch, MJ Blue, LA Swafford, K Maze, L Riggins, K Hayward, T Safdar, N AF Livorsi, D. Knobloch, M. J. Blue, L. A. Swafford, K. Maze, L. Riggins, K. Hayward, T. Safdar, N. TI A rapid assessment of barriers and facilitators to safety culture in an intensive care unit SO INTERNATIONAL NURSING REVIEW LA English DT Article DE Safety Culture; ICU ID PATIENT SAFETY AB The Hospital Survey on Patient Safety was used to identify opportunities for safety culture improvement in a 30-bed intensive care unit. Based on the survey results, a core team decided to focus on three safety domains: reporting errors, approachability of authority figures and handovers. The project team subsequently interviewed 39 intensive care unit staff members, gathering information on these three domains that will inform future safety efforts. Numerous barriers and facilitators to improvement were described. This mixed-methods approach could be applied in other hospitals seeking to quickly yet thoroughly understand how their safety culture can be improved. Developing local strategies to reduce these barriers may promote a safer patient experience at our hospital. C1 [Livorsi, D.] Univ Iowa, Carver Coll Med, Div Infect Dis, Iowa City, IA 52246 USA. [Knobloch, M. J.; Safdar, N.] Univ Wisconsin, Sch Med, Madison, WI USA. [Blue, L. A.] Sidney & Lois Eskenazi Hosp, Patient Care Serv, Indianapolis, IN USA. [Swafford, K.; Maze, L.; Riggins, K.] Sidney & Lois Eskenazi Hosp, Indianapolis, IN USA. [Hayward, T.] Indiana Univ Sch Med, Dept Surg, Indianapolis, IN 46202 USA. [Safdar, N.] William S Middleton Mem Vet Adm Med Ctr, Madison, WI USA. [Livorsi, D.] Iowa City VAMC, Antimicrobial Stewardship, Iowa City, IA 52246 USA. RP Livorsi, D (reprint author), Univ Iowa, Carver Coll Med, Div Infect Dis, Iowa City, IA 52246 USA.; Livorsi, D (reprint author), Iowa City VAMC, Antimicrobial Stewardship, Iowa City, IA 52246 USA. EM daniel-livorsi@uiowa.edu FU Health Research and Educational Trust FX This project was funded by a grant from the Health Research and Educational Trust as part of the Project Protect Fellowship. NR 12 TC 0 Z9 0 U1 2 U2 2 PU WILEY-BLACKWELL PI HOBOKEN PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA SN 0020-8132 EI 1466-7657 J9 INT NURS REV JI Int. Nurs. Rev. PD SEP PY 2016 VL 63 IS 3 BP 372 EP 376 DI 10.1111/inr.12254 PG 5 WC Nursing SC Nursing GA DY0VD UT WOS:000384813400013 PM 27250081 ER PT J AU Gellad, WF Good, CB AF Gellad, Walid F. Good, Chester B. TI Prescription of Brand-Name Medications When Generic Alternatives Are Available-Patently Unfair SO JAMA INTERNAL MEDICINE LA English DT Editorial Material C1 [Gellad, Walid F.; Good, Chester B.] Univ Pittsburgh, Div Gen Med, Pittsburgh, PA USA. [Gellad, Walid F.; Good, Chester B.] Univ Pittsburgh, Ctr Pharmaceut Policy & Prescribing, Pittsburgh, PA USA. [Gellad, Walid F.; Good, Chester B.] Vet Affairs Pittsburgh Healthcare Syst, Ctr Hlth Equ Res & Promot, Pittsburgh, PA USA. [Good, Chester B.] US Dept Vet Affairs, Pharm Benefits Management Serv, Hines, IL USA. [Good, Chester B.] Univ Pittsburgh, Sch Pharm, Dept Pharm & Therapeut, Pittsburgh, PA 15261 USA. RP Gellad, WF (reprint author), Univ Pittsburgh, Div Gen Internal Med, Univ Dr,Bldg 151C, Pittsburgh, PA 15240 USA. EM walid.gellad@pitt.edu NR 9 TC 0 Z9 0 U1 1 U2 1 PU AMER MEDICAL ASSOC PI CHICAGO PA 330 N WABASH AVE, STE 39300, CHICAGO, IL 60611-5885 USA SN 2168-6106 EI 2168-6114 J9 JAMA INTERN MED JI JAMA Intern. Med. PD SEP PY 2016 VL 176 IS 9 BP 1323 EP 1324 DI 10.1001/jamainternmed.2016.3389 PG 3 WC Medicine, General & Internal SC General & Internal Medicine GA DX2MR UT WOS:000384204800020 PM 27367570 ER PT J AU Mi, Z Halfter, W Abrahamson, EE Klunk, WE Mathis, CA Mufson, EJ Ikonomovic, MD AF Mi, Zhiping Halfter, Willi Abrahamson, Eric E. Klunk, William E. Mathis, Chester A. Mufson, Elliott J. Ikonomovic, Milos D. TI Tenascin-C Is Associated with Cored Amyloid-beta Plaques in Alzheimer Disease and Pathology Burdened Cognitively Normal Elderly SO JOURNAL OF NEUROPATHOLOGY AND EXPERIMENTAL NEUROLOGY LA English DT Article DE beta-amyloid; Alzheimer disease; Astrocytes; Extracellular matrix; Inflammation; Microglia; Tau; Tenascin ID GLYCOGEN-SYNTHASE KINASE-3-BETA; PITTSBURGH COMPOUND-B; EXTRACELLULAR-MATRIX; NEUROFIBRILLARY TANGLES; SULFATE PROTEOGLYCANS; NEURITIC PLAQUES; A-BETA; NEUROPATHOLOGIC ASSESSMENT; FIBRIL FORMATION; TAU-PROTEIN AB Tenascin-C (TN-C) is an extracellular matrix glycoprotein linked to inflammatory processes in pathological conditions including Alzheimer disease (AD). We examined the distribution of TN-C immunoreactivity (ir) in relation to amyloid-beta (A beta) plaques and vascular A beta deposits in autopsy brain tissues from 14 patients with clinical and neuropathological AD and 10 aged-matched controls with no cognitive impairment; 5 of the controls had A beta plaques and 5 did not. TN-C ir was abundant in cortical white matter and subpial cerebral gray matter in all cases, whereas TN-C ir was weak in blood vessels. In all cases with A beta plaques but not in plaque-free controls, TN-C ir was detected as large (> 100 mm in diameter) diffuse extracellular deposits in cortical grey matter. TN-C plaques completely overlapped and surrounded cored A beta plaques labeled with X-34, a fluorescent derivative of Congo red, and they were associated with reactive astrocytes astrocytes, microglia and phosphorylated tau-containing dystrophic neurites. Diffuse A beta plaques lacking amyloid cores, reactive glia or dystrophic neurites showed no TN-C ir. In cases with cerebral amyloid angiopathy, TN-C ir in vessel walls did not spread into the surrounding neuropil. These results suggest a role for TN-C in A beta plaque pathogenesis and its potential as a biomarker and therapy target. C1 [Mi, Zhiping; Abrahamson, Eric E.; Klunk, William E.; Ikonomovic, Milos D.] Univ Pittsburgh, Dept Neurol, Pittsburgh, PA 15260 USA. [Halfter, Willi] Univ Pittsburgh, Dept Neurobiol, Pittsburgh, PA USA. [Klunk, William E.; Ikonomovic, Milos D.] Univ Pittsburgh, Dept Psychiat, Pittsburgh, PA USA. [Mathis, Chester A.] Univ Pittsburgh, Dept Radiol, Pittsburgh, PA 15260 USA. [Mi, Zhiping; Abrahamson, Eric E.; Ikonomovic, Milos D.] VA Pittsburgh Healthcare Syst, Geriatr Res Educ & Clin Ctr, Pittsburgh, PA USA. [Mufson, Elliott J.] Barrow Neurol Inst, Dept Neurobiol, Pittsburgh, PA USA. RP Ikonomovic, MD (reprint author), Univ Pittsburgh, Sch Med, Dept Neurol, BST South, 200 Lothrop St,Room S521, Pittsburgh, PA 15213 USA. EM ikonomovicmd@upmc.edu FU NIA NIH HHS [P01 AG025204, P50 AG005133] NR 72 TC 2 Z9 2 U1 2 U2 2 PU OXFORD UNIV PRESS INC PI CARY PA JOURNALS DEPT, 2001 EVANS RD, CARY, NC 27513 USA SN 0022-3069 EI 1554-6578 J9 J NEUROPATH EXP NEUR JI J. Neuropathol. Exp. Neurol. PD SEP PY 2016 VL 75 IS 9 BP 868 EP 876 DI 10.1093/jnen/nlw062 PG 9 WC Clinical Neurology; Neurosciences; Pathology SC Neurosciences & Neurology; Pathology GA DX8WJ UT WOS:000384671300005 PM 27444354 ER PT J AU Piel, J AF Piel, Jennifer TI Informed Consent in Right-To-Try Cases SO JOURNAL OF THE AMERICAN ACADEMY OF PSYCHIATRY AND THE LAW LA English DT Editorial Material ID EXPANDED ACCESS C1 [Piel, Jennifer] Univ Washington, Dept Psychiat, Seattle, WA 98195 USA. [Piel, Jennifer] VA Puget Sound Hlth Care Syst, 1660 South Columbian Way, Seattle, WA 98108 USA. RP Piel, J (reprint author), VA Puget Sound Hlth Care Syst, 1660 South Columbian Way, Seattle, WA 98108 USA. EM jennifer.piel@va.gov NR 15 TC 0 Z9 0 U1 3 U2 3 PU AMER ACAD PSYCHIATRY & LAW PI BLOOMFIELD PA ONE REGENCY DR, PO BOX 30, BLOOMFIELD, CT 06002 USA SN 1093-6793 EI 1943-3662 J9 J AM ACAD PSYCHIATRY JI J. Am. Acad. Psychiatry Law PD SEP 1 PY 2016 VL 44 IS 3 BP 290 EP 296 PG 7 WC Law; Psychiatry SC Government & Law; Psychiatry GA DX6SB UT WOS:000384512300001 PM 27644860 ER PT J AU Tan-Shalaby, JL Carrick, J Edinger, K Genovese, D Liman, AD Passero, VA Shah, RB AF Tan-Shalaby, Jocelyn L. Carrick, Jennifer Edinger, Krystal Genovese, Dana Liman, Andrew D. Passero, Vida A. Shah, Rashmikant B. TI Modified Atkins diet in advanced malignancies-final results of a safety and feasibility trial within the Veterans Affairs Pittsburgh Healthcare System (vol 13, 52, 2016) SO NUTRITION & METABOLISM LA English DT Correction C1 [Tan-Shalaby, Jocelyn L.; Carrick, Jennifer; Edinger, Krystal; Genovese, Dana; Liman, Andrew D.; Passero, Vida A.; Shah, Rashmikant B.] Vet Affairs Pittsburgh Healthcare Syst, Pittsburgh, PA 15261 USA. [Tan-Shalaby, Jocelyn L.; Edinger, Krystal; Genovese, Dana; Liman, Andrew D.; Passero, Vida A.] Univ Pittsburgh, Sch Med, Pittsburgh, PA 15260 USA. RP Tan-Shalaby, JL (reprint author), Vet Affairs Pittsburgh Healthcare Syst, Pittsburgh, PA 15261 USA.; Tan-Shalaby, JL (reprint author), Univ Pittsburgh, Sch Med, Pittsburgh, PA 15260 USA. EM jocelyn.tan@va.gov NR 1 TC 0 Z9 0 U1 0 U2 0 PU BIOMED CENTRAL LTD PI LONDON PA 236 GRAYS INN RD, FLOOR 6, LONDON WC1X 8HL, ENGLAND SN 1743-7075 J9 NUTR METAB JI Nutr. Metab. PD SEP 1 PY 2016 VL 13 AR 61 DI 10.1186/s12986-016-0120-z PG 1 WC Nutrition & Dietetics SC Nutrition & Dietetics GA DX7QQ UT WOS:000384584000001 PM 27594893 ER PT J AU Pandol, SJ Forsmark, CE Hart, PA AF Pandol, Stephen J. Forsmark, Chris E. Hart, Phil A. CA Consortium Study Chronic Pancreati TI Acceleration of our understanding of recurrent acute and chronic pancreatitis SO PANCREATOLOGY LA English DT Editorial Material ID FIBROSIS; RISK C1 [Pandol, Stephen J.] Univ Calif Los Angeles, Cedars Sinai Med Ctr, Los Angeles, CA 90048 USA. [Pandol, Stephen J.] US Dept Vet Affairs, Los Angeles, CA 90024 USA. [Forsmark, Chris E.] Univ Florida, Gainesville, FL USA. [Hart, Phil A.] Ohio State Univ, Div Gastroenterol Hepatol & Nutr, Wexner Med Ctr, Columbus, OH 43210 USA. RP Pandol, SJ (reprint author), Univ Calif Los Angeles, Cedars Sinai Med Ctr, Los Angeles, CA 90048 USA.; Pandol, SJ (reprint author), US Dept Vet Affairs, Los Angeles, CA 90024 USA. EM Stephen.Pandol@cshs.org RI Hart, Phil/A-9842-2016 OI Hart, Phil/0000-0003-4346-6196 FU NCI NIH HHS [P01 CA163200]; NIAAA NIH HHS [P50 AA011999, R01 AA024464]; NIDDK NIH HHS [P01 DK098108, R41 DK111337, U01 DK108314] NR 12 TC 1 Z9 1 U1 1 U2 1 PU ELSEVIER SCIENCE BV PI AMSTERDAM PA PO BOX 211, 1000 AE AMSTERDAM, NETHERLANDS SN 1424-3903 EI 1424-3911 J9 PANCREATOLOGY JI Pancreatology PD SEP-OCT PY 2016 VL 16 IS 5 BP 692 EP 693 DI 10.1016/j.pan.2016.08.002 PG 2 WC Gastroenterology & Hepatology SC Gastroenterology & Hepatology GA DY0KM UT WOS:000384785700002 PM 27542963 ER PT J AU Burgo-Black, AL Brown, JL Boyce, RM Hunt, SC AF Burgo-Black, A. Lucile Brown, Jeffrey L. Boyce, Ross M. Hunt, Stephen C. TI The Importance of Taking a Military History SO PUBLIC HEALTH REPORTS LA English DT Article DE veteran's health; military culture training; deployment health ID CARE; VETERANS; IRAQ; AFGHANISTAN; FAMILIES C1 [Burgo-Black, A. Lucile] Yale Univ, Sch Med, New Haven, CT USA. [Burgo-Black, A. Lucile] VA Connecticut Healthcare Syst, West Haven, CT USA. [Burgo-Black, A. Lucile; Hunt, Stephen C.] Vet Hlth Adm, Postdeployment Integrated Care Initiat, Patient Care Serv, Washington, DC USA. [Brown, Jeffrey L.] New York Med Coll, Dept Pediat, Valhalla, NY 10595 USA. [Brown, Jeffrey L.] Weill Cornell Med Coll, Dept Psychiat, New York, NY USA. [Boyce, Ross M.] Univ North Carolina Chapel Hill, Div Infect Dis, Chapel Hill, NC USA. [Hunt, Stephen C.] Univ Washington, Dept Med, Seattle, WA USA. [Hunt, Stephen C.] VA Puget Sound Healthcare Syst, Seattle, WA USA. RP Burgo-Black, AL (reprint author), Yale Univ, VA Connecticut Healthcare Syst, Gen Internal Med Primary Care, 20 Kenter Pl, New Haven, CT 06515 USA. EM lucille.burgo@va.gov NR 20 TC 0 Z9 0 U1 4 U2 4 PU SAGE PUBLICATIONS INC PI THOUSAND OAKS PA 2455 TELLER RD, THOUSAND OAKS, CA 91320 USA SN 0033-3549 EI 1468-2877 J9 PUBLIC HEALTH REP JI Public Health Rep. PD SEP-OCT PY 2016 VL 131 IS 5 BP 711 EP 713 DI 10.1177/0033354916660073 PG 3 WC Public, Environmental & Occupational Health SC Public, Environmental & Occupational Health GA DX3LT UT WOS:000384275300010 PM 28123212 ER PT J AU Cypel, YS Hamlett-Berry, K Barth, SK Christofferson, DE Davey, VJ Eber, S Schneiderman, AI Bossarte, RM AF Cypel, Yasmin S. Hamlett-Berry, Kim Barth, Shannon K. Christofferson, Dana E. Davey, Victoria J. Eber, Stephanie Schneiderman, Aaron I. Bossarte, Robert M. TI Cigarette Smoking and Sociodemographic, Military, and Health Characteristics of Operation Enduring Freedom and Operation Iraqi Freedom Veterans: 2009-2011 National Health Study for a New Generation of US Veterans SO PUBLIC HEALTH REPORTS LA English DT Article DE veterans; cigarettes; smoking; OEF/OIF; Operation Iraqi Freedom; Operation Enduring Freedom; health; Afghanistan; Iraq ID POSTTRAUMATIC-STRESS-DISORDER; POPULATION-BASED COHORT; GENDER-DIFFERENCES; NICOTINE DEPENDENCE; SUBSTANCE USE; TOBACCO USE; AIR-FORCE; AFGHANISTAN; PREVALENCE; PERSONNEL AB Objective: We examined the sociodemographic, military, and health characteristics of current cigarette smokers, former smokers, and nonsmokers among Operation Enduring Freedom (OEF) / Operation Iraqi Freedom (OIF) veterans and estimated smoking prevalence to better understand cigarette use in this population. Methods: We analyzed data from the US Department of Veterans Affairs (VA) 2009-2011 National Health Study for a New Generation of US Veterans. On the basis of a stratified random sample of 60 000 OEF/OIF veterans, we sought responses to a 72-item questionnaire via mail, telephone, or Internet. Cigarette smoking status was based on self-reported cigarette use in the past year. We used multinomial logistic regression to evaluate associations between smoking status and sociodemographic, military, and health characteristics. Results: Among 19 911 veterans who provided information on cigarette smoking, 5581 were current smokers (weighted percentage: 32.5%, 95% confidence interval [CI]: 31.7-33.2). Current smokers were more likely than nonsmokers or former smokers to be younger, to have less education or income, to be separated/divorced or never married/single, and to have served on active duty or in the army. Comparing current smokers and nonsmokers, some significant associations from adjusted analyses included the following: having a Mental Component Summary score (a measure of overall mental health) above the mean of the US population relative to below the mean (adjusted odds ratio [aOR] = 0.81, 95% CI: 0.73-0.90); having physician diagnosed depression (aOR = 1.52, 95% CI: 1.33-1.74), respiratory conditions (aOR = 1.16, 95% CI: 1.04-1.30), or repeated seizures/blackouts/convulsions (aOR = 1.80, 95% CI: 1.22-2.67); heavy alcohol use vs never use (aOR = 5.49, 95% CI: 4.57-6.59); a poor vs excellent perception of overall health (aOR = 3.79, 95% CI: 2.60-5.52); and being deployed vs nondeployed (aOR = 0.87, 95% CI: 0.78-0.96). Using health care services from the VA protected against current smoking. Conclusion: Mental and physical health, substance use, and military service characteristics shape cigarette-smoking patterns in OEF/OIF veterans. C1 [Cypel, Yasmin S.; Barth, Shannon K.; Eber, Stephanie; Schneiderman, Aaron I.; Bossarte, Robert M.] US Dept Vet Affairs, Vet Hlth Adm, Off Patient Care Serv, Postdeployment Hlth Serv, Washington, DC USA. [Hamlett-Berry, Kim; Christofferson, Dana E.] US Dept Vet Affairs, Vet Hlth Adm, Off Patient Care Serv, Mental Hlth Serv, Washington, DC USA. [Davey, Victoria J.] US Dept Vet Affairs, Vet Hlth Adm, Off Res & Dev, Washington, DC USA. RP Cypel, YS (reprint author), US Dept Vet Affairs, Vet Hlth Adm, Postdeployment Hlth Serv 10P4Q, 810 Vermont Ave NW, Washington, DC 20420 USA. EM yasmin.cypel@va.gov FU VA Post-Deployment Health Services, Epidemiology Program FX This study was funded by the VA Post-Deployment Health Services, Epidemiology Program. The views expressed in this article are solely those of the authors and do not necessarily reflect the position or policy of the VA or the US government. NR 67 TC 0 Z9 0 U1 2 U2 4 PU SAGE PUBLICATIONS INC PI THOUSAND OAKS PA 2455 TELLER RD, THOUSAND OAKS, CA 91320 USA SN 0033-3549 EI 1468-2877 J9 PUBLIC HEALTH REP JI Public Health Rep. PD SEP-OCT PY 2016 VL 131 IS 5 BP 714 EP 727 DI 10.1177/0033354916664864 PG 14 WC Public, Environmental & Occupational Health SC Public, Environmental & Occupational Health GA DX3LT UT WOS:000384275300011 PM 28123213 ER PT J AU Treger, R Hanna, RM Lee, BM Lopez, EA Wilson, J Corry, D AF Treger, Richard Hanna, Ramy M. Lee, Brian M. Lopez, Eduardo A. Wilson, James Corry, Dalila TI Delayed clearance of hepatitis B surface antigen and development of hepatitis B surface antibody in a chronic hemodialysis patient SO SAUDI JOURNAL OF KIDNEY DISEASES AND TRANSPLANTATION LA English DT Article ID VIRUS INFECTION; NATURAL-HISTORY; CIRRHOSIS; DISEASE; SEROCONVERSION; VACCINATION; LOAD AB The introduction of hepatitis B vaccination and infection control in 1977 has greatly decreased the prevalence of hepatitis B. Currently, approximately 2.8% of the end-stage renal disease population is hepatitis B positive with a presence in 27.7% of the USA hemodialysis (HD) units according to the Dialysis Outcomes and Practice Patterns Study data. The behavior of hepatitis B infection differs significantly between immunocompetent and immunosuppressed hosts. Immunosuppressed hosts present more subtly with complications of chronic hepatitis B infection, being more challenging to detect. It is also well known that patients with chronic infection on HD have a small chance of clearing the virus. We report here a case of a hepatitis B positive HD patient who underwent spontaneous delayed serological clearance of hepatitis B surface antigen and development of immunity via appearance of hepatitis B surface antibody. This is a rare occurrence, and the few similar reported cases will be discussed. C1 [Treger, Richard; Corry, Dalila] Greater Los Angeles Vet Affairs Healthcare Syst, Div Nephrol, Los Angeles, CA USA. [Treger, Richard; Hanna, Ramy M.; Lee, Brian M.; Wilson, James; Corry, Dalila] UCLA, David Geffen Sch Med, Dept Med, Los Angeles, CA 90095 USA. [Treger, Richard; Hanna, Ramy M.; Lee, Brian M.; Wilson, James; Corry, Dalila] Olive View UCLA Med Ctr, Div Nephrol, Los Angeles, CA USA. [Hanna, Ramy M.] Cedars Sinai Med Ctr, Dept Med, Div Nephrol, Los Angeles, CA 90048 USA. [Lopez, Eduardo A.] Kaiser Permanente Panorama City, Dept Nephrol, Los Angeles, CA USA. [Wilson, James] UCLA, David Geffen Sch Med, Director UCLA Stone Ctr, Surg Consultat Nephrol, Los Angeles, CA 90095 USA. RP Hanna, RM (reprint author), Cedars Sinai Med Ctr, Off Towers,8635 West Third St,Suite 495, Los Angeles, CA 90048 USA. EM rhannamd81@yahoo.com OI Hanna, Ramy/0000-0003-1807-8909 NR 22 TC 0 Z9 0 U1 1 U2 1 PU MEDKNOW PUBLICATIONS & MEDIA PVT LTD PI MUMBAI PA B-9, KANARA BUSINESS CENTRE, OFF LINK RD, GHAKTOPAR-E, MUMBAI, 400075, INDIA SN 1319-2442 EI 2320-3838 J9 SAUDI J KIDNEY DIS T JI Saudi J. Kidney Dis. Transplant. PD SEP-OCT PY 2016 VL 27 IS 5 BP 1047 EP 1051 DI 10.4103/1319-2442.190886 PG 5 WC Urology & Nephrology SC Urology & Nephrology GA DX7JL UT WOS:000384562800028 PM 27752020 ER PT J AU Horn, T Keller, JA Pucillo, TM Iqbal, J Mansfield, P Keller, MA AF Horn, T. Keller, J. A. Pucillo, T. M. Iqbal, J. Mansfield, P. Keller, M. A. TI Novel RHCE*ce Alleles Containing c.307T Cause C Typing Discrepancies SO TRANSFUSION LA English DT Meeting Abstract CT AABB Annual Meeting CY OCT 22-25, 2016 CL Orlando, FL SP AABB C1 [Horn, T.; Keller, J. A.; Keller, M. A.] Amer Red Cross, Natl Mol Lab, Philadelphia, PA USA. [Pucillo, T. M.] Amer Red Cross, Immunohematol Reference Lab, Baltimore, MD USA. [Mansfield, P.] Amer Red Cross, Immunohematol Reference Lab, Philadelphia, PA USA. [Iqbal, J.] Vet Affairs Greater Los Angeles Healthcare Syst, Pathol & Lab Med, Los Angeles, CA USA. NR 0 TC 0 Z9 0 U1 0 U2 0 PU WILEY-BLACKWELL PI HOBOKEN PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA SN 0041-1132 EI 1537-2995 J9 TRANSFUSION JI Transfusion PD SEP PY 2016 VL 56 SU 4 SI SI MA SP334 BP 159A EP 159A PG 1 WC Hematology SC Hematology GA DX8NS UT WOS:000384646400438 ER PT J AU Kalil, AC Metersky, ML Klompas, M Muscedere, J Sweeney, DA Palmer, LB Napolitano, LM O'Grady, NP Bartlett, JG Carratala, J El Solh, AA Ewig, S Fey, PD File, TM Restrepo, MI Roberts, JA Waterer, GW Cruse, P Knight, SL Brozek, JL AF Kalil, Andre C. Metersky, Mark L. Klompas, Michael Muscedere, John Sweeney, Daniel A. Palmer, Lucy B. Napolitano, Lena M. O'Grady, Naomi P. Bartlett, John G. Carratala, Jordi El Solh, Ali A. Ewig, Santiago Fey, Paul D. File, Thomas M., Jr. Restrepo, Marcos I. Roberts, Jason A. Waterer, Grant W. Cruse, Peggy Knight, Shandra L. Brozek, Jan L. TI Management of Adults With Hospital-acquired and Ventilator-associated Pneumonia: 2016 Clinical Practice Guidelines by the Infectious Diseases Society of America and the American Thoracic Society SO CLINICAL INFECTIOUS DISEASES LA English DT Article ID CONSENSUS; COLISTIN AB It is important to realize that guidelines cannot always account for individual variation among patients. They are not intended to supplant physician judgment with respect to particular patients or special clinical situations. IDSA considers adherence to these guidelines to be voluntary, with the ultimate determination regarding their application to be made by the physician in the light of each patient's individual circumstances. These guidelines are intended for use by healthcare professionals who care for patients at risk for hospital-acquired pneumonia (HAP) and ventilator-associated pneumonia (VAP), including specialists in infectious diseases, pulmonary diseases, critical care, and surgeons, anesthesiologists, hospitalists, and any clinicians and healthcare providers caring for hospitalized patients with nosocomial pneumonia. The panel's recommendations for the diagnosis and treatment of HAP and VAP are based upon evidence derived from topic-specific systematic literature reviews. C1 [Kalil, Andre C.] Univ Nebraska Med Ctr, Div Infect Dis, Dept Internal Med, Omaha, NE 68198 USA. [Metersky, Mark L.] Univ Connecticut, Sch Med, Div Pulm & Crit Care Med, Farmington, CT USA. [Klompas, Michael] Brigham & Womens Hosp, 75 Francis St, Boston, MA 02115 USA. [Klompas, Michael] Harvard Med Sch, Boston, MA USA. [Klompas, Michael] Harvard Pilgrim Hlth Care Inst, Boston, MA USA. [Muscedere, John] Queens Univ, Dept Med, Crit Care Program, Kingston, ON, Canada. [Sweeney, Daniel A.] Univ Calif San Diego, Div Pulm Crit Care & Sleep Med, San Diego, CA 92103 USA. [Palmer, Lucy B.] SUNY Stony Brook, Dept Med, Div Pulm Crit Care & Sleep Med, Stony Brook, NY 11794 USA. [Napolitano, Lena M.] Univ Michigan, Dept Surg, Div Trauma Crit Care & Emergency Surg, Ann Arbor, MI 48109 USA. [O'Grady, Naomi P.] NIH, Dept Crit Care Med, Bldg 10, Bethesda, MD 20892 USA. [Bartlett, John G.] Johns Hopkins Univ, Sch Med, Baltimore, MD USA. [Carratala, Jordi] Univ Barcelona, Dept Infect Dis, Hosp Univ Bellvitge, Bellvitge Biomed Res Inst,Spanish Network Res Inf, E-08007 Barcelona, Spain. [El Solh, Ali A.] SUNY Buffalo, Vet Affairs Western New York Healthcare Syst, Dept Med, Div Pulm Crit Care & Sleep Med, New York, NY USA. [Ewig, Santiago] EVK Herne, Dept Resp & Infect Dis, Thoraxzentrum Ruhrgebiet, Herne, Germany. [Ewig, Santiago] Augusta Kranken Anstalt Bochum, Bochum, Germany. [Fey, Paul D.] Univ Nebraska Med Ctr, Dept Pathol & Microbiol, Omaha, NE USA. [File, Thomas M., Jr.] Summa Hlth Syst, Akron, OH USA. [Restrepo, Marcos I.] South Texas Vet Hlth Care Syst, Div Pulm & Crit Care Med, Dept Med, San Antonio, TX USA. [Restrepo, Marcos I.] Univ Texas Hlth Sci Ctr San Antonio, San Antonio, TX 78229 USA. [Roberts, Jason A.] Univ Queensland, Burns Trauma & Crit Care Res Ctr, Brisbane, Qld 4072, Australia. [Roberts, Jason A.] Royal Brisbane & Womens Hosp, Herston, Qld, Australia. [Waterer, Grant W.] Univ Western Australia, Sch Med & Pharmacol, Perth, WA, Australia. [Cruse, Peggy; Knight, Shandra L.] Natl Jewish Hlth, Lib Serv, Denver, CO USA. [Cruse, Peggy; Knight, Shandra L.] Natl Jewish Hlth, Knowledge Serv, Denver, CO USA. [Brozek, Jan L.] McMaster Univ, Dept Clin Epidemiol & Biostat, Hamilton, ON, Canada. [Brozek, Jan L.] McMaster Univ, Dept Med, Hamilton, ON, Canada. RP Kalil, AC (reprint author), Univ Nebraska Med Ctr, Div Infect Dis, Dept Internal Med, Omaha, NE 68198 USA. EM akalil@unmc.edu FU IDSA; ATS FX The IDSA and the ATS provided meeting facilities for face-to-face meetings, financial support for conference calls, and administrative support. Industry funding to support guideline development was not permitted. NR 6 TC 10 Z9 11 U1 4 U2 12 PU OXFORD UNIV PRESS INC PI CARY PA JOURNALS DEPT, 2001 EVANS RD, CARY, NC 27513 USA SN 1058-4838 EI 1537-6591 J9 CLIN INFECT DIS JI Clin. Infect. Dis. PD SEP 1 PY 2016 VL 63 IS 5 BP 575 EP 582 DI 10.1093/cid/ciw504 PG 8 WC Immunology; Infectious Diseases; Microbiology SC Immunology; Infectious Diseases; Microbiology GA DW7TZ UT WOS:000383856300002 PM 27521441 ER PT J AU Kalil, AC Metersky, ML Klompas, M Muscedere, J Sweeney, DA Palmer, LB Napolitano, LM O'Grady, NP Bartlett, JG Carratala, J El Solh, AA Ewig, S Fey, PD File, TM Restrepo, MI Roberts, JA Waterer, GW Cruse, P Knight, SL Brozek, JL AF Kalil, Andre C. Metersky, Mark L. Klompas, Michael Muscedere, John Sweeney, Daniel A. Palmer, Lucy B. Napolitano, Lena M. O'Grady, Naomi P. Bartlett, John G. Carratala, Jordi El Solh, Ali A. Ewig, Santiago Fey, Paul D. File, Thomas M., Jr. Restrepo, Marcos I. Roberts, Jason A. Waterer, Grant W. Cruse, Peggy Knight, Shandra L. Brozek, Jan L. TI Management of Adults With Hospital-acquired and Ventilator-associated Pneumonia: 2016 Clinical Practice Guidelines by the Infectious Diseases Society of America and the American Thoracic Society SO CLINICAL INFECTIOUS DISEASES LA English DT Article ID INTENSIVE-CARE-UNIT; RESISTANT STAPHYLOCOCCUS-AUREUS; CRITICALLY-ILL PATIENTS; GRAM-NEGATIVE BACTERIA; COMBINATION ANTIBIOTIC-THERAPY; RANDOMIZED CONTROLLED-TRIAL; DE-ESCALATION THERAPY; PSEUDOMONAS-AERUGINOSA BACTEREMIA; RESPIRATORY-TRACT INFECTIONS; PROTECTED SPECIMEN BRUSH AB It is important to realize that guidelines cannot always account for individual variation among patients. They are not intended to supplant physician judgment with respect to particular patients or special clinical situations. IDSA considers adherence to these guidelines to be voluntary, with the ultimate determination regarding their application to be made by the physician in the light of each patient's individual circumstances. These guidelines are intended for use by healthcare professionals who care for patients at risk for hospital-acquired pneumonia (HAP) and ventilator-associated pneumonia (VAP), including specialists in infectious diseases, pulmonary diseases, critical care, and surgeons, anesthesiologists, hospitalists, and any clinicians and healthcare providers caring for hospitalized patients with nosocomial pneumonia. The panel's recommendations for the diagnosis and treatment of HAP and VAP are based upon evidence derived from topic-specific systematic literature reviews. C1 [Kalil, Andre C.] Univ Nebraska Med Ctr, Div Infect Dis, Dept Internal Med, Omaha, NE 68198 USA. [Metersky, Mark L.] Univ Connecticut, Sch Med, Div Pulm & Crit Care Med, Farmington, CT USA. [Klompas, Michael] Brigham & Womens Hosp, 75 Francis St, Boston, MA 02115 USA. [Klompas, Michael] Harvard Med Sch, Boston, MA USA. [Klompas, Michael] Harvard Pilgrim Hlth Care Inst, Boston, MA USA. [Muscedere, John] Queens Univ, Dept Med, Crit Care Program, Kingston, ON, Canada. [Sweeney, Daniel A.] Univ Calif San Diego, Div Pulm Crit Care & Sleep Med, San Diego, CA 92103 USA. [Palmer, Lucy B.] SUNY Stony Brook, Dept Med, Div Pulm Crit Care & Sleep Med, Stony Brook, NY 11794 USA. [Napolitano, Lena M.] Univ Michigan, Dept Surg, Div Trauma Crit Care & Emergency Surg, Ann Arbor, MI 48109 USA. [O'Grady, Naomi P.] NIH, Dept Crit Care Med, Bethesda, MD 20892 USA. [Bartlett, John G.] Johns Hopkins Univ, Sch Med, Baltimore, MD USA. [Carratala, Jordi] Univ Barcelona, Spanish Network Res Infect Dis, Bellvitge Biomed Res Inst, Dept Infect Dis,Hosp Univ Bellvitge, E-08007 Barcelona, Spain. [El Solh, Ali A.] SUNY Buffalo, Dept Med, Div Pulm Crit Care & Sleep Med, Vet Affairs Western New York Healthcare Syst, New York, NY USA. [Ewig, Santiago] EVK Herne, Thoraxzentrum Ruhrgebiet, Dept Resp & Infect Dis, Herne, Germany. [Ewig, Santiago] Augusta Kranken Anstalt Bochum, Bochum, Germany. [Fey, Paul D.] Univ Nebraska Med Ctr, Dept Pathol & Microbiol, Omaha, NE USA. [File, Thomas M., Jr.] Summa Hlth Syst, Akron, OH USA. [Restrepo, Marcos I.] South Texas Vet Hlth Care Syst, Div Pulm & Crit Care Med, Dept Med, San Antonio, TX USA. [Restrepo, Marcos I.] Univ Texas Hlth Sci Ctr San Antonio, San Antonio, TX 78229 USA. [Roberts, Jason A.] Univ Queensland, Burns Trauma & Crit Care Res Ctr, Brisbane, Qld 4072, Australia. [Roberts, Jason A.] Royal Brisbane & Womens Hosp, Herston, Qld, Australia. [Waterer, Grant W.] Univ Western Australia, Sch Med & Pharmacol, Perth, WA, Australia. [Cruse, Peggy; Knight, Shandra L.] Natl Jewish Hlth, Lib Serv, Denver, CO USA. [Cruse, Peggy; Knight, Shandra L.] Natl Jewish Hlth, Knowledge Serv, Denver, CO USA. [Brozek, Jan L.] McMaster Univ, Dept Clin Epidemiol & Biostat, Hamilton, ON, Canada. [Brozek, Jan L.] McMaster Univ, Dept Med, Hamilton, ON, Canada. RP Kalil, AC (reprint author), Univ Nebraska Med Ctr, Div Infect Dis, Dept Internal Med, Omaha, NE 68198 USA. EM akalil@unmc.edu OI Carratala, Jordi/0000-0003-3209-2563 FU IDSA; ATS FX The IDSA and the ATS provided meeting facilities for face-to-face meetings, financial support for conference calls, and administrative support. Industry funding to support guideline development was not permitted. NR 364 TC 46 Z9 50 U1 5 U2 6 PU OXFORD UNIV PRESS INC PI CARY PA JOURNALS DEPT, 2001 EVANS RD, CARY, NC 27513 USA SN 1058-4838 EI 1537-6591 J9 CLIN INFECT DIS JI Clin. Infect. Dis. PD SEP 1 PY 2016 VL 63 IS 5 BP E61 EP E111 DI 10.1093/cid/ciw353 PG 51 WC Immunology; Infectious Diseases; Microbiology SC Immunology; Infectious Diseases; Microbiology GA DW7TZ UT WOS:000383856300001 PM 27418577 ER PT J AU Pauls, Q Durkalski-Mauldin, V Brawman-Mintzer, O Lawrence, C Whichard, R Cotton, PB AF Pauls, Qi Durkalski-Mauldin, Valerie Brawman-Mintzer, Olga Lawrence, Chris Whichard, Rebekah Cotton, Peter B. TI Duloxetine for the Treatment of Patients with Suspected Sphincter of Oddi Dysfunction: A Pilot Study SO DIGESTIVE DISEASES AND SCIENCES LA English DT Article DE Sphincter of Oddi dysfunction; Abdominal pain; Biliary disease; Pharmacotherapy ID IRRITABLE-BOWEL-SYNDROME; FINDINGS TYPE-I; ABDOMINAL-PAIN; DISORDERS; PRESENTATIONS; DISABILITY; PLACEBO; TRIAL AB To examine the tolerability and efficacy of duloxetine in patients with suspected sphincter of Oddi dysfunction (SOD). An open-label, single-center, 12-week trial of duloxetine 60 mg once daily was conducted in 20 patients with suspected SOD. All patients were evaluated by expert pancreato-biliary specialists. The primary outcome measure was a Patient Global Impression of Change (PGIC) scale. Secondary measures included the pain burden, assessed by the Recurrent Abdominal Pain Intensity and Disability scale, the Short-Form Health Survey, and the Hospital Anxiety and Depression Scale. A positive clinical response was defined as a PGIC score of much or very much improved at 3 months and was estimated using a two-sided 90 % confidence interval. The primary outcome was analyzed using a one-sample binomial test at a significance level of 0.10. Of the 20 screened patients, 18 were enrolled; 14 completed at least one post-baseline evaluation; and 10 patients completed the third month endpoint visit. Patients missing the third month visit were considered non-responders for the primary outcome. Response rates were 90 % for study completers (n = 10; 90 % CI 74-100; p = 0.02) and 64 % for patients who completed at least one post-baseline evaluation (n = 14; 90 % CI 43-85; p = 0.42). Seven patients did not complete the study due to adverse events (mostly fatigue and nausea). Duloxetine showed an indication of efficacy in the treatment of pain in patients with suspected SOD, but adverse events limited its use. These preliminary, open-label results justify definitive placebo-controlled trials. C1 [Pauls, Qi; Durkalski-Mauldin, Valerie] Med Univ South Carolina, Dept Publ Hlth Sci, Charleston, SC USA. [Lawrence, Chris; Whichard, Rebekah; Cotton, Peter B.] Med Univ South Carolina, Ctr Digest Dis, Suite 249,MSC 702,114 Doughty St, Charleston, SC 29425 USA. [Brawman-Mintzer, Olga] Med Univ South Carolina, Dept Psychiat, Charleston, SC USA. [Brawman-Mintzer, Olga] Ralph H Johnson VAMC, Charleston, SC USA. RP Cotton, PB (reprint author), Med Univ South Carolina, Ctr Digest Dis, Suite 249,MSC 702,114 Doughty St, Charleston, SC 29425 USA. EM Petercotto@gmail.com FU Lilly Pharmaceuticals, USA FX The study was investigator-initiated and funded by an unrestricted research grant from Lilly Pharmaceuticals, USA. Lilly had no input on the design and management of the study or on the analysis of the data. NR 15 TC 2 Z9 2 U1 1 U2 1 PU SPRINGER PI DORDRECHT PA VAN GODEWIJCKSTRAAT 30, 3311 GZ DORDRECHT, NETHERLANDS SN 0163-2116 EI 1573-2568 J9 DIGEST DIS SCI JI Dig. Dis. Sci. PD SEP PY 2016 VL 61 IS 9 BP 2704 EP 2709 DI 10.1007/s10620-016-4187-1 PG 6 WC Gastroenterology & Hepatology SC Gastroenterology & Hepatology GA DU1TP UT WOS:000381992700031 PM 27165434 ER PT J AU Sever, S White, DL Garcia, JM AF Sever, Sakine White, Donna L. Garcia, Jose M. TI Is there an effect of ghrelin/ghrelin analogs on cancer? A systematic review SO ENDOCRINE-RELATED CANCER LA English DT Review DE ghrelin; cancer; tumor growth; metastasis; in vivo; cachexia ID GH REPLACEMENT THERAPY; IGF-BINDING PROTEIN-3; GROWTH-FACTOR (IGF)-I; HELICOBACTER-PYLORI INFECTION; PLASMA GHRELIN CONCENTRATION; PRADER-WILLI-SYNDROME; CELL LUNG-CANCER; BREAST-CANCER; CIRCULATING GHRELIN; COLORECTAL-CANCER AB Ghrelin is a hormone with multiple physiologic functions, including promotion of growth hormone release, stimulation of appetite and regulation of energy homeostasis. Treatment with ghrelin/ghrelin-receptor agonists is a prospective therapy for disease-related cachexia and malnutrition. In vitro studies have shown high expression of ghrelin in cancer tissue, although its role including its impact in cancer risk and progression has not been established. We performed a systematic literature review to identify peer-reviewed human or animal in vivo original research studies of ghrelin, ghrelin-receptor agonists, or ghrelin genetic variants and the risk, presence, or growth of cancer using structured searches in PubMed database as well as secondary searches of article reference lists, additional reviews and meta-analyses. Overall, 45 (73.8%) of the 61 studies reviewed, including all 11 involving exogenous ghrelin/ghrelin-receptor agonist treatment, reported either a null (no statistically significant difference) or inverse association of ghrelin/ghrelin-receptor agonists or ghrelin genetic variants with cancer risk, presence or growth; 10 (16.7%) studies reported positive associations; and 6 (10.0%) reported both negative or null and positive associations. Differences in serum ghrelin levels in cancer cases vs controls (typically lower) were reported for some but not all cancers. The majority of in vivo studies showed a null or inverse association of ghrelin with risk and progression of most cancers, suggesting that ghrelin/ghrelin-receptor agonist treatment may have a favorable safety profile to use for cancer cachexia. Additional large-scale prospective clinical trials as well as basic bioscientific research are warranted to further evaluate the safety and benefits of ghrelin treatment in patients with cancer. C1 [Sever, Sakine; Garcia, Jose M.] Baylor Coll Med, Div Endocrinol Diabet & Metab, Alkek Bldg Biomedical Res, Houston, TX 77030 USA. [White, Donna L.] Baylor Coll Med, Med Ctr, Sect Gastroenterol & Hepatol, Houston, TX 77030 USA. [White, Donna L.] Michael E DeBakey VA Med Ctr, Sect Hlth Serv Res IQuESt, Clin Epidemiol & Comparat Effectiveness Program, HSR&D Ctr Innovat 152, Houston, TX USA. [White, Donna L.] Baylor Coll Med, Texas Med Ctr, Ctr Digest Dis, Houston, TX 77030 USA. [White, Donna L.] Baylor Coll Med, Dan L Duncan Comprehens Canc Ctr, Houston, TX 77030 USA. [White, Donna L.; Garcia, Jose M.] Michael E DeBakey VA Med Ctr, CTRID, Houston, TX 77030 USA. [Garcia, Jose M.] Baylor Coll Med, Dept Mol & Cellular Biol, Houston, TX 77030 USA. [Garcia, Jose M.] Baylor Coll Med, Huffington Ctr Aging, Houston, TX 77030 USA. [Garcia, Jose M.] Vet Affairs Puget Sound Hlth Care Syst, Geriatr Res Educ & Clin Ctr, Seattle, WA 98108 USA. [Garcia, Jose M.] Univ Washington, Seattle, WA 98195 USA. RP Garcia, JM (reprint author), Baylor Coll Med, Div Endocrinol Diabet & Metab, Alkek Bldg Biomedical Res, Houston, TX 77030 USA.; Garcia, JM (reprint author), Michael E DeBakey VA Med Ctr, CTRID, Houston, TX 77030 USA.; Garcia, JM (reprint author), Baylor Coll Med, Dept Mol & Cellular Biol, Houston, TX 77030 USA.; Garcia, JM (reprint author), Baylor Coll Med, Huffington Ctr Aging, Houston, TX 77030 USA.; Garcia, JM (reprint author), Vet Affairs Puget Sound Hlth Care Syst, Geriatr Res Educ & Clin Ctr, Seattle, WA 98108 USA.; Garcia, JM (reprint author), Univ Washington, Seattle, WA 98195 USA. EM jose.garcia@va.gov FU National Institute of Diabetes Digestive and Kidney Diseases [R03 DK095082]; Michael E DeBakey Veterans Affairs Health Services Research Center of Innovations [CIN13-413]; Aeterna Zentaris (USA); Helsinn Therapeutics (USA); Department of Veterans Affairs (MERIT grants) [I01-BX000507, I01 CX000174]; Aeterna Zentaris; Department of Veterans Affairs (NIA) [T32AG000183, AG040583] FX D L White receives research support from the National Institute of Diabetes Digestive and Kidney Diseases (R03 DK095082, PI: White) and the Michael E DeBakey Veterans Affairs Health Services Research Center of Innovations (CIN13-413). J M Garcia has received consulting or advisory fees from Aeterna Zentaris and Helsinn Therapeutics (USA), and research grants from the Department of Veterans Affairs (MERIT grants I01-BX000507 and I01 CX000174, and the NIA T32AG000183 and AG040583), Aeterna Zentaris, and Helsinn Therapeutics (USA). Support for developing this manuscript was provided by Helsinn Therapeutics. NR 140 TC 2 Z9 2 U1 1 U2 1 PU BIOSCIENTIFICA LTD PI BRISTOL PA EURO HOUSE, 22 APEX COURT WOODLANDS, BRADLEY STOKE, BRISTOL BS32 4JT, ENGLAND SN 1351-0088 EI 1479-6821 J9 ENDOCR-RELAT CANCER JI Endocr.-Relat. Cancer PD SEP PY 2016 VL 23 IS 9 BP R393 EP R409 DI 10.1530/ERC-16-0130 PG 17 WC Oncology; Endocrinology & Metabolism SC Oncology; Endocrinology & Metabolism GA DX2HX UT WOS:000384190100003 PM 27552970 ER PT J AU Hogan, MF Meier, DT Zraika, S Templin, AT Mellati, M Hull, RL Leissring, MA Kahn, SE AF Hogan, Meghan F. Meier, Daniel T. Zraika, Sakeneh Templin, Andrew T. Mellati, Mahnaz Hull, Rebecca L. Leissring, Malcolm A. Kahn, Steven E. TI Inhibition of Insulin-Degrading Enzyme Does Not Increase Islet Amyloid Deposition in Vitro SO ENDOCRINOLOGY LA English DT Article ID BETA-CELL APOPTOSIS; FIBRIL FORMATION; TRANSGENIC MICE; PANCREATIC-ISLETS; POLYPEPTIDE; DEGRADATION; SECRETION; AMYLIN; MOUSE; PATHOPHYSIOLOGY AB Islet amyloid deposition in human type 2 diabetes results in beta-cell loss. These amyloid deposits contain the unique amyloidogenic peptide human islet amyloid polypeptide (hIAPP), which is also a known substrate of the protease insulin-degrading enzyme (IDE). Whereas IDE inhibition has recently been demonstrated to improve glucose metabolism in mice, inhibiting it has also been shown to increase cell death when synthetic hIAPP is applied exogenously to a beta-cell line. Thus, we wanted to determine whether a similar deleterious effect is observed when hIAPP is endogenously produced and secreted from islets. To address this issue, we cultured hIAPP transgenic mouse islets that have the propensity to form amyloid for 48 and 144 hours in 16.7 mM glucose in the presence and absence of the IDE inhibitor 1. At neither time interval did IDE inhibition increase amyloid formation or beta-cell loss. Thus, the inhibition of IDE may represent an approach to improve glucose metabolism in human type 2 diabetes, without inducing amyloid deposition and its deleterious effects. C1 [Hogan, Meghan F.; Meier, Daniel T.; Zraika, Sakeneh; Templin, Andrew T.; Mellati, Mahnaz; Hull, Rebecca L.; Kahn, Steven E.] Vet Affairs Puget Sound Hlth Care Syst, Dept Med, Div Metab Endocrinol & Nutr, Seattle, WA 98108 USA. [Hogan, Meghan F.; Meier, Daniel T.; Zraika, Sakeneh; Templin, Andrew T.; Mellati, Mahnaz; Hull, Rebecca L.; Kahn, Steven E.] Univ Washington, Seattle, WA 98108 USA. [Leissring, Malcolm A.] Univ Calif Irvine, Inst Memory Impairments & Neurol Disorders, Irvine, CA 92697 USA. RP Hogan, MF (reprint author), Vet Affairs Puget Sound Hlth Care Syst, Div Metab Endocrinol & Nutr, 1660 South Columbian Way 151, Seattle, WA 98108 USA. EM mfhogan@uw.edu OI Kahn, Steven/0000-0001-7307-9002 FU Department of Veterans Affairs Grant [BX001060]; Veterans Affairs Puget Sound Health Care System (Seattle, WA); National Institutes of Health [P30DK017047, 5T32HL007028, T32DK007247]; Swiss National Foundation Fellowship; Dick and Julia McAbee Endowed Fellowship FX This work was supported, in whole or in part, by Department of Veterans Affairs Grant BX001060; Veterans Affairs Puget Sound Health Care System (Seattle, WA) and National Institutes of Health Grants P30DK017047 (to the University of Washington Diabetes Research Center), Grant 5T32HL007028 (to M.F.H.), and T32DK007247 (to A.T.T.); Swiss National Foundation Fellowship (to D.T.M.); and Dick and Julia McAbee Endowed Fellowship (to D.T.M.). NR 31 TC 0 Z9 0 U1 3 U2 3 PU ENDOCRINE SOC PI WASHINGTON PA 2055 L ST NW, SUITE 600, WASHINGTON, DC 20036 USA SN 0013-7227 EI 1945-7170 J9 ENDOCRINOLOGY JI Endocrinology PD SEP PY 2016 VL 157 IS 9 BP 3462 EP 3468 DI 10.1210/en.2016-1410 PG 7 WC Endocrinology & Metabolism SC Endocrinology & Metabolism GA DX1NA UT WOS:000384132900022 PM 27404391 ER PT J AU Baliram, R Latif, R Morshed, SA Zaidi, M Davies, TF AF Baliram, R. Latif, R. Morshed, S. A. Zaidi, M. Davies, T. F. TI T-3 Regulates a Human Macrophage-Derived TSH-beta Splice Variant: Implications for Human Bone Biology SO ENDOCRINOLOGY LA English DT Article ID THYROID-STIMULATING HORMONE; MONOCYTIC LEUKEMIA-CELLS; THP-1 CELLS; POSTMENOPAUSAL WOMEN; DENDRITIC CELLS; DIFFERENTIATION; THYROTROPIN; ALPHA; GENE; OSTEOBLASTOGENESIS AB TSH and thyroid hormones (T-3 and T-4) are intimately involved in bone biology. We have previously reported the presence of a murine TSH-beta splice variant (TSH-beta v) expressed specifically in bone marrow-derived macrophages and that exerted an osteoprotective effect by inducing osteoblas-togenesis. To extend this observation and its relevance to human bone biology, we set out to identify and characterize a TSH-beta variant in human macrophages. Real-time PCR analyses using human TSH-beta-specific primers identified a 364-bp product in macrophages, bone marrow, and peripheral blood mononuclear cells that was sequence verified and was homologous to a human TSH-beta v previously reported. We then examined TSH-beta v regulation using the THP-1 human monocyte cell line matured into macrophages. After 4 days, 46.1% of the THP-1 cells expressed the macrophage markers CD-14 and macrophage colony-stimulating factor and exhibited typical morphological characteristics of macrophages. Real-time PCR analyses of these cells treated in a dose-dependent manner with T-3 showed a 14-fold induction of human TSH-beta v mRNA and variant protein. Furthermore, these human TSH-beta v-positive cells, induced by T-3 exposure, had categorized into both M1 and M2 macrophage phenotypes as evidenced by the expression of macrophage colony-stimulating factor for M1 and CCL-22 for M2. These data indicate that in hyperthyroidism, bone marrow resident macrophages have the potential to exert enhanced osteoprotective effects by oversecreting human TSH-beta v, which may exert its local osteoprotective role via osteoblast and osteoclast TSH receptors. C1 [Baliram, R.; Latif, R.; Morshed, S. A.; Davies, T. F.] Icahn Sch Med Mt Sinai, Mt Sinai Beth Israel Med Ctr, Thyroid Res Unit, New York, NY 10029 USA. [Baliram, R.; Latif, R.; Zaidi, M.; Davies, T. F.] Icahn Sch Med Mt Sinai, Mt Sinai Beth Israel Med Ctr, Mt Sinai Bone Program, New York, NY 10029 USA. [Baliram, R.] James J Peters Vet Affairs Med Ctr, Res Bldg Room 2F-28,130 West Kingsbridge Rd, Bronx, NY 10468 USA. RP Baliram, R (reprint author), James J Peters Vet Affairs Med Ctr, Res Bldg Room 2F-28,130 West Kingsbridge Rd, Bronx, NY 10468 USA. EM annie.baliram@mssm.edu FU National Institutes of Health [DK069713, DK052464]; Veterans Affairs Merit Review Program FX This work was supported in part by Grants DK069713 and DK052464 from the National Institutes of Health (to T.F.D.) and the Veterans Affairs Merit Review Program (to T.F.D.). NR 34 TC 2 Z9 2 U1 1 U2 3 PU ENDOCRINE SOC PI WASHINGTON PA 2055 L ST NW, SUITE 600, WASHINGTON, DC 20036 USA SN 0013-7227 EI 1945-7170 J9 ENDOCRINOLOGY JI Endocrinology PD SEP PY 2016 VL 157 IS 9 BP 3658 EP 3667 DI 10.1210/en.2015-1974 PG 10 WC Endocrinology & Metabolism SC Endocrinology & Metabolism GA DX1NA UT WOS:000384132900038 PM 27300765 ER PT J AU Pieters, HC Iwaki, T Vickrey, BG Mathern, GW Baca, CB AF Pieters, Huibrie C. Iwaki, Tomoko Vickrey, Barbara G. Mathern, Gary W. Baca, Christine B. TI "It was five years of hell": Parental experiences of navigating and processing the slow and arduous time to pediatric resective epilepsy surgery SO EPILEPSY & BEHAVIOR LA English DT Article DE Parent; Pediatric; Epilepsy surgery; Decision-making; Proxy report; Patient empowerment ID MEDICALLY REFRACTORY EPILEPSY; SHARED DECISION-MAKING; IMPROVED OUTCOMES; ONSET EPILEPSY; PEER SUPPORT; CHILDREN; NEUROLOGISTS; ATTITUDES; CARE; HEMISPHERECTOMY AB Objective: Children with medically refractory epilepsy stand to benefit from surgery and live a life free of seizures. However, a large proportion of potentially eligible children do not receive a timely referral for a surgical evaluation. We aimed to describe experiences during the arduous time before the referral and the parent-reported facilitators that helped them move forward through this slow time. Methods: Individual semi-structured interviews with 37 parents of children who had previously undergone epilepsy surgery at UCLA (2006-2011) were recorded, transcribed, and systematically analyzed by two independent coders using thematic analysis. Clinical data were extracted from medical records. Results: Parents, 41.3 years of age on average, were mostly Caucasian, English-speaking, mothers, married, and employed. The mean age at surgery for children was 8.2 years with a mean time from epilepsy onset to surgery of 5.4 years. Parental decision-making was facilitated when parents eventually received a presurgical referral and navigated to a multidisciplinary team that they trusted to care for their child with medically refractory epilepsy. Four themes described the experiences that parents used to feel a sense of moving forward. The first theme, processing, involved working through feelings and was mostly done alone. The second theme, navigating the complex unknowns of the health-care system, was more active and purposeful. Processing co-occurred with navigating in a fluid intersection, the third theme, which was evidenced by deliberate actions. The fourth theme, facilitators, explained helpful ways of processing and navigating; parents utilized these mechanisms to turn vulnerable times following the distress of their child's diagnosis into an experience of productivity. Significance: To limit parental distress and remediate the slow and arduous journey to multidisciplinary care at a comprehensive epilepsy center for a surgical evaluation, we suggest multi-pronged interventions to modify barriers associated with parents, providers, and health-care systems. Based on the facilitators that moved parents of our sample forward, we provide practical suggestions such as increased peer support, developing the role of patient navigators and communication strategies with parents before, during, and after referral to a comprehensive epilepsy center and presurgical evaluation. Published by Elsevier Inc. C1 [Pieters, Huibrie C.] Univ Calif Los Angeles, Sch Nursing, Los Angeles, CA 90024 USA. [Iwaki, Tomoko] NYU, Silver Sch Social Work, New York, NY USA. [Vickrey, Barbara G.] Icahn Sch Med Mt Sinai, Dept Neurol, New York, NY 10029 USA. [Mathern, Gary W.] Univ Calif Los Angeles, Dept Neurosurg, Los Angeles, CA USA. [Baca, Christine B.] Univ Calif Los Angeles, Dept Neurol, 710 Westwood Blvd,C-249, Los Angeles, CA 90024 USA. [Baca, Christine B.] VA Greater Los Angeles Hlth Care Syst, Dept Neurol, Los Angeles, CA USA. RP Baca, CB (reprint author), Univ Calif Los Angeles, Dept Neurol, 710 Westwood Blvd,C-249, Los Angeles, CA 90024 USA. EM cbower@mednet.ucla.edu FU Epilepsy Foundation grant [213971]; National Cancer Institute; UCLA Faculty Career Development Award for Assistant Professors [R21CA167218-02]; NIH [U54 N5081764, RO1 NS38992]; UniHealth Foundation; California Community Foundation; Veterans Administration Health Services Research and Development (VA HSRD) [IIR-12-337-3] FX This project was funded by an Epilepsy Foundation grant (PI Baca: 213971).; Dr. Pieters is supported by a grant from the National Cancer Institute and UCLA Faculty Career Development Award for Assistant Professors (R21CA167218-02).; Dr. Vickrey receives support from NIH U54 N5081764, UniHealth Foundation, and the California Community Foundation.; Dr. Mathern is the Davies/Crandall endowed chair for epilepsy research at UCLA and is co-editor-in-chief of Epilepsia and Epilepsia Open and is on the editorial board of Neurology. He receives funding from NIH RO1 NS38992.; Dr. Baca is a co-investigator on grant from the Veterans Administration Health Services Research and Development (VA HSR&D IIR-12-337-3) and is the PI for the AES/EF Junior Investigator Research Award. NR 43 TC 1 Z9 1 U1 3 U2 3 PU ACADEMIC PRESS INC ELSEVIER SCIENCE PI SAN DIEGO PA 525 B ST, STE 1900, SAN DIEGO, CA 92101-4495 USA SN 1525-5050 EI 1525-5069 J9 EPILEPSY BEHAV JI Epilepsy Behav. PD SEP PY 2016 VL 62 BP 276 EP 284 DI 10.1016/j.yebeh.2016.07.019 PG 9 WC Behavioral Sciences; Clinical Neurology; Psychiatry SC Behavioral Sciences; Neurosciences & Neurology; Psychiatry GA DX5AP UT WOS:000384392500047 PM 27521720 ER PT J AU Weintraub, D Kales, HC Marras, C AF Weintraub, Daniel Kales, Helen C. Marras, Connie TI The Danger of Not Treating Parkinson Disease Psychosis Reply SO JAMA NEUROLOGY LA English DT Letter ID MORTALITY C1 [Weintraub, Daniel] Philadelphia Vet Affairs Med Ctr, Parkinsons Dis Res Educ & Clin Ctr, Philadelphia, PA USA. [Weintraub, Daniel] Philadelphia Vet Affairs Med Ctr, Mental Illness Res Educ & Clin Ctr, Philadelphia, PA USA. [Weintraub, Daniel] Univ Penn, Perelman Sch Med, Dept Psychiat, Philadelphia, PA 19104 USA. [Weintraub, Daniel] Univ Penn, Dept Neurol, Perelman Sch Med, Philadelphia, PA 19104 USA. [Kales, Helen C.] Ctr Clin Management Res, Dept Vet Affairs Hlth Serv Res & Dev, Ann Arbor, MI USA. [Kales, Helen C.] Vet Affairs Ann Arbor Healthcare Syst, Geriatr Res Educ & Clin Ctr, Ann Arbor, MI USA. [Kales, Helen C.] Univ Michigan, Dept Psychiat, Ann Arbor, MI 48109 USA. [Marras, Connie] Univ Toronto, TorontoWestern Hosp, Edmond J Safra Program Parkinsons Dis, Morton & Gloria Shulman Movement Disorder Ctr, Toronto, ON, Canada. RP Weintraub, D (reprint author), Univ Penn, Perelman Sch Med, 3615 Chestnut St,Ste 330, Philadelphia, PA 19104 USA. EM daniel.weintraub@uphs.upenn.edu NR 4 TC 0 Z9 0 U1 0 U2 0 PU AMER MEDICAL ASSOC PI CHICAGO PA 330 N WABASH AVE, STE 39300, CHICAGO, IL 60611-5885 USA SN 2168-6149 EI 2168-6157 J9 JAMA NEUROL JI JAMA Neurol. PD SEP PY 2016 VL 73 IS 9 BP 1156 EP 1157 DI 10.1001/jamaneurol.2016.2274 PG 3 WC Clinical Neurology SC Neurosciences & Neurology GA DX2MV UT WOS:000384205200026 PM 27400239 ER PT J AU Yule, S Sacks, GD Maggard-Gibbons, M AF Yule, Steven Sacks, Greg D. Maggard-Gibbons, Melinda TI Innovative Approaches for Modifying Surgical Culture SO JAMA SURGERY LA English DT Editorial Material ID NONTECHNICAL SKILLS; IMPLEMENTATION; INFECTIONS; MORTALITY; PROGRAM C1 [Yule, Steven] Brigham & Womens Hosp, STRATUS Ctr Med Simulat, 75 Francis St, Boston, MA 02115 USA. [Yule, Steven] Harvard Med Sch, Boston, MA USA. [Sacks, Greg D.; Maggard-Gibbons, Melinda] Univ Calif Los Angeles, David Geffen Sch Med, Dept Surg, 10833 LeConte Ave,CHS 72-215, Los Angeles, CA 90095 USA. [Sacks, Greg D.; Maggard-Gibbons, Melinda] VA Greater Los Angeles Healthcare Syst, Los Angeles, CA USA. RP Maggard-Gibbons, M (reprint author), Univ Calif Los Angeles, David Geffen Sch Med, Dept Surg, 10833 LeConte Ave,CHS 72-215, Los Angeles, CA 90095 USA. EM mmaggard@mednet.ucla.edu NR 9 TC 1 Z9 1 U1 2 U2 2 PU AMER MEDICAL ASSOC PI CHICAGO PA 330 N WABASH AVE, STE 39300, CHICAGO, IL 60611-5885 USA SN 2168-6254 EI 2168-6262 J9 JAMA SURG JI JAMA Surg. PD SEP PY 2016 VL 151 IS 9 BP 791 EP 792 DI 10.1001/jamasurg.2016.0425 PG 2 WC Surgery SC Surgery GA DX1IO UT WOS:000384120400005 PM 27168456 ER PT J AU Servetas, SL Carpenter, BM Haley, KP Gilbreath, JJ Gaddy, JA Merrell, DS AF Servetas, Stephanie L. Carpenter, Beth M. Haley, Kathryn P. Gilbreath, Jeremy J. Gaddy, Jennifer A. Merrell, D. Scott TI Characterization of Key Helicobacter pylori Regulators Identifies a Role for ArsRS in Biofilm Formation SO JOURNAL OF BACTERIOLOGY LA English DT Article ID FERRIC UPTAKE REGULATOR; HUMAN GASTRIC-MUCOSA; HP0165-HP0166 2-COMPONENT SYSTEM; COMPLETE GENOME SEQUENCE; ABIOTIC SURFACES; MOLECULAR CHARACTERIZATION; MEMBRANE-VESICLES; ACID ACCLIMATION; GENE-EXPRESSION; FUR AB Helicobacter pylori must be able to rapidly respond to fluctuating conditions within the stomach. Despite this need for constant adaptation, H. pylori encodes few regulatory proteins. Of the identified regulators, the ferric uptake regulator (Fur), the nickel response regulator (NikR), and the two-component acid response system (ArsRS) are each paramount to the success of this pathogen. While numerous studies have individually examined these regulatory proteins, little is known about their combined effect. Therefore, we constructed a series of isogenic mutant strains that contained all possible single, double, and triple regulatory mutations in Fur, NikR, and ArsS. A growth curve analysis revealed minor variation in growth kinetics across the strains; these were most pronounced in the triple mutant and in strains lacking ArsS. Visual analysis showed that strains lacking ArsS formed large aggregates and a biofilm-like matrix at the air-liquid interface. Biofilm quantification using crystal violet assays and visualization via scanning electron microscopy (SEM) showed that all strains lacking ArsS or containing a nonphosphorylatable form of ArsR (ArsR-D52N mutant) formed significantly more biofilm than the wild-type strain. Molecular characterization of biofilm formation showed that strains containing mutations in the ArsRS pathway displayed increased levels of cell aggregation and adherence, both of which are key to biofilm development. Furthermore, SEM analysis revealed prevalent coccoid cells and extracellular matrix formation in the ArsR-D52N, Delta nikR Delta arsS, and Delta fur Delta nikR Delta arsS mutant strains, suggesting that these strains may have an exacerbated stress response that further contributes to biofilm formation. Thus, H. pylori ArsRS has a previously unrecognized role in biofilm formation. C1 [Servetas, Stephanie L.; Carpenter, Beth M.; Gilbreath, Jeremy J.; Merrell, D. Scott] Uniformed Serv Univ Hlth Sci, Dept Microbiol & Immunol, Bethesda, MD 20814 USA. [Haley, Kathryn P.; Gaddy, Jennifer A.] Vanderbilt Univ, Dept Med, Nashville, TN USA. [Gaddy, Jennifer A.] US Dept Vet Affairs, Tennessee Valley Hlth Care Syst, Nashville, TN USA. [Carpenter, Beth M.] Univ Maryland, Univ Coll, Nat Sci Biotechnol Environm Management & Lab Mana, Adelphi, MD USA. [Gilbreath, Jeremy J.] BioFire Diagnost, Salt Lake City, UT USA. RP Merrell, DS (reprint author), Uniformed Serv Univ Hlth Sci, Dept Microbiol & Immunol, Bethesda, MD 20814 USA. EM douglas.merrell@usuhs.edu FU HHS \ National Institutes of Health (NIH) [T32-AI095202, P30DK058404]; U.S. Department of Veterans Affairs (VA) [1IK2BX001701]; U.S. Department of Defense (DOD); Henry M. Jackson Foundation (HJF) FX This work, including the efforts of D. Scott Merrell, was funded by HHS vertical bar National Institutes of Health (NIH). This work, including the efforts of Kathryn P. Haley and Jennifer A. Gaddy, was funded by HHS vertical bar National Institutes of Health (NIH) (T32-AI095202 and P30DK058404). This work, including the efforts of Kathryn P. Haley and Jennifer A. Gaddy, was funded by U.S. Department of Veterans Affairs (VA) (1IK2BX001701). This work, including the efforts of D. Scott Merrell, was funded by U.S. Department of Defense (DOD). This work, including the efforts of Stephanie L. Servetas, was funded by Henry M. Jackson Foundation (HJF). NR 72 TC 2 Z9 2 U1 4 U2 4 PU AMER SOC MICROBIOLOGY PI WASHINGTON PA 1752 N ST NW, WASHINGTON, DC 20036-2904 USA SN 0021-9193 EI 1098-5530 J9 J BACTERIOL JI J. Bacteriol. PD SEP PY 2016 VL 198 IS 18 BP 2536 EP 2548 DI 10.1128/JB.00324-16 PG 13 WC Microbiology SC Microbiology GA DX4IB UT WOS:000384343300018 PM 27432830 ER PT J AU Reeves, GR Gupta, S Forman, DE AF Reeves, Gordon R. Gupta, Shuchita Forman, Daniel E. TI Evolving Role of Exercise Testing in Contemporary Cardiac Rehabilitation SO JOURNAL OF CARDIOPULMONARY REHABILITATION AND PREVENTION LA English DT Review DE cardiac rehabilitation; exercise testing; functional assessment ID 6-MINUTE WALK TEST; AMERICAN-HEART-ASSOCIATION; RANDOMIZED CONTROLLED-TRIAL; CORONARY-ARTERY-DISEASE; PEAK OXYGEN-UPTAKE; OLDER-ADULTS; ELDERLY-PATIENTS; SCIENTIFIC STATEMENT; CARDIOVASCULAR PREVENTION; THERAPEUTIC INTERVENTIONS AB Symptom-limited (maximal) exercise testing before cardiac rehabilitation (CR) was once an unambiguous standard of care. In particular, it served as an important screen for residual ischemia and instability before initiating a progressive exercise training regimen. However, improved revascularization and therapy for coronary heart disease has led many clinicians to downplay this application of exercise testing, especially because such testing is also a potential encumbrance to CR enrollment (delaying ease and efficiency of enrollment after procedures and hospitalizations) and patient burden (eg, added costs, logistic hassle, and anxiety). Nonetheless, exercise testing has enduring value for CR, especially because it reveals dynamic physiological responses as well as ischemia, arrhythmias, and symptoms pertinent to exercise prescription and training and to overall stability and prognosis. Moreover, as indications for CR have expanded, the value of exercise testing and functional assessment is more relevant than ever in the growing population of eligible patients, including those with heart failure, valvular heart disease, and posttransplantation, especially as current patients also tend to be more clinically complex, with advanced ages, multimorbidity, frailty, and obesity. This review focuses on the appropriate use of exercise testing in the CR setting. Graded exercise tests, cardiopulmonary exercise tests, submaximal walking tests, and other functional assessments (strength, frailty) for CR are discussed. C1 [Reeves, Gordon R.; Gupta, Shuchita] Thomas Jefferson Univ, Sidney Kimmel Med Coll, Med, Philadelphia, PA 19107 USA. [Forman, Daniel E.] Univ Pittsburgh, Med Ctr, Geriatr Cardiol Sect, Div Cardiol, Pittsburgh, PA USA. [Forman, Daniel E.] Univ Pittsburgh, Med Ctr, Geriatr Cardiol Sect, Div Geriatr, Pittsburgh, PA USA. [Forman, Daniel E.] Univ Pittsburgh, VA Pittsburgh Healthcare Syst, Geriatr Res Educ & Clin Ctr, Pittsburgh, PA USA. [Forman, Daniel E.] Univ Pittsburgh, Dept Med, Pittsburgh, PA USA. RP Forman, DE (reprint author), Geriatr Cardiol Sect, 3471 Fifth Ave,Ste 500, Pittsburgh, PA 15213 USA. EM formand@pitt.edu FU NIA [P30 AG024827, R01AG045551]; VA RRD [F0834-R] FX Dr Forman is supported in part from NIA grant P30 AG024827 and VA RR&D F0834-R. Dr Reeves is supported in part from NIA grant R01AG045551. NR 72 TC 3 Z9 4 U1 8 U2 8 PU LIPPINCOTT WILLIAMS & WILKINS PI PHILADELPHIA PA TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA SN 1932-7501 EI 1932-751X J9 J CARDIOPULM REHABIL JI J. Cardiopulm. Rehabil. Prev. PD SEP-OCT PY 2016 VL 36 IS 5 BP 309 EP 319 DI 10.1097/HCR.0000000000000176 PG 11 WC Cardiac & Cardiovascular Systems SC Cardiovascular System & Cardiology GA DX1HN UT WOS:000384117600001 PM 27120040 ER PT J AU Myrga, JM Failla, MD Ricker, JH Dixon, CE Conley, YP Arenth, PM Wagner, AK AF Myrga, John M. Failla, Michelle D. Ricker, Joseph H. Dixon, C. Edward Conley, Yvette P. Arenth, Patricia M. Wagner, Amy K. TI A Dopamine Pathway Gene Risk Score for Cognitive Recovery Following Traumatic Brain Injury: Methodological Considerations, Preliminary Findings, and Interactions With Sex SO JOURNAL OF HEAD TRAUMA REHABILITATION LA English DT Article DE cognition; dopamine; genetics; Rehabilomics; traumatic brain injury ID CATECHOL-O-METHYLTRANSFERASE; COMT VAL(158)MET POLYMORPHISM; PREFRONTAL CORTEX; MOLECULAR HETEROSIS; TRANSPORTER EXPRESSION; GENDER-DIFFERENCES; HEALTHY-ADULTS; WORKING-MEMORY; FEMALE RATS; RECEPTOR AB Objectives: With evidence of sexual dimorphism involving the dopamine (DA)-pathway, and the importance of DA pathways in traumatic brain injury (TBI) recovery, we hypothesized that sex x DA-gene interactions may influence cognition post-TBI. Participants: Adult survivors of severe TBI (n = 193) consecutively recruited from a level 1 trauma center. Design: Risk allele assignments were made for multiple DA pathway genes using a sex-specific stratified approach. Genetic risk alleles, and their impacts on cognition, were assessed at 6 and 12 months postinjury using unweighted, semiweighted, and weighted gene risk score (GRS) approaches. Main Measures: A cognitive composite score generated from 8 standardized neuropsychological tests targeting multiple cognitive domains. Results: A significant sex x gene interaction was observed at 6 and 12 months for ANKK1 rs1800497 (6M: P =.002, 12M: P =.001) and COMT rs4680 (6M: P =.048; 12M: P =.004); DRD2 rs6279 (P =.001) and VMAT rs363226 (P =.043) genotypes were independently associated with cognition at 6 months, with trends for a sex x gene interaction at 12 months. All GRS methods were significant predictors of cognitive performance in multivariable models. Weighted GRS multivariate models captured the greatest variance in cognition: R-2 = 0.344 (6 months); R-2 = 0.441 (12 months), significantly increasing the variance captured from the base prediction models. Conclusions: A sex-specific DA-pathway GRS may be a valuable tool when predicting cognitive recovery post-TBI. Future work should validate these findings and explore how DA-pathway genetics may guide therapeutic intervention. C1 [Myrga, John M.; Failla, Michelle D.; Dixon, C. Edward; Arenth, Patricia M.; Wagner, Amy K.] Univ Pittsburgh, Sch Med, Dept Phys Med & Rehabil, Pittsburgh, PA USA. [Failla, Michelle D.; Dixon, C. Edward; Wagner, Amy K.] Univ Pittsburgh, Sch Med, Ctr Neurosci, Pittsburgh, PA USA. [Ricker, Joseph H.] NYU, Sch Med, Dept Rehabil Med, New York, NY USA. [Dixon, C. Edward] Vet Affairs Pittsburgh Hlth Care Syst, Educ & Clin Ctr, Geriatr Res, Pittsburgh, PA USA. [Conley, Yvette P.] Univ Pittsburgh, Sch Publ Hlth, Dept Human Genet, Pittsburgh, PA 15260 USA. [Conley, Yvette P.] Univ Pittsburgh, Sch Nursing, Hlth Promot & Dev, Pittsburgh, PA 15261 USA. [Dixon, C. Edward; Conley, Yvette P.; Wagner, Amy K.] Univ Pittsburgh, Safar Ctr Resuscitat Res, Pittsburgh, PA USA. RP Wagner, AK (reprint author), Univ Pittsburgh, Dept Phys Med & Rehabil, 3471 Fifth Ave,Ste 202, Pittsburgh, PA 15213 USA. EM wagnerak@upmc.edu FU NIDILRR [H133A120087]; NIH [R01 HD048162, R01 NR013342]; DOD [W81XWH-071-0701] FX This research was supported by the following: NIDILRR: H133A120087; NIH: R01 HD048162; DOD: W81XWH-071-0701; NIH: R01 NR013342. NR 102 TC 2 Z9 2 U1 7 U2 7 PU LIPPINCOTT WILLIAMS & WILKINS PI PHILADELPHIA PA TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA SN 0885-9701 EI 1550-509X J9 J HEAD TRAUMA REHAB JI J. Head Trauma Rehabil. PD SEP-OCT PY 2016 VL 31 IS 5 BP E15 EP E29 DI 10.1097/HTR.0000000000000199 PG 15 WC Clinical Neurology; Rehabilitation SC Neurosciences & Neurology; Rehabilitation GA DX2ZY UT WOS:000384243600003 PM 26580694 ER PT J AU Leung, AM AF Leung, Angela M. TI Thyroid Emergencies SO JOURNAL OF INFUSION NURSING LA English DT Article DE hypothyroidism; hyperthyroidism; ICU; myxedema coma; thyroid emergencies; thyroid storm ID CLINICAL-FEATURES; EARLY-PREGNANCY; HORMONE ACTION; STORM; HYPOTHYROIDISM; THYROTOXICOSIS; ASSOCIATION; GUIDELINES; THYROXINE; CHILDREN AB Myxedema coma and thyroid storm are thyroid emergencies associated with increased mortality. Prompt recognition of these states-which represent the severe, life-threatening conditions of extremely reduced or elevated circulating thyroid hormone concentrations, respectively-is necessary to initiate treatment. Management of myxedema coma and thyroid storm requires both medical and supportive therapies and should be treated in an intensive care unit setting. C1 [Leung, Angela M.] Univ Calif Los Angeles, David Geffen Sch Med, Div Endocrinol, Med, Los Angeles, CA 90095 USA. [Leung, Angela M.] VA Greater Los Angeles Healthcare Syst, Los Angeles, CA USA. RP Leung, AM (reprint author), VA Greater Los Angeles Healthcare Syst, Div Endocrinol 111D, 11301 Wilshire Blvd, Los Angeles, CA 90073 USA. EM AMLeung@mednet.ucla.edu NR 30 TC 0 Z9 0 U1 0 U2 0 PU LIPPINCOTT WILLIAMS & WILKINS PI PHILADELPHIA PA TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA SN 1533-1458 EI 1539-0667 J9 J INFUS MURS JI J. Infus.Nurs. PD SEP-OCT PY 2016 VL 39 IS 5 BP 281 EP 286 DI 10.1097/NAN.0000000000000186 PG 6 WC Nursing SC Nursing GA DX1GI UT WOS:000384114000004 PM 27598067 ER PT J AU Villasana, LE Peters, A Westbrook, GL Schnell, E AF Villasana, Laura E. Peters, Austin Westbrook, Gary L. Schnell, Eric TI Sex Differences in Post-Traumatic Hippocampal Neurogenesis SO JOURNAL OF WOMENS HEALTH LA English DT Meeting Abstract C1 [Villasana, Laura E.; Peters, Austin; Schnell, Eric] Oregon Hlth & Sci Univ, Dept Anesthesiol & Perioperat Med, Portland, OR 97201 USA. [Peters, Austin] Oregon Hlth & Sci Univ, Sch Med, Portland, OR 97201 USA. [Westbrook, Gary L.] Oregon Hlth & Sci Univ, Vollum Inst, Portland, OR 97201 USA. [Schnell, Eric] Portland VA Med Ctr, Portland, OR USA. NR 0 TC 0 Z9 0 U1 0 U2 0 PU MARY ANN LIEBERT, INC PI NEW ROCHELLE PA 140 HUGUENOT STREET, 3RD FL, NEW ROCHELLE, NY 10801 USA SN 1540-9996 EI 1931-843X J9 J WOMENS HEALTH JI J. Womens Health PD SEP PY 2016 VL 25 IS 9 MA P-49 BP 974 EP 974 PG 1 WC Public, Environmental & Occupational Health; Medicine, General & Internal; Obstetrics & Gynecology; Women's Studies SC Public, Environmental & Occupational Health; General & Internal Medicine; Obstetrics & Gynecology; Women's Studies GA DW9YP UT WOS:000384019000066 ER PT J AU Collins, CDE Ivry, B Bowen, JD Cheng, EM Dobson, R Goodin, DS Lechner-Scott, J Kappos, L Galea, I AF Collins, Christian D. E. Ivry, Ben Bowen, James D. Cheng, Eric M. Dobson, Ruth Goodin, Douglas S. Lechner-Scott, Jeannette Kappos, Ludwig Galea, Ian TI A comparative analysis of Patient-Reported Expanded Disability Status Scale tools SO MULTIPLE SCLEROSIS JOURNAL LA English DT Article DE Expanded disability status scale; Kurtzke scale; Neurostatus; multiple sclerosis; Patient-reported Expanded Disability Status Scale; patient reported; self administered ID RATING NEUROLOGIC IMPAIRMENT; MULTIPLE-SCLEROSIS; FUNCTIONAL-SYSTEMS; SELF-ASSESSMENT; AGREEMENT; EDSS; INTERRATER; VALIDATION; SCORES AB Background: Patient-Reported Expanded Disability Status Scale (PREDSS) tools are an attractive alternative to the Expanded Disability Status Scale (EDSS) during long term or geographically challenging studies, or in pressured clinical service environments. Objectives: Because the studies reporting these tools have used different metrics to compare the PREDSS and EDSS, we undertook an individual patient data level analysis of all available tools. Methods: Spearman's rho and the Bland-Altman method were used to assess correlation and agreement respectively. Results: A systematic search for validated PREDSS tools covering the full EDSS range identified eight such tools. Individual patient data were available for five PREDSS tools. Excellent correlation was observed between EDSS and PREDSS with all tools. A higher level of agreement was observed with increasing levels of disability. In all tools, the 95% limits of agreement were greater than the minimum EDSS difference considered to be clinically significant. However, the intra-class coefficient was greater than that reported for EDSS raters of mixed seniority. The visual functional system was identified as the most significant predictor of the PREDSS-EDSS difference. Conclusion: This analysis will (1) enable researchers and service providers to make an informed choice of PREDSS tool, depending on their individual requirements, and (2) facilitate improvement of current PREDSS tools. C1 [Collins, Christian D. E.; Ivry, Ben; Galea, Ian] Univ Southampton, Southampton Gen Hosp, Clin Neurosci Clin & Expt Sci, Fac Med, Mailpoint 806,Level D, Southampton SO16 6YD, Hants, England. [Bowen, James D.] Swedish Neurosci Inst, Multiple Sclerosis Ctr, Seattle, WA USA. [Cheng, Eric M.] Univ Calif Los Angeles, David Geffen Sch Med, Dept Neurol, VA Greater Los Angeles Healthcare Syst, Los Angeles, CA 90095 USA. [Dobson, Ruth] Queen Mary Univ London, Blizard Inst, Barts & London Sch Med & Dent, London, England. [Goodin, Douglas S.] Univ Calif San Francisco, Dept Neurol, San Francisco, CA USA. [Lechner-Scott, Jeannette] Univ Newcastle, Hunter Med Res Inst, Callaghan, NSW 2308, Australia. [Lechner-Scott, Jeannette] John Hunter Hosp, Dept Neurol, Newcastle, NSW, Australia. [Kappos, Ludwig] Univ Basel Hosp, Dept Med, Basel, Switzerland. [Kappos, Ludwig] Univ Basel Hosp, Dept Clin Res, Basel, Switzerland. [Kappos, Ludwig] Univ Basel Hosp, Dept Biomed, Basel, Switzerland. [Kappos, Ludwig] Univ Basel Hosp, Dept Biomed Engn, Basel, Switzerland. [Galea, Ian] Univ Hosp Southampton NHS Fdn Trust, Wessex Neurosci Ctr, Southampton, Hants, England. RP Galea, I (reprint author), Univ Southampton, Southampton Gen Hosp, Clin Neurosci Clin & Expt Sci, Fac Med, Mailpoint 806,Level D, Southampton SO16 6YD, Hants, England. EM I.Galea@soton.ac.uk RI Galea, Ian/B-7997-2011 OI Galea, Ian/0000-0002-1268-5102 FU University of Southampton; National Institute of Health Research (NIHR) FX This study was funded by the University of Southampton and National Institute of Health Research (NIHR). NR 27 TC 0 Z9 0 U1 0 U2 0 PU SAGE PUBLICATIONS LTD PI LONDON PA 1 OLIVERS YARD, 55 CITY ROAD, LONDON EC1Y 1SP, ENGLAND SN 1352-4585 EI 1477-0970 J9 MULT SCLER J JI Mult. Scler. J. PD SEP PY 2016 VL 22 IS 10 BP 1349 EP 1358 DI 10.1177/1352458515616205 PG 10 WC Clinical Neurology; Neurosciences SC Neurosciences & Neurology GA DV5KP UT WOS:000382966300014 PM 26564998 ER PT J AU Gilmartin, HM Sousa, KH Battaglia, C AF Gilmartin, Heather M. Sousa, Karen H. Battaglia, Catherine TI Capturing the Central Line Bundle Infection Prevention Interventions: Comparison of Reflective and Composite Modeling Methods SO NURSING RESEARCH LA English DT Article DE critical care; epidemiology; factor analysis; iatrogenic infection; statistical models ID BLOOD-STREAM INFECTIONS; FORMATIVE MEASUREMENT; ORGANIZATIONAL RESEARCH; HEALTH; INDICATORS; REDUCTION; COHORT AB Background The central line (CL) bundle interventions are important for preventing central line-associated bloodstream infections (CLABSIs), but a modeling method for testing the CL bundle interventions within a health systems framework is lacking. Objectives Guided by the Quality Health Outcomes Model (QHOM), this study tested the CL bundle interventions in reflective and composite, latent, variable measurement models to assess the impact of the modeling approaches on an investigation of the relationships between adherence to the CL bundle interventions, organizational context, and CLABSIs. Methods A secondary data analysis study was conducted using data from 614 U.S. hospitals that participated in the Prevention of Nosocomial Infection and Cost-Effectiveness Refined study. The sample was randomly split into exploration and validation subsets. Results The two CL bundle modeling approaches resulted in adequate fitting structural models (RMSEA = .04; CFI = .94) and supported similar relationships within the QHOM. Adherence to the CL bundle had a direct effect on organizational context (reflective = .23; composite = .20; p = .01) and CLABSIs (reflective = -.28; composite = -.25; p = .01). The relationship between context and CLABSIs was not significant. Both modeling methods resulted in partial support of the QHOM. Discussion There were little statistical, but large, conceptual differences between the reflective and composite modeling approaches. The empirical impact of the modeling approaches was inconclusive, for both models resulted in a good fit to the data. Lessons learned are presented. The comparison of modeling approaches is recommended when initially modeling variables that have never been modeled or with directional ambiguity to increase transparency and bring confidence to study findings. C1 [Gilmartin, Heather M.; Battaglia, Catherine] Denver VA Med Ctr, Denver Seattle Ctr Innovat, Dept Vet Affairs, 1055 Clermont St, Denver, CO 80220 USA. [Sousa, Karen H.] Univ Colorado, Coll Nursing, Res & Extramural Affairs, Anschutz Med Campus, Aurora, CO USA. RP Gilmartin, HM (reprint author), Denver VA Med Ctr, Denver Seattle Ctr Innovat, Dept Vet Affairs, 1055 Clermont St, Denver, CO 80220 USA. EM Heather.gilmartin@va.gov FU National Institute of Nursing Research [R01NR010107] FX The authors acknowledge that funding for the PNICER study was provided by the National Institute of Nursing Research (R01NR010107). NR 43 TC 0 Z9 0 U1 2 U2 2 PU LIPPINCOTT WILLIAMS & WILKINS PI PHILADELPHIA PA TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA SN 0029-6562 EI 1538-9847 J9 NURS RES JI Nurs. Res. PD SEP-OCT PY 2016 VL 65 IS 5 BP 397 EP 407 DI 10.1097/NNR.0000000000000168 PG 11 WC Nursing SC Nursing GA DX4BX UT WOS:000384325100008 PM 27579507 ER PT J AU Yaffe, K Nasrallah, I Hoang, TD Lauderdale, DS Knutson, KL Carnethon, MR Launer, LJ Lewis, CE Sidney, S AF Yaffe, Kristine Nasrallah, Ilya Hoang, Tina D. Lauderdale, Diane S. Knutson, Kristen L. Carnethon, Mercedes R. Launer, Lenore J. Lewis, Cora E. Sidney, Stephen TI Sleep Duration and White Matter Quality in Middle-Aged Adults SO SLEEP LA English DT Article DE sleep duration; white matter integrity; white matter hyperintensities; midlife ID COGNITIVE DECLINE; OLDER-ADULTS; MEMORY IMPAIRMENT; TEST-PERFORMANCE; HEALTH; WOMEN; RISK; METAANALYSIS; INTEGRITY; DISEASE AB Study Objectives: Sleep duration has been associated with risk of dementia and stroke, but few studies have investigated the relationship between sleep duration and brain MRI measures, particularly in middle age. Methods: In a prospective cohort of 613 black and white adults (mean age = 45.4 years) enrolled in the Coronary Artery Risk Development in Young Adults (CARDIA) study, participants reported typical sleep duration, dichotomized into moderate sleep duration (> 6 to <= 8 h) and short sleep duration (<= 6 h) at baseline (2005-2006). Five years later, we obtained brain MRI markers of white matter including fractional anisotropy, mean diffusivity, and white matter hyperintensities. Results: Compared to moderate sleepers, short sleepers had an elevated ratio of white matter hyperintensities to normal tissue in the parietal region (OR = 2.31, 95% CI: 1.47, 3.61) adjusted for age, race/sex, education, hypertension, stroke/TIA, depression, smoking status, and physical activity. White matter diffusivity was also higher, approximately a 0.2 standard deviation difference, in frontal, parietal, and temporal white matter regions, among those reporting shorter sleep duration in (P < 0.05 for all). Conclusions: Short sleep duration was associated with worse markers of white matter integrity in midlife. These mid-life differences in white matter may underlie the link between poor sleep and risk of dementia and stroke. C1 [Yaffe, Kristine] Univ Calif San Francisco, Dept Psychiat, San Francisco, CA USA. [Yaffe, Kristine] Univ Calif San Francisco, Dept Neurol, San Francisco, CA USA. [Yaffe, Kristine] Univ Calif San Francisco, Dept Epidemiol, San Francisco, CA 94143 USA. [Yaffe, Kristine] Univ Calif San Francisco, Dept Biostat, San Francisco, CA 94143 USA. [Yaffe, Kristine] San Francisco VA Med Ctr, San Francisco, CA USA. [Nasrallah, Ilya] Hosp Univ Penn, Dept Radiol, 3400 Spruce St, Philadelphia, PA 19104 USA. [Hoang, Tina D.] Northern Calif Inst Res & Educ, San Francisco, CA USA. [Lauderdale, Diane S.] Univ Chicago, Dept Publ Hlth Sci, Chicago, IL 60637 USA. [Knutson, Kristen L.] Univ Chicago, Dept Med, 5841 S Maryland Ave, Chicago, IL 60637 USA. [Carnethon, Mercedes R.] Northwestern Univ, Dept Prevent Med, Chicago, IL 60611 USA. [Launer, Lenore J.] NIA, Intramural Res Program, Bethesda, MD 20892 USA. [Lewis, Cora E.] Univ Alabama Birmingham, Dept Med, Birmingham, AL 35294 USA. [Sidney, Stephen] Kaiser Permanente Northern Calif, Div Res, Oakland, CA USA. RP Yaffe, K (reprint author), Univ Calif San Francisco, Box 181,4150 Clement St, San Francisco, CA 94121 USA. EM kristine.yaffe@ucsf.edu FU National Heart, Lung, and Blood Institute (NHLBI); University of Alabama at Birmingham [HHSN268201300025C, HHSN268201300026C]; Northwestern University [HHSN268201300027C]; University of Minnesota [HHSN268201300028C]; Kaiser Foundation Research Institute [HHSN268201300029C]; Johns Hopkins University School of Medicine [HHSN268200900041C]; Intramural Research Program of the National Institute on Aging (NIA); NIA [AG0005, K24 AG031155]; NHLBI [HHSN268201300025C, HHSN268201300026C, HHSN268201300027C, HHSN268201300029C, AG0005, HL122658] FX This was not an industry supported study. The Coronary Artery Risk Development in Young Adults Study (CARDIA) is conducted and supported by the National Heart, Lung, and Blood Institute (NHLBI) in collaboration with the University of Alabama at Birmingham (HHSN268201300025C & HHSN268201300026C), Northwestern University (HHSN268201300027C), University of Minnesota (HHSN268201300028C), Kaiser Foundation Research Institute (HHSN268201300029C), and Johns Hopkins University School of Medicine (HHSN268200900041C). CARDIA is also partially supported by the Intramural Research Program of the National Institute on Aging (NIA) and an intra-agency agreement between NIA and NHLBI (AG0005). The CARDIA Cognitive Function Ancillary Study is supported by NHLBI HL122658. Dr. Yaffe is also supported by NIA K24 AG031155. This manuscript has been reviewed by CARDIA for scientific content. Drs. Yaffe, Carnethon, Lewis, and Sidney report grant support for the CARDIA study NHLBI HL122658, HHSN268201300027C, HHSN268201300025C & HHSN268201300026C, HHSN268201300029C. The other authors have indicated no financial conflicts of interest. NR 47 TC 0 Z9 0 U1 2 U2 5 PU AMER ACAD SLEEP MEDICINE PI WESTCHESTER PA ONE WESTBROOK CORPORATE CTR, STE 920, WESTCHESTER, IL 60154 USA SN 0161-8105 EI 1550-9109 J9 SLEEP JI Sleep PD SEP 1 PY 2016 VL 39 IS 9 BP 1743 EP 1747 DI 10.5665/sleep.6104 PG 5 WC Clinical Neurology; Neurosciences SC Neurosciences & Neurology GA DX4EG UT WOS:000384333400014 PM 27397561 ER PT J AU Gilmore, AK Brignone, E Painter, JM Lehavot, K Fargo, J Suo, Y Simpson, T Carter, ME Blais, RK Gundlapalli, AV AF Gilmore, Amanda K. Brignone, Emily Painter, Janelle M. Lehavot, Keren Fargo, Jamison Suo, Ying Simpson, Tracy Carter, Marjorie E. Blais, Rebecca K. Gundlapalli, Adi V. TI Military Sexual Trauma and Co-occurring Posttraumatic Stress Disorder, Depressive Disorders, and Substance Use Disorders among Returning Afghanistan and Iraq Veterans SO WOMENS HEALTH ISSUES LA English DT Article ID MENTAL-HEALTH DIAGNOSES; RANDOMIZED CONTROLLED-TRIAL; WOMEN VETERANS; GENDER-DIFFERENCES; RISK-FACTORS; ALCOHOL MISUSE; CARE; FEMALE; PTSD; PREFERENCES AB Purpose: Posttraumatic stress disorder (PTSD), depressive disorders (DD), and substance use disorders (SUD) are prevalent among veterans. A positive military sexual trauma (MST) screen is associated with higher likelihood of each of these disorders. The current study examined the associations between MST, gender, and co-occurring PTSD, DD, and SUD among veterans receiving services at the Department of Veterans Affairs to inform assessment and treatment. We were specifically interested in the interactions between MST and gender on co-occurring disorders. Methods: The sample included 494,822 Department of Veterans Affairs service-seeking veterans (12.5% women) deployed to Iraq and Afghanistan who recently separated from the military and were screened for MST between 2004 and 2013. Main Findings: Veterans with positive MST screens had higher odds than those with negative screens of individual and co-occurring PTSD, DD, and SUD. The association between positive MST screens and diagnostic outcomes, including PTSD, was stronger for women than for men, and the association between positive MST screens and some diagnostic outcomes, including DD, was stronger for men than for women. Conclusions: These results highlight the importance of assessing for and recognizing the potential MST and gender interactions in the clinical context among veterans with co-occurring PTSD, DD, and/or SUD. (C) 2016 Jacobs Institute of Women's Health. Published by Elsevier Inc. C1 [Gilmore, Amanda K.] Med Univ South Carolina, Dept Psychiat, Natl Crime Victims Res & Treatment Ctr, Charleston, SC USA. [Gilmore, Amanda K.; Painter, Janelle M.; Lehavot, Keren; Simpson, Tracy] VA Puget Sound Hlth Care Syst, Seattle Div, Seattle, WA USA. [Brignone, Emily; Fargo, Jamison; Blais, Rebecca K.] Utah State Univ, Dept Psychol, Logan, UT 84322 USA. [Brignone, Emily; Fargo, Jamison; Suo, Ying; Carter, Marjorie E.; Gundlapalli, Adi V.] VA Salt Lake City Hlth Care Syst, Salt Lake City, UT USA. [Suo, Ying; Gundlapalli, Adi V.] Univ Utah, Dept Internal Med, Salt Lake City, UT 84112 USA. RP Gilmore, AK (reprint author), Natl Crime Victims & Treatment Ctr, Dept Psychiat, 67 President St,MSC 861, Charleston, SC 29425 USA. EM gilmoram@musc.edu FU U.S. Department of Veterans Affairs, Veterans Health Administration, Office of Research and Development, Health Services Research and Development Projects [HIR 10-002, IIR 12-084]; Career Development Award from CSRD [IK2 CX000867]; NIMH [T32] FX Funding for this project was provided by grants from the U.S. Department of Veterans Affairs, Veterans Health Administration, Office of Research and Development, Health Services Research and Development Projects # HIR 10-002 and # IIR 12-084 (PI: AVG). Resources and administrative support were provided by the VA Salt Lake City Health Care System (IDEAS Center). Dr. Lehavot was supported by a Career Development Award from CSR&D (IK2 CX000867). Dr. Gilmore was supported by an NIMH-funded T32 (PIs: Kilpatrick & Danielson). NR 41 TC 0 Z9 0 U1 1 U2 1 PU ELSEVIER SCIENCE INC PI NEW YORK PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA SN 1049-3867 EI 1878-4321 J9 WOMEN HEALTH ISS JI Womens Health Iss. PD SEP-OCT PY 2016 VL 26 IS 5 BP 546 EP 554 DI 10.1016/j.whi.2016.07.001 PG 9 WC Public, Environmental & Occupational Health; Women's Studies SC Public, Environmental & Occupational Health; Women's Studies GA DX1TT UT WOS:000384150600011 PM 27528358 ER PT J AU Messacar, K Schreiner, TL Van Haren, K Yang, M Glaser, CA Tyler, KL Dominguez, SR AF Messacar, Kevin Schreiner, Teri L. Van Haren, Keith Yang, Michele Glaser, Carol A. Tyler, Kenneth L. Dominguez, Samuel R. TI Acute flaccid myelitis: A clinical review of US cases 2012-2015 SO ANNALS OF NEUROLOGY LA English DT Review ID POLIOMYELITIS-LIKE ILLNESS; ACUTE NEUROLOGICAL ILLNESS; ENTEROVIRUS 71 INFECTION; UPPER RESPIRATORY-TRACT; UNITED-STATES; MRI FINDINGS; CHILDREN; D68; PARALYSIS; OUTBREAK AB This review highlights clinical features of the increasing cases of acute flaccid paralysis associated with anterior myelitis noted in the United States from 2012 to 2015. Acute flaccid myelitis refers to acute flaccid limb weakness with spinal cord gray matter lesions on imaging or evidence of spinal cord motor neuron injury on electrodiagnostic testing. Although some individuals demonstrated improvement in motor weakness and functional deficits, most have residual weakness a year or more after onset. Epidemiological evidence and biological plausibility support an association between enterovirus D68 and the recent increase in acute flaccid myelitis cases in the United States. Ann Neurol 2016;80:326-338 C1 [Messacar, Kevin] Childrens Hosp Colorado, Dept Pediat, Sect Hosp Med, Aurora, CO USA. [Messacar, Kevin; Dominguez, Samuel R.] Childrens Hosp Colorado, Dept Pediat, Sect Pediat Infect Dis, Aurora, CO USA. [Schreiner, Teri L.; Yang, Michele] Childrens Hosp Colorado, Dept Pediat, Neurol Sect, Aurora, CO USA. Univ Colorado, Sch Med, Aurora, CO USA. [Van Haren, Keith] Stanford Univ, Dept Neurol, Sch Med, Stanford, CA 94305 USA. [Glaser, Carol A.] Kaiser Permanente Med Ctr, Oakland, CA USA. [Glaser, Carol A.] Univ Calif San Francisco, San Francisco, CA 94143 USA. [Tyler, Kenneth L.] Univ Colorado, Sch Med, Dept Neurol, Denver, CO USA. [Tyler, Kenneth L.] Univ Colorado, Sch Med, Dept Med, Denver, CO USA. [Tyler, Kenneth L.] Univ Colorado, Sch Med, Dept Immunol Microbiol, Denver, CO USA. [Tyler, Kenneth L.] Denver Vet Affairs Med Ctr, Neurol Serv, Denver, CO USA. RP Messacar, K (reprint author), Childrens Hosp Colorado, Dept Hosp Med, B055,13123 East 16th Ave, Aurora, CO 80045 USA.; Messacar, K (reprint author), Childrens Hosp Colorado, Dept Infect Dis, B055,13123 East 16th Ave, Aurora, CO 80045 USA.; Messacar, K (reprint author), Univ Colorado, Sch Med, B055,13123 East 16th Ave, Aurora, CO 80045 USA. EM Kevin.messacar@childrenscolorado.org FU NIAID NIH HHS [T32 AI052066]; NINDS NIH HHS [K23 NS087151] NR 56 TC 3 Z9 4 U1 4 U2 6 PU WILEY-BLACKWELL PI HOBOKEN PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA SN 0364-5134 EI 1531-8249 J9 ANN NEUROL JI Ann. Neurol. PD SEP PY 2016 VL 80 IS 3 BP 326 EP 338 DI 10.1002/ana.24730 PG 13 WC Clinical Neurology; Neurosciences SC Neurosciences & Neurology GA DW9YH UT WOS:000384018200003 PM 27422805 ER PT J AU Byblow, W Schlaug, G Wittenberg, G AF Byblow, Winston Schlaug, Gottfried Wittenberg, George TI What's the perfect dose for practice to make perfect? SO ANNALS OF NEUROLOGY LA English DT Editorial Material ID CHRONIC STROKE PATIENTS; MOTOR RECOVERY; THERAPY; STIMULATION; INTEGRITY; DEPENDS; MUSIC; BRAIN C1 [Byblow, Winston] Univ Auckland, Dept Exercise Sci, Auckland, New Zealand. [Byblow, Winston] Univ Auckland, Ctr Brain Res, Auckland, New Zealand. [Schlaug, Gottfried] Beth Israel Deaconess Med Ctr, Dept Neurol, Div Stroke Recovery & Neurorestorat, Neuroimaging & Stroke Recovery Lab, Boston, MA 02215 USA. [Schlaug, Gottfried] Harvard Med Sch, Boston, MA USA. [Wittenberg, George] US Dept Vet Affairs, Maryland Exercise & Robot Ctr Excellence, Geriatr Res Educ & Clin Ctr, Baltimore, MD USA. [Wittenberg, George] Univ Maryland, Lab Res Arm Funct & Therapy, Older Amer Independence Ctr, Dept Neurol,Div Gerontol & Geriatr Med, Baltimore, MD 21201 USA. [Wittenberg, George] Univ Maryland, Lab Res Arm Funct & Therapy, Older Amer Independence Ctr, Div Gerontol & Geriatr Med,Dept Phys Therapy & Re, Baltimore, MD 21201 USA. [Wittenberg, George] Univ Maryland, Lab Res Arm Funct & Therapy, Older Amer Independence Ctr, Div Gerontol & Geriatr Med,Dept Med, Baltimore, MD 21201 USA. RP Byblow, W (reprint author), Univ Auckland, Dept Exercise Sci, Auckland, New Zealand.; Byblow, W (reprint author), Univ Auckland, Ctr Brain Res, Auckland, New Zealand. OI Wittenberg, George/0000-0001-5603-1197 NR 18 TC 1 Z9 1 U1 0 U2 1 PU WILEY-BLACKWELL PI HOBOKEN PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA SN 0364-5134 EI 1531-8249 J9 ANN NEUROL JI Ann. Neurol. PD SEP PY 2016 VL 80 IS 3 BP 339 EP 341 DI 10.1002/ana.24735 PG 3 WC Clinical Neurology; Neurosciences SC Neurosciences & Neurology GA DW9YH UT WOS:000384018200004 PM 27447540 ER PT J AU Graf, SA Vaughn, JE Chauncey, TR Storer, BE Gopal, AK Holmberg, LA McCune, JS Bensinger, WI Maloney, DG Press, OW Storb, R Sorror, ML AF Graf, Solomon A. Vaughn, Jennifer E. Chauncey, Thomas R. Storer, Barry E. Gopal, Ajay K. Holmberg, Leona A. McCune, Jeannine S. Bensinger, William I. Maloney, David G. Press, Oliver W. Storb, Rainer Sorror, Mohamed L. TI Comorbidities, Alcohol Use Disorder, and Age Predict Outcomes after Autologous Hematopoietic Cell Transplantation for Lymphoma SO BIOLOGY OF BLOOD AND MARROW TRANSPLANTATION LA English DT Article DE Lymphoma; Autologous; Transplant; HCT-CI; Alcohol ID BONE-MARROW-TRANSPLANTATION; NON-HODGKIN-LYMPHOMA; HIGH-DOSE THERAPY; ELDERLY-PATIENTS; PSYCHOSOCIAL FACTORS; RESPONSE CRITERIA; REDUCED-INTENSITY; MULTIPLE-MYELOMA; SCREENING SCORES; INDEX AB Autologous hematopoietic cell transplantation (HCT) is a treatment option for many patients diagnosed with lymphoma. The effects of patient-specific factors on outcomes after autologous HCT are not well characterized. Here, we studied a sequential cohort of 754 patients with lymphoma treated with autologous HCT between 2000 and 2010. In multivariate analysis, patient-specific factors that were statistically significantly associated with nonrelapse mortality (NRM) included HCT-specific comorbidity index (HCT-CI) scores >= 3 (HR, 1.94; P = .05), a history of alcohol use disorder (AUD) (HR, 2.17; P = .004), and older age stratified by decade (HR, 1.29; P = .02). HCT-CI >= 3, a history of AUD, and age > 50 were combined into a composite risk model: NRM and overall mortality rates at 5 years increased from 6% to 30% and 32% to 58%, respectively, in patients with 0 versus all 3 risk factors. The HCT-CI is a valid tool in predicting mortality risks after autologous HCT for lymphoma. AUD and older age exert independent prognostic impact on outcomes. Whether AUD indicates additional organ dysfunction or sociobehavioral abnormality warrants further investigation. The composite model may improve risk stratification before autologous HCT. Published by Elsevier Inc. on behalf of the American Society for Blood and Marrow Transplantation. C1 [Graf, Solomon A.; Vaughn, Jennifer E.; Chauncey, Thomas R.; Storer, Barry E.; Gopal, Ajay K.; Holmberg, Leona A.; McCune, Jeannine S.; Bensinger, William I.; Maloney, David G.; Press, Oliver W.; Storb, Rainer; Sorror, Mohamed L.] Fred Hutchinson Canc Res Ctr, Div Clin Res, 1124 Columbia St, Seattle, WA 98104 USA. [Graf, Solomon A.; Vaughn, Jennifer E.; Chauncey, Thomas R.; Gopal, Ajay K.; Holmberg, Leona A.; Bensinger, William I.; Maloney, David G.; Press, Oliver W.; Storb, Rainer; Sorror, Mohamed L.] Univ Washington, Dept Med, Seattle, WA USA. [Graf, Solomon A.; Chauncey, Thomas R.] Vet Affairs Puget Sound Hlth Care Syst, Seattle, WA USA. [Vaughn, Jennifer E.] Virginia Tech Carilion Sch Med, Dept Med, Blue Ridge Canc Care, Roanoke, VA USA. [Storer, Barry E.] Univ Washington, Dept Biostat, Seattle, WA 98195 USA. [McCune, Jeannine S.] Univ Washington, Dept Pharm, Seattle, WA 98195 USA. RP Sorror, ML (reprint author), Fred Hutchinson Canc Res Ctr, POB 19024,Mail Stop D5-280, Seattle, WA 98109 USA. EM msorror@fredhutch.org FU National Institutes of Health [CA018029, HL088021, T32 HL007093-38, K24 CA184039]; American Cancer Society [RSG-13-084-01-CPHPS]; Patient-Centered Outcomes Research Institute [CE-1304-7451] FX Financial disclosure: This study was supported by the National Institutes of Health (grant numbers CA018029 and HL088021 to M.L.S., T32 HL007093-38 to S.A.G., T32 HL007093-38 to J.E.V., K24 CA184039 to A.K.G), the American Cancer Society (Research Scholar grant no. RSG-13-084-01-CPHPS to M.L.S.), and the Patient-Centered Outcomes Research Institute [contract no. CE-1304-7451 to M.L.S.). NR 35 TC 0 Z9 0 U1 0 U2 0 PU ELSEVIER SCIENCE INC PI NEW YORK PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA SN 1083-8791 EI 1523-6536 J9 BIOL BLOOD MARROW TR JI Biol. Blood Marrow Transplant. PD SEP PY 2016 VL 22 IS 9 BP 1582 EP 1587 DI 10.1016/j.bbmt.2016.06.007 PG 6 WC Hematology; Immunology; Transplantation SC Hematology; Immunology; Transplantation GA DT8YK UT WOS:000381781400007 PM 27311969 ER PT J AU Cuevas, AG O'Brien, K Saha, S AF Cuevas, Adolfo G. O'Brien, Kerth Saha, Somnath TI African American Experiences in Healthcare: "I Always Feel Like I'm Getting Skipped Over" SO HEALTH PSYCHOLOGY LA English DT Article DE communication; medical mistrust; patient-provider relationships; perceived discrimination; race concordance ID PATIENT-PROVIDER COMMUNICATION; QUALITY-OF-CARE; MEDICATION ADHERENCE; RACIAL-DISCRIMINATION; DECISION-MAKING; RACIAL/ETHNIC DISCRIMINATION; PERCEIVED DISCRIMINATION; PHYSICIAN COMMUNICATION; DISPARITIES RESEARCH; BLACK PATIENTS AB Objective: Although African Americans perceive discrimination in health care settings, experience higher levels of medical mistrust compared with European Americans, and experience poorer communication with health care providers, little is known as to how these barriers to quality patient-provider relationships arise and manifest themselves. This study examined experiences of African American community members regarding these barriers and additionally explored participants' perspectives on race in the patient-provider relationship. Methods: Focus groups were conducted as part of a study exploring participants' experiences and relationships in health care settings. Sixty African American adults were recruited through community settings and activities to participate in 1 of 9 focus groups segmented by gender. Transcripts were reviewed for content related to perceived discrimination, mistrust, poor communication, and race discordance. Themes providing insight into participants' subjective experience of these potential relationship barriers were derived through qualitative coding (using NVivo 10) and iterative discussion. Results: Perceived discrimination arose when African American patients, particularly women, felt their symptoms or problems were discredited. Medical mistrust occurred when clinicians did not convey respect to patients, leaving patients to wonder whether their clinician's treatment was discriminatory or not. Poor communication arose when clinicians did not acknowledge patients' perspectives during interactions. Patients often viewed these actions as discriminatory. Conclusions: African Americans experience poor communication with their health care providers, medical mistrust, and perceived discrimination when accessing health care in numerous and sometimes interrelated ways. The investigators recommend ways to reduce the experience of such barriers and to improve patient-provider relationships for African Americans in health care. C1 [Cuevas, Adolfo G.; O'Brien, Kerth] Portland State Univ, Dept Psychol, Portland, OR 97207 USA. [Saha, Somnath] Portland VA Med Ctr, Portland, OR USA. [Saha, Somnath] Oregon Hlth & Sci Univ, Dept Med Informat & Clin Epidemiol, Publ Hlth & Prevent Med, Portland, OR 97201 USA. RP Cuevas, AG (reprint author), Harvard TH Chan Sch Publ Hlth, Dept Social & Behav Sci, Kresge Bldg,Rm 604a,677 Huntington Ave, Boston, MA 02115 USA. EM acuevas@hsph.harvard.edu OI Cuevas, Adolfo/0000-0001-9875-3825; O'Brien, Kerth/0000-0002-1566-7364 FU Robert Wood Johnson Foundation FX Project EQUALED was funded by a grant from the Robert Wood Johnson Foundation. The authors thank Cameron T. McCabe for his feedback on the manuscript, and Thomas Kindermann and Yves Labissiere for their feedback and critique on early iterations of this work. In addition we thank the community leaders and organizations involved in Project EQUALED, whose expertise and collaboration helped to create this project and make it a success. NR 52 TC 3 Z9 3 U1 8 U2 11 PU AMER PSYCHOLOGICAL ASSOC PI WASHINGTON PA 750 FIRST ST NE, WASHINGTON, DC 20002-4242 USA SN 0278-6133 EI 1930-7810 J9 HEALTH PSYCHOL JI Health Psychol. PD SEP PY 2016 VL 35 IS 9 BP 987 EP 995 DI 10.1037/hea0000368 PG 9 WC Psychology, Clinical; Psychology SC Psychology GA DW6XB UT WOS:000383793600007 PM 27175576 ER PT J AU Turner, TH Renfroe, JB Morella, K Marriott, BP AF Turner, Travis H. Renfroe, Jenna B. Morella, Kristen Marriott, Bernadette P. CA BRAVO Working Grp TI Evaluating cognitive effort in a randomized controlled trial SO INTERNATIONAL JOURNAL OF METHODS IN PSYCHIATRIC RESEARCH LA English DT Article DE clinical trials; malingering; effort; neurocognition; suicide ID PREDICTS SUICIDAL-BEHAVIOR; TRAUMATIC BRAIN-INJURY; PERFORMANCE TEST-II AB Many randomized controlled trials (RCTs) of neuropsychiatric conditions involve cognitive outcome measures; however, validity of cognitive data relies on adequate effort during testing, and such screening is seldom performed. Given well-established rates of 10 to 30% poor effort in clinical settings, this is not a trivial concern. This preliminary study evaluated effort during cognitive testing in an RCT of omega-3 supplementation to reduce suicidality in a high-risk psychiatric population. An interim analysis of sustained attentions measures from the Connors Performance Test (CPT-2) at baseline for the first 60 participants was conducted. Previously validated cut points to detect insufficient effort on the CPT-2 were applied. At baseline, 12% (7) were identified as giving poor effort. Follow-up analyses indicated less psychiatric distress and suicidality among those who gave poor effort. Results suggest comparable likelihood of a poor effort on cognitive testing in clinical and RCT participation. Reduced psychiatric distress in the poor effort group raises concern regarding interpretation of other measures. The importance of screening cognitive data for effort in RCTs is highlighted. Future studies will examine effort at follow-up visits, and explore relationships to attrition, adherence, and response to treatment. Copyright (c) 2016 John Wiley & Sons, Ltd. C1 [Turner, Travis H.] Ralph H Johnson VAMC, Mental Hlth Serv, Charleston, SC USA. [Turner, Travis H.; Marriott, Bernadette P.] Dept Psychiat & Behav Sci, Charleston, SC USA. [Turner, Travis H.; Renfroe, Jenna B.] Med Univ South Carolina, Dept Neurol Neurosci, Movement Disorders Program, Charleston, SC USA. [Morella, Kristen] Med Univ South Carolina, Dept Publ Hlth Sci, Charleston, SC USA. [Marriott, Bernadette P.] Med Univ South Carolina, Div Gastroenterol & Hepatol, Nutr Sect, Dept Med, Charleston, SC USA. RP Turner, TH (reprint author), VAMC MH 116, RHJ, 109 Bee St, Charleston, SC 29401 USA. EM turnertr@musc.edu FU Department of Defense (DoD) [W81XWH-13-2-0015]; US Army Medical Research and Materiel Command (USAMRMC); Congressionally Directed Medical Research Programs (CDMRP) through the US Army Medical Research Acquisition Authority (USAMRAA); intramural program of the National Institute on Alcohol Abuse and Alcoholism FX The BRAVO study is sponsored by award # W81XWH-13-2-0015 from the Department of Defense (DoD), US Army Medical Research and Materiel Command (USAMRMC), Congressionally Directed Medical Research Programs (CDMRP) through the US Army Medical Research Acquisition Authority (USAMRAA). The intramural program of the National Institute on Alcohol Abuse and Alcoholism also provides support for this study. The BRAVO study team wishes to acknowledge the excellent support of Samantha Wise in all aspects of the study. NR 14 TC 0 Z9 0 U1 0 U2 0 PU WILEY-BLACKWELL PI HOBOKEN PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA SN 1049-8931 EI 1557-0657 J9 INT J METH PSYCH RES JI Int. J. Methods Psychiatr. Res. PD SEP PY 2016 VL 25 IS 3 BP 199 EP 204 DI 10.1002/mpr.1505 PG 6 WC Psychiatry SC Psychiatry GA DW6HE UT WOS:000383750200005 PM 27074873 ER PT J AU May, FP Whitman, CB Varlyguina, K Bromley, EG Spiegel, BMR AF May, Folasade P. Whitman, Cynthia B. Varlyguina, Ksenia Bromley, Erica G. Spiegel, Brennan M. R. TI Addressing Low Colorectal Cancer Screening in African Americans: Using Focus Groups to Inform the Development of Effective Interventions SO JOURNAL OF CANCER EDUCATION LA English DT Article DE African American; Colorectal cancer; Screening; Disparities; Qualitative ID CARE; KNOWLEDGE AB African Americans have the highest burden of colorectal cancer (CRC) in the United States of America (USA) yet lower CRC screening rates than whites. Although poor screening has prompted efforts to increase screening uptake, there is a persistent need to develop public health interventions in partnership with the African American community. The aim of this study was to conduct focus groups with African Americans to determine preferences for the content and mode of dissemination of culturally tailored CRC screening interventions. In June 2013, 45-75-year-old African Americans were recruited through online advertisements and from an urban Veterans Affairs system to create four focus groups. A semi-structured interview script employing open-ended elicitation was used, and transcripts were analyzed using ATLAS.ti software to code and group data into a concept network. A total of 38 participants (mean age = 54) were enrolled, and 59 ATLAS.ti codes were generated. Commonly reported barriers to screening included perceived invasiveness of colonoscopy, fear of pain, and financial concerns. Facilitators included poor diet/health and desire to prevent CRC. Common sources of health information included media and medical providers. CRC screening information was commonly obtained from medical personnel or media. Participants suggested dissemination of CRC screening education through commercials, billboards, influential African American public figures, Internet, and radio. Participants suggested future interventions include culturally specific information, including details about increased risk, accessing care, and dispelling of myths. Public health interventions to improve CRC screening among African Americans should employ media outlets, emphasize increased risk among African Americans, and address race-specific barriers. Specific recommendations are presented for developing future interventions. C1 [May, Folasade P.; Spiegel, Brennan M. R.] VA Greater Angeles Healthcare Syst, Div Gastroenterol, Dept Med, Los Angeles, CA USA. [May, Folasade P.; Bromley, Erica G.; Spiegel, Brennan M. R.] Univ Calif Los Angeles, David Geffen Sch Med, Dept Med, Div Digest Dis, Los Angeles, CA 90095 USA. [May, Folasade P.; Spiegel, Brennan M. R.] Univ Calif Los Angeles, Fielding Sch Publ Hlth, Dept Hlth Policy & Management, Los Angeles, CA 90095 USA. [May, Folasade P.; Whitman, Cynthia B.; Varlyguina, Ksenia; Spiegel, Brennan M. R.] Cedars Sinai Med Ctr, Dept Med, CS CORE, Los Angeles, CA 90048 USA. RP May, FP (reprint author), VA Greater Angeles Healthcare Syst, Div Gastroenterol, Dept Med, Los Angeles, CA USA.; May, FP (reprint author), Univ Calif Los Angeles, David Geffen Sch Med, Dept Med, Div Digest Dis, Los Angeles, CA 90095 USA.; May, FP (reprint author), Univ Calif Los Angeles, Fielding Sch Publ Hlth, Dept Hlth Policy & Management, Los Angeles, CA 90095 USA.; May, FP (reprint author), Cedars Sinai Med Ctr, Dept Med, CS CORE, Los Angeles, CA 90048 USA. EM fmay@mednet.ucla.edu FU NIH Training grant [T32DK07180-40] FX This research was supported by the NIH Training grant (T32DK07180-40) for Dr. May. There was no sponsor for this research or publication. NR 25 TC 2 Z9 2 U1 4 U2 4 PU SPRINGER PI NEW YORK PA 233 SPRING ST, NEW YORK, NY 10013 USA SN 0885-8195 EI 1543-0154 J9 J CANCER EDUC JI J. Cancer Educ. PD SEP PY 2016 VL 31 IS 3 BP 567 EP 574 DI 10.1007/s13187-015-0842-z PG 8 WC Oncology; Education, Scientific Disciplines; Public, Environmental & Occupational Health SC Oncology; Education & Educational Research; Public, Environmental & Occupational Health GA DU1UA UT WOS:000381993900023 PM 25963898 ER PT J AU Sahlem, GL Short, EB Kerns, S Snipes, J DeVries, W Fox, JB Burns, C Schmidt, M Nahas, ZH George, MS Sackeim, HA AF Sahlem, Gregory L. Short, E. Baron Kerns, Suzanne Snipes, Jon DeVries, William Fox, James B. Burns, Carol Schmidt, Matthew Nahas, Ziad H. George, Mark S. Sackeim, Harold A. TI Expanded Safety and Efficacy Data for a New Method of Performing Electroconvulsive Therapy: Focal Electrically Administered Seizure Therapy SO JOURNAL OF ECT LA English DT Article DE electroconvulsive therapy; ECT; depression; FEAST; efficacy; cognitive adverse effects ID RANDOMIZED CONTROLLED-TRIAL; MAGNETIC COIL STIMULATION; ELECTRODE PLACEMENT; MAJOR DEPRESSION; PERIPHERAL-NERVE; DOUBLE-BLIND; UNIDIRECTIONAL CURRENTS; ANATOMICAL VARIABILITY; CONVULSIVE THERAPY; MOTOR CORTEX AB Objective Electroconvulsive therapy (ECT) is the most rapid and effective antidepressant treatment but with concerns about cognitive adverse effects. A new form of ECT, focal electrically administered seizure therapy (FEAST), was designed to increase the focality of stimulation and better match stimulus parameters with neurophysiology. We recently reported on the safety and feasibility of FEAST in a cohort (n = 17) of depressed patients. We now report on the safety, feasibility, preliminary efficacy, and cognitive effects of FEAST in a new cohort. Methods Open-label FEAST was administered to 20 depressed adults (6 men; 3 with bipolar disorder; age 49.1 10.6 years). Clinical and cognitive assessments were obtained at baseline and end of course. Time to orientation recovery was assessed at each treatment. Nonresponders switched to conventional ECT. Results Participants tolerated the treatment well with no dropouts. Five patients (25%) transitioned from FEAST to conventional ECT due to inadequate response. After FEAST (mean, 9.3 +/- 3.5 sessions; range, 4-14), there was a 58.1% +/- 36.0% improvement in Hamilton Rating Scale for Depression scores compared with that in the baseline (P < 0.0001); 13 (65%) of 20 patients met response criteria, and 11 (55%) of 20 met remission criteria. Patients achieved reorientation (4 of 5 items) in 4.4 +/- 3.0 minutes (median, 4.5 minutes), timed from eyes opening. There was no deterioration in neuropsychological measures. Conclusions These findings provide further support for the safety and efficacy of FEAST. The remission and response rates were in the range found using conventional ECT, and the time to reorientation may be quicker. However, without a randomized comparison group, conclusions are tentative. C1 [Sahlem, Gregory L.; Short, E. Baron; Kerns, Suzanne; Snipes, Jon; DeVries, William; Fox, James B.; Burns, Carol; Schmidt, Matthew; Nahas, Ziad H.; George, Mark S.] Med Univ South Carolina, Dept Psychiat, Brain Stimulat Div, 67 President St,502 N, Charleston, SC 29425 USA. [Schmidt, Matthew; Sackeim, Harold A.] Columbia Univ, Dept Psychiat, New York, NY USA. [Schmidt, Matthew; Sackeim, Harold A.] Columbia Univ, Dept Radiol, New York, NY USA. [Nahas, Ziad H.] Amer Univ Beirut, Med Ctr, Dept Psychiat, Beirut, Lebanon. [George, Mark S.] Ralph H Johnson VA Med Ctr, Charleston, SC USA. RP Sahlem, GL (reprint author), Med Univ South Carolina, Dept Psychiat, Brain Stimulat Div, 67 President St,502 N, Charleston, SC 29425 USA. EM sahlem@musc.edu FU MECTA Corporation FX This study was supported in part by an unrestricted educational grant from the MECTA Corporation. The MECTA Corporation also provided a custom-modified MECTA spECTrum 5000Q device. Dr Sackeim is the inventor on a patent for FEAST (US8712532 B2) and serves as a consultant to the MECTA Corporation and Neuronetics, Inc. All other authors have no conflicts of interest or financial disclosures to report. NR 65 TC 3 Z9 3 U1 3 U2 3 PU LIPPINCOTT WILLIAMS & WILKINS PI PHILADELPHIA PA TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA SN 1095-0680 EI 1533-4112 J9 J ECT JI J. ECT PD SEP PY 2016 VL 32 IS 3 BP 197 EP 203 DI 10.1097/YCT.0000000000000328 PG 7 WC Behavioral Sciences; Psychiatry SC Behavioral Sciences; Psychiatry GA DW8OB UT WOS:000383914300027 PM 27379790 ER PT J AU Swetz, KM AF Swetz, Keith M. TI Response to Legalized Physician-Assisted Death: Check Yourself Before You Wreck Yourself SO JOURNAL OF PALLIATIVE MEDICINE LA English DT Letter C1 [Swetz, Keith M.] Univ Alabama Birmingham, Ctr Palliat & Support Care, 1720 2nd Ave South,BDB 650, Birmingham, AL 35294 USA. [Swetz, Keith M.] Birmingham Vet Affairs Med Ctr, Birmingham, AL USA. RP Swetz, KM (reprint author), Univ Alabama Birmingham, Ctr Palliat & Support Care, 1720 2nd Ave South,BDB 650, Birmingham, AL 35294 USA. EM kswetz@uabmc.edu NR 4 TC 1 Z9 1 U1 1 U2 1 PU MARY ANN LIEBERT, INC PI NEW ROCHELLE PA 140 HUGUENOT STREET, 3RD FL, NEW ROCHELLE, NY 10801 USA SN 1096-6218 EI 1557-7740 J9 J PALLIAT MED JI J. Palliat. Med. PD SEP PY 2016 VL 19 IS 9 BP 902 EP 903 DI 10.1089/jpm.2016.0162 PG 2 WC Health Care Sciences & Services SC Health Care Sciences & Services GA DU5HF UT WOS:000382242100002 PM 27135596 ER PT J AU Gidwani, R Joyce, N Kinosian, B Faricy-Anderson, K Levy, C Miller, SC Ersek, M Wagner, T Mor, V AF Gidwani, Risha Joyce, Nina Kinosian, Bruce Faricy-Anderson, Katherine Levy, Cari Miller, Susan C. Ersek, Mary Wagner, Todd Mor, Vincent TI Gap between Recommendations and Practice of Palliative Care and Hospice in Cancer Patients SO JOURNAL OF PALLIATIVE MEDICINE LA English DT Article ID OF-LIFE CARE; RANDOMIZED CONTROLLED-TRIAL; VETERANS AFFAIRS; END; OUTCOMES; SYSTEM AB Background: Specialty societies recommend patients with advanced cancer receive early exposure to palliative care and exposure to hospice care. Objective: We sought to understand real-world practice of care, specifically, the timing of palliative care, and how timing and duration of hospice care varied across Medicare, VA, and VA-Purchased care. Design: We conducted a retrospective analysis of administrative data for veterans aged 65 years or older who died with cancer in 2012. Multilevel logistic regression was used to evaluate the likelihood of receiving palliative care, receiving hospice care, and receiving hospice care for at least three days. Setting: Medicare, VA, and VA-Purchased care environments. Measurements: The receipt and timing of palliative care within VA and the receipt and timing of hospice care across three healthcare environments. Results: Most veterans received hospice care (71%), whereas fewer received palliative care (52%). Among all cancer decedents, 59% received hospice care for their last three days of life. Patients who received hospice care did so a median of 20 days before death (interquartile range [IQR]: 7-46). Patients who received palliative care did so a median of 38 days before death (IQR: 13-94). Adjusted analyses revealed significant differences in receipt of palliative care across cancer type, and significant differences in receipt of hospice care across cancer type. After adjusting for age and cancer type, patients who received VA hospice care were significantly less likely to receive it for at least three days compared with patients who received VA-Purchased or Medicare hospice care. Conclusions: There remains a gap between recommended timing of supportive services and real-world practice of care. Results suggest that difficulties in prognosticating death are not fully responsible for underexposure to hospice. C1 [Gidwani, Risha; Wagner, Todd] VA Palo Alto Hlth Care Syst, Ctr Innovat Implementat Ci2i, HERC, 795 Willow Rd,152 MPD, Menlo Pk, CA 94025 USA. [Gidwani, Risha] Stanford Univ, Div Gen Med Disciplines, Stanford, CA 94305 USA. [Joyce, Nina; Miller, Susan C.; Mor, Vincent] Brown Univ, Sch Publ Hlth, Dept Hlth Serv Policy & Practice, Providence, RI 02912 USA. [Kinosian, Bruce; Ersek, Mary] Philadelphia VA Med Ctr, Philadelphia, PA USA. [Kinosian, Bruce] Hosp Univ Penn, 3400 Spruce St, Philadelphia, PA 19104 USA. [Faricy-Anderson, Katherine] Brown Univ, Alpert Med Sch, Providence, RI 02912 USA. [Faricy-Anderson, Katherine; Miller, Susan C.; Mor, Vincent] Providence VA Med Ctr, Providence, RI USA. [Levy, Cari] Eastern Colorado VA Healthcare Syst, Denver, CO USA. [Ersek, Mary] Univ Penn, Sch Nursing, Philadelphia, PA 19104 USA. [Wagner, Todd] Stanford Univ, Dept Hlth Res & Policy, Stanford, CA 94305 USA. RP Gidwani, R (reprint author), VA Palo Alto Hlth Care Syst, Ctr Innovat Implementat Ci2i, HERC, 795 Willow Rd,152 MPD, Menlo Pk, CA 94025 USA. EM risha.gidwani@va.gov FU VA Health Services Research and Development [IIR 12-121]; Department of Veterans Affairs, Veterans Health Administration, Office of Research and Development, Health Services Research and Development; VA Information Resource Center [SDR 02-237, 98-004]; Department of Veterans Affairs, Veterans Health Administration, Office of Research and Development, Health Services Research and Development [IIR 12-121] FX Funding support was provided by VA Health Services Research and Development (IIR 12-121). This work was presented at the American Society of Clinical Oncology's Palliative Care Symposium in October 2015. Support for VA/CMS data is provided by the Department of Veterans Affairs, Veterans Health Administration, Office of Research and Development, Health Services Research and Development, and VA Information Resource Center (Project Nos. SDR 02-237 and 98-004). Support for this research study is also provided by the Department of Veterans Affairs, Veterans Health Administration, Office of Research and Development, Health Services Research and Development (Project No. IIR 12-121). NR 23 TC 2 Z9 2 U1 1 U2 1 PU MARY ANN LIEBERT, INC PI NEW ROCHELLE PA 140 HUGUENOT STREET, 3RD FL, NEW ROCHELLE, NY 10801 USA SN 1096-6218 EI 1557-7740 J9 J PALLIAT MED JI J. Palliat. Med. PD SEP PY 2016 VL 19 IS 9 BP 957 EP 963 DI 10.1089/jpm.2015.0514 PG 7 WC Health Care Sciences & Services SC Health Care Sciences & Services GA DU5HF UT WOS:000382242100012 PM 27228478 ER PT J AU Singer, AE Goebel, JR Kim, YS Dy, SM Ahluwalia, SC Clifford, M Dzeng, E O'Hanlon, CE Motala, A Walling, AM Goldberg, J Meeker, D Ochotorena, C Shanman, R Cui, MK Lorenz, KA AF Singer, Adam E. Goebel, Joy R. Kim, Yan S. Dy, Sydney M. Ahluwalia, Sangeeta C. Clifford, Megan Dzeng, Elizabeth O'Hanlon, Claire E. Motala, Aneesa Walling, Anne M. Goldberg, Jaime Meeker, Daniella Ochotorena, Claudia Shanman, Roberta Cui, Mike Lorenz, Karl A. TI Populations and Interventions for Palliative and End-of-Life Care: A Systematic Review SO JOURNAL OF PALLIATIVE MEDICINE LA English DT Review ID RANDOMIZED CONTROLLED-TRIAL; CANCER PAIN MANAGEMENT; EVIDENCE-BASED RECOMMENDATIONS; CELL LUNG-CANCER; OBSTRUCTIVE PULMONARY-DISEASE; HEART-FAILURE MANAGEMENT; COPING STRATEGY PROGRAM; TERMINALLY-ILL PATIENTS; PATIENT-HELD RECORDS; FRAIL OLDER-PEOPLE AB Importance: Evidence supports palliative care effectiveness. Given workforce constraints and the costs of new services, payers and providers need help to prioritize their investments. They need to know which patients to target, which personnel to hire, and which services best improve outcomes. Objective: To inform how payers and providers should identify patients with "advanced illness'' and the specific interventions they should implement, we reviewed the evidence to identify (1) individuals appropriate for palliative care and (2) elements of health service interventions (personnel involved, use of multidisciplinary teams, and settings of care) effective in achieving better outcomes for patients, caregivers, and the healthcare system. Evidence Review: Systematic searches of MEDLINE, EMBASE, PsycINFO, Web of Science, and Cochrane Database of Systematic Reviews databases (1/1/2001-1/8/2015). Results: Randomized controlled trials (124) met inclusion criteria. The majority of studies in cancer (49%, 38 of 77 studies) demonstrated statistically significant patient or caregiver outcomes (e.g., p < 0.05), as did those in congestive heart failure (CHF) (62%, 13 of 21), chronic obstructive pulmonary disease (COPD; 58%, 11 of 19), and dementia (60%, 15 of 25). Most prognostic criteria used clinicians' judgment (73%, 22 of 30). Most interventions included a nurse (70%, 69 of 98), and many were nurse-only (39%, 27 of 69). Social workers were well represented, and home-based approaches were common (56%, 70 of 124). Home interventions with visits were more effective than those without (64%, 28 of 44; vs. 46%, 12 of 26). Interventions improved communication and care planning (70%, 12 of 18), psychosocial health (36%, 12 of 33, for depressive symptoms; 41%, 9 of 22, for anxiety), and patient (40%, 8 of 20) and caregiver experiences (63%, 5 of 8). Many interventions reduced hospital use (65%, 11 of 17), but most other economic outcomes, including costs, were poorly characterized. Palliative care teams did not reliably lower healthcare costs (20%, 2 of 10). Conclusions: Palliative care improves cancer, CHF, COPD, and dementia outcomes. Effective models include nurses, social workers, and home-based components, and a focus on communication, psychosocial support, and the patient or caregiver experience. High-quality research on intervention costs and cost outcomes in palliative care is limited. C1 [Singer, Adam E.; Walling, Anne M.] Univ Calif Los Angeles, David Geffen Sch Med, Los Angeles, CA 90095 USA. [Singer, Adam E.; Ahluwalia, Sangeeta C.; Clifford, Megan; O'Hanlon, Claire E.; Motala, Aneesa; Walling, Anne M.; Shanman, Roberta; Lorenz, Karl A.] RAND Corp, 1776 Main St,POB 2138, Santa Monica, CA 90407 USA. [Goebel, Joy R.] Calif State Univ Long Beach, Sch Nursing, Long Beach, CA 90840 USA. [Kim, Yan S.] Kaiser Permanente Northern Calif, Div Res, Oakland, CA USA. [Dy, Sydney M.] Johns Hopkins Bloomberg Sch Publ Hlth, Dept Hlth Policy & Management, Baltimore, MD USA. [Dzeng, Elizabeth] Univ Calif San Francisco, Div Hosp Med, San Francisco, CA 94143 USA. [O'Hanlon, Claire E.] RAND Corp, Pardee RAND Grad Sch, Santa Monica, CA USA. [Walling, Anne M.] Vet Affairs Greater Los Angeles Healthcare Syst, Los Angeles, CA USA. [Goldberg, Jaime] Cedars Sinai Med Ctr, Support Care Med, Los Angeles, CA 90048 USA. [Meeker, Daniella] Univ Southern Calif, Dept Prevent Med, Los Angeles, CA USA. [Ochotorena, Claudia] Cedars Sinai Med Ctr, Los Angeles, CA 90048 USA. [Cui, Mike] RAND Corp, Pittsburgh, PA USA. [Lorenz, Karl A.] Stanford Univ, Sch Med, Stanford, CA 94305 USA. RP Singer, AE (reprint author), RAND Corp, 1776 Main St,POB 2138, Santa Monica, CA 90407 USA. EM asinger@rand.org FU National Institute of Nursing Research [R01 NR013372]; Cambia Health Foundation; California HealthCare Foundation; NIH/National Center for Advancing Translational Science (NCATS) UCLA CTSI [UL1 TR000124]; NIH; [T32 GM008042] FX This work was supported by grant R01 NR013372 from the National Institute of Nursing Research, a Cambia Health Foundation Sojourns Award, and the California HealthCare Foundation. Dr. Singer received support from grant T32 GM008042 as a member of the Medical Scientist Training Program at the University of California, Los Angeles. Dr. Walling received support from the NIH/National Center for Advancing Translational Science (NCATS) UCLA CTSI grant UL1 TR000124 and the NIH loan repayment program. NR 146 TC 5 Z9 5 U1 24 U2 30 PU MARY ANN LIEBERT, INC PI NEW ROCHELLE PA 140 HUGUENOT STREET, 3RD FL, NEW ROCHELLE, NY 10801 USA SN 1096-6218 EI 1557-7740 J9 J PALLIAT MED JI J. Palliat. Med. PD SEP PY 2016 VL 19 IS 9 BP 995 EP 1008 DI 10.1089/jpm.2015.0367 PG 14 WC Health Care Sciences & Services SC Health Care Sciences & Services GA DU5HF UT WOS:000382242100019 PM 27533892 ER PT J AU Krauss, JC Boonstra, PS Vantsevich, AV Friedman, CP AF Krauss, John C. Boonstra, Philip S. Vantsevich, Anna V. Friedman, Charles P. TI Is the problem list in the eye of the beholder? An exploration of consistency across physicians SO JOURNAL OF THE AMERICAN MEDICAL INFORMATICS ASSOCIATION LA English DT Article DE medical problem list; coordination of patient care; ranked-biased overlap; electronic health record; ranked lists ID ELECTRONIC PROBLEM LIST; PRIMARY-CARE PROVIDERS; ATTITUDES; SPECIALISTS; ACCURACY; RECORDS AB Objective Quantify the variability of patients' problem lists - in terms of the number, type, and ordering of problems - across multiple physicians and assess physicians' criteria for organizing and ranking diagnoses. Materials and Methods In an experimental setting, 32 primary care physicians generated and ordered problem lists for three identical complex internal medicine cases expressed as detailed 2- to 4-page abstracts and subsequently expressed their criteria for ordering items in the list. We studied variability in problem list length. We modified a previously validated rank-based similarity measure, with range of zero to one, to quantify agreement between pairs of lists and calculate a single consensus problem list that maximizes agreement with each physician. Physicians' reasoning for the ordering of the problem lists was recorded. Results Subjects' problem lists were highly variable. The median problem list length was 8 (range: 3-14) for Case A, 10 (range: 4-20) for Case B, and 7 (range: 3-13) for Case C. The median indices of agreement - taking into account the length, content, and order of lists - over all possible physician pairings was 0.479, 0.371, 0.509, for Cases A, B, and C, respectively. The median agreements between the physicians' lists and the consensus list for each case were 0.683, 0.581, and 0.697 (for Cases A, B, and C, respectively). Out of a possible 1488 pairings, 2 lists were identical. Physicians most frequently ranked problem list items based on their acuity and immediate threat to health. Conclusions The problem list is a physician's mental model of a patient's health status. These mental models were found to vary significantly between physicians, raising questions about whether problem lists created by individual physicians can serve their intended purpose to improve care coordination. C1 [Krauss, John C.] Univ Michigan, Sch Med, Dept Internal Med, Div Hematol Oncol, 3-219 Canc Ctr,1500 E Med Ctr Dr, Ann Arbor, MI 48109 USA. [Boonstra, Philip S.] Univ Michigan, Sch Publ Hlth, Dept Biostat, 2,1415 Washington Hts, Ann Arbor, MI 48109 USA. [Vantsevich, Anna V.] San Francisco VA Med Ctr, Mental Hlth Serv, 4150 Clement St, San Francisco, CA 94121 USA. [Friedman, Charles P.] Univ Michigan, Sch Med, Dept Learning Hlth Sci, Ann Arbor, MI 48109 USA. RP Krauss, JC (reprint author), Univ Michigan, Sch Med, Dept Internal Med, Div Hematol Oncol, 3-219 Canc Ctr,1500 E Med Ctr Dr, Ann Arbor, MI 48109 USA. EM jkrauss@med.umich.edu FU National Institutes of Health [P30 CA 046592] FX P.S.B. was supported by the National Institutes of Health (P30 CA 046592). NR 37 TC 0 Z9 0 U1 4 U2 4 PU OXFORD UNIV PRESS PI OXFORD PA GREAT CLARENDON ST, OXFORD OX2 6DP, ENGLAND SN 1067-5027 EI 1527-974X J9 J AM MED INFORM ASSN JI J. Am. Med. Inf. Assoc. PD SEP PY 2016 VL 23 IS 5 BP 859 EP 865 DI 10.1093/jamia/ocv211 PG 7 WC Computer Science, Information Systems; Computer Science, Interdisciplinary Applications; Health Care Sciences & Services; Information Science & Library Science; Medical Informatics SC Computer Science; Health Care Sciences & Services; Information Science & Library Science; Medical Informatics GA DW6SU UT WOS:000383782300003 PM 27002075 ER PT J AU Pevnick, JM Palmer, KA Shane, R Wu, CN Bell, DS Diaz, F Cook-Wiens, G Jackevicius, CA AF Pevnick, Joshua M. Palmer, Katherine A. Shane, Rita Wu, Cindy N. Bell, Douglas S. Diaz, Frank Cook-Wiens, Galen Jackevicius, Cynthia A. TI Potential benefit of electronic pharmacy claims data to prevent medication history errors and resultant inpatient order errors SO JOURNAL OF THE AMERICAN MEDICAL INFORMATICS ASSOCIATION LA English DT Article DE medication reconciliation; adverse drug events; health information exchange ID HOSPITALIZED-PATIENTS; RECONCILIATION; ADMISSION; RECORDS; DISCREPANCIES; METAANALYSIS; ACCURACY; BARRIERS; CARE AB Objective We sought to assess the potential of a widely available source of electronic medication data to prevent medication history errors and resultant inpatient order errors. Methods We used admission medication history (AMH) data from a recent clinical trial that identified 1017 AMH errors and 419 resultant inpatient order errors among 194 hospital admissions of predominantly older adult patients on complex medication regimens. Among the subset of patients for whom we could access current Surescripts electronic pharmacy claims data (SEPCD), two pharmacists independently assessed error severity and our main outcome, which was whether SEPCD (1) was unrelated to the medication error; (2) probably would not have prevented the error; (3) might have prevented the error; or (4) probably would have prevented the error. Results Seventy patients had both AMH errors and current, accessible SEPCD. SEPCD probably would have prevented 110 (35%) of 315 AMH errors and 46 (31%) of 147 resultant inpatient order errors. When we excluded the least severe medication errors, SEPCD probably would have prevented 99 (47%) of 209 AMH errors and 37 (61%) of 61 resultant inpatient order errors. SEPCD probably would have prevented at least one AMH error in 42 (60%) of 70 patients. Conclusion When current SEPCD was available for older adult patients on complex medication regimens, it had substantial potential to prevent AMH errors and resultant inpatient order errors, with greater potential to prevent more severe errors. Further study is needed to measure the benefit of SEPCD in actual use at hospital admission. C1 [Pevnick, Joshua M.] Cedars Sinai Med Ctr, Dept Med, Div Gen Internal Med, 8700 Beverly Blvd, Los Angeles, CA 90048 USA. [Palmer, Katherine A.; Shane, Rita; Wu, Cindy N.; Diaz, Frank] Cedars Sinai Med Ctr, Dept Pharm Serv, 8700 Beverly Blvd, Los Angeles, CA 90048 USA. [Shane, Rita] UCSF Sch Pharm, San Francisco, CA USA. [Bell, Douglas S.] RAND Hlth, Santa Monica, CA USA. [Bell, Douglas S.] Univ Calif Los Angeles, David Geffen Sch Med, Div Gen Internal Med & Hlth Serv Res, Los Angeles, CA 90095 USA. [Cook-Wiens, Galen] Cedars Sinai Med Ctr, Samuel Oschin Comprehens Canc Inst, Biostat Bioinformat & Res Informat Ctr, Los Angeles, CA USA. [Jackevicius, Cynthia A.] Western Univ Hlth Sci, Coll Pharm, Dept Pharm Practice & Adm, Pomona, CA USA. [Jackevicius, Cynthia A.] Inst Clin Evaluat Sci, Toronto, ON, Canada. [Jackevicius, Cynthia A.] Univ Toronto, Fac Med, Dept Hlth Policy Management & Evaluat, Toronto, ON, Canada. [Jackevicius, Cynthia A.] Vet Affairs Greater Los Angeles Healthcare Syst, Los Angeles, CA USA. [Jackevicius, Cynthia A.] Univ Hlth Network, Toronto, ON, Canada. RP Pevnick, JM (reprint author), Cedars Sinai Hlth Syst, 8700 Beverly Blvd,PACT 400-8G, Los Angeles, CA 90048 USA. EM jpevnick@gmail.com FU NIH/National Center for Advancing Translational Science UCLA CTSI Grant [KL2TR000122, UL1TR000124] FX This research was supported by NIH/National Center for Advancing Translational Science UCLA CTSI Grant Numbers KL2TR000122 (Dr Pevnick) and UL1TR000124 (Dr Bell). The authors have no conflicts of interest to disclose. NR 29 TC 0 Z9 0 U1 2 U2 2 PU OXFORD UNIV PRESS PI OXFORD PA GREAT CLARENDON ST, OXFORD OX2 6DP, ENGLAND SN 1067-5027 EI 1527-974X J9 J AM MED INFORM ASSN JI J. Am. Med. Inf. Assoc. PD SEP PY 2016 VL 23 IS 5 BP 942 EP 950 DI 10.1093/jamia/ocv171 PG 9 WC Computer Science, Information Systems; Computer Science, Interdisciplinary Applications; Health Care Sciences & Services; Information Science & Library Science; Medical Informatics SC Computer Science; Health Care Sciences & Services; Information Science & Library Science; Medical Informatics GA DW6SU UT WOS:000383782300013 PM 26911817 ER PT J AU Espay, AJ Coffey, CS Foster, ED Uribe, L Caspell-Garcia, CJ Weintraub, D AF Espay, A. J. Coffey, C. S. Foster, E. D. Uribe, L. Caspell-Garcia, C. J. Weintraub, D. CA Parkinson's Progression Marker TI Dopaminergic medications and mood enhancement in Parkinson disease SO MOVEMENT DISORDERS LA English DT Meeting Abstract C1 Univ Cincinnati, Dept Neurol, James J & Joan A Gardner Family Ctr Parkinsons Di, Cincinnati, OH USA. Univ Iowa, Coll Publ Hlth, Dept Biostat, Iowa City, IA USA. Univ Penn, Dept Neurol, Perelman Sch Med, Philadelphia, PA 19104 USA. Univ Penn, Dept Psychiat, Perelman Sch Med, Philadelphia, PA 19104 USA. Philadelphia VA Med Ctr, Dept Vet Affairs, Philadelphia, PA USA. NR 0 TC 0 Z9 0 U1 0 U2 0 PU WILEY-BLACKWELL PI HOBOKEN PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA SN 0885-3185 EI 1531-8257 J9 MOVEMENT DISORD JI Mov. Disord. PD SEP PY 2016 VL 31 IS 9 BP E11 EP E11 PG 1 WC Clinical Neurology SC Neurosciences & Neurology GA DW6PO UT WOS:000383773600034 ER PT J AU Van Laar, AD Webb, K Burton, EA Greenamyre, JT AF Van Laar, A. D. Webb, K. Burton, E. A. Greenamyre, J. T. TI PRESENTATION: A novel, progressive, endogenous synucleinopathy model of PD in rats SO MOVEMENT DISORDERS LA English DT Meeting Abstract C1 [Van Laar, A. D.; Webb, K.; Burton, E. A.; Greenamyre, J. T.] Univ Pittsburgh, Pittsburgh Inst Neurodegenerat Dis, Pittsburgh, PA USA. [Van Laar, A. D.; Burton, E. A.; Greenamyre, J. T.] Univ Pittsburgh, Sch Med, Dept Neurol, Pittsburgh, PA 15261 USA. [Webb, K.] Univ Pittsburgh, Dept Neurosci, Pittsburgh, PA USA. [Burton, E. A.; Greenamyre, J. T.] VA Pittsburgh Healthcare Syst, Geriatr Res Educ & Clin Ctr, Pittsburgh, PA USA. [Burton, E. A.] Univ Pittsburgh, Sch Med, Dept Microbiol & Mol Genet, Pittsburgh, PA USA. NR 0 TC 0 Z9 0 U1 0 U2 0 PU WILEY-BLACKWELL PI HOBOKEN PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA SN 0885-3185 EI 1531-8257 J9 MOVEMENT DISORD JI Mov. Disord. PD SEP PY 2016 VL 31 IS 9 BP E1 EP E1 PG 1 WC Clinical Neurology SC Neurosciences & Neurology GA DW6PO UT WOS:000383773600002 ER PT J AU Harper, DC Moore, RL Cleveland, C Miltner, RS Froelich, K McGuinness, T Waldrop, J Fogger, S Davis, AH Selleck, CS AF Harper, Doreen C. Moore, Randy L. Cleveland, Cynthia Miltner, Rebecca S. Froelich, Kimberly McGuinness, Teena Waldrop, Jessica Fogger, Susanne Davis, Amanda Hood Selleck, Cynthia S. TI Transforming veterans health care through academic-practice partnerships SO NURSING OUTLOOK LA English DT Article DE Academic-practice partnerships; Mental health; Nursing education; Veterans health; Veterans Health Administration AB The Veterans Health Affairs Office of Academic Affiliations (OAA) has invested in the creation of academic-practice partnerships to transform the care of veterans and their families. This article details how a long-standing relationship between the University of Alabama at Birmingham School of Nursing and the Birmingham Veterans Affairs Medical Center grew into such a partnership. The three programs that now exist within the Birmingham Veterans Affairs Nursing Academic Partnership (VANAP) umbrella are described, including an undergraduate VA nurse scholars program that has sustained beyond OAA funding, a VANAP graduate education program for psychiatric mental health nurse practitioners (NPs), and a Mental Health NP Residency. Key features of the programs are noted as are outcomes and lessons learned for building mutual goals and a sustainable academic-practice partnership. With the recent passage of the Veterans Choice Program, the importance of educating all nurses about veterans and veterans' health is stressed. C1 [Harper, Doreen C.; Miltner, Rebecca S.; McGuinness, Teena; Fogger, Susanne; Selleck, Cynthia S.] Univ Alabama Birmingham, Sch Nursing, 1720 2nd Ave South,NB 443A, Birmingham, AL 35294 USA. [Moore, Randy L.; Cleveland, Cynthia; Froelich, Kimberly; Waldrop, Jessica; Davis, Amanda Hood] Birmingham Vet Affairs Med Ctr, Birmingham, AL USA. RP Selleck, CS (reprint author), Univ Alabama Birmingham, Sch Nursing, 1720 2nd Ave South,NB 443A, Birmingham, AL 35294 USA. EM cselleck@uab.edu OI Miltner, Rebecca/0000-0002-4653-0328 FU Birmingham Veterans Affairs Medical Center; University of Alabama at Birmingham School of Nursing FX This publication was supported in part by the Veterans Affairs Nursing Academic Partnership between the Birmingham Veterans Affairs Medical Center and the University of Alabama at Birmingham School of Nursing. NR 9 TC 2 Z9 2 U1 2 U2 2 PU ELSEVIER SCIENCE INC PI NEW YORK PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA SN 0029-6554 EI 1528-3968 J9 NURS OUTLOOK JI Nurs. Outlook PD SEP-OCT PY 2016 VL 64 IS 5 SI SI BP 424 EP 430 DI 10.1016/j.outlook.2016.05.001 PG 7 WC Nursing SC Nursing GA DW6CE UT WOS:000383733200006 PM 27262737 ER PT J AU Coxe, DN Conner, BT Lauerer, J Skipper, J York, J Fraggos, M Stuart, GW AF Coxe, D. Nicole Conner, Brian T. Lauerer, Joy Skipper, Janice York, Janet Fraggos, Mary Stuart, Gail W. TI A prism of excellence: The Charleston Veterans Administration Nursing Academic Partnership SO NURSING OUTLOOK LA English DT Article DE Veterans; Academic; Partnership; Academic-service partnerships; Nursing education; Veteran-centric care ID IMPLEMENTATION AB Background: The Veterans Administration (VA) has been committed to academic affiliate training partnerships for nearly 70 years in efforts to enhance veteran centric health care. One such effort, the VA Nursing Academy (VANA) program, was developed in 2007 in response to the nationwide nursing shortage and began as a five-year pilot with funding competitively awarded to 15 partnerships between local VA medical centers and schools of nursing. The VANA program evolved into the VA Nursing Academic Partnership (VANAP) program following the initial pilot. Purpose: This article describes the development and evolution of the Charleston VANAP, which includes the Ralph H Johnson VA Medical Center (RHJ VAMC) and the Medical University of South Carolina College of Nursing (MUSC CON). Methods: The VA Office of Academic Affiliations (OAA) funded a large portion of the initial five years of the Charleston VANAP. Once the national funding source ceased, the RHJ VAMC and the MUSC CON entered into a Memorandum of Understanding (MOU) to offer in-kind contributions to the partnership. Discussion: The Charleston VANAP is the only program in the nation to offer three different nurse trainee programs and this article highlights some of the more notable achievements from each program. Conclusion: The Charleston VANAP is a comprehensive partnership between the RHJ VAMC and the MUSC CON that truly demonstrates a commitment to assure that the very best care be provided to Veterans, our Nation's heroes. C1 [Coxe, D. Nicole; Skipper, Janice; Fraggos, Mary] Ralph H Johnson VA Med Ctr, Charleston, SC USA. [Conner, Brian T.; Lauerer, Joy; York, Janet; Stuart, Gail W.] Med Univ South Carolina, Charleston, SC USA. [Conner, Brian T.; Lauerer, Joy; York, Janet; Stuart, Gail W.] Med Univ South Carolina, Coll Nursing, 99 Jonathan Lucas St, Charleston, SC 29425 USA. [Lauerer, Joy; York, Janet] Ralph H Johnson VA Med Ctr, PMHNP Residency Program, Charleston, SC USA. RP Conner, BT (reprint author), Med Univ South Carolina, Coll Nursing, 99 Jonathan Lucas St, Charleston, SC 29425 USA. EM connerb@musc.edu FU Office of Academic Affiliations; Department of Veterans Affairs FX The Charleston VANAP is supported by the Office of Academic Affiliations and the Department of Veterans Affairs. The authors acknowledge the mentorship of Dr. Mary Doughtery, Ms. Johnnie Guttery, Dr. Carole Hair, and Dr. Jemica Carter (Nursing Education, VA Office of Academic Affiliations) in the implementation of all three Charleston VANAP programs. The authors also wish to acknowledge Dr. Amelia Joseph, Dr. Nancy Duffy, and Dr. Charlene Pope as the authors of the original Charleston VANAP request for proposals; Dr. Donald (Hugh) Myrick, as a co-author of the PHMNP Residency request for proposals; Vanessa Gant-Clark, Erica Grate-Simmons, Steven Lesieur, and Dr. Stacy Gaillard as key VANAP faculty that were instrumental in the development of the VANAP curriculum; the PMHNP residency faculty and preceptors; and Dr. Christopher Pelic, Associate Chief of Staff/Education. NR 23 TC 0 Z9 0 U1 2 U2 2 PU ELSEVIER SCIENCE INC PI NEW YORK PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA SN 0029-6554 EI 1528-3968 J9 NURS OUTLOOK JI Nurs. Outlook PD SEP-OCT PY 2016 VL 64 IS 5 SI SI BP 431 EP 439 DI 10.1016/j.outlook.2016.05.003 PG 9 WC Nursing SC Nursing GA DW6CE UT WOS:000383733200007 PM 27349633 ER PT J AU Pongas, G Fojo, T AF Pongas, Georgios Fojo, Tito TI BEZ235: When Promising Science Meets Clinical Reality SO ONCOLOGIST LA English DT Editorial Material ID RENAL-CELL CARCINOMA; PHASE-III TRIAL; PANCREATIC NEUROENDOCRINE TUMORS; INTERFERON-ALPHA; DOUBLE-BLIND; TEMSIROLIMUS; MTOR; EVEROLIMUS; THERAPY; CANCER C1 [Fojo, Tito] Columbia Univ, Med Ctr, Div Hematol Oncol, Herbert Irving Pavil,9th Floor, New York, NY 10032 USA. James J Peter VA Med Ctr, Bronx, NY USA. RP Fojo, T (reprint author), Columbia Univ, Med Ctr, Div Hematol Oncol, Herbert Irving Pavil,9th Floor, New York, NY 10032 USA. EM atf2116@columbia.edu NR 32 TC 0 Z9 0 U1 2 U2 2 PU ALPHAMED PRESS PI DURHAM PA 318 BLACKWELL ST, STE 260, DURHAM, NC 27701-2884 USA SN 1083-7159 EI 1549-490X J9 ONCOLOGIST JI Oncologist PD SEP PY 2016 VL 21 IS 9 BP 1033 EP 1034 DI 10.1634/theoncologist.2016-0243 PG 2 WC Oncology SC Oncology GA DW1HJ UT WOS:000383393600003 PM 27566248 ER PT J AU Holland, CL Nkumsah, MA Morrison, P Tarr, JA Rubio, D Rodriguez, KL Kraemer, KL Day, N Arnold, RM Chang, JC AF Holland, Cynthia L. Nkumsah, Michelle Abena Morrison, Penelope Tarr, Jill A. Rubio, Doris Rodriguez, Keri L. Kraemer, Kevin L. Day, Nancy Arnold, Robert M. Chang, Judy C. TI "Anything above marijuana takes priority": Obstetric providers' attitudes and counseling strategies regarding perinatal marijuana use SO PATIENT EDUCATION AND COUNSELING LA English DT Article DE Patient-provider communication; Substance use; Pregnancy; Marijuana ID PRENATAL MARIJUANA; FAMILY PHYSICIANS; SUBSTANCE USE; ILLICIT-DRUG; PREGNANCY; ALCOHOL; DISORDERS; EXPOSURE; OUTCOMES; ABUSE AB Objective: To describe obstetric provider attitudes, beliefs, approaches, concerns, and needs about addressing perinatal marijuana use with their pregnant patients. Methods: We conducted individual semi-structured interviews with obstetric providers and asked them to describe their thoughts and experiences about addressing perinatal marijuana use. Interviews were transcribed verbatim, coded and reviewed to identify themes. Results: Fifty-one providers participated in semi-structured interviews. Providers admitted they were not familiar with identified risks of marijuana use during pregnancy, they perceived marijuana was not as dangerous as other illicit drugs, and they believed patients did not view marijuana as a drug. Most provider counseling strategies focused on marijuana's status as an illegal drug and the risk of child protective services being contacted if patients tested positive at time of delivery. Conclusions: When counseling about perinatal marijuana use, obstetric providers focus more on legal issues than on health risks. They describe needing more information regarding medical consequences of marijuana use during pregnancy. Practice implications: Provider training should include information about potential consequences of perinatal marijuana use and address ways to improve obstetric providers' counseling. Future studies should assess changes in providers' attitudes as more states consider the legalization of marijuana. (C) 2016 Elsevier Ireland Ltd. All rights reserved. C1 [Holland, Cynthia L.; Nkumsah, Michelle Abena; Morrison, Penelope; Tarr, Jill A.; Chang, Judy C.] Magee Womens Res Inst, Dept Obstet Gynecol & Reprod Sci, 300 Halket St, Pittsburgh, PA 15213 USA. [Rubio, Doris; Rodriguez, Keri L.; Kraemer, Kevin L.; Arnold, Robert M.; Chang, Judy C.] UPMC Presbyterian Hosp, Dept Med, Div Gen Internal Med, Suite W933, Pittsburgh, PA 15213 USA. [Rubio, Doris; Kraemer, Kevin L.; Arnold, Robert M.; Chang, Judy C.] Univ Pittsburgh, Ctr Res Hlth Care, 230 McKee Pl,Suite 600, Pittsburgh, PA 15213 USA. [Rubio, Doris; Kraemer, Kevin L.] Univ Pittsburgh, Clin & Translat Sci Inst, 200 Meyran Ave, Pittsburgh, PA 15213 USA. [Rodriguez, Keri L.] Vet Affairs Pittsburgh Healthcare Syst, CHERP, Univ Dr 151C, Pittsburgh, PA 15240 USA. [Day, Nancy] Univ Pittsburgh, Dept Psychiat, 3800 OHara St, Pittsburgh, PA 15213 USA. [Arnold, Robert M.] UPMC Montefiore, Sect Palliat Care & Med Eth, Inst Enhance Palliat Care, 932W,200 Lothrop St, Pittsburgh, PA 15213 USA. [Arnold, Robert M.] UPMC Montefiore, Inst Doctor Patient Commun, 932W,200 Lothrop St, Pittsburgh, PA 15213 USA. [Nkumsah, Michelle Abena] Univ Pittsburgh, Dietrich Sch Arts & Sci, 139 Univ Pl, Pittsburgh, PA 15260 USA. RP Chang, JC (reprint author), Univ Pittsburgh, Magee Womens Res Inst, Dept Obstet Gynecol & Reprod Sci, Ctr Res Hlth Care,Div Gen Internal Med,Dept Inter, 3380 Blvd Allies,Suite 328, Pittsburgh, PA 15213 USA. EM chanjc@mail.magee.edu OI RUBIO, DORIS/0000-0001-9540-6174 FU National Institute of Drug Abuse (NIDA) [1R01DA026410-01A1]; Pennsylvania Department of Health; Magee Womens Hospital Volunteer Service Board; National Institutes of Health [UL1TR000005] FX Study funded by the National Institute of Drug Abuse (NIDA) 1R01DA026410-01A1 (PI Chang), the Pennsylvania Department of Health, and the Magee Womens Hospital Volunteer Service Board, and supported by the National Institutes of Health through Grant Number UL1TR000005. Funders had no role in study design, collection analysis and interpretation of data; writing the report; and the preparation, review, approval or decision to submit the report for publication. The content does not represent the official views of the National Institute of Drug Abuse, the Pennsylvania Department of Health, Magee-Womens Hospital, or the University of Pittsburgh Medical Center. NR 43 TC 2 Z9 2 U1 2 U2 5 PU ELSEVIER IRELAND LTD PI CLARE PA ELSEVIER HOUSE, BROOKVALE PLAZA, EAST PARK SHANNON, CO, CLARE, 00000, IRELAND SN 0738-3991 J9 PATIENT EDUC COUNS JI Patient Educ. Couns. PD SEP PY 2016 VL 99 IS 9 BP 1446 EP 1451 DI 10.1016/j.pec.2016.06.003 PG 6 WC Public, Environmental & Occupational Health; Social Sciences, Interdisciplinary SC Public, Environmental & Occupational Health; Social Sciences - Other Topics GA DW0VI UT WOS:000383360700003 PM 27316326 ER PT J AU Bokhour, BG Fix, GM Gordon, HS Long, JA DeLaughter, K Orner, MB Pope, C Houston, TK AF Bokhour, Barbara G. Fix, Gemmae M. Gordon, Howard S. Long, Judith A. DeLaughter, Kathryn Orner, Michelle B. Pope, Charlene Houston, Thomas K. TI Can stories influence African-American patients' intentions to change hypertension management behaviors? A randomized control trial SO PATIENT EDUCATION AND COUNSELING LA English DT Article DE Hypertension; Narrative communication; African-American; Disparities; Health literacy; Education ID FUNCTIONAL HEALTH LITERACY; BLOOD-PRESSURE CONTROL; NARRATIVE COMMUNICATION; SELF-MANAGEMENT; PREVENTION; ADHERENCE; EDUCATION; ILLNESS; INTERVENTIONS; PROMOTION AB Objectives: Information-only interventions for hypertension management have limited effectiveness, particularly among disadvantaged populations. We assessed the impact of viewing African-American patients' stories of successfully controlling hypertension on intention to change hypertension management behaviors and engagement with educational materials. Methods: In a three-site randomized trial, 618 African-American Veterans with uncontrolled hypertension viewed an information-only DVD about hypertension (control) or a DVD adding videos of African-American Veterans telling stories about successful hypertension management (intervention). After viewing, patients were asked about their engagement with the DVD, and their intentions to change behavior. Mean scores were compared with two-sided t-tests. Results: Results favored the Stories intervention, with significantly higher emotional engagement versus control (4.3 vs. 2.2 p < 0.0001). Intervention patients reported significantly greater intentions to become more physically active (4.6 vs. 4.4, p = 0.018), use salt substitutes (3.9 vs. 3.4, p = 0.006), talk openly with their doctor about hypertension (4.6 vs. 4.5, p = 0.049), and remember to take hypertension medication (4.8 vs. 4.6, p = 0.04). Conclusion: Patients were more emotionally engaged and reported intentions to change behavior when watching real patient hypertension management success stories. Practice implications: Stories may be more influential than information alone, and represent a scalable approach to modifying behavioral intention. Published by Elsevier Ireland Ltd. C1 [Bokhour, Barbara G.; Fix, Gemmae M.; DeLaughter, Kathryn; Orner, Michelle B.; Houston, Thomas K.] ENRM Vet Affairs Med Ctr, Ctr Healthcare Org & Implementat Res, Bedford, MA 01730 USA. [Bokhour, Barbara G.; Fix, Gemmae M.] Boston Univ, Sch Publ Hlth, Dept Hlth Law Policy & Management, Boston, MA 02215 USA. [Gordon, Howard S.] Jesse Brown Vet Affairs Med Ctr, Ctr Innovat Complex Chron Healthcare, Washington, DC USA. [Gordon, Howard S.] Univ Illinois, Coll Med, Dept Med, Sect Acad Internal Med, Chicago, IL 60680 USA. [Long, Judith A.] Corporal Michael J Crescenz Philadelphia VA Med C, Ctr Hlth Equ Res & Promot, Philadelphia, PA USA. [Long, Judith A.] Univ Penn, Sch Med, Div Gen Internal Med, Philadelphia, PA 19104 USA. [Pope, Charlene] Ralph H Johnson VA Med Ctr, Charleston, SC USA. [Pope, Charlene] Med Univ South Carolina, Coll Nursing, Charleston, SC USA. [Houston, Thomas K.] Univ Massachusetts, Div Hlth Informat & Implementat Sci, Quantitat Hlth Sci, Sch Med, Amherst, MA 01003 USA. RP Bokhour, BG (reprint author), ENRM Vet Affairs Med Ctr, Ctr Healthcare Org & Implementat Res, Bedford, MA 01730 USA. EM Barbara.Bokhour@va.gov; Gemmae.Fix@va.gov; Howard.Gordon@va.gov; jalong@upenn.edu; Kathryn.Delaughter@va.gov; Michelle.Orner@va.gov; Charlene.Pope@va.gov; Thomas.Houston@va.gov RI Gordon, Howard/E-4420-2010 OI Gordon, Howard/0000-0002-6712-5954; Fix, Gemmae/0000-0001-6055-4177 FU US Department of Veterans Affairs, Health Services Research and Development [IIR 10-132]; Quality Enhancement Research Initiative, eHealth QUERI [EHQ10-190]; University of Massachusetts Clinical and Translational Sciences Award [1 UL1 TR001453 01] FX This study was funded by the US Department of Veterans Affairs, Health Services Research and Development, Grant # IIR 10-132 and the Quality Enhancement Research Initiative, eHealth QUERI, grant # EHQ10-190, Dr. Houston was also funded by the University of Massachusetts Clinical and Translational Sciences Award (1 UL1 TR001453 01). We would also like to thank the patients who agreed to tell their stories on camera, and have those stories shared far and wide to other patients. NR 48 TC 1 Z9 1 U1 5 U2 7 PU ELSEVIER IRELAND LTD PI CLARE PA ELSEVIER HOUSE, BROOKVALE PLAZA, EAST PARK SHANNON, CO, CLARE, 00000, IRELAND SN 0738-3991 J9 PATIENT EDUC COUNS JI Patient Educ. Couns. PD SEP PY 2016 VL 99 IS 9 BP 1482 EP 1488 DI 10.1016/j.pec.2016.06.024 PG 7 WC Public, Environmental & Occupational Health; Social Sciences, Interdisciplinary SC Public, Environmental & Occupational Health; Social Sciences - Other Topics GA DW0VI UT WOS:000383360700008 PM 27387121 ER PT J AU Hassamal, S Miotto, K Wang, TS Saxon, AJ AF Hassamal, Sameer Miotto, Karen Wang, Tisha Saxon, Andrew J. TI A narrative review: The effects of opioids on sleep disordered breathing in chronic pain patients and methadone maintained patients SO AMERICAN JOURNAL ON ADDICTIONS LA English DT Review ID MAINTENANCE TREATMENT; METABOLIC SYNDROME; HEART HEALTH; RISK-FACTOR; APNEA; THERAPY; SMOKING; PATHOPHYSIOLOGY; BUPRENORPHINE; REVERSAL AB Background and ObjectivesOpioids increase the risk for sleep disordered breathing (SDB), but there are few studies examining the prevalence and risk factors for SDB, specifically central sleep apnea (CSA), and obstructive sleep apnea (OSA) in chronic pain patients on opioids as well as methadone maintained patients (MMPs). MethodsA literature review was conducted in which SDB was confirmed by polysomnography (PSG) in chronic pain patients on opioids as well as patients with a diagnosis of an opioid use disorder or opioid dependence on methadone maintenance treatment (MMT). ResultsAbout 22 reports were included. Six were with MMPs, and 16 were with chronic pain patients on opioids. Among MMPs, the prevalence of SDB ranged from 42.3% to 70%; 0-60% had CSA and 10-35.2% had OSA. In chronic pain patients on opioids, the prevalence of SDB ranged from 71% to 100%; 17-80% had CSA and 20-39% had OSA. In MMPs, studies found a positive association between BMI, weight gain, duration of MMT, non-Caucasian race and the number of obstructive apneas, as well as blood methadone concentrations and the number of central apneas. In chronic pain patients on opioids, older age, higher BMI, male gender, and higher opioid doses predicted more obstructive apneas; older age, lower BMI, male gender, higher pain levels, higher benzodiazepine doses, and higher opioid doses predicted more central apneas. Conclusion and Scientific SignificanceCSA and OSA are common in MMPs and chronic pain patients on opioids. Among chronic pain patients, higher opioid doses appear to be a risk factor for CSA, and to a lesser extent OSA. Therefore, it is important for providers to screen these patient populations for SDB. (Am J Addict 2016;25:452-465) C1 [Hassamal, Sameer] UCLA Kern, Dept Addict Psychiat, 1700 Mt Vernon Ave, Bakersfield, CA 93306 USA. [Miotto, Karen] Univ Calif Los Angeles, David Geffen Sch Med, Dept Psychiat & Biobehav Sci, Semel Inst Neurosci & Human Behav, Los Angeles, CA 90095 USA. [Wang, Tisha] Univ Calif Los Angeles, David Geffen Sch Med, Div Pulm Crit Care & Sleep Med, Dept Med, Los Angeles, CA 90095 USA. [Saxon, Andrew J.] Vet Affairs Puget Sound Hlth Care Syst, Ctr Excellence Subst Abuse Treatment & Educ, Seattle, WA USA. RP Hassamal, S (reprint author), UCLA Kern, Dept Addict Psychiat, 1700 Mt Vernon Ave, Bakersfield, CA 93306 USA. EM shassama@gmail.com NR 80 TC 1 Z9 1 U1 3 U2 3 PU WILEY-BLACKWELL PI HOBOKEN PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA SN 1055-0496 EI 1521-0391 J9 AM J ADDICTION JI Am. J. Addict. PD SEP PY 2016 VL 25 IS 6 BP 452 EP 465 DI 10.1111/ajad.12424 PG 14 WC Substance Abuse SC Substance Abuse GA DV9TB UT WOS:000383283800002 PM 27554389 ER PT J AU Newsome, H Mandapathil, M Koh, YW Duvvuri, U AF Newsome, Hillary Mandapathil, Magis Koh, Yoon Woo Duvvuri, Umamaheswar TI Utility of the Highly Articulated Flex Robotic System for Head and Neck Procedures: A Cadaveric Study SO ANNALS OF OTOLOGY RHINOLOGY AND LARYNGOLOGY LA English DT Article DE TORS; thyroid surgery; neck dissection; salivary gland; head and neck surgery ID TRANSORAL SURGERY; DISSECTION; CARCINOMA; CANCER AB Objective: Robotic head and neck surgery potentially reduces the morbidity associated with traditional open procedures. This study's goal was to employ a novel highly articulated robotic system (Flex Robotic System) for head and neck procedures, including a postauricular facelift approach thyroidectomy, submandibular gland (SMG) removal, and cervical lymphadenectomy. Study Design: It was hypothesized that the Medrobotics Flex Robotic System could be used for transcervical head and neck surgical procedures. Methods: Three fresh upper body human cadavers were used. The Flex Robotic System was used to complete a thyroidectomy, neck dissection, and SMG removal on each cadaver. Results: A postauricular incision and flap was manually raised. The robotic system was positioned on the right side of the cadaver's head. The system's manually controlled flexible instruments and highly shapeable, robot-assisted scope were used to perform a thyroid lobectomy. Neck dissection and SMG removal were also performed. Conclusions: Although a promising technology, the current robotic system (Intuitive Surgical Inc, Sunnyvale, California, USA) has limitations due to its rigid and large configuration, which decreases exposure and access. The new system's shapeable, computer-assisted scope seeks to reduce some of these difficulties and may be better adapted for transcervical approaches to the neck operations. C1 [Newsome, Hillary; Duvvuri, Umamaheswar] Univ Pittsburgh, Med Ctr, Vet Affairs Pittsburgh Hlth Syst, UPMC Dept Otolaryngol Head & Neck Surg, Pittsburgh, PA USA. [Mandapathil, Magis] Univ Marburg, Dept Otorhinolaryngol Head & Neck Surg, Baldingerstr, Marburg, Germany. [Koh, Yoon Woo] Yonsei Univ, Dept Otorhinolaryngol, Severance Hosp, Seoul, South Korea. RP Duvvuri, U (reprint author), Univ Pittsburgh, Med Ctr, Inst Eye & Ear, Vet Affairs Pittsburgh Hlth Syst,Dept Otolaryngol, Suite 500,200 Lothrop St, Pittsburgh, PA 15213 USA. EM duvvuriu@upmc.edu FU BLR&D Career Development Award; PNC Foundation FX The author(s) disclosed receipt of the following financial support for the research, authorship, and/or publication of this article: This work was funded in part by funds from BLR&D Career Development Award and the PNC Foundation (U.D.) NR 16 TC 0 Z9 0 U1 4 U2 4 PU SAGE PUBLICATIONS INC PI THOUSAND OAKS PA 2455 TELLER RD, THOUSAND OAKS, CA 91320 USA SN 0003-4894 EI 1943-572X J9 ANN OTO RHINOL LARYN JI Ann. Otol. Rhinol. Laryngol. PD SEP PY 2016 VL 125 IS 9 BP 758 EP 763 DI 10.1177/0003489416653409 PG 6 WC Otorhinolaryngology SC Otorhinolaryngology GA DU4XS UT WOS:000382216900010 PM 27287677 ER PT J AU Liu, LCY Voors, AA Teerlink, JR Cotter, G Davison, BA Felker, GM Filippatos, G Chen, YK Greenberg, BH Ponikowski, P Pang, PS Prescott, MF Hua, TA Severin, TM Metra, M AF Liu, Licette C. Y. Voors, Adriaan A. Teerlink, John R. Cotter, Gad Davison, Beth A. Felker, G. Michael Filippatos, Gerasimos Chen, Yakuan Greenberg, Barry H. Ponikowski, Piotr Pang, Peter S. Prescott, Margaret F. Hua, Tsushung A. Severin, Thomas M. Metra, Marco TI Effects of serelaxin in acute heart failure patients with renal impairment: results from RELAX-AHF SO CLINICAL RESEARCH IN CARDIOLOGY LA English DT Article DE Serelaxin; Acute heart failure; Renal function; Renal impairment; Number needed to treat ID GLOMERULAR-FILTRATION-RATE; SERUM CYSTATIN-C; RECOMBINANT HUMAN RELAXIN; PLACEBO-CONTROLLED TRIAL; CHRONIC KIDNEY-DISEASE; RANDOMIZED-TRIALS; HORMONE RELAXIN; CONSCIOUS RATS; DOUBLE-BLIND; CREATININE AB Serelaxin showed beneficial effects on clinical outcome and trajectories of renal markers in patients with acute heart failure. We aimed to study the interaction between renal function and the treatment effect of serelaxin. In the current post hoc analysis of the RELAX-AHF trial, we included all patients with available estimated glomerular filtration rate (eGFR) at baseline (n = 1132). Renal impairment was defined as an eGFR < 60 ml/min/1.73 m(2) estimated by creatinine. 817 (72.2 %) patients had a baseline eGFR < 60 ml/min/1.73 m(2). In placebo-treated patients, baseline renal impairment was related to a higher 180 day cardiovascular (HR 3.12, 95 % CI 1.33-7.30) and all-cause mortality (HR 2.81, 95 % CI 1.34-5.89). However, in serelaxin-treated patients, the risk of cardiovascular and all-cause mortality was less pronounced (HR 1.19, 95 % CI 0.54 -2.64; p for interaction = 0.106, and HR 1.15 95 % CI 0.56-2.34 respectively; p for interaction = 0.088). In patients with renal impairment, treatment with serelaxin resulted in a more pronounced all-cause mortality reduction (HR 0.53, 95 % CI 0.34-0.83), compared with patients without renal impairment (HR 1.30, 95 % CI 0.51-3.29). Renal dysfunction was associated with higher cardiovascular and all-cause mortality in placebo-treated patients, but not in serelaxin-treated patients. The observed reduction in (cardiovascular) mortality in RELAX-AHF was more pronounced in patients with renal dysfunction. These observations need to be confirmed in the ongoing RELAX-AHF-2 trial. C1 [Liu, Licette C. Y.; Voors, Adriaan A.] Univ Groningen, Univ Med Ctr Groningen, Dept Cardiol, Hanzepl 1, NL-9713 GZ Groningen, Netherlands. [Teerlink, John R.] Univ Calif San Francisco, San Francisco Vet Affairs Med Ctr, San Francisco, CA 94143 USA. [Cotter, Gad; Davison, Beth A.] Momentum Res, Durham, NC USA. [Felker, G. Michael] Duke Univ, Sch Med, Duke Heart Ctr, Durham, NC USA. [Filippatos, Gerasimos] Univ Athens, Attikon Univ Hosp, Sch Med, Athens, Greece. [Chen, Yakuan] Columbia Univ, Med Ctr, New York, NY USA. [Greenberg, Barry H.] Univ Calif San Diego, San Diego, CA 92103 USA. [Ponikowski, Piotr] Med Univ, Clin Mil Hosp, Wroclaw, Poland. [Pang, Peter S.] Indiana Univ Sch Med, Indianapolis, IN 46202 USA. [Prescott, Margaret F.; Hua, Tsushung A.; Severin, Thomas M.] Novartis Pharmaceut, Basel, Switzerland. [Metra, Marco] Univ Brescia, Brescia, Italy. RP Voors, AA (reprint author), Univ Groningen, Univ Med Ctr Groningen, Dept Cardiol, Hanzepl 1, NL-9713 GZ Groningen, Netherlands. EM a.a.voors@umcg.nl RI Ponikowski, Piotr/O-6454-2015 OI Ponikowski, Piotr/0000-0002-3391-7064 FU Alere; Bayer; Cardio3Biosciences; Celladon; Ceva; European Committee; Dutch Heart Foundation; Novartis; Servier; Torrent; Vifor; Amgen; Corthera; Cardio3 Bioscience; Cytokinetics; Merck; Takeda; Teva; Trevena; Otsuka; Roche Diagnostics; NHLBI; European Union; Abbott; PDL BioPharma; Novartis Pharma FX LCYL, YC have nothing to disclose. AAV has received consultancy fees and/or research grants from Alere, Bayer, Cardio3Biosciences, Celladon, Ceva, European Committee, Dutch Heart Foundation, Novartis, Servier, Torrent, and Vifor. JRT has received research grants or consulting fees from Amgen, Bayer, Corthera, Cardio3 Bioscience, Cytokinetics, Merck, Novartis, Takeda, Teva, and Trevena. GC and BAD are employees of Momentum Research, which has provided consulting and trial management services to NovaCardia, Merck, Corthera, Novartis, Nile Therapeutics, Bioheart, Cardio3 Biosciences, Amgen, Celadon, Targegen, Trevena, Sorbent Therapeutics, and NIH. GMF reports consulting income from Novartis, Medpace, Amgen, Otsuka, Trevena, Roche Diagnostics, Merck, BG Medicine, Medtronic, and St Judes and grant fundings from Amgen, Otsuka, Roche Diagnostics, and NHLBI. GF is an executive committee member and consultant to Corthera (a Novartis company), Bayer, Cardiorentis, and has received research grants from Amgen, European Union. BHG served as a consultant for Corthera and Novartis. PP was a consultant for Astellas, Bayer, EKR Therapeutics, J&J, the Medicines Company, Medtronic, Novartis, Otsuka, Palatin Technologies, PDL BioPharma, Pericor Therapeutics, SigmaTau, Solvay Pharmaceuticals, and Trevena; has received honoraria from Alere, Beckman-Coulter, BiogenIdec, Corthera, Ikaria, Nile Therapeutics, Momentum Research, and Overcome; has received research support from Abbott, Merck and PDL BioPharma; and has received travel support from MyLife and equipment support from Sonosite. PSP, in the last 1 year is or has been a Consultant for: Intersection Medical, INSYS. Janssen, Medtronic, Novartis, Trevena, scPharmaceuticals, Cardioxyl, Roche Diagnostics, Relypsa, Honoraria: Palatin Technologies. MP, TAH and TMS are employees of and receive salary, benefits, and stocks options from Novartis Pharma. MM has received consulting income from Abbott Vascular, Bayer, Corthera, and Novartis, as well as travel support and honoraria from Servier and Novartis. NR 40 TC 2 Z9 2 U1 4 U2 5 PU SPRINGER HEIDELBERG PI HEIDELBERG PA TIERGARTENSTRASSE 17, D-69121 HEIDELBERG, GERMANY SN 1861-0684 EI 1861-0692 J9 CLIN RES CARDIOL JI Clin. Res. Cardiol. PD SEP PY 2016 VL 105 IS 9 BP 727 EP 737 DI 10.1007/s00392-016-0979-8 PG 11 WC Cardiac & Cardiovascular Systems SC Cardiovascular System & Cardiology GA DU2BL UT WOS:000382015600002 PM 27017514 ER PT J AU Taber, DJ Hunt, KJ Fominaya, CE Payne, EH Gebregziabher, M Srinivas, TR Baliga, PK Egede, LE AF Taber, David J. Hunt, Kelly J. Fominaya, Cory E. Payne, Elizabeth H. Gebregziabher, Mulugeta Srinivas, Titte R. Baliga, Prabhakar K. Egede, Leonard E. TI Impact of Cardiovascular Risk Factors on Graft Outcome Disparities in Black Kidney Transplant Recipients SO HYPERTENSION LA English DT Article DE cardiovascular disease; diabetes mellitus; graft survival; hypertension; prevalence ID RENAL-ALLOGRAFT SURVIVAL; HIGH BLOOD-PRESSURE; AFRICAN-AMERICAN; RACIAL-DIFFERENCES; ETHNIC DISPARITIES; ORGAN TRANSPLANT; PATIENT SURVIVAL; UNITED NETWORK; ADHERENCE; DISEASE AB Although outcome inequalities for non-Hispanic black (NHB) kidney transplant recipients are well documented, there is paucity in data assessing the impact of cardiovascular disease (CVD) risk factors on this disparity in kidney transplantation. This was a longitudinal study of a national cohort of veteran kidney recipients transplanted between January 2001 and December 2007. Data included baseline characteristics acquired through the United States Renal Data System linked to detailed clinical follow-up information acquired through the Veterans Affairs electronic health records. Analyses were conducted using sequential multivariable modeling (Cox regression), incorporating blocks of variables into iterative nested models; 3139 patients were included (2095 non-Hispanic whites [66.7%] and 1044 NHBs [33.3%]). NHBs had a higher prevalence of hypertension (100% versus 99%; P<0.01) and post-transplant diabetes mellitus (59% versus 53%; P<0.01) with reduced control of hypertension (blood pressure <140/90 60% versus 69%; P<0.01), diabetes mellitus (A1c <7%, 35% versus 47%; P<0.01), and low-density lipoprotein (<100 mg/dL, 55% versus 61%; P<0.01). Adherence to medications used to manage CVD risk was significantly lower in NHBs. In the fully adjusted models, the independent risk of graft loss in NHBs was substantially reduced (unadjusted hazard ratio, 2.00 versus adjusted hazard ratio, 1.49). CVD risk factors and control reduced the influence of NHB race by 9% to 18%. Similar trends were noted for mortality, and estimates were robust across in sensitivity analyses. These results demonstrate that NHB kidney transplant recipients have significantly higher rates of CVD risk factors and reduced CVD risk control. These issues are likely partly related to medication nonadherence and meaningfully contribute to racial disparities for graft outcomes. C1 [Taber, David J.; Baliga, Prabhakar K.] Med Univ South Carolina, Div Transplant Surg, Coll Med, Charleston, SC USA. [Srinivas, Titte R.] Med Univ South Carolina, Div Transplant Nephrol, Charleston, SC USA. [Srinivas, Titte R.] Med Univ South Carolina, Div Transplant Nephrol, Charleston, SC USA. [Taber, David J.; Fominaya, Cory E.] Ralph H Johnson VAMC, Dept Pharm Serv, Charleston, SC USA. [Egede, Leonard E.] Ralph H Johnson VAMC, Vet Affairs HSR&D Hlth Equ & Rural Outreach Innov, Charleston, SC USA. RP Taber, DJ (reprint author), Med Univ South Carolina, Div Transplant Surg, 96 Jonathan Lucas St,MSC 611, Charleston, SC 29425 USA. EM taberd@musc.edu OI Gebregziabher, Mulugeta/0000-0002-4826-481X FU National Institute of Diabetes and Digestive and Kidney Diseases of the National Institutes of Health [K23DK099440] FX Research reported in this publication was supported by the National Institute of Diabetes and Digestive and Kidney Diseases of the National Institutes of Health under Award Number K23DK099440. NR 63 TC 0 Z9 0 U1 1 U2 1 PU LIPPINCOTT WILLIAMS & WILKINS PI PHILADELPHIA PA TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA SN 0194-911X EI 1524-4563 J9 HYPERTENSION JI Hypertension PD SEP PY 2016 VL 68 IS 3 BP 715 EP + DI 10.1161/HYPERTENSIONAHA.116.07775 PG 21 WC Peripheral Vascular Disease SC Cardiovascular System & Cardiology GA DT1ZK UT WOS:000381280400028 PM 27402921 ER PT J AU Quast, J Knobloch, MJ Patterson, E Purvis, S Shirley, D Safdar, N AF Quast, Joshua Knobloch, Mary Jo Patterson, Erin Purvis, Suzanne Shirley, Daniel Safdar, Nasia TI Understanding Inpatient Perceptions of Indwelling Urinary Catheters Using the Health Belief Model SO INFECTION CONTROL AND HOSPITAL EPIDEMIOLOGY LA English DT Article AB Patient interviews using the Health Belief Model framework identified thematic patient perceptions of indwelling urinary catheters and catheter-associated urinary tract infections. Generally, patients perceived catheters as convenient and were unaware of catheter alternatives and risks for infection. Better patient education is needed to reduce urinary catheter use and infections. C1 [Quast, Joshua; Knobloch, Mary Jo; Safdar, Nasia] Univ Wisconsin, Dept Med, Div Infect Dis, Madison, WI USA. [Knobloch, Mary Jo; Patterson, Erin; Safdar, Nasia] William S Middleton Mem Vet Adm Med Ctr, Madison, WI USA. [Purvis, Suzanne] Univ Wisconsin, Dept Med, Div Geriatr, Madison, WI USA. [Shirley, Daniel] Univ Wisconsin, Dept Med, Div Hosp Med, Madison, WI USA. RP Safdar, N (reprint author), 1685 Highland Ave, Madison, WI 53705 USA. EM ns2@medicine.wisc.edu FU Agency for Healthcare Research and Quality [R03HS023791] FX Agency for Healthcare Research and Quality (grant R03HS023791). NR 9 TC 0 Z9 0 U1 5 U2 5 PU CAMBRIDGE UNIV PRESS PI NEW YORK PA 32 AVENUE OF THE AMERICAS, NEW YORK, NY 10013-2473 USA SN 0899-823X EI 1559-6834 J9 INFECT CONT HOSP EP JI Infect. Control Hosp. Epidemiol. PD SEP PY 2016 VL 37 IS 9 BP 1098 EP 1100 DI 10.1017/ice.2016.120 PG 3 WC Public, Environmental & Occupational Health; Infectious Diseases SC Public, Environmental & Occupational Health; Infectious Diseases GA DV4LJ UT WOS:000382896800013 PM 27225225 ER PT J AU Lopez, MS Dempsey, RJ Vemuganti, R AF Lopez, Mary S. Dempsey, Robert J. Vemuganti, Raghu TI Resveratrol preconditioning induces cerebral ischemic tolerance but has minimal effect on cerebral microRNA profiles SO JOURNAL OF CEREBRAL BLOOD FLOW AND METABOLISM LA English DT Article DE Acute stroke; basic science; focal ischemia; genetics; neuroprotection ID TRAUMATIC BRAIN-INJURY; SPINAL-CORD-INJURY; OXIDATIVE STRESS; SUBARACHNOID HEMORRHAGE; BEHAVIORAL IMPAIRMENTS; UP-REGULATION; EXPRESSION; MOUSE; RATS; REPERFUSION AB The health benefits of the plant-derived polyphenol resveratrol were established in multiple disease systems. Notably, pre-treatment with resveratrol was shown to be neuroprotective in several models of cerebral ischemia. Mechanisms of resveratrol-mediated neuroprotection have been explored in the context of canonical resveratrol targets, but epigenetic and non-coding RNA processes have not yet been evaluated. Resveratrol was shown to alter microRNAs in cancer and cardiac ischemia. Previous studies also showed that ischemic preconditioning that induces ischemic tolerance significantly alters cerebral microRNA levels, particularly those that target neuroprotective pathways. Therefore, we tested if resveratrol-mediated ischemic tolerance also alters microRNA expression with a goal to identify microRNAs that are amenable to manipulation to induce neuroprotection after cerebral ischemia. Hence, we tested the microRNA profiles in mouse brain following intraperitoneal administration of resveratrol that induced significant tolerance against transient focal ischemia. We analyzed microRNA profiles using microarrays from both Affymetrix and LC Sciences that contain probes for all known mouse microRNAs. The results show that there is no consistent change in any of the microRNAs tested between resveratrol and vehicle groups indicating that microRNAs play a minimal role in resveratrol-mediated cerebral ischemic tolerance. C1 [Lopez, Mary S.; Dempsey, Robert J.; Vemuganti, Raghu] Univ Wisconsin, Dept Neurol Surg, 600 Highland Ave, Madison, WI 53792 USA. [Lopez, Mary S.; Vemuganti, Raghu] Univ Wisconsin, Cellular & Mol Pathol Training Program, Madison, WI USA. [Dempsey, Robert J.; Vemuganti, Raghu] Univ Wisconsin, Neurosci Training Program, Madison, WI USA. [Vemuganti, Raghu] William S Middleton Mem Vet Adm Med Ctr, Madison, WI USA. RP Vemuganti, R (reprint author), Univ Wisconsin, Dept Neurol Surg, 600 Highland Ave, Madison, WI 53792 USA. EM vemuganti@neurosurgery.wisc.edu FU UW Cellular & Molecular Pathology Graduate Training Program by the National Institutes of Health [T32GM081061]; Department of Neurological Surgery, University of Wisconsin-Madison FX The author(s) disclosed receipt of the following financial support for the research, authorship, and/or publication of this article: Mary Lopez received a fellowship from the UW Cellular & Molecular Pathology Graduate Training Program supported by the National Institutes of Health Award T32GM081061. This work was partially supported by the Department of Neurological Surgery, University of Wisconsin-Madison. NR 43 TC 2 Z9 2 U1 6 U2 10 PU NATURE PUBLISHING GROUP PI NEW YORK PA 75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA SN 0271-678X EI 1559-7016 J9 J CEREBR BLOOD F MET JI J. Cereb. Blood Flow Metab. PD SEP PY 2016 VL 36 IS 9 BP 1644 EP 1650 DI 10.1177/0271678X16656202 PG 7 WC Endocrinology & Metabolism; Hematology; Neurosciences SC Endocrinology & Metabolism; Hematology; Neurosciences & Neurology GA DV5UU UT WOS:000382996800015 PM 27323784 ER PT J AU Loring, Z Cohen, JK Morgan, J Yang, J Zimmet, J AF Loring, Zak Cohen, Jenny K. Morgan, Juliet Yang, Joseph Zimmet, Jeffrey TI The late presenting STEMI: How ECG scores can be used to estimate event time SO JOURNAL OF ELECTROCARDIOLOGY LA English DT Article DE STEMI; ECG scores; Clinical decision-making ID MYOCARDIAL-INFARCTION; ANGIOPLASTY; ANTERIOR; SALVAGE; TRIALS; SIZE AB Introduction: Patients presenting with ST elevation myocardial infarction (STEMI) derive significant benefit from timely percutaneous coronary intervention (PCI). Electrocardiogram (ECG) scoring systems can complement history to estimate the infarction age and inform clinical decision-making. Case: A 76 year old man presented with eight days of dyspnea on exertion and chest pain. Triage ECG showed ST elevation and Q waves in the anterior leads. The patient was taken for coronary angiography and found to have a 100% occlusion of the left anterior descending artery. Discussion: Determining timing of acute coronary syndromes is challenging. ECG indices aid clinical history by quantifying infarction acuity. (C) 2016 Elsevier Inc. All rights reserved. C1 [Loring, Zak; Cohen, Jenny K.; Morgan, Juliet] Univ Calif San Francisco, Dept Med, San Francisco, CA 94143 USA. [Yang, Joseph; Zimmet, Jeffrey] Univ Calif San Francisco, Dept Med, Div Cardiol, San Francisco, CA 94143 USA. [Zimmet, Jeffrey] San Francisco VA Med Ctr, Dept Med, Div Cardiol, San Francisco, CA 94121 USA. RP Loring, Z (reprint author), Univ Calif San Francisco, 505 Parnassus Ave, San Francisco, CA 94143 USA. EM zak.loring@ucsf.edu NR 8 TC 0 Z9 0 U1 2 U2 3 PU CHURCHILL LIVINGSTONE INC MEDICAL PUBLISHERS PI PHILADELPHIA PA CURTIS CENTER, INDEPENDENCE SQUARE WEST, PHILADELPHIA, PA 19106-3399 USA SN 0022-0736 EI 1532-8430 J9 J ELECTROCARDIOL JI J. Electrocardiol. PD SEP-OCT PY 2016 VL 49 IS 5 BP 740 EP 743 DI 10.1016/j.jelectrocard.2016.06.013 PG 4 WC Cardiac & Cardiovascular Systems SC Cardiovascular System & Cardiology GA DV8VS UT WOS:000383215400020 PM 27426204 ER PT J AU Aspinall, SL Sales, MM Good, CB Calabrese, V Glassman, PA Burk, M Moore, VR Neuhauser, MM Golterman, L Ourth, H Valentino, MA Cunningham, FE AF Aspinall, Sherrie L. Sales, Mariscelle M. Good, Chester B. Calabrese, Vincent Glassman, Peter A. Burk, Muriel Moore, Von R. Neuhauser, Melinda M. Golterman, Lori Ourth, Heather Valentino, Michael A. Cunningham, Francesca E. TI Pharmacy Benefits Management in the Veterans Health Administration Revisited: A Decade of Advancements, 2004-2014 SO JOURNAL OF MANAGED CARE & SPECIALTY PHARMACY LA English DT Article ID CARE-SYSTEM AB Over the past decade, the Department of Veterans Affairs (VA) Pharmacy Benefits Management Services (PBM) has enhanced its formulary management activities and added programs to ensure that the national drug plan continues to meet the pharmacy needs of veterans and to promote safe and appropriate drug therapy in the face of rising medication expenditures. This article describes the broad range of services provided by the VA PBM that work in partnership to deliver a high-quality and sustainable pharmacy benefit for veterans. In support of formulary management, VA PBM pharmacists prepare extensive clinical guidance documents (e.g., drug monographs and criteria for use) that are used by physicians and pharmacists with operational and clinical oversight of the VA national formulary. The VA PBM has utilized various contracting techniques and continually evaluates drug utilization data to identify opportunities for potential savings. Remarkably, since before 2004, the average acquisition cost for a 1-month supply of medication has remained fairly stable at approximately $13-$15. Two new VA PBM programs are the VA Center for Medication Safety (VA MedSAFE) and the Clinical Pharmacy Practice Office (CPPO). VA MedSAFE is a comprehensive pharmacovigilance program focused on the detection, assessment, and prevention of adverse drug events, and CPPO is dedicated to improving safe and appropriate medication use by supporting and expanding clinical pharmacy practice. Moving forward, the VA PBM will consider new initiatives to stay at the forefront of providing quality care while maintaining economic viability. Copyright (C) 2016, Academy of Managed Care Pharmacy. All rights reserved. C1 [Aspinall, Sherrie L.; Sales, Mariscelle M.; Calabrese, Vincent; Burk, Muriel; Moore, Von R.; Neuhauser, Melinda M.; Ourth, Heather; Cunningham, Francesca E.] VA Pharm Benefits Management Serv, Hines, IL USA. [Aspinall, Sherrie L.] VA Pittsburgh Healthcare Syst, Ctr Hlth Equ Res & Promot, Univ Dr 151C,Bldg 30, Pittsburgh, PA 15240 USA. [Aspinall, Sherrie L.] Univ Pittsburgh, Sch Pharm, Pittsburgh, PA USA. [Good, Chester B.] Univ Pittsburgh, Sch Pharm, Ctr Hlth Equ Res & Promot, VA Pittsburgh Healthcare Syst, Pittsburgh, PA USA. [Good, Chester B.] Sch Med, Pittsburgh, PA USA. [Good, Chester B.; Golterman, Lori; Valentino, Michael A.] VA Pharm Benefits Management Serv, Washington, DC USA. [Glassman, Peter A.] VA Greater Los Angeles Healthcare Syst, Dept Med, Los Angeles, CA USA. [Glassman, Peter A.] Univ Calif Los Angeles, David Geffen Sch Med, Los Angeles, CA 90095 USA. RP Aspinall, SL (reprint author), VA Pittsburgh Healthcare Syst, Ctr Hlth Equ Res & Promot, Univ Dr 151C,Bldg 30, Pittsburgh, PA 15240 USA. EM shenie.aspinall@va.gov FU VA Pharmacy Benefits Management Services (VA PBM), Hines, Illinois; VA Pittsburgh Healthcare System, Pittsburgh, Pennsylvania FX No outside funding supported this research. This work was supported by VA Pharmacy Benefits Management Services (VA PBM), Hines, Illinois, and VA Pittsburgh Healthcare System, Pittsburgh, Pennsylvania. Glassman is co-director of the VA Center for Medication Safety, which is part of the VA PBM He is also part of the Medical Advisory Panel for the VA PMB. All other authors are employed by the VA PBM The views expressed in this article are those of the authors, and no official endorsement by the U.S. Department of Veteran Affairs or the U.S. government is intended or should be inferred. NR 11 TC 0 Z9 0 U1 1 U2 1 PU ACAD MANAGED CARE PHARMACY PI ALEXANDRIA PA 100 N PITT ST, 400, ALEXANDRIA, VA 22314-3134 USA SN 2376-0540 EI 2376-1032 J9 J MANAG CARE SPEC PH JI J. Manag. Care Spec. Pharm. PD SEP PY 2016 VL 22 IS 9 BP 1058 EP 1063 PG 6 WC Health Care Sciences & Services; Pharmacology & Pharmacy SC Health Care Sciences & Services; Pharmacology & Pharmacy GA DV4NG UT WOS:000382901700007 PM 27579828 ER PT J AU Wang, CY Kundaria, S Fernandez-Miranda, J Duvvuri, U AF Wang, Chengyuan Kundaria, Summit Fernandez-Miranda, Juan Duvvuri, Umamaheswar TI A description of the anatomy of the glossopharyngeal nerve as encountered in transoral surgery SO LARYNGOSCOPE LA English DT Article DE Glossopharyngeal nerve; transoral surgery; parapharyngeal space; anatomy ID SURGICAL ANATOMY; NEURALGIA; TONSILLECTOMY; BLOCK AB Objectives/HypothesisTo illustrate detailed anatomy of the extracranial portion of the glossopharyngeal nerve in the parapharyngeal space as encountered during transoral surgery. Study DesignProspective cadaveric dissection. All dissections were performed transorally and confirmed with transcervical dissection. MethodsEight color-injected cadaveric heads (16 sides) were dissected to demonstrate the course and anatomy of the glossopharyngeal nerve. Conventional external dissections were performed to verify our anatomic measurements. Anatomical measurements of the glossopharyngeal nerve, including segments, branches in each segment, relationship with stylopharyngeus muscle, internal carotid artery, and pharyngeal branch of Vagus were recorded and analyzed. ResultsThe glossopharyngeal nerve was separated into three segments according to the relationship with the stylopharyngeus muscle. Total lengths of the glossopharyngeal nerve are 32.6 3.1 (left side) and 30.6 3.7 (right side) mm, respectively. The average number of branches in the upper, middle, and lower segments is 3 (range 1-3), 4 (range 2-4), and 3 (range 1-3), respectively. The total number of branches is 8 (range 6-9). The average diameter of the main trunk of the glossopharyngeal nerve is 1.2 +/- 0.3 mm, and the average diameter of the lingual branch of the glossopharyngeal nerve is approximately 0.6 +/- 0.2 mm. In 75% of cases, pharyngeal branch of Vagus crosses the glossopharyngeal nerve, whereas in 25% of cases it parallels the course of the glossopharyngeal nerve to form the pharyngeal nerve plexus to innervate the pharyngeal wall. ConclusionUnderstanding the precise and detailed anatomy of the glossopharyngeal nerve in the parapharyngeal space is important in transoral surgery for indications such as transoral robotic surgery or transoral laser microsurgery tumor resection, lingual tonsillectomy, glossopharyngeal neuralgia, glossopharyngeal nerve block, and internal carotid artery dissection. Level of EvidenceN/A. Laryngoscope, 126:2010-2015, 2016 C1 [Wang, Chengyuan] China Japan Friendship Hosp, Dept Otolaryngol Head & Neck Surg, Beijing, Peoples R China. [Wang, Chengyuan] Shenmu Cty Hosp, Dept Head & Neck Surg, Yulin, Shanxi Province, Peoples R China. [Wang, Chengyuan; Kundaria, Summit; Duvvuri, Umamaheswar] Vet Affairs Pittsburgh Hlth Syst, Pittsburgh, PA USA. [Wang, Chengyuan; Kundaria, Summit; Duvvuri, Umamaheswar] Univ Pittsburgh, Inst Eye & Ear, Med Ctr, UPMC Dept Otolaryngol Head & Neck Surg, Pittsburgh, PA 15213 USA. [Wang, Chengyuan; Fernandez-Miranda, Juan] Univ Pittsburgh, Med Ctr, Dept Neurosurg, Pittsburgh, PA USA. RP Duvvuri, U (reprint author), Univ Pittsburgh, Vet Affairs Pittsburgh Hlth Syst, Dept Otolaryngol, Med Ctr,Eye & Ear Inst, Suite 500,200 Lothrop St, Pittsburgh, PA 15213 USA. EM duvuriu@upmc.edu FU Department of Veterans Affairs Bureau of Labor Statistics RD; pittsburgh national corporation (PNC) Foundation FX This work was funded in part by the Department of Veterans Affairs Bureau of Labor Statistics R&D, and the pittsburgh national corporation (PNC) Foundation (U.D.). The authors have no other funding, financial relationships, or conflicts of interest to disclose. NR 15 TC 0 Z9 0 U1 3 U2 3 PU WILEY-BLACKWELL PI HOBOKEN PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA SN 0023-852X EI 1531-4995 J9 LARYNGOSCOPE JI Laryngoscope PD SEP PY 2016 VL 126 IS 9 BP 2010 EP 2015 DI 10.1002/lary.25706 PG 6 WC Medicine, Research & Experimental; Otorhinolaryngology SC Research & Experimental Medicine; Otorhinolaryngology GA DV9VD UT WOS:000383289400021 PM 27312369 ER PT J AU Scalea, JR Redfield, RR Foley, DP AF Scalea, Joseph R. Redfield, Robert R. Foley, David P. TI Liver transplant outcomes using ideal donation after circulatory death livers are superior to using older donation after brain death donor livers SO LIVER TRANSPLANTATION LA English DT Article ID CARDIAC DEATH; GRAFT-SURVIVAL; EXPERIENCE; KIDNEY; POOL; ALLOGRAFTS; EXPANSION; VOLUME; AGE AB Multiple reports have demonstrated that liver transplantation following donation after circulatory death (DCD) is associated with poorer outcomes when compared with liver transplantation from donation after brain death (DBD) donors. We hypothesized that carefully selected, underutilized DCD livers recovered from younger donors have excellent outcomes. We performed a retrospective study of the United Network for Organ Sharing database to determine graft survivals for patients who received liver transplants from DBD donors of age60 years, DBD donors<60 years, and DCD donors<50 years of age. Between January 2002 and December 2014, 52,271 liver transplants were performed in the United States. Of these, 41,181 (78.8%) underwent transplantation with livers from DBD donors of age<60 years, 8905 (17.0%) from DBD donors60 years old, and 2195 (4.2%) livers from DCD donors<50 years of age. DCD livers of age<50 years with<6 hours of cold ischemia time (CIT) had superior graft survival when compared with DBD liversage 60 years (P<0.001). In 2014, there were 133 discarded DCD livers; of these, 111 (83.4%) were from donors60 years old. Careful donor organ and recipient selection can lead to excellent results, despite previous reports suggesting otherwise. Increased acceptance of these DCD livers would lead to shorter wait list times and increased national liver transplant rates. Liver Transplantation 22 1197-1204 2016 AASLD C1 [Scalea, Joseph R.; Redfield, Robert R.; Foley, David P.] Univ Wisconsin, Dept Surg, Div Transplantat, Sch Med & Publ Hlth, 600 Highland Ave,Suite H4-7, Madison, WI 53792 USA. [Foley, David P.] William S Middleton Mem Vet Adm Med Ctr, Vet Adm Surg Serv, Madison, WI USA. RP Scalea, JR (reprint author), Univ Wisconsin, Dept Surg, Div Transplantat, Sch Med & Publ Hlth, 600 Highland Ave,Suite H4-7, Madison, WI 53792 USA. EM scalea@surgery.wisc.edu NR 25 TC 3 Z9 3 U1 0 U2 0 PU WILEY-BLACKWELL PI HOBOKEN PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA SN 1527-6465 EI 1527-6473 J9 LIVER TRANSPLANT JI Liver Transplant. PD SEP PY 2016 VL 22 IS 9 BP 1197 EP 1204 DI 10.1002/lt.24494 PG 8 WC Gastroenterology & Hepatology; Surgery; Transplantation SC Gastroenterology & Hepatology; Surgery; Transplantation GA DV9VI UT WOS:000383289900004 PM 27314220 ER PT J AU Crytzer, TM Hong, EK Dicianno, BE Pearlman, J Schmeler, M Cooper, RA AF Crytzer, Theresa M. Hong, Eun-Kyoung Dicianno, Brad E. Pearlman, Jon Schmeler, Mark Cooper, Rory A. TI Identifying characteristic back shapes from anatomical scans of wheelchair users to improve seating design SO MEDICAL ENGINEERING & PHYSICS LA English DT Article DE Assistive technology; Backrest; Back contour; Back scanning; Back shapes; Pelvic obliquity; Posture; Root mean square error; Seating; Wheelchair; Back support ID SPINAL-CORD-INJURY; SITTING BIOMECHANICS; CEREBRAL-PALSY; SCOLIOSIS; PRESSURE; REQUIREMENTS; PROPULSION; ALIGNMENT; COMFORT; WORK AB Spinal deformities are common in people who require the use of a wheelchair for mobility as a result of spinal cord injuries and other disabilities. Sitting positions vary between individuals with disabilities who use wheelchairs and individuals without disabilities. In individuals with spinal cord injury, spinal deformities can result in the development of back contours that deviate from the shape of standard rigid back support shells. The purpose of this study was to distinguish and classify various back contours of wheelchair users by utilizing digital anatomic scanning technology in order to inform the future development of back supports that would enhance postural support for those with spinal deformities. The three dimensional (3D) locations of bony landmarks were digitized when participants were in position, using a mechanical wand linked to the FastScan(tm) system commonly used to measure surface contours. Raw FastScantm data were transformed according to bony landmarks. A total of 129 individuals participated in this study. A wide range of back contours were identified and categorized. Although participant characteristics (e.g., gender, diagnosis) were similar amongst the contour groups; no one characteristic explained the contours. Participants who were seated in a forward lean position had a higher amount of pelvic obliquity compared to those seated in an upright position; however, participants' back contour was not correlated with pelvic obliquity. In conclusion, an array of different back shapes were classified in our cohort through 3D laser scanning technology. The methods and technology applied in this study could be replicated in future studies to categorize ranges of back shapes in larger populations of people with spinal cord injuries. Preliminary evidence indicates that customized postural support may be warranted to optimize positioning and posture when a standard rigid shell does not align with contours of a person's back. To optimize positioning, a range of contoured rigid backrests as well as height and angle adjustability are likely needed. (C) 2016 IPEM. Published by Elsevier Ltd. All rights reserved. C1 [Crytzer, Theresa M.; Hong, Eun-Kyoung; Dicianno, Brad E.; Pearlman, Jon; Cooper, Rory A.] Vet Affairs Pittsburgh Healthcare Syst, Human Engn Res Labs, 6425 Penn Ave,Suite 400, Pittsburgh, PA 15206 USA. [Crytzer, Theresa M.; Hong, Eun-Kyoung; Dicianno, Brad E.; Pearlman, Jon; Schmeler, Mark; Cooper, Rory A.] Univ Pittsburgh, Dept Rehabil Sci & Technol, Pittsburgh, PA USA. [Dicianno, Brad E.] Univ Pittsburgh, Med Ctr, Dept Phys Med & Rehabil, Pittsburgh, PA USA. RP Cooper, RA (reprint author), Vet Affairs Pittsburgh Healthcare Syst, Human Engn Res Labs, 6425 Penn Ave,Suite 400, Pittsburgh, PA 15206 USA. EM rcooper@pitt.edu FU VA Center of Excellence for Wheelchairs and Associated Rehabilitation [B6789C]; Paralyzed Veterans of America FX Supported by The VA Center of Excellence for Wheelchairs and Associated Rehabilitation (Grant B6789C) and Paralyzed Veterans of America. The contents of this paper do not represent the views of the Department of Veterans Affairs or the United States Government. NR 45 TC 1 Z9 1 U1 8 U2 10 PU ELSEVIER SCI LTD PI OXFORD PA THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, OXON, ENGLAND SN 1350-4533 EI 1873-4030 J9 MED ENG PHYS JI Med. Eng. Phys. PD SEP PY 2016 VL 38 IS 9 SI SI BP 999 EP 1007 DI 10.1016/j.medengphy.2016.06.017 PG 9 WC Engineering, Biomedical SC Engineering GA DV5YN UT WOS:000383006700024 PM 27426985 ER PT J AU Bhavsar, KV Lin, S Rahimy, E Joseph, A Freund, KB Sarraf, D Cunningham, ET AF Bhavsar, Kavita V. Lin, Sally Rahimy, Ehsan Joseph, Anthony Freund, K. Bailey Sarraf, David Cunningham, Emmett T., Jr. TI Acute macular neuroretinopathy: A comprehensive review of the literature SO SURVEY OF OPHTHALMOLOGY LA English DT Review DE acute macular neuroretinopathy; AMNR; AMN; AMOR; optical coherence tomography; multimodal imaging; paracentral acute middle maculopathy; PAMM; deep capillary ischemia; DCI ID OPTICAL COHERENCE TOMOGRAPHY; ACUTE MIDDLE MACULOPATHY; LASER OPHTHALMOSCOPE FINDINGS; DEEP CAPILLARY ISCHEMIA; WHITE DOT SYNDROME; MULTIFOCAL ELECTRORETINOGRAM; ENHANCED VISUALIZATION; RETINOPATHY; OCT; ABNORMALITIES AB Acute macular neuroretinopathy is a relatively rare condition originally defined by the presence of intraretinal, reddish-brown, wedge-shaped lesions, the apices of which tend to point toward the fovea. Acute onset of paracentral scotomas corresponding to the clinically evident lesions is both common and characteristic. Although the pathogenesis of acute macular neuroretinopathy is complex, recent research suggests a microvascular etiology. Advances in multimodal imaging have enabled better characterization of this retinal disorder and have led to newly proposed diagnostic criteria. We review 101 reported cases in the English and non-English language literature identified from 1975, when acute macular neuroretinopathy was first described, to December, 2014. We discuss common risk factors, demographic and clinical characteristics, and multimodal imaging findings, which together provide insights into pathogenesis and guide areas of future investigation. (C) 2016 Elsevier Inc. All rights reserved. C1 [Bhavsar, Kavita V.; Freund, K. Bailey] Vitreous Retina Macula Consultants New York, Dept Ophthalmol, New York, NY USA. [Bhavsar, Kavita V.; Freund, K. Bailey] Manhattan Eye Ear & Throat Hosp, Dept Ophthalmol, LuEsther T Mertz Retinal Res Ctr, New York, NY 10021 USA. [Bhavsar, Kavita V.; Freund, K. Bailey] NYU, Dept Ophthalmol, Langone Med Ctr, 550 1St Ave, New York, NY 10016 USA. [Bhavsar, Kavita V.; Freund, K. Bailey] Columbia Univ, Dept Ophthalmol, New York, NY 10027 USA. [Lin, Sally; Cunningham, Emmett T., Jr.] Calif Pacific Med Ctr, Dept Ophthalmol, San Francisco, CA USA. [Rahimy, Ehsan] Wills Eye Hosp & Res Inst, Dept Ophthalmol, Philadelphia, PA USA. [Joseph, Anthony; Sarraf, David] Univ Calif Los Angeles, Jules Stein Eye Inst, Dept Ophthalmol, Los Angeles, CA 90024 USA. [Joseph, Anthony; Sarraf, David] Greater Los Angeles VA Healthcare Ctr, Dept Ophthalmol, Los Angeles, CA USA. [Cunningham, Emmett T., Jr.] Stanford Univ, Sch Med, Dept Ophthalmol, Stanford, CA 94305 USA. [Cunningham, Emmett T., Jr.] UCSF Sch Med, Dept Ophthalmol, Francis I Proctor Fdn, San Francisco, CA USA. [Cunningham, Emmett T., Jr.] West Coast Retina Med Grp, Dept Ophthalmol, San Francisco, CA USA. RP Freund, KB (reprint author), Vitreous Retina Macula Consultants New York, 460 Pk Ave, New York, NY 10022 USA. EM kbfnyf@aol.com OI Freund, K. Bailey/0000-0002-7888-9773 FU Portland VA Healthcare System; Pacific Vision Foundation FX Dr. Bhaysar is currently at Casey Eye Institute, Portland, OR. She receives support from the Portland VA Healthcare System. Dr. Lin is currently at the Department of Ophthalmology, Kaiser Permanente Medical Center, Union City, CA. This work was supported in part by the Pacific Vision Foundation (Sally Lin and Ehsan Rahimy). NR 76 TC 3 Z9 3 U1 1 U2 3 PU ELSEVIER SCIENCE INC PI NEW YORK PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA SN 0039-6257 EI 1879-3304 J9 SURV OPHTHALMOL JI Surv. Ophthalmol. PD SEP-OCT PY 2016 VL 61 IS 5 BP 538 EP 565 DI 10.1016/j.survophthal.2016.03.003 PG 28 WC Ophthalmology SC Ophthalmology GA DV8WI UT WOS:000383217000002 PM 26973287 ER PT J AU Lo-Ciganic, WH Donohue, JM Jones, BL Perera, S Thorpe, JM Thorpe, CT Marcum, ZA Gellad, WF AF Lo-Ciganic, Wei-Hsuan Donohue, Julie M. Jones, Bobby L. Perera, Subashan Thorpe, Joshua M. Thorpe, Carolyn T. Marcum, Zachary A. Gellad, Walid F. TI Trajectories of Diabetes Medication Adherence and Hospitalization Risk: A Retrospective Cohort Study in a Large State Medicaid Program SO JOURNAL OF GENERAL INTERNAL MEDICINE LA English DT Article DE diabetes; oral hypoglycemics; medication adherence; group-based trajectory models; Medicaid ID BLOOD-PRESSURE CONTROL; COMPLICATIONS SEVERITY INDEX; SELF-REPORTED ADHERENCE; HEALTH-CARE; ADMINISTRATIVE DATA; THERAPY; COSTS; NONADHERENCE; HYPERTENSION; VETERANS AB Numerous interventions are available to boost medication adherence, but the targeting of these interventions often relies on crude measures of poor adherence. Group-based trajectory models identify individuals with similar longitudinal prescription filling patterns. Identifying distinct adherence trajectories may be more useful for targeting interventions, although the association between adherence trajectories and clinical outcomes is unknown. To examine the association between adherence trajectories for oral hypoglycemics and subsequent hospitalizations among diabetes patients. Retrospective cohort study. A total of 16,256 Pennsylvania Medicaid enrollees, non-dually eligible for Medicare, initiating oral hypoglycemics between 2007 and 2009. We used group-based trajectory models to identify trajectories of oral hypoglycemics in the 12 months post-treatment initiation, using monthly proportion of days covered (PDC) as the adherence measure. Multivariable Cox proportional hazard models were used to examine the association between trajectories and time to first diabetes-related hospitalization/emergency department (ED) visits in the following year. We used the C-index to compare prediction performance between adherence trajectories and dichotomous cutpoints (annual PDC < 80 vs. aeyen80 %). The mean annual PDC was 0.58 (SD 0.32). Seven trajectories were identified: perfect adherers (9 % of the cohort), nearly perfect adherers (31.4 %), moderate adherers (21.0 %), low adherers (11.0 %), late discontinuers (6.8 %), early discontinuers (9.7 %), and non-adherers with only one fill (11.1 %). Compared to perfect adherers, trajectories of moderate adherers (HR = 1.48, 95 % CI 1.25, 1.75), low adherers (HR = 1.51, 95 % CI 1.25, 1.83), and non-adherers with only one fill (HR = 1.35, 95 % CI 1.09, 1.67) had greater risk of diabetes-related hospitalizations/ED visits. Predictive accuracy was improved using trajectories compared to dichotomized cutpoints (C-index = 0.714 vs. 0.652). Oral hypoglycemic treatment trajectories were highly variable in this large Medicaid cohort. Low and moderate adherers and those filling only one prescription had a modestly higher risk of hospitalizations/ED visits compared to perfect adherers. Trajectory models may be valuable in identifying specific non-adherence patterns for targeting interventions. C1 [Lo-Ciganic, Wei-Hsuan] Univ Arizona, Coll Pharm, Dept Pharm Practice & Sci, Tucson, AZ 85721 USA. [Donohue, Julie M.] Univ Pittsburgh, Grad Sch Publ Hlth, Dept Hlth Policy & Management, Pittsburgh, PA USA. [Donohue, Julie M.; Thorpe, Joshua M.; Thorpe, Carolyn T.; Gellad, Walid F.] Univ Pittsburgh, Ctr Pharmaceut Policy & Prescribing, Pittsburgh, PA USA. [Jones, Bobby L.] Univ Pittsburgh, Dept Psychiat, Med Ctr, Pittsburgh, PA USA. [Perera, Subashan] Univ Pittsburgh, Grad Sch Publ Hlth, Dept Biostat, Pittsburgh, PA 15261 USA. [Perera, Subashan; Gellad, Walid F.] Univ Pittsburgh, Sch Med, Dept Med, Pittsburgh, PA 15213 USA. [Thorpe, Joshua M.; Thorpe, Carolyn T.] Univ Pittsburgh, Sch Pharm, Dept Pharm & Therapeut, Pittsburgh, PA 15261 USA. [Thorpe, Joshua M.; Thorpe, Carolyn T.; Gellad, Walid F.] Vet Affairs Pittsburgh Healthcare Syst, Ctr Hlth Equity Res & Promot, Pittsburgh, PA USA. [Marcum, Zachary A.] Univ Washington, Sch Pharm, Dept Pharm, Seattle, WA 98195 USA. RP Lo-Ciganic, WH (reprint author), Univ Arizona, Coll Pharm, Dept Pharm Practice & Sci, Tucson, AZ 85721 USA. EM lociganic@pharmacy.arizona.edu OI Donohue, Julie/0000-0003-2418-6017 FU Pittsburgh Claude D. Pepper Older Americans Independence Center [NIA P30 AGAG024827] FX Dr. Perera is supported by the Pittsburgh Claude D. Pepper Older Americans Independence Center (NIA P30 AGAG024827). NR 58 TC 2 Z9 2 U1 3 U2 6 PU SPRINGER PI NEW YORK PA 233 SPRING ST, NEW YORK, NY 10013 USA SN 0884-8734 EI 1525-1497 J9 J GEN INTERN MED JI J. Gen. Intern. Med. PD SEP PY 2016 VL 31 IS 9 BP 1052 EP 1060 DI 10.1007/s11606-016-3747-6 PG 9 WC Health Care Sciences & Services; Medicine, General & Internal SC Health Care Sciences & Services; General & Internal Medicine GA DT6NJ UT WOS:000381600700014 PM 27229000 ER PT J AU Rendon, P Dhaliwal, G Kim, B Aguayo, A Pierce, JR AF Rendon, Patrick Dhaliwal, Gurpreet Kim, Benjamin Aguayo, Alberto Pierce, J. Rush, Jr. TI Look No Further: An Exercise in Clinical Reasoning SO JOURNAL OF GENERAL INTERNAL MEDICINE LA English DT Editorial Material DE clinical reasoning; diagnosis; chief complaint ID AUTOIMMUNE HEMOLYTIC-ANEMIA; DIAGNOSIS C1 [Rendon, Patrick; Aguayo, Alberto; Pierce, J. Rush, Jr.] Univ New Mexico, Hlth Sci Ctr, Div Hosp Med, Dept Internal Med, MSC10 5550,1 Univ New Mexico, Albuquerque, NM 87131 USA. [Dhaliwal, Gurpreet; Kim, Benjamin] Univ Calif San Francisco, Dept Med, San Francisco, CA USA. [Dhaliwal, Gurpreet] San Francisco VA Med Ctr, Med Serv, San Francisco, CA USA. RP Rendon, P (reprint author), Univ New Mexico, Hlth Sci Ctr, Div Hosp Med, Dept Internal Med, MSC10 5550,1 Univ New Mexico, Albuquerque, NM 87131 USA. EM prendon@salud.unm.edu NR 7 TC 0 Z9 0 U1 1 U2 1 PU SPRINGER PI NEW YORK PA 233 SPRING ST, NEW YORK, NY 10013 USA SN 0884-8734 EI 1525-1497 J9 J GEN INTERN MED JI J. Gen. Intern. Med. PD SEP PY 2016 VL 31 IS 9 BP 1097 EP 1101 DI 10.1007/s11606-016-3635-0 PG 5 WC Health Care Sciences & Services; Medicine, General & Internal SC Health Care Sciences & Services; General & Internal Medicine GA DT6NJ UT WOS:000381600700025 PM 27075183 ER PT J AU Beidas, RS Marcus, S Wolk, CB Powell, B Aarons, GA Evans, AC Hurford, MO Hadley, T Adams, DR Walsh, LM Babbar, S Barg, F Mandell, DS AF Beidas, Rinad S. Marcus, Steven Wolk, Courtney Benjamin Powell, Byron Aarons, Gregory A. Evans, Arthur C. Hurford, Matthew O. Hadley, Trevor Adams, Danielle R. Walsh, Lucia M. Babbar, Shaili Barg, Frances Mandell, David S. TI A Prospective Examination of Clinician and Supervisor Turnover Within the Context of Implementation of Evidence-Based Practices in a Publicly-Funded Mental Health System SO ADMINISTRATION AND POLICY IN MENTAL HEALTH AND MENTAL HEALTH SERVICES RESEARCH LA English DT Article DE Turnover; Implementation; Mental health services ID CHILD-WELFARE SYSTEMS; STAFF TURNOVER; ORGANIZATIONAL-CLIMATE; JOB-SATISFACTION; BURNOUT; SETTINGS; SERVICES; SUPPORT; CULTURE; MODEL AB Staff turnover rates in publicly-funded mental health settings are high. We investigated staff and organizational predictors of turnover in a sample of individuals working in an urban public mental health system that has engaged in a system-level effort to implement evidence-based practices. Additionally, we interviewed staff to understand reasons for turnover. Greater staff burnout predicted increased turnover, more openness toward new practices predicted retention, and more professional recognition predicted increased turnover. Staff reported leaving their organizations because of personal, organizational, and financial reasons; just over half of staff that left their organization stayed in the public mental health sector. Implications include an imperative to focus on turnover, with a particular emphasis on ameliorating staff burnout. C1 [Beidas, Rinad S.; Wolk, Courtney Benjamin; Powell, Byron; Evans, Arthur C.; Hurford, Matthew O.; Hadley, Trevor; Adams, Danielle R.; Walsh, Lucia M.; Babbar, Shaili; Mandell, David S.] Univ Penn, Dept Psychiat, Perelman Sch Med, 3535 Market St,3015, Philadelphia, PA 19104 USA. [Marcus, Steven] Univ Penn, Sch Social Policy & Practice, Philadelphia, PA 19104 USA. [Marcus, Steven] Philadelphia Vet Affairs Med Ctr, Ctr Hlth Equ Res & Promot, Philadelphia, PA USA. [Aarons, Gregory A.] Univ Calif San Diego, Dept Psychiat, San Diego, CA 92103 USA. [Evans, Arthur C.; Hurford, Matthew O.] Dept Behav Hlth & Intellectual Disabil Serv, Philadelphia, PA USA. [Hurford, Matthew O.] Community Behav Hlth, Philadelphia, PA USA. [Barg, Frances] Univ Penn, Dept Family Med & Community Hlth, Perelman Sch Med, Philadelphia, PA 19104 USA. [Powell, Byron] Univ North Carolina Chapel Hill, Gillings Sch Global Publ Hlth, Dept Hlth Policy & Management, 1105C McGavran Greenberg Hall,Campus Box 7411, Chapel Hill, NC 27599 USA. [Hurford, Matthew O.] Community Care Behav Hlth Org, Pittsburgh, PA USA. RP Beidas, RS (reprint author), Univ Penn, Dept Psychiat, Perelman Sch Med, 3535 Market St,3015, Philadelphia, PA 19104 USA. EM rbeidas@upenn.edu; bjpowell@unc.edu RI Mandell, David/H-2730-2012 OI Mandell, David/0000-0001-8240-820X; Powell, Byron/0000-0001-5245-1186 FU Department of Behavioral Health and Intellectual disAbility Services; NIMH [K23 MH099179, F32 MH103955]; Implementation Research Institute (IRI), at the George Warren Brown School of Social Work, Washington University in St. Louis; National Institute of Mental Health [R25 MH080916]; Quality Enhancement Research Initiative (QUERI), Department of Veterans Affairs Contract, Veterans Health Administration, Office of Research & Development, Health Services Research & Development Service FX We are especially grateful for the support that the Department of Behavioral Health and Intellectual disAbility Services has provided for this project, and for the Evidence Based Practice and Innovation (EPIC) group. Funding for this research project was supported by the following grants from NIMH: (K23 MH099179, Beidas; F32 MH103955, Benjamin Wolk). Additionally, the preparation of this article was supported in part by the Implementation Research Institute (IRI), at the George Warren Brown School of Social Work, Washington University in St. Louis; through an award from the National Institute of Mental Health (R25 MH080916) and Quality Enhancement Research Initiative (QUERI), Department of Veterans Affairs Contract, Veterans Health Administration, Office of Research & Development, Health Services Research & Development Service. Dr. Beidas was an IRI fellow from 2012 to 2014. We would like to thank for the following experts who provided their time and input on this project: Dr. Marc Atkins, Dr. Ross Brownson, Dr. David Chambers, Dr. Bruce Chorpita, Dr. Charles Glisson, Dr. Nicholas Ialongo, Dr. John Landsverk, Dr. Enola Proctor, Dr. Ronnie Rubin. NR 47 TC 4 Z9 4 U1 4 U2 6 PU SPRINGER PI NEW YORK PA 233 SPRING ST, NEW YORK, NY 10013 USA SN 0894-587X EI 1573-3289 J9 ADM POLICY MENT HLTH JI Adm. Policy. Ment. Health PD SEP PY 2016 VL 43 IS 5 BP 640 EP 649 DI 10.1007/s10488-015-0673-6 PG 10 WC Health Policy & Services; Public, Environmental & Occupational Health SC Health Care Sciences & Services; Public, Environmental & Occupational Health GA DS9YM UT WOS:000381139400002 PM 26179469 ER PT J AU Cummings, JR Case, BG Ji, X Marcus, SC AF Cummings, Janet R. Case, Brady G. Ji, Xu Marcus, Steven C. TI Availability of Youth Services in US Mental Health Treatment Facilities SO ADMINISTRATION AND POLICY IN MENTAL HEALTH AND MENTAL HEALTH SERVICES RESEARCH LA English DT Article DE Children and adolescents; Access to services; Mental health facilities ID SUPPLEMENT NCS-A; ADOLESCENTS; CHILD; PSYCHIATRISTS; CARE; PEDIATRICIANS; DISORDERS; ACCESS AB Despite concern about access to mental health (MH) services for youth, little is known about the specialty treatment infrastructure serving this population. We used national data to examine which types of MH treatment facilities (hospital- and community-based) were most likely to offer youth services and which types of communities were most likely to have this infrastructure. Larger (p < 0.001) and privately owned (p < 0.001) facilities were more likely to offer youth services. Rural counties, counties in which a majority of residents were nonwhite, and/or counties with a higher percentage of uninsured residents were less likely to have a community-based MH treatment facility that served youth (p < 0.001). C1 [Cummings, Janet R.; Ji, Xu] Emory Univ, Rollins Sch Publ Hlth, Dept Hlth Policy & Management, 1518 Clifton Rd NE, Atlanta, GA 30322 USA. [Case, Brady G.] Bradley Hosp, Hlth Serv Res Program, East Providence, RI USA. [Case, Brady G.] Brown Univ, Dept Psychiat & Human Behav, Alpert Med Sch, Providence, RI 02912 USA. [Case, Brady G.] Brown Sch Publ Hlth, Dept Hlth Serv Policy & Practice, Providence, RI USA. [Marcus, Steven C.] Philadelphia Vet Affairs Med Ctr, Ctr Hlth Equ Res & Promot, Philadelphia, PA USA. [Marcus, Steven C.] Univ Penn, Sch Social Policy & Practice, Philadelphia, PA 19104 USA. RP Cummings, JR (reprint author), Emory Univ, Rollins Sch Publ Hlth, Dept Hlth Policy & Management, 1518 Clifton Rd NE, Atlanta, GA 30322 USA. EM jrcummi@emory.edu OI Case, Brady/0000-0001-9512-0416 FU National Institute of Mental Health [K01MH095823] FX Research reported in this publication was supported by the National Institute of Mental Health (K01MH095823). The content is solely the responsibility of the authors and does not necessarily represent the official views of the National Institutes of Health. NR 38 TC 2 Z9 2 U1 2 U2 5 PU SPRINGER PI NEW YORK PA 233 SPRING ST, NEW YORK, NY 10013 USA SN 0894-587X EI 1573-3289 J9 ADM POLICY MENT HLTH JI Adm. Policy. Ment. Health PD SEP PY 2016 VL 43 IS 5 BP 717 EP 727 DI 10.1007/s10488-015-0685-2 PG 11 WC Health Policy & Services; Public, Environmental & Occupational Health SC Health Care Sciences & Services; Public, Environmental & Occupational Health GA DS9YM UT WOS:000381139400008 PM 26467795 ER PT J AU Singer, AE Ash, T Ochotorena, C Lorenz, KA Chong, K Shreve, ST Ahluwalia, SC AF Singer, Adam E. Ash, Tayla Ochotorena, Claudia Lorenz, Karl A. Chong, Kelly Shreve, Scott T. Ahluwalia, Sangeeta C. TI A Systematic Review of Family Meeting Tools in Palliative and Intensive Care Settings SO AMERICAN JOURNAL OF HOSPICE & PALLIATIVE MEDICINE LA English DT Review DE communication; professional-family relations; interdisciplinary communication; palliative care; psychology; caregivers; review ID OF-LIFE CARE; CRITICALLY-ILL; DECISION-MAKING; MEDICAL-RECORD; END; UNIT; COMMUNICATION; ICU; CONSENSUS; RECOMMENDATIONS AB Purpose: Family meetings can be challenging, requiring a range of skills and participation. We sought to identify tools available to aid the conduct of family meetings in palliative, hospice, and intensive care unit settings. Methods: We systematically reviewed PubMed for articles describing family meeting tools and abstracted information on tool type, usage, and content. Results: We identified 16 articles containing 23 tools in 7 categories: meeting guide (n = 8), meeting planner (n = 5), documentation template (n = 4), meeting strategies (n = 2), decision aid/screener (n = 2), family checklist (n = 1), and training module (n = 1). We found considerable variation across tools in usage and content and a lack of tools supporting family engagement. Conclusion: There is need to standardize family meeting tools and develop tools to help family members effectively engage in the process. C1 [Singer, Adam E.] Univ Calif Los Angeles, David Geffen Sch Med, Los Angeles, CA 90095 USA. [Singer, Adam E.; Lorenz, Karl A.; Ahluwalia, Sangeeta C.] RAND Corp, Santa Monica, CA USA. [Ash, Tayla] Harvard Univ, TH Chan Sch Publ Hlth, Boston, MA 02115 USA. [Ochotorena, Claudia] Drexel Univ, Coll Nursing & Hlth Profess, Philadelphia, PA 19104 USA. [Lorenz, Karl A.; Chong, Kelly; Shreve, Scott T.] Greater Los Angeles VA Hlth Care Syst, Qual Improvement Resource Ctr, Los Angeles, CA USA. [Lorenz, Karl A.] Stanford Univ, Sch Med, Stanford, CA 94305 USA. [Lorenz, Karl A.] VA Palo Alto Hlth Care Syst, Palo Alto, CA USA. [Shreve, Scott T.] Penn State Coll Med, Lebanon, NH USA. [Ahluwalia, Sangeeta C.] Univ Calif Los Angeles, Fielding Sch Publ Hlth, Los Angeles, CA USA. RP Singer, AE (reprint author), 1776 Main St,POB 2138, Santa Monica, CA 90407 USA. EM asinger@rand.org FU Medical Scientist Training Program at the University of California, Los Angeles [T32 GM008042]; National Palliative Care Research Center; VA/NIMH Implementation Research Fellowship [R25 MH080916-01A2]; VA palliative care Quality Improvement Resource Center FX The authors disclosed receipt of the following financial support for the research, authorship, and/or publication of this article: Dr. Singer received support from grant T32 GM008042 as a member of the Medical Scientist Training Program at the University of California, Los Angeles. Dr. Ahluwalia was supported by a career development award from the National Palliative Care Research Center and a VA/NIMH Implementation Research Fellowship (R25 MH080916-01A2). This work was funded by the VA palliative care Quality Improvement Resource Center in order to identify family meeting tools for use in quality improvement. NR 43 TC 0 Z9 0 U1 5 U2 5 PU SAGE PUBLICATIONS INC PI THOUSAND OAKS PA 2455 TELLER RD, THOUSAND OAKS, CA 91320 USA SN 1049-9091 EI 1938-2715 J9 AM J HOSP PALLIAT ME JI Am. J. Hosp. Palliat. Med. PD SEP PY 2016 VL 33 IS 8 BP 797 EP 806 DI 10.1177/1049909115594353 PG 10 WC Health Care Sciences & Services SC Health Care Sciences & Services GA DU9EH UT WOS:000382518600012 PM 26213225 ER PT J AU Al-Niaimi, A Rice, LW Shitanshu, U Garvens, B Fitzgerald, M Zerbel, S Safdar, N AF Al-Niaimi, Ahmed Rice, Laurel W. Shitanshu, Uppal Garvens, Bonnie Fitzgerald, Megan Zerbel, Sara Safdar, Nasia TI Safety and tolerability of chlorhexidine gluconate (2%) as a vaginal operative preparation in patients undergoing gynecologic surgery SO AMERICAN JOURNAL OF INFECTION CONTROL LA English DT Article DE Gynecologic surgery; chlorhexidine 2%; vaginal irritation; patient safety ID POVIDONE-IODINE; HYSTERECTOMY; TRIAL; PREVENTION; ANTISEPSIS; INFECTION AB Background: The use of chlorhexidine gluconate (CHG) as an intraoperative vaginal preparation has been shown to be more effective than vaginal povidone-iodine (PI) in decreasing vaginal bacterial colony counts. However, PI remains the standard vaginal preparation because of concerns of CHG's potential for vaginal irritation. The primary outcome of this study is a comparison of the rate of patient-reported vaginal irritation between 2% CHG and PI. Methods: Consecutive patients were enrolled in a pre-post study. Group 1 consisted of consecutive patients who received PI as a vaginal preparation. Group 2 consisted of consecutive patients who received 2% CHG as a vaginal preparation. Patients used a standardized instrument to report irritation to trained nurse practitioners 1 day after surgery. Results: A total of 117 patients received vaginal operative preparation during the course of the study, with 64 patients in group 1 and 53 patients in group 2. Of the patients in group 1, 60 (93.7%) reported no vaginal irritation, 3 (4.69%) reported mild irritation, and 1 (1.56%) reported moderate irritation. In group 2 (2% CHG vaginal preparation), all of the patients (100%) reported no vaginal irritation (P = .38). Conclusions: The use of 2% CHG as a vaginal operative preparation is not associated with increased vaginal irritation compared with PI in gynecologic surgery. It can safely be used, taking advantage of its efficacy in reducing vaginal bacterial colony counts. Published by Elsevier Inc. on behalf of Association for Professionals in Infection Control and Epidemiology, Inc. C1 [Al-Niaimi, Ahmed; Rice, Laurel W.; Garvens, Bonnie; Fitzgerald, Megan; Zerbel, Sara; Safdar, Nasia] Univ Wisconsin Med, Sch & Publ Hlth, Madison, WI USA. [Shitanshu, Uppal] Univ Michigan, Ann Arbor, MI 48109 USA. [Safdar, Nasia] William S Middleton Mem Vet Adm Med Ctr, Madison, WI USA. RP Safdar, N (reprint author), Univ Wisconsin, Dept Med, Infect Dis Sect, 600 Highland Ave,Box 5158, Madison, WI 53792 USA. EM ns2@medicine.wisc.edu NR 12 TC 1 Z9 1 U1 0 U2 0 PU MOSBY-ELSEVIER PI NEW YORK PA 360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA SN 0196-6553 EI 1527-3296 J9 AM J INFECT CONTROL JI Am. J. Infect. Control PD SEP 1 PY 2016 VL 44 IS 9 BP 996 EP 998 DI 10.1016/j.ajic.2016.02.036 PG 3 WC Public, Environmental & Occupational Health; Infectious Diseases SC Public, Environmental & Occupational Health; Infectious Diseases GA DV0AH UT WOS:000382579100011 PM 27234011 ER PT J AU Bennet, CS Dahagam, CR Virani, SS Martin, SS Blumenthal, RS Michos, ED McEvoy, JW AF Bennet, Catherine S. Dahagam, Chanukya R. Virani, Salim S. Martin, Seth S. Blumenthal, Roger S. Michos, Erin D. McEvoy, John W. TI Lipid Management Guidelines from the Departments of Veteran Affairs and Defense: A Critique SO AMERICAN JOURNAL OF MEDICINE LA English DT Review DE Atherosclerotic cardiovascular disease; Coronary artery calcium; Dyslipidemia; Guidelines; Veterans Affairs ID CORONARY-ARTERY CALCIUM; HEART-DISEASE RISK; HEINZ NIXDORF RECALL; STATIN THERAPY; CARDIOVASCULAR-DISEASE; PRIMARY PREVENTION; ASYMPTOMATIC ADULTS; LOWERING THERAPY; REDUCING LIPIDS; FOLLOW-UP AB In December 2014, the US Department of Veterans Affairs and Department of Defense (VA/DoD) published an independent clinical practice guideline for the management of dyslipidemia and cardiovascular disease risk, adding to the myriad of recently published guidelines on this topic. The VA/DoD guidelines differ from major US guidelines published by the American College of Cardiology/American Heart Association in 2013 in the following ways: recommending moderate-intensity statins for the majority of patients with statin indications regardless of atherosclerotic cardiovascular disease risk; advocating for limited on-treatment lipid monitoring; and deemphasizing ancillary data, such as coronary artery calcium testing, to improve atherosclerotic cardiovascular disease risk estimation. In the context of manifold treatment recommendations from numerous guideline committees, the VA/DoD recommendations may generate further confusion and mixed messages among healthcare providers about the optimal treatment of dyslipidemia. In this review, we critically appraise the VA/DoD recommendations with a focus on the evidence base for each area where the VA/DoD guidelines differ from the American College of Cardiology/American Heart Association guidelines. We also call for harmonization of lipid treatment guidelines to ensure high-quality and consistent care for patients with, and at risk for, atherosclerotic cardiovascular disease. (C) 2016 Elsevier Inc. All rights reserved. C1 [Bennet, Catherine S.; Martin, Seth S.; Blumenthal, Roger S.; Michos, Erin D.; McEvoy, John W.] Johns Hopkins Sch Med, Dept Med, Div Cardiol, Baltimore, MD USA. [Dahagam, Chanukya R.] MedStar Franklin Sq Med Ctr, Dept Med, Baltimore, MD USA. [Virani, Salim S.] Baylor Coll Med, Michael E DeBakey Vet Affairs Med Ctr, Houston, TX 77030 USA. [Virani, Salim S.] Baylor Coll Med, Cardiol Sect, Dept Med, Houston, TX 77030 USA. [Martin, Seth S.; Blumenthal, Roger S.; Michos, Erin D.; McEvoy, John W.] Johns Hopkins Sch Med, Ciccarone Ctr Prevent Heart Dis, Baltimore, MD USA. RP McEvoy, JW (reprint author), Johns Hopkins Univ, Sch Med, Div Cardiol, Dept Med, 600 N Wolfe St,Blalock 524C, Baltimore, MD 21287 USA. EM jmcevoy1@jhmi.edu OI Virani, Salim/0000-0001-9541-6954 NR 51 TC 0 Z9 0 U1 0 U2 2 PU ELSEVIER SCIENCE INC PI NEW YORK PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA SN 0002-9343 EI 1555-7162 J9 AM J MED JI Am. J. Med. PD SEP PY 2016 VL 129 IS 9 BP 906 EP 912 DI 10.1016/j.amjmed.2016.04.012 PG 7 WC Medicine, General & Internal SC General & Internal Medicine GA DU6FO UT WOS:000382309900028 PM 27154781 ER PT J AU Shi, P Chen, EY Cs-Szabo, G Chee, A Tannoury, C Qin, L An, S An, S An, HS Zhang, YJ AF Shi, Peng Chen, Er-Yun Cs-Szabo, Gabriella Chee, Ana Tannoury, Chadi Qin, Ling Lin, Han An, Steven An, Howard S. Zhang, Yejia TI Biglycan Inhibits Capsaicin-Induced Substance P Release by Cultured Dorsal Root Ganglion Neurons SO AMERICAN JOURNAL OF PHYSICAL MEDICINE & REHABILITATION LA English DT Article DE Intervertebral Disc; Pain; Dorsal Root Ganglion (DRG); Biglycan; Capsaicin ID LOW-BACK-PAIN; LUMBAR INTERVERTEBRAL DISCS; ANULUS FIBROSUS; RECEPTOR; NERVE; EXPRESSION; INGROWTH AB Objective: The purpose of this study was to examine the inhibitory effects of biglycan on substance P release from cultured sensory neurons in response to capsaicin. Study Design: In vitro study of cultured primary sensory neurons from the rabbit dorsal root ganglion (DRG). We interrogated the culture system function with capsaicin. Biglycan is an important structural component of the intervertebral disc that may regulate growth factors and inflammatory mediators. We tested the hypothesis that biglycan inhibits substance P release in response to capsaicin. Results: The DRG cultures were shown to contain both neurons and astrocytes by immunostaining using antibodies recognizing neuron and glial cell markers. Cultured DRG cells respond to capsaicin in a dose-and time-dependent manner (capsaicin dose ranges from 5 to 500 mu mol/L; stimulation time ranges from 0 to 60 minutes). The neurons preincubated with biglycan released 27% less substance P compared with neurons without biglycan (n = 4, P = 0.036). Conclusion: We have established a DRG cell culture system, which contains both sensory neurons and the supporting astrocytes. Biglycan, an inhibitor of substance P release by DRG cultures, may serve as an ingredient in intradiscal injectables to reduce back pain. C1 [Shi, Peng; Chee, Ana; An, Steven; An, Howard S.] Rush Univ, Med Ctr, Dept Orthoped Surg, Chicago, IL 60612 USA. [Chen, Er-Yun] Rush Univ, Med Ctr, Dept Neurol Sci, Chicago, IL 60612 USA. [Cs-Szabo, Gabriella] Rush Univ, Med Ctr, Dept Biochem, Chicago, IL 60612 USA. [Tannoury, Chadi] Boston Univ, Med Ctr, Dept Orthoped Surg, Boston, MA USA. [Lin, Han] Drexel Univ, Sch Biomed Engn Sci & Hlth Syst, Philadelphia, PA 19104 USA. [Zhang, Yejia] Univ Penn, Dept Phys Med & Rehabil, Perelman Sch Med, Philadelphia, PA 19104 USA. [Qin, Ling; Zhang, Yejia] Univ Penn, Dept Orthoped Surg, Perelman Sch Med, Philadelphia, PA 19104 USA. [Zhang, Yejia] Philadelphia Vet Affairs Med Ctr, Translat Musculoskeletal Res Ctr, Philadelphia, PA USA. RP Zhang, YJ (reprint author), Philadelphia Vet Affairs Med Ctr, Translat Musculoskeletal Res Ctr, Philadelphia, PA USA.; Zhang, YJ (reprint author), Univ Penn, Dept Phys Med & Rehabil, Dept Orthoped Surg, Perelman Sch Med, Philadelphia, PA 19104 USA. RI Han, Lin/D-2602-2014 OI Han, Lin/0000-0003-4180-1288; Tannoury, Chadi/0000-0002-2369-432X FU Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD) [1 K08 HD049598] FX Yejia Zhang, MD, PhD has been supported by the Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD, 1 K08 HD049598). This work has been presented at the Inaugural ICMRS-ASBMR International Chinese Musculoskeletal Research Conference (ICMRC) in 2013 in Suzhou, PR China as a poster presentation. This work has also been presented at the 2014 Philadelphia Spine Research Society Meeting in Philadelphia, PA as a podium presentation. PS performed rabbit dissections, cell culture, and ELISA; EC performed confocal microscopy; YZ and HSA are responsible for conceptual design, data interpretation, and securing funding. YZ has access to all data collected. All authors critically reviewed and approved the manuscript. Financial disclosure statements have been obtained, and no conflicts of interest have been reported by the authors or by any individuals in control of the content of this article. NR 27 TC 0 Z9 0 U1 0 U2 3 PU LIPPINCOTT WILLIAMS & WILKINS PI PHILADELPHIA PA TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA SN 0894-9115 EI 1537-7385 J9 AM J PHYS MED REHAB JI Am. J. Phys. Med. Rehabil. PD SEP PY 2016 VL 95 IS 9 BP 656 EP 662 DI 10.1097/PHM.0000000000000460 PG 7 WC Rehabilitation; Sport Sciences SC Rehabilitation; Sport Sciences GA DU5LE UT WOS:000382252400008 PM 26945213 ER PT J AU Klabunde, CN Zheng, YY Quinn, VP Beaber, EF Rutter, CM Halm, EA Chubak, J Doubeni, CA Haas, JS Kamineni, A Schapira, MM Vacek, PM Garcia, MP Corley, DA AF Klabunde, Carrie N. Zheng, Yingye Quinn, Virginia P. Beaber, Elisabeth F. Rutter, Carolyn M. Halm, Ethan A. Chubak, Jessica Doubeni, Chyke A. Haas, Jennifer S. Kamineni, Aruna Schapira, Marilyn M. Vacek, Pamela M. Garcia, Michael P. Corley, Douglas A. CA PROSPR Consortium TI Influence of Age and Comorbidity on Colorectal Cancer Screening in the Elderly SO AMERICAN JOURNAL OF PREVENTIVE MEDICINE LA English DT Article ID COST-EFFECTIVENESS; FOLLOW-UP; AMERICAN-COLLEGE; BREAST; HEALTH; WOMEN; CARE; RECOMMENDATIONS; COLONOSCOPY; STRATEGIES AB Introduction: Expert recommendations differ for colorectal cancer screening in the elderly. Recent studies suggest that healthy adults aged >75 years may benefit from screening. This study examined screening use and follow-up, and how they varied by health status within age strata, among a large cohort of elderly individuals in community settings. Methods: A population-based, longitudinal cohort study was conducted among health plan members aged 65-89 years enrolled during 2011-2012 in three integrated healthcare systems participating in the Population-Based Research Optimizing Screening through Personalized Regimens consortium. Comorbidity measurements used the Charlson index. Analyses, conducted in 2015, comprised descriptive statistics and multivariable modeling that estimated age by comorbidity-specific percentages of patients for two outcomes: colorectal cancer screening uptake and follow-up of abnormal fecal blood tests. Results: Among 846,267 patients, 72% were up-to-date with colorectal cancer screening. Of patients with a positive fecal blood test, 65% received follow-up colonoscopy within 3 months. Likelihood of being up-to-date and receiving timely follow-up was significantly lower for patients aged >= 76 years than their younger counterparts (p < 0.001). Comorbidity was less influential than age and more strongly related to timely follow-up than being up-to-date. In all age groups, considerable numbers of patients with no/low comorbidity were not up-to-date or did not receive timely follow-up. Conclusions: In three integrated healthcare systems, many older, relatively healthy patients were not screening up-to-date, and some relatively young, healthy patients did not receive timely follow-up. Findings suggest a need for re-evaluating age-based screening guidelines and improving screening completion among the elderly. Published by Elsevier Inc. on behalf of American Journal of Preventive Medicine C1 [Klabunde, Carrie N.] NIH, Off Dis Prevent, Off Director, 6100 Execut Blvd,Suite 2B03, Rockville, MD 20852 USA. [Zheng, Yingye; Beaber, Elisabeth F.; Garcia, Michael P.] Fred Hutchinson Canc Res Ctr, Div Publ Hlth Sci, 1124 Columbia St, Seattle, WA 98104 USA. [Quinn, Virginia P.] Kaiser Permanente Southern Calif, Res & Evaluat, Pasadena, CA USA. [Rutter, Carolyn M.] RAND Corp, Santa Monica, CA USA. [Halm, Ethan A.] Univ Texas Southwestern Med Ctr, Dept Internal Med & Clin Sci, Dallas, TX USA. [Chubak, Jessica; Kamineni, Aruna] Grp Hlth Res Inst, Seattle, WA USA. [Doubeni, Chyke A.] Univ Penn, Perelman Sch Med, Dept Family Med & Community Hlth, Philadelphia, PA 19104 USA. [Doubeni, Chyke A.] Univ Penn, Perelman Sch Med, Dept Epidemiol, Philadelphia, PA 19104 USA. [Haas, Jennifer S.] Brigham & Womens Hosp, 75 Francis St, Boston, MA 02115 USA. [Haas, Jennifer S.] Harvard Med Sch, Boston, MA USA. [Schapira, Marilyn M.] Univ Penn, Perelman Sch Med, Dept Med, Philadelphia, PA 19104 USA. [Schapira, Marilyn M.] Philadelphia VA Med Ctr, Ctr Hlth Equ Res & Promot, Philadelphia, PA USA. [Vacek, Pamela M.] Univ Vermont, Coll Med, Med Biostat Unit, Burlington, VT USA. [Corley, Douglas A.] Kaiser Permanente Div Res, Oakland, CA USA. RP Klabunde, CN (reprint author), NIH, Off Dis Prevent, Off Director, 6100 Execut Blvd,Suite 2B03, Rockville, MD 20852 USA. EM klabundc@od.nih.gov FU National Cancer Institute of NIH PROSPR cooperative agreements [U01CA163304, U54CA163261, U5U54CA163262, U54CA163303, U54CA 163307, U54CA163308, U54CA163313] FX The authors thank the participating Population-Based Research Optimizing Screening through Personalized Regimens (PROSPR) Research Centers for the data they have provided for this study. A list of PROSPR investigators and contributing research staff is provided at: http://healthcaredelivery.cancer.gov/prospr/. The findings and conclusions in this report are those of the authors and do not necessarily represent the official position of NIH. The National Cancer Institute of NIH supported the research for this manuscript through the PROSPR cooperative agreements (grant numbers U01CA163304, U54CA163261, U5U54CA163262, U54CA163303, U54CA 163307, U54CA163308, U54CA163313). NR 41 TC 1 Z9 1 U1 4 U2 5 PU ELSEVIER SCIENCE INC PI NEW YORK PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA SN 0749-3797 EI 1873-2607 J9 AM J PREV MED JI Am. J. Prev. Med. PD SEP PY 2016 VL 51 IS 3 BP E67 EP E75 DI 10.1016/j.amepre.2016.04.018 PG 9 WC Public, Environmental & Occupational Health; Medicine, General & Internal SC Public, Environmental & Occupational Health; General & Internal Medicine GA DU6CC UT WOS:000382299700002 PM 27344108 ER PT J AU Matoba, Y Nonaka, N Takagi, Y Imamura, E Narukawa, M Nakamachi, T Shioda, S Banks, WA Nakamura, M AF Matoba, Yuko Nonaka, Naoko Takagi, Yoshitoki Imamura, Eisaku Narukawa, Masayuki Nakamachi, Tomoya Shioda, Seiji Banks, William A. Nakamura, Masanori TI Pituitary adenylate cyclase-activating polypeptide enhances saliva secretion via direct binding to PACAP receptors of major salivary glands in mice SO ANATOMICAL RECORD-ADVANCES IN INTEGRATIVE ANATOMY AND EVOLUTIONARY BIOLOGY LA English DT Article DE salivary gland; PACAP; PAC1R; pillar cell ID EPIDERMAL-GROWTH-FACTOR; RAT SUBMANDIBULAR-GLAND; ISCHEMIA-INDUCED DEATH; BLOOD-BRAIN-BARRIER; IMMUNOHISTOCHEMICAL LOCALIZATION; HIPPOCAMPAL-NEURONS; PEPTIDE; CELLS; INTERNALIZATION; HYPOSALIVATION AB Xerostomia, or dry mouth, is a common syndrome that is generally treated with artificial saliva; however, no other effective methods have yet been established. Saliva secretion is mainly under the control of the autonomic nervous system. Pituitary adenylate cyclase-activating polypeptide (PACAP) is recognized as a multifunctional neuropeptide in various organs. In this study, we examined the effect of PACAP on saliva secretion, and detected the distribution of the PACAP type 1 receptor (PAC1R) in major salivary glands, including the parotid, submandibular, and sublingual glands, in 9-week-old male C57BL/6 mice. Intranasal administration of PACAP 38 increased the amount of saliva secreted, which was not inhibited by atropine pretreatment. Immunohistochemical analysis showed that PAC1R was distributed in the three major salivary glands. In the parotid and sublingual glands, PAC1R was detected in striated duct cells, whereas in the submandibular gland, a strong PAC1R immunoreaction was detected in tall columnar epithelial cells in the granular ducts (i.e., pillar cells), as well as in some striated duct cells. PACAP significantly increased the concentration of epidermal growth factor in saliva. These results suggest that PACAP directly regulates saliva secretion by controlling the absorption activity in the ducts, and that pillar cells regulate the function of granular epithelial cells in the granular duct, such as the secretion of growth factors into the saliva. Collectively, these results suggest the possibility of PACAP as a new effective treatment of xerostomia. Anat Rec, 299:1293-1299, 2016. (c) 2016 Wiley Periodicals, Inc. C1 [Matoba, Yuko; Nonaka, Naoko; Takagi, Yoshitoki; Imamura, Eisaku; Narukawa, Masayuki; Nakamura, Masanori] Showa Univ, Dept Oral Anat & Dev Biol, Sch Dent, Shinagawa Ku, 1-5-8 Hatanodai, Tokyo 1428555, Japan. [Matoba, Yuko; Imamura, Eisaku] Yokohama Gen Hosp, Div Oral Surg, Aoba Ku, Yokohama, Kanagawa, Japan. [Nonaka, Naoko; Banks, William A.] Vet Affairs Puget Sound Hlth Care Syst, Geriatr Res Educ & Clin Ctr, Seattle, WA USA. [Nakamachi, Tomoya] Toyama Univ, Lab Regulatory Biol, Grad Sch Sci & Engn, Toyama, Toyama, Japan. [Shioda, Seiji] Hoshi Univ, Global Res Ctr Innovat Life Sci, Shinagawa Ku, Tokyo, Japan. RP Nakamura, M (reprint author), Showa Univ, Dept Oral Anat & Dev Biol, Sch Dent, Shinagawa Ku, 1-5-8 Hatanodai, Tokyo 1428555, Japan. EM masanaka@dent.showa-u.ac.jp FU Ministry of Education, Culture, Sports, Science and Technology of Japan [20592148, 21592342, 15K11022] FX Grant sponsor: Grant-in-Aid for Scientific Research from the Ministry of Education, Culture, Sports, Science and Technology of Japan; Grant numbers: 20592148, 21592342, and 15K11022. NR 42 TC 0 Z9 0 U1 4 U2 4 PU WILEY-BLACKWELL PI HOBOKEN PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA SN 1932-8486 EI 1932-8494 J9 ANAT REC JI Anat. Rec. PD SEP PY 2016 VL 299 IS 9 BP 1293 EP 1299 DI 10.1002/ar.23388 PG 7 WC Anatomy & Morphology SC Anatomy & Morphology GA DV1TI UT WOS:000382703600011 PM 27339371 ER PT J AU Offermann, FJ Eagan, A Offermann, AC Subhash, SS Miller, SL Radonovich, LJ AF Offermann, Francis J. Eagan, Aaron Offermann, Aidan C. Subhash, Shobha S. Miller, Shelly L. Radonovich, Lewis J. TI Potential airborne pathogen transmission in a hospital with and without surge control ventilation system modifications SO BUILDING AND ENVIRONMENT LA English DT Article DE Aerosol; Infectious disease; Negative pressure AB To better understand the transport of airborne particulate matter (PM) in hospital environments when surge control strategies are implemented, tests were conducted in a recently decommissioned hospital during a one-week period. An aerosol was released within a patient room and concentrations measured in the room and hallway with and without surge control ventilation system modifications. The average hallway protection efficiencies were high (>98%) both for the baseline ventilation configuration and when the ventilation system was modified for whole floor negative pressure, indicating very little PM reached the hallway. During entry/exit events through the patient room door into the hallway, the average minimum hallway protection efficiencies were lower during the modified ventilation operation (93-94%) than for the baseline operation (98-99%). These lower hallway protection efficiencies may be explained by the 52% reduction in the outdoor air ventilation being supplied to the hallway during the modified operation mode. This suggests that patient room doors should remain closed to control PM movement into the hallway. In addition, if there is concern about airborne infection transmission, an anteroom may be used to further reduce the transport of particles from the patient rooms to the hallways of the ward. (C) 2016 Elsevier Ltd. All rights reserved. C1 [Offermann, Francis J.; Offermann, Aidan C.] Indoor Environm Engn, San Francisco, CA USA. [Miller, Shelly L.] Univ Colorado, Mech Engn, Boulder, CO 80309 USA. [Eagan, Aaron; Subhash, Shobha S.; Radonovich, Lewis J.] US Dept Vet Affairs, Natl Ctr Occupat Hlth & Infect Control, Washington, DC USA. RP Miller, SL (reprint author), Univ Colorado, Mech Engn, Boulder, CO 80309 USA. EM offermann@iee-sf.com; shelly.miller@colorado.edu OI MILLER, SHELLY/0000-0002-1967-7551 FU U.S. Department of Veterans Affairs FX We would like to acknowledge the cooperation of the University of Florida Health for providing the opportunity for this testing in the building before it was torn down. Support for this project was provided by the U.S. Department of Veterans Affairs. NR 14 TC 0 Z9 0 U1 2 U2 7 PU PERGAMON-ELSEVIER SCIENCE LTD PI OXFORD PA THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, ENGLAND SN 0360-1323 EI 1873-684X J9 BUILD ENVIRON JI Build. Environ. PD SEP PY 2016 VL 106 BP 175 EP 180 DI 10.1016/j.buildenv.2016.06.029 PG 6 WC Construction & Building Technology; Engineering, Environmental; Engineering, Civil SC Construction & Building Technology; Engineering GA DV0IB UT WOS:000382600100015 ER PT J AU Shamsi, MM Mahdavi, M Quinn, LS Gharakhanlou, R Isanegad, A AF Shamsi, M. Molanouri Mahdavi, M. Quinn, L. S. Gharakhanlou, R. Isanegad, A. TI Effect of resistance exercise training on expression of Hsp70 and inflammatory cytokines in skeletal muscle and adipose tissue of STZ-induced diabetic rats SO CELL STRESS & CHAPERONES LA English DT Article DE Hsp70; Inflammatory cytokines; Skeletal muscle; Adipose tissue; Resistance training; Type 1 diabetes ID HEAT-SHOCK PROTEINS; METABOLIC RISK-FACTORS; INSULIN-RESISTANCE; STRESS-RESPONSE; NEONATAL STREPTOZOTOCIN; EXTRACELLULAR HSP70; PLANTARIS MUSCLE; TIME-COURSE; HYPERTROPHY; MECHANISMS AB Impairment of adipose tissue and skeletal muscles accrued following type 1 diabetes is associated with protein misfolding and loss of adipose mass and skeletal muscle atrophy. Resistance training can maintain muscle mass by changing both inflammatory cytokines and stress factors in adipose tissue and skeletal muscle. The purpose of this study was to determine the effects of a 5-week ladder climbing resistance training program on the expression of Hsp70 and inflammatory cytokines in adipose tissue and fast-twitch flexor hallucis longus (FHL) and slow-twitch soleus muscles in healthy and streptozotocin-induced diabetic rats. Induction of diabetes reduced body mass, while resistance training preserved FHL muscle weight in diabetic rats without any changes in body mass. Diabetes increased Hsp70 protein content in skeletal muscles, adipose tissue, and serum. Hsp70 protein levels were decreased in normal and diabetic rats by resistance training in the FHL, but not soleus muscle. Furthermore, resistance training decreased inflammatory cytokines in FHL skeletal muscle. On the other hand, Hsp70 and inflammatory cytokine protein levels were increased by training in adipose tissue. Also, significant positive correlations between inflammatory cytokines in adipose tissue and skeletal muscles with Hsp70 protein levels were observed. In conclusion, we found that in diabetic rats, resistance training decreased inflammatory cytokines and Hsp70 protein levels in fast skeletal muscle, increased adipose tissue inflammatory cytokines and Hsp70, and preserved FHL muscle mass. These results suggest that resistance training can maintain skeletal muscle mass in diabetes by changing inflammatory cytokines and stress factors such as Hsp70 in skeletal muscle and adipose tissue. C1 [Shamsi, M. Molanouri; Gharakhanlou, R.] Tarbiat Modares Univ, Phys Educ & Sport Sci Dept, Fac Humanities, Jala Ale Ahmad Exp, POB 14117-13116, Tehran, Iran. [Mahdavi, M.] Pasteur Inst Iran, Dept Immunol, 69 Pasteur Ave, Tehran, Iran. [Quinn, L. S.] VA Puget Sound Hlth Care Syst, Res Serv, Seattle, WA 98108 USA. [Quinn, L. S.] Univ Washington, Dept Med, Div Gerontol & Geriatr Med, Seattle, WA 98108 USA. [Isanegad, A.] Shahed Univ, Fac Humanities, Phys Educ & Sport Sci Dept, POB 14117-13116, Tehran, Iran. [Isanegad, A.] Shahed Univ, Immunoregulat Res Ctr, POB 14117-13116, Tehran, Iran. RP Shamsi, MM (reprint author), Tarbiat Modares Univ, Phys Educ & Sport Sci Dept, Fac Humanities, Jala Ale Ahmad Exp, POB 14117-13116, Tehran, Iran. EM molanouri@modares.ac.ir FU Research Center of Tarbiat Modarres University (TMU), Tehran, Iran FX This work was supported by the Research Center of Tarbiat Modarres University (TMU), Tehran, Iran. We wish to thank Professor Yaghob Fathoallahy for their kind help and sincere cooperation. NR 71 TC 0 Z9 0 U1 5 U2 6 PU SPRINGER PI DORDRECHT PA VAN GODEWIJCKSTRAAT 30, 3311 GZ DORDRECHT, NETHERLANDS SN 1355-8145 EI 1466-1268 J9 CELL STRESS CHAPERON JI Cell Stress Chaperones PD SEP PY 2016 VL 21 IS 5 BP 783 EP 791 DI 10.1007/s12192-016-0703-7 PG 9 WC Cell Biology SC Cell Biology GA DV1BQ UT WOS:000382655300005 ER PT J AU Sievers, CK Kratz, JD Zurbriggen, LD LoConte, NK Lubner, SJ Uboha, N Mulkerin, D Matkowskyj, KA Deming, DA AF Sievers, Chelsie K. Kratz, Jeremy D. Zurbriggen, Luke D. LoConte, Noelle K. Lubner, Sam J. Uboha, Natalya Mulkerin, Daniel Matkowskyj, Kristina A. Deming, Dustin A. TI The Multidisciplinary Management of Colorectal Cancer: Present and Future Paradigms SO CLINICS IN COLON AND RECTAL SURGERY LA English DT Article DE colon cancer; rectal cancer; chemotherapy ID RANDOMIZED CONTROLLED-TRIAL; III COLON-CANCER; ADJUVANT TREATMENT; 1ST-LINE TREATMENT; ANTIBODY THERAPY; PLUS CETUXIMAB; RAS MUTATIONS; POOR SURVIVAL; STAGE-II; PHASE-I AB As treatment strategies for patients with colorectal cancer advance, there has now become an ever-increasing need for multidisciplinary teams to care for these patients. Recent investigations into the timing and duration of perioperative therapy, as well as, the rise of molecular profiling have led to more systemic chemotherapeutic options. The most efficacious use, in terms of timing and patient selection, of these therapies in the setting of modern operative and radiotherapy techniques requires the generation of care teams discussing cases at multidisciplinary conferences. This review highlights the role of multidisciplinary team conferences, advances in perioperative chemotherapy, current clinical biomarkers, and emerging therapeutic agents for molecular subtypes of metastatic colon cancer. As our understanding of relevant molecular subtypes increases and as data becomes available on treatment response, the treatment of colorectal cancer will become more precise and effective. C1 [Sievers, Chelsie K.; Matkowskyj, Kristina A.] Univ Wisconsin, Dept Oncol, Madison, WI USA. [Sievers, Chelsie K.] Univ Wisconsin, Dept Med, Div Gastroenterol & Hepatol, Madison, WI USA. [Kratz, Jeremy D.; Zurbriggen, Luke D.; LoConte, Noelle K.; Lubner, Sam J.; Uboha, Natalya; Mulkerin, Daniel; Deming, Dustin A.] Univ Wisconsin, Dept Med, Div Hematol & Oncol, Madison, WI USA. [LoConte, Noelle K.; Lubner, Sam J.; Uboha, Natalya; Mulkerin, Daniel; Matkowskyj, Kristina A.; Deming, Dustin A.] Univ Wisconsin, Carbone Canc Ctr, Madison, WI USA. [Matkowskyj, Kristina A.; Deming, Dustin A.] William S Middleton Mem Vet Adm Med Ctr, Madison, WI USA. [Matkowskyj, Kristina A.] Univ Wisconsin, Dept Pathol & Lab Med, Madison, WI USA. RP Deming, DA (reprint author), 600 Highland Ave,K6-544, Madison, WI 53792 USA. EM ddeming@medicine.wisc.edu FU National Institutes of Health [P30 CA014520] FX This project was supported by the National Institutes of Health P30 CA014520 (Core Grant, University of Wisconsin Carbone Cancer Center, Madison, WI). NR 60 TC 1 Z9 1 U1 5 U2 5 PU THIEME MEDICAL PUBL INC PI NEW YORK PA 333 SEVENTH AVE, NEW YORK, NY 10001 USA SN 1531-0043 EI 1530-9681 J9 CLIN COLON RECT SURG JI Clin. Colon Rectal Surg. PD SEP PY 2016 VL 29 IS 3 BP 232 EP 238 DI 10.1055/s-0036-1584292 PG 7 WC Gastroenterology & Hepatology; Surgery SC Gastroenterology & Hepatology; Surgery GA DT1LA UT WOS:000381243000008 PM 27582648 ER PT J AU Gukovskaya, AS Pandol, SJ Gukovsky, I AF Gukovskaya, Anna S. Pandol, Stephen J. Gukovsky, Ilya TI New insights into the pathways initiating and driving pancreatitis SO CURRENT OPINION IN GASTROENTEROLOGY LA English DT Review DE acute pancreatitis; autophagy; calcium; chronic pancreatitis; lysosomes; mitochondrial permeability transition pore ID NEUTROPHIL EXTRACELLULAR TRAPS; SENSITIVE CALCIUM POOL; ACINAR-CELL; TRYPSIN ACTIVATION; PROTEIN-SYNTHESIS; CA2+ RELEASE; MOUSE MODELS; INFLAMMATION; AUTOPHAGY; MICE AB Purpose of review In this article, we discuss recent studies that advance our understanding of molecular and cellular factors initiating and driving pancreatitis, with the emphasis on the role of acinar cell organelle disorders. Recent findings The central physiologic function of the pancreatic acinar cell to synthesize, store, and secrete digestive enzymes critically relies on coordinated actions of the endoplasmic reticulum (ER), the endolysosomal system, mitochondria, and autophagy. Recent studies begin to unravel the roles of these organelles' disordering in the mechanism of pancreatitis. Mice deficient in key autophagy mediators Atg5 or Atg7, or lysosome-associated membrane protein-2, exhibit dysregulation of multiple signaling and metabolic pathways in pancreatic acinar cells and develop spontaneous pancreatitis. Mitochondria! dysfunction caused by sustained opening of the permeability transition pore is shown to mediate pancreatitis in several clinically relevant experimental models, and its inhibition by pharmacologic or genetic means greatly reduces local and systemic pathologic responses. Experimental pancreatitis is also alleviated with inhibitors of ORAI1, a key component of the plasma membrane channel mediating pathologic rise in acinar cell cytosolic Ca2+. Pancreatitis-promoting mutations are increasingly associated with the ER stress. These findings suggest novel pathways and drug targets for pancreatitis treatment. In addition, the recent studies identify new mediators (e.g., neutrophil extracellular traps) of the inflammatory and other responses of pancreatitis. Summary The recent findings illuminate a critical role of organelles regulating the autophagic, endolysosomal, mitochondrial, and ER pathways in maintaining pancreatic acinar cell homeostasis and secretory function; provide compelling evidence that organelle disordering is a key pathogenic mechanism initiating and driving pancreatitis; and identify molecular and cellular factors that could be targeted to restore organellar functions and thus alleviate or treat pancreatitis. C1 [Gukovskaya, Anna S.; Gukovsky, Ilya] Univ Calif Los Angeles, Los Angeles, CA USA. [Gukovskaya, Anna S.; Gukovsky, Ilya] VA Greater Los Angeles Healthcare Syst, Los Angeles, CA USA. [Pandol, Stephen J.] Cedars Sinai Med Ctr, Los Angeles, CA 90048 USA. RP Gukovskaya, AS (reprint author), Univ Calif Los Angeles, David Geffen Sch Med, Dept Med, 11301 Wilshire Blvd,Bldg 258-340, Los Angeles, CA 90073 USA.; Gukovskaya, AS (reprint author), West Los Angeles Healthcare Ctr, Pancreat Res Grp, 11301 Wilshire Blvd,Bldg 258-340, Los Angeles, CA 90073 USA. EM agukovsk@ucla.edu FU NIH [R01DK59936, R01AA19730, P01 DK98108, P50 AA11999, DoD PR140717P2, U01 DK108314, NWU2014-04-01]; Veterans Administration Merit Review FX The work was supported in part by the NIH grants R01DK59936, R01AA19730, P01 DK98108, P50 AA11999, DoD PR140717P2, U01 DK108314, NWU2014-04-01; and by Veterans Administration Merit Review. NR 63 TC 1 Z9 1 U1 9 U2 10 PU LIPPINCOTT WILLIAMS & WILKINS PI PHILADELPHIA PA TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA SN 0267-1379 EI 1531-7056 J9 CURR OPIN GASTROEN JI Curr. Opin. Gastroenterol. PD SEP PY 2016 VL 32 IS 5 BP 429 EP 435 DI 10.1097/MOG.0000000000000301 PG 7 WC Gastroenterology & Hepatology SC Gastroenterology & Hepatology GA DU7XS UT WOS:000382428500013 ER PT J AU Gregg, T Poudel, C Schmidt, BA Dhillon, RS Sdao, SM Truchan, NA Baar, EL Fernandez, LA Denu, JM Eliceiri, KW Rogers, JD Kimple, ME Lamming, DW Merrins, MJ AF Gregg, Trillian Poudel, Chetan Schmidt, Brian A. Dhillon, Rashpal S. Sdao, Sophia M. Truchan, Nathan A. Baar, Emma L. Fernandez, Luis A. Denu, John M. Eliceiri, Kevin W. Rogers, Jeremy D. Kimple, Michelle E. Lamming, Dudley W. Merrins, Matthew J. TI Pancreatic beta-Cells From Mice Offset Age-Associated Mitochondrial Deficiency With Reduced K-ATP Channel Activity SO DIABETES LA English DT Article ID INSULIN-SECRETION; METABOLIC OSCILLATIONS; CYTOCHROME-C; ISLETS; GLUCOSE; FLUORESCENCE; CA2+; MECHANISMS; NADH; GLYCOLYSIS AB Aging is accompanied by impaired glucose homeostasis and an increased risk of type 2 diabetes, culminating in the failure of insulin secretion from pancreatic beta-cells. To investigate the effects of age on beta-cell metabolism, we established a novel assay to directly image islet metabolism with NAD(P)H fluorescence lifetime imaging (FLIM). We determined that impaired mitochondrial activity underlies an age-dependent loss of insulin secretion in human islets. NAD(P)H FLIM revealed a comparable decline in mitochondrial function in the pancreatic islets of aged mice (W24 months), the result of 52% and 57% defects in flux through complex I and II, respectively, of the electron transport chain. However, insulin secretion and glucose tolerance are preserved in aged mouse islets by the heightened metabolic sensitivity of the beta-cell triggering pathway, an adaptation clearly encoded in the metabolic and Ca2+ oscillations that trigger insulin release (Ca2+ plateau fraction: young 0.211 +/- 0.006, aged 0.380 +/- 0.007, P < 0.0001). This enhanced sensitivity is driven by a reduction in K-ATP channel conductance (diazoxide: young 5.1 +/- 0.2 nS; aged 3.5 +/- 0.5 nS, P < 0.01), resulting in an similar to 2.8 mmol/L left shift in the beta-cell glucose threshold. The results demonstrate how mice but not humans are able to successfully compensate for age-associated metabolic dysfunction by adjusting beta-cell glucose sensitivity and highlight an essential mechanism for ensuring the maintenance of insulin secretion. C1 [Gregg, Trillian; Poudel, Chetan; Schmidt, Brian A.; Truchan, Nathan A.; Baar, Emma L.; Kimple, Michelle E.; Lamming, Dudley W.; Merrins, Matthew J.] Univ Wisconsin Madison, Dept Med, Div Endocrinol Diabet & Metab, Madison, WI 53706 USA. [Gregg, Trillian] Univ Wisconsin Madison, Biophys Grad Training Program, Madison, WI USA. [Gregg, Trillian; Poudel, Chetan; Eliceiri, Kevin W.; Rogers, Jeremy D.; Merrins, Matthew J.] Univ Wisconsin Madison, Lab Opt & Computat Instrumentat, Madison, WI 53706 USA. [Dhillon, Rashpal S.; Denu, John M.; Merrins, Matthew J.] Univ Wisconsin Madison, Dept Biomol Chem, Madison, WI 53706 USA. [Sdao, Sophia M.] Univ Wisconsin Madison, Integrated Program Biochem, Madison, WI USA. [Fernandez, Luis A.] Univ Wisconsin Madison, Div Transplantat, Dept Surg, Madison, WI USA. [Eliceiri, Kevin W.; Rogers, Jeremy D.] Univ Wisconsin Madison, Dept Biomed Engn, Madison, WI USA. [Kimple, Michelle E.; Lamming, Dudley W.; Merrins, Matthew J.] William S Middleton Mem Vet Adm Med Ctr, Madison, WI 53705 USA. RP Lamming, DW; Merrins, MJ (reprint author), Univ Wisconsin Madison, Dept Med, Div Endocrinol Diabet & Metab, Madison, WI 53706 USA.; Merrins, MJ (reprint author), Univ Wisconsin Madison, Lab Opt & Computat Instrumentat, Madison, WI 53706 USA.; Merrins, MJ (reprint author), Univ Wisconsin Madison, Dept Biomol Chem, Madison, WI 53706 USA.; Lamming, DW; Merrins, MJ (reprint author), William S Middleton Mem Vet Adm Med Ctr, Madison, WI 53705 USA. EM dlamming@medicine.wisc.edu; merrins@wisc.edu FU National Institutes of Health (NIH) Molecular Biophysics Training Grant [T32-GM-08293]; Laboratory for Optical and Computational Instrumentation; Wisconsin Alumni Research Foundation Dissertation Fellowship; American Diabetes Association [1-14-BS-115, 1-16-IBS-212]; NIH National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK) [R01-DK-102598]; NIH NIA [R00-AG-041765, R21-AG-050135]; Glenn Foundation Award; American Federation for Aging Research; NIH NIDDK [K01-DK-101683]; University of Wisconsin-Madison School of Medicine and Public Health and Department of Medicine FX T.G. received support from a National Institutes of Health (NIH) Molecular Biophysics Training Grant (T32-GM-08293), the Laboratory for Optical and Computational Instrumentation, and a Wisconsin Alumni Research Foundation Dissertation Fellowship. The Kimple laboratory was supported by grants to M.E.K. from the American Diabetes Association (1-14-BS-115) and the NIH National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK) (R01-DK-102598). The Lamming laboratory is supported by a grant to D.W.L. from the NIH NIA (R00-AG-041765) and a Glenn Foundation Award for research in the biological mechanisms of aging. This research was conducted while D.W.L. was a research grant recipient from the American Federation for Aging Research. The Merrins laboratory is supported by grants to M.J.M. from the NIH NIDDK (K01-DK-101683) and the American Diabetes Association (1-16-IBS-212). The Merrins and Lamming laboratories are jointly supported by a grant from the NIH NIA (R21-AG-050135), and both laboratories are supported by startup funds from the University of Wisconsin-Madison School of Medicine and Public Health and Department of Medicine. NR 51 TC 0 Z9 0 U1 3 U2 5 PU AMER DIABETES ASSOC PI ALEXANDRIA PA 1701 N BEAUREGARD ST, ALEXANDRIA, VA 22311-1717 USA SN 0012-1797 EI 1939-327X J9 DIABETES JI Diabetes PD SEP PY 2016 VL 65 IS 9 BP 2700 EP 2710 DI 10.2337/db16-0432 PG 11 WC Endocrinology & Metabolism SC Endocrinology & Metabolism GA DU3GW UT WOS:000382099800024 PM 27284112 ER PT J AU Clark, AM Ma, B Taylor, DL Griffith, L Wells, A AF Clark, Amanda M. Ma, Bo Taylor, D. Lansing Griffith, Linda Wells, Alan TI Liver metastases: Microenvironments and ex-vivo models SO EXPERIMENTAL BIOLOGY AND MEDICINE LA English DT Article DE Liver metastasis; metastatic models; tumor microenvironment; hepatic niche; microphysiological ID HEPATIC STELLATE CELLS; COLON-CARCINOMA CELLS; MACROPHAGE-MEDIATED CYTOTOXICITY; EXPERIMENTAL MELANOMA METASTASIS; STIMULATED KUPFFER CELLS; E-CADHERIN EXPRESSION; TUMOR-NECROSIS-FACTOR; BREAST-CANCER; HEPATOCELLULAR-CARCINOMA; ENDOTHELIAL-CELLS AB The liver is a highly metastasis-permissive organ, tumor seeding of which usually portends mortality. Its unique and diverse architectural and cellular composition enable the liver to undertake numerous specialized functions, however, this distinctive biology, notably its hemodynamic features and unique microenvironment, renders the liver intrinsically hospitable to disseminated tumor cells. The particular focus for this perspective is the bidirectional interactions between the disseminated tumor cells and the unique resident cell populations of the liver; notably, parenchymal hepatocytes and non-parenchymal liver sinusoidal endothelial, Kupffer, and hepatic stellate cells. Understanding the early steps in the metastatic seeding, including the decision to undergo dormancy versus outgrowth, has been difficult to study in 2D culture systems and animals due to numerous limitations. In response, tissue-engineered biomimetic systems have emerged. At the cutting-edge of these developments are ex vivo 'microphysiological systems' (MPS) which are cellular constructs designed to faithfully recapitulate the structure and function of a human organ or organ regions on a milli-to micro-scale level and can be made all human to maintain species-specific interactions. Hepatic MPSs are particularly attractive for studying metastases as in addition to the liver being a main site of metastatic seeding, it is also the principal site of drug metabolism and therapy-limiting toxicities. Thus, using these hepatic MPSs will enable not only an enhanced understanding of the fundamental aspects of metastasis but also allow for therapeutic agents to be fully studied for efficacy while also monitoring pharmacologic aspects and predicting toxicities. The review discusses some of the hepatic MPS models currently available and although only one MPS has been validated to relevantly modeling metastasis, it is anticipated that the adaptation of the other hepatic models to include tumors will not be long in coming. C1 [Clark, Amanda M.; Ma, Bo; Wells, Alan] Univ Pittsburgh, Dept Pathol, Pittsburgh, PA 15213 USA. [Taylor, D. Lansing; Wells, Alan] Univ Pittsburgh, Dept Bioengn, Pittsburgh, PA 15213 USA. [Taylor, D. Lansing; Wells, Alan] Univ Pittsburgh, Dept Computat & Syst Biol, Pittsburgh, PA 15213 USA. [Taylor, D. Lansing; Wells, Alan] Univ Pittsburgh, McGowan Inst Regenerat Med, Pittsburgh, PA 15213 USA. [Taylor, D. Lansing] Univ Pittsburgh, Drug Discovery Inst, Pittsburgh, PA 15213 USA. [Taylor, D. Lansing] Univ Pittsburgh, Inst Canc, Pittsburgh, PA 15213 USA. [Griffith, Linda] MIT, Dept Biol Engn, Cambridge, MA 02139 USA. [Wells, Alan] VA Pittsburgh Healthcare Syst, Pittsburgh VA Med Ctr, Pittsburgh, PA 15240 USA. RP Wells, A (reprint author), Univ Pittsburgh, Dept Pathol, Pittsburgh, PA 15213 USA.; Wells, A (reprint author), Univ Pittsburgh, Dept Bioengn, Pittsburgh, PA 15213 USA.; Wells, A (reprint author), Univ Pittsburgh, Dept Computat & Syst Biol, Pittsburgh, PA 15213 USA.; Wells, A (reprint author), Univ Pittsburgh, McGowan Inst Regenerat Med, Pittsburgh, PA 15213 USA.; Wells, A (reprint author), VA Pittsburgh Healthcare Syst, Pittsburgh VA Med Ctr, Pittsburgh, PA 15240 USA. EM wellsa@upmc.edu OI Wells, Alan/0000-0002-1637-8150 FU NIH [UH3TR000496, UH3TR000503]; VA Merit Award FX We thank the members of the Wells, Taylor and Griffith groups and the UPitt Drug Discovery Institute for helpful discussions and feedback. We also thank our collaborators Donna Stolz, Raman Venkataramanan at UPitt, Doug Lauffenburger, and Dave Trumper at MIT. Concepts herein were funded through NIH grants UH3TR000496 (Griffith) and UH3TR000503 (Taylor), and a VA Merit Award (Wells). NR 126 TC 2 Z9 2 U1 4 U2 7 PU SAGE PUBLICATIONS LTD PI LONDON PA 1 OLIVERS YARD, 55 CITY ROAD, LONDON EC1Y 1SP, ENGLAND SN 1535-3702 EI 1535-3699 J9 EXP BIOL MED JI Exp. Biol. Med. PD SEP PY 2016 VL 241 IS 15 BP 1639 EP 1652 DI 10.1177/1535370216658144 PG 14 WC Medicine, Research & Experimental SC Research & Experimental Medicine GA DU6FU UT WOS:000382310500002 PM 27390264 ER PT J AU Salameh, TS Rhea, EM Banks, WA Hanson, AJ AF Salameh, Therese S. Rhea, Elizabeth M. Banks, William A. Hanson, Angela J. TI Insulin resistance, dyslipidemia, and apolipoprotein E interactions as mechanisms in cognitive impairment and Alzheimer's disease SO EXPERIMENTAL BIOLOGY AND MEDICINE LA English DT Article DE Alzheimer's disease; apolipoprotein E; dyslipidemia; insulin resistance; cognition ID BLOOD-BRAIN-BARRIER; CENTRAL-NERVOUS-SYSTEM; GROWTH-FACTOR EXPRESSION; GALANIN-LIKE PEPTIDE; INTRANASAL INSULIN; AMYLOID-BETA; E GENOTYPE; APOE GENOTYPE; GLUCOSE-METABOLISM; DIABETES-MELLITUS AB An increased risk for Alzheimer's disease is associated with dyslipidemia and insulin resistance. A separate literature shows the genetic risk for developing Alzheimer's disease is strongly correlated to the presence of the E4 isoform of the apolipoprotein E carrier protein. Understanding how apolipoprotein E carrier protein, lipids, amyloid beta peptides, glucose, central nervous system insulin, and peripheral insulin interact with one another in Alzheimer's disease is an area of increasing interest. Here, we will review the evidence relating apolipoprotein E carrier protein, lipids, and insulin action to Alzheimer's disease and Ab peptides and then propose mechanisms as to how these factors might interact with one another to impair cognition and promote Alzheimer's disease. C1 [Salameh, Therese S.; Rhea, Elizabeth M.; Banks, William A.; Hanson, Angela J.] Vet Affairs Puget Sound Hlth Care Syst, Geriatr Res Educ & Clin Ctr, Seattle, WA 98108 USA. [Salameh, Therese S.; Rhea, Elizabeth M.; Banks, William A.; Hanson, Angela J.] Univ Washington, Sch Med, Dept Med, Div Gerontol & Geriatr Med, Seattle, WA 98195 USA. RP Banks, WA (reprint author), Vet Affairs Puget Sound Hlth Care Syst, Geriatr Res Educ & Clin Ctr, Seattle, WA 98108 USA.; Banks, WA (reprint author), Univ Washington, Sch Med, Dept Med, Div Gerontol & Geriatr Med, Seattle, WA 98195 USA. EM wabanks1@uw.edu FU National Institutes of Health National Institute on Aging [RO1 - AG046619, K23 AG047978-01]; AFAR Hartford Center of Excellence Award; Veterans Affairs Puget Sound Health Care System, Seattle, Washington; [T32 - AG000057] FX This research was supported by the National Institutes of Health National Institute on Aging RO1 - AG046619 for Salameh and Banks, K23 AG047978-01 and AFAR Hartford Center of Excellence Award to Hanson, and T32 - AG000057 for Rhea. This article results from work supported by resources from the Veterans Affairs Puget Sound Health Care System, Seattle, Washington. NR 105 TC 1 Z9 1 U1 5 U2 5 PU SAGE PUBLICATIONS LTD PI LONDON PA 1 OLIVERS YARD, 55 CITY ROAD, LONDON EC1Y 1SP, ENGLAND SN 1535-3702 EI 1535-3699 J9 EXP BIOL MED JI Exp. Biol. Med. PD SEP PY 2016 VL 241 IS 15 BP 1676 EP 1683 DI 10.1177/1535370216660770 PG 8 WC Medicine, Research & Experimental SC Research & Experimental Medicine GA DU6FU UT WOS:000382310500006 PM 27470930 ER PT J AU Drel, VR Tan, CY Barnes, JL Gorin, Y Lee, DY Wagner, B AF Drel, Viktor R. Tan, Chunyan Barnes, Jeffrey L. Gorin, Yves Lee, Doug-Yoon Wagner, Brent TI Centrality of bone marrow in the severity of gadolinium-based contrast-induced systemic fibrosis SO FASEB JOURNAL LA English DT Article DE nephrogenic fibrosing dermopathy; skin diseases; NADPH oxidase; chemokine CCL2; CCR2 ID ACTIVATION; BIODISTRIBUTION; MACROPHAGES; FIBROCYTES; OXIDASE; INJURY; AGENTS; CELLS; MICE AB Systemic fibrosis can be induced in humans with gadolinium-based contrast, and cumulative doses correlate with severity. Bone marrow-derived fibrocytes accumulate in the dermis. Whether target organs liberate chemokines to recruit these fibrocytes or whether fibrocytes are stimulated to home to the affected tissue is unknown. Transgenic (tagged) donor rats were treated with gadolinium-based contrast. Bone marrow was obtained from diseased animals and age-matched controls. Rats with subtotal nephrectomies were lethally irradiated and underwent salvage transplantation with either the contrast-naive or contrast-exposed bone marrow. Groups were randomly assigned to control or contrast treatment. Contrast treatment led to dermal fibrosis, and this was exacerbated in recipients of contrast-exposed marrow. Fibronectin, C-C chemokine receptors (CCRs)2 and 7, and oxidative stress were all increased in skin from contrast-treated animalsall parameters more severe in recipients of contrast-treated animals. The respective ligands, monocyte chemoattractant protein and C-C motif ligand 19, were both elevated in skin from contrast-treated animals. Coadministration of gadolinium-based contrast and a CCR2 inhibitor reduced the severity of skin disease as well as dermal cellularity. The functional role of chemokines in the effects of gadolinium-based contrast was further confirmed in in situ coculture studies using neutralizing CCR2 antibodies. These data implicate dermal liberation of specific chemokines in the recruitment of circulating bone marrow-derived cells. The disease is augmented by bone marrow exposure to contrast, which explains why multiple exposures correlate with severity.Drel, V. R., Tan, C., Barnes, J. L., Gorin, Y., Lee, D.-Y., Wagner, B. Centrality of bone marrow in the severity of gadolinium-based contrast-induced systemic fibrosis. C1 [Drel, Viktor R.; Tan, Chunyan; Barnes, Jeffrey L.; Gorin, Yves; Lee, Doug-Yoon; Wagner, Brent] Univ Texas Hlth Sci Ctr San Antonio, San Antonio, TX 78229 USA. [Barnes, Jeffrey L.; Wagner, Brent] South Texas Vet Hlth Care Syst, San Antonio, TX USA. RP Wagner, B (reprint author), Univ Texas Hlth Sci Ctr San Antonio, Div Nephrol, Dept Med, 7703 Floyd Curl Dr,MC 7882, San Antonio, TX 78229 USA. EM wagnerb@uthscsa.edu FU Veterans Administration Merit [I01 BX001958]; U.S. National Institutes of Health (NIH) National Institute of Diabetes and Digestive and Kidney Diseases [R01-DK102085, R01-DK080106, R01-DK079996, R01-DK78971]; NIH National Center for Advancing Translational Sciences/Linked Specialized Center Cooperative Agreement [UL1-TR001120]; Qatar National Research Fund, National Priorities Research Program [NPRP8-1750-3-360] FX This work was funded by Veterans Administration Merit Award I01 BX001958 (to B.W.), U.S. National Institutes of Health (NIH) National Institute of Diabetes and Digestive and Kidney Diseases Grants R01-DK102085 (to B.W.), R01-DK080106 (to J.L.B.), R01-DK079996 (to Y.G.), and R01-DK78971 (to Y.G.), NIH National Center for Advancing Translational Sciences/Linked Specialized Center Cooperative Agreement Grant UL1-TR001120 (to Y.G.), and an award from the Qatar National Research Fund, National Priorities Research Program (NPRP8-1750-3-360) (to Y.G.). Author contributions: B. Wagner and Y. Gorin designed the research, analyzed the data, and wrote the paper; J. L. Barnes provided the hPAP donor animals; and C. Tan, D.-Y. Lee, and V. R. Drel performed the experiments. The authors declare no conflicts of interest. NR 23 TC 1 Z9 1 U1 1 U2 1 PU FEDERATION AMER SOC EXP BIOL PI BETHESDA PA 9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA SN 0892-6638 EI 1530-6860 J9 FASEB J JI Faseb J. PD SEP PY 2016 VL 30 IS 9 BP 3026 EP 3038 DI 10.1096/fj.201500188R PG 13 WC Biochemistry & Molecular Biology; Biology; Cell Biology SC Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology GA DV3JD UT WOS:000382816300004 PM 27221979 ER PT J AU Yuen, EK Gros, K Welsh, KE McCauley, J Resnick, HS Danielson, CK Price, M Ruggiero, KJ AF Yuen, Erica K. Gros, Kirstin Welsh, Kyleen E. McCauley, Jenna Resnick, Heidi S. Danielson, Carla K. Price, Matthew Ruggiero, Kenneth J. TI Development and preliminary testing of a web-based, self-help application for disaster-affected families SO HEALTH INFORMATICS JOURNAL LA English DT Article DE ehealth; evidence-based practice; healthcare service innovation and IT; IT design and development methodologies; telecare ID RANDOMIZED CONTROLLED-TRIAL; POSTTRAUMATIC-STRESS-DISORDER; DEPRESSION; ANXIETY; INTERVENTION; ADOLESCENTS; PROGRAM AB Technology-based self-help interventions have the potential to increase access to evidence-based mental healthcare, especially for families affected by natural disasters. However, development of these interventions is a complex process and poses unique challenges. Usability testing, which assesses the ability of individuals to use an application successfully, can have a significant impact on the quality of a self-help intervention. This article describes (a) the development of a novel web-based multi-module self-help intervention for disaster-affected adolescents and their parents and (b) a mixed-methods formal usability study to evaluate user response. A total of 24 adolescents were observed, videotaped, and interviewed as they used the depressed mood component of the self-help intervention. Quantitative results indicated an above-average user experience, and qualitative analysis identified 120 unique usability issues. We discuss the challenges of developing self-help applications, including design considerations and the value of usability testing in technology-based interventions, as well as our plan for widespread dissemination. C1 [Yuen, Erica K.] Univ Tampa, Tampa, FL 33606 USA. [Gros, Kirstin; Ruggiero, Kenneth J.] Ralph H Johnson Vet Affairs Med Ctr, Charleston, SC USA. [Gros, Kirstin; Welsh, Kyleen E.; McCauley, Jenna; Resnick, Heidi S.; Danielson, Carla K.; Ruggiero, Kenneth J.] Med Univ South Carolina, Charleston, SC USA. [Price, Matthew] Univ Vermont, Burlington, VT 05405 USA. RP Yuen, EK (reprint author), Univ Tampa, Dept Psychol, 401 W Kennedy Blvd,Box Q, Tampa, FL 33606 USA. EM eyuen@ut.edu FU National Institute of Mental Health (NIMH) [R01 MH081056]; NIMH [T32 MH018869] FX The author(s) disclosed receipt of the following financial support for the research, authorship, and/or publication of this article: This study was funded by National Institute of Mental Health (NIMH) Grant #R01 MH081056 (PI: Ruggiero). Dr. Price was supported by NIMH Grant T32 MH018869 (PI: Kilpatrick). Views presented in this article do not necessarily reflect those of the funding agency. NR 43 TC 0 Z9 0 U1 2 U2 2 PU SAGE PUBLICATIONS INC PI THOUSAND OAKS PA 2455 TELLER RD, THOUSAND OAKS, CA 91320 USA SN 1460-4582 EI 1741-2811 J9 HEALTH INFORM J JI Health Inform. J. PD SEP PY 2016 VL 22 IS 3 BP 659 EP 675 DI 10.1177/1460458215579292 PG 17 WC Health Care Sciences & Services; Medical Informatics SC Health Care Sciences & Services; Medical Informatics GA DU9NC UT WOS:000382543400018 PM 25933798 ER PT J AU Deutsch, MB Liang, LJ Jimenez, EE Mather, MJ Mendez, MF AF Deutsch, Mariel B. Liang, Li-Jung Jimenez, Elvira E. Mather, Michelle J. Mendez, Mario F. TI Are we comparing frontotemporal dementia and Alzheimer disease patients with the right measures? SO INTERNATIONAL PSYCHOGERIATRICS LA English DT Article DE Alzheimer disease; behavioral and psychological symptoms of dementia; frontotemporal dementia; neuropsychiatric symptoms; research design and methodology ID COGNITIVE IMPAIRMENT; VARIANT AB Background: Clinical research studies of behavioral variant frontotemporal dementia (bvFTD) often use Alzheimer disease (AD) as a comparison group for control of dementia variables, using tests of cognitive function to match the groups. These two dementia syndromes, however, are very different in clinical manifestations, and the comparable severity of these dementias may not be reflected by commonly used cognitive scales such as the Mini-Mental State Examination (MMSE). Methods: We evaluated different measures of dementia severity and symptoms among 20 people with bvFTD compared to 24 with early-onset AD. Results: Despite similar ages, disease-duration, education, and cognitive performance on two tests of cognitive function, the MMSE and the Montreal Cognitive Assessment (MoCA), the bvFTD participants, compared to the AD participants, were significantly more impaired on other measures of disease severity, including function (Functional Assessment Questionnaire (FAQ)), neuropsychiatric symptoms (Neuropsychiatric Inventory (NPI)), and global dementia stage (Clinical Dementia Rating Scales (CDRs)). However, when we adjusted for the frontotemporal lobar degeneration-CDR (FTLD-CDR) in the analyses, the two dementia groups were comparable across all measures despite significant differences on the cognitive scales. Conclusion: We found tests of cognitive functions (MMSE and MoCA) to be insufficient measures for ensuring comparability between bvFTD and AD groups. In clinical studies, the FTLD-CDR, which includes additional language and behavior items, may be a better overall way to match bvFTD and AD groups on dementia severity. C1 [Deutsch, Mariel B.; Jimenez, Elvira E.; Mather, Michelle J.; Mendez, Mario F.] Univ Calif Los Angeles, David Geffen Sch Med, Dept Neurol, Los Angeles, CA 90095 USA. [Deutsch, Mariel B.; Jimenez, Elvira E.; Mendez, Mario F.] Vet Affairs Greater Los Angeles Healthcare Syst, Neurobehav Unit, Los Angeles, CA USA. [Liang, Li-Jung] Univ Calif Los Angeles, David Geffen Sch Med, Med Stat Core, Los Angeles, CA 90095 USA. [Mendez, Mario F.] Univ Calif Los Angeles, David Geffen Sch Med, Psychiat & Biobehav Sci, Los Angeles, CA 90095 USA. RP Deutsch, MB (reprint author), Icahn Sch Med Mt Sinai, Dept Neurol, 1 Gustave L Levy Pl,Box 1139, New York, NY 10029 USA. EM mariel.deutsch@mssm.edu OI Deutsch, Mariel/0000-0003-1228-8868 FU NIH [R01AG034499-05] FX Dr. Mendez has previously received a grant (#R01AG034499-05) from the NIH, and receives royalties from Oxford University Press, Cambridge for book publications. The remaining authors have reported no conflicts of interest. NR 16 TC 1 Z9 1 U1 2 U2 2 PU CAMBRIDGE UNIV PRESS PI NEW YORK PA 32 AVENUE OF THE AMERICAS, NEW YORK, NY 10013-2473 USA SN 1041-6102 EI 1741-203X J9 INT PSYCHOGERIATR JI Int. Psychogeriatr. PD SEP PY 2016 VL 28 IS 9 BP 1481 EP 1485 DI 10.1017/S1041610216000582 PG 5 WC Psychology, Clinical; Geriatrics & Gerontology; Gerontology; Psychiatry; Psychology SC Psychology; Geriatrics & Gerontology; Psychiatry GA DU7HP UT WOS:000382385000008 PM 27079571 ER PT J AU Gaggar, A Weathington, N AF Gaggar, Amit Weathington, Nathaniel TI Bioactive extracellular matrix fragments in lung health and disease SO JOURNAL OF CLINICAL INVESTIGATION LA English DT Review ID BRONCHIOLITIS OBLITERANS SYNDROME; OBSTRUCTIVE PULMONARY-DISEASE; NEUTROPHIL ELASTASE CLEAVES; EPITHELIAL-CELL MIGRATION; PROLINE-GLYCINE-PROLINE; TOLL-LIKE RECEPTORS; LAMININ-5 GAMMA-2-CHAIN; PROLYL ENDOPEPTIDASE; CHEMOTACTIC ACTIVITY; POTENTIAL ROLE AB The extracellular matrix (ECM) is the noncellular component critical in the maintenance of organ structure and the regulation of tissue development, organ structure, and cellular signaling. The ECM is a dynamic entity that undergoes continuous degradation and resynthesis. In addition to compromising structure, degradation of the ECM can liberate bioactive fragments that cause cellular activation and chemotaxis of a variety of cells. These fragments are termed matrikines, and their cellular activities are sentinel in the development and progression of tissue injury seen in chronic lung disease. Here, we discuss the matrikines that are known to be active in lung biology and their roles in lung disease. We also consider the use of matrikines as disease markers and potential therapeutic targets in lung disease. C1 [Gaggar, Amit] Univ Alabama Birmingham, Dept Med, Div Pulm & Crit Care Med, Birmingham, AL USA. [Gaggar, Amit] Birmingham Vet Affairs Med Ctr, Birmingham, AL USA. [Gaggar, Amit] Program Protease & Matrix Biol, Birmingham, AL USA. [Weathington, Nathaniel] Univ Pittsburgh, Dept Med, Div Pulm Allergy & Crit Care Med, Pittsburgh, PA USA. RP Weathington, N (reprint author), 3459 Fifth Ave,MUH NW 628, Pittsburgh, PA 15213 USA.; Gaggar, A (reprint author), 1900 Univ Ave THT 422, Birmingham, AL 35294 USA. EM agaggar@uabmc.edu; weathingtonnm@upmc.edu FU NIH [HL102371, HL126135]; Veterans Administration [1 I01 BX001756]; American Lung Association; Ismail Moustapha Scholar Fund FX We thank J.E. Blalock for his thoughtful reading of this manuscript. These studies were funded in part by grants from the NIH (HL102371 to A. Gaggar; HL126135 to N. Weathington), the Veterans Administration (1 I01 BX001756 to A. Gaggar), the American Lung Association (to N. Weathington), and the Ismail Moustapha Scholar Fund (to A. Gaggar). NR 115 TC 0 Z9 0 U1 5 U2 12 PU AMER SOC CLINICAL INVESTIGATION INC PI ANN ARBOR PA 35 RESEARCH DR, STE 300, ANN ARBOR, MI 48103 USA SN 0021-9738 EI 1558-8238 J9 J CLIN INVEST JI J. Clin. Invest. PD SEP PY 2016 VL 126 IS 9 BP 3176 EP 3184 DI 10.1172/JCI83147 PG 9 WC Medicine, Research & Experimental SC Research & Experimental Medicine GA DU9CI UT WOS:000382513400004 PM 27584731 ER PT J AU Hamilton, BE Woltjer, RL Prola-Netto, J Nesbit, GM Gahramanov, S Pham, T Wagner, J Neuwelt, EA AF Hamilton, Bronwyn E. Woltjer, Randall L. Prola-Netto, Joao Nesbit, Gary M. Gahramanov, Seymur Thao Pham Wagner, Jaime Neuwelt, Edward A. TI Ferumoxytol-enhanced MRI differentiation of meningioma from dural metastases: a pilot study with immunohistochemical observations SO JOURNAL OF NEURO-ONCOLOGY LA English DT Article DE Blood-brain barrier; Contrast agents; Extraaxial masses; Ferumoxytol; Immunohistochemistry; MRI ID BRAIN-TUMORS; ULTRASTRUCTURE; JUNCTIONS; CELLS AB Malignant dural neoplasms are not reliably distinguished from benign dural neoplasms with contrast-enhanced magnetic resonance imaging (MRI). MRI enhancement in central nervous system (CNS) diseases imaged with ferumoxytol has been attributed to intracellular uptake in macrophages rather than vascular leakage. We compared imaging to histopathology and immunohistochemistry in meningiomas and dural metastases having ferumoxytol-enhanced MRI (FeMRI) and gadolinium-enhanced MRI (GdMRI) in order to correlate enhancement patterns to macrophage presence and vascular state. All patients having extraaxial CNS tumors were retrospectively selected from one of two ongoing FeMRI studies. Enhancement was compared between GdMRI and FeMRI. Diagnoses were confirmed histologically and/or by characteristic imaging. Tumor and vascular histology was reviewed. Immunohistochemical staining for CD68 (a macrophage marker), Connexin-43 (Cx43) (a marker of normal gap junctions), and smooth muscle actin (SMA) as a marker of vascularity, was performed in seven study cases with available tissue. Immunohistochemistry was performed on archival material from 33 subjects outside of the current study as controls: 20 WHO grade I cases of meningioma and 13 metastatic tumors. Metastases displayed marked delayed enhancement on FeMRI, similar to GdMRI. Four patients with dural metastases and one patient with meningioma showed similar enhancement on FeMRI and GdMRI. Five meningiomas with typical enhancement on GdMRI lacked enhancement on FeMRI. Enhancement on FeMRI was better associated with decreased Cx43 expression than intralesional macrophages. These pilot data suggest that FeMRI may better differentiate metastatic disease from meningiomas than GdMRI, and that differences in tumor vasculature rather than macrophage presence could underlie differences in contrast enhancement. C1 [Hamilton, Bronwyn E.; Prola-Netto, Joao; Nesbit, Gary M.] Oregon Hlth & Sci Univ, Dept Neuroradiol, Portland, OR 97201 USA. [Woltjer, Randall L.; Thao Pham] Oregon Hlth & Sci Univ, Dept Pathol, Portland, OR 97201 USA. [Nesbit, Gary M.] Oregon Hlth & Sci Univ, Dotter Intervent Inst, Portland, OR 97201 USA. [Gahramanov, Seymur] Univ New Mexico, Dept Neurosurg, Albuquerque, NM 87131 USA. [Wagner, Jaime] Miami Cardiac & Vasc Inst, Miami, FL USA. [Neuwelt, Edward A.] Oregon Hlth & Sci Univ, Dept Neurol, 3181 SW Sam Jackson Pk Rd,L603, Portland, OR 97239 USA. [Neuwelt, Edward A.] Oregon Hlth & Sci Univ, Dept Neurosurg, Portland, OR 97201 USA. [Neuwelt, Edward A.] Portland VA Med Ctr, Portland, OR 97239 USA. RP Neuwelt, EA (reprint author), Oregon Hlth & Sci Univ, Dept Neurol, 3181 SW Sam Jackson Pk Rd,L603, Portland, OR 97239 USA.; Neuwelt, EA (reprint author), Oregon Hlth & Sci Univ, Dept Neurosurg, Portland, OR 97201 USA.; Neuwelt, EA (reprint author), Portland VA Med Ctr, Portland, OR 97239 USA. EM neuwelte@ohsu.edu FU Veterans Administration merit review Grant; National Institute of Health [NS44687, CA137488]; Walter S. and Lucienne Driskill Foundation FX This work was supported by a Veterans Administration merit review Grant and by National Institute of Health Grants NS44687, and CA137488, and by the Walter S. and Lucienne Driskill Foundation to EAN. The authors thank Samantha Rolph and Emily Hochhalter Youngers for their help with manuscript preparation. NR 11 TC 0 Z9 0 U1 3 U2 3 PU SPRINGER PI NEW YORK PA 233 SPRING ST, NEW YORK, NY 10013 USA SN 0167-594X EI 1573-7373 J9 J NEURO-ONCOL JI J. Neuro-Oncol. PD SEP PY 2016 VL 129 IS 2 BP 301 EP 309 DI 10.1007/s11060-016-2175-0 PG 9 WC Oncology; Clinical Neurology SC Oncology; Neurosciences & Neurology GA DU3CC UT WOS:000382087400012 PM 27393348 ER PT J AU Sands, KA Shahripour, RB Kumar, G Barlinn, K Lyerly, MJ Harsany, M Cure, J Yakov, YL Alexandrov, AW Alexandrov, AV AF Sands, Kara A. Shahripour, Reza Bavarsad Kumar, Gyanendra Barlinn, Kristian Lyerly, Michael J. Harsany, Michal Cure, Joel Yakov, Yuri L. Alexandrov, Anne W. Alexandrov, Andrei V. TI Acute Isolated Central Facial Palsy as Manifestation of Middle Cerebral Artery Ischemia SO JOURNAL OF NEUROIMAGING LA English DT Article DE Stroke; isolated central facial palsy; middle cerebral artery ischemia ID LACUNAR SYNDROME; STROKE; THROMBOLYSIS; INFARCTION AB BACKGROUNDIsolated central facial palsy (I-CFP) is attributed to a lacunar syndrome affecting the corona radiata region or pons. We examined our acute stroke registry for patients presenting with I-CFP and localized their symptoms to a vascular lesion. SUBJECT & METHODSOur database of consecutive patients with symptoms of acute cerebral ischemia admitted from January 2008 to December 2012 was reviewed for NIH Stroke Scale (NIHSS) scores and subcomponents. All patients with I-CFP dysarthria (total NIHSS 3) had contrast-enhanced MR-angiography and transcranial Doppler as standard of care. All ischemic lesions were localized by MRI within 72 hours from symptom onset. RESULTSOf 2,202 patients with acute cerebral ischemia, 879 patients (35%) had NIHSS score 3 points (mean age 63 + 15 years, 46 % women). Nine patients (.4%) presented with I-CFP +/- dysarthria. Of these, only 1 had a lesion in the corona radiata and patent MCA, 1 had a pontine lesion without proximal vessel occlusion (2/9, or 22%). Remaining 7 patients (78%) had flow-limiting thromboembolic mid-to-distal M1/proximal M2 MCA disease. Of these, 6 (86%) patients had a prominent early anterior temporal artery on MRA and nonlacunar ischemic lesions on MRI. CONCLUSIONSContrary to current teaching of lesion localization for an I-CFP, our study revealed the majority of acute patients presenting with this symptom had evidence of flow-limiting thromboembolic MCA disease rather than a lacunar lesion. Our findings underscore the essential role of comprehensive vascular imaging in patients presenting with I-CFP, which is commonly associated with acute flow-limiting thromboembolic MCA disease. C1 [Sands, Kara A.; Shahripour, Reza Bavarsad; Kumar, Gyanendra; Lyerly, Michael J.; Yakov, Yuri L.; Alexandrov, Anne W.; Alexandrov, Andrei V.] Univ Alabama Birmingham, Dept Neurol, Comprehens Stroke Ctr, UAB Stn, Birmingham, AL 35294 USA. [Barlinn, Kristian] Tech Univ Dresden, Dresden Univ Stroke Ctr, Dresden, Germany. [Lyerly, Michael J.] Birmingham Vet Affairs Med Ctr, Birmingham, AL USA. [Harsany, Michal] St Annes Univ Hosp, Int Clin Res Ctr, Brno, Czech Republic. [Harsany, Michal] Masaryk Univ, Fac Med, Brno, Czech Republic. [Harsany, Michal] St Annes Univ Hosp, Dept Neurol, Brno, Czech Republic. [Cure, Joel] Univ Alabama Birmingham, Dept Neuroradiol, Birmingham, AL USA. [Yakov, Yuri L.; Alexandrov, Anne W.; Alexandrov, Andrei V.] Univ Tennessee, Med Ctr, Dept Neurol, Memphis, TN USA. RP Alexandrov, AV (reprint author), Univ Tennessee, Hlth Sci Ctr, Dept Neurol, 855 Monroe Ave,Suite 415, Memphis, TN 38163 USA. EM aalexa30@uthsc.edu OI Lyerly, Michael/0000-0003-4236-1018 NR 20 TC 0 Z9 0 U1 3 U2 3 PU WILEY-BLACKWELL PI HOBOKEN PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA SN 1051-2284 EI 1552-6569 J9 J NEUROIMAGING JI J. Neuroimaging PD SEP-OCT PY 2016 VL 26 IS 5 BP 499 EP 502 DI 10.1111/jon.12338 PG 4 WC Clinical Neurology; Neuroimaging; Radiology, Nuclear Medicine & Medical Imaging SC Neurosciences & Neurology; Radiology, Nuclear Medicine & Medical Imaging GA DV4AW UT WOS:000382868200006 PM 27061014 ER PT J AU Busch, RA Heneghan, AF Pierre, JF Neuman, JC Reimer, CA Wang, XY Kimple, ME Kudsk, KA AF Busch, Rebecca A. Heneghan, Aaron F. Pierre, Joseph F. Neuman, Joshua C. Reimer, Claire A. Wang, Xinying Kimple, Michelle E. Kudsk, Kenneth A. TI Bombesin Preserves Goblet Cell Resistin-Like Molecule During Parenteral Nutrition but Not Other Goblet Cell Products SO JOURNAL OF PARENTERAL AND ENTERAL NUTRITION LA English DT Article DE parenteral nutrition; enteric nervous system; small intestine; innate immunity; goblet cells; mucin 2; trefoil factor 3; resistin-like molecule; bombesin ID PENETRATING ABDOMINAL-TRAUMA; RESPIRATORY-TRACT IMMUNITY; LYMPHOID-TISSUE; MUCOSAL IMMUNITY; BARRIER FUNCTION; FED MICE; GASTROINTESTINAL-TRACT; BACTERIAL PNEUMONIA; ENTERAL NUTRITION; SEPTIC MORBIDITY AB Introduction: Parenteral nutrition (PN) increases the risk of infection in critically ill patients and is associated with defects in gastrointestinal innate immunity. Goblet cells produce mucosal defense compounds, including mucin (principally MUC2), trefoil factor 3 (TFF3), and resistin-like molecule (RELM). Bombesin (BBS), a gastrin-releasing peptide analogue, experimentally reverses PN-induced defects in Paneth cell innate immunity. We hypothesized that PN reduces goblet cell product expression and PN+BBS would reverse these PN-induced defects. Methods: Two days after intravenous cannulation, male Institute of Cancer Research mice were randomized to chow (n = 15), PN (n = 13), or PN+BBS (15 mu g tid) (n = 12) diets for 5 days. Defined segments of ileum and luminal fluid were analyzed for MUC2, TFF3, and RELM by quantitative reverse transcriptase polymerase chain reaction and Western blot. Th2 cytokines interleukin (IL)-4 and IL-13 were measured by enzyme-linked immunosorbent assay. Results: Compared with chow, PN significantly reduced MUC2 in ileum (P < .01) and luminal fluid (P = .01). BBS supplementation did not improve ileal or luminal MUC2 compared with PN (P > .3). Compared with chow, PN significantly reduced TFF3 in ileum (P < .02) and luminal fluid (P < .01). BBS addition did not improve ileal or luminal TFF3 compared with PN (P > .3). Compared with chow, PN significantly reduced ileal RELM (P < .01). BBS supplementation significantly increased ileal RELM to levels similar to chow (P < .03 vs PN; P > .6 vs chow). Th2 cytokines were decreased with PN and returned to chow levels with BBS. Conclusion: PN significantly impairs the goblet cell component of innate mucosal immunity. BBS only preserves goblet cell RELM during PN but not other goblet cell products measured. C1 [Heneghan, Aaron F.; Kudsk, Kenneth A.] William S Middleton Mem Vet Adm Med Ctr, Vet Adm Surg Serv, Madison, WI USA. [Busch, Rebecca A.; Heneghan, Aaron F.; Pierre, Joseph F.; Reimer, Claire A.; Wang, Xinying; Kudsk, Kenneth A.] Univ Wisconsin, Dept Surg, Sch Med & Publ Hlth, Madison, WI USA. [Pierre, Joseph F.] Univ Chicago, Dept Med, Div Gastroenterol, 5841 S Maryland Ave, Chicago, IL 60637 USA. [Neuman, Joshua C.] Univ Wisconsin, Dept Nutr Sci, Sch Med & Publ Hlth, 1415 Linden Dr, Madison, WI 53706 USA. [Wang, Xinying] Nanjing Univ, Sch Med, Jinling Hosp, Dept Surg, Nanjing, Jiangsu, Peoples R China. [Kimple, Michelle E.] Univ Wisconsin, Dept Med, Div Endocrinol Diabet & Metab, Sch Med & Publ Hlth, Madison, WI USA. RP Kudsk, KA (reprint author), Univ Wisconsin, Sch Med & Publ Hlth, 600 Highland Ave,Clin Sci Ctr H4-736, Madison, WI 53792 USA. EM kudsk@surgery.wisc.edu FU Biomedical Laboratory Research & Development Service of the VA Office of Research and Development [I01BX001672]; National Institute of Health (NIH) [R01 DK102598]; NIH [T32 CA090217, T32 DK007074, T32 AG000213] FX The project described was supported by award number I01BX001672 from the Biomedical Laboratory Research & Development Service of the VA Office of Research and Development. The contents of this article do not represent the views of the Veterans Affairs or the United States government. This material is also based upon work supported by the National Institute of Health (NIH) grant R01 DK102598 (MEK) and NIH training grants T32 CA090217 (RAB), T32 DK007074 (JFP), and T32 AG000213 (JCN). NR 49 TC 1 Z9 1 U1 2 U2 3 PU SAGE PUBLICATIONS INC PI THOUSAND OAKS PA 2455 TELLER RD, THOUSAND OAKS, CA 91320 USA SN 0148-6071 EI 1941-2444 J9 JPEN-PARENTER ENTER JI J. Parenter. Enter. Nutr. PD SEP PY 2016 VL 40 IS 7 BP 1042 EP 1049 DI 10.1177/0148607115585353 PG 8 WC Nutrition & Dietetics SC Nutrition & Dietetics GA DV1VA UT WOS:000382708700018 PM 25934045 ER PT J AU Cox, KS Mouilso, ER Venners, MR Defever, ME Duviviere, L Rauch, SAM Strom, TQ Joiner, TE Tuerk, PW AF Cox, Keith S. Mouilso, Emily R. Venners, Margaret R. Defever, Mahrie E. Duviviere, Leticia Rauch, Sheila A. M. Strom, Thad Q. Joiner, Thomas E. Tuerk, Peter W. TI Reducing suicidal ideation through evidence-based treatment for posttraumatic stress disorder SO JOURNAL OF PSYCHIATRIC RESEARCH LA English DT Article DE Suicide; Suicidal ideation; Suicide prevention; Posttraumatic stress disorder (PTSD); Evidence-based treatments (EBTs); Effectiveness research ID VETERANS; RISK; PTSD; HEALTH; CARE; THERAPY; IRAQ AB Background: Suicide is a major public health concern in military and civilian contexts. Veteran populations are at increased risk for suicide, especially veterans with mental health disorders such as Posttraumatic Stress Disorder (PTSD). Suicidal ideation (SI) is a primary risk factor for suicide. Methods: We investigated changes in SI in a multi-site sample of treatment seeking veterans from three separate Veterans Health Administration (VA) medical centers (n = 289) who received Prolonged Exposure (PE) therapy, an evidence-based treatment (EBT) for PTSD. SI and PTSD symptoms were assessed, using self-report instruments, throughout routine clinical care. Results: Both PTSD and SI symptoms reduced over the course of treatment (d-type effect sizes of 1.47 and 0.27, respectively). While SI was associated with PTSD symptoms at all time points, appropriately specified, time lagged models indicated that changes in PTSD symptoms were predictive of future declines in SI, while the converse was not true. Conclusions: Results indicate that treating PTSD symptoms with an EBT for PTSD can be an effective way to reduce SI, at least partially, and for some patients. These data are significant in light of the resources and programming devoted to addressing SI in the VA relative to available empirical evidence regarding the effectiveness of developed strategies. The findings demonstrate the importance of facilitating EBT referrals for specific disorders as a component of broad-based suicide outreach and preventions strategies. (C) 2016 Elsevier Ltd. All rights reserved. C1 [Cox, Keith S.] Univ North Carolina Asheville, Dept Psychol, One Univ Hts, Asheville, NC 28803 USA. [Mouilso, Emily R.] Univ Georgia, Dept Psychol, 125 Baldwin St, Athens, GA 30602 USA. [Venners, Margaret R.; Defever, Mahrie E.] VA Ann Arbor Hlth Care Syst, 2215 Fuller Rd, Ann Arbor, MI 48105 USA. [Venners, Margaret R.; Defever, Mahrie E.] Univ Michigan, Sch Med, Dept Psychiat, 4250 Plymouth Rd, Ann Arbor, MI 48109 USA. [Duviviere, Leticia] Evidence Based Practice Inst, 3303 South Irving St, Seattle, WA 98144 USA. [Rauch, Sheila A. M.] Emory Univ, Sch Med, Dept Psychiat & Behav Sci, 12 Execut Pk Dr NE 200, Atlanta, GA 30329 USA. [Strom, Thad Q.] Minneapolis VA Hlth Care Syst, 1 Vet Dr, Minneapolis, MN 55417 USA. [Strom, Thad Q.] Univ Minnesota, Sch Med, Dept Psychiat, Minneapolis, MN 55454 USA. [Joiner, Thomas E.] Florida State Univ, Dept Psychol, 1107 West Call St, Tallahassee, FL 32304 USA. [Tuerk, Peter W.] Ralph H Johnson VA Med Ctr, 109 Bee St, Charleston, SC 29401 USA. [Tuerk, Peter W.] Med Univ South Carolina, Dept Psychiat & Behav Sci, 67 President St,MSC 861, Charleston, SC 29425 USA. RP Cox, KS (reprint author), Univ North Carolina Asheville, Dept Psychol, One Univ Hts, Asheville, NC 28803 USA. EM kcox2@unca.edu FU Department of Veteran Affairs, Veterans Health Administration, Office of Research and Development, Clinical Sciences Research and Development [CDA-2] FX Dr. Tuerk's contribution to this work was supported by a Career Development Award (CDA-2) from the Department of Veteran Affairs, Veterans Health Administration, Office of Research and Development, Clinical Sciences Research and Development (PI: Peter W. Tuerk). NR 38 TC 1 Z9 1 U1 5 U2 5 PU PERGAMON-ELSEVIER SCIENCE LTD PI OXFORD PA THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, ENGLAND SN 0022-3956 EI 1879-1379 J9 J PSYCHIATR RES JI J. Psychiatr. Res. PD SEP PY 2016 VL 80 BP 59 EP 63 DI 10.1016/j.jpsychires.2016.05.011 PG 5 WC Psychiatry SC Psychiatry GA DU6TI UT WOS:000382347100010 PM 27295122 ER PT J AU de Boer, IH Zelnick, L Afkarian, M Ayers, E Curtin, L Himmelfarb, J Ikizler, TA Kahn, SE Kestenbaum, B Utzschneider, K AF de Boer, Ian H. Zelnick, Leila Afkarian, Maryam Ayers, Ernest Curtin, Laura Himmelfarb, Jonathan Ikizler, T. Alp Kahn, Steven E. Kestenbaum, Bryan Utzschneider, Kristina TI Impaired Glucose and Insulin Homeostasis in Moderate-Severe CKD SO JOURNAL OF THE AMERICAN SOCIETY OF NEPHROLOGY LA English DT Article ID CHRONIC KIDNEY-DISEASE; GLOMERULAR-FILTRATION-RATE; RENAL-DISEASE; ORAL GLUCOSE; RESISTANCE; METABOLISM; CLEARANCE; SENSITIVITY; SECRETION; INTOLERANCE AB Kidney disease leads to clinically relevant disturbances in glucose and insulin homeostasis, but the pathophysiology in moderate-severe CKD remains incompletely defined. In a cross-sectional study of 59 participants with nondiabetic CKD (mean eGFR =37.6 ml/min per 1.73 m(2)) and 39 healthy control subjects, we quantified insulin sensitivity, clearance, and secretion and glucose tolerance using hyperinsulinemic-euglycemic clamp and intravenous and oral glucose tolerance tests. Participants with CKD had lower insulin sensitivity than participants without CKD (mean[SD] 3.9[2.0] versus 5.0 [2.0] mg/min per mu U/ml; P<0.01). Insulin clearance correlated with insulin sensitivity (r=0.72; P<0.001) and was also lower in participants with CKD than controls (876 [226] versus 998 [212] ml/min; P<0.01). Adjustment for physical activity, diet, fat mass, and fatfree mass in addition to demographics and smoking partially attenuated associations of CKD with insulin sensitivity (adjusted difference, -0.7; 95% confidence interval, -1.4 to 0.0 mg/min per mu U/ml) and insulin clearance (adjusted difference, -85; 95% confidence interval, -160 to -10 ml/min). Among participants with CKD, eGFR did not significantly correlate with insulin sensitivity or clearance. Insulin secretion and glucose tolerance did not differ significantly between groups, but 65% of participants with CKD had impaired glucose tolerance. In conclusion, moderate-severe CKD associated with reductions in insulin sensitivity and clearance that are explained, in part, by differences in lifestyle and body composition. We did not observe a CKD-specific deficit in insulin secretion, but the combination of insulin resistance and inadequate augmentation of insulin secretion led to a high prevalence of impaired glucose tolerance. C1 [de Boer, Ian H.; Zelnick, Leila; Afkarian, Maryam; Ayers, Ernest; Curtin, Laura; Himmelfarb, Jonathan; Kestenbaum, Bryan] Univ Washington, Div Nephrol, Seattle, WA 98195 USA. [de Boer, Ian H.; Zelnick, Leila; Afkarian, Maryam; Ayers, Ernest; Curtin, Laura; Himmelfarb, Jonathan; Kestenbaum, Bryan] Univ Washington, Kidney Res Inst, Seattle, WA 98195 USA. [Kahn, Steven E.; Utzschneider, Kristina] Univ Washington, Div Metab Endocrinol & Nutr, Seattle, WA 98195 USA. [de Boer, Ian H.; Kahn, Steven E.; Utzschneider, Kristina] Vet Affairs Puget Sound Hlth Care Syst, Seattle, WA USA. [Ikizler, T. Alp] Vanderbilt Univ, Med Ctr, Div Nephrol, Nashville, TN USA. [Ikizler, T. Alp] Vanderbilt Univ, Med Ctr, Vanderbilt Ctr Kidney Dis, Nashville, TN USA. RP de Boer, IH (reprint author), Box 359606,325 9th Ave, Seattle, WA 98104 USA. EM deboer@u.washington.edu FU National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK) [R01DK087726]; NIDDK [UL1TR000423, P01DK017047, P30DK035816, R01DK088762, R01DK099199] FX The Study of Glucose and Insulin in Renal Disease was funded by Grant R01DK087726 from the National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK). Additional support came from NIDDK Grants UL1TR000423, P01DK017047, P30DK035816, R01DK088762, and R01DK099199. NR 40 TC 5 Z9 5 U1 1 U2 2 PU AMER SOC NEPHROLOGY PI WASHINGTON PA 1725 I ST, NW STE 510, WASHINGTON, DC 20006 USA SN 1046-6673 EI 1533-3450 J9 J AM SOC NEPHROL JI J. Am. Soc. Nephrol. PD SEP PY 2016 VL 27 IS 9 BP 2861 EP 2871 DI 10.1681/ASN.2015070756 PG 11 WC Urology & Nephrology SC Urology & Nephrology GA DU5SB UT WOS:000382270500030 PM 26823551 ER PT J AU Helsel, LTCBS David, MEA Antevil, CDRJL AF Helsel, L. T. C. Bryan S. David, Maj Elizabeth A. Antevil, C. D. R. Jared L. TI Special considerations of military cardiothoracic surgeons SO JOURNAL OF THORACIC AND CARDIOVASCULAR SURGERY LA English DT Editorial Material ID OPERATION-IRAQI-FREEDOM; COMBAT CASUALTY CARE C1 [Helsel, L. T. C. Bryan S.] San Antonio Mil Med Ctr, Dept Cardiothorac Surg, 3551 Roger Brooke Dr, San Antonio, TX 78234 USA. [Helsel, L. T. C. Bryan S.] Audie L Murphy Vet Affairs Med Ctr, Dept Cardiothorac Surg, San Antonio, TX USA. [David, Maj Elizabeth A.] David Grant Med Ctr, Heart Lung Vasc Ctr, Travis Air Force Base, CA USA. [David, Maj Elizabeth A.] Univ Calif Davis, Med Ctr, Sect Gen Thorac Surg, Sacramento, CA 95817 USA. [Antevil, C. D. R. Jared L.] Walter Reed Natl Mil Med Ctr, Dept Cardiothorac Surg, Bethesda, MD USA. RP Helsel, LTCBS (reprint author), San Antonio Mil Med Ctr, Dept Cardiothorac Surg, 3551 Roger Brooke Dr, San Antonio, TX 78234 USA. EM deltaguns@aol.com NR 13 TC 0 Z9 0 U1 0 U2 0 PU MOSBY-ELSEVIER PI NEW YORK PA 360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA SN 0022-5223 EI 1097-685X J9 J THORAC CARDIOV SUR JI J. Thorac. Cardiovasc. Surg. PD SEP PY 2016 VL 152 IS 3 BP 664 EP 666 DI 10.1016/j.jtcvs.2016.04.089 PG 3 WC Cardiac & Cardiovascular Systems; Respiratory System; Surgery SC Cardiovascular System & Cardiology; Respiratory System; Surgery GA DU5HB UT WOS:000382241700015 ER PT J AU Zhuang, YH Berens-Norman, HM Leser, JS Clarke, P Tyler, KL AF Zhuang, Yonghua Berens-Norman, Heather M. Leser, J. Smith Clarke, Penny Tyler, Kenneth L. TI Mitochondrial p53 Contributes to Reovirus-Induced Neuronal Apoptosis and Central Nervous System Injury in a Mouse Model of Viral Encephalitis SO JOURNAL OF VIROLOGY LA English DT Article ID INDEPENDENT CELL-DEATH; TISSUE-INJURY; BAK; ACTIVATION; MEMBRANE; PATHWAY; PROTEIN; BRAIN; PHOSPHORYLATION; ANTAGONIZES AB The tumor suppressor p53 plays a critical part in determining cell fate both as a regulator of the transcription of several proapoptotic genes and through its binding interactions with Bcl-2 family proteins at mitochondria. We now demonstrate that p53 protein levels are increased in infected brains during reovirus encephalitis. This increase occurs in the cytoplasm of reovirus-infected neurons and is associated with the activation of caspase 3. Increased levels of p53 in reovirus-infected brains are not associated with increased expression levels of p53 mRNA, suggesting that p53 regulation occurs at the protein level. Increased levels of p53 are also not associated with the increased expression levels of p53-regulated, proapoptotic genes. In contrast, upregulated p53 accumulates in mitochondria. Previous reports demonstrated that the binding of p53 to Bak at mitochondria causes Bak activation and results in apoptosis. We now show that Bak is activated and that activated Bak is bound to p53 during reovirus encephalitis. In addition, survival is enhanced in reovirus-infected Bak(-/-) mice compared to controls, demonstrating a role for Bak in reovirus pathogenesis. Inhibition of the mitochondrial translocation of p53 with pifithrin mu prevents the formation of p53/Bak complexes following reovirus infection of ex vivo brain slice cultures and results in decreased apoptosis and tissue injury. These results suggest that the mitochondrial localization of p53 regulates reovirus-induced pathogenesis in the central nervous system (CNS) through its interactions with Bak. IMPORTANCE There are virtually no specific treatments of proven efficacy for virus-induced neuroinvasive diseases. A better understanding of the pathogenesis of virus-induced CNS injury is crucial for the rational development of novel therapies. Our studies demonstrate that p53 is activated in the brain following reovirus infection and may provide a therapeutic target for virus-induced CNS disease. C1 [Zhuang, Yonghua; Leser, J. Smith; Clarke, Penny; Tyler, Kenneth L.] Univ Colorado Denver, Dept Neurol, Aurora, CO 80045 USA. [Berens-Norman, Heather M.] Univ Colorado Denver, Internal Med Residency Program, Aurora, CO USA. [Berens-Norman, Heather M.] Univ Colorado Denver, Phys Scientist Training Program, Aurora, CO USA. [Tyler, Kenneth L.] Univ Colorado Denver, Dept Immunol & Microbiol, Aurora, CO USA. [Tyler, Kenneth L.] Univ Colorado Denver, Dept Med, Aurora, CO USA. [Tyler, Kenneth L.] Denver VA Med Ctr, Denver, CO USA. RP Clarke, P (reprint author), Univ Colorado Denver, Dept Neurol, Aurora, CO 80045 USA. EM Penny.Clarke@ucdenver.edu FU HHS \ National Institutes of Health (NIH) [R33AI101064, RO1NS076512, T32AI052066]; U.S. Department of Veterans Affairs (VA) [BX000963] FX This work, including the efforts of Kenneth L. Tyler, was funded by HHS vertical bar National Institutes of Health (NIH) (R33AI101064 and RO1NS076512). This work, including the efforts of Heather M. Berens-Norman, was funded by HHS vertical bar National Institutes of Health (NIH) (T32AI052066). This work, including the efforts of Kenneth L. Tyler, was funded by U.S. Department of Veterans Affairs (VA) (BX000963). NR 37 TC 1 Z9 1 U1 0 U2 1 PU AMER SOC MICROBIOLOGY PI WASHINGTON PA 1752 N ST NW, WASHINGTON, DC 20036-2904 USA SN 0022-538X EI 1098-5514 J9 J VIROL JI J. Virol. PD SEP PY 2016 VL 90 IS 17 BP 7684 EP 7691 DI 10.1128/JVI.00583-16 PG 8 WC Virology SC Virology GA DU6EM UT WOS:000382306800009 PM 27307572 ER PT J AU Apelo, SIA Lamming, DW AF Apelo, Sebastian I. Arriola Lamming, Dudley W. TI mTORC2 Puts Its Shoulder to Krebs' Wheel SO MOLECULAR CELL LA English DT Editorial Material ID GLUTAMINE-METABOLISM; MECHANISTIC TARGET; RAPAMYCIN; PATHWAY AB In this issue of Molecular Cell, Moloughney et al. (2016) find that mTORC2 responds to falling levels of glucose and glutamine catabolites, promoting glutaminolysis and preserving the TCA cycle and hexosamine biosynthesis. C1 [Apelo, Sebastian I. Arriola; Lamming, Dudley W.] Univ Wisconsin, Dept Med, Madison, WI 53705 USA. [Apelo, Sebastian I. Arriola; Lamming, Dudley W.] William S Middleton Mem Vet Adm Med Ctr, Madison, WI 53705 USA. RP Lamming, DW (reprint author), Univ Wisconsin, Dept Med, Madison, WI 53705 USA.; Lamming, DW (reprint author), William S Middleton Mem Vet Adm Med Ctr, Madison, WI 53705 USA. EM dlamming@medicine.wisc.edu OI Lamming, Dudley/0000-0002-0079-4467 NR 10 TC 1 Z9 1 U1 3 U2 5 PU CELL PRESS PI CAMBRIDGE PA 600 TECHNOLOGY SQUARE, 5TH FLOOR, CAMBRIDGE, MA 02139 USA SN 1097-2765 EI 1097-4164 J9 MOL CELL JI Mol. Cell PD SEP 1 PY 2016 VL 63 IS 5 BP 723 EP 725 DI 10.1016/j.molcel.2016.08.016 PG 4 WC Biochemistry & Molecular Biology; Cell Biology SC Biochemistry & Molecular Biology; Cell Biology GA DU9MO UT WOS:000382542000002 ER PT J AU Carreno, FR Donegan, JJ Boley, AM Shah, A DeGuzman, M Frazer, A Lodge, DJ AF Carreno, F. R. Donegan, J. J. Boley, A. M. Shah, A. DeGuzman, M. Frazer, A. Lodge, D. J. TI Activation of a ventral hippocampus-medial prefrontal cortex pathway is both necessary and sufficient for an antidepressant response to ketamine SO MOLECULAR PSYCHIATRY LA English DT Article ID RESISTANT MAJOR DEPRESSION; NMDA RECEPTOR BLOCKADE; D-ASPARTATE ANTAGONIST; NUCLEUS-ACCUMBENS; BASOLATERAL AMYGDALA; DENDRITIC MORPHOLOGY; NEUROTROPHIC FACTOR; NEURONS; RAT; STRESS AB A single sub-anesthetic dose of ketamine exerts rapid and sustained antidepressant effects. Here, we examined the role of the ventral hippocampus (vHipp)-medial prefrontal cortex (mPFC) pathway in ketamine's antidepressant response. Inactivation of the vHipp with lidocaine prevented the sustained, but not acute, antidepressant-like effect of ketamine as measured by the forced swim test (FST). Moreover, optogenetic as well as pharmacogenetic specific activation of the vHipp-mPFC pathway using DREADDs (designer receptors exclusively activated by designer drugs) mimicked the antidepressant-like response to ketamine; importantly, this was pathway specific, in that activation of a vHipp to nucleus accumbens circuit did not do this. Furthermore, optogenetic inactivation of the vHipp/mPFC pathway at the time of FST completely reversed ketamine's antidepressant response. In addition, we found that a transient increase in TrkB receptor phosphorylation in the vHipp contributes to ketamine's sustained antidepressant response. These data demonstrate that activity in the vHipp-mPFC pathway is both necessary and sufficient for the antidepressant-like effect of ketamine. C1 [Carreno, F. R.; Donegan, J. J.; Boley, A. M.; Shah, A.; DeGuzman, M.; Frazer, A.; Lodge, D. J.] Univ Texas Hlth Sci Ctr San Antonio, Ctr Biomed Neurosci, Dept Pharmacol, 7703 Floyd Curl Dr,Mail Code 7764, San Antonio, TX 78229 USA. [Frazer, A.] South Texas Vet Hlth Care Syst, Audie L Murphy Div, San Antonio, TX USA. RP Carreno, FR (reprint author), Univ Texas Hlth Sci Ctr San Antonio, Ctr Biomed Neurosci, Dept Pharmacol, 7703 Floyd Curl Dr,Mail Code 7764, San Antonio, TX 78229 USA. EM Carrenof@uthscsa.edu FU NIMH [MH082933, MH090067]; NARSAD award from the Maltz Family Foundation FX This work was supported by NIMH grants MH082933 (AF) and MH090067 (DJL) and a NARSAD award from the Maltz Family Foundation (DJL). NR 44 TC 7 Z9 7 U1 4 U2 8 PU NATURE PUBLISHING GROUP PI LONDON PA MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND SN 1359-4184 EI 1476-5578 J9 MOL PSYCHIATR JI Mol. Psychiatr. PD SEP PY 2016 VL 21 IS 9 BP 1298 EP 1308 DI 10.1038/mp.2015.176 PG 11 WC Biochemistry & Molecular Biology; Neurosciences; Psychiatry SC Biochemistry & Molecular Biology; Neurosciences & Neurology; Psychiatry GA DU6MK UT WOS:000382328900019 PM 26619811 ER PT J AU Albergotti, WG Davis, KS Abberbock, S Bauman, JE Ohr, J Clump, DA Heron, DE Duvvuri, U Kim, S Johnson, JT Ferris, RL AF Albergotti, William G. Davis, Kara S. Abberbock, Shira Bauman, Julie E. Ohr, James Clump, David A. Heron, Dwight E. Duvvuri, Umamaheswar Kim, Seungwon Johnson, Jonas T. Ferris, Robert L. TI Association of pretreatment body mass index and survival in human papillomavirus positive oropharyngeal squamous cell carcinoma SO ORAL ONCOLOGY LA English DT Article DE Body mass index; Survival; Oropharyngeal squamous cell carcinoma; Human papillomavirus ID NECK-CANCER; WEIGHT-LOSS; HEAD; OBESITY; IMPACT; OUTCOMES; CHEMORADIATION; CHEMORADIOTHERAPY; PREDICTORS; RADIATION AB Background: Pretreatment body mass index (BMI) > 25 kg/m(2) is a positive prognostic factor in patients with head and neck cancer. Previous studies have not been adequately stratified by human papilloma virus (HPV) status or subsite. Our objective is to determine prognostic significance of pretreatment BMI on overall survival in HPV+ oropharyngeal squamous cell carcinoma (OPSCC). Methods: This is a retrospective review of patients with HPV+ OPSCC treated between 8/1/2006 and 8/31/2014. Patients were stratified by BMI status (>/< 25 kg/m(2)). Univariate and multivariate analyses of survival were performed. Results: 300 patients met our inclusion/exclusion criteria. Patients with a BMI > 25 kg/m(2) had a longer overall survival (HR = 0.49, P = 0.01) as well as a longer disease-specific survival (HR = 0.43, P = 0.02). Overall survival remained significantly associated with high BMI on multivariate analysis (HR = 0.54, P = 0.04). Conclusions: Pre-treatment normal or underweight BMI status is associated with worse overall survival in HPV+ OPSCC. (C) 2016 Elsevier Ltd. All rights reserved. C1 [Albergotti, William G.; Davis, Kara S.; Heron, Dwight E.; Duvvuri, Umamaheswar; Kim, Seungwon; Johnson, Jonas T.; Ferris, Robert L.] Univ Pittsburgh, Med Ctr, Dept Otolaryngol Head & Neck Surg, Pittsburgh, PA USA. [Abberbock, Shira] Univ Pittsburgh, Inst Canc, Biostat Facil, Pittsburgh, PA USA. [Bauman, Julie E.; Ohr, James] Univ Pittsburgh, Dept Med, Div Med Oncol, Pittsburgh, PA USA. [Clump, David A.; Heron, Dwight E.] Univ Pittsburgh, Inst Canc, Dept Radiat Oncol, Pittsburgh, PA USA. [Duvvuri, Umamaheswar] Vet Affairs Pittsburgh Hlth Syst, Pittsburgh, PA USA. RP Albergotti, WG (reprint author), Univ Pittsburgh, Med Ctr, Dept Otolaryngol, Inst Eye & Ear, 200 Lothrop St,Suite 500, Pittsburgh, PA 15213 USA. EM albergottiwg@upmc.edu FU University of Pittsburgh Cancer Institute Biostatistics Facility [P30CA047904]; Career Development Award from Department of Veterans Affairs; BLRD; PNC Foundation FX Contract grant sponsor: This project was conducted using the University of Pittsburgh Cancer Institute Biostatistics Facility that is supported in part by award P30CA047904.; This works was supported in part by a Career Development Award from the Department of Veterans Affairs, BLR&D and a Grant from the PNC Foundation (U.D.). NR 29 TC 0 Z9 0 U1 1 U2 1 PU ELSEVIER SCIENCE BV PI AMSTERDAM PA PO BOX 211, 1000 AE AMSTERDAM, NETHERLANDS SN 1368-8375 EI 1879-0593 J9 ORAL ONCOL JI Oral Oncol. PD SEP PY 2016 VL 60 BP 55 EP 60 DI 10.1016/j.oraloncology.2016.07.003 PG 6 WC Oncology; Dentistry, Oral Surgery & Medicine SC Oncology; Dentistry, Oral Surgery & Medicine GA DU5DP UT WOS:000382232700009 PM 27531873 ER PT J AU Lin, Y Mallen-St Clair, J Wang, GY Luo, J Palma-Diaz, F Lai, C Elashoff, DA Sharma, S Dubinett, SM St John, M AF Lin, Yuan Mallen-St Clair, Jon Wang, Guanyu Luo, Jie Palma-Diaz, Fernando Lai, Chi Elashoff, David A. Sharma, Sherven Dubinett, Steven M. St John, Maie TI p38 MAPK mediates epithelial-mesenchymal transition by regulating p38IP and Snail in head and neck squamous cell carcinoma SO ORAL ONCOLOGY LA English DT Article DE EMT; p38; p38IP; Snail; HNSCC ID TRANSCRIPTION FACTOR SNAIL; E-CADHERIN; P38-INTERACTING PROTEIN; KAPPA-B; EXPRESSION; CANCER; CYCLOOXYGENASE-2; PROGRESSION; REPRESSOR; RECEPTOR AB Background: In the present study, we investigated the role of p38-p38IP signaling in the inflammation-induced promotion of epithelial-to-mesenchymal transition (EMT) in Head and Neck Squamous Cell Carcinoma (HNSCC). Methods: Quantitative RT-PCR, western blot analysis, spheroid modeling and immunohistochemical staining of human HNSCC tissue sections were used. Results: p38 inhibitor treated and p38 shRNA HNSCC cell lines demonstrate a significant upregulation in E-cadherin mRNA and a decrease in the mRNA expression of Snail. p38 binds to and stabilizes p38IP, a subunit of histone SPT3-TAF9-GCN5 acetyltransferase (STAGA), resulting in enhanced transcription of Snail. p38 shRNA HNSCC cell lines show a less invasive phenotype in a spheroid model. In clinical HNSCC samples, p38 interacting protein (p38IP) is significantly increased compared to adjacent normal tissue. An inverse relationship between p38, p38IP and E-cadherin is demonstrated. Conclusions: Herein we provide the first report that p38-p38IP is required for the Snail-induced E-cadherin down-regulation and cell invasion in HNSCC. (C) 2016 Elsevier Ltd. All rights reserved. C1 [Lin, Yuan; Wang, Guanyu; Luo, Jie; Sharma, Sherven; Dubinett, Steven M.] Jonsson Comprehens Canc Ctr, Lung Canc Res Program, Los Angeles, CA 90034 USA. [Lin, Yuan; Wang, Guanyu; Luo, Jie; Sharma, Sherven; Dubinett, Steven M.] Dept Med, Div Pulm & Crit Care Med, Los Angeles, CA USA. [Mallen-St Clair, Jon; St John, Maie] Dept Head & Neck Surg, Los Angeles, CA USA. [Palma-Diaz, Fernando; Lai, Chi; Sharma, Sherven; Dubinett, Steven M.] Dept Pathol & Lab Med, Los Angeles, CA USA. [Sharma, Sherven; Dubinett, Steven M.; St John, Maie] Jonsson Comprehens Canc Ctr, Los Angeles, CA 90034 USA. [Elashoff, David A.; St John, Maie] UCLA Head & Neck Canc Program, Los Angeles, CA USA. [Sharma, Sherven; Dubinett, Steven M.] Univ Calif Los Angeles, David Geffen Sch Med, Dept Biostat, Los Angeles, CA 90095 USA. [Sharma, Sherven; Dubinett, Steven M.] Vet Affairs Greater Los Angeles Healthcare Syst, Los Angeles, CA 90073 USA. RP St John, M (reprint author), Univ Calif Los Angeles, David Geffen Sch Med, 37-131 CHS,10833 Le Conte Ave, Los Angeles, CA 90095 USA. EM mstjohn@mednet.ucla.edu FU American Academy of Otolaryngology-American Head & Neck Society Surgeon Scientist Career Development Award; Tobacco-Related Disease Research Program of the University of California; STOP Cancer Foundation; Jonsson Cancer Center, NIDCR [DE021193]; VA Merit Review Research Funds; NCI [RO1 CA111851] FX This study was supported by the American Academy of Otolaryngology-American Head & Neck Society Surgeon Scientist Career Development Award (MSJ), the Tobacco-Related Disease Research Program of the University of California (MSJ), the STOP Cancer Foundation (MSJ), The Jonsson Cancer Center, NIDCR DE021193 (MSJ), the VA Merit Review Research Funds (SD), and NCI RO1 CA111851 (SD). NR 32 TC 0 Z9 0 U1 3 U2 3 PU ELSEVIER SCIENCE BV PI AMSTERDAM PA PO BOX 211, 1000 AE AMSTERDAM, NETHERLANDS SN 1368-8375 EI 1879-0593 J9 ORAL ONCOL JI Oral Oncol. PD SEP PY 2016 VL 60 BP 81 EP 89 DI 10.1016/j.oraloncology.2016.06.010 PG 9 WC Oncology; Dentistry, Oral Surgery & Medicine SC Oncology; Dentistry, Oral Surgery & Medicine GA DU5DP UT WOS:000382232700013 PM 27531877 ER PT J AU Abram, TJ Floriano, PN Christodoulides, N James, R Kerr, AR Thornhill, MH Redding, SW Vigneswaran, N Speight, PM Vick, J Murdoch, C Freeman, C Hegarty, AM D'Apice, K Phelan, JA Corby, PM Khouly, I Bouquot, J Demian, NM Weinstock, YE Rowan, S Yeh, CK McGuff, HS Miller, FR Gaur, S Karthikeyan, K Taylor, L Le, C Nguyen, M Talavera, H Raja, R Wong, J McDevitt, JT AF Abram, Timothy J. Floriano, Pierre N. Christodoulides, Nicolaos James, Robert Kerr, A. Ross Thornhill, Martin H. Redding, Spencer W. Vigneswaran, Nadarajah Speight, Paul M. Vick, Julie Murdoch, Craig Freeman, Christine Hegarty, Anne M. D'Apice, Katy Phelan, Joan A. Corby, Patricia M. Khouly, Ismael Bouquot, Jerry Demian, Nagi M. Weinstock, Y. Etan Rowan, Stephanie Yeh, Chih-Ko McGuff, H. Stan Miller, Frank R. Gaur, Surabhi Karthikeyan, Kailash Taylor, Leander Le, Cathy Nguyen, Michael Talavera, Humberto Raja, Rameez Wong, Jorge McDevitt, John T. TI 'Cytology-on-a-chip' based sensors for monitoring of potentially malignant oral lesions SO ORAL ONCOLOGY LA English DT Article DE Cytology; Oral cancer; Oral epithelial dysplasia; Microfluidic; High content analysis; Machine learning; Random forest; LASSO ID DYSPLASIA CLASSIFICATION; EXFOLIATIVE CYTOLOGY; SYSTEM; CANCER; ENUMERATION; PLATFORM AB Despite significant advances in surgical procedures and treatment, long-term prognosis for patients with oral cancer remains poor, with survival rates among the lowest of major cancers. Better methods are desperately needed to identify potential malignancies early when treatments are more effective. Objective: To develop robust classification models from cytology-on-a-chip measurements that mirror diagnostic performance of gold standard approach involving tissue biopsy. Materials and methods: Measurements were recorded from 714 prospectively recruited patients with suspicious lesions across 6 diagnostic categories (each confirmed by tissue biopsy -histopathology) using a powerful new 'cytology-on-a-chip' approach capable of executing high content analysis at a single cell level. Over 200 cellular features related to biomarker expression, nuclear parameters and cellular morphology were recorded per cell. By cataloging an average of 2000 cells per patient, these efforts resulted in nearly 13 million indexed objects. Results: Binary "low-risk"/"high-risk" models yielded AUC values of 0.88 and 0.84 for training and validation models, respectively, with an accompanying difference in sensitivity + specificity of 6.2%. In terms of accuracy, this model accurately predicted the correct diagnosis approximately 70% of the time, compared to the 69% initial agreement rate of the pool of expert pathologists. Key parameters identified in these models included cell circularity, Ki67 and EGFR expression, nuclear-cytoplasmic ratio, nuclear area, and cell area. Conclusions: This chip-based approach yields objective data that can be leveraged for diagnosis and management of patients with PMOL as well as uncovering new molecular-level insights behind cytological differences across the OED spectrum. (C) 2016 Elsevier Ltd. All rights reserved. C1 [Abram, Timothy J.; Christodoulides, Nicolaos; Gaur, Surabhi; Karthikeyan, Kailash; Taylor, Leander; Le, Cathy; Nguyen, Michael; Talavera, Humberto; Raja, Rameez; Wong, Jorge; McDevitt, John T.] Rice Univ, Dept Bioengn, Houston, TX USA. [Floriano, Pierre N.] NeoTherma Oncol, Houston, TX USA. [James, Robert; Vick, Julie] Rho Inc, Chapel Hill, NC USA. [Kerr, A. Ross; Phelan, Joan A.] NYU, Coll Dent, Dept Oral & Maxillofacial Pathol, Radiol & Med, New York, NY USA. [Thornhill, Martin H.; Murdoch, Craig; Freeman, Christine] Univ Sheffield, Sch Clin Dent, Acad Unit Oral & Maxillofacial Med & Surg, Sheffield, S Yorkshire, England. [Redding, Spencer W.; Rowan, Stephanie; Yeh, Chih-Ko] Univ Texas Hlth Sci Ctr San Antonio, Dept Comprehens Dent, San Antonio, TX 78229 USA. [Redding, Spencer W.; Rowan, Stephanie; Yeh, Chih-Ko; Miller, Frank R.] Univ Texas Hlth Sci Ctr San Antonio, Canc Therapy & Res Ctr, San Antonio, TX 78229 USA. [Vigneswaran, Nadarajah; Bouquot, Jerry] Univ Texas Hlth Sci Ctr San Antonio, Dept Diagnost & Biomed Sci, San Antonio, TX 78229 USA. [Speight, Paul M.] Univ Sheffield, Sch Clin Dent, Acad Unit Oral & Maxillofacial Pathol, Sheffield, S Yorkshire, England. [Hegarty, Anne M.; D'Apice, Katy] Sheffield Teaching Hosp Natl Hlth Serv Fdn Trust, Charles Clifford Dent Hosp, Unit Oral Med, Sheffield, S Yorkshire, England. [Corby, Patricia M.] NYU, Sch Med, Dept Populat Hlth & Radiat Oncol, New York, NY USA. [Khouly, Ismael] NYU, Coll Dent, Bluestone Ctr Clin Res, New York, NY USA. [Demian, Nagi M.] Univ Texas Hlth Sci Ctr Houston, Dept Oral & Maxillofacial Surg, Houston, TX 77030 USA. [Weinstock, Y. Etan] Univ Texas Hlth Sci Ctr Houston, Dept Otolaryngol Head & Neck Surg, Houston, TX 77030 USA. [Yeh, Chih-Ko] South Texas Vet Hlth Care Syst, Geriatr Res Educ & Clin Ctr, San Antonio, TX USA. [McGuff, H. Stan] Univ Texas Hlth Sci Ctr San Antonio, Dept Pathol, San Antonio, TX 78229 USA. [Miller, Frank R.] Univ Texas Hlth Sci Ctr San Antonio, Dept Otolaryngol Head & Neck Surg, San Antonio, TX 78229 USA. [McDevitt, John T.] Rice Univ, Dept Chem, Houston, TX USA. [McDevitt, John T.] NYU, Dept Biomat, New York, NY USA. RP McDevitt, JT (reprint author), NYU, Bioengn Inst, Dept Biomat, 433 First Ave,Room 820, New York, NY 10010 USA. EM mcdevitt@nyu.edu OI McDevitt, John T/0000-0001-8789-9351; Murdoch, Craig/0000-0001-9724-122X FU National Institutes of Health (NIH) through the National Institute of Dental and Craniofacial Research [1RC2DE020785-01, 5RC2DE020785-02, 3RC2DE020785-02S1, 3RC2DE020785-02S2]; Renaissance Health Service Corporation; Delta Dental of Michigan FX Funding for this work was provided by the National Institutes of Health (NIH) through the National Institute of Dental and Craniofacial Research (Award Number 1RC2DE020785-01, 5RC2DE020785-02, 3RC2DE020785-02S1, 3RC2DE020785-02S2). The content of this paper is solely the responsibility of the authors and does not necessarily represent or reflect the official views of the NIH or the US government. Segments of this work are supported by Renaissance Health Service Corporation and Delta Dental of Michigan. NR 36 TC 0 Z9 0 U1 3 U2 7 PU ELSEVIER SCIENCE BV PI AMSTERDAM PA PO BOX 211, 1000 AE AMSTERDAM, NETHERLANDS SN 1368-8375 EI 1879-0593 J9 ORAL ONCOL JI Oral Oncol. PD SEP PY 2016 VL 60 BP 103 EP 111 DI 10.1016/j.oraloncology.2016.07.002 PG 9 WC Oncology; Dentistry, Oral Surgery & Medicine SC Oncology; Dentistry, Oral Surgery & Medicine GA DU5DP UT WOS:000382232700016 PM 27531880 ER PT J AU Meneses, SRF Goode, AP Nelson, AE Lin, J Jordan, JM Allen, KD Bennell, KL Lohmander, LS Fernandes, L Hochberg, MC Underwood, M Conaghan, PG Liu, S McAlindon, TE Golightly, YM Hunter, DJ AF Meneses, S. R. F. Goode, A. P. Nelson, A. E. Lin, J. Jordan, J. M. Allen, K. D. Bennell, K. L. Lohmander, L. S. Fernandes, L. Hochberg, M. C. Underwood, M. Conaghan, P. G. Liu, S. McAlindon, T. E. Golightly, Y. M. Hunter, D. J. TI Clinical algorithms to aid osteoarthritis guideline dissemination SO OSTEOARTHRITIS AND CARTILAGE LA English DT Review DE Osteoarthritis; Management; Guidelines ID EVIDENCE-BASED RECOMMENDATIONS; EULAR-STANDING-COMMITTEE; KNEE OSTEOARTHRITIS; TASK-FORCE; HIP OSTEOARTHRITIS; MANAGEMENT; PAIN; CONSENSUS; QUALITY; ESCISIT AB Background: Numerous scientific organisations have developed evidence-based recommendations aiming to optimise the management of osteoarthritis (OA). Uptake, however, has been suboptimal. The purpose of this exercise was to harmonize the recent recommendations and develop a user-friendly treatment algorithm to facilitate translation of evidence into practice. Methods: We updated a previous systematic review on clinical practice guidelines (CPGs) for OA management. The guidelines were assessed using the Appraisal of Guidelines for Research and Evaluation for quality and the standards for developing trustworthy CPGs as established by the National Academy of Medicine (NAM). Four case scenarios and algorithms were developed by consensus of a multidisciplinary panel. Results: Sixteen guidelines were included in the systematic review. Most recommendations were directed toward physicians and allied health professionals, and most had multi-disciplinary input. Analysis for trustworthiness suggests that many guidelines still present a lack of transparency. A treatment algorithm was developed for each case scenario advised by recommendations from guidelines and based on panel consensus. Conclusion: Strategies to facilitate the implementation of guidelines in clinical practice are necessary. The algorithms proposed are examples of how to apply recommendations in the clinical context, helping the clinician to visualise the patient flow and timing of different treatment modalities. (C) 2016 Osteoarthritis Research Society International. Published by Elsevier Ltd. All rights reserved. C1 [Meneses, S. R. F.] Univ Sao Paulo, Sch Med, Dept Physiotherapy Occupat Therapy & Speech Thera, Sao Paulo, Brazil. [Meneses, S. R. F.; Liu, S.; Hunter, D. J.] Univ Sydney, Royal North Shore Hosp, Dept Rheumatol, Sydney, NSW, Australia. [Meneses, S. R. F.; Liu, S.; Hunter, D. J.] Univ Sydney, Inst Bone & Joint Res, Kolling Inst, Sydney, NSW, Australia. [Goode, A. P.] Duke Univ, Dept Orthoped Surg, Durham, NC USA. [Nelson, A. E.; Jordan, J. M.; Allen, K. D.; Golightly, Y. M.] Univ N Carolina, Dept Med, Chapel Hill, NC USA. [Nelson, A. E.; Jordan, J. M.; Allen, K. D.; Golightly, Y. M.] Univ N Carolina, Thurston Arthrit Res Ctr, Chapel Hill, NC USA. [Lin, J.] Peking Univ, Peoples Hosp, Inst Bone & Joint, Beijing, Peoples R China. [Jordan, J. M.] Gillings Sch Global Publ Hlth, Dept Epidemiol, Chapel Hill, NC USA. [Jordan, J. M.] Univ N Carolina, Dept Orthopaed, Chapel Hill, NC USA. [Allen, K. D.] US Dept Vet Affairs, Med Ctr, Hlth Serv Res & Dev Serv, Durham, NC USA. [Bennell, K. L.] Univ Melbourne, Ctr Hlth Exercise & Sports Med, Dept Physiotherapy, Melbourne, Vic 3010, Australia. [Lohmander, L. S.] Lund Univ, Dept Clin Sci, Orthopaed, S-22100 Lund, Sweden. [Fernandes, L.] Odense Univ Hosp, Dept Rehabil, Odense C, Denmark. [Hochberg, M. C.] Univ Maryland, Sch Med, Dept Epidemiol & Publ Hlth, Baltimore, MD 21201 USA. [Hochberg, M. C.] Vet Affairs Maryland Hlth Care Syst, Med Care Clin Ctr, Baltimore, MD USA. [Underwood, M.] Warwick Med Sch, Warwick Clin Trials Unit, Warwick, England. [Conaghan, P. G.] Univ Leeds, Leeds Inst Rheumat & Musculoskeletal Med, Leeds, W Yorkshire, England. [Conaghan, P. G.] NIHR Leeds Musculoskeletal Biomed Res Unit, Leeds, W Yorkshire, England. [McAlindon, T. E.] Tufts Med Ctr, Dept Rheumatol, Boston, MA USA. [Golightly, Y. M.] Univ N Carolina, Injury Prevent Res Ctr, Chapel Hill, NC USA. RP Meneses, SRF (reprint author), Royal North Shore Hosp, Dept Rheumatol, Clin Adm, 7C,Level 7,Reserve Rd, St Leonards, NSW 2065, Australia. EM sarah.meneses@usp.br RI ; Underwood, Martin/D-6364-2015 OI Meneses, Sarah/0000-0003-2587-1649; Underwood, Martin/0000-0002-0309-1708; Bennell, Kim/0000-0003-4982-5639 NR 36 TC 0 Z9 0 U1 2 U2 4 PU ELSEVIER SCI LTD PI OXFORD PA THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, OXON, ENGLAND SN 1063-4584 EI 1522-9653 J9 OSTEOARTHR CARTILAGE JI Osteoarthritis Cartilage PD SEP PY 2016 VL 24 IS 9 BP 1487 EP 1499 DI 10.1016/j.joca.2016.04.004 PG 13 WC Orthopedics; Rheumatology SC Orthopedics; Rheumatology GA DU5PY UT WOS:000382265000001 PM 27095418 ER PT J AU Chinman, M McCarthy, S Mitchell-Miland, C Daniels, K Youk, A Edelen, M AF Chinman, Matthew McCarthy, Sharon Mitchell-Miland, Chantele Daniels, Karin Youk, Ada Edelen, Maria TI Early Stages of Development of a Peer Specialist Fidelity Measure SO PSYCHIATRIC REHABILITATION JOURNAL LA English DT Article DE peer specialists; serious mental illness; fidelity ID SEVERE MENTAL-ILLNESS; HEALTH-SERVICES; SUPPORT; IMPLEMENTATION; METAANALYSIS; INDIVIDUALS; PROVIDERS; MODEL AB Objective: Research on peer specialists (individuals with serious mental illness supporting others with serious mental illness in clinical and other settings) has not yet included the measurement of fidelity. Without measuring fidelity, it is unclear whether the absence of impact in some studies is attributable to ineffective peer specialist services or because the services were not true to the intended role. This article describes the initial development of a peer specialist fidelity measure for 2 content areas: services provided by peer specialists and factors that either support or hamper the performance of those services. Method: A literature search identified 40 domains; an expert panel narrowed the number of domains and helped generate and then review survey items to operationalize those domains. Twelve peer specialists, individuals with whom they work, and their supervisors participated in a pilot test and cognitive interviews regarding item content. Results: Peer specialists tended to rate themselves as having engaged in various peer service activities more than did the supervisors and individuals with whom they work. A subset of items tapping peer specialist services "core" to the role regardless of setting had higher ratings. Participants stated the measure was clear, appropriate, and could be useful in improving performance. Conclusions and Implications for Practice: Although preliminary, findings were consistent with organizational research on performance ratings of supervisors and employees made in the workplace. Several changes in survey content and administration were identified. With continued work, the measure could crystalize the role of peer specialists and aid in research and clinical administration. C1 [Chinman, Matthew; McCarthy, Sharon; Mitchell-Miland, Chantele; Daniels, Karin; Youk, Ada] VA Pittsburgh Healthcare Syst, Res Off Bldg,151R,Univ Dr C, Pittsburgh, PA 15240 USA. [Edelen, Maria] RAND Corp, Boston, MA USA. RP Chinman, M (reprint author), VA Pittsburgh Healthcare Syst, Res Off Bldg,151R,Univ Dr C, Pittsburgh, PA 15240 USA. EM chinman@rand.org FU Department of Veterans Affairs FX Financial support for the article was provided by the Department of Veterans Affairs. The contents do not represent the views of the Department of Veterans Affairs or the U.S. government. We thank the peer specialists, veterans, and supervisors who participated in the pilot test and cognitive interviews. We would also like to thank Daniel O'Brien-Mazza for providing support for this project. NR 33 TC 2 Z9 2 U1 2 U2 2 PU CENTER PSYCHIATRIC REHABILITATION PI BOSTON PA BOSTON UNIV, 930 COMMONWEALTH AVE, BOSTON, MA 02215 USA SN 1095-158X EI 1559-3126 J9 PSYCHIATR REHABIL J JI Psychiatr. Rehabil. J. PD SEP PY 2016 VL 39 IS 3 SI SI BP 256 EP 265 DI 10.1037/prj0000209 PG 10 WC Psychiatry; Rehabilitation SC Psychiatry; Rehabilitation GA DV4LL UT WOS:000382897000009 PM 27618462 ER PT J AU Bowers, ME Flory, JD Abu-Amara, D Marmara, CD Yehuda, R AF Bowers, Mallory E. Flory, Janine D. Abu-Amara, Duna Marmara, Charles D. Yehuda, Rachel TI Association between estradiol and posttraumatic stress disorder in men and women military veterans SO PSYCHONEUROENDOCRINOLOGY LA English DT Meeting Abstract CT 46th Annual Conference of the International-Society-of-Psychoneuroendocrinology - Personalized Medicine in the Neurosciences - Genetics, Imaging, and Hormones CY SEP 08-11, 2016 CL Miami, FL SP Int Soc Psychoneuroendocrinol C1 [Bowers, Mallory E.; Flory, Janine D.; Yehuda, Rachel] Icahn Sch Med Mt Sinai, New York, NY 10029 USA. [Bowers, Mallory E.; Flory, Janine D.; Yehuda, Rachel] James J Peters Bronx Vet Affairs Med Ctr, Bronx, NY USA. [Abu-Amara, Duna; Marmara, Charles D.] NYU, Langone Sch Med, New York, NY 10003 USA. EM mallory.bowers@mssm.edu NR 0 TC 0 Z9 0 U1 2 U2 2 PU PERGAMON-ELSEVIER SCIENCE LTD PI OXFORD PA THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, ENGLAND SN 0306-4530 J9 PSYCHONEUROENDOCRINO JI Psychoneuroendocrinology PD SEP PY 2016 VL 71 SU S BP 4 EP 5 DI 10.1016/j.psyneuen.2016.07.020 PG 2 WC Endocrinology & Metabolism; Neurosciences; Psychiatry SC Endocrinology & Metabolism; Neurosciences & Neurology; Psychiatry GA DV0FX UT WOS:000382594500010 ER PT J AU Daskalakis, NP AF Daskalakis, Nikolaos P. TI Epigenetic regulation in association with treatment response in PTSD SO PSYCHONEUROENDOCRINOLOGY LA English DT Meeting Abstract CT 46th Annual Conference of the International-Society-of-Psychoneuroendocrinology - Personalized Medicine in the Neurosciences - Genetics, Imaging, and Hormones CY SEP 08-11, 2016 CL Miami, FL SP Int Soc Psychoneuroendocrinol C1 [Daskalakis, Nikolaos P.] Icahn Sch Med Mt Sinai, New York, NY 10029 USA. [Daskalakis, Nikolaos P.] James J Peters Vet Affairs Med Ctr, Bronx, NY USA. EM nikolaos.daskalakis@mssm.edu NR 0 TC 0 Z9 0 U1 2 U2 2 PU PERGAMON-ELSEVIER SCIENCE LTD PI OXFORD PA THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, ENGLAND SN 0306-4530 J9 PSYCHONEUROENDOCRINO JI Psychoneuroendocrinology PD SEP PY 2016 VL 71 SU S BP 10 EP 11 DI 10.1016/j.psyneuen.2016.07.037 PG 2 WC Endocrinology & Metabolism; Neurosciences; Psychiatry SC Endocrinology & Metabolism; Neurosciences & Neurology; Psychiatry GA DV0FX UT WOS:000382594500027 ER PT J AU Daskalakis, NP AF Daskalakis, Nikolaos P. TI Integrative systems biology approach to identify novel glucocorticoid-based biomarkers and treatment targets for PTSD SO PSYCHONEUROENDOCRINOLOGY LA English DT Meeting Abstract CT 46th Annual Conference of the International-Society-of-Psychoneuroendocrinology - Personalized Medicine in the Neurosciences - Genetics, Imaging, and Hormones CY SEP 08-11, 2016 CL Miami, FL SP Int Soc Psychoneuroendocrinol C1 [Daskalakis, Nikolaos P.] Icahn Sch Med Mt Sinai, New York, NY 10029 USA. [Daskalakis, Nikolaos P.] James J Peters Vet Affairs Med Ctr, Bronx, NY USA. EM nikolaos.daskalakis@mssm.edu NR 0 TC 0 Z9 0 U1 2 U2 2 PU PERGAMON-ELSEVIER SCIENCE LTD PI OXFORD PA THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, ENGLAND SN 0306-4530 J9 PSYCHONEUROENDOCRINO JI Psychoneuroendocrinology PD SEP PY 2016 VL 71 SU S BP 71 EP 71 DI 10.1016/j.psyneuen.2016.07.185 PG 1 WC Endocrinology & Metabolism; Neurosciences; Psychiatry SC Endocrinology & Metabolism; Neurosciences & Neurology; Psychiatry GA DV0FX UT WOS:000382594500173 ER PT J AU Brody, AL Hubert, R Mamoun, MS Enoki, R Garcia, LY Abraham, P Young, P Mandelkern, MA AF Brody, Arthur L. Hubert, Robert Mamoun, Michael S. Enoki, Ryutaro Garcia, Lizette Y. Abraham, Paul Young, Paulina Mandelkern, Mark A. TI Nicotinic acetylcholine receptor availability in cigarette smokers: effect of heavy caffeine or marijuana use SO PSYCHOPHARMACOLOGY LA English DT Article DE Positron emission tomography; Tobacco dependence; Nicotinic acetylcholine receptors; Caffeine; Marijuana; Cannabis; Brain imaging; Neuroimaging; Human; Cigarette smoking ID LATERAL PREFRONTAL CORTEX; TOBACCO SMOKING; HUMAN-BRAIN; COMMUNITY SAMPLE; MENTAL-ILLNESS; UNITED-STATES; UP-REGULATION; CANNABIS USE; CESSATION; BINDING AB Upregulation of alpha(4)beta(2)* nicotinic acetylcholine receptors (nAChRs) is one of the most well-established effects of chronic cigarette smoking on the brain. Prior research by our group gave a preliminary indication that cigarette smokers with concomitant use of caffeine or marijuana have altered nAChR availability. We sought to determine if smokers with heavy caffeine or marijuana use have different levels of alpha(4)beta(2)* nAChRs than smokers without these drug usages. One hundred and one positron emission tomography (PET) scans, using the radiotracer 2-FA (a ligand for beta(2)*-containing nAChRs), were obtained from four groups of males: non-smokers without heavy caffeine or marijuana use, smokers without heavy caffeine or marijuana use, smokers with heavy caffeine use (mean four coffee cups per day), and smokers with heavy marijuana use (mean 22 days of use per month). Total distribution volume (Vt/fp) was determined for the brainstem, prefrontal cortex, and thalamus, as a measure of nAChR availability. A significant between-group effect was found, resulting from the heavy caffeine and marijuana groups having the highest Vt/fp values (especially for the brainstem and prefrontal cortex), followed by smokers without such use, followed by non-smokers. Direct between-group comparisons revealed significant differences for Vt/fp values between the smoker groups with and without heavy caffeine or marijuana use. Smokers with heavy caffeine or marijuana use have higher alpha(4)beta(2)* nAChR availability than smokers without these drug usages. These findings are likely due to increased nicotine exposure but could also be due to an interaction on a cellular/molecular level. C1 [Brody, Arthur L.; Hubert, Robert; Mamoun, Michael S.; Enoki, Ryutaro; Garcia, Lizette Y.; Abraham, Paul; Young, Paulina; Mandelkern, Mark A.] VA Greater Los Angeles Healthcare Syst, Dept Psychiat, Los Angeles, CA 90073 USA. [Brody, Arthur L.] Univ Calif Los Angeles, Dept Psychiat, Los Angeles, CA 90095 USA. [Mandelkern, Mark A.] Univ Calif Irvine, Dept Phys, Irvine, CA 92717 USA. [Brody, Arthur L.] 300 UCLA Med Plaza,Suite 2200, Los Angeles, CA 90095 USA. RP Brody, AL (reprint author), VA Greater Los Angeles Healthcare Syst, Dept Psychiat, Los Angeles, CA 90073 USA.; Brody, AL (reprint author), Univ Calif Los Angeles, Dept Psychiat, Los Angeles, CA 90095 USA.; Brody, AL (reprint author), 300 UCLA Med Plaza,Suite 2200, Los Angeles, CA 90095 USA. EM abrody@ucla.edu FU National Institute on Drug Abuse [R01 DA20872]; Department of Veterans Affairs, Office of Research and Development (CSR&D Merit Review Award) [I01 CX000412]; Tobacco-Related Disease Research Program [23XT-0002] FX This work was supported by the National Institute on Drug Abuse (R01 DA20872), the Department of Veterans Affairs, Office of Research and Development (CSR&D Merit Review Award I01 CX000412), and the Tobacco-Related Disease Research Program (#23XT-0002) to ALB. The authors report no biomedical financial interests or potential conflicts of interest. NR 65 TC 0 Z9 0 U1 8 U2 10 PU SPRINGER PI NEW YORK PA 233 SPRING ST, NEW YORK, NY 10013 USA SN 0033-3158 EI 1432-2072 J9 PSYCHOPHARMACOLOGY JI Psychopharmacology PD SEP PY 2016 VL 233 IS 17 BP 3249 EP 3257 DI 10.1007/s00213-016-4367-x PG 9 WC Neurosciences; Pharmacology & Pharmacy; Psychiatry SC Neurosciences & Neurology; Pharmacology & Pharmacy; Psychiatry GA DT6HY UT WOS:000381586500016 PM 27370018 ER PT J AU Sampson, S Smith, J Vincent, H Aufiero, D Zall, M Botto-van-Bemden, A AF Sampson, Steven Smith, Jay Vincent, Hunter Aufiero, Danielle Zall, Mona Botto-van-Bemden, Angie TI Intra-articular bone marrow concentrate injection protocol: short-term efficacy in osteoarthritis SO REGENERATIVE MEDICINE LA English DT Article DE bone marrow concentrate; orthobiologics; osteoarthritis; platelet-rich plasma ID PLATELET-RICH PLASMA; MESENCHYMAL STEM-CELLS; KNEE OSTEOARTHRITIS; CARTILAGE REPAIR; DOUBLE-BLIND; PAIN; BIOPSY; MICROFRACTURE; REGENERATION; ASPIRATION AB Aim: Evaluate intra-articular injection of bone marrow concentrate (BMC), followed by platelet-rich plasma (PRP) injection at 8 weeks follow-up in moderate/severe osteoarthritis. Design: Single center, retrospective Case Series (n = 125). Methods: Bone marrow was aspirated/concentrated using a standardized technique. Patients received a single intra-articular injection of BMC, with follow-up injection of PRP at 8 weeks. Results: Median absolute pain reduction in all joints was five points (71.4%) on visual analog scale. Median patient satisfaction was 9.0/10, while 91.7% indicated that they would repeat the procedure and 94% said that they would recommend the procedure to a friend. Conclusion: Intra-articular injection of BMC, followed by a PRP injection, can provide short-term benefits in moderate-to-severe osteoarthritis. C1 [Sampson, Steven; Aufiero, Danielle] Univ Calif Los Angeles, David Geffen Sch Med, 10833 Le Conte Ave, Los Angeles, CA 90095 USA. [Sampson, Steven; Aufiero, Danielle] Western Univ Hlth Sci, 309 E 2nd St, Pomona, CA 91766 USA. [Sampson, Steven; Aufiero, Danielle] Touro Coll Osteopath Med, 230 W 125th St 1, New York, NY 10027 USA. [Sampson, Steven; Aufiero, Danielle] Orthobiol Inst TOBI, Woodland Hills, CA 91365 USA. [Smith, Jay] Mayo Clin, Coll Med, Ctr Sports Med, Dept PM&R, 200 1st St SW, Rochester, MN 55905 USA. [Smith, Jay] Mayo Clin, Coll Med, Ctr Sports Med, Dept Radiol, 200 1st St SW, Rochester, MN 55905 USA. [Smith, Jay] Mayo Clin, Coll Med, Ctr Sports Med, Dept Anat, 200 1st St SW, Rochester, MN 55905 USA. [Vincent, Hunter] Univ Calif Davis, Med Ctr, Dept Phys Med & Rehabil, 4860 Y St, Sacramento, CA 95817 USA. [Zall, Mona] Greater Los Angeles VA Med Ctr, Dept Phys Med & Rehabil, 11301 Wilshire Blvd, Los Angeles, CA 90073 USA. [Botto-van-Bemden, Angie] Musculoskeletal Res Int, Clin Res Experts, 1004 Avocado Isle, Ft Lauderdale, FL 33315 USA. RP Vincent, H (reprint author), Univ Calif Davis, Med Ctr, Dept Phys Med & Rehabil, 4860 Y St, Sacramento, CA 95817 USA. EM huntervincent35@gmail.com NR 45 TC 0 Z9 0 U1 1 U2 1 PU FUTURE MEDICINE LTD PI LONDON PA UNITEC HOUSE, 3RD FLOOR, 2 ALBERT PLACE, FINCHLEY CENTRAL, LONDON, N3 1QB, ENGLAND SN 1746-0751 EI 1746-076X J9 REGEN MED JI Regen. Med. PD SEP PY 2016 VL 11 IS 6 BP 511 EP 520 DI 10.2217/rme-2016-0081 PG 10 WC Cell & Tissue Engineering; Engineering, Biomedical SC Cell Biology; Engineering GA DU6EA UT WOS:000382305600004 PM 27527808 ER PT J AU Garcia, BJ Loxton, AG Dolganov, GM Van, TT Davis, JL de Jong, BC Voskuil, MI Leach, SM Schoolnik, GK Walzl, G Strong, M Walter, ND AF Garcia, Benjamin J. Loxton, Andre G. Dolganov, Gregory M. Van, Tran T. Davis, J. Lucian de Jong, Bouke C. Voskuil, Martin I. Leach, Sonia M. Schoolnik, Gary K. Walzl, Gerhard Strong, Michael Walter, Nicholas D. TI Sputum is a surrogate for bronchoalveolar lavage for monitoring Mycobacterium tuberculosis transcriptional profiles in TB patients SO TUBERCULOSIS LA English DT Article DE Mycobacterium tuberculosis/genetics; Mycobacterium tuberculosis/physiology; Sputum/microbiology; Bronchoalveolar lavage/microbiology; Computational biology/methods; * Gene expression profiling; Tuberculosis; pulmonary/epidemiology/*microbiology ID GENE-EXPRESSION; ADAPTATION; PERSISTENCE AB Pathogen-targeted transcriptional profiling in human sputum may elucidate the physiologic state of Mycobacterium tuberculosis (M. tuberculosis) during infection and treatment. However, whether M. tuberculosis transcription in sputum recapitulates transcription in the lung is uncertain. We therefore compared M. tuberculosis transcription in human sputum and bronchoalveolar lavage (BAL) samples from 11 HIV-negative South African patients with pulmonary tuberculosis. We additionally compared these clinical samples with in vitro log phase aerobic growth and hypoxic non-replicating persistence (NRP-2). Of 2179 M. tuberculosis transcripts assayed in sputum and BAL via multiplex RT-PCR, 194 (8.9%) had a p-value <0.05, but none were significant after correction for multiple testing. Categorical enrichment analysis indicated that expression of the hypoxia-responsive DosR regulon was higher in BAL than in sputum. M. tuberculosis transcription in BAL and sputum was distinct from both aerobic growth and NRP-2, with a range of 396-1020 transcripts significantly differentially expressed after multiple testing correction. Collectively, our results indicate that M. tuberculosis transcription in sputum approximates M. tuberculosis transcription in the lung. Minor differences between M. tuberculosis transcription in BAL and sputum suggested lower oxygen concentrations or higher nitric oxide concentrations in BAL. M. tuber-culosis-targeted transcriptional profiling of sputa may be a powerful tool for understanding M. tuberculosis pathogenesis and monitoring treatment responses in vivo. Published by Elsevier Ltd. C1 [Garcia, Benjamin J.; Leach, Sonia M.; Strong, Michael; Walter, Nicholas D.] Natl Jewish Hlth, Ctr Genes Environm & Hlth, Denver, CO USA. [Garcia, Benjamin J.; Leach, Sonia M.; Strong, Michael] Univ Colorado Denver, Computat Biosci Program, Anschutz Med Campus,Mailstop 8303, Aurora, CO 80045 USA. [Loxton, Andre G.; Walzl, Gerhard] Univ Stellenbosch, DST NRF Ctr Excellence Biomed TB Res, Cape Town, South Africa. [Loxton, Andre G.; Walzl, Gerhard] Univ Stellenbosch, SAMRC Ctr TB Res, Div Mol Biol & Human Genet, Dept Biomed Sci, Cape Town, South Africa. [Dolganov, Gregory M.; Van, Tran T.; Schoolnik, Gary K.] Stanford Univ, Dept Microbiol & Immunol, Stanford, CA 94305 USA. [Davis, J. Lucian] Yale Sch Publ Hlth, Epidemiol Microbial Dis, New Haven, CT USA. [Davis, J. Lucian] Yale Sch Med, Pulm Crit Care & Sleep Med, New Haven, CT USA. [de Jong, Bouke C.] Inst Trop Med, Antwerp, Belgium. [Voskuil, Martin I.] Univ Colorado, Sch Med, Dept Immunol & Microbiol, Aurora, CO USA. [Walter, Nicholas D.] Denver Vet Affairs Med Ctr, Pulm Sect, Denver, CO USA. [Walter, Nicholas D.] Univ Colorado Denver, Div Pulm Sci & Crit Care Med, Anschutz Med Campus, Aurora, CO USA. RP Garcia, BJ (reprint author), Univ Colorado Denver, Computat Biosci Program, Anschutz Med Campus,Mailstop 8303, Aurora, CO 80045 USA. EM benjamin.garcia@ucdenver.edu OI Walzl, Gerhard/0000-0003-2487-125X; Garcia, Benjamin/0000-0001-5524-6946 FU National Institutes of Health [UL1 RR025780, 2T15LM009451-06]; European Research Council-INTERRUPTB [311725]; Veteran's Administration [CDA1IK2CX000914-01A1]; Boettcher Foundation Webb-Waring Award FX This work was supported by National Institutes of Health [grant numbers UL1 RR025780, 2T15LM009451-06 (to BJG), European Research Council-INTERRUPTB starting grant nr. 311725 (to BdJ), and Veteran's Administration [CDA1IK2CX000914-01A1 (to NDW)], and a Boettcher Foundation Webb-Waring Award (to MS). NR 18 TC 0 Z9 0 U1 1 U2 3 PU CHURCHILL LIVINGSTONE PI EDINBURGH PA JOURNAL PRODUCTION DEPT, ROBERT STEVENSON HOUSE, 1-3 BAXTERS PLACE, LEITH WALK, EDINBURGH EH1 3AF, MIDLOTHIAN, SCOTLAND SN 1472-9792 J9 TUBERCULOSIS JI Tuberculosis PD SEP PY 2016 VL 100 BP 89 EP 94 DI 10.1016/j.tube.2016.07.004 PG 6 WC Immunology; Microbiology; Respiratory System SC Immunology; Microbiology; Respiratory System GA DU4RX UT WOS:000382201400012 PM 27553415 ER PT J AU Li, Z Scott, MJ Fan, EK Li, Y Liu, J Xiao, G Li, S Billiar, TR Wilson, MA Jiang, Y Fan, J AF Li, Z. Scott, M. J. Fan, E. K. Li, Y. Liu, J. Xiao, G. Li, S. Billiar, T. R. Wilson, M. A. Jiang, Y. Fan, J. TI Tissue damage negatively regulates LPS-induced macrophage necroptosis SO CELL DEATH AND DIFFERENTIATION LA English DT Article ID HEMORRHAGIC-SHOCK; PROGRAMMED NECROSIS; LUNG INFLAMMATION; NLRP3 INFLAMMASOME; ENDOTHELIAL-CELLS; TLR4 ENDOCYTOSIS; BONE-MARROW; IN-VIVO; ACTIVATION; RECEPTOR AB Infection is a common clinical complication following tissue damage resulting from surgery and severe trauma. Studies have suggested that cell pre-activation by antecedent trauma/tissue damage profoundly impacts the response of innate immune cells to a secondary infectious stimulus. Cell necroptosis, a form of regulated inflammatory cell death, is one of the mechanisms that control cell release of inflammatory mediators from important innate immune executive cells such as macrophages (M.), which critically regulate the progress of inflammation. In this study, we investigated the mechanism and role of trauma/tissue damage in the regulation of LPS-induced M. necroptosis using a mouse model simulating long-bone fracture. We demonstrate that LPS acting through Toll-like receptor (TLR) 4 promotes M. necroptosis. However, necroptosis is ameliorated by high-mobility group box 1 (HMGB1) release from damaged tissue. We show that HMGB1 acting through cell surface receptor for advanced glycation end products (RAGE) upregulates caveolin-1 expression, which in turn induces caveolae-mediated TLR4 internalization and desensitization to decrease M. necroptosis. We further show that RAGE-MyD88 activation of Cdc42 and subsequent activation of transcription factor Sp1 serves as a mechanism underlying caveolin-1 transcriptional upregulation. These results reveal a previous unidentified protective role of damage-associated molecular pattern (DAMP) molecules in restricting inflammation in response to exogenous pathogen-associated molecular pattern molecules. C1 [Li, Z.; Scott, M. J.; Li, Y.; Billiar, T. R.; Wilson, M. A.; Fan, J.] Univ Pittsburgh, Sch Med, Dept Surg, Pittsburgh, PA 15213 USA. [Li, Z.; Li, Y.; Wilson, M. A.; Fan, J.] Vet Affairs Pittsburgh Healthcare Syst, Res & Dev, Pittsburgh, PA 15240 USA. [Li, Z.; Liu, J.; Jiang, Y.] Southern Med Univ, Dept Pathophysiol, Guangzhou 510515, Guangdong, Peoples R China. [Fan, E. K.] Univ Pittsburgh, Sch Arts & Sci, Pittsburgh, PA 15213 USA. [Xiao, G.] South Univ Sci & Technol China, Dept Biol, Shenzhen 518055, Peoples R China. [Xiao, G.] South Univ Sci & Technol China, Shenzhen Key Lab Cell Microenvironm, Shenzhen 518055, Peoples R China. [Xiao, G.] Rush Univ, Med Ctr, Dept Biochem, Chicago, IL 60612 USA. [Li, S.] Univ Pittsburgh, Sch Pharm, Ctr Pharmacogenet, Dept Pharmaceut Sci, Pittsburgh, PA 15261 USA. [Billiar, T. R.; Fan, J.] Univ Pittsburgh, McGowan Inst Regenerat Med, Pittsburgh, PA 15219 USA. RP Jiang, Y; Fan, J (reprint author), Univ Pittsburgh, Sch Med, Dept Surg, Bldg 1,2W109,151U-L,Univ Dr,VAPHS, Pittsburgh, PA 15240 USA. EM jiang48231@163.com; jif7@pitt.edu FU National Institutes of Health [R01-HL-079669, R56-HL-123882]; National Institutes of Health Center Grant [P50-GM-53789]; VA Merit Award [1I01BX002729]; National Key Basic Research Program (China) [2010CB529704]; PCSIRT [IRT0731]; National Natural Science Foundation of China [30670828] FX This work was supported by the National Institutes of Health Grant R01-HL-079669 (JF and MAW), National Institutes of Health Center Grant P50-GM-53789 (TRB and JF), National Institutes of Health Grant R56-HL-123882 (JF), VA Merit Award 1I01BX002729 (JF), National Key Basic Research Program 2010CB529704 (JY China), PCSIRT IRT0731 (JY), and National Natural Science Foundation of China 30670828 (JY). NR 60 TC 1 Z9 1 U1 8 U2 15 PU NATURE PUBLISHING GROUP PI LONDON PA MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND SN 1350-9047 EI 1476-5403 J9 CELL DEATH DIFFER JI Cell Death Differ. PD SEP PY 2016 VL 23 IS 9 BP 1428 EP 1447 DI 10.1038/cdd.2016.21 PG 20 WC Biochemistry & Molecular Biology; Cell Biology SC Biochemistry & Molecular Biology; Cell Biology GA DS8ZY UT WOS:000381072800002 PM 26943325 ER PT J AU Salmon, AB AF Salmon, Adam B. TI Beyond Diabetes: Does Obesity-Induced Oxidative Stress Drive the Aging Process? SO ANTIOXIDANTS LA English DT Review DE reactive oxygen species; mitochondria; inflammation; adipose; fatty acid oxidation; longevity; health span ID HIGH-FAT DIET; MUSCLE INSULIN-RESISTANCE; METHIONINE SULFOXIDE REDUCTASE; MN-SUPEROXIDE-DISMUTASE; LIFE-SPAN; ADIPOSE-TISSUE; MITOCHONDRIAL DYSFUNCTION; DROSOPHILA-MELANOGASTER; CARDIOVASCULAR-DISEASE; COGNITIVE IMPAIRMENT AB Despite numerous correlative data, a causative role for oxidative stress in mammalian longevity has remained elusive. However, there is strong evidence that increased oxidative stress is associated with exacerbation of many diseases and pathologies that are also strongly related to advanced age. Obesity, or increased fat accumulation, is one of the most common chronic conditions worldwide and is associated with not only metabolic dysfunction but also increased levels of oxidative stress in vivo. Moreover, obesity is also associated with significantly increased risks of cardiovascular disease, neurological decline and cancer among many other diseases as well as a significantly increased risk of mortality. In this review, we investigate the possible interpretation that the increased incidence of these diseases in obesity may be due to chronic oxidative stress mediating segmental acceleration of the aging process. Understanding how obesity can alter cellular physiology beyond that directly related to metabolic function could open new therapeutic areas of approach to extend the period of healthy aging among people of all body composition. C1 [Salmon, Adam B.] South Texas Vet Hlth Care Syst, Geriatr Res Educ & Clin Ctr, San Antonio, TX 78245 USA. [Salmon, Adam B.] Univ Texas Hlth Sci Ctr San Antonio, Dept Mol Med, Sam & Ann Barshop Inst Longev & Aging Studies, San Antonio, TX 78245 USA. RP Salmon, AB (reprint author), South Texas Vet Hlth Care Syst, Geriatr Res Educ & Clin Ctr, San Antonio, TX 78245 USA.; Salmon, AB (reprint author), Univ Texas Hlth Sci Ctr San Antonio, Dept Mol Med, Sam & Ann Barshop Inst Longev & Aging Studies, San Antonio, TX 78245 USA. EM salmona@uthscsa.edu OI Salmon, Adam/0000-0002-1475-7843 NR 123 TC 1 Z9 1 U1 5 U2 12 PU MDPI AG PI BASEL PA ST ALBAN-ANLAGE 66, CH-4052 BASEL, SWITZERLAND SN 2076-3921 J9 ANTIOXIDANTS JI Antioxidants PD SEP PY 2016 VL 5 IS 3 AR 24 DI 10.3390/antiox5030024 PG 14 WC Chemistry, Medicinal SC Pharmacology & Pharmacy GA DU9AT UT WOS:000382509300004 ER PT J AU Napoli, N Schafer, AL Lui, LY Cauley, JA Strotmeyer, ES Le Blanc, ES Hoffman, AR Lee, CG Black, DM Schwartz, AV AF Napoli, Nicola Schafer, Anne L. Lui, Li-Yung Cauley, Jane A. Strotmeyer, Elsa S. Le Blanc, Erin S. Hoffman, Andrew R. Lee, Christine G. Black, Dennis M. Schwartz, Ann V. TI Serum 25-hydroxyvitamin D level and incident type 2 diabetes in older men, the Osteoporotic Fractures in Men (MrOS) study SO BONE LA English DT Article DE Type 2 diabetes; Vitamin D; Older men ID VITAMIN-D DEFICIENCY; MENDELIAN RANDOMIZATION; RISK; METAANALYSIS; OBESITY; CALCIUM AB The association between vitamin D status and diabetes risk is inconsistent among observational studies, and most of the available studies have been with women. In the present study we investigated the association between serum 25-hydroxyvitamin D (25(OH)D) levels and incident type 2 diabetes (T2D) in older men (>= 65 years old) who participated in the multisite Osteoporotic Fractures in Men (MrOS) study enrolled from March 2000 to April 2002. Baseline 25(OH)D levels were available in 1939 subjects without prevalent T2D. Clinical information, body mass index (BMI) and other factors related to T2D were assessed at the baseline visit. Incident diabetes, defined by self report and medication use, was determined over an average follow-up of 6.4 years. At baseline, participants were, on average, 73.3 (+/- 5.7) years old, had a mean BMI in the overweight range (272 kg/m(2) +/- 3.6) and had total serum 25(OH)D of 26.1 ng/ml (+/- 8.3). Incident diabetes was diagnosed in 139 subjects. Cox regression analysis showed a trend toward a protective effect of higher 25 (OH)D levels with a lower risk of T2D (HR 0.87, 95% CI: 0.73-1.04 per 1 SD increase of 25(OH)D). After adjusted for BMI and other potential confounders, the relationship between 25(OH)D levels and incident diabetes was further attenuated (HR 1.03, 95% Cl 0.85-1.25). No significant difference in the incidence of diabetes emerged after analyzing study subjects according to baseline 25(OH)D quartiles. In conclusion, 25(OH)D levels were not associated with incident T2D in older men. (C) 2016 Published by Elsevier Inc. C1 [Napoli, Nicola] Univ Campus Biomed Roma, Rome, Italy. [Napoli, Nicola] Washington Univ, Div Bone & Mineral Dis, St Louis, MO 63130 USA. [Schafer, Anne L.; Black, Dennis M.; Schwartz, Ann V.] Univ Calif San Francisco, San Francisco, CA 94143 USA. [Schafer, Anne L.] San Francisco VA Med Ctr, San Francisco, CA USA. [Lui, Li-Yung] Calif Pacific Med Ctr, San Francisco, CA USA. [Cauley, Jane A.; Strotmeyer, Elsa S.] Ctr Aging & Populat Hlth, Grad Sch Publ Hlth, Dept Epidemiol, Pittsburgh, PA USA. [Le Blanc, Erin S.] Kaiser Permanente, Ctr Hlth Res NW, Rockville, MD USA. [Hoffman, Andrew R.] Stanford Univ, Stanford, CA 94305 USA. [Lee, Christine G.] Vet Affairs Hlth Care Syst, Portland, OR USA. RP Napoli, N (reprint author), Univ Campus Biomed Roma, Unit Endocrinol & Diabet, Dept Med, Via Alvaro del Portillo 21, I-00128 Rome, Italy. EM n.napoli@unicampus.it OI Cauley, Jane A/0000-0003-0752-4408 FU National Institutes of Health; National Institute on Aging (NIA); National Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS); National Center for Advancing Translational Sciences (NCATS); NIH Roadmap for Medical Research [U01 AR45580, U01 AR45614, U01 AR45632, U01 AR45647, U01 AR45654, U01 AR45583, U01 AG18197, U01 AG027810, UL1 TR000128]; Ministero della Salute [GR09-277]; American Diabetes Association [1-04-JF-46]; VA Clinical Science Research and Development Career Development Award [5IK2CW000729-02, 5IK2CX000549-05] FX The Osteoporotic Fractures in Men (MrOS) study is supported by National Institutes of Health funding. The following institutes provide support: the National Institute on Aging (NIA), the National Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS), the National Center for Advancing Translational Sciences (NCATS), and NIH Roadmap for Medical Research under the following grant numbers: U01 AR45580, U01 AR45614, U01 AR45632, U01 AR45647, U01 AR45654, U01 AR45583, U01 AG18197, U01 AG027810, and UL1 TR000128.; NN is supported by research grant provided by Ministero della Salute GR09-277.; The American Diabetes Association provided funding for Elsa Strotmeyer's grant "Longitudinal changes in BMD with diabetes mellitus" (1-04-JF-46, Strotmeyer ES).; CGL receives support from a VA Clinical Science Research and Development Career Development Award, project number 5IK2CW000729-02. ALS receives support from a VA Clinical Science Research and Development Career Development Award, project number 5IK2CX000549-05. NR 23 TC 2 Z9 2 U1 0 U2 2 PU ELSEVIER SCIENCE INC PI NEW YORK PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA SN 8756-3282 EI 1873-2763 J9 BONE JI Bone PD SEP PY 2016 VL 90 BP 181 EP 184 DI 10.1016/j.bone.2016.07.001 PG 4 WC Endocrinology & Metabolism SC Endocrinology & Metabolism GA DT1MK UT WOS:000381246600022 PM 27393241 ER PT J AU Norvell, DC Williams, RM Turner, AP Czerniecki, JM AF Norvell, Daniel C. Williams, Rhonda M. Turner, Aaron P. Czerniecki, Joseph M. TI The development and validation of a novel outcome measure to quantify mobility in the dysvascular lower extremity amputee: the amputee single item mobility measure SO CLINICAL REHABILITATION LA English DT Article DE Amputation; diabetes; peripheral arterial disease; patient-reported outcome; mobility; validity ID LOWER-LIMB AMPUTATION; QUALITY-OF-LIFE; HEALTH-STATUS; PROSTHETIC PROFILE; PEOPLE; QUESTIONNAIRE; SCALES; REHABILITATION; RESPONSIVENESS; RELIABILITY AB Objective: This study describes the development and psychometric evaluation of a novel patient-reported single-item mobility measure. Design: Prospective cohort study. Setting: Four Veteran's Administration Medical Centers. Subjects: Individuals undergoing their first major unilateral lower extremity amputation; 198 met inclusion criteria; of these, 113 (57%) enrolled. Interventions: None. Main measures: The Amputee Single Item Mobility Measure, a single item measure with scores ranging from 0 to 6, was developed by an expert panel, and concurrently administered with the Locomotor Capabilities Index-5 (LCI-5) and other outcome measures at six weeks, four months, and 12 months post-amputation. Criterion and construct validity, responsiveness, and floor/ceiling effects were evaluated. Responsiveness was assessed using the standardized response mean. Results: The overall mean 12-month Amputee Single Item Mobility Measure score was 3.391.4. Scores for transmetatarsal, transtibial, and transfemoral amputees were 4.2 (+/- 1.3), 3.2 (+/- 1.5), and 2.9 (+/- 1.1), respectively. Amputee Single Item Mobility Measure scores demonstrated large and statistically significant correlations with the LCI-5 scores at six weeks (r=0.72), four months (r=0.81), and 12 months (r=0.86). At four months and 12months, the correlation between Amputee Single Item Mobility Measure scores and hours of prosthetic use were r=0.69 and r=0.66, respectively, and between Amputee Single Item Mobility Measure scores and Trinity Amputation and Prosthesis Experience Scales functional restriction scores were r=0.45 and r=0.67, respectively. Amputee Single Item Mobility Measure scores increased significantly from six weeks to 12months post-amputation. Minimal floor/ceiling effects were demonstrated. Conclusions: In the unilateral dysvascular amputee, the Amputee Single Item Mobility Measure has strong criterion and construct validity, excellent responsiveness, and does not exhibit floor/ceiling effects. C1 [Norvell, Daniel C.] Spectrum Res Inc, 705 S 9th St,Suite 203, Tacoma, WA 98407 USA. [Williams, Rhonda M.; Turner, Aaron P.; Czerniecki, Joseph M.] VA Puget Sound Hlth Care Syst, Seattle, WA USA. [Williams, Rhonda M.; Turner, Aaron P.; Czerniecki, Joseph M.] Univ Washington, Dept Rehabil Med, Seattle, WA 98195 USA. RP Norvell, DC (reprint author), Spectrum Res Inc, 705 S 9th St,Suite 203, Tacoma, WA 98407 USA. EM dan@specri.com FU US Department of Veterans Affairs, Office of Research and Development, Rehabilitation Research and Development [A41241, B4927W] FX The author(s) disclosed receipt of the following financial support for the research, authorship, and/or publication of this article: This material is based upon work supported by the US Department of Veterans Affairs, Office of Research and Development, Rehabilitation Research and Development (Merit Review A41241 Joseph Czerniecki, PI and Career Development Award B4927W Aaron Turner, PI). NR 38 TC 0 Z9 0 U1 5 U2 6 PU SAGE PUBLICATIONS LTD PI LONDON PA 1 OLIVERS YARD, 55 CITY ROAD, LONDON EC1Y 1SP, ENGLAND SN 0269-2155 EI 1477-0873 J9 CLIN REHABIL JI Clin. Rehabil. PD SEP PY 2016 VL 30 IS 9 BP 878 EP 889 DI 10.1177/0269215516644308 PG 12 WC Rehabilitation SC Rehabilitation GA DU8FK UT WOS:000382448500005 PM 27496697 ER PT J AU Bolton, CE Quint, JK Dransfield, MT AF Bolton, Charlotte E. Quint, Jennifer K. Dransfield, Mark T. TI Cardiovascular disease in COPD: time to quash a silent killer SO LANCET RESPIRATORY MEDICINE LA English DT Editorial Material ID OBSTRUCTIVE PULMONARY-DISEASE; MYOCARDIAL-INFARCTION; EXACERBATION; MORTALITY; SURVIVAL; TORCH; RISK C1 [Bolton, Charlotte E.] Univ Nottingham, Nottingham Resp Res Unit, Sch Med, Nottingham, England. [Quint, Jennifer K.] Imperial Coll London, Natl Heart & Lung Inst, Dept Resp Epidemiol Occupat Med & Publ Hlth, London, England. [Dransfield, Mark T.] Univ Alabama Birmingham, Div Pulm Allergy & Crit Care Med, Birmingham, AL 35294 USA. [Dransfield, Mark T.] Birmingham VA Med Ctr, Birmingham, AL 35294 USA. RP Dransfield, MT (reprint author), Univ Alabama Birmingham, Div Pulm Allergy & Crit Care Med, Birmingham, AL 35294 USA.; Dransfield, MT (reprint author), Birmingham VA Med Ctr, Birmingham, AL 35294 USA. EM mdransfield@uabmc.edu NR 11 TC 0 Z9 0 U1 3 U2 3 PU ELSEVIER SCI LTD PI OXFORD PA THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, OXON, ENGLAND SN 2213-2600 J9 LANCET RESP MED JI Lancet Resp. Med. PD SEP PY 2016 VL 4 IS 9 BP 687 EP 689 PG 3 WC Critical Care Medicine; Respiratory System SC General & Internal Medicine; Respiratory System GA DU7TO UT WOS:000382417700008 PM 27599243 ER PT J AU Pavord, ID Lettis, S Anzueto, A Barnes, N AF Pavord, Ian D. Lettis, Sally Anzueto, Antonio Barnes, Neil TI Blood eosinophil count and pneumonia risk in patients with chronic obstructive pulmonary disease: a patient-level meta-analysis SO LANCET RESPIRATORY MEDICINE LA English DT Article ID INHALED FLUTICASONE FUROATE; COMMUNITY-ACQUIRED PNEUMONIA; RANDOMIZED CONTROLLED-TRIALS; INCREASED MORTALITY; LUNG-FUNCTION; MU-G; COPD; EXACERBATIONS; CORTICOSTEROIDS; VILANTEROL AB Background Inhaled corticosteroids are important in the management of chronic obstructive pulmonary disease (COPD), but can slightly increase the risk of pneumonia in patients with moderate-to-severe COPD. Patients with circulating eosinophil counts of 2% or more of blood leucocytes respond better to inhaled corticosteroids than do those with counts of less than 2% and it was therefore postulated that blood eosinophil count might also have an effect on the risk of pneumonia in patients with COPD. In this post-hoc meta-analysis, we investigate whether a 2% threshold can identify patients who differ in their risk of pneumonia, irrespective of inhaled corticosteroid treatment. Methods From the GlaxoSmithRline trial registry, we selected randomised, double-blind, clinical trials of patients with COPD that had: inhaled corticosteroid arms (fluticasone propionate and salmeterol or fluticasone furoate and vilanterol); a control arm (not given inhaled fluticasone); and pre-randomisation measurements of blood eosinophil counts and were of at least 24 weeks in duration. With use of specified terms from the Medical Dictionary for Regulatory Activities we identified pneumonia adverse events in patient-level data. We calculated number of patients with pneumonia events, stratified by baseline blood eosinophil count (<2% vs >= 2% of blood leucocytes) and whether or not patients had received inhaled corticosteroids. Findings We identified ten trials (conducted between 1998 and 2011), with eosinophil count data available for 10 861 patients with COPD. 4043 patients had baseline blood eosinophil counts of less than 2% and 6818 patients had baseline blood eosinophil counts of 2% or more. 149 (3.7%) patients with counts less than 2% had one or more pneumonia adverse events compared with 215 (3.2%) with counts of 2% or more (hazard ratio [HR] 1.31; 95% CI 1.06-1.62). In patients not treated with inhaled corticosteroids, 40 (3.8%) patients with less than 2% blood eosinophil counts had a pneumonia event versus 48 (2.4%) with 2% or more blood eosinophils (HR 1.53; 95% CI 1.01-2.31). In patients treated with inhaled corticosteroids, events occurred in 107 (4.5%) versus 164 (3.9%; HR 1.25; 95% CI 0.98-1.60), respectively. Interpretation Using 2% baseline eosinophil count as a threshold, patients with COPD with lower blood eosinophil counts had more pneumonia events than did those with higher counts. The magnitude of this increased risk was small and should be further explored in large, prospective studies. These data should be considered when making treatment decisions, alongside existing evidence that patients with COPD and baseline blood eosinophil counts less than 2% have a poorer response to inhaled corticosteroids. C1 [Pavord, Ian D.] Univ Oxford, Nuffield Dept Med, Resp Med Unit, Oxford OX1 2JD, England. [Lettis, Sally] GSK, Stat & Programming, Stockley Pk, England. [Anzueto, Antonio] Univ Texas Hlth Sci Ctr San Antonio, South Texas Vet Hlth Care Syst, San Antonio, TX 78229 USA. [Barnes, Neil] GSK, Resp Med Franchise, Brentford, England. [Barnes, Neil] Batts & London Sch Med & Dent, William Harvey Res Inst, London, England. RP Pavord, ID (reprint author), Univ Oxford, Nuffield Dept Med, Resp Med Unit, Oxford OX1 2JD, England.; Pavord, ID (reprint author), Univ Oxford, Oxford OX3 7FZ, England. EM ian.pavord@ndm.ox.ac.uk FU Glaxo SmithKline FX Glaxo SmithKline. NR 34 TC 2 Z9 2 U1 1 U2 3 PU ELSEVIER SCI LTD PI OXFORD PA THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, OXON, ENGLAND SN 2213-2600 J9 LANCET RESP MED JI Lancet Resp. Med. PD SEP PY 2016 VL 4 IS 9 BP 731 EP 741 DI 10.1016/S2213-2600(16)301485 PG 11 WC Critical Care Medicine; Respiratory System SC General & Internal Medicine; Respiratory System GA DU7TO UT WOS:000382417700020 PM 27460163 ER PT J AU Yam, FK Lew, T Eraly, SA Lin, HW Hirsch, JD Devor, M AF Yam, Felix K. Lew, Tiffany Eraly, Satish A. Lin, Hsiang-Wen Hirsch, Jan D. Devor, Michelle TI Changes in medication regimen complexity and the risk for 90-day hospital readmission and/or emergency department visits in US Veterans with heart failure SO RESEARCH IN SOCIAL & ADMINISTRATIVE PHARMACY LA English DT Article DE Medication regimen complexity index; MRCI; Heart failure; Patient readmission; Outcomes assessment; Polypharmacy ID OLDER-PEOPLE; ADHERENCE; INDEX; DISCHARGE; THERAPY; INTERVENTION; VALIDATION; MORTALITY AB Background: Heart failure (HF) hospitalization is associated with multiple medication modifications. These modifications often increase medication regimen complexity and may increase the risk of readmission and/or emergency department (ED) visit. Objectives: To determine the association between changes in medication regimen complexity (MRC) during hospitalization of patients with heart failure and the risk of readmission or ED visit at 90 days. Secondary objectives include examining the association between changes in MRC and time to readmission as well as the relationship between number of medications and MRC. Methods: This was a retrospective cohort study that included U.S. Veterans hospitalized with heart failure. MRC was quantified using the medication regimen complexity index (MRCI). The change in MRCI was the difference between admission MRCI and discharge MRCI recorded during the index hospitalization. Demographic and clinical data were collected to characterize the study population. Patient data for up to one year after discharge was recorded to identify hospital readmissions and ED visits. Results: A total of 174 patients were included in the analysis. Sixty-two patients (36%) were readmitted or had an ED visit at 90 days from the index hospitalization. The mean change (SD) in MRCI during the index hospitalization among the cohort was 4.7 (8.3). After multivariate logistic regression analysis, each unit increase in MRCI score was associated with a 4% lower odds of readmission or ED visit at 90 days but this finding was not statistically significant (OR 0.955; 95% CI 0.911-1.001). In the cox proportional hazard model, the median time to hospital readmission or ED visit was 214 days. Each unit increase in MRCI score was associated with a modest but non-significant increase in probability of survival from readmission or ED visit (HR 0.978; 95% CI 0.955, 1.001). Conclusion: Changes in medication regimen complexity that occur during hospitalization may also be associated with optimization of medical therapy and do not necessarily portend worse outcomes in patients with HF. Published by Elsevier Inc. C1 [Yam, Felix K.; Hirsch, Jan D.] Univ Calif San Diego, Skaggs Sch Pharm & Pharmaceut Sci, 9500 Gilman Dr,MC 0764, La Jolla, CA 92093 USA. [Yam, Felix K.; Eraly, Satish A.; Hirsch, Jan D.; Devor, Michelle] VA San Diego Healthcare Syst, 3350 La Jolla Village Dr, San Diego, CA USA. [Lew, Tiffany] San Francisco VA Med Ctr, 4150 Clement St 119, San Francisco, CA 94121 USA. [Eraly, Satish A.; Devor, Michelle] Univ Calif San Diego, Sch Med, 9500 Gilman Dr, La Jolla, CA 92093 USA. [Lin, Hsiang-Wen] China Med Univ, Coll Pharm, 91 Hsueh Shih Rd, Taichung 40402, Taiwan. RP Yam, FK (reprint author), Univ Calif San Diego, Skaggs Sch Pharm & Pharmaceut Sci, 9500 Gilman Dr,MC 0764, La Jolla, CA 92093 USA. EM fyam@ucsd.edu FU American Foundation for Pharmaceutical Education (AFPE) Pharmacy Faculty Fellow Award FX This work was supported by the American Foundation for Pharmaceutical Education (AFPE) Pharmacy Faculty Fellow Award. The funding source had no role in the design, conduct of the study; collection, management, analysis or interpretation of the data; or preparation, review or approval of the manuscript. NR 26 TC 2 Z9 2 U1 3 U2 5 PU ELSEVIER SCIENCE INC PI NEW YORK PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA SN 1551-7411 EI 1934-8150 J9 RES SOC ADMIN PHARM JI Res. Soc. Adm. Pharm. PD SEP-OCT PY 2016 VL 12 IS 5 BP 713 EP 721 DI 10.1016/j.sapharm.2015.10.004 PG 9 WC Public, Environmental & Occupational Health; Pharmacology & Pharmacy SC Public, Environmental & Occupational Health; Pharmacology & Pharmacy GA DU5SG UT WOS:000382271000004 PM 26621388 ER PT J AU Hood, RL Liguore, WA Moore, C Pflibsen, L Meshul, CK AF Hood, Rebecca L. Liguore, William A. Moore, Cynthia Pflibsen, Lacey Meshul, Charles K. TI Exercise intervention increases spontaneous locomotion but fails to attenuate dopaminergic system loss in a progressive MPTP model in aged mice SO BRAIN RESEARCH LA English DT Article DE Parkinson's disease; Aging; Exercise; MPTP; Dopamine; Striatum ID CHRONIC MOUSE MODEL; IDIOPATHIC PARKINSONS-DISEASE; RANDOMIZED CLINICAL-TRIAL; RESTORES MOTOR DEFICITS; TREADMILL EXERCISE; ENDURANCE EXERCISE; SUBSTANTIA-NIGRA; SEVERE NEURODEGENERATION; PHYSICAL-EXERCISE; LESIONED MOUSE AB While exercise is commonly recommended for PD patients to improve motor function, little is known about the disease-altering potential of exercise. Although others have demonstrated neuroprotective or neurorestorative effects of exercise in animal models of PD, the majority of these studies utilize young animals. In order to assess the effects of exercise intervention in a more clinically relevant model, we have subjected aged mice to progressive 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP) lesioning and daily treadmill exercise, initiated early in the course of the disease. The MPTP model elicited a 55% reduction in striatal TH as measured by immunohistochemistry compared to sedentary controls, and exercise did not attenuate this loss in exercised MPTP animals. Furthermore, striatal TH and DAT loss, as assessed by western blotting, were not significantly impacted by treadmill exercise in MPTP-lesioned mice. We did find an increase in spontaneous locomotion in exercised mice that was not decreased by MPTP lesioning. This finding may be due, in part, to an increase in TH expression in the motor cortex in exercised MPTP mice. (C) 2016 Elsevier B.V. All rights reserved. C1 [Hood, Rebecca L.; Meshul, Charles K.] Oregon Hlth & Sci Univ, Dept Behav Neurosci, 3181 SW Sam Jackson Pk Rd,L470, Portland, OR 97239 USA. [Liguore, William A.; Moore, Cynthia; Pflibsen, Lacey; Meshul, Charles K.] Portland VA Med Ctr, 3710 SW US Vet Hosp Rd, Portland, OR 97239 USA. RP Hood, RL (reprint author), Oregon Hlth & Sci Univ, Dept Behav Neurosci, 3181 SW Sam Jackson Pk Rd,L470, Portland, OR 97239 USA. EM hoodr@ohsu.edu; liguorew@gmail.com; moorecy@ohsu.edu; Pflibsel11@up.edu; meshulc@ohsu.edu FU United States (U.S.) Department of Veterans Affairs Biomedical Laboratory Research and Development [1BX 001643] FX This work was supported by Merit Review #1BX 001643 to CKM from the United States (U.S.) Department of Veterans Affairs Biomedical Laboratory Research and Development. The contents do not represent the views of the U.S. Department of Veterans Affairs or the United States Government. NR 62 TC 1 Z9 1 U1 6 U2 8 PU ELSEVIER SCIENCE BV PI AMSTERDAM PA PO BOX 211, 1000 AE AMSTERDAM, NETHERLANDS SN 0006-8993 EI 1872-6240 J9 BRAIN RES JI Brain Res. PD SEP 1 PY 2016 VL 1646 BP 535 EP 542 DI 10.1016/j.brainres.2016.06.032 PG 8 WC Neurosciences SC Neurosciences & Neurology GA DT9TH UT WOS:000381844700060 PM 27350080 ER PT J AU Ioannou, GN Beste, LA Chang, MF Green, PK Lowy, E Tsui, JI Su, F Berry, K AF Ioannou, George N. Beste, Lauren A. Chang, Michael F. Green, Pamela K. Lowy, Elliott Tsui, Judith I. Su, Feng Berry, Kristin TI Effectiveness of Sofosbuvir, Ledipasvir/Sofosbuvir, or Paritaprevir/Ritonavir/Ombitasvir and Dasabuvir Regimens for Treatment of Patients With Hepatitis C in the Veterans Affairs National Health Care System SO GASTROENTEROLOGY LA English DT Article DE Harvoni; Viekira; DAA; VA ID GENOTYPE 1 INFECTION; SUSTAINED VIROLOGICAL RESPONSE; HEPATOCELLULAR-CARCINOMA; VIRUS-INFECTION; LIVER-DISEASE; US VETERANS; HCV; RIBAVIRIN; CIRRHOSIS; LEDIPASVIR AB BACKGROUND & AIMS: We investigated the real-world effectiveness of sofosbuvir, ledipasvir/sofosbuvir, and paritaprevir/ritonavir/ombitasvir and dasabuvir (PrOD) in treatment of different subgroups of patients infected with hepatitis C virus (HCV) genotypes 1, 2, 3, or 4. METHODS: We performed a retrospective analysis of data from 17,487 patients with HCV infection (13,974 with HCV genotype 1; 2131 with genotype 2; 1237 with genotype 3; and 135 with genotype 4) who began treatment with sofosbuvir (n = 2986), ledipasvir/sofosbuvir (n = 11,327), or PrOD (n = 3174), with or without ribavirin, from January 1, 2014 through June 20, 2015 in the Veterans Affairs health care system. Data through April 15, 2016 were analyzed to assess completion of treatments and sustained virologic response 12 weeks after treatment (SVR12). Mean age of patients was 61 = 7 years, 97% were male, 52% were non-Hispanic white, 29% were non-Hispanic black, 32% had a diagnosis of cirrhosis (9.9% with decompensated cirrhosis), 36% had a Fibrosis-4 index score >3.25 (indicator of cirrhosis), and 29% had received prior antiviral treatment. RESULTS: An SVR12 was achieved by 92.8% (95% confidence interval [CI], 92.3%-93.2%) of subjects with HCV genotype 1 infection (no significant difference between ledipasvir/sofosbuvir and PrOD regimens), 86.2% (95% CI, 84.6%-87.7%) of those with genotype 2 infection (treated with sofosbuvir and ribavirin), 74.8% (95% CI, 72.2%-77.3%) of those with genotype 3 infection (77.9% in patients given ledipasvir/sofosbuvir plus ribavirin, 87.0% in patients given sofosbuvir and pegylated-interferon plus ribavirin, and 70.6% of patients given sofosbuvir plus ribavirin), and 89.6% (95% CI 82.8%-93.9%) of those with genotype 4 infection. Among patients with cirrhosis, 90.6% of patients with HCV genotype 1, 77.3% with HCV genotype 2, 65.7% with HCV genotype 3, and 83.9% with HCV genotype 4 achieved an SVR12. Among previously treated patients, 92.6% with genotype 1; 80.2% with genotype 2; 69.2% with genotype 3; and 93.5% with genotype 4 achieved SVR12. Among treatment-naive patients, 92.8% with genotype 1; 88.0% with genotype 2; 77.5% with genotype 3; and 88.3% with genotype 4 achieved SVR12. Eight-week regimens of ledipasvir/sofosbuvir produced an SVR12 in 94.3% of eligible patients with HCV genotype 1 infection; this regimen was underused. CONCLUSIONS: High proportions of patients with HCV infections genotypes 1-4 (ranging from 75% to 93%) in the Veterans Affairs national health care system achieved SVR12, approaching the results reported in clinical trials, especially in patients with genotype 1 infection. An 8-week regimen of ledipasvir/sofosbuvir is effective for eligible patients with HCV genotype 1 infection and could reduce costs. There is substantial room for improvement in SVRs among persons with cirrhosis and genotype 2 or 3 infections. C1 [Ioannou, George N.] Vet Affairs Puget Sound Hlth Care Syst, Div Gastroenterol, S-111 Gastro,1660 S Columbian Way, Seattle, WA 98108 USA. [Ioannou, George N.; Beste, Lauren A.; Green, Pamela K.; Lowy, Elliott; Berry, Kristin] Vet Affairs Puget Sound Hlth Care Syst, Hlth Serv Res & Dev, Seattle, WA USA. [Ioannou, George N.] Univ Washington, Div Gastroenterol, Seattle, WA 98195 USA. [Beste, Lauren A.] Vet Affairs Puget Sound Hlth Care Syst, Div Gen Internal Med, Seattle, WA USA. [Beste, Lauren A.; Tsui, Judith I.; Su, Feng] Univ Washington, Div Gen Internal Med, Seattle, WA 98195 USA. [Chang, Michael F.] Vet Affairs Portland Hlth Care Syst, Div Gastroenterol, Portland, OR USA. [Chang, Michael F.] Oregon Hlth & Sci Univ, Portland, OR USA. RP Ioannou, GN (reprint author), Vet Affairs Puget Sound Hlth Care Syst, Div Gastroenterol, S-111 Gastro,1660 S Columbian Way, Seattle, WA 98108 USA. EM georgei@medicine.washington.edu FU Merit Review grants [I01CX000320, I01CX001156]; Clinical Science Research and Development, Office of Research and Development, Veterans Affairs FX This study was funded by Merit Review grants (I01CX000320 and I01CX001156), Clinical Science Research and Development, Office of Research and Development, Veterans Affairs (to George N. Ioannou). The contents do not represent the views of the US Department of Veterans Affairs or the US Government. NR 36 TC 14 Z9 14 U1 4 U2 7 PU W B SAUNDERS CO-ELSEVIER INC PI PHILADELPHIA PA 1600 JOHN F KENNEDY BOULEVARD, STE 1800, PHILADELPHIA, PA 19103-2899 USA SN 0016-5085 EI 1528-0012 J9 GASTROENTEROLOGY JI Gastroenterology PD SEP PY 2016 VL 151 IS 3 BP 457 EP + DI 10.1053/j.gastro.2016.05.049 PG 20 WC Gastroenterology & Hepatology SC Gastroenterology & Hepatology GA DU5CO UT WOS:000382230000023 PM 27267053 ER PT J AU Anand, V Hyun, C Khan, QM Hall, C Hessefort, N Sonnenberg, A Fimmel, CJ AF Anand, Vijay Hyun, Christian Khan, Qasim M. Hall, Curtis Hessefort, Norbert Sonnenberg, Amnon Fimmel, Claus J. TI Identification and Fibrosis Staging of Hepatitis C Patients Using the Electronic Medical Record System SO JOURNAL OF CLINICAL GASTROENTEROLOGY LA English DT Article DE fibrosis scoring algorithm; hepatitis C virus infection; liver fibrosis; receiver operating characteristic curve ID VIRUS-INFECTION; CIRRHOSIS; INDEX AB Background and Aims: The aim of this study was to noninvasively assess the severity of chronic hepatitis C virus (HCV) in large patient populations. It would be helpful if fibrosis scores could be calculated solely on the basis of data contained in the patients' electronic medical records (EMR). We performed a pilot study to identify all HCV-infected patients in a large health care system, and predict their fibrosis stage on the basis of demographic and laboratory data using common data from their EMR. Materials and Methods: HCV-infected patients were identified using the EMR. The liver biopsies of 191 HCV patients were graded using the Ishak and Metavir scoring systems. Demographic and laboratory data were extracted from the EMR and used to calculate the aminotransferase to platelet ratio index, Fib-4, Fibrosis Index, Forns, Goteborg University Cirrhosis Index, Lok Index, and Vira-HepC. Results: In total, 869 HCV-infected patients were identified from a population of over 1 million. In the subgroup of patients with liver biopsies, all 7 algorithms were significantly correlated with the fibrosis stage. The degree of correlation was moderate, with correlation coefficients ranging from 0.22 to 0.60. For the detection of advanced fibrosis (Metavir 3 or 4), the areas under the receiver operating characteristic curve ranged from 0.71 to 0.84, with no significant differences between the individual scores. Sensitivities, specificities, and positive and negative predictive values were within the previously reported range. All scores tended to perform better for higher fibrosis stages. Conclusions: Our study demonstrates that HCV-infected patients can be identified and their fibrosis staged using commonly available EMR-based algorithms. C1 [Anand, Vijay; Hyun, Christian; Khan, Qasim M.; Hall, Curtis; Hessefort, Norbert; Fimmel, Claus J.] NorthShore Univ Hlth Syst, Dept Internal Med, Gastroenterol Sect, Evanston, IL 60201 USA. [Sonnenberg, Amnon] Portland VA Med Ctr, Portland, OR 97239 USA. [Sonnenberg, Amnon] Oregon Hlth & Sci Univ, Portland, OR 97239 USA. RP Fimmel, CJ (reprint author), NorthShore Univ Hlth Syst, Div Gastroenterol, 2650 Ridge Ave, Evanston, IL 60201 USA. EM cfimmel@northshore.org FU Gilead Sciences Inc. FX Supported with funding from Gilead Sciences Inc. to C.J.F. NR 17 TC 0 Z9 0 U1 1 U2 1 PU LIPPINCOTT WILLIAMS & WILKINS PI PHILADELPHIA PA TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA SN 0192-0790 EI 1539-2031 J9 J CLIN GASTROENTEROL JI J. Clin. Gastroenterol. PD SEP PY 2016 VL 50 IS 8 BP 664 EP 669 DI 10.1097/MCG.0000000000000519 PG 6 WC Gastroenterology & Hepatology SC Gastroenterology & Hepatology GA DT4TB UT WOS:000381472800013 PM 26974763 ER PT J AU Okeke, FC Shaw, S Hunt, KK Korsten, MA Rosman, AS AF Okeke, Francis C. Shaw, Spencer Hunt, Kristel K. Korsten, Mark A. Rosman, Alan S. TI Safety of Propofol Used as a Rescue Agent During Colonoscopy SO JOURNAL OF CLINICAL GASTROENTEROLOGY LA English DT Article DE propofol; sedation; colonoscopy ID GASTROINTESTINAL ENDOSCOPY; ADMINISTERED PROPOFOL; SCREENING COLONOSCOPY; MODERATE SEDATION; ABDOMINAL-PAIN; METAANALYSIS AB Goal: The goal of this study was to evaluate the safety of propofol when used by gastroenterologists in patients who have an inadequate response to standard sedation (narcotics and benzodiazepines). Background: Many patients fail to achieve adequate sedation from narcotics and benzodiazepines during colonoscopy. The administration of propofol for colonoscopy is increasing, although its use by gastroenterologists is controversial. Study: We performed a retrospective review of our hospital's colonoscopy records from January 2006 to December 2009 to identify 403 subjects undergoing screening colonoscopies who required propofol (20 to 30mg every 3 min as needed) because of inadequate response to standard sedation. We also randomly selected 403 controls undergoing screening colonoscopies from the same time period that only required standard sedation. The incidence of adverse effects was then compared. Results: There were no major adverse events in either group. The rates of minor adverse events in the propofol and control group were 0.02 and 0.01, respectively (P=0.56). Adverse effects in the propofol group included: transient hypotension (n=1), nausea/vomiting (n=3), agitation (n=2), and rash (n=1). Adverse effects seen with standard sedation included: transient hypotension (n=2), nausea/vomiting (n=1), and oversedation (n=2). Patients who received propofol were more likely to be younger, had a history of illicit drug use, and a longer procedure time (P<0.05). Conclusions: Adjunctive propofol administered by gastroenterologist for conscious sedation was not associated with increased incidence of adverse events. It may be of value in patients who do not respond to conventional sedation. C1 [Okeke, Francis C.] Johns Hopkins Univ, Dept Med, Div Hosp Med CIMS, Bayview Med Ctr, Baltimore, MD 21218 USA. [Shaw, Spencer; Hunt, Kristel K.; Korsten, Mark A.; Rosman, Alan S.] James J Peters Vet Affairs Med Ctr, 130 West Kingsbridge Rd, Bronx, NY 10468 USA. RP Rosman, AS (reprint author), James J Peters Vet Affairs Med Ctr, 130 West Kingsbridge Rd, Bronx, NY 10468 USA. EM alan.rosman@va.gov NR 26 TC 0 Z9 0 U1 1 U2 1 PU LIPPINCOTT WILLIAMS & WILKINS PI PHILADELPHIA PA TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA SN 0192-0790 EI 1539-2031 J9 J CLIN GASTROENTEROL JI J. Clin. Gastroenterol. PD SEP PY 2016 VL 50 IS 8 BP E77 EP E80 DI 10.1097/MCG.0000000000000445 PG 4 WC Gastroenterology & Hepatology SC Gastroenterology & Hepatology GA DT4TB UT WOS:000381472800003 PM 26565970 ER PT J AU Yehuda, R Daskalakis, NP Bierer, LM Bader, HN Klengel, T Holsboer, F Binder, EB AF Yehuda, Rachel Daskalakis, Nikolaos P. Bierer, Linda M. Bader, Heather N. Klengel, Torsten Holsboer, Florian Binder, Elisabeth B. TI Holocaust Exposure Induced Intergenerational Effects on FKBP5 Methylation SO BIOLOGICAL PSYCHIATRY LA English DT Article DE Cortisol; Epigenetics; FKBP5; Intergenerational; PTSD; Stress ID POSTTRAUMATIC-STRESS-DISORDER; TRADE-CENTER ATTACKS; CHILDHOOD TRAUMA; GLUCOCORTICOID-RECEPTOR; PARENTAL PTSD; CORTISOL-LEVELS; MATERNAL-CARE; SURVIVORS; RISK; EXPRESSION AB BACKGROUND: The involvement of epigenetic mechanisms in intergenerational transmission of stress effects has been demonstrated in animals but not in humans. METHODS: Cytosine methylation within the gene encoding for FK506 binding protein 5 (FKBP5) was measured in Holocaust survivors (n = 32), their adult offspring (n = 22), and demographically comparable parent (n = 8) and offspring (n 5 9) control subjects, respectively. Cytosine-phosphate-guanine sites for analysis were chosen based on their spatial proximity to the intron 7 glucocorticoid response elements. RESULTS: Holocaust exposure had an effect on FKBP5 methylation that was observed in exposed parents as well in their offspring. These effects were observed at bin 3/site 6. Interestingly, in Holocaust survivors, methylation at this site was higher in comparison with control subjects, whereas in Holocaust offspring, methylation was lower. Methylation levels for exposed parents and their offspring were significantly correlated. In contrast to the findings at bin 3/site 6, offspring methylation at bin 2/sites 3 to 5 was associated with childhood physical and sexual abuse in interaction with an FKBP5 risk allele previously associated with vulnerability to psychological consequences of childhood adversity. The findings suggest the possibility of site specificity to environmental influences, as sites in bins 3 and 2 were differentially associated with parental trauma and the offspring's own childhood trauma, respectively. FKBP5 methylation averaged across the three bins examined was associated with wake-up cortisol levels, indicating functional relevance of the methylation measures. CONCLUSIONS: This is the first demonstration of an association of preconception parental trauma with epigenetic alterations that is evident in both exposed parent and offspring, providing potential insight into how severe psychophysiological trauma can have intergenerational effects. C1 [Yehuda, Rachel; Daskalakis, Nikolaos P.; Bierer, Linda M.; Bader, Heather N.] Icahn Sch Med Mt Sinai, Traumat Stress Studies Div, Dept Psychiat, New York, NY 10029 USA. [Yehuda, Rachel; Daskalakis, Nikolaos P.; Bierer, Linda M.; Bader, Heather N.] James J Peters Vet Affairs Med Ctr, PTSD Clin Res Program, Mental Hlth Care Ctr, Bronx, NY USA. James J Peters Vet Affairs Med Ctr, Lab Clin Neuroendocrinol & Neurochem, Bronx, NY USA. [Klengel, Torsten; Binder, Elisabeth B.] Max Planck Inst Psychiat, Dept Translat Res Psychiat, Munich, Germany. [Holsboer, Florian] Max Planck Inst Psychiat, Munich, Germany. [Holsboer, Florian] HMNC Holding GmbH, Munich, Germany. [Klengel, Torsten; Binder, Elisabeth B.] Emory Univ, Sch Med, Dept Psychiat & Behav Sci, Atlanta, GA USA. RP Yehuda, R (reprint author), Mt Sinai Sch Med, Mental Hlth Care Ctr, James J Peters Vet Affairs Med Ctr, Dept Psychiat, 526 OOMH PTSD 116-A,130 West Kingsbridge Rd, Bronx, NY 10468 USA. EM rachel.yehuda@va.gov OI Klengel, Torsten/0000-0001-7045-9229; Daskalakis, Nikolaos/0000-0003-1660-9112 FU National Institute of Mental Health [R01 MH 64675-01, 1RC1MH088101-01]; National Institutes of Health [5 M01 RR00071]; European Research Council starting Grant, G x E molmech, FP7 framework program [281338] FX This work was supported by National Institute of Mental Health R01 MH 64675-01 "Biology of Risk and PTSD in Holocaust Survivor Offspring" and 1RC1MH088101-01 "Identification of an Epigenetic Risk Marker for PTSD" and, in part, by a Grant (5 M01 RR00071) for the Mount Sinai General Clinical Research Center from the National Institutes of Health. The National Institutes of Health had no further role in the study design; in the collection, analysis, and interpretation of the data; in the writing of the report; or in the decision to submit the article for publication. European Research Council starting Grant (Grant #281338) G x E molmech, FP7 framework program to EB. NR 56 TC 27 Z9 27 U1 34 U2 54 PU ELSEVIER SCIENCE INC PI NEW YORK PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA SN 0006-3223 EI 1873-2402 J9 BIOL PSYCHIAT JI Biol. Psychiatry PD SEP 1 PY 2016 VL 80 IS 5 BP 372 EP 380 DI 10.1016/j.biopsych.2015.08.005 PG 9 WC Neurosciences; Psychiatry SC Neurosciences & Neurology; Psychiatry GA DS5RR UT WOS:000380840500009 PM 26410355 ER PT J AU Lee, DC Long, JA Sevick, MA Yi, SS Athens, JK Elbel, B Wall, SP AF Lee, David C. Long, Judith A. Sevick, Mary Ann Yi, Stella S. Athens, Jessica K. Elbel, Brian Wall, Stephen P. TI The local geographic distribution of diabetic complications in New York City: Associated population characteristics and differences by type of complication SO DIABETES RESEARCH AND CLINICAL PRACTICE LA English DT Article DE Population health; Diabetic complications; Geographic variation ID FACTOR SURVEILLANCE SYSTEM; UNITED-STATES; DISEASE; RISK; PREVALENCE; VALIDATION; VALIDITY; DATABASE; CARE; IDENTIFICATION AB Aims: To identify population characteristics associated with local variation in the prevalence of diabetic complications and compare the geographic distribution of different types of complications in New York City. Methods: Using an all-payer database of emergency visits, we identified the proportion of unique adults with diabetes who also had cardiac, neurologic, renal and lower extremity complications. We performed multivariable regression to identify associations of demographic and socioeconomic factors, and diabetes-specific emergency department use with the prevalence of diabetic complications by Census tract. We also used geospatial analysis to compare local hotspots of diabetic complications. Results: We identified 4.6 million unique New York City adults, of which 10.5% had diabetes. Adjusting for demographic and socioeconomic factors, diabetes-specific emergency department use was associated with severe microvascular renal and lower extremity complications (p-values < 0.001), but not with severe macrovascular cardiac or neurologic complications (p-values of 0.39 and 0.29). Our hotspot analysis demonstrated significant geographic heterogeneity in the prevalence of diabetic complications depending on the type of complication. Notably, the geographic distribution of hotspots of myocardial infarction were inversely correlated with hotspots of end-stage renal disease and lower extremity amputations (coefficients: -0.28 and -0.28). Conclusions: We found differences in the local geographic distribution of diabetic complications, which highlight the contrasting risk factors for developing macrovascular versus microvascular diabetic complications. Based on our analysis, we also found that high diabetes-specific emergency department use was correlated with poor diabetic outcomes. Emergency department utilization data can help identify the location of specific populations with poor glycemic control. (C) 2016 Elsevier Ireland Ltd. All rights reserved. C1 [Lee, David C.; Wall, Stephen P.] NYU, Sch Med, Ronald O Perelman Dept Emergency Med, 560 First Ave, New York, NY 10016 USA. [Lee, David C.; Sevick, Mary Ann; Yi, Stella S.; Athens, Jessica K.; Elbel, Brian] NYU, Sch Med, Dept Populat Hlth, 227 East 30th St, New York, NY 10016 USA. [Long, Judith A.] Univ Penn, Perelman Sch Med, Div Gen Internal Med, 423 Guardian Dr, Philadelphia, PA 19104 USA. [Long, Judith A.] Corporal Michael J Crescenz Vet Affairs Med Ctr, Ctr Hlth Equ Res, 3900 Woodland Ave, Philadelphia, PA 19104 USA. [Elbel, Brian] NYU, Wagner Grad Sch Publ Serv, 295 Lafayette St, New York, NY 10012 USA. RP Lee, DC (reprint author), 462 First Ave,Room A345, New York, NY 10016 USA. EM david.lee@nyumc.org OI Wall, Stephen/0000-0003-3965-5074; Elbel, Brian/0000-0003-1615-9430; Yi, Stella/0000-0002-9943-2609 NR 40 TC 0 Z9 0 U1 1 U2 1 PU ELSEVIER IRELAND LTD PI CLARE PA ELSEVIER HOUSE, BROOKVALE PLAZA, EAST PARK SHANNON, CO, CLARE, 00000, IRELAND SN 0168-8227 EI 1872-8227 J9 DIABETES RES CLIN PR JI Diabetes Res. Clin. Pract. PD SEP PY 2016 VL 119 BP 88 EP 96 DI 10.1016/j.diabres.2016.07.008 PG 9 WC Endocrinology & Metabolism SC Endocrinology & Metabolism GA DT7DI UT WOS:000381646900012 PM 27497144 ER PT J AU Walsh, K Zinzow, HM Badour, CL Ruggiero, KJ Kilpatrick, DG Resnick, HS AF Walsh, Kate Zinzow, Heidi M. Badour, Christal L. Ruggiero, Kenneth J. Kilpatrick, Dean G. Resnick, Heidi S. TI Understanding Disparities in Service Seeking Following Forcible Versus Drug- or Alcohol-Facilitated/Incapacitated Rape SO JOURNAL OF INTERPERSONAL VIOLENCE LA English DT Article DE sexual assault; alcohol and drugs; support seeking ID POSTTRAUMATIC-STRESS-DISORDER; CHILD SEXUAL-ABUSE; NATIONAL SAMPLE; COLLEGE-WOMEN; MEDICAL-CARE; ASSAULT; EXPERIENCES; CONSUMPTION; SURVIVORS; POLICE AB Victims of drug- or alcohol-facilitated/incapacitated rape (DAFR/IR) are substantially less likely to seek medical, rape crisis, or police services compared with victims of forcible rape (FR); however, reasons for these disparities are poorly understood. The current study examined explanatory mechanisms in the pathway from rape type (FR vs. DAFR/IR) to disparities in post-rape service seeking (medical, rape crisis, criminal justice). Participants were 445 adult women from a nationally representative household probability sample who had experienced FR, DAFR/IR, or both since age 14. Personal characteristics (age, race, income, prior rape history), rape characteristics (fear, injury, loss of consciousness), and post-rape acknowledgment, medical concerns, and service seeking were collected. An indirect effects model using bootstrapped standard errors was estimated to examine pathways from rape type to service seeking. DAFR/IR-only victims were less likely to seek services compared with FR victims despite similar post-rape medical concerns. FR victims were more likely to report fear during the rape and a prior rape history, and to acknowledge the incident as rape; each of these characteristics was positively associated with service seeking. However, only prior rape history and acknowledgment served as indirect paths to service seeking; acknowledgment was the strongest predictor of service seeking. Diminished acknowledgment of the incident as rape may be especially important to explaining why DAFR/IR victims are less likely than FR victims to seek services. Public service campaigns designed to increase awareness of rape definitions, particularly around DAFR/IR, are important to reducing disparities in rape-related service seeking. C1 [Walsh, Kate] Columbia Univ, New York, NY USA. [Zinzow, Heidi M.] Clemson Univ, Dept Psychol, Clemson, SC 29631 USA. [Badour, Christal L.; Kilpatrick, Dean G.; Resnick, Heidi S.] Med Univ South Carolina, Dept Psychiat & Behav Sci, Natl Crime Victims Res & Treatment Ctr, 67 President St MSC 861,2 South, Charleston, SC USA. [Ruggiero, Kenneth J.] Med Univ South Carolina, Coll Nursing, Technol Applicat Ctr Healthful Lifestyles, Charleston, SC USA. [Badour, Christal L.; Ruggiero, Kenneth J.] Ralph H Johnson VA Med Ctr, Charleston, SC USA. RP Resnick, HS (reprint author), Med Univ South Carolina, Dept Psychiat & Behav Sci, Natl Crime Victims Res & Treatment Ctr, 67 President St MSC 861,2 South, Charleston, SC USA. EM resnickh@musc.edu FU National Institute on Drug Abuse [R01DA023099, T32DA031099]; National Institute of Child Health and Human Development [5R01HD046830]; National Institute of Justice [2005-WG-BX-0006] FX The author(s) disclosed receipt of the following financial support for the research, authorship, and/or publication of this article: Manuscript preparation was supported by several grants from the National Institute on Drug Abuse (R01DA023099, T32DA031099). Study data collection was supported by grants from the National Institute of Child Health and Human Development (5R01HD046830) and the National Institute of Justice (2005-WG-BX-0006). NR 34 TC 0 Z9 0 U1 10 U2 13 PU SAGE PUBLICATIONS INC PI THOUSAND OAKS PA 2455 TELLER RD, THOUSAND OAKS, CA 91320 USA SN 0886-2605 EI 1552-6518 J9 J INTERPERS VIOLENCE JI J. Interpers. Violence PD SEP PY 2016 VL 31 IS 14 BP 2475 EP 2491 DI 10.1177/0886260515576968 PG 17 WC Criminology & Penology; Family Studies; Psychology, Applied SC Criminology & Penology; Family Studies; Psychology GA DS7TL UT WOS:000380985700005 PM 25846758 ER PT J AU Schwehm, A Robinson, DG Gallego, JA Karlsgodt, KH Ikuta, T Peters, BD Malhotra, AK Szeszko, PR AF Schwehm, Andrew Robinson, Delbert G. Gallego, Juan A. Karlsgodt, Katherine H. Ikuta, Toshikazu Peters, Bart D. Malhotra, Anil K. Szeszko, Philip R. TI Age and Sex Effects on White Matter Tracts in Psychosis from Adolescence through Middle Adulthood SO NEUROPSYCHOPHARMACOLOGY LA English DT Article ID ONSET SCHIZOPHRENIA; 1ST-EPISODE SCHIZOPHRENIA; WORKING-MEMORY; ABNORMALITIES; INTEGRITY; DISORDER; ACTIVATION; ANISOTROPY; DEFICITS; RISK AB There is controversy regarding specificity of white matter abnormalities in psychosis, their deviation from healthy aging, and the influence of sex on these measures. We used diffusion tensor imaging to characterize putative white matter microstructure in 224 patients with psychosis and healthy volunteers across the age range of 15-64 years. Sixty-five younger (age <30 years; 47M/18F) patients with psychosis (all experiencing a first episode of illness) and 48 older (age >= 30 years; 30M/18F) patients were age-matched to younger and older healthy volunteer groups (N = 63 (40M/23F) and N = 48 (29M/19F), respectively). The trajectories of two inter-hemispheric (splenium and genu), two projection (cortico-pontine and anterior thalamic), and five bilateral association (inferior fronto-occipital, inferior longitudinal, superior longitudinal, cingulum, and uncinate) tracts were quantified using tractography to derive measures of fractional anisotropy and mean, axial, and radial diffusivity. Fractional anisotropy was significantly lower in the inferior longitudinal fasciculus and superior longitudinal fasciculus in all patients compared with all healthy volunteers, with comparable effect sizes observed in both the younger and older patients compared with their respective healthy volunteer groups. Moreover, age-associated differences in fractional anisotropy within these tracts were comparable between groups across the age span. In addition, female patients had significantly lower fractional anisotropy across all tracts compared with female controls regardless of age. Our findings demonstrate comparable putative white matter abnormalities in two independent samples of patients with psychosis and argue against their progression in patients. These data further highlight the novel and potentially underappreciated role of sex in understanding white matter dysfunction in the neurobiology of psychosis. C1 [Schwehm, Andrew] St Johns Univ, Dept Psychol, Jamaica, NY USA. [Robinson, Delbert G.; Gallego, Juan A.; Karlsgodt, Katherine H.; Peters, Bart D.; Malhotra, Anil K.] Feinstein Inst Med Res, Ctr Psychiat Neurosci, Manhasset, NY USA. [Robinson, Delbert G.; Gallego, Juan A.; Karlsgodt, Katherine H.; Peters, Bart D.; Malhotra, Anil K.] North Shore LIJ Hlth Syst, Zucker Hillside Hosp, Div Psychiat Res, Glen Oaks, NY USA. [Robinson, Delbert G.; Gallego, Juan A.; Karlsgodt, Katherine H.; Malhotra, Anil K.] Hofstra North Shore LIJ Sch Med, Dept Psychiat, Hempstead, NY USA. [Robinson, Delbert G.; Gallego, Juan A.; Karlsgodt, Katherine H.; Malhotra, Anil K.] Hofstra North Shore LIJ Sch Med, Dept Mol Med, Hempstead, NY USA. [Ikuta, Toshikazu] Univ Mississippi, Sch Appl Sci, Dept Commun Sci & Disorders, Oxford, MS USA. [Szeszko, Philip R.] James J Peters Vet Affairs Med Ctr, Bronx, NY USA. [Szeszko, Philip R.] Icahn Sch Med Mt Sinai, Dept Psychiat, New York, NY USA. RP Szeszko, PR (reprint author), Mental Hlth Care Ctr, James J Peters Vet Affairs Med Ctr, 130W Kingsbridge Rd, Bronx, NY 10468 USA. EM Philip.Szeszko@va.gov OI Schwehm, Andrew/0000-0002-3840-9296; Ikuta, Toshikazu/0000-0003-0848-302X FU Brain and Behavior Research Foundation; National Institute of Mental Health [MH76995, MH079800]; NSLIJ Research Institute General Clinical Research Center [M01 RR18535]; Advanced Center for Intervention and Services Research [MH74543]; Center for Intervention Development and Applied Research [MH80173]; Bristol Meyers Squibb; Janssen; Otsuka FX This work was supported in part by grants from the Brain and Behavior Research Foundation (to Dr Szeszko) and the National Institute of Mental Health to Dr Szeszko (MH76995) and Dr Maihotra (MH079800), the NSLIJ Research Institute General Clinical Research Center (M01 RR18535), an Advanced Center for Intervention and Services Research (MH74543), and a Center for Intervention Development and Applied Research (MH80173). Dr Malhotra serves on the advisory boards of Genomind, LLC and FORUM Pharmaceuticals. Dr Robinson has been a consultant to Asubio and Otsuka, and he has received grants from Bristol Meyers Squibb, Janssen, and Otsuka. The other authors declare no conflict of interest. NR 41 TC 0 Z9 0 U1 1 U2 6 PU NATURE PUBLISHING GROUP PI LONDON PA MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND SN 0893-133X EI 1740-634X J9 NEUROPSYCHOPHARMACOL JI Neuropsychopharmacology PD SEP PY 2016 VL 41 IS 10 BP 2473 EP 2480 DI 10.1038/npp.2016.47 PG 8 WC Neurosciences; Pharmacology & Pharmacy; Psychiatry SC Neurosciences & Neurology; Pharmacology & Pharmacy; Psychiatry GA DT7FV UT WOS:000381653400006 PM 27067129 ER PT J AU Shorter, D Nielsen, DA Hamon, SC Nielsen, EM Kosten, TR Newton, TF De La Garza, R AF Shorter, Daryl Nielsen, David A. Hamon, Sara C. Nielsen, Ellen M. Kosten, Thomas R. Newton, Thomas F. De La Garza, Richard, II TI The alpha-1 adrenoceptor (ADRA1A) genotype moderates the magnitude of acute cocaine-induced subjective effects in cocaine-dependent individuals SO PHARMACOGENETICS AND GENOMICS LA English DT Article DE ADRA1A; cocaine; genotype; polymorphism; subjective effects ID DOPAMINE-BETA-HYDROXYLASE; PHARMACOGENETIC RANDOMIZED-TRIAL; TRANSPORTER KNOCKOUT MICE; POPULATION-STRUCTURE; INCENTIVE SALIENCE; CONSTITUTIVE ACTIVITY; INDUCED REINSTATEMENT; INHIBITOR NEPICASTAT; PREFRONTAL CORTEX; STRIA TERMINALIS AB Objectives We examined whether a functional variant of the ADRA1A gene moderated cocaine-induced subjective effects in a group of cocaine-dependent individuals. Methods This study was a within-participant, double-blind, placebo-controlled inpatient human laboratory evaluation of 65 nontreatment-seeking, cocaine-dependent [ Diagnostic and Statistical Manual of Mental Disorders, 4th ed. (DSM-IV)] individuals aged 18-55 years. Participants received both placebo (saline, IV) and cocaine (40 mg, IV), and subjective responses were assessed 15 min before receiving an infusion and at 5 min intervals for the subsequent 20 min. The rs1048101 variant of the alpha(1A)-adrenoceptor (ADRA1A) gene was genotyped and it was evaluated whether the Cys to Arg substitution at codon 347 in exon 2 (Cys347Arg) moderated the magnitude of the subjective effects produced by cocaine. Results Thirty (46%) participants were found to have the major allele CC genotype and 35 (44%) carried at least one minor T-allele of rs1048101 (TT or TC genotype). Individuals with the CC genotype showed greater responses for 'desire' (P < 0.0001),'high' (P < 0.0001),'any drug effect' (P < 0.0001), 'like cocaine' (P < 0.0001), and 'likely to use cocaine if given access' (P < 0.05) with experiment-wise significance. Conclusion This study indicates that the ADRA1A genotype could be used to identify individuals for whom acute cocaine exposure may be more rewarding and by inference may result in greater difficulty in establishing and/or maintaining abstinence from cocaine. Copyright (C) 2016 Wolters Kluwer Health, Inc. All rights reserved. C1 [Shorter, Daryl; Nielsen, David A.; Kosten, Thomas R.; Newton, Thomas F.; De La Garza, Richard, II] Baylor Coll Med, Michael E DeBakey VA Med Ctr MEDVAMC, Houston, TX 77030 USA. [Shorter, Daryl; Nielsen, David A.; Nielsen, Ellen M.; Kosten, Thomas R.; Newton, Thomas F.; De La Garza, Richard, II] Baylor Coll Med, Menninger Dept Psychiat & Behav Sci, Houston, TX 77030 USA. [Hamon, Sara C.] Rockefeller Univ, Lab Stat Genet, 1230 York Ave, New York, NY 10021 USA. RP Shorter, D (reprint author), Michael E DeBakey Vet Adm Med Ctr, 2002 Holcombe Blvd,Bldg 121,Off 121-137, Houston, TX 77030 USA. EM shorter@bcm.edu FU United States (US) Department of Veterans Affairs Clinical Sciences Research and Development Service [I01BX007080]; NIH/NIDA through MD Anderson's Cancer Center [P50 DA018197, NIH/NIDA DA026120]; Toomim Family Fund FX D.S. was supported in part by the Career Development Award I01BX007080 from the United States (US) Department of Veterans Affairs Clinical Sciences Research and Development Service. D.A.N., T.R.K., T.F.N., and R.D.L.G. were supported by NIH/NIDA P50 DA018197, through MD Anderson's Cancer Center Support Grant NIH/NIDA DA026120, and the Toomim Family Fund. This material is the result of work supported with resources and the use of facilities at the Michael E. DeBakey VA Medical Center. NR 57 TC 0 Z9 0 U1 2 U2 3 PU LIPPINCOTT WILLIAMS & WILKINS PI PHILADELPHIA PA TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA SN 1744-6872 EI 1744-6880 J9 PHARMACOGENET GENOM JI Pharmacogenet. Genomics PD SEP PY 2016 VL 26 IS 9 BP 428 EP 435 DI 10.1097/FPC.0000000000000234 PG 8 WC Biotechnology & Applied Microbiology; Genetics & Heredity; Pharmacology & Pharmacy SC Biotechnology & Applied Microbiology; Genetics & Heredity; Pharmacology & Pharmacy GA DS5ON UT WOS:000380831700004 PM 27379509 ER PT J AU Wander, PL Enquobahrie, DA Pritchard, CC McKnight, B Rice, K Christiansen, M Lemaitre, RN Rea, T Siscovick, D Sotoodehnia, N AF Wander, P. L. Enquobahrie, D. A. Pritchard, C. C. McKnight, B. Rice, K. Christiansen, M. Lemaitre, R. N. Rea, T. Siscovick, D. Sotoodehnia, N. TI Circulating microRNAs and sudden cardiac arrest outcomes SO RESUSCITATION LA English DT Article DE Cardiac arrest; Outcomes; Epigenetics; microRNAs; Epidemiology ID ACUTE MYOCARDIAL-INFARCTION; TRAUMATIC BRAIN-INJURY; PLASMA; BIOMARKER; DISEASE; MIR-124 AB Aim: MicroRNAs (miRNAs) have regulatory functions in organs critical in resuscitation from sudden cardiac arrest due to ventricular fibrillation (VF-SCA); therefore, circulating miRNAs may be markers of VF-SCA outcome. Methods: We measured candidate miRNAs (N=45) in plasma using qRT-PCR among participants of a population-based VF-SCA study. Participants were randomly selected cases who died in the field (DF, n=15), died in hospital (DH, n=15), or survived to discharge (DC, n=15), and, age-, sex-, and race-matched controls (n=15). MiRNA levels were compared using ANOVA, t-tests, and fold-changes. Results: Mean age of groups ranged from 66.9 to 69.7. Most participants were male (53-67%) and white (67%). Comparing cases to controls, plasma levels of 17 miRNAs expressed in heart, brain, liver, and other tissues (including miR-29c,-34a,-122,-145,-200a,-210,-499-5p, and-663b) were higher and three nonspecific miRNAs lower (miR-221,-330-3p, and-9-5p). Among DH or DC compared with DF cases, levels of two miRNAs (liver-specific miR-122 and non-specific miR-205) were higher and two heart-specific miRNAs (miR-208b and-499-5p) lower. Among DC vs. DF cases, levels of three miRNAs (miR-122, and non-specific miR-200a and-205) were higher and four heart-specific miRNAs (miR-133a,-133b,-208b, and-499-5p) lower. Among DC vs. DH cases, levels of two non-specific miRNAs (miR-135a and-9-3p) were lower. Conclusions: Circulating miRNAs expressed in heart, brain, and other tissues differ between VF-SCA cases and controls and are related to resuscitation outcomes. Measurement of miRNAs may clarify mechanisms underlying resuscitation, improve prognostication, and guide development of therapies. Results require replication. Published by Elsevier Ireland Ltd. C1 [Wander, P. L.; Christiansen, M.; Lemaitre, R. N.; Rea, T.; Sotoodehnia, N.] Univ Washington, Dept Med, Cardiovasc Hlth Res Unit, Seattle, WA USA. [Enquobahrie, D. A.; Sotoodehnia, N.] Univ Washington, Dept Epidemiol, Seattle, WA 98195 USA. [Pritchard, C. C.] Univ Washington, Dept Lab Med, Seattle, WA 98195 USA. [McKnight, B.; Rice, K.] Univ Washington, Dept Biostat, Seattle, WA 98195 USA. [Wander, P. L.] VA Puget Sound Hlth Care Syst, Seattle, WA USA. [Rea, T.] Publ Hlth Seattle & King Cty, Emergency Med Serv Div, Seattle, WA USA. [Siscovick, D.] New York Acad Med, New York, NY USA. [Sotoodehnia, N.] Univ Washington, Dept Med, Div Cardiol, Seattle, WA USA. RP Wander, PL (reprint author), Univ Washington, Dept Med, Div Gen Internal Med, 325 Ninth Ave,Box 359780, Seattle, WA 98104 USA. EM lwander@u.washington.edu OI Wander, Pandora/0000-0003-3671-1464 FU National Institute of Diabetes and Digestive and Kidney Diseases of the National Institutes of Health [K08DK103945]; National Heart, Lung, and Blood Institute [R01-HL091244, R01-HL092111, R01-HL088456, R01-HL111089]; University of Washington Nutrition and Obesity Research Center [P30 DK035816]; Locke Charitable Foundation; Medic One Foundation; Alpha Phi Foundation; Laughlin Family FX Our gratitude to Hye Son Yi, who performed the laboratory assays for this report. Research reported in this manuscript was supported by the National Institute of Diabetes and Digestive and Kidney Diseases of the National Institutes of Health under award number K08DK103945 and grants from the National Heart, Lung, and Blood Institute (R01-HL091244, R01-HL092111, R01-HL088456, R01-HL111089), the University of Washington Nutrition and Obesity Research Center (P30 DK035816), and the Locke Charitable Foundation, the Medic One Foundation, the Alpha Phi Foundation, and the Laughlin Family. The content is solely the responsibility of the authors and does not necessarily represent the official views of the National Institutes of Health. NR 28 TC 0 Z9 0 U1 0 U2 3 PU ELSEVIER IRELAND LTD PI CLARE PA ELSEVIER HOUSE, BROOKVALE PLAZA, EAST PARK SHANNON, CO, CLARE, 00000, IRELAND SN 0300-9572 J9 RESUSCITATION JI Resuscitation PD SEP PY 2016 VL 106 BP 96 EP 101 PG 6 WC Critical Care Medicine; Emergency Medicine SC General & Internal Medicine; Emergency Medicine GA DT7DT UT WOS:000381648000031 PM 27423422 ER PT J AU Ruben, MA Hall, JA AF Ruben, Mollie A. Hall, Judith A. TI Healthcare Providers' Nonverbal Behavior can Lead Patients to Show Their Pain More Accurately: An Analogue Study SO JOURNAL OF NONVERBAL BEHAVIOR LA English DT Article DE Nonverbal expression; Physical pain; Person perception; Interpersonal accuracy; Doctor-patient communication ID FACIAL EXPRESSIONS; COMMUNICATION; EMPATHY; MODEL; PERSONALITY; DECEPTION; PHYSICIAN; JUDGMENT AB Accurate pain assessment is a joint function of both the judge perceiving correct (valid) cues of pain and targets displaying valid indicators of pain. The present research examined whether the judgeability of pain expressions could be altered by manipulating the nonverbal supportiveness of a videotaped physician who guided targets through an experimentally induced pain experience in the laboratory. Ten-s video clips of these targets during their pain experience were viewed by 95 na < ve judges who assessed each target's pain on an 11-point numeric rating scale. In addition, the video clips were rated by independent coders on 9-point scales (focused, calm, tense, distressed, composed, fidgety, determined, bored, and nervous). Judges' pain assessment accuracy was calculated by correlating their inferred pain rating for each target with targets' self-reported pain. Pain targets assigned to interact with the nonverbally supportive physician displayed more valid impressions of their pain and judges had higher pain assessment accuracy when viewing these targets compared to targets assigned to interact with the nonverbally unsupportive physician. Interventions for caregivers and healthcare providers that emphasize the importance of nonverbal behavior when interacting with pain sufferers are discussed. C1 [Ruben, Mollie A.] US Dept Vet Affairs, CHOIR, 150 S Huntington Ave,Bdg 9, Boston, MA 02130 USA. [Hall, Judith A.] Northeastern Univ, Dept Psychol, Boston, MA 02115 USA. RP Ruben, MA (reprint author), US Dept Vet Affairs, CHOIR, 150 S Huntington Ave,Bdg 9, Boston, MA 02130 USA. EM Mollie.Ruben@va.gov NR 39 TC 0 Z9 0 U1 14 U2 14 PU SPRINGER PI NEW YORK PA 233 SPRING ST, NEW YORK, NY 10013 USA SN 0191-5886 EI 1573-3653 J9 J NONVERBAL BEHAV JI J. Nonverbal Behav. PD SEP PY 2016 VL 40 IS 3 BP 221 EP 234 DI 10.1007/s10919-016-0230-3 PG 14 WC Psychology, Social SC Psychology GA DS3JU UT WOS:000380679900004 ER PT J AU Tetrault, JM Tate, JP Edelman, EJ Gordon, AJ Lo Re, V Lim, JK Rimland, D Goulet, J Crystal, S Gaither, JR Gibert, CL Rodriguez-Barradas, MC Fiellin, LE Bryant, K Justice, AC Fiellin, DA AF Tetrault, Jeanette M. Tate, Janet P. Edelman, E. Jennifer Gordon, Adam J. Lo Re, Vincent, III Lim, Joseph K. Rimland, David Goulet, Joseph Crystal, Stephen Gaither, Julie R. Gibert, Cynthia L. Rodriguez-Barradas, Maria C. Fiellin, Lynn E. Bryant, Kendall Justice, Amy C. Fiellin, David A. TI Hepatic Safety of Buprenorphine in HIV-Infected and Uninfected Patients With Opioid Use Disorder: The Role of HCV-Infection SO JOURNAL OF SUBSTANCE ABUSE TREATMENT LA English DT Article DE Buprenorphine; HIV; Hepatitis C; Drug induced liver injury ID LIVER-ENZYME ELEVATION; DEPENDENT PATIENTS; NALOXONE TREATMENT; INDIVIDUALS; THERAPY; HEALTH; TRIAL; RISK AB Introduction: Individuals with HIV and hepatitis C (HCV) infection, alcohol use disorder, or who are prescribed potentially hepatotoxic medications may be at increased risk for buprenorphine (BUP) associated hepatotoxicity. Materials and methods: We examined a cohort of HIV-infected and uninfected patients receiving an initial BUP prescription between 2003 and 2012. We compared changes in alanine and aspartate aminotransferases (ALT and AST) and total bilirubin (TB) stratified by HIV status. We identified cases of liver enzyme elevation (LEE), TB elevation (TBE), and conducted chart review to assess for cases of drug induced liver injury (DILI) and death. We examined associations between age, sex, race, HIV-infection, HCV-infection, alcohol use disorder, and prescription of other potentially heptatotoxic medications with the composite endpoint of LEE, TBE, and DILI. Results: Of 666 patients prescribed BUP, 36% were HIV-infected, 98% were male, 60% had RNA-confirmed HCV infection, 50% had a recent diagnosis of alcohol use disorder, and 64% were prescribed other potentially hepatotoxic medications. No clinically significant changes were observed in median ALT, AST and TB and these changes did not differ between HIV-infected and uninfected patients. Compared with uninfected patients, HIV-infected (OR 73, 95% CI 2.1-26.1, p = 0.002), HCV-infected (OR 4.9 95% CI 1.6-15.2, p = 0.007) or HIV/HCV co-infected patients (OR 6.9, 95%CI 2.1-22.2, p = 0.001) were more likely to have the composite endpoint of LEE, TB elevation or DILI, in analyses that excluded 60 patients with evidence of pre-existing liver injury. 31 patients had LEE, 14/187 HIV-infected and 17/340 uninfected (p = 0.25); 11 had TBE, including 9/186 HIV-infected and 2/329 uninfected (p = 0.002); 8 experienced DILI, 4/202 HIV-infected and 4/204 uninfected (p = 0.45). There were no significant associations with alcohol use disorder or prescription of other potentially hepatotoxic medications after adjustment for HIV/HCV status. Conclusions: Liver enzymes and TB are rarely elevated in HIV-infected and uninfected patients receiving BUP. Risk of hepatotoxicity was greater in individuals infected with HIV, HCV, or HIV/HCV co-infection, who may benefit from increased monitoring. (C) 2016 Elsevier Inc. All rights reserved. C1 [Tetrault, Jeanette M.; Tate, Janet P.; Edelman, E. Jennifer; Lim, Joseph K.; Fiellin, Lynn E.; Justice, Amy C.; Fiellin, David A.] Yale Univ, Sch Med, Dept Internal Med, New Haven, CT 06510 USA. [Tate, Janet P.; Lim, Joseph K.; Justice, Amy C.] VA Connecticut Hlth Care Syst, West Haven, CT USA. [Gordon, Adam J.] VA Pittsburgh Healthcare Syst, Pittsburgh, PA USA. [Gordon, Adam J.] Univ Pittsburgh, Pittsburgh, PA USA. [Lo Re, Vincent, III] Univ Penn, Sch Med, Philadelphia, PA 19104 USA. [Rimland, David] VA Med Ctr, Atlanta, GA USA. [Rimland, David] Emory Univ, Sch Med, Atlanta, GA USA. [Goulet, Joseph] Yale Univ, Sch Med, Dept Psychiat, New Haven, CT USA. [Crystal, Stephen] Rutgers State Univ, Inst Hlth, Ctr Hlth Serv Res, New Brunswick, NJ USA. [Gaither, Julie R.; Justice, Amy C.; Fiellin, David A.] Yale Univ, Sch Publ Hlth, Ctr Interdisciplinary Res AIDS, New Haven, CT USA. [Gibert, Cynthia L.] VA Med Ctr, Washington, DC USA. [Gibert, Cynthia L.] George Washington Univ, Sch Med & Hlth Sci, Washington, DC 20052 USA. [Rodriguez-Barradas, Maria C.] Michael E DeBakey VA Med Ctr, Houston, TX USA. [Rodriguez-Barradas, Maria C.] Baylor Coll, Sch Med, Houston, TX USA. [Bryant, Kendall] NIAAA, Bethesda, MD USA. RP Tetrault, JM (reprint author), 367 Cedar St,Suite 305, New Haven, CT 06510 USA. EM jeanette.tetrault@yale.edu OI Fiellin, David/0000-0002-4006-010X; Goulet, Joseph/0000-0002-0842-804X FU Department of Veterans Affairs, Veterans Health Administration, and Office of Research and Development; [U10 AA013566]; [U24 AA020794]; [U01 AA020790]; [U19 HS021112]; [R01 HS018372] FX This material is based upon work supported by the Department of Veterans Affairs, Veterans Health Administration, and Office of Research and Development We must disclaim that the views expressed in this article are those of the authors and do not necessarily reflect the position or policy of the Department of Veterans Affairs.; Supported by. U10 AA013566, U24 AA020794, U01 AA020790, U19 HS021112, R01 HS018372 NR 25 TC 0 Z9 0 U1 0 U2 0 PU PERGAMON-ELSEVIER SCIENCE LTD PI OXFORD PA THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, ENGLAND SN 0740-5472 J9 J SUBST ABUSE TREAT JI J. Subst. Abus. Treat. PD SEP PY 2016 VL 68 BP 62 EP 67 DI 10.1016/j.jsat.2016.06.002 PG 6 WC Psychology, Clinical; Substance Abuse SC Psychology; Substance Abuse GA DS2GB UT WOS:000380579300008 PM 27431048 ER PT J AU Rozanova, J Noulas, P Smart, K Roy, A Southwick, SM Davidson, L Harpaz-Rotem, I AF Rozanova, Julia Noulas, Paraskevi Smart, Kathleen Roy, Alicia Southwick, Steven M. Davidson, Larry Harpaz-Rotem, Ilan TI "I'm Coming Home, Tell the World I'm Coming Home". The Long Homecoming and Mental Health Treatment of Iraq and Afghanistan War Veterans SO PSYCHIATRIC QUARTERLY LA English DT Article DE Young US veterans; Mental healthcare resistance; Qualitative interviews; Sense of identity; Pragmatic career-building goals ID MILITARY PERSONNEL; PERCEIVED BARRIERS; CARE; STIGMA; RISK; HOMELESSNESS; ACCOUNTS AB This study explored the journey of American armed forces personnel from their decision to join the service, through their service in an active military conflict and how these factors may be associated with potential resistance for mental healthcare. The data came from qualitative interviews with 46 OIF/OEF/OND active-duty military, reservists, and discharged veterans of the average age of 25 years, who presented for a new episode of mental health treatment to a large Veterans Affairs Hospital (VAH) in Northeastern United States in 2011-2012. Qualitative analysis of veterans' perceptions revealed several major themes describing how a mental health diagnosis would negatively impact both their sense of identity and pragmatic career-building goals: enlisting as a career-building avenue, 'noble superhero' identity, escaping from hardship, and mental illness as a career-killer. Findings suggest that factors making young veterans resist mental healthcare may be reduced by partnering VAH psychiatrists with career counselors, and by enhancing military leadership's awareness and understanding about how to support soldiers with emotional and mental health needs, with a goal to eliminating stigma. C1 [Rozanova, Julia] Yale Sch Med, Dept Internal Med, 135 Coll St Suite 351, New Haven, CT 06510 USA. [Noulas, Paraskevi; Smart, Kathleen; Roy, Alicia] VA Connecticut Healthcare Syst, 950 Campbell Ave, West Haven, CT 06516 USA. [Roy, Alicia; Southwick, Steven M.; Davidson, Larry; Harpaz-Rotem, Ilan] US Dept Vet Affairs, Natl Ctr Posttraumat Stress Disorder, 950 Campbell Ave, West Haven, CT 06516 USA. [Southwick, Steven M.; Harpaz-Rotem, Ilan] Yale Sch Med, Dept Psychiat, 300 George St,Suite 901, New Haven, CT 06511 USA. [Davidson, Larry] Yale Program Recovery & Community Hlth, 319 Peck St,Bldg 1, New Haven, CT 06513 USA. RP Rozanova, J (reprint author), Yale Sch Med, Dept Internal Med, 135 Coll St Suite 351, New Haven, CT 06510 USA. EM julia.rozanova@yale.edu; Paraskevi.Noulas2@va.gov; steven.southwick@yale.edu; larry.davidson@yale.edu; ilan.harpaz-rotem@yale.edu FU Department of Veterans Affairs (VA) Health Services Research & Development (HSRD) [PPO-09-265-1] FX Funding for this research was available through a Department of Veterans Affairs (VA) Health Services Research & Development (HSR&D) Merit Review award PPO-09-265-1 awarded to the senior author. The views presented here are those of the authors and do not represent the position of any federal agency or of the United States Government. NR 37 TC 0 Z9 0 U1 14 U2 14 PU SPRINGER PI NEW YORK PA 233 SPRING ST, NEW YORK, NY 10013 USA SN 0033-2720 EI 1573-6709 J9 PSYCHIAT QUART JI Psychiatr. Q. PD SEP PY 2016 VL 87 IS 3 BP 427 EP 443 DI 10.1007/s11126-015-9398-7 PG 17 WC Psychiatry SC Psychiatry GA DR6IL UT WOS:000380005500005 PM 26566926 ER PT J AU Smucny, J Olincy, A Tregellas, JR AF Smucny, Jason Olincy, Ann Tregellas, Jason R. TI Nicotine restores functional connectivity of the ventral attention network in schizophrenia SO NEUROPHARMACOLOGY LA English DT Article DE Attention; Connectivity; fMRI; Nicotine; Schizophrenia; Ventral attention network ID AUDITORY SELECTIVE ATTENTION; PURSUIT EYE-MOVEMENT; BRAIN NETWORKS; PSYCHOPHYSIOLOGICAL INTERACTIONS; HEMODYNAMIC-RESPONSE; TRANSDERMAL NICOTINE; LEVEL METAANALYSIS; STIMULUS; FMRI; NONSMOKERS AB While previous work has suggested that nicotine may transiently improve attention deficits in schizophrenia, the neuronal mechanisms are poorly understood. This study is the first to examine the effects of nicotine on connectivity within the ventral attention network (VAN) during a selective attention task in schizophrenia. Using a crossover design, 17 nonsmoking patients with schizophrenia and 20 age/gender-matched nonsmoking healthy controls performed a go/no-go task with environmental noise distractors during application of a 7 mg nicotine or placebo patch. Psychophysiological interaction analysis was performed to analyze task-associated changes in connectivity between a ventral parietal cortex (VPC) seed and the inferior frontal gyrus (IFG), key components of the human VAN. Effects of nicotine on resting state VAN connectivity were also examined. A significant diagnosis x drug interaction was observed on task-associated connectivity between the VPC seed and the left IFG (F(1,35) = 8.03, p < 0.01). This effect was driven by decreased connectivity after placebo in patients and greater connectivity after nicotine. Resting state connectivity analysis showed a significant main effect of diagnosis between the seed and right IFG (F = 4.25, p = 0.023) due to increased connectivity in patients during placebo, but no drug x diagnosis interactions or main effects of drug. This study is the first to demonstrate that 1) the VAN is disconnected in schizophrenia during selective attention, and 2) nicotine may normalize this pathological state. (C) 2016 Elsevier Ltd. All rights reserved. C1 [Smucny, Jason; Tregellas, Jason R.] Univ Colorado Anschutz Med Campus, Neurosci Program, Aurora, CO 80045 USA. [Olincy, Ann; Tregellas, Jason R.] Denver VA Med Ctr, Res Serv, Denver, CO 80220 USA. [Smucny, Jason; Olincy, Ann; Tregellas, Jason R.] Univ Colorado Anschutz Med Campus, Dept Psychiat, Aurora, CO 80045 USA. RP Smucny, J (reprint author), Univ Colorado Anschutz Med Campus, Dept Psychiat, Aurora, CO 80045 USA. EM Jason.smucny@ucdenver.edu OI Smucny, Jason/0000-0001-5656-7987 FU VA Biomedical Laboratory and Clinical Science Research and Development Service [CX000459]; Brain and Behavior Research Foundation; NIH [MH-089095, DK-103691, MH-102224]; NIH fellowship [MH-102879] FX This work was supported by the VA Biomedical Laboratory and Clinical Science Research and Development Service grant CX000459 (grant to Dr. Tregellas), the Brain and Behavior Research Foundation (grant to Dr. Tregellas), NIH grants MH-089095, DK-103691, MH-102224 (grants to Dr. Tregellas), and NIH fellowship MH-102879 (grant to Mr. Smucny). NR 62 TC 2 Z9 2 U1 5 U2 13 PU PERGAMON-ELSEVIER SCIENCE LTD PI OXFORD PA THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, ENGLAND SN 0028-3908 EI 1873-7064 J9 NEUROPHARMACOLOGY JI Neuropharmacology PD SEP PY 2016 VL 108 BP 144 EP 151 DI 10.1016/j.neuropharm.2016.04.015 PG 8 WC Neurosciences; Pharmacology & Pharmacy SC Neurosciences & Neurology; Pharmacology & Pharmacy GA DQ1IA UT WOS:000378953500015 PM 27085606 ER PT J AU Kuffer, AL O'Donovan, A Burri, A Maercker, A AF Kuffer, Andreas Lorenz O'Donovan, Aoife Burri, Andrea Maercker, Andreas TI Posttraumatic Stress Disorder, Adverse Childhood Events, and Buccal Cell Telomere Length in Elderly Swiss Former Indentured Child Laborers SO FRONTIERS IN PSYCHIATRY LA English DT Article DE PTSD; adverse childhood events; old adults; buccal cell telomere length; qPCR; Swiss indentured child laborers ID TRAUMA QUESTIONNAIRE; GERIATRIC DEPRESSION; GERMAN VERSION; RELIABILITY; VALIDITY; MORTALITY; SYNCHRONY; VETERANS; DISEASE; HEALTH AB Posttraumatic stress disorder (PTSD) is associated with increased risk for age-related diseases and early mortality. Accelerated biological aging could contribute to this elevated risk. The aim of the present study was to assess buccal cell telomere length (BTL) - a proposed marker of biological age - in men and women with and without PTSD. The role of childhood trauma was assessed as a potential additional risk factor for shorter telomere length. The sample included 62 former indentured Swiss child laborers (age: M = 76.19, SD = 6.18) and 58 healthy controls (age: M = 71.85, SD = 5.97). Structured clinical interviews were conducted to screen for PTSD and other psychiatric disorders. The Childhood Trauma Questionnaire (CTQ) was used to assess childhood trauma exposure. Quantitative polymerase chain reaction was used to measure BTL. Covariates include age, sex, years of education, self-evaluated financial situation, depression, and mental and physical functioning. Forty-eight (77.42%) of the former indentured child laborers screened positive for childhood trauma, and 21 (33.87%) had partial or full-blown PTSD. Results did not support our hypotheses that PTSD and childhood trauma would be associated with shorter BTL. In fact, results revealed a trend toward longer BTL in participants with partial or full PTSD [F(2,109) = 3.27, p = 0.04, eta(2) = 0.06], and longer BTL was marginally associated with higher CTQ scores (age adjusted: beta = 0.17 [95% CI: - 0.01 to 0.35], t = 1.90, p = 0.06). Furthermore, within- group analyses indicated no significant association between BTL and CTQ scores. To the best of our knowledge, this is the first study exploring the association between childhood trauma and BTL in older individuals with and without PTSD. Contrary to predictions, there were no significant differences in BTL between participants with and without PTSD in our adjusted analyses, and childhood adversity was not associated with BTL. Possible explanations and future research possibilities are discussed. C1 [Kuffer, Andreas Lorenz; Maercker, Andreas] Univ Zurich, Dept Psychol, Div Psychopathol & Clin Intervent, Zurich, Switzerland. [Kuffer, Andreas Lorenz; Maercker, Andreas] Univ Zurich, Univ Res Prior Program Dynam Hlth Aging, Zurich, Switzerland. [Kuffer, Andreas Lorenz; O'Donovan, Aoife] Univ Calif San Francisco, Dept Psychiat, San Francisco, CA 94143 USA. [Kuffer, Andreas Lorenz; O'Donovan, Aoife] San Francisco VA Med Ctr, San Francisco, CA 94121 USA. [Burri, Andrea] Auckland Univ Technol, Hlth & Rehabil Res Inst, Auckland, New Zealand. [Burri, Andrea] North Shore Hosp, Dept Anaesthesia & Perioperat Med, Waitemata Pain Serv, Auckland, New Zealand. RP Kuffer, AL (reprint author), Univ Zurich, Dept Psychol, Div Psychopathol & Clin Intervent, Zurich, Switzerland.; Kuffer, AL (reprint author), Univ Zurich, Univ Res Prior Program Dynam Hlth Aging, Zurich, Switzerland.; Kuffer, AL (reprint author), Univ Calif San Francisco, Dept Psychiat, San Francisco, CA 94143 USA.; Kuffer, AL (reprint author), San Francisco VA Med Ctr, San Francisco, CA 94121 USA. EM andreas.kueffer@ucsf.edu FU NCATS NIH HHS [KL2 TR000143]; NIMH NIH HHS [K01 MH109871] NR 52 TC 1 Z9 1 U1 5 U2 7 PU FRONTIERS MEDIA SA PI LAUSANNE PA PO BOX 110, EPFL INNOVATION PARK, BUILDING I, LAUSANNE, 1015, SWITZERLAND SN 1664-0640 J9 FRONT PSYCHIATRY JI Front. Psychiatry PD AUG 31 PY 2016 VL 7 AR 147 DI 10.3389/fpsyt.2016.00147 PG 9 WC Psychiatry SC Psychiatry GA DU5YW UT WOS:000382290600001 PM 27630582 ER PT J AU Du, PC Sohaskey, CD Shi, LB AF Du, Peicheng Sohaskey, Charles D. Shi, Lanbo TI Transcriptional and Physiological Changes during Mycobacterium tuberculosis Reactivation from Non-replicating Persistence SO FRONTIERS IN MICROBIOLOGY LA English DT Article DE tuberculosis; gene expression profiling; RNA-Seq; reactivation; lag phase; metabolism and physiology; transcription regulon/subnetwork ID SIGNAL-TRANSDUCTION SYSTEM; ALTERNATIVE SIGMA-FACTOR; GLOBAL GENE-EXPRESSION; IRON ACQUISITION; IN-VITRO; LATENT TUBERCULOSIS; CRYSTAL-STRUCTURE; HYPOXIC RESPONSE; NITRIC-OXIDE; DNA-REPAIR AB Mycobacterium tuberculosis can persist for years in the hostile environment of the host in a non-replicating or slowly replicating state. While active disease predominantly results from reactivation of a latent infection, the molecular mechanisms of M. tuberculosis reactivation are still poorly understood. We characterized the physiology and global transcriptomic profiles of M. tuberculosis during reactivation from hypoxia-induced non-replicating persistence. We found that M. tuberculosis reactivation upon reaeration was associated with a lag phase, in which the recovery of cellular physiological and metabolic functions preceded the resumption of cell replication. Enrichment analysis of the transcriptomic dynamics revealed changes to many metabolic pathways and transcription regulons/subnetworks that orchestrated the metabolic and physiological transformation in preparation for cell division. In particular, we found that M. tuberculosis reaeration lag phase is associated with down-regulation of persistence-associated regulons/subnetworks, including DosR, MprA, SigH, SigE, and CIgR, as well as metabolic pathways including those involved in the uptake of lipids and their catabolism. More importantly, we identified a number of up-regulated transcription regulons and metabolic pathways, including those involved in metal transport and remobilization, second messenger-mediated responses, DNA repair and recombination, and synthesis of major cell wall components. We also found that inactivation of the major alternative sigma factors SigE or SigH disrupted exit from persistence, underscoring the importance of the global transcriptional reprogramming during M. tuberculosis reactivation. Our observations suggest that M. tuberculosis lag phase is associated with a global gene expression reprogramming that defines the initiation of a reactivation process. C1 [Du, Peicheng] Rutgers State Univ, Off Adv Res Comp, New Brunswick, NJ USA. [Sohaskey, Charles D.] US Dept Vet Affairs, VA Long Beach Healthcare Syst, Long Beach, CA USA. [Shi, Lanbo] Rutgers State Univ, New Jersey Med Sch, Publ Hlth Res Inst, Newark, NJ 08901 USA. RP Shi, LB (reprint author), Rutgers State Univ, New Jersey Med Sch, Publ Hlth Res Inst, Newark, NJ 08901 USA. EM shila@njms.rutgers.edu FU National Institutes of Health [AI090328A, AI083855Z] FX We thank Erika Shor for commenting and editing the manuscript and Pratik Datta for critical reading of the manuscript. The work was supported by National Institutes of Health Grants AI090328A and AI083855Z to LS. NR 85 TC 0 Z9 0 U1 5 U2 9 PU FRONTIERS MEDIA SA PI LAUSANNE PA PO BOX 110, EPFL INNOVATION PARK, BUILDING I, LAUSANNE, 1015, SWITZERLAND SN 1664-302X J9 FRONT MICROBIOL JI Front. Microbiol. PD AUG 31 PY 2016 VL 7 AR 1346 DI 10.3389/fmicb.2016.01346 PG 15 WC Microbiology SC Microbiology GA DU5QO UT WOS:000382266600001 PM 27630619 ER PT J AU Kantarci, K Tosakulwong, N Lesnick, TG Zuk, SM Gunter, JL Gleason, CE Wharton, W Dowling, NM Vemuri, P Senjem, ML Shuster, LT Bailey, KR Rocca, WA Jack, CR Asthana, S Miller, VM AF Kantarci, Kejal Tosakulwong, Nirubol Lesnick, Timothy G. Zuk, Samantha M. Gunter, Jeffrey L. Gleason, Carey E. Wharton, Whitney Dowling, N. Maritza Vemuri, Prashanthi Senjem, Matthew L. Shuster, Lynne T. Bailey, Kent R. Rocca, Walter A. Jack, Clifford R., Jr. Asthana, Sanjay Miller, Virginia M. TI Effects of hormone therapy on brain structure A randomized controlled trial SO NEUROLOGY LA English DT Article ID WHITE-MATTER HYPERINTENSITIES; ESTROGEN REPLACEMENT THERAPY; CONJUGATED EQUINE ESTROGENS; POSTMENOPAUSAL WOMEN; ALZHEIMER-DISEASE; MENOPAUSAL WOMEN; MENSTRUAL-CYCLE; OLDER WOMEN; WHIMS-MRI; VOLUMES AB Objective: To investigate the effects of hormone therapy on brain structure in a randomized, double-blinded, placebo-controlled trial in recently postmenopausal women. Methods: Participants (aged 42-56 years, within 5-36 months past menopause) in the Kronos Early Estrogen Prevention Study were randomized to (1) 0.45 mg/d oral conjugated equine estrogens (CEE), (2) 50 mu g/d transdermal 17 beta-estradiol, or (3) placebo pills and patch for 48 months. Oral progesterone (200 mg/d) was given to active treatment groups for 12 days each month. MRI and cognitive testing were performed in a subset of participants at baseline, and at 18, 36, and 48 months of randomization (n = 95). Changes in whole brain, ventricular, and white matter hyperintensity volumes, and in global cognitive function, were measured. Results: Higher rates of ventricular expansion were observed in both the CEE and the 17b-estradiol groups compared to placebo; however, the difference was significant only in the CEE group (p = 0.01). Rates of ventricular expansion correlated with rates of decrease in brain volume (r = -0.58; p <= 0.001) and with rates of increase in white matter hyperintensity volume (r = 0.27; p = 0.01) after adjusting for age. The changes were not different between the CEE and 17 beta-estradiol groups for any of the MRI measures. The change in global cognitive function was not different across the groups. Conclusions: Ventricular volumes increased to a greater extent in recently menopausal women who received CEE compared to placebo but without changes in cognitive performance. Because the sample size was small and the follow-up limited to 4 years, the findings should be interpreted with caution and need confirmation. Classification of evidence: This study provides Class I evidence that brain ventricular volume increased to a greater extent in recently menopausal women who received oral CEE compared to placebo. C1 [Kantarci, Kejal; Zuk, Samantha M.; Gunter, Jeffrey L.; Vemuri, Prashanthi; Senjem, Matthew L.; Jack, Clifford R., Jr.] Mayo Clin, Dept Radiol, Rochester, MN USA. [Tosakulwong, Nirubol; Lesnick, Timothy G.; Bailey, Kent R.; Rocca, Walter A.] Mayo Clin, Dept Hlth Sci Res, Rochester, MN USA. [Shuster, Lynne T.] Mayo Clin, Dept Internal Med, Rochester, MN USA. [Rocca, Walter A.] Mayo Clin, Dept Neurol, Rochester, MN USA. [Miller, Virginia M.] Mayo Clin, Dept Surg & Physiol & Biomed Engn, Rochester, MN USA. [Gleason, Carey E.; Asthana, Sanjay] Univ Wisconsin, Dept Med, Sch Med & Publ Hlth, Madison, WI USA. William S Middleton Mem Vet Adm Med Ctr, Geriatr Res Educ & Clin Ctr, Madison, WI USA. [Wharton, Whitney] Emory Univ, Dept Neurol, Atlanta, GA 30322 USA. [Dowling, N. Maritza] Univ Wisconsin, Dept Biostat & Med Informat, Madison, WI USA. RP Kantarci, K (reprint author), Mayo Clin, Dept Radiol, Rochester, MN USA. EM kantarci.kejal@mayo.edu FU Aurora Foundation [NS66147, AG029624, AG44170] FX This study is funded by the Aurora Foundation to the Kronos Longevity Research Institute and the NIH (NS66147, AG029624, and AG44170). The funding sources had no role in study design, collection, analysis, interpretation, or decision to submit this paper. The corresponding author had full access to all the data in the study and had final responsibility for the decision to submit for publication. NR 38 TC 4 Z9 4 U1 2 U2 2 PU LIPPINCOTT WILLIAMS & WILKINS PI PHILADELPHIA PA TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA SN 0028-3878 EI 1526-632X J9 NEUROLOGY JI Neurology PD AUG 30 PY 2016 VL 87 IS 9 BP 887 EP 896 DI 10.1212/WNL.0000000000002970 PG 10 WC Clinical Neurology SC Neurosciences & Neurology GA DW9LJ UT WOS:000383980600013 PM 27473135 ER PT J AU Hirsch, J Vacas, S Terrando, N Yuan, M Sands, LP Kramer, J Bozic, K Maze, MM Leung, JM AF Hirsch, Jan Vacas, Susana Terrando, Niccolo Yuan, Miao Sands, Laura P. Kramer, Joel Bozic, Kevin Maze, Mervyn M. Leung, Jacqueline M. TI Perioperative cerebrospinal fluid and plasma inflammatory markers after orthopedic surgery SO JOURNAL OF NEUROINFLAMMATION LA English DT Article DE Blood-brain barrier; Surgery; Delirium; Immune response ID POSTOPERATIVE COGNITIVE DYSFUNCTION; NON-NEUROLOGICAL SURGERY; MARROW-DERIVED MACROPHAGES; TOTAL KNEE ARTHROPLASTY; CENTRAL-NERVOUS-SYSTEM; HIP-FRACTURE; CYTOKINE PRODUCTION; FEMUR FRACTURE; RATING-SCALE; DELIRIUM AB Background: Postoperative delirium is prevalent in older patients and associated with worse outcomes. Recent data in animal studies demonstrate increases in inflammatory markers in plasma and cerebrospinal fluid (CSF) even after aseptic surgery, suggesting that inflammation of the central nervous system may be part of the pathogenesis of postoperative cognitive changes. We investigated the hypothesis that neuroinflammation was an important cause for postoperative delirium and cognitive dysfunction after major non-cardiac surgery. Methods: After Institutional Review Board approval and informed consent, we recruited patients undergoing major knee surgery who received spinal anesthesia and femoral nerve block with intravenous sedation. All patients had an indwelling spinal catheter placed at the time of spinal anesthesia that was left in place for up to 24 h. Plasma and CSF samples were collected preoperatively and at 3, 6, and 18 h postoperatively. Cytokine levels were measured using ELISA and Luminex. Postoperative delirium was determined using the confusion assessment method, and cognitive dysfunction was measured using validated cognitive tests (word list, verbal fluency test, digit symbol test). Results: Ten patients with complete datasets were included. One patient developed postoperative delirium, and six patients developed postoperative cognitive dysfunction. Postoperatively, at different time points, statistically significant changes compared to baseline were present in IL-5, IL-6, I-8, IL-10, monocyte chemotactic protein (MCP)-1, macrophage inflammatory protein (MIP)-1 alpha, IL-6/IL-10, and receptor for advanced glycation end products in plasma and in IFN-gamma, IL-6, IL-8, IL-10, MCP-1, MIP-1 alpha, MIP-1 beta, IL-8/IL-10, and TNF-alpha in CSF. Conclusions: Substantial pro-and anti-inflammatory activity in the central neural system after surgery was found. If confirmed by larger studies, persistent changes in cytokine levels may serve as biomarkers for novel clinical trials. C1 [Hirsch, Jan; Vacas, Susana; Terrando, Niccolo; Maze, Mervyn M.; Leung, Jacqueline M.] Univ Calif San Francisco, Dept Anesthesia & Perioperat Care, 521 Parnassus Ave, San Francisco, CA 94143 USA. [Hirsch, Jan] San Francisco VA Med Ctr, Anesthesia Serv, Mail 129,4150 Clement St, San Francisco, CA 94121 USA. [Yuan, Miao; Sands, Laura P.] Virginia Tech Univ, Ctr Gerontol, 230 Grove Lane,0555, Blacksburg, VA 24061 USA. [Kramer, Joel] Univ Calif San Francisco, Dept Neurol, Memory & Aging Ctr, 1500 Owens St 320, San Francisco, CA 94158 USA. [Bozic, Kevin] Univ Calif San Francisco, Dept Orthoped Surg, 500 Parnassus Ave,MU 320W, San Francisco, CA 94143 USA. RP Hirsch, J (reprint author), Univ Calif San Francisco, Dept Anesthesia & Perioperat Care, 521 Parnassus Ave, San Francisco, CA 94143 USA.; Hirsch, J (reprint author), San Francisco VA Med Ctr, Anesthesia Serv, Mail 129,4150 Clement St, San Francisco, CA 94121 USA. EM jan.hirsch@ucsf.edu RI Sands, Laura/E-8919-2015 OI Sands, Laura/0000-0003-2446-4486 FU National Institutes of Health of the United States [NIH 1RO1AG031795-05, NIH 1R01 GM104194] FX This manuscript received funding from the National Institutes of Health of the United States (NIH 1RO1AG031795-05 to JL and NIH 1R01 GM104194 to MM). NR 63 TC 1 Z9 1 U1 5 U2 9 PU BIOMED CENTRAL LTD PI LONDON PA 236 GRAYS INN RD, FLOOR 6, LONDON WC1X 8HL, ENGLAND SN 1742-2094 J9 J NEUROINFLAMM JI J. Neuroinflamm. PD AUG 30 PY 2016 VL 13 AR 211 DI 10.1186/s12974-016-0681-9 PG 12 WC Immunology; Neurosciences SC Immunology; Neurosciences & Neurology GA DV4ET UT WOS:000382878900003 PM 27577265 ER PT J AU Baenninger, A Hernandez, LD Rieger, K Ford, JM Kottlow, M Koenig, T AF Baenninger, Anja Hernandez, Laura Diaz Rieger, Kathryn Ford, Judith M. Kottlow, Mara Koenig, Thomas TI inefficient Preparatory fMri-BoLD network Activations Predict Working Memory Dysfunctions in Patients with Schizophrenia (vol 7, 29, 2016) SO FRONTIERS IN PSYCHIATRY LA English DT Correction DE schizophrenia; working memory; temporally coherent networks; state-dependent information processing; simultaneous EEG-fMRI; covariance mapping C1 [Baenninger, Anja; Hernandez, Laura Diaz; Kottlow, Mara; Koenig, Thomas] Univ Bern, Univ Hosp Psychiat & Psychotherapy, Translat Res Ctr, Bern, Switzerland. [Baenninger, Anja; Ford, Judith M.] San Francisco VA Med Ctr, San Francisco, CA 94121 USA. [Hernandez, Laura Diaz; Rieger, Kathryn; Kottlow, Mara; Koenig, Thomas] Univ Bern, Ctr Cognit Learning & Memory, Bern, Switzerland. [Ford, Judith M.] Univ Calif San Francisco, Dept Psychiat, San Francisco, CA USA. RP Baenninger, A (reprint author), Univ Bern, Univ Hosp Psychiat & Psychotherapy, Translat Res Ctr, Bern, Switzerland.; Baenninger, A (reprint author), San Francisco VA Med Ctr, San Francisco, CA 94121 USA. EM anja.baenninger@puk.unibe.ch NR 1 TC 0 Z9 0 U1 3 U2 3 PU FRONTIERS MEDIA SA PI LAUSANNE PA PO BOX 110, EPFL INNOVATION PARK, BUILDING I, LAUSANNE, 1015, SWITZERLAND SN 1664-0640 J9 FRONT PSYCHIATRY JI Front. Psychiatry PD AUG 29 PY 2016 VL 7 AR 141 DI 10.3389/fpsyt.2016.00141 PG 3 WC Psychiatry SC Psychiatry GA DU1UH UT WOS:000381994800001 PM 27582711 ER PT J AU Choby, JE Skaar, EP AF Choby, Jacob E. Skaar, Eric P. TI Heme Synthesis and Acquisition in Bacterial Pathogens SO JOURNAL OF MOLECULAR BIOLOGY LA English DT Article DE iron uptake; hemoglobin; Isd system; heme toxicity; NEAT domain ID NONTYPABLE HAEMOPHILUS-INFLUENZAE; TRANSFER-RNA REDUCTASE; STAPHYLOCOCCUS-AUREUS HEME; DELTA-AMINOLEVULINIC-ACID; OUTER-MEMBRANE PROTEIN; GROUP-A STREPTOCOCCUS; SMALL-COLONY VARIANTS; HAPTOGLOBIN BINDING-PROTEINS; SHIGELLA-DYSENTERIAE SHUS; DETERMINANT ISD PROTEINS AB Bacterial pathogens require the iron-containing cofactor heme to cause disease. Heme is essential to the function of hemoproteins, which are involved in energy generation by the electron transport chain, detoxification of host immune effectors, and other processes. During infection, bacterial pathogens must synthesize heme or acquire heme from the host; however, host heme is sequestered in high-affinity hemoproteins. Pathogens have evolved elaborate strategies to acquire heme from host sources, particularly hemoglobin, and both heme acquisition and synthesis are important for pathogenesis. Paradoxically, excess heme is toxic to bacteria and pathogens must rely on heme detoxification strategies. Heme is a key nutrient in the struggle for survival between host and pathogen, and its study has offered significant insight into the molecular mechanisms of bacterial pathogenesis. (C) 2016 Elsevier Ltd. All rights reserved. C1 [Choby, Jacob E.; Skaar, Eric P.] Vanderbilt Univ, Sch Med, Dept Pathol Microbiol & Immunol, 1161 21st Ave S, Nashville, TN 37212 USA. [Skaar, Eric P.] US Dept Vet Affairs, Tennessee Valley Healthcare Syst, Nashville, TN 37203 USA. RP Skaar, EP (reprint author), Vanderbilt Univ, Sch Med, Dept Pathol Microbiol & Immunol, 1161 21st Ave S, Nashville, TN 37212 USA.; Skaar, EP (reprint author), US Dept Vet Affairs, Tennessee Valley Healthcare Syst, Nashville, TN 37203 USA. EM eric.skaar@vanderbilt.edu FU NIH [T32 GM065086, AI069233, AI073843] FX We thank members of the Skaar laboratory for critical review of this manuscript. J.E.C. is supported by NIH T32 GM065086. Heme acquisition, synthesis, and toxicity research in the Skaar laboratory is supported by NIH grants AI069233 and AI073843. NR 246 TC 6 Z9 6 U1 8 U2 8 PU ACADEMIC PRESS LTD- ELSEVIER SCIENCE LTD PI LONDON PA 24-28 OVAL RD, LONDON NW1 7DX, ENGLAND SN 0022-2836 EI 1089-8638 J9 J MOL BIOL JI J. Mol. Biol. PD AUG 28 PY 2016 VL 428 IS 17 SI SI BP 3408 EP 3428 DI 10.1016/j.jmb.2016.03.018 PG 21 WC Biochemistry & Molecular Biology SC Biochemistry & Molecular Biology GA DW0FD UT WOS:000383315400006 PM 27019298 ER PT J AU Hightower, CD Hightower, LS Tatman, PJ Morgan, PM Gioe, T Singh, JA AF Hightower, Charles D. Hightower, Lisa S. Tatman, Penny J. Morgan, Patrick M. Gioe, Terence Singh, Jasvinder A. TI How often is the office visit needed? Predicting total knee arthroplasty revision risk using pain/function scores SO BMC HEALTH SERVICES RESEARCH LA English DT Article DE Total knee arthroplasty; TKA; Revision risk; Pain; Function; American Knee Society Scores; AKS scores ID TOTAL JOINT REPLACEMENT; CLINICAL RATING SYSTEM; OUTPATIENT FOLLOW-UP; TOTAL HIP; UNITED-STATES; OXFORD HIP; ASSOCIATION; POPULATION; DEMAND; LONG AB Background: Most patients have favorable outcomes after primary total knee arthroplasty (TKA). Well-validated methods to predict the risk of poor outcomes have not been developed or implemented. Several patients have annual clinic visits despite well-funcitoning TKA, as a routine practice, to detect early failure requiring revision surgery. It is not known whether assessment of pain and function can be used as a predictive tool for early failure and revision to guide practice. Our objective was to determine whether pain and function can predict revision after TKA. Methods: We retrospectively studied data from a large prospectively gathered TKA registry to examine changes in outcome scores for primary TKAs undergoing revision compared to those not requiring revision to determine the factors that are predictive for revision. Results: Of the 1,012 patients, 721 had had a single-sided primary TKA and had American Knee Society (AKS) Scores for three or more visits. 46 patients underwent revision, 23 acutely (fracture, traumatic component failure or acute infection) and 23 for latent causes (late implant loosening, progressive osteolysis, or pain and indolent infection). Mean age was 70 years for the non-revision patients, and 64 years for those revised. Both AKS Clinical and AKS Function Scores for non-revised patients were higher than in revision patients, higher in acute revision compared to latent revision patients. Significant predictors of revision surgery were preoperative, 3- and 15-month postoperative AKS Clinical Scores and 3-month AKS Function Scores. At 15-month post-TKA, a patient with a low calculated probability of revision, 32 % or less, was unlikely to require revision surgery with a negative predictive value of 99 %. Conclusion: Time dependent interval evaluation post-TKA with the AKS outcome scores may provide the ability to assign risk of revision to patients at the 15-month follow-up visit. If these findings can be replicated using a patient-reported measure, a virtual follow-up with patient-reported outcomes and X-ray review may be an alternative to clinic visit for patients doing well. C1 [Hightower, Charles D.] Alaska Native Med Ctr, Anchorage, AK USA. [Hightower, Lisa S.] Virginia Tech, Dept Agr & Extens Educ, Blacksburg, VA USA. [Tatman, Penny J.] Hlth East Educ & Res Dept, St Paul, MN USA. [Morgan, Patrick M.] Univ MN, Dept Orthopaed Surg, Sch Med, Minneapolis, MN USA. [Gioe, Terence] Minneapolis VAMC, Dept Orthopaed Surg, Minneapolis, MN USA. [Singh, Jasvinder A.] Birmingham VAMC, Fac Off Tower 805B,510 20th St S, Birmingham, AL 35294 USA. [Singh, Jasvinder A.] Univ Alabama Birmingham, Fac Off Tower 805B,510 20th St S, Birmingham, AL 35294 USA. RP Singh, JA (reprint author), Birmingham VAMC, Fac Off Tower 805B,510 20th St S, Birmingham, AL 35294 USA.; Singh, JA (reprint author), Univ Alabama Birmingham, Fac Off Tower 805B,510 20th St S, Birmingham, AL 35294 USA. EM Jasvinder.md@gmail.com FU Birmingham Veterans affairs medical centers FX This material is the result of work supported by the facilities and resources at the Minneapolis and the Birmingham Veterans affairs medical centers. No additional funding was obtained to conduct this study. NR 25 TC 0 Z9 0 U1 0 U2 0 PU BIOMED CENTRAL LTD PI LONDON PA 236 GRAYS INN RD, FLOOR 6, LONDON WC1X 8HL, ENGLAND SN 1472-6963 J9 BMC HEALTH SERV RES JI BMC Health Serv. Res. PD AUG 24 PY 2016 VL 16 AR 429 DI 10.1186/s12913-016-1669-y PG 7 WC Health Care Sciences & Services SC Health Care Sciences & Services GA DU8DV UT WOS:000382444400001 PM 27553056 ER PT J AU Heo, SJ Han, WM Szczesny, SE Cosgrove, BD Elliott, DM Lee, DA Duncan, RL Mauck, RL AF Heo, Su-Jin Han, Woojin M. Szczesny, Spencer E. Cosgrove, Brian D. Elliott, Dawn M. Lee, David A. Duncan, Randall L. Mauck, Robert L. TI Mechanically Induced Chromatin Condensation Requires Cellular Contractility in Mesenchymal Stem Cells SO BIOPHYSICAL JOURNAL LA English DT Article ID TGF-BETA; GENE-EXPRESSION; BIOPHYSICAL REGULATION; HISTONE MODIFICATIONS; DIFFERENTIATION; PROTEIN; STRAIN; PROLIFERATION; ORGANIZATION; ARCHITECTURE AB Mechanical cues play important roles in directing the lineage commitment of mesenchymal stem cells (MSCs). In this study, we explored the molecular mechanisms by which dynamic tensile loading (DL) regulates chromatin organization in this cell type. Our previous findings indicated that the application of DL elicited a rapid increase in chromatin condensation through purinergic signaling mediated by ATP. Here, we show that the rate and degree of condensation depends on the frequency and duration of mechanical loading, and that ATP release requires actomyosin-based cellular contractility. Increases in baseline cellular contractility via the addition of an activator of G-protein coupled receptors (lysophosphatidic acid) induced rapid ATP release, resulting in chromatin condensation independent of loading. Conversely, inhibition of contractility through pretreatment with either a RhoA/Rock inhibitor (Y27632) or MLCK inhibitor (ML7) abrogated ATP release in response to DL, blocking load-induced chromatin condensation. With loading, ATP release occurred very rapidly (within the first 10-20 s), whereas changes in chromatin occurred at a later time point (similar to 10 min), suggesting a downstream biochemical pathway mediating this process. When cells were pretreated with blockers of the transforming growth factor (TGF) superfamily, purinergic signaling in response to DL was also eliminated. Further analysis showed that this pretreatment decreased contractility, implicating activity in the TGF pathway in the establishment of the baseline contractile state of MSCs (in the absence of exogenous ligands). These data indicate that chromatin condensation in response to DL is regulated through the interplay between purinergic and RhoA/Rock signaling, and that ligandless activity in the TGF/bone morphogenetic proteins signaling pathway contributes to the establishment of baseline contractility in MSCs. C1 [Heo, Su-Jin; Szczesny, Spencer E.; Cosgrove, Brian D.; Mauck, Robert L.] Univ Penn, Perelman Sch Med, Dept Orthopaed Surg, McKay Orthopaed Res Lab, Philadelphia, PA 19104 USA. [Heo, Su-Jin; Han, Woojin M.; Cosgrove, Brian D.; Mauck, Robert L.] Univ Penn, Sch Engn & Appl Sci, Dept Bioengn, Philadelphia, PA 19104 USA. [Szczesny, Spencer E.; Cosgrove, Brian D.; Mauck, Robert L.] Philadelphia VA Med Ctr, Translat Musculoskeletal Res Ctr, Philadelphia, PA USA. [Elliott, Dawn M.; Duncan, Randall L.] Univ Delaware, Dept Biomed Engn, Newark, DE USA. [Duncan, Randall L.] Univ Delaware, Dept Biol Sci, Newark, DE USA. [Lee, David A.] Queen Mary Univ London, Sch Engn & Mat Sci, Inst Bioengn, London, England. RP Mauck, RL (reprint author), Univ Penn, Perelman Sch Med, Dept Orthopaed Surg, McKay Orthopaed Res Lab, Philadelphia, PA 19104 USA.; Mauck, RL (reprint author), Univ Penn, Sch Engn & Appl Sci, Dept Bioengn, Philadelphia, PA 19104 USA.; Mauck, RL (reprint author), Philadelphia VA Med Ctr, Translat Musculoskeletal Res Ctr, Philadelphia, PA USA. EM lemauck@mail.med.upenn.edu FU National Institutes of Health [R01AR056624, R01 EB02425, T32 AR007132, P30 AR050950]; Perelman School of Medicine; University of Pennsylvania University Research Foundation Award FX This work was supported by the National Institutes of Health (R01AR056624, R01 EB02425, T32 AR007132, and P30 AR050950). Additional support was provided by a Montague Research Award from the Perelman School of Medicine and a University of Pennsylvania University Research Foundation Award. The authors would like to acknowledge technical contributions to this work from Dr. Stephen D. Thorpe, and J. Caplan for assistance with confocal microscopy. NR 48 TC 1 Z9 1 U1 4 U2 5 PU CELL PRESS PI CAMBRIDGE PA 600 TECHNOLOGY SQUARE, 5TH FLOOR, CAMBRIDGE, MA 02139 USA SN 0006-3495 EI 1542-0086 J9 BIOPHYS J JI Biophys. J. PD AUG 23 PY 2016 VL 111 IS 4 BP 864 EP 874 DI 10.1016/j.bpj.2016.07.006 PG 11 WC Biophysics SC Biophysics GA DU3GR UT WOS:000382099300019 PM 27558729 ER PT J AU Wang, J Sinnett-Smith, J Stevens, JV Young, SH Rozengurt, E AF Wang, Jia Sinnett-Smith, James Stevens, Jan V. Young, Steven H. Rozengurt, Enrique TI Biphasic Regulation of Yes-associated Protein (YAP) Cellular Localization, Phosphorylation, and Activity by G Protein-coupled Receptor Agonists in Intestinal Epithelial Cells: A NOVEL ROLE FOR PROTEIN KINASE D (PKD) SO JOURNAL OF BIOLOGICAL CHEMISTRY LA English DT Article DE angiotensin II; G protein-coupled receptor (GPCR); protein kinase C (PKC); protein kinase D (PKD); yes-associated protein (YAP) ID ACTIVATION LOOP SER(744); NUCLEAR EXPORT SIGNALS; HIPPO PATHWAY; IN-VIVO; DNA-SYNTHESIS; ANG-II; G(Q)-COUPLED RECEPTORS; LYSOPHOSPHATIDIC ACID; ANTITUMOR-ACTIVITY; PHORBOL ESTERS AB We examined the regulation of Yes-associated protein (YAP) localization, phosphorylation, and transcriptional activity in intestinal epithelial cells. Our results show that stimulation of intestinal epithelial IEC-18 cells with the G protein-coupled receptor (GPCR) agonist angiotensin II, a potent mitogen for these cells, induced rapid translocation of YAP from the nucleus to the cytoplasm (within 15 min) and a concomitant increase in YAP phosphorylation at Ser(127) and Ser(397). Angiotensin II elicited YAP phosphorylation and cytoplasmic accumulation in a dose-dependent manner (ED50 = 0.3 nm). Similar YAP responses were provoked by stimulation with vasopressin or serum. Treatment of the cells with the protein kinase D (PKD) family inhibitors CRT0066101 and kb NB 142-70 prevented the increase in YAP phosphorylation on Ser(127) and Ser(397) via Lats2, YAP cytoplasmic accumulation, and increase in the mRNA levels of YAP/TEAD-regulated genes (Ctgf and Areg). Furthermore, siRNA-mediated knockdown of PKD1, PKD2, and PKD3 markedly attenuated YAP nuclear-cytoplasmic shuttling, phosphorylation at Ser(127), and induction of Ctgf and Areg expression in response to GPCR activation. These results identify a novel role for the PKD family in the control of biphasic localization, phosphorylation, and transcriptional activity of YAP in intestinal epithelial cells. In turn, YAP and TAZ are necessary for the stimulation of the proliferative response of intestinal epithelial cells to GPCR agonists that act via PKD. The discovery of interaction between YAP and PKD pathways identifies a novel cross-talk in signal transduction and demonstrates, for the first time, that the PKDs feed into the YAP pathway. C1 [Wang, Jia; Sinnett-Smith, James; Stevens, Jan V.; Young, Steven H.; Rozengurt, Enrique] Univ Calif Los Angeles, David Geffen Sch Med, Div Digest Dis, Dept Med, Los Angeles, CA 90095 USA. [Sinnett-Smith, James; Rozengurt, Enrique] Univ Calif Los Angeles, CURE Digest Dis Res Ctr, Los Angeles, CA 90095 USA. [Rozengurt, Enrique] Univ Calif Los Angeles, Inst Mol Biol, Los Angeles, CA 90095 USA. [Sinnett-Smith, James; Young, Steven H.; Rozengurt, Enrique] Vet Affairs Greater Los Angeles Hlth Care Syst, Los Angeles, CA 90073 USA. RP Rozengurt, E (reprint author), Univ Calif Los Angeles, Dept Med, Sch Med, 900 Vet Ave,Warren Hall Rm 11-124, Los Angeles, CA 90095 USA. EM erozengurt@mednet.ucla.edu FU National Institutes of Health [R01DK100405, P30DK41301, P01CA163200]; Department of Veterans Affair Grant [1I01BX001473]; Ronald S. Hirshberg Endowed Chair of Pancreatic Cancer Research FX This work was supported by National Institutes of Health Grants R01DK100405, P30DK41301, and P01CA163200, by Department of Veterans Affair Grant 1I01BX001473 (to E.R.), and by the Ronald S. Hirshberg Endowed Chair of Pancreatic Cancer Research (to E.R.). The authors declare that they have no conflicts of interest with the contents of this article. The content is solely the responsibility of the authors and does not necessarily represent the official views of the National Institutes of Health. NR 75 TC 1 Z9 1 U1 3 U2 4 PU AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC PI BETHESDA PA 9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA SN 0021-9258 EI 1083-351X J9 J BIOL CHEM JI J. Biol. Chem. PD AUG 19 PY 2016 VL 291 IS 34 BP 17988 EP 18005 DI 10.1074/jbc.M115.711275 PG 18 WC Biochemistry & Molecular Biology SC Biochemistry & Molecular Biology GA DV9DX UT WOS:000383241300041 PM 27369082 ER PT J AU Lai, DM Shu, Q Fan, J AF Lai, Deng-Ming Shu, Qiang Fan, Jie TI The origin and role of innate lymphoid cells in the lung SO MILITARY MEDICAL RESEARCH LA English DT Review DE Innate lymphoid cells; Innate immunity; Lung diseases; Airway; Cell interaction; Cytokines ID OBSTRUCTIVE PULMONARY-DISEASE; TRANSCRIPTION FACTOR GATA3; ANTI-INTERLEUKIN-17 MONOCLONAL-ANTIBODY; ALTERNATIVELY ACTIVATED MACROPHAGES; INDUCED AIRWAY HYPERREACTIVITY; NATURAL HELPER-CELLS; TYPE-2 IMMUNITY; T-CELL; ALLERGIC INFLAMMATION; INTESTINAL INFLAMMATION AB Innate lymphoid cells (ILCs), a newly identified member of the lymphoid population, play a critical role in the transition from innate to adaptive immunity in host defense. ILCs are important in mucosal barrier immunity, tissue homeostasis, and immune regulation throughout the body. Significant alterations in ILC responses in lung diseases have been observed and reported. Emerging evidence has shown that ILCs are importantly involved in the pathogenesis and development of a variety of lung diseases, i.e., helminth infections, allergic airway inflammation, and airway hyper-responsiveness. However, as a tissue-resident cell population, the role of ILCs in the lung remains poorly characterized. In this review, we discuss the role of ILCs in lung diseases, the mechanisms underlying the ILC-mediated regulation of immunity, and the therapeutic potential of modulating ILC responses. C1 [Lai, Deng-Ming; Shu, Qiang] Zhejiang Univ, Dept Cardiovasc Surg, Sch Med, Childrens Hosp, Hangzhou 310052, Zhejiang, Peoples R China. [Lai, Deng-Ming; Fan, Jie] Univ Pittsburgh, Sch Med, Dept Surg, Pittsburgh, PA 15213 USA. [Fan, Jie] Vet Affairs Pittsburgh Healthcare Syst, Res & Dev, Pittsburgh, PA 15240 USA. RP Fan, J (reprint author), Univ Pittsburgh, Sch Med, Dept Surg, Pittsburgh, PA 15213 USA.; Fan, J (reprint author), Vet Affairs Pittsburgh Healthcare Syst, Res & Dev, Pittsburgh, PA 15240 USA. EM jif7@pitt.edu FU BLRD VA [I01 BX002729]; NHLBI NIH HHS [R01 HL076179, R01 HL079669, R56 HL123882] NR 124 TC 2 Z9 2 U1 2 U2 3 PU BIOMED CENTRAL LTD PI LONDON PA 236 GRAYS INN RD, FLOOR 6, LONDON WC1X 8HL, ENGLAND SN 2054-9369 J9 MILITARY MED RES JI MILITARY MED. RES. PD AUG 19 PY 2016 VL 3 AR UNSP 25 DI 10.1186/s40779-016-0093-2 PG 10 WC Medicine, General & Internal SC General & Internal Medicine GA DU3CT UT WOS:000382089100002 PM 27547445 ER PT J AU Ojha, S Fainberg, HP Wilson, V Pelella, G Castellanos, M May, ST Lotto, AA Sacks, H Symonds, ME Budge, H AF Ojha, Shalini Fainberg, Hernan P. Wilson, Victoria Pelella, Giuseppe Castellanos, Marcos May, Sean T. Lotto, Attilio A. Sacks, Harold Symonds, Michael E. Budge, Helen TI Gene pathway development in human epicardial adipose tissue during early life SO JCI INSIGHT LA English DT Article ID BROWN FAT; PROTEIN; OBESITY; TRANSCRIPTOME; ADIPOCYTES; NETWORKS AB Studies in rodents and newborn humans demonstrate the influence of brown adipose tissue (BAT) in temperature control and energy balance and a critical role in the regulation of body weight. Here, we obtained samples of epicardial adipose tissue (EAT) from neonates, infants, and children in order to evaluate changes in their transcriptional landscape by applying a systems biology approach. Surprisingly, these analyses revealed that the transition to infancy is a critical stage for changes in the morphology of EAT and is reflected in unique gene expression patterns of a substantial proportion of thermogenic gene transcripts (similar to 10%). Our results also indicated that the pattern of gene expression represents a distinct developmental stage, even after the rebound in abundance of thermogenic genes in later childhood. Using weighted gene coexpression network analyses, we found precise anthropometric-specific correlations with changes in gene expression and the decline of thermogenic capacity within EAT. In addition, these results indicate a sequential order of transcriptional events affecting cellular pathways, which could potentially explain the variation in the amount, or activity, of BAT in adulthood. Together, these results provide a resource to elucidate gene regulatory mechanisms underlying the progressive development of BAT during early life. C1 [Ojha, Shalini; Fainberg, Hernan P.; Wilson, Victoria; Symonds, Michael E.; Budge, Helen] Univ Nottingham, Univ Hosp, Queens Med Ctr, Div Child Hlth Obstet & Gynaecol,Sch Med, Nottingham, England. [Pelella, Giuseppe; Lotto, Attilio A.] Univ Hosp Leicester NHS Trust, Leicester, Leics, England. [Castellanos, Marcos; May, Sean T.] Univ Nottingham, Sch Biosci, Nottingham Arabidopsis Stock Ctr, Nottingham, England. [Sacks, Harold] Univ Calif Los Angeles, David Geffen Sch Med, VA Endocrinol & Diabet Div, VA Greater Los Angeles Healthcare Syst, Los Angeles, CA 90095 USA. [Sacks, Harold] Univ Calif Los Angeles, David Geffen Sch Med, Dept Med, Los Angeles, CA 90095 USA. [Pelella, Giuseppe; Lotto, Attilio A.] Alder Hey Childrens NHS Fdn Trust, Liverpool, Merseyside, England. RP Symonds, ME (reprint author), Univ Nottingham, Div Child Hlth Obstet & Gynaecol, Queens Med Ctr, Univ Hosp, Nottingham NG7 2UH, England. EM Michael.symonds@nottingham.ac.uk RI may, sean/B-6838-2012 OI may, sean/0000-0001-5282-3250 FU Biotechnology and Biological Sciences Research Council [BB/E022758/1, BB/E01772X/1, BB/I001271/1, BBS/B/1356X, G17764, G18881] NR 38 TC 1 Z9 1 U1 1 U2 1 PU AMER SOC CLINICAL INVESTIGATION INC PI ANN ARBOR PA 35 RESEARCH DR, STE 300, ANN ARBOR, MI 48103 USA SN 2379-3708 J9 JCI INSIGHT JI JCI Insight PD AUG 18 PY 2016 VL 1 IS 13 AR e87460 DI 10.1172/jci.insight.87460 PG 13 WC Medicine, Research & Experimental SC Research & Experimental Medicine GA EB1NO UT WOS:000387119700005 PM 27699231 ER PT J AU Coca, SG Nadkarni, GN Garg, AX Koyner, J Thiessen-Philbrook, H McArthur, E Shlipak, MG Parikh, CR AF Coca, Steven G. Nadkarni, Girish N. Garg, Amit X. Koyner, Jay Thiessen-Philbrook, Heather McArthur, Eric Shlipak, Michael G. Parikh, Chirag R. CA TRIBE-AKI Consortium TI First Post-Operative Urinary Kidney Injury Biomarkers and Association with the Duration of AKI in the TRIBE-AKI Cohort SO PLOS ONE LA English DT Article ID LONG-TERM SURVIVAL; CARDIAC-SURGERY; PREVENTION TRIALS; POOR OUTCOMES; IMPACT AB Background We previously demonstrated that assessment of the duration of AKI, in addition to magnitude of rise in creatinine alone, adds prognostic information for long-term survival. We evaluated whether post-operative kidney injury biomarkers in urine collected immediately after cardiac surgery associate with duration of serum creatinine elevation. Methods We studied 1199 adults undergoing cardiac surgery in a prospective cohort study (TRIBE-AKI) and examined the association between the levels of five urinary biomarkers individually at 0-6 hours after surgery: interleukin-18 (IL-18), neutrophil gelatinase-associated lipocalin (NGAL), kidney injury molecule-1 (KIM-1), liver fatty acid binding protein (L-FABP) and albumin with duration of serum creatinine-based AKIN criteria for AKI (0 (no AKI), 1-2, 3-6, >= 7 days). Results Overall, 407 (34%) patients had at least stage 1 AKI, of whom 251 (61.7%) had duration of 1-2 days, 118 (28.9%) had duration 3-6 days, and 38 (9.3%) had duration of >= 7 days. Higher concentrations of all biomarkers (per log increase) were independently associated with a greater odds of a longer duration of AKI; odds ratios and 95% confidence intervals using ordinal logistic regression were the following: IL-18: 1.22, 1.13-1.32; KIM-1: 1.36, 1.21-1.52; albumin 1.20, 1.09-1.32; L-FABP 1.11, 1.04-1.19; NGAL 1.06, 1.00-1.14). AKI duration of 7 days or longer was associated with a 5-fold adjusted risk of mortality at 3 years. Conclusions There was an independent dose-response association between urinary levels of injury biomarkers immediately after cardiac surgery and longer duration of AKI. Duration of AKI was also associated with long term mortality. Future studies should explore the potential utility of these urinary kidney injury biomarkers to enrich enrollment of patients at risk for longer duration of AKI into trials of interventions to prevent or treat post-operative AKI. C1 [Coca, Steven G.; Nadkarni, Girish N.] Icahn Sch Med Mt Sinai, Dept Med, Div Nephrol, New York, NY 10029 USA. [Garg, Amit X.; Thiessen-Philbrook, Heather; McArthur, Eric] Western Univ, Dept Med, Div Nephrol, London, ON, Canada. [Koyner, Jay] Univ Chicago, Pritzker Sch Med, Dept Med, Nephrol Sect, Chicago, IL 60637 USA. [Shlipak, Michael G.] Univ Calif San Francisco, Div Gen Internal Med, San Francisco VA Med Ctr, San Francisco, CA 94143 USA. [Parikh, Chirag R.] Yale Univ, Sch Med, Dept Internal Med, Program Appl Translat Res, New Haven, CT 06510 USA. RP Parikh, CR (reprint author), Yale Univ, Sch Med, Dept Internal Med, Program Appl Translat Res, New Haven, CT 06510 USA. EM chirag.parikh@yale.edu FU Institute for Clinical Evaluative Sciences (ICES) - Ontario Ministry of Health and Long-Term Care (MOHLTC); National Institutes of Health (NIH) [R01HL085757]; NIH [K23DK080132, T32-DK007757, K24DK090203, P30 DK079310-07, U01DK082185]; Dr. Adam Linton Chair in Kidney Health Analytics; [K23 DK081616] FX This study was supported by the Institute for Clinical Evaluative Sciences (ICES), which is funded by an annual grant from the Ontario Ministry of Health and Long-Term Care (MOHLTC). The opinions, results and conclusions reported in this paper are those of the authors and are independent from the funding sources. No endorsement by ICES or the MOHLTC is intended or should be inferred. This study was supported by the National Institutes of Health (NIH) (R01HL085757 to CRP) to fund the TRIBE-AKI Consortium to study novel biomarkers of AKI in cardiac surgery. SGC has been supported by an NIH Career Development Award (K23DK080132). GNN is supported in part by the NIH (T32-DK007757). JLK has been supported by K23 DK081616. C.R.P. is supported by the NIH (K24DK090203) and P30 DK079310-07 O'Brien Center Grant. SGC, AXG, and CRP are also members of the NIH-sponsored Assess, Serial Evaluation, and Subsequent Sequelae in Acute Kidney Injury Consortium (U01DK082185). AXG is supported by the Dr. Adam Linton Chair in Kidney Health Analytics. The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.; Lead Author of the TRIBE AKI consortium: Chirag R. Parikh. Email: chirag.parikh@yale.edu. Section of Nephrology, Department of Medicine, Yale University School of Medicine, VA CT Healthcare System, and the Program of Applied Translational Research, New Haven, CT, USA. Members of TRIBE-AKI consortium: U of Chicago: Dr. Jai Raman, Dr. Valluvan Jeevanandam, Dr. Shahab Akhter. U of Colorado: Dr. Charles Edelstein. Danbury Hospital: Dr. Cary Passik, Ms. Judy Nagy. Duke University: Dr. Madhav Swaminathan. London, Ontario: Dr. Michael Chu, Dr. Martin Goldbach, Dr. Lin Ruo Guo, Dr. Neil McKenzie, Dr. Mary Lee Myers, Dr. Richard Novick, Dr. Mac Quantz. Montreal Children's: Dr. Michael Zappitelli, Dr. Ana Palijan. Yale-New Haven: Dr. Michael Dewar, Dr. Umer Darr, Dr. Sabet Hashim, Dr. John Elefteriades, Dr. Arnar Geirsson, Dr. Susan Garwood, Dr. Isabel Butrymowicz, Dr. Harlan Krumholz. Additional Contributions: We thank Dr. Stephanie Dixon for her analytic support. This study was supported by the Institute for Clinical Evaluative Sciences (ICES), which is funded by an annual grant from the Ontario Ministry of Health and Long-Term Care (MOHLTC). The opinions, results and conclusions reported in this paper are those of the authors and are independent from the funding sources. No endorsement by ICES or the MOHLTC is intended or should be inferred. This study was supported by the National Institutes of Health (NIH) (R01HL085757 to C.R.P.) to fund the TRIBE-AKI Consortium to study novel biomarkers of AKI in cardiac surgery. S.G.C. has been supported by an NIH Career Development Award (K23DK080132). G.N.N is supported in part by the NIH (T32-DK007757). JLK has been supported by K23 DK081616. C.R.P. is supported by the NIH (K24DK090203) and P30 DK079310-07 O'Brien Center Grant. S.G.C., A.X.G., and C.R.P. are also members of the NIH-sponsored Assess, Serial Evaluation, and Subsequent Sequelae in Acute Kidney Injury Consortium (U01DK082185). AXG is supported by the Dr. Adam Linton Chair in Kidney Health Analytics. NR 15 TC 1 Z9 1 U1 3 U2 3 PU PUBLIC LIBRARY SCIENCE PI SAN FRANCISCO PA 1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA SN 1932-6203 J9 PLOS ONE JI PLoS One PD AUG 18 PY 2016 VL 11 IS 8 AR e0161098 DI 10.1371/journal.pone.0161098 PG 11 WC Multidisciplinary Sciences SC Science & Technology - Other Topics GA DT6ES UT WOS:000381577000053 PM 27537050 ER PT J AU Osier, ND Dixon, CE AF Osier, Nicole D. Dixon, C. Edward TI The Controlled Cortical Impact Model: Applications, Considerations for Researchers, and Future Directions SO FRONTIERS IN NEUROLOGY LA English DT Review DE controlled cortical impact; experimental brain injury; brain trauma; pre-clinical; review ID TRAUMATIC BRAIN-INJURY; CHRONIC METHYLPHENIDATE TREATMENT; WATER MAZE PERFORMANCE; SPINAL-CORD CONTUSION; RATS POSSIBLE ROLE; COGNITIVE DEFICITS; MEMORY DEFICITS; AXONAL INJURY; HEAD-INJURY; ENVIRONMENTAL ENRICHMENT AB Controlled cortical impact (CCI) is a mechanical model of traumatic brain injury (TBI) that was developed nearly 30 years ago with the goal of creating a testing platform to determine the biomechanical properties of brain tissue exposed to direct mechanical deformation. Initially used to model TB's produced by automotive crashes, the CCI model rapidly transformed into a standardized technique to study TBI mechanisms and evaluate therapies. CCI is most commonly produced using a device that rapidly accelerates a rod to impact the surgically exposed cortical dural surface. The tip of the rod can be varied in size and geometry to accommodate scalability to difference species. Typically, the rod is actuated by a pneumatic piston or electromagnetic actuator. With some limits, CCI devices can control the velocity, depth, duration, and site of impact. The CCI model produces morphologic and cerebrovascular injury responses that resemble certain aspects of human TBI. Commonly observed are graded histologic and axonal derangements, disruption of the blood brain barrier, subdural and intra-parenchymal hematoma, edema, inflammation, and alterations in cerebral blood flow. The CCI model also produces neurobehavioral and cognitive impairments similar to those observed clinically. In contrast to other TBI models, the CCI device induces a significantly pronounced cortical contusion, but is limited in the extent to which it models the diffuse effects of TBI; a related limitation is that not all clinical TBI cases are characterized by a contusion. Another perceived limitation is that a non -clinically relevant craniotomy is performed. Biomechanically, this is irrelevant at the tissue level. However, craniotomies are not atraumatic and the effects of surgery should be controlled by including surgical sham control groups. CCI devices have also been successfully used to impact closed skulls to study mild and repetitive TBI. Future directions for CCI research surround continued refinements to the model through technical improvements in the devices (e.g., minimizing mechanical sources of variation). Like all TBI models, publications should report key injury parameters as outlined in the NIH common data elements (CDEs) for pre-clinical TBI. C1 [Osier, Nicole D.] Univ Pittsburgh, Sch Nursing, Dept Acute & Tertiary Care, Pittsburgh, PA 15261 USA. [Osier, Nicole D.; Dixon, C. Edward] Safar Ctr Resuscitat Res, Pittsburgh, PA USA. [Dixon, C. Edward] Univ Pittsburgh, Sch Med, Dept Neurosurg, Pittsburgh, PA 15261 USA. [Dixon, C. Edward] VA Pittsburgh Healthcare Syst, Pittsburgh, PA USA. RP Dixon, CE (reprint author), Safar Ctr Resuscitat Res, Pittsburgh, PA USA.; Dixon, CE (reprint author), Univ Pittsburgh, Sch Med, Dept Neurosurg, Pittsburgh, PA 15261 USA.; Dixon, CE (reprint author), VA Pittsburgh Healthcare Syst, Pittsburgh, PA USA. EM dixoec@upmc.edu FU National Institute of Health (NIH) [R01NS40125, R01NS091062, F31NR014957, T32NR009759]; Department of Veterans Affairs grant [I01RX001127]; American Association of Neuroscience Nursing/Neuroscience Nursing Foundation; International Society for Nurses in Genetics, Sigma Theta Tau International Eta Chapter; Pittsburgh foundation FX This work was supported by several grants from the National Institute of Health (NIH) Grants: R01NS40125, R01NS091062, F31NR014957, and T32NR009759. Additional support came from the Department of Veterans Affairs grant I01RX001127. Further support for this work comes from the following professional societies: the American Association of Neuroscience Nursing/Neuroscience Nursing Foundation, the International Society for Nurses in Genetics, Sigma Theta Tau International Eta Chapter, and The Pittsburgh foundation. NR 165 TC 0 Z9 0 U1 1 U2 4 PU FRONTIERS MEDIA SA PI LAUSANNE PA PO BOX 110, EPFL INNOVATION PARK, BUILDING I, LAUSANNE, 1015, SWITZERLAND SN 1664-2295 J9 FRONT NEUROL JI Front. Neurol. PD AUG 17 PY 2016 VL 7 AR UNSP 134 DI 10.3389/fneur.2016.00134 PG 14 WC Clinical Neurology; Neurosciences SC Neurosciences & Neurology GA DT7MA UT WOS:000381669700001 PM 27582726 ER PT J AU He, XY Qian, YB Li, ZG Fan, EK Li, YH Wu, L Billiar, TR Wilson, MA Shi, XY Fan, J AF He, Xingying Qian, Yongbing Li, Zhigang Fan, Erica K. Li, Yuehua Wu, Liang Billiar, Timothy R. Wilson, Mark A. Shi, Xueyin Fan, Jie TI TLR4-Upregulated IL-1 beta and IL-1RI Promote Alveolar Macrophage Pyroptosis and Lung Inflammation through an Autocrine Mechanism SO SCIENTIFIC REPORTS LA English DT Article ID INTERLEUKIN-1 RECEPTOR COMPLEX; ACTIVATION; DISEASE; INFLAMMASOMES; RECRUITMENT; EXPRESSION; APOPTOSIS; PROTEIN; DOMAIN; DEATH AB Acute lung injury (ALI) is a major component of multiple organ dysfunction syndrome (MODS) following pulmonary infection. Alveolar macrophages (AM) are at the center of the pathogenesis of the development of ALI. Interleukin-1 beta (IL-1 beta) is one of the key pro-inflammatory mediators, and its maturation is tightly controlled by the formation and activation of the inflammasome. The biological effects of IL-1 beta are mediated through IL-1 receptor (IL-1R). In this study, we investigated the influence of LPS-induced IL-1 beta release and IL-1RI upregulation on the development of lung inflammation. We demonstrated that in AM, LPS-TLR4 signaling not only activates Nlrp3 inflammasome activation and subsequent release of IL-1 beta, but also up-regulates IL-1RI expression on AM surface through MyD88 and NF-kappa B dependent signaling. The upregulated IL-1RI, therefore, sensitizes AM to IL-1 beta and results in pyroptosome formation, which in turn leads to AM pyroptosis, a type of caspase-1-dependent inflammatory cell death. We further showed that AM pyroptosis exaggerates lung inflammation. The present study demonstrates a novel mechanism underlying LPS-induced innate immunity; that is, a secondary upregulation of IL-1 beta-IL-1RI signaling is responsible for AM pyroptosis and augmented lung injury in response to LPS. C1 [He, Xingying; Wu, Liang; Shi, Xueyin] Second Mil Med Univ, Changzheng Hosp, Dept Anesthesiol, Shanghai 200003, Peoples R China. [He, Xingying; Li, Zhigang; Li, Yuehua; Wu, Liang; Billiar, Timothy R.; Wilson, Mark A.; Fan, Jie] Univ Pittsburgh, Sch Med, Dept Surg, Pittsburgh, PA 15213 USA. [Qian, Yongbing] Jiaotong Univ, Shanghai Hosp 1, Dept Crit Care Med, Sch Med, Shanghai 201600, Peoples R China. [Fan, Erica K.] Univ Pittsburgh, Dept Biol Sci, Sch Arts & Sci, Pittsburgh, PA 15213 USA. [Li, Yuehua; Wilson, Mark A.; Fan, Jie] Vet Affairs Pittsburgh Healthcare Syst, Res & Dev, Pittsburgh, PA 15240 USA. [Billiar, Timothy R.; Fan, Jie] Univ Pittsburgh, McGowan Inst Regenerat Med, Pittsburgh, PA 15219 USA. [Shi, Xueyin] Jiaotong Univ, Sch Med, Shanghai Xinghua Hosp, Dept Anesthesiol, Shanghai 200092, Peoples R China. RP Shi, XY (reprint author), Second Mil Med Univ, Changzheng Hosp, Dept Anesthesiol, Shanghai 200003, Peoples R China.; Fan, J (reprint author), Univ Pittsburgh, Sch Med, Dept Surg, Pittsburgh, PA 15213 USA.; Fan, J (reprint author), Vet Affairs Pittsburgh Healthcare Syst, Res & Dev, Pittsburgh, PA 15240 USA.; Fan, J (reprint author), Univ Pittsburgh, McGowan Inst Regenerat Med, Pittsburgh, PA 15219 USA.; Shi, XY (reprint author), Jiaotong Univ, Sch Med, Shanghai Xinghua Hosp, Dept Anesthesiol, Shanghai 200092, Peoples R China. EM shixueyin1128@163.com; jif7@pitt.edu FU National Institutes of Health Grant [R01-HL-079669, R56-HL-123882]; National Institutes of Health Center Grant [P50-GM-53789]; VA Merit Award [1I01BX002729]; Key Program of Medical Science Development of PLA [BWS12J027]; National Natural Science Foundation of China [81372103]; Shanghai Pujiang Program [15PJD003] FX This work was supported by the National Institutes of Health Grant R01-HL-079669 (J.F. and M.A.W.), National Institutes of Health Center Grant P50-GM-53789 (T.R.B. and J.F.), National Institutes of Health Grant R56-HL-123882 (J.F.), VA Merit Award 1I01BX002729 (J.F.), Key Program of Medical Science Development of PLA BWS12J027 (X.S.), National Natural Science Foundation of China 81372103 (X.S.), and Shanghai Pujiang Program 15PJD003 (X.H.). NR 23 TC 3 Z9 3 U1 5 U2 5 PU NATURE PUBLISHING GROUP PI LONDON PA MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND SN 2045-2322 J9 SCI REP-UK JI Sci Rep PD AUG 16 PY 2016 VL 6 AR 31663 DI 10.1038/srep31663 PG 11 WC Multidisciplinary Sciences SC Science & Technology - Other Topics GA EH9XJ UT WOS:000392124800001 PM 27526865 ER PT J AU Aparici, CM Win, AZ AF Aparici, Carina Mari Win, Aung Zaw TI Acute Calculous Cholecystitis Missed on Computed Tomography and Ultrasound but Diagnosed with Fluorodeoxyglucose-Positron Emission Tomography/Computed Tomography SO JOURNAL OF CLINICAL IMAGING SCIENCE LA English DT Article DE Acute calculous cholecystitis; computed tomography; fluorodeoxyglucose-positron emission tomography/computed tomography; ultrasound ID GALLBLADDER AB We present a case of a 69-year-old patient who underwent ascending aortic aneurysm repair with aortic valve replacement. On postsurgical day 12, he developed leukocytosis and low-grade fevers. The chest computed tomography (CT) showed a periaortic hematoma which represents a postsurgical change from aortic aneurysm repair, and a small pericardial effusion. The abdominal ultrasound showed cholelithiasis without any sign of cholecystitis. Finally, a fluorodeoxyglucose (FDG) - positron emission tomography (PET)/CT examination was ordered to find the cause of fever of unknown origin, and it showed increased FDG uptake in the gallbladder wall, with no uptake in the lumen. FDG-PET/CT can diagnose acute cholecystitis in patients with nonspecific clinical symptoms and laboratory results. C1 [Aparici, Carina Mari] Univ Calif San Francisco, Dept Radiol, San Francisco, CA 94143 USA. [Win, Aung Zaw] San Francisco VA Med Ctr, Dept Radiol, 4150 Clement St, San Francisco, CA 94121 USA. RP Win, AZ (reprint author), San Francisco VA Med Ctr, Dept Radiol, 4150 Clement St, San Francisco, CA 94121 USA. EM aungzwin@gmail.com NR 11 TC 0 Z9 0 U1 0 U2 0 PU MEDKNOW PUBLICATIONS & MEDIA PVT LTD PI MUMBAI PA B-9, KANARA BUSINESS CENTRE, OFF LINK RD, GHAKTOPAR-E, MUMBAI, 400075, INDIA SN 2156-7514 EI 2156-5597 J9 J CLIN IMAG SCI JI J. Clin. Imag. Sci. PD AUG 16 PY 2016 VL 6 BP 1 EP 3 AR UNSP 31 DI 10.4103/2156-7514.188474 PG 3 WC Radiology, Nuclear Medicine & Medical Imaging SC Radiology, Nuclear Medicine & Medical Imaging GA DX6WC UT WOS:000384524800001 PM 27625897 ER PT J AU Shekelle, P AF Shekelle, Paul TI In adults = 75 years of age with hypertension, intensive vs standard BP-lowering treatment reduced CV events SO ANNALS OF INTERNAL MEDICINE LA English DT Editorial Material C1 Greater Los Angeles VA Healthcare Syst, Los Angeles, CA USA. RP Shekelle, P (reprint author), Greater Los Angeles VA Healthcare Syst, Los Angeles, CA USA. NR 0 TC 0 Z9 0 U1 2 U2 2 PU AMER COLL PHYSICIANS PI PHILADELPHIA PA INDEPENDENCE MALL WEST 6TH AND RACE ST, PHILADELPHIA, PA 19106-1572 USA SN 0003-4819 EI 1539-3704 J9 ANN INTERN MED JI Ann. Intern. Med. PD AUG 16 PY 2016 VL 165 IS 4 BP JC14 EP JC14 DI 10.7326/ACPJC-2016-165-4-014 PG 1 WC Medicine, General & Internal SC General & Internal Medicine GA DT1UI UT WOS:000381267200032 PM 27538175 ER PT J AU Figlewicz, DP AF Figlewicz, Dianne P. TI Expression of receptors for insulin and leptin in the ventral tegmental area/substantia nigra (VTA/SN) of the rat: Historical perspective SO BRAIN RESEARCH LA English DT Review DE Dopamine; Fluorescence immunocytochemistry; Reward; Ingestive behavior ID HIGH-FAT DIET; INTRAVENTRICULAR INSULIN; FOOD-DEPRIVATION; MESSENGER-RNA; DOPAMINE TRANSPORTER; PLACE PREFERENCE; ENERGY-BALANCE; BRAIN; INCREASES; REWARD AB Since the publication of the observation that dopaminergic neurons in the ventral tegmental area/substantia nigra of the rat express receptors for insulin and leptin, numerous studies have extended and validated these findings. Thus, these major metabolic hormones have effects on synaptic and cell signaling function of the midbrain dopamine neurons, across a range of concentrations that reflect physiologic (fasting vs. fed) and pathophysiologic (diabetes) circumstances. The capacity of metabolic hormones to alter reward behaviors, including palatability-related food intake; motivation for food; and the conditioning of place preference by food, is now appreciated as an integral part of the larger actions of these hormones to regulate caloric homeostasis. Finally, the delineation of metabolic hormone effects on the CNS reward circuitry of normal animals provides the rationale and experimental basis for evaluating dysfunction of reward circuitry in obesity and diabetes. This article is part-of a Special Issue entitled SI:50th Anniversary Issue. Published by Elsevier B.V. C1 [Figlewicz, Dianne P.] VA Puget Sound Hlth Care Syst, BSLRD, Seattle, WA 98108 USA. [Figlewicz, Dianne P.] Univ Washington, Dept Psychiat & Behav Sci, Seattle, WA 98195 USA. RP Figlewicz, DP (reprint author), VAPSHCS 151, 1660 So Columbian Way, Seattle, WA 98108 USA. EM latte@uw.edu FU VA Puget Sound Health Care System, Seattle, Washington; NIH [DK40963]; American Recovery and Reinvestment Act (ARRA) [NIH DK 40963] FX I particularly thank my colleagues of many years, Dr. Patti Szot and Dr. Al Sipols. Their assistance and advice made the completion of all the studies described here possible. I thank again the coauthors of the original study, Dr. Scott Ng-Evans, a postdoctoral fellow in the lab; Dr. Denis Baskin, a long-time colleague and collaborator; and Marcy Hoen and Joyce Murphy, who provided expert technical assistance. Dianne Figlewicz Lattemann is a Senior Research Career Scientist, Biomedical Laboratory Research Program, Department of Veterans Affairs Puget Sound Health Care System, Seattle, Washington. The author's research described in this article is the result of work supported by resources from the VA Puget Sound Health Care System, Seattle, Washington, and was supported by NIH grant DK40963 and by the American Recovery and Reinvestment Act (ARRA) (Grant No. NIH DK 40963). NR 29 TC 1 Z9 1 U1 3 U2 4 PU ELSEVIER SCIENCE BV PI AMSTERDAM PA PO BOX 211, 1000 AE AMSTERDAM, NETHERLANDS SN 0006-8993 EI 1872-6240 J9 BRAIN RES JI Brain Res. PD AUG 15 PY 2016 VL 1645 SI SI BP 68 EP 70 DI 10.1016/j.brainres.2015.12.041 PG 3 WC Neurosciences SC Neurosciences & Neurology GA DT5QJ UT WOS:000381537400021 PM 26731335 ER PT J AU John, MD Greene, M Hessol, NA Zepf, R Parrott, AH Foreman, C Bourgeois, J Gandhi, M Hare, CB AF John, Malcolm D. Greene, Meredith Hessol, Nancy A. Zepf, Roland Parrott, Amanda Hutton Foreman, Cameron Bourgeois, James Gandhi, Monica Hare, C. Bradley TI Geriatric Assessments and Association With VACS Index Among HIV-Infected Older Adults in San Francisco SO JAIDS-JOURNAL OF ACQUIRED IMMUNE DEFICIENCY SYNDROMES LA English DT Article DE functional status; geriatrics; HIV; mental health; and social support ID VETERANS AGING COHORT; HUMAN-IMMUNODEFICIENCY-VIRUS; ANTIRETROVIRAL THERAPY; AIDS; FRAILTY; AGE; DISEASE; RISK; PERFORMANCE; IMPAIRMENT AB Objectives:To perform geriatric assessments in older HIV-infected adults in San Francisco and examine the association with age and the Veterans Aging Cohort Study (VACS) index scores.Methods:A cross-sectional study was conducted from 2012 to 2014 among HIV-infected patients 50 years at 2 San Francisco-based HIV clinics. We evaluated 4 health domains: (1) physical health and function (activities of daily living), instrumental activities of daily living (IADL), falls, gait speed, (2) social support (physical and perceived support, loneliness), (3) mental health (depression, anxiety, posttraumatic stress disorder) and cognition, and (4) behavioral and general health (antiretroviral adherence and quality of life). Contingency table and rank-sum analyses examined associations between these domains with age and VACS index scores.Results:Three hundred fifty-nine patients completed assessments (median age 57; 85% male; 57% white; 72% >high school education). On functional assessment, 39% reported dependence with 1 IADL, and 40% reported falls in the previous year. Fifty-eight percent experienced loneliness, 60% the lowest levels of perceived social support, 55% depression, and 12% posttraumatic stress disorder. Forty percent had possible mild cognitive impairment. Thirty percent reported poor or fair quality of life. Older age was associated with lower CD4 counts, balance problems, slower gait, lower anxiety, poorer general health, and higher antiretroviral adherence. VACS Index score was associated with dependence in 1 IADL and antiretroviral adherence.Conclusion:In a large sample of older HIV-infected adults, multiple significant aging-related conditions were identified. Integrating geriatric assessment tools into HIV/AIDS clinical care may help target interventions to optimize clinical care and quality of life for older HIV-infected individuals. C1 [John, Malcolm D.; Hessol, Nancy A.; Zepf, Roland; Parrott, Amanda Hutton; Foreman, Cameron; Gandhi, Monica; Hare, C. Bradley] Univ Calif San Francisco, Dept Med, Div Infect Dis, San Francisco, CA USA. [Greene, Meredith] Univ Calif San Francisco, Div Geriatr, Dept Med, San Francisco, CA USA. [Greene, Meredith] San Francisco VA Med Ctr, Sect Geriatr & Palliat Med, San Francisco, CA USA. [Hessol, Nancy A.] Univ Calif San Francisco, Dept Clin Pharm, San Francisco, CA 94143 USA. [Bourgeois, James] Univ Calif San Francisco, Dept Psychiat, San Francisco, CA USA. [Hare, C. Bradley] Kaiser Permanente Med Grp San Francisco Med Ctr, Div Infect Dis, San Francisco, CA USA. RP John, MD (reprint author), 350 Parnassus Ave,Suite 908 Box 0378, San Francisco, CA 94143 USA. EM Malcolm.John@ucsf.edu FU University of California HIV/AIDS Research Program (CHRP) [A116894]; National Institutes of Health [5-T32-AG000212]; NIA at the NIH [P30AG044281] FX This research was funded by grant number A116894 from the University of California HIV/AIDS Research Program (CHRP). M.G. received salary support from the National Institutes of Health (5-T32-AG000212) during this project and receives support from the P30AG044281 from the NIA at the NIH. NR 37 TC 1 Z9 1 U1 5 U2 8 PU LIPPINCOTT WILLIAMS & WILKINS PI PHILADELPHIA PA TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA SN 1525-4135 EI 1077-9450 J9 JAIDS-J ACQ IMM DEF JI JAIDS PD AUG 15 PY 2016 VL 72 IS 5 BP 534 EP 541 DI 10.1097/QAI.0000000000001009 PG 8 WC Immunology; Infectious Diseases SC Immunology; Infectious Diseases GA DT3KC UT WOS:000381378700011 PM 27028497 ER PT J AU Hensley, K Poteshkina, A Johnson, MF Eslami, P Gabbita, SP Hristov, AM Venkova-Hristova, KM Harris-White, ME AF Hensley, Kenneth Poteshkina, Aleksandra Johnson, Ming F. Eslami, Pirooz Gabbita, S. Prasad Hristov, Alexandar M. Venkova-Hristova, Kalina M. Harris-White, Marni E. TI Autophagy Modulation by Lanthionine Ketimine Ethyl Ester Improves Long-Term Outcome after Central Fluid Percussion Injury in the Mouse SO JOURNAL OF NEUROTRAUMA LA English DT Article DE autophagy; behavior; diffuse axon injury; pathology ID TRAUMATIC BRAIN-INJURY; DIFFUSE AXONAL INJURY; NEURONAL CELL-DEATH; CLOSED-HEAD INJURY; CAENORHABDITIS-ELEGANS; ALZHEIMERS-DISEASE; NEUROFILAMENT COMPACTION; MAMMALIAN TARGET; RAPAMYCIN MTOR; NERVE-FIBERS AB Diffuse axonal injury is recognized as a progressive and long-term consequence of traumatic brain injury. Axonal injury can have sustained negative consequences on neuronal functions such as anterograde and retrograde transport and cellular processes such as autophagy that depend on cytoarchitecture and axon integrity. These changes can lead to somatic atrophy and an inability to repair and promote plasticity. Obstruction of the autophagic process has been noted after brain injury, and rapamycin, a drug used to stimulate autophagy, has demonstrated positive effects in brain injury models. The optimization of drugs to promote beneficial autophagy without negative side effects could be used to attenuate traumatic brain injury and promote improved outcome. Lanthionine ketimine ethyl ester, a bioavailable derivative of a natural sulfur amino acid metabolite, has demonstrated effects on autophagy both in vitro and in vivo. Thirty minutes after a moderate central fluid percussion injury and throughout the survival period, lanthionine ketimine ethyl ester was administered, and mice were subsequently evaluated for learning and memory impairments and biochemical and histological changes over a 5-week period. Lanthionine ketimine ethyl ester, which we have shown previously to modulate autophagy markers and alleviate pathology and slow cognitive decline in the 3 x TgAD mouse model, spared cognition and pathology after central fluid percussion injury through a mechanism involving autophagy modulation. C1 [Hensley, Kenneth; Hristov, Alexandar M.; Venkova-Hristova, Kalina M.] Univ Toledo, Dept Pathol, Hlth Sci Campus, Toledo, OH USA. [Hensley, Kenneth] Univ Toledo, Dept Neurosci, Hlth Sci Campus, Toledo, OH USA. [Gabbita, S. Prasad] P2D Biosci Inc, Cincinnati, OH USA. [Poteshkina, Aleksandra; Johnson, Ming F.; Eslami, Pirooz; Harris-White, Marni E.] Vet Adm Greater Los Angeles Healthcare Syst, Los Angeles, CA USA. [Harris-White, Marni E.] Univ Calif Los Angeles, David Geffen Sch Med, Dept Med, 11301 Wilshire Blvd 151, Los Angeles, CA 90073 USA. RP Harris-White, ME (reprint author), Univ Calif Los Angeles, David Geffen Sch Med, Dept Med, 11301 Wilshire Blvd 151, Los Angeles, CA 90073 USA. EM marni@ucla.edu NR 90 TC 2 Z9 2 U1 1 U2 3 PU MARY ANN LIEBERT, INC PI NEW ROCHELLE PA 140 HUGUENOT STREET, 3RD FL, NEW ROCHELLE, NY 10801 USA SN 0897-7151 EI 1557-9042 J9 J NEUROTRAUM JI J. Neurotrauma PD AUG 15 PY 2016 VL 33 IS 16 BP 1501 EP + DI 10.1089/neu.2015.4196 PG 14 WC Critical Care Medicine; Clinical Neurology; Neurosciences SC General & Internal Medicine; Neurosciences & Neurology GA DU6ED UT WOS:000382305900004 PM 26530250 ER PT J AU Wang, X Beste, LA Maier, MM Zhou, XH AF Wang, Xuan Beste, Lauren A. Maier, Marissa M. Zhou, Xiao-Hua TI Double robust estimator of average causal treatment effect for censored medical cost data SO STATISTICS IN MEDICINE LA English DT Article DE average causal treatment effect; censored data; double robust estimator; inverse probability weighted; lifetime medical cost data ID DEPENDENT TERMINAL EVENT; PROPENSITY SCORE; LONGITUDINAL DATA; REGRESSION; TIMES; MODEL AB In observational studies, estimation of average causal treatment effect on a patient's response should adjust for confounders that are associated with both treatment exposure and response. In addition, the response, such as medical cost, may have incomplete follow-up. In this article, a double robust estimator is proposed for average causal treatment effect for right censored medical cost data. The estimator is double robust in the sense that it remains consistent when either the model for the treatment assignment or the regression model for the response is correctly specified. Double robust estimators increase the likelihood the results will represent a valid inference. Asymptotic normality is obtained for the proposed estimator, and an estimator for the asymptotic variance is also derived. Simulation studies show good finite sample performance of the proposed estimator and a real data analysis using the proposed method is provided as illustration. Copyright (c) 2016 John Wiley & Sons, Ltd. C1 [Wang, Xuan; Zhou, Xiao-Hua] Univ Washington, Dept Biostat, Seattle, WA 98195 USA. [Beste, Lauren A.] Univ Washington, VA Puget Sound Hlth Care Syst, Div Gen Internal Med, VA Natl Liver Dis Database,Sch Med, Seattle, WA USA. [Maier, Marissa M.] Oregon Hlth & Sci Univ, HIV Hepatitis & Publ Hlth Pathogens Program, VA Portland Hlth Care Syst,Div Infect Dis, Infect Dis Sect,Off Patient Care Serv,VHA, Portland, OR 97201 USA. [Zhou, Xiao-Hua] Seattle HSR Ctr Innovat Veteran Cr & Value Driven, Dept Vet Affairs Med Ctr, Seattle, WA USA. RP Zhou, XH (reprint author), Univ Washington, Dept Biostat, Seattle, WA 98195 USA. EM azhou@u.washington.edu FU US Department of Veterans Affairs, Veterans Affairs Health Administration Research Career Scientist Award [RCS 05-196] FX Xiao-Hua (Andrew) Zhou, PhD, is presently the Core Investigator and Biostatistics Unit Director at the Seattle HSR&D Center of Innovation for Veteran-Centered and Value-Driven Care, Department of Veterans Affairs Medical Center, Seattle, WA. The views expressed in this article are those of the authors and do not necessarily represent the views of the Department of Veterans Affairs. Dr. Zhou's work was supported in part by US Department of Veterans Affairs, Veterans Affairs Health Administration Research Career Scientist Award (RCS 05-196), NR 23 TC 0 Z9 0 U1 2 U2 3 PU WILEY-BLACKWELL PI HOBOKEN PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA SN 0277-6715 EI 1097-0258 J9 STAT MED JI Stat. Med. PD AUG 15 PY 2016 VL 35 IS 18 BP 3101 EP 3116 DI 10.1002/sim.6876 PG 16 WC Mathematical & Computational Biology; Public, Environmental & Occupational Health; Medical Informatics; Medicine, Research & Experimental; Statistics & Probability SC Mathematical & Computational Biology; Public, Environmental & Occupational Health; Medical Informatics; Research & Experimental Medicine; Mathematics GA DR6PZ UT WOS:000380025100005 PM 26818601 ER PT J AU Tan-Shalaby, JL Carrick, J Edinger, K Genovese, D Liman, AD Passero, VA Shah, RB AF Tan-Shalaby, Jocelyn L. Carrick, Jennifer Edinger, Krystal Genovese, Dana Liman, Andrew D. Passero, Vida A. Shah, Rashmikant B. TI Modified Atkins diet in advanced malignancies - final results of a safety and feasibility trial within the Veterans Affairs Pittsburgh Healthcare System SO NUTRITION & METABOLISM LA English DT Article ID KETOGENIC DIET; METABOLIC MANAGEMENT; ADVANCED CANCER; KETONE-BODIES; EXPRESSION; THERAPY; LEPTIN; CELLS; GLIOBLASTOMA; EPILEPSY AB Background: Dysfunctional mitochondrial processes limit malignant cells ability to use energy from fatty acids and ketones. Animal studies using ketogenic diets for cancer show encouraging results. We tested the diet's safety and feasibility in cancer patients across a broad variety of solid tumors. Methods: We recruited 17 advanced cancer patients who were not on chemotherapy. They consumed 20 to 40 g of carbohydrates daily with evaluations performed weekly until week 4, then every 4 weeks until 16 weeks. Quality of life questionnaires monitored for tolerability and compliance. Positron emission/computerized tomography was ordered at baseline, 4,8 and 16 weeks. Student t-testing evaluated differences between baseline and last visit scores for quality of life, weight, body mass index, and serum parameters. Correlations between weight loss and serum ketones, glucose, lipids and creatinine were done. Two-tailed unpaired t-testing of the mean weight loss compared responders against non-responders. Results: Eleven out of seventeen enrolled patients were evaluable. Mean age was 65+/- 11.7 years, weight 203 +/- 4.98 lbs. (92 +/- 2.3 kgs.) and previous treatment failures was 1.7, +/- 0.97. All lost significant weight with hematologic, biochemical and lipid tests remaining stable. Quality of life scores slightly improved. At 4,8 and 16 weeks, six (54.5 %), five (45.4 %) and four (36 %) patients were stable or improved. We observed no correlations between serum glucose, ketones or lipids. Clinical response did not correlate with ketosis or glycemia. Responders (stable disease or partial responders) lost statistically more weight than non-responders. Dietary compliance was difficult. Only three patients continued dieting past 16 weeks. Out of these, two patients developed brain metastases and were on steroids. They survived 80 and 116 weeks respectively. The third patient underwent residual tumor resection and has no disease at 131 weeks. Conclusions: Modified Atkins diets are safe and feasible in advanced cancer. Quality of life was preserved. Patients who lost at least 10 % of their body weight responded the best. Steroid intake affected optimal ketone and glucose levels. Despite this, survival improved in some melanoma and lung cancer patients. Further studies are recommended. C1 [Tan-Shalaby, Jocelyn L.; Carrick, Jennifer; Edinger, Krystal; Genovese, Dana; Liman, Andrew D.; Passero, Vida A.; Shah, Rashmikant B.] Vet Affairs Pittsburgh Healthcare Syst, Pittsburgh, PA 15261 USA. [Tan-Shalaby, Jocelyn L.; Edinger, Krystal; Genovese, Dana; Liman, Andrew D.; Passero, Vida A.] Univ Pittsburgh, Sch Med, Pittsburgh, PA 15260 USA. RP Tan-Shalaby, JL (reprint author), Vet Affairs Pittsburgh Healthcare Syst, Pittsburgh, PA 15261 USA.; Tan-Shalaby, JL (reprint author), Univ Pittsburgh, Sch Med, Pittsburgh, PA 15260 USA. EM jocelyn.tan@va.gov FU Veterans Research Foundation of Pittsburgh FX Tammy Cobaugh for her help in drafting the initial trial protocol; Samantha Bonant, Alanna Caffas and and Sharlene Wylie for research assistance Becky Englert RN, Lynn Marmarelli RN and Pamela Malicki RN for patient recruitment and followup; Mary Kay Winkelman for her secretarial contribution; Joseph Mikolic for statistical analysis; Mariam Shalaby for proofreading and technical support. I am grateful to the Veterans Research Foundation of Pittsburgh for their overall support and confidence in this project. I would like to thank Dr. Thomas Seyfried, Professor of Biology at Boston College, for his critical comments and valuable feedback during the editing and revision of the final manuscript. NR 28 TC 2 Z9 2 U1 6 U2 10 PU BIOMED CENTRAL LTD PI LONDON PA 236 GRAYS INN RD, FLOOR 6, LONDON WC1X 8HL, ENGLAND SN 1743-7075 J9 NUTR METAB JI Nutr. Metab. PD AUG 12 PY 2016 VL 13 AR 52 DI 10.1186/s12986-016-0113-y PG 12 WC Nutrition & Dietetics SC Nutrition & Dietetics GA DT9CY UT WOS:000381794300001 PM 27525031 ER PT J AU Bibbins-Domingo, K Grossman, DC Curry, SJ Davidson, KW Epling, JW Garcia, FAR Gillman, MW Kemper, AR Krist, AH Kurth, AE Landefeld, CS LeFevre, M Mangione, CM Phillips, WR Phipps, MG Pignone, MP Siu, AL AF Bibbins-Domingo, Kirsten Grossman, David C. Curry, Susan J. Davidson, Karina W. Epling, John W., Jr. Garcia, Francisco A. R. Gillman, Matthew W. Kemper, Alex R. Krist, Alex H. Kurth, Ann E. Landefeld, C. Seth LeFevre, Michael Mangione, Carol M. Phillips, William R. Phipps, Maureen G. Pignone, Michael P. Siu, Albert L. CA US Preventive Serv Task Force TI Screening for Lipid Disorders in Children and Adolescents US Preventive Services Task Force Recommendation Statement SO JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION LA English DT Review ID FAMILIAL HYPERCHOLESTEROLEMIA; BLOOD; DYSLIPIDEMIA; PREVALENCE; CHILDHOOD; THERAPY; DISEASE; TRENDS; RISK AB IMPORTANCE Elevations in levels of total, low-density lipoprotein, and non-high-density lipoprotein cholesterol; lower levels of high-density lipoprotein cholesterol; and, to a lesser extent, elevated triglyceride levels are associated with risk of cardiovascular disease in adults. OBJECTIVE To update the 2007 US Preventive Services Task Force (USPSTF) recommendation on screening for lipid disorders in children, adolescents, and young adults. EVIDENCE REVIEW The USPSTF reviewed the evidence on screening for lipid disorders in children and adolescents 20 years or younger-1 review focused on screening for heterozygous familial hypercholesterolemia, and 1 review focused on screening for multifactorial dyslipidemia. FINDINGS Evidence on the quantitative difference in diagnostic yield between universal and selective screening approaches, the effectiveness and harms of long-term treatment and the harms of screening, and the association between changes in intermediate outcomes and improvements in adult cardiovascular health outcomes are limited. Therefore, the USPSTF concludes that the balance of benefits and harms cannot be determined. CONCLUSIONS AND RECOMMENDATION The USPSTF concludes that the current evidence is insufficient to assess the balance of benefits and harms of screening for lipid disorders in children and adolescents 20 years or younger. (I statement) C1 [Bibbins-Domingo, Kirsten] Univ Calif San Francisco, San Francisco, CA 94143 USA. [Grossman, David C.] Grp Hlth Res Inst, Seattle, WA USA. [Curry, Susan J.] Univ Iowa, Iowa City, IA USA. [Davidson, Karina W.] Columbia Univ, New York, NY USA. [Epling, John W., Jr.] SUNY Upstate Med Univ, Syracuse, NY 13210 USA. [Garcia, Francisco A. R.] Pima Cty Dept Hlth, Tucson, AZ USA. [Gillman, Matthew W.] Harvard Med Sch, Boston, MA USA. [Gillman, Matthew W.] Harvard Pilgrim Hlth Care Inst, Boston, MA USA. [Kemper, Alex R.] Duke Univ, Durham, NC USA. [Krist, Alex H.] Fairfax Family Practice Residency, Fairfax, VA USA. [Krist, Alex H.] Virginia Commonwealth Univ, Richmond, VA 23284 USA. [Kurth, Ann E.] Yale Univ, New Haven, CT USA. [Landefeld, C. Seth] Univ Alabama Birmingham, Birmingham, AL USA. [LeFevre, Michael] Univ Missouri, Columbia, MO 65211 USA. [Mangione, Carol M.] Univ Calif Los Angeles, Los Angeles, CA USA. [Phillips, William R.] Univ Washington, Seattle, WA 98195 USA. [Phipps, Maureen G.] Brown Univ, Providence, RI 02912 USA. [Pignone, Michael P.] Univ Texas Austin, Austin, TX 78712 USA. [Siu, Albert L.] Mt Sinai Sch Med, New York, NY USA. [Siu, Albert L.] James J Peters Vet Affairs Med Ctr, Bronx, NY USA. RP Bibbins-Domingo, K (reprint author), Univ Calif San Francisco, San Francisco, CA 94143 USA. OI Epling, John W/0000-0001-9445-8669 FU Agency for Healthcare Research and Quality (AHRQ) FX The USPSTF is an independent, voluntary body. The US Congress mandates that the Agency for Healthcare Research and Quality (AHRQ) support the operations of the USPSTF. NR 32 TC 3 Z9 3 U1 3 U2 3 PU AMER MEDICAL ASSOC PI CHICAGO PA 330 N WABASH AVE, STE 39300, CHICAGO, IL 60611-5885 USA SN 0098-7484 EI 1538-3598 J9 JAMA-J AM MED ASSOC JI JAMA-J. Am. Med. Assoc. PD AUG 9 PY 2016 VL 316 IS 6 BP 625 EP 633 DI 10.1001/jama.2016.9852 PG 9 WC Medicine, General & Internal SC General & Internal Medicine GA DS7TK UT WOS:000380985600015 ER PT J AU Duan-Porter, W Goldstein, KM McDuffie, JR Hughes, JM Clowse, MEB Klap, RS Masilamani, V LaPointe, NMA Nagi, A Gierisch, JM Williams, JW AF Duan-Porter, Wei Goldstein, Karen M. McDuffie, Jennifer R. Hughes, Jaime M. Clowse, Megan E. B. Klap, Ruth S. Masilamani, Varsha LaPointe, Nancy M. Allen Nagi, Avishek Gierisch, Jennifer M. Williams, John W., Jr. TI Reporting of Sex Effects by Systematic Reviews on Interventions for Depression, Diabetes, and Chronic Pain SO ANNALS OF INTERNAL MEDICINE LA English DT Article ID RANDOMIZED-CONTROLLED-TRIAL; LOW-BACK-PAIN; ACUTE MYOCARDIAL-INFARCTION; CARDIOVASCULAR RISK-FACTORS; SELF-MANAGEMENT EDUCATION; INDIVIDUAL PATIENT DATA; LOW-GLYCEMIC-INDEX; QUALITY-OF-LIFE; CLINICAL-TRIALS; KNEE OSTEOARTHRITIS AB Systematic reviews (SRs) have the potential to contribute uniquely to the evaluation of sex and gender differences (termed "sex effects"). This article describes the reporting of sex effects by SRs on interventions for depression, type 2 diabetes mellitus, and chronic pain conditions (chronic low back pain, knee osteoarthritis, and fibromyalgia). It includes SRs published since 1 October 2009 that evaluate medications, behavioral interventions, exercise, quality improvement, and some condition-specific treatments. The reporting of sex effects by primary randomized, controlled trials is also examined. Of 313 eligible SRs (86 for depression, 159 for type 2 diabetes mellitus, and 68 for chronic pain), few (n = 29) reported sex effects. Most SRs reporting sex effects used metaregression, whereas 9 SRs used subgroup analysis or individual-patient data meta-analysis. The proportion of SRs reporting the sex distribution of primary studies varied from a low of 31% (n = 8) for low back pain to a high of 68% (n = 23) for fibromyalgia. Primary randomized, controlled trials also infrequently reported sex effects, and most lacked an adequate sample size to examine them. Therefore, all SRs should report the proportion of women enrolled in primary studies and evaluate sex effects using appropriate methods whenever power is adequate. C1 Durham Vet Affairs Med Ctr, Durham, NC USA. [Clowse, Megan E. B.] Duke Univ, Sch Med, 200 Trent Dr,7 Baker House, Durham, NC 27710 USA. [Hughes, Jaime M.] Univ N Carolina, Campus Box 7200, Chapel Hill, NC 27599 USA. Vet Affairs Greater Los Angeles Healthcare Syst, Los Angeles, CA USA. Durham Vet Affairs Med Ctr, Hlth Adm Hlth Serv Res & Dev, 411 West Chapel Hill St,Suite 600, Durham, NC 27701 USA. [Duan-Porter, Wei; McDuffie, Jennifer R.; Masilamani, Varsha; Nagi, Avishek] Durham Vet Affairs Med Ctr, Hlth Serv Res & Dev, 411 West Chapel Hill St,Suite 600, Durham, NC 27701 USA. [Goldstein, Karen M.; Gierisch, Jennifer M.] Durham Vet Affairs Med Ctr, Hlth Serv Res & Dev, 508 Fulton St, Durham, NC 27705 USA. [Klap, Ruth S.] Vet Affairs West Los Angeles Med Ctr, 11301 Wilshire Blvd,Bldg 206,Room 231, Los Angeles, CA 90073 USA. [LaPointe, Nancy M. Allen] Duke Univ, Med Ctr, Duke Clin Res Inst, POB 17969, Durham, NC 27715 USA. [Williams, John W., Jr.] Durham Vet Affairs Med Ctr, Hlth Serv Res & Dev, 411 West Chapel Hill St,Suite 500, Durham, NC 27701 USA. RP Duan-Porter, W (reprint author), Durham Vet Affairs Med Ctr, Hlth Adm Hlth Serv Res & Dev, 411 West Chapel Hill St,Suite 600, Durham, NC 27701 USA. EM wei.duan-porter@duke.edu FU Veterans Affairs Office of Academic Affiliations [TPM 21-022]; Veterans Health Administration Health Services Research Development [13-263] FX By the Veterans Affairs Office of Academic Affiliations (fellowship support TPM 21-022; Dr. Duan-Porter) and the Veterans Health Administration Health Services Research & Development (Career Development Award 13-263; Dr. Goldstein). NR 122 TC 0 Z9 0 U1 5 U2 9 PU AMER COLL PHYSICIANS PI PHILADELPHIA PA INDEPENDENCE MALL WEST 6TH AND RACE ST, PHILADELPHIA, PA 19106-1572 USA SN 0003-4819 EI 1539-3704 J9 ANN INTERN MED JI Ann. Intern. Med. PD AUG 2 PY 2016 VL 165 IS 3 BP 184 EP + DI 10.7326/M15-2877 PG 21 WC Medicine, General & Internal SC General & Internal Medicine GA DS2HA UT WOS:000380583300007 PM 27111355 ER PT J AU Cain, KD Sehgal, BR Covinsky, KE Kaelber, DC Sehgal, AR AF Cain, Katrice D. Sehgal, Bindu R. Covinsky, Kenneth E. Kaelber, David C. Sehgal, Ashwini R. TI The Clinical Impact of Medical Journals SO ANNALS OF INTERNAL MEDICINE LA English DT Letter C1 [Cain, Katrice D.; Sehgal, Ashwini R.] Case Western Reserve Univ, Metrohlth Med Ctr, Ctr Reducing Hlth Dispar, Cleveland, OH 44106 USA. [Sehgal, Bindu R.] Premier Phys Ctr, Westlake, OH USA. [Covinsky, Kenneth E.] Univ Calif San Francisco, San Francisco Vet Affairs Med Ctr, San Francisco, CA 94143 USA. [Kaelber, David C.] Case Western Reserve Univ, Metrohlth Med Ctr, Ctr Clin Informat Res & Educ, Cleveland, OH USA. RP Cain, KD (reprint author), Case Western Reserve Univ, Metrohlth Med Ctr, Ctr Reducing Hlth Dispar, Cleveland, OH 44106 USA. NR 4 TC 1 Z9 1 U1 1 U2 2 PU AMER COLL PHYSICIANS PI PHILADELPHIA PA INDEPENDENCE MALL WEST 6TH AND RACE ST, PHILADELPHIA, PA 19106-1572 USA SN 0003-4819 EI 1539-3704 J9 ANN INTERN MED JI Ann. Intern. Med. PD AUG 2 PY 2016 VL 165 IS 3 BP 227 EP 228 DI 10.7326/M16-1096 PG 2 WC Medicine, General & Internal SC General & Internal Medicine GA DS2HA UT WOS:000380583300016 PM 27294687 ER PT J AU Kahle, KT Flores, B Bharucha-Goebel, D Zhang, JW Donkervoort, S Hegde, M Hussain, G Duran, D Liang, B Sun, DD Bonnemann, CG Delpire, E AF Kahle, Kristopher T. Flores, Bianca Bharucha-Goebel, Diana Zhang, Jinwei Donkervoort, Sandra Hegde, Madhuri Hussain, Gulnaz Duran, Daniel Liang, Bo Sun, Dandan Bonnemann, Carsten G. Delpire, Eric TI Peripheral motor neuropathy is associated with defective kinase regulation of the KCC3 cotransporter SO Science Signaling LA English DT Article ID CATION-CHLORIDE COTRANSPORTERS; CONDITIONAL MOUSE MODEL; CELL-VOLUME HOMEOSTASIS; K+-CL-COTRANSPORTER; CORPUS-CALLOSUM; MISSENSE MUTATIONS; ANDERMANN-SYNDROME; HEREDITARY MOTOR; DISEASE; MICE AB Using exome sequencing, we identified a de novo mutation (c.2971A>G; T991A) in SLC12A6, the gene encoding the K+-Cl(-)cotransporter KCC3, in a patient with an early-onset, progressive, and severe peripheral neuropathy primarily affecting motor neurons. Normally, the WNK kinase-dependent phosphorylation of T-991 tonically inhibits KCC3; however, cell swelling triggers Thr(991) dephosphorylation to activate the transporter and restore cell volume. KCC3 (T991A) mutation in patient cells abolished Thr(991) phosphorylation, resulted in constitutive KCC3 activity, and compromised cell volume homeostasis. KCC3(T991A/T991A) mutant mice exhibited constitutive KCC3 activity and recapitulated aspects of the clinical, electrophysiological, and histopathological findings of the patient. These results suggest that the function of the peripheral nervous system depends on finely tuned, kinase-regulated KCC3 activity and implicate abnormal cell volume homeostasis as a previously unreported mechanism of axonal degeneration. C1 [Kahle, Kristopher T.; Zhang, Jinwei; Duran, Daniel] Yale Sch Med, Ctr Mendelian Genom, Dept Neurosurg, New Haven, CT 06510 USA. [Kahle, Kristopher T.; Zhang, Jinwei; Duran, Daniel] Yale Sch Med, Ctr Mendelian Genom, Dept Pediat & Cellular & Mol Physiol, New Haven, CT 06510 USA. [Flores, Bianca; Delpire, Eric] Vanderbilt Univ, Sch Med, Dept Anesthesiol, Nashville, TN 37232 USA. [Bharucha-Goebel, Diana; Donkervoort, Sandra; Bonnemann, Carsten G.] NINDS, Neuromuscular & Neurogenet Disorders Childhood Se, Neurogenet Branch, Bethesda, MD 20814 USA. [Bharucha-Goebel, Diana] Childrens Natl Hlth Syst, Dept Neurol, Washington, DC 20010 USA. [Zhang, Jinwei] Univ Dundee, Coll Life Sci, Prot Phosphorylat & Ubiquitylat Unit, MRC, Dundee DD15EH, Scotland. [Hegde, Madhuri] Emory Univ, Dept Human Genet, Atlanta, GA 30322 USA. [Hussain, Gulnaz; Sun, Dandan] Univ Pittsburgh, Dept Neurol, Pittsburgh, PA 15213 USA. [Hussain, Gulnaz; Sun, Dandan] Vet Affairs Pittsburgh Hlth Care Syst, Geriatr Res, Educ & Clin Ctr, Pittsburgh, PA 15240 USA. [Liang, Bo] Harvard Med Sch, Dept MicroBiol, Boston, MA 02114 USA. [Liang, Bo] Harvard Med Sch, Dept Immunobiol, Boston, MA 02114 USA. RP Delpire, E (reprint author), Vanderbilt Univ, Sch Med, Dept Anesthesiol, Nashville, TN 37232 USA.; Bonnemann, CG (reprint author), NINDS, Neuromuscular & Neurogenet Disorders Childhood Se, Neurogenet Branch, Bethesda, MD 20814 USA. EM carsten.bonnemann@nih.gov; eric.delpire@vanderbilt.edu OI Duran, Daniel/0000-0001-6888-252X; Zhang, Jinwei/0000-0001-8683-509X FU NIH [GM74771, 2T32MH064913-11A1, T32-AR056993]; Harvard-Massachusetts Institute of Technology Neuroscience Grant; Manton Center for Orphan Disease Research at Harvard Medical School; March of Dimes Basil O'Connor Award; NINDS FX This work was supported by NIH research grant GM74771 (E.D.). K.T.K. was supported by a Harvard-Massachusetts Institute of Technology Neuroscience Grant, the Manton Center for Orphan Disease Research at Harvard Medical School, and the March of Dimes Basil O'Connor Award. C.G.B. is supported by intramural funds of the NINDS. B.F. and D.B.G. received support from NIH grants 2T32MH064913-11A1 and T32-AR056993, respectively. NR 51 TC 3 Z9 3 U1 1 U2 1 PU AMER ASSOC ADVANCEMENT SCIENCE PI WASHINGTON PA 1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA SN 1945-0877 EI 1937-9145 J9 SCI SIGNAL JI Sci. Signal. PD AUG 2 PY 2016 VL 9 IS 439 AR ra77 DI 10.1126/scisignal.aae0546 PG 14 WC Biochemistry & Molecular Biology; Cell Biology SC Biochemistry & Molecular Biology; Cell Biology GA DS4VJ UT WOS:000380779400001 PM 27485015 ER PT J AU Zhu, X Wu, C Waldron, R Lugea, A Pandol, S Li, L AF Zhu, X. Wu, C. Waldron, R. Lugea, A. Pandol, S. Li, L. TI Pancreatic stellate cells express insulin receptor (IR) and IGF-1 receptor (IGF-1R) on the cell surface: implication for pancreatic fibrogenesis in type 2 diabetes SO DIABETOLOGIA LA English DT Meeting Abstract CT 52nd Annual Meeting of the European-Association-for-the-Study-of-Diabetes (EASD) CY SEP 12-16, 2016 CL Munich, GERMANY SP European Assoc Study Diabet C1 [Zhu, X.; Wu, C.; Li, L.] Southeast Univ, Nanjing, Jiangsu, Peoples R China. [Waldron, R.; Lugea, A.; Pandol, S.] Cedars Sinai Med Ctr, Los Angeles, CA 90048 USA. [Waldron, R.; Lugea, A.; Pandol, S.] Univ Calif Los Angeles, VA Greater Los Angeles Healthcare Syst, Los Angeles, CA USA. NR 0 TC 0 Z9 0 U1 0 U2 0 PU SPRINGER PI NEW YORK PA 233 SPRING ST, NEW YORK, NY 10013 USA SN 0012-186X EI 1432-0428 J9 DIABETOLOGIA JI Diabetologia PD AUG PY 2016 VL 59 SU 1 MA 537 BP S257 EP S258 PG 2 WC Endocrinology & Metabolism SC Endocrinology & Metabolism GA EQ8ZJ UT WOS:000398373701342 ER PT J AU Singh, JA Yu, SH AF Singh, Jasvinder A. Yu, Shaohua TI Time Trends, Predictors, and Outcome of Emergency Department Use for Gout: A Nationwide US Study SO JOURNAL OF RHEUMATOLOGY LA English DT Article DE GOUT; EMERGENCY ROOM; CHARGES; HOSPITALIZATION; INPATIENT USE; HEALTHCARE USE ID HEALTH-CARE UTILIZATION; HOSPITAL ADMISSIONS; GENERAL-POPULATION; TREATMENT PATTERNS; UNITED-STATES; ARTHRITIS; HYPERURICEMIA; COMORBIDITIES; COSTS AB Objective. To assess gout-related emergency department (ED) use/charges and discharge disposition. Methods. We used the US National ED Sample (NEDS) data to examine the time trends in total ED visits and charges and ED-related hospitalizations with gout as the primary diagnosis. We assessed multivariable-adjusted predictors of ED charges and hospitalization for gout-related visits using the 2012 NEDS data. Results. There were 180,789, 201,044, and 205,152 ED visits in 2009, 2010, and 2012 with gout as the primary diagnosis, with total ED charges of $195 million, $239 million, and $287 million, respectively; these accounted for 0.14%-0.16% of all ED visits. Mean/median 2012 ED charges/visit were $1398/$956. Of all gout-related ED visits, 7.7% were admitted to the hospital in 2012. Mean/median length of hospital stay was 3.9/2.6 days and mean/median inpatient charge/admission with gout as the primary diagnosis was $22,066/$15,912 in 2012. In multivariable-adjusted analyses, these factors were associated with higher ED charges: older age, female sex, highest income quartile, being uninsured, metropolitan residence, Western United States hospital location, heart disease, renal failure, heart failure, hypertension (HTN), diabetes, osteoarthritis (OA), and chronic obstructive pulmonary disease (COPD). These factors were associated with higher odds of hospitalization: older age, Northeast location, metropolitan teaching hospital, higher income quartile, heart disease, renal failure, heart failure, hyperlipidemia, HTN, diabetes, COPD, and OA, whereas self-pay insurance status was associated with lower odds of hospitalization, following an ED visit for gout. Conclusion. Absolute ED use and charges for gout increased over time, but relative use remained stable. Modifiable comorbidity factors associated with higher gout-related use should be targeted to reduce morbidity and healthcare use. C1 [Singh, Jasvinder A.] Birmingham VA Med Ctr, Med Serv, Birmingham, AL USA. [Singh, Jasvinder A.; Yu, Shaohua] UAB, Sch Med, Dept Med, Birmingham, AL USA. [Singh, Jasvinder A.; Yu, Shaohua] UAB, Sch Publ Hlth, Div Epidemiol, Birmingham, AL USA. [Singh, Jasvinder A.] Mayo Clin, Coll Med, Dept Orthoped Surg, Rochester, MN USA. RP Singh, JA (reprint author), Univ Alabama Birmingham, Fac Off Tower 805B,510 20th St S, Birmingham, AL 35294 USA. EM Jasvinder.md@gmail.com FU UAB Division of Rheumatology; US National Institute of Arthritis and Musculoskeletal and Skin Diseases [P50 AR060772] FX Supported by research funds from the UAB Division of Rheumatology and the resources and use of facilities at the Birmingham VA Medical Center. JAS is also supported by a grant from the US National Institute of Arthritis and Musculoskeletal and Skin Diseases (P50 AR060772). NR 20 TC 1 Z9 1 U1 3 U2 3 PU J RHEUMATOL PUBL CO PI TORONTO PA 365 BLOOR ST E, STE 901, TORONTO, ONTARIO M4W 3L4, CANADA SN 0315-162X EI 1499-2752 J9 J RHEUMATOL JI J. Rheumatol. PD AUG PY 2016 VL 43 IS 8 BP 1581 EP 1588 DI 10.3899/jrheum.151419 PG 8 WC Rheumatology SC Rheumatology GA DS6HG UT WOS:000380882300021 ER PT J AU Hou, LP Bergen, SE Akula, N Song, J Hultman, CM Landen, M Adli, M Alda, M Ardau, R Arias, B Aubry, JM Backlund, L Badner, JA Barrett, TB Bauer, M Baune, BT Bellivier, F Benabarre, A Bengesser, S Berrettini, WH Bhattacharjee, AK Biernacka, JM Birner, A Bloss, CS Brichant-Petitjean, C Bui, ET Byerley, W Cervantes, P Chillotti, C Cichon, S Colom, F Coryell, W Craig, DW Cruceanu, C Czerski, PM Davis, T Dayer, A Degenhardt, F Del Zompo, M DePaulo, JR Edenberg, HJ Etain, B Falkai, P Foroud, T Forstner, AJ Frisen, L Frye, MA Fullerton, JM Gard, S Garnham, JS Gershon, ES Goes, FS Greenwood, TA Grigoroiu-Serbanescu, M Hauser, J Heilbronner, U Heilmann-Heimbach, S Herms, S Hipolito, M Hitturlingappa, S Hoffmann, P Hofmann, A Jamain, S Jimenez, E Kahn, JP Kassem, L Kelsoe, JR Kittel-Schneider, S Kliwicki, S Koller, DL Konig, B Lackner, N Laje, G Lang, M Lavebratt, C Lawson, WB Leboyer, M Leckband, SG Liu, CY Maaser, A Mahon, PB Maier, W Maj, M Manchia, M Martinsson, L McCarthy, MJ McElroy, SL McInnis, MG McKinney, R Mitchell, PB Mitjans, M Mondimore, FM Monteleone, P Muhleisen, TW Nievergelt, CM Nothen, MM Novak, T Nurnberger, JI Nwulia, EA Osby, U Pfennig, A Potash, JB Propping, P Reif, A Reininghaus, E Rice, J Rietschel, M Rouleau, GA Rybakowski, JK Schalling, M Scheftner, WA Schofield, PR Schork, NJ Schulze, TG Schumacher, J Schweizer, BW Severino, G Shekhtman, T Shilling, PD Simhandl, C Slaney, CM Smith, EN Squassina, A Stamm, T Stopkova, P Streit, F Strohmaier, J Szelinger, S Tighe, SK Tortorella, A Turecki, G Vieta, E Volkert, J Witt, SH Wright, A Zandi, PP Zhang, P Zollner, S McMahon, FJ AF Hou, Liping Bergen, Sarah E. Akula, Nirmala Song, Jie Hultman, Christina M. Landen, Mikael Adli, Mazda Alda, Martin Ardau, Raffaella Arias, Barbara Aubry, Jean-Michel Backlund, Lena Badner, Judith A. Barrett, Thomas B. Bauer, Michael Baune, Bernhard T. Bellivier, Frank Benabarre, Antonio Bengesser, Susanne Berrettini, Wade H. Bhattacharjee, Abesh Kumar Biernacka, Joanna M. Birner, Armin Bloss, Cinnamon S. Brichant-Petitjean, Clara Bui, Elise T. Byerley, William Cervantes, Pablo Chillotti, Caterina Cichon, Sven Colom, Francesc Coryell, William Craig, David W. Cruceanu, Cristiana Czerski, Piotr M. Davis, Tony Dayer, Alexandre Degenhardt, Franziska Del Zompo, Maria DePaulo, J. Raymond Edenberg, Howard J. Etain, Bruno Falkai, Peter Foroud, Tatiana Forstner, Andreas J. Frisen, Louise Frye, Mark A. Fullerton, Janice M. Gard, Sebastien Garnham, Julie S. Gershon, Elliot S. Goes, Fernando S. Greenwood, Tiffany A. Grigoroiu-Serbanescu, Maria Hauser, Joanna Heilbronner, Urs Heilmann-Heimbach, Stefanie Herms, Stefan Hipolito, Maria Hitturlingappa, Shashi Hoffmann, Per Hofmann, Andrea Jamain, Stephane Jimenez, Esther Kahn, Jean-Pierre Kassem, Layla Kelsoe, John R. Kittel-Schneider, Sarah Kliwicki, Sebastian Koller, Daniel L. Koenig, Barbara Lackner, Nina Laje, Gonzalo Lang, Maren Lavebratt, Catharina Lawson, William B. Leboyer, Marion Leckband, Susan G. Liu, Chunyu Maaser, Anna Mahon, Pamela B. Maier, Wolfgang Maj, Mario Manchia, Mirko Martinsson, Lina McCarthy, Michael J. McElroy, Susan L. McInnis, Melvin G. McKinney, Rebecca Mitchell, Philip B. Mitjans, Marina Mondimore, Francis M. Monteleone, Palmiero Muehleisen, Thomas W. Nievergelt, Caroline M. Noethen, Markus M. Novak, Tomas Nurnberger, John I., Jr. Nwulia, Evaristus A. Osby, Urban Pfennig, Andrea Potash, James B. Propping, Peter Reif, Andreas Reininghaus, Eva Rice, John Rietschel, Marcella Rouleau, Guy A. Rybakowski, Janusz K. Schalling, Martin Scheftner, William A. Schofield, Peter R. Schork, Nicholas J. Schulze, Thomas G. Schumacher, Johannes Schweizer, Barbara W. Severino, Giovanni Shekhtman, Tatyana Shilling, Paul D. Simhandl, Christian Slaney, Claire M. Smith, Erin N. Squassina, Alessio Stamm, Thomas Stopkova, Pavla Streit, Fabian Strohmaier, Jana Szelinger, Szabolcs Tighe, Sarah K. Tortorella, Alfonso Turecki, Gustavo Vieta, Eduard Volkert, Julia Witt, Stephanie H. Wright, Adam Zandi, Peter P. Zhang, Peng Zollner, Sebastian McMahon, Francis J. TI Genome-wide association study of 40,000 individuals identifies two novel loci associated with bipolar disorder SO HUMAN MOLECULAR GENETICS LA English DT Article ID TO-CASE RATIO; X-CHROMOSOME; GENETIC ASSOCIATION; STATISTICAL POWER; SPECTRUM DISORDER; LITHIUM TREATMENT; COMPLEX TRAITS; RISK LOCI; SCHIZOPHRENIA; POPULATION AB Bipolar disorder (BD) is a genetically complex mental illness characterized by severe oscillations of mood and behaviour. Genome-wide association studies (GWAS) have identified several risk loci that together account for a small portion of the heritability. To identify additional risk loci, we performed a two-stage meta-analysis of >9 million genetic variants in 9,784 bipolar disorder patients and 30,471 controls, the largest GWAS of BD to date. In this study, to increase power we used similar to 2,000 lithium-treated cases with a long-term diagnosis of BD from the Consortium on Lithium Genetics, excess controls, and analytic methods optimized for markers on the X-chromosome. In addition to four known loci, results revealed genome-wide significant associations at two novel loci: an intergenic region on 9p21.3 (rs12553324, P = 5.87 x 10(-9); odds ratio (OR) = 1.12) and markers within ERBB2 (rs2517959, P = 4.53 x 10(-9); OR = 1.13). No significant X-chromosome associations were detected and X-linked markers explained very little BD heritability. The results add to a growing list of common autosomal variants involved in BD and illustrate the power of comparing well-characterized cases to an excess of controls in GWAS. C1 [Hou, Liping; Akula, Nirmala; Bui, Elise T.; Kassem, Layla; Laje, Gonzalo; Schulze, Thomas G.; McMahon, Francis J.] NIMH, Intramural Res Program, NIH, US Dept HHS, Bethesda, MD 20892 USA. [Bergen, Sarah E.; Song, Jie; Hultman, Christina M.; Landen, Mikael] Karolinska Inst, Dept Med Epidemiol & Biostat, Stockholm, Sweden. [Bergen, Sarah E.] Broad Inst MIT & Harvard, Stanley Ctr Psychiat Res, Cambridge, MA USA. [Landen, Mikael] Gothenburg Univ, Sahlgrenska Acad, Inst Neurosci & Physiol, Gothenburg, Sweden. [Adli, Mazda; Stamm, Thomas] Charite, Campus Charite Mitte, Dept Psychiat & Psychotherapy, Berlin, Germany. [Alda, Martin; Garnham, Julie S.; Slaney, Claire M.] Dalhousie Univ, Dept Psychiat, Halifax, NS, Canada. [Ardau, Raffaella; Chillotti, Caterina] Hosp Univ Agcy Cagliari, Clin Pharmacol Unit, Cagliari, Italy. [Arias, Barbara; Mitjans, Marina] Univ Barcelona, CIBERSAM, Dept Biol Anim, Unitat Antropol Dp Biol Anim,Fac Biol, Barcelona, Spain. [Arias, Barbara; Mitjans, Marina] Univ Barcelona, CIBERSAM, Inst Biomed IBUB, Barcelona, Spain. [Aubry, Jean-Michel; Dayer, Alexandre] Univ Hosp Geneva, Mood Disorders Unit, Dept Mental Hlth & Psychiat, Geneva, Switzerland. [Backlund, Lena; Lavebratt, Catharina; Schalling, Martin] Karolinska Inst, Dept Mol Med & Surg, Stockholm, Sweden. [Backlund, Lena; Lavebratt, Catharina; Osby, Urban; Schalling, Martin] Karolinska Univ Hosp, Ctr Mol Med, Stockholm, Sweden. [Badner, Judith A.; Gershon, Elliot S.] Univ Chicago, Dept Psychiat & Behav Neurosci, Chicago, IL 60637 USA. [Barrett, Thomas B.] Portland VA Med Ctr, Portland, OR USA. [Bauer, Michael; Pfennig, Andrea] Tech Univ Dresden, Univ Hosp Carl Gustav Carus, Dept Psychiat & Psychotherapy, Dresden, Germany. [Baune, Bernhard T.; Davis, Tony; Hitturlingappa, Shashi] Univ Adelaide, Discipline Psychiat, Adelaide, SA, Australia. [Bellivier, Frank; Brichant-Petitjean, Clara] Univ Paris Diderot, INSERM UMR S 1144, Pole Psychiat, Grp Hosp Lariboisiere F Widal,AP HP, Paris, France. [Benabarre, Antonio; Colom, Francesc; Jimenez, Esther; Vieta, Eduard] Univ Barcelona, IDIBAPS, CIBERSAM, Bipolar Disorder Program,Inst Neurosci,Hosp Clin, Barcelona, Spain. [Bengesser, Susanne; Birner, Armin; Lackner, Nina; Reininghaus, Eva] Med Univ Graz, Special Outpatient Ctr Bipolar Affect Disorder, Graz, Austria. [Berrettini, Wade H.] Univ Penn, Dept Psychiat, Philadelphia, PA 19104 USA. [Bhattacharjee, Abesh Kumar; Greenwood, Tiffany A.; Kelsoe, John R.; McKinney, Rebecca; Nievergelt, Caroline M.; Shekhtman, Tatyana; Shilling, Paul D.] Univ Calif San Diego, Dept Psychiat, San Diego, CA 92103 USA. [Biernacka, Joanna M.] Mayo Clin, Dept Hlth Sci Res, Rochester, MN USA. [Biernacka, Joanna M.; Frye, Mark A.] Mayo Clin, Dept Psychiat & Psychol, Rochester, MN USA. [Bloss, Cinnamon S.; Schork, Nicholas J.; Smith, Erin N.] Scripps Translat Sci Inst, La Jolla, CA USA. [Byerley, William] Univ Calif San Francisco, Dept Psychiat, San Francisco, CA USA. [Cervantes, Pablo] McGill Univ, Ctr Hlth, Disorders Program, Montreal, PQ, Canada. [Cichon, Sven; Degenhardt, Franziska; Forstner, Andreas J.; Heilmann-Heimbach, Stefanie; Herms, Stefan; Hoffmann, Per; Hofmann, Andrea; Maaser, Anna; Muehleisen, Thomas W.; Noethen, Markus M.; Propping, Peter; Schumacher, Johannes] Univ Bonn, Inst Human Genet, Bonn, Germany. [Cichon, Sven; Degenhardt, Franziska; Forstner, Andreas J.; Heilmann-Heimbach, Stefanie; Herms, Stefan; Hoffmann, Per; Hofmann, Andrea; Maaser, Anna; Muehleisen, Thomas W.; Noethen, Markus M.; Schumacher, Johannes] Univ Bonn, Life Brain Ctr, Dept Genom, Bonn, Germany. [Cichon, Sven; Hoffmann, Per; Muehleisen, Thomas W.] Res Ctr Julich, Inst Neurosci & Med INM 1, Julich, Germany. [Cichon, Sven; Herms, Stefan; Hoffmann, Per] Univ Basel, Div Med Genet, Basel, Switzerland. [Cichon, Sven; Herms, Stefan; Hoffmann, Per] Univ Basel, Dept Biomed, Basel, Switzerland. [Coryell, William] Univ Iowa Hosp & Clin, Iowa City, IA 52242 USA. [Craig, David W.; Szelinger, Szabolcs] Translat Genom Res Inst, Phoenix, AZ USA. [Cruceanu, Cristiana; Turecki, Gustavo] McGill Univ, Douglas Mental Hlth Univ Inst, Montreal, PQ, Canada. [Czerski, Piotr M.; Hauser, Joanna] Poznan Univ Med Sci, Psychiat Genet Unit, Poznan, Poland. [Del Zompo, Maria; Manchia, Mirko; Severino, Giovanni; Squassina, Alessio] Univ Cagliari, Dept Biomed Sci, Cagliari, Italy. [DePaulo, J. Raymond; Goes, Fernando S.; Mahon, Pamela B.; Mondimore, Francis M.; Schulze, Thomas G.; Schweizer, Barbara W.] Johns Hopkins Sch Med, Dept Psychiat & Behav Sci, Baltimore, MD USA. [Edenberg, Howard J.] Indiana Univ Sch Med, Dept Biochem & Mol Biol, Indianapolis, IN 46202 USA. [Etain, Bruno; Jamain, Stephane; Leboyer, Marion] Univ Paris Est Creteil, INSERM U955, Psychiat Translat, Pole Psychiat & Addictol,Hop Univ Henri Mondor, Creteil, France. [Falkai, Peter] Ludwig Maximilians Univ Munchen, Dept Psychiat & Psychotherapy, Munich, Germany. [Foroud, Tatiana; Koller, Daniel L.] Indiana Univ Sch Med, Dept Med & Mol Genet, Indianapolis, IN 46202 USA. [Frisen, Louise; Martinsson, Lina] Karolinska Inst, Dept Clin Neurosci, Stockholm, Sweden. [Frisen, Louise] Child & Adolescent Psychiat Res Ctr, Stockholm, Sweden. [Fullerton, Janice M.] Neurosci Res Australia, Psychiat Genet, Sydney, NSW, Australia. [Fullerton, Janice M.; Schofield, Peter R.] Univ New South Wales, Sch Med Sci, Sydney, NSW 2052, Australia. [Gard, Sebastien] Hop Charles Perrens, Psychiat Serv, Bordeaux, France. [Grigoroiu-Serbanescu, Maria] Alexandru Obregia Clin Psychiat Hosp, Biometr Psychiat Genet Res Unit, Bucharest, Romania. [Heilbronner, Urs; Schulze, Thomas G.] Ludwig Maximilians Univ Munchen, Inst Psychiat Phen & Genom, Munich, Germany. [Heilbronner, Urs; Schulze, Thomas G.] Georg August Univ Gottingen, Univ Med Ctr, Dept Psychiat & Psychotherapy, Gottingen, Germany. [Hipolito, Maria; Lawson, William B.; Nwulia, Evaristus A.] Howard Univ Hosp, Dept Psychiat & Behav Sci, Washington, DC USA. [Kahn, Jean-Pierre] Univ Lorraine, Ctr Psychotherap Nancy, Serv Psychiat & Psychol Clin, Nancy, France. [Kittel-Schneider, Sarah; Reif, Andreas; Volkert, Julia] Univ Hosp Frankfurt, Dept Psychiat Psychosomat Med & Psychotherapy, Frankfurt, Germany. [Kliwicki, Sebastian; Rybakowski, Janusz K.] Poznan Univ Med Sci, Dept Adult Psychiat, Poznan, Poland. [Koenig, Barbara] Landesklinikum Neunkirchen, Dept Psychiat & Psychotherapeuth Med, Neunkirchen, Austria. [Lang, Maren; Rietschel, Marcella; Schulze, Thomas G.; Streit, Fabian; Strohmaier, Jana; Witt, Stephanie H.] Heidelberg Univ, Dept Genet Epidemiol Psychiat, Cent Inst Mental Hlth, Med Fac Mannheim, Mannheim, Germany. [Leckband, Susan G.] VA San Diego Healthcare Syst, Dept Pharm, San Diego, CA USA. [Liu, Chunyu] Univ Illinois, Dept Psychiat, Chicago, IL 60612 USA. [Maier, Wolfgang] Univ Bonn, Dept Psychiat, Bonn, Germany. [Maj, Mario; Monteleone, Palmiero; Tortorella, Alfonso] Univ Naples SUN, Dept Psychiat, Naples, Italy. [Manchia, Mirko] Dalhousie Univ, Dept Pharmacol, Halifax, NS, Canada. [McCarthy, Michael J.] VA San Diego Healthcare Syst, Dept Psychiat, San Diego, CA USA. [McElroy, Susan L.] Univ Cincinnati, Coll Med, Lindner Ctr HOPE, Mason, OH USA. [McInnis, Melvin G.; Zhang, Peng; Zollner, Sebastian] Univ Michigan, Dept Psychiat, Ann Arbor, MI USA. [Mitchell, Philip B.; Wright, Adam] Univ New South Wales, Sch Psychiat, Sydney, NSW, Australia. [Mitchell, Philip B.; Wright, Adam] Black Dog Inst, Sydney, NSW, Australia. [Monteleone, Palmiero] Univ Salerno, Dept Med & Surg, Neurosci Sect, Salerno, Italy. [Novak, Tomas; Stopkova, Pavla] Natl Inst Mental Hlth, Klecany, Czech Republic. [Nurnberger, John I., Jr.] Indiana Univ Sch Med, Dept Psychiat, Indianapolis, IN 46202 USA. [Nurnberger, John I., Jr.] Karolinska Inst, Dept Neurobiol Care Sci & Soc, Stockholm, Sweden. [Potash, James B.; Tighe, Sarah K.] Univ Iowa, Sch Med, Dept Psychiat, Carver Coll Med, Iowa City, IA 52242 USA. [Rice, John] Washington Univ, Sch Med, Dept Psychiat, St Louis, MO 63110 USA. [Rouleau, Guy A.] McGill Univ, Montreal Neurol Inst & Hosp, Montreal, PQ, Canada. [Scheftner, William A.] Rush Univ, Med Ctr, Chicago, IL 60612 USA. [Schofield, Peter R.] Neurosci Res Australia, Mental Illness, Sydney, NSW, Australia. [Simhandl, Christian] Bipolar Ctr Wiener Neustadt, Wiener Neustadt, Austria. [Zandi, Peter P.] Johns Hopkins Bloomberg Sch Publ Hlth, Dept Mental Hlth, Baltimore, MD USA. RP McMahon, FJ (reprint author), NIMH, Human Genet Branch, Intramural Res Program, 35 Convent Dr,Rm 1A201, Bethesda, MD 20892 USA. EM mcmahonf@mail.nih.gov RI Novak, Tomas/B-8008-2017; Serbanescu, Maria/D-4306-2011 OI Novak, Tomas/0000-0001-9156-9654; Serbanescu, Maria/0000-0002-1304-6687; Mitjans, Marina/0000-0001-5543-7320; Squassina, Alessio/0000-0001-7415-7607; Maaser, Anna/0000-0002-9440-0712; Dayer, Alexandre/0000-0002-4490-9780; Manchia, Mirko/0000-0003-4175-6413; JIMENEZ, ESTHER/0000-0001-6929-6207 FU National Institute of Mental Health (NIMH) [ZIA-MH00284311]; NARSAD Young Investigator Award FX This work was supported by the National Institute of Mental Health (NIMH) Intramural Research Program (ZIA-MH00284311; NCT00001174) and a NARSAD Young Investigator Award to L.H. NR 62 TC 3 Z9 3 U1 6 U2 6 PU OXFORD UNIV PRESS PI OXFORD PA GREAT CLARENDON ST, OXFORD OX2 6DP, ENGLAND SN 0964-6906 EI 1460-2083 J9 HUM MOL GENET JI Hum. Mol. Genet. PD AUG 1 PY 2016 VL 25 IS 15 BP 3383 EP 3394 DI 10.1093/hmg/ddw181 PG 12 WC Biochemistry & Molecular Biology; Genetics & Heredity SC Biochemistry & Molecular Biology; Genetics & Heredity GA EJ2YK UT WOS:000393077300018 PM 27329760 ER PT J AU Soni, NJ Franco-Sadud, R Schnobrich, D Dancel, R Tierney, DM Salame, G Restrepo, MI McHardy, P AF Soni, Nilam J. Franco-Sadud, Ricardo Schnobrich, Daniel Dancel, Ria Tierney, David M. Salame, Gerard Restrepo, Marcos I. McHardy, Paul TI Ultrasound guidance for lumbar puncture SO NEUROLOGY-CLINICAL PRACTICE LA English DT Review ID GUIDED SPINAL-ANESTHESIA; EPIDURAL-ANESTHESIA; EMERGENCY-DEPARTMENT; LANDMARKS; SPACE; ULTRASONOGRAPHY; LEVEL; IDENTIFICATION; VISUALIZATION; METAANALYSIS AB Purpose of review: To review the literature and describe techniques to use ultrasound to guide performance of lumbar puncture (LP). Recent findings: Ultrasound evaluation of the lumbar spine has been shown in randomized trials to improve LP success rates while reducing the number of attempts and the number of traumatic taps. Summary: Ultrasound mapping of the lumbar spine reveals anatomical information that is not obtainable by physical examination, including depth of the ligamentum flavum, width of the interspinous spaces, and spinal bone abnormalities, including scoliosis. Using static ultrasound, the lumbar spine anatomy is visualized in transverse and longitudinal planes and the needle insertion site is marked. Using real-time ultrasound guidance, the needle tip is tracked in a paramedian plane as it traverses toward the ligamentum flavum. Future research should focus on efficient methods to train providers, cost-effectiveness of ultrasound-guided LP, and the role of new needle-tracking technologies to facilitate the procedure. C1 [Soni, Nilam J.] South Texas Vet Hlth Care Syst, Sect Hosp Med, San Antonio, TX USA. [Soni, Nilam J.; Restrepo, Marcos I.] South Texas Vet Hlth Care Syst, Sect Pulm & Crit Care Med, San Antonio, TX USA. Univ Texas Hlth Sci Ctr San Antonio, San Antonio, TX 78229 USA. [Franco-Sadud, Ricardo] Med Coll Wisconsin, Div Gen Internal Med, Sect Hosp Med, Milwaukee, WI 53226 USA. [Schnobrich, Daniel] Univ Minnesota, Div Gen Internal Med, Minneapolis, MN USA. [Dancel, Ria] Univ N Carolina, Div Gen Med & Epidemiol, Chapel Hill, NC USA. [Tierney, David M.] Abbott NW Hosp, Dept Med Educ, Minneapolis, MN USA. [Salame, Gerard] Univ Colorado, Denver Hlth Hosp, Div Hosp Med, Boulder, CO 80309 USA. [McHardy, Paul] Sunnybrook Hlth Sci Ctr, Dept Anesthesia, Toronto, ON, Canada. RP Soni, NJ (reprint author), South Texas Vet Hlth Care Syst, Sect Hosp Med, San Antonio, TX USA.; Soni, NJ (reprint author), South Texas Vet Hlth Care Syst, Sect Pulm & Crit Care Med, San Antonio, TX USA. EM sonin@uthscsa.edu FU National Heart, Lung, and Blood Institute [K23HL096054] FX Partially supported by award K23HL096054 (MIR) from the National Heart, Lung, and Blood Institute. NR 42 TC 1 Z9 1 U1 0 U2 0 PU LIPPINCOTT WILLIAMS & WILKINS PI PHILADELPHIA PA TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA SN 2163-0402 EI 2163-0933 J9 NEUROL-CLIN PRACT JI Neurol.-Clin. Pract. PD AUG PY 2016 VL 6 IS 4 BP 358 EP 368 DI 10.1212/CPJ.0000000000000265 PG 11 WC Clinical Neurology SC Neurosciences & Neurology GA EJ3GW UT WOS:000393101600014 ER PT J AU Zapata, JA Widera, E AF Zapata, Josue A. Widera, Eric TI Partial Codes-A Symptom of a Larger Problem SO JAMA INTERNAL MEDICINE LA English DT Editorial Material C1 [Zapata, Josue A.] Univ Calif San Francisco, Dept Internal Med, San Francisco, CA 94143 USA. [Zapata, Josue A.] San Francisco VA Med Ctr, Div Hosp Med, San Francisco, CA USA. [Widera, Eric] San Francisco VA Med Ctr, Palliat Care & Hosp Serv, San Francisco, CA USA. [Widera, Eric] Univ Calif San Francisco, Div Geriatr, San Francisco, CA 94143 USA. RP Zapata, JA (reprint author), Univ Calif San Francisco, San Francisco VA Med Ctr, Dept Internal Med, 4150 Clement St,Bldg 203,1A-81, San Francisco, CA 94121 USA. EM josue.zapata@ucsf.edu NR 8 TC 0 Z9 0 U1 0 U2 0 PU AMER MEDICAL ASSOC PI CHICAGO PA 330 N WABASH AVE, STE 39300, CHICAGO, IL 60611-5885 USA SN 2168-6106 EI 2168-6114 J9 JAMA INTERN MED JI JAMA Intern. Med. PD AUG PY 2016 VL 176 IS 8 BP 1058 EP 1059 DI 10.1001/jamainternmed.2016.2540 PG 2 WC Medicine, General & Internal SC General & Internal Medicine GA DT0AN UT WOS:000381145000005 PM 27295527 ER PT J AU Leventhal, JS Ross, MJ AF Leventhal, Jeremy S. Ross, Michael J. TI LAPping up dead cells to prevent lupus nephritis: a novel role for noncanonical autophagy in autoimmunity SO KIDNEY INTERNATIONAL LA English DT Editorial Material ID DEFICIENCY; CLEARANCE AB The mechanisms underlying the development of systemic lupus erythematosus and lupus nephritis remain poorly understood. A recent study demonstrates that deficiencies in the immune system's ability to degrade scavenged dead cells via noncanonical autophagy is sufficient to break immune tolerance and produce features commonly seen in lupus, including circulating autoantibodies, inflammatory cytokines, and nephritis. This work provides a possible mechanism for the association of polymorphisms in autophagy genes with the risk of lupus. C1 [Leventhal, Jeremy S.; Ross, Michael J.] Icahn Sch Med Mt Sinai, Dept Med, Div Nephrol, New York, NY 10029 USA. [Leventhal, Jeremy S.; Ross, Michael J.] James J Peters Bronx Vet Affairs Med Ctr, Div Renal, Bronx, NY USA. RP Leventhal, JS (reprint author), Icahn Sch Med Mt Sinai, Div Nephrol, 1 Gustave L Levy Pl,Box 1243, New York, NY 10029 USA. EM Jeremy.leventhal@mssm.edu FU NIDDK NIH HHS [R01 DK108346, K08 DK090217, R01 DK101338] NR 9 TC 0 Z9 0 U1 5 U2 5 PU ELSEVIER SCIENCE INC PI NEW YORK PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA SN 0085-2538 EI 1523-1755 J9 KIDNEY INT JI Kidney Int. PD AUG PY 2016 VL 90 IS 2 BP 238 EP 239 DI 10.1016/j.kint.2016.06.001 PG 2 WC Urology & Nephrology SC Urology & Nephrology GA EI6BZ UT WOS:000392581300001 PM 27418084 ER PT J AU Navar, AM Peterson, ED Li, S Goldberg, AC Virani, SS Roger, VL Robinson, JG Wilson, PWF Elassal, J Lee, LV Wang, TY AF Navar, A. M. Peterson, E. D. Li, S. Goldberg, A. C. Virani, S. S. Roger, V. L. Robinson, J. G. Wilson, P. W. F. Elassal, J. Lee, L. V. Wang, T. Y. TI Are clinicians following statin intensity recommendations? Insights in 135 U.S community practices in the PALM registry SO EUROPEAN HEART JOURNAL LA English DT Meeting Abstract CT Congress of the European-Society-of-Cardiology (ESC) CY AUG 27-31, 2016 CL Rome, ITALY SP European Soc Cardiol C1 [Navar, A. M.; Peterson, E. D.; Li, S.; Wang, T. Y.] Duke Clin Res Inst, Durham, NC USA. [Goldberg, A. C.] Washington Univ, Sch Med, St Louis, MO USA. [Virani, S. S.] VA Med Ctr, Houston, TX USA. [Roger, V. L.] Mayo Clin, Rochester, MN USA. [Robinson, J. G.] Univ Iowa, Iowa City, IA USA. [Wilson, P. W. F.] Emory Univ, Atlanta, GA 30322 USA. [Elassal, J.] Regeneron Pharmaceut Inc, 777 Old Saw Mill River Rd, Tarrytown, NY 10591 USA. [Lee, L. V.] Sanofi Pharmaceut, Bridgewater, MA USA. NR 0 TC 0 Z9 0 U1 1 U2 1 PU OXFORD UNIV PRESS PI OXFORD PA GREAT CLARENDON ST, OXFORD OX2 6DP, ENGLAND SN 0195-668X EI 1522-9645 J9 EUR HEART J JI Eur. Heart J. PD AUG 1 PY 2016 VL 37 SU 1 MA 273 BP 32 EP 32 PG 1 WC Cardiac & Cardiovascular Systems SC Cardiovascular System & Cardiology GA DW7YL UT WOS:000383869500098 ER PT J AU Tanimoto, T Parsenghian, MH Petrov, AD Nakahara, T Kawai, H Nishimura, R Weisbart, RH Chan, G Richieri, RA Reynolds, GT Sengupta, PP Haider, N Blankenberg, FG Strauss, HW Narula, J AF Tanimoto, T. Parsenghian, M. H. Petrov, A. D. Nakahara, T. Kawai, H. Nishimura, R. Weisbart, R. H. Chan, G. Richieri, R. A. Reynolds, G. T. Sengupta, P. P. Haider, N. Blankenberg, F. G. Strauss, H. W. Narula, J. TI Cardioprotective effects of Fv-HSP70 injection on ischemic/reperfusion injury SO EUROPEAN HEART JOURNAL LA English DT Meeting Abstract CT Congress of the European-Society-of-Cardiology (ESC) CY AUG 27-31, 2016 CL Rome, ITALY SP European Soc Cardiol C1 [Tanimoto, T.; Petrov, A. D.; Nakahara, T.; Kawai, H.; Sengupta, P. P.; Haider, N.; Strauss, H. W.; Narula, J.] Mt Sinai Sch Med, Cardiol, New York, NY USA. [Parsenghian, M. H.; Richieri, R. A.; Reynolds, G. T.] Rubicon Biotechnol, Lake Forest, IL USA. [Nishimura, R.; Weisbart, R. H.] Univ Calif Los Angeles, Los Angeles, CA USA. [Chan, G.] Vet Affairs Greater Los Angeles Healthcare Syst, Los Angeles, CA USA. [Blankenberg, F. G.] Lucile Salter Packard Childrens Hosp, Stanford, CA USA. NR 0 TC 0 Z9 0 U1 0 U2 0 PU OXFORD UNIV PRESS PI OXFORD PA GREAT CLARENDON ST, OXFORD OX2 6DP, ENGLAND SN 0195-668X EI 1522-9645 J9 EUR HEART J JI Eur. Heart J. PD AUG 1 PY 2016 VL 37 SU 1 MA P1801 BP 370 EP 370 PG 1 WC Cardiac & Cardiovascular Systems SC Cardiovascular System & Cardiology GA DW7YL UT WOS:000383869501567 ER PT J AU Halbach, M Abraham, WT Butter, C Ducharme, A Klug, D Little, WC Lovett, E Schafer, JE Senni, E Swarup, V Wachter, R Weaver, FA Zile, MR Muller-Ehmsen, J AF Halbach, M. Abraham, W. T. Butter, C. Ducharme, A. Klug, D. Little, W. C. Lovett, E. Schafer, J. E. Senni, E. Swarup, V. Wachter, R. Weaver, F. A. Zile, M. R. Muller-Ehmsen, J. TI Baroreflex activation therapy for the treatment of heart failure with reduced ejection fraction in patients with and without coronary artery disease SO EUROPEAN HEART JOURNAL LA English DT Meeting Abstract CT Congress of the European-Society-of-Cardiology (ESC) CY AUG 27-31, 2016 CL Rome, ITALY SP European Soc Cardiol C1 [Halbach, M.] Cologne Univ Hosp, Ctr Heart, Dept Internal Med 3, Cologne, Germany. [Abraham, W. T.] Ohio State Univ, Div Cardiovasc Med, Columbus, OH 43210 USA. [Butter, C.] Immanuel Heart Ctr Bernau, Med Sch Brandenburg, Dept Cardiol, Bernau, Germany. [Ducharme, A.] Univ Montreal, Montreal Heart Inst, Montreal, PQ, Canada. [Klug, D.] Lille Univ Hosp, Dept Cardiol A, Lille, France. [Little, W. C.] Univ Mississippi, Med Ctr, Div Cardiol, Jackson, MS 39216 USA. [Lovett, E.] CVRx Inc, Minneapolis, MN USA. [Schafer, J. E.] NAMSA Inc, Dept Stat, Minneapolis, MN USA. [Senni, E.] Osped Papa Giovanni XXIII, Cardiovasc Dept, Bergamo, Italy. [Swarup, V.] Arizona Heart Hosp, Dept Electrophysiol, Phoenix, AZ USA. [Wachter, R.] Univ Med Gottingen, Gottingen, Germany. [Wachter, R.] German Cardiovasc Res Ctr, Clin Cardiol & Pneumol, Gottingen, Germany. [Weaver, F. A.] Univ Southern Calif, Div Vasc Surg & Endovasc Therapy, Keck Sch Med, Los Angeles, CA USA. [Zile, M. R.] Med Univ South Carolina, Ralph H Johnson Dept Vet Affairs Med Ctr, Charleston, SC USA. [Muller-Ehmsen, J.] Asklepios Clin Altona, Dept Med, Hamburg, Germany. NR 0 TC 0 Z9 0 U1 1 U2 1 PU OXFORD UNIV PRESS PI OXFORD PA GREAT CLARENDON ST, OXFORD OX2 6DP, ENGLAND SN 0195-668X EI 1522-9645 J9 EUR HEART J JI Eur. Heart J. PD AUG 1 PY 2016 VL 37 SU 1 MA P3612 BP 724 EP 725 PG 2 WC Cardiac & Cardiovascular Systems SC Cardiovascular System & Cardiology GA DW7YL UT WOS:000383869503409 ER PT J AU Navar, AM Wang, TY Zakroysky, P Li, S Goldberg, AC Virani, SS Roger, VL Robinson, JG Wilson, PWF Lee, LV Elassal, J Peterson, ED AF Navar, A. M. Wang, T. Y. Zakroysky, P. Li, S. Goldberg, A. C. Virani, S. S. Roger, V. L. Robinson, J. G. Wilson, P. W. F. Lee, L. V. Elassal, J. Peterson, E. D. TI Patient receptiveness to statin therapy is higher when presented with lifetime risk rather than 10-year risk of cardiovascular disease: insights from the PALM registry SO EUROPEAN HEART JOURNAL LA English DT Meeting Abstract CT Congress of the European-Society-of-Cardiology (ESC) CY AUG 27-31, 2016 CL Rome, ITALY SP European Soc Cardiol C1 [Navar, A. M.; Wang, T. Y.; Zakroysky, P.; Li, S.; Peterson, E. D.] Duke Clin Res Inst, Durham, NC USA. [Goldberg, A. C.] Washington Univ, Sch Med, St Louis, MO USA. [Virani, S. S.] VA Med Ctr, Houston, TX USA. [Roger, V. L.] Mayo Clin, Rochester, MN USA. [Robinson, J. G.] Univ Iowa, Iowa City, IA USA. [Wilson, P. W. F.] Emory Univ, Atlanta, GA 30322 USA. [Lee, L. V.] Sanofi Pharmaceut, Bridgewater, NJ USA. [Elassal, J.] Regeneron Pharmaceut, Tarrytown, NY USA. NR 0 TC 0 Z9 0 U1 0 U2 0 PU OXFORD UNIV PRESS PI OXFORD PA GREAT CLARENDON ST, OXFORD OX2 6DP, ENGLAND SN 0195-668X EI 1522-9645 J9 EUR HEART J JI Eur. Heart J. PD AUG 1 PY 2016 VL 37 SU 1 MA P5927 BP 1216 EP 1216 PG 1 WC Cardiac & Cardiovascular Systems SC Cardiovascular System & Cardiology GA DW7YL UT WOS:000383869506080 ER PT J AU Arora, M Gowda, S Tuscano, J AF Arora, Mili Gowda, Sonia Tuscano, Joseph TI A comprehensive review of lenalidomide in B-cell non-Hodgkin lymphoma SO THERAPEUTIC ADVANCES IN HEMATOLOGY LA English DT Review DE lenalidomide; non-Hodgkin lymphoma; rituximab ID SINGLE-AGENT LENALIDOMIDE; PHASE-II; PLUS RITUXIMAB; PROGNOSTIC-FACTORS; OPEN-LABEL; TRIAL; MULTICENTER; INDOLENT; THERAPY; DEXAMETHASONE AB Lenalidomide, an immunomodulatory drug that the US Food and Drug Administration (FDA) approved for the treatment of multiple myeloma, 5q-myelodysplasia and mantle-cell lymphoma (MCL), has encouraging efficacy in other B-cell malignancies. Its unique mechanism of action is in part due to altering the tumor microenvironment and potentiating the activity of T and natural-killer (NK) cells. Impressive clinical activity and excellent tolerability allows broad applicability. Lenalidomide has been used in a wide range of B-cell malignancies for years, but in 2013, the FDA marked its approval as a single agent only in relapsed/refractory mantle-cell lymphoma. Perhaps most impressive is the efficacy of lenalidomide when combined with monoclonal antibodies. Impressive efficacy and toxicity profiles with the combination of lenalidomide and rituximab in B-cell lymphomas in both the upfront and relapsed/refractory setting may allow a shift in our current treatment paradigm in both indolent and aggressive non-Hodgkin lymphoma (NHL). This review will summarize the current data in the relapsed/refractory and front-line setting of NHL with single-agent lenalidomide as well as its use in combination with other agents. C1 [Tuscano, Joseph] UC Davis Med Ctr, Northern Carolina Healthcare Syst, Div Hematol & Oncol, Dept Internal Med,Dept Vet Affairs, 4501 X St, Sacramento, CA 95817 USA. [Arora, Mili; Gowda, Sonia] Dept Internal Med, Div Hematol & Oncol, Sacramento, CA USA. [Arora, Mili] US Dept Vet Affairs, Northern Carolina Healthcare Syst, Sacramento, CA USA. RP Tuscano, J (reprint author), UC Davis Med Ctr, Northern Carolina Healthcare Syst, Div Hematol & Oncol, Dept Internal Med,Dept Vet Affairs, 4501 X St, Sacramento, CA 95817 USA. EM joseph.tuscano@ucdmc.ucdavis.edu NR 51 TC 1 Z9 1 U1 0 U2 0 PU SAGE PUBLICATIONS LTD PI LONDON PA 1 OLIVERS YARD, 55 CITY ROAD, LONDON EC1Y 1SP, ENGLAND SN 2040-6207 EI 2040-6215 J9 THER ADV HEMATOL JI Ther. Adv. Hematol. PD AUG PY 2016 VL 7 IS 4 BP 209 EP 221 DI 10.1177/2040620716652861 PG 13 WC Hematology SC Hematology GA DW5AF UT WOS:000383653400004 PM 27493711 ER PT J AU Pasquina, PF Isaacson, BM Johnson, E Rhoades, DS Lindholm, MP Grindle, GG Cooper, RA AF Pasquina, Paul F. Isaacson, Brad M. Johnson, Elizabeth Rhoades, Daniel S. Lindholm, Mark P. Grindle, Garrett G. Cooper, Rory A. TI A Patient-Controlled Analgesia Adaptor to Mitigate Postsurgical Pain for Combat Casualties With Multiple Limb Amputation: A Case Series SO MILITARY MEDICINE LA English DT Article ID REHABILITATION AB The use of explosive armaments during Operation Iraqi Freedom, Operation Enduring Freedom, and Operation New Dawn has resulted in a significant number of injured U.S. service members. These weapons often generate substantial extremity trauma requiring multiple surgical procedures to preserve life, limb, and restore function. For those individuals who require multiple surgeries, the use of patient-controlled analgesia (PCA) devices can be an effective way to achieve adequate pain management and promote successful rehabilitation and recovery during inpatient treatment. A subpopulation of patients are unable to independently control a PCA device because of severe multiple limb dysfunction and/or loss. In response to the needs of these patients, our team designed and developed a custom adaptor to assist service members who would otherwise not be able to use a PCA. Patient feedback of the device indicated a positive response, improved independence, and overall satisfaction during inpatient hospitalization. C1 [Pasquina, Paul F.; Isaacson, Brad M.; Johnson, Elizabeth; Rhoades, Daniel S.; Lindholm, Mark P.] Uniformed Serv Univ Hlth Sci, Ctr Rehabil Sci Res, Dept Phys Med & Rehabil, 4301 Jones Bridge Rd, Bethesda, MD 20814 USA. [Pasquina, Paul F.; Isaacson, Brad M.; Rhoades, Daniel S.; Lindholm, Mark P.] Walter Reed Natl Mil Med Ctr, Dept Rehabil, 8901 Wisconsin Ave, Bethesda, MD 20889 USA. [Isaacson, Brad M.; Johnson, Elizabeth] Henry M Jackson Fdn Adv Mil Med, 6720A Rockledge Dr,100, Bethesda, MD 20817 USA. [Grindle, Garrett G.; Cooper, Rory A.] Univ Pittsburgh, US Dept Vet Affairs, Human Engn Res Labs, 6425 Penn Ave,Suite 400, Pittsburgh, PA 15206 USA. [Grindle, Garrett G.; Cooper, Rory A.] Univ Pittsburgh, Dept Rehabil Sci & Technol, 6425 Penn Ave,Suite 400, Pittsburgh, PA 15206 USA. RP Pasquina, PF (reprint author), Uniformed Serv Univ Hlth Sci, Ctr Rehabil Sci Res, Dept Phys Med & Rehabil, 4301 Jones Bridge Rd, Bethesda, MD 20814 USA.; Pasquina, PF (reprint author), Walter Reed Natl Mil Med Ctr, Dept Rehabil, 8901 Wisconsin Ave, Bethesda, MD 20889 USA. FU Department of Defense [HU0001-11-1-0004, HU0001-15-2-0003]; Henry M. Jackson Foundation for the Advancement of Military Medicine FX This article is based on a work supported by the Department of Defense to the Center for Rehabilitation Science Research, Department of Physical Medicine and Rehabilitation, Uniformed Services University of Health Sciences (HU0001-11-1-0004, HU0001-15-2-0003) and The Henry M. Jackson Foundation for the Advancement of Military Medicine. NR 13 TC 0 Z9 0 U1 0 U2 0 PU ASSOC MILITARY SURG US PI BETHESDA PA 9320 OLD GEORGETOWN RD, BETHESDA, MD 20814 USA SN 0026-4075 EI 1930-613X J9 MIL MED JI Milit. Med. PD AUG PY 2016 VL 181 IS 8 BP E948 EP E951 DI 10.7205/MILMED-D-15-00315 PG 4 WC Medicine, General & Internal SC General & Internal Medicine GA DW5MI UT WOS:000383688900002 PM 27483540 ER PT J AU Gullbrand, SE Ashinsky, BG Martin, JT Pickup, S Smith, LJ Mauck, RL Smith, HE AF Gullbrand, Sarah E. Ashinsky, Beth G. Martin, John T. Pickup, Stephen Smith, Lachlan J. Mauck, Robert L. Smith, Harvey E. TI Correlations Between Quantitative T2 and T1 rho MRI, Mechanical Properties and Biochemical Composition in a Rabbit Lumbar Intervertebral Disc Degeneration Model SO JOURNAL OF ORTHOPAEDIC RESEARCH LA English DT Article DE T2; T1 rho; magnetic resonance imaging; intervertebral disc degeneration; biomechanics ID RELAXATION-TIMES; NUCLEUS PULPOSUS; PROTEOGLYCAN CONTENT; CARTILAGE; CHYMOPAPAIN; T-2 AB Improved diagnostic measures for intervertebral disc degeneration are necessary to facilitate early detection and treatment. The aim of this study was to correlate changes in mechanical and biochemical properties with the quantitative MRI parameters T2 and T1 rho in rabbit lumbar discs using an ex vivo chymopapain digestion model. Rabbit lumbar spinal motion segments from animals less than 6 months of age were injected with 100 mu l of saline (control) or chymopapain at 3, 15, or 100U/ml (n = 5 per group). T2 and T1 rho MRI series were obtained at 4.7T. Specimens were mechanically tested in tension-compression and creep. Normalized nucleus pulposus (NP) water and GAG contents were quantified. Stepwise multiple linear regression was performed to determine which parameters contributed significantly to changes in NP T2 and T1 rho. When all groups were included, multiple regression yielded a model with GAG, compressive modulus, and the creep time constants as variables significantly impacting T2 (multiple r(2) = 0.64, p = 0.006). GAG and neutral zone (NZ) modulus were identified as variables contributing to T1 rho (multiple r(2) = 0.28, p = 0.08). When specimens with advanced degeneration were excluded from the multiple regression analysis, T2 was significantly predicted by compressive modulus, tau(1), and water content (multiple r(2) = 0.71, p = 0.009), while no variables were significant predictors in the model for T1 rho. These results indicate that quantitative MRI can detect changes in the mechanical and biochemical properties of the degenerated disc. T2 may be more sensitive to early stage degenerative changes than T1 rho, while both quantitative MRI parameters are sensitive to advanced degeneration. (C) 2016 Orthopaedic Research Society. Published by Wiley Periodicals, Inc. C1 [Gullbrand, Sarah E.; Ashinsky, Beth G.; Martin, John T.; Smith, Lachlan J.; Mauck, Robert L.; Smith, Harvey E.] Univ Penn, McKay Orthopaed Res Lab, Dept Orthopaed Surg, Philadelphia, PA 19104 USA. [Gullbrand, Sarah E.; Martin, John T.; Smith, Lachlan J.; Mauck, Robert L.; Smith, Harvey E.] Philadelphia VA Med Ctr, Translat Musculoskeletal Res Ctr, Philadelphia, PA 19104 USA. [Pickup, Stephen] Univ Penn, Dept Radiol, Philadelphia, PA 19104 USA. [Smith, Lachlan J.] Univ Penn, Dept Neurosurg, Philadelphia, PA 19104 USA. RP Smith, HE (reprint author), Univ Penn, McKay Orthopaed Res Lab, Dept Orthopaed Surg, Philadelphia, PA 19104 USA.; Smith, HE (reprint author), Philadelphia VA Med Ctr, Translat Musculoskeletal Res Ctr, Philadelphia, PA 19104 USA. EM harvey.smith@uphs.upenn.edu FU Department of Veterans' Affairs [IK2 RX00147]; Penn Center for Musculoskeletal Disorders [P30 AR050950] FX Grant sponsor: Department of Veterans' Affairs; Grant number: IK2 RX00147; Grant sponsor: Penn Center for Musculoskeletal Disorders; Grant number: P30 AR050950. NR 33 TC 2 Z9 2 U1 2 U2 2 PU WILEY-BLACKWELL PI HOBOKEN PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA SN 0736-0266 EI 1554-527X J9 J ORTHOP RES JI J. Orthop. Res. PD AUG PY 2016 VL 34 IS 8 SI SI BP 1382 EP 1388 DI 10.1002/jor.23269 PG 7 WC Orthopedics SC Orthopedics GA DW5VU UT WOS:000383716300010 PM 27105019 ER PT J AU Muriuki, MG Havey, RM Voronov, LI Carandang, G Zindrick, MR Lorenz, MA Lomasney, L Patwardhan, AG AF Muriuki, Muturi G. Havey, Robert M. Voronov, Leonard I. Carandang, Gerard Zindrick, Michael R. Lorenz, Mark A. Lomasney, Laurie Patwardhan, Avinash G. TI Effects of Motion Segment Level, Pfirrmann Intervertebral Disc Degeneration Grade and Gender on Lumbar Spine Kinematics SO JOURNAL OF ORTHOPAEDIC RESEARCH LA English DT Article DE range of motion; high and low flexibility zone; rotational stiffness; hysteresis; MRI ID ANULUS FIBROSUS; FLEXIBILITY; STIFFNESS; MECHANICS; BEHAVIOR AB MRI allows non-invasive assessment of intervertebral disc degeneration with the added clinical benefit of using nonionizing radiation. What has remained unclear is the relationship between assessed disc degeneration and lumbar spine kinematics. Kinematic outcomes of 54 multi-segment (L1-Sacrum) lumbar spine specimens were calculated to discover if such an underlying relationship exists with degeneration assessed using the Pfirrmann grading system. Further analyses were also conducted to determine if kinematic outcomes were affected by motion segment level, gender or applied compressive preload. Range of motion, hysteresis, high flexibility zone size and rotational stiffness in flexion-extension, lateral bending and axial rotation were the kinematic outcomes. Caudal intervertebral discs in our study sample were more degenerative than cranial discs. L5-S1 discs had the largest flexion-extension range of motion (p < 0.005) and L1-L2 discs the lowest flexion high flexibility zone size (p < 0.013). No other strict cranial-caudal differences in kinematic outcomes were found. Low flexibility zone rotational stiffness increased with disc degeneration grade in extension, lateral bending and axial rotation (p < 0.001). Trends towards higher hysteresis and lower range of motion with increased degeneration were observed in flexion-extension and lateral bending. Applied compressive preload increased flexion-extension hysteresis and augmented the effect of degeneration on hysteresis (p < 0.0005). Female specimens had about one degree larger range of motion in all rotational modes, and higher flexion extension hysteresis (p = 0.016). These results suggest that gender differences exist in lumbar spine kinematics. Additionally high disc loads, applied compressive preload or applied moment, are needed to kinematically distinguish discs with different levels of degeneration. (C) 2016 Orthopaedic Research Society. Published by Wiley Periodicals, Inc. C1 [Muriuki, Muturi G.; Havey, Robert M.; Voronov, Leonard I.; Carandang, Gerard; Zindrick, Michael R.; Lorenz, Mark A.; Patwardhan, Avinash G.] US Dept Vet Affairs, Musculoskeletal Biomech Lab, Edward Hines Jr VA Hosp, Hines, IL 60141 USA. [Havey, Robert M.; Voronov, Leonard I.; Zindrick, Michael R.; Lorenz, Mark A.; Patwardhan, Avinash G.] Loyola Univ Chicago, Dept Orthopaed Surg & Rehabil, Maywood, IL USA. [Lomasney, Laurie] Loyola Univ Chicago, Dept Radiol, Maywood, IL USA. [Zindrick, Michael R.; Lorenz, Mark A.] Hinsdale Orthopaed Associates, Hinsdale, IL USA. RP Muriuki, MG (reprint author), US Dept Vet Affairs, Musculoskeletal Biomech Lab, Edward Hines Jr VA Hosp, Hines, IL 60141 USA. EM muturi_muriuki@yahoo.com OI Muriuki, Muturi/0000-0002-0620-9169 FU US Department of Veterans Affairs FX This work was supported in part by the US Department of Veterans Affairs. NR 26 TC 2 Z9 2 U1 0 U2 0 PU WILEY-BLACKWELL PI HOBOKEN PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA SN 0736-0266 EI 1554-527X J9 J ORTHOP RES JI J. Orthop. Res. PD AUG PY 2016 VL 34 IS 8 SI SI BP 1389 EP 1398 DI 10.1002/jor.23232 PG 10 WC Orthopedics SC Orthopedics GA DW5VU UT WOS:000383716300011 PM 26990567 ER PT J AU Ellimoottil, C Skolarus, T Gettman, M Boxer, R Kutikov, A Lee, BR Shelton, J Morgan, T AF Ellimoottil, Chandy Skolarus, Ted Gettman, Matthew Boxer, Richard Kutikov, Alexander Lee, Benjamin R. Shelton, Jeremy Morgan, Todd TI Telemedicine in Urology: State of the Art SO UROLOGY LA English DT Review ID RANDOMIZED CONTROLLED-TRIAL; REMOTE VIDEO VISITS; RADICAL PROSTATECTOMY; FOLLOW-UP; CARE; SURGERY; TELEHEALTH; SATISFACTION; SYSTEM; REIMBURSEMENT AB Whereas telemedicine is recognized as one of the fastest-growing components of the healthcare system, the status of telemedicine use in urology is largely unknown. In this narrative review, we detail studies that investigate the use of televisits and teleconsultations for urologic conditions. Moreover, we discuss current regulatory and reimbursement policies. Finally, we discuss the significant barriers to widespread dissemination and implementation of telemedicine and reasons why the field of urology may be positioned to become a leader in the provision of telemedicine services. Published by Elsevier Inc. C1 Univ Michigan, Dept Urol, Ann Arbor, MI 48109 USA. [Ellimoottil, Chandy] Univ Michigan, Inst Healthcare Policy & Innovat, 2800 Plymouth Rd,NCRC Bldg 14,G100-13, Ann Arbor, MI 48109 USA. VA Ann Arbor Healthcare Syst, Ctr Clin Management Res, Ann Arbor, MI USA. Mayo Clin, Coll Med, Dept Urol, Rochester, MN USA. Univ Calif Los Angeles, Dept Urol, Los Angeles, CA USA. Temple Univ Hlth Syst, Fox Chase Canc Ctr, Div Urol Oncol, Philadelphia, PA USA. Univ Arizona, Dept Urol, Tucson, AZ USA. Vet Affairs Greater Los Angeles, Los Angeles, CA USA. RP Ellimoottil, C (reprint author), Univ Michigan, Inst Healthcare Policy & Innovat, 2800 Plymouth Rd,NCRC Bldg 14,G100-13, Ann Arbor, MI 48109 USA. EM cellimoo@med.umich.edu FU Agency for Healthcare Research and Quality [1F32HS024193-01] FX This research was supported by the Agency for Healthcare Research and Quality (1F32HS024193-01 to Dr. Ellimoottil). NR 51 TC 2 Z9 2 U1 2 U2 2 PU ELSEVIER SCIENCE INC PI NEW YORK PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA SN 0090-4295 EI 1527-9995 J9 UROLOGY JI Urology PD AUG PY 2016 VL 94 BP 10 EP 15 DI 10.1016/j.urology.2016.02.061 PG 6 WC Urology & Nephrology SC Urology & Nephrology GA DW5OU UT WOS:000383696400010 PM 27109596 ER PT J AU Bennett, CL Prasad, SM Kennedy, WA AF Bennett, Charles L. Prasad, Sandip M. Kennedy, William A., II TI Telemedicine in Urology: State of the Art SO UROLOGY LA English DT Editorial Material C1 [Bennett, Charles L.] Univ South Carolina, Coll Pharm, Hollins Natl Canc Inst, Designated Canc Ctr, Charleston, SC 29424 USA. [Prasad, Sandip M.] Med Univ South Carolina, Dept Urol, Charleston, SC USA. [Prasad, Sandip M.] Ralph H Johnson VAMC, Dept Surg, Urol Sect, Charleston, SC USA. [Kennedy, William A., II] Stanford Univ, Med Ctr, Dept Urol, Palo Alto, CA 94304 USA. RP Bennett, CL (reprint author), Univ South Carolina, Coll Pharm, Hollins Natl Canc Inst, Designated Canc Ctr, Charleston, SC 29424 USA. NR 2 TC 0 Z9 0 U1 0 U2 0 PU ELSEVIER SCIENCE INC PI NEW YORK PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA SN 0090-4295 EI 1527-9995 J9 UROLOGY JI Urology PD AUG PY 2016 VL 94 BP 15 EP 16 DI 10.1016/j.urology.2016.02.062 PG 2 WC Urology & Nephrology SC Urology & Nephrology GA DW5OU UT WOS:000383696400011 PM 27207146 ER PT J AU Habib, SL Abboud, HE AF Habib, Samy L. Abboud, Hanna E. TI Tuberin regulates reactive oxygen species in renal proximal cells, kidney from rodents, and kidney from patients with tuberous sclerosis complex SO CANCER SCIENCE LA English DT Article DE Kidney; renal cells; reactive oxygen species; tumor suppressor gene; tumorigenesis ID OXIDATIVE DNA-DAMAGE; NADPH-OXIDASE; DIABETIC-NEPHROPATHY; ENDOTHELIAL-CELLS; PROSTATE-CANCER; EXPRESSION; DISEASE; SUPEROXIDE; NOX4; ACTIVATION AB Reactive oxygen species (ROS) are an important endogenous source of DNA damage and oxidative stress in all cell types. Deficiency in tuberin resulted in increased oxidative DNA damage in renal cells. In this study, the role of tuberin in the regulating of ROS and NADPH oxidases was investigated. Formation of ROS and activity of NADPH oxidases were significantly higher in mouse embryonic fibroblasts and in primary culture of rat renal proximal tubular epithelial tuberin-deficient cells compared to wild-type cells. In addition, expression of NADPH oxidase (Nox)1, Nox2, and Nox4 (Nox isoforms) was higher in mouse embryonic fibroblasts and renal proximal tubular epithelial tuberin-deficient cells compared to wild-type cells. Furthermore, activity levels of NADPH oxidases and protein expression of all Nox isoforms were higher in the renal cortex of rat deficient in tuberin. However, treatment of tuberin-deficient cells with rapamycin showed significant decrease in protein expression of all Nox. Significant increase in protein kinase C beta II expression was detected in tuberin-deficient cells, whereas inhibition of protein kinase C beta II by bisindolylmaleimide I resulted in decreased protein expression of all Nox isoforms. In addition, treatment of mice deficient in tuberin with rapamycin resulted in significant decrease in all Nox protein expression. Moreover, protein and mRNA expression of all Nox were highly expressed in tumor kidney tissue of patients with tuberous sclerosis complex compared to control kidney tissue of normal subjects. These data provide the first evidence that tuberin plays a novel role in regulating ROS generation, NADPH oxidase activity, and Nox expression that may potentially be involved in development of kidney tumor in patients with tuberous sclerosis complex. C1 [Habib, Samy L.; Abboud, Hanna E.] South Texas Vet Hlth Care Syst, Geriatr Res Educ & Clin Dept, San Antonio, TX USA. [Habib, Samy L.] Univ Texas Hlth Sci Ctr San Antonio, Dept Cellular & Struct Biol, San Antonio, TX 78229 USA. [Abboud, Hanna E.] Univ Texas Hlth Sci Ctr San Antonio, Dept Med, San Antonio, TX 78229 USA. RP Habib, SL (reprint author), Univ Texas Hlth Sci Ctr San Antonio, 7703 Floyd Curl Dr, San Antonio, TX 78229 USA. EM habib@uthscsa.edu FU American Heart Association; South Texas Veterans Healthcare System FX American Heart Association; South Texas Veterans Healthcare System. NR 46 TC 0 Z9 0 U1 1 U2 1 PU WILEY-BLACKWELL PI HOBOKEN PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA SN 1347-9032 EI 1349-7006 J9 CANCER SCI JI Cancer Sci. PD AUG PY 2016 VL 107 IS 8 BP 1092 EP 1100 DI 10.1111/cas.12984 PG 9 WC Oncology SC Oncology GA EB0BU UT WOS:000387009200004 PM 27278252 ER PT J AU Funk, LM Jolles, SA Voils, CI AF Funk, Luke M. Jolles, Sally A. Voils, Corrine I. TI Obesity as a disease: has the AMA resolution had an impact on how physicians view obesity? SO SURGERY FOR OBESITY AND RELATED DISEASES LA English DT Editorial Material DE Health services; Obesity; Public health ID BARIATRIC SURGERY; WEIGHT BIAS; CARE AB Background: In 2013, the American Medical Association (AMA) passed a resolution characterizing obesity as a disease. It is unclear whether primary care physicians (PCPs) agree with this characterization and how their agreement or lack thereof affects their treatment of patients with obesity. Objectives: We sought to understand PCP opinions about the AMA obesity resolution and how it has affected management of patients with obesity. Setting: Small, medium, and large communities in Wisconsin Methods: Focus groups were conducted with PCPs in Wisconsin. PCPs were asked whether they considered obesity a disease and what they factored into this consideration, including the AMA decision. A directed approach to content analysis was used to analyze the data. A taxonomy of consensus codes was developed, coding summaries were generated, and representative quotes were identified. Results: Three focus groups comprising a total of 16 PCP participants were conducted. Not all PCPs were aware of the AMA resolution. PCPs held divergent opinions on whether obesity represented a disease, primarily focusing their considerations on obesity as a risk factor versus a disease. They also discussed how considering obesity as a disease affects the patient doctor relationship, insurance coverage, physician reimbursement, and research. Conclusion: The AMA resolution did not appear to have made a significant impact on PCP opinions or management practices in our focus groups in Wisconsin. Follow-up surveys that quantify the prevalance of these opinions and practices at the state and national levels would be highly informative. (Surg Obes Relat Dis 2016;12:1431-1435.) Published by Elsevier Inc. on behalf of American Society for Metabolic and Bariatric Surgery. C1 [Funk, Luke M.; Jolles, Sally A.] William S Middleton Mem Vet Adm Med Ctr, Madison, WI USA. [Funk, Luke M.; Jolles, Sally A.] Univ Wisconsin, Dept Surg, Wisconsin Surg Outcomes Res Program WiSOR, Sch Med & Publ Hlth, Madison, WI USA. [Voils, Corrine I.] Vet Affairs Med Ctr, Ctr Hlth Serv Res Primary Care, Durham, NC USA. [Voils, Corrine I.] Duke Univ, Med Ctr, Dept Med, Durham, NC 27710 USA. RP Funk, LM (reprint author), Univ Wisconsin, Sch Med & Publ Hlth, Dept Surg, 600 Highland Ave,H4-728 Clin Sci Ctr, Madison, WI 53792 USA. EM funk@surgery.wisc.edu NR 14 TC 1 Z9 1 U1 3 U2 3 PU ELSEVIER SCIENCE INC PI NEW YORK PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA SN 1550-7289 EI 1878-7533 J9 SURG OBES RELAT DIS JI Surg. Obes. Relat. Dis. PD AUG PY 2016 VL 12 IS 7 BP 1431 EP 1435 DI 10.1016/j.soard.2016.05.009 PG 5 WC Surgery SC Surgery GA EA9TJ UT WOS:000386987300031 PM 27444860 ER PT J AU Decker, BK Harris, PL Muder, RR Hong, JH Singh, N Sonel, AF Clancy, CJ AF Decker, Brooke K. Harris, Patricia L. Muder, Robert R. Hong, Jae H. Singh, Nina Sonel, Ali F. Clancy, Cornelius J. TI Improving the Diagnosis of Legionella Pneumonia within a Healthcare System through a Systematic Consultation and Testing Program SO ANNALS OF THE AMERICAN THORACIC SOCIETY LA English DT Article AB Rationale: Legionella testing is not recommended for all patients with pneumonia, but rather for particular patient subgroups. As a result, the overall incidence of Legionella pneumonia may be underestimated. Objectives: To determine the incidence of Legionella pneumonia in a veteran population in an endemic area after introduction of a systematic infectious diseases consultation and testing program. Methods: In response to a 2011-2012 outbreak, the VA Pittsburgh Healthcare System mandated infectious diseases consultations and testing for Legionella by urine antigen and sputum culture in all patients with pneumonia. Measurements and Main Results: Between January 2013 and December 2015, 1,579 cases of pneumonia were identified. The incidence of pneumonia was 788/100,000 veterans per year, including 352/100,000 veterans per year and 436/100,000 veterans per year with community-associated pneumonia (CAP) and health care-associated pneumonia, respectively. Ninety-eight percent of patients with suspected pneumonia were tested for Legionella by at least one method. Legionella accounted for 1% of pneumonia cases (n = 16), including 1.7% (12/706) and 0.6% (4/873) of CAP and health care-associated pneumonia, respectively. The yearly incidences of Legionella pneumonia and Legionella CAP were 7.99 and 5.99/100,000 veterans, respectively. The sensitivities of urine antigen and sputum culture were 81% and 60%, respectively; the specificity of urine antigen was >99.97%. Urine antigen testing and Legionella cultures increased by 65% and 330%, respectively, after introduction of our program. Conclusions: Systematic testing of veterans in an endemic area revealed a higher incidence of Legionella pneumonia and CAP than previously reported. Widespread urine antigen testing was not limited by false positivity. C1 [Decker, Brooke K.; Hong, Jae H.; Singh, Nina; Clancy, Cornelius J.] Infect Dis Sect, Pittsburgh, PA USA. [Harris, Patricia L.; Sonel, Ali F.] VA Pittsburgh Healthcare Syst, Pittsburgh, PA USA. [Decker, Brooke K.; Muder, Robert R.; Hong, Jae H.; Singh, Nina; Clancy, Cornelius J.] Univ Pittsburgh, Div Infect Dis, Pittsburgh, PA USA. RP Decker, BK (reprint author), VA Pittsburgh Healthcare Syst, Infect Dis Sect, Univ Dr C ID Sect,111E-U, Pittsburgh, PA 15240 USA. EM brooke.decker@va.gov NR 0 TC 0 Z9 0 U1 0 U2 0 PU AMER THORACIC SOC PI NEW YORK PA 25 BROADWAY, 18 FL, NEW YORK, NY 10004 USA SN 1546-3222 EI 2325-6621 J9 ANN AM THORAC SOC JI Ann. Am. Thoracic Society PD AUG PY 2016 VL 13 IS 8 BP 1289 EP 1293 DI 10.1513/AnnalsATS.201510-715BC PG 5 WC Respiratory System SC Respiratory System GA DZ8JV UT WOS:000386117600019 PM 27243279 ER PT J AU Berning, JN Poor, AD Buckley, SM Patel, KR Lederer, DJ Goldstein, NE Brodie, D Baldwin, MR AF Berning, Joel N. Poor, Armeen D. Buckley, Sarah M. Patel, Komal R. Lederer, David J. Goldstein, Nathan E. Brodie, Daniel Baldwin, Matthew R. TI A Novel Picture Guide to Improve Spiritual Care and Reduce Anxiety in Mechanically Ventilated Adults in the Intensive Care Unit SO ANNALS OF THE AMERICAN THORACIC SOCIETY LA English DT Article AB Rationale: Hospital chaplains provide spiritual care that helps patients facing serious illness cope with their symptoms and prognosis, yet because mechanically ventilated patients cannot speak, spiritual care of these patients has been limited. Objectives: To determine the feasibility and measure the effects of chaplain-led picture-guided spiritual care for mechanically ventilated adults in the intensive care unit (ICU). Methods: We conducted a quasi-experimental study at a tertiary care hospital between March 2014 and July 2015. Fifty mechanically ventilated adults in medical or surgical ICUs without delirium or dementia received spiritual care by a hospital chaplain using an illustrated communication card to assess their spiritual affiliations, emotions, and needs and were followed until hospital discharge. Feasibility was assessed as the proportion of participants able to identify spiritual affiliations, emotions, and needs using the card. Among the first 25 participants, we performed semistructured interviews with 8 ICU survivors to identify how spiritual care helped them. For the subsequent 25 participants, we measured anxiety (on 100-mm visual analog scales [VAS]) immediately before and after the first chaplain visit, and we performed semistructured interviews with 18 ICU survivors with added measurements of pain and stress (on +/- 100-mm VAS). Measurements and Main Results: The mean (SD) age was 59 (+/- 16) years, median mechanical ventilation days was 19.5 (interquartile range, 7-29 d), and 15 (30%) died in-hospital. Using the card, 50 (100%) identified a spiritual affiliation, 47 (94%) identified one or more emotions, 45 (90%) rated their spiritual pain, and 36 (72%) selected a chaplain intervention. Anxiety after the first visit decreased 31% (mean score change, -20; 95% confidence interval, -33 to -7). Among 28 ICU survivors, 26 (93%) remembered the intervention and underwent semistructured interviews, of whom 81% felt more capable of dealing with their hospitalization and 0% felt worse. The 18 ICU survivors who underwent additional VAS testing during semistructured follow-up interviews reported a 49-point reduction in stress (95% confidence interval, -72 to -24) and no significant change in physical pain that they attributed to picture-guided spiritual care. Conclusions: Chaplain-led picture-guided spiritual care is feasible among mechanically ventilated adults and shows potential for reducing anxiety during and stress after an ICU admission. C1 [Berning, Joel N.] NewYork Presbyterian Hosp, Pastoral Care & Educ Dept, New York, NY USA. [Poor, Armeen D.; Buckley, Sarah M.; Patel, Komal R.; Lederer, David J.; Brodie, Daniel; Baldwin, Matthew R.] Columbia Univ, Coll Phys & Surg, Div Pulm Allergy & Crit Care, New York, NY USA. [Lederer, David J.] Columbia Univ, Dept Epidemiol, Mailman Sch Publ Hlth, New York, NY USA. [Goldstein, Nathan E.] Icahn Sch Med Mt Sinai, Dept Geriatr & Palliat Med, New York, NY 10029 USA. [Goldstein, Nathan E.] James J Peters VA Med Ctr, Geriatr Res Educ & Clin Ctr, New York, NY USA. RP Baldwin, MR (reprint author), Div Pulm Allergy & Crit Care, 622 West 168th St,PH-8E Room 101, New York, NY 10032 USA. EM mrb45@cumc.columbia.edu FU National Institutes of Health [UL1 TR000040, KL2 TR000081, K23AG045560] FX Supported by National Institutes of Health grants UL1 TR000040, KL2 TR000081, and K23AG045560. The views expressed in this article do not communicate an official position of National Institutes of Health. NR 0 TC 0 Z9 0 U1 2 U2 2 PU AMER THORACIC SOC PI NEW YORK PA 25 BROADWAY, 18 FL, NEW YORK, NY 10004 USA SN 1546-3222 EI 2325-6621 J9 ANN AM THORAC SOC JI Ann. Am. Thoracic Society PD AUG PY 2016 VL 13 IS 8 BP 1333 EP 1342 DI 10.1513/AnnalsATS.201512-831OC PG 10 WC Respiratory System SC Respiratory System GA DZ8JV UT WOS:000386117600025 PM 27097049 ER PT J AU Kamdar, BB Knauert, MP Jones, SF Parsons, EC Parthasarathy, S Pisani, MA AF Kamdar, Biren B. Knauert, Melissa P. Jones, Shirley F. Parsons, Elizabeth C. Parthasarathy, Sairam Pisani, Margaret A. CA Sleep ICU SLEEPii Task Force TI Perceptions and Practices Regarding Sleep in the Intensive Care Unit A Survey of 1,223 Critical Care Providers SO ANNALS OF THE AMERICAN THORACIC SOCIETY LA English DT Article AB Rationale: Poor sleep affects a majority of critically ill patients and is believed to be associated with adverse intensive care unit (ICU) outcomes such as delirium. While recent guidelines recommend sleep promotion efforts to improve delirium and other ICU outcomes, little is known about critical care providers' beliefs regarding sleep in the ICU. Objectives: To evaluate providers' perceptions and practices regarding sleep in the ICU. Methods: From April to July 2014, the Sleep in the ICU Survey was disseminated to ICU providers via institutional e-mail lists and four international critical care society distribution lists. Measurements and Main Results: A total of 1,223 surveys were completed by providers from 24 countries. Respondents were primarily nurses (59%) or physicians (39%). Most respondents indicated that ICU patients experienced " poor" or " very poor" sleep 75%) and that poor sleep could affect the ICU recovery process (88%). Respondents also felt that poor sleep was associated with negative ICU outcomes such as the development of delirium (97%), longer length of stay (88%), poor participation in physical therapy (87%), and delayed liberation from mechanical ventilation (83%). The minority (32%) of providers had sleep-promoting protocols; these providers tended to believe their patients slept longer and experienced better sleep quality. Conclusions: Though most clinicians believe that sleep in the ICU is poor and adversely affects patient outcomes, a minority of the ICUs represented by our respondents have sleep promotion protocols. These findings highlight discordant provider perceptions and practices surrounding sleep in the ICU, as well as a possible lack of available evidence-based guidelines for promoting sleep in the ICU. C1 [Kamdar, Biren B.] Univ Calif Los Angeles, David Geffen Sch Med, Div Pulm & Crit Care Med, 10833 Le Conte Ave,Room 37-131 CHS, Los Angeles, CA 90095 USA. [Knauert, Melissa P.; Pisani, Margaret A.] Yale Univ, Sch Med, Sect Pulm Crit Care & Sleep Med, New Haven, CT USA. [Jones, Shirley F.] Texas A&M Hlth Sci Ctr Coll Med, Baylor Scott & White Healthcare, Div Pulm Crit Care & Sleep Med, Temple, TX USA. [Parsons, Elizabeth C.] Univ Washington, Div Pulm & Crit Care Med, VA Puget Sound Hlth Care Syst, Seattle, WA 98195 USA. [Parthasarathy, Sairam] Univ Arizona, Div Pulm & Crit Care Med, Tucson, AZ USA. RP Kamdar, BB (reprint author), Univ Calif Los Angeles, David Geffen Sch Med, Div Pulm & Crit Care Med, 10833 Le Conte Ave,Room 37-131 CHS, Los Angeles, CA 90095 USA. EM bkamdar@mednet.ucla.edu OI Kamdar, Biren/0000-0002-9245-6229 FU UCLA Clinical and Translational Science Institute (CTSI) National Institutes of Health (NIH)/National Center for Advancing Translational Sciences (NCATS) [UCLA UL1TR000124]; Yale Claude D. Pepper Older Americans Independence Center [P30AG021342]; NIH/NCATS [KL2 TR000140] FX B.B.K. is currently supported by a Career Development Award from the UCLA Clinical and Translational Science Institute (CTSI) National Institutes of Health (NIH)/National Center for Advancing Translational Sciences (NCATS) (UCLA UL1TR000124). M.P.K. is currently supported by a Career Development Award from the Yale Claude D. Pepper Older Americans Independence Center (P30AG021342) and by a CTSA grant from the NIH/NCATS (KL2 TR000140). The views expressed here are those of the authors and do not reflect the position or policy of the Department of Veterans Affairs. NR 0 TC 0 Z9 0 U1 1 U2 1 PU AMER THORACIC SOC PI NEW YORK PA 25 BROADWAY, 18 FL, NEW YORK, NY 10004 USA SN 1546-3222 EI 2325-6621 J9 ANN AM THORAC SOC JI Ann. Am. Thoracic Society PD AUG PY 2016 VL 13 IS 8 BP 1370 EP 1377 DI 10.1513/AnnalsATS.201601-087OC PG 8 WC Respiratory System SC Respiratory System GA DZ8JV UT WOS:000386117600029 PM 27104770 ER PT J AU Beavers, WN Skaar, EP AF Beavers, William N. Skaar, Eric P. TI Neutrophil-generated oxidative stress and protein damage in Staphylococcus aureus SO PATHOGENS AND DISEASE LA English DT Review DE Staphylococcus aureus; oxidative stress; neutrophils; protein oxidation; antioxidant defenses; host-pathogen interface ID NITRIC-OXIDE SYNTHASE; SMALL-COLONY VARIANTS; HYDROPEROXIDE REDUCTASE AHPC; REPRESSES BIOFILM FORMATION; PEROXIDE-CHLORIDE SYSTEM; HYPOCHLOROUS ACID; HYDROGEN-PEROXIDE; SUPEROXIDE-DISMUTASE; TYROSINE NITRATION; BACILLUS-SUBTILIS AB Staphylococcus aureus is a ubiquitous, versatile and dangerous pathogen. It colonizes over 30% of the human population, and is one of the leading causes of death by an infectious agent. During S. aureus colonization and invasion, leukocytes are recruited to the site of infection. To combat S. aureus, leukocytes generate an arsenal of reactive species including superoxide, hydrogen peroxide, nitric oxide and hypohalous acids that modify and inactivate cellular macromolecules, resulting in growth defects or death. When S. aureus colonization cannot be cleared by the immune system, antibiotic treatment is necessary and can be effective. Yet, this organism quickly gains resistance to each new antibiotic it encounters. Therefore, it is in the interest of human health to acquire a deeper understanding of how S. aureus evades killing by the immune system. Advances in this field will have implications for the design of future S. aureus treatments that complement and assist the host immune response. In that regard, this review focuses on how S. aureus avoids host-generated oxidative stress, and discusses the mechanisms used by S. aureus to survive oxidative damage including antioxidants, direct repair of damaged proteins, sensing oxidant stress and transcriptional changes. This review will elucidate areas for studies to identify and validate future antimicrobial targets. C1 [Beavers, William N.; Skaar, Eric P.] Vanderbilt Univ, Sch Med, Dept Pathol Microbiol & Immunol, US Dept Vet Affairs,Vanderbilt Inst Chem Biol,Med, 1161 21st Ave South, Nashville, TN 37232 USA. [Skaar, Eric P.] Vanderbilt Univ, Sch Med, Tennessee Valley Healthcare Syst, US Dept Vet Affairs,Vanderbilt Inst Chem Biol, 1161 21st Ave S, Nashville, TN 37232 USA. RP Skaar, EP (reprint author), Vanderbilt Univ, Dept Microbiol & Immunol, 1161 21st Ave South, Nashville, TN 37232 USA. EM eric.skaar@vanderbilt.edu FU National Institutes of Health [T32 AI007474 21, R01 AI069233, R01 AI73843] FX The writing of this manuscript was supported by the National Institutes of Health through fellowships to WNB (T32 AI007474 21) and research grants to EPS (R01 AI069233 and R01 AI73843). NR 153 TC 1 Z9 1 U1 6 U2 6 PU OXFORD UNIV PRESS PI OXFORD PA GREAT CLARENDON ST, OXFORD OX2 6DP, ENGLAND SN 2049-632X J9 PATHOG DIS JI Pathog. Dis. PD AUG PY 2016 VL 74 IS 6 AR ftw060 DI 10.1093/femspd/ftw060 PG 15 WC Immunology; Infectious Diseases; Microbiology SC Immunology; Infectious Diseases; Microbiology GA DY3UG UT WOS:000385019700008 ER PT J AU Falvey, JR Burke, RE Malone, D Ridgeway, KJ McManus, BM Stevens-Lapsley, JE AF Falvey, Jason R. Burke, Robert E. Malone, Daniel Ridgeway, Kyle J. McManus, Beth M. Stevens-Lapsley, Jennifer E. TI Role of Physical Therapists in Reducing Hospital Readmissions: Optimizing Outcomes for Older Adults During Care Transitions From Hospital to Community SO PHYSICAL THERAPY LA English DT Editorial Material ID RANDOMIZED CONTROLLED-TRIAL; LOW-INCOME SENIORS; LENGTH-OF-STAY; FUNCTIONAL STATUS; HEART-FAILURE; DISCHARGE SUMMARIES; 30-DAY READMISSION; GAIT SPEED; HOME; RISK AB Hospital readmissions in older adult populations are an emerging quality indicator for acute care hospitals. Recent evidence has linked functional decline during and after hospitalization with an elevated risk of hospital readmission. However, models of care that have been developed to reduce hospital readmission rates do not adequately address functional deficits. Physical therapists, as experts in optimizing physical function, have a strong opportunity to contribute meaningfully to care transition models and demonstrate the value of physical therapy interventions in reducing readmissions. Thus, the purposes of this perspective article are: (1) to describe the need for physical therapist input during care transitions for older adults and (2) to outline strategies for expanding physical therapy participation in care transitions for older adults, with an overall goal of reducing avoidable 30-day hospital readmissions. C1 [Falvey, Jason R.; Malone, Daniel; Ridgeway, Kyle J.; Stevens-Lapsley, Jennifer E.] Univ Colorado Anschutz Med Campus, Dept Phys Med & Rehabil, Phys Therapy Program, Mail Stop C244,13121 East 17th Ave,Room 3116, Aurora, CO 80045 USA. [Falvey, Jason R.] Denver Vet Affairs Med Ctr, Denver, CO 80220 USA. [Burke, Robert E.] Univ Colorado Anschutz Med Campus, Res & Hosp Med Sect, Denver VA Med Ctr, Aurora, CO USA. [Burke, Robert E.] Univ Colorado Anschutz Med Campus, Dept Med, Aurora, CO USA. [Ridgeway, Kyle J.] Univ Colorado Hosp, Aurora, CO USA. [McManus, Beth M.] Univ Colorado Anschutz Med Campus, Sch Publ Hlth, Dept Hlth Syst Management & Policy, Aurora, CO USA. [Stevens-Lapsley, Jennifer E.] Vet Affairs Geriatr Res Educ & Clin Ctr, Denver, CO USA. RP Falvey, JR (reprint author), Univ Colorado Anschutz Med Campus, Dept Phys Med & Rehabil, Phys Therapy Program, Mail Stop C244,13121 East 17th Ave,Room 3116, Aurora, CO 80045 USA.; Falvey, JR (reprint author), Denver Vet Affairs Med Ctr, Denver, CO 80220 USA. EM Jason.Falvey@ucdenver.edu FU NICHD NIH HHS [K12 HD055931] NR 66 TC 2 Z9 2 U1 1 U2 1 PU AMER PHYSICAL THERAPY ASSOC PI ALEXANDRIA PA 1111 N FAIRFAX ST, ALEXANDRIA, VA 22314 USA SN 0031-9023 EI 1538-6724 J9 PHYS THER JI Phys. Ther. PD AUG PY 2016 VL 96 IS 8 BP 1124 EP 1133 DI 10.2522/ptj.20150526 PG 10 WC Orthopedics; Rehabilitation SC Orthopedics; Rehabilitation GA DZ9AQ UT WOS:000386165800002 PM 26939601 ER PT J AU Ferrario, CM Ahmad, S Varagic, J Cheng, CP Groban, L Wang, H Collawn, JF Dell'Italia, LJ AF Ferrario, Carlos M. Ahmad, Sarfaraz Varagic, Jasmina Cheng, Che Ping Groban, Leanne Wang, Hao Collawn, James F. Dell'Italia, Louis J. TI Intracrine angiotensin II functions originate from noncanonical pathways in the human heart SO AMERICAN JOURNAL OF PHYSIOLOGY-HEART AND CIRCULATORY PHYSIOLOGY LA English DT Review DE angiotensin-(1-12); angiotensin converting enzyme inhibitors; heart chymase; hypertension; heart failure ID MAST-CELL CHYMASE; MOLECULAR-WEIGHT ANGIOTENSINOGEN; CONVERTING ENZYME-INHIBITION; AMINO-ACID-SEQUENCE; BLOOD-PRESSURE; CARDIOVASCULAR EVENTS; INTRACELLULAR RENIN; RECEPTOR BLOCKERS; FORMING PATHWAYS; CARDIAC RENIN AB Although it is well-known that excess renin angiotensin system (RAS) activity contributes to the pathophysiology of cardiac and vascular disease, tissue-based expression of RAS genes has given rise to the possibility that intracellularly produced angiotensin II (Ang II) may be a critical contributor to disease processes. An extended form of angiotensin I (Ang I), the dodecapeptide angiotensin-(1-12) [Ang-(1-12)], that generates Ang II directly from chymase, particularly in the human heart, reinforces the possibility that an alternative noncanonical renin independent pathway for Ang II formation may be important in explaining the mechanisms by which the hormone contributes to adverse cardiac and vascular remodeling. This review summarizes the work that has been done in evaluating the functional significance of Ang-(1-12) and how this substrate generated from angiotensinogen by a yet to be identified enzyme enhances knowledge about Ang II pathological actions. C1 [Ferrario, Carlos M.; Ahmad, Sarfaraz; Varagic, Jasmina] Wake Forest Univ, Hlth Sci Ctr, Dept Surg, Winston Salem, NC 27109 USA. [Ferrario, Carlos M.; Ahmad, Sarfaraz; Varagic, Jasmina] Wake Forest Univ, Hlth Sci Ctr, Dept Internal Med Nephrol, Winston Salem, NC 27109 USA. [Ferrario, Carlos M.; Ahmad, Sarfaraz; Varagic, Jasmina] Wake Forest Univ, Hlth Sci Ctr, Dept Physiol Pharmacol, Winston Salem, NC 27109 USA. [Varagic, Jasmina; Groban, Leanne] Wake Forest Univ, Hypertens & Vasc Res Ctr, Winston Salem, NC 27109 USA. [Cheng, Che Ping] Wake Forest Univ, Hlth Sci Ctr, Dept Internal Med, Sect Cardiovasc Med, Winston Salem, NC 27109 USA. [Groban, Leanne; Wang, Hao] Wake Forest Univ, Hlth Sci Ctr, Dept Anesthesiol, Winston Salem, NC 27109 USA. [Collawn, James F.; Dell'Italia, Louis J.] Univ Alabama Birmingham, Dept Cell Biol, Birmingham, AL 35294 USA. [Collawn, James F.; Dell'Italia, Louis J.] Univ Alabama Birmingham, Dept Microbiol, Birmingham, AL 35294 USA. [Collawn, James F.; Dell'Italia, Louis J.] Univ Alabama Birmingham, Dept Physiol, Birmingham, AL 35294 USA. [Dell'Italia, Louis J.] Univ Alabama Birmingham, Div Cardiovasc Dis, Birmingham, AL 35294 USA. [Dell'Italia, Louis J.] Birmingham Vet Affairs Med Ctr, Dept Vet Affairs, Birmingham, AL USA. RP Ferrario, CM (reprint author), Wake Forest Univ, Hlth Sci Ctr, Winston Salem, NC 27157 USA. EM cferrari@wakehealth.edu FU National Heart, Lung, and Blood Institute of the National Institutes of Health [2P01 HL-051952] FX The studies described here were funded, in part, by Program Project Grant 2P01 HL-051952 from the National Heart, Lung, and Blood Institute of the National Institutes of Health. NR 160 TC 2 Z9 3 U1 0 U2 0 PU AMER PHYSIOLOGICAL SOC PI BETHESDA PA 9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA SN 0363-6135 EI 1522-1539 J9 AM J PHYSIOL-HEART C JI Am. J. Physiol.-Heart Circul. Physiol. PD AUG PY 2016 VL 311 IS 2 BP H404 EP H414 DI 10.1152/ajpheart.00219.2016 PG 11 WC Cardiac & Cardiovascular Systems; Physiology; Peripheral Vascular Disease SC Cardiovascular System & Cardiology; Physiology GA DY3DK UT WOS:000384970800010 PM 27233763 ER PT J AU Karp, JF DiNapoli, EA Wetherell, J Bolon, C Rodriguez, E Shega, J Weiner, DK AF Karp, Jordan F. DiNapoli, Elizabeth A. Wetherell, Julie Bolon, Chloe Rodriguez, Eric Shega, Joseph Weiner, Debra K. TI Deconstructing Chronic Low Back Pain in the Older Adult-Step by Step Evidence and Expert-Based Recommendations for Evaluation and Treatment: Part IX: Anxiety SO PAIN MEDICINE LA English DT Article DE Anxiety; Low Back Pain; Chronic Pain; Avoidance Behavior; Cognitive Behavior Therapy; Fear ID COGNITIVE-BEHAVIORAL THERAPY; PRIMARY-CARE PATIENTS; CHRONIC MUSCULOSKELETAL PAIN; LATE-LIFE ANXIETY; PSYCHIATRIC-DISORDERS; MENTAL-DISORDERS; CONTROLLED-TRIAL; METAANALYSIS; PREVALENCE; DEPRESSION AB Objective. As a part of a series of articles designed to deconstruct chronic low back pain (CLBP) in older adults, this article focuses on anxiety-a significant contributor of reduced health-related quality of life, increased use of medical services, and heightened disability in older adults with CLBP. Methods. A modified Delphi technique was used to develop an algorithm for the screening and clinical care of older adults with CLBP and anxiety. A 4-member content expert panel and a nine-member primary care panel were involved in this iterative development process. Evidence underlying the recommendations is not strictly based on VA populations; therefore, the algorithm can be applied in both VHA and civilian settings. The illustrative clinical case was taken from one of the contributor's clinical practice. Results. We present a treatment algorithm and supporting tables to be used by providers treating older adults who have anxiety and CLBP. A case of an older adult with anxiety and CLBP is provided to illustrate the approach to management. Conclusions. To promote early engagement in evidence-based treatments, providers should routinely evaluate anxiety in older adults with CLBP using a screening and treatment algorithm. C1 [Karp, Jordan F.; Weiner, Debra K.] VA Pittsburgh Healthcare Syst, Geriatr Res Educ & Clin Ctr, Pittsburgh, PA USA. [Karp, Jordan F.; DiNapoli, Elizabeth A.; Bolon, Chloe; Weiner, Debra K.] Univ Pittsburgh, Dept Psychiat, Pittsburgh, PA USA. [Karp, Jordan F.; Weiner, Debra K.] Univ Pittsburgh, Dept Anesthesiol, Pittsburgh, PA USA. [Karp, Jordan F.; Weiner, Debra K.] Univ Pittsburgh, Clin & Translat Sci Inst, Pittsburgh, PA USA. [DiNapoli, Elizabeth A.] VA Pittsburgh Healthcare Syst, Mental Illness Res Educ & Clin Ctr, Pittsburgh, PA USA. [Wetherell, Julie] VA San Diego Healthcare Syst, San Diego, CA USA. [Wetherell, Julie] Univ Calif San Diego, San Diego, CA 92103 USA. [Rodriguez, Eric; Weiner, Debra K.] Univ Pittsburgh, Sch Med, Div Geriatr Med, Pittsburgh, PA USA. [Shega, Joseph] VITAS Healthcare, Miami, FL USA. RP Weiner, DK (reprint author), 3471 Fifth Ave,Suite 500, Pittsburgh, PA 15213 USA. EM Debra.Weiner@va.gov FU Department of Veterans Affairs, Veterans Health Administration, Office of Research and Development, Rehabilitation Research and Development Service FX This material is based on work supported by the Department of Veterans Affairs, Veterans Health Administration, Office of Research and Development, Rehabilitation Research and Development Service. NR 57 TC 2 Z9 2 U1 9 U2 9 PU OXFORD UNIV PRESS PI OXFORD PA GREAT CLARENDON ST, OXFORD OX2 6DP, ENGLAND SN 1526-2375 EI 1526-4637 J9 PAIN MED JI Pain Med. PD AUG PY 2016 VL 17 IS 8 BP 1423 EP 1435 DI 10.1093/pm/pnw135 PG 13 WC Medicine, General & Internal SC General & Internal Medicine GA DZ1WQ UT WOS:000385632800006 PM 27346887 ER PT J AU Karras, E Lu, NJ Zuo, GX Tu, XM Stephens, B Draper, J Thompson, C Bossarte, RM AF Karras, Elizabeth Lu, Naiji Zuo, Guoxin Tu, Xin M. Stephens, Brady Draper, John Thompson, Caitlin Bossarte, Robert M. TI Measuring Associations of the Department of Veterans Affairs' Suicide Prevention Campaign on the Use of Crisis Support Services SO SUICIDE AND LIFE-THREATENING BEHAVIOR LA English DT Article ID MASS-MEDIA CAMPAIGNS; HEALTH BEHAVIOR; CALLS AB Campaigns have become popular in public health approaches to suicide prevention; however, limited empirical investigation of their impact on behavior has been conducted. To address this gap, utilization patterns of crisis support services associated with the Department of Veterans Affairs' Veterans Crisis Line (VCL) suicide prevention campaign were examined. Daily call data for the National Suicide Prevention Lifeline, VCL, and 1-800-SUICIDE were modeled using a novel semi-varying coefficient method. Analyses reveal significant increases in call volume to both targeted and broad resources during the campaign. Findings underscore the need for further research to refine measurement of the effects of these suicide prevention efforts. C1 [Karras, Elizabeth; Tu, Xin M.; Stephens, Brady] US Dept Vet Affairs, VISN Ctr Excellence Suicide Prevent 2, 400 Ft Hill Ave, Canandaigua, NY 14424 USA. [Karras, Elizabeth; Tu, Xin M.] Univ Rochester, Dept Psychiat, Rochester, NY USA. [Lu, Naiji; Tu, Xin M.] Univ Rochester, Dept Biostat & Computat Biol, Rochester, NY USA. [Zuo, Guoxin] Cent China Normal Univ, Sch Math & Stat, Wuhan, Peoples R China. [Draper, John] Link2Hlth Solut Inc, Natl Suicide Prevent Lifeline, New York, NY USA. [Thompson, Caitlin] US Dept Vet Affairs, Mental Hlth Serv, Suicide Prevent & Community Engagement Program, Washington, DC USA. [Bossarte, Robert M.] US Dept Vet Affairs, Program Epidemiol, Postdeployment Hlth Off Publ Hlth, Washington, DC USA. [Bossarte, Robert M.] Harvard Univ, Dept Epidemiol, Cambridge, MA 02138 USA. RP Karras, E (reprint author), US Dept Vet Affairs, VISN Ctr Excellence Suicide Prevent 2, 400 Ft Hill Ave, Canandaigua, NY 14424 USA. EM Elizabeth.Karras@va.gov NR 22 TC 1 Z9 1 U1 4 U2 4 PU WILEY-BLACKWELL PI HOBOKEN PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA SN 0363-0234 EI 1943-278X J9 SUICIDE LIFE-THREAT JI Suicide Life-Threat. Behav. PD AUG PY 2016 VL 46 IS 4 BP 447 EP 456 DI 10.1111/sltb.12231 PG 10 WC Psychiatry; Psychology, Multidisciplinary SC Psychiatry; Psychology GA DZ2XM UT WOS:000385706100005 PM 26880716 ER PT J AU Virani, SS AF Virani, Salim S. TI The 2013 ACC/AHA Cholesterol Management Guideline: Clearing the Confusion from Noncontroversial Components SO TEXAS HEART INSTITUTE JOURNAL LA English DT Editorial Material DE Cholesterol LDL/blood; coronary artery disease/prevention & control; guideline implementation; hypercholesterolemia/drug therapy; provider behavior; risk assessment; societies, medical; statins C1 [Virani, Salim S.] Hlth Serv Res & Dev Ctr Innovat, Michael E DeBakey Vet Affairs Med Ctr, Hlth Policy Qual & Informat Program, Houston, TX 77030 USA. [Virani, Salim S.] Baylor Coll Med, Dept Med, Sect Cardiovasc Res, Houston, TX 77030 USA. [Virani, Salim S.] Methodist DeBakey Heart & Vasc Ctr, Ctr Cardiovasc Dis Prevent, Houston, TX 77030 USA. RP Virani, SS (reprint author), Michael E DeBakey VA Med Ctr, Hlth Serv Res & Dev 152, 2002 Holcombe Blvd, Houston, TX 77030 USA. EM virani@bcm.edu OI Virani, Salim/0000-0001-9541-6954 NR 6 TC 0 Z9 0 U1 0 U2 0 PU TEXAS HEART INST PI HOUSTON PA PO BOX 20345, HOUSTON, TX 77225-0345 USA SN 1526-6702 J9 TEX HEART I J JI Tex. Heart Inst. J. PD AUG PY 2016 VL 43 IS 4 BP 313 EP 314 DI 10.14503/THIJ-16-5798 PG 2 WC Cardiac & Cardiovascular Systems SC Cardiovascular System & Cardiology GA DZ5RH UT WOS:000385918700010 PM 27547139 ER PT J AU Kasinath, BS AF Kasinath, Balakuntalam S. TI The podocyte and the proteoglycan SO AMERICAN JOURNAL OF PHYSIOLOGY-RENAL PHYSIOLOGY LA English DT Editorial Material ID GLOMERULAR-BASEMENT-MEMBRANE; HEPARAN-SULFATE; PROTEINURIA C1 [Kasinath, Balakuntalam S.] Univ Texas San Antonio, Hlth Sci Ctr, South Texas Vet Hlth Care Syst, San Antonio, TX USA. RP Kasinath, BS (reprint author), Univ Texas San Antonio, Hlth Sci Ctr, Dept Med, MC7882,7703 Floyd Curl Dr, San Antonio, TX 78229 USA. EM kasinath@uthscsa.edu NR 9 TC 0 Z9 0 U1 0 U2 0 PU AMER PHYSIOLOGICAL SOC PI BETHESDA PA 9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA SN 1931-857X EI 1522-1466 J9 AM J PHYSIOL-RENAL JI Am. J. Physiol.-Renal Physiol. PD AUG 1 PY 2016 VL 311 IS 2 BP F310 EP F311 DI 10.1152/ajprenal.00295.2016 PG 2 WC Physiology; Urology & Nephrology SC Physiology; Urology & Nephrology GA DY3FP UT WOS:000384976500008 PM 27226109 ER PT J AU Uchendu, US Omalu, BI Cifu, DX Egede, LE AF Uchendu, Uchenna S. Omalu, Bennet I. Cifu, David X. Egede, Leonard E. TI Repeated Concussions: Time to Spur Action Among Vulnerable Veterans SO AMERICAN JOURNAL OF PUBLIC HEALTH LA English DT Editorial Material ID TRAUMATIC BRAIN-INJURY; ENCEPHALOPATHY C1 [Uchendu, Uchenna S.] US Dept Vet Affairs, Washington, DC USA. [Omalu, Bennet I.] Univ Calif Davis, Dept Pathol, Davis, CA 95616 USA. [Cifu, David X.] Virginia Commonwealth Univ, Sch Med, Richmond, VA 23284 USA. [Cifu, David X.] US Dept Vet Affairs, Richmond, VA USA. [Egede, Leonard E.] Med Univ South Carolina, Charleston, SC USA. [Egede, Leonard E.] US Dept Vet Affairs, Charleston, SC USA. RP Uchendu, US (reprint author), US Dept Vet Affairs, Off Hlth Equ, 810 Vermont Ave NW, Washington, DC 20420 USA. EM Uchenna.Uchendu2@va.gov NR 7 TC 0 Z9 0 U1 2 U2 2 PU AMER PUBLIC HEALTH ASSOC INC PI WASHINGTON PA 800 I STREET, NW, WASHINGTON, DC 20001-3710 USA SN 0090-0036 EI 1541-0048 J9 AM J PUBLIC HEALTH JI Am. J. Public Health PD AUG PY 2016 VL 106 IS 8 BP 1366 EP 1368 DI 10.2105/AJPH.2016.303293 PG 4 WC Public, Environmental & Occupational Health SC Public, Environmental & Occupational Health GA DY3HK UT WOS:000384981200024 PM 27310350 ER PT J AU Kopterides, P Mayr, FB Yende, S AF Kopterides, Petros Mayr, Florian B. Yende, Sachin TI Understanding the sepsis mortality belt: time to buckle down! SO ANNALS OF TRANSLATIONAL MEDICINE LA English DT Editorial Material ID UNITED-STATES C1 [Kopterides, Petros; Mayr, Florian B.; Yende, Sachin] Univ Pittsburgh, Dept Crit Care Med, CRISMA Ctr, Pittsburgh, PA USA. [Mayr, Florian B.; Yende, Sachin] Vet Affairs Pittsburgh Healthcare Syst, Univ Dr Campus,Room 2A128, Pittsburgh, PA 15240 USA. RP Mayr, FB (reprint author), Vet Affairs Pittsburgh Healthcare Syst, Univ Dr Campus,Room 2A128, Pittsburgh, PA 15240 USA. EM florian.mayr@va.gov NR 10 TC 0 Z9 0 U1 0 U2 0 PU AME PUBL CO PI SHEUNG WAN PA ROOM 604 6-F HOLLYWOOD CENTER, 77-91, QUEENS ROAD, SHEUNG WAN, HONG KONG 00000, PEOPLES R CHINA SN 2305-5839 EI 2305-5847 J9 ANN TRANSL MED JI ANN. TRANSL. MED. PD AUG PY 2016 VL 4 IS 16 AR 319 DI 10.21037/atm.2016.08.01 PG 2 WC Medicine, Research & Experimental SC Research & Experimental Medicine GA DY0NM UT WOS:000384793500021 PM 27668239 ER PT J AU Mc Causland, FR Asafu-Adjei, J Betensky, RA Palevsky, PM Waikar, SS AF Mc Causland, Finnian R. Asafu-Adjei, Josephine Betensky, Rebecca A. Palevsky, Paul M. Waikar, Sushrut S. TI Comparison of Urine Output among Patients Treated with More Intensive Versus Less Intensive RRT: Results from the Acute Renal Failure Trial Network Study SO CLINICAL JOURNAL OF THE AMERICAN SOCIETY OF NEPHROLOGY LA English DT Article ID ACUTE KIDNEY INJURY; CRITICALLY-ILL PATIENTS; CONTINUOUS VENOVENOUS HEMOFILTRATION; REPLACEMENT THERAPY; HEMODIALYSIS; RECOVERY; SURVIVAL; MULTICENTER; PROGNOSIS; OUTCOMES AB Background and objectives Intensive RRT may have adverse effects that account for the absence of benefit observed in randomized trials of more intensive versus less intensive RRT. We wished to determine the association of more intensive RRT with changes in urine output as a marker of worsening residual renal function in critically ill patients with severe AKI. Design, setting, participants, & measurements The Acute Renal Failure Trial Network Study (n=1124) was a multicenter trial that randomized critically ill patients requiring initiation of RRT to more intensive (hemodialysis or sustained low-efficiency dialysis six times per week or continuous venovenous hemodiafiltration at 35 ml/kg per hour) versus less intensive (hemodialysis or sustained low-efficiency dialysis three times per week or continuous venovenous hemodiafiltration at 20 ml/kg per hour) RRT. Mixed linear regression models were fit to estimate the association of RRT intensity with change in daily urine output in survivors through day 7 (n=871); Cox regression models were fit to determine the association of RRT intensity with time to >= 50% decline in urine output in all patients through day 28. Results Mean age of participants was 60 +/- 15 years old, 72% were men, and 30% were diabetic. In unadjusted models, among patients who survived >= 7 days, mean urine output was, on average, 31.7 ml/d higher (95% confidence interval, 8.2 to 55.2 ml/d) for the less intensive group compared with the more intensive group (P=0.01). More intensive RRT was associated with 29% greater unadjusted risk of decline in urine output of >= 50% (hazard ratio, 1.29; 95% confidence interval, 1.10 to 1.51). Conclusions More intensive versus less intensive RRT is associated with a greater reduction in urine output during the first 7 days of therapy and a greater risk of developing a decline in urine output of >= 50% in critically ill patients with severe AKI. C1 [Mc Causland, Finnian R.; Waikar, Sushrut S.] Brigham & Womens Hosp, Dept Med, Div Renal, Boston, MA 02115 USA. [Mc Causland, Finnian R.; Waikar, Sushrut S.] Harvard Med Sch, Boston, MA USA. [Asafu-Adjei, Josephine] Univ North Carolina Chapel Hill, Sch Nursing, Dept Biostat, Chapel Hill, NC USA. [Betensky, Rebecca A.] Harvard Sch Publ Hlth, Dept Biostat, Boston, MA USA. [Palevsky, Paul M.] Vet Affairs Pittsburgh Healthcare Syst, Renal Sect, Pittsburgh, PA USA. [Palevsky, Paul M.] Univ Pittsburgh, Sch Med, Dept Med, Renal Electrolyte Div, Pittsburgh, PA 15213 USA. RP Mc Causland, FR (reprint author), Brigham & Womens Hosp, MRB 4, Boston, MA 02446 USA. EM fmccausland@partners.org FU American Heart Association; NIDDK [DK102511, DK093574, DK075941, U01DK085660, R01DK103784]; Cooperative Studies Program of the Department of Veterans Affairs (VA) Office of Research and Development; NIDDK FX F.R.M. was supported by an American Heart Association award from 2014 to 2015 and is currently supported by NIDDK grant DK102511. S.S.W. is supported by NIDDK grants DK093574, DK075941, U01DK085660, and R01DK103784. The ATN Study was performed by the ATN Study investigators and supported by the Cooperative Studies Program of the Department of Veterans Affairs (VA) Office of Research and Development and the NIDDK. NR 36 TC 3 Z9 3 U1 1 U2 1 PU AMER SOC NEPHROLOGY PI WASHINGTON PA 1725 I ST, NW STE 510, WASHINGTON, DC 20006 USA SN 1555-9041 EI 1555-905X J9 CLIN J AM SOC NEPHRO JI Clin. J. Am. Soc. Nephrol. PD AUG PY 2016 VL 11 IS 8 BP 1335 EP 1342 DI 10.2215/CJN.10991015 PG 8 WC Urology & Nephrology SC Urology & Nephrology GA DY1BP UT WOS:000384830200006 PM 27449661 ER PT J AU Afkarian, M Katz, R Bansal, N Correa, A Kestenbaum, B Himmelfarb, J de Boer, IH Young, B AF Afkarian, Maryam Katz, Ronit Bansal, Nisha Correa, Adolfo Kestenbaum, Bryan Himmelfarb, Jonathan de Boer, Ian H. Young, Bessie TI Diabetes, Kidney Disease, and Cardiovascular Outcomes in the Jackson Heart Study SO CLINICAL JOURNAL OF THE AMERICAN SOCIETY OF NEPHROLOGY LA English DT Article ID GLOMERULAR-FILTRATION-RATE; ALL-CAUSE MORTALITY; UNITED-STATES; COLLABORATIVE METAANALYSIS; ATHEROSCLEROSIS RISK; GENERAL-POPULATION; ETHNIC DISPARITIES; ALBUMINURIA; COMPLICATIONS; EPIDEMIOLOGY AB Background and objectives Blacks have high rates of cardiovascular disease and mortality. Diabetes and CKD, risk factors for cardiovascular mortality in the general population, are common among blacks. We sought to assess their contribution to cardiovascular disease and mortality in blacks. Design, setting, participants, & measurements This observational cohort study was of 3211 participants in the Jackson Heart Study (enrolled 2000-2004). Rates of incident stroke, incident coronary heart disease, and cardiovascular mortality were quantified in participants with diabetes, CKD (eGFR < 60 ml/min per 1.73 m(2), urine albumin-to-creatinine ratio >= 30 mg/g, or both), or both through 2012, with a median follow-up of 6.99 years. Results Four hundred fifty-six (14.2%) participants had only diabetes, 257 (8.0%) had only CKD, 201 (6.3%) had both, and 2297 (71.5%) had neither. Diabetes without CKD was associated with excess risks of incident stroke, incident coronary heart disease, and cardiovascular mortality after adjustment for demographic and clinical covariates, including prevalent cardiovascular disease (excess incidence rates, 2.6; 95% confidence interval, 0.5 to 4.7; 2.6; 95% confidence interval, 0.3 to 4.8; and 2.4; 95% confidence interval, 0.4 to 4.3 per 1000 person-years, respectively). CKD without diabetes was associated with comparable nonsignificant excess risks for incident stroke and coronary heart disease (2.5; 95% confidence interval, -0.1 to 5.2 and 2.4; 95% confidence interval, -0.8 to 5.5 per 1000 person-years, respectively) but a larger excess risk for cardiovascular mortality (7.3; 95% confidence interval, 3.0 to 11.5 per 1000 person-years). Diabetes and CKD together were associated with greater excess risks for incident stroke (13.8; 95% confidence interval, 5.3 to 22.3 per 1000 person-years), coronary heart disease (12.8; 95% confidence interval, 4.9 to 20.8 per 1000 person-years), and cardiovascular mortality (14.8; 95% confidence interval, 7.2 to 22.3 per 1000 person-years). The excess risks associated with the combination of diabetes and CKD were larger than those associated with established risk factors, including prevalent cardiovascular disease. Conclusions The combination of diabetes and kidney disease is associated with substantial excess risks of cardiovascular events and mortality among blacks. C1 [Afkarian, Maryam; Katz, Ronit; Bansal, Nisha; Kestenbaum, Bryan; Himmelfarb, Jonathan] Univ Washington, Kidney Res Inst, Seattle, WA 98195 USA. [Afkarian, Maryam; Katz, Ronit; Bansal, Nisha; Kestenbaum, Bryan; Himmelfarb, Jonathan] Univ Washington, Div Nephrol, Seattle, WA 98195 USA. [Correa, Adolfo] Univ Mississippi, Med Ctr, Dept Med, Jackson Heart Study, Jackson, MS 39216 USA. [de Boer, Ian H.; Young, Bessie] Univ Washington, Kidney Res Inst, Div Nephrol, Vet Affairs Puget Sound, Seattle, WA 98195 USA. RP Afkarian, M (reprint author), Box 359606,325 9th Ave, Seattle, WA 98104 USA. EM afkarian@u.washington.edu FU National Institute of Diabetes, Digestive, and Kidney Disease (NIDDK) [K23DK089017, R01DK104706]; Satellite Healthcare; National Institutes of Health NIDDK [1R01DK102134-01]; NIDDK [R01DK087726, R01DK088762]; Veterans Affairs Puget Sound Health Care System (Seattle, WA); National Heart, Lung, and Blood Institute [HHSN268201300046C, HHSN268201300047C, HHSN268201300048C, HHSN268201300049C, HHSN268201300050C]; National Institute on Minority Health and Health Disparities FX M.A. was supported by grants K23DK089017 and R01DK104706 from the National Institute of Diabetes, Digestive, and Kidney Disease (NIDDK) and a Norman S. Coplon Extramural Grant from Satellite Healthcare. R.K., I.H.d.B., and B.Y. were supported by National Institutes of Health NIDDK grant 1R01DK102134-01. I.H.d.B. was supported by grants R01DK087726 and R01DK088762 from the NIDDK. I.H.d.B. and B.Y. are also supported, in part, by funding from the Veterans Affairs Puget Sound Health Care System (Seattle, WA). The Jackson Heart Study is supported by contracts HHSN268201300046C, HHSN268201300047C, HHSN268201300048C, HHSN268201300049C, and HHSN268201300050C from the National Heart, Lung, and Blood Institute and the National Institute on Minority Health and Health Disparities. NR 40 TC 3 Z9 3 U1 1 U2 1 PU AMER SOC NEPHROLOGY PI WASHINGTON PA 1725 I ST, NW STE 510, WASHINGTON, DC 20006 USA SN 1555-9041 EI 1555-905X J9 CLIN J AM SOC NEPHRO JI Clin. J. Am. Soc. Nephrol. PD AUG PY 2016 VL 11 IS 8 BP 1384 EP 1391 DI 10.2215/CJN.13111215 PG 8 WC Urology & Nephrology SC Urology & Nephrology GA DY1BP UT WOS:000384830200012 PM 27340284 ER PT J AU Mair, CA Quinones, AR Pasha, MA AF Mair, Christine A. Quinones, Ana R. Pasha, Maha A. TI Care Preferences Among Middle-Aged and Older Adults With Chronic Disease in Europe: Individual Health Care Needs and National Health Care Infrastructure SO GERONTOLOGIST LA English DT Article DE Caregiving-informal; Caregiving-formal; Health care policy ID LONG-TERM-CARE; PUBLIC-ATTITUDES; FAMILY CAREGIVERS; WELFARE-STATE; NURSING-HOME; PERCEPTIONS; DEMENTIA; CONTEXTS; POLICIES; MODERATE AB Purpose of the Study: The purpose of this study is to expand knowledge of care options for aging populations cross-nationally by examining key individual-level and nation-level predictors of European middle-aged and older adults' preferences for care. Design and Methods: Drawing on data from the Survey of Health, Ageing and Retirement in Europe and the Organisation for Economic Co-operation and Development, we analyze old age care preferences of a sample of 6,469 adults aged 50 and older with chronic disease in 14 nations. Using multilevel modeling, we analyze associations between individual-level health care needs and nation-level health care infrastructure and preference for family-based (vs. state-based) personal care. Results: We find that middle-aged and older adults with chronic disease whose health limits their ability to perform paid work, who did not receive personal care from informal sources, and who live in nations with generous long-term care funding are less likely to prefer family-based care and more likely to prefer state-based care. Implications: We discuss these findings in light of financial risks in later life and the future role of specialized health support programs, such as long-term care. C1 [Mair, Christine A.] Univ Maryland Baltimore Cty, Dept Sociol & Anthropol, 1000 Hilltop Circle, Baltimore, MD 21250 USA. [Quinones, Ana R.; Pasha, Maha A.] Oregon Hlth & Sci Univ, Dept Publ Hlth & Prevent Med, Portland VA Med Ctr, Portland, OR 97201 USA. RP Mair, CA (reprint author), Univ Maryland Baltimore Cty, Dept Sociol & Anthropol, 1000 Hilltop Circle, Baltimore, MD 21250 USA. EM christine_mair@umbc.edu FU NHLBI NIH HHS [R25 HL105430] NR 38 TC 1 Z9 1 U1 3 U2 3 PU OXFORD UNIV PRESS INC PI CARY PA JOURNALS DEPT, 2001 EVANS RD, CARY, NC 27513 USA SN 0016-9013 EI 1758-5341 J9 GERONTOLOGIST JI Gerontologist PD AUG PY 2016 VL 56 IS 4 BP 687 EP 701 DI 10.1093/geront/gnu119 PG 15 WC Gerontology SC Geriatrics & Gerontology GA DY0AU UT WOS:000384760000012 PM 26035873 ER PT J AU Post, RM Kupka, R Keck, PE McElroy, SL Altshuler, LL Frye, MA Rowe, M Grunze, H Suppes, T Leverich, GS Nolen, WA AF Post, Robert M. Kupka, Ralph Keck, Paul E., Jr. McElroy, Susan L. Altshuler, Lori L. Frye, Mark A. Rowe, Michael Grunze, Heinz Suppes, Trisha Leverich, Gabriele S. Nolen, Willem A. TI Further Evidence of a Cohort Effect in Bipolar Disorder: More Early Onsets and Family History of Psychiatric Illness in More Recent Epochs SO JOURNAL OF CLINICAL PSYCHIATRY LA English DT Article DE Bipolar Disorder ID AGE-OF-ONSET; MENTAL-HEALTH-SURVEY; MOOD-DISORDERS; LIFETIME PREVALENCE; UNITED-STATES; BIRTH-COHORT; AT-ONSET; PARENTS; RISK; METAANALYSIS AB Objective: Given that a cohort effect is rarely mentioned as one of the possible contributors to the increased incidence of childhood-onset bipolar disorder in the United States, we reexamined evidence for the phenomenon within our outpatient Bipolar Collaborative Network. Methods: 968 outpatients (mean age, 41 years) with DSM bipolar disorder from 1995 to 2002 from 4 sites in the United States and 3 in the Netherlands and Germany (abbreviated as Europe) gave informed consent and provided detailed demographic, illness, and family history information on a patient questionnaire. Family history of bipolar disorder, depression, suicide attempt, alcohol abuse, substance abuse, and "other" illness was collected for each parent and the 4 grandparents. Age at onset and family history of illness burden were then assessed as a function of the age of the patient at network entry. Results: Data for patients aged 35 years or older (n = 613) were included in the first analysis. Compared to older patients, those who were younger when they entered the network had an earlier age at onset of their bipolar disorder (r = 0.33, P < .001). Similarly, the youngest patients at entry (representing the most recent cohorts) had parents and grandparents with more psychiatric illness than patients born in earlier cohorts (n = 968). Conclusions: These preliminary data, taken with the substantial literature, suggest a cohort effect for earlier age at onset of bipolar disorder and greater burden of psychiatric disorders in 2 generations of direct progenitors of our patients. The resulting likely increase in severity of bipolar illness in future generations based on this earlier age at onset and increased familial loading, particularly in the United States, deserves focused clinical and public health attention and attempts at amelioration. C1 [Post, Robert M.; Rowe, Michael; Leverich, Gabriele S.] Bipolar Collaborat Network, Bethesda, MD USA. [Post, Robert M.] George Washington Univ, Dept Psychiat & Behav Sci, Washington, DC USA. [Kupka, Ralph] Vrije Univ Amsterdam Med Ctr, Dept Psychiat, Amsterdam, Netherlands. [Keck, Paul E., Jr.] Univ Cincinnati, Dept Psychiat & Behav Neurosci, Coll Med, Cincinnati, OH 45221 USA. [Keck, Paul E., Jr.; McElroy, Susan L.] Lindner Ctr HOPE, Mason, OH USA. [McElroy, Susan L.] Univ Cincinnati, Biol Psychiat Program, Coll Med, Cincinnati, OH 45221 USA. [Altshuler, Lori L.] Univ Calif Los Angeles, David Geffen Sch Med, Dept Psychiat & Biobehav Sci, Los Angeles, CA 90095 USA. [Altshuler, Lori L.] VA Greater Los Angeles Healthcare Syst, Dept Psychiat, West Los Angeles Healthcare Ctr, Los Angeles, CA USA. [Frye, Mark A.] Mayo Clin, Dept Psychiat & Psychol, Rochester, MN USA. [Grunze, Heinz] Newcastle Univ, Inst Neurosci & Campus Aging & Vital, Wolfson Res Ctr, Newcastle Upon Tyne, Tyne & Wear, England. [Suppes, Trisha] Stanford Univ, Sch Med, Dept Psychiat & Behav Sci, Palo Alto, CA 94304 USA. [Suppes, Trisha] VA Palo Alto Hlth Care Syst, Palo Alto, CA USA. [Nolen, Willem A.] Univ Groningen, Univ Med Ctr Groningen, NL-9700 AB Groningen, Netherlands. RP Post, RM (reprint author), 5415 W Cedar Ln,Ste 201-B, Bethesda, MD 20814 USA. EM robert.post@speakeasy.net OI Grunze, Heinz/0000-0003-4712-8979 FU Stanley Medical Research Institute FX Support was provided by the Stanley Medical Research Institute from 1995-2002. NR 47 TC 3 Z9 3 U1 3 U2 5 PU PHYSICIANS POSTGRADUATE PRESS PI MEMPHIS PA P O BOX 752870, MEMPHIS, TN 38175-2870 USA SN 0160-6689 EI 1555-2101 J9 J CLIN PSYCHIAT JI J. Clin. Psychiatry PD AUG PY 2016 VL 77 IS 8 BP 1043 EP 1049 DI 10.4088/JCP.15m10121 PG 7 WC Psychology, Clinical; Psychiatry SC Psychology; Psychiatry GA DY0OO UT WOS:000384796300017 PM 27379705 ER PT J AU Naimark, DMJ Grams, ME Matsushita, K Black, C Drion, I Fox, CS Inker, LA Ishani, A Jee, SH Kitamura, A Lea, JP Nally, J Peralta, CA Rothenbacher, D Ryu, S Tonelli, M Yatsuya, H Coresh, J Gansevoort, RT Warnock, DG Woodward, M de Jong, PE AF Naimark, David M. J. Grams, Morgan E. Matsushita, Kunihiro Black, Corri Drion, Iefke Fox, Caroline S. Inker, Lesley A. Ishani, Areef Jee, Sun Ha Kitamura, Akihiko Lea, Janice P. Nally, Joseph Peralta, Carmen Alicia Rothenbacher, Dietrich Ryu, Seungho Tonelli, Marcello Yatsuya, Hiroshi Coresh, Josef Gansevoort, Ron T. Warnock, David G. Woodward, Mark de Jong, Paul E. CA CKD Prognosis Consortium TI Past Decline Versus Current eGFR and Subsequent Mortality Risk SO JOURNAL OF THE AMERICAN SOCIETY OF NEPHROLOGY LA English DT Article ID GLOMERULAR-FILTRATION-RATE; CHRONIC KIDNEY-DISEASE; STAGE RENAL-DISEASE; COLLABORATIVE METAANALYSIS; POPULATION COHORTS; HIGHER ALBUMINURIA; ALL-CAUSE; CARDIOVASCULAR-DISEASE; DEATH; EQUATION AB A single determination of eGFR associates with subsequent mortality risk. Prior decline in eGFR indicates loss of kidney function, but the relationship to mortality risk is uncertain. We conducted an individual-level meta-analysis of the risk of mortality associated with antecedent eGFR slope, adjusting for established risk factors, including last eGFR, among 1.2 million subjects from 12 CKD and 22 other cohorts within the CKD Prognosis Consortium. Over a 3-year antecedent period, 12% of participants in the CKD cohorts and 11% in the other cohorts had an eGFR slope, <-5 ml/min per 1.73 m(2) per year, whereas 7% and 4% had a slope >5 ml/min per 1.73 m(2) per year, respectively. Compared with a slope of 0 ml/min per 1.73 m(2) per year, a slope of -6 ml/min per 1.73 m(2) per year associated with adjusted hazard ratios for all-cause mortality of 1.25 (95% confidence interval [95% CI], 1.09 to 1.44) among CKD cohorts and 1.15 (95% CI, 1.01 to 1.31) among other cohorts during a follow-up of 3.2 years. A slope of +6 ml/min per 1.73 m(2) per year also associated with higher all-cause mortality risk, with adjusted hazard ratios of 1.58 (95% CI, 1.29 to 1.95) among CKD cohorts and 1.43 (95% CI, 1.11 to 1.84) among other cohorts. Results were similar for cardiovascular and noncardiovascular causes of death and stronger for longer antecedent periods (3 versus <3 years). We conclude that prior decline or rise in eGFR associates with an increased risk of mortality, independent of current eGFR. C1 [Naimark, David M. J.] Univ Toronto, Sunnybrook Hlth Sci Ctr, Div Nephrol, Toronto, ON, Canada. [Naimark, David M. J.] Univ Toronto, Fac Med, Inst Hlth Policy Management & Evaluat, Toronto, ON, Canada. [Grams, Morgan E.; Matsushita, Kunihiro; Coresh, Josef; Woodward, Mark] Johns Hopkins Bloomberg Sch Publ Hlth, Dept Epidemiol, Baltimore, MD USA. [Grams, Morgan E.] Johns Hopkins Univ, Dept Med, Div Nephrol, Baltimore, MD USA. [Black, Corri] Univ Aberdeen, Inst Appl Hlth Sci, Aberdeen, Scotland. [Drion, Iefke] Isala Clin, Ctr Diabet, Zwolle, Netherlands. [Fox, Caroline S.] NHLBI, Framingham Heart Study, Ctr Populat Studies, Framingham, MA USA. [Fox, Caroline S.] Brigham & Womens Hosp, Div Endocrinol, 75 Francis St, Boston, MA 02115 USA. [Fox, Caroline S.] Harvard Med Sch, Boston, MA USA. [Inker, Lesley A.] Tufts Med Ctr, Div Nephrol, Boston, MA USA. [Ishani, Areef] Minneapolis Vet Affairs Hlth Care Syst, Nephrol Sect, Minneapolis, MN USA. [Jee, Sun Ha] Yonsei Univ, Inst Hlth Promot, Grad Sch Publ Hlth, Dept Epidemiol & Hlth Promot, Seoul, South Korea. [Kitamura, Akihiko] Osaka Ctr Canc & Cardiovasc Dis Prevent, Osaka, Japan. [Lea, Janice P.] Emory Univ, Sch Med, Div Renal, Atlanta, GA 30322 USA. [Nally, Joseph] Glickman Urol & Kidney Inst, Dept Hypertens & Nephrol, Cleveland, OH USA. [Peralta, Carmen Alicia] Univ Calif San Francisco, Dept Med, San Francisco, CA USA. [Peralta, Carmen Alicia] San Francisco VA Med Ctr, San Francisco, CA USA. [Rothenbacher, Dietrich] German Canc Res Ctr, Div Clin Epidemiol & Aging Res, Heidelberg, Germany. [Rothenbacher, Dietrich] Univ Ulm, Inst Epidemiol & Med Biometry, Ulm, Germany. [Ryu, Seungho] Sunkgyunkwan Univ, Sch Med, Kangbuk Samsung Hosp, Seoul, South Korea. [Tonelli, Marcello] Univ Calgary, Dept Med, Calgary, AB, Canada. [Yatsuya, Hiroshi] Fujita Hlth Univ, Dept Publ Hlth, Toyoake, Aichi, Japan. [Gansevoort, Ron T.; de Jong, Paul E.] Univ Groningen, Univ Med Ctr Groningen, Dept Nephrol, Groningen, Netherlands. [Warnock, David G.] Univ Alabama Birmingham, Dept Med, Birmingham, AL 35294 USA. [Woodward, Mark] Univ Oxford, Nuffield Dept Populat Hlth, George Inst Global Hlth, Oxford, England. [Woodward, Mark] Univ Sydney, George Inst Global Hlth, Sydney, NSW, Australia. RP Coresh, J (reprint author), Chron Kidney Dis Prognosis Consortium, Data Coordinating Ctr, 2024 East Monument St, Baltimore, MD 21287 USA. EM ckdpc@jhmi.edu RI Tonelli, Marcello/B-3028-2009; Brenner, Hermann/B-4627-2017 OI Brenner, Hermann/0000-0002-6129-1572 FU US National Kidney Foundation; National Institute of Diabetes and Digestive and Kidney Diseases [R01DK100446-01]; National Institutes of Health FX The Chronic Kidney Disease Prognosis Consortium (CKD-PC) Data Coordinating Center is funded, in part, by a program grant from the US National Kidney Foundation (funding sources include AbbVie and Amgen, Inc.) and National Institute of Diabetes and Digestive and Kidney Diseases Grant R01DK100446-01. A variety of sources have supported enrollment and data collection, including laboratory measurements, as well as follow-up in the collaborating cohorts of the CKD-PC. These funding sources include government agencies, such as the National Institutes of Health, and medical research councils as well as foundations and industry sponsors, and they are listed in Supplemental Appendix 3. Individual cohort and collaborator support is listed in Supplemental Appendix 3. NR 29 TC 0 Z9 0 U1 2 U2 2 PU AMER SOC NEPHROLOGY PI WASHINGTON PA 1725 I ST, NW STE 510, WASHINGTON, DC 20006 USA SN 1046-6673 EI 1533-3450 J9 J AM SOC NEPHROL JI J. Am. Soc. Nephrol. PD AUG PY 2016 VL 27 IS 8 BP 2456 EP 2466 DI 10.1681/ASN.2015060688 PG 11 WC Urology & Nephrology SC Urology & Nephrology GA DY3PM UT WOS:000385006100025 PM 26657865 ER PT J AU Lanham, HJ Palmer, RF Leykum, LK McDaniel, RR Nutting, PA Stange, KC Crabtree, BF Miller, WL Jaen, CR AF Lanham, Holly Jordan Palmer, Raymond F. Leykum, Luci K. McDaniel, Reuben R., Jr. Nutting, Paul A. Stange, Kurt C. Crabtree, Benjamin F. Miller, William L. Jaen, Carlos Roberto TI Trust and Reflection in Primary Care Practice Redesign SO HEALTH SERVICES RESEARCH LA English DT Article DE Practice redesign; relationships; reflection; sensemaking; learning ID CENTERED MEDICAL HOME; NATIONAL DEMONSTRATION PROJECT; COMPLEXITY SCIENCE; HEALTH-CARE; TRANSFORMATION; LESSONS; TEAMS; ORGANIZATIONS; SENSEMAKING; SAFETY AB Objective. To test a conceptual model of relationships, reflection, sensemaking, and learning in primary care practices transitioning to patient-centered medical homes (PCMH). Data Sources/Study Setting. Primary data were collected as part of the American Academy of Family Physicians' National Demonstration Project of the PCMH. Study Design. We conducted a cross-sectional survey of clinicians and staff from 36 family medicine practices across the United States. Surveys measured seven characteristics of practice relationships (trust, diversity, mindfulness, heedful interrelation, respectful interaction, social/task relatedness, and rich and lean communication) and three organizational attributes (reflection, sensemaking, and learning) of practices. Data Collection/Extraction Methods. We surveyed 396 clinicians and practice staff. We performed a multigroup path analysis of the data. Parameter estimates were calculated using a Bayesian estimation method. Principal Findings. Trust and reflection were important in explaining the characteristics of practice relationships and their associations with sensemaking and learning. The strongest associations between relationships, sensemaking, and learning were found under conditions of high trust and reflection. The weakest associations were found under conditions of low trust and reflection. Conclusions. Trust and reflection appear to play a key role in moderating relationships, sensemaking, and learning in practices undergoing practice redesign. C1 [Lanham, Holly Jordan; Leykum, Luci K.] Univ Texas Hlth Sci Ctr San Antonio, Dept Med Hosp Med, 7703 Floyd Curl Dr, San Antonio, TX 78229 USA. [Lanham, Holly Jordan; Palmer, Raymond F.] Univ Texas Hlth Sci Ctr San Antonio, Dept Family & Community Med, 7703 Floyd Curl Dr, San Antonio, TX 78229 USA. [Lanham, Holly Jordan; Leykum, Luci K.] South Texas Vet Hlth Care Syst, San Antonio, TX USA. [Lanham, Holly Jordan; Leykum, Luci K.; McDaniel, Reuben R., Jr.] Univ Texas Austin, Dept Informat Risk & Operat Management, McCombs Sch Business, San Antonio, TX USA. [Nutting, Paul A.] Ctr Res Strategies, Denver, CO USA. [Stange, Kurt C.] Case Western Reserve Univ, Dept Family Med, Case Comprehens Canc Ctr, Cleveland, OH 44106 USA. [Stange, Kurt C.] Case Western Reserve Univ, Dept Epidemiol & Biostat, Case Comprehens Canc Ctr, Cleveland, OH 44106 USA. [Stange, Kurt C.] Case Western Reserve Univ, Dept Sociol, Case Comprehens Canc Ctr, Cleveland, OH 44106 USA. [Crabtree, Benjamin F.] Rutgers Robert Wood Johnson Med Sch, Dept Family Med & Community Hlth, New Brunswick, NJ USA. [Miller, William L.] Lehigh Valley Hlth Network, Dept Family Med, Allentown, PA USA. [Jaen, Carlos Roberto] Univ Texas Hlth Sci Ctr San Antonio, Dept Family & Community Med, Res Adv Community Hlth Ctr, San Antonio, TX 78229 USA. [Jaen, Carlos Roberto] Univ Texas Hlth Sci Ctr San Antonio, Dept Epidemiol & Biostat, Res Adv Community Hlth Ctr, San Antonio, TX 78229 USA. RP Lanham, HJ (reprint author), Univ Texas Hlth Sci Ctr San Antonio, Dept Med Hosp Med, 7703 Floyd Curl Dr, San Antonio, TX 78229 USA.; Lanham, HJ (reprint author), Univ Texas Hlth Sci Ctr San Antonio, Dept Family & Community Med, 7703 Floyd Curl Dr, San Antonio, TX 78229 USA.; Lanham, HJ (reprint author), South Texas Vet Hlth Care Syst, San Antonio, TX USA.; Lanham, HJ (reprint author), Univ Texas Austin, Dept Informat Risk & Operat Management, McCombs Sch Business, San Antonio, TX USA. EM lanham@uthscsa.edu FU American Academy of Family Physicians; Commonwealth Fund, a national, private foundation based in New York City; Department of Veterans Affairs; Veterans Health Administration; Health Services Research and Development Service [CDA 07-022]; South Texas Veterans Health Care System; Charles and Elizabeth Prothro Chair in Health Care Management, the University of Texas at Austin; Harry and Elsa Jiler American Cancer Society; National Cancer Institute [K05 CA140237] FX The authors express their appreciation for the cooperation and dedication of the physicians and staff of the family practices that participated in the NDP. We also thank the anonymous reviewers for their comments and insights. The American Academy of Family Physicians provided funding support for this evaluation, including a Research Center grant. The evaluation was also partially supported by the Commonwealth Fund, a national, private foundation based in New York City that supports independent research on health care issues and makes grants to improve health care practice and policy. LKL was supported by the Department of Veterans Affairs, Veterans Health Administration, and Health Services Research and Development Service (CDA 07-022) and her investigator salary support is provided through this funding and through the South Texas Veterans Health Care System. RMD receives support from the Charles and Elizabeth Prothro Chair in Health Care Management, the University of Texas at Austin. KCS was supported in part by the Harry and Elsa Jiler American Cancer Society Clinical Research Professorship. BFC was supported in part by a National Cancer Institute K05 Senior Investigator Award (K05 CA140237). NR 72 TC 1 Z9 1 U1 5 U2 6 PU WILEY-BLACKWELL PI HOBOKEN PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA SN 0017-9124 EI 1475-6773 J9 HEALTH SERV RES JI Health Serv. Res. PD AUG PY 2016 VL 51 IS 4 BP 1489 EP 1514 DI 10.1111/1475-6773.12415 PG 26 WC Health Care Sciences & Services; Health Policy & Services SC Health Care Sciences & Services GA DX9VO UT WOS:000384745300010 PM 26611650 ER PT J AU Altawalbeh, SM Thorpe, CT Zgibor, JC Kane-Gill, S Kang, YH Thorpe, JM AF Altawalbeh, Shoroq M. Thorpe, Carolyn T. Zgibor, Janice C. Kane-Gill, Sandra Kang, Yihuang Thorpe, Joshua M. TI Antileukotriene Agents Versus Long-Acting Beta-Agonists in Older Adults with Persistent Asthma: A Comparison of Add-On Therapies SO JOURNAL OF THE AMERICAN GERIATRICS SOCIETY LA English DT Article DE asthma; older adults; cardiovascular; Medicare ID INHALED CORTICOSTEROIDS; UNITED-STATES; CONTROLLER MEDICATIONS; CARDIOVASCULAR-DISEASE; RESOURCE UTILIZATION; ELDERLY-PATIENTS; MONTELUKAST; SAFETY; EXACERBATIONS; SURVEILLANCE AB ObjectivesTo compare the effectiveness and cardiovascular safety of long-acting beta-agonists (LABAs) with those of leukotriene receptor antagonists (LTRAs) as add-on treatments in older adults with asthma already taking inhaled corticosteroids (ICSs). DesignRetrospective cohort study. SettingMedicare fee-for-service (FFS) claims (2009-10) for a 10% random sample of beneficiaries continuously enrolled in Parts A, B, and D in 2009. ParticipantsMedicare beneficiaries aged 66 and older continuously enrolled in FFS Medicare with Part D coverage with a diagnosis of asthma before 2009 treated exclusively with ICSs plus LABAs or ICSs plus LTRAs (N = 14,702). MeasurementsThe augmented inverse propensity-weighted estimator was used to compare the effect of LABA add-on therapy with that of LTRA add-on therapy on asthma exacerbations requiring inpatient, emergency, or outpatient care and on cardiovascular (CV) events, adjusting for demographic characteristics, comorbidities, and county-level healthcare-access variables. ResultsThe primary analysis showed that LTRA add-on treatment was associated with greater odds of asthma-related hospitalizations or emergency department visits (odds ratio (OR) = 1.4, P < .001), as well as outpatient exacerbations requiring oral corticosteroids or antibiotics (OR = 1.41, P < .001) than LABA treatment. LTRA add-on therapy was also less effective in controlling acute symptoms, as indicated by greater use of short-acting beta agonists (rate ratio = 1.58, P < .001). LTRA add-on treatment was associated with lower odds of experiencing a CV event than LABA treatment (OR = 0.86, P = .006). ConclusionThis study provides new evidence specific to older adults to help healthcare providers weigh the risks and benefits of these add-on treatments. Further subgroup analysis is needed to personalize asthma treatments in this high-risk population. C1 [Altawalbeh, Shoroq M.] Univ Pittsburgh, Dept Pharmaceut Sci, Ctr Clin Pharmaceut Sci, Pittsburgh, PA USA. [Thorpe, Carolyn T.; Kane-Gill, Sandra; Thorpe, Joshua M.] Univ Pittsburgh, Sch Pharm, Dept Pharm & Therapeut, Pittsburgh, PA 15261 USA. [Thorpe, Carolyn T.; Thorpe, Joshua M.] Vet Affairs Pittsburgh Healthcare Syst, Ctr Hlth Equ Res & Promot, Pittsburgh, PA USA. [Zgibor, Janice C.] Univ Pittsburgh, Grad Sch Publ Hlth, Dept Epidemiol, Pittsburgh, PA USA. Natl Sun Yat Sen Univ, Dept Informat Management, Kaohsiung, Taiwan. RP Altawalbeh, SM (reprint author), Univ Pittsburgh, Sch Pharm, Dept Pharmaceut Sci, 3501 Terrace St,916 Salk, Pittsburgh, PA 15261 USA. EM sha55@pitt.edu FU University of Pittsburgh School of Pharmacy; Pittsburgh Claude D. Pepper Older Americans Independence Center [NIA P30 AGAG024827] FX The University of Pittsburgh School of Pharmacy and the Pittsburgh Claude D. Pepper Older Americans Independence Center (NIA P30 AGAG024827) provided support for this study. NR 50 TC 0 Z9 0 U1 0 U2 0 PU WILEY-BLACKWELL PI HOBOKEN PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA SN 0002-8614 EI 1532-5415 J9 J AM GERIATR SOC JI J. Am. Geriatr. Soc. PD AUG PY 2016 VL 64 IS 8 BP 1592 EP 1600 DI 10.1111/jgs.14235 PG 9 WC Geriatrics & Gerontology; Gerontology SC Geriatrics & Gerontology GA DW3KW UT WOS:000383541500009 PM 27351988 ER PT J AU Linos, E Chren, MM Cenzer, IS Covinsky, KE AF Linos, Eleni Chren, Mary-Margaret Cenzer, Irena Stijacic Covinsky, Kenneth E. TI Skin Cancer in US Elderly Adults: Does Life Expectancy Play a Role in Treatment Decisions? SO JOURNAL OF THE AMERICAN GERIATRICS SOCIETY LA English DT Article DE skin cancer; basal cell carcinoma; squamous cell carcinoma; end of life ID BASAL-CELL CARCINOMA; OLDER-ADULTS; VALIDATION; INDEX; CARE; END AB ObjectivesTo examine whether life expectancy influences treatment pattern of nonmelanoma skin cancer, or keratinocyte carcinoma (KC), the most common malignancy and the fifth most costly cancer to Medicare. DesignNationally representative cross-sectional study. SettingNationally representative Health and Retirement Study linked to Medicare claims. ParticipantsTreatments (N = 9,653) from individuals aged 65 and older treated for basal or squamous cell carcinoma between 1992 and 2012 (N = 2,702) were included. MeasurementsLimited life expectancy defined according to aged 85 and older, medical comorbidities, Charlson Comorbidity Index score of 3 or greater, difficulty in at least one activity of daily living (ADL), and a Lee index of 13 or greater. Treatment type (Mohs micrographic surgery (MMS) (most intensive, highest cost), excision, or electrodesiccation and curettage (ED&C) (least intensive, lowest cost)), according to procedure code. ResultsMost KCs (61%) were treated surgically. Rates of MMS (19%), excision (42%), and ED&C (39%) were no different in participants with limited life expectancy and those with normal life expectancy. For example, 19% of participants with difficulty or dependence in ADLs, 20% of those with a Charlson comorbidity score greater than 3, and 15% of those in their last year of life underwent MMS; participants who died within 1 year of diagnosis were treated in the same way as those who lived longer. ConclusionA one-size-fits-all approach in which advanced age, health status, functional status, and prognosis are not associated with intensiveness of treatment appears to guide treatment for KC, a generally nonfatal condition. Although intensive treatment of skin cancer when it causes symptoms may be indicated regardless of life expectancy, persons with limited life expectancy should be given choices to ensure that the treatment matches their goals and preferences. C1 [Linos, Eleni; Chren, Mary-Margaret] Univ Calif San Francisco, Dept Dermatol, San Francisco, CA 94143 USA. [Cenzer, Irena Stijacic; Covinsky, Kenneth E.] Univ Calif San Francisco, Dept Med, Div Geriatr, San Francisco, CA USA. [Cenzer, Irena Stijacic; Covinsky, Kenneth E.] San Francisco VA Med Ctr, San Francisco, CA USA. RP Linos, E (reprint author), Dept Dermatol, 2340 Sutter St,Room N421 Mail Code Box 0808, San Francisco, CA 94143 USA. EM linose@derm.ucsf.edu FU National Institutes of Health through the National Center for Research Resources [KL2RR024130]; National Institute of Arthritis and Musculoskeletal and Skin Diseases [K24 AR052667, R01 AR 054983]; National Institute of Nursing Research [R01 NR013347]; Claude D. Pepper Older Americans Independence Center at the National Institute on Aging, National Institutes of Health [P30 AG044281] FX This work was supported by the National Institutes of Health through the National Center for Research Resources (Grant KL2RR024130 to EL), the National Institute of Arthritis and Musculoskeletal and Skin Diseases (Grants K24 AR052667 and R01 AR 054983 to MMC), the National Institute of Nursing Research (Grant R01 NR013347 to KC), and the Claude D. Pepper Older Americans Independence Center at the National Institute on Aging, National Institutes of Health (Grant P30 AG044281 to KC). NR 23 TC 0 Z9 0 U1 5 U2 5 PU WILEY-BLACKWELL PI HOBOKEN PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA SN 0002-8614 EI 1532-5415 J9 J AM GERIATR SOC JI J. Am. Geriatr. Soc. PD AUG PY 2016 VL 64 IS 8 BP 1610 EP 1615 DI 10.1111/jgs.14202 PG 6 WC Geriatrics & Gerontology; Gerontology SC Geriatrics & Gerontology GA DW3KW UT WOS:000383541500011 PM 27303932 ER PT J AU Abdalla, T Roda, MA Li, JD Blalock, JE Gaggar, A Xu, X AF Abdalla, T. Roda, Abdul M. Li, J. -D Blalock, J. E. Gaggar, A. Xu, X. TI Prolyl endopeptidase (PE) activity in the immune system of smoking mice SO EUROPEAN JOURNAL OF IMMUNOLOGY LA English DT Meeting Abstract CT International Congress of Immunology (ICI) CY AUG 21-26, 2016 CL Melbourne, AUSTRALIA C1 [Abdalla, T.; Li, J. -D; Blalock, J. E.; Gaggar, A.; Xu, X.] Univ Alabama Birmingham, Med, Birmingham, AL USA. [Roda, Abdul M.] Univ Utrecht, Pharmaceut Sci, Utrecht, Netherlands. [Blalock, J. E.; Gaggar, A.; Xu, X.] UAB Program Protease & Matrix Biol, Birmingham, AL USA. [Gaggar, A.] Birmingham VA Med Ctr, Birmingham, AL USA. NR 0 TC 0 Z9 0 U1 0 U2 0 PU WILEY-BLACKWELL PI HOBOKEN PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA SN 0014-2980 EI 1521-4141 J9 EUR J IMMUNOL JI Eur. J. Immunol. PD AUG PY 2016 VL 46 SU 1 SI SI MA 353 BP 407 EP 407 PG 1 WC Immunology SC Immunology GA DW4KA UT WOS:000383610401009 ER PT J AU Collins, SP Levy, PD Martindale, JL Dunlap, ME Storrow, AB Pang, PS Albert, NM Felker, GM Fermann, GJ Fonarow, GC Givertz, MM Hollander, JE Lanfear, DE Lenihan, DJ Lindenfeld, JM Peacock, WF Sawyer, DB Teerlink, JR Butler, J AF Collins, Sean P. Levy, Phillip D. Martindale, Jennifer L. Dunlap, Mark E. Storrow, Alan B. Pang, Peter S. Albert, Nancy M. Felker, G. Michael Fermann, Gregory J. Fonarow, Gregg C. Givertz, Michael M. Hollander, Judd E. Lanfear, David E. Lenihan, Daniel J. Lindenfeld, JoAnn M. Peacock, W. Frank Sawyer, Douglas B. Teerlink, John R. Butler, Javed TI Clinical and Research Considerations for Patients With Hypertensive Acute Heart Failure: A Consensus Statement from the Society for Academic Emergency Medicine and the Heart Failure Society of America Acute Heart Failure Working Group SO ACADEMIC EMERGENCY MEDICINE LA English DT Article ID CARDIOGENIC PULMONARY-EDEMA; WORSENING RENAL-FUNCTION; SCANDINAVIAN ENALAPRIL SURVIVAL; HAND-CARRIED ULTRASOUND; BLOOD-PRESSURE; ISOSORBIDE-DINITRATE; NONINVASIVE VENTILATION; FLUID ACCUMULATION; TRANSDERMAL NITROGLYCERIN; INTRAVENOUS ENALAPRILAT AB Management approaches for patients in the emergency department (ED) who present with acute heart failure (AHF) have largely focused on intravenous diuretics. Yet, the primary pathophysiologic derangement underlying AHF in many patients is not solely volume overload. Patients with hypertensive AHF (H-AHF) represent a clinical phenotype with distinct pathophysiologic mechanisms that result in elevated ventricular filling pressures. To optimize treatment response and minimize adverse events in this subgroup, we propose that clinical management be tailored to a conceptual model of disease that is based on these mechanisms. This consensus statement reviews the relevant pathophysiology, clinical characteristics, approach to therapy, and considerations for clinical trials in ED patients with H-AHF. (C) 2016 by the Society for Academic Emergency Medicine C1 [Collins, Sean P.; Storrow, Alan B.] Vanderbilt Univ, Dept Emergency Med, 221 Kirkland Hall, Nashville, TN 37235 USA. [Levy, Phillip D.] Wayne State Univ, Dept Emergency Med, Detroit, MI USA. [Martindale, Jennifer L.] SUNY Downstate, Dept Emergency Med, Brooklyn, NY USA. [Dunlap, Mark E.] Case Western Univ, Dept Med, Cleveland, OH USA. [Pang, Peter S.] Indiana Univ, Dept Emergency Med, Indianapolis, IN 46204 USA. [Albert, Nancy M.] Cleveland Clin, Dept Med, Cleveland, OH 44106 USA. [Felker, G. Michael] Duke Univ, Dept Med, Durham, NC USA. [Fermann, Gregory J.] Univ Cincinnati, Dept Emergency Med, Cincinnati, OH USA. [Fonarow, Gregg C.] Univ Calif Los Angeles, Dept Med, Los Angeles, CA 90024 USA. [Givertz, Michael M.] Harvard Med Sch, Dept Med, Boston, MA USA. [Hollander, Judd E.] Thomas Jefferson Univ, Dept Emergency Med, Philadelphia, PA 19107 USA. [Lanfear, David E.] Henry Ford Hlth Syst, Dept Med, Detroit, MI USA. [Lenihan, Daniel J.; Lindenfeld, JoAnn M.] Vanderbilt Univ, Dept Med, Nashville, TN USA. [Peacock, W. Frank] Baylor Coll Med, Dept Emergency Med, Houston, TX 77030 USA. [Sawyer, Douglas B.] Maine Med Ctr, Dept Med, Portland, ME 04102 USA. [Teerlink, John R.] San Francisco VA Med Ctr, Dept Med, San Francisco, CA USA. [Butler, Javed] SUNY Stony Brook, Dept Med, Stony Brook, NY 11794 USA. RP Collins, SP (reprint author), Vanderbilt Univ, Dept Emergency Med, 221 Kirkland Hall, Nashville, TN 37235 USA. EM sean.collins@vanderbilt.edu NR 91 TC 0 Z9 0 U1 3 U2 3 PU WILEY-BLACKWELL PI HOBOKEN PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA SN 1069-6563 EI 1553-2712 J9 ACAD EMERG MED JI Acad. Emerg. Med. PD AUG PY 2016 VL 23 IS 8 BP 922 EP 931 DI 10.1111/acem.13025 PG 10 WC Emergency Medicine SC Emergency Medicine GA DW1BQ UT WOS:000383378200011 PM 27286136 ER PT J AU Baker, JF Sauer, BC Cannon, GW Teng, CC Michaud, K Ibrahim, S Jorgenson, E Davis, L Caplan, L Cannella, A Mikuls, TR AF Baker, Joshua F. Sauer, Brian C. Cannon, Grant W. Teng, Chia-Chen Michaud, Kaleb Ibrahim, Said Jorgenson, Erik Davis, Lisa Caplan, Liron Cannella, Amy Mikuls, Ted R. TI Changes in Body Mass Related to the Initiation of Disease-Modifying Therapies in Rheumatoid Arthritis SO ARTHRITIS & RHEUMATOLOGY LA English DT Article ID WEIGHT CHANGE; RISK-FACTORS; US VETERANS; INDEX; LEFLUNOMIDE; METHOTREXATE; MORTALITY; ACCURACY; COMORBIDITY; INHIBITORS AB Objective. Unintentional weight loss is important and can be predictive of long-term outcomes in patients with rheumatoid arthritis (RA). This study was undertaken to assess how primary therapies for RA may influence changes in body mass index (BMI) in RA patients from a large administrative database. Methods. Unique dispensing episodes of methotrexate, prednisone, leflunomide, and tumor necrosis factor inhibitors (TNFi) administered to RA patients were identified from the US Department of Veterans Affairs pharmacy databases. Values for C-reactive protein (CRP) level and BMI closest to the time point within 30 days of the treatment course start date and at follow-up time points were linked. Missing laboratory values were imputed. Weight loss was defined as a decrease in BMI of >1 kg/m(2). Regression models were used to evaluate changes in BMI during each drug treatment as compared to treatment with methotrexate. To assess the impact of confounding by indication, propensity scores for use of each drug were incorporated in analyses using matched-weighting techniques. Results. In total, 52,662 treatment courses in 32,859 RA patients were identified. At 6 months from the date of prescription fill, weight gain was seen among patients taking methotrexate, those taking prednisone, and those taking TNFi. On average, compared to methotrexate-treated patients, prednisone-treated patients had significantly more weight gain, while leflunomide-treated patients demonstrated weight loss. In multivariable models, more weight loss (beta = 20.41 kg/m(2), 95% confidence interval [95% CI] -0.46, -0.36; P < 0.001) and a greater risk of weight loss (odds ratio 1.73, 95% CI 1.55, 1.79; P < 0.001) were evident among those receiving leflunomide compared to those receiving methotrexate. Treatment with prednisone was associated with greater weight gain (beta = 0.072 kg/m(2), 95% CI 0.042, 0.10; P < 0.001). These associations persisted in analyses adjusted for propensity scores and in sensitivity analyses. Conclusion. Leflunomide is associated with significantly more, but modest, weight loss, while prednisone is associated with greater weight gain compared to other therapies for RA. C1 [Baker, Joshua F.; Jorgenson, Erik] Philadelphia VA Med Ctr, Philadelphia, PA USA. [Baker, Joshua F.; Ibrahim, Said; Jorgenson, Erik] Univ Penn, Philadelphia, PA 19104 USA. [Sauer, Brian C.; Cannon, Grant W.; Teng, Chia-Chen] Salt Lake City VA Med Ctr, Salt Lake City, UT USA. [Sauer, Brian C.; Cannon, Grant W.; Teng, Chia-Chen] Univ Utah, Salt Lake City, UT USA. [Michaud, Kaleb; Cannella, Amy; Mikuls, Ted R.] Univ Nebraska Med Ctr, Omaha, NE USA. [Michaud, Kaleb] Natl Data Bank Rheumat Dis, Wichita, KS USA. [Ibrahim, Said] Philadelphia VA Med Ctr, Ctr Hlth Equ Res & Promot, Philadelphia, PA USA. [Davis, Lisa; Caplan, Liron] Denver VA Med Ctr, Denver, CO USA. [Cannella, Amy; Mikuls, Ted R.] VA Nebraska Western Iowa Hlth Care Syst, Omaha, NE USA. RP Baker, JF (reprint author), Hosp Univ Penn, Div Rheumatol, Dept Med, 5 White Bldg,3600 Spruce St, Philadelphia, PA 19104 USA. EM bakerjo@uphs.upenn.edu FU Veterans Affairs Clinical Science Research and Development Career Development Award [IK2-CX000955]; K24 Mid-Career Development Award from National Institutes of Musculoskeletal and Skin Disorders [1K24-AR-055259-01]; Veterans Affairs Merit Award FX Supported by a Veterans Affairs Clinical Science Research and Development Career Development Award (IK2-CX000955 to Dr. Baker), a K24 Mid-Career Development Award from the National Institutes of Musculoskeletal and Skin Disorders (1K24-AR-055259-01 to Dr. Ibrahim), and a Veterans Affairs Merit Award (to Dr. Mikuls). NR 35 TC 1 Z9 1 U1 2 U2 2 PU WILEY-BLACKWELL PI HOBOKEN PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA SN 2326-5191 EI 2326-5205 J9 ARTHRITIS RHEUMATOL JI Arthritis Rheumatol. PD AUG PY 2016 VL 68 IS 8 BP 1818 EP 1827 DI 10.1002/art.39647 PG 10 WC Rheumatology SC Rheumatology GA DW2UX UT WOS:000383498400006 PM 26882094 ER PT J AU Wolf, BJ Spainhour, JC Arthur, JM Janech, MG Petri, M Oates, JC AF Wolf, Bethany J. Spainhour, John C. Arthur, John M. Janech, Michael G. Petri, Michelle Oates, Jim C. TI Development of Biomarker Models to Predict Outcomes in Lupus Nephritis SO ARTHRITIS & RHEUMATOLOGY LA English DT Article ID MONOCYTE CHEMOATTRACTANT; ERYTHEMATOSUS; CLASSIFICATION; URINE; CELLS; INFLAMMATION; CHEMOKINES; PROTEIN-1; EFFICACY; SAFETY AB Objective. The American College of Rheumatology guidelines for the treatment of lupus nephritis recommend change in induction therapy when response to therapy has not occurred within 6 months. Response is not defined, and renal fibrosis can occur while waiting for this end point. Therefore, a decision support tool to better define response is needed to guide clinicians when starting patients on therapy. This study was undertaken to identify biomarker models with sufficient predictive power to develop such a tool. Methods. Urine samples from 140 patients with biopsy-proven lupus nephritis who had not yet started induction therapy were analyzed for a panel of urinary biomarkers. Univariate receiver operating characteristic (ROC) curves were generated for each individual biomarker and compared to the ROC area under the curve values from machine learning models developed using random forest algorithms. Biomarker models of outcome developed with novel markers in addition to clinical markers were compared to those developed with traditional clinical markers alone. Results. Models developed with the combined traditional and novel biomarker panels demonstrated clinically meaningful predictive power. Markers most predictive of response were chemokines, cytokines, and markers of cellular damage. Conclusion. This is the first study to demonstrate the power of low-abundance biomarker panels and machine learning algorithms for predicting lupus nephritis outcomes. This is a critical first step in research to develop clinically meaningful decision support tools. C1 [Wolf, Bethany J.; Spainhour, John C.; Arthur, John M.; Janech, Michael G.; Oates, Jim C.] Med Univ South Carolina, Charleston, SC USA. [Spainhour, John C.] Georgia Inst Technol, Atlanta, GA 30332 USA. [Spainhour, John C.] Emory Univ, Atlanta, GA 30322 USA. [Arthur, John M.; Janech, Michael G.; Oates, Jim C.] Ralph H Johnson VA Med Ctr, Charleston, SC USA. [Petri, Michelle] Johns Hopkins Univ, Sch Med, Baltimore, MD USA. RP Oates, JC (reprint author), Dept Med, Div Rheumatol & Immunol, Clin Sci Bldg,96 Jonathan Lucas St,Suite 816, Charleston, SC 29425 USA. EM oatesjc@musc.edu FU VA Merit Award [1I01CX000218-01]; NIH/National Institute of Arthritis and Musculoskeletal and Skin Diseases [R21-AR-051719]; Medical University of South Carolina General and Clinical Research Center [M01-RR-001070]; South Carolina Clinical and Translational Research Institute; academic home at the Medical University of South Carolina (through NIH/National Center for Research Resources) [UL1-RR-029882]; Multidisciplinary Clinical Research Center at the Medical University of South Carolina [P60-A-R062755]; VA Research Enhancement Award Program award; NephCure Kidney International Young Investigator Career Development Award; Hopkins Lupus Cohort [AR-43727]; NIH/National Center for Research Resources [UL1-RR-025005] FX Supported in part by a VA Merit Award (1I01CX000218-01), NIH/National Institute of Arthritis and Musculoskeletal and Skin Diseases grant R21-AR-051719, the Medical University of South Carolina General and Clinical Research Center (through NIH grant M01-RR-001070), the South Carolina Clinical and Translational Research Institute, with an academic home at the Medical University of South Carolina (through NIH/National Center for Research Resources grant number UL1-RR-029882), and the Multidisciplinary Clinical Research Center at the Medical University of South Carolina (through NIH grant P60-A-R062755). Support also came from a VA Research Enhancement Award Program award. Subject material (urine samples for biomarker analysis and clinical data) were provided by Genentech (from the Lupus Nephritis Assessment of Rituximab [LUNAR] study; ClinicalTrials.gov identifier: NCT00282347) and Bristol-Myers Squibb (from the Abatacept in Lupus Nephritis study; ClinicalTrials.gov identifier: NCT00430677) and their investigators. Dr. Janech's work was supported by a NephCure Kidney International Young Investigator Career Development Award. Dr. Petri's work was supported by the Hopkins Lupus Cohort (through NIH grant AR-43727) and NIH/National Center for Research Resources grant UL1-RR-025005. NR 38 TC 3 Z9 3 U1 4 U2 4 PU WILEY-BLACKWELL PI HOBOKEN PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA SN 2326-5191 EI 2326-5205 J9 ARTHRITIS RHEUMATOL JI Arthritis Rheumatol. PD AUG PY 2016 VL 68 IS 8 BP 1955 EP 1963 DI 10.1002/art.39623 PG 9 WC Rheumatology SC Rheumatology GA DW2UX UT WOS:000383498400020 PM 26867033 ER PT J AU Saag, KG Whelton, A Becker, MA MacDonald, P Hunt, B Gunawardhana, L AF Saag, Kenneth G. Whelton, Andrew Becker, Michael A. MacDonald, Patricia Hunt, Barbara Gunawardhana, Lhanoo TI Impact of Febuxostat on Renal Function in Gout Patients With Moderate-to-Severe Renal Impairment SO ARTHRITIS & RHEUMATOLOGY LA English DT Article ID CHRONIC KIDNEY-DISEASE; URIC-ACID; HYPERURICEMIA; URATE; ALLOPURINOL; GUIDELINES; EFFICACY; SAFETY; CLASSIFICATION; COMORBIDITIES AB Objective. Renal impairment is a risk factor for gout and a barrier to optimal gout management. We undertook this exploratory study to obtain data that have been heretofore limited regarding the safety and efficacy of febuxostat in patients with moderate-to-severe renal impairment (estimated glomerular filtration rate [GFR] 15-50 ml/minute/1.73m(2)). Methods. Ninety-six gout patients with moderate-to-severe renal impairment were enrolled in a 12-month multicenter, randomized, double-blind, placebo-controlled study. Patients were randomly assigned at a 1: 1: 1 ratio to receive 30 mg febuxostat twice daily, 40/80 mg febuxostat once daily, or placebo. The primary efficacy end point was the change in serum creatinine (Cr) level from baseline to month 12. Secondary end points included the change in estimated GFR from baseline to month 12 and the proportion of patients with a serum uric acid (UA) level of <6.0 mg/dl at month 12. Results. At month 12, there were no significant differences in the change in serum Cr level from baseline, or in the change in estimated GFR from baseline, in either febuxostat group compared to the placebo group. The proportion of patients with a serum UA level of <6.0 mg/dl at month 12 was significantly greater in both febuxostat groups compared to the placebo group (both P < 0.001). At least 1 treatment-emergent adverse event (TEAE) occurred in 78.1% of patients receiving 30 mg febuxostat twice daily, 87.5% of patients receiving 40/80 mg febuxostat once daily, and 78.1% of patients receiving placebo. TEAEs most frequently involved the categories of renal failure and impairment and renal function analyses. Conclusion. Febuxostat proved to be efficacious in serum UA reduction and was well tolerated in gout patients with moderate-to-severe renal impairment. Patients randomly assigned to receive febuxostat demonstrated significantly lower serum UA levels and no significant deterioration in renal function. C1 [Saag, Kenneth G.] Birmingham VA Med Ctr, Birmingham, AL USA. [Saag, Kenneth G.] Univ Alabama Birmingham, Birmingham, AL USA. [Whelton, Andrew] Johns Hopkins Univ, Baltimore, MD USA. [Becker, Michael A.] Univ Chicago, Pritzker Sch Med, Chicago, IL 60637 USA. [MacDonald, Patricia; Hunt, Barbara; Gunawardhana, Lhanoo] Takeda Pharmaceut, Deerfield, IL USA. RP Saag, KG (reprint author), Univ Alabama Birmingham, Div Clin Immunol, Dept Med, 1720 2nd Ave South, Birmingham, AL 35294 USA.; Saag, KG (reprint author), Univ Alabama Birmingham, Div Rheumatol, Dept Med, 1720 2nd Ave South, Birmingham, AL 35294 USA. EM Ksaag@uab.edu FU Takeda Pharmaceuticals FX Under the direction of the authors, Meryl Gersh of AlphaBioCom provided writing, editing, and formatting assistance; this work was funded by Takeda Pharmaceuticals. NR 24 TC 5 Z9 6 U1 2 U2 2 PU WILEY-BLACKWELL PI HOBOKEN PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA SN 2326-5191 EI 2326-5205 J9 ARTHRITIS RHEUMATOL JI Arthritis Rheumatol. PD AUG PY 2016 VL 68 IS 8 BP 2035 EP 2043 DI 10.1002/art.39654 PG 9 WC Rheumatology SC Rheumatology GA DW2UX UT WOS:000383498400028 PM 26894653 ER PT J AU Finn, JP Nguyen, KL Han, F Zhou, Z Salusky, I Ayad, I Hu, P AF Finn, J. P. Nguyen, K. -L. Han, F. Zhou, Z. Salusky, I. Ayad, I. Hu, P. TI Cardiovascular MRI with ferumoxytol SO CLINICAL RADIOLOGY LA English DT Review ID SUPERPARAMAGNETIC IRON-OXIDE; MAGNETIC-RESONANCE ANGIOGRAPHY; ACUTE KIDNEY INJURY; AORTIC-VALVE IMPLANTATION; NEPHROGENIC SYSTEMIC FIBROSIS; ACUTE MYOCARDIAL-INFARCTION; CONGENITAL HEART-DISEASE; BLOOD-POOL AGENT; CONTRAST AGENT; SPATIAL-RESOLUTION AB The practice of contrast-enhanced magnetic resonance angiography (CEMRA) has changed significantly in the span of a decade. Concerns regarding gadolinium (Gd)-associated nephrogenic systemic fibrosis in those with severely impaired renal function spurred developments in low-dose CEMRA and non-contrast MRA as well as efforts to seek alternative MR contrast agents. Originally developed for MR imaging use, ferumoxytol (an ultra-small superparamagnetic iron oxide nanoparticle), is currently approved by the US Food and Drug Administration for the treatment of iron deficiency anaemia in adults with renal disease. Since its clinical availability in 2009, there has been rising interest in the scientific and clinical use of ferumoxytol as an MR contrast agent. The unique physicochemical and pharmacokinetic properties of ferumoxytol, including its long intravascular half-life and high r(1) relaxivity, support a spectrum of MRI applications beyond the scope of Gd-based contrast agents. Moreover, whereas Gd is not found in biological systems, iron is essential for normal metabolism, and nutritional iron deficiency poses major public health challenges worldwide. Once the carbohydrate shell of ferumoxytol is degraded, the elemental iron at its core is incorporated into the reticuloendothelial system. These considerations position ferumoxytol as a potential game changer in the field of CEMRA and MRI. In this paper, we aim to summarise our experience with the cardiovascular applications of ferumoxytol and provide a brief synopsis of ongoing investigations on ferumoxytol-enhanced MR applications. (C) 2016 Published by Elsevier Ltd on behalf of The Royal College of Radiologists. C1 [Finn, J. P.; Nguyen, K. -L.; Han, F.; Zhou, Z.; Salusky, I.; Ayad, I.; Hu, P.] Univ Calif Los Angeles, David Geffen Sch Med, Diagnost Cardiovasc Imaging Lab, Los Angeles, CA 90095 USA. [Finn, J. P.; Han, F.; Zhou, Z.; Hu, P.] Univ Calif Los Angeles, David Geffen Sch Med, Dept Radiol Sci, Los Angeles, CA 90095 USA. [Nguyen, K. -L.] Univ Calif Los Angeles, David Geffen Sch Med, Div Cardiol, Los Angeles, CA 90095 USA. [Nguyen, K. -L.] VA Greater Los Angeles Healthcare Syst, Los Angeles, CA USA. [Salusky, I.] Univ Calif Los Angeles, David Geffen Sch Med, Dept Anesthesiol, Los Angeles, CA 90095 USA. [Salusky, I.] Univ Calif Los Angeles, David Geffen Sch Med, Div Pediat Nephrol, Los Angeles, CA 90095 USA. RP Finn, JP (reprint author), Univ Calif Los Angeles, Dept Radiol Sci, Peter V Ueberroth Bldg Suite 3371, Los Angeles, CA 90095 USA. EM pfinn@mednet.ucla.edu OI Nguyen, Kim-Lien/0000-0002-8854-2976 FU National Heart, Lung, and Blood Institute [R01HL127153] FX This work is supported by grant R01HL127153 from the National Heart, Lung, and Blood Institute. NR 65 TC 3 Z9 3 U1 2 U2 3 PU W B SAUNDERS CO LTD PI LONDON PA 32 JAMESTOWN RD, LONDON NW1 7BY, ENGLAND SN 0009-9260 EI 1365-229X J9 CLIN RADIOL JI Clin. Radiol. PD AUG PY 2016 VL 71 IS 8 SI SI BP 796 EP 806 DI 10.1016/j.crad.2016.03.020 PG 11 WC Radiology, Nuclear Medicine & Medical Imaging SC Radiology, Nuclear Medicine & Medical Imaging GA DW0ST UT WOS:000383353400009 PM 27221526 ER PT J AU Tiffany, E Wilder, CM Miller, SC Winhusen, T AF Tiffany, Elizabeth Wilder, Christine M. Miller, Shannon C. Winhusen, Theresa TI Knowledge of and interest in opioid overdose education and naloxone distribution among US veterans on chronic opioids for addiction or pain SO DRUGS-EDUCATION PREVENTION AND POLICY LA English DT Article DE Education; harm reduction; methadone; naloxone; opiate; opiates; opiate use; risk ID TAKE-HOME NALOXONE; NONFATAL HEROIN OVERDOSE; INJECTION-DRUG USERS; FRANCISCO BAY AREA; UNITED-STATES; INTRAMUSCULAR NALOXONE; SCREENING-TEST; PREVENTION; INTRANASAL; MANAGEMENT AB Aims: The Veterans Health Administration (VHA) is implementing opioid overdose (OOD) education and naloxone distribution to reduce rising rates of OOD deaths. This study assessed knowledge and interest in OOD prevention with naloxone at a VHA hospital where naloxone kits were not yet available. Methods: Veterans receiving opioids for 3 months, including 52 from the Opioid Substitution Clinic (OSC) and 38 from the Pain Management Clinic (PMC), were interviewed about their attitudes and experience with OOD and naloxone. Findings: 52% of OSC and 21% of PMC veterans reported having ever experienced an OOD. Less than half had heard of naloxone and none owned a naloxone kit. After a brief explanation, 73% of OSC and 55% of PMC veterans reported wanting a kit. Veterans who reported wanting a kit were more likely to have witnessed (p<0.001) and/or experienced (p<0.001) an OOD and were more likely to have used intravenous drugs in their lifetimes (p<0.05). Conclusions: Participants were not well informed about naloxone but many OSC veterans had a history of OOD and were interested in having a naloxone kit. There was also a subgroup of veterans prescribed opioids for chronic pain who had a history of OOD and were interested in naloxone. C1 [Tiffany, Elizabeth; Wilder, Christine M.; Miller, Shannon C.; Winhusen, Theresa] Univ Cincinnati, Dept Psychiat & Behav Neurosci, Coll Med, 260 Stetson St 3200, Cincinnati, OH 45219 USA. [Wilder, Christine M.; Miller, Shannon C.] US Dept Vet Affairs, Med Ctr, Cincinnati, OH USA. RP Tiffany, E (reprint author), Univ Cincinnati, Dept Psychiat & Behav Neurosci, Coll Med, 260 Stetson St 3200, Cincinnati, OH 45219 USA. EM kraftem@ucmail.uc.edu FU Department of Veterans Affairs; Research in Addiction Medicine Scholars (RAMS) Program, National Institute on Drug Abuse [R25DA033211] FX This report is based upon work supported by the Department of Veterans Affairs and the Research in Addiction Medicine Scholars (RAMS) Program, National Institute on Drug Abuse Award Number R25DA033211. NR 42 TC 3 Z9 3 U1 3 U2 5 PU TAYLOR & FRANCIS LTD PI ABINGDON PA 2-4 PARK SQUARE, MILTON PARK, ABINGDON OR14 4RN, OXON, ENGLAND SN 0968-7637 EI 1465-3370 J9 DRUG-EDUC PREV POLIC JI Drug-Educ. Prev. Policy PD AUG PY 2016 VL 23 IS 4 BP 322 EP 327 DI 10.3109/09687637.2015.1106442 PG 6 WC Substance Abuse SC Substance Abuse GA DW8CU UT WOS:000383881700007 ER PT J AU Schlosser, RJ Mulligan, JK Hyer, JM Karnezis, TT Gudis, DA Soler, ZM AF Schlosser, Rodney J. Mulligan, Jennifer K. Hyer, J. Madison Karnezis, Tom T. Gudis, David A. Soler, Zachary M. TI Mucous Cytokine Levels in Chronic Rhinosinusitis-Associated Olfactory Loss SO JAMA OTOLARYNGOLOGY-HEAD & NECK SURGERY LA English DT Article ID ENDOSCOPIC SINUS SURGERY; NECROSIS-FACTOR-ALPHA; NASAL POLYPS; IDENTIFICATION; INTERLEUKIN-6; MODEL AB IMPORTANCE Olfactory loss is a frequent symptom of patients with chronic rhinosinusitis (CRS), but our understanding of how inflammatory cytokines affect olfaction is limited. OBJECTIVES To examine whether inflammatory cytokines are present in the olfactory cleft and whether they correlate with objective olfaction. DESIGN, SETTING, AND PARTICIPANTS In this cross-sectional study, patients with CRS underwent quantitative olfactory testing using the Sniffin Sticks test to calculate a composite threshold discrimination identification (TDI) score from October 21, 2013, to November 12, 2015. Nasal mucus was collected using a sponge placed in the olfactory cleft for 5 minutes, and Cytometric Bead Array was used to measure secreted immunomodulatory products. Correlations between TDI score and secreted mediators were then calculated. Data analysis was performed from October 15, 2015, to December 17, 2015. MAIN OUTCOMES AND MEASURES Composite TDI scores and mean secreted mediator levels in mucus from the olfactory cleft. RESULTS Thirty-four patients were enrolled (mean [SD] age, 57.3 [15.7] years; female, 21 [61.8%]; white, 26 [76.5]). The TDI scores were lower in patients with CRS with nasal polyps (CRSwNP) than in patients with CRS without nasal polyps (CRSsNP) (difference, 8.7; 95% CI, 2.5-15.0; P = .007). Interleukin (IL) 5 levels were inversely correlated with TDI scores in patients with CRSwNP and those with CRSsNP (mean [SE] beta estimate, -46.56 [15.11]; P = .005), whereas IL-6, IL-7, and vascular endothelial growth factor A were positively correlated with TDI scores only in the CRSwNP cohort. Subscale olfactory TDI scores followed similar correlations to composite TDI scores. CONCLUSIONS AND RELEVANCE In this study, inflammatory cytokines were found in mucus collected from the olfactory cleft. Levels of IL-5, in addition to other cytokines, were associated with objective olfactory function. Further inquiry is needed to establish the source of mucous cytokines and establish whether they play a causal role in olfactory loss. C1 [Schlosser, Rodney J.; Mulligan, Jennifer K.; Karnezis, Tom T.; Gudis, David A.; Soler, Zachary M.] Med Univ South Carolina, Dept Otolaryngol Head & Neck Surg, 135 Rutledge Ave,Mail Stop Code 550, Charleston, SC 29425 USA. [Schlosser, Rodney J.] Ralph H Johnson Vet Affairs Med Ctr, Charleston, SC USA. [Mulligan, Jennifer K.] Med Univ South Carolina, Dept Pediat, Charleston, SC 29425 USA. [Hyer, J. Madison] Med Univ South Carolina, Dept Publ Hlth Sci, Charleston, SC 29425 USA. RP Soler, ZM (reprint author), Med Univ South Carolina, Dept Otolaryngol Head & Neck Surg, 135 Rutledge Ave,Mail Stop Code 550, Charleston, SC 29425 USA. EM solerz@musc.edu FU National Institute on Deafness and Other Communication Disorders [R03 DC013651-01]; OptiNose; IntersectENT FX All authors have completed and submitted the ICMJE Form for Disclosure of Potential Conflicts of Interest. Dr Schlosser reported receiving grant support from OptiNose and IntersectENT and working as a consultant for Olympus and Meda. Dr Soler reported receiving support from grant R03 DC013651-01 from the National Institute on Deafness and Other Communication Disorders and working as a consultant for Olympus. No other disclosures were reported. NR 23 TC 2 Z9 2 U1 2 U2 2 PU AMER MEDICAL ASSOC PI CHICAGO PA 330 N WABASH AVE, STE 39300, CHICAGO, IL 60611-5885 USA SN 2168-6181 EI 2168-619X J9 JAMA OTOLARYNGOL JI JAMA Otolaryngol-Head Neck Surg. PD AUG PY 2016 VL 142 IS 8 BP 731 EP 737 DI 10.1001/jamaoto.2016.0927 PG 7 WC Otorhinolaryngology; Surgery SC Otorhinolaryngology; Surgery GA DW6PS UT WOS:000383774000003 PM 27228459 ER PT J AU Aaron, SE Gregory, CM Simpson, AN AF Aaron, Stacey E. Gregory, Chris M. Simpson, Annie N. TI Lower Odds of Poststroke Symptoms of Depression When Physical Activity Guidelines Met: National Health and Nutrition Examination Survey 2011-2012 SO JOURNAL OF PHYSICAL ACTIVITY & HEALTH LA English DT Article DE Patient Health Questionnaire-9; Global Physical Activity Questionnaire; MET-minute/week ID QUALITY-OF-LIFE; ANTIDEPRESSANT THERAPY; FUNCTIONAL RECOVERY; STROKE PATIENTS; POST STROKE; ADULTS; EXERCISE; METAANALYSIS; ASSOCIATION; DISORDERS AB Background: One-third of individuals with stroke report symptoms of depression, which has a negative impact on recovery. Physical activity (PA) is a potentially effective therapy. Our objective was to examine the associations of subjectively assessed PA levels and symptoms of depression in a nationally representative stroke sample. Methods: We conducted a cross-sectional study of 175 adults in the National Health and Nutrition Examination Survey 2011-2012 cycle. Moderate, vigorous, and combination equivalent PA metabolic equivalent (MET)-minutes per week averages were derived from the Global Physical Activity Questionnaire, and the 2008 Physical Activity Guidelines/American College of Sports Medicine recommendations of >= 500 MET -minutes per week of moderate, vigorous, or combination equivalent PA were used as cut points. Depression symptoms were measured using the Patient Health Questionnaire-9. Results: Meeting moderate PA guidelines resulted in 74% lower odds of having depression symptoms (P < .0001) and 89% lower odds of major symptoms of depression (P = .0003). Meeting vigorous guidelines showed a 91% lower odds of having mild symptoms of depression (P = .04). Participating in some moderate, vigorous, or combination equivalent PA revealed the odds of depression symptoms 13 times greater compared with meeting guidelines (P = .005); odds of mild symptoms of depression were 9 times greater (P = .01); and odds of major symptoms of depression were 15 times greater (P = .006). Conclusions: There is a lower risk of developing mild symptoms of depression when vigorous guidelines for PA are met and developing major symptoms of depression when moderate guidelines met. Participating in some PA is not enough to reduce the risk of depression symptoms. C1 [Aaron, Stacey E.; Gregory, Chris M.] Med Univ South Carolina, Dept Hlth Sci & Res, Charleston, SC 29425 USA. [Gregory, Chris M.] Med Univ South Carolina, Div Phys Therapy, Charleston, SC USA. [Gregory, Chris M.] Ralph H Johnson VA Med Ctr, Charleston, SC USA. [Simpson, Annie N.] Med Univ South Carolina, Dept Healthcare Leadership & Management, Charleston, SC USA. RP Aaron, SE (reprint author), Med Univ South Carolina, Dept Hlth Sci & Res, Charleston, SC 29425 USA. EM aarons@musc.edu FU NIGMS NIH HHS [P20 GM109040] NR 41 TC 0 Z9 0 U1 1 U2 1 PU HUMAN KINETICS PUBL INC PI CHAMPAIGN PA 1607 N MARKET ST, PO BOX 5076, CHAMPAIGN, IL 61820-2200 USA SN 1543-3080 EI 1543-5474 J9 J PHYS ACT HEALTH JI J. Phys. Act. Health PD AUG PY 2016 VL 13 IS 8 BP 903 EP 909 DI 10.1123/jpah.2015-0446 PG 7 WC Public, Environmental & Occupational Health SC Public, Environmental & Occupational Health GA DW1OV UT WOS:000383413400014 PM 27145542 ER PT J AU Sautter, FJ Glynn, SM Becker-Cretu, JJ Senturk, D Armelie, AP Wielt, DB AF Sautter, Frederic J. Glynn, Shirley M. Becker-Cretu, Julia J. Senturk, Damla Armelie, Aaron P. Wielt, Dustin B. TI Structured Approach Therapy for Combat-Related PTSD in Returning US Veterans: Complementary Mediation by Changes in Emotion Functioning SO JOURNAL OF TRAUMATIC STRESS LA English DT Article ID POSTTRAUMATIC-STRESS-DISORDER; IRAQ; AFGHANISTAN; SYMPTOMS; TRIAL; SCALE; FEAR; WAR AB To address the impact of combat-related posttraumatic stress disorder (PTSD) on U.S. Operation Enduring Freedom (OEF) and Operation Iraqi Freedom (OIF) veterans, the investigators developed a 12-session manualized PTSD treatment for couples called structured approach therapy (SAT). A randomized controlled trial had shown that 29 OEF/OIF veterans with combat-related PTSD who had participated in SAT showed significantly greater reductions in PTSD compared to 28 veterans receiving a 12-session PTSD family education intervention (Sautter, Glynn, Cretu, Senturk, & Vaught, 2015). We conducted supplemental follow-up and mediation analyses, which tested the hypothesis that changes in emotion functioning play a significant role in the decreases in PTSD symptoms primarily observed in veterans who had received SAT. Veterans assigned to the SAT condition showed significantly greater decreases than those assigned to PTSD family education in emotion regulation problems (p < .001, Cohen's f(2) = .18) and fear of intense emotions (p <.001, Cohen's f2 =.152). Decreases in both emotion regulation problems (mediated effect: ab =.36), and fear of intense emotions (mediated effect: ab =.24) were found to be complementary mediators of reductions in PTSD symptoms greater with SAT. These findings suggest that SAT may aid veterans in improving their ability to regulate trauma-related emotions. C1 [Sautter, Frederic J.] Southeast Louisiana Vet Hlth Care Syst, New Orleans, LA USA. [Sautter, Frederic J.; Becker-Cretu, Julia J.; Armelie, Aaron P.] Tulane Univ, Sch Med, Dept Psychiat, 1430 Tulane Ave, New Orleans, LA 70112 USA. [Glynn, Shirley M.] VA Greater Angeles Healthcare Syst, Los Angeles, CA USA. [Glynn, Shirley M.] Univ Calif Los Angeles, Welcome Back Vet Family Resilience Ctr, Los Angeles, CA USA. [Senturk, Damla] Univ Calif Los Angeles, Dept Biostat, Los Angeles, CA USA. [Senturk, Damla] Univ Calif Los Angeles, Dept Stat, Los Angeles, CA USA. [Wielt, Dustin B.] Raymond G Murphy VA Med Ctr, Albuquerque, NM USA. RP Sautter, FJ (reprint author), Tulane Univ, Sch Med, Dept Psychiat & Behav Sci, 1440 Canal St TB 53, New Orleans, LA 70112 USA. EM fredericsautter@msn.com FU VA Research Rehabilitation and Development (RRD) Program [B6756R]; South Central Mental Illness Research Education and Clinical Center (MIRECC) FX This work was supported in part by a Merit Review grant (No. B6756R) from the VA Research Rehabilitation and Development (RR&D) Program and a Supplemental Funding Award from the South Central Mental Illness Research Education and Clinical Center (MIRECC) to Frederic J. Sautter. The authors thank Dr. Michelle Sherman for her consultation in developing both treatment manuals, and Dr. Amanda Vaught, Marin Casselli, and Allison Abel for their contributions. NR 15 TC 0 Z9 0 U1 2 U2 3 PU WILEY-BLACKWELL PI HOBOKEN PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA SN 0894-9867 EI 1573-6598 J9 J TRAUMA STRESS JI J. Trauma Stress PD AUG PY 2016 VL 29 IS 4 BP 384 EP 387 DI 10.1002/jts.22120 PG 4 WC Psychology, Clinical; Psychiatry SC Psychology; Psychiatry GA DW2MW UT WOS:000383477500014 PM 27472747 ER PT J AU Surdel, MC Dutter, BF Sulikowski, GA Skaar, EP AF Surdel, Matthew C. Dutter, Brendan F. Sulikowski, Gary A. Skaar, Eric P. TI Bacterial Nitric Oxide Synthase Is Required for the Staphylococcus aureus Response to Heme Stress SO ACS INFECTIOUS DISEASES LA English DT Article DE Staphylococcus aureus; heme stress response; nitric oxide synthase; small-molecule optimization ID US HOSPITALS; INFECTIONS; TOXICITY; BIOSYNTHESIS; VIRULENCE; IRON; ACTIVATION; MOLECULE; SYSTEM; GENE AB Staphylococcus aureus is a pathogen that causes significant morbidity and mortality worldwide. Within the vertebrate host, S. aureus requires heme as a nutrient iron source and as a cofactor for multiple cellular processes. Although required for pathogenesis, excess heme is toxic. S. aureus employs a two-component system, the heme sensor system (HssRS), to sense and protect against heme toxicity. Upon activation, HssRS induces the expression of the heme-regulated transporter (HrtAB), an efflux pump that alleviates heme toxicity. The ability to sense and respond to heme is critical for the pathogenesis of numerous Gram-positive organisms, yet the mechanism of heme sensing remains unknown. Compound '3981 was identified in a high-throughput screen as an activator of staphylococcal HssRS that triggers HssRS independently of heme accumulation. '3981 is toxic to S. aureus; however, derivatives of '3981 were synthesized that lack toxicity while retaining HssRS activation, enabling the interrogation of the heme stress response without confounding toxic effects of the parent molecule. Using '3981 derivatives as probes of the heme stress response, numerous genes required for '3981-induced activation of HssRS were uncovered. Specifically, multiple genes involved in the production of nitric oxide were identified, including the gene encoding bacterial nitric oxide synthase (bNOS). bNOS protects S. aureus from oxidative stress imposed by heme. Taken together, this work identifies bNOS as crucial for the S. aureus heme stress response, providing evidence that nitric oxide synthesis and heme sensing are intertwined. C1 [Surdel, Matthew C.; Skaar, Eric P.] Vanderbilt Univ, Med Ctr, Dept Pathol Microbiol & Immunol, Nashville, TN 37232 USA. [Dutter, Brendan F.; Sulikowski, Gary A.] Vanderbilt Univ, Dept Chem, Vanderbilt Inst Chem Biol, Nashville, TN 37232 USA. [Skaar, Eric P.] US Dept Vet Affairs, Tennessee Valley Healthcare Syst, Nashville, TN 37212 USA. RP Skaar, EP (reprint author), Vanderbilt Univ, Med Ctr, Dept Pathol Microbiol & Immunol, Nashville, TN 37232 USA.; Skaar, EP (reprint author), US Dept Vet Affairs, Tennessee Valley Healthcare Syst, Nashville, TN 37212 USA. EM eric.skaar@vanderbilt.edu FU National Institute of General Medical Studies for the Vanderbilt Medical-Scientist Training Program [T32 GM07347, R01AI069233, R01AI073843, T32GM065086] FX We thank members of the E.P.S laboratory for their critical reading of the manuscript. The reagents were provided by the Network on Antimicrobial Resistance in Staphylococcus aureus for distribution by BEI Resources, Nebraska Transposon Mutant Library Screening Array, NR-48501. This work was supported by Public Health Service award T32 GM07347 from the National Institute of General Medical Studies for the Vanderbilt Medical-Scientist Training Program (M.C.S.), R01AI069233 (M.C.S. and E.P.S), R01AI073843 (M.C.S. and E.P.S.), and T32GM065086 (B.F.D.). NR 37 TC 0 Z9 0 U1 1 U2 1 PU AMER CHEMICAL SOC PI WASHINGTON PA 1155 16TH ST, NW, WASHINGTON, DC 20036 USA SN 2373-8227 J9 ACS INFECT DIS JI ACS Infect. Dis. PD AUG PY 2016 VL 2 IS 8 BP 572 EP 578 DI 10.1021/acsinfecdis.6b00081 PG 7 WC Chemistry, Medicinal; Infectious Diseases SC Pharmacology & Pharmacy; Infectious Diseases GA DT6HI UT WOS:000381584900006 PM 27626297 ER PT J AU Dinkler, JM Sugar, CA Escarce, JJ Ong, MK Mangione, CM AF Dinkler, John M. Sugar, Catherine A. Escarce, Jose J. Ong, Michael K. Mangione, Carol M. TI Does Age Matter? Association Between Usual Source of Care and Hypertension Control in the US Population: Data From NHANES 2007-2012 SO AMERICAN JOURNAL OF HYPERTENSION LA English DT Article DE age; blood pressure; hypertension; usual source of care ID BLOOD-PRESSURE; UNITED-STATES; ENDOTHELIAL DYSFUNCTION; NATIONAL-HEALTH; ADULTS; PREVENTION; IMPUTATION; PHYSICIAN; PATTERNS; SERVICES AB The positive role of having a usual source of care (USOC) on the receipt of preventative services is known. However, associations between USOC and hypertension control and the differential association across age groups is unknown in the US population. We used data from the National Health and Nutrition Examination Survey (NHANES) from 2007 to 2012. Multivariable logistic regression was used to evaluate the association between having a USOC and hypertension control. The differential effect of USOC on hypertension control by age was assessed using predicted marginal effects across age groups in the multivariable logistic model. In adjusted analyses, those with a USOC had higher odds of hypertension control (odds ratio = 3.89, 95% confidence interval (CI): 2.15-6.98). The marginal effect of having a USOC is associated with a 30 percentage point higher probability of controlled blood pressure compared to those without a USOC (marginal probability = 0.30, 95% CI: 0.19-0.41). The marginal effect of USOC on hypertension control varied by age groups, with a statistically significantly lower marginal effect of USOC on hypertension seen among those older than 74 years of age (marginal probability = 0.27, 95% CI: 0.18-0.36) and younger than 35 years of age (marginal probability = 0.23, 95% CI: 0.14-0.33). Having a USOC is significantly associated with improved hypertension control in the US population. The variation in the association across age groups has important implications in targeting age-specific antihypertensive strategies to reduce the burden of hypertension in the US population. C1 [Dinkler, John M.] Univ Calif Los Angeles, Dept Med, Div Cardiol, Los Angeles, CA 90024 USA. [Dinkler, John M.; Escarce, Jose J.; Mangione, Carol M.] UCLA Fielding Sch Publ Hlth, Dept Hlth Policy & Management, Los Angeles, CA 90024 USA. [Sugar, Catherine A.] UCLA Fielding Sch Publ Hlth, Dept Biostat, Los Angeles, CA USA. [Escarce, Jose J.; Ong, Michael K.; Mangione, Carol M.] Univ Calif Los Angeles, David Geffen Sch Med, Dept Med, Div Gen Internal Med & Hlth Serv Res, Los Angeles, CA 90095 USA. [Ong, Michael K.] VA Greater Los Angeles Healthcare Syst, Los Angeles, CA USA. RP Dinkler, JM (reprint author), Univ Calif Los Angeles, Dept Med, Div Cardiol, Los Angeles, CA 90024 USA.; Dinkler, JM (reprint author), UCLA Fielding Sch Publ Hlth, Dept Hlth Policy & Management, Los Angeles, CA 90024 USA. EM jdinkler@mednet.ucla.edu FU National Institutes of Health [T32HL007895-16] FX Dr Dinkler receives grant funding from the National Institutes of Health (T32HL007895-16). NR 37 TC 1 Z9 1 U1 3 U2 4 PU OXFORD UNIV PRESS PI OXFORD PA GREAT CLARENDON ST, OXFORD OX2 6DP, ENGLAND SN 0895-7061 EI 1941-7225 J9 AM J HYPERTENS JI Am. J. Hypertens. PD AUG PY 2016 VL 29 IS 8 BP 934 EP 940 DI 10.1093/ajh/hpw010 PG 7 WC Peripheral Vascular Disease SC Cardiovascular System & Cardiology GA DV8HQ UT WOS:000383178500006 PM 26884134 ER PT J AU Ho, AK Bartels, CM Thorpe, CT Pandhi, N Smith, MA Johnson, HM AF Ho, Aaron K. Bartels, Christie M. Thorpe, Carolyn T. Pandhi, Nancy Smith, Maureen A. Johnson, Heather M. TI Achieving Weight Loss and Hypertension Control Among Obese Adults: A US Multidisciplinary Group Practice Observational Study SO AMERICAN JOURNAL OF HYPERTENSION LA English DT Article DE blood pressure; hypertension; obesity; primary care; weight management ID BODY-MASS INDEX; HIGH BLOOD-PRESSURE; SCIENTIFIC STATEMENT; ADMINISTRATIVE DATA; MORTALITY RISK; YOUNG-ADULTS; COMMITTEE; EDUCATION; OVERWEIGHT; MANAGEMENT AB Among adults with hypertension, obesity independently contributes to cardiovascular disease. Weight loss and hypertension control are critical to reduce cardiovascular events. The purpose of this study was to evaluate rates and predictors of achieving weight loss among adults who achieved hypertension control within 1 year of developing incident hypertension. Retrospective electronic health record analysis was performed of a parts per thousand yen18 year olds with a body mass index a parts per thousand yen30.0kg/m(2), who received regular primary care from 2008 to 2011 and achieved hypertension control. Exclusions were less than 60 days follow-up, prior hypertension diagnosis, prior antihypertensive prescription, or pregnancy. The primary outcome was clinically significant weight loss (a parts per thousand yen5kg); the secondary outcome was modest (2.0-4.9kg) weight loss. Multinomial logistic regression identified predictors of achieving weight loss (a parts per thousand yen5 or 2.0-4.9kg) compared to no significant weight loss (< 2kg). Of the 2,906 obese patients who achieved hypertension control, 72% (n = 2,089) did not achieve at least 2.0kg weight loss. Overall, 12% (n = 351) achieved a parts per thousand yen5kg weight loss. Young adults (18-39 year olds; odds ratio (OR): 2.47, 95% confidence interval (CI): 1.63-3.47), middle-aged adults (40-59 year olds; OR: 2.32, 95% CI: 1.59-3.37), and patients prescribed antihypertensive medication (OR: 1.37, 95% CI: 1.07-1.76) were more likely to achieve clinically significant weight loss and hypertension control. Age remained a significant predictor for 2.0-4.9kg weight loss. Despite achieving hypertension control, the majority of obese patients did not achieve clinically significant weight loss. Effective weight loss interventions with dedicated hypertension treatment are needed to decrease cardiovascular events in this high-risk population. C1 [Ho, Aaron K.; Bartels, Christie M.; Johnson, Heather M.] Univ Wisconsin, Dept Med, Sch Med & Publ Hlth, Madison, WI 53706 USA. [Bartels, Christie M.; Pandhi, Nancy; Smith, Maureen A.; Johnson, Heather M.] Univ Wisconsin, Hlth Innovat Program, Sch Med & Publ Hlth, Madison, WI 53706 USA. [Thorpe, Carolyn T.] Vet Affairs Pittsburgh Healthcare Syst, Hlth Serv Res & Dev, Pittsburgh, PA USA. [Thorpe, Carolyn T.] Univ Pittsburgh, Sch Pharm, Dept Pharm & Therapeut, Pittsburgh, PA 15261 USA. [Pandhi, Nancy; Smith, Maureen A.] Univ Wisconsin, Dept Family Med, Sch Med & Publ Hlth, Madison, WI USA. [Smith, Maureen A.] Univ Wisconsin, Dept Populat Hlth Sci, Sch Med & Publ Hlth, Madison, WI USA. [Smith, Maureen A.] Univ Wisconsin, Dept Surg, Sch Med & Publ Hlth, Madison, WI USA. RP Johnson, HM (reprint author), Univ Wisconsin, Dept Med, Sch Med & Publ Hlth, Madison, WI 53706 USA.; Johnson, HM (reprint author), Univ Wisconsin, Hlth Innovat Program, Sch Med & Publ Hlth, Madison, WI 53706 USA. EM hm2@medicine.wisc.edu FU Clinical and Translational Science Award program, previously through the National Center for Research Resources (NCRR) [UL1RR025011]; National Center for Advancing Translational Sciences of the National Institutes of Health (NIH) [U54TR000021]; National Heart, Lung, and Blood Institute of the NIH [K23HL112907]; University of Wisconsin (UW) Centennial Scholars Program of the University of Wisconsin School of Medicine and Public Health; National Institute of Arthritis and Musculoskeletal and Skin Diseases of the NIH [K23AR062381]; National Institute on Aging of the NIH [K08AG029527] FX The authors gratefully acknowledge Katie Ronk, BS and Patrick Ferguson, MPH for data preparation and Jamie LaMantia, BS and Colleen Brown, BA for manuscript preparation. This original research was supported by the Clinical and Translational Science Award program, previously through the National Center for Research Resources (NCRR - UL1RR025011) and now by the National Center for Advancing Translational Sciences of the National Institutes of Health (NIH) under award number U54TR000021. H.M.J. is supported by the National Heart, Lung, and Blood Institute of the NIH (K23HL112907) and also by the University of Wisconsin (UW) Centennial Scholars Program of the University of Wisconsin School of Medicine and Public Health. C.M.B. is supported by the National Institute of Arthritis and Musculoskeletal and Skin Diseases of the NIH (K23AR062381). N.P. is supported by the National Institute on Aging of the NIH (K08AG029527). The content is solely the responsibility of the authors and does not necessarily represent the official views of the NIH. Additional funding for this project was provided by the UW Health Innovation Program and the UW School of Medicine and Public Health from The Wisconsin Partnership Program. Some preliminary findings reported in this manuscript were presented in poster form at the American Heart Association 2014 Annual Scientific Sessions in Chicago, IL on 15-19 November 2014. NR 39 TC 1 Z9 1 U1 3 U2 4 PU OXFORD UNIV PRESS PI OXFORD PA GREAT CLARENDON ST, OXFORD OX2 6DP, ENGLAND SN 0895-7061 EI 1941-7225 J9 AM J HYPERTENS JI Am. J. Hypertens. PD AUG PY 2016 VL 29 IS 8 BP 984 EP 991 DI 10.1093/ajh/hpw020 PG 8 WC Peripheral Vascular Disease SC Cardiovascular System & Cardiology GA DV8HQ UT WOS:000383178500012 PM 26917445 ER PT J AU ter Maaten, JM Damman, K Hanberg, JS Givertz, MM Metra, M O'Connor, CM Teerlink, JR Ponikowski, P Cotter, G Davison, B Cleland, JG Bloomfield, DM Hillege, HL van Veldhuisen, DJ Voors, AA Testani, JM AF ter Maaten, Jozine M. Damman, Kevin Hanberg, Jennifer S. Givertz, Michael M. Metra, Marco O'Connor, Christopher M. Teerlink, John R. Ponikowski, Piotr Cotter, Gad Davison, Beth Cleland, John G. Bloomfield, Daniel M. Hillege, Hans L. van Veldhuisen, Dirk J. Voors, Adriaan A. Testani, Jeffrey M. TI Hypochloremia, Diuretic Resistance, and Outcome in Patients With Acute Heart Failure SO CIRCULATION-HEART FAILURE LA English DT Article DE blood urea nitrogen; chlorides; creatinine; diuretics; electrolytes ID SENSING MECHANISM; EUROPEAN-SOCIETY; TASK-FORCE; CHLORIDE; ASSOCIATION; ROLOFYLLINE; GUIDELINES; MANAGEMENT; ANTAGONIST; CARDIOLOGY AB Background-Chloride plays a role in renal salt sensing, neurohormonal activation, and regulation of diuretic targets, and hypochloremia predicts mortality in acute heart failure (AHF). AHF therapies, such as diuretics, alter chloride homeostasis. We studied the association between (changes in) chloride levels and diuretic responsiveness, decongestion, and mortality in patients with AHF. Methods and Results-Patients hospitalized for AHF in the PROTECT trial (n=2033) with serum chloride levels within 24 hours of admission and 14 days later were studied (n=1960). Hypochloremia was defined as serum chloride <96 mEq/L. Mean baseline chloride was 100.8+/-5.0 mEq/L. Low baseline chloride was associated with high bicarbonate, poor diuretic response, less hemoconcentration, and worsening heart failure (all P<0.01). Newly developed hypochloremia at day 14 was common and associated with a decline in renal function and an increase in blood urea nitrogen (P<0.01). In multivariable analyses, chloride measured at day 14, but not baseline chloride, was strongly and independently associated with mortality through 180 days (hazard ratio per unit decrease: 1.07 [1.03-1.10]; P<0.001). In comparison, sodium was not significantly associated with mortality after multivariable adjustment at any time point. Hypochloremia at baseline that resolved was not associated with mortality (P=0.55), but new or persistent hypochloremia at day 14 was associated with increased mortality (hazard ratio: 3.11 [2.17-4.46]; P<0.001). Conclusions-Low serum chloride at AHF hospital admission was strongly associated with impaired decongestion. New or persistent hypochloremia 14 days later was independently associated with reduced survival, whereas hypochloremia that resolved by day 14 was not. C1 [ter Maaten, Jozine M.; Damman, Kevin; Hillege, Hans L.; van Veldhuisen, Dirk J.; Voors, Adriaan A.] Univ Groningen, Univ Med Ctr Groningen, NL-9700 AB Groningen, Netherlands. [ter Maaten, Jozine M.; Hanberg, Jennifer S.; Testani, Jeffrey M.] Yale Univ, Sch Med, Program Appl Translat Res, New Haven, CT USA. [Givertz, Michael M.] Brigham & Womens Hosp, 75 Francis St, Boston, MA 02115 USA. [Metra, Marco] Univ Brescia, I-25121 Brescia, Italy. [O'Connor, Christopher M.] Inova Heart & Vasc Inst, Falls Church, VA USA. [Teerlink, John R.] Univ Calif San Francisco, San Francisco, CA 94143 USA. [Teerlink, John R.] San Francisco VA Med Ctr, San Francisco, CA USA. [Ponikowski, Piotr] Med Univ, Clin Mil Hosp, Wroclaw, Poland. [Cotter, Gad; Davison, Beth] Momentum Res, Durham, NC USA. [Cleland, John G.] Univ Hull, Kingston Upon Hull, Yorks, England. [Bloomfield, Daniel M.] Merck Res Labs, Rahway, NJ USA. [Testani, Jeffrey M.] Yale Univ, Sch Med, Dept Internal Med, New Haven, CT 06510 USA. RP Voors, AA (reprint author), Univ Med Ctr Groningen, Hanzepl 1, NL-9713 GZ Groningen, Netherlands. EM a.a.voors@umcg.nl RI Ponikowski, Piotr/O-6454-2015 OI Ponikowski, Piotr/0000-0002-3391-7064 FU NovoCardia, a subsidiary of Merck FX The PROTECT trial was supported by NovoCardia, a subsidiary of Merck. NR 20 TC 2 Z9 2 U1 2 U2 2 PU LIPPINCOTT WILLIAMS & WILKINS PI PHILADELPHIA PA TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA SN 1941-3289 EI 1941-3297 J9 CIRC-HEART FAIL JI Circ.-Heart Fail. PD AUG PY 2016 VL 9 IS 8 AR UNSP e003109 DI 10.1161/CIRCHEARTFAILURE.116.003109 PG 9 WC Cardiac & Cardiovascular Systems SC Cardiovascular System & Cardiology GA DU5EQ UT WOS:000382235400009 ER PT J AU Kanwal, F Kramer, JR El-Serag, HB Frayne, S Clark, J Cao, YM Taylor, T Smith, D White, D Asch, SM AF Kanwal, Fasiha Kramer, Jennifer R. El-Serag, Hashem B. Frayne, Susan Clark, Jack Cao, Yumei Taylor, Thomas Smith, Donna White, Donna Asch, Steven M. TI Race and Gender Differences in the Use of Direct Acting Antiviral Agents for Hepatitis C Virus SO CLINICAL INFECTIOUS DISEASES LA English DT Article DE Veterans; healthcare disparities; access; quality; hepatitis ID GENOTYPE 1 INFECTION; RACIAL-DIFFERENCES; VETERANS-AFFAIRS; HCV; ABT-450/R-OMBITASVIR; LEDIPASVIR; SOFOSBUVIR; DASABUVIR; RIBAVIRIN; CIRRHOSIS AB Background. Direct acting antiviral agents (DAA) are highly effective yet expensive. Disparities by race and/or gender often exist in the use of costly medical advances as they become available. Methods. We examined a cohort of hepatitis C virus (HCV) patients who received care at the Veterans Administration facilities nationwide. We evaluated the effect of race and gender on DAA receipt after adjusting for socioeconomic status, liver disease severity, comorbidity, and propensity for healthcare use. To determine if disparities had changed over time, we conducted a similar analysis of HCV patients who were seen in the previous standard of care treatment era. Results. Of the 145 596 patients seen in the current DAA era, 17 791 (10.2%) received treatment during the first 16 months of DAA approval. Black patients had 21% lower odds of receiving DAA than whites (odds ratio [OR] = 0.79; 95% confidence interval [CI],.75,.84). Overall, women were as likely to receive treatment as men (OR = 0.99; 95% CI,.90-1.09). However, the odds of receiving DAAs were 29% lower for younger women compared with younger men (OR = 0.71, 95% CI, .54-.93). Similar to the DAA cohort, black patients had significantly lower odds of receiving treatment than whites (OR = 0.74, 95% CI, .69-.79) in the previous treatment era. The racial difference between the 2 eras did not reach statistical significance. Conclusions. There were unexplained differences among HCV population subgroups in the receipt of new DAA treatment. Targeted interventions are needed for black patients and younger women. C1 [Kanwal, Fasiha; Kramer, Jennifer R.; El-Serag, Hashem B.; Cao, Yumei; Smith, Donna; White, Donna] Baylor Coll Med, Michael E DeBakey Vet Affairs Med Ctr, Ctr Innovat Qual Effectiveness & Safety IQuESt, Houston, TX 77030 USA. [Kanwal, Fasiha; El-Serag, Hashem B.] Baylor Coll Med, Sect Gastroenterol & Hepatol, Houston, TX 77030 USA. [Kanwal, Fasiha; Kramer, Jennifer R.; El-Serag, Hashem B.; White, Donna] Baylor Coll Med, Sect Hlth Serv Res, Houston, TX 77030 USA. [Kanwal, Fasiha; El-Serag, Hashem B.] Baylor Coll Med, Dept Med, Houston, TX 77030 USA. [Frayne, Susan; Taylor, Thomas; Asch, Steven M.] VA Palo Alto Healthcare Syst, Fostering High Value Care, Ctr Innovat Implementat Ci2i, Stanford, CA USA. [Clark, Jack] Edith Nourse Rogers Mem Vet Hosp, Ctr Healthcare Org & Implementat, Boston, MA USA. [Clark, Jack] Boston Univ, Sch Publ Hlth, Dept Hlth Policy & Management, Boston, MA 02215 USA. RP Kanwal, F (reprint author), Michael E DeBakey VA, Ctr Innovat Qual Effectiveness & Safety IQuESt, 2002 Holcombe Blvd,Ste 152, Houston, TX 77030 USA.; Kanwal, F (reprint author), Baylor Coll Med, 2002 Holcombe Blvd,Ste 152, Houston, TX 77030 USA. EM kanwal@bcm.edu FU Department of Veterans Affairs, Veterans Health Administration, Office of Research and Development Service [VA IIR 13-059] FX The research was supported in part by the Department of Veterans Affairs, Veterans Health Administration, Office of Research and Development Service (VA IIR 13-059). F.K. is a physician research scientist at the Center for Innovations in Quality, Effectiveness, and Safety (#CIN 13-413), Michael E. DeBakey Veterans Affairs Medical Center, Houston, Texas. NR 31 TC 0 Z9 0 U1 0 U2 0 PU OXFORD UNIV PRESS INC PI CARY PA JOURNALS DEPT, 2001 EVANS RD, CARY, NC 27513 USA SN 1058-4838 EI 1537-6591 J9 CLIN INFECT DIS JI Clin. Infect. Dis. PD AUG 1 PY 2016 VL 63 IS 3 BP 291 EP 299 DI 10.1093/cid/ciw249 PG 9 WC Immunology; Infectious Diseases; Microbiology SC Immunology; Infectious Diseases; Microbiology GA DV8QP UT WOS:000383201900001 PM 27131869 ER PT J AU Taylor, L McMillan, P Liachko, N Saxton, A Strovas, T Kraemer, B AF Taylor, L. McMillan, P. Liachko, N. Saxton, A. Strovas, T. Kraemer, B. TI TTBK1/2 hyper-activation drives pTau and pTDP accumulation SO JOURNAL OF NEUROCHEMISTRY LA English DT Meeting Abstract CT 10th International Conference on Frontotemporal Dementias CY AUG 31-SEP 02, 2016 CL Munich, GERMANY C1 [Taylor, L.; Kraemer, B.] Univ Washington, Med Gerontol & Geriatr Med, Seattle, WA 98195 USA. [McMillan, P.; Liachko, N.; Saxton, A.; Strovas, T.; Kraemer, B.] Vet Affairs Puget Sound Hlth Care Syst, Geriatr Res Educ & Clin Ctr, Seattle, WA USA. [Saxton, A.; Kraemer, B.] Seattle Inst Biomed & Clin Res, Seattle, WA USA. NR 0 TC 0 Z9 0 U1 0 U2 0 PU WILEY-BLACKWELL PI HOBOKEN PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA SN 0022-3042 EI 1471-4159 J9 J NEUROCHEM JI J. Neurochem. PD AUG PY 2016 VL 138 SU 1 SI SI MA DB11 BP 236 EP 236 PG 1 WC Biochemistry & Molecular Biology; Neurosciences SC Biochemistry & Molecular Biology; Neurosciences & Neurology GA DU9WI UT WOS:000382568400041 ER PT J AU Fong, SS Navarrete, CD Perfecto, SE Carr, AR Jimenez, EE Mendez, MF AF Fong, S. S. Navarrete, C. D. Perfecto, S. E. Carr, A. R. Jimenez, E. E. Mendez, M. F. TI Emotion and moral dilemmas in behavioral variant frontotemporal dementia SO JOURNAL OF NEUROCHEMISTRY LA English DT Meeting Abstract CT 10th International Conference on Frontotemporal Dementias CY AUG 31-SEP 02, 2016 CL Munich, GERMANY C1 [Fong, S. S.; Perfecto, S. E.; Jimenez, E. E.; Mendez, M. F.] Univ Calif Los Angeles, Los Angeles, CA USA. [Fong, S. S.; Carr, A. R.; Jimenez, E. E.; Mendez, M. F.] VA Greater Los Angeles Healthcare Ctr, Neurol, Los Angeles, CA USA. [Navarrete, C. D.] Michigan State Univ, Psychol, E Lansing, MI 48824 USA. [Mendez, M. F.] Univ Calif Los Angeles, Psychiat & Biobehav Sci, Los Angeles, CA USA. NR 0 TC 0 Z9 0 U1 2 U2 2 PU WILEY-BLACKWELL PI HOBOKEN PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA SN 0022-3042 EI 1471-4159 J9 J NEUROCHEM JI J. Neurochem. PD AUG PY 2016 VL 138 SU 1 SI SI MA P55 BP 264 EP 265 PG 2 WC Biochemistry & Molecular Biology; Neurosciences SC Biochemistry & Molecular Biology; Neurosciences & Neurology GA DU9WI UT WOS:000382568400111 ER PT J AU Paholpak, P Li-Jung, L Carr, DR Jimenez, E Barrows, RJ Sabodash, V Mendez, MF AF Paholpak, P. Li-Jung, L. Carr, D. R. Jimenez, E. Barrows, R. J. Sabodash, V. Mendez, M. F. TI Prolonged visual facial gaze in frontotemporal dementia SO JOURNAL OF NEUROCHEMISTRY LA English DT Meeting Abstract CT 10th International Conference on Frontotemporal Dementias CY AUG 31-SEP 02, 2016 CL Munich, GERMANY C1 [Paholpak, P.] Khon Kaen Univ, Psychiat, Khon Kaen, Thailand. [Paholpak, P.; Carr, D. R.; Jimenez, E.; Barrows, R. J.; Sabodash, V.; Mendez, M. F.] Univ Calif Los Angeles, Neurol, Los Angeles, CA USA. [Paholpak, P.; Jimenez, E.; Barrows, R. J.; Sabodash, V.; Mendez, M. F.] Greater Los Angeles VA Healthcare Syst, Neurol, Los Angeles, CA USA. [Li-Jung, L.] Univ Calif Los Angeles, Med, Los Angeles, CA USA. NR 0 TC 0 Z9 0 U1 0 U2 0 PU WILEY-BLACKWELL PI HOBOKEN PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA SN 0022-3042 EI 1471-4159 J9 J NEUROCHEM JI J. Neurochem. PD AUG PY 2016 VL 138 SU 1 SI SI MA P53 BP 264 EP 264 PG 1 WC Biochemistry & Molecular Biology; Neurosciences SC Biochemistry & Molecular Biology; Neurosciences & Neurology GA DU9WI UT WOS:000382568400109 ER PT J AU Paholpak, P Carr, DR Barsuglia, JP Barrows, RJ Jimenez, E Lee, GJ Mendez, MF AF Paholpak, P. Carr, D. R. Barsuglia, J. P. Barrows, R. J. Jimenez, E. Lee, G. J. Mendez, M. F. TI Person-based vs. generalized impulsivity disinhibition in frontotemporal dementia and Alzheimer's disease SO JOURNAL OF NEUROCHEMISTRY LA English DT Meeting Abstract CT 10th International Conference on Frontotemporal Dementias CY AUG 31-SEP 02, 2016 CL Munich, GERMANY C1 [Paholpak, P.] Khon Kaen Univ, Psychiat, Khon Kaen, Thailand. [Paholpak, P.; Carr, D. R.; Barrows, R. J.; Jimenez, E.; Mendez, M. F.] Univ Calif Los Angeles, Neurol, Los Angeles, CA USA. [Paholpak, P.; Carr, D. R.; Barsuglia, J. P.; Barrows, R. J.; Jimenez, E.; Mendez, M. F.] Greater Los Angeles VA Healthcare Syst, Neurol, Los Angeles, CA USA. [Lee, G. J.] Loma Linda Univ, Psychol, Loma Linda, CA 92350 USA. NR 0 TC 0 Z9 0 U1 0 U2 0 PU WILEY-BLACKWELL PI HOBOKEN PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA SN 0022-3042 EI 1471-4159 J9 J NEUROCHEM JI J. Neurochem. PD AUG PY 2016 VL 138 SU 1 SI SI MA P54 BP 264 EP 264 PG 1 WC Biochemistry & Molecular Biology; Neurosciences SC Biochemistry & Molecular Biology; Neurosciences & Neurology GA DU9WI UT WOS:000382568400110 ER PT J AU Fong, S Mendez, MF AF Fong, S. Mendez, M. F. TI Variables affecting emotional reactivity to socioemotional stimuli in frontotemporal dementia SO JOURNAL OF NEUROCHEMISTRY LA English DT Meeting Abstract CT 10th International Conference on Frontotemporal Dementias CY AUG 31-SEP 02, 2016 CL Munich, GERMANY C1 [Fong, S.; Mendez, M. F.] Univ Calif Los Angeles, Neurol, Los Angeles, CA USA. [Fong, S.; Mendez, M. F.] VA Greater Los Angeles Healthcare Ctr, Neurol, Los Angeles, CA USA. NR 0 TC 0 Z9 0 U1 0 U2 0 PU WILEY-BLACKWELL PI HOBOKEN PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA SN 0022-3042 EI 1471-4159 J9 J NEUROCHEM JI J. Neurochem. PD AUG PY 2016 VL 138 SU 1 SI SI MA P148 BP 298 EP 298 PG 1 WC Biochemistry & Molecular Biology; Neurosciences SC Biochemistry & Molecular Biology; Neurosciences & Neurology GA DU9WI UT WOS:000382568400202 ER PT J AU Fong, SS Carr, AR Daianu, M Deutsch, MB Jimenez, EE Juarez, KO Mather, MM Paholpak, P Perfecto, SE Thompson, PM Mendez, MF AF Fong, S. S. Carr, A. R. Daianu, M. Deutsch, M. B. Jimenez, E. E. Juarez, K. O. Mather, M. M. Paholpak, P. Perfecto, S. E. Thompson, P. M. Mendez, M. F. TI The attribution of animacy and agency in frontotemporal dementia vs. Alzheimer's disease SO JOURNAL OF NEUROCHEMISTRY LA English DT Meeting Abstract CT 10th International Conference on Frontotemporal Dementias CY AUG 31-SEP 02, 2016 CL Munich, GERMANY C1 [Fong, S. S.; Deutsch, M. B.; Jimenez, E. E.; Juarez, K. O.; Mather, M. M.; Paholpak, P.; Perfecto, S. E.; Mendez, M. F.] Univ Calif Los Angeles, Neurol, Los Angeles, CA USA. [Fong, S. S.; Carr, A. R.; Deutsch, M. B.; Jimenez, E. E.; Juarez, K. O.; Mather, M. M.; Paholpak, P.; Mendez, M. F.] VA Greater Los Angeles Healthcare Ctr, Neurol, Los Angeles, CA USA. [Daianu, M.; Thompson, P. M.] Univ Southern Calif, Imaging Genet Ctr, Mark & Mary Stevens Neuroimaging & Informat Inst, Los Angeles, CA USA. [Deutsch, M. B.] Icahn Sch Med Mt Sinai, Neurol, New York, NY 10029 USA. [Paholpak, P.] Khon Kaen Univ, Psychiat, Khon Kaen, Thailand. [Thompson, P. M.] Univ Southern Calif, Psychiat, Los Angeles, CA USA. [Thompson, P. M.] Univ Southern Calif, Radiol, Los Angeles, CA USA. [Thompson, P. M.] Univ Southern Calif, Engn, Los Angeles, CA USA. [Thompson, P. M.] Univ Southern Calif, Pediat, Los Angeles, CA USA. [Thompson, P. M.] Univ Southern Calif, Ophthalmol, Los Angeles, CA USA. [Thompson, P. M.] Univ Southern Calif, Neurol, Los Angeles, CA USA. NR 0 TC 0 Z9 0 U1 0 U2 0 PU WILEY-BLACKWELL PI HOBOKEN PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA SN 0022-3042 EI 1471-4159 J9 J NEUROCHEM JI J. Neurochem. PD AUG PY 2016 VL 138 SU 1 SI SI MA P153 BP 300 EP 300 PG 1 WC Biochemistry & Molecular Biology; Neurosciences SC Biochemistry & Molecular Biology; Neurosciences & Neurology GA DU9WI UT WOS:000382568400207 ER PT J AU Varley, PR Feske, U Gao, S Stone, RA Zhang, SJ Monte, R Arnold, RM Hall, DE AF Varley, Patrick R. Feske, Ulrike Gao, Shasha Stone, Roslyn A. Zhang, Sijian Monte, Robert Arnold, Robert M. Hall, Daniel E. TI Time required to review research protocols at 10 Veterans Affairs Institutional Review Boards SO JOURNAL OF SURGICAL RESEARCH LA English DT Article DE Quality improvement; Ethics committee; Efficiency ID CLINICAL-RESEARCH; QUALITY; MULTICENTER; OVERSIGHT; EVENTS; REFORM; COSTS AB Background: Despite perceptions that institutional review boards ( IRBs) delay research, little is known about how long it takes to secure IRB approval. We retrospectively quantified IRB review times at 10 large Veterans Affairs (VA) IRBs. Methods: We collected IRB records pertaining to a stratified random sample of research protocols drawn from 10 of the 26 largest VA IRBs. Two independent analysts abstracted dates from the IRB records, from which we calculated overall and incremental review times. We used multivariable linear regression to assess variation in total and incremental review times by IRB and review level (i.e., exempt, expedited, or full board) and to identify potential targets for efforts to improve the efficiency and uniformity of the IRB review process. Results: In a sample of 277 protocols, the mean review time was 112 d (95% confidence interval [CI]: 105-120). Compared with full-board reviews at IRB 1, average review times at IRBs 3, 8, 9, and 10 were 27 (95% CI: 6-48), 37 (95% CI: 11-63), 45 (95% CI: 20-69), and 24 (95% CI: 2-45) d shorter, and at IRB 6, times were 56 (95% CI: 28-84) d longer. Across all IRBs, expedited reviews were 44 (95% CI: 30-58) d shorter on average than were full-board reviews, with no significant difference between exempt and full-board reviews. However, after subtracting the time required for Research and Development Committee review, exempt reviews were 21 (95% CI: 1-41) d shorter on average than were full-board reviews. Conclusions: IRB review times differ significantly by IRB and review level. Few VA IRBs approach a consensus panel goal of 60 d for IRB review. The unexpectedly longer review times for exempt protocols in the VA can be attributed to time required for Research and Development Committee review. Prospective, routine collection of key time points in the IRB review process could inform IRB-specific initiatives for reducing VA IRB review times. Published by Elsevier Inc. C1 [Varley, Patrick R.; Hall, Daniel E.] Univ Pittsburgh, Dept Surg, Pittsburgh, PA USA. [Feske, Ulrike; Gao, Shasha; Stone, Roslyn A.; Zhang, Sijian; Hall, Daniel E.] VA Pittsburgh Healthcare Syst, Ctr Hlth Equ Res & Promot, Bldg 30,Univ Dr,151C, Pittsburgh, PA 15240 USA. [Monte, Robert] VA Pittsburgh Healthcare Syst, Vet Engn Resource Ctr, Pittsburgh, PA USA. [Arnold, Robert M.] Univ Pittsburgh, Dept Gen Internal Med, Pittsburgh, PA USA. RP Hall, DE (reprint author), VA Pittsburgh Healthcare Syst, Ctr Hlth Equ Res & Promot, Bldg 30,Univ Dr,151C, Pittsburgh, PA 15240 USA. EM hallde@upmc.edu FU U.S. Department of Veterans Affairs, Veterans Health Administration, Office of Research and Development, Health Services Research and Development [CDA 08-281, SDR 11-399-1] FX This research was supported by supported by the U.S. Department of Veterans Affairs, Veterans Health Administration, Office of Research and Development, Health Services Research and Development (CDA 08-281 and SDR 11-399-1). We are grateful to Laura Lupovitz for her careful coding of IRB review times, the staff of the VA Pittsburgh Veterans Engineering Resource Center for their assistance with process flow mapping, and for the participation and support of the IRB staff at each of the participating institutions. Weare also grateful to Michael Fine, Bruce Ling, Charles Lidz, Galen Switzer, Susan Zickmund, Barbara Hanusa and Aram Dobalian who were involved in other parts of this research and served throughout as advisors to our team. NR 25 TC 0 Z9 0 U1 0 U2 0 PU ACADEMIC PRESS INC ELSEVIER SCIENCE PI SAN DIEGO PA 525 B ST, STE 1900, SAN DIEGO, CA 92101-4495 USA SN 0022-4804 EI 1095-8673 J9 J SURG RES JI J. Surg. Res. PD AUG PY 2016 VL 204 IS 2 BP 481 EP 489 DI 10.1016/j.jss.2016.06.004 PG 9 WC Surgery SC Surgery GA DU5CP UT WOS:000382230100027 PM 27565086 ER PT J AU Fearing, CM Melton, DW Lei, XF Hancock, H Wang, HZ Sarwar, ZU Porter, L McHale, M McManus, LM Shireman, PK AF Fearing, Caitlin M. Melton, David W. Lei, Xiufen Hancock, Heather Wang, Hanzhou Sarwar, Zaheer U. Porter, Laurel McHale, Matthew McManus, Linda M. Shireman, Paula K. TI Increased Adipocyte Area in Injured Muscle With Aging and Impaired Remodeling in Female Mice SO JOURNALS OF GERONTOLOGY SERIES A-BIOLOGICAL SCIENCES AND MEDICAL SCIENCES LA English DT Article DE Sarcopenia; Muscle regeneration; Monocyte; macrophage ID CONTRACTION-INDUCED INJURY; MOUSE SKELETAL-MUSCLE; AGE-RELATED-CHANGES; SATELLITE CELLS; MALE RATS; FIBRO/ADIPOGENIC PROGENITORS; MACROPHAGE PHENOTYPE; STEM-CELLS; OLD RATS; REGENERATION AB We demonstrated that young male and female mice similarly regenerated injured skeletal muscle; however, female mice transiently increased adipocyte area within regenerated muscle in a sex hormone-dependent manner. We extended these observations to investigate the effect of aging and sex on sarcopenia and muscle regeneration. Cardiotoxin injury to the tibialis anterior muscle of young, middle, and old-aged C57Bl/6J male and female mice was used to measure regenerated myofiber cross-sectional area (CSA), adipocyte area, residual necrosis, and inflammatory cell recruitment. Baseline (uninjured) myofiber CSA was decreased in old mice of both sexes compared to young and middle-aged mice. Regenerated CSA was similar in male mice in all age groups until baseline CSA was attained but decreased in middle and old age female mice compared to young females. Furthermore, adipocyte area within regenerated muscle was transiently increased in young females compared to young males and these sex-dependent increases persisted in middle and old age female mice and were associated with increased Pparg. Young female mice had more pro-inflammatory monocytes/macrophages in regenerating muscle than young male mice and increased Sca-1(+)CD45(-)cells. In conclusion, sex and age influence pro-inflammatory cell recruitment, muscle regeneration, and adipocyte area following skeletal muscle injury. C1 [Fearing, Caitlin M.; Melton, David W.; Lei, Xiufen; Hancock, Heather; Wang, Hanzhou; Sarwar, Zaheer U.; Porter, Laurel; McHale, Matthew; Shireman, Paula K.] Univ Texas Hlth Sci Ctr San Antonio, Dept Surg, San Antonio, TX 78229 USA. [Melton, David W.] Univ Texas Hlth Sci Ctr San Antonio, Dept Cellular & Struct Biol, San Antonio, TX 78229 USA. [Melton, David W.; McManus, Linda M.; Shireman, Paula K.] Univ Texas Hlth Sci Ctr San Antonio, Sam & Ann Barshop Inst Longev & Aging Studies, San Antonio, TX 78229 USA. [McManus, Linda M.] Univ Texas Hlth Sci Ctr San Antonio, Dept Pathol, San Antonio, TX 78229 USA. [McManus, Linda M.] Univ Texas Hlth Sci Ctr San Antonio, Dept Periodont, San Antonio, TX 78229 USA. [Shireman, Paula K.] South Texas Vet Hlth Care Syst, San Antonio, TX USA. RP Shireman, PK (reprint author), Univ Texas Hlth Sci Ctr San Antonio, Dept Surg, Div Vasc & Endovasc Surg, 7703 Floyd Curl Dr MSC 7741, San Antonio, TX 78229 USA. EM shireman@uthscsa.edu FU National Institutes of Health [HL074236, HL110743, CA054174]; Nathan Shock Centers of Excellence in Basic Biology of Aging [AG013319]; Veterans Administration Merit Review [1I01BX001186]; University of Texas Health Science Center, San Antonio; CTSA grant [UL1 TR001120] FX These studies were supported, in part, by grants from the National Institutes of Health (HL074236, HL110743), Nathan Shock Centers of Excellence in Basic Biology of Aging (AG013319), and the Veterans Administration Merit Review (1I01BX001186). Data were generated in the Flow Cytometry Facility, which was supported by the University of Texas Health Science Center, San Antonio and a grant from the National Institutes of Health (CA054174) to the Cancer Therapy & Research Center and UL1 TR001120 (CTSA grant). NR 71 TC 1 Z9 1 U1 1 U2 1 PU OXFORD UNIV PRESS INC PI CARY PA JOURNALS DEPT, 2001 EVANS RD, CARY, NC 27513 USA SN 1079-5006 EI 1758-535X J9 J GERONTOL A-BIOL JI J. Gerontol. Ser. A-Biol. Sci. Med. Sci. PD AUG PY 2016 VL 71 IS 8 BP 992 EP 1004 DI 10.1093/gerona/glv104 PG 13 WC Geriatrics & Gerontology; Gerontology SC Geriatrics & Gerontology GA DV9BX UT WOS:000383235400002 PM 26273023 ER PT J AU Yaffe, K Peltz, CB Ewing, SK McCulloch, CE Cummings, SR Cauley, JA Hillier, TA Ensrud, KE AF Yaffe, Kristine Peltz, Carrie B. Ewing, Susan K. McCulloch, Charles E. Cummings, Steve R. Cauley, Jane A. Hillier, Teresa A. Ensrud, Kristine E. TI Long-term Cognitive Trajectories and Mortality in Older Women SO JOURNALS OF GERONTOLOGY SERIES A-BIOLOGICAL SCIENCES AND MEDICAL SCIENCES LA English DT Article DE Cognitive trajectories; Global cognition; Executive function; All-cause mortality; Cardiovascular mortality; Oldest old ID ALZHEIMERS-DISEASE; EXECUTIVE FUNCTION; COMMUNITY SAMPLE; RISK-FACTORS; ASSOCIATION; DECLINE; SURVIVAL; DEMENTIA; HEALTH; LIFE AB Few studies have examined whether change in cognition is linked to mortality. This study examined the relationship between cognitive trajectories in older age and risk of death. We studied community-dwelling, nondemented women aged 65+ (mean age = 71) enrolled in a prospective study of aging and followed up to 25 years. A modified Mini-Mental State Examination (mMMSE) and Trail Making Task Part B (TMTB) were administered at multiple visits during follow-up. We examined the association between cognitive trajectories (analyzed by quintiles) from baseline to age 80 (n = 7,477 for mMMSE and n = 6,503 for TMTB) and all-cause mortality after age 80 using Cox regression models, both unadjusted and adjusted for education, physical activity, alcohol, depression score, current smoking and history of hypertension and diabetes. Cause of death was determined from death certificates, classified as cardiovascular, cancer and other. Women with greater rate of decline were older, less educated, less physically active, had higher depression score and were more likely to have a history of hypertension and diabetes (all p < .01). Participants with the greatest decline (quintile 1) had an increased risk of death (mMMSE hazard ratio [HR] = 1.28; TMTB HR = 1.43] and those with the least decline (quintile 5) had a decreased risk of death (mMMSE HR = 0.73; TMTB HR = 0.61) compared with intermediate decliners (quintiles 2-4). Cognitive trajectories were associated with cardiovascular mortality and other causes of death, but not cancer deaths. Our study suggests that greater decline in general cognition or executive function is associated with higher rates of mortality in oldest-old women. C1 [Yaffe, Kristine; Ewing, Susan K.; McCulloch, Charles E.; Cummings, Steve R.] Univ Calif San Francisco, Dept Psychiat, San Francisco, CA USA. [Yaffe, Kristine; Ewing, Susan K.; McCulloch, Charles E.; Cummings, Steve R.] Univ Calif San Francisco, Dept Neurol, San Francisco, CA USA. [Yaffe, Kristine; Ewing, Susan K.; McCulloch, Charles E.; Cummings, Steve R.] Univ Calif San Francisco, Dept Epidemiol & Biostat, San Francisco, CA 94143 USA. [Yaffe, Kristine; Peltz, Carrie B.] San Francisco VA Med Ctr, Dept Mental Hlth, San Francisco, CA USA. [Peltz, Carrie B.] NCIRE Vet Hlth Res Inst, San Francisco, CA USA. [Cauley, Jane A.] Univ Pittsburgh, Dept Epidemiol, Pittsburgh, PA 15260 USA. [Hillier, Teresa A.] Kaiser Permanente Ctr Hlth Res Northwest Hawaii, Portland, OR USA. [Ensrud, Kristine E.] Univ Minnesota, Sch Publ Hlth, Minneapolis, MN USA. [Ensrud, Kristine E.] Minneapolis VA Hlth Care Syst, Dept Med, Minneapolis, MN USA. RP Peltz, CB (reprint author), 4150 Clement St 116H, San Francisco, CA 94121 USA. EM carrie.peltz2@va.gov OI Cauley, Jane A/0000-0003-0752-4408 FU National Institutes of Health; National Institute on Aging [R01 AG005407, R01 AR35582, R01 AR35583, R01 AR35584, R01 AG005394, R01 AG027574, R01 AG027576] FX The Study of Osteoporotic Fractures is supported by National Institutes of Health funding. The National Institute on Aging provides support under the following grant numbers: R01 AG005407, R01 AR35582, R01 AR35583, R01 AR35584, R01 AG005394, R01 AG027574, and R01 AG027576. NR 40 TC 0 Z9 0 U1 3 U2 5 PU OXFORD UNIV PRESS INC PI CARY PA JOURNALS DEPT, 2001 EVANS RD, CARY, NC 27513 USA SN 1079-5006 EI 1758-535X J9 J GERONTOL A-BIOL JI J. Gerontol. Ser. A-Biol. Sci. Med. Sci. PD AUG PY 2016 VL 71 IS 8 BP 1074 EP 1080 DI 10.1093/gerona/glw003 PG 7 WC Geriatrics & Gerontology; Gerontology SC Geriatrics & Gerontology GA DV9BX UT WOS:000383235400012 PM 26843186 ER PT J AU Mouilso, ER Tuerk, PW Schnurr, PP Rauch, SAM AF Mouilso, Emily R. Tuerk, Peter W. Schnurr, Paula P. Rauch, Sheila A. M. TI Addressing the Gender Gap: Prolonged Exposure for PTSD in Veterans SO PSYCHOLOGICAL SERVICES LA English DT Article DE effectiveness; female veterans; posttraumatic stress disorder; prolonged exposure therapy ID POSTTRAUMATIC-STRESS-DISORDER; COGNITIVE PROCESSING THERAPY; TRAUMATIC BRAIN-INJURY; HEALTH-STATUS; SEXUAL TRAUMA; WOMEN; MILITARY; OUTCOMES; FEMALE; CARE AB As the proportion of women serving in the United States military continues to increase, more female veterans are being treated for posttraumatic stress disorder (PTSD) in Department of Veterans Affairs (VA) health care settings. Prolonged Exposure (PE) therapy is an evidence-based treatment for PTSD and is often used in VA settings. However, only a few studies have investigated the effectiveness of PE specifically for female veterans with appropriate power. Results of these studies have varied, with similar effects between female and male veterans on par with civilian effects, and more recently, better outcomes for female veterans receiving PE compared with male veterans. The current study contextualizes the evidence from those studies and considers new data regarding clinical outcomes pre- and posttreatment for a large (N = 325) sample of male and female veterans treated with PE in a PTSD specialty clinic. Results indicate a large statistically significant decrease in PTSD as measured by PTSD Checklist (PCL) scores for both male and female veterans treated with PE (d = 1.33). No difference in effectiveness and no difference in treatment completion rates were found between male and female veterans. Our findings support the effectiveness of PE for the treatment of PTSD in female as well as male veterans. Results are compared and contrasted to previous findings in the literature taking into account heterogeneity in methodological and ecological factors among the studies. Emphasis is placed on context of care issues to further the empirical conversation regarding meeting the mental health needs of female veterans. C1 [Mouilso, Emily R.; Tuerk, Peter W.] Ralph H Johnson VA Med Ctr, Charleston, SC USA. [Mouilso, Emily R.; Tuerk, Peter W.] Med Univ South Carolina, Charleston, SC USA. [Schnurr, Paula P.] Natl Ctr PTSD, White River Jct, VT USA. [Schnurr, Paula P.] Geisel Sch Med Dartmouth, Hanover, NH USA. [Rauch, Sheila A. M.] Dept Vet Affairs Ann Arbor Healthcare Syst, Ann Arbor, MI USA. [Rauch, Sheila A. M.] Univ Michigan, Sch Med, Ann Arbor, MI 48109 USA. [Mouilso, Emily R.] Charlie Norwood VA Med Ctr, Augusta, GA 30901 USA. RP Mouilso, ER (reprint author), Charlie Norwood VA Med Ctr, Augusta, GA 30901 USA. EM emilymouilso@gmail.com FU Department of Veteran Affairs, Veterans Health Administration, Office of Research and Development, Clinical Sciences Research and Development FX Dr. Peter W. Tuerk's contribution to this article was partially supported by a Career Development Award (CDA-2) from the Department of Veteran Affairs, Veterans Health Administration, Office of Research and Development, Clinical Sciences Research and Development (PI: Peter W. Tuerk). NR 54 TC 2 Z9 2 U1 1 U2 2 PU AMER PSYCHOLOGICAL ASSOC PI WASHINGTON PA 750 FIRST ST NE, WASHINGTON, DC 20002-4242 USA SN 1541-1559 EI 1939-148X J9 PSYCHOL SERV JI Psychol. Serv. PD AUG PY 2016 VL 13 IS 3 BP 308 EP 316 DI 10.1037/ser0000040 PG 9 WC Psychology, Clinical SC Psychology GA DV7HC UT WOS:000383106000012 PM 26121077 ER PT J AU Henderson, AW Turner, AP Williams, RM Norvell, DC Hakimi, KN Czerniecki, JM AF Henderson, Alison W. Turner, Aaron P. Williams, Rhonda M. Norvell, Daniel C. Hakimi, Kevin N. Czerniecki, Joseph M. TI Sexual Activity After Dysvascular Lower Extremity Amputation SO REHABILITATION PSYCHOLOGY LA English DT Article DE amputation; sexual activity; dysvascular disease; satisfaction with life ID QUALITY-OF-LIFE; LOWER-LIMB AMPUTATION; PAIN GRADE QUESTIONNAIRE; ERECTILE DYSFUNCTION; MAJOR DEPRESSION; SINGLE-ITEM; SELF-REPORT; NATIONAL-SURVEY; ADULT AMPUTEES; PHANTOM PAIN AB Objective: This study examined the prevalence and correlates of sexual activity among individuals experiencing their first dysvascular lower extremity amputation. Design: A prospective cohort was recruited from 4 Veterans Affairs Medical Centers. Of 198 potential participants who met inclusion criteria, 113 (57%) agreed to participate within 7 days of amputation (baseline) and 6 weeks, 4 months, and 12 months post-amputation; 105 completed the sexual activity items at baseline. Measures included self-reported frequency of sexual activity; desire for more or less sexual activity; importance of sexual activity to satisfaction with life; Patient Health Questionnaire-9; Locomotor Capability Index-5; pain intensity/frequency; quality of life. Results: Depending on the time period post-amputation, 11%-24% reported engaging in any sexual activity, although a majority indicated that sexual activity is very important to their satisfaction with life. Frequency of sexual activity increased between 6 weeks and 4 and 12 months post-amputation. In univariate analyses, older age was associated with decreased sexual activity at all time points; at 4 and 12 months, greater mobility was associated with increased sexual activity. In multivariable models, mobility was associated with sexual activity at 4 and 12 months; age and race remained associated with sexual activity at 4 and 12 months, respectively. At all time points, frequency and importance of sexual activity were significantly associated with one another. Conclusions: Although a minority of individuals engaged in any sexual activity during the study period, it remained an important factor in overall satisfaction with life. Younger age and improved mobility were associated with increased sexual activity. Rehabilitation specialists are encouraged to address sexuality and, if relevant, incorporate it into rehabilitation goals. Impact and Implications Although individuals with lower extremity amputation (LEA) endorse continued interest in sexual activity, this important aspect of life is often underemphasized by care providers and researchers alike. This study is the first to examine sexual activity among those with recent LEA longitudinally, evaluating the frequency as well as correlates of sexual activity at four time points in the year following amputation. Consistent with their healthy peers of comparable age, individuals with recent LEA secondary to dysvascular disease continue to identify sexual activity as important to their overall satisfaction with life, although only a minority (depending on the time period post-amputation, between 11 and 24%) report engaging in any sexual activity in the year following amputation. In practice, many rehabilitation care providers often fail to address sexuality and sexual activity explicitly among those with recent dysvascular LEA. Rehabilitation psychologists, physicians and other care providers can play a key role in ensuring sexuality is addressed, possibly framing it within the broader context of activities of daily living (ADLs), particularly as increased mobility is associated with increased frequency of sexual activity. C1 [Henderson, Alison W.] Vet Affairs VA Puget Sound Hlth Care Syst, Ctr Excellence Limb Loss Prevent & Prosthet Engn, Seattle, WA 98108 USA. [Turner, Aaron P.; Williams, Rhonda M.; Hakimi, Kevin N.; Czerniecki, Joseph M.] VA Puget Sound Hlth Care Syst, Rehabil Care Serv, Seattle, WA 98108 USA. [Turner, Aaron P.; Williams, Rhonda M.; Hakimi, Kevin N.; Czerniecki, Joseph M.] Univ Washington, Dept Rehabil Med, Seattle, WA 98195 USA. [Norvell, Daniel C.] Spectrum Res Inc, Tacoma, WA USA. RP Turner, AP (reprint author), VA Puget Sound Hlth Care Syst, RCS-117,1660 South Columbian Way, Seattle, WA 98108 USA. EM Aaron.Turner@va.gov FU U.S. Department of Veterans Affairs, Office of Research and Development, Rehabilitation Research and Development Service [A41241, B4927W] FX This work was supported by Merit Review Award A41241 and Career Development Award B4927W from the U.S. Department of Veterans Affairs, Office of Research and Development, Rehabilitation Research and Development Service. The contents do not represent the views of the U.S. Department of Veterans Affairs or the U.S. government. NR 66 TC 0 Z9 0 U1 7 U2 7 PU EDUCATIONAL PUBLISHING FOUNDATION-AMERICAN PSYCHOLOGICAL ASSOC PI WASHINGTON PA 750 FIRST ST, NE, WASHINGTON, DC 20002-4242 USA SN 0090-5550 EI 1939-1544 J9 REHABIL PSYCHOL JI Rehabil. Psychol. PD AUG PY 2016 VL 61 IS 3 BP 260 EP 268 DI 10.1037/rep0000087 PG 9 WC Psychology, Clinical; Rehabilitation SC Psychology; Rehabilitation GA DV9HR UT WOS:000383251900005 PM 27253221 ER PT J AU Edwards, KS Parish, SJ Rosen, RC Garvert, DW Spangler, SL Ruzek, JI AF Edwards, Katharine S. Parish, Sharon J. Rosen, Raymond C. Garvert, Donn W. Spangler, Shana L. Ruzek, Josef I. TI A Standardized Patient Methodology to Assess Cognitive-Behavioral Therapy (CBT) Skills Performance: Development and Testing in a Randomized Controlled Trial of Web-Based Training SO TRAINING AND EDUCATION IN PROFESSIONAL PSYCHOLOGY LA English DT Article DE dissemination; training; assessment; standardized patient; objective standardized clinical examination (OSCE) ID STRUCTURED CLINICAL EXAMINATION; SUBSTANCE-ABUSE; PROFESSIONAL PSYCHOLOGY; COMPETENCE BENCHMARKS; TREATMENT PROVIDERS; INTERVENTION; PSYCHIATRY; IMPLEMENTATION; DISSEMINATION; SCALE AB Competency-based training is increasingly important in mental health as practitioners are trained in the use of evidence-based treatments for posttraumatic stress disorder (PTSD) and other disorders. Clinical skills according to this model are assessed in various ways, including the use of standardized patient (SP) interviews. This study investigated the reliability and feasibility of using a telephone-based SP interview to evaluate cognitive-behavioral therapy (CBT) skills within a large, randomized trial of online training. This paper describes the development of a standardized SP methodology for the larger study, including case illustration, SP training, development of trainee skills assessment metrics, and rater training. A post hoc substudy evaluated SP performance across time. For the larger study, 2 out of 3 skills assessment metrics showed satisfactory performance and demonstrated consistently good interitem and interrater reliability. The substudy found that SPs were adherent and faithful to their intended character, with little evidence of performance drift. Based on these findings, telephone SP methodologies are a promising technology for large-scale clinical skills assessment in psychology. C1 [Edwards, Katharine S.] Stanford Univ, Stanford, CA 94305 USA. [Parish, Sharon J.] Weill Cornell Med Sch, New York, NY USA. [Parish, Sharon J.] NewYork Presbyterian Hosp, Med Serv, Westchester Div, New York, NY USA. [Rosen, Raymond C.] New England Res Inst Inc, Watertown, MA USA. [Garvert, Donn W.; Ruzek, Josef I.] VA Palo Alto Hlth Care Syst, Natl Ctr PTSD, Menlo Pk, CA USA. [Spangler, Shana L.] VA Greater Los Angeles Healthcare Syst, PTSD, North Hills, CA USA. RP Edwards, KS (reprint author), Stanford Univ, Dept Cardiovasc Med, 300 Pasteur Dr,Room H2103, Stanford, CA 94305 USA. EM ksedwards@stanford.edu NR 49 TC 0 Z9 0 U1 4 U2 6 PU EDUCATIONAL PUBLISHING FOUNDATION-AMERICAN PSYCHOLOGICAL ASSOC PI WASHINGTON PA 750 FIRST ST, NE, WASHINGTON, DC 20002-4242 USA SN 1931-3918 EI 1931-3926 J9 TRAIN EDUC PROF PSYC JI Train. Educ. Prof. Psychol. PD AUG PY 2016 VL 10 IS 3 BP 149 EP 156 DI 10.1037/tep0000119 PG 8 WC Psychology, Educational SC Psychology GA DV7HQ UT WOS:000383107400004 ER PT J AU Wise, R Anzueto, A Dahl, R Dusser, D Calverley, P AF Wise, Robert Anzueto, Antonio Dahl, Ronald Dusser, Daniel Calverley, Peter TI Tiotropium safety in 'real-world' populations SO BRITISH JOURNAL OF CLINICAL PHARMACOLOGY LA English DT Letter ID OBSTRUCTIVE PULMONARY-DISEASE; TIOSPIR TRIAL; RESPIMAT; COPD C1 [Wise, Robert] Johns Hopkins Univ, Sch Med, Baltimore, MD 21218 USA. [Anzueto, Antonio] Univ Texas San Antonio, San Antonio, TX USA. [Anzueto, Antonio] South Texas Vet Hlth Care Syst, San Antonio, TX USA. [Dahl, Ronald] Odense Univ Hosp, Odense C, Denmark. [Dusser, Daniel] Univ Paris 05, Sorbonne Paris Cite, Hop Cochin, AP HP,Serv Pneumol, Paris, France. [Calverley, Peter] Univ Liverpool, Inst Ageing & Chron Dis, Liverpool, Merseyside, England. RP Wise, R (reprint author), Johns Hopkins Univ, Sch Med, Baltimore, MD 21218 USA. EM rwise@jhmi.edu NR 10 TC 1 Z9 1 U1 1 U2 1 PU WILEY-BLACKWELL PI HOBOKEN PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA SN 0306-5251 EI 1365-2125 J9 BRIT J CLIN PHARMACO JI Br. J. Clin. Pharmacol. PD AUG PY 2016 VL 82 IS 2 BP 562 EP 563 DI 10.1111/bcp.12972 PG 2 WC Pharmacology & Pharmacy SC Pharmacology & Pharmacy GA DU9AV UT WOS:000382509500025 PM 27197835 ER PT J AU Govani, SM Wiitala, WL Stidham, RW Saini, SD Hou, JK Feagins, LA Sussman, JB Higgins, PDR Waljee, AK AF Govani, Shail M. Wiitala, Wyndy L. Stidham, Ryan W. Saini, Sameer D. Hou, Jason K. Feagins, Linda A. Sussman, Jeremy B. Higgins, Peter D. R. Waljee, Akbar K. TI Age Disparities in the Use of Steroid-sparing Therapy for Inflammatory Bowel Disease SO INFLAMMATORY BOWEL DISEASES LA English DT Article DE corticosteroids; elderly; escalation ID ULCERATIVE-COLITIS; RISK; EPIDEMIOLOGY; MANAGEMENT AB Background:Corticosteroids are effective rescue therapies for patients with inflammatory bowel disease (IBD), but have significant side effects, which may be amplified in the growing population of elderly patients with IBD. We aimed to compare the use of steroids and steroid-sparing therapies (immunomodulators and biologics) and rates of complications among elderly (65) and younger patients in a national cohort of veterans with IBD.Methods:We used national Veterans Health Administrative data to conduct a retrospective study of veterans with IBD between 2002 and 2010. Medications and the incidence of complications were obtained from the Veterans Health Administrative Decision Support Systems. Multivariate logistic regression accounting for facility-level clustering was used to identify predictors of use of steroid-sparing medications.Results:We identified 30,456 veterans with IBD. Of these, 94% were men and 40% were more than 65, and 32% were given steroids. Elderly veterans were less likely to receive steroids (23.8% versus 38.3%, P < 0.001) and were less likely to be prescribed steroid-sparing medications (25.5% versus 46.9%, respectively, P < 0.001). In multivariate analysis controlling for sex, age <65 (odds ratio, 2.19; 95% CI, 1.54-3.11) and gastroenterology care (odds ratio, 8.42; 95% CI, 6.18-11.47) were associated with initiation of steroid-sparing medications. After starting steroids, fracture rates increased in the elderly patients with IBD, whereas increases in venous thromboembolism and infections after starting steroids affected both age groups.Conclusions:Elderly veterans are less likely to receive steroids and steroid-sparing medications than younger veterans; elderly patients exposed to steroids were more likely to have fractures than the younger population. C1 [Govani, Shail M.; Stidham, Ryan W.; Saini, Sameer D.; Sussman, Jeremy B.; Higgins, Peter D. R.; Waljee, Akbar K.] Univ Michigan Hlth Syst, Dept Internal Med, Ann Arbor, MI USA. [Govani, Shail M.; Saini, Sameer D.] VA Ann Arbor Healthcare Syst, Ann Arbor, MI USA. [Wiitala, Wyndy L.; Sussman, Jeremy B.; Waljee, Akbar K.] VA Ctr Clin Management Res, Ann Arbor, MI USA. [Saini, Sameer D.; Sussman, Jeremy B.; Waljee, Akbar K.] Univ Michigan, Inst Healthcare Policy & Innovat, Ann Arbor, MI 48109 USA. [Hou, Jason K.] Houston VA HSR&D Ctr Excellence, Michael E DeBakey Vet Affairs Med Ctr, Houston, TX USA. [Hou, Jason K.] Baylor Coll Med, Dept Internal Med, Sect Gastroenterol & Hepatol, Houston, TX 77030 USA. [Feagins, Linda A.] Univ Texas Southwestern Med Ctr Dallas, Dept Internal Med, VA North Texas Hlth Care Syst, Div Gastroenterol & Hepatol, Dallas, TX USA. RP Govani, SM (reprint author), Dept Internal Med, 2215 Fuller Rd,Room 111D, Ann Arbor, MI 48105 USA. EM shailg@umich.edu FU VA HSR&D CDA-2 Career Development Award [1IK2HX000775]; VA HSR&D Center for Innovations in Quality, Effectiveness and Safety at the Michael E. DeBakey VA Medical Center, Houston, TX [CIN 13-413]; VA CDA [13-021] FX A. K. Waljee's research is funded by a VA HSR&D CDA-2 Career Development Award 1IK2HX000775. J. K. Hou's research is funded by the VA HSR&D Center for Innovations in Quality, Effectiveness and Safety (#CIN 13-413), at the Michael E. DeBakey VA Medical Center, Houston, TX. J. B. Sussman is supported by VA CDA 13-021. The sponsor had no role in the design and conduct of the study; collection, management, analysis, and interpretation of the data; preparation, review, or approval of the manuscript; or decision to submit the manuscript for publication. NR 21 TC 0 Z9 0 U1 0 U2 0 PU LIPPINCOTT WILLIAMS & WILKINS PI PHILADELPHIA PA TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA SN 1078-0998 EI 1536-4844 J9 INFLAMM BOWEL DIS JI Inflamm. Bowel Dis. PD AUG PY 2016 VL 22 IS 8 BP 1923 EP 1928 DI 10.1097/MIB.0000000000000817 PG 6 WC Gastroenterology & Hepatology SC Gastroenterology & Hepatology GA DT4TX UT WOS:000381475100019 PM 27416039 ER PT J AU DiNapoli, EA Bramoweth, AD Cinna, C Kasckow, J AF DiNapoli, Elizabeth A. Bramoweth, Adam D. Cinna, Christopher Kasckow, John TI Sedative hypnotic use among veterans with a newly reported mental health disorder SO INTERNATIONAL PSYCHOGERIATRICS LA English DT Article DE sedatives and hypnotics; veterans; mental health; aged; inappropriate prescriptions ID INAPPROPRIATE MEDICATION USE; BENZODIAZEPINE USE; OLDER-ADULTS; ELDERLY VETERANS; PRIMARY-CARE; INSOMNIA; METAANALYSIS; COMMUNITY; PEOPLE; THERAPY AB Background: This study compared sedative hypnotic use by type of mental health diagnosis and determined factors associated with use among older veterans (65+ years) with a newly reported mental health disorder. Methods: This study used data from veterans who received primary care services at VA Pittsburgh Healthcare System (VAPHS) from January 1, 2007 to December 31, 2011 (n = 879). Results: Sedative hypnotics were commonly used in older veterans within 12-months following a newly reported mental health disorder (19.9%), particularly amongst those with insomnia (41.7%). The number of newly reported mental health disorders was a significant factor associated with sedative hypnotic use, with the odds of use increasing by more than 200% in older adults with two newly reported disorders compared to those with one newly reported mental health disorder. Conclusions: Continued efforts are needed to improve provider and patient awareness of the risks associated with sedative hypnotic use in older adults, as well as to increase access to and receipt of non-pharmacological mental health treatments for this vulnerable population. C1 [DiNapoli, Elizabeth A.; Bramoweth, Adam D.; Cinna, Christopher; Kasckow, John] VA Pittsburgh Healthcare Syst, VISN Mental Illness Res Educ & Clin Ctr MIRECC 4, Pittsburgh, PA USA. [DiNapoli, Elizabeth A.; Bramoweth, Adam D.] Univ Pittsburgh, Sch Med, Dept Psychiat, Pittsburgh, PA USA. [Cinna, Christopher] Duquesne Univ, Ctr Social & Publ Policy, Pittsburgh, PA 15219 USA. [Kasckow, John] VA Pittsburgh Healthcare Syst, Ctr Hlth Equ Res & Promot, Pittsburgh, PA USA. [Kasckow, John] Univ Pittsburgh, Med Ctr, Western Psychiat Inst & Clin, Pittsburgh, PA USA. RP Bramoweth, AD (reprint author), VA Pittsburgh Healthcare Syst, Res Off Bldg 151R,Univ Dr, Pittsburgh, PA 15240 USA. EM Adam.Bramoweth@va.gov NR 33 TC 0 Z9 0 U1 2 U2 2 PU CAMBRIDGE UNIV PRESS PI NEW YORK PA 32 AVENUE OF THE AMERICAS, NEW YORK, NY 10013-2473 USA SN 1041-6102 EI 1741-203X J9 INT PSYCHOGERIATR JI Int. Psychogeriatr. PD AUG PY 2016 VL 28 IS 8 BP 1391 EP 1398 DI 10.1017/S1041610216000521 PG 8 WC Psychology, Clinical; Geriatrics & Gerontology; Gerontology; Psychiatry; Psychology SC Psychology; Geriatrics & Gerontology; Psychiatry GA DU7IV UT WOS:000382388300017 PM 27073116 ER PT J AU Fischer, SM Bekelman, D Bailey, FA AF Fischer, Stacy M. Bekelman, David Bailey, F. Amos TI Family Assessment of Quality of Care in the Last Month of Life SO JAMA INTERNAL MEDICINE LA English DT Editorial Material ID PALLIATIVE CARE; END C1 [Fischer, Stacy M.; Bekelman, David; Bailey, F. Amos] Univ Colorado, Div Gen Internal Med, Dept Med, Sch Med, Anschutz Med Campus,Mail Stop B180, Aurora, CO 80045 USA. [Bekelman, David] Eastern Colorado Hlth Care Syst, Div Geriatr, Dept Internal Med, Dept Vet Affairs, Denver, CO USA. [Bailey, F. Amos] Birmingham VA Med Ctr, Birmingham Atlanta Geriatr Res Educ & Clin Ctr, Birmingham, AL USA. RP Bailey, FA (reprint author), Univ Colorado, Div Gen Internal Med, Dept Med, Sch Med, Anschutz Med Campus,Mail Stop B180, Aurora, CO 80045 USA. EM amos.bailey@ucdenver.edu NR 5 TC 0 Z9 0 U1 1 U2 1 PU AMER MEDICAL ASSOC PI CHICAGO PA 330 N WABASH AVE, STE 39300, CHICAGO, IL 60611-5885 USA SN 2168-6106 EI 2168-6114 J9 JAMA INTERN MED JI JAMA Intern. Med. PD AUG PY 2016 VL 176 IS 8 BP 1102 EP 1104 DI 10.1001/jamainternmed.2016.1208 PG 4 WC Medicine, General & Internal SC General & Internal Medicine GA DT0AN UT WOS:000381145000018 PM 27367457 ER PT J AU Chen-Scarabelli, C Scarabelli, TM AF Chen-Scarabelli, Carol Scarabelli, Tiziano M. TI Syncope While Driving in Denmark SO JAMA INTERNAL MEDICINE LA English DT Letter C1 [Chen-Scarabelli, Carol; Scarabelli, Tiziano M.] Birmingham VA Med Ctr, 700 S 19th St, Birmingham, AL 35233 USA. [Scarabelli, Tiziano M.] Univ Alabama Birmingham, Med Ctr, Birmingham, AL USA. RP Chen-Scarabelli, C (reprint author), Birmingham VA Med Ctr, 700 S 19th St, Birmingham, AL 35233 USA. EM chenscarabelli@hotmail.com NR 4 TC 0 Z9 0 U1 0 U2 0 PU AMER MEDICAL ASSOC PI CHICAGO PA 330 N WABASH AVE, STE 39300, CHICAGO, IL 60611-5885 USA SN 2168-6106 EI 2168-6114 J9 JAMA INTERN MED JI JAMA Intern. Med. PD AUG PY 2016 VL 176 IS 8 BP 1230 EP 1230 DI 10.1001/jamainternmed.2016.3723 PG 1 WC Medicine, General & Internal SC General & Internal Medicine GA DT0AN UT WOS:000381145000051 PM 27479671 ER PT J AU Zgierska, AE Burzinski, CA Cox, J Kloke, J Singles, J Mirgain, S Stegner, A Cook, DB Backonja, M AF Zgierska, Aleksandra E. Burzinski, Cindy A. Cox, Jennifer Kloke, John Singles, Janice Mirgain, Shilagh Stegner, Aaron Cook, Dane B. Backonja, Miroslav TI Mindfulness Meditation-Based Intervention Is Feasible, Acceptable, and Safe for Chronic Low Back Pain Requiring Long-Term Daily Opioid Therapy SO JOURNAL OF ALTERNATIVE AND COMPLEMENTARY MEDICINE LA English DT Article ID CHRONIC NONCANCER PAIN; 3-YEAR FOLLOW-UP; PRIMARY-CARE; STRESS REDUCTION; GUIDELINES; TRIALS; MODEL AB Objective: Although mindfulness meditation (MM) is increasingly used for chronic pain treatment, limited evidence supports its clinical application for opioid-treated chronic low back pain (CLBP). The goal of this study was to determine feasibility, acceptability, and safety of an MM-based intervention in patients with CLBP requiring daily opioid therapy. Design: 26-week pilot randomized controlled trial comparing MM-based intervention, combined with usual care, to usual care alone. Setting: Outpatient. Patients: Adults with CLBP treated with >= 30 mg of morphine-equivalent dose (MED) per day for 3 months or longer. Interventions: Targeted MM-based intervention consisted of eight weekly 2-hour group sessions and home practice (30 minutes/d, 6 days/wk) during the study. "Usual care'' for opioid-treated CLBP was provided to participants by their regular clinicians. Outcome measures: Feasibility and acceptability of the MM intervention were assessed by adherence to intervention protocol and treatment satisfaction among experimental participants. Safety was evaluated by inquiry about side effects/adverse events and opioid dose among all study participants. Results: Thirty-five participants enrolled during the 10-week recruitment period. The mean age (+/- standard deviation) was 51.8 +/- 9.7 years; the patients were predominantly female, with substantial CLBP-related pain and disability, and treated with 148.3 +/- 129.2mg of MED per day. All participants completed baseline assessments; none missed both follow-up assessments or withdrew. Among experimental participants (n = 21), 19 attended 1 or more intervention sessions and 14 attended 4 or more. They reported, on average, 164.0 +/- 122.1 minutes of formal practice per week during the 26-week study and 103.5 +/- 111.5 minutes of brief, informal practice per week. Seventeen patients evaluated the intervention, indicating satisfaction; their qualitative responses described the course as useful for pain management (n = 10) and for improving pain coping skills (n = 8). No serious adverse events or safety concerns occurred among the study participants. Conclusions: MM-based intervention is feasible, acceptable, and safe in opioid-treated CLBP. C1 [Zgierska, Aleksandra E.; Burzinski, Cindy A.; Cox, Jennifer] Univ Wisconsin, Sch Med & Publ Hlth, Dept Family Med & Community Hlth, 1100 Delaplaine Court, Madison, WI 53715 USA. [Kloke, John] Univ Wisconsin, Sch Med & Publ Hlth, Dept Biostat & Med Informat, Madison, WI USA. [Singles, Janice; Mirgain, Shilagh] Univ Wisconsin, Sch Med & Publ Hlth, Dept Orthoped & Rehabil, Madison, WI USA. [Stegner, Aaron; Cook, Dane B.] William S Middleton Mem Vet Adm Med Ctr, Res Serv, Madison, WI USA. [Stegner, Aaron; Cook, Dane B.] Univ Wisconsin, Sch Educ, Dept Kinesiol, Madison, WI USA. [Backonja, Miroslav] Univ Wisconsin, Dept Neurol, Sch Med & Publ Hlth, Madison, WI 53706 USA. [Backonja, Miroslav] PRAHS Clin Res Co Lifetree, Salt Lake City, UT USA. RP Zgierska, AE (reprint author), Univ Wisconsin, Sch Med & Publ Hlth, Dept Family Med & Community Hlth, 1100 Delaplaine Court, Madison, WI 53715 USA. EM Aleksandra.Zgierska@fammed.wisc.edu FU National Institutes of Health (NIH) National Institute on Alcohol Abuse and Alcoholism [K23AA017508]; University of Wisconsin-Madison; NIH National Center for Advancing Translational Sciences [UL1TR000427] FX The study is registered on ClinicalTrials.gov (NCT01775995). Dr. Zgierska's work was supported by the K23AA017508 award from the National Institutes of Health (NIH) National Institute on Alcohol Abuse and Alcoholism and by funds from the University of Wisconsin-Madison. The project was also supported by the Clinical and Translational Science Award program through the NIH National Center for Advancing Translational Sciences, grant UL1TR000427. The content is solely the responsibility of the authors and does not necessarily represent the official views of the NIH. NR 51 TC 1 Z9 1 U1 6 U2 10 PU MARY ANN LIEBERT, INC PI NEW ROCHELLE PA 140 HUGUENOT STREET, 3RD FL, NEW ROCHELLE, NY 10801 USA SN 1075-5535 EI 1557-7708 J9 J ALTERN COMPLEM MED JI J. Altern. Complement Med. PD AUG PY 2016 VL 22 IS 8 BP 610 EP 620 DI 10.1089/acm.2015.0314 PG 11 WC Integrative & Complementary Medicine SC Integrative & Complementary Medicine GA DU6AA UT WOS:000382293700006 PM 27267151 ER PT J AU Scott, JC Woods, SP Wrocklage, KM Schweinsburg, BC Southwick, SM Krystal, JH AF Scott, J. Cobb Woods, Steven Paul Wrocklage, Kristen M. Schweinsburg, Brian C. Southwick, Steven M. Krystal, John H. TI Prospective Memory in Posttraumatic Stress Disorder SO JOURNAL OF THE INTERNATIONAL NEUROPSYCHOLOGICAL SOCIETY LA English DT Article DE Posttraumatic stress disorder; Neuropsychology; Cognitive abilities; Prospective memory; Memory; Anxiety ID INTENTIONS SCREENING-TEST; NEUROPSYCHOLOGICAL PERFORMANCE; NEUROCOGNITIVE DISORDERS; FUNCTIONAL OUTCOMES; COGNITIVE FUNCTION; LOCUS-COERULEUS; HIV-INFECTION; YOUNG-ADULTS; OLDER-ADULTS; PTSD AB Objectives: Neuropsychological studies of posttraumatic stress disorder (PTSD) have revealed deficits in attention/working memory, processing speed, executive functioning, and retrospective memory. However, little is known about prospective memory (PM) in PTSD, a clinically relevant aspect of episodic memory that supports the encoding and retrieval of intentions for future actions. Methods: Here we examined PM performance in 40 veterans with PTSD compared to 38 trauma comparison (TC) veterans who were exposed to combat but did not develop PTSD. All participants were administered the Memory for Intentions Test (MIST; Raskin, Buckheit, & Sherrod, 2010), a standardized and validated measure of PM, alongside a comprehensive neurocognitive battery, structured diagnostic interviews for psychiatric conditions, and behavioral questionnaires. Results: Veterans with PTSD performed moderately lower than TC on time-based PM, with errors primarily characterized as PM failure errors (i.e., omissions). However, groups did not differ in event-based PM, ongoing task performance, or post-test recognition of PM intentions for each trial. Lower time-based PM performance was specifically related to hyperarousal symptoms of PTSD. Time-based-performance was also associated with neuropsychological measures of retrospective memory and executive functions in the PTSD group. Nevertheless, PTSD was significantly associated with poorer PM above and beyond age and performance in retrospective memory and executive functions. Discussion: Results provide initial evidence of PM dysfunction in PTSD, especially in strategic monitoring during time-based PM tasks. Findings have potential implications for everyday functioning and health behaviors in persons with PTSD, and deserve replication and future study. C1 [Scott, J. Cobb] Philadelphia VA Med Ctr, Mental Illness Res Educ & Clin Ctr VISN4, Philadelphia, PA USA. [Scott, J. Cobb] Univ Penn, Perelman Sch Med, Dept Psychiat, Philadelphia, PA 19104 USA. [Woods, Steven Paul] Univ Houston, Dept Psychol, Houston, TX USA. [Wrocklage, Kristen M.; Schweinsburg, Brian C.; Southwick, Steven M.; Krystal, John H.] Natl Ctr PTSD, Clin Neurosci Div, VA Connecticut Healthcare Syst, West Haven, CT USA. [Wrocklage, Kristen M.; Schweinsburg, Brian C.; Southwick, Steven M.; Krystal, John H.] Yale Univ, Sch Med, Dept Psychiat, New Haven, CT USA. [Krystal, John H.] Yale Univ, Sch Med, Dept Neurobiol, New Haven, CT USA. [Krystal, John H.] Yale New Haven Med Ctr, Psychiat Serv, 20 York St, New Haven, CT 06504 USA. RP Scott, JC (reprint author), Philadelphia VA Med Ctr, MIRECC 116, 3900 Woodland Ave, Philadelphia, PA 19104 USA. EM scott1@upenn.edu FU Department of Veterans Affairs Career Development Award [IK2CX000772]; National Center for PTSD (NCPTSD); National Center for Advancing Translational Science [1UH2TR000960-01]; Department of Veterans Affairs (NCPTSD); National Institute on Alcohol Abuse and Alcoholism [P50AA12870, M01RR00125]; Yale Center for Clinical Investigation [UL1 RR024139]; Neuroimaging Core for the VA/DOD Consortium; [R01MH073419]; [R01DA034497] FX This study is dedicated to the memory of Henry Krystal, M.D., pioneer of the impact of massive psychic trauma, who died on October 8, 2015. This work was supported by a Department of Veterans Affairs Career Development Award (IK2CX000772) to Dr. Scott, as well as the National Center for PTSD (NCPTSD). Dr. Krystal's participation was supported by the National Center for Advancing Translational Science (1UH2TR000960-01), the Department of Veterans Affairs (NCPTSD), the Neuroimaging Core for the VA/DOD Consortium to Alleviate PTSD, the National Institute on Alcohol Abuse and Alcoholism (P50AA12870, M01RR00125), and the Yale Center for Clinical Investigation (UL1 RR024139). Dr. Woods is supported by R01MH073419 and R01DA034497. The views expressed in this article are those of the authors and do not necessarily reflect the position or policy of the Department of Veterans Affairs. The authors declare no conflicts of interest. NR 77 TC 0 Z9 0 U1 15 U2 15 PU CAMBRIDGE UNIV PRESS PI NEW YORK PA 32 AVENUE OF THE AMERICAS, NEW YORK, NY 10013-2473 USA SN 1355-6177 EI 1469-7661 J9 J INT NEUROPSYCH SOC JI J. Int. Neuropsychol. Soc. PD AUG PY 2016 VL 22 IS 7 BP 724 EP 734 DI 10.1017/S1355617716000564 PG 11 WC Clinical Neurology; Neurosciences; Psychiatry; Psychology SC Neurosciences & Neurology; Psychiatry; Psychology GA DU8SQ UT WOS:000382485100004 PM 27353125 ER PT J AU Anstead, GM AF Anstead, Gregory M. TI The centenary of the discovery of trench fever, an emerging infectious disease of World War 1 SO LANCET INFECTIOUS DISEASES LA English DT Review ID BARTONELLA-QUINTANA; RICKETTSIA QUINTANA; DISORDERED ACTION; RELAPSING FEVER; WAR; EPIDEMIC; ETIOLOGY; HENSELAE; ORIGIN; FORCES AB In 1915, a British medical officer on the Western Front reported on a soldier with relapsing fever, headache, dizziness, lumbago, and shin pain. Within months, additional cases were described, mostly in frontline troops, and the new disease was called trench fever. More than 1 million troops were infected with trench fever during World War 1, with each affected soldier unfit for duty for more than 60 days. Diagnosis was challenging, because there were no pathognomonic signs and symptoms and the causative organism could not be cultured. For 3 years, the transmission and cause of trench fever were hotly debated. In 1918, two commissions identified that the disease was louse-borne. The bacterium Rickettsia quintana was consistently found in the gut and faeces of lice that had fed on patients with trench fever and its causative role was accepted in the 1920s. The organism was cultured in the 1960s and reclassified as Bartonella quintana; it was also found to cause endocarditis, peliosis hepatis, and bacillary angiomatosis. Subsequently, B quintana infection has been identified in new populations in the Andes, in homeless people in urban areas, and in individuals with HIV. The story of trench fever shows how war can lead to the recrudescence of an infectious disease and how medicine approached an emerging infection a century ago. C1 [Anstead, Gregory M.] South Texas Vet Hlth Care Syst, Med Serv, San Antonio, TX USA. [Anstead, Gregory M.] Univ Texas Hlth Sci Ctr San Antonio, Div Infect Dis, Dept Med, San Antonio, TX 78229 USA. RP Anstead, GM (reprint author), Univ Texas Hlth Sci Ctr San Antonio, Div Infect Dis, Dept Med, San Antonio, TX 78229 USA. EM anstead@uthscsa.edu NR 81 TC 0 Z9 0 U1 1 U2 1 PU ELSEVIER SCI LTD PI OXFORD PA THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, OXON, ENGLAND SN 1473-3099 EI 1474-4457 J9 LANCET INFECT DIS JI Lancet Infect. Dis. PD AUG PY 2016 VL 16 IS 8 BP E164 EP E172 DI 10.1016/S1473-3099(16)30003-2 PG 9 WC Infectious Diseases SC Infectious Diseases GA DU4XH UT WOS:000382215700003 PM 27375211 ER PT J AU Zimmaro, LA Salmon, P Naidu, H Rowe, J Phillips, K Rebholz, WN Giese-Davis, J Cash, E Dreeben, SJ Bayley-Veloso, R Jablonski, ME Hicks, A Siwik, C Sephton, SE AF Zimmaro, Lauren A. Salmon, Paul Naidu, Hemali Rowe, Jonathan Phillips, Kala Rebholz, Whitney N. Giese-Davis, Janine Cash, Elizabeth Dreeben, Samuel J. Bayley-Veloso, Rene Jablonski, Megan E. Hicks, Allison Siwik, Chelsea Sephton, Sandra E. TI Association of Dispositional Mindfulness with Stress, Cortisol, and Well-Being Among University Undergraduate Students SO MINDFULNESS LA English DT Article DE Mindfulness; Stress; Cortisol; Well-being; Undergraduate ID RANDOMIZED CONTROLLED-TRIAL; QUALITY-OF-LIFE; COLLEGE-STUDENTS; FUNCTIONAL CONNECTIVITY; ADRENOCORTICAL ACTIVITY; PSYCHOLOGICAL STRESS; LONG-TERM; MEDITATION; REDUCTION; HEALTH AB Mindfulness has been associated with better psychological and physical health; although, the mechanisms of these benefits are poorly understood. We explored the role of mindfulness in stress-health pathways among undergraduates at a large public university. Participants reported on demographic and academic variables and completed data collection at two time points during the academic semester, approximately one month apart. At each collection, measures of mindfulness, perceived stress, and psychological well-being were gathered. Students provided two days of home-based saliva collection for assessment of cortisol. Mean scores were computed for each of the measures, over the two assessments. Hierarchical multiple regressions adjusting for GPA, hours of paid employment per week, minority status, and living situation explored the impact of mindfulness in our stress-health model. Students with higher dispositional mindfulness reported significantly less perceived stress and had lower overall mean diurnal cortisol. Mindfulness was associated with greater psychological well-being. Exploratory analyses suggested that future research should explore the potential mediating or moderating relationships between mindfulness, perceived stress, and cortisol. Findings suggest that mindfulness may help attenuate both psychological and physiological stress responses to college stress. C1 [Zimmaro, Lauren A.; Salmon, Paul; Naidu, Hemali; Rowe, Jonathan; Phillips, Kala; Rebholz, Whitney N.; Cash, Elizabeth; Bayley-Veloso, Rene; Jablonski, Megan E.; Hicks, Allison; Siwik, Chelsea; Sephton, Sandra E.] Univ Louisville, Dept Psychol & Brain Sci, Louisville, KY 40292 USA. [Giese-Davis, Janine] Univ Calgary, Dept Oncol, Div Psychosocial Oncol, Calgary, AB, Canada. [Cash, Elizabeth] Univ Louisville, Sch Med, Dept Otolaryngol Head & Neck Surg & Communicat Di, Louisville, KY 40292 USA. [Dreeben, Samuel J.] South Texas Vet Hlth Care Syst, Psychol Serv, San Antonio, TX USA. [Sephton, Sandra E.] Univ Louisville, James Graham Brown Canc Ctr, Louisville, KY 40292 USA. RP Sephton, SE (reprint author), Univ Louisville, Dept Psychol & Brain Sci, Louisville, KY 40292 USA.; Sephton, SE (reprint author), Univ Louisville, James Graham Brown Canc Ctr, Louisville, KY 40292 USA. EM psalmon@louisville.edu; sephton@louisville.edu FU Office of the Vice President for Research at the University of Louisville FX This study was funded through an undergraduate research grant from the Office of the Vice President for Research at the University of Louisville, awarded to Paul Salmon, Ph.D. NR 70 TC 0 Z9 0 U1 19 U2 30 PU SPRINGER PI DORDRECHT PA VAN GODEWIJCKSTRAAT 30, 3311 GZ DORDRECHT, NETHERLANDS SN 1868-8527 EI 1868-8535 J9 MINDFULNESS JI Mindfulness PD AUG PY 2016 VL 7 IS 4 BP 874 EP 885 DI 10.1007/s12671-016-0526-8 PG 12 WC Psychology, Clinical; Psychiatry SC Psychology; Psychiatry GA DV3XX UT WOS:000382860000009 ER PT J AU Felleman, BI Stewart, DG Simpson, TL Heppner, PS Kearney, DJ AF Felleman, Benjamin I. Stewart, David G. Simpson, Tracy L. Heppner, Pia S. Kearney, David J. TI Predictors of Depression and PTSD Treatment Response Among Veterans Participating in Mindfulness-Based Stress Reduction SO MINDFULNESS LA English DT Article DE Mindfulness; PTSD; Depression; Treatment ID COGNITIVE-BEHAVIORAL THERAPY; INTIMATE PARTNER VIOLENCE; POSTTRAUMATIC-STRESS; PROCESSING THERAPY; ANXIETY DISORDERS; MAJOR DEPRESSION; MODERATORS; PROGRAM; INTERVENTION; REPLICATION AB Posttraumatic stress disorder (PTSD) and depression are prevalent and often co-occur among veterans. There is growing interest in the effects of mindfulness-based interventions among veterans. This study examined PTSD and depression outcomes, and baseline predictors of response, among veterans who participated in mindfulness-based stress reduction (MBSR). Participants included 116 veterans with PTSD before and after MBSR. Multilevel modeling assessed baseline predictors of change in PTSD and depressive symptoms. There were clinically significant reductions in PTSD and depression symptoms posttreatment and at 4 months follow-up. For PTSD, effect sizes were in the medium range posttreatment (d = -.63) and at follow-up (d = -.69), and for depression posttreatment (d = -.58) and at follow-up (d = -.70). Baseline PTSD was a significant predictor of slope (beta = .03, p = .04) on PTSD outcomes; higher baseline PTSD predicted greater rate of reduction in symptoms. For depression (beta = .04, p < .01,), those with severe or moderately severe depression exhibited the greatest rate of improvement. However, veterans with high symptom severity did remain symptomatic post-MBSR. These findings show preliminary support for MBSR in facilitating symptom reduction for veterans with severe PTSD and co-occurring depression. C1 [Felleman, Benjamin I.; Stewart, David G.] Seattle Pacific Univ, Dept Psychol Family & Community, 3307 Third Ave W Ste 107, Seattle, WA 98119 USA. [Felleman, Benjamin I.; Heppner, Pia S.] VA San Diego Hlth Care Syst, 3350 La Jolla Village Dr,116B, San Diego, CA 92161 USA. [Simpson, Tracy L.] VA Puget Sound Hlth Care Syst, Ctr Excellence Subst Abuse Treatment & Educ CESAT, 1660 South Columbian Way, Seattle, WA USA. [Simpson, Tracy L.] Univ Washington, Sch Med, Dept Psychiat & Behav Sci, 1959 NE Pacific St, Seattle, WA 98195 USA. [Heppner, Pia S.] Univ Calif San Diego, Dept Psychiat, Gilman Dr,MC 0603, San Diego, CA USA. [Kearney, David J.] VA Puget Sound Hlth Care Syst, 1660 South Columbian Way, Seattle, WA USA. [Kearney, David J.] Univ Washington, Sch Med, Dept Med, 1959 NE Pacific St, Seattle, WA 98195 USA. RP Felleman, BI (reprint author), Seattle Pacific Univ, Dept Psychol Family & Community, 3307 Third Ave W Ste 107, Seattle, WA 98119 USA.; Felleman, BI (reprint author), VA San Diego Hlth Care Syst, 3350 La Jolla Village Dr,116B, San Diego, CA 92161 USA. EM benjamin.felleman@va.gov NR 54 TC 0 Z9 0 U1 7 U2 16 PU SPRINGER PI DORDRECHT PA VAN GODEWIJCKSTRAAT 30, 3311 GZ DORDRECHT, NETHERLANDS SN 1868-8527 EI 1868-8535 J9 MINDFULNESS JI Mindfulness PD AUG PY 2016 VL 7 IS 4 BP 886 EP 895 DI 10.1007/s12671-016-0527-7 PG 10 WC Psychology, Clinical; Psychiatry SC Psychology; Psychiatry GA DV3XX UT WOS:000382860000010 ER PT J AU Heilbronner, S Monk, IR Brozyna, JR Heinrichs, DE Skaar, EP Peschel, A Foster, TJ AF Heilbronner, Simon Monk, Ian R. Brozyna, Jeremy R. Heinrichs, David E. Skaar, Eric P. Peschel, Andreas Foster, Timothy J. TI Competing for Iron: Duplication and Amplification of the isd Locus in Staphylococcus lugdunensis HKU09-01 Provides a Competitive Advantage to Overcome Nutritional Limitation SO PLOS GENETICS LA English DT Article ID GENE AMPLIFICATION; HAEMOPHILUS-INFLUENZAE; GENOME SEQUENCE; B LOCUS; AUREUS; RESISTANCE; EVOLUTION; HEME; ACQUISITION; TRANSPOSON AB Staphylococcus lugdunensis is a coagulase negative bacterial pathogen that is particularly associated with severe cases of infectious endocarditis. Unique amongst the coagulase-negative staphylococci, S. lugdunensis harbors an iron regulated surface determinant locus (isd). This locus facilitates the acquisition of heme as a source of nutrient iron during infection and allows iron limitation caused by "nutritional immunity" to be overcome. The isd locus is duplicated in S. lugdunensis HKU09-01 and we show here that the duplication is intrinsically unstable and undergoes accordion-like amplification and segregation leading to extensive isd copy number variation. Amplification of the locus increased the level of expression of Isd proteins and improved binding of hemoglobin to the cell surface of S. lugdunensis. Furthermore, Isd overexpression provided an advantage when strains were competing for a limited amount of hemoglobin as the sole source of iron. Gene duplications and amplifications (GDA) are events of fundamental importance for bacterial evolution and are frequently associated with antibiotic resistance in many species. As such, GDAs are regarded as evolutionary adaptions to novel selective pressures in hostile environments pointing towards a special importance of isd for S. lugdunensis. For the first time we show an example of a GDA that involves a virulence factor of a Gram-positive pathogen and link the GDA directly to a competitive advantage when the bacteria were struggling with selective pressures mimicking "nutritional immunity". C1 [Heilbronner, Simon; Monk, Ian R.; Foster, Timothy J.] Trinity Coll Dublin, Dept Microbiol, Dublin, Ireland. [Heilbronner, Simon; Peschel, Andreas] Univ Tubingen, Interfac Inst Microbiol & Infect Med, Infect Biol, Tubingen, Germany. [Monk, Ian R.] Univ Melbourne, Doherty Inst Infect & Immun, Dept Microbiol & Immunol, Parkville, Vic, Australia. [Brozyna, Jeremy R.; Heinrichs, David E.] Univ Western Ontario, Dept Microbiol & Immunol, London, ON, Canada. [Skaar, Eric P.] Vanderbilt Univ, Sch Med, Dept Pathol Microbiol & Immunol, Nashville, TN 37212 USA. [Skaar, Eric P.] Tennessee Valley Healthcare Syst, US Dept Vet Affairs, Nashville, TN USA. RP Heilbronner, S (reprint author), Trinity Coll Dublin, Dept Microbiol, Dublin, Ireland.; Heilbronner, S (reprint author), Univ Tubingen, Interfac Inst Microbiol & Infect Med, Infect Biol, Tubingen, Germany. EM simon.heilbronner@uni-tuebingen.de OI Monk, Ian/0000-0001-6982-8074 FU Irish Research Council for Science, Engineering and Technology [RS2000192]; Science Foundation Ireland [08/IN.1/B1854]; German Academic exchange (DAAD) [50722682]; European Research Council [GA 655978]; German Research Council [SFB766]; NIH [R01 AI069233, R01 AI073843]; Department of Veterans Affairs [INFB-024-13F]; Canadian Institutes of Health Research [MOP-38002]; Deutsche Forschungsgemeinschaft; "Open Access Publishing Fund" of the University of Tubingen FX We acknowledge the support of the Irish Research Council for Science, Engineering and Technology for an Embark scholarship (RS2000192) to SH (http://www.research.ie/. We acknowledge the support of the Science Foundation Ireland for a Programme Investigator grant (08/IN.1/B1854) to TJF (http://www.sfi.ie/). We acknowledge the support of the German Academic exchange (DAAD) for a stipend for the "retrieval of German Scientist working abroad" (50722682) to SH (https://www.daad.de/en/). We acknowledge the support of the European Research Council for their support by providing a MSC-individual fellowship (GA 655978) to SH (https://erc.europa.eu/). Work in the laboratory of AP was supported by the SFB766 grant from the German Research Council (http://www.dfg.de/en/). Work in the laboratory of EPS is supported by NIH R01 AI069233 and R01 AI073843 (http://grants.nih.gov/grants/oer.htm) and Department of Veterans Affairs Merit Award INFB-024-13F (http://www.research.va.gov/default.cfm). Work in the laboratory of DEH is supported by Canadian Institutes of Health Research grant MOP-38002 (http://www.cihr-irsc.gc.ca/e/193.html). We acknowledge support by "Deutsche Forschungsgemeinschaft" and the "Open Access Publishing Fund" of the University of Tubingen. The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript. NR 48 TC 0 Z9 0 U1 3 U2 4 PU PUBLIC LIBRARY SCIENCE PI SAN FRANCISCO PA 1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA SN 1553-7404 J9 PLOS GENET JI PLoS Genet. PD AUG PY 2016 VL 12 IS 8 AR e1006246 DI 10.1371/journal.pgen.1006246 PG 25 WC Genetics & Heredity SC Genetics & Heredity GA DU7LA UT WOS:000382394500041 PM 27575058 ER PT J AU West, RK Ravona-Springer, R Heymann, A Schmeidler, J Leroith, D Koifman, K D'Arcy, RCN Song, XW Guerrero-Berroa, E Preiss, R Hoffman, H Sano, M Silverman, JM Schnaider-Beeri, M AF West, Rebecca K. Ravona-Springer, Ramit Heymann, Anthony Schmeidler, James Leroith, Derek Koifman, Keren D'Arcy, Ryan C. N. Song, Xiaowei Guerrero-Berroa, Elizabeth Preiss, Rachel Hoffman, Hadas Sano, Mary Silverman, Jeremy M. Schnaider-Beeri, Michal TI Waist circumference is correlated with poorer cognition in elderly type 2 diabetes women SO ALZHEIMERS & DEMENTIA LA English DT Article DE Cognitive performance; Waist circumference; Type 2 diabetes mellitus; Risk factors; Dementia ID RISK-FACTORS; CARDIOVASCULAR RISK; DEMENTIA; IMPAIRMENT; OLDER; ASSOCIATION; ADIPOSITY; OBESITY; DECLINE AB Introduction: Waist circumference is associated with type 2 diabetes (T2D) and cognition, yet the relationship between waist circumference and cognition in individuals with T2D is not well understood. Methods: We studied the relationship of waist circumference with five cognitive outcomes (executive functioning, language/semantic categorization, attention/working memory, episodic memory, and an overall cognition measure) in 845 cognitively normal elderly with type 2 diabetes (T2D). esults: In women, waist circumference was correlated with significantly lower language and/or semantic categorization performance (P < .0001), executive functioning (P = .026), and overall cognition (P = .003) after controlling for age, education, BMI, and cardiovascular, diabetes related, APOE 64, and inflammatory potential confounders. Attention/working memory (P = .532) and episodic memory (P = .144) were not associated with waist circumference. These correlations were not found in men. Discussion: These results suggest that central adiposity in elderly women with T2D may increase their risk for dementia. (C) 2016 Published by Elsevier Inc. on behalf of The Alzheimer's Association. C1 [West, Rebecca K.; Schmeidler, James; Guerrero-Berroa, Elizabeth; Sano, Mary; Silverman, Jeremy M.; Schnaider-Beeri, Michal] Icahn Sch Med Mt Sinai, Dept Psychiat, New York, NY 10029 USA. [Ravona-Springer, Ramit; Koifman, Keren; Preiss, Rachel; Hoffman, Hadas; Schnaider-Beeri, Michal] Sheba Med Ctr, Joseph Sagol Neurosci Ctr, Ramat Gan, Israel. [Heymann, Anthony] Maccabi Healthcare Serv, Tel Aviv, Israel. [Heymann, Anthony] Tel Aviv Univ, Sackler Sch Med, Dept Family Med, Tel Aviv, Israel. [Leroith, Derek] Icahn Sch Med Mt Sinai, Dept Med, New York, NY 10029 USA. [D'Arcy, Ryan C. N.; Song, Xiaowei] Simon Fraser Univ, Metro Vancouver, BC, Canada. [D'Arcy, Ryan C. N.; Song, Xiaowei] Fraser Hlth, Surrey Mem Hosp, Metro Vancouver, BC, Canada. [Guerrero-Berroa, Elizabeth; Sano, Mary; Silverman, Jeremy M.] James J Peters Vet Affairs Med Ctr, Bronx, NY USA. RP West, RK (reprint author), Icahn Sch Med Mt Sinai, Dept Psychiat, New York, NY 10029 USA. EM rebecca.west@mssm.edu FU MA grants [R01 AG034087, P50 AG05138]; Helen Bader Foundation; Alzheimer's Association [MNIRGD-14-321113]; Irma T. Hirschl Scholar award FX This study was supported by MA grants R01 AG034087 to Dr. Beeri and P50 AG05138 to Dr. Sano, the Helen Bader Foundation, and the Alzheimer's Association grant MNIRGD-14-321113 to Dr. Guerrero-Berroa, and the Irma T. Hirschl Scholar award to Dr. Beeri. NR 20 TC 0 Z9 0 U1 2 U2 2 PU ELSEVIER SCIENCE INC PI NEW YORK PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA SN 1552-5260 EI 1552-5279 J9 ALZHEIMERS DEMENT JI Alzheimers. Dement. PD AUG PY 2016 VL 12 IS 8 BP 925 EP 929 DI 10.1016/j.jalz.2016.03.017 PG 5 WC Clinical Neurology SC Neurosciences & Neurology GA DT1ND UT WOS:000381248500009 PM 27149905 ER PT J AU McIlvennan, CK Swetz, KM AF McIlvennan, Colleen K. Swetz, Keith M. TI Lack of Agreement With What We Think Is Right Does Not Necessarily Equal an Ethical Problem: Respecting Patients' Goals of Care SO AMERICAN JOURNAL OF BIOETHICS LA English DT Editorial Material ID LIFE; END; PERSPECTIVES; DEVICE C1 [McIlvennan, Colleen K.] Univ Colorado, Sch Med, Boulder, CO 80309 USA. [Swetz, Keith M.] Univ Alabama, Sch Med, Tuscaloosa, AL 35487 USA. [Swetz, Keith M.] Birmingham Vet Affairs Med Ctr, Birmingham, AL USA. RP Swetz, KM (reprint author), UAB Ctr Palliat & Support Care, 1720 2nd Ave South BDB 650, Birmingham, AL 35294 USA. EM kswetz@uabmc.edu NR 10 TC 1 Z9 1 U1 1 U2 1 PU ROUTLEDGE JOURNALS, TAYLOR & FRANCIS LTD PI ABINGDON PA 2-4 PARK SQUARE, MILTON PARK, ABINGDON OX14 4RN, OXON, ENGLAND SN 1526-5161 EI 1536-0075 J9 AM J BIOETHICS JI Am. J. Bioeth. PD AUG PY 2016 VL 16 IS 8 BP 13 EP 15 DI 10.1080/15265161.2016.1187220 PG 3 WC Ethics; Medical Ethics; Social Issues; Social Sciences, Biomedical SC Social Sciences - Other Topics; Medical Ethics; Social Issues; Biomedical Social Sciences GA DS6OI UT WOS:000380901100006 PM 27366837 ER PT J AU Blosnich, JR Brenner, LA Bossarte, RM AF Blosnich, John R. Brenner, Lisa A. Bossarte, Robert M. TI Population mental health among US military veterans: results of the Veterans Health Module of the Behavioral Risk Factor Surveillance System, 2011-2012 SO ANNALS OF EPIDEMIOLOGY LA English DT Article DE Veterans health; Suicidal ideation; Attempted suicide; Mental health services ID SUICIDE MORTALITY; UNITED-STATES; IDEATION; SERVICE; HISTORY AB Purpose: To examine mental health indicators, in aggregate and stratified by sex, among a population based sample of U.S. military veterans. Methods: Data are from veteran who completed the Veterans Health Module (VHM) of the 2011 and 2012 Behavioral Risk Factor Surveillance System (n = 10,406). VHM items included lifetime diagnoses of mental illnesses, service in a combat zone, sources of mental health care, and past 12-month suicidal ideation and attempt. We used weighted, multiple logistic regression models, adjusted for sociodemographics, to examine differences in suicidal ideation and attempt among men and women. Results: Overall, 5.0% of the sample reported recent suicidal ideation and 1.0% reported attempting suicide. Among men, unemployment was positively associated with suicidal ideation, and combat exposure was negatively associated with suicidal ideation. Being separated, divorced, or widowed was positively associated with suicidal ideation among women. After adjusting for sociodemographic and VHM variables, veterans who sought mental health treatment from both Veterans Affairs (VA) and non-VA facilities had more than fourfold increased odds of suicidal ideation than veteran who sought mental health treatment from only VA facilities (adjusted odds ratio = 4.02; 95% confidence interval 1.23-13.13). Conclusions: Correlates of suicidal ideation differ between male and female veterans. Veterans who use both non-VA and VA facilities for mental health services may have greater risk of self-directed violence. Published by Elsevier Inc. C1 [Blosnich, John R.] VA Pittsburgh Healthcare Syst, Ctr Hlth Equ Res & Promot, Pittsburgh, PA USA. [Brenner, Lisa A.] Rocky Mt Mental Illness Res Educ & Clin Ctr, Denver, CO USA. [Brenner, Lisa A.] Univ Colorado, Anschutz Sch Med, Dept Psychiat, Aurora, CO USA. [Brenner, Lisa A.] Univ Colorado, Anschutz Sch Med, Dept Neurol, Aurora, CO USA. [Brenner, Lisa A.] Univ Colorado, Anschutz Sch Med, Dept Phys Med & Rehabil, Aurora, CO USA. [Bossarte, Robert M.] US Dept Vet Affairs, Post Deployment Hlth Serv, Washington, DC USA. [Bossarte, Robert M.] Univ Rochester, Dept Psychiat, Rochester, NY USA. RP Blosnich, JR (reprint author), VA Pittsburgh Healthcare Syst, US Dept Vet Affairs, Ctr Hlth Equ Res & Promot, Univ Dr C 151C U,Bldg 30, Pittsburgh, PA 15240 USA. EM john.blosnich@va.gov FU VA Health Service Research Development [CDA 14-408] FX This work was supported by a career development award to [name masked for review] from VA Health Service Research & Development (CDA 14-408). The opinions expressed in this work are those of the authors and do not necessarily represent those of the funders, institutions, the Department of Veterans Affairs, or the U.S. Government. NR 24 TC 0 Z9 0 U1 6 U2 6 PU ELSEVIER SCIENCE INC PI NEW YORK PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA SN 1047-2797 EI 1873-2585 J9 ANN EPIDEMIOL JI Ann. Epidemiol. PD AUG PY 2016 VL 26 IS 8 BP 592 EP 596 DI 10.1016/j.annepidem.2016.06.009 PG 5 WC Public, Environmental & Occupational Health SC Public, Environmental & Occupational Health GA DU3HU UT WOS:000382102200010 PM 27448820 ER PT J AU Kesinger, MR Juengst, SB Bertisch, H Niemeier, JP Krellman, JW Pugh, M Kumar, RG Sperry, JL Arenth, PM Fann, JR Wagner, AK AF Kesinger, Matthew R. Juengst, Shannon B. Bertisch, Hillary Niemeier, Janet P. Krellman, Jason W. Pugh, MaryJo Kumar, Raj G. Sperry, Jason L. Arenth, Patricia M. Fann, Jesse R. Wagner, Amy K. TI Acute Trauma Factor Associations With Suicidality Across the First 5 Years After Traumatic Brain Injury SO ARCHIVES OF PHYSICAL MEDICINE AND REHABILITATION LA English DT Article DE Brain injuries; Injury Severity Score; Multiple trauma; Rehabilitation; Suicidal ideation; Suicide; attempted ID DEPLOYED MILITARY PERSONNEL; SUBSTANCE-ABUSE; RISK-FACTORS; CHRONIC PAIN; FOLLOW-UP; DEPRESSION; IDEATION; REHABILITATION; POPULATION; PREVALENCE AB Objective: To determine whether severity of head and extracranial injuries (ECI) is associated with suicidal ideation (SI) or suicide attempt (SA) after traumatic brain injury (TBI). Design: Factors associated with SI and SA were assessed in this inception cohort study using data collected 1, 2, and 5 years post-TBI from the National Trauma Data Bank and Traumatic Brain Injury Model Systems (TRIMS) databases. Setting: Level I trauma centers, inpatient rehabilitation centers, and the community. Participants: Participants with TBI from 15 TBIMS Centers with linked National Trauma Data Bank trauma data (N=3575). Interventions: Not applicable. Main Outcome Measures: SI was measured via the Patient Health Questionnaire 9 (question 9). SA in the last year was assessed via interview. ECI was measured by the Injury Severity Scale (nonhead) and categorized as none, mild, moderate, or severe. Results: There were 293 (8.2%) participants who had SI without SA and 109 (3.0%) who had SA at least once in the first 5 years postinjury. Random effects logit modeling showed a higher likelihood of SI when ECI was severe (odds ratio = 2.73; 95% confidence interval, 1.55-4.82; P=.001). Drug use at time of injury was also associated with SI (odds ratio =1.69; 95% confidence interval, 1.11-2.86; P=.015). Severity of ECI was not associated with SA. Conclusions: Severe ECI carried a nearly 3-fold increase in the odds of SI after TBI, but it was not related to SA. Head injury severity and less severe ECI were not associated with SI or SA. These findings warrant additional work to identify factors associated with severe ECI that make individuals more susceptible to SI after TBI. (C) 2016 by the American Congress of Rehabilitation Medicine C1 [Kesinger, Matthew R.] Univ Pittsburgh, Sch Med, Pittsburgh, PA USA. [Juengst, Shannon B.; Kumar, Raj G.; Arenth, Patricia M.; Wagner, Amy K.] Univ Pittsburgh, Sch Med, Dept Phys Med & Rehabil, 3471 Fifth Ave, Pittsburgh, PA 15213 USA. [Bertisch, Hillary] NYU, Dept Rehabil Med, Sch Med, New York, NY USA. [Niemeier, Janet P.] Carolinas Med Ctr, Dept Phys Med & Rehabil, Charlotte, NC 28203 USA. [Niemeier, Janet P.] Univ N Carolina, Chapel Hill, NC USA. [Krellman, Jason W.] Icahn Sch Med Mt Sinai, Dept Rehabil Med, New York, NY 10029 USA. [Pugh, MaryJo] South Texas Vet Hlth Care Syst, San Antonio, TX USA. [Pugh, MaryJo] Univ Texas Hlth Sci Ctr San Antonio, San Antonio, TX 78229 USA. [Sperry, Jason L.] Univ Pittsburgh, Sch Med, Dept Surg, Pittsburgh, PA USA. [Fann, Jesse R.] Univ Washington, Dept Psychiat & Behav Sci, Seattle, WA 98195 USA. [Wagner, Amy K.] Univ Pittsburgh, Dept Neurosci, Pittsburgh, PA USA. [Wagner, Amy K.] Univ Pittsburgh, Ctr Neurosci, Pittsburgh, PA 15260 USA. [Wagner, Amy K.] Univ Pittsburgh, Safar Ctr Resuscitat Res, Pittsburgh, PA USA. RP Juengst, SB (reprint author), Univ Pittsburgh, Sch Med, Dept Phys Med & Rehabil, 3471 Fifth Ave, Pittsburgh, PA 15213 USA. EM sbj7@pitt.edu FU National Institute on Disability, Independent Living, and Rehabilitation Research (NIDILRR) [90DP0041]; NIDILRR [90DP0038, 90DP0047]; National Institutes of Health [NIH K23GM093032]; National Institute of Mental Health Medical Student Research Fellowship [TL1TR000005, R25 MH054318]; Rusk Advanced Rehabilitation Research Training Postdoctoral Fellowship [NIDILRR 90AR5014-01-00]; Polytrauma Rehabilitation Center Traumatic Brain Injury Model System; Department of Veterans Affairs (VA) FX Support for the collection of the original data was by the National Institute on Disability, Independent Living, and Rehabilitation Research (NIDILRR) (grant no. 90DP0041); and the National Trauma Data Bank. Support for the content of this article was by the NIDILRR (grant nos. 90DP0038 and 90DP0047); the National Institutes of Health (grant no. NIH K23GM093032); the National Institute of Mental Health Medical Student Research Fellowship (fellowship no. TL1TR000005) administered by the University of Pittsburgh (grant no. R25 MH054318); a Rusk Advanced Rehabilitation Research Training Postdoctoral Fellowship (grant no. NIDILRR 90AR5014-01-00); and the Polytrauma Rehabilitation Center Traumatic Brain Injury Model System.; The Polytrauma Rehabilitation Center Traumatic Brain Injury Model System is a funded collaboration between the Department of Veterans Affairs (VA) and the National Institute on Disability, Independent Living, and Rehabilitation Research (NIDILRR). The NIDILRR is a center within the Administration for Community Living (ACL), Department of Health and Human Services (HHS). The contents of this article do not necessarily represent the policy of the VA, NIDILRR, ACL, NIH, or HHS, and endorsement of this content by the Federal Government should not be assumed. NR 52 TC 1 Z9 1 U1 2 U2 2 PU W B SAUNDERS CO-ELSEVIER INC PI PHILADELPHIA PA 1600 JOHN F KENNEDY BOULEVARD, STE 1800, PHILADELPHIA, PA 19103-2899 USA SN 0003-9993 EI 1532-821X J9 ARCH PHYS MED REHAB JI Arch. Phys. Med. Rehabil. PD AUG PY 2016 VL 97 IS 8 BP 1301 EP 1308 DI 10.1016/j.apmr.2016.02.017 PG 8 WC Rehabilitation; Sport Sciences SC Rehabilitation; Sport Sciences GA DT1LM UT WOS:000381244200012 PM 26987622 ER PT J AU Payne, GA Hage, FG Acharya, D AF Payne, Gregory A. Hage, Fadi G. Acharya, Deepak TI Transplant allograft vasculopathy: Role of multimodality imaging in surveillance and diagnosis SO JOURNAL OF NUCLEAR CARDIOLOGY LA English DT Article DE Cardiac allograft vasculopathy; myocardial perfusion imaging; coronary flow reserve; multimodality imaging ID DOBUTAMINE STRESS ECHOCARDIOGRAPHY; CORONARY-ARTERY-DISEASE; MYOCARDIAL-PERFUSION RESERVE; CARDIAC MAGNETIC-RESONANCE; COMPUTED-TOMOGRAPHY ANGIOGRAPHY; POSITRON-EMISSION-TOMOGRAPHY; HEART-TRANSPLANT; INTRAVASCULAR ULTRASOUND; LONG-TERM; ENDOTHELIAL DYSFUNCTION AB Cardiac allograft vasculopathy (CAV) is a challenging long-term complication of cardiac transplantation and remains a leading long-term cause of graft failure, re-transplantation, and death. CAV is an inflammatory vasculopathy distinct from traditional atherosclerotic coronary artery disease. Historically, the surveillance and diagnosis of CAV has been dependent on serial invasive coronary angiography with intravascular imaging. Although commonly practiced, angiography is not without significant limitations. Technological advances have provided sophisticated imaging techniques for CAV assessment. It is now possible to assess the vascular lumen, vessel wall characteristics, absolute blood flow, perfusion reserve, myocardial contractile function, and myocardial metabolism and injury in a noninvasive, expeditious manner with little risk. The current article will review key imaging modalities for the surveillance, diagnosis, and prognosis of CAV and discuss coronary physiology of transplanted hearts with emphasis on the clinical implications for provocative and vasodilator stress testing. C1 [Payne, Gregory A.; Hage, Fadi G.; Acharya, Deepak] Univ Alabama Birmingham, Sch Med, Div Cardiovasc Med, Tinsley Harrison Tower,Room 321, Birmingham, AL 35294 USA. [Hage, Fadi G.] Birmingham Vet Affairs Med Ctr, Cardiol Sect, Birmingham, AL USA. RP Acharya, D (reprint author), Univ Alabama Birmingham, Sch Med, Div Cardiovasc Med, Tinsley Harrison Tower,Room 321, Birmingham, AL 35294 USA. EM dacharya@uab.edu OI Hage, Fadi/0000-0002-1397-4942 NR 83 TC 1 Z9 1 U1 0 U2 0 PU SPRINGER PI NEW YORK PA 233 SPRING ST, NEW YORK, NY 10013 USA SN 1071-3581 EI 1532-6551 J9 J NUCL CARDIOL JI J. Nucl. Cardiol. PD AUG PY 2016 VL 23 IS 4 BP 713 EP 727 DI 10.1007/s12350-015-0373-3 PG 15 WC Cardiac & Cardiovascular Systems; Radiology, Nuclear Medicine & Medical Imaging SC Cardiovascular System & Cardiology; Radiology, Nuclear Medicine & Medical Imaging GA DS9DF UT WOS:000381082100013 PM 26711101 ER PT J AU Farag, AA Hage, FG AF Farag, Ayman A. Hage, Fadi G. TI Medical therapy for the treatment of myocardial ischemia SO JOURNAL OF NUCLEAR CARDIOLOGY LA English DT Editorial Material C1 [Farag, Ayman A.; Hage, Fadi G.] Univ Alabama Birmingham, Dept Med, Div Cardiovasc Dis, THT 311,1900 Univ BLVD, Birmingham, AL 35294 USA. [Hage, Fadi G.] Birmingham Vet Affairs Med Ctr, Cardiol Sect, Birmingham, AL USA. RP Hage, FG (reprint author), Univ Alabama Birmingham, Dept Med, Div Cardiovasc Dis, THT 311,1900 Univ BLVD, Birmingham, AL 35294 USA. EM fadihage@uab.edu OI Hage, Fadi/0000-0002-1397-4942 NR 5 TC 0 Z9 0 U1 1 U2 2 PU SPRINGER PI NEW YORK PA 233 SPRING ST, NEW YORK, NY 10013 USA SN 1071-3581 EI 1532-6551 J9 J NUCL CARDIOL JI J. Nucl. Cardiol. PD AUG PY 2016 VL 23 IS 4 BP 837 EP 839 DI 10.1007/s12350-015-0118-3 PG 3 WC Cardiac & Cardiovascular Systems; Radiology, Nuclear Medicine & Medical Imaging SC Cardiovascular System & Cardiology; Radiology, Nuclear Medicine & Medical Imaging GA DS9DF UT WOS:000381082100031 PM 25824020 ER PT J AU George, MD McGill, NK Baker, JF AF George, Michael D. McGill, Neilia-Kay Baker, Joshua F. TI Creatine kinase in the US population Impact of demographics, comorbidities, and body composition on the normal range SO MEDICINE LA English DT Article DE body composition; body mass index; CDC; Centers for Disease Control and Prevention; CK; creatine kinase; creatine phosphokinase; National Health and Nutrition Examination Survey; NHANES; race ID GENERAL-POPULATION; RACIAL-DIFFERENCES; GENDER; AGE AB Background: Creatine kinase (CK) values are a critical part of the workup of suspected myopathies and are often assessed in patients that develop myalgia on statin therapy. CK elevations may influence the initiation and cessation of statin treatment, and incidentally discovered CK elevation may lead to further testing. A number of factors influence CK levels in healthy patients, but current reference ranges do not incorporate important influencers of CK such as race. Objectives of this study were to evaluate clinical factors associated with CK among healthy individuals and to develop practical reference ranges for important subgroups to improve test interpretation. Methods: CK was evaluated in nonpregnant participants >= 20 years old from the cross-sectional National Health and Nutrition Examination Survey (NHANES) 2011-2014. Linear and logistic regression stratified by sex identified clinical factors associated with CK levels. Adjustment for anthropomorphic measures assessed whether age and race-ethnicity differences in CK were explained by differences in body composition. The 95th and 97.5th percentiles of CK in sex/race-ethnicity subgroups were calculated, excluding patients with recent strenuous exercise. Results: A total of 10,096 nonpregnant adults were studied. Black race was strongly associated with CK. The odds ratio of having an abnormal CK for black women was 5.08 (95% CI 3.65-7.08) and for black men was 8.39 (95% CI 6.11-11.52). CK was substantially lower in older men. Differences in CK by age but not race-ethnicity were largely explained by body composition. Women with low body mass index were less likely to have an elevated CK, and overweight or obese men had an almost 2-fold greater odds of having an elevated CK. The 97.5th percentile of CK was 382 (95% CI 295-469) in white men, 1001 (95% CI 718-1284) in black men, 295 (95% CI 216-374) in white women, and 487 (95% CI 310-664) in black women. Conclusion: CK is substantially higher in men and in black patients. Differences in body size and composition are also important but do not explain racial differences in CK. The 95th and 97.5th percentiles in sex and race-ethnicity subgroups provide a practical guide for clinicians interpreting CK values. C1 [George, Michael D.; McGill, Neilia-Kay; Baker, Joshua F.] Univ Penn, Div Rheumatol, Philadelphia, PA 19104 USA. [Baker, Joshua F.] Philadelphia VA Med Ctr, Philadelphia, PA USA. [Baker, Joshua F.] Univ Penn, Ctr Clin Epidemiol & Biostat, Philadelphia, PA 19104 USA. RP George, MD (reprint author), Univ Penn, Div Rheumatol, Philadelphia, PA 19104 USA. EM michael.george@uphs.upenn.edu FU NIH [5T32AR007442-28]; Veterans Affairs Clinical Science Research & Development Career Development Award [IK2 CX000955] FX Dr. George is funded by an NIH T32 training grant (5T32AR007442-28). Dr. Baker is funded by a Veterans Affairs Clinical Science Research & Development Career Development Award (IK2 CX000955). The contents of this work do not represent the views of the Department of the Veterans Affairs or the United States Government. NR 18 TC 1 Z9 1 U1 0 U2 0 PU LIPPINCOTT WILLIAMS & WILKINS PI PHILADELPHIA PA TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA SN 0025-7974 EI 1536-5964 J9 MEDICINE JI Medicine (Baltimore) PD AUG PY 2016 VL 95 IS 33 AR e4344 DI 10.1097/MD.0000000000004344 PG 7 WC Medicine, General & Internal SC General & Internal Medicine GA DU5KR UT WOS:000382251100012 PM 27537560 ER PT J AU Vina, ER Ran, D Ashbeck, EL Ibrahim, SA Hannon, MJ Zhou, JJ Kwoh, CK AF Vina, Ernest R. Ran, Di Ashbeck, Erin L. Ibrahim, Said A. Hannon, Michael J. Zhou, Jin J. Kwoh, C. Kent TI Patient preferences for total knee replacement surgery: Relationship to clinical outcomes and stability of patient preferences over 2 years SO SEMINARS IN ARTHRITIS AND RHEUMATISM LA English DT Review DE Osteoarthritis; Knee replacement surgery; Treatment preference; Orthopedic consultation ID TOTAL JOINT ARTHROPLASTY; SOCIAL SUPPORT; OSTEOARTHRITIS; HIP; RECOMMENDATIONS; HEALTH; RACE; WILLINGNESS; MANAGEMENT; ARTHRITIS AB Objective: Evaluate the relationship between patient preferences for total knee replacement (TKR) with receipt of TKR, and assess participant characteristics that may influence change in willingness to undergo TKR. Methods: Structured interviews of knee osteoarthritis (OA) patients were conducted. Logistic regression models were conducted to assess the association between baseline willingness and eventual receipt of TKR, adjusted for sociodemographic and clinical variables. Mixed models for repeated measures were used to estimate the effects of sex, race, social support, Delta WOMAC, and orthopedic consult on change in willingness. Results: A total of 589 participants were willing, and 215 participants were unwilling to undergo TKR. Willing participants, compared to others, were more often White (69.4% vs. 48.4%), with more than a high school education (60.8% vs. 47.0%) and employed (39.1% vs. 26.5%). At follow-up, the odds of having TKR were twice as high among those who were willing to have the procedure at baseline, but this was no longer significant when adjusted for demographic variables (adjusted OR = 1.82, 95% CI: 0.89-3.69). Willingness to undergo TKR declined over 2 years. Among those who were willing to undergo TKR at baseline but did not obtain one, only 66.5% were still willing at the 2-year follow-up. This decline was less among those who had a greater increase (> median) in WOMAC disability (adjusted Delta = -0.34, 95% CI: -0.47 to -0.20) than those who had minimal change in their WOMAC disability (p = 0.08). The decline in willingness was also less among those who had seen an orthopedic surgeon (adjusted Delta = -0.32, 95% CI: -0.46 to -0.17) than those who did not (p = 0.05). Conclusions: Preference for TKR was consistent with TKR surgery utilization, but not after controlling for patient demographic characteristics. Willingness to undergo TKR declined over time, but this decrease was mitigated by worsening OA-related disability and by consultation with an orthopedic surgeon. (C) 2016 Elsevier Inc. All rights reserved. C1 [Vina, Ernest R.; Ran, Di; Ashbeck, Erin L.; Kwoh, C. Kent] Univ Arizona, Arthrit Ctr, Div Rheumatol, Dept Med, 1501 N Campbell Ave,POB 245093, Tucson, AZ 85724 USA. [Ibrahim, Said A.] Univ Penn, Dept Med, Ctr Hlth Equ Res & Promot, Philadelphia VA Med Ctr, Philadelphia, PA 19104 USA. [Hannon, Michael J.] Univ Pittsburgh, Dept Med, Div Rheumatol & Clin Immunol, Philadelphia, PA USA. [Ran, Di; Zhou, Jin J.] Univ Arizona, Mel & Enid Zuckerman Coll Publ Hlth, Epidemiol & Biostat Dept, Tucson, AZ USA. RP Vina, ER (reprint author), Univ Arizona, Arthrit Ctr, Div Rheumatol, Dept Med, 1501 N Campbell Ave,POB 245093, Tucson, AZ 85724 USA. EM evina@email.arizona.edu OI Vina, Ernest/0000-0001-8135-1731 FU NIAMS NIH HHS [P60 AR054731] NR 34 TC 0 Z9 0 U1 2 U2 2 PU W B SAUNDERS CO-ELSEVIER INC PI PHILADELPHIA PA 1600 JOHN F KENNEDY BOULEVARD, STE 1800, PHILADELPHIA, PA 19103-2899 USA SN 0049-0172 EI 1532-866X J9 SEMIN ARTHRITIS RHEU JI Semin. Arthritis Rheum. PD AUG PY 2016 VL 46 IS 1 BP 27 EP 33 DI 10.1016/j.semarthrit.2016.03.012 PG 7 WC Rheumatology SC Rheumatology GA DT4JY UT WOS:000381447200003 PM 27132535 ER PT J AU McFarland, LV Huang, Y Wang, L Malfertheiner, P AF McFarland, Lynne V. Huang, Ying Wang, Lin Malfertheiner, Peter TI Systematic review and meta-analysis: Multi-strain probiotics as adjunct therapy for Helicobacter pylori eradication and prevention of adverse events SO UNITED EUROPEAN GASTROENTEROLOGY JOURNAL LA English DT Review DE Probiotics; Helicobacter pylori; meta-analysis; adverse events; diarrhea ID RANDOMIZED-CONTROLLED-TRIALS; BIFIDOBACTERIUM-CONTAINING YOGURT; STANDARD TRIPLE THERAPY; QUADRUPLE THERAPY; PLUS LACTOFERRIN; SEQUENTIAL THERAPY; PUBLICATION BIAS; RESCUE THERAPY; LACTOBACILLUS; INFECTION AB Background Eradication rates with triple therapy for Helicobacter pylori infections have currently declined to unacceptable levels worldwide. Newer quadruple therapies are burdened with a high rate of adverse events. Whether multi-strain probiotics can improve eradication rates or diminish adverse events remains uncertain. Methods Relevant publications in which patients with H. pylori infections were randomized to a multi-strain probiotic or control were identified in PubMed, Cochrane Databases, and other sources from 1 January 1960-3 June 2015. Primary outcomes included eradication rates, incidence of any adverse event and the incidence of antibiotic-associated diarrhea. As probiotic efficacy is strain-specific, pooled relative risks and 95% confidence intervals were calculated using meta-analysis stratified by similar multi-strain probiotic mixtures. Results A total of 19 randomized controlled trials (20 treatment arms, n=2730) assessing one of six mixtures of strains of probiotics were included. Four multi-strain probiotics significantly improved H. pylori eradication rates, five significantly prevented any adverse reactions and three significantly reduced antibiotic-associated diarrhea. Only two probiotic mixtures (Lactobacillus acidophilus/Bifidobacterium animalis and an eight-strain mixture) had significant efficacy for all three outcomes. Conclusions Our meta-analysis found adjunctive use of some multi-strain probiotics may improve H. pylori eradication rates and prevent the development of adverse events and antibiotic-associated diarrhea, but not all mixtures were effective. C1 [McFarland, Lynne V.] Univ Washington, Dept Med Chem, Seattle, WA 98195 USA. [Huang, Ying; Wang, Lin] Fudan Univ, Childrens Hosp, Div Gastroenterol, Shanghai, Peoples R China. [Malfertheiner, Peter] Univ Klinikum Magdeburg AOR, Magdeburg, Germany. RP McFarland, LV (reprint author), VA Puget Sound Healthcare Syst, 1660 South Columbian Way,S-152, Seattle, WA 98108 USA. EM lvmcfarl@u.washington.edu NR 71 TC 0 Z9 0 U1 6 U2 12 PU SAGE PUBLICATIONS INC PI THOUSAND OAKS PA 2455 TELLER RD, THOUSAND OAKS, CA 91320 USA SN 2050-6406 EI 2050-6414 J9 UNITED EUR GASTROENT JI United European Gastroenterol. J. PD AUG PY 2016 VL 4 IS 4 BP 546 EP 561 DI 10.1177/2050640615617358 PG 16 WC Gastroenterology & Hepatology SC Gastroenterology & Hepatology GA DS7EQ UT WOS:000380946200009 PM 27536365 ER PT J AU Tian, HJ Du, JJ Wen, J Liu, Y Montgomery, SR Scott, TP Aghdsi, B Xiong, CJ Suzuki, A Hayashi, T Ruangchainikom, M Phan, K Weintraub, G Raed, A Murray, SS Daubs, MD Yang, XJ Yuan, XB Wang, JC Lu, YF AF Tian, Haijun Du, Juanjuan Wen, Jing Liu, Yang Montgomery, Scott R. Scott, Trevor P. Aghdsi, Bayan Xiong, Chengjie Suzuki, Akinobu Hayashi, Tetsuo Ruangchainikom, Monchai Phan, Kevin Weintraub, Gil Raed, Alobaidaan Murray, Samuel S. Daubs, Michael D. Yang, Xianjin Yuan, Xu-bo Wang, Jeffrey C. Lu, Yunfeng TI Growth-Factor Nanocapsules That Enable Tunable Controlled Release for Bone Regeneration SO ACS NANO LA English DT Article DE protein nanocapsule; degradable polymer; controlled release; bone regeneration; inflammation ID CONTROLLED DRUG-DELIVERY; ANTERIOR CERVICAL-SPINE; MORPHOGENETIC PROTEIN; IN-VIVO; RODENT MODEL; HYDROGELS; MATRICES; THERAPY; FUSION; INFLAMMATION AB Growth factors are of great potential in regenerative medicine. However, their clinical applications are largely limited by the short in vivo half-lives and the narrow therapeutic window. Thus, a robust controlled release system remains an unmet medical need for growth factor-based therapies. In this research, a nanoscale controlled release system (degradable protein nanocapsule) is established via in situ polymerization on growth factor. The release rate can be finely tuned by engineering the surface polymer composition. Improved therapeutic outcomes can be achieved with growth factor nanocapsules, as illustrated in spinal cord fusion mediated by bone morphogenetic protein-2 nanocapsules. C1 [Tian, Haijun; Du, Juanjuan; Wen, Jing; Liu, Yang; Lu, Yunfeng] Univ Calif Los Angeles, Dept Chem & Biomol Engn, Los Angeles, CA 90095 USA. [Tian, Haijun; Montgomery, Scott R.; Scott, Trevor P.; Aghdsi, Bayan; Xiong, Chengjie; Suzuki, Akinobu; Hayashi, Tetsuo; Ruangchainikom, Monchai; Phan, Kevin; Weintraub, Gil; Raed, Alobaidaan; Wang, Jeffrey C.] Univ Calif Los Angeles, Dept Orthopaed Surg, Los Angeles, CA 90095 USA. [Yang, Xianjin; Yuan, Xu-bo] Tianjin Univ, Dept Mat Sci, Tianjin 300072, Peoples R China. [Tian, Haijun] Bethune Sch Medics, Dept Surg, Shijiazhuang 050000, Peoples R China. [Tian, Haijun] Second Mil Med Univ, Changzheng Hosp, Dept Orthopaed Surg, Shanghai 200003, Peoples R China. [Murray, Samuel S.] VA Greater Los Angeles Healthcare Syst, Res Serv, North Hills, CA 91343 USA. [Daubs, Michael D.] Univ Nevada, Sch Med, Dept Surg, Div Orthopaed Surg, Las Vegas, NV 89102 USA. [Wang, Jeffrey C.] Univ Southern Calif, Dept Orthopaed Surg, Los Angeles, CA 90033 USA. RP Lu, YF (reprint author), Univ Calif Los Angeles, Dept Chem & Biomol Engn, Los Angeles, CA 90095 USA.; Wang, JC (reprint author), Univ Calif Los Angeles, Dept Orthopaed Surg, Los Angeles, CA 90095 USA.; Yuan, XB (reprint author), Tianjin Univ, Dept Mat Sci, Tianjin 300072, Peoples R China.; Wang, JC (reprint author), Univ Southern Calif, Dept Orthopaed Surg, Los Angeles, CA 90033 USA. EM xbyuan@tju.edu.cn; Jeffrey.wang@med.usc.edu; luucla@ucla.edu FU National Nature Science Foundation of China [81402229]; International Science and Technology Cooperation Program of China [2012DFA51690] FX This work was supported by the National Nature Science Foundation of China (Grant No. 81402229) and International Science and Technology Cooperation Program of China (Grant No. 2012DFA51690). NR 45 TC 0 Z9 0 U1 21 U2 34 PU AMER CHEMICAL SOC PI WASHINGTON PA 1155 16TH ST, NW, WASHINGTON, DC 20036 USA SN 1936-0851 EI 1936-086X J9 ACS NANO JI ACS Nano PD AUG PY 2016 VL 10 IS 8 BP 7362 EP 7369 DI 10.1021/acsnano.5b07950 PG 8 WC Chemistry, Multidisciplinary; Chemistry, Physical; Nanoscience & Nanotechnology; Materials Science, Multidisciplinary SC Chemistry; Science & Technology - Other Topics; Materials Science GA DU1HP UT WOS:000381959100015 PM 27227573 ER PT J AU Buland, JR Wasserloos, KJ Tyurin, VA Tyurina, YY Amoscato, AA Mallampalli, RK Chen, BB Zhao, J Zhao, YT Ofori-Acquah, S Kagan, VE Pitt, BR AF Buland, Justin R. Wasserloos, Karla J. Tyurin, Vladimir A. Tyurina, Yulia Y. Amoscato, Andrew A. Mallampalli, Rama K. Chen, Bill B. Zhao, Jing Zhao, Yutong Ofori-Acquah, Solomon Kagan, Valerian E. Pitt, Bruce R. TI Biosynthesis of oxidized lipid mediators via lipoprotein-associated phospholipase A(2) hydrolysis of extracellular cardiolipin induces endothelial toxicity SO AMERICAN JOURNAL OF PHYSIOLOGY-LUNG CELLULAR AND MOLECULAR PHYSIOLOGY LA English DT Article DE cardiolipin; pulmonary endothelium; octadecadienoic acid; lineolic acid; lipoprotein-associated phospholipase A(2) ID PLATELET-ACTIVATING-FACTOR; ACUTE LUNG INJURY; RESPIRATORY-DISTRESS-SYNDROME; MASS-SPECTROMETRIC CHARACTERIZATION; BRONCHOALVEOLAR LAVAGE FLUID; FACTOR ACETYLHYDROLASE; PHOSPHATIDYLSERINE PEROXIDATION; OXIDATIVE LIPIDOMICS; ACUTE-INFLAMMATION; DOUBLE-BLIND AB We (66) have previously described an NSAID-insensitive intramitochondrial biosynthetic pathway involving oxidation of the polyunsaturated mitochondrial phospholipid, cardiolipin (CL), followed by hydrolysis [by calcium-independent mitochondrial calcium-independent phospholipase A(2)-gamma (iPLA(2)gamma)] of oxidized CL (CLox), leading to the formation of lysoCL and oxygenated octadecadienoic metabolites. We now describe a model system utilizing oxidative lipidomics/mass spectrometry and bioassays on cultured bovine pulmonary artery endothelial cells (BPAECs) to assess the impact of CLox that we show, in vivo, can be released to the extracellular space and may be hydrolyzed by lipoprotein-associated PLA(2) (Lp-PLA(2)). Chemically oxidized liposomes containing bovine heart CL produced multiple oxygenated species. Addition of Lp-PLA(2) hydrolyzed CLox and produced (oxygenated) monolysoCL and dilysoCL and oxidized octadecadienoic metabolites including 9- and 13-hydroxyoctadecadienoic (HODE) acids. CLox caused BPAEC necrosis that was exacerbated by Lp-PLA(2). Lower doses of nonlethal CLox increased permeability of BPAEC monolayers. This effect was exacerbated by Lp-PLA(2) and partially mimicked by authentic monolysoCL or 9- or 13-HODE. Control mice plasma contained virtually no detectable CLox; in contrast, 4 h after Pseudomonas aeruginosa (P. aeruginosa) infection, 34 +/- 8 mol% (n = 6; P < 0.02) of circulating CL was oxidized. In addition, molar percentage of monolysoCL increased twofold after P. aeruginosa in a subgroup analyzed for these changes. Collectively, these studies suggest an important role for 1) oxidation of CL in proinflammatory environments and 2) possible hydrolysis of CLox in extracellular spaces producing lysoCL and oxidized octadecadienoic acid metabolites that may lead to impairment of pulmonary endothelial barrier function and necrosis. C1 [Buland, Justin R.] Childrens Hosp Pittsburgh, Pittsburgh, PA 15213 USA. [Wasserloos, Karla J.; Tyurin, Vladimir A.; Tyurina, Yulia Y.; Amoscato, Andrew A.; Kagan, Valerian E.; Pitt, Bruce R.] Univ Pittsburgh, Grad Sch Publ Hlth, Pittsburgh, PA USA. [Buland, Justin R.; Zhao, Yutong; Ofori-Acquah, Solomon] Univ Pittsburgh, Sch Med, Pittsburgh, PA USA. [Buland, Justin R.; Zhao, Jing; Zhao, Yutong; Ofori-Acquah, Solomon] Vasc Med Inst, Pittsburgh, PA USA. [Mallampalli, Rama K.; Chen, Bill B.; Zhao, Jing; Zhao, Yutong] Univ Pittsburgh, Sch Med, Dept Med, Div Pulm Allergy & Crit Care Med, Pittsburgh, PA 15213 USA. [Mallampalli, Rama K.; Chen, Bill B.; Zhao, Jing; Zhao, Yutong] Univ Pittsburgh, Sch Med, Acute Lung Injury Ctr Excellence, Pittsburgh, PA USA. [Mallampalli, Rama K.] VA Pittsburgh Hlth Care Syst, Pittsburgh, PA USA. [Mallampalli, Rama K.] Univ Pittsburgh, Sch Med, Dept Cell Biol & Physiol, Pittsburgh, PA USA. RP Pitt, BR (reprint author), Univ Pittsburgh, Grad Sch Publ Hlth, Dept Environm Occupat Hlth, Bridgeside Point 1,100 Technol Dr, Pittsburgh, PA 15219 USA. EM brucep@pitt.edu FU Children's Hospital of Pittsburgh Scholars Award; NIH [PO1 114,453, UL1 TR000005, K12HD052892]; University of Pittsburgh Vascular Medicine Institute FX This work was supported in part by grants from the University of Pittsburgh Vascular Medicine Institute, Children's Hospital of Pittsburgh Scholars Award, NIH PO1 114,453, UL1 TR000005, and K12HD052892. NR 73 TC 0 Z9 0 U1 6 U2 6 PU AMER PHYSIOLOGICAL SOC PI BETHESDA PA 9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA SN 1040-0605 EI 1522-1504 J9 AM J PHYSIOL-LUNG C JI Am. J. Physiol.-Lung Cell. Mol. Physiol. PD AUG 1 PY 2016 VL 311 IS 2 BP L303 EP L316 DI 10.1152/ajplung.00038.2016 PG 14 WC Physiology; Respiratory System SC Physiology; Respiratory System GA DT6XP UT WOS:000381628600011 PM 27233995 ER PT J AU Humphrey, MB Nakamura, MC AF Humphrey, Mary Beth Nakamura, Mary C. TI A Comprehensive Review of Immunoreceptor Regulation of Osteoclasts SO CLINICAL REVIEWS IN ALLERGY & IMMUNOLOGY LA English DT Review DE Osteoclast; Immunoreceptor; ITAM; Fc receptor; RANK; Osteoimmunology ID DAP12-ASSOCIATING LECTIN (MDL)-1; DNAX-ACTIVATING PROTEIN; HUMAN DENDRITIC CELLS; MYELOID CELLS; FCR-GAMMA; BONE LOSS; IMMUNE-SYSTEM; SIALIC-ACID; FUNCTIONAL OSTEOCLASTS; MEDIATED COSTIMULATION AB Osteoclasts require coordinated co-stimulation by several signaling pathways to initiate and regulate their cellular differentiation. Receptor activator for NF-kappa B ligand (RANKL or TNFSF11), a tumor necrosis factor (TNF) superfamily member, is the master cytokine required for osteoclastogenesis with essential co-stimulatory signals mediated by immunoreceptor tyrosine-based activation motif (ITAM)-signaling adaptors, DNAX-associated protein 12 kDa size (DAP12) and Fc epsilon RI gamma chain (FcR gamma). The ITAM-signaling adaptors do not have an extracellular ligand-binding domain and, therefore, must pair with ligand-binding immunoreceptors to interact with their extracellular environment. DAP12 pairs with a number of different immunoreceptors including triggering receptor expressed on myeloid cells 2 (TREM2), myeloid DAP12-associated lectin (MDL-1), and sialic acid-binding immunoglobulin-type lectin 15 (Siglec-15); while FcR gamma pairs with a different set of receptors including osteoclast-specific activating receptor (OSCAR), paired immunoglobulin receptor A (PIR-A), and Fc receptors. The ligands for many of these receptors in the bone microenvironment remain unknown. Here, we will review immunoreceptors known to pair with either DAP12 or FcR gamma that have been shown to regulate osteoclastogenesis. Co-stimulation and the effects of ITAM-signaling have turned out to be complex, and now include paradoxical findings that ITAM-signaling adaptor-associated receptors can inhibit osteoclastogenesis and immunoreceptor tyrosine-based inhibitory motif (ITIM) receptors can promote osteoclastogenesis. Thus, co-stimulation of osteoclastogenesis continues to reveal additional complexities that are important in the regulatory mechanisms that seek to maintain bone homeostasis. C1 [Humphrey, Mary Beth] Univ Oklahoma, Hlth Sci Ctr, Dept Med, Div Rheumatol Immunol & Allergy, 975 NE 10th St,BRC209, Oklahoma City, OK 73104 USA. [Nakamura, Mary C.] Univ Calif San Francisco, Dept Med, Div Rheumatol, San Francisco, CA USA. [Nakamura, Mary C.] San Francisco Vet Adm Med Ctr, Arthrit Immunol Sect, 4150 Clement St 111R, San Francisco, CA 94121 USA. RP Nakamura, MC (reprint author), Univ Calif San Francisco, Dept Med, Div Rheumatol, San Francisco, CA USA.; Nakamura, MC (reprint author), San Francisco Vet Adm Med Ctr, Arthrit Immunol Sect, 4150 Clement St 111R, San Francisco, CA 94121 USA. EM marybeth-humphrey@ouhsc.edu; mary.nakamura@ucsf.edu FU NIH [AR064211, AG046282]; VA Merit Review; UCSF-Stanford Arthritis Center of Excellence - Great Western Region of the Arthritis Foundation; Rheumatology Research Foundation; Russell/Engleman Rheumatology Research Center FX We thank T. P. Quinn for helpful suggestions and editing the manuscript. M. B. H. is supported by NIH grant AR064211. M. C. N. is supported by a VA Merit Review, NIH grant AG046282, the UCSF-Stanford Arthritis Center of Excellence funded by the Great Western Region of the Arthritis Foundation, the Rheumatology Research Foundation, and the Russell/Engleman Rheumatology Research Center. NR 81 TC 1 Z9 1 U1 4 U2 7 PU HUMANA PRESS INC PI TOTOWA PA 999 RIVERVIEW DRIVE SUITE 208, TOTOWA, NJ 07512 USA SN 1080-0549 EI 1559-0267 J9 CLIN REV ALLERG IMMU JI Clin. Rev. Allergy Immunol. PD AUG PY 2016 VL 51 IS 1 BP 48 EP 58 DI 10.1007/s12016-015-8521-8 PG 11 WC Allergy; Immunology SC Allergy; Immunology GA DS9BC UT WOS:000381075800004 PM 26573914 ER PT J AU Luo, T Nocon, A Fry, J Sherban, A Rui, XL Jiang, BB Xu, XJ Han, JY Yan, Y Yang, Q Li, Q Zang, MW AF Luo, Ting Nocon, Allison Fry, Jessica Sherban, Alex Rui, Xianliang Jiang, Bingbing Xu, X. Julia Han, Jingyan Yan, Yun Yang, Qin Li, Qifu Zang, Mengwei TI AMPK Activation by Metformin Suppresses Abnormal Extracellular Matrix Remodeling in Adipose Tissue and Ameliorates Insulin Resistance in Obesity SO DIABETES LA English DT Article ID PROTEIN-KINASE; LIVER FIBROSIS; LIPID-METABOLISM; GENE-EXPRESSION; ADIPOCYTE; MICE; ATHEROSCLEROSIS; ROSIGLITAZONE; HOMEOSTASIS; MECHANISM AB Fibrosis is emerging as a hallmark of metabolically dysregulated white adipose tissue (WAT) in obesity. Although adipose tissue fibrosis impairs adipocyte plasticity, little is known about how aberrant extracellular matrix (ECM) remodeling of WAT is initiated during the development of obesity. Here we show that treatment with the antidiabetic drug metformin inhibits excessive ECM deposition in WAT of ob/ob mice and mice with diet-induced obesity, as evidenced by decreased collagen deposition surrounding adipocytes and expression of fibrotic genes including the collagen cross-linking regulator LOX. Inhibition of interstitial fibrosis by metformin is likely attributable to the activation of AMPK and the suppression of transforming growth factor-beta 1 (TGF-beta 1)/Smad3 signaling, leading to enhanced systemic insulin sensitivity. The ability of metformin to repress TGF-beta 1-induced fibrogenesis is abolished by the dominant negative AMPK in primary cells from the stromal vascular fraction. TGF-beta 1-induced insulin resistance is suppressed by AMPK agonists and the constitutively active AMPK in 3T3L1 adipocytes. In omental fat depots of obese humans, interstitial fibrosis is also associated with AMPK inactivation, TGF-beta 1/Smad3 induction, aberrant ECM production, myofibroblast activation, and adipocyte apoptosis. Collectively, integrated AMPK activation and TGF-beta 1/Smad3 inhibition may provide a potential therapeutic approach to maintain ECM flexibility and combat chronically uncontrolled adipose tissue expansion in obesity. C1 [Luo, Ting; Nocon, Allison; Fry, Jessica; Sherban, Alex; Rui, Xianliang; Jiang, Bingbing; Xu, X. Julia; Han, Jingyan; Zang, Mengwei] Boston Univ, Sch Med, Dept Med, Boston, MA 02118 USA. [Luo, Ting; Li, Qifu] Chongqing Med Univ, Dept Endocrinol, Affiliated Hosp 1, Chongqing, Peoples R China. [Yan, Yun] Childrens Mercy Hosp, Dept Pediat, Div Endocrinol, Kansas City, MO 64108 USA. [Yan, Yun] Univ Missouri, Kansas City, MO 64110 USA. [Yang, Qin] Univ Calif Irvine, Dept Med Physiol & Biophys, Ctr Diabet Res & Treatment, Irvine, CA USA. [Yang, Qin] Univ Calif Irvine, Ctr Epigenet & Metab, Irvine, CA USA. [Zang, Mengwei] Univ Texas Hlth Sci Ctr San Antonio, Ctr Hlth Aging, Barshop Inst Longev & Aging Studies, San Antonio, TX 78229 USA. [Zang, Mengwei] Univ Texas Hlth Sci Ctr San Antonio, Dept Mol Med, San Antonio, TX 78229 USA. [Zang, Mengwei] Audie L Murphy VA Hosp, Geriatr Res Educ & Clin Ctr, San Antonio, TX 78229 USA. [Zang, Mengwei] South Texas Vet Hlth Care Syst, San Antonio, TX 78229 USA. RP Zang, MW (reprint author), Boston Univ, Sch Med, Dept Med, Boston, MA 02118 USA.; Zang, MW (reprint author), Univ Texas Hlth Sci Ctr San Antonio, Dept Mol Med, San Antonio, TX 78229 USA.; Zang, MW (reprint author), Audie L Murphy VA Hosp, Geriatr Res Educ & Clin Ctr, San Antonio, TX 78229 USA.; Zang, MW (reprint author), South Texas Vet Hlth Care Syst, San Antonio, TX 78229 USA. EM zang@uthscsa.edu FU National Institutes of Health [R01 DK076942, R01 DK100603, R21AA021181]; American Diabetes Association [1-15-BS-216]; Boston University Clinical and Translational Science Award [1UL1TR001430] FX This work was supported by the National Institutes of Health (grant nos. R01 DK076942, R01 DK100603, and R21AA021181 [to M.Z.]) and the American Diabetes Association Award 1-15-BS-216 (to M.Z.). M.Z. also received a Boston University Clinical and Translational Science Award (1UL1TR001430). NR 44 TC 4 Z9 4 U1 8 U2 19 PU AMER DIABETES ASSOC PI ALEXANDRIA PA 1701 N BEAUREGARD ST, ALEXANDRIA, VA 22311-1717 USA SN 0012-1797 EI 1939-327X J9 DIABETES JI Diabetes PD AUG PY 2016 VL 65 IS 8 BP 2295 EP 2310 DI 10.2337/db15-1122 PG 16 WC Endocrinology & Metabolism SC Endocrinology & Metabolism GA DS4KQ UT WOS:000380750400024 PM 27207538 ER PT J AU Mundinger, TO Mei, Q Foulis, AK Fligner, CL Hull, RL Taborsky, GJ AF Mundinger, Thomas O. Mei, Qi Foulis, Alan K. Fligner, Corinne L. Hull, Rebecca L. Taborsky, Gerald J., Jr. TI Human Type 1 Diabetes Is Characterized by an Early, Marked, Sustained, and Islet-Selective Loss of Sympathetic Nerves SO DIABETES LA English DT Article ID INSULIN-INDUCED HYPOGLYCEMIA; INCREASED GLUCAGON-SECRETION; AUTONOMIC NERVOUS-SYSTEM; PANCREATIC-POLYPEPTIDE; GLUCOSE COUNTERREGULATION; IMPAIRED GLUCAGON; MELLITUS; STIMULATION; EPINEPHRINE; NEUROPATHY AB In humans, the glucagon response to moderate-to-marked insulin-induced hypoglycemia (IIH) is largely mediated by the autonomic nervous system. Because this glucagon response is impaired early in type 1 diabetes, we sought to determine if these patients, like animal models of autoimmune diabetes, have an early and severe loss of islet sympathetic nerves. We also tested whether this nerve loss is a permanent feature of type 1 diabetes, is islet-selective, and is not seen in type 2 diabetes. To do so, we quantified pancreatic islet and exocrine sympathetic nerve fiber area from autopsy samples of patients with type 1 or 2 diabetes and control subjects without diabetes. Our central finding is that patients with either very recent onset (<2 weeks) or long duration (>10 years) of type 1 diabetes have a severe loss of islet sympathetic nerves (Delta = -88% and Delta = -79%, respectively). In contrast, patients with type 2 diabetes lose no islet sympathetic nerves. There is no loss of exocrine sympathetic nerves in either type 1 or type 2 diabetes. We conclude that patients with type 1, but not type 2, diabetes have an early, marked, sustained, and islet-selective loss of sympathetic nerves, one that may impair their glucagon response to IIH. C1 [Mundinger, Thomas O.; Mei, Qi; Hull, Rebecca L.; Taborsky, Gerald J., Jr.] Univ Washington, Dept Med, Seattle, WA 98195 USA. [Foulis, Alan K.] Southern Gen Hosp, Dept Pathol, Glasgow, Lanark, Scotland. [Fligner, Corinne L.] Univ Washington, Dept Pathol, Seattle, WA 98195 USA. [Hull, Rebecca L.; Taborsky, Gerald J., Jr.] VA Puget Sound Hlth Care Syst, Seattle, WA USA. RP Mundinger, TO (reprint author), Univ Washington, Dept Med, Seattle, WA 98195 USA. EM mundin@u.washington.edu FU U.S. National Institutes of Health [R01-DK-088082, R01-DK-050154]; Biomedical Laboratory Research and Development Service of the U.S. Department of Veterans Affairs; University of Washington Diabetes Research Center [P30-DK-017047] FX This work was supported by U.S. National Institutes of Health grants R01-DK-088082 (R.L.H.) and R01-DK-050154 (G.J.T.), the Biomedical Laboratory Research and Development Service of the U.S. Department of Veterans Affairs (G.J.T.), and University of Washington Diabetes Research Center grant P30-DK-017047. NR 56 TC 2 Z9 2 U1 2 U2 2 PU AMER DIABETES ASSOC PI ALEXANDRIA PA 1701 N BEAUREGARD ST, ALEXANDRIA, VA 22311-1717 USA SN 0012-1797 EI 1939-327X J9 DIABETES JI Diabetes PD AUG PY 2016 VL 65 IS 8 BP 2322 EP 2330 DI 10.2337/db16-0284 PG 9 WC Endocrinology & Metabolism SC Endocrinology & Metabolism GA DS4KQ UT WOS:000380750400026 PM 27207540 ER PT J AU Zhang, W Wu, MR Kim, T Jariwala, RH Garvey, WJ Luo, NL Kang, MS Ma, E Tian, L Steverson, D Yang, QL Fu, YC Garvey, WT AF Zhang, Wei Wu, Mengrui Kim, Teayoun Jariwala, Ravi H. Garvey, W. John Luo, Nanlan Kang, Minsung Ma, Elizabeth Tian, Ling Steverson, Dennis Yang, Qinglin Fu, Yuchang Garvey, W. Timothy TI Skeletal Muscle TRIB3 Mediates Glucose Toxicity in Diabetes and High-Fat Diet-Induced Insulin Resistance SO DIABETES LA English DT Article ID GLUTAMINE-FRUCTOSE-6-PHOSPHATE AMIDOTRANSFERASE; TRIBBLES HOMOLOG; TRANSPORT SYSTEM; HEXOSAMINE BIOSYNTHESIS; INDUCED DESENSITIZATION; BIOCHEMICAL PATHWAYS; GLUT4 TRANSLOCATION; METABOLIC SYNDROME; TRANSGENIC MICE; TRB3 AB In the current study, we used muscle-specific TRIB3 over-expressing (MOE) and knockout (MKO) mice to determine whether TRIB3 mediates glucose-induced insulin resistance in diabetes and whether alterations in TRIB3 expression as a function of nutrient availability have a regulatory role in metabolism. In streptozotocin diabetic mice, TRIB3 MOE exacerbated, whereas MKO prevented, glucose-induced insulin resistance and impaired glucose oxidation and defects in insulin signal transduction compared with wild-type (WT) mice, indicating that glucose-induced insulin resistance was dependent on TRIB3. In response to a high-fat diet, TRIB3 MOE mice exhibited greater weight gain and worse insulin resistance in vivo compared with WT mice, coupled with decreased AKT phosphorylation, increased inflammation and oxidative stress, and upregulation of lipid metabolic genes coupled with downregulation of glucose metabolic genes in skeletal muscle. These effects were prevented in the TRIB3 MKO mice relative to WT mice. In conclusion, TRIB3 has a pathophysiological role in diabetes and a physiological role in metabolism. Glucose-induced insulin resistance and insulin resistance due to diet-induced obesity both depend on muscle TRIB3. Under physiological conditions, muscle TRIB3 also influences energy expenditure and substrate metabolism, indicating that the decrease and increase in muscle TRIB3 under fasting and nutrient excess, respectively, are critical for metabolic homeostasis. C1 [Zhang, Wei; Jariwala, Ravi H.; Garvey, W. John; Luo, Nanlan; Kang, Minsung; Ma, Elizabeth; Tian, Ling; Steverson, Dennis; Yang, Qinglin; Fu, Yuchang; Garvey, W. Timothy] Univ Alabama Birmingham, Dept Nutr Sci, Birmingham, AL 35294 USA. [Wu, Mengrui] Univ Alabama Birmingham, Dept Mol & Cellular Pathol, Birmingham, AL USA. [Kim, Teayoun] Univ Alabama Birmingham, Dept Med Endocrinol Diabet & Metab, Birmingham, AL USA. [Garvey, W. Timothy] Birmingham Vet Affairs Med Ctr, Birmingham, AL 35233 USA. RP Zhang, W; Garvey, WT (reprint author), Univ Alabama Birmingham, Dept Nutr Sci, Birmingham, AL 35294 USA.; Garvey, WT (reprint author), Birmingham Vet Affairs Med Ctr, Birmingham, AL 35233 USA. EM siweizh@uab.edu; garveyt@uab.edu FU National Institutes of Health [DK-038765, DK-083562]; Department of Veterans Affairs Merit Review Program; American Diabetes Association [1-13-IN-19]; National Institute of Diabetes and Digestive and Kidney Diseases [P60 DK079626] FX This work was supported by grants from the National Institutes of Health (DK-038765 and DK-083562), the Department of Veterans Affairs Merit Review Program, and the American Diabetes Association (1-13-IN-19) and by a grant from the National Institute of Diabetes and Digestive and Kidney Diseases to the UAB Diabetes Research Center Core Facilities (P60 DK079626). NR 44 TC 0 Z9 0 U1 3 U2 3 PU AMER DIABETES ASSOC PI ALEXANDRIA PA 1701 N BEAUREGARD ST, ALEXANDRIA, VA 22311-1717 USA SN 0012-1797 EI 1939-327X J9 DIABETES JI Diabetes PD AUG PY 2016 VL 65 IS 8 BP 2380 EP 2391 DI 10.2337/db16-0154 PG 12 WC Endocrinology & Metabolism SC Endocrinology & Metabolism GA DS4KQ UT WOS:000380750400031 PM 27207527 ER PT J AU Davison, BA Metra, M Senger, S Edwards, C Milo, O Bloomfield, DM Cleland, JG Dittrich, HC Givertz, MM O'Connor, CM Massie, BM Ponikowski, P Teerlink, JR Voors, AA Cotter, G AF Davison, Beth A. Metra, Marco Senger, Stefanie Edwards, Christopher Milo, Olga Bloomfield, Daniel M. Cleland, John G. Dittrich, Howard C. Givertz, Michael M. O'Connor, Christopher M. Massie, Barry M. Ponikowski, Piotr Teerlink, John R. Voors, Adriaan A. Cotter, Gad TI Patient journey after admission for acute heart failure: length of stay, 30-day readmission and 90-day mortality SO EUROPEAN JOURNAL OF HEART FAILURE LA English DT Article DE Acute heart failure; Length of stay; Prognosis; Regional differences; Global variation; Outcomes ID HOSPITALIZATION INSIGHTS; PROTECT TRIAL; ASCEND-HF; CARE; ROLOFYLLINE; ANTAGONIST; OUTCOMES; EUROPE; RATES AB AimsThe course of patients following admission for acute heart failure (AHF) is of major importance to patients and healthcare providers. We examined predictors and associations of length of stay (LOS), 30-day post-discharge readmission and 90-day post-discharge mortality in 1990 patients enrolled in the PROTECT study. Methods and resultsPROTECT was a randomized study that examined the effect of the adenosine blocker rolofylline in patients within 24h of admission for AHF with mild to moderate renal impairment. Geographic-region-adjusted multivariable models showed that LOS was only partly explained by the severity of heart failure (HF), comorbidities (diabetes mellitus, renal impairment, ischaemic heart disease) and degree of metabolic dysfunction (cholesterol and albumin) at baseline (adjusted R-2 0.27). Addition of in-hospital worsening heart failure (WHF) and changes in metabolic markers contributed significantly to prediction of LOS [R-2 difference 0.050, 95% confidence interval (CI) 0.0282-0.072]. Thirty-day HF readmission was associated with more severe HF and previous HF admission but not with LOS (odds ratios 1.00, 95% CI 0.97-1.04). Death within 90days after discharge was associated with older age, more severe HF, worse renal function, and lower sodium and bicarbonate at admission; LOS was a strong predictor of 90-day post-discharge mortality. ConclusionsIn patients admitted for AHF, LOS is not well-predicted by traditional markers of disease severity, but strongly associated with the occurrence of in-hospital WHF. Longer LOS is a strong predictor of early mortality after discharge but not of readmission. These findings may help focus efforts to reduce LOS and post-discharge outcomes on patients' subgroups at increased risk. C1 [Davison, Beth A.; Senger, Stefanie; Edwards, Christopher; Milo, Olga; Cotter, Gad] Momentum Res Inc, 3100 Tower Blvd,Suite 802, Durham, NC 27707 USA. [Metra, Marco] Univ Brescia, Brescia, Italy. [Bloomfield, Daniel M.] Merck Res Labs, Rahway, NJ USA. [Cleland, John G.] Univ Hull, Kingston Upon Hull, Yorks, England. [Cleland, John G.] Imperial Coll, Natl Heart & Lung Inst, London, England. [Dittrich, Howard C.] Univ Iowa, Carver Coll Med, Cardiovasc Res Ctr, Iowa City, IA USA. [Givertz, Michael M.] Brigham & Womens Hosp, 75 Francis St, Boston, MA 02115 USA. [O'Connor, Christopher M.] Duke Univ, Med Ctr, Duke Clin Res Inst, Durham, NC USA. [Massie, Barry M.; Teerlink, John R.] Univ Calif San Francisco, San Francisco, CA 94143 USA. [Massie, Barry M.; Teerlink, John R.] San Francisco VA Med Ctr, San Francisco, CA USA. [Ponikowski, Piotr] Klin Kardiol, Wroclaw, Poland. [Voors, Adriaan A.] Univ Groningen, Univ Med Ctr Groningen, Groningen, Netherlands. RP Davison, BA (reprint author), Momentum Res Inc, 3100 Tower Blvd,Suite 802, Durham, NC 27707 USA. EM bethdavison@momentum-research.com RI Ponikowski, Piotr/O-6454-2015 OI Ponikowski, Piotr/0000-0002-3391-7064; Senger, Stefanie/0000-0003-4144-1040 FU Novacardia of Merck FX The PROTECT trials were sponsored by Novacardia, a subsidiary of Merck. No external funding was received for the preparation of this manuscript. NR 20 TC 4 Z9 4 U1 2 U2 4 PU WILEY-BLACKWELL PI HOBOKEN PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA SN 1388-9842 EI 1879-0844 J9 EUR J HEART FAIL JI Eur. J. Heart Fail. PD AUG PY 2016 VL 18 IS 8 BP 1041 EP 1050 DI 10.1002/ejhf.540 PG 10 WC Cardiac & Cardiovascular Systems SC Cardiovascular System & Cardiology GA DS8PL UT WOS:000381045200012 PM 27114058 ER PT J AU Collins, SP Levy, PD Martindale, JL Dunlap, ME Storrow, AB Pang, PS Albert, NM Felker, GM Fermann, GJ Fonarow, GC Givertz, MM Hollander, JE Lanfear, DJ Lenihan, DJ Lindenfeld, JM Peacock, WF Sawyer, DB Teerlink, JR Butler, J AF Collins, Sean P. Levy, Phillip D. Martindale, Jennifer L. Dunlap, Mark E. Storrow, Alan B. Pang, Peter S. Albert, Nancy M. Felker, G. Michael Fermann, Gregory J. Fonarow, Gregg C. Givertz, Michael M. Hollander, Judd E. Lanfear, David J. Lenihan, Daniel J. Lindenfeld, Joann M. Peacock, W. Frank Sawyer, Douglas B. Teerlink, John R. Butler, Javed TI Clinical and Research Considerations for Patients With Hypertensive Acute Heart Failure: A Consensus Statement from the Society of Academic Emergency Medicine and the Heart Failure Society of America Acute Heart Failure Working Group SO JOURNAL OF CARDIAC FAILURE LA English DT Article DE Heart failure; Hypertension; Emergency ID CARDIOGENIC PULMONARY-EDEMA; WORSENING RENAL-FUNCTION; SCANDINAVIAN ENALAPRIL SURVIVAL; HAND-CARRIED ULTRASOUND; BLOOD-PRESSURE; ISOSORBIDE-DINITRATE; NONINVASIVE VENTILATION; FLUID ACCUMULATION; TRANSDERMAL NITROGLYCERIN; INTRAVENOUS ENALAPRILAT AB Management approaches for patients in the emergency department (ED) who present with acute heart failure (AHF) have largely focused on intravenous diuretics. Yet, the primary pathophysiologic derangement underlying AHF in many patients is not solely volume overload. Patients with hypertensive AHF (H-AHF) represent a clinical phenotype with distinct pathophysiologic mechanisms that result in elevated ventricular filling pressures. To optimize treatment response and minimize adverse events in this subgroup, we propose that clinical management be tailored to a conceptual model of disease based on these mechanisms. This consensus statement reviews the relevant pathophysiology, clinical characteristics, approach to therapy, and considerations for clinical trials in ED patients with H-AHF. C1 [Collins, Sean P.; Storrow, Alan B.] Vanderbilt Univ, Dept Emergency Med, 1313 21st Ave South,312 Oxford House, Nashville, TN 37232 USA. [Levy, Phillip D.] Wayne State Univ, Dept Emergency Med, Detroit, MI USA. [Martindale, Jennifer L.] SUNY Downstate, Dept Emergency Med, New York, NY USA. [Dunlap, Mark E.] Case Western Univ, Dept Med, Cleveland, OH USA. [Pang, Peter S.] Indiana Univ, Dept Emergency Med, Indianapolis, IN 46204 USA. [Albert, Nancy M.] Cleveland Clin, Dept Med, Cleveland, OH 44106 USA. [Felker, G. Michael] Duke Univ, Dept Med, Raleigh, NC USA. [Fermann, Gregory J.] Univ Cincinnati, Dept Emergency Med, Cincinnati, OH USA. [Fonarow, Gregg C.] Univ Calif Los Angeles, Dept Med, Los Angeles, CA 90024 USA. [Givertz, Michael M.] Harvard Med Sch, Dept Med, Boston, MA USA. [Hollander, Judd E.] Thomas Jefferson Univ, Dept Emergency Med, Philadelphia, PA 19107 USA. [Lanfear, David J.] Henry Ford Hlth Syst, Dept Med, Detroit, MI USA. [Lenihan, Daniel J.; Lindenfeld, Joann M.] Vanderbilt Univ, Dept Med, Nashville, TN USA. [Peacock, W. Frank] Baylor Coll Med, Dept Emergency Med, Houston, TX 77030 USA. [Sawyer, Douglas B.] Maine Med Ctr, Dept Med, Portland, ME 04102 USA. [Teerlink, John R.] San Francisco VA Med Ctr, Dept Med, San Francisco, CA USA. [Butler, Javed] SUNY Stony Brook, Dept Med, Long Isl City, NY USA. RP Collins, SP (reprint author), Vanderbilt Univ, Dept Emergency Med, 1313 21st Ave South,312 Oxford House, Nashville, TN 37232 USA. EM sean.collins@vanderbilt.edu NR 91 TC 1 Z9 1 U1 2 U2 3 PU CHURCHILL LIVINGSTONE INC MEDICAL PUBLISHERS PI PHILADELPHIA PA CURTIS CENTER, INDEPENDENCE SQUARE WEST, PHILADELPHIA, PA 19106-3399 USA SN 1071-9164 EI 1532-8414 J9 J CARD FAIL JI J. Card. Fail. PD AUG PY 2016 VL 22 IS 8 BP 618 EP 627 DI 10.1016/j.cardfail.2016.04.015 PG 10 WC Cardiac & Cardiovascular Systems SC Cardiovascular System & Cardiology GA DS8WX UT WOS:000381064800007 PM 27262665 ER PT J AU Sarkar, S Esserman, DA Skanderson, M Levin, FL Justice, AC Lim, JK AF Sarkar, Souvik Esserman, Denise A. Skanderson, Melissa Levin, Forrest L. Justice, Amy C. Lim, Joseph K. TI Disparities in hepatitis C testing in US veterans born 1945-1965 SO JOURNAL OF HEPATOLOGY LA English DT Article DE HCV; Hepatitis C virus; Epidemiology; Variances; Testing; Veterans; U.S ID SERVICES TASK-FORCE; VIRUS-INFECTION; UNITED-STATES; COST-EFFECTIVENESS; ANTIVIRAL THERAPY; NATIONAL-HEALTH; AFFAIRS CARE; GENOTYPE 1; PREVALENCE; SOFOSBUVIR AB Background & Aims: Universal one-time antibody testing for hepatitis C virus (HCV) infection has been recommended by the centers for disease control (CDC) and the United States preventative services task force (USPSTF) for Americans born 1945-1965 (birth cohort). Limited data exists addressing national HCV testing practices. We studied patterns and predictors of HCV testing across the U.S. within the birth cohort utilizing data from the national corporate data warehouse of the U.S. Veterans Administration(VA) health system. Methods: Testing was defined as any HCV test including antibody, RNA or genotype performed during 2000-2013. Results: Of 6,669,388 birth cohort veterans, 4,221,135 (63%) received care within the VA from 2000-2013 with two or more visits. Of this group, 2,139,935 (51%) had HCV testing with 8.1% HCV antibody and 5.4% RNA positive. Significant variation in testing was observed across centers (range: 7-83%). Older, male, African-Americans, with established risk factors and receiving care from urban centers of excellence were more likely to be tested. Among veterans free of other established risk factors (HIV negative, HBV negative, ALT <= 40 U/L, FIB-4 <= 1.45, or APRI < 0.5), HCV antibody and RNA were positive in 2.8% and 0.9%, respectively, comparable to established national average. At least 2.4-4.4% of veterans had scores suggesting advanced fibrosis (APRI P1.5 or FIB-4 > 3.25) with > 30-43% having positive HCV RNA but > 16-20% yet to undergo testing for HCV. Conclusions: Significant disparities are observed in HCV testing within the United States VA health system. Examination of the predictors of testing and HCV positivity may help inform national screening policies. Lay summary: Analysis of United States Veterans Administration data show significant disparities in hepatitis C virus testing of veterans born 1945-1965 (birth cohort). A fifth of those not tested had evidence of advanced liver fibrosis. Our data suggests some predictors for this disparity and will potentially help inform future policy measures in the era of universal birth cohort testing for HCV. (C) 2016 European Association for the Study of the Liver. Published by Elsevier B.V. All rights reserved. C1 [Sarkar, Souvik; Lim, Joseph K.] Yale Univ, Sch Med, Sect Digest Dis, 333 Cedar St,1080 LMP, New Haven, CT USA. [Sarkar, Souvik] Univ Calif Davis, Div Gastroenterol & Hepatol, Davis, CA 95616 USA. [Esserman, Denise A.] Yale Sch Publ Hlth, Dept Biostat, New Haven, CT USA. [Skanderson, Melissa] VA Pittsburgh Healthcare Syst, Pittsburgh, PA USA. [Levin, Forrest L.; Justice, Amy C.] VA Connecticut Healthcare Syst, Dept Internal Med, West Haven, CT USA. [Justice, Amy C.] Yale Univ, Sch Med, Dept Internal Med, New Haven, CT 06510 USA. [Justice, Amy C.] Yale Sch Publ Hlth, Dept Hlth Policy & Management, New Haven, CT USA. RP Lim, JK (reprint author), Yale Univ, Sch Med, Sect Digest Dis, 333 Cedar St,1080 LMP, New Haven, CT USA. EM joseph.lim@yale.edu OI Sarkar, Souvik/0000-0002-9358-4257; Justice, Amy/0000-0003-0139-5502 FU Department of Veterans Affairs; Veterans Health Administration; Office of Research and Development; NIAAA [U24 AA020794, U01 AA020790, U10 AA01356]; NCATS [UL1TR000142]; NIDDK [P30 DK034989, 2T32DK007356-36] FX NIAAA U24 AA020794, U01 AA020790, U10 AA01356, completed (ACJ); NCATS UL1TR000142 (DAE); NIDDK P30 DK034989 (JKL); NIDDK 2T32DK007356-36 (SS). This material is based upon work supported by the Department of Veterans Affairs, Veterans Health Administration, and Office of Research and Development. We must disclaim that the views expressed in this article are those of the authors and do not necessarily reflect the position or policy of the Department of Veterans Affairs. NR 35 TC 3 Z9 3 U1 1 U2 1 PU ELSEVIER SCIENCE BV PI AMSTERDAM PA PO BOX 211, 1000 AE AMSTERDAM, NETHERLANDS SN 0168-8278 EI 1600-0641 J9 J HEPATOL JI J. Hepatol. PD AUG PY 2016 VL 65 IS 2 BP 259 EP 265 DI 10.1016/j.jhep.2016.04.012 PG 7 WC Gastroenterology & Hepatology SC Gastroenterology & Hepatology GA DS2AH UT WOS:000380516900008 PM 27130843 ER PT J AU Chren, MM Arron, ST AF Chren, Mary-Margaret Arron, Sarah T. TI Research that Guides Clinical Decisions SO JOURNAL OF INVESTIGATIVE DERMATOLOGY LA English DT Editorial Material ID RANDOMIZED CONTROLLED-TRIAL; BASAL-CELL CARCINOMA; PHOTODYNAMIC THERAPY; MEDICAL LITERATURE; TOPICAL IMIQUIMOD; USERS GUIDES; PREVENTION; TIME; CARE AB The centerpiece of evidence-based medicine is the randomized controlled trial, a rigorous experiment. We use the study by Roozeboom et al. to illustrate how research guides clinical decisions. We describe levels of evidence, review criteria for assessing a trial regarding noninferiority of a therapy, and discuss challenges for evidence-based medicine in guiding care precisely targeted to an individual patient. C1 [Chren, Mary-Margaret; Arron, Sarah T.] Univ Calif San Francisco, Dept Dermatol, Program Clin Res, San Francisco, CA 94143 USA. [Chren, Mary-Margaret; Arron, Sarah T.] San Francisco VA Med Ctr, Dermatol Serv, San Francisco, CA USA. RP Chren, MM (reprint author), Univ Calif San Francisco, Dept Dermatol, Mt Zion Canc Res Bldg,2340 Sutter St,Room N412, San Francisco, CA 94143 USA. EM chrenm@derm.ucsf.edu NR 10 TC 0 Z9 0 U1 1 U2 1 PU ELSEVIER SCIENCE INC PI NEW YORK PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA SN 0022-202X EI 1523-1747 J9 J INVEST DERMATOL JI J. Invest. Dermatol. PD AUG PY 2016 VL 136 IS 8 BP 1535 EP 1537 DI 10.1016/j.jid.2016.04.031 PG 3 WC Dermatology SC Dermatology GA DS2HE UT WOS:000380585200075 PM 27450497 ER PT J AU Smith, KM Xie, SX Weintraub, D AF Smith, Kara M. Xie, Sharon X. Weintraub, Daniel TI Incident impulse control disorder symptoms and dopamine transporter imaging in Parkinson disease SO JOURNAL OF NEUROLOGY NEUROSURGERY AND PSYCHIATRY LA English DT Article ID AGONIST WITHDRAWAL SYNDROME; COMPULSIVE DISORDERS; BEHAVIORS; MEDICATION; DEPRESSION; PET; QUESTIONNAIRE; ASSOCIATION; RELEASE; RISK AB Objective To describe the incidence of, and clinical and neurobiological risk factors for, new-onset impulse control disorder (ICD) symptoms and related behaviours in early Parkinson disease (PD). Methods The Parkinson's Progression Markers Initiative is an international, multicenter, prospective study of de novo patients with PD untreated at baseline and assessed annually, including serial dopamine transporter imaging (DAT-SPECT) and ICD assessment (Questionnaire for Impulsive-Compulsive Disorders in Parkinson's Disease short form, QUIP). Participants were included if they screened negative on the QUIP at baseline. Kaplan-Meier curves and generalised estimating equations examined frequency and predictors of incident ICD symptoms. Results Participants were seen at baseline (n=320), year 1 (n=284), year 2 (n=217) and year 3 (n=96). Estimated cumulative incident rates of ICD symptoms and related behaviours were 8% (year 1), 18% (year 2) and 25% (year 3) and increased each year in those on dopamine replacement therapy (DRT) and decreased in those not on DRT. In participants on DRT, risk factors for incident ICD symptoms were younger age (OR=0.97, p=0.05), a greater decrease in right caudate (OR=4.03, p=0.01) and mean striatal (OR=6.90, p=0.04) DAT availability over the first year, and lower right putamen (OR=0.06, p=0.01) and mean total striatal (OR=0.25, p=0.04) DAT availability at any post-baseline visit. Conclusions The rate of incident ICD symptoms increases with time and initiation of DRT in early PD. In this preliminary study, a greater decrease or lower DAT binding over time increases risk of incident ICD symptoms, conferring additional risk to those taking DRT. C1 [Smith, Kara M.] Univ Penn, Dept Neurol, Perelman Sch Med, 330 S 9th St, Philadelphia, PA 19107 USA. [Xie, Sharon X.] Univ Penn, Dept Biostat & Epidemiol, Perelman Sch Med, Philadelphia, PA 19107 USA. [Weintraub, Daniel] Univ Penn, Dept Psychiat, Perelman Sch Med, Philadelphia, PA 19107 USA. [Weintraub, Daniel] Philadelphia Vet Affairs Med Ctr, Parkinsons Dis Res Educ & Clin Ctr PADRECC, Philadelphia, PA USA. [Weintraub, Daniel] Philadelphia Vet Affairs Med Ctr, MIRECC, Philadelphia, PA USA. RP Smith, KM (reprint author), Univ Penn, Dept Neurol, Perelman Sch Med, 330 S 9th St, Philadelphia, PA 19107 USA. EM karasmi@gmail.com FU Michael J Fox Foundation for Parkinson's Research; Abbott; Avid Radiopharmaceuticals; Biogen Idec; Covance; Bristol-Myers Squibb; Meso Scale Discovery; Piramal; Eli Lilly and Co; F. Hoffman-La Roche Ltd; GE Healthcare; Genentech; GlaxoSmithKline; Merck and Co; Pfizer Inc; UCB Pharma SA FX Supported by the Michael J Fox Foundation for Parkinson's Research and funding partners: Abbott, Avid Radiopharmaceuticals, Biogen Idec, Covance, Bristol-Myers Squibb, Meso Scale Discovery, Piramal, Eli Lilly and Co, F. Hoffman-La Roche Ltd, GE Healthcare, Genentech, GlaxoSmithKline, Merck and Co, Pfizer Inc, and UCB Pharma SA. NR 36 TC 3 Z9 3 U1 2 U2 2 PU BMJ PUBLISHING GROUP PI LONDON PA BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND SN 0022-3050 EI 1468-330X J9 J NEUROL NEUROSUR PS JI J. Neurol. Neurosurg. Psychiatry PD AUG PY 2016 VL 87 IS 8 BP 864 EP 870 DI 10.1136/jnnp-2015-311827 PG 7 WC Clinical Neurology; Psychiatry; Surgery SC Neurosciences & Neurology; Psychiatry; Surgery GA DS1VP UT WOS:000380392200011 PM 26534930 ER PT J AU Sharma, A Lavie, CJ Sharma, SK Garg, A Vallakati, A Mukherjee, D Marmur, JD AF Sharma, Abhishek Lavie, Carl J. Sharma, Samin K. Garg, Akash Vallakati, Ajay Mukherjee, Debabrata Marmur, Jonathan D. TI Duration of Dual Antiplatelet Therapy After Drug-Eluting Stent Implantation in Patients With and Without Acute Coronary Syndrome: A Systematic Review of Randomized Controlled Trials SO MAYO CLINIC PROCEEDINGS LA English DT Article ID ST-SEGMENT ELEVATION; MYOCARDIAL-INFARCTION; STOPPING CLOPIDOGREL; ADVERSE EVENTS; METAANALYSIS; INTERVENTION; ASPIRIN; RISK; TERM; DISCONTINUATION AB In this systemic review we evaluated the efficacy and safety of long duration dual anti-platelet therapy (DAPT) (L-DAPT) compared with short duration DAPT (S-DAPT) after drug-eluting stent(DES) implantation in patients who presented with or without acute coronary syndromes (ACS). We identified 8 randomized controlled trials in which 30,975 patients were randomized to S-DAPT versus L-DAPT (12,421 ACS and 18,554 non-ACS). Short duration dual anti-platelet therapy was associated with an increase in target vessel revascularization (TVR) in ACS patients, but the difference was not significant for non-ACS patients (odds ratio [OR] 5.04 [95% CI, 1.28-19.76], and OR, 0.89 [95% CI, 0.51-1.55], respectively). The risk of cardiac mortality was not significantly different with S-DAPT and L-DAPT for ACS (OR, 1.69 [95% CI, 0.82-3.50]) and non-ACS patients (OR, 0.89 [95% CI, 0.57-1.37]). For all cause mortality, myocardial infarction, and stent thrombosis, most of the events were derived from the DAPT study, thus a meta-analysis was not performed for these end points. Based on our review of the literature, we conclude that S-DAPT was associated with higher rates of stent thrombosis and myocardial infarction, and non-significant differences in all-cause mortality, with no significant interactions according to ACS vs non-ACS. However, in non-ACS patients, the benefit-risk profile favored S-DAPT, with lower all-cause mortality, whereas the trends were reversed in ACS. Additional studies are required to determine if the benefit-risk profile of S-DAPT vs L-DAPT varies according to clinical syndrome. (C) 2016 Mayo Foundation for Medical Education and Research C1 [Sharma, Abhishek; Marmur, Jonathan D.] Suny Downstate Med Ctr, Div Cardiovasc Med, Brooklyn, NY USA. [Lavie, Carl J.] Univ Queensland, Dept Cardiovasc Dis, John Ochsner Heart & Vasc Inst, Ochsner Clin Sch,Sch Med, New Orleans, LA USA. [Sharma, Samin K.] Icahn Sch Med Mt Sinai, Mt Sinai Med Ctr, Inst Heart & Vasc, Dept Cardiovasc Med, New York, NY 10029 USA. [Garg, Akash] Icahn Sch Med Mt Sinai, Dept Med, James J Peters VA Med Ctr, New York, NY 10029 USA. [Vallakati, Ajay] Case Western Reserve Univ, Metrohlth Med Ctr, Div Cardiol, Cleveland, OH USA. [Mukherjee, Debabrata] Texas Tech Univ, Div Cardiol, El Paso, TX USA. RP Sharma, A (reprint author), 125 96th St,Apt 5B, Brooklyn, NY 11209 USA. EM abhisheksharma4mamc@gmail.com RI Lavie, Carl/A-6014-2011 NR 34 TC 0 Z9 0 U1 0 U2 1 PU ELSEVIER SCIENCE INC PI NEW YORK PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA SN 0025-6196 EI 1942-5546 J9 MAYO CLIN PROC JI Mayo Clin. Proc. PD AUG PY 2016 VL 91 IS 8 BP 1084 EP 1093 DI 10.1016/j.mayocp.2016.06.004 PG 10 WC Medicine, General & Internal SC General & Internal Medicine GA DS4KN UT WOS:000380750100013 PM 27492914 ER PT J AU McConnell, HL Schwartz, DL Richardson, BE Woltjer, RL Muldoon, LL Neuwelt, EA AF McConnell, Heather L. Schwartz, Daniel L. Richardson, Brian E. Woltjer, Randall L. Muldoon, Leslie L. Neuwelt, Edward A. TI Ferumoxytol nanoparticle uptake in brain during acute neuroinflammation is cell-specific SO NANOMEDICINE-NANOTECHNOLOGY BIOLOGY AND MEDICINE LA English DT Article DE Neuroinflammation; MRI; Iron oxide nanoparticles; Macrophages; Contrast agents ID IRON-OXIDE NANOPARTICLES; MRI; PSEUDOPROGRESSION; VISUALIZATION; GLIOBLASTOMA; GADOTERIDOL; ASTROCYTES; THERAPY; DISEASE; BARRIER AB Ferumoxytol ultrasmall superparamagnetic iron oxide nanoparticles can enhance contrast between neuroinflamed and normal-appearing brain tissue when used as a contrast agent for high-sensitivity magnetic resonance imaging (MRI). Here we used an anti-dextran antibody (Dx1) that binds the nanoparticle's carboxymethyldextran coating to differentiate ferumoxytol from endogenous iron and localize it unequivocally in brain tissue. Intravenous injection of ferumoxytol into immune-competent rats that harbored human tumor xenograft-induced inflammatory brain lesions resulted in heterogeneous and lesion-specific signal enhancement on MRI scans in vivo. We used Dx1 immunolocalization and electron microscopy to identify ferumoxytol in affected tissue post-MRI. We found that ferumoxytol nanoparticles were taken up by astrocyte endfeet surrounding cerebral vessels, astrocyte processes, and CD163(+)/CD68(+) macrophages, but not by tumor cells. These results provide a biological basis for the delayed imaging changes seen with ferumoxytol and indicate that ferumoxytol-MRI can be used to assess the inflammatory component of brain lesions in the clinic. Published by Elsevier Inc. C1 [McConnell, Heather L.; Muldoon, Leslie L.; Neuwelt, Edward A.] Oregon Hlth & Sci Univ, Dept Neurol, Portland, OR 97201 USA. [Schwartz, Daniel L.] Oregon Hlth & Sci Univ, Adv Imaging Res Ctr, Portland, OR 97201 USA. [Richardson, Brian E.] Oregon Hlth & Sci Univ, Dept Mol & Med Genet, Portland, OR 97201 USA. [Woltjer, Randall L.] Oregon Hlth & Sci Univ, Dept Pathol, Portland, OR 97201 USA. [Neuwelt, Edward A.] Oregon Hlth & Sci Univ, Dept Neurosurg, Portland, OR 97201 USA. [Neuwelt, Edward A.] Portland VA Med Ctr, Dept Vet Affairs, Portland, OR USA. RP Neuwelt, EA (reprint author), Oregon Hlth & Sci Univ, Portland, OR 97239 USA. EM mcconneh@ohsu.edu; schwartd@ohsu.edu; brian@brianerichardson.com; woltjerr@ohsu.edu; muldoonl@ohsu.edu; neuwelte@ohsu.edu FU Walter S. and Lucienne Driskill Foundation; National Institutes of Health (NIH) [NS44687, CA137488, NS061800]; National Center for Advancing Translational Sciences at the NIH [TL1TR000129] FX This work was supported by the Walter S. and Lucienne Driskill Foundation and National Institutes of Health (NIH) grants NS44687 and CA137488 to EAN and NS061800 to Sue Aicher, and an Oregon Clinical and Translational Research Institute grant TL1TR000129 from the National Center for Advancing Translational Sciences at the NIH to HLM. Funding sources had no role in study design, collection or analysis of data, writing of the manuscript, or in the decision to submit the manuscript for publication. NR 28 TC 1 Z9 1 U1 6 U2 10 PU ELSEVIER SCIENCE BV PI AMSTERDAM PA PO BOX 211, 1000 AE AMSTERDAM, NETHERLANDS SN 1549-9634 EI 1549-9642 J9 NANOMED-NANOTECHNOL JI Nanomed.-Nanotechnol. Biol. Med. PD AUG PY 2016 VL 12 IS 6 BP 1535 EP 1542 DI 10.1016/j.nano.2016.03.009 PG 8 WC Nanoscience & Nanotechnology; Medicine, Research & Experimental SC Science & Technology - Other Topics; Research & Experimental Medicine GA DT8DF UT WOS:000381718600011 PM 27071335 ER PT J AU Menon, S McCullough, LB Beyth, RJ Ford, ME Espadas, D Braun, UK AF Menon, Shailaja McCullough, Laurence B. Beyth, Rebecca J. Ford, Marvella E. Espadas, Donna Braun, Ursula K. TI Use of a values inventory as a discussion aid about end-of-life care: A pilot randomized controlled trial SO PALLIATIVE & SUPPORTIVE CARE LA English DT Article DE Advance care planning; Terminal care; Randomized controlled trial; Veterans; Outpatients; Ambulatory care ID QUESTION PROMPT LIST; DECISION-MAKING; ADVANCED CANCER; COMMUNICATION-SKILLS; ADVANCE DIRECTIVES; BREAST-CANCER; DISCUSSIONS; PHYSICIANS; PREFERENCES; CAREGIVERS AB Objective: We examined the utility of a brief values inventory as a discussion aid to elicit patients' values and goals for end-of-life (EoL) care during audiotaped outpatient physician -patient encounters. Method: Participants were seriously ill male outpatients (n = 120) at a large urban Veterans Affairs medical center. We conducted a pilot randomized controlled trial, randomizing 60 patients to either the intervention (with the values inventory) or usual care. We used descriptive statistics and qualitative methods to analyze the data. We coded any EoL discussions and recorded the length of such discussions. Results: A total of 8 patients (13%) in the control group and 13 (23%) in the intervention group had EoL discussions with a physician (p = 0.77). All EoL discussions in the control group were initiated by the physician, compared with only five (38%) in the intervention group. Because most EoL discussions took place toward the end of the encounter, discussions were usually brief. Significance of results: The outpatient setting has been promoted as a better place for discussing EoL care than a hospital during an acute hospitalization for a chronic serious illness. However, the low effectiveness of our intervention calls into question the feasibility of discussing EoL care during a single outpatient visit. Allowing extra time or an extra visit for EoL discussions might increase the efficacy of advance care planning. C1 [Menon, Shailaja; Espadas, Donna; Braun, Ursula K.] Michael E DeBakey VA Med Ctr, VA Hlth Serv Res & Dev Ctr Innovat Qual Effect &, Houston, TX USA. [Menon, Shailaja; Espadas, Donna] Baylor Coll Med, Dept Med, Sect Hlth Serv Res, Houston, TX 77030 USA. [McCullough, Laurence B.] Baylor Coll Med, Ctr Med Eth & Hlth Policy, Houston, TX 77030 USA. [Beyth, Rebecca J.] Univ Florida, Coll Med, Dept Med, Geriatr Res Educ Clin Ctr,North Florida South Geo, Gainesville, FL USA. [Ford, Marvella E.] Med Univ South Carolina, Hollings Canc Ctr, Dept Publ Hlth Sci & Canc Dispar, Charleston, SC 29425 USA. [Braun, Ursula K.] Baylor Coll Med, Dept Med, Sect Geriatr, Houston, TX 77030 USA. RP Menon, S (reprint author), VA Med Ctr, 152,2002 Holcombe Blvd, Houston, TX 77030 USA. EM smenon@bcm.edu FU Department of Veterans Affairs, Veterans Health Administration, Health Services Research and Development Service [IIR-02-224]; Geriatric Academic Career Award through the Health Resources and Services Administration [KO1HP20480]; VA Health Services Research and Development Center for Innovations in Quality, Effectiveness, and Safety at the Michael E. DeBakey VA Medical Center in Houston, Texas [CIN 13-413]; Keck Center's Agency for Healthcare Research and Quality training fellowship FX Thanks are extended to the patients and providers who took part in our study. This project was supported by the Department of Veterans Affairs, Veterans Health Administration, Health Services Research and Development Service, grant IIR-02-224 (Ursula Braun, Laurence McCullough). Dr. Braun was also supported by a Geriatric Academic Career Award (KO1HP20480) through the Health Resources and Services Administration. This research was also supported in part by resources at the VA Health Services Research and Development Center for Innovations in Quality, Effectiveness, and Safety (#CIN 13-413) at the Michael E. DeBakey VA Medical Center in Houston, Texas. Dr. Menon was supported by a Keck Center's Agency for Healthcare Research and Quality training fellowship in patient safety and quality. The views expressed in this article are those of the authors and do not necessarily represent the views of the Department of Veterans Affairs, the U.S. government, the Health Resources and Services Administration, or Baylor College of Medicine. NR 39 TC 0 Z9 0 U1 3 U2 3 PU CAMBRIDGE UNIV PRESS PI NEW YORK PA 32 AVENUE OF THE AMERICAS, NEW YORK, NY 10013-2473 USA SN 1478-9515 EI 1478-9523 J9 PALLIAT SUPPORT CARE JI Palliat. Support Care PD AUG PY 2016 VL 14 IS 4 BP 330 EP 340 DI 10.1017/S1478951515001091 PG 11 WC Health Policy & Services SC Health Care Sciences & Services GA DT2DH UT WOS:000381290500004 PM 26458331 ER PT J AU Becerra, MB Becerra, BJ Teodorescu, M AF Becerra, Monideepa B. Becerra, Benjamin J. Teodorescu, Mihaela TI Healthcare burden of obstructive sleep apnea and obesity among asthma hospitalizations: Results from the US-based Nationwide Inpatient Sample SO RESPIRATORY MEDICINE LA English DT Article DE Asthma; Obstructive sleep apnea; Obesity; Nationwide Inpatient Sample; Respiratory therapy ID BODY-MASS INDEX; QUALITY-OF-LIFE; GENDER-DIFFERENCES; INCREASED PREVALENCE; NOCTURNAL ASTHMA; ADULTS; RISK; POPULATION; WOMEN; ASSOCIATION AB Background: Studies have highlighted the significant comorbidities of both obesity and obstructive sleep apnea (OSA) among asthma patients in outpatient settings, but such data in the inpatient setting is sparse. Methods: Using 2009-2011 U.S. Nationwide Inpatient Sample; survey-weighted regression analyses were conducted to address the role of obesity, OSA, and both obesity and OSA on length of stay (LOS), total hospital charges, need for respiratory therapy, and disposition among adults with primary asthma hospitalization (n = 179,789). Results: Males had a higher prevalence of OSA than females (5.23% vs. 3.88%), while females had a higher prevalence of obesity (17.21% vs. 8.95%) and both obesity and OSA (7.11% vs. 6.19%). Increased hospital LOS was associated with presence of obesity (incidence rate ratio [IRR] males = 1.07, IRR females = 1.08), OSA (IRR males = 1.07, IRR females = 1.14), and both obesity and OSA (IRR males = 1.19, IRR females = 1.24). Increased total hospital charges was related to obesity (8.64% for males and 9.61% for females), OSA (15.39% for males and 19.13% for females), and both comorbidities (24.94% for males and 28.50% for females). Presence of OSA alone increased odds of need for respiratory therapy for males (odds ratio [OR] = 2.56) and females (OR = 3.22), as did presence of both comorbidities (OR males = 2.85, OR females = 3.60). Odds of routine disposition was lower among females with both comorbidities (OR = 0.82). Conclusion: Compared to obesity alone, OSA and both obesity and OSA are associated with increased health resource utilization and poorer inpatient outcomes. This demonstrates the need for further clinical investigations of early detection of OSA among such at-risk populations. (C) 2016 Elsevier Ltd. All rights reserved. C1 [Becerra, Monideepa B.] Calif State Univ San Bernardino, Dept Hlth Sci & Human Ecol, San Bernardino, CA 92407 USA. [Becerra, Benjamin J.] Loma Linda Univ, Sch Allied Hlth Profess, Loma Linda, CA 92350 USA. [Teodorescu, Mihaela] William S Middleton Mem Vet Adm Med Ctr, Med Serv, James B Skatrud Pulm Sleep Res Lab, Madison, WI USA. [Teodorescu, Mihaela] Univ Wisconsin, Div Allergy Pulm & Crit Care Med, Sch Med & Publ Hlth, Madison, WI USA. RP Becerra, BJ (reprint author), Loma Linda Univ, Sch Allied Hlth Profess, Loma Linda, CA 92350 USA. EM bbecerra@llu.edu NR 45 TC 0 Z9 0 U1 2 U2 2 PU W B SAUNDERS CO LTD PI LONDON PA 32 JAMESTOWN RD, LONDON NW1 7BY, ENGLAND SN 0954-6111 EI 1532-3064 J9 RESP MED JI Respir. Med. PD AUG PY 2016 VL 117 BP 230 EP 236 DI 10.1016/j.rmed.2016.06.020 PG 7 WC Cardiac & Cardiovascular Systems; Respiratory System SC Cardiovascular System & Cardiology; Respiratory System GA DS5WM UT WOS:000380853700030 PM 27492536 ER PT J AU Roberts, ES Belland, L Rivera-Reyes, L Hwang, U AF Roberts, Eleanor S. Belland, Laura Rivera-Reyes, Laura Hwang, Ula TI The effect of surgical consult in the treatment of abdominal pain in older adults in the ED SO AMERICAN JOURNAL OF EMERGENCY MEDICINE LA English DT Article ID EMERGENCY-DEPARTMENT; POSTOPERATIVE PAIN; ANALGESIA; QUALITY; IMPACT; CARE AB Objective: The objective was to determine whether need for surgical consult contributes to delayed or reduced analgesic administration in older adults presenting to the emergency department with abdominal pain. Methods: Secondary data analyses from a prospective cohort study consisting of adults >= 65 years in age presenting to the emergency department with a chief concern of abdominal pain from November 1, 2012, through October 31, 2014, were performed. Measurements included administration of analgesics, time to administration, type given, and pain score reduction. Covariates for adjusted analyses included age, sex, race/ethnicity, and Emergency Severity Index. Results: A total of 3522 patients were included, of which 281 (8.7%) received any consult. Consult patients were less likely to receive any analgesic medication (53.0%) compared with nonconsult patients (62.5%) (relative risk = 0.80; 95% confidence interval, 0.70-0.91). However, among those patients receiving analgesic medications, there were no differences in likelihood of receiving an opioid, time to administration, or pain score reduction. When analyzing patients who received a surgical consult (n = 154, 4.4%), these associations were notably stronger. Surgical consult patients had a lower rate of analgesic administration (46.8%) compared with nonconsult patients (62.4%) (relative risk = 0.75; 95% confidence interval, 0.63-0.89). Again, no differences were found in likelihood of receiving any opioid, time to administration, or pain score reduction. Conclusion: Need for abdominal surgical consult is associated with decreased administration of analgesics in older patients, possibly indicating a continued need to improve management in this setting. This difference, however, did not impact pain score reductions. (C) 2016 Elsevier Inc. All rights reserved. C1 [Roberts, Eleanor S.; Belland, Laura; Rivera-Reyes, Laura; Hwang, Ula] Icahn Sch Med Mt Sinai, Dept Emergency Med, 1 Gustave L Levy Pl,Box 1062, New York, NY 10029 USA. [Belland, Laura] Columbia Univ, Med Ctr, Ctr Family & Community Med, 610 W 158th St, New York, NY 10032 USA. [Hwang, Ula] Icahn Sch Med Mt Sinai, Brookdale Dept Geriatr & Palliat Med, New York, NY 10029 USA. [Hwang, Ula] James J Peters VAMC, Geriatr Res Educ & Clin Ctr, Bronx, NY USA. RP Roberts, ES (reprint author), 50 E 98th St Apt 8J-3, New York, NY 10029 USA. EM Eleanor.roberts@icahn.mssm.edu FU National Institutes of HealthR21 [AG040734]; Icahn School of Medicine Summer Student Research Stipend FX National Institutes of HealthR21 AG040734 (Hwang); Icahn School of Medicine Summer Student Research Stipend (Roberts). NR 17 TC 0 Z9 0 U1 0 U2 0 PU W B SAUNDERS CO-ELSEVIER INC PI PHILADELPHIA PA 1600 JOHN F KENNEDY BOULEVARD, STE 1800, PHILADELPHIA, PA 19103-2899 USA SN 0735-6757 EI 1532-8171 J9 AM J EMERG MED JI Am. J. Emerg. Med. PD AUG PY 2016 VL 34 IS 8 BP 1524 EP 1527 DI 10.1016/j.ajem.2016.05.010 PG 4 WC Emergency Medicine SC Emergency Medicine GA DS4LK UT WOS:000380752400036 PM 27241564 ER PT J AU Zhong, F Mallipattu, SK Estrada, C Menon, M Salem, F Jain, MK Chen, HY Wang, YJ Lee, K He, JC AF Zhong, Fang Mallipattu, Sandeep K. Estrada, Chelsea Menon, Madhav Salem, Fadi Jain, Mukesh K. Chen, Hongyu Wang, Yongjun Lee, Kyung He, John C. TI Reduced Kruppel-Like Factor 2 Aggravates Glomerular Endothelial Cell Injury and Kidney Disease in Mice with Unilateral Nephrectomy SO AMERICAN JOURNAL OF PATHOLOGY LA English DT Article ID RENAL HEMODYNAMIC-RESPONSE; PROINFLAMMATORY ACTIVATION; TRANSCRIPTION FACTORS; NITRIC-OXIDE; KLF2; EXPRESSION; REGULATOR; DIFFERENTIATION; DEFICIENCY; PODOCYTES AB Loss of functional nephrons induces compensatory glomerular hyperfiltration and hypertrophy, leading to the progression of chronic kidney disease. Kruppel-like factor 2 (KLF2), a shear-stress inducible transcription factor, confers protection against endothelial injury. Because glomerular hyperfiltration is associated with shear stress, we hypothesized that KLF2 may be an important factor in the compensatory response to unilateral nephrectomy (UNX). To test this hypothesis, endothelial cell specific Klf2 heterozygous knockout mice (KO) and their wild-type Littermate control (WT) underwent either UNX or sham-operation. WT-UNX mice developed compensatory renal hypertrophy as expected, whereas K0-UNX mice did not. K0-UNX mice exhibited higher blood pressure, reduced glomerular filtration rate, and significant increase in proteinuria and glomerulosclerosis compared to WT-UNX. Expression of endothelial nitric oxide synthase (official name Nos3), a known transcriptional target gene of KLF2, was significantly reduced and dysregulation of other endothelial genes was also observed in the glomeruli of K0-UNX when compared to WT-UNX and sham-operated mice. Furthermore, both podocyte number and expression of podocyte markers were also significantly reduced in K0-UNX glomeruli, indicating a potential cross talk between glomerular endothelial cells and podocytes. Finally, decreased renal expression of KLF2 in nephrectomy patients was associated with the progression of kidney disease. Taken together, our data demonstrate a protective role of KLF2 against glomerular endothelial cell injury and progression of chronic kidney disease in the model of compensatory renal hypertrophy. C1 [Zhong, Fang; Menon, Madhav; Lee, Kyung; He, John C.] Icahn Sch Med Mt Sinai, Dept Med Nephrol, New York, NY USA. [Salem, Fadi] Icahn Sch Med Mt Sinai, Dept Pathol, New York, NY USA. [Zhong, Fang; Chen, Hongyu; Wang, Yongjun] Zhejiang Chinese Med Univ, Hang Zhou Hosp Tradit Chinese Med, Dept Nephrol, Hangzhou, Zhejiang, Peoples R China. [Mallipattu, Sandeep K.; Estrada, Chelsea] SUNY Stony Brook, Dept Med, Div Nephrol, Stony Brook, NY USA. [Jain, Mukesh K.] Case Western Reserve Univ, Case Cardiovasc Inst Res Inst, Dept Med, Cleveland, OH USA. [He, John C.] James J Peters Vet Affairs Med Ctr, Renal Sect, Bronx, NY USA. RP He, JC (reprint author), Mt Sinai Sch Med, Div Nephrol, Box 1243,One Gustave L Levy Pl, New York, NY 10029 USA. EM cijiang.he@mssm.edu FU Chinese 973 fund [2012CB517601]; VA Merit Award; NIH [1R01DK078897, 1R01DK088541, P01-DK-56492, K08DK102519] FX Supported by Chinese 973 fund 2012CB517601 (J.C.H.), VA Merit Award (J.C.H.), and NIH 1R01DK078897, 1R01DK088541, and P01-DK-56492 (J.C.H.) and K08DK102519 (S.K.M.). NR 37 TC 2 Z9 2 U1 3 U2 5 PU ELSEVIER SCIENCE INC PI NEW YORK PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA SN 0002-9440 EI 1525-2191 J9 AM J PATHOL JI Am. J. Pathol. PD AUG PY 2016 VL 186 IS 8 BP 2021 EP 2031 DI 10.1016/j.ajpath.2016.03.018 PG 11 WC Pathology SC Pathology GA DS2ON UT WOS:000380623500005 PM 27317905 ER PT J AU White, MB Rajagopalan, S Yoshikawa, TT AF White, Mary B. Rajagopalan, Shobita Yoshikawa, Thomas T. TI Infectious Diarrhea Norovirus and Clostridium difficile in Older Adults SO CLINICS IN GERIATRIC MEDICINE LA English DT Article DE Norovirus; Gastroenteritis; Long-term care; Elderly; Clostridium difficile infection; Infectious diarrhea; Long-term care facilities; Aging ID TERM-CARE FACILITIES; HEALTH-CARE; UNITED-STATES; RISK-FACTORS; NORWALK VIRUS; GASTROENTERITIS; OUTBREAKS; PREVENTION; MORTALITY; DISEASE AB Norovirus infection usually results in acute gastroenteritis, often with incapacitating nausea, vomiting, and diarrhea. It is highly contagious and resistant to eradication with alcohol-based hand sanitizer. Appropriate preventative and infection control measures can mitigate the morbidity and mortality associated with norovirus infection. Clostridium difficile infection is the leading cause of health care-associated diarrhea in the United States. Antibiotic use is by far the most common risk factor for C difficile colonization and infection. Appropriate preventive measures and judicious use of antibiotics can help mitigate the morbidity and mortality associated with C difficile infection. C1 [White, Mary B.; Yoshikawa, Thomas T.] VA Greater Los Angeles Healthcare Syst, Dept Vet Affairs, 11300 Wilshire Blvd, Los Angeles, CA 90073 USA. [Rajagopalan, Shobita] Cty Los Angeles Dept Publ Hlth, Curtis Tucker Hlth Ctr, 123 West Manchester Blvd, Inglewood, CA 90301 USA. RP Rajagopalan, S (reprint author), 123 West Manchester Blvd,Suite 220C, Inglewood, CA 90301 USA. EM srajagopalan@ph.lacounty.gov NR 58 TC 0 Z9 1 U1 5 U2 7 PU W B SAUNDERS CO-ELSEVIER INC PI PHILADELPHIA PA 1600 JOHN F KENNEDY BOULEVARD, STE 1800, PHILADELPHIA, PA 19103-2899 USA SN 0749-0690 EI 1879-8853 J9 CLIN GERIATR MED JI Clin. Geriatr. Med. PD AUG PY 2016 VL 32 IS 3 BP 509 EP + DI 10.1016/j.cger.2016.02.008 PG 15 WC Geriatrics & Gerontology SC Geriatrics & Gerontology GA DS7NA UT WOS:000380969000008 PM 27394020 ER PT J AU Scott, J Goetz, MB AF Scott, Jake Goetz, Matthew Bidwell TI Human Immunodeficiency Virus/Acquired Immunodeficiency Syndrome in Older Adults SO CLINICS IN GERIATRIC MEDICINE LA English DT Article DE Human immunodeficiency virus; Acquired immunodeficiency syndrome; Antiretroviral therapy; Immunocompromised host; Epidemiology ID COMBINATION ANTIRETROVIRAL THERAPY; HIV MEDICINE ASSOCIATION; METABOLIC SYNDROME; MYOCARDIAL-INFARCTION; INCREASED RISK; UNITED-STATES; INFECTION; DIAGNOSIS; DISEASES; COLLABORATION AB Improved survival with combination antiretroviral therapy has led to a dramatic increase in the number of human immunodeficiency virus (HIV)-infected individuals 50 years of age or older such that by 2020 more than 50% of HIV -infected persons in the United States will be above this age. Recent studies confirm that antiretroviral therapy should be offered to all HIV -infected patients regardless of age, symptoms, CD4+ cell count, or HIV viral load. However, when compared with HIV-uninfected populations, even with suppression of measurable HIV replication, older individuals are at greater risk for cardiovascular disease, malignancies, liver disease, and other comorbidities. C1 [Scott, Jake; Goetz, Matthew Bidwell] Univ Calif Los Angeles, David Geffen Sch Med, Infect Dis Sect, VA Greater Los Angeles Healthcare Syst,Dept Med, 11301 Wilshire Blvd, Los Angeles, CA 90073 USA. RP Goetz, MB (reprint author), VA Greater Los Angeles Healthcare Syst, Infect Dis, 111-F,11301 Wilshire Blvd, Los Angeles, CA 90073 USA. EM Matthew.Goetz@va.gov NR 35 TC 0 Z9 0 U1 1 U2 1 PU W B SAUNDERS CO-ELSEVIER INC PI PHILADELPHIA PA 1600 JOHN F KENNEDY BOULEVARD, STE 1800, PHILADELPHIA, PA 19103-2899 USA SN 0749-0690 EI 1879-8853 J9 CLIN GERIATR MED JI Clin. Geriatr. Med. PD AUG PY 2016 VL 32 IS 3 BP 571 EP + DI 10.1016/j.cger.2016.02.010 PG 14 WC Geriatrics & Gerontology SC Geriatrics & Gerontology GA DS7NA UT WOS:000380969000012 PM 27394024 ER PT J AU Wang, Z Mandel, H Levingston, CA Young, MRI AF Wang, Zhewu Mandel, Howard Levingston, Corinne A. Young, M. Rita I. TI An exploratory approach demonstrating immune skewing and a loss of coordination among cytokines in plasma and saliva of Veterans with combat-related PTSD SO HUMAN IMMUNOLOGY LA English DT Article DE Cytokines; Immune regulation; Inflammation; Plasma; Post-traumatic stress disorder; PTSD; Saliva ID POSTTRAUMATIC-STRESS-DISORDER; DSM-IV; BRAIN; INFLAMMATION; DISEASE; MODEL; INTERLEUKIN-6; PREVALENCE; DEPRESSION; BIOMARKERS AB Studies have suggested PTSD to be associated with an inflammatory state, although few studies have examined the balances between stimulatory and inhibitory immune mediators in PTSD. An exploratory approach was taken to assess the immune imbalances between Th1 stimulatory, inflammatory and inhibitory mediators associated with PTSD. This approach focused on a tightly-controlled and relatively homogeneous population of Veterans, all with similar levels of combat exposure in the Afghanistan and Iraq wars, but some testing negative and others testing positive for PTSD. Although the sample size was small (6 controls and 7 with PTSD) and a limitation of this study, the results showed significant imbalances in immune cytokines favoring a Th1 and inflammatory state, with reduced levels of inhibitory cytokines in Veterans with PTSD. This was particularly prominent in the saliva of PTSD subjects compared to in their plasma. Published by Elsevier Inc. C1 [Wang, Zhewu; Mandel, Howard; Levingston, Corinne A.; Young, M. Rita I.] Ralph H Johnson VA Med Ctr, 109 Bee St, Charleston, SC 29401 USA. [Wang, Zhewu; Young, M. Rita I.] Med Univ South Carolina, Charleston, SC USA. RP Young, MRI (reprint author), Ralph H Johnson VA Med Ctr, 109 Bee St, Charleston, SC 29401 USA. EM youngmr@musc.edu FU Clinical Sciences Research & Development Program of the Department of Veterans Affairs (Merit Review Grants) [1 I01 CX000851, 1 I01 CX000487] FX This work was supported by the Clinical Sciences Research & Development Program of the Department of Veterans Affairs (Merit Review Grants 1 I01 CX000851 to MRIY and 1 I01 CX000487 to ZW). NR 42 TC 0 Z9 0 U1 5 U2 5 PU ELSEVIER SCIENCE INC PI NEW YORK PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA SN 0198-8859 EI 1879-1166 J9 HUM IMMUNOL JI Hum. Immunol. PD AUG PY 2016 VL 77 IS 8 BP 652 EP 657 DI 10.1016/j.humimm.2016.05.018 PG 6 WC Immunology SC Immunology GA DS7NV UT WOS:000380971100009 PM 27216157 ER PT J AU Morinelli, TA Luttrell, LM Strungs, EG Ullian, ME AF Morinelli, Thomas A. Luttrell, Louis M. Strungs, Erik G. Ullian, Michael E. TI Angiotensin II receptors and peritoneal dialysis-induced peritoneal fibrosis SO INTERNATIONAL JOURNAL OF BIOCHEMISTRY & CELL BIOLOGY LA English DT Article DE Angiotensin II; Arrestin; AT1R; Fibrosis; Peritoneal mesothelial cells ID SMOOTH-MUSCLE-CELLS; PROTEIN-COUPLED RECEPTORS; GROWTH-FACTOR-BETA; NF-KAPPA-B; TYPE-1 RECEPTOR; AT(1) RECEPTOR; MESOTHELIAL CELLS; BLOOD-PRESSURE; HIGH GLUCOSE; NUCLEAR-LOCALIZATION AB The vasoactive hormone angiotensin II initiates its major hemodynamic effects through interaction with AT1 receptors, a member of the class of G protein-coupled receptors. Acting through its AT1R, angiotensin II regulates blood pressure and renal salt and water balance. Recent evidence points to additional pathological influences of activation of AT1R, in particular inflammation, fibrosis and atherosclerosis. The transcription factor nuclear factor kappa B, a key mediator in inflammation and atherosclerosis, can be activated by angiotensin II through a mechanism that may involve arrestin-dependent AT1 receptor internalization. Peritoneal dialysis is a therapeutic modality for treating patients with end-stage kidney disease. The effectiveness of peritoneal dialysis at removing waste from the circulation is compromised over time as a consequence of peritoneal dialysis-induced peritoneal fibrosis. The non-physiological dialysis solution used in peritoneal dialysis, i.e. highly concentrated, hyperosmotic glucose, acidic pH as well as large volumes infused into the peritoneal cavity, contributes to the development of fibrosis. Numerous trials have been conducted altering certain components of the peritoneal dialysis fluid in hopes of preventing or delaying the fibrotic response with limited success. We hypothesize that structural activation of AT1R by hyperosmotic peritoneal dialysis fluid activates the internalization process and subsequent signaling through the transcription factor nuclear factor kappa B, resulting in the generation of pro-fibrotic/pro-inflammatory mediators producing peritoneal fibrosis. (C) 2016 Elsevier Ltd. All rights reserved. C1 [Morinelli, Thomas A.; Ullian, Michael E.] Med Univ South Carolina, Dept Med, Div Nephrol, Charleston, SC 29425 USA. [Luttrell, Louis M.; Strungs, Erik G.] Med Univ South Carolina, Div Endocrinol, Dept Med, Charleston, SC 29425 USA. [Luttrell, Louis M.; Ullian, Michael E.] Ralph H Johnson Vet Affairs Med Ctr, Res Serv, Charleston, SC 29401 USA. RP Morinelli, TA (reprint author), Med Univ South Carolina, Dept Med, Div Nephrol, Charleston, SC 29425 USA. EM morinelt@musc.edu FU Dialysis Clinic, Incorporated; National Institutes of Health [R01 DK55524, GM095497]; Research Service of the Charleston, SC Veterans Affairs Medical Center FX The work was supported by Dialysis Clinic, Incorporated (T.A.M./M.E.U.), National Institutes of Health Grant R01 DK55524 AND GM095497 (L.M.L.) and the Research Service of the Charleston, SC Veterans Affairs Medical Center (L.M.L./M.E.U.). The contents of this article do not represent the views of the Department of Veterans Affairs or the United States Government NR 127 TC 0 Z9 0 U1 2 U2 2 PU PERGAMON-ELSEVIER SCIENCE LTD PI OXFORD PA THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, ENGLAND SN 1357-2725 EI 1878-5875 J9 INT J BIOCHEM CELL B JI Int. J. Biochem. Cell Biol. PD AUG PY 2016 VL 77 BP 240 EP 250 DI 10.1016/j.biocel.2016.04.016 PN B PG 11 WC Biochemistry & Molecular Biology; Cell Biology SC Biochemistry & Molecular Biology; Cell Biology GA DT7EN UT WOS:000381650000009 PM 27167177 ER PT J AU Senders, A Sando, K Wahbeh, H Hiller, AP Shinto, L AF Senders, Angela Sando, Kelsi Wahbeh, Helane Hiller, Amie Peterson Shinto, Lynne TI Managing psychological stress in the multiple sclerosis medical visit: Patient perspectives and unmet needs SO JOURNAL OF HEALTH PSYCHOLOGY LA English DT Article DE health psychology; patient satisfaction; psychological distress; qualitative methods; verbal communication ID PRIMARY-CARE; RANDOMIZED-TRIAL; LIFE EVENTS; HEALTH; MS; MANAGEMENT; METAANALYSIS; DEPRESSION; ILLNESS; LESIONS AB Psychological stress can negatively impact multiple sclerosis. To further understand how stress is addressed in the multiple sclerosis medical visit, 34 people with multiple sclerosis participated in focus groups. Transcripts were analyzed by inductive thematic analysis. The majority of participants did not discuss stress with their provider, citing barriers to communication such as lack of time, poor coordination between specialties, physician reliance on pharmaceutical prescription, and patient lack of self-advocacy. Participants recommended several ways to better manage psychological well-being in the clinical setting. These findings provide a foundation for future studies aimed at minimizing the detrimental effect of stress in multiple sclerosis. C1 [Senders, Angela; Wahbeh, Helane; Hiller, Amie Peterson; Shinto, Lynne] Oregon Hlth & Sci Univ, Portland, OR 97201 USA. [Senders, Angela; Sando, Kelsi] Natl Coll Nat Med, Portland, OR USA. [Hiller, Amie Peterson] Portland VA Med Ctr, Portland, OR USA. RP Senders, A (reprint author), Oregon Hlth & Sci Univ, Dept Neurol, 3181 SW Sam Jackson Pk Rd,Mail Code CR120, Portland, OR 97239 USA. EM senders@ohsu.edu FU Oregon Clinical & Translational Research Institute from the National Center for Research Resources [UL1 RR024140]; National Center for Advancing Translational Sciences of the National Institutes of Health); National Center for Complementary and Alternative Medicine of the National Institutes of Health [AT002688, 2R25AT002878-05A1]; Agency for Healthcare Research Quality [5T32HS017582-05] FX The authors disclosed receipt of the following financial support for the research, authorship, and/or publication of this article: This work was supported by the Oregon Clinical & Translational Research Institute (grant number UL1 RR024140 from the National Center for Research Resources and the National Center for Advancing Translational Sciences of the National Institutes of Health); the National Center for Complementary and Alternative Medicine of the National Institutes of Health (grant numbers AT002688 and 2R25AT002878-05A1); and the Agency for Healthcare Research Quality (grant number 5T32HS017582-05). NR 42 TC 2 Z9 2 U1 4 U2 4 PU SAGE PUBLICATIONS LTD PI LONDON PA 1 OLIVERS YARD, 55 CITY ROAD, LONDON EC1Y 1SP, ENGLAND SN 1359-1053 EI 1461-7277 J9 J HEALTH PSYCHOL JI J. Health Psychol. PD AUG PY 2016 VL 21 IS 8 BP 1676 EP 1687 DI 10.1177/1359105314562084 PG 12 WC Psychology, Clinical SC Psychology GA DS7UL UT WOS:000380988300017 PM 25527612 ER PT J AU Just, E Casarett, DJ Asch, DA Dai, DW Feudtner, C AF Just, Erica Casarett, David J. Asch, David A. Dai, Dingwei Feudtner, Chris TI Differences in Terminal Hospitalization Care Between US Men and Women SO JOURNAL OF PAIN AND SYMPTOM MANAGEMENT LA English DT Article DE Sex differences; end-of-life care ID SEX-BASED DISPARITIES; OF-LIFE CARE; UNITED-STATES; MEDICATION USE; OUTCOMES; GENDER; RATES AB Context. In many settings, men and women receive different care. Objectives. We sought to determine whether men and women receive different care during terminal hospitalizations. Methods. We analyzed data of 98,314 adult patients who died while hospitalized in 458 acute care hospitals in the U.S. during 2011. We examined sex-based differences in lengths of stay (LOS), resuscitation status, and intensive interventions and processes of care, adjusting for patient-and hospital-level characteristics. Results. Women represented half of the sample (48,509; 49.34%), were older than men (73.8 vs. 70.6 years, P < 0.0001), and less likely to be married (27.7% vs. 48.3%, P < 0.001). Among all patients, median LOS was four days (interquartile range 2-10); 19.1% of subjects received cardiopulmonary resuscitation; 37.6% had a do-not-resuscitate order during the admission; and 51.6% received mechanical ventilation. Compared with men, women had slightly shorter hospitalizations (adjusted LOS: - 0.16 days; 95% CI - 0.19, - 0.12) and were more likely to have a do-not-resuscitate order (odds ratio [ OR] 1.08; 95% CI 1.05, 1.11). Women remained less likely to receive care in an intensive care unit (OR 0.95; 95% CI 0.93, 0.98), cardiopulmonary resuscitation (OR 0.83; 95% CI 0.80, 0.86), mechanical ventilation (OR 0.94; 95% CI 0.91, 0.97), hemodialysis (adjusted OR 0.81; 95% CI 0.78, 0.86), or surgical procedures (OR 0.88; 95% CI 0.84, 0.93). Conclusion. Men who die in hospitals receive more aggressive care than women. Further research should examine potential causes of this overall pattern. (C) 2016 American Academy of Hospice and Palliative Medicine. Published by Elsevier Inc. All rights reserved. C1 [Just, Erica] Tulane Univ, Sch Med, Dept Med, New Orleans, LA 70112 USA. [Just, Erica] Tulane Univ, Sch Med, Dept Pediat, New Orleans, LA 70112 USA. [Casarett, David J.; Asch, David A.] Univ Penn, Dept Med, Perelman Sch Med, Philadelphia, PA 19104 USA. [Casarett, David J.] Univ Penn, Dept Med Eth & Hlth Policy, Perelman Sch Med, Philadelphia, PA 19104 USA. [Feudtner, Chris] Univ Penn, Dept Pediat, Perelman Sch Med, Philadelphia, PA 19104 USA. [Casarett, David J.; Asch, David A.; Feudtner, Chris] Univ Penn, Leonard Davis Inst, Philadelphia, PA 19104 USA. [Asch, David A.] Philadelphia VA Med Ctr, VA Ctr Hlth Equ Res & Promot, Philadelphia, PA USA. [Dai, Dingwei; Feudtner, Chris] Childrens Hosp Philadelphia, CHOP North Room 1523,34th & Civ Ctr Blvd, Philadelphia, PA 19104 USA. RP Feudtner, C (reprint author), Childrens Hosp Philadelphia, CHOP North Room 1523,34th & Civ Ctr Blvd, Philadelphia, PA 19104 USA. EM feudtner@email.chop.edu OI Feudtner, Chris/0000-0002-5879-0434 FU Health Resources and Services Administration (HRSA) [T32 HP10026]; AHRQ [R01HS018425] FX This study was supported by Health Resources and Services Administration (HRSA) T32 HP10026 and AHRQ R01HS018425. The funding organizations had no role in the design of the study beyond the critique offered by the peer-review process and had no role in the conduct of the study, including the collection, analysis, and preparation of the data or the drafting, editing, review, or approval of the manuscript. The content is solely the responsibility of the authors and does not necessarily represent the official views of the Agency for Healthcare Research and Quality. The authors declare that they have no relevant financial relationships to disclose. The authors thank Wenjun Zhong for assistance with the preparation of the manuscript. NR 23 TC 0 Z9 0 U1 1 U2 2 PU ELSEVIER SCIENCE INC PI NEW YORK PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA SN 0885-3924 EI 1873-6513 J9 J PAIN SYMPTOM MANAG JI J. Pain Symptom Manage. PD AUG PY 2016 VL 52 IS 2 BP 205 EP 211 DI 10.1016/j.jpainsymman.2016.01.013 PG 7 WC Health Care Sciences & Services; Medicine, General & Internal; Clinical Neurology SC Health Care Sciences & Services; General & Internal Medicine; Neurosciences & Neurology GA DT7RD UT WOS:000381683000009 PM 27220946 ER PT J AU Smith, AK Ritchie, CS Wallhagen, ML AF Smith, Alexander K. Ritchie, Christine S. Wallhagen, Margaret L. TI Hearing Loss in Hospice and Palliative Care: A National Survey of Providers SO JOURNAL OF PAIN AND SYMPTOM MANAGEMENT LA English DT Article DE Hearing loss; aging; hospice; palliative care; communication ID OLDER-ADULTS; AID USE; PREVALENCE; EPIDEMIOLOGY; IMPAIRMENT AB Context. Age-related hearing loss can impair patient-provider communication about symptom management, goals of care, and end-of-life decision-making. Objectives. To determine whether hospice and palliative care providers screen for or received training about hearing loss, believe it impacts patient care, and use strategies to optimize communication. Methods. This was a national survey of hospice and palliative care providers conducted via email and social media. Survey questions were pilot tested with multidisciplinary providers in San Francisco. Results. Of 510 responses (55% age 50+ years, 65% female, 64% in practice 5+ years, 57% practiced hospital-based palliative care, 45% hospice), 315 were physicians, 50 nurses, 48 nurse practitioners, 58 social workers, and 39 chaplains. Ninety-one percent reported that hearing loss has some or great impact on the quality of care for older adults. Eighty-eight percent recalled a situation where hearing loss created a communication problem with a patient and 56% a communication problem with a caregiver. Eighty-seven percent of physicians, nurses, and nurse practitioners reported not screening for hearing loss. Although 61% felt comfortable with their communication skills for patients with hearing loss, only 21% reported having received formal training in its management, 31% were unfamiliar with resources for patients with hearing loss, and 38% had never heard of a pocket talker amplification device. Conclusion. Hospice and palliative medicine providers believe age-related hearing loss impacts care yet most do not screen. Although they feel they are managing well, few have formal training. Knowledge about management approaches and resources is suboptimal. (C) 2016 American Academy of Hospice and Palliative Medicine. Published by Elsevier Inc. All rights reserved. C1 [Smith, Alexander K.; Ritchie, Christine S.] Univ Calif San Francisco, Div Geriatr, San Francisco, CA 94143 USA. [Wallhagen, Margaret L.] Univ Calif San Francisco, Dept Physiol Nursing, San Francisco, CA USA. [Smith, Alexander K.] Vet Affairs Med Ctr, Geriatr Palliat & Extended Care, San Francisco, CA 94121 USA. [Ritchie, Christine S.] Jewish Home San Francisco, San Francisco, CA USA. RP Smith, AK (reprint author), UCSF, San Francisco VA Med Ctr, Div Geriatr, 4150 Clement St,181G, San Francisco, CA 94121 USA. EM aksmith@ucsf.edu FU National Institute on Aging [1K23AG040772]; American Federation for Aging Research FX Dr. Smith was funded by a K23 Beeson award from the National Institute on Aging (1K23AG040772) and the American Federation for Aging Research. The authors have no other disclosures. NR 12 TC 1 Z9 1 U1 2 U2 4 PU ELSEVIER SCIENCE INC PI NEW YORK PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA SN 0885-3924 EI 1873-6513 J9 J PAIN SYMPTOM MANAG JI J. Pain Symptom Manage. PD AUG PY 2016 VL 52 IS 2 BP 254 EP 258 DI 10.1016/j.jpainsymman.2016.02.007 PG 5 WC Health Care Sciences & Services; Medicine, General & Internal; Clinical Neurology SC Health Care Sciences & Services; General & Internal Medicine; Neurosciences & Neurology GA DT7RD UT WOS:000381683000015 PM 27046300 ER PT J AU Liu, YM Cohen, ME Hall, BL Ko, CY Bilimoria, KY AF Liu, Yaoming Cohen, Mark E. Hall, Bruce L. Ko, Clifford Y. Bilimoria, Karl Y. TI Evaluation and Enhancement of Calibration in the American College of Surgeons NSQIP Surgical Risk Calculator SO JOURNAL OF THE AMERICAN COLLEGE OF SURGEONS LA English DT Article ID PREDICTION MODELS; REGRESSION-MODELS; ADJUSTMENT; INDIVIDUALS; QUALITY AB BACKGROUND: The American College of Surgeon (ACS) NSQIP Surgical Risk Calculator has been widely adopted as a decision aid and informed consent tool by surgeons and patients. Previous evaluations showed excellent discrimination and combined discrimination and calibration, but model calibration alone, and potential benefits of recalibration, were not explored. Because lack of calibration can lead to systematic errors in assessing surgical risk, our objective was to assess calibration and determine whether spline-based adjustments could improve it. STUDY DESIGN: We evaluated Surgical Risk Calculator model calibration, as well as discrimination, for each of 11 outcomes modeled from nearly 3 million patients (2010 to 2014). Using independent random subsets of data, we evaluated model performance for the Development (60% of records), Validation (20%), and Test (20%) datasets, where prediction equations from the Development dataset were recalibrated using restricted cubic splines estimated from the Validation dataset. We also evaluated performance on data subsets composed of higher-risk operations. RESULTS: The nonrecalibrated Surgical Risk Calculator performed well, but there was a slight tendency for predicted risk to be overestimated for lowest- and highest-risk patients and underestimated for moderate-risk patients. After recalibration, this distortion was eliminated, and p values for miscalibration were most often nonsignificant. Calibration was also excellent for subsets of higher-risk operations, though observed calibration was reduced due to instability associated with smaller sample sizes. CONCLUSIONS: Performance of NSQIP Surgical Risk Calculator models was shown to be excellent and improved with recalibration. Surgeons and patients can rely on the calculator to provide accurate estimates of surgical risk. (C) 2016 by the American College of Surgeons. Published by Elsevier Inc. All rights reserved. C1 [Liu, Yaoming; Cohen, Mark E.; Hall, Bruce L.; Ko, Clifford Y.; Bilimoria, Karl Y.] Amer Coll Surg, Div Res & Optimal Patient Care, Chicago, IL USA. [Bilimoria, Karl Y.] Northwestern Univ, SOQIC, Dept Surg, Chicago, IL 60611 USA. [Bilimoria, Karl Y.] Northwestern Univ, Ctr Healthcare Studies, Feinberg Sch Med, Chicago, IL 60611 USA. [Bilimoria, Karl Y.] Northwestern Univ, Northwestern Med, Chicago, IL 60611 USA. [Hall, Bruce L.] Washington Univ, Dept Surg, St Louis, MO USA. [Hall, Bruce L.] Washington Univ, Ctr Hlth Policy, St Louis, MO USA. [Hall, Bruce L.] Washington Univ, Olin Business Sch, St Louis, MO USA. [Hall, Bruce L.] John Cochran Vet Affairs Med Ctr, St Louis, MO USA. [Hall, Bruce L.] BJC Healthcare, St Louis, MO USA. [Ko, Clifford Y.] Univ Calif Los Angeles, David Geffen Sch Med, Los Angeles, CA 90095 USA. [Ko, Clifford Y.] VA Greater Los Angeles Healthcare Syst, Los Angeles, CA USA. RP Cohen, ME (reprint author), Amer Coll Surg, 633 N St Clair St,22nd Floor, Chicago, IL 60611 USA. EM markcohen@facs.org NR 18 TC 5 Z9 5 U1 0 U2 1 PU ELSEVIER SCIENCE INC PI NEW YORK PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA SN 1072-7515 EI 1879-1190 J9 J AM COLL SURGEONS JI J. Am. Coll. Surg. PD AUG PY 2016 VL 223 IS 2 BP 231 EP 239 DI 10.1016/j.jamcollsurg.2016.03.040 PG 9 WC Surgery SC Surgery GA DS4KY UT WOS:000380751200007 PM 27212006 ER PT J AU Fathi, R Sheehan, OC Garrigues, SK Saliba, D Leff, B Ritchie, CS AF Fathi, Roya Sheehan, Orla C. Garrigues, Sarah K. Saliba, Debra Leff, Bruce Ritchie, Christine S. TI Development of an Interdisciplinary Team Communication Framework and Quality Metrics for Home-Based Medical Care Practices SO JOURNAL OF THE AMERICAN MEDICAL DIRECTORS ASSOCIATION LA English DT Article DE Long-term care; interdisciplinary access; home care; house calls; communication; care coordination ID JUST-IN-TIME; PALLIATIVE CARE; HEALTH-CARE; APPROPRIATENESS METHOD; DECISION-MAKING; UNITED-STATES; IMPACT; STANDARDS; OUTCOMES; RECORD AB Background: The unique needs of homebound adults receiving home-based medical care (HBMC) (ie, home-based primary care and home-based palliative care services) are ideally provided by interdisciplinary care teams (IDTs) that provide coordinated care. The composition of team members from an array of organizations and the unique dimension of providing care in the home present specific challenges to timely access and communication of patient care information. The objective of this work was to develop a conceptual framework and corresponding quality indicators (QIs) that assess how IDT members for HBMC practices access and communicate key patient information with each other. Methods: A systematic review of peer-reviewed and gray literature was performed to inform a framework for care coordination in the home and the development of candidate QIs to assess processes by which all IDT members optimally access and use patient information. A technical expert panel (TEP) participated in a modified Delphi process to assess the validity and feasibility of each QI and to identify which would be most suitable for testing in the field. Results: Thematic analysis of literature revealed 4 process themes for how HBMC practices might engage in high-quality care coordination: using electronic medical records, conducting interdisciplinary team meetings, sharing standardized patient assessments, and communicating via secure e-messaging. Based on these themes, 9 candidate QIs were developed to reflect these processes. Three candidate QIs were assessed by the TEP as valid and feasible to measure in an HBMC practice setting. These indicators focused on use of IDT meetings, standardized patient assessments, and secure e-messaging. Conclusion: Translating the complex issue of care coordination into QIs will improve care delivered to vulnerable home-limited adults who receive HBMC. Guided by the literature, we developed a framework to reflect optimal care coordination in the home setting and identified 3 candidate QIs to field-test in HBMC practices. Published by Elsevier Inc. on behalf of AMDA - The Society for Post-Acute and Long-Term Care Medicine. This is an open access article under the CC BY-NC-ND license. C1 [Fathi, Roya; Garrigues, Sarah K.; Ritchie, Christine S.] Univ Calif San Francisco, Div Geriatr, 3333 Calif St,Suite 380, San Francisco, CA 94145 USA. [Fathi, Roya] San Francisco VA Med Ctr, VA Qual Scholars Fellowship Program, San Francisco, CA USA. [Sheehan, Orla C.] Johns Hopkins Univ, Sch Med, Ctr Aging & Hlth, Div Geriatr Med & Gerontol, Baltimore, MD USA. [Saliba, Debra] Univ Calif Los Angeles, JH Borun Ctr, Los Angeles, CA USA. [Saliba, Debra] Los Angeles VA GRECC, Los Angeles, CA USA. [Leff, Bruce] Johns Hopkins Univ, Sch Med, Div Geriatr Med & Gerontol, Baltimore, MD USA. [Ritchie, Christine S.] Jewish Home San Francisco, San Francisco, CA USA. RP Fathi, R (reprint author), Univ Calif San Francisco, Div Geriatr, 3333 Calif St,Suite 380, San Francisco, CA 94145 USA. EM roya.fathi@ucsf.edu FU Commonwealth Fund [20140041] FX This work was supported by the Commonwealth Fund (20140041), a national private foundation based in New York City that supports independent research on health care and makes grants to improve health care practice and policy. The views presented here are those of the authors and not necessarily those of the Commonwealth Fund, its directors, officers, or staff. NR 60 TC 0 Z9 0 U1 6 U2 14 PU ELSEVIER SCIENCE INC PI NEW YORK PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA SN 1525-8610 EI 1538-9375 J9 J AM MED DIR ASSOC JI J. Am. Med. Dir. Assoc. PD AUG 1 PY 2016 VL 17 IS 8 BP 725 EP + DI 10.1016/j.jamda.2016.03.018 PG 15 WC Geriatrics & Gerontology SC Geriatrics & Gerontology GA DS4OF UT WOS:000380759700010 PM 27217093 ER PT J AU Huang, G Wharton, W Bhasin, S Harman, SM Pencina, KM Tsitouras, P Li, ZY Hally, KA Asthana, S Storer, TW Basaria, S AF Huang, Grace Wharton, Whitney Bhasin, Shalender Harman, S. Mitchell Pencina, Karol M. Tsitouras, Panayiotis Li, Zhuoying Hally, Kathleen A. Asthana, Sanjay Storer, Thomas W. Basaria, Shehzad TI Effects of long-term testosterone administration on cognition in older men with low or low-to-normal testosterone concentrations: a prespecified secondary analysis of data from the randomised, double-blind, placebo-controlled TEAAM trial SO LANCET DIABETES & ENDOCRINOLOGY LA English DT Article ID HEALTH INITIATIVE MEMORY; ESTROGEN PLUS PROGESTIN; ALZHEIMER-DISEASE; ELDERLY-MEN; VISUOSPATIAL COGNITION; POSTMENOPAUSAL WOMEN; SERUM TESTOSTERONE; BRAIN; SUPPLEMENTATION; DECLINE AB Background The effects of testosterone on cognitive function in older men are incompletely understood. We aimed to establish the effects of long-term testosterone administration on multiple domains of cognitive function in older men with low or low-to-normal testosterone concentrations. Methods We did the randomised, double-blind, placebo-controlled, parallel-group TEAAM trial at three medical centres in Boston, Phoenix, and Los Angeles, USA. Men aged 60 years and older with low or low-to-normal testosterone concentrations (3.47-13.9 nmol/L, or free testosterone <173 pmol/L) were randomly assigned (1: 1), via computer-generated randomisation, to receive either 7.5 g of 1% testosterone gel or placebo gel daily for 3 years. Randomisation was stratified by age (60-75 years vs >75 years) and study site. The testosterone dose was adjusted to achieve concentrations of 17.3-31.2 nmol/L. Participants and all study personnel were masked to treatment allocation. Multiple domains of cognitive function were assessed as prespecified secondary outcomes by use of standardised tests at baseline and months 6, 18, and 36. We did analyses by intention to treat (in men who had baseline assessments of cognitive function) and per protocol (restricted to participants who completed the study drug and had both baseline and 36 month assessments of cognitive function). The TEAAM trial is registered with ClinicalTrials.gov, number NCT00287586. Findings Between Sept 1, 2004, and Feb 12, 2009, we randomly assigned 308 participants to receive either testosterone (n=156) or placebo (n=152). 280 men had baseline cognitive assessments (n=140 per group). Mean follow-up time was 29.0 months (SD 11.5) in the testosterone group and 31.1 months (9.5) in the placebo group. The last participant completed the study on May 11, 2012. In the testosterone group, mean concentrations of serum total testosterone increased from 10.6 nmol/L (SD 2.2) to 19.7 nmol/L (9.2) and free testosterone concentrations increased from 222 pmol/L (62) to 364 pmol/L (222). In the placebo group, mean concentrations of serum total testosterone were 10.7 nmol/L (SD 2.3) at baseline and 11.1 nmol/L (3.2) post-intervention and free testosterone concentrations were 210 pmol/L (61) and 172 pmol/L (49), respectively. We recorded no between-group differences in changes in visuospatial ability (mean difference: Complex Figure Test -0.51, 95% CI -2.0 to 1.0), phonemic or category verbal fluency (phonemic fluency test 0.90, -1.3 to 3.1; categorical fluency test 1.1, -0.3 to 2.6), verbal memory (paragraph recall test 0.29, -1.2 to 1.8), manual dexterity (Grooved Pegboard Test 4.2, -1.3 to 9.7), and attention or executive function (Stroop Interference Test -2.6, -7.4 to 2.3) after adjustment for age, education, and baseline cognitive function. In both the intention-to-treat and per-protocol (n=86 per group) populations, changes in cognitive function scores were not related significantly to changes in total or free testosterone, or oestradiol concentrations. Interpretation Testosterone administration for 36 months in older men with low or low-to-normal testosterone concentrations did not improve cognitive function. Future long-term trials are needed to investigate the efficacy of testosterone replacement in patients with impaired cognition, such as people with Alzheimer's disease. C1 [Huang, Grace; Bhasin, Shalender; Pencina, Karol M.; Li, Zhuoying; Hally, Kathleen A.; Storer, Thomas W.; Basaria, Shehzad] Harvard Med Sch, Brigham & Womens Hosp, Sect Mens Hlth Aging & Metab, Boston, MA 02115 USA. [Wharton, Whitney] Emory Univ, Dept Neurol, Atlanta, GA 30322 USA. [Harman, S. Mitchell; Tsitouras, Panayiotis] Kronos Longev Res Inst, Phoenix, AZ USA. [Harman, S. Mitchell] Phoenix VA Hlth Care Syst, Phoenix, AZ USA. [Tsitouras, Panayiotis] Univ Oklahoma, Hlth Sci Ctr, Dept Geriatr Med, Oklahoma City, OK USA. [Asthana, Sanjay] Univ Wisconsin, Sch Med & Publ Hlth, Madison, WI USA. [Asthana, Sanjay] William S Middleton Mem Vet Adm Med Ctr, Geriatr Res Educ & Clin Ctr, Madison, WI USA. [Asthana, Sanjay] Wisconsin Alzheimers Dis Res Ctr, Madison, WI USA. RP Huang, G (reprint author), Harvard Med Sch, Brigham & Womens Hosp, Sect Mens Hlth Aging & Metab, Boston, MA 02115 USA. EM ghuang7@partners.org FU AbbVie Pharmaceuticals; Aurora Foundation; Boston Claude D Pepper Older Americans Independence Center; Boston University's Clinical and Translational Science Institute FX AbbVie Pharmaceuticals, Aurora Foundation, Boston Claude D Pepper Older Americans Independence Center, and Boston University's Clinical and Translational Science Institute. NR 32 TC 1 Z9 1 U1 5 U2 7 PU ELSEVIER SCIENCE INC PI NEW YORK PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA SN 2213-8587 J9 LANCET DIABETES ENDO JI Lancet Diabetes Endocrinol. PD AUG PY 2016 VL 4 IS 8 BP 657 EP 665 DI 10.1016/S2213-8587(16)30102-4 PG 9 WC Endocrinology & Metabolism SC Endocrinology & Metabolism GA DS4OY UT WOS:000380761600019 PM 27377542 ER PT J AU Wang, HD Wolock, TM Carter, A Nguyen, G Kyu, HH Gakidou, E Hay, SI Mills, EJ Trickey, A Msemburi, W Coates, MM Mooney, MD Fraser, MS Sligar, A Salomon, J Larson, HJ Friedman, J Abajobir, AA Abate, KH Abbas, KM Abd El Razek, MM Abd-Allah, F Abdulle, AM Abera, SF Abubakar, I Abu-Raddad, LJ Abu-Rmeileh, NME Abyu, GY Adebiyi, AO Adedeji, IA Adelekan, AL Adofo, K Adou, AK Ajala, ON Akinyemiju, TF Akseer, N Al Lami, FH Al-Aly, Z Alam, K Alam, NKM Alasfoor, D Aldhahri, SFS Aldridge, RW Alegretti, MA Aleman, AV Alemu, ZA Alfonso-Cristancho, R Ali, R Alkerwi, A Alla, F Al-Raddadi, RMS Alsharif, U Alvarez, E Alvis-Guzman, N Amare, AT Amberbir, A Amegah, AK Ammar, W Amrock, SM Antonio, CAT Anwari, P Arnlov, J Al Artaman, Asayesh, H Asghar, RJ Assadi, R Atique, S Atkins, LS Avokpaho, EFGA Awasthi, A Quintanilla, BPA Bacha, U Badawi, A Barac, A Barnighausen, T Basu, A Bayou, TA Bayou, YT Bazargan-Hejazi, S Beardsley, J Bedi, N Bennett, DA Bensenor, IM Betsu, BD Beyene, AS Bhatia, E Bhutta, ZA Biadgilign, S Bikbov, B Birlik, SM Bisanzio, D Brainin, M Brazinova, A Breitborde, NJK Brown, A Burch, M Butt, ZA Campuzano, JC Cardenas, R Carrero, JJ Castaneda-Orjuela, CA Rivas, JC Catala-Lopez, F Chang, HY Chang, JC Chavan, L Chen, WQ Chiang, PPC Chibalabala, M Chisumpa, VH Choi, JYJ Christopher, DJ Ciobanu, LG Cooper, C Dahiru, T Damtew, SA Dandona, L Dandona, R das Neves, J de Jager, P De Leo, D Degenhardt, L Dellavalle, RP Deribe, K Deribew, A Jarlais, DCD Dharmaratne, SD Ding, EL Doshi, PP Driscoll, TR Dubey, M Elshrek, YM Elyazar, I Endries, AY Ermakov, SP Eshrati, B Esteghamati, A Faghmous, IDA Sofia e Sa Farinha, C Faro, A Farvid, MS Farzadfar, F Fereshtehnejad, SM Fernandes, JC Fischer, F Fitchett, JRA Foigt, N Fullman, N Furst, T Gankpe, FG Gebre, T Gebremedhin, AT Gebru, AA Geleijnse, JM Gessner, BD Gething, PW Ghiwot, TT Giroud, M Gishu, MD Glaser, E Goenka, S Goodridge, A Gopalani, SV Goto, A Gugnani, HC Guimaraes, MDC Gupta, R Gupta, R Gupta, V Haagsma, J Hafezi-Nejad, N Hagan, H Hailu, GB Hamadeh, RR Hamidi, S Hammami, M Hankey, GJ Hao, YT Harb, HL Harikrishnan, S Haro, JM Harun, KM Havmoeller, R Hedayati, MT Heredia-Pi, IB Hoek, HW Horino, M Horita, N Hosgood, HD Hoy, DG Hsairi, M Hu, GQ Huang, H Huang, JJ Iburg, KM Idrisov, BT Innos, K Iyer, VJ Jacobsen, KH Jahanmehr, N Jakovljevic, MB Javanbakht, M Jayatilleke, AU Jeemon, P Jha, V Jiang, GH Jiang, Y Jibat, T Jonas, JB Kabir, Z Kamal, R Kan, HD Karch, A Karema, CK Karletsos, D Kasaeian, A Kaul, A Kawakami, N Kayibanda, JF Keiyoro, PN Kemp, AH Kengne, AP Kesavachandran, CN Khader, YS Khalil, I Khan, AR Khan, EA Khang, YH Khubchandani, J Kim, YJ Kinfu, Y Kivipelto, M Kokubo, Y Kosen, S Koul, PA Koyanagi, A Defo, BK Bicer, BK Kulkarni, VS Kumar, GA Lal, DK Lam, H Lam, JO Langan, SM Lansingh, VC Larsson, A Leigh, J Leung, R Li, YM Lim, SS Lipshultz, SE Liu, SW Lloyd, BK Logroscino, G Lotufo, PA Lunevicius, R Abd El Razek, HM Mahdavi, M Majdan, M Majeed, A Makhlouf, C Malekzadeh, R Mapoma, CC Marcenes, W Martinez-Raga, J Marzan, MB Masiye, F Mason-Jones, AJ Mayosi, BM Mckee, M Meaney, PA Mehndiratta, MM Mekonnen, AB Melaku, YA Memiah, P Memish, ZA Mendoza, W Meretoja, A Meretoja, TJ Mhimbira, FA Miller, TR Mikesell, J Mirarefin, M Mohammad, KA Mohammed, S Mokdad, AH Monasta, L Moradi-Lakeh, M Mori, R Mueller, UO Murimira, B Murthy, GVS Naheed, A Naldi, L Nangia, V Nash, D Nawaz, H Nejjari, C Ngalesoni, FN Ngirabega, JDD Le Nguyen, Q Nisar, MI Norheim, OF Norman, RE Nyakarahuka, L Ogbo, FA Oh, IH Ojelabi, FA Olusanya, BO Olusanya, JO Opio, JN Oren, E Ota, E Padukudru, MA Park, HY Park, JH Patil, ST Patten, SB Paul, VK Pearson, K Peprah, EK Pereira, DM Perico, N Pesudovs, K Petzold, M Phillips, MR Pillay, JD Plass, D Polinder, S Pourmalek, F Prokop, DM Qorbani, M Rafay, A Rahimi, K Rahimi-Movaghar, V Rahman, M Rahman, MHU Rahman, SU Rai, RK Rajsic, S Ram, U Rana, SM Rao, PV Remuzzi, G Rojas-Rueda, D Ronfani, L Roshandel, G Roy, A Ruhago, GM Saeedi, MY Sagar, R Saleh, MM Sanabria, JR Santos, IS Sarmiento-Suarez, R Sartorius, B Sawhney, M Schutte, AE Schwebel, DC Seedat, S Sepanlou, SG Servan-Mori, EE Shaikh, MA Sharma, R She, J Sheikhbahaei, S Shen, JB Shibuya, K Shin, HH Sigfusdottir, ID Silpakit, N Silva, DAS Silveira, DGA Simard, EP Sindi, S Singh, JA Singh, OP Singh, PK Skirbekk, V Sliwa, K Soneji, S Sorensen, RJD Soriano, JB Soti, DO Sreeramareddy, CT Stathopoulou, V Steel, N Sunguya, BF Swaminathan, S Sykes, BL Tabares-Seisdedos, R Talongwa, RT Tavakkoli, M Taye, B Tedla, BA Tekle, T Shifa, GT Temesgen, AM Terkawi, AS Tesfay, FH Tessema, GA Thapa, K Thomson, AJ Thorne-Lyman, AL Tobe-Gai, R Topor-Madry, R Towbin, JA Tran, BX Dimbuene, ZT Tsilimparis, N Tura, AK Ukwaja, KN Uneke, CJ Uthman, OA Venketasubramanian, N Vladimirov, SK Vlassov, VV Vollset, SE Wang, LH Weiderpass, E Weintraub, RG Werdecker, A Westerman, R Wijeratne, T Wilkinson, JD Wiysonge, CS Wolfe, CDA Won, SH Wong, JQ Xu, GL Yadav, AK Yakob, B Yalew, AZ Yano, YC Yaseri, M Yebyo, HG Yip, P Yonemoto, N Yoon, SJ Younis, MZ Yu, CH Yu, SC Zaidi, Z Zaki, ME Zeeb, H Zhang, H Zhao, Y Zodpey, S Zoeckler, L Zuhlke, LJ Lopez, AD Murray, CJL AF Wang, Haidong Wolock, Tim M. Carter, Austin Nguyen, Grant Kyu, Hmwe Hmwe Gakidou, Emmanuela Hay, Simon I. Mills, Edward J. Trickey, Adam Msemburi, William Coates, Matthew M. Mooney, Meghan D. Fraser, Maya S. Sligar, Amber Salomon, Joshua Larson, Heidi J. Friedman, Joseph Abajobir, Amanuel Alemu Abate, Kalkidan Hassen Abbas, Kaja M. Abd El Razek, Mohamed Magdy Abd-Allah, Foad Abdulle, Abdishakur M. Abera, Semaw Ferede Abubakar, Ibrahim Abu-Raddad, Laith J. Abu-Rmeileh, Niveen M. E. Abyu, Gebre Yitayih Adebiyi, Akindele Olupelumi Adedeji, Isaac Akinkunmi Adelekan, Ademola Lukman Adofo, Koranteng Adou, Arsene Kouablan Ajala, Oluremi N. Akinyemiju, Tomi F. Akseer, Nadia Al Lami, Faris Hasan Al-Aly, Ziyad Alam, Khurshid Alam, Noore K. M. Alasfoor, Deena Aldhahri, Saleh Fahed S. Aldridge, Robert William Alegretti, Miguel Angel Aleman, Alicia V. Alemu, Zewdie Aderaw Alfonso-Cristancho, Rafael Ali, Raghib Alkerwi, Ala'a Alla, Francois Al-Raddadi, Rajaa Mohammad Salem Alsharif, Ubai Alvarez, Elena Alvis-Guzman, Nelson Amare, Azmeraw T. Amberbir, Alemayehu Amegah, Adeladza Kofi Ammar, Walid Amrock, Stephen Marc Antonio, Carl Abelardo T. Anwari, Palwasha Arnlov, Johan Al Artaman Asayesh, Hamid Asghar, Rana Jawad Assadi, Reza Atique, Suleman Atkins, Lydia S. Avokpaho, Euripide Frinel G. Arthur Awasthi, Ashish Quintanilla, Beatriz Paulina Ayala Bacha, Umar Badawi, Alaa Barac, Aleksandra Barnighausen, Till Basu, Arindam Bayou, Tigist Assefa Bayou, Yibeltal Tebekaw Bazargan-Hejazi, Shahrzad Beardsley, Justin Bedi, Neeraj Bennett, Derrick A. Bensenor, Isabela M. Betsu, Balem Demtsu Beyene, Addisu Shunu Bhatia, Eesh Bhutta, Zulfiqar A. Biadgilign, Sibhatu Bikbov, Boris Birlik, Sait Mentes Bisanzio, Donal Brainin, Michael Brazinova, Alexandra Breitborde, Nicholas J. K. Brown, Alexandria Burch, Michael Butt, Zahid A. Campuzano, Julio Cesar Cardenas, Rosario Carrero, Juan Jesus Castaneda-Orjuela, Carlos A. Rivas, Jacqueline Castillo Catala-Lopez, Ferran Chang, Hsing-Yi Chang, Jung-chen Chavan, Laxmikant Chen, Wanqing Chiang, Peggy Pei-Chia Chibalabala, Mirriam Chisumpa, Vesper Hichilombwe Choi, Jee-Young Jasmine Christopher, Devasahayam Jesudas Ciobanu, Liliana G. Cooper, Cyrus Dahiru, Tukur Damtew, Solomon Abreha Dandona, Lalit Dandona, Rakhi das Neves, Jose de Jager, Pieter De Leo, Diego Degenhardt, Louisa Dellavalle, Robert P. Deribe, Kebede Deribew, Amare Jarlais, Don C. Des Dharmaratne, Samath D. Ding, Eric L. Doshi, Pratik Pinal Driscoll, Tim R. Dubey, Manisha Elshrek, Yousef Mohamed Elyazar, Iqbal Endries, Aman Yesuf Ermakov, Sergey Petrovich Eshrati, Babak Esteghamati, Alireza Faghmous, Imad D. A. Sofia e Sa Farinha, Carla Faro, Andre Farvid, Maryam S. Farzadfar, Farshad Fereshtehnejad, Seyed-Mohammad Fernandes, Joao C. Fischer, Florian Fitchett, Joseph Robert Ander Foigt, Nataliya Fullman, Nancy Furst, Thomas Gankpe, Fortune Gbetoho Gebre, Teshome Gebremedhin, Amanuel Tesfay Gebru, Alemseged Aregay Geleijnse, Johanna M. Gessner, Bradford D. Gething, Peter W. Ghiwot, Tsegaye Tewelde Giroud, Maurice Gishu, Melkamu Dedefo Glaser, Elizabeth Goenka, Shifalika Goodridge, Amador Gopalani, Sameer Vali Goto, Atsushi Gugnani, Harish Chander Guimaraes, Mark D. C. Gupta, Rahul Gupta, Rajeev Gupta, Vipin Haagsma, Juanita Hafezi-Nejad, Nima Hagan, Holly Hailu, Gessessew Bugssa Hamadeh, Randah Ribhi Hamidi, Samer Hammami, Mouhanad Hankey, Graeme J. Hao, Yuantao Harb, Hilda L. Harikrishnan, Sivadasanpillai Haro, Josep Maria Harun, Kimani M. Havmoeller, Rasmus Hedayati, Mohammad T. Heredia-Pi, Ileana Beatriz Hoek, Hans W. Horino, Masako Horita, Nobuyuki Hosgood, H. Dean Hoy, Damian G. Hsairi, Mohamed Hu, Guoqing Huang, Hsiang Huang, John J. Iburg, Kim Moesgaard Idrisov, Bulat T. Innos, Kaire Iyer, Veena J. Jacobsen, Kathryn H. Jahanmehr, Nader Jakovljevic, Mihajlo B. Javanbakht, Mehdi Jayatilleke, Achala Upendra Jeemon, Panniyammakal Jha, Vivekanand Jiang, Guohong Jiang, Ying Jibat, Tariku Jonas, Jost B. Kabir, Zubair Kamal, Ritul Kan, Haidong Karch, Andre Karema, Corine Kakizi Karletsos, Dimitris Kasaeian, Amir Kaul, Anil Kawakami, Norito Kayibanda, Jeanne Francoise Keiyoro, Peter Njenga Kemp, Andrew Haddon Kengne, Andre Pascal Kesavachandran, Chandrasekharan Nair Khader, Yousef Saleh Khalil, Ibrahim Khan, Abdur Rahman Khan, Ejaz Ahmad Khang, Young-Ho Khubchandani, Jagdish Kim, Yun Jin Kinfu, Yohannes Kivipelto, Miia Kokubo, Yoshihiro Kosen, Soewarta Koul, Parvaiz A. Koyanagi, Ai Defo, Barthelemy Kuate Bicer, Burcu Kucuk Kulkarni, Veena S. Kumar, G. Anil Lal, Dharmesh Kumar Lam, Hilton Lam, Jennifer O. Langan, Sinead M. Lansingh, Van C. Larsson, Anders Leigh, James Leung, Ricky Li, Yongmei Lim, Stephen S. Lipshultz, Steven E. Liu, Shiwei Lloyd, Belinda K. Logroscino, Giancarlo Lotufo, Paulo A. Lunevicius, Raimundas Abd El Razek, Hassan Magdy Mahdavi, Mahdi Majdan, Marek Majeed, Azeem Makhlouf, Carla Malekzadeh, Reza Mapoma, Chabila C. Marcenes, Wagner Martinez-Raga, Jose Marzan, Melvin Barrientos Masiye, Felix Mason-Jones, Amanda J. Mayosi, Bongani M. Mckee, Martin Meaney, Peter A. Mehndiratta, Man Mohan Mekonnen, Alemayehu B. Melaku, Yohannes Adama Memiah, Peter Memish, Ziad A. Mendoza, Walter Meretoja, Atte Meretoja, Tuomo J. Mhimbira, Francis Apolinary Miller, Ted R. Mikesell, Joseph Mirarefin, Mojde Mohammad, Karzan Abdulmuhsin Mohammed, Shafiu Mokdad, Ali H. Monasta, Lorenzo Moradi-Lakeh, Maziar Mori, Rintaro Mueller, Ulrich O. Murimira, Brighton Murthy, Gudlavalleti Venkata Satyanarayana Naheed, Aliya Naldi, Luigi Nangia, Vinay Nash, Denis Nawaz, Haseeb Nejjari, Chakib Ngalesoni, Frida Namnyak Ngirabega, Jean De Dieu Quyen Le Nguyen Nisar, Muhammad Imran Norheim, Ole F. Norman, Rosana E. Nyakarahuka, Luke Ogbo, Felix Akpojene Oh, In-Hwan Ojelabi, Foluke Adetola Olusanya, Bolajoko Olubukunola Olusanya, Jacob Olusegun Opio, John Nelson Oren, Eyal Ota, Erika Padukudru, Mahesh Anand Park, Hye-Youn Park, Jae-Hyun Patil, Snehal T. Patten, Scott B. Paul, Vinod K. Pearson, Katherine Peprah, Emmanuel Kwame Pereira, David M. Perico, Norberto Pesudovs, Konrad Petzold, Max Phillips, Michael Robert Pillay, Julian David Plass, Dietrich Polinder, Suzanne Pourmalek, Farshad Prokop, David M. Qorbani, Mostafa Rafay, Anwar Rahimi, Kazem Rahimi-Movaghar, Vafa Rahman, Mahfuzar Rahman, Mohammad Hifz Ur Rahman, Sajjad Ur Rai, Rajesh Kumar Rajsic, Sasa Ram, Usha Rana, Saleem M. Rao, Paturi Vishnupriya Remuzzi, Giuseppe Rojas-Rueda, David Ronfani, Luca Roshandel, Gholamreza Roy, Ambuj Ruhago, George Mugambage Saeedi, Mohammad Yahya Sagar, Rajesh Saleh, Muhammad Muhammad Sanabria, Juan R. Santos, Itamar S. Sarmiento-Suarez, Rodrigo Sartorius, Benn Sawhney, Monika Schutte, Aletta E. Schwebel, David C. Seedat, Soraya Sepanlou, Sadaf G. Servan-Mori, Edson E. Shaikh, Masood Ali Sharma, Rajesh She, Jun Sheikhbahaei, Sara Shen, Jiabin Shibuya, Kenji Shin, Hwashin Hyun Sigfusdottir, Inga Dora Silpakit, Naris Santos Silva, Diego Augusto Alves Silveira, Dayane Gabriele Simard, Edgar P. Sindi, Shireen Singh, Jasvinder A. Singh, Om Prakash Singh, Prashant Kumar Skirbekk, Vegard Sliwa, Karen Soneji, Samir Sorensen, Reed J. D. Soriano, Joan B. Soti, David O. Sreeramareddy, Chandrashekhar T. Stathopoulou, Vasiliki Steel, Nicholas Sunguya, Bruno F. Swaminathan, Soumya Sykes, Bryan L. Tabares-Seisdedos, Rafael Talongwa, Roberto Tchio Tavakkoli, Mohammad Taye, Bineyam Tedla, Bemnet Amare Tekle, Tesfaye Shifa, Girma Temam Temesgen, Awoke Misganaw Terkawi, Abdullah Sulieman Tesfay, Fisaha Haile Tessema, Gizachew Assefa Thapa, Kiran Thomson, Alan J. Thorne-Lyman, Andrew L. Tobe-Gai, Ruoyan Topor-Madry, Roman Towbin, Jeffrey Allen Bach Xuan Tran Dimbuene, Zacharie Tsala Tsilimparis, Nikolaos Tura, Abera Kenay Ukwaja, Kingsley Nnanna Uneke, Chigozie Jesse Uthman, Olalekan A. Venketasubramanian, N. Vladimirov, Sergey K. Vlassov, Vasiliy Victorovich Vollset, Stein Emil Wang, Linhong Weiderpass, Elisabete Weintraub, Robert G. Werdecker, Andrea Westerman, Ronny Wijeratne, Tissa Wilkinson, James D. Wiysonge, Charles Shey Wolfe, Charles D. A. Won, Sungho Wong, John Q. Xu, Gelin Yadav, Ajit Kumar Yakob, Bereket Yalew, Ayalnesh Zemene Yano, Yuichiro Yaseri, Mehdi Yebyo, Henock Gebremedhin Yip, Paul Yonemoto, Naohiro Yoon, Seok-Jun Younis, Mustafa Z. Yu, Chuanhua Yu, Shicheng Zaidi, Zoubida Zaki, Maysaa El Sayed Zeeb, Hajo Zhang, Hao Zhao, Yong Zodpey, Sanjay Zoeckler, Leo Zuhlke, Liesl Joanna Lopez, Alan D. Murray, Christopher J. L. CA GBD 2015 HIV Collaborators TI Estimates of global, regional, and national incidence, prevalence, and mortality of HIV, 1980-2015: the Global Burden of Disease Study 2015 SO LANCET HIV LA English DT Article ID PROJECTION PACKAGE; SYSTEMATIC ANALYSIS; UNAIDS ESTIMATION; MALE CIRCUMCISION; 188 COUNTRIES; INFECTION; PREVENTION; EPIDEMIC; MODEL; TRIAL AB Background Timely assessment of the burden of HIV/AIDS is essential for policy setting and programme evaluation. In this report from the Global Burden of Disease Study 2015 (GBD 2015), we provide national estimates of levels and trends of HIV/AIDS incidence, prevalence, coverage of antiretroviral therapy (ART), and mortality for 195 countries and territories from 1980 to 2015. Methods For countries without high-quality vital registration data, we estimated prevalence and incidence with data from antenatal care clinics and population-based seroprevalence surveys, and with assumptions by age and sex on initial CD4 distribution at infection, CD4 progression rates (probability of progression from higher to lower CD4 cell-count category), on and off antiretroviral therapy (ART) mortality, and mortality from all other causes. Our estimation strategy links the GBD 2015 assessment of all-cause mortality and estimation of incidence and prevalence so that for each draw from the uncertainty distribution all assumptions used in each step are internally consistent. We estimated incidence, prevalence, and death with GBD versions of the Estimation and Projection Package (EPP) and Spectrum software originally developed by the Joint United Nations Programme on HIV/AIDS (UNAIDS). We used an open-source version of EPP and recoded Spectrum for speed, and used updated assumptions from systematic reviews of the literature and GBD demographic data. For countries with high-quality vital registration data, we developed the cohort incidence bias adjustment model to estimate HIV incidence and prevalence largely from the number of deaths caused by HIV recorded in cause-of-death statistics. We corrected these statistics for garbage coding and HIV misclassification. Findings Global HIV incidence reached its peak in 1997, at 3.3 million new infections (95% uncertainty interval [UI] 3.1-3.4 million). Annual incidence has stayed relatively constant at about 2.6 million per year (range 2.5-2.8 million) since 2005, after a period of fast decline between 1997 and 2005. The number of people living with HIV/AIDS has been steadily increasing and reached 38.8 million (95% UI 37.6-40.4 million) in 2015. At the same time, HIV/AIDS mortality has been declining at a steady pace, from a peak of 1.8 million deaths (95% UI 1.7-1.9 million) in 2005, to 1.2 million deaths (1.1-1.3 million) in 2015. We recorded substantial heterogeneity in the levels and trends of HIV/AIDS across countries. Although many countries have experienced decreases in HIV/AIDS mortality and in annual new infections, other countries have had slowdowns or increases in rates of change in annual new infections. Interpretation Scale-up of ART and prevention of mother-to-child transmission has been one of the great successes of global health in the past two decades. However, in the past decade, progress in reducing new infections has been slow, development assistance for health devoted to HIV has stagnated, and resources for health in low-income countries have grown slowly. Achievement of the new ambitious goals for HIV enshrined in Sustainable Development Goal 3 and the 90-90-90 UNAIDS targets will be challenging, and will need continued efforts from governments and international agencies in the next 15 years to end AIDS by 2030. Copyright (C) The Author(s). Published by Elsevier Ltd. This is an Open Access article under the CC BY license C1 [Wang, Haidong; Wolock, Tim M.; Carter, Austin; Nguyen, Grant; Kyu, Hmwe Hmwe; Gakidou, Emmanuela; Hay, Simon I.; Msemburi, William; Coates, Matthew M.; Mooney, Meghan D.; Fraser, Maya S.; Sligar, Amber; Larson, Heidi J.; Friedman, Joseph; Brown, Alexandria; Dandona, Lalit; Fullman, Nancy; Haagsma, Juanita; Khalil, Ibrahim; Lim, Stephen S.; Mikesell, Joseph; Mokdad, Ali H.; Moradi-Lakeh, Maziar; Pearson, Katherine; Silpakit, Naris; Sorensen, Reed J. D.; Temesgen, Awoke Misganaw; Vollset, Stein Emil; Zoeckler, Leo; Murray, Christopher J. L.] Inst Hlth Metr & Evaluat, Seattle, WA 98121 USA. [Alfonso-Cristancho, Rafael; Harun, Kimani M.; Prokop, David M.] Univ Washington, Seattle, WA 98195 USA. [Mills, Edward J.] Univ Ottawa, Ottawa, ON, Canada. [Trickey, Adam] Univ Bristol, Sch Social & Community Med, Bristol, Avon, England. [Ajala, Oluremi N.; Barnighausen, Till; Ding, Eric L.; Farvid, Maryam S.] Harvard Univ, Harvard TH Chan Sch Publ Hlth, Boston, MA 02115 USA. [Thorne-Lyman, Andrew L.] Harvard Univ, TH Chan Sch Publ Hlth, Dept Nutr, Boston, MA 02115 USA. [Won, Sungho] Harvard Univ, Channing Div Network Med, Brigham & Womens Hosp, Harvard Med Sch, Boston, MA 02115 USA. [Salomon, Joshua; Fitchett, Joseph Robert Ander] Harvard Univ, Boston, MA 02115 USA. [Abajobir, Amanuel Alemu] Univ Queensland, Sch Publ Hlth, Brisbane, Qld, Australia. [Hoy, Damian G.] Univ Queensland, Sch Populat Hlth, Brisbane, Qld, Australia. [Alam, Noore K. M.] Univ Queensland, Brisbane, Qld, Australia. [Abate, Kalkidan Hassen; Gebremedhin, Amanuel Tesfay; Ghiwot, Tsegaye Tewelde] Jimma Univ, Jimma, Ethiopia. [Abbas, Kaja M.] Virginia Tech, Blacksburg, VA USA. [Abd El Razek, Mohamed Magdy] Aswan Univ Hosp, Aswan, Egypt. [Abd-Allah, Foad] Cairo Univ, Dept Neurol, Cairo, Egypt. [Abdulle, Abdishakur M.] New York Univ Abu Dhabi, Abu Dhabi, U Arab Emirates. [Abera, Semaw Ferede] Mekelle Univ, Sch Publ Hlth, Coll Hlth Sci, Mekelle, Ethiopia. [Melaku, Yohannes Adama] Mekelle Univ, Sch Publ Hlth, Mekelle, Ethiopia. [Tesfay, Fisaha Haile] Mekelle Univ, Coll Hlth Sci, Mekelle, Ethiopia. [Abyu, Gebre Yitayih; Bayou, Tigist Assefa; Betsu, Balem Demtsu; Gebru, Alemseged Aregay; Hailu, Gessessew Bugssa; Tekle, Tesfaye; Yalew, Ayalnesh Zemene; Yebyo, Henock Gebremedhin] Mekelle Univ, Mekelle, Ethiopia. [Abera, Semaw Ferede; Gebru, Alemseged Aregay; Hailu, Gessessew Bugssa] Kilte Awlaelo Hlth & Demog Surveillance Syst, Mekelle, Ethiopia. [Abubakar, Ibrahim; Aldridge, Robert William] UCL, London, England. [Abu-Raddad, Laith J.] Weill Cornell Med Coll Qatar, Infect Dis Epidemiol Grp, Doha, Qatar. [Abu-Rmeileh, Niveen M. E.] Birzeit Univ, Inst Community & Publ Hlth, Ramallah, Israel. [Adebiyi, Akindele Olupelumi] Univ Ibadan, Coll Med, Ibadan, Nigeria. [Adedeji, Isaac Akinkunmi] Univ Ibadan, Dept Sociol, Ibadan, Nigeria. [Adelekan, Ademola Lukman; Ojelabi, Foluke Adetola] Univ Ibadan, Ibadan, Nigeria. [Adebiyi, Akindele Olupelumi] Univ Coll Hosp, Ibadan, Nigeria. [Adedeji, Isaac Akinkunmi] Olabisi Onabanjo Univ, Ago Iwoye, Nigeria. [Adelekan, Ademola Lukman] Publ Hlth Promot Alliance, Osogbo, Nigeria. [Adofo, Koranteng] Kwame Nkrumah Univ Sci & Technol, Kumasi, Ghana. [Adou, Arsene Kouablan] Assoc Ivoirienne Bien Etre Familial, Abidjan, Cote Ivoire. [Ajala, Oluremi N.] Univ Pittsburgh, Med Ctr, McKeesport, PA USA. [Akinyemiju, Tomi F.] Univ Alabama Birmingham, Dept Epidemiol, Birmingham, AL USA. [Schwebel, David C.; Singh, Jasvinder A.] Univ Alabama Birmingham, Birmingham, AL USA. [Akseer, Nadia] Hosp Sick Children, Toronto, ON, Canada. [Al Lami, Faris Hasan] Baghdad Coll Med, Baghdad, Iraq. [Al-Aly, Ziyad] Washington Univ, St Louis, MO USA. [Alam, Khurshid; Weintraub, Robert G.] Murdoch Childrens Res Inst, Melbourne, Vic, Australia. [Chiang, Peggy Pei-Chia] Univ Melbourne, Gen Practice & Primary Hlth Care Acad Ctr, Melbourne, Vic, Australia. [Meretoja, Atte] Univ Melbourne, Dept Med & Florey, Melbourne, Vic, Australia. [Lopez, Alan D.] Univ Melbourne, Melbourne Sch Populat & Global Hlth, Melbourne, Vic, Australia. [Alam, Khurshid; Weintraub, Robert G.; Wijeratne, Tissa] Univ Melbourne, Melbourne, Vic, Australia. [Driscoll, Tim R.] Univ Sydney, Sydney Sch Publ Hlth, Sydney, NSW, Australia. [Alam, Khurshid; Kemp, Andrew Haddon; Leigh, James; Mekonnen, Alemayehu B.] Univ Sydney, Sydney, NSW, Australia. [Alam, Noore K. M.] Queensland Hlth, Herston, Qld, Australia. [Karema, Corine Kakizi] Minist Hlth, Malaria & Other Parasit Dis Div, Al Khuwair, Oman. [Alsharif, Ubai] Minist Hlth, Al Khuwair, Oman. [Aldhahri, Saleh Fahed S.] King Saud Univ, Riyadh, Saudi Arabia. [Terkawi, Abdullah Sulieman] King Fahad Med City, Dept Anesthesiol, Riyadh, Saudi Arabia. [Aldhahri, Saleh Fahed S.] King Fahad Med City, Riyadh, Saudi Arabia. [Alegretti, Miguel Angel] Univ Republica, Dept Prevent & Social Med, Montevideo, Uruguay. [Aleman, Alicia V.] Univ Republica, Sch Med, Montevideo, Uruguay. [Alemu, Zewdie Aderaw] Debre Markos Univ, Addis Ababa, Ethiopia. [Cooper, Cyrus] Univ Oxford, NIHR Musculoskeletal Biomed Res Ctr, Oxford, England. [Deribew, Amare] Univ Oxford, Nuffield Dept Med, Oxford, England. [Gething, Peter W.] Univ Oxford, Dept Zool, Oxford, England. [Ali, Raghib; Bennett, Derrick A.; Bisanzio, Donal; Rahimi, Kazem] Univ Oxford, Oxford, England. [Alkerwi, Ala'a] Luxembourg Inst Hlth, Strassen, Luxembourg. [Alla, Francois] Univ Lorraine, Sch Publ Hlth, Nancy, France. [Karema, Corine Kakizi] Minist Hlth, Malaria & Other Parasit Dis Div, Riyadh, Saudi Arabia. [Al-Raddadi, Rajaa Mohammad Salem; Saeedi, Mohammad Yahya] Minist Hlth, Riyadh, Saudi Arabia. [Alsharif, Ubai] Charite, Berlin, Germany. [Alvarez, Elena] Govt, Madrid, Spain. [Alvis-Guzman, Nelson] Univ Cartagena, Cartagena De Indias, Colombia. [Amare, Azmeraw T.] Univ Groningen, Univ Med Ctr Groningen, Dept Epidemiol, Groningen, Netherlands. [Hoek, Hans W.] Univ Groningen, Univ Med Ctr Groningen, Dept Psychiat, Groningen, Netherlands. [Amare, Azmeraw T.] Bahir Dar Univ, Coll Med & Hlth Sci, Bahir Dar, Ethiopia. [Amare, Azmeraw T.] Univ Adelaide, Discipline Psychiat, Sch Med, Adelaide, SA, Australia. [Melaku, Yohannes Adama] Univ Adelaide, Sch Med, Adelaide, SA, Australia. [Ciobanu, Liliana G.; Tessema, Gizachew Assefa] Univ Adelaide, Adelaide, SA, Australia. [Amberbir, Alemayehu] Dignitas Int, Zomba, Malawi. [Amegah, Adeladza Kofi] Univ Cape Coast, Cape Coast, Ghana. [Ammar, Walid; Harb, Hilda L.] Minist Publ Hlth, Beirut, Lebanon. [Amrock, Stephen Marc] Oregon Hlth & Sci Univ, Portland, OR 97201 USA. [Antonio, Carl Abelardo T.] Univ Philippines, Coll Publ Hlth, Dept Hlth Policy & Adm, Manila, Philippines. [Arnlov, Johan; Larsson, Anders] Uppsala Univ, Dept Med Sci, Uppsala, Sweden. [Arnlov, Johan] Dalarna Univ, Falun, Sweden. [Asayesh, Hamid] Qom Univ Med Sci, Dept Emergency Med, Sch Paramed, Qom, Iran. [Asghar, Rana Jawad] South Asian Publ Hlth Forum, Islamabad, Pakistan. [Assadi, Reza] Mashhad Univ Med Sci, Mashhad, Iran. [Atique, Suleman] Taipei Med Univ, Grad Inst Biomed Informat, Taipei, Taiwan. [Atkins, Lydia S.] Minist Hlth, Wellness Human Serv & Gender Relat, Castries, St Lucia. [Avokpaho, Euripide Frinel G. Arthur] Africare Benin, Cotonou, Benin. [Avokpaho, Euripide Frinel G. Arthur] LERAS Afrique, Parakou, Benin. [Awasthi, Ashish; Bhatia, Eesh] Sanjay Gandhi Postgraduate Inst Med Sci, Lucknow, Uttar Pradesh, India. [Quintanilla, Beatriz Paulina Ayala] La Trobe Univ, Judith Lumley Ctr Mother Infant & Family Hlth Res, Melbourne, Vic, Australia. [Quintanilla, Beatriz Paulina Ayala] Peruvian Natl Inst Hlth, Lima, Peru. [Bacha, Umar] Univ Management & Technol, Sch Hlth Sci, Lahore, Pakistan. [Badawi, Alaa] Publ Hlth Agcy Canada, Toronto, ON, Canada. [Barac, Aleksandra] Univ Belgrade, Fac Med, Belgrade, Serbia. [Barnighausen, Till] Wellcome Trust Africa Ctr Hlth & Populat Studies, Somkhele, Mtubatuba, South Africa. [Basu, Arindam] Univ Canterbury, Sch Hlth Sci, Christchurch, New Zealand. [Bayou, Yibeltal Tebekaw] Jhpiego Ethiopia, Addis Ababa, Ethiopia. [Bazargan-Hejazi, Shahrzad] Charles R Drew Univ Med & Sci, 1621 E 120th St, Los Angeles, CA 90059 USA. [Beardsley, Justin] Univ Oxford, Ho Hi Minh City, Vietnam. [Bedi, Neeraj] Coll Publ Hlth & Trop Med, Jazan, Saudi Arabia. [Santos, Itamar S.] Univ Sao Paulo, Dept Internal Med, Sao Paulo, Brazil. [Bensenor, Isabela M.; Kemp, Andrew Haddon; Lotufo, Paulo A.] Univ Sao Paulo, Sao Paulo, Brazil. [Beyene, Addisu Shunu] Haramaya Univ, Harar, Ethiopia. [Bhutta, Zulfiqar A.] Aga Khan Univ, Med Ctr, Karachi, Pakistan. [Nisar, Muhammad Imran] Aga Khan Univ, Karachi, Pakistan. [Bhutta, Zulfiqar A.] Hosp Sick Children, Toronto, ON, Canada. [Biadgilign, Sibhatu] Independent Publ Hlth Consultants, Addis Ababa, Ethiopia. [Bikbov, Boris] AI Evdokimov Moscow State Univ Med & Dent, Moscow, Russia. [Bikbov, Boris] Acad VI Shumakov Fed Res Ctr Transplantol & Artif, Moscow, Russia. [Birlik, Sait Mentes] GBS CIDP Int Fdn, Menemen, Turkey. [Brainin, Michael] Danube Univ Krems, Krems, Austria. [Brazinova, Alexandra] Trnava Univ, Fac Hlth Sci & Social Work, Trnava, Slovakia. [Majdan, Marek] Trnava Univ, Fac Hlth Sci & Social Work, Dept Publ Hlth, Trnava, Slovakia. [Brazinova, Alexandra] Int Neurotrama Res Org, Vienna, Austria. [Breitborde, Nicholas J. K.] Ohio State Univ, Columbus, OH 43210 USA. [Breitborde, Nicholas J. K.; Oren, Eyal] Univ Arizona, Tucson, AZ USA. [Burch, Michael] Great Ormond St Hosp Sick Children, London, England. [Butt, Zahid A.] Al Shifa Trust Eye Hosp, Rawalpindi, Pakistan. [Campuzano, Julio Cesar; Heredia-Pi, Ileana Beatriz; Servan-Mori, Edson E.] Natl Inst Publ Hlth, Cuernavaca, Morelos, Mexico. [Cardenas, Rosario] Univ Autonoma Metropolitana, Mexico City, DF, Mexico. [Fereshtehnejad, Seyed-Mohammad] Karolinska Inst, Dept Neurobiol, Care Sci & Soc, Stockholm, Sweden. [Kivipelto, Miia] Karolinska Inst, Aging Res Ctr, Stockholm, Sweden. [Weiderpass, Elisabete] Karolinska Inst, Dept Med Epidemiol & Biostat, Stockholm, Sweden. [Carrero, Juan Jesus; Havmoeller, Rasmus; Sindi, Shireen] Karolinska Inst, Stockholm, Sweden. [Castaneda-Orjuela, Carlos A.] Colombian Natl Hlth Observ, Inst Nacl Salud, Bogota, DC, Colombia. [Castaneda-Orjuela, Carlos A.] Univ Nacl Colombia, Epidemiol & Publ Hlth Evaluat Grp, Dept Publ Hlth, Bogota, Colombia. [Rivas, Jacqueline Castillo] Caja Costarricense Seguro Social, San Jose, Costa Rica. [Rivas, Jacqueline Castillo] Univ Costa Rica, San Pedro, Montes De Oca, Costa Rica. [Tabares-Seisdedos, Rafael] CIBERSAM, Dept Med, Valencia, Spain. [Catala-Lopez, Ferran] Univ Valencia, INCLIVA Hlth Res Inst, Valencia, Spain. [Catala-Lopez, Ferran] Ottawa Hosp Res Inst, Clin Epidemiol Program, Ottawa, ON, Canada. [Chang, Hsing-Yi] Natl Hlth Res Inst, Zhunan Town, Taiwan. [Chang, Hsing-Yi] Natl Yang Ming Univ, Taipei, Taiwan. [Chang, Jung-chen] Natl Taiwan Univ, Coll Med, Taipei, Taiwan. [Chavan, Laxmikant] World Hlth Org, New Delhi, India. [Chen, Wanqing] Chinese Acad Med Sci, Inst Canc, Beijing, Peoples R China. [Chibalabala, Mirriam] Univ Zambia, PATH, Malaria Control & Eliminat Partnership Africa, Lusaka, Zambia. [Chisumpa, Vesper Hichilombwe; Mapoma, Chabila C.; Masiye, Felix] Univ Zambia, Lusaka, Zambia. [de Jager, Pieter] Univ Witwatersrand, Sch Publ Hlth, Johannesburg, South Africa. [Chisumpa, Vesper Hichilombwe; Petzold, Max] Univ Witwatersrand, Johannesburg, South Africa. [Choi, Jee-Young Jasmine] Seoul Natl Univ, Seoul Natl Univ Hosp, Seoul, South Korea. [Khang, Young-Ho] Seoul Natl Univ, Coll Med, Seoul, South Korea. [Won, Sungho] Seoul Natl Univ, Seoul, South Korea. [Choi, Jee-Young Jasmine] Seoul Natl Univ, Med Lib, Seoul, South Korea. [Christopher, Devasahayam Jesudas] Christian Med Coll & Hosp, Vellore, Tamil Nadu, India. [Cooper, Cyrus] Univ Southampton, MRC Lifecourse, Epidemiol Unit, Southampton, Hants, England. [Cooper, Cyrus] Univ Southampton, NIHR Biomed Res Ctr, Southampton, Hants, England. [Cooper, Cyrus] Univ Hosp Southampton NHS Fdn Trust, Southampton, Hants, England. [Mohammed, Shafiu] Ahmadu Bello Univ, Hlth Syst & Policy Res Unit, Zaria, Nigeria. [Dahiru, Tukur] Ahmadu Bello Univ, Zaria, Nigeria. [Damtew, Solomon Abreha] Wolaita Sodo Univ, Wolaita Sodo, Ethiopia. [Damtew, Solomon Abreha; Shifa, Girma Temam] Univ Addis Ababa, Sch Publ Hlth, Addis Ababa, Ethiopia. [Jeemon, Panniyammakal] Publ Hlth Fdn India, Ctr Control Chron Condit, New Delhi, India. [Dandona, Lalit; Dandona, Rakhi; Goenka, Shifalika; Kumar, G. Anil; Lal, Dharmesh Kumar; Murthy, Gudlavalleti Venkata Satyanarayana; Zodpey, Sanjay] Publ Hlth Fdn India, New Delhi, India. [das Neves, Jose] Univ Porto, Inst Biomed Engn, Oporto, Portugal. [das Neves, Jose] Univ Porto, Inst Invest & Inovacao Saude, Oporto, Portugal. [de Jager, Pieter] Natl Inst Occupat Hlth, Natl Hlth Lab Serv, Johannesburg, South Africa. [De Leo, Diego] Griffith Univ, Brisbane, Qld, Australia. [Degenhardt, Louisa] Univ New South Wales, Natl Drug & Alcohol Res Ctr, Sydney, NSW, Australia. [Dellavalle, Robert P.] Univ Colorado, Sch Med, Aurora, CO USA. [Dellavalle, Robert P.] Colorado Sch Publ Hlth, Aurora, CO USA. [Deribe, Kebede] Brighton & Sussex Med Sch, Brighton, E Sussex, England. [Deribew, Amare] KEMRI Wellcome Trust Res Programme, Kilifi, Kenya. [Jarlais, Don C. Des] Mt Sinai Beth Israel, New York, NY USA. [Jarlais, Don C. Des] Icahn Sch Med Mt Sinai, New York, NY 10029 USA. [Dharmaratne, Samath D.] Univ Peradeniya, Dept Community Med, Fac Med, Peradeniya, Sri Lanka. [Doshi, Pratik Pinal] Univ Southern Calif, Los Angeles, CA USA. [Dubey, Manisha; Rahman, Mahfuzar; Ram, Usha; Yadav, Ajit Kumar] Int Inst Populat Sci, Bombay, Maharashtra, India. [Elyazar, Iqbal] Univ Tripoli, Dept Food Sci, Fac Agr, Tripoli, Libya. [Elyazar, Iqbal] Eijkman Oxford Clin Res Unit, Jakarta, Indonesia. [Endries, Aman Yesuf; Shifa, Girma Temam] Arba Minch Univ, Arba Minch, Ethiopia. [Ermakov, Sergey Petrovich] Russian Acad Sci, Inst Social & Econ Studies Populat, Moscow, Russia. [Ermakov, Sergey Petrovich] Minist Hlth Russian Federat, Fed Res Inst Hlth Org & Informat, Moscow, Russia. [Eshrati, Babak] Minist Hlth & Med Educ, Tehran, Iran. [Eshrati, Babak] Arak Univ Med Sci, Arak, Iran. [Esteghamati, Alireza; Hafezi-Nejad, Nima; Sheikhbahaei, Sara] Univ Tehran Med Sci, Endocrinol & Metab Res Ctr, Terhan, Iran. [Farzadfar, Farshad] Univ Tehran Med Sci, Noncommunicable Dis Res Ctr, Endocrinol & Metab Populat Sci Inst, Terhan, Iran. [Kasaeian, Amir] Univ Tehran Med Sci, Hematol Oncol & Stem Cell Transplantat Res Ctr, Terhan, Iran. [Malekzadeh, Reza; Roshandel, Gholamreza; Sepanlou, Sadaf G.] Univ Tehran Med Sci, Digest Dis Res Inst, Terhan, Iran. [Rahimi-Movaghar, Vafa] Univ Tehran Med Sci, Sina Trauma & Surg Res Ctr, Terhan, Iran. [Yaseri, Mehdi] Univ Tehran Med Sci, Terhan, Iran. [Faghmous, Imad D. A.; Langan, Sinead M.; Mckee, Martin; Murthy, Gudlavalleti Venkata Satyanarayana] London Sch Hyg & Trop Med, Dept Infect Dis Epidemiol, London, England. [Sofia e Sa Farinha, Carla] DGS Directorate Gen Hlth, Lisbon, Portugal. [Sofia e Sa Farinha, Carla] Univ Aberta, Lisbon, Portugal. [Faro, Andre] Univ Fed Sergipe, Aracaju, Brazil. [Farvid, Maryam S.] Inst Hlth Policy, Boston, MA USA. [Fernandes, Joao C.] Univ Coimbra, Pharmacol & Expt Therapeut, Inst Biomed Imaging & Life Sci, Fac Med, Coimbra, Portugal. [Fischer, Florian] Univ Bielefeld, Bielefeld, Germany. [Foigt, Nataliya] Acad Med Sci, Inst Gerontol, Kiev, Ukraine. [Furst, Thomas] Imperial Coll London, Dept Infect Dis Epidemiol, London, England. [Majeed, Azeem] Imperial Coll London, London, England. [Gankpe, Fortune Gbetoho] Leras Afrique, Cotonou, Benin. [Gankpe, Fortune Gbetoho] CHU Hassan II, Fes, Morocco. [Gebre, Teshome] Task Force Global Hlth, Decatur, GA USA. [Gebremedhin, Amanuel Tesfay] Univ Munich, Munich, Germany. [Geleijnse, Johanna M.] Wageningen Univ, Div Human Nutr, Wageningen, Netherlands. [Jibat, Tariku] Wageningen Univ, Wageningen, Netherlands. [Gessner, Bradford D.] Agence Medecine Prevent, Paris, France. [Giroud, Maurice] Univ Hosp Dijon, Dijon, France. [Gishu, Melkamu Dedefo; Tura, Abera Kenay] Haramaya Univ, Dire Dawa, Ethiopia. [Gishu, Melkamu Dedefo] Kersa Hlth & Demog Surveillance Syst, Harar, Ethiopia. [Glaser, Elizabeth] Brandeis Univ, Heller Sch Social Policy & Management, Waltham, MA USA. [Goodridge, Amador] INDICASAT AIP, Inst Invest Cientif, City Of Knowledge, Panama. [Goodridge, Amador] INDICASAT AIP, Serv Alta Tecnol, City Of Knowledge, Panama. [Gopalani, Sameer Vali] Govt Federated States Micronesia, Dept Hlth & Social Aff airs, Palikir, Micronesia. [Goto, Atsushi] Tokyo Womens Med Univ, Dept Publ Hlth, Tokyo, Japan. [Gugnani, Harish Chander] St James Sch Med, Dept Microbiol, The Quarter, Anguilla. [Gugnani, Harish Chander] St James Sch Med, Dept Epidemiol & Biostat, The Quarter, Anguilla. [Guimaraes, Mark D. C.] Univ Fed Minas Gerais, Belo Horizonte, MG, Brazil. West Virginia Bur Publ Hlth, Charleston, WV USA. Eternal Heart Care Ctr, Jaipur, Rajasthan, India. Res Inst, Jaipur, Rajasthan, India. [Gupta, Vipin] Univ Delhi, Delhi, India. [Hagan, Holly] NYU, New York, NY USA. [Hamadeh, Randah Ribhi] Arabian Gulf Univ, Manama, Bahrain. [Hamidi, Samer] Hamdan Bin Mohammed Smart Univ, Dubai, U Arab Emirates. [Hammami, Mouhanad] Wayne Cty Dept Hlth & Human Serv, Detroit, MI USA. [Hankey, Graeme J.] Univ Western Australia, Sch Med & Pharmacol, Perth, WA, Australia. [Hankey, Graeme J.] Harry Perkins Inst Med Res, Nedlands, WA, Australia. [Hankey, Graeme J.] Western Australian Neurosci Res Inst, Nedlands, WA, Australia. [Hao, Yuantao] Sun Yat Sen Univ, Sch Publ Hlth, Guangzhou, Guangdong, Peoples R China. [Harikrishnan, Sivadasanpillai] Sree Chitra Tirunal Inst Med Sci & Technol, Trivandrum, Kerala, India. [Koyanagi, Ai] Res & Dev Unit, Barcelona, Spain. [Haro, Josep Maria] Parc Sanitari Sant Joan de Deu CIBERSAM, Barcelona, Spain. [Haro, Josep Maria] Univ Barcelona, Barcelona, Spain. [Harun, Kimani M.] Kenyatta Univ, Nairobi, Kenya. [Hedayati, Mohammad T.] Mazandaran Univ Med Sci, Sari, Iran. [Hoek, Hans W.] Columbia Univ, Dept Epidemiol, New York, NY USA. [Skirbekk, Vegard] Columbia Univ, New York, NY USA. [Horino, Masako] Nevada Div Behav & Publ Hlth, Carson City, NV USA. [Horino, Masako] Univ Calif Los Angeles, Fielding Sch Publ Hlth, Los Angeles, CA USA. [Horita, Nobuyuki] Yokohama City Univ, Sch Med, Yokohama, Kanagawa, Japan. [Hosgood, H. Dean] Albert Einstein Coll Med, Bronx, NY 10467 USA. [Hoy, Damian G.] Secretariat Pacific Commun, Publ Hlth Div, Noumea, New Caledonia. [Hsairi, Mohamed] Natl Inst Publ Hlth, Tunis, Tunisia. [Hu, Guoqing] Cent S Univ, Dept Epidemiol & Hlth Stat, Sch Publ Hlth, Changsha, Hunan, Peoples R China. [Huang, Hsiang] Cambridge Hlth Alliance, Cambridge, MA USA. [Huang, John J.] Yale Univ, New Haven, CT USA. [Iburg, Kim Moesgaard] Aarhus Univ, Aarhus, Denmark. [Idrisov, Bulat T.] Bashkir State Med Univ, Ufa, Russia. [Idrisov, Bulat T.] Boston Univ, Boston Med Ctr, Boston, MA 02215 USA. Boston Univ, Boston Med Ctr, Boston, MA 02215 USA. [Innos, Kaire] Natl Inst Hlth Dev, Tallinn, Estonia. [Iyer, Veena J.] Indian Inst Publ Hlth Gandhinagar, Ahmadabad, Gujarat, India. [Jacobsen, Kathryn H.] George Mason Univ, Dept Global & Community Hlth, Fairfax, VA 22030 USA. [Jahanmehr, Nader] Shahid Beheshti Med Univ, Tehran, Iran. [Jakovljevic, Mihajlo B.] Univ Kragujevac, Fac Med Sci, Kragujevac, Serbia. [Javanbakht, Mehdi] Univ Aberdeen, Aberdeen, Scotland. [Jayatilleke, Achala Upendra] Postgrad Inst Med, Colombo, Sri Lanka. [Jayatilleke, Achala Upendra] Inst Violence & Injury Prevent, Colombo, Sri Lanka. [Jha, Vivekanand] Postgrad Inst Med Educ & Res, Chandigarh, India. [Jiang, Guohong] Tianjin Ctr Dis Control & Prevent, Tianjin, Peoples R China. [Jiang, Ying] Univ Occupat & Environm Hlth, Dept Hlth Dev, Inst Ind Ecol Sci, Dept Environm Epidemiol, Kitakyushu, Fukuoka, Japan. [Deribe, Kebede] Univ Addis Ababa, Sch Publ Hlth, Debre Zeit, Ethiopia. [Jibat, Tariku] Univ Addis Ababa, Debre Zeit, Ethiopia. [Jonas, Jost B.] Heidelberg Univ, Dept Ophthalmol, Med Fac Mannheim, Mannheim, Germany. [Kabir, Zubair] Univ Coll Cork, Cork, Ireland. [Kamal, Ritul; Kesavachandran, Chandrasekharan Nair] CSIR, Indian Inst Toxicol Res, Lucknow, Uttar Pradesh, India. [She, Jun] Fudan Univ, Zhongshan Hosp, Shanghai, Peoples R China. [Zhang, Hao] Fudan Univ, Zhongshan Hosp, Dept Nephrol, Shanghai, Peoples R China. [Kan, Haidong] Fudan Univ, Shanghai, Peoples R China. [Karch, Andre] Helmholtz Ctr Infect Res, Epidemiol & Stat Methods Res Grp, Braunschweig, Germany. [Karch, Andre] German Ctr Infect Res, Hannover Braunschweig Site, Braunschweig, Germany. [Karletsos, Dimitris] Clinton Hlth Access Initiat, Boston, MA USA. [Kaul, Anil] Oklahoma State Univ, Tulsa, OK USA. [Kawakami, Norito] Univ Tokyo, Sch Publ Hlth, Tokyo, Japan. [Shibuya, Kenji] Univ Tokyo, Tokyo, Japan. [Kayibanda, Jeanne Francoise] Ottawa Hlth Res Inst, Ottawa, ON, Canada. [Keiyoro, Peter Njenga] Inst Trop & Infect Dis, Nairobi, Kenya. [Keiyoro, Peter Njenga] Sch Continuing & Distance Educ, Nairobi, Kenya. [Kengne, Andre Pascal] South African Med Res Council, Cape Town, South Africa. [Sliwa, Karen] Univ Cape Town, Fac Hlth Sci, Hatter Inst Cardiovascular Res Africa, Cape Town, South Africa. [Kengne, Andre Pascal; Mayosi, Bongani M.] Univ Cape Town, Cape Town, South Africa. [Khader, Yousef Saleh] Jordan Univ Sci & Technol, Irbid, Jordan. [Khan, Abdur Rahman] Univ Louisville, Louisville, KY 40292 USA. [Khan, Ejaz Ahmad] Hlth Serv Acad, Islamabad, Pakistan. [Khan, Ejaz Ahmad] Expanded Programme Immunizat, Islamabad, Pakistan. [Khubchandani, Jagdish] Ball State Univ, Muncie, IN 47306 USA. [Kim, Yun Jin] SouthernUniv Coll, Skudai, Malaysia. [Kinfu, Yohannes] Univ Canberra, Canberra, ACT, Australia. [Kokubo, Yoshihiro] Natl Cerebral & Cardiovasc Ctr, Dept Prevent Cardiol, Suita, Osaka, Japan. [Kosen, Soewarta] NIHRD, Ctr Community Empowerment Hlth Policy & Humanitie, Jakarta, Indonesia. [Koul, Parvaiz A.] Sherikashmir Inst Med Sci, Srinagar, Jammu & Kashmir, India. [Defo, Barthelemy Kuate] Univ Montreal, Dept Demog, Montreal, PQ, Canada. [Defo, Barthelemy Kuate] Univ Montreal, Publ Hlth Res Inst, Montreal, PQ, Canada. [Defo, Barthelemy Kuate] Univ Montreal, Dept Social & Prevent Med, Sch Publ Hlth, Montreal, PQ, Canada. [Bicer, Burcu Kucuk] Hacettepe Univ, Inst Publ Hlth, Ankara, Turkey. [Kulkarni, Veena S.] Univ Arkansas, State Univ, Fayetteville, AR 72701 USA. [Lam, Hilton] Natl Inst Hlth, Inst Hlth Policy & Dev Studies, Manila, Philippines. [Lam, Jennifer O.] Johns Hopkins Univ, Bloomberg Sch Publ Hlth, Baltimore, MD USA. [Bach Xuan Tran] Johns Hopkins Univ, Baltimore, MD USA. [Lansingh, Van C.] Help Me See Inc, New York, NY USA. [Lansingh, Van C.] Inst Mexicano Oftalmol, Queretaro, Mexico. [Leung, Ricky] SUNY Albany, Rensselaer, NY USA. [Li, Yongmei] San Francisco VA Med Ctr, San Francisco, CA USA. Wayne State Univ, Sch Med, Miami, FL USA. [Lipshultz, Steven E.; Wilkinson, James D.] Childrens Hosp Michigan, Detroit, MI 48201 USA. [Liu, Shiwei; Wang, Linhong] Natl Ctr Chron & Noncommunicable Dis Control & Pr, Beijing, Peoples R China. [Yu, Shicheng] Chinese Ctr Dis Control & Prevent, Beijing, Peoples R China. [Lloyd, Belinda K.] Monash Univ, Eastern Hlth Clin Sch, Fitzroy, Vic, Australia. [Lloyd, Belinda K.] Eastern Hlth, Turning Point, Melbourne, Vic, Australia. [Logroscino, Giancarlo] Univ Bari, Bari, Italy. [Lunevicius, Raimundas] Aintree Univ Hosp Natl Hlth Serv Fdn Trust, Liverpool, Merseyside, England. [Lunevicius, Raimundas] Univ Liverpool, Sch Med, Liverpool, Merseyside, England. [Abd El Razek, Hassan Magdy; Zaki, Maysaa El Sayed] Mansoura Fac Med, Mansoura, Egypt. [Polinder, Suzanne] Erasmus Univ, Dept Publ Hlth, Univ Med Ctr, Rotterdam, Netherlands. [Mahdavi, Mahdi] Erasmus Univ, Rotterdam, Netherlands. [Mahdavi, Mahdi] Iranian Minist Hlth, Tehran, Iran. [Marcenes, Wagner] Queen Mary Univ London, London, England. [Martinez-Raga, Jose] Hosp Univ Doctor Peset, Valencia, Spain. [Martinez-Raga, Jose] Univ CEU UCH, Moncada, Spain. [Marzan, Melvin Barrientos] Univ East Ramon Magsaysay, Mem Med Ctr, Quezon City, Philippines. [Mason-Jones, Amanda J.] Univ York, Dept Hlth Sci, York, N Yorkshire, England. [Meaney, Peter A.] Univ Penn, Pereleman Sch Med, Philadelphia, PA 19104 USA. [Meaney, Peter A.] Childrens Hosp Philadelphia, Philadelphia, PA 19104 USA. [Mehndiratta, Man Mohan] Janakpuri Superspecialty Hosp, New Delhi, India. [Mekonnen, Alemayehu B.; Tedla, Bemnet Amare; Tessema, Gizachew Assefa] Univ Gondar, Gondar, Ethiopia. [Memish, Ziad A.] Univ West Florida, Pensacola, FL 32514 USA. [Memish, Ziad A.] Saudi Minist Hlth, Riyadh, Saudi Arabia. [Memish, Ziad A.] Alfaisal Univ, Coll Med, Riyadh, Saudi Arabia. [Mendoza, Walter] United Nations Populat Fund, Lima, Peru. [Meretoja, Atte] Univ Helsinki, Cent Hosp, Dept Neurol, Helsinki, Finland. [Meretoja, Tuomo J.] Helsinki Univ Hosp, Ctr Comprehens Canc, Breast Surg Unit, Helsinki, Finland. [Meretoja, Tuomo J.] Univ Helsinki, Helsinki, Finland. [Mhimbira, Francis Apolinary] Ifakara Hlth Inst, Bagamoyo, Tanzania. [Miller, Ted R.] Pacific Inst Res & Evaluat, Calverton, MD USA. [Miller, Ted R.] Curtin Univ, Ctr Populat Hlth, Perth, WA, Australia. [Mirarefin, Mojde] Hunger Act Los Angeles, Los Angeles, CA USA. [Mohammad, Karzan Abdulmuhsin] Univ Salahaddin, Erbil, Iraq. [Mohammed, Shafiu] Heidelberg Univ, Inst Publ Hlth, Heidelberg, Germany. [Monasta, Lorenzo; Ronfani, Luca] IRCCS Burlo Garofolo, Inst Maternal & Child Hlth, Trieste, Italy. [Moradi-Lakeh, Maziar] Iran Univ Med Sci, Dept Community Med, Gastrointestinal & Liver Dis Res Ctr, Tehran, Iran. [Mori, Rintaro] Natl Ctr Child Hlth & Dev, Tokyo, Japan. [Werdecker, Andrea] Fed Inst Populat Res, Competence Ctr Mortal Follow Up German Natl Cohor, Wiesbaden, Germany. [Mueller, Ulrich O.; Westerman, Ronny] Fed Inst Populat Res, Wiesbaden, Germany. [Murimira, Brighton] Minist Hlth & Child Care, AIDS & TB Unit, Bindura, Zimbabwe. [Murimira, Brighton] Zimbabwe Natl Family Planning Council, Harare, Zimbabwe. [Naheed, Aliya] Int Ctr Diarrhoeal Dis Res, Dhaka, Bangladesh. [Naldi, Luigi] Azienda Osped Papa Giovanni XXIII, Bergamo, Italy. [Nangia, Vinay] Suraj Eye Inst, Nagpur, Maharashtra, India. [Nash, Denis] CUNY, Sch Publ Hlth, New York, NY 10021 USA. [Nawaz, Haseeb] Southern Illinois Univ, Springfield, IL USA. [Nejjari, Chakib] Fac Med, Fes, Morocco. [Ngalesoni, Frida Namnyak] Minist Hlth & Social Welf, Dar Es Salaam, Tanzania. [Ngirabega, Jean De Dieu] East African Community Hlth Res Commiss, Kigali, Rwanda. [Quyen Le Nguyen] Duy Tan Univ, Inst Global Hlth Innovat, Da Nang, Vietnam. [Vollset, Stein Emil] Univ Bergen, Dept Global Publ Hlth & Primary Care, Bergen, Norway. [Norheim, Ole F.] Univ Bergen, Bergen, Norway. [Norman, Rosana E.] Queensland Univ Technol, Inst Hlth & Biomed Innovat, Brisbane, Qld, Australia. [Nyakarahuka, Luke] Makerere Univ, Kampala, Uganda. Amer Univ Beirut, Ctr Res Populat & Hlth, Fac Hlth Sci, Beirut, Lebanon. [Ogbo, Felix Akpojene] Univ Western Sydney, Sydney, NSW, Australia. [Oh, In-Hwan] Kyung Hee Univ, Dept Prevent Med, Sch Med, Seoul, South Korea. [Olusanya, Bolajoko Olubukunola] Ctr Healthy Start Initiat, Ikoyi, Nigeria. [Olusanya, Jacob Olusegun] Ctr Healthy Start Initiat, Lagos, Nigeria. [Opio, John Nelson] Lira Dist Local Govt, Lira Municipal Council, Lira, Uganda. [Ota, Erika] Natl Res Inst Child Hlth & Dev, Tokyo, Japan. [Padukudru, Mahesh Anand] JSS Univ, JSS Med Coll, Mysore, Karnataka, India. [Park, Hye-Youn] Calif Air Resources Board, Sacramento, CA USA. [Park, Jae-Hyun] Sungkyunkwan Univ, Dept Social & Prevent Med, Samsung Biomed Res Inst, Sch Med, Suwon, South Korea. Univ Calgary, Calgary, AB, Canada. [Patil, Snehal T.] Sch Dent Sci, Karad, India. [Patten, Scott B.] Univ Calgary, Dept Community Hlth Sci, Calgary, AB, Canada. [Paul, Vinod K.; Roy, Ambuj; Sagar, Rajesh] All India Inst Med Sci, New Delhi, India. [Peprah, Emmanuel Kwame] NHLBI, Bldg 10, Bethesda, MD 20892 USA. [Pereira, David M.] Fiocruz MS, Rio De Janeiro, Brazil. [Perico, Norberto; Remuzzi, Giuseppe] IRCCS Mario Negri Inst Pharmacol Res, Ctr Anna Maria Astori, Bergamo, Italy. [Pesudovs, Konrad; Tesfay, Fisaha Haile] Flinders Univ S Australia, Adelaide, SA, Australia. [Petzold, Max] Hlth Metr Unit, Gothenburg, Sweden. [Phillips, Michael Robert] Shanghai Jiao Tong Univ, Sch Med, Shanghai, Peoples R China. [Simard, Edgar P.] Emory Univ, Rollins Sch Publ Hlth, Atlanta, GA 30322 USA. [Phillips, Michael Robert] Emory Univ, Atlanta, GA 30322 USA. [Pillay, Julian David] Durban Univ Technol, Durban, South Africa. [Plass, Dietrich] Sect Exposure Assessment & Environm Hlth Indicato, Berlin, Germany. [Pourmalek, Farshad] Univ British Columbia, Vancouver, BC, Canada. [Qorbani, Mostafa] Alborz Univ Med Sci, Dept Community Med, Sch Med, Karaj, Iran. [Rafay, Anwar; Rana, Saleem M.] Contech Int Hlth Consultants, Lahore, Pakistan. [Rafay, Anwar; Rana, Saleem M.] Contech Sch Publ Hlth, Lahore, Pakistan. [Rahman, Mahfuzar] BRAC, Res & Evaluat Div, Dhaka, Bangladesh. [Rahman, Sajjad Ur] Hamad Med Corp, Doha, Qatar. [Rai, Rajesh Kumar] Soc Hlth & Demog Surveillance, Suri, India. [Rajsic, Sasa] UMIT, ERAWEB Program, Hall In Tirol, Austria. [Rao, Paturi Vishnupriya] Diabet Res Soc, Hyderabad, Andhra Pradesh, India. [Rao, Paturi Vishnupriya] Diabet Res Ctr, Hyderabad, Andhra Pradesh, India. [Remuzzi, Giuseppe] Azienda Osped Papa Giovanni XXIII, Bergamo, Italy. [Rojas-Rueda, David] ISGlobal, Ctr Res Environm Epidemiol, Barcelona, Spain. [Roshandel, Gholamreza] Golestan Univ Med Sci, Golestan Res Ctr Gastroenterol & Hepatol, Gorgan, Iran. [Ruhago, George Mugambage; Sunguya, Bruno F.] Muhimbili Univ Hlth & Allied Sci, Dar Es Salaam, Tanzania. [Saleh, Muhammad Muhammad] Dev Res & Projects Ctr, Abuja, Nigeria. [Sanabria, Juan R.] Case Western Reserve Univ, Cleveland, OH 44106 USA. [Sanabria, Juan R.] RFU Chicago Med Sch, Canc Treatment Centers Amer, N Chicago, IL USA. [Sarmiento-Suarez, Rodrigo] Univ Ciencias Aplicadas & Ambient, Bogota, DC, Colombia. [Sartorius, Benn; Yakob, Bereket] Univ KwaZulu Natal, Durban, South Africa. [Sawhney, Monika] Marshall Univ, Huntington, WV USA. [Schutte, Aletta E.] North West Univ, Hypertens Africa Res Team, Potchefstroom, South Africa. [Seedat, Soraya; Wiysonge, Charles Shey] Univ Stellenbosch, Cape Town, South Africa. [Sharma, Rajesh] Indian Inst Technol Ropar, Roopnagar, India. [Shen, Jiabin] Res Inst Nationwide Childrens Hosp, Columbus, OH USA. [Shen, Jiabin] Ohio State Univ, Coll Med, Columbus, OH 43210 USA. [Shin, Hwashin Hyun] Hlth Canada, Ottawa, ON, Canada. [Sigfusdottir, Inga Dora] Reykjavik Univ, Reykjavik, Iceland. [Santos Silva, Diego Augusto] Univ Fed Santa Catarina, Florianopolis, SC, Brazil. [Alves Silveira, Dayane Gabriele] Univ Brasilia, Brasilia, DF, Brazil. [Singh, Om Prakash] Banaras Hindu Univ, Dept Med, Inst Med Sci, Varanasi, Uttar Pradesh, India. [Singh, Prashant Kumar] Inst Human Dev, New Delhi, India. [Skirbekk, Vegard] Norwegian Inst Publ Hlth, Oslo, Norway. [Soneji, Samir] Dartmouth Coll, 1 Med Ctr Dr, Lebanon, NH 03756 USA. [Soriano, Joan B.] Univ Autonoma Madrid, Inst Invest Hosp Univ Princesa, Catedra UAM Linde, Palma de Mallorca, Spain. [Karema, Corine Kakizi] Minist Hlth, Malaria & Other Parasit Dis Div, Nairobi, Kenya. [Soti, David O.] Minist Hlth, Nairobi, Kenya. [Sreeramareddy, Chandrashekhar T.] Int Med Univ, Dept Community Med, Kuala Lumpur, Malaysia. [Stathopoulou, Vasiliki] Attikon Univ Hosp, Athens, Greece. [Steel, Nicholas] Univ East Anglia, Norwich, Norfolk, England. [Steel, Nicholas] Publ Hlth England, London, England. [Swaminathan, Soumya] Natl Inst Res TB, Madras, Tamil Nadu, India. [Sykes, Bryan L.] Univ Calif Irvine, Dept Criminol, Irvine, CA USA. [Sykes, Bryan L.] Univ Calif Irvine, Dept Law & Soc, Irvine, CA USA. [Sykes, Bryan L.] Univ Calif Irvine, Dept Sociol, Irvine, CA USA. [Sykes, Bryan L.] Univ Calif Irvine, Dept Publ Hlth, Irvine, CA USA. [Talongwa, Roberto Tchio] MINSANTE, Minist Hlth, Yaounde, Cameroon. [Tavakkoli, Mohammad] Westchester Med Ctr, Valhalla, NY USA. [Taye, Bineyam] Univ Addis Ababa, Addis Ababa, Ethiopia. [Tedla, Bemnet Amare] James Cook Univ, Cairns, Qld, Australia. [Terkawi, Abdullah Sulieman] Univ Virginia, Dept Anesthesiol, Charlottesville, VA USA. [Terkawi, Abdullah Sulieman] Cleveland Clin, Outcomes Res Consortium, Cleveland, OH USA. [Thapa, Kiran] Inst Med, Kathmandu, Nepal. [Thomson, Alan J.] Adapt Knowledge Management, Victoria, BC, Canada. [Thorne-Lyman, Andrew L.] WorldFish, Bayan Lepas, Penang, Malaysia. [Tobe-Gai, Ruoyan] Natl Ctr Child Hlth & Dev, Tokyo, Japan. [Topor-Madry, Roman] Jagiellonian Univ, Inst Publ Hlth, Krakow, Poland. [Topor-Madry, Roman] Casimir Great Fdn Innovat & Dev, Krakow, Poland. [Towbin, Jeffrey Allen] Le Bonheur Childrens Hosp, Memphis, TN USA. [Towbin, Jeffrey Allen] Univ Tennessee, Hlth Sci Ctr, Memphis, TN USA. [Towbin, Jeffrey Allen] St Jude Childrens Res Hosp, 332 N Lauderdale St, Memphis, TN 38105 USA. [Bach Xuan Tran] Hanoi Med Univ, Hanoi, Vietnam. [Dimbuene, Zacharie Tsala] Univ Kinshasa, Dept Populat Sci & Dev, Fac Econ & Management, Kinshasa, Zaire. [Tsilimparis, Nikolaos] Univ Heart Ctr Hamburg, Hamburg, Germany. [Ukwaja, Kingsley Nnanna] Fed Teaching Hosp, Dept Internal Med, Abakaliki, Nigeria. [Uneke, Chigozie Jesse] Ebonyi State Univ, Abakaliki, Nigeria. [Uthman, Olalekan A.] Univ Warwick, Warwick Med Sch, Coventry, W Midlands, England. [Venketasubramanian, N.] Raffles Hosp, Raffles Neurosci Ctr, Singapore, Singapore. [Vladimirov, Sergey K.] Fed Res Inst Hlth Org & Informat, Moscow, Russia. [Vlassov, Vasiliy Victorovich] Natl Res Univ, Higher Sch Econ, Moscow, Russia. [Vollset, Stein Emil] Norwegian Inst Publ Hlth, Bergen, Norway. [Weiderpass, Elisabete] Norway Inst Populat Based Canc Res, Dept Res, Canc Registry, Oslo, Norway. [Weiderpass, Elisabete] Univ Tromso, Fac Hlth Sci, Dept Community Med, Tromso, Norway. [Weiderpass, Elisabete] Folkhalsan Res Ctr, Genet Epidemiol Grp, Helsinki, Finland. [Weintraub, Robert G.] Royal Childrens Hosp, Melbourne, Vic, Australia. [Weintraub, Robert G.] German Natl Cohort Consortium, Heidelberg, Germany. [Wijeratne, Tissa] Western Hlth Footscray, Footscray, Vic, Australia. [Wilkinson, James D.] Wayne State Univ, Sch Med, Detroit, MI USA. [Wolfe, Charles D. A.] Kings Coll London, Div Hlth & Social Care Res, London, England. [Wolfe, Charles D. A.] Guys & St Thomas NHS Fdn Trust, Natl Inst Hlth Res, Comprehens Biomed Res Ctr, London, England. [Wolfe, Charles D. A.] Kings Coll London, London, England. [Wong, John Q.] Manila Univ, Ateneo Sch Med & Publ Hlth, Pasig, Philippines. [Xu, Gelin] Nanjing Univ, Sch Med, Dept Neurol, Jinling Hosp, Nanjing, Jiangsu, Peoples R China. [Yano, Yuichiro] Northwestern Univ, Dept Prevent Med, Chicago, IL 60611 USA. [Yaseri, Mehdi] Ophthalm Res Ctr, Tehran, Iran. [Yebyo, Henock Gebremedhin] Univ Zurich, Zurich, Switzerland. [Yip, Paul] Univ Hong Kong, Social Work & Social Adm Dept, Hong Kong, Hong Kong, Peoples R China. [Yip, Paul] Univ Hong Kong, Hong Kong Jockey Club Ctr Suicide Res & Prevent, Hong Kong, Hong Kong, Peoples R China. [Yonemoto, Naohiro] Kyoto Univ, Dept Biostat, Sch Publ Hlth, Kyoto, Japan. [Yoon, Seok-Jun] Korea Univ, Dept Prevent Med, Coll Med, Seoul, South Korea. [Younis, Mustafa Z.] Jackson State Univ, Jackson, MS USA. [Yu, Chuanhua] Wuhan Univ, Dept Epidemiol & Biostat, Sch Publ Hlth, Wuhan, Peoples R China. [Yu, Chuanhua] Wuhan Univ, Global Hlth Inst, Wuhan, Peoples R China. [Zaidi, Zoubida] Univ Hosp, Setif, Algeria. [Zeeb, Hajo] Leibniz Inst Prevent Res & Epidemiol, Bremen, Germany. [Zhang, Hao] Shanghai Inst Kidney Dis & Dialysis, Shanghai, Peoples R China. [Zhao, Yong] Chongqing Med Univ, Chongqing, Peoples R China. [Zuhlke, Liesl Joanna] Red Cross War Mem Childrens Hosp, Cape Town, South Africa. RP Wang, HD (reprint author), Inst Hlth Metr & Evaluat, Seattle, WA 98121 USA.; Wang, HD (reprint author), Univ Washington, Inst Hlth Metr & Evaluat, Seattle, WA 98121 USA. EM haidong@uw.edu RI ; Gishu, Melkamu Dedefo/C-3747-2017; Alsharif, Ubai/C-6527-2017; Lotufo, Paulo/A-9843-2008; Karch, Andre/D-6973-2017; Hedayati, Mohammad T./E-2304-2017; Patten, Scott/B-4434-2011; Pereira, David/M-9286-2013; NORMAN, ROSANA/F-2774-2010; Abbas, Kaja/E-6590-2017; Jayatilleke, Achala/H-1714-2017; Roshandel, gholamreza/N-2260-2016; Weiderpass, Elisabete/M-4029-2016; das Neves, Jose/J-8369-2013; Jacobsen, Kathryn/B-5857-2008; Hankey, Graeme /H-4968-2014; Degenhardt, Louisa/D-4515-2012; Ronfani, Luca/B-6668-2013; Salomon, Joshua/D-3898-2009; Monasta, Lorenzo/B-1388-2012; Beyene, Tariku Jibat/A-6875-2017; Martinez-Raga, Jose/B-6251-2017; Majdan, Marek/K-5017-2012 OI Deribe, Kebede/0000-0002-8526-6996; Uthman, Olalekan/0000-0002-8567-3081; Khang, Young-Ho/0000-0002-9585-8266; Kemp, Andrew/0000-0003-1146-3791; Kamal, Ritul/0000-0001-9741-1698; Glaser, Elizabeth/0000-0002-1918-057X; Amegah, A Kofi/0000-0001-5868-6402; Atique, Suleman/0000-0002-5149-0703; Norheim, Ole F./0000-0002-5748-5956; Hoek, Hans/0000-0001-6353-5465; Hay, Simon/0000-0002-0611-7272; Moradi-Lakeh, Maziar/0000-0001-7381-5305; Alkerwi, Ala'a/0000-0002-7448-3936; Schutte, Aletta/0000-0001-9217-4937; Sindi, Shireen/0000-0002-3786-0552; Leung, Ricky/0000-0002-2852-6771; Pesudovs, Konrad/0000-0002-6322-9369; Aldridge, Robert/0000-0003-0542-0816; Catala-Lopez, Ferran/0000-0002-3833-9312; Javanbakht, Mehdi/0000-0002-8661-8439; Gething, Peter/0000-0001-6759-5449; Langan, Sinead/0000-0002-7022-7441; Wiysonge, Charles/0000-0002-1273-4779; Sreeramareddy, Chandrashekhar/0000-0002-5693-7631; Heredia-Pi, Ileana Beatriz/0000-0002-9998-9239; Miller, Ted/0000-0002-0958-2639; Xu, Gelin/0000-0002-6194-0341; GEBREMDHIN, AMANUEL TESFAY/0000-0003-2459-1805; Al-Aly, Ziyad/0000-0002-2600-0434; assadi, reza/0000-0002-5016-2994; Vlassov, Vasiliy/0000-0001-5203-549X; Birlik, Sait Mentes/0000-0002-9889-8837; Castaneda-Orjuela, Carlos/0000-0002-8735-6223; Yakob, Bereket/0000-0002-8383-6449; Fernandes, Joao/0000-0003-1556-1698; Santos, Itamar/0000-0003-3212-8466; Jakovljevic, Mihajlo/0000-0002-9160-6846; Gishu, Melkamu Dedefo/0000-0002-3466-1232; Alsharif, Ubai/0000-0002-4024-3950; Lotufo, Paulo/0000-0002-4856-8450; Karch, Andre/0000-0003-3014-8543; Hedayati, Mohammad T./0000-0001-6415-4648; Patten, Scott/0000-0001-9871-4041; Pereira, David/0000-0003-0384-7592; NORMAN, ROSANA/0000-0002-9742-1957; Abbas, Kaja/0000-0003-0563-1576; Jayatilleke, Achala/0000-0002-0855-7925; Roshandel, gholamreza/0000-0002-5494-0722; Weiderpass, Elisabete/0000-0003-2237-0128; das Neves, Jose/0000-0002-2317-2759; Jacobsen, Kathryn/0000-0002-4198-6246; Hankey, Graeme /0000-0002-6044-7328; Degenhardt, Louisa/0000-0002-8513-2218; Ronfani, Luca/0000-0001-5710-3914; Salomon, Joshua/0000-0003-3929-5515; Monasta, Lorenzo/0000-0001-7774-548X; Beyene, Tariku Jibat/0000-0002-7474-1966; Martinez-Raga, Jose/0000-0002-2856-6562; Majdan, Marek/0000-0001-8037-742X; Olusanya, Bolajoko/0000-0002-3826-0583; Goenka, Shifalika/0000-0001-6993-2883; Awasthi, Ashish/0000-0002-9308-9782 FU Bill AMP; Melinda Gates Foundation; National Institute of Mental Health, National Institutes of Health (NIH) [R01MH110163]; National Institute on Aging, NIH [P30AG047845]; Qatar National Research Fund (NPRP) [04-924-3-251]; Bill AMP; Melinda Gates Foundation [OPP1068048]; Fundacao para a Ciencia e a Tecnologia, Portugal [SFRH/BPD/92934/2013]; Wellcome Trust Fellowship in Public Health and Tropical Medicine [099876]; Swiss National Science Foundation (SNSF) [P300P3-154634]; Sistema Nacional de Investigadores de Panama-SNI; Wellcome Trust-DBT India Alliance Clinical and Public Health Intermediate Fellowship; Academy of Finland; Swedish Research Council; Alzheimerfonden; Alzheimer's Research AMP; Prevention Foundation; Center for Innovative Medicine (CIMED) at Karolinska Institutet South Campus; AXA Research Fund; Wallenberg Clinical Scholars Award from the Knut och Alice Wallenbergs Foundation; Sheika Salama Bint Hamdan Al Nahyan Foundation; ISCIII (General Branch Evaluation and Promotion of Health Research); European Regional Development Fund (ERDF-FEDER); National Institute for Health Research (NIHR) Clinician Scientist Fellowship [NIHR/CS/010/014]; NIHR; EU Innovative Medicines Initiative; Centre for Strategic AMP; International Studies; WHO; German National Cohort Consortium [O1ER1511D]; NIHR Oxford Biomedical Research Centre; NIHR Career Development Fellowship; Oxford Martin School; International Society of Nephrology (ISN); FAPESP (Brazilian public agency); Fonds de la recherche en sante du Quebec (FRSQ); Generalitat Valenciana [PROMETEOII/2015/021]; ISCIII-FEDER [PI14/00894]; Strategic Public Policy Research [HKU7003-SPPR-12]; [CP13/00150]; [PI15/00862] FX We thank the countless individuals who have contributed to the Global Burden of Disease (GBD) Study 2015 in various capacities. We specifically thank Jeffrey Eaton and John Stover. HW and CJLM received funding for this study from the Bill & Melinda Gates Foundation; the National Institute of Mental Health, National Institutes of Health (NIH; R01MH110163); and the National Institute on Aging, NIH (P30AG047845). LJAR acknowledges the support of Qatar National Research Fund (NPRP 04-924-3-251) who provided the main funding for generating the data provided to the GBD-Institute for Health Metrics and Evaluation effort. BPAQ acknowledges institutional support from PRONABEC (National Program of Scholarship and Educational Loan), provided by the Peruvian government. DB is supported by the Bill & Melinda Gates Foundation (grant number OPP1068048). JDN was supported in his contribution to this work by a Fellowship from Fundacao para a Ciencia e a Tecnologia, Portugal (SFRH/BPD/92934/2013). KD is supported by a Wellcome Trust Fellowship in Public Health and Tropical Medicine (grant number 099876). TF received financial support from the Swiss National Science Foundation (SNSF; project number P300P3-154634). AG acknowledges funding from Sistema Nacional de Investigadores de Panama-SNI. PJ is supported by Wellcome Trust-DBT India Alliance Clinical and Public Health Intermediate Fellowship. MK receives research support from the Academy of Finland, the Swedish Research Council, Alzheimerfonden, Alzheimer's Research & Prevention Foundation, Center for Innovative Medicine (CIMED) at Karolinska Institutet South Campus, AXA Research Fund, Wallenberg Clinical Scholars Award from the Knut och Alice Wallenbergs Foundation, and the Sheika Salama Bint Hamdan Al Nahyan Foundation. AK's work was supported by the Miguel Servet contract financed by the CP13/00150 and PI15/00862 projects, integrated into the National R&D&I and funded by the ISCIII (General Branch Evaluation and Promotion of Health Research), and the European Regional Development Fund (ERDF-FEDER). SML is funded by a National Institute for Health Research (NIHR) Clinician Scientist Fellowship (grant number NIHR/CS/010/014). HJL reports grants from the NIHR, EU Innovative Medicines Initiative, Centre for Strategic & International Studies, and WHO. WM is Program analyst, Population and Development, in the Peru Country Office of the United Nations Population Fund, which does not necessarily endorse this study. For UOM, funding from the German National Cohort Consortium (O1ER1511D) is gratefully acknowledged. KR reports grants from NIHR Oxford Biomedical Research Centre, NIHR Career Development Fellowship, and Oxford Martin School during the conduct of the study. GR acknowledges that work related to this paper has been done on the behalf of the GBD Genitourinary Disease Expert Group supported by the International Society of Nephrology (ISN). ISS reports grants from FAPESP (Brazilian public agency). RSS receives institutional support from Universidad de Ciencias Aplicadas y Ambientales, UDCA, Bogota Colombia. SS receives postdoctoral funding from the Fonds de la recherche en sante du Quebec (FRSQ), including its renewal. RTS was supported in part by grant number PROMETEOII/2015/021 from Generalitat Valenciana and the national grant PI14/00894 from ISCIII-FEDER. PY acknowledges support from Strategic Public Policy Research (HKU7003-SPPR-12). NR 54 TC 18 Z9 19 U1 49 U2 70 PU ELSEVIER INC PI SAN DIEGO PA 525 B STREET, STE 1900, SAN DIEGO, CA 92101-4495 USA SN 2352-3018 J9 LANCET HIV JI Lancet HIV PD AUG PY 2016 VL 3 IS 8 BP E361 EP E387 DI 10.1016/S2352-3018(16)30087-X PG 27 WC Immunology; Infectious Diseases SC Immunology; Infectious Diseases GA DS5SK UT WOS:000380842400010 ER PT J AU Wells, JM Farris, RF Gosdin, TA Dransfield, MT Wood, ME Bell, SC Rowe, SM AF Wells, J. Michael Farris, Roopan F. Gosdin, Taylor A. Dransfield, Mark T. Wood, Michelle E. Bell, Scott C. Rowe, Steven M. TI Pulmonary artery enlargement and cystic fibrosis pulmonary exacerbations: a cohort study SO LANCET RESPIRATORY MEDICINE LA English DT Article ID TRANSMEMBRANE CONDUCTANCE REGULATOR; LUNG-DISEASE; CARDIAC-FUNCTION; HYPERTENSION; COPD; CFTR; ECHOCARDIOGRAPHY; PATHOPHYSIOLOGY; EXPRESSION; MANAGEMENT AB Background Acute pulmonary exacerbations are associated with progressive lung function decline and increased mortality in cystic fibrosis. The role of pulmonary vascular disease in pulmonary exacerbations is unknown. We aimed to assess the association between pulmonary artery enlargement (defined as pulmonary artery diameter to ascending aorta diameter [PA:A] ratio >1), a marker of pulmonary vascular disease, and exacerbations. Methods In this cohort study, we used clinical, CT imaging, and prospective exacerbation data from a previous prospective clinical trial (derivation cohort) and from The Prince Charles Hospital (TPCH; Brisbane, QLD, Australia) cystic fibrosis registry (validation cohort). In our derivation cohort, we included adults aged 18 years or older with cystic fibrosis and at least one CFTR nonsense mutation, who were enrolled in the trial between Sept 8, 2009, and Nov 30, 2010, randomly assigned to receive placebo, and had baseline CT imaging. Our validation cohort included adult patients with cystic fibrosis who had CT imaging performed between Jan 1, 2002, and Dec 31, 2014. We measured the PA: A ratio at the level of the pulmonary artery bifurcation on CT scans. Patients in each cohort were separated into two groups on the basis of PA: A ratio (>1 or <= 1) and were followed up for 1 year in the derivation cohort and 2 years in the validation cohort. The primary endpoint was the development of one or more acute pulmonary exacerbations during follow-up. We used linear and logistic regression models to determine associations between clinical factors, the PA: A ratio, and pulmonary exacerbations. We used Cox regression to determine the time to first exacerbation in the validation cohort. Findings 37 (50%) of 74 patients in the derivation cohort and 89 (47%) of 190 patients in the validation cohort had enlarged pulmonary arteries (PA: A>1). 50 (68%) patients in the derivation cohort had one or more exacerbations at 1 year and 133 (70%) patients in the validation cohort had one or more exacerbations at 2 years. At baseline, patients with pulmonary artery enlargement were younger than those without enlargement in both cohorts and had elevated sweat chloride concentrations in the derivation cohort (100.5 mmol/L [SD 10.9] vs 90.4 mmol/L [19.9]; difference 10.1 mmol/L [95% CI 2.5- 177], p=0.017). Pulmonary artery enlargement was associated with exacerbations in the derivation cohort (odds ratio 3.49 [95% CI 1.18-10.3], p=0.023) when adjusted for sex, body-mass index (BMI), forced expiratory volume in 1 s (FEV1), and PA: A greater than 1, and in the validation cohort (2.41 [1.06-5.52], p=0.037) when adjusted for sex, BMI, chronic Pseudomonas aeruginosa infection, FEV1/FVC (forced vital capacity), PA: A greater than 1, and previous exacerbation. The time to first exacerbation was shorter in patients with enlarged pulmonary arteries than in those with normal-sized pulmonary arteries in the validation cohort (hazard ratio 1.66 [95% CI 1.18-2.34], p=0.0038) in unadjusted analysis, but not when adjusted for sex, BMI, exacerbations within 1 year before index CT scan, FEV1/FVC, and chronic Paeruginosa infection (1.14 [0.80-1.62], p=0.82). Interpretation Pulmonary artery enlargement is prevalent in adult patients with cystic fibrosis and was associated with acute pulmonary exacerbation risk in two well characterised cohorts. The PA: A ratio could be a predictive marker in cystic fibrosis. C1 [Wells, J. Michael; Farris, Roopan F.; Dransfield, Mark T.; Rowe, Steven M.] Univ Alabama Birmingham, Dept Med, Birmingham, AL 35294 USA. [Wells, J. Michael; Gosdin, Taylor A.; Dransfield, Mark T.; Rowe, Steven M.] Univ Alabama Birmingham, Div Pulm Allergy & Crit Care, Birmingham, AL USA. [Wells, J. Michael; Gosdin, Taylor A.; Dransfield, Mark T.; Rowe, Steven M.] Univ Alabama Birmingham, UAB Lung Hlth Ctr, Birmingham, AL USA. [Wells, J. Michael; Dransfield, Mark T.; Rowe, Steven M.] Univ Alabama Birmingham, Cyst Fibrosis Res Ctr, Birmingham, AL USA. [Wells, J. Michael; Dransfield, Mark T.] Birmingham VA Med Ctr, Birmingham, AL USA. [Wood, Michelle E.; Bell, Scott C.] Prince Charles Hosp Brisbane, Adult Cyst Fibrosis Ctr, Brisbane, Qld, Australia. [Wood, Michelle E.; Bell, Scott C.] Berghofer Med Res Inst, QIMR, Brisbane, Qld, Australia. [Wood, Michelle E.; Bell, Scott C.] Univ Queensland, Sch Med, Brisbane, Qld, Australia. RP Wells, JM (reprint author), Univ Alabama Birmingham, Div Pulm Allergy & Crit Care Med, 1900 Univ Blvd,THT 422, Birmingham, AL 35294 USA. EM jmwells@uabmc.edu FU US National Heart, Lung, and Blood Institute/National Institutes of Health; Cystic Fibrosis Foundation; University of Alabama at Birmingham; Queensland Health Fellowship FX US National Heart, Lung, and Blood Institute/National Institutes of Health, Cystic Fibrosis Foundation, the University of Alabama at Birmingham, and the Queensland Health Fellowship. NR 37 TC 0 Z9 0 U1 1 U2 1 PU ELSEVIER SCI LTD PI OXFORD PA THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, OXON, ENGLAND SN 2213-2600 J9 LANCET RESP MED JI Lancet Resp. Med. PD AUG PY 2016 VL 4 IS 8 BP 636 EP 645 DI 10.1016/S2213-2600(16)30105-9 PG 10 WC Critical Care Medicine; Respiratory System SC General & Internal Medicine; Respiratory System GA DS5QI UT WOS:000380836800027 PM 27298019 ER PT J AU Reich, A Werth, VP Furukawa, F Kuhn, A Szczech, J Samotij, D Szepietowski, JC AF Reich, A. Werth, V. P. Furukawa, F. Kuhn, A. Szczech, J. Samotij, D. Szepietowski, J. C. TI Treatment of cutaneous lupus erythematosus: current practice variations SO LUPUS LA English DT Article DE CLE; CCLE; DLE; ICLE; LET; SCLE; therapy ID DOUBLE-BLIND; CLOBETASOL PROPIONATE; CONTROLLED-TRIAL; TACROLIMUS; EFFICACY; OINTMENT; SPECTRUM; SAFETY AB The treatment of cutaneous lupus erythematous (CLE) remains a challenge. Most of the therapeutic options used in CLE have not been tested in randomized controlled studies and to date no agent has been approved. Therefore, CLE treatment is mostly based on personal experience. To better characterize therapeutic habits among physicians treating CLE patients, a questionnaire-based study about various aspects of topical and systemic treatment for CLE has been performed. The questionnaire was distributed among CLE experts, mostly from Japan, the USA, and Europe. A total of 82 completed questionnaires were assessed. High-potent and potent corticosteroids as well as calcineurin inhibitors were the most often recommended topical treatment for all CLE subtypes. The most relevant factors for initiation of systemic therapy were severity of skin lesions, concomitant involvement of internal organs, CLE subtype and lack of response to topical therapies. Corticosteroids and antimalarials were considered as the most suitable and effective systemic drugs for CLE patients. However, significant differences were observed between various CLE subtypes and between different countries regarding the assessment of various topical and systemic treatment options. In conclusion, great variability of obtained answers underlines the need of development of CLE treatment guidelines suitable for different disease subtypes. C1 [Reich, A.; Szczech, J.; Samotij, D.; Szepietowski, J. C.] Wroclaw Med Univ, Dept Dermatol Venereol & Allergol, Ul Chalubinskiego 1, PL-50368 Wroclaw, Poland. [Werth, V. P.] Philadelphia Vet Affairs Med Ctr, Philadelphia, PA USA. [Werth, V. P.] Univ Penn, Sch Med, Dept Dermatol, Philadelphia, PA 19104 USA. [Furukawa, F.] Wakayama Med Univ, Dept Dermatol, Wakayama, Japan. [Kuhn, A.] Univ Med Ctr, Interdisciplinary Ctr Clin Trials, Mainz, Germany. RP Reich, A (reprint author), Wroclaw Med Univ, Dept Dermatol Venereol & Allergol, Ul Chalubinskiego 1, PL-50368 Wroclaw, Poland. EM adam.reich@umed.wroc.pl NR 15 TC 0 Z9 0 U1 0 U2 1 PU SAGE PUBLICATIONS LTD PI LONDON PA 1 OLIVERS YARD, 55 CITY ROAD, LONDON EC1Y 1SP, ENGLAND SN 0961-2033 EI 1477-0962 J9 LUPUS JI Lupus PD AUG PY 2016 VL 25 IS 9 BP 964 EP 972 DI 10.1177/0961203316628997 PG 9 WC Rheumatology SC Rheumatology GA DS7RV UT WOS:000380981500003 PM 26821963 ER PT J AU Wong, ES Wang, V Liu, CF Hebert, PL Maciejewski, ML AF Wong, Edwin S. Wang, Virginia Liu, Chuan-Fen Hebert, Paul L. Maciejewski, Matthew L. TI Do Veterans Health Administration Enrollees Generalize to Other Populations? SO MEDICAL CARE RESEARCH AND REVIEW LA English DT Article DE veterans; comparative research; propensity score models; Medicare; Medicaid ID OBSTRUCTIVE PULMONARY-DISEASE; RANDOMIZED CONTROLLED-TRIAL; NURSE FOLLOW-UP; CARE-SYSTEM; BEHAVIORAL-MODEL; MEDICAL-CARE; AUTOMATED CALLS; GLUCOSE CONTROL; AFFAIRS; OUTCOMES AB The Veterans Health Administration (VHA) has historically served a disproportionately male patient population with lower income and greater rates of mental illness than non-VHA populations. The generalizability of research based on VHA enrollees is unknown because the overlap between VHA and non-VHA populations has never been empirically examined. This study used 2013 National Health Interview Survey data to examine the extent to which VHA enrollees had similar demographic and health characteristics as individuals with Medicaid, Medicare, or private insurance coverage, based on propensity score models. A majority of male VHA enrollees were similar to Medicare beneficiaries suggesting greater generalizability of VHA studies than commonly hypothesized. Overlap declined when comparing with Medicaid enrollees or privately insured individuals, suggesting more limited generalizability of VHA studies to these populations. C1 [Wong, Edwin S.; Liu, Chuan-Fen; Hebert, Paul L.] VA Puget Sound Hlth Care Syst, Seattle, WA USA. [Wong, Edwin S.; Liu, Chuan-Fen; Hebert, Paul L.] Univ Washington, Seattle, WA 98195 USA. [Wang, Virginia; Maciejewski, Matthew L.] Durham VA Med Ctr, Durham, NC USA. [Wang, Virginia; Maciejewski, Matthew L.] Duke Univ, Durham, NC USA. RP Wong, ES (reprint author), VA Puget Sound Hlth Care Syst, Ctr Innovat Vet Ctr & Value Driven Care, 1660 S Columbian Way,HSR&D MS-152, Seattle, WA 98108 USA. EM edwin.wong@va.gov FU U.S. Department of Veterans Affairs Health Services Research & Development Career Development Award [CDA 13-024] FX The author(s) disclosed receipt of the following financial support for the research, authorship, and/or publication of this article: Dr. Wong is supported by a U.S. Department of Veterans Affairs Health Services Research & Development Career Development Award (CDA 13-024). Dr. Maciejewski is a Department of Veterans Affairs Research Career Scientist (RCS 10-391). NR 29 TC 2 Z9 2 U1 0 U2 0 PU SAGE PUBLICATIONS INC PI THOUSAND OAKS PA 2455 TELLER RD, THOUSAND OAKS, CA 91320 USA SN 1077-5587 EI 1552-6801 J9 MED CARE RES REV JI Med. Care Res. Rev. PD AUG PY 2016 VL 73 IS 4 BP 493 EP 507 DI 10.1177/1077558715617382 PG 15 WC Health Care Sciences & Services; Health Policy & Services SC Health Care Sciences & Services GA DS7JI UT WOS:000380959200006 PM 26589675 ER PT J AU Qiao, DH Meyer, K Friedl, A AF Qiao, Dianhua Meyer, Kristy Friedl, Andreas TI Glypican 1 Stimulates S Phase Entry and DNA Replication in Human Glioma Cells and Normal Astrocytes (Retraction of vol 33, pg 4408, 2013) SO MOLECULAR AND CELLULAR BIOLOGY LA English DT Correction C1 [Qiao, Dianhua; Meyer, Kristy; Friedl, Andreas] Univ Wisconsin, Dept Pathol & Lab Med, Madison, WI 53706 USA. [Friedl, Andreas] William S Middleton Mem Vet Adm Med Ctr, Pathol & Lab Med Serv, Dept Vet Affairs Med Ctr, 2500 Overlook Terrace, Madison, WI 53705 USA. [Friedl, Andreas] Univ Wisconsin, Carbone Canc Ctr, Madison, WI USA. RP Qiao, DH (reprint author), Univ Wisconsin, Dept Pathol & Lab Med, Madison, WI 53706 USA. NR 1 TC 0 Z9 0 U1 2 U2 2 PU AMER SOC MICROBIOLOGY PI WASHINGTON PA 1752 N ST NW, WASHINGTON, DC 20036-2904 USA SN 0270-7306 EI 1098-5549 J9 MOL CELL BIOL JI Mol. Cell. Biol. PD AUG PY 2016 VL 36 IS 15 BP 2105 EP 2105 DI 10.1128/MCB.00321-16 PG 1 WC Biochemistry & Molecular Biology; Cell Biology SC Biochemistry & Molecular Biology; Cell Biology GA DS1QL UT WOS:000380371200009 PM 27418536 ER PT J AU Fryer, SL Roach, BJ Wiley, K Loewy, RL Ford, JM Mathalon, DH AF Fryer, Susanna L. Roach, Brian J. Wiley, Katherine Loewy, Rachel L. Ford, Judy M. Mathalon, Daniel H. TI Reduced Amplitude of Low-Frequency Brain Oscillations in the Psychosis Risk Syndrome and Early Illness Schizophrenia SO NEUROPSYCHOPHARMACOLOGY LA English DT Article ID RESTING-STATE FMRI; NAIVE 1ST-EPISODE SCHIZOPHRENIA; FUNCTIONAL CONNECTIVITY; INTERRATER RELIABILITY; PREDICTIVE-VALIDITY; PRODROMAL SYNDROMES; CLINICAL RISK; FLUCTUATIONS; MRI; CHILDREN AB Low-frequency oscillations (LFOs) of the blood oxygen level-dependent (BOLD) signal are gaining interest as potential biomarkers sensitive to neuropsychiatric pathology. Schizophrenia has been associated with alterations in intrinsic LFOs that covary with cognitive deficits and symptoms. However, the extent to which LFO dysfunction is present before schizophrenia illness onset remains unknown. Resting-state FMRI data were collected from clinical high-risk (CHR; n = 45) youth, early illness schizophrenia (ESZ; n = 74) patients, and healthy controls (HCs; n = 85) aged 12-35 years. Age-adjusted voxelwise fractional amplitude of low-frequency fluctuations (fALFF; 0.01 - 0.08 Hz) of the BOLD signal was compared among the three groups. Main effects of Group (p<0.005 height threshold, familywise error cluster-level corrected p<0.05) were followed up via Tukey-corrected pairwise comparisons. Significant main effects of Group (p<0.05) revealed decreased fALFF in ESZ and CHR groups relative to HCs, with values in the CHR group falling between those of ESZ and HC groups. These differences were identified primarily in posterior cortex, including temporoparietal regions, extending into occipital and cerebellar lobes. Less LFO activity was related to greater symptom severity in both CHR and ESZ groups in several of these posterior cortical regions. These data support an intermediate phenotype of reduced posterior cortical LFO amplitude in CHR individuals, with resting fALFF values smaller than in HCs but higher than in ESZ patients. Findings indicate that LFO magnitude alterations relate to clinical symptoms and predate psychosis onset but are more pronounced in the early stages of schizophrenia. C1 [Fryer, Susanna L.; Loewy, Rachel L.; Ford, Judy M.; Mathalon, Daniel H.] Univ Calif San Francisco, Dept Psychiat, San Francisco, CA USA. [Fryer, Susanna L.; Roach, Brian J.; Wiley, Katherine; Ford, Judy M.; Mathalon, Daniel H.] San Francisco VA Med Ctr, San Francisco, CA USA. RP Mathalon, DH (reprint author), San Francisco VA Med Ctr, Psychiat Serv 116D, 4150 Clement St, San Francisco, CA 94121 USA. EM daniel.mathalon@ucsf.edu FU [NIMH: MH076989]; [VA: CX001028] FX This research was supported by NIMH: MH076989 (to DH Mathalon) and VA: CX001028 (to SL Fryer). We thank Nicholas Diaz for assistance with manuscript preparation. NR 50 TC 3 Z9 3 U1 8 U2 10 PU NATURE PUBLISHING GROUP PI LONDON PA MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND SN 0893-133X EI 1740-634X J9 NEUROPSYCHOPHARMACOL JI Neuropsychopharmacology PD AUG PY 2016 VL 41 IS 9 BP 2388 EP 2398 DI 10.1038/npp.2016.51 PG 11 WC Neurosciences; Pharmacology & Pharmacy; Psychiatry SC Neurosciences & Neurology; Pharmacology & Pharmacy; Psychiatry GA DS1SC UT WOS:000380377300021 PM 27067126 ER PT J AU Di Tullio, MR Qian, M Thompson, JLP Labovitz, AJ Mann, DL Sacco, RL Pullicino, PM Freudenberger, RS Teerlink, JR Graham, S Lip, GYH Levin, B Mohr, JP Buchsbaum, R Estol, CJ Lok, DJ Ponikowski, P Anker, SD Homma, S AF Di Tullio, Marco R. Qian, Min Thompson, John L. P. Labovitz, Arthur J. Mann, Douglas L. Sacco, Ralph L. Pullicino, Patrick M. Freudenberger, Ronald S. Teerlink, John R. Graham, Susan Lip, Gregory Y. H. Levin, Bruce Mohr, J. P. Buchsbaum, Richard Estol, Conrado J. Lok, Dirk J. Ponikowski, Piotr Anker, Stefan D. Homma, Shunichi CA WARCEF Investigators TI Left Ventricular Ejection Fraction and Risk of Stroke and Cardiac Events in Heart Failure Data From the Warfarin Versus Aspirin in Reduced Ejection Fraction Trial SO STROKE LA English DT Article DE aspirin; echocardiography; heart failure; heart ventricles; stroke; warfarin ID BLOOD-PRESSURE; SINUS RHYTHM; THROMBOEMBOLIC EVENTS; BROAD-SPECTRUM; MORTALITY; INSIGHTS; OUTCOMES; ASSOCIATION; SURVIVAL; EFFICACY AB Background and Purpose-In heart failure (HF), left ventricular ejection fraction (LVEF) is inversely associated with mortality and cardiovascular outcomes. Its relationship with stroke is controversial, as is the effect of antithrombotic treatment. We studied the relationship of LVEF with stroke and cardiovascular events in patients with HF and the effect of different antithrombotic treatments. Methods-In the Warfarin Versus Aspirin in Reduced Ejection Fraction (WARCEF) trial, 2305 patients with systolic HF (LVEF <= 35%) and sinus rhythm were randomized to warfarin or aspirin and followed for 3.5 +/- 1.8 years. Although no differences between treatments were observed on primary outcome (death, stroke, or intracerebral hemorrhage), warfarin decreased the stroke risk. The present report compares the incidence of stroke and cardiovascular events across different LVEF and treatment subgroups. Results-Baseline LVEF was inversely and linearly associated with primary outcome, mortality and its components (sudden and cardiovascular death), and HF hospitalization, but not myocardial infarction. A relationship with stroke was only observed for LVEF of <15% (incidence rates: 2.04 versus 0.95/100 patient-years; P=0.009), which more than doubled the adjusted stroke risk (adjusted hazard ratio, 2.125; 95% CI, 1.182-3.818; P=0.012). In warfarin-treated patients, each 5% LVEF decrement significantly increased the stroke risk (adjusted hazard ratio, 1.346; 95% CI, 1.044-1.737; P=0.022; P value for interaction=0.04). Conclusions-In patients with systolic HF and sinus rhythm, LVEF is inversely associated with death and its components, whereas an association with stroke exists for very low LVEF values. An interaction with warfarin treatment on stroke risk may exist. C1 [Di Tullio, Marco R.; Homma, Shunichi] Columbia Univ, Dept Med, Div Cardiol, Med Ctr, New York, NY USA. [Qian, Min; Thompson, John L. P.; Levin, Bruce; Buchsbaum, Richard] Columbia Univ, Med Ctr, Dept Biostat, Mailman Sch Publ Hlth, New York, NY USA. [Mohr, J. P.] Columbia Univ, Med Ctr, Dept Neurol, New York, NY USA. [Labovitz, Arthur J.] Univ S Florida, Dept Cardiovasc Med, Tampa, FL USA. [Mann, Douglas L.] Washington Univ, Dept Med, Cardiovasc Div, St Louis, MO USA. [Sacco, Ralph L.] Univ Miami, Dept Neurol, Miami, FL USA. [Sacco, Ralph L.] Univ Miami, Dept Epidemiol, Miami, FL USA. [Sacco, Ralph L.] Univ Miami, Dept Publ Hlth, Miami, FL USA. [Pullicino, Patrick M.] Kent Inst Med & Hlth Sci, Canterbury, Kent, England. [Freudenberger, Ronald S.] Lehigh Valley Hosp, Dept Med, Div Cardiol, Allentown, PA USA. [Teerlink, John R.] Univ Calif San Francisco, San Francisco Vet Affairs Med Ctr, Cardiol Sect, San Francisco, CA 94143 USA. [Graham, Susan] SUNY Upstate Med Univ, Dept Med, Div Cardiol, Buffalo, NY USA. [Lip, Gregory Y. H.] Univ Birmingham, Ctr Cardiovasc Sci, City Hosp, Birmingham, W Midlands, England. [Estol, Conrado J.] Ctr Neurol Tratamiento & Rehabil, Buenos Aires, DF, Argentina. [Mann, Douglas L.] Deventer Hosp, Dept Cardiol, Deventer, Netherlands. [Ponikowski, Piotr] Wroclaw Med Univ, Mil Hosp, Dept Heart Dis, Wroclaw, Poland. [Anker, Stefan D.] Univ Med Gottingen, Dept Innovat Clin Trials, Gottingen, Germany. RP Di Tullio, MR (reprint author), Div Cardiol, PH 3-342,622 W,168th St, New York, NY 10032 USA. EM md42@cumc.columbia.edu RI Ponikowski, Piotr/O-6454-2015 OI Ponikowski, Piotr/0000-0002-3391-7064 FU National Institute of Neurological Diseases and Stroke (NINDS) [U01-NS-043975, U01-NS-039143] FX The study was funded by U01-NS-043975 (Dr Homma) and U01-NS-039143 (Dr Thompson) from the National Institute of Neurological Diseases and Stroke (NINDS). NR 17 TC 4 Z9 4 U1 3 U2 6 PU LIPPINCOTT WILLIAMS & WILKINS PI PHILADELPHIA PA TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA SN 0039-2499 EI 1524-4628 J9 STROKE JI Stroke PD AUG PY 2016 VL 47 IS 8 BP 2031 EP 2037 DI 10.1161/STROKEAHA.116.013679 PG 7 WC Clinical Neurology; Peripheral Vascular Disease SC Neurosciences & Neurology; Cardiovascular System & Cardiology GA DS5GC UT WOS:000380808400022 PM 27354224 ER PT J AU Beste, LA Mattox, EA Pichler, R Young, BA Au, DH Kirsh, SF Germani, MW Hedeen, A Harp, BK Chang, MF AF Beste, Lauren A. Mattox, Elizabeth A. Pichler, Raimund Young, Bessie A. Au, David H. Kirsh, Susan F. Germani, Maureen W. Hedeen, Ashley Harp, Bonnie K. Chang, Michael F. TI Primary Care Team Members Report Greater Individual Benefits from Long- Versus Short-Term Specialty Telemedicine Mentorship SO TELEMEDICINE AND E-HEALTH LA English DT Article DE telehealth; ECHO; veterans; education; professional development ID GENERALIST-SUBSPECIALIST COMMUNICATION; PROJECT ECHO; OUTCOMES; ACCESS; SATISFACTION; EXTENSION; CHILDREN; COMPLEX AB Background: Primary care providers who participate in structured specialty telemedicine mentorship report improvements in clinical content mastery, professional satisfaction, and specialist communication. Introduction: Although these programs require investments of infrastructure resources and time, the duration of participation required to accrue optimal benefits is not known. We aimed to assess whether duration of participation is related to improved benefits of a longitudinal telemedicine-based mentorship program, specifically regarding perceived specialty care access, acquisition of new knowledge and skills, team integration, and overall job satisfaction. Materials and Methods: We conducted an e-mail survey of Veterans Affairs-based primary care team members in the United States' Pacific Northwest region who engaged in a longitudinal telemedicine mentorship program (n = 78). Results: After adjustment for potential confounding factors, respondents who engaged in telemedicine mentorship for >= 1 year were significantly more likely to strongly agree that telemedicine mentorship improved patient access to specialty care (adjusted odds ratio [AOR] = 9.3, p < 0.005) and was useful in treating other patients on their panels (AOR = 3.7, p = 0.04). Participation >= 1 year was also associated with higher self-reported knowledge and competencies (AOR = 4.0, p = 0.03) and with perception of integration into a clinical team (AOR = 5.6, p = 0.01), but not with overall job satisfaction. Conclusion: Telemedicine-based specialty mentorship programs are highly valued by primary care-based participants, and self-reported benefits accumulate beyond 1 year of participation. C1 [Beste, Lauren A.] VA Puget Sound Hlth Care Syst, Gen Med Serv, 1660 S Columbian Way, Seattle, WA 98108 USA. [Beste, Lauren A.; Young, Bessie A.; Au, David H.; Germani, Maureen W.; Hedeen, Ashley; Harp, Bonnie K.] VA Puget Sound Hlth Care Syst, Hlth Serv Res & Dev Ctr Innovat, Seattle, WA USA. [Beste, Lauren A.] Univ Washington, Div Gen Internal Med, Seattle, WA 98195 USA. [Mattox, Elizabeth A.; Au, David H.] VA Puget Sound Hlth Care Syst, Pulm & Crit Care Sect, Hosp & Specialty Med, Seattle, WA USA. [Pichler, Raimund; Young, Bessie A.] VA Puget Sound Hlth Care Syst, Hosp & Specialty Med, Nephrol Sect, Seattle, WA USA. [Pichler, Raimund; Young, Bessie A.; Harp, Bonnie K.] Univ Washington, Div Nephrol, Seattle, WA 98195 USA. [Pichler, Raimund; Young, Bessie A.; Harp, Bonnie K.] Univ Washington, Kidney Res Inst, Seattle, WA 98195 USA. [Au, David H.] Univ Washington, Div Pulm & Crit Care, Seattle, WA 98195 USA. [Kirsh, Susan F.] Dept Vet Hlth Adm, Off Specialty Care Serv, Patient Care Serv, Washington, DC USA. [Kirsh, Susan F.] Louis Stokes Cleveland VA Med Ctr, Cleveland, OH USA. [Kirsh, Susan F.] Case Western Reserve Univ, Sch Med, Cleveland, OH USA. [Chang, Michael F.] VA Portland Hlth Care Syst, Gastroenterol & Hepatol Serv, Portland, OR USA. [Chang, Michael F.] Oregon Hlth & Sci Univ, Div Gastroenterol & Hepatol, Portland, OR 97201 USA. RP Beste, LA (reprint author), VA Puget Sound Hlth Care Syst, Gen Med Serv, 1660 S Columbian Way, Seattle, WA 98108 USA. EM lauren.beste@va.gov FU VA Office of Patient Care Services, Specialty Care Services program office; VA Office of Rural Health FX The views expressed in this article are those of the authors and do not necessarily reflect the position or policy of the Department of Veterans Affairs. This material is the result of work supported by resources from the VA Puget Sound Health Care System (Seattle, Washington) and the VA Portland Health Care System (Portland, OR). Funding support was provided by the VA Office of Patient Care Services, Specialty Care Services program office, and by the VA Office of Rural Health. NR 26 TC 0 Z9 0 U1 3 U2 3 PU MARY ANN LIEBERT, INC PI NEW ROCHELLE PA 140 HUGUENOT STREET, 3RD FL, NEW ROCHELLE, NY 10801 USA SN 1530-5627 EI 1556-3669 J9 TELEMED E-HEALTH JI Telemed. e-Health PD AUG PY 2016 VL 22 IS 8 BP 699 EP 706 DI 10.1089/tmj.2015.0185 PG 8 WC Health Care Sciences & Services SC Health Care Sciences & Services GA DS5EZ UT WOS:000380805400011 PM 26959098 ER PT J AU Young, BA Katz, R Boulware, LE Kestenbaum, B de Boer, IH Wang, W Fulop, T Bansal, N Robinson-Cohen, C Griswold, M Powe, NR Himmelfarb, J Correa, A AF Young, Bessie A. Katz, Ronit Boulware, L. Ebony Kestenbaum, Bryan de Boer, Ian H. Wang, Wei Fueloep, Tibor Bansal, Nisha Robinson-Cohen, Cassianne Griswold, Michael Powe, Neil R. Himmelfarb, Jonathan Correa, Adolfo TI Risk Factors for Rapid Kidney Function Decline Among African Americans: The Jackson Heart Study (JHS) SO AMERICAN JOURNAL OF KIDNEY DISEASES LA English DT Article DE Chronic kidney disease (CKD); African American; ethnic differences; kidney disease progression; disease trajectory; rapid kidney function decline; estimated glomerular filtration rate (eGFR); risk factor; renal failure; Jackson Heart Study (JHS) ID BODY-MASS INDEX; STAGE RENAL-DISEASE; UNITED-STATES; ETHNIC-DIFFERENCES; RACIAL-DIFFERENCES; APOL1 VARIANTS; YOUNG-ADULTS; ASSOCIATION; POPULATION; PREVALENCE AB Background: Racial differences in rapid kidney function decline exist, but less is known regarding factors associated with rapid decline among African Americans. Greater understanding of potentially modifiable risk factors for early kidney function loss may help reduce the burden of kidney failure in this high-risk population. Study Design: Prospective cohort study. Setting & Participants: 3,653 African American participants enrolled in the Jackson Heart Study (JHS) with kidney function data from 2 of 3 examinations (2000-2004 and 2009-2013). Estimated glomerular filtration rate (eGFR) was calculated from serum creatinine using the CKD-EPI creatinine equation. Predictors: Demographics, socioeconomic status, lifestyle, and clinical risk factors for kidney failure. Outcomes: Rapid decline was defined as a >= 30% decline in eGFR during follow-up. We quantified the association of risk factors with rapid decline in multivariable models. Measurements: Clinical (systolic blood pressure and albuminuria [albumin-creatinine ratio]) and modifiable risk factors. Results: Mean age was 54 +/- 12 (SD) years, 37% weremen, average body mass index was 31.8 +/- 7.1 kg/m(2), 19% had diabetes mellitus (DM), and mean eGFR was 96.0 +/- 20 mL/min/1.73 m(2) with an annual rate of decline of 1.27 mL/min/1.73 m(2). Those with rapid decline (11.5%) were older, were more likely to be of low/middle income, and had higher systolic blood pressures and greater DM than those with nonrapid decline. Factors associated with >= 30% decline were older age (adjusted OR per 10 years older, 1.51; 95% CI, 1.34-1.71), cardiovascular disease (adjusted OR, 1.53; 95% CI, 1.12-2.10), higher systolic blood pressure (adjusted OR per 17 mm Hg greater, 1.22; 95% CI, 1.06-1.41), DM (adjusted OR, 2.63; 95% CI, 2.02-3.41), smoking (adjusted OR, 1.60; 95% CI, 1.10-2.31), and albumin-creatinine ratio >30 mg/g (adjusted OR, 1.55; 95% CI, 1.08-1.21). Conversely, results did not support associations of waist circumference, C-reactive protein level, and physical activity with rapid decline. Limitations: No midstudy creatinine measurement at examination 2 (2005-2008). Conclusions: Rapid decline heterogeneity exists among African Americans in JHS. Interventions targeting potentially modifiable factors may help reduce the incidence of kidney failure. Published by Elsevier Inc. on behalf of the National Kidney Foundation, Inc. This is a US Government Work. There are no restrictions on its use. C1 [Young, Bessie A.] Vet Affairs Puget Sound Hlth Care Syst, Ctr Innovat, Seattle, WA USA. [Young, Bessie A.; de Boer, Ian H.] Vet Affairs Puget Sound Hlth Care Syst, Hosp & Specialty Med, Seattle, WA USA. [Young, Bessie A.; Katz, Ronit; Kestenbaum, Bryan; de Boer, Ian H.; Bansal, Nisha; Robinson-Cohen, Cassianne; Himmelfarb, Jonathan] Univ Washington, Kidney Res Inst, Seattle, WA 98195 USA. [Young, Bessie A.; Katz, Ronit; Kestenbaum, Bryan; de Boer, Ian H.; Bansal, Nisha; Robinson-Cohen, Cassianne; Himmelfarb, Jonathan] Univ Washington, Div Nephrol, Seattle, WA 98195 USA. [Boulware, L. Ebony] Duke Univ, Dept Med, Durham, NC USA. [Wang, Wei; Griswold, Michael] Univ Mississippi, Med Ctr, Ctr Biostat & Bioinformat, Jackson, MS 39216 USA. [Fueloep, Tibor; Correa, Adolfo] Univ Mississippi, Med Ctr, Dept Med, Jackson, MS 39216 USA. [Powe, Neil R.] Univ Calif San Francisco, Dept Med, San Francisco, CA USA. RP Young, BA (reprint author), VA Puget Sound Hlth Care Syst, Hosp & Specialty Med, 1660 Columbian Way S,RDU 111A, Seattle, WA 98108 USA.; Young, BA (reprint author), VA Puget Sound Hlth Care Syst, Ctr Innovat Vet Ctr & Value Driven Care COIN, 1660 Columbian Way S,RDU 111A, Seattle, WA 98108 USA. EM youngb@uw.edu OI Robinson-Cohen, Cassianne/0000-0003-4783-7046 FU Dr Young's National Institutes of Health (NIH) National Institute of Diabetes and Digestive and Kidney Diseases [1R01DK102134-01]; National Heart, Lung and Blood Institute (NHLBI) [HHSN268201300046C, HHSN268201300047C, HHSN268201300048C, HHSN268201 300049C, HHSN268201300050C]; National Institute on Minority Health and Health Disparities; Veterans Affairs Puget Sound Health Care System FX This study was supported by Dr Young's National Institutes of Health (NIH) National Institute of Diabetes and Digestive and Kidney Diseases grant 1R01DK102134-01. The JHS is supported by contracts HHSN268201300046C, HHSN268201300047C, HHSN268201300048C, HHSN268201 300049C, and HHSN268201300050C from the National Heart, Lung and Blood Institute (NHLBI) and the National Institute on Minority Health and Health Disparities. Drs Young and de Boer are also supported in part by funding from the Veterans Affairs Puget Sound Health Care System. NR 43 TC 3 Z9 3 U1 2 U2 3 PU W B SAUNDERS CO-ELSEVIER INC PI PHILADELPHIA PA 1600 JOHN F KENNEDY BOULEVARD, STE 1800, PHILADELPHIA, PA 19103-2899 USA SN 0272-6386 EI 1523-6838 J9 AM J KIDNEY DIS JI Am. J. Kidney Dis. PD AUG PY 2016 VL 68 IS 2 BP 229 EP 239 DI 10.1053/j.ajkd.2016.02.046 PG 11 WC Urology & Nephrology SC Urology & Nephrology GA DS4LZ UT WOS:000380753900014 PM 27066930 ER PT J AU Li, J Brock, J Jack, B Mittman, B Naylor, M Sorra, J Mays, G Williams, MV AF Li, Jing Brock, Jane Jack, Brian Mittman, Brian Naylor, Mary Sorra, Joann Mays, Glen Williams, Mark V. CA Project ACHIEVE Team TI Project ACHIEVE - using implementation research to guide the evaluation of transitional care effectiveness (vol 16, 70, 2016) SO BMC HEALTH SERVICES RESEARCH LA English DT Correction C1 [Li, Jing] Univ Kentucky, Ctr Hlth Serv Res, Lexington, KY USA. [Li, Jing] Univ Kentucky, Internal Med, Lexington, KY USA. [Brock, Jane] Telligen, Care Transit Theme Support Ctr, Englewood, CO USA. [Jack, Brian] Boston Univ, Sch Med, Family Med, Boston, MA 02118 USA. [Mittman, Brian] Kaiser Permanente, Res & Evaluat, Pasadena, CA USA. [Mittman, Brian] US Dept Vet Affairs, Greater Los Angeles Healthcare Syst, VA Ctr Implementat Practice & Res, Los Angeles, CA USA. [Mittman, Brian] Univ Calif Los Angeles, Clin Translat Sci Inst, Sch Med, Los Angeles, CA USA. [Naylor, Mary] Univ Penn, Sch Nursing, NewCourtland Ctr Transit & Hlth, Philadelphia, PA 19104 USA. [Sorra, Joann] Westat Corp, Washington, DC USA. [Mays, Glen] Univ Kentucky, Natl Coordinating Ctr Publ Hlth Serv & Syst Res, Lexington, KY USA. [Williams, Mark V.] Univ Kentucky, Dept Internal Med, Ctr Hlth Serv Res, Kentucky Clin J525, Lexington, KY 40536 USA. RP Williams, MV (reprint author), Univ Kentucky, Dept Internal Med, Ctr Hlth Serv Res, Kentucky Clin J525, Lexington, KY 40536 USA. EM mark.will@uky.edu NR 2 TC 0 Z9 0 U1 1 U2 1 PU BIOMED CENTRAL LTD PI LONDON PA 236 GRAYS INN RD, FLOOR 6, LONDON WC1X 8HL, ENGLAND SN 1472-6963 J9 BMC HEALTH SERV RES JI BMC Health Serv. Res. PD AUG 1 PY 2016 VL 16 AR 326 DI 10.1186/s12913-016-1560-x PG 1 WC Health Care Sciences & Services SC Health Care Sciences & Services GA DS2XX UT WOS:000380648300002 ER PT J AU Albertini, MR Ranheim, EA Zuleger, CL Sondel, PM Hank, JA Bridges, A Newton, MA McFarland, T Collins, J Clements, E Henry, MB Neuman, HB Weber, S Whalen, G Galili, U AF Albertini, Mark R. Ranheim, Erik A. Zuleger, Cindy L. Sondel, Paul M. Hank, Jacquelyn A. Bridges, Alan Newton, Michael A. McFarland, Thomas Collins, Jennifer Clements, Erin Henry, Mary Beth Neuman, Heather B. Weber, Sharon Whalen, Giles Galili, Uri TI Phase I study to evaluate toxicity and feasibility of intratumoral injection of alpha-gal glycolipids in patients with advanced melanoma SO CANCER IMMUNOLOGY IMMUNOTHERAPY LA English DT Article DE Immunotherapy; alpha-Gal glycolipids; Cancer vaccines; Melanoma ID CARCINOMA-SPECIFIC IMMUNOTHERAPY; ANTI-GAL; INCREASED IMMUNOGENICITY; CANCER-IMMUNOTHERAPY; UNTREATED MELANOMA; GALACTOSYL EPITOPE; IGG ANTIBODY; T-CELLS; VACCINE; SURVIVAL AB Effective uptake of tumor cell-derived antigens by antigen-presenting cells is achieved pre-clinically by in situ labeling of tumor with alpha-gal glycolipids that bind the naturally occurring anti-Gal antibody. We evaluated toxicity and feasibility of intratumoral injections of alpha-gal glycolipids as an autologous tumor antigen-targeted immunotherapy in melanoma patients (pts). Pts with unresectable metastatic melanoma, at least one cutaneous, subcutaneous, or palpable lymph node metastasis, and serum anti-Gal titer a parts per thousand yen1:50 were eligible for two intratumoral alpha-gal glycolipid injections given 4 weeks apart (cohort I: 0.1 mg/injection; cohort II: 1.0 mg/injection; cohort III: 10 mg/injection). Monitoring included blood for clinical, autoimmune, and immunological analyses and core tumor biopsies. Treatment outcome was determined 8 weeks after the first alpha-gal glycolipid injection. Nine pts received two intratumoral injections of alpha-gal glycolipids (3 pts/cohort). Injection-site toxicity was mild, and no systemic toxicity or autoimmunity could be attributed to the therapy. Two pts had stable disease by RECIST lasting 8 and 7 months. Tumor nodule biopsies revealed minimal to no change in inflammatory infiltrate between pre- and post-treatment biopsies except for 1 pt (cohort III) with a post-treatment inflammatory infiltrate. Two and four weeks post-injection, treated nodules in 5 of 9 pts exhibited tumor cell necrosis without neutrophilic or lymphocytic inflammatory response. Non-treated tumor nodules in 2 of 4 evaluable pts also showed necrosis. Repeated intratumoral injections of alpha-gal glycolipids are well tolerated, and tumor necrosis was seen in some tumor nodule biopsies after tumor injection with alpha-gal glycolipids. C1 [Albertini, Mark R.; Ranheim, Erik A.; Zuleger, Cindy L.; Sondel, Paul M.; Hank, Jacquelyn A.; Newton, Michael A.; McFarland, Thomas; Collins, Jennifer; Clements, Erin; Neuman, Heather B.; Weber, Sharon] Univ Wisconsin, Carbone Canc Ctr, Madison, WI USA. [Albertini, Mark R.; Zuleger, Cindy L.; Bridges, Alan; McFarland, Thomas] Univ Wisconsin, Sch Med & Publ Hlth, Dept Med, Madison, WI USA. [Albertini, Mark R.; Bridges, Alan] William S Middleton Mem Vet Adm Med Ctr, Med Serv, Madison, WI USA. [Ranheim, Erik A.] Univ Wisconsin, Dept Pathol, Sch Med & Publ Hlth, Madison, WI 53706 USA. [Sondel, Paul M.; Hank, Jacquelyn A.] Univ Wisconsin, Dept Human Oncol, Sch Med & Publ Hlth, Madison, WI USA. [Sondel, Paul M.] Univ Wisconsin, Dept Pediat, Sch Med & Publ Hlth, Madison, WI USA. [Newton, Michael A.] Univ Wisconsin, Dept Biostat & Med Informat, Sch Med & Publ Hlth, Madison, WI USA. [Henry, Mary Beth; Neuman, Heather B.; Weber, Sharon] Univ Wisconsin, Dept Surg, Sch Med & Publ Hlth, Madison, WI USA. [Whalen, Giles; Galili, Uri] Univ Massachusetts, Dept Surg, Sch Med, Worcester, MA USA. [Albertini, Mark R.] Univ Wisconsin, Ctr Clin Sci, Room K6-530,600 Highland Ave, Madison, WI 53792 USA. RP Albertini, MR (reprint author), Univ Wisconsin, Carbone Canc Ctr, Madison, WI USA.; Albertini, MR (reprint author), Univ Wisconsin, Sch Med & Publ Hlth, Dept Med, Madison, WI USA.; Albertini, MR (reprint author), William S Middleton Mem Vet Adm Med Ctr, Med Serv, Madison, WI USA.; Albertini, MR (reprint author), Univ Wisconsin, Ctr Clin Sci, Room K6-530,600 Highland Ave, Madison, WI 53792 USA. EM mralbert@wisc.edu FU NIH from the National Cancer Institute [CA130295, P30 CA014520]; Clinical and Translational Science Award (CTSA) program, through the NIH National Center for Advancing Translational Sciences (NCATS) [UL1TR000427]; Ann's Hope Foundation; Tim Eagle Memorial; Jay Van Sloan Memorial from the Steve Leuthold Family; Gretchen and Andrew Dawes Melanoma Research Fund; Agalimmune FX Support was provided by NIH Grants CA130295, P30 CA014520 from the National Cancer Institute, by resources at the William S. Middleton Memorial Veterans Hospital, Madison, WI, and by the Clinical and Translational Science Award (CTSA) program, through the NIH National Center for Advancing Translational Sciences (NCATS), Grant UL1TR000427. The content is solely the responsibility of the authors and does not necessarily represent the official views of the NIH or the views of the Department of Veterans Affairs or the US Government. Additional support was provided by Ann's Hope Foundation, the Tim Eagle Memorial, the Jay Van Sloan Memorial from the Steve Leuthold Family, the Gretchen and Andrew Dawes Melanoma Research Fund, and Agalimmune. NR 41 TC 0 Z9 0 U1 4 U2 5 PU SPRINGER PI NEW YORK PA 233 SPRING ST, NEW YORK, NY 10013 USA SN 0340-7004 EI 1432-0851 J9 CANCER IMMUNOL IMMUN JI Cancer Immunol. Immunother. PD AUG PY 2016 VL 65 IS 8 BP 897 EP 907 DI 10.1007/s00262-016-1846-1 PG 11 WC Oncology; Immunology SC Oncology; Immunology GA DS1OW UT WOS:000380366800002 PM 27207605 ER PT J AU Dai, XP Bragina, O Zhang, TS Yang, YR Rao, GR Bragin, DE Statom, G Nemoto, EM AF Dai, Xingping Bragina, Olga Zhang, Tongsheng Yang, Yirong Rao, Gutti R. Bragin, Denis E. Statom, Gloria Nemoto, Edwin M. TI High Intracranial Pressure Induced Injury in the Healthy Rat Brain SO CRITICAL CARE MEDICINE LA English DT Article DE cerebral arteriovenous oxygen difference; cerebral blood flow; Fluoro-Jade stain; intracranial hypertension; ischemia; microvascular shunting ID CEREBRAL PERFUSION-PRESSURE; METABOLIC-RATE; VENOUS SYSTEM; HYPERTENSION; OXYGEN; HYPOTHERMIA; VOLUME; FLOW AB Objectives: We recently showed that increased intracranial pressure to 50 mm Hg in the healthy rat brain results in microvascular shunt flow characterized by tissue hypoxia, edema, and increased blood-brain barrier permeability. We now determined whether increased intracranial pressure results in neuronal injury by Fluoro-Jade stain and whether changes in cerebral blood flow and cerebral metabolic rate for oxygen suggest nonnutritive microvascular shunt flow. Design: Intracranial pressure was elevated by a reservoir of artificial cerebrospinal fluid connected to the cisterna magna. Arterial blood gases, cerebral arterial-venous oxygen content difference, and cerebral blood flow by MRI were measured. Fluoro-Jade stain neurons were counted in histologic sections of the right and left dorsal and lateral cortices and hippocampus. Setting: University laboratory. Subjects: Male Sprague Dawley rats. Interventions: Arterial pressure support if needed by IV dopamine infusion and base deficit corrected by sodium bicarbonate. Measurements and Main Results: Fluoro-Jade stain neurons increased 2.5- and 5.5-fold at intracranial pressures of 30 and 50 mm Hg and cerebral perfusion pressures of 57 +/- 4 (mean +/- sem) and 47 +/- 6 mm Hg, respectively (p < 0.001) (highest in the right and left cortices). Voxel frequency histograms of cerebral blood flow showed a pattern consistent with microvascular shunt flow by dispersion to higher cerebral blood flow at high intracranial pressure and decreased cerebral metabolic rate for oxygen. Conclusions: High intracranial pressure likely caused neuronal injury because of a transition from normal capillary flow to nonnutritive microvascular shunt flow resulting in tissue hypoxia and edema, and it is manifest by a reduction in the cerebral metabolic rate for oxygen. C1 [Dai, Xingping] Cent S Univ, Xiangya Hosp, Integrated Tradit Chinese & Western Med, Changsha, Hunan, Peoples R China. [Dai, Xingping; Bragina, Olga; Zhang, Tongsheng; Bragin, Denis E.; Statom, Gloria; Nemoto, Edwin M.] Univ New Mexico, Dept Neurosurg, Albuquerque, NM 87131 USA. [Yang, Yirong] Univ New Mexico, Coll Pharm, BRaIN Imaging Ctr, Dept Pharmaceut Sci, Albuquerque, NM 87131 USA. [Rao, Gutti R.] VA Pittsburgh Hlth Care Syst, Dept Pathol & Lab Med, Pittsburgh, PA USA. RP Nemoto, EM (reprint author), Univ New Mexico, Dept Neurosurg, BRaIN Ctr, 1101 Yale Blvd NE,Domenici Hall,Rm 1131B, Albuquerque, NM 87131 USA. EM ENemoto@salud.unm.edu RI Bragina, Olga/H-6696-2016; Bragin, Denis/E-5494-2016 OI Bragina, Olga/0000-0003-2810-9764; Bragin, Denis/0000-0003-4894-0061 FU National Institutes of Health (NIH) [NS061216, NS051639]; China Scholarship Council [201206375041]; AHA [12BGIA11730011UNM, 12BGIA11730011]; HSC COBRE program [P20 RR15636]; NIH-NINDS CoBRE Pilot Project [P30GM103400]; UNM SOM Dedicated Health Research Fund Pilot Project; Department of Neurosurgery; UNM HSC COBRE program [P20 RR15636]; AHA Chinese Govt. UNM COBRE FX Dr. Nemoto received support for article research from the National Institutes of Health (NIH), The China Scholarship Council Grant (#201206375041 to Dr. Xingping Dai), AHA 12BGIA11730011UNM HSC COBRE program (P20 RR15636), NIH-NINDS CoBRE Pilot Project P30GM103400, UNM SOM Dedicated Health Research Fund Pilot Project, and the Department of Neurosurgery. Dr. Dai disclosed other support from the AHA 12BGIA11730011; NIH Grants NS061216, NS051639 and UNM HSC COBRE program (P20 RR15636); NIH-NINDS CoBRE Pilot Project P30GM103400; UNM SOM Dedicated Health Research Fund Pilot Project; and the Department of Neurosurgery. He received funding from The China Scholarship Council Grant (#201206375041). Dr. Zhang received support for article research from the NIH and received funding from the China Scholarship Council Grant (#201206375041 for Dr. Dai). Dr. Yang received support for article research from the NIH and disclosed work for hire. Dr. Statom received support for article research from the NIH and AHA Chinese Govt. UNM COBRE. The remaining authors have disclosed that they do not have any potential conflicts of interest. NR 28 TC 0 Z9 0 U1 4 U2 5 PU LIPPINCOTT WILLIAMS & WILKINS PI PHILADELPHIA PA TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA SN 0090-3493 EI 1530-0293 J9 CRIT CARE MED JI Crit. Care Med. PD AUG PY 2016 VL 44 IS 8 BP E633 EP E638 DI 10.1097/CCM.0000000000001625 PG 6 WC Critical Care Medicine SC General & Internal Medicine GA DS2RK UT WOS:000380631000037 PM 26974548 ER PT J AU Smith, JA Mayeux, PR Schnellmann, RG AF Smith, Joshua A. Mayeux, Philip R. Schnellmann, Rick G. TI Delayed Mitogen-Activated Protein Kinase/Extracellular Signal-Regulated Kinase Inhibition by Trametinib Attenuates Systemic Inflammatory Responses and Multiple Organ Injury in Murine Sepsis SO CRITICAL CARE MEDICINE LA English DT Article DE inflammation; mitogen-activated protein kinase/extracellular signal-regulated kinase; multiple organ failure; sepsis; trametinib ID ACUTE KIDNEY INJURY; ACUTE-RENAL-FAILURE; PERITUBULAR CAPILLARY DYSFUNCTION; MITOCHONDRIAL BIOGENESIS; ANIMAL-MODELS; MICROVASCULAR DYSFUNCTION; POLYMICROBIAL SEPSIS; MOUSE MODEL; INDUCTION; IMPROVES AB Objective: The mitogen-activated protein kinase/extracellular signal-regulated kinase signaling pathway is an essential component of innate immunity necessary for mediating proinflammatory responses in the setting of sepsis. We previously demonstrated that the mitogen-activated protein kinase 1/2 inhibitor trametinib prevents endotoxin-induced renal injury in mice. We therefore assessed efficacy of trametinib in a more clinically relevant experimental model of sepsis. Design: Controlled in vivo laboratory study. Setting: University animal research laboratory. Subjects: Male C57BL/6 mice. Interventions: Mice were subjected to cecal ligation and puncture to induce sepsis or underwent sham operation as controls. Six hours after cecal ligation and puncture, mice were randomized to four experimental groups as follows: 1) sham control; 2) sham control + trametinib (1 mg/kg, IP); 3) cecal ligation and puncture; and 4) cecal ligation and puncture + trametinib. All animals received buprenorphine (0.05 mg/kg, SC) and imipenem/cilastatin (14 mg/kg, SC) in 1.5 mL of warm saline (40 mL/kg) at the 6-hour time point. Mice were euthanized at 18 hours after induction of cecal ligation and puncture. Measurements and Main Results: Trametinib inhibition of mitogen-activated protein kinase/extracellular signal-regulated kinase signaling 6 hours after cecal ligation and puncture attenuated increases in circulating proinflammatory cytokines (tumor necrosis factor-alpha, interleukin-1 beta, interleukin-6, and granulocyte macrophage colony-stimulating factor) and hypothermia at 18 hours. Trametinib also attenuated multiple organ injury as determined by serum creatinine, alanine aminotransferase, lactate dehydrogenase, and creatine kinase. At the organ level, trametinib completely restored peritubular capillary perfusion in the kidney. Restoration of microvascular perfusion was associated with reduced messenger RNA expression of well-characterized markers of proximal tubule injury. mitogen-activated protein kinase/extracellular signal-regulated kinase blockade attenuated cecal ligation and puncture-mediated up-regulation of cytokines (tumor necrosis factor-alpha, interleukin-1 beta) and restored interleukin-6 to control levels in the renal cortex, indicating the protective effects on the proximal tubule occur primarily through modulation of the proinflammatory response in sepsis. Conclusions: These data reveal that the mitogen-activated protein kinase/extracellular signal-regulated kinase inhibitor trametinib attenuates systemic inflammation and multiple organ damage in a clinically relevant model of sepsis. Because trametinib has been safely used in humans, we propose that this drug might represent a translatable approach to limit organ injury in septic patients. C1 [Smith, Joshua A.; Schnellmann, Rick G.] Univ Colorado Denver, Dept Med, Aurora, CO 80045 USA. [Mayeux, Philip R.] Univ Arkansas Med Sci, Dept Pharmacol & Toxicol, Little Rock, AR 72205 USA. [Schnellmann, Rick G.] Ralph H Johnson Vet Adm Med Ctr, Charleston, SC USA. RP Schnellmann, RG (reprint author), Univ Colorado Denver, Dept Med, Aurora, CO 80045 USA.; Schnellmann, RG (reprint author), Ralph H Johnson Vet Adm Med Ctr, Charleston, SC USA. EM schnell@musc.edu FU National Institute of General Medical Sciences; National Center for Research Resources [UL1-RR029882, C06-RR015455]; South Carolina Clinical and Translational Research Institute at the Medical University of South Carolina; National Institutes of Health (NIH); NIH, National Institute of General Medical Sciences (NIGMS); Biomedical Laboratory Research, and Development Program of the Department of Veterans Affairs; NIH [R01 GM106419, P20GM103542-02]; Journal of Pharmacology and Experimental Therapeutics; NIGMS [GM084147]; Biomedical Laboratory Research and Development Program of the Department of Veterans Affairs [5I01 BX-000851] FX Supported, in part, by National Institute of General Medical Sciences; National Center for Research Resources (UL1-RR029882); and the South Carolina Clinical and Translational Research Institute at the Medical University of South Carolina. Animal facilities were funded by National Center for Research Resources (C06-RR015455).; Mr. Smith received support for article research from the National Institutes of Health (NIH). His institution received grant support from the NIH, National Institute of General Medical Sciences (NIGMS), and Biomedical Laboratory Research, and Development Program of the Department of Veterans Affairs. Dr. Mayeux received support for article research from the NIH and received funding from the Journal of Pharmacology and Experimental Therapeutics (Associate Editor). His institution received grant support from the NIH R01 GM106419. Dr. Schnellmann received support for article research from the NIH. His institution received funding from the NIH ((and P20GM103542-02 [to South Carolina COBRE in Oxidants, Redox Balance, and Stress Signaling), NIGMS (GM084147), and the Biomedical Laboratory Research and Development Program of the Department of Veterans Affairs (5I01 BX-000851). NR 50 TC 3 Z9 3 U1 1 U2 3 PU LIPPINCOTT WILLIAMS & WILKINS PI PHILADELPHIA PA TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA SN 0090-3493 EI 1530-0293 J9 CRIT CARE MED JI Crit. Care Med. PD AUG PY 2016 VL 44 IS 8 BP E711 EP E720 DI 10.1097/CCM.0000000000001672 PG 10 WC Critical Care Medicine SC General & Internal Medicine GA DS2RK UT WOS:000380631000044 PM 27031380 ER PT J AU Nguyen, KL Hu, P Ennis, DB Shao, JX Pham, KA Chen, JJ AF Nguyen, Kim-Lien Hu, Peng Ennis, Daniel B. Shao, Jiaxin Pham, Kimberly A. Chen, Joseph J. TI Cardiac MRI: a Translational Imaging Tool for Characterizing Anthracycline-Induced Myocardial Remodeling SO CURRENT ONCOLOGY REPORTS LA English DT Review DE Cardiac magnetic resonance imaging; Cardiotoxicity; Cardio-oncology; Anthracyclines; Translational imaging ID CARDIOVASCULAR MAGNETIC-RESONANCE; CORONARY-HEART-DISEASE; EMISSION COMPUTED-TOMOGRAPHY; SENSITIVE INVERSION-RECOVERY; STEADY-STATE PRECESSION; LONG-TERM SURVIVORS; EXTRACELLULAR VOLUME; CHILDHOOD-CANCER; CE-MARC; INTERSTUDY REPRODUCIBILITY AB Cardiovascular side effects of cancer therapeutics are the leading causes of morbidity and mortality in cancer survivors. Anthracyclines (AC) serve as the backbone of many anti-cancer treatment strategies, but dose-dependent myocardial injury limits their use. Cumulative AC exposure can disrupt the dynamic equilibrium of the myocardial microarchitecture while repeated injury and repair leads to myocyte loss, interstitial myocardial fibrosis, and impaired contractility. Although children are assumed to have greater myocardial plasticity, AC exposure at a younger age portends worse prognosis. In older patients, there is lower overall survival once they develop cardiovascular disease. Because aberrations in the myocardial architecture predispose the heart to a decline in function, early detection with sensitive imaging tools is crucial and the implications for resource utilization are substantial. As a comprehensive imaging modality, cardiac magnetic resonance (CMR) imaging is able to go beyond quantification of ejection fraction and myocardial deformation to characterize adaptive microstructural and microvascular changes that are important to myocardial tissue health. Herein, we describe CMR as an established translational imaging tool that can be used clinically to characterize ACassociated myocardial remodeling. C1 [Nguyen, Kim-Lien; Hu, Peng; Shao, Jiaxin] Univ Calif Los Angeles, David Geffen Sch Med, Diagnost Cardiovasc Imaging Lab, Los Angeles, CA 90095 USA. [Nguyen, Kim-Lien; Hu, Peng; Shao, Jiaxin; Pham, Kimberly A.; Chen, Joseph J.] VA Greater Los Angeles Healthcare Syst, 11301 Wilshire Blvd,MC 111E, Los Angeles, CA 90024 USA. [Nguyen, Kim-Lien; Shao, Jiaxin; Pham, Kimberly A.; Chen, Joseph J.] Univ Calif Los Angeles, David Geffen Sch Med, Div Cardiol, 11301 Wilshire Blvd,MC 111E, Los Angeles, CA 90024 USA. [Hu, Peng; Ennis, Daniel B.; Shao, Jiaxin] Univ Calif Los Angeles, David Geffen Sch Med, Dept Radiol Sci, Los Angeles, CA 90095 USA. RP Nguyen, KL (reprint author), Univ Calif Los Angeles, David Geffen Sch Med, Diagnost Cardiovasc Imaging Lab, Los Angeles, CA 90095 USA.; Nguyen, KL (reprint author), VA Greater Los Angeles Healthcare Syst, 11301 Wilshire Blvd,MC 111E, Los Angeles, CA 90024 USA.; Nguyen, KL (reprint author), Univ Calif Los Angeles, David Geffen Sch Med, Div Cardiol, 11301 Wilshire Blvd,MC 111E, Los Angeles, CA 90024 USA. EM klnguyen@ucla.edu RI Shao, Jiaxin/S-3993-2016 OI Shao, Jiaxin/0000-0001-9998-3622; Nguyen, Kim-Lien/0000-0002-8854-2976 FU UCLA Jonsson Comprehensive Cancer Foundation; UCLA CTSI grant [UL1TR000124] FX This work is supported by pilot grants from the UCLA Jonsson Comprehensive Cancer Foundation and UCLA CTSI grant UL1TR000124. NR 100 TC 2 Z9 2 U1 1 U2 5 PU SPRINGER PI NEW YORK PA 233 SPRING ST, NEW YORK, NY 10013 USA SN 1523-3790 EI 1534-6269 J9 CURR ONCOL REP JI Curr. Oncol. Rep. PD AUG PY 2016 VL 18 IS 8 AR 48 DI 10.1007/s11912-016-0533-x PG 14 WC Oncology SC Oncology GA DS3GE UT WOS:000380670300002 PM 27292153 ER PT J AU LeMond, LM Grady, K Goodlin, S AF LeMond, Lisa M. Grady, Kathleen Goodlin, Sarah TI Certain Uncertainties: Provider Decision-Making for Destination Therapy Left Ventricular Assist Devices SO JOURNAL OF CARDIAC FAILURE LA English DT Meeting Abstract CT 20th Annual Scientific Meeting of the Heart-Failure-Society-of-America CY SEP 17-20, 2016 CL Kissimmee, FL SP Heart Failure Soc Amer C1 [LeMond, Lisa M.] Univ Colorado Hosp, Aurora, CO USA. [Grady, Kathleen] Northwestern Univ, Chicago, IL 60611 USA. [Goodlin, Sarah] Portland VA Med Ctr, Portland, OR USA. NR 0 TC 0 Z9 0 U1 0 U2 0 PU CHURCHILL LIVINGSTONE INC MEDICAL PUBLISHERS PI PHILADELPHIA PA CURTIS CENTER, INDEPENDENCE SQUARE WEST, PHILADELPHIA, PA 19106-3399 USA SN 1071-9164 EI 1532-8414 J9 J CARD FAIL JI J. Card. Fail. PD AUG PY 2016 VL 22 IS 8 SU S MA 044 BP S17 EP S18 PG 2 WC Cardiac & Cardiovascular Systems SC Cardiovascular System & Cardiology GA DS8WW UT WOS:000381064700044 ER PT J AU Sommerfeld, AJ Althouse, AD Prince, J Hickey, GW AF Sommerfeld, Alex J. Althouse, Andrew D. Prince, Jennifer Hickey, Gavin W. TI Obstructive Sleep Apnea is Associated with Increased Readmissions in CHF Patients SO JOURNAL OF CARDIAC FAILURE LA English DT Meeting Abstract CT 20th Annual Scientific Meeting of the Heart-Failure-Society-of-America CY SEP 17-20, 2016 CL Kissimmee, FL SP Heart Failure Soc Amer C1 [Sommerfeld, Alex J.; Althouse, Andrew D.; Hickey, Gavin W.] Univ Pittsburgh, Pittsburgh, PA USA. [Sommerfeld, Alex J.; Althouse, Andrew D.; Prince, Jennifer; Hickey, Gavin W.] VA Pittsburgh Hlth Syst, Pittsburgh, PA USA. NR 0 TC 0 Z9 0 U1 0 U2 0 PU CHURCHILL LIVINGSTONE INC MEDICAL PUBLISHERS PI PHILADELPHIA PA CURTIS CENTER, INDEPENDENCE SQUARE WEST, PHILADELPHIA, PA 19106-3399 USA SN 1071-9164 EI 1532-8414 J9 J CARD FAIL JI J. Card. Fail. PD AUG PY 2016 VL 22 IS 8 SU S MA 255 BP S88 EP S88 PG 1 WC Cardiac & Cardiovascular Systems SC Cardiovascular System & Cardiology GA DS8WW UT WOS:000381064700247 ER PT J AU Readhead, B Haure-Mirande, JV Zhang, B Haroutunian, V Gandy, S Schadt, EE Dudley, JT Ehrlich, ME AF Readhead, B. Haure-Mirande, J-V Zhang, B. Haroutunian, V. Gandy, S. Schadt, E. E. Dudley, J. T. Ehrlich, M. E. TI Molecular systems evaluation of oligomerogenic APP(E693Q) and fibrillogenic APP(KM670/671NL)/PSEN1(Delta exon9) mouse models identifies shared features with human Alzheimer's brain molecular pathology SO MOLECULAR PSYCHIATRY LA English DT Article ID AMYLOID PRECURSOR PROTEIN; A-BETA OLIGOMER; GENE SET ENRICHMENT; MICROGLIAL ACTIVATION; TRANSGENIC MICE; DISEASE; EXPRESSION; TRANSCRIPTION; SP1; METAANALYSIS AB Identification and characterization of molecular mechanisms that connect genetic risk factors to initiation and evolution of disease pathophysiology represent major goals and opportunities for improving therapeutic and diagnostic outcomes in Alzheimer's disease (AD). Integrative genomic analysis of the human AD brain transcriptome holds potential for revealing novel mechanisms of dysfunction that underlie the onset and/or progression of the disease. We performed an integrative genomic analysis of brain tissue-derived transcriptomes measured from two lines of mice expressing distinct mutant AD-related proteins. The first line expresses oligomerogenic mutant APP(E693Q) inside neurons, leading to the accumulation of amyloid beta (A beta) oligomers and behavioral impairment, but never develops parenchymal fibrillar amyloid deposits. The second line expresses APP(KM670/671NL)/PSEN1(Delta exon9) in neurons and accumulates fibrillar A beta amyloid and amyloid plaques accompanied by neuritic dystrophy and behavioral impairment. We performed RNA sequencing analyses of the dentate gyrus and entorhinal cortex from each line and from wild-type mice. We then performed an integrative genomic analysis to identify dysregulated molecules and pathways, comparing transgenic mice with wild-type controls as well as to each other. We also compared these results with datasets derived from human AD brain. Differential gene and exon expression analysis revealed pervasive alterations in APP/A beta metabolism, epigenetic control of neurogenesis, cytoskeletal organization and extracellular matrix (ECM) regulation. Comparative molecular analysis converged on FMR1 (Fragile X Mental Retardation 1), an important negative regulator of APP translation and oligomerogenesis in the post-synaptic space. Integration of these transcriptomic results with human postmortem AD gene networks, differential expression and differential splicing signatures identified significant similarities in pathway dysregulation, including ECM regulation and neurogenesis, as well as strong overlap with AD-associated co-expression network structures. The strong overlap in molecular systems features supports the relevance of these findings from the AD mouse models to human AD. C1 [Readhead, B.; Zhang, B.; Schadt, E. E.; Dudley, J. T.; Ehrlich, M. E.] Icahn Sch Med Mt Sinai, Dept Genet, New York, NY 10029 USA. [Readhead, B.; Zhang, B.; Schadt, E. E.; Dudley, J. T.] Icahn Sch Med Mt Sinai, Dept Genom Sci, New York, NY 10029 USA. [Readhead, B.; Zhang, B.; Schadt, E. E.; Dudley, J. T.; Ehrlich, M. E.] Icahn Sch Med Mt Sinai, Icahn Inst Genom Sci & Multiscale Biol, New York, NY 10029 USA. [Haure-Mirande, J-V; Gandy, S.; Ehrlich, M. E.] Icahn Sch Med Mt Sinai, Alzheimers Dis Res Ctr, Dept Neurol, One Gustave L Levy Pl Box 1137, New York, NY 10029 USA. [Haroutunian, V.; Gandy, S.] Icahn Sch Med Mt Sinai, Alzheimers Dis Res Ctr, Dept Psychiat, New York, NY 10029 USA. [Haroutunian, V.; Gandy, S.] James J Peters VA Med Ctr, New York, NY USA. [Gandy, S.] Ctr Cognit Hlth & NFL Neurol Care, Dept Neurol, New York, NY USA. [Gandy, S.] Icahn Sch Med Mt Sinai, Dept Pediat, New York, NY 10029 USA. RP Ehrlich, ME (reprint author), Icahn Sch Med Mt Sinai, Alzheimers Dis Res Ctr, Dept Neurol, One Gustave L Levy Pl Box 1137, New York, NY 10029 USA.; Dudley, JT (reprint author), Icahn Sch Med Mt Sinai, Dept Genet & Genom Sci, 770 Lexington Ave, New York, NY 10065 USA. EM joel.dudley@mssm.edu; michelle.ehrlich@mssm.edu FU NIH [multi-PI U01 AG046170, multi-PI R34 AG049649, R01 NS075685, P50 AG005138, R01 DK098242, U54 CA189201, HHSN271201300031C]; VA MERIT [RRD MERIT I01RX000684, BLRD MERIT I01BX000348]; Cure Alzheimer's Fund Research Consortium FX We thank the Mount Sinai Genomics Core Facility for carrying out the RNA sequencing. We would like to recognize the federal and foundation support that made this research possible. NIH support for this work included multi-PI U01 AG046170 (to EES, SG, VH, MEE), multi-PI R34 AG049649 (JTD, SG), R01 NS075685 (SG), P50 AG005138 to Mary Sano (SG), R01 DK098242 to JTD, U54 CA189201 to JTD, and HHSN271201300031C to VH. VA MERIT support included RRD MERIT I01RX000684 (SG) and BLRD MERIT I01BX000348 (SG). The Cure Alzheimer's Fund Research Consortium also supported this work (SG). The computational resources and staff expertise provided by the Department of Scientific Computing at the Icahn School of Medicine at Mount Sinai also contributed to the performance of this research. Data for the human LOAD DEX analysis were generated from postmortem brain tissue collected through the Mount Sinai VA Medical Center Brain Bank (generously provided by Dr. Eric Schadt), and the Mount Sinai NIH Brain and Tissue Repository (generously provided by Dr. Vahram Haroutunian). The results published here are based on data obtained from the Accelerating Medicines Partnership for Alzheimer's Disease (AMP-AD) Target Discovery Consortium data portal and can be accessed at doi:10.7303/syn2580853. NR 89 TC 0 Z9 0 U1 2 U2 2 PU NATURE PUBLISHING GROUP PI LONDON PA MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND SN 1359-4184 EI 1476-5578 J9 MOL PSYCHIATR JI Mol. Psychiatr. PD AUG PY 2016 VL 21 IS 8 BP 1099 EP 1111 DI 10.1038/mp.2015.167 PG 13 WC Biochemistry & Molecular Biology; Neurosciences; Psychiatry SC Biochemistry & Molecular Biology; Neurosciences & Neurology; Psychiatry GA DS4GN UT WOS:000380739500014 PM 26552589 ER PT J AU Pross, SE Bourne, AL Cheung, SW AF Pross, Seth E. Bourne, Andrea L. Cheung, Steven W. TI TeleAudiology in the Veterans Health Administration SO OTOLOGY & NEUROTOLOGY LA English DT Article DE Hearing aids; TeleAudiology; TeleHealth; Veterans administration ID INTERNATIONAL OUTCOME INVENTORY; HEARING-AID USE; UNITED-STATES; OLDER-ADULTS AB Objective: To assess effectiveness of TeleAudiology for hearing aid services. Study Design: Retrospective case-control. Setting: Ambulatory Veterans Health Administration and Community-Based Outpatient Clinics (CBOCs). Patients: 42,697 veterans who received hearing aids from January through September, 2014. Intervention(s): TeleAudiology (TA) and conventional in-person (IP) audiology care. Main Outcome Measure(s): International Outcome Inventory for Hearing Aids (IOI-HA) outcomes data. The IOI-HA is a 7-item survey used to assess hearing aid effectiveness. Scored from 7 to 35 points, higher scores are more favorable. Results: Among veterans nationwide who received hearing aids and completed the IOI-HA survey, 1,009 received TA and 41,688 received IP care. TA and IP groups have comparable mean IOI-HA values (TA = 29.6, SD = 3.9; IP = 28.7, SD = 4.2). Although comparison showed a statistically significant difference (p<0.0001, t test), principally because of large sample size, the distinction is not clinically meaningful. Subgroup analysis of veterans from San Francisco and six affiliated CBOCs showed 169 received TA and 338 received IP care. TA and IP groups have similar mean age (TA = 74, SD = 9.8; IP = 76, SD = 10.3) and sex distribution (TA male = 100%; IP male = 96%) with statistically significant (p<0.01, t test) but clinically insignificant differences. Mean IOI-HA scores (TA = 30.7, SD = 3.6; IP = 30.5, SD = 3.1) are not different between groups (p>0.05, t test). Conclusion: TA and IP encounters to provide hearing aid services to veterans are comparable, as both are highly effective based on IOI-HA results. The noninferiority of TA suggests its adoption to non-veterans may improve access while preserving high satisfaction. Financial impact of migration to TA will require future econometric analysis. C1 [Pross, Seth E.] Johns Hopkins Univ, Dept Otolaryngol Head & Neck Surg, Baltimore, MD USA. [Bourne, Andrea L.] San Francisco VA Med Ctr, Audiol & Speech Pathol Serv, San Francisco, CA USA. [Cheung, Steven W.] Univ Calif San Francisco, Dept Otolaryngol Head & Neck Surg, San Francisco, CA USA. RP Cheung, SW (reprint author), 2233 Post St,3rd Floor, San Francisco, CA 94115 USA. EM Steven.Cheung@ucsf.edu FU Coleman Memorial and Hearing Research, Inc. FX Coleman Memorial and Hearing Research, Inc. Funds. NR 14 TC 0 Z9 0 U1 0 U2 0 PU LIPPINCOTT WILLIAMS & WILKINS PI PHILADELPHIA PA TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA SN 1531-7129 EI 1537-4505 J9 OTOL NEUROTOL JI Otol. Neurotol. PD AUG PY 2016 VL 37 IS 7 BP 847 EP 850 DI 10.1097/MAO.0000000000001058 PG 4 WC Clinical Neurology; Otorhinolaryngology SC Neurosciences & Neurology; Otorhinolaryngology GA DS2NQ UT WOS:000380621200020 PM 27273404 ER PT J AU Flanagan, JC Korte, KJ Killeen, TK Back, SE AF Flanagan, Julianne C. Korte, Kristina J. Killeen, Therese K. Back, Sudie E. TI Concurrent Treatment of Substance Use and PTSD SO CURRENT PSYCHIATRY REPORTS LA English DT Review DE Substance use disorders; Addiction; Posttraumatic stress disorder; Clinical trials; Integrated intervention ID POSTTRAUMATIC-STRESS-DISORDER; COMORBID ALCOHOL DEPENDENCE; RANDOMIZED CONTROLLED-TRIAL; COGNITIVE-BEHAVIORAL THERAPY; SOCIAL ANXIETY DISORDER; PROLONGED EXPOSURE; FUNCTIONAL CONNECTIVITY; PILOT TRIAL; ALPHA-1-ADRENERGIC ANTAGONIST; PHARMACOLOGICAL-TREATMENT AB Substance use disorders (SUD) and posttraumatic stress disorder (PTSD) are chronic, debilitating conditions that frequently co-occur. Individuals with co-occurring SUD and PTSD suffer a more complicated course of treatment and less favorable treatment outcomes compared to individuals with either disorder alone. The development of effective psychosocial and pharmacological interventions for co-occurring SUD and PTSD is an active and critically important area of investigation. Several integrated psychosocial treatments for cooccurring SUD and PTSD have demonstrated promising outcomes. While recent studies examining medications to treat co-occurring SUD and PTSD have yielded encouraging findings, there remain substantial gaps in the evidence base regarding the treatment of co-occurring SUD and PTSD. This review will summarize the findings from clinical trials targeting a reduction in SUD and PTSD symptoms simultaneously. These results may improve our knowledge base and subsequently enhance our ability to develop effective interventions for this complex comorbid condition. C1 [Flanagan, Julianne C.; Korte, Kristina J.; Killeen, Therese K.; Back, Sudie E.] Med Univ South Carolina, 5 Charleston Ctr Dr,Suite 151, Charleston, SC 29455 USA. [Back, Sudie E.] Ralph H Johnson VAMC, 109 Bee St, Charleston, SC 29401 USA. RP Flanagan, JC (reprint author), Med Univ South Carolina, 5 Charleston Ctr Dr,Suite 151, Charleston, SC 29455 USA. EM Hellmuth@musc.edu FU National Institute on Child Health and Human Development; Office of Research on Women's Health [K12HD055885]; National Institute of Alcohol Abuse and Alcoholism [T32AA007474] FX This manuscript is the result of work supported, in part, by the National Institute on Child Health and Human Development and the Office of Research on Women's Health (K12HD055885) and the National Institute of Alcohol Abuse and Alcoholism (T32AA007474). NR 100 TC 3 Z9 3 U1 12 U2 18 PU SPRINGER PI NEW YORK PA 233 SPRING ST, NEW YORK, NY 10013 USA SN 1523-3812 EI 1535-1645 J9 CURR PSYCHIAT REP JI Curr. Psychiatry Rep. PD AUG PY 2016 VL 18 IS 8 AR 70 DI 10.1007/s11920-016-0709-y PG 9 WC Psychiatry SC Psychiatry GA DR8HR UT WOS:000380139500003 PM 27278509 ER PT J AU Boehme, AK Hays, AN Kicielinski, KP Arora, K Kapoor, N Lyerly, MJ Gadpaille, A Shiue, H Albright, K Miller, D Elkind, MSV Harrigan, MR AF Boehme, Amelia K. Hays, Angela N. Kicielinski, Kimberly P. Arora, Kanika Kapoor, Niren Lyerly, Michael J. Gadpaille, Alissa Shiue, Harn Albright, Karen Miller, David Elkind, Mitchell S. V. Harrigan, Mark R. TI Systemic Inflammatory Response Syndrome and Outcomes in Intracerebral Hemorrhage SO NEUROCRITICAL CARE LA English DT Article DE Intracerebral hemorrhage; Stroke; Inflammation; Epidemiology; Systemic inflammatory response syndrome ID SUBARACHNOID HEMORRHAGE; ISCHEMIC-STROKE; PLASMINOGEN ACTIVATOR; RISK-FACTORS; THROMBOLYSIS; PREDICTORS; INFARCTION; VASOSPASM; MORTALITY; SEVERITY AB To identify the patients at greatest odds for systemic inflammatory response syndrome (SIRS) and examine the association between SIRS and outcomes in patients presenting with intracerebral hemorrhage (ICH). We retrospectively reviewed consecutive patients presenting to a tertiary care center from 2008 to 2013 with ICH. SIRS was defined according to standard criteria as 2 or more of the following: (1) body temperature < 36 or > 38 A degrees C, (2) heart rate > 90 beats per minute, (3) respiratory rate > 20, or (4) white blood cell count < 4000/mm(3) or > 12,000/mm(3) or > 10 % polymorphonuclear leukocytes for > 24 h in the absence of infection. The outcomes of interest, discharge modified Rankin Scale (mRS 4-6), death, and poor discharge disposition (discharge anywhere but home or inpatient rehab) were assessed using logistic regression. A total of 249 ICH patients met inclusion criteria and 53 (21.3 %) developed SIRS during their hospital stay. A score was developed (ranging from 0 to 3) to identify patients at greatest risk for developing SIRS. Adjusting for stroke severity, SIRS was associated with mRS 4-6 (OR 5.25, 95 %CI 2.09-13.2) and poor discharge disposition (OR 3.74, 95 %CI 1.58-4.83) but was not significantly associated with death (OR 1.75, 95 %CI 0.58-5.32). We found that 33 % of the effect of ICH score on poor functional outcome at discharge was explained by the development of SIRS in the hospital (Sobel 2.11, p = 0.03). We observed that approximately 20 % of patients with ICH develop SIRS, and that patients with SIRS were at increased risk of having poor functional outcome at discharge. C1 [Boehme, Amelia K.; Elkind, Mitchell S. V.] Columbia Univ, Dept Neurol, Coll Phys & Surg, New York, NY 10032 USA. [Hays, Angela N.; Arora, Kanika; Lyerly, Michael J.; Gadpaille, Alissa; Shiue, Harn] Univ Alabama Birmingham, Dept Neurol, UAB Stn, Birmingham, AL 35294 USA. [Kicielinski, Kimberly P.; Harrigan, Mark R.] Univ Alabama Birmingham, Dept Neurosurg, Birmingham, AL 35294 USA. [Kapoor, Niren] Univ Penn, Dept Neurol, Div Neurocrit Care, Philadelphia, PA 19104 USA. [Albright, Karen] Birmingham VA Med Ctr, GRECC, Birmingham, AL 35233 USA. [Albright, Karen] Univ Alabama Birmingham, Sch Publ Hlth, Dept Epidemiol, Birmingham, AL 35249 USA. [Hays, Angela N.; Miller, David] Univ Alabama Birmingham, Dept Anesthesiol, Birmingham, AL 35294 USA. [Elkind, Mitchell S. V.] Columbia Univ, Dept Epidemiol, Mailman Sch Publ Hlth, New York, NY 10032 USA. [Boehme, Amelia K.] Columbia Univ, Dept Neurol, Gertrude Sergievsky Ctr, 710 W 168th St,Room 612, New York, NY 10032 USA. RP Boehme, AK (reprint author), Columbia Univ, Dept Neurol, Coll Phys & Surg, New York, NY 10032 USA.; Boehme, AK (reprint author), Columbia Univ, Dept Neurol, Gertrude Sergievsky Ctr, 710 W 168th St,Room 612, New York, NY 10032 USA. EM akb2188@cumc.columbia.edu OI Lyerly, Michael/0000-0003-4236-1018 FU NINDS NIH [T32 NS007153-31] FX Dr. Boehme is supported by NINDS NIH T32 NS007153-31. The content is solely the responsibility of the authors and does not necessarily represent the official views of the NINDS or the NIH. NR 38 TC 3 Z9 3 U1 0 U2 0 PU HUMANA PRESS INC PI TOTOWA PA 999 RIVERVIEW DRIVE SUITE 208, TOTOWA, NJ 07512 USA SN 1541-6933 EI 1556-0961 J9 NEUROCRIT CARE JI Neurocrit. Care PD AUG PY 2016 VL 25 IS 1 BP 133 EP 140 DI 10.1007/s12028-016-0255-9 PG 8 WC Critical Care Medicine; Clinical Neurology SC General & Internal Medicine; Neurosciences & Neurology GA DR8LZ UT WOS:000380150700018 PM 26920909 ER PT J AU Balbale, SN Locatelli, SM LaVela, SL AF Balbale, Salva N. Locatelli, Sara M. LaVela, Sherri L. TI Through Their Eyes: Lessons Learned Using Participatory Methods in Health Care Quality Improvement Projects SO QUALITATIVE HEALTH RESEARCH LA English DT Article DE health care; guided tours; participatory action research (PAR); photography; photovoice; qualitative; United States ID PATIENT-CENTERED CARE; PUBLIC-HEALTH; MOBILE METHODS; PHOTOVOICE; REFLECTIONS; SYSTEM; PERCEPTIONS; EXPLORE; NEEDS; TRANSFORMATION AB In this methodological article, we examine participatory methods in depth to demonstrate how these methods can be adopted for quality improvement (QI) projects in health care. We draw on existing literature and our QI initiatives in the Department of Veterans Affairs to discuss the application of photovoice and guided tours in QI efforts. We highlight lessons learned and several benefits of using participatory methods in this area. Using participatory methods, evaluators can engage patients, providers, and other stakeholders as partners to enhance care. Participant involvement helps yield actionable data that can be translated into improved care practices. Use of these methods also helps generate key insights to inform improvements that truly resonate with stakeholders. Using participatory methods is a valuable strategy to harness participant engagement and drive improvements that address individual needs. In applying these innovative methodologies, evaluators can transcend traditional approaches to uniquely support evaluations and improvements in health care. C1 [Balbale, Salva N.; Locatelli, Sara M.; LaVela, Sherri L.] US Dept Vet Affairs, Ctr Evaluat Practices & Experiences Patient Ctr C, Hines, IL USA. RP Balbale, SN (reprint author), Northwestern Univ, Feinberg Sch Med, 633 N St Clair St,20th Floor, Chicago, IL 60611 USA. EM salva.balbale@northwestern.edu FU Department of Veterans Affairs, Office of Patient-Centered Care and Cultural Transformation; Office of Research and Development Health Services Research and Development, Quality Enhancement Research Initiative [PEC-13-002] FX The authors disclosed receipt of the following financial support for the research, authorship, and/or publication of this article: Funding was received from the Department of Veterans Affairs, Office of Patient-Centered Care and Cultural Transformation, and the Office of Research and Development Health Services Research and Development, Quality Enhancement Research Initiative (PEC-13-002). NR 75 TC 1 Z9 1 U1 4 U2 6 PU SAGE PUBLICATIONS INC PI THOUSAND OAKS PA 2455 TELLER RD, THOUSAND OAKS, CA 91320 USA SN 1049-7323 EI 1552-7557 J9 QUAL HEALTH RES JI Qual. Health Res. PD AUG PY 2016 VL 26 IS 10 SI SI BP 1382 EP 1392 DI 10.1177/1049732315618386 PG 11 WC Information Science & Library Science; Social Sciences, Interdisciplinary; Social Sciences, Biomedical SC Information Science & Library Science; Social Sciences - Other Topics; Biomedical Social Sciences GA DR7FT UT WOS:000380066100007 PM 26667882 ER PT J AU Barry, CL Epstein, AJ Fiellin, DA Fraenkel, L Busch, SH AF Barry, Colleen L. Epstein, Andrew J. Fiellin, David A. Fraenkel, Liana Busch, Susan H. TI Estimating demand for primary care-based treatment for substance and alcohol use disorders SO ADDICTION LA English DT Article DE Alcohol use disorders; collaborative care; economics; financing; primary care; substance use disorders ID LATE-LIFE DEPRESSION; COLLABORATIVE CARE; COST-EFFECTIVENESS; BRIEF INTERVENTION; RANDOMIZED-TRIAL; DRUG-USE; DRINKING; MANAGEMENT; HEALTH; METAANALYSIS AB Background and AimsWhile there is broad recognition of the high societal costs of substance use disorders (SUD), treatment rates are low. We examined whether, in the United States, participants with substance or alcohol use disorder would report a greater willingness to enter SUD treatment located in a primary care setting (primary care) or more commonly found specialty care setting in the United States (usual care). DesignRandomized survey-embedded experiment. SettingUS web-based research panel in which participants were randomized to read one-paragraph vignettes describing treatment in usual care (specialty drug or alcohol treatment center), primary care or collaborative care within a primary care setting. ParticipantsA total of 42451 panelists aged 18+ were screened for substance or alcohol use disorder using validated diagnostic criteria. Participants included 344 with a substance use disorder and 634 with an alcohol use disorder not in treatment with no prior treatment history. MeasuresWillingness to enter treatment across vignettes by condition. FindingsAmong participants with a substance use disorder, 24.6% of those randomized to usual care reported being willing to enter drug treatment compared with 37.2% for primary care [12.6 percentage point difference; 95% confidence interval (CI)=0.8, 24.4) and 34.0% for collaborative care (9.4 percentage point difference; 95% CI=-2.0, 20.8). Among participants with an alcohol use disorder, 17.6% of those randomized to usual care reported being willing to enter alcohol treatment compared with 20.3% for primary care (2.6 percentage point difference; 95% CI=-4.9, 10.1) and 20.8% for collaborative care (3.1 percentage point difference; 95% CI=-4.3, 10.6). The most common reason for not being willing to enter drug (63%) and alcohol (78%) treatment was the belief that treatment was not needed. ConclusionsIn the United States, people diagnosed with substance or alcohol use disorders appear to be more willing to enter treatment in a primary care setting than in a specialty drug treatment center. Expanding availability of primary care-based substance use disorder treatment could increase treatment rates in the United States. C1 [Barry, Colleen L.] Johns Hopkins Bloomberg Sch Publ Hlth, Dept Hlth Policy & Management, 624 North Broadway,Hampton House 403, Baltimore, MD 21205 USA. [Barry, Colleen L.] Johns Hopkins Bloomberg Sch Publ Hlth, Dept Mental Hlth, Baltimore, MD USA. [Barry, Colleen L.; Epstein, Andrew J.] Univ Penn, Leonard Davis Inst Hlth Econ, Philadelphia, PA 19104 USA. [Epstein, Andrew J.] Univ Penn, Dept Med, Perelman Sch Med, Div Gen Internal Med, Philadelphia, PA 19104 USA. [Epstein, Andrew J.] Philadelphia Vet Affairs Med Ctr, Dept Vet Affairs, Ctr Hlth Equ Res & Promot, Philadelphia, PA USA. [Fiellin, David A.; Fraenkel, Liana] Yale Sch Med, Dept Gen Internal Med, New Haven, CT USA. [Fiellin, David A.; Busch, Susan H.] Yale Sch Publ Hlth, Dept Hlth Policy & Management, New Haven, CT USA. [Fraenkel, Liana] VA Connecticut Healthcare Syst, West Haven, CT USA. RP Barry, CL (reprint author), Johns Hopkins Bloomberg Sch Publ Hlth, Dept Hlth Policy & Management, 624 North Broadway,Hampton House 403, Baltimore, MD 21205 USA. EM cbarry@jhu.edu OI Fiellin, David/0000-0002-4006-010X FU National Institute on Drug Abuse [R01DA026414] FX The authors gratefully acknowledge funding from the National Institute on Drug Abuse (R01DA026414). NR 43 TC 1 Z9 1 U1 3 U2 6 PU WILEY-BLACKWELL PI HOBOKEN PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA SN 0965-2140 EI 1360-0443 J9 ADDICTION JI Addiction PD AUG PY 2016 VL 111 IS 8 BP 1376 EP 1384 DI 10.1111/add.13364 PG 9 WC Substance Abuse; Psychiatry SC Substance Abuse; Psychiatry GA DR5NE UT WOS:000379948900012 PM 26899802 ER PT J AU Ling, W Hillhouse, MP Saxon, AJ Mooney, LJ Thomas, CM Ang, A Matthews, AG Hasson, A Annon, J Sparenborg, S Liu, DS McCormack, J Church, S Swafford, W Drexler, K Schuman, C Ross, S Wiest, K Korthuis, PT Lawson, W Brigham, GS Knox, PC Dawes, M Rotrosen, J AF Ling, Walter Hillhouse, Maureen P. Saxon, Andrew J. Mooney, Larissa J. Thomas, Christie M. Ang, Alfonso Matthews, Abigail G. Hasson, Albert Annon, Jeffrey Sparenborg, Steve Liu, David S. McCormack, Jennifer Church, Sarah Swafford, William Drexler, Karen Schuman, Carolyn Ross, Stephen Wiest, Katharina Korthuis, P. Todd Lawson, William Brigham, Gregory S. Knox, Patricia C. Dawes, Michael Rotrosen, John TI Buprenorphine plus naloxone plus naltrexone for the treatment of cocaine dependence: the Cocaine Use Reduction with Buprenorphine (CURB) study SO ADDICTION LA English DT Article DE Buprenorphine plus naloxone; cocaine use disorder; double-blind; multi-site trial; naltrexone; pharmacotherapy; placebo-controlled; treatment ID ABUSE CLINICAL-TRIALS; OPIOID DEPENDENCE; RANDOMIZED-TRIAL; ADDICTION; ANTAGONIST; MODULATION; METHADONE; MODELS AB AimsTo examine the safety and effectiveness of buprenorphine+naloxone sublingual tablets (BUP, as Suboxone((R))) provided after administration of extended-release injectable naltrexone (XR-NTX, as Vivitrol((R))) to reduce cocaine use in participants who met DSM-IV criteria for cocaine dependence and past or current opioid dependence or abuse. MethodsThis multi-centered, double-blind, placebo-controlled study, conducted under the auspices of the National Drug Abuse Treatment Clinical Trials Network, randomly assigned 302 participants at sites in California, Oregon, Washington, Colorado, Texas, Georgia, Ohio, New York and Washington DC, USA to one of three conditions provided with XR-NTX: 4mg/day BUP (BUP4, n=100), 16mg/day BUP (BUP16, n=100, or no buprenorphine (placebo; PLB, n=102). Participants received pharmacotherapy for 8weeks, with three clinic visits per week. Cognitive behavioral therapy was provided weekly. Follow-up assessments occurred at 1 and 3months post-intervention. The planned primary outcome was urine drug screen (UDS)-corrected, self-reported cocaine use during the last 4weeks of treatment. Planned secondary analyses assessed cocaine use by UDS, medication adherence, retention and adverse events. ResultsNo group differences were found between groups for the primary outcome (BUP4 versus PLB, P=0.262; BUP16 versus PLB, P=0.185). Longitudinal analysis of UDS data during the evaluation period using generalized linear mixed equations found a statistically significant difference between BUP16 and PLB [P=0.022, odds ratio (OR)=1.71] but not for BUP4 (P=0.105, OR=1.05). No secondary outcome differences across groups were found for adherence, retention or adverse events. ConclusionsBuprenorphine+naloxone, used in combination with naltrexone, may be associated with reductions in cocaine use among people who meet DSM-IV criteria for cocaine dependence and past or current opioid dependence or abuse. C1 [Ling, Walter; Hillhouse, Maureen P.; Mooney, Larissa J.; Thomas, Christie M.; Ang, Alfonso; Hasson, Albert; Annon, Jeffrey] Univ Calif Los Angeles, Los Angeles, CA USA. [Saxon, Andrew J.] Vet Affairs Puget Sound Hlth Care Syst, Seattle, WA USA. [Sparenborg, Steve; Liu, David S.] NIDA, Bethesda, MD 20892 USA. [Matthews, Abigail G.; McCormack, Jennifer] Emmes Corp, Rockville, MD USA. [Church, Sarah] Albert Einstein Coll Med, Bronx, NY 10467 USA. [Swafford, William] ARTS, Denver, CO USA. [Drexler, Karen] Atlanta VA Med Ctr, Atlanta, GA USA. [Schuman, Carolyn] BAART Programs, San Francisco, CA USA. [Ross, Stephen] Bellevue Hosp Ctr, New York, NY 10016 USA. [Wiest, Katharina] CODA, Portlad, OR USA. [Korthuis, P. Todd] Oregon Hlth & Sci Univ, Portland, OR 97201 USA. [Lawson, William] Howard Univ, Washington, DC 20059 USA. [Brigham, Gregory S.] Maryhaven Treatment Ctr, Columbus, OH USA. [Knox, Patricia C.] RCKC, Kent, WA USA. [Dawes, Michael] South Texas Vet Hlth Care Syst, San Antonio, TX USA. [Rotrosen, John] NYU, Sch Med, New York, NY USA. RP Ling, W (reprint author), UCLA Integrated Subst Abuse Programs, 1640 South Sepulveda Blvd,Suite 120, Los Angeles, CA 90025 USA. EM lwalter@ucla.edu FU National Institute on Drug Abuse [DA13045, DA13035, DA13046, DA015815, HHSN271200900034C / N01DA-92217, HHSN271201200017C / N01DA-12-2229, HHSN271201400028C / N01DA-14-2237]; Reckitt Benckiser Pharmaceuticals; Alkermes Pharmaceuticals FX Support provided through the National Institute on Drug Abuse (DA13045; DA13035; DA13046, DA015815, HHSN271200900034C / N01DA-92217, HHSN271201200017C / N01DA-12-2229, HHSN271201400028C / N01DA-14-2237); Reckitt Benckiser Pharmaceuticals, Alkermes Pharmaceuticals. NR 27 TC 2 Z9 2 U1 3 U2 7 PU WILEY-BLACKWELL PI HOBOKEN PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA SN 0965-2140 EI 1360-0443 J9 ADDICTION JI Addiction PD AUG PY 2016 VL 111 IS 8 BP 1416 EP 1427 DI 10.1111/add.13375 PG 12 WC Substance Abuse; Psychiatry SC Substance Abuse; Psychiatry GA DR5NE UT WOS:000379948900017 PM 26948856 ER PT J AU Grasing, K Mathur, D DeSouza, C Newton, TF Moody, DE Sturgill, M AF Grasing, Kenneth Mathur, Deepan DeSouza, Cherilyn Newton, Thomas F. Moody, David E. Sturgill, Marc TI Cocaine cardiovascular effects and pharmacokinetics after treatment with the acetylcholinesterase inhibitor donepezil SO AMERICAN JOURNAL ON ADDICTIONS LA English DT Article ID ALZHEIMERS-DISEASE; CHOLINESTERASE ACTIVITY; MASS-SPECTROMETRY; CARBOXYLESTERASE; METABOLITES; PATHOLOGY; ACCUMBENS; TOXICITY; PLASMA; SAFETY AB BackgroundIn rodents, cholinesterase inhibitors can cause sustained decreases in the reinforcing effects of cocaine. Nonetheless, cocaine is metabolized by butyrylcholinesterase (BuChE), raising concerns that cholinesterase inhibition could increase its peripheral concentrations, perhaps augmenting toxicity. Although donepezil is approved for use in patients and selective for inhibiting acetylcholinesterase over BuChE, no studies have reported cocaine bioavailability in human subjects receiving donepezil. MethodsTwelve cocaine-dependent veterans received three days of treatment with either oral placebo or 5mg daily of donepezil, followed by cross-over to the opposite treatment. During both oral treatments, double-blind intravenous cocaine was administered at .0, .18, and .36mg/kg in a laboratory setting, followed by determinations of heart rate, blood pressure, and plasma concentrations of cocaine and major metabolites. ResultsIntravenous cocaine produced dose-related increases in systolic blood pressure that were most pronounced over the initial 30minutes after treatment. Oral donepezil attenuated drug-induced elevations of systolic blood pressure following low-dose cocaine (.18mg/kg). No significant difference in blood pressure following treatment with placebo or donepezil after high-dose cocaine (.36mg/kg). Peak values of blood pressure and heart rate were unaffected by donepezil. Plasma concentrations of cocaine and metabolites did not differ in donepezil- and placebo-treated participants. Conclusions and Scientific SignificanceWe conclude that donepezil can attenuate drug-induced increases in systolic blood pressure following low-dose cocaine, but does not otherwise modify the cardiovascular effects of intravenous cocaine. Clinically significant changes in cocaine bioavailability and cardiovascular effects do not occur following this dose of donepezil. (Am J Addict 2016;25:392-399) C1 [Grasing, Kenneth; Mathur, Deepan; DeSouza, Cherilyn] Kansas City Vet Affairs Med Ctr, Subst Abuse Res Lab, Kansas City, MO USA. [Grasing, Kenneth] Univ Kansas, Sch Med, Dept Med, Div Clin Pharmacol, Kansas City, KS USA. [DeSouza, Cherilyn] Univ Kansas, Sch Med, Dept Psychiat, Kansas City, KS USA. [Newton, Thomas F.] Baylor Coll Med, Dept Psychiat & Behav Sci, Houston, TX 77030 USA. [Newton, Thomas F.] Baylor Coll Med, Michael E DeBakey Dept Vet Affairs Med Ctr, Houston, TX 77030 USA. [Moody, David E.] Univ Utah, Dept Pharmacol & Toxicol, Ctr Human Toxicol, 112 Skaggs Hall, Salt Lake City, UT 84112 USA. [Sturgill, Marc] Rutgers State Univ, Ernest Mario Sch Pharm, Dept Pharm Practice & Adm, Piscataway, NJ USA. RP Grasing, K (reprint author), Kansas City VA Med Ctr, Subst Abuse Res Lab, 4801 Linwood Blvd, Kansas City, MO 64128 USA. EM kgrasing@kumc.edu FU National Institutes of Health, Institute on Drug Abuse, Bethesda, MD [R21-DA029787]; Medical Research Service, Department of Veterans Affairs, Washington, DC [589-KG-0012] FX This study was supported by grant R21-DA029787 issued to KG by the National Institutes of Health, Institute on Drug Abuse, Bethesda, MD 20892-9581; and grant 589-KG-0012 issued to KG by the Medical Research Service, Department of Veterans Affairs, Washington, DC, 20420. NR 36 TC 0 Z9 0 U1 1 U2 1 PU WILEY-BLACKWELL PI HOBOKEN PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA SN 1055-0496 EI 1521-0391 J9 AM J ADDICTION JI Am. J. Addict. PD AUG PY 2016 VL 25 IS 5 BP 392 EP 399 DI 10.1111/ajad.12402 PG 8 WC Substance Abuse SC Substance Abuse GA DR6RM UT WOS:000380029000006 PM 27392137 ER PT J AU Cheng, G AF Cheng, Gang TI A Case of Lung Squamous Cell Carcinoma With Duodenal Metastasis on FDG PET/CT SO CLINICAL NUCLEAR MEDICINE LA English DT Editorial Material DE non-small cell lung cancer; duodenum; metastasis; FDG PET ID SMALL-BOWEL METASTASES; RARE COMPLICATION C1 [Cheng, Gang] Philadelphia VA Med Ctr, Dept Radiol, 3900 Woodland Ave, Philadelphia, PA 19104 USA. [Cheng, Gang] Hosp Univ Penn, Dept Radiol, 3400 Spruce St, Philadelphia, PA 19104 USA. RP Cheng, G (reprint author), Philadelphia VA Med Ctr, Dept Radiol, 3900 Woodland Ave, Philadelphia, PA 19104 USA. EM gangcheng99@yahoo.com NR 10 TC 0 Z9 0 U1 0 U2 0 PU LIPPINCOTT WILLIAMS & WILKINS PI PHILADELPHIA PA TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA SN 0363-9762 EI 1536-0229 J9 CLIN NUCL MED JI Clin. Nucl. Med. PD AUG PY 2016 VL 41 IS 8 BP 659 EP 660 DI 10.1097/RLU.0000000000001225 PG 2 WC Radiology, Nuclear Medicine & Medical Imaging SC Radiology, Nuclear Medicine & Medical Imaging GA DR1LE UT WOS:000379666200027 PM 27055139 ER PT J AU Mukherjee, R Mareninova, OA Odinokova, IV Huang, W Murphy, J Chvanov, M Javed, MA Wen, L Booth, DM Cane, MC Awais, M Gavillet, B Pruss, RM Schaller, S Molkentin, JD Tepikin, AV Petersen, OH Pandol, SJ Gukovsky, I Criddle, DN Gukovskaya, AS Sutton, R AF Mukherjee, Rajarshi Mareninova, Olga A. Odinokova, Irina V. Huang, Wei Murphy, John Chvanov, Michael Javed, Muhammad A. Wen, Li Booth, David M. Cane, Matthew C. Awais, Muhammad Gavillet, Bruno Pruss, Rebecca M. Schaller, Sophie Molkentin, Jeffery D. Tepikin, Alexei V. Petersen, Ole H. Pandol, Stephen J. Gukovsky, Ilya Criddle, David N. Gukovskaya, Anna S. Sutton, Robert CA NIHR Pancreas Biomedical Res Unit TI Mechanism of mitochondrial permeability transition pore induction and damage in the pancreas: inhibition prevents acute pancreatitis by protecting production of ATP SO GUT LA English DT Article ID INOSITOL TRISPHOSPHATE RECEPTORS; ACINAR-CELLS; TRYPSINOGEN ACTIVATION; CA2+ RELEASE; BILE-ACIDS; INTRACELLULAR ACTIVATION; HEREDITARY PANCREATITIS; ENDOPLASMIC-RETICULUM; ZYMOGEN ACTIVATION; MOUSE MODEL AB Objective Acute pancreatitis is caused by toxins that induce acinar cell calcium overload, zymogen activation, cytokine release and cell death, yet is without specific drug therapy. Mitochondrial dysfunction has been implicated but the mechanism not established. Design We investigated the mechanism of induction and consequences of the mitochondrial permeability transition pore (MPTP) in the pancreas using cell biological methods including confocal microscopy, patch clamp technology and multiple clinically representative disease models. Effects of genetic and pharmacological inhibition of the MPTP were examined in isolated murine and human pancreatic acinar cells, and in hyperstimulation, bile acid, alcoholic and choline-deficient, ethionine-supplemented acute pancreatitis. Results MPTP opening was mediated by toxin-induced inositol trisphosphate and ryanodine receptor calcium channel release, and resulted in diminished ATP production, leading to impaired calcium clearance, defective autophagy, zymogen activation, cytokine production, phosphoglycerate mutase 5 activation and necrosis, which was prevented by intracellular ATP supplementation. When MPTP opening was inhibited genetically or pharmacologically, all biochemical, immunological and histopathological responses of acute pancreatitis in all four models were reduced or abolished. Conclusions This work demonstrates the mechanism and consequences of MPTP opening to be fundamental to multiple forms of acute pancreatitis and validates the MPTP as a drug target for this disease. C1 [Mukherjee, Rajarshi; Huang, Wei; Murphy, John; Chvanov, Michael; Javed, Muhammad A.; Wen, Li; Booth, David M.; Awais, Muhammad; Tepikin, Alexei V.; Criddle, David N.; Sutton, Robert; NIHR Pancreas Biomedical Res Unit] Royal Liverpool Univ Hosp, NIHR Liverpool Pancreas Biomed Res Unit, 5th Floor UCD,Daulby St, Liverpool L69 3GA, Merseyside, England. [Mukherjee, Rajarshi; Huang, Wei; Murphy, John; Chvanov, Michael; Javed, Muhammad A.; Wen, Li; Booth, David M.; Cane, Matthew C.; Awais, Muhammad; Tepikin, Alexei V.; Criddle, David N.; Sutton, Robert] Univ Liverpool, Inst Translat Med, Liverpool, Merseyside, England. [Mareninova, Olga A.; Odinokova, Irina V.; Pandol, Stephen J.; Gukovsky, Ilya; Gukovskaya, Anna S.] Univ Calif Los Angeles, Vet Affairs Greater Los Angeles Healthcare Syst, Los Angeles, CA USA. [Mareninova, Olga A.; Odinokova, Irina V.; Pandol, Stephen J.; Gukovsky, Ilya; Gukovskaya, Anna S.] Southern Calif Res Ctr Alcohol Liver & Pancreat D, Los Angeles, CA USA. [Odinokova, Irina V.] Russian Acad Sci, Inst Theoret & Expt Biophys, Pushchino, Russia. [Huang, Wei] Sichuan Univ, West China Hosp, Dept Integrated Tradit & Western Med, Sichuan Prov Pancreatitis Ctr, Chengdu, Peoples R China. [Gavillet, Bruno] Debiopharm Res & Mfg SA, Lausanne, Switzerland. [Pruss, Rebecca M.; Schaller, Sophie] Trophos SA, Marseille, France. [Molkentin, Jeffery D.] Childrens Hosp, Med Ctr, Howard Hughes Med Inst, Cincinnati, OH 45229 USA. [Petersen, Ole H.] Cardiff Univ, Cardiff Sch Biosci, Cardiff, S Glam, Wales. RP Sutton, R (reprint author), Royal Liverpool Univ Hosp, NIHR Liverpool Pancreas Biomed Res Unit, 5th Floor UCD,Daulby St, Liverpool L69 3GA, Merseyside, England.; Gukovskaya, AS (reprint author), UCLA Vet Affairs Greater Los Angeles Healthcare S, West Los Angeles Vet Affairs Healthcare Ctr, 11301 Wilshire Blvd,Blg 258,Rm 340, Los Angeles, CA 90073 USA. EM agukovsk@ucla.edu; r.sutton@liverpool.ac.uk OI Cane, Matthew/0000-0002-7874-294X FU US Veterans Administration Merit Review; NIH [R01DK59936, R01AA19730]; Southern California Research Center for Alcoholic Liver and Pancreatic Diseases; American Gastroenterological Association Foundation Designated Research Scholar Award in Pancreatitis; Russian Federation BR grant [09-04-00739]; UK/China Postgraduate Research Scholarship for Excellence; Liverpool China Scholarship Council Award; CORE, UK; UK Medical Research Council; Royal College of Surgeons of England; UK NIHR Biomedical Research Unit Funding Scheme FX This work was supported by US Veterans Administration Merit Review (ASG), NIH grants R01DK59936 (ASG) and R01AA19730 (IG and OAM), Southern California Research Center for Alcoholic Liver and Pancreatic Diseases (SJP and ASG), American Gastroenterological Association Foundation Designated Research Scholar Award in Pancreatitis (OAM), Russian Federation BR grant 09-04-00739 (IVO), UK/China Postgraduate Research Scholarship for Excellence (WH), Liverpool China Scholarship Council Award (LW), CORE, UK (RM, JM, MAJ), UK Medical Research Council (DMB, MC, MCC, OHP, AVT, DNC and RS), Royal College of Surgeons of England (MAJ) and UK NIHR Biomedical Research Unit Funding Scheme (MA, AVT, DNC and RS). NR 59 TC 8 Z9 8 U1 7 U2 15 PU BMJ PUBLISHING GROUP PI LONDON PA BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND SN 0017-5749 EI 1468-3288 J9 GUT JI Gut PD AUG PY 2016 VL 65 IS 8 BP 1333 EP 1346 DI 10.1136/gutjnl-2014-308553 PG 14 WC Gastroenterology & Hepatology SC Gastroenterology & Hepatology GA DR2TL UT WOS:000379756700014 PM 26071131 ER PT J AU Gildener-Leapman, N Kim, J Abberbock, S Choby, GW Mandal, R Duvvuri, U Ferris, RL Kim, S AF Gildener-Leapman, Neil Kim, Jeehong Abberbock, Shira Choby, Garret W. Mandal, Rajarsi Duvvuri, Umamaheswar Ferris, Robert L. Kim, Seungwon TI Utility of up-front transoral robotic surgery in tailoring adjuvant therapy SO HEAD AND NECK-JOURNAL FOR THE SCIENCES AND SPECIALTIES OF THE HEAD AND NECK LA English DT Article; Proceedings Paper CT Triological-Society 118th Annual Meeting at the Combined Otolaryngology Spring Meetings (COSM) / Spring Meeting of the American-Rhinologic-Society (ARS) / Meeting of the American-Society-of-Head-and-Neck-Surgery CY APR 22-26, 2015 CL Boston, MA SP Triol Soc, Amer Rhinol Soc DE transoral robotic surgery (TORS); adjuvant therapy; oropharyngeal squamous cell carcinoma (OPSCC); oropharynx; decision-making ID SQUAMOUS-CELL CARCINOMA; OROPHARYNGEAL CANCER; LASER MICROSURGERY; ASSISTED SURGERY; NECK-CANCER; HEAD; OUTCOMES AB BackgroundThe purpose of this study was to describe how the up-front transoral robotic surgery (TORS) approach could be used to individually tailor adjuvant therapy based on surgical pathology. MethodsBetween January 2009 and December 2013, 76 patients received TORS for oropharyngeal squamous cell carcinoma (OPSCC). Clinical predictors of adjuvant therapy were analyzed and comparisons were made between recommended treatment guidelines for up-front surgery versus definitive nonsurgical approaches. ResultsAdvanced N classification, human papillomavirus (HPV)-positive tumor, extracapsular spread (ECS; 26 of 76), perineural invasion (PNI; 14 of 76), and positive margins (7 of 76) were significant predictors of adjuvant chemoradiotherapy (CRT) (p < .05). Up-front TORS deintensified adjuvant therapy; 76% of stage I/II and 46% of stage III/IV patients avoided CRT. Conversely, pathologic staging resulted in 33% of patients who would have received radiotherapy (RT) alone based on clinical staging, to be intensified to receive adjuvant CRT. ConclusionThe TORS approach deintensifies adjuvant therapy and provides valuable pathologic information to intensify treatment in select patients. TORS may be less effective in deintensification of adjuvant therapy in patients with clinically advanced N classification disease. (c) 2016 Wiley Periodicals, Inc. Head Neck 38:1201-1207, 2016 C1 [Gildener-Leapman, Neil] Albany Med Coll, Dept Surg, Div Otolaryngol Head & Neck Surg, Albany, NY 12208 USA. [Kim, Jeehong] Univ Pittsburgh, Sch Med, Pittsburgh, PA USA. [Abberbock, Shira] Univ Pittsburgh, Biostat Facil, Inst Canc, Pittsburgh, PA USA. [Choby, Garret W.; Mandal, Rajarsi; Duvvuri, Umamaheswar; Ferris, Robert L.; Kim, Seungwon] Univ Pittsburgh, Med Ctr, Dept Otolaryngol Head & Neck Surg, Pittsburgh, PA USA. [Duvvuri, Umamaheswar] VA Pittsburgh Hlth Syst, Dept Otolaryngol, Pittsburgh, PA USA. RP Kim, S (reprint author), Univ Pittsburgh, Dept Otolaryngol, Med Ctr, 200 Lothrop St,EEI 500, Pittsburgh, PA 15213 USA. EM kimsw2@upmc.edu FU NCI NIH HHS [P50 CA097190, T32 CA060397] NR 15 TC 1 Z9 1 U1 2 U2 4 PU WILEY-BLACKWELL PI HOBOKEN PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA SN 1043-3074 EI 1097-0347 J9 HEAD NECK-J SCI SPEC JI Head Neck-J. Sci. Spec. Head Neck PD AUG PY 2016 VL 38 IS 8 BP 1201 EP 1207 DI 10.1002/hed.24390 PG 7 WC Otorhinolaryngology; Surgery SC Otorhinolaryngology; Surgery GA DR5JY UT WOS:000379940500014 PM 27225507 ER PT J AU Romo, RD Lee, SJ AF Romo, Rafael D. Lee, Sei J. TI Changes in Social Function as a Trigger to Screen for Cognitive Impairment SO JOURNAL OF GENERAL INTERNAL MEDICINE LA English DT Editorial Material C1 [Romo, Rafael D.; Lee, Sei J.] San Francisco VA Med Ctr, Geriatr Serv, 4150 Clement St 181G, San Francisco, CA 94121 USA. [Romo, Rafael D.; Lee, Sei J.] San Francisco VA Med Ctr, Palliat Serv, 4150 Clement St 181G, San Francisco, CA 94121 USA. [Romo, Rafael D.; Lee, Sei J.] San Francisco VA Med Ctr, Extended Care Serv, 4150 Clement St 181G, San Francisco, CA 94121 USA. [Romo, Rafael D.; Lee, Sei J.] Univ Calif San Francisco, Div Geriatr, San Francisco, CA 94143 USA. RP Romo, RD (reprint author), San Francisco VA Med Ctr, Geriatr Serv, 4150 Clement St 181G, San Francisco, CA 94121 USA.; Romo, RD (reprint author), San Francisco VA Med Ctr, Palliat Serv, 4150 Clement St 181G, San Francisco, CA 94121 USA.; Romo, RD (reprint author), San Francisco VA Med Ctr, Extended Care Serv, 4150 Clement St 181G, San Francisco, CA 94121 USA. EM Rafael.Romo@ucsf.edu FU NIA NIH HHS [P30 AG044281] NR 9 TC 0 Z9 0 U1 0 U2 0 PU SPRINGER PI NEW YORK PA 233 SPRING ST, NEW YORK, NY 10013 USA SN 0884-8734 EI 1525-1497 J9 J GEN INTERN MED JI J. Gen. Intern. Med. PD AUG PY 2016 VL 31 IS 8 BP 826 EP 827 DI 10.1007/s11606-016-3755-6 PG 2 WC Health Care Sciences & Services; Medicine, General & Internal SC Health Care Sciences & Services; General & Internal Medicine GA DR4KY UT WOS:000379871600004 PM 27245052 ER PT J AU Petrillo, LA Dzeng, E Smith, AK AF Petrillo, Laura A. Dzeng, Elizabeth Smith, Alexander K. TI California's End of Life Option Act: Opportunities and Challenges Ahead SO JOURNAL OF GENERAL INTERNAL MEDICINE LA English DT Editorial Material DE end of life care; palliative care; physician-assisted death; aging; health policy ID CARE C1 [Petrillo, Laura A.; Smith, Alexander K.] Univ Calif San Francisco, Dept Med, Div Geriatr, San Francisco, CA USA. [Petrillo, Laura A.; Smith, Alexander K.] San Francisco VA Med Ctr, San Francisco, CA USA. [Dzeng, Elizabeth] Univ Calif San Francisco, Dept Med, Div Hosp Med, San Francisco, CA USA. RP Petrillo, LA (reprint author), UCSF, Div Geriatr, 4150 Clement St 181G, San Francisco, CA 94141 USA. EM laura.petrillo@ucsf.edu FU NIA NIH HHS [K23 AG040772, P30 AG044281] NR 5 TC 0 Z9 0 U1 0 U2 1 PU SPRINGER PI NEW YORK PA 233 SPRING ST, NEW YORK, NY 10013 USA SN 0884-8734 EI 1525-1497 J9 J GEN INTERN MED JI J. Gen. Intern. Med. PD AUG PY 2016 VL 31 IS 8 BP 828 EP 829 DI 10.1007/s11606-016-3713-3 PG 2 WC Health Care Sciences & Services; Medicine, General & Internal SC Health Care Sciences & Services; General & Internal Medicine GA DR4KY UT WOS:000379871600005 PM 27114358 ER PT J AU Akers, SR Werner, TJ Rubello, D Alavi, A Cheng, G AF Akers, Scott R. Werner, Thomas J. Rubello, Domenico Alavi, Abass Cheng, Gang TI F-18-FDG uptake and clearance in patients with compromised renal function SO NUCLEAR MEDICINE COMMUNICATIONS LA English DT Article DE clearance; delayed imaging; F-18-FDG PET; renal function; standardized uptake value ID DUAL TIME-POINT; FDG-PET; NORMAL-TISSUES; GLUCOSE AB ObjectiveThe aim of this study is to evaluate whether compromised renal function has an effect on the uptake and clearance of 2-deoxy-2-[F-18]fluoro-d-glucose (F-18-FDG) in normal tissues on F-18-FDG PET/CT imaging.Patients and methodsPatients were divided into three groups on the basis of their renal function status: 25 patients with normal renal function [estimated glomerular filtration rate (eGFR)>90ml/min], 21 patients with mildly compromised renal function (90eGFR60ml/min), and 12 patients with moderate or severe compromised renal function (eGFR<60ml/min). All patients underwent F-18-FDG PET/CT imaging at 1, 2, and 3h after tracer injection. Maximum standardized uptake values (SUVmax) were obtained in regions of interest for multiple tissue types.ResultsSerial SUV values from 1 to 3h were measured for different tissues including the aortic blood pool, liver, spleen, lung, lymph nodes, and skeletal muscles. The SUV values of F-18-FDG uptake showed significantly decreased activity from 1 to 2h as well as from 2 to 3h for each tissue type, irrespective of renal function. There was no significant difference in SUVmean values between patients with normal and compromised renal functions, which was consistently observed for each tissue type and at each time point. In fact, the variance in individual SUV values within a group was more than the variance of SUV means between the groups with different renal functions for all tissue types and at 1-, 2-, or 3-h time points. Finally, the lack of dependence of SUV values in normal tissues on renal function is shown by very low r(2) values when comparing SUV and eGFR.ConclusionOur data suggest that compromised renal function does not significantly compromise clearance of background activity of F-18-FDG PET imaging. As a result, adjustment of F-18-FDG dose or imaging time is not necessary in renal-impaired patients to achieve optimal imaging. C1 [Akers, Scott R.; Cheng, Gang] Philadelphia VA Med Ctr, Dept Radiol, 3900 Woodland Ave, Philadelphia, PA 19104 USA. [Werner, Thomas J.; Alavi, Abass; Cheng, Gang] Hosp Univ Penn, Dept Radiol, 3400 Spruce St, Philadelphia, PA 19104 USA. [Rubello, Domenico] Santa Maria della Misericordia Hosp, Dept Nucl Med, Intervent Radiol NeuroRadiol,Pathol,Microbiol, PET CT Ctr,Radiol,Med Phys,Clin Lab,Biomarkers La, Rovigo, Italy. RP Cheng, G (reprint author), Philadelphia VA Med Ctr, Dept Radiol, 3900 Woodland Ave, Philadelphia, PA 19104 USA. EM gangcheng99@yahoo.com FU Department of Veterans Affairs (VISN 4 CPPF Grant) FX This study was supported in part by a pilot grant from the Department of Veterans Affairs (VISN 4 CPPF Grant). The content of this article does not necessarily reflect the views of the Department of Veterans Affairs or of the US Government. NR 12 TC 0 Z9 0 U1 2 U2 2 PU LIPPINCOTT WILLIAMS & WILKINS PI PHILADELPHIA PA TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA SN 0143-3636 EI 1473-5628 J9 NUCL MED COMMUN JI Nucl. Med. Commun. PD AUG PY 2016 VL 37 IS 8 BP 825 EP 832 DI 10.1097/MNM.0000000000000513 PG 8 WC Radiology, Nuclear Medicine & Medical Imaging SC Radiology, Nuclear Medicine & Medical Imaging GA DR7WN UT WOS:000380110500007 PM 27058366 ER PT J AU Kelley-Cook, E Nguyen, G Lee, S Edwards, TM Sanchez-Reilly, S AF Kelley-Cook, Esther Nguyen, George Lee, Shuko Edwards, Tressia M. Sanchez-Reilly, Sandra TI Medication Needs Vary for Terminally Ill Vietnam Era Veterans With and Without a Diagnosis of PTSD SO AMERICAN JOURNAL OF HOSPICE & PALLIATIVE MEDICINE LA English DT Article DE posttraumatic stress disorder (PTSD); end of life; Vietnam Veterans; palliative care; terminal care; pharmacotherapy ID POSTTRAUMATIC-STRESS-DISORDER; INTIMATE PARTNER; COMBAT VETERANS; US VETERANS; DEPRESSION; INSOMNIA; RISK; LIFE; END AB This retrospective pilot study aims to evaluate the clinical impact of palliative care in the treatment of terminally ill Vietnam Veterans with a history of posttraumatic stress disorder (PTSD) versus those without PTSD, as it pertains to medications for symptom control at the end of life (EOL). Active prescriptions for benzodiazepines, hypnotics, antidepressants, and antipsychotic medications at the EOL were recorded. During EOL care, 28 (72%) participants with PTSD used these medications versus 55 (40%) of the non-PTSD participants (P = .0005). There was significant correlation between a lifetime diagnosis of PTSD with antidepressant use (P = .0002) and hypnotics (P = .0085) during EOL care but not with benzodiazepines or antipsychotics. The higher utilization of certain medication classes among participants with PTSD may indicate that PTSD treatment should continue at the EOL to improve care. C1 [Kelley-Cook, Esther; Sanchez-Reilly, Sandra] Univ Texas Hlth Sci Ctr San Antonio, 7400 Merton Minter Blvd, San Antonio, TX 78229 USA. [Nguyen, George] Baylor Scott & White Hlth Care Syst, Temple, TX USA. [Lee, Shuko; Edwards, Tressia M.; Sanchez-Reilly, Sandra] South Texas Vet Hlth Care Syst, San Antonio, TX USA. RP Sanchez-Reilly, S (reprint author), Univ Texas Hlth Sci Ctr San Antonio, 7400 Merton Minter Blvd, San Antonio, TX 78229 USA.; Sanchez-Reilly, S (reprint author), South Texas Vet Hlth Care Syst GRECC 182, 7400 Merton Minter Blvd, San Antonio, TX 78229 USA. EM Sanchezreill@uthscsa.edu FU South Texas Veterans Health Care System, San Antonio, Texas FX The authors disclosed receipt of the following financial support for the research, authorship, and/or publication of this article: This study is the result of work supported with resources and the use of facilities at the South Texas Veterans Health Care System, San Antonio, Texas. NR 16 TC 0 Z9 0 U1 1 U2 3 PU SAGE PUBLICATIONS INC PI THOUSAND OAKS PA 2455 TELLER RD, THOUSAND OAKS, CA 91320 USA SN 1049-9091 EI 1938-2715 J9 AM J HOSP PALLIAT ME JI Am. J. Hosp. Palliat. Med. PD AUG PY 2016 VL 33 IS 7 BP 625 EP 632 DI 10.1177/1049909115586556 PG 8 WC Health Care Sciences & Services SC Health Care Sciences & Services GA DR3MR UT WOS:000379807800002 PM 25991568 ER PT J AU Thai, JN Barnhart, CE Cagle, J Smith, AK AF Thai, Julie N. Barnhart, Caroline E. Cagle, John Smith, Alexander K. TI "It Just Consumes Your Life": Quality of Life for Informal Caregivers of Diverse Older Adults With Late-Life Disability SO AMERICAN JOURNAL OF HOSPICE & PALLIATIVE MEDICINE LA English DT Article DE caregiving; geriatrics; quality of life; disability; palliative care; informal caregivers ID LARGE SOCIAL NETWORK; LONG-TERM-CARE; FAMILY CAREGIVERS; STRESS PROCESS; TRANSITIONS; LONELINESS; SPREAD; HEALTH AB Little is known about the quality of life (QoL) for informal caregivers of disabled older adults aged 65+ with diverse backgrounds. Forty-two caregivers were interviewed in English and Cantonese about their caregiving experiences, their recollections of QoL over time, and the factors influencing their appraisals. Overall, 52% of caregivers experienced a decline in QoL. Factors associated with decreased QoL were less time for self, competing financial demands, and the physical and emotional impact of the patient's illness. Factors associated with no change in QoL were minimal caregiving responsibilities, a sense of filial duty, and QoL being consistently poor over time. Factors associated with improved QoL were perceived rewards in caregiving, receiving institutional help, and increased experience. Chinese caregivers were more likely to cite filial duty as their motivator for continued caregiving than were Caucasian caregivers. In conclusion, informal caregivers take on a huge burden in enabling older adults to age in the community. These caregivers need more support in maintaining their QoL. C1 [Thai, Julie N.; Barnhart, Caroline E.; Smith, Alexander K.] Univ Calif San Francisco, Dept Med, Div Geriatr, San Francisco, CA USA. [Barnhart, Caroline E.; Smith, Alexander K.] San Francisco VA Med Ctr, Geriatr Palliat & Extended Care, San Francisco, CA USA. [Cagle, John] Univ Maryland, Sch Social Work, 525 W Redwood St, Baltimore, MD 21201 USA. RP Smith, AK (reprint author), Univ Calif San Francisco, Div Geriatr, 4250 Clement St,Bldg 1,Room 181G, San Francisco, CA 94121 USA. EM aksmith@ucsf.edu FU "Medical Student Training in Aging Research (MSTAR)" Program - National Institute on Aging [T35AG026736]; John A. Hartford Foundation; MetLife Foundation; Lillian R. Gleitsman Foundation; National Institute on Aging (NIA) [5T32AG000212]; Beeson Career Development Award from National Institute on Aging; American Federation of Aging Research [K23AG040772]; ASP-T FX The authors disclosed receipt of the following financial support for the research, authorship, and/or publication of this article: Julie Thai's effort on this project was supported by the "Medical Student Training in Aging Research (MSTAR)" Program funded by the National Institute on Aging (T35AG026736), the John A. Hartford Foundation, the MetLife Foundation, and the Lillian R. Gleitsman Foundation. Dr Cagle's efforts were supported by a training grant from the National Institute on Aging (NIA), 5T32AG000212. Dr Smith's effort on this project was supported by the Beeson Career Development Award from the National Institute on Aging and the American Federation of Aging Research (K23AG040772) and by the ASP-T. Franklin Williams Society of General Internal Medicine Scholars Award in Geriatrics. NR 21 TC 1 Z9 1 U1 5 U2 12 PU SAGE PUBLICATIONS INC PI THOUSAND OAKS PA 2455 TELLER RD, THOUSAND OAKS, CA 91320 USA SN 1049-9091 EI 1938-2715 J9 AM J HOSP PALLIAT ME JI Am. J. Hosp. Palliat. Med. PD AUG PY 2016 VL 33 IS 7 BP 644 EP 650 DI 10.1177/1049909115583044 PG 7 WC Health Care Sciences & Services SC Health Care Sciences & Services GA DR3MR UT WOS:000379807800005 PM 25948041 ER PT J AU Vina, ER Richardson, D Medvedeva, E Kwoh, CK Collier, A Ibrahim, SA AF Vina, Ernest R. Richardson, Diane Medvedeva, Elina Kwoh, C. Kent Collier, Aliya Ibrahim, Said A. TI Does a Patient-centered Educational Intervention Affect African-American Access to Knee Replacement? A Randomized Trial SO CLINICAL ORTHOPAEDICS AND RELATED RESEARCH LA English DT Article ID TOTAL JOINT REPLACEMENT; RACE/ETHNICITY DISPARITIES; PHYSICIANS PERCEPTIONS; PROVIDER CONTRIBUTION; SOCIOECONOMIC-STATUS; RACIAL DISPARITIES; DECISION-MAKING; UNITED-STATES; OSTEOARTHRITIS; HEALTH AB A TKA is the most effective and cost-effective surgical option for moderate to severe osteoarthritis (OA) of the knee. Yet, black patients are less willing to undergo knee replacement surgery than white patients. Decision aids help people understand treatment options and consider the personal importance of possible benefits and harms of treatments, including TKA. We asked: (1) Does a patient-centered intervention consisting of a decision aid for knee OA and motivational interviewing improve the proportion of referrals of blacks with knee OA to orthopaedic surgery? (2) Does the intervention increase patients' willingness to undergo TKA? Adults who self-identified as black who were at least 50 years old with moderate to severe knee OA were enrolled from urban primary care clinics in a two-group randomized, controlled trial. A total of 1253 patients were screened for eligibility, and 760 were excluded for not meeting inclusion criteria, declining to participate, or other reasons. Four hundred ninety-three patients were randomized and completed the intervention; three had missing referral data at followup. The mean age of the patients was 61 years, and 51% were women. The majority had an annual household income less than USD 15,000. Participants in the treatment group were shown a decision-aid video and had a brief session with a trained counselor in motivational interviewing. Participants in the control group received an educational booklet about OA that did not mention joint replacement. The two groups had comparable demographic and socioeconomic characteristics. The primary outcome was referral to orthopaedic surgery 12 months after treatment exposure. Receipt of referral was defined as the receipt of a recommendation or prescription from a primary care provider for orthopaedic evaluation. The secondary outcome was change in patient willingness to undergo TKA based on patient self-report. The odds of receiving a referral to orthopaedic surgery did not differ between the two study groups (36%, 90 of 253 of the control group; 32%, 76 of 240 of the treatment group; odds ratio [OR], 0.81; 95% CI, 0.56-1.18; p = 0.277). At 2 weeks followup, there was no difference between the treatment and the control groups in terms of increased willingness to consider TKA relative to baseline (34%, 67 of 200 patients in the treatment group; 33%, 68 of 208 patients in the control group; OR, 1.06; p = 0.779). At 12 months followup, the percent increase in willingness to undergo TKA still did not differ between patients in the treatment and control groups (29%, 49 of 174 in the treatment group; 27%, 51 of 191 in the control group; OR, 1.10; p = 0.679). A combination decision aid and motivational interviewing strategy was no better than an educational pamphlet in improving patients' preferences toward joint replacement surgery for knee OA. The type of intervention treatment also did not affect access to surgical evaluation. Other tools that target patient knowledge, beliefs, and attitudes regarding surgical treatments for OA may be further developed and tested in the future. Level I, therapeutic study. C1 Univ Penn, Philadelphia, PA 19104 USA. Philadelphia VA Med Ctr, Philadelphia, PA USA. Univ Pittsburgh, Pittsburgh, PA USA. [Vina, Ernest R.; Kwoh, C. Kent] Univ Arizona, Sch Med, 1501 N Campbell Ave, Tucson, AZ 85724 USA. [Vina, Ernest R.; Kwoh, C. Kent] Univ Arizona, Arthrit Ctr, 1501 N Campbell Ave, Tucson, AZ 85724 USA. [Richardson, Diane; Medvedeva, Elina; Ibrahim, Said A.] Philadelphia VA Med Ctr, Ctr Hlth Equ Res & Promot, Philadelphia, PA USA. [Collier, Aliya; Ibrahim, Said A.] Univ Penn, Perelman Sch Med, Philadelphia, PA 19104 USA. RP Vina, ER (reprint author), Univ Arizona, Sch Med, 1501 N Campbell Ave, Tucson, AZ 85724 USA.; Vina, ER (reprint author), Univ Arizona, Arthrit Ctr, 1501 N Campbell Ave, Tucson, AZ 85724 USA. EM evina@email.arizona.edu OI Vina, Ernest/0000-0001-8135-1731 FU NIH/National Institute of Arthritis and Musculoskeletal Skin Diseases [1-RO1-AR-054474-5, K24AR055259] FX Funding was received from the NIH/National Institute of Arthritis and Musculoskeletal Skin Diseases Grant# 1-RO1-AR-054474-5 (SI) and K24AR055259 (SI). NR 39 TC 1 Z9 1 U1 4 U2 4 PU SPRINGER PI NEW YORK PA 233 SPRING ST, NEW YORK, NY 10013 USA SN 0009-921X EI 1528-1132 J9 CLIN ORTHOP RELAT R JI Clin. Orthop. Rel. Res. PD AUG PY 2016 VL 474 IS 8 BP 1755 EP 1764 DI 10.1007/s11999-016-4834-z PG 10 WC Orthopedics; Surgery SC Orthopedics; Surgery GA DQ1WW UT WOS:000378992200003 PM 27075333 ER PT J AU Kaunitz, JD AF Kaunitz, Jonathan D. TI DDS Elementary Style: A Brief Guide for Authors SO DIGESTIVE DISEASES AND SCIENCES LA English DT Editorial Material C1 [Kaunitz, Jonathan D.] UCLA Sch Med, Greater Los Angeles VA Healthcare Syst, Dept Med & Surg, Los Angeles, CA 90073 USA. RP Kaunitz, JD (reprint author), UCLA Sch Med, Greater Los Angeles VA Healthcare Syst, Dept Med & Surg, Los Angeles, CA 90073 USA. EM jake@ucla.edu NR 2 TC 0 Z9 0 U1 3 U2 3 PU SPRINGER PI DORDRECHT PA VAN GODEWIJCKSTRAAT 30, 3311 GZ DORDRECHT, NETHERLANDS SN 0163-2116 EI 1573-2568 J9 DIGEST DIS SCI JI Dig. Dis. Sci. PD AUG PY 2016 VL 61 IS 8 BP 2147 EP 2150 DI 10.1007/s10620-016-4223-1 PG 4 WC Gastroenterology & Hepatology SC Gastroenterology & Hepatology GA DR3FE UT WOS:000379787200001 PM 27312030 ER PT J AU Flax-Goldenberg, R Kulkarni, KS Carson, KA Pinto, JM Martin-Harris, B Lefton-Greif, MA AF Flax-Goldenberg, Renee Kulkarni, Kopal S. Carson, Kathryn A. Pinto, Jeanne M. Martin-Harris, Bonnie Lefton-Greif, Maureen A. TI Concordance Between Aspiration Detected on Upper Gastrointestinal Series and Videofluoroscopic Swallow Study in Bottle-Fed Children SO DYSPHAGIA LA English DT Article DE Aspiration; Radiation dosage; UGI; VFSS; Deglutition; Children AB The increasing incidence of pediatric dysphagia has raised questions about how to identify children at risk for aspiration. Multiple investigative imaging modalities are considered in diagnostic algorithms, since dysphagia may involve any or all phases of swallowing. Although upper gastrointestinal (UGI) series and videofluoroscopic swallow study (VFSS) are common procedures, the utility of UGI for detection of aspiration and the impact of oropharyngeal imaging during UGI on radiation exposure have not been well described. We hypothesized that diagnosis of aspiration on UGI would be predictive of aspiration on VFSS and screening swallows during UGI would increase radiation exposure. A retrospective review was completed of bottle-fed children undergoing UGI series within 1 month before/after standardized VFSS. UGI was imaged at 3 frames per second (fps) pulsed and VFSS at 30 fps continuous fluoroscopy. Cumulative radiation dose (CD) and dose area product (DAP) were recorded. VFSS and UGI were performed in 49 patients; however, only 21 (43 %) had documentation of swallow function on an UGI series. All children with aspiration on UGI demonstrated thin liquid aspiration on VFSS; however, 53 % without aspiration on UGI aspirated on VFSS. CD for UGI with versus without swallowing documentation was significantly higher (median = 0.33 vs. 0.21 mGy, p = 0.02) but within variability ranges reported for fluoroscopy equipment. DAP was not significantly higher for UGI with documentation of swallowing compared to without documentation of swallowing (median = 4.11 vs. 3.02 mu Gy cm(2), p = 0.09). UGI findings are specific but not sensitive markers for aspiration on VFSS. Imaging of swallowing on UGI may have an appreciable increase on radiation exposure. C1 [Flax-Goldenberg, Renee] Johns Hopkins Univ, Sch Med, Div Pediat Radiol, Russell H Morgan Dept Radiol & Radiol Sci, Sheikh Zayed Tower,Room 4174,1800 Orleans St, Baltimore, MD 21287 USA. [Kulkarni, Kopal S.] Johns Hopkins Univ Hosp, Russell H Morgan Dept Radiol & Radiol Sci, 601 N Caroline St,Room 4210, Baltimore, MD 21287 USA. [Carson, Kathryn A.] Johns Hopkins Bloomberg Sch Publ Hlth, Dept Epidemiol, Welch Ctr Prevent Epidemiol & Clin Res, 2024 East Monument St,Suite 2-500, Baltimore, MD 21287 USA. [Pinto, Jeanne M.; Lefton-Greif, Maureen A.] Johns Hopkins Univ, Sch Med, Dept Pediat, Eudowood Div Pediat Resp Sci, David M Rubenstein Bldg,200 North Wolfe St, Baltimore, MD 21287 USA. [Martin-Harris, Bonnie] Med Univ South Carolina, Coll Med, Dept Otolaryngol Head & Neck Surg, 135 Rutledge Ave,MSC 550, Charleston, SC 29425 USA. [Martin-Harris, Bonnie] Med Univ South Carolina, Evelyn Trammell Inst Voice & Swallowing, Charleston, SC 29425 USA. [Martin-Harris, Bonnie] Ralph H Johnson Vet Affairs Med Ctr, Charleston, SC 29425 USA. [Lefton-Greif, Maureen A.] Johns Hopkins Univ, Sch Med, Dept Otolaryngol Head & Neck Surg, Baltimore, MD 21287 USA. [Lefton-Greif, Maureen A.] Johns Hopkins Univ, Sch Med, Dept Phys Med & Rehabil, Baltimore, MD 21287 USA. RP Lefton-Greif, MA (reprint author), Johns Hopkins Univ, Sch Med, Dept Pediat, Eudowood Div Pediat Resp Sci, David M Rubenstein Bldg,200 North Wolfe St, Baltimore, MD 21287 USA.; Lefton-Greif, MA (reprint author), Johns Hopkins Univ, Sch Med, Dept Otolaryngol Head & Neck Surg, Baltimore, MD 21287 USA.; Lefton-Greif, MA (reprint author), Johns Hopkins Univ, Sch Med, Dept Phys Med & Rehabil, Baltimore, MD 21287 USA. EM mlefton@jhmi.edu FU NIDCD NIH HHS [R01 DC011290] NR 16 TC 0 Z9 0 U1 2 U2 2 PU SPRINGER PI NEW YORK PA 233 SPRING ST, NEW YORK, NY 10013 USA SN 0179-051X EI 1432-0460 J9 DYSPHAGIA JI Dysphagia PD AUG PY 2016 VL 31 IS 4 BP 505 EP 510 DI 10.1007/s00455-016-9705-y PG 6 WC Otorhinolaryngology SC Otorhinolaryngology GA DR2LJ UT WOS:000379735700003 PM 27048206 ER PT J AU Koutroumpakis, E Dasyam, AK Furlan, A Slivka, A Gougol, A Zeh, HJ Lee, KK Zureikat, AH Whitcomb, DC Yadav, D Papachristou, GI AF Koutroumpakis, Efstratios Dasyam, Anil K. Furlan, Alessandro Slivka, Adam Gougol, Amir Zeh, Herbert J., III Lee, Kenneth K. Zureikat, Amer H. Whitcomb, David C. Yadav, Dhiraj Papachristou, Georgios I. TI Isolated Peripancreatic Necrosis in Acute Pancreatitis Is Infrequent and Leads to Severe Clinical Course Only When Extensive A Prospective Study From a US Tertiary Center SO JOURNAL OF CLINICAL GASTROENTEROLOGY LA English DT Article DE acute pancreatitis; pancreatic necrosis; peripancreatic necrosis ID DETERMINANT-BASED CLASSIFICATION; NECROTIZING PANCREATITIS; ATLANTA CLASSIFICATION; REVISION; SYSTEMS AB Goals: To explore the diagnostic challenges, management, and clinical outcomes of patients with isolated peripancreatic necrosis (PPN), with emphasis on the extent of involvement, and compare them to pancreatic necrosis (PN). Background: PPN, a relatively new term, has been included as a separate entity in the Revised Atlanta Classification. Study: Clinical data of recruited acute pancreatitis patients were recorded prospectively. Contrast-enhanced computed tomographic scans were reviewed by expert radiologists blinded to clinical outcomes. Results: In total, 271 of the 400 acute pancreatitis patients underwent contrast-enhanced computed tomography, of which 29 (11%) had PPN (14: limited; 15: extensive) and 124 (46%) PN (40: <30%, 16: 30% to 50%, 68: >50% of parenchyma). Patients with PPN were similar to PN in age (56 y), gender (55% male), and body mass index (29 kg/m(2)). Nutritional support was provided in 18 (62%) patients with PPN and 97 (78%) with PN (P=0.12). Drainage/debridement was required in 2 patients (7%) with PPN and 64 (53%) with parenchymal necrosis (P<0.001). Persistent organ failure rates did not differ significantly (34% vs. 51%, P=0.17), but hospital stay was shorter in patients with PPN (15 vs. 20 d, P=0.05). Limited PPN required no intervention and had similar persistent organ failure rates and hospitalization length with interstitial pancreatitis (both P>0.12). Extensive PPN mainly developed in patients with persistent organ failure (60%) and rarely required drainage (2/15). Conclusions: PPN prevalence was lower than PN with a ratio of 1:4. PPN rarely required intervention. Utilizing the extent of involvement has the potential to classify PPN and PN with escalating clinical significance and guide management. C1 [Koutroumpakis, Efstratios; Slivka, Adam; Gougol, Amir; Whitcomb, David C.; Yadav, Dhiraj; Papachristou, Georgios I.] Univ Pittsburgh, Med Ctr, Div Gastroenterol Hepatol & Nutr, Dept Med, Pittsburgh, PA USA. [Dasyam, Anil K.; Furlan, Alessandro] Univ Pittsburgh, Med Ctr, Div Abdominal Imaging, Dept Radiol, Pittsburgh, PA USA. [Zeh, Herbert J., III; Lee, Kenneth K.; Zureikat, Amer H.] Univ Pittsburgh, Med Ctr, Div Surg Oncol, Dept Surg, Pittsburgh, PA USA. [Papachristou, Georgios I.] Vet Affairs Pittsburgh Hlth Syst, Div Gastroenterol & Hepatol, Dept Med, Pittsburgh, PA USA. RP Papachristou, GI (reprint author), UPMC Presbyterian, 200 Lothrop St,3rd Floor, Pittsburgh, PA 15213 USA. EM papachri@pitt.edu FU Veterans Affairs Merit Review Award [PRO00000496] FX Supported by a Veterans Affairs Merit Review Award (PRO00000496; PI: G.I.P.) NR 21 TC 1 Z9 1 U1 4 U2 4 PU LIPPINCOTT WILLIAMS & WILKINS PI PHILADELPHIA PA TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA SN 0192-0790 EI 1539-2031 J9 J CLIN GASTROENTEROL JI J. Clin. Gastroenterol. PD AUG PY 2016 VL 50 IS 7 BP 589 EP 595 DI 10.1097/MCG.0000000000000482 PG 7 WC Gastroenterology & Hepatology SC Gastroenterology & Hepatology GA DR1MI UT WOS:000379669200012 PM 26828244 ER PT J AU Ellingson, LD Schwabacher, IJ Kim, Y Welk, GJ Cook, DB AF Ellingson, Laura D. Schwabacher, Isaac J. Kim, Youngwon Welk, Gregory J. Cook, Dane B. TI Validity of an Integrative Method for Processing Physical Activity Data SO MEDICINE AND SCIENCE IN SPORTS AND EXERCISE LA English DT Article DE ActiGraph; activPAL; SOJOURNS; MACHINE LEARNING; SEDENTARY; MEASUREMENT ID SEDENTARY BEHAVIOR; ENERGY-EXPENDITURE; ACCELEROMETER DATA; WEARABLE MONITORS; HEALTH; TIME; PREDICTION; WRIST; VALIDATION; SYSTEMS AB Accurate assessments of both physical activity and sedentary behaviors are crucial to understand the health consequences of movement patterns and to track changes over time and in response to interventions. Purpose: The study evaluates the validity of an integrative, machine learning method for processing activity monitor data in relation to a portable metabolic analyzer (Oxycon mobile [OM]) and direct observation (DO). Methods: Forty-nine adults (age 18-40 yr) each completed 5-min bouts of 15 activities ranging from sedentary to vigorous intensity in a laboratory setting while wearing ActiGraph (AG) on the hip, activPAL on the thigh, and OM. Estimates of energy expenditure (EE) and categorization of activity intensity were obtained from the AG processed with Lyden's sojourn (SOJ) method and from our new sojourns including posture (SIP) method, which integrates output from the AG and activPAL. Classification accuracy and estimates of EE were then compared with criterion measures (OM and DO) using confusion matrices and comparisons of the mean absolute error of log-transformed data (MAE ln Q). Results: The SIP method had a higher overall classification agreement (79%, 95% CI = 75%-82%) than the SOJ (56%, 95% CI = 52%-59%) based on DO. Compared with OM, estimates of EE from SIP had lower mean absolute error of log-transformed data than SOJ for light-intensity (0.21 vs 0.27), moderate-intensity (0.33 vs 0.42), and vigorous-intensity (0.16 vs 0.35) activities. Conclusions: The SIP method was superior to SOJ for distinguishing between sedentary and light activities as well as estimating EE at higher intensities. Thus, SIP is recommended for research in which accuracy of measurement across the full range of activity intensities is of interest. C1 [Ellingson, Laura D.; Kim, Youngwon; Welk, Gregory J.] Iowa State Univ, Dept Kinesiol, 239 Forker, Ames, IA 50011 USA. [Ellingson, Laura D.; Schwabacher, Isaac J.; Cook, Dane B.] Univ Wisconsin, Dept Kinesiol, Madison, WI USA. [Schwabacher, Isaac J.; Cook, Dane B.] William S Middleton Mem Vet Adm Med Ctr, Madison, WI USA. [Kim, Youngwon] Univ Cambridge, Epidemiol Unit, MRC, Cambridge, England. RP Ellingson, LD (reprint author), Iowa State Univ, Dept Kinesiol, 239 Forker, Ames, IA 50011 USA. EM ellingl@iastate.edu FU Bodymedia/Jawbone FX The authors thank all the participants for their participation in the current study. They also thank Rachel Devick and Paul Hibbing for their assistance in data collection. Authors Y. Kim and G. J. Welk declare that they have had ongoing research support from Bodymedia/Jawbone to assist in cross validation of algorithms and in testing of new prototype monitors. The data reported here were collected as part of a larger study designed to test new monitoring technologies, but the new devices were not reported in the present study. The present study was conducted independently from Bodymedia/Jawbone, but the authors acknowledge that funding from Bodymedia/Jawbone supported the data collection. The SIP software detailed in this article was developed by Isaac Schwabacher in the laboratory of Dr. Cook at the University of Wisconsin-Madison. The contents of this study do not represent the views of the U.S. Department of Veterans Affairs or the United States Government. The findings of the current study do not constitute endorsement by the American College of Sports Medicine. NR 41 TC 0 Z9 0 U1 10 U2 14 PU LIPPINCOTT WILLIAMS & WILKINS PI PHILADELPHIA PA TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA SN 0195-9131 EI 1530-0315 J9 MED SCI SPORT EXER JI Med. Sci. Sports Exerc. PD AUG PY 2016 VL 48 IS 8 BP 1629 EP 1638 DI 10.1249/MSS.0000000000000915 PG 10 WC Sport Sciences SC Sport Sciences GA DR2TP UT WOS:000379757100024 PM 27015380 ER PT J AU Campbell, DG Bonner, LM Bolkan, CR Lanto, AB Zivin, K Waltz, TJ Klap, R Rubenstein, LV Chaney, EF AF Campbell, Duncan G. Bonner, Laura M. Bolkan, Cory R. Lanto, Andrew B. Zivin, Kara Waltz, Thomas J. Klap, Ruth Rubenstein, Lisa V. Chaney, Edmund F. TI Stigma Predicts Treatment Preferences and Care Engagement Among Veterans Affairs Primary Care Patients with Depression SO ANNALS OF BEHAVIORAL MEDICINE LA English DT Article DE Depression; Stigma; Treatment preferences; Treatment engagement; Primary care; Veterans ID MENTAL-HEALTH TREATMENT; COMORBIDITY SURVEY REPLICATION; POSTTRAUMATIC-STRESS-DISORDER; NATIONAL-GUARD SOLDIERS; PERCEIVED STIGMA; HELP-SEEKING; SELF-STIGMA; MILITARY PERSONNEL; COGNITIVE THERAPY; MAJOR DEPRESSION AB Whereas stigma regarding mental health concerns exists, the evidence for stigma as a depression treatment barrier among patients in Veterans Affairs (VA) primary care (PC) is mixed. This study tests whether stigma, defined as depression label avoidance, predicted patients' preferences for depression treatment providers, patients' prospective engagement in depression care, and care quality. We conducted cross-sectional and prospective analyses of existing data from 761 VA PC patients with probable major depression. Relative to low-stigma patients, those with high stigma were less likely to prefer treatment from mental health specialists. In prospective controlled analyses, high stigma predicted lower likelihood of the following: taking medications for mood, treatment by mental health specialists, treatment for emotional concerns in PC, and appropriate depression care. High stigma is associated with lower preferences for care from mental health specialists and confers risk for minimal depression treatment engagement. C1 [Campbell, Duncan G.] Univ Montana, Dept Psychol, Missoula, MT 59812 USA. [Bonner, Laura M.] VA Puget Sound Hlth Care Syst, Geriatr Res Educ & Clin Ctr, Seattle, WA USA. [Bonner, Laura M.; Chaney, Edmund F.] VA Puget Sound Hlth Care Syst, Hlth Serv Res & Dev Serv, Seattle, WA USA. [Bonner, Laura M.; Chaney, Edmund F.] Univ Washington, Sch Med, Dept Psychiat & Behav Sci, Seattle, WA 98195 USA. [Bolkan, Cory R.] Washington State Univ Vancouver, Dept Human Dev, Vancouver, WA USA. [Lanto, Andrew B.; Klap, Ruth; Rubenstein, Lisa V.] VA Greater Los Angeles Healthcare Syst, VA HSR&D Ctr Study Healthcare Innovat Implementat, Los Angeles, CA USA. [Zivin, Kara; Waltz, Thomas J.] VA Ann Arbor Hlth Care Syst, Ctr Clin Management Res Hlth Serv Res & Dev Serv, Ann Arbor, MI USA. [Zivin, Kara] Univ Michigan, Sch Med, Dept Psychiat, Ann Arbor, MI USA. [Zivin, Kara] Univ Michigan, Inst Social Res, Ann Arbor, MI USA. [Waltz, Thomas J.] Eastern Michigan Univ, Dept Psychol, Ypsilanti, MI 48197 USA. [Rubenstein, Lisa V.] Univ Calif Los Angeles, Sch Med, Los Angeles, CA USA. [Rubenstein, Lisa V.] RAND, Hlth Program, Santa Monica, CA USA. RP Campbell, DG (reprint author), Univ Montana, Dept Psychol, Missoula, MT 59812 USA. EM duncan.campbell@umontana.edu OI Waltz, Thomas/0000-0001-7976-430X FU Intramural VA [VA999999] NR 66 TC 0 Z9 0 U1 3 U2 9 PU SPRINGER PI NEW YORK PA 233 SPRING ST, NEW YORK, NY 10013 USA SN 0883-6612 EI 1532-4796 J9 ANN BEHAV MED JI Ann. Behav. Med. PD AUG PY 2016 VL 50 IS 4 BP 533 EP 544 DI 10.1007/s12160-016-9780-1 PG 12 WC Psychology, Multidisciplinary SC Psychology GA DQ3DH UT WOS:000379082500006 PM 26935310 ER PT J AU Raynor, W Houshmand, S Gholami, S Emamzadehfard, S Rajapakse, CS Blomberg, BA Werner, TJ Hoilund-Carlsen, PF Baker, JF Alavi, A AF Raynor, William Houshmand, Sina Gholami, Saeid Emamzadehfard, Sahra Rajapakse, Chamith S. Blomberg, Bjorn Alexander Werner, Thomas J. Hoilund-Carlsen, Poul F. Baker, Joshua F. Alavi, Abass TI Evolving Role of Molecular Imaging with F-18-Sodium Fluoride PET as a Biomarker for Calcium Metabolism SO CURRENT OSTEOPOROSIS REPORTS LA English DT Review DE 18F-sodiumfluoride; Metabolic bone disease; Positron emission tomography; Quantitative radionuclide imaging; Regional bone formation ID POSITRON-EMISSION-TOMOGRAPHY; REGIONAL BONE METABOLISM; EARLY-STAGE OSTEOARTHRITIS; CORONARY-ARTERY-DISEASE; F-18-FLUORIDE PET; PARATHYROID-HORMONE; POSTMENOPAUSAL WOMEN; ANKYLOSING-SPONDYLITIS; RISK-FACTORS; ATHEROSCLEROTIC PLAQUE AB F-18-sodium fluoride (NaF) as an imaging tracer portrays calcium metabolic activity either in the osseous structures or in soft tissue. Currently, clinical use of NaF-PET is confined to detecting metastasis to the bone, but this approach reveals indirect evidence for disease activity and will have limited use in the future in favor of more direct approaches that visualize cancer cells in the read marrow where they reside. This has proven to be the case with FDG-PET imaging in most cancers. However, a variety of studies support the application of NaF-PET to assess benign osseous diseases. In particular, bone turnover can be measured from NaF uptake to diagnose osteoporosis. Several studies have evaluated the efficacy of bisphosphonates and their lasting effects as treatment for osteoporosis using bone turnover measured by NaF-PET. Additionally, NaF uptake in vessels tracks calcification in the plaques at the molecular level, which is relevant to coronary artery disease. Also, NaF-PET imaging of diseased joints is able to project disease progression in osteoarthritis, rheumatoid arthritis, and ankylosing spondylitis. Further studies suggest potential use of NaF-PET in domains such as back pain, osteosarcoma, stress-related fracture, and bisphosphonate-induced osteonecrosis of the jaw. The critical role of NaF-PET in disease detection and characterization of many musculoskeletal disorders has been clearly demonstrated in the literature, and these methods will become more widespread in the future. The data from PET imaging are quantitative in nature, and as such, it adds a major dimension to assessing disease activity. C1 [Raynor, William; Houshmand, Sina; Gholami, Saeid; Emamzadehfard, Sahra; Alavi, Abass] Hosp Univ Penn, Dept Radiol, 3400 Spruce St, Philadelphia, PA 19104 USA. [Rajapakse, Chamith S.] Hosp Univ Penn, Dept Radiol, Philadelphia, PA 19104 USA. [Blomberg, Bjorn Alexander; Hoilund-Carlsen, Poul F.] Odense Univ Hosp, Dept Nucl Med, Odense, Denmark. [Blomberg, Bjorn Alexander] Univ Med Ctr Utrecht, Dept Radiol & Nucl Med, Utrecht, Netherlands. [Baker, Joshua F.] Philadelphia Vet Affairs Med Ctr, Philadelphia, PA USA. [Baker, Joshua F.] Hosp Univ Penn, Dept Med, Div Rheumatol, Philadelphia, PA 19104 USA. [Baker, Joshua F.] Univ Penn, Ctr Clin Epidemiol & Biostat, Philadelphia, PA 19104 USA. RP Alavi, A (reprint author), Hosp Univ Penn, Dept Radiol, 3400 Spruce St, Philadelphia, PA 19104 USA. EM abass.alavi@uphs.upenn.edu NR 87 TC 2 Z9 2 U1 5 U2 12 PU SPRINGER PI NEW YORK PA 233 SPRING ST, NEW YORK, NY 10013 USA SN 1544-2241 J9 CURR OSTEOPOROS REP JI Curr. Osteoporos. Rep. PD AUG PY 2016 VL 14 IS 4 BP 115 EP 125 DI 10.1007/s11914-016-0312-5 PG 11 WC Endocrinology & Metabolism SC Endocrinology & Metabolism GA DQ2FZ UT WOS:000379019100001 PM 27301549 ER PT J AU Oluloro, A Petrik, AF Turner, A Kapka, T Rivelli, J Carney, PA Saha, S Coronado, GD AF Oluloro, Ann Petrik, Amanda F. Turner, Ann Kapka, Tanya Rivelli, Jennifer Carney, Patricia A. Saha, Somnath Coronado, Gloria D. TI Timeliness of Colonoscopy After Abnormal Fecal Test Results in a Safety Net Practice SO JOURNAL OF COMMUNITY HEALTH LA English DT Article DE Colorectal cancer; Federally qualified health center; Hispanic/Latino; Colonoscopy; Gastroenterology referral ID OCCULT BLOOD-TEST; CANCER SCREENING-PROGRAM; COLORECTAL-CANCER; FOLLOW-UP; UNITED-STATES; BARRIERS; IMPROVEMENT AB Fecal testing can only reduce colorectal cancer mortality if patients with an abnormal test result receive a follow-up colonoscopy. As part of the Strategies and Opportunities to STOP Colon Cancer in Priority Populations (STOP CRC) project, we examined factors associated with adherence to follow-up colonoscopy among patients with abnormal fecal test results. As part of STOP CRC outreach, Virginia Garcia Memorial Health Center staff distributed 1753 fecal immunochemical tests (FIT), of which 677 (39 %) were completed, and 56 had an abnormal result (8 %). Project staff used logistic regression analyses to examine factors associated with colonoscopy referral and completion. Of the 56 patients with abnormal FIT results; 45 (80 %) had evidence of a referral for colonoscopy, 32 (57 %) had evidence of a completed colonoscopy within 18 months, and 14 (25 %) within 60 days of an abnormal fecal test result. In adjusted analysis, Hispanics had lower odds of completing follow-up colonoscopy within 60 days than non-Hispanic whites (adjusted OR 0.20; 95 % CI 0.04, 0.92). Colonoscopy within 60 days trended lower for women than for men (adjusted OR 0.25; 95 % CI 0.06-1.04). Among the 24 patients lacking medical record evidence of a colonoscopy, 19 (79 %) had a documented reason, including clinician did not pursue, patient refused, and colonoscopy not indicated. No reason was found for 21 %. Improvements are needed to increase rates of follow-up colonoscopy completion, especially among female and Hispanic patients. C1 [Oluloro, Ann; Petrik, Amanda F.; Kapka, Tanya; Rivelli, Jennifer; Coronado, Gloria D.] Kaiser Permanente Northwest, Ctr Hlth Res, 3800 N Interstate Ave, Portland, OR 97227 USA. [Oluloro, Ann; Carney, Patricia A.; Saha, Somnath] Oregon Hlth & Sci Univ, 3181 SW Sam Jackson Pk Rd, Portland, OR 97239 USA. [Turner, Ann; Kapka, Tanya] Virginia Garcia Mem Hlth Ctr, 226 SE 8th Ave, Hillsboro, OR 97123 USA. [Saha, Somnath] Portland VA Med Ctr, Gen Internal Med Sect, 3710 SW US Vet Hosp Rd P3HSRD, Portland, OR 97239 USA. RP Oluloro, A (reprint author), Kaiser Permanente Northwest, Ctr Hlth Res, 3800 N Interstate Ave, Portland, OR 97227 USA.; Oluloro, A (reprint author), Oregon Hlth & Sci Univ, 3181 SW Sam Jackson Pk Rd, Portland, OR 97239 USA. EM oluloroa@ohsu.edu FU National Institutes of Health through National Center for Complementary & Alternative Medicine [UH2AT007782]; National Cancer Institute [4UH3CA188640-02] FX Research reported in this publication was supported by the National Institutes of Health through the National Center for Complementary & Alternative Medicine under Award Number UH2AT007782 and the National Cancer Institute under Award Number 4UH3CA188640-02. The content is solely the responsibility of the authors and does not necessarily represent the official views of the National Center for Complementary & Alternative Medicine or the National Cancer Institute. Dr. Saha's contribution to this work was supported with resources and the use of facilities at the VA Portland Health Care System. NR 31 TC 2 Z9 2 U1 1 U2 1 PU SPRINGER PI NEW YORK PA 233 SPRING ST, NEW YORK, NY 10013 USA SN 0094-5145 EI 1573-3610 J9 J COMMUN HEALTH JI J. Community Health PD AUG PY 2016 VL 41 IS 4 BP 864 EP 870 DI 10.1007/s10900-016-0165-y PG 7 WC Health Policy & Services; Public, Environmental & Occupational Health SC Health Care Sciences & Services; Public, Environmental & Occupational Health GA DQ4HC UT WOS:000379163700023 PM 26874943 ER PT J AU Gerlock, AA Szarka, JG Cox, K Harel, O AF Gerlock, April A. Szarka, Jackie G. Cox, Koriann Harel, Ofer TI Comparing Intimately Violent to Non-violent Veterans in Treatment for Posttraumatic Stress Disorder SO JOURNAL OF FAMILY VIOLENCE LA English DT Article DE PTSD; Abuse; Veterans; Couples; Treatment ID ADMINISTERED PTSD SCALE; ABUSE SCREENING-TEST; US ARMY SOLDIERS; PARTNER VIOLENCE; COMBAT VETERANS; DOMESTIC VIOLENCE; MILITARY VETERANS; VIETNAM VETERANS; ALCOHOL-USE; AGGRESSION AB The impact on relationships and adjustment to life after warzone deployments is a major concern, especially when the Veteran also struggles with posttraumatic stress disorder (PTSD). In this manuscript, we describe and compare Veterans who are intimately violent to non-violent Veterans who are in treatment for PTSD. In order to accurately identify the presence of intimate partner violence (IPV) we relied on both Veterans' and their partners' reports in the form of interviews and questionnaires. Additionally, we examined the following variables to determine if PTSD severity, childhood witnessing of inter-parental IPV, substance use/abuse, mutuality, and demographic variables could reliably differentiate Veterans perpetrating IPV from those who were not. Of the overall sample (N = 882; Veterans and partners), 43% of the male Veterans met our operationally defined criteria for IPV. Among the variables identified above, only the level of relationship mutuality significantly differentiated the intimately violent from non-violent. C1 [Gerlock, April A.; Szarka, Jackie G.; Cox, Koriann] VA Puget Sound Hlth Care Syst, Seattle Denver Ctr Innovat Vet Ctr & Value Driven, Hlth Serv Res & Dev, 1100 Olive Way,Suite 1400, Seattle, WA 98101 USA. [Harel, Ofer] Univ Connecticut, Dept Stat, Storrs, CT 06269 USA. RP Gerlock, AA (reprint author), VA Puget Sound Hlth Care Syst, Seattle Denver Ctr Innovat Vet Ctr & Value Driven, Hlth Serv Res & Dev, 1100 Olive Way,Suite 1400, Seattle, WA 98101 USA. EM April.Gerlock@va.gov NR 50 TC 0 Z9 0 U1 7 U2 11 PU SPRINGER/PLENUM PUBLISHERS PI NEW YORK PA 233 SPRING ST, NEW YORK, NY 10013 USA SN 0885-7482 EI 1573-2851 J9 J FAM VIOLENCE JI J. Fam. Violence PD AUG PY 2016 VL 31 IS 6 BP 667 EP 678 DI 10.1007/s10896-016-9814-2 PG 12 WC Psychology, Clinical; Family Studies SC Psychology; Family Studies GA DQ5CQ UT WOS:000379222400001 ER PT J AU Xie, Y LaFleur, J Kamauu, A Knippenberg, K DuVail, SL Haselkorn, J Nelson, RE AF Xie, Yan LaFleur, Joanne Kamauu, Aaron Knippenberg, Kristin DuVail, Scott L. Haselkorn, Jodie Nelson, Richard E. TI Rates of Early Treatment for US Veterans With Multiple Sclerosis SO JOURNAL OF PHARMACY TECHNOLOGY LA English DT Article AB Background: Early treatment of patients with multiple sclerosis (MS) may prevent neurological damage and reduce the risk of disability. However, little is known about the timing of treatment initiation following diagnosis and long-term outcomes in the general population of the Department of Veterans Affairs (VA) benefits-eligible patients. Objective: Our objective was to characterize treatment for MS patients in the VA at various time points following diagnosis date. Methods: In our historical database cohort study of US veterans, we calculated the proportion of MS patients from 1999 through 2010 with at least one prescription for a medication used to treat the condition at 6, 12, 24, 36, 48, 60, and 72 months following the index date. We also stratified the treatments given into 3 categories based on their role within the course of the disease: disease modifying, relapse, and symptom. Finally, we performed our calculations separately by MS subtype: relapsing-remitting, secondary-progressive, primary-progressive, and progressive-relapsing. Results: A total of 6803 patients were included in the analysis. Only 27.4% of MS patients received a prescription for MS medication within the first 6 months after diagnosis. The most common treatments were interferon beta-I a, glatiramer, amantadine, and prednisone, with disease-modifying agents being more than twice as frequently prescribed as medications for relapse or symptoms. Patients with relapsing-remitting MS were the most likely to be treated, followed by progressive-relapsing MS. Conclusions: Our results suggest that treatment rates are low in VA MS patients in the 6 years following their first diagnosis of MS. C1 [Xie, Yan] Abbvie Inc, N Chicago, IL USA. [LaFleur, Joanne; Knippenberg, Kristin; DuVail, Scott L.; Nelson, Richard E.] Salt Lake City Vet Affairs Hlth Care Syst, Salt Lake City, UT USA. [LaFleur, Joanne; Knippenberg, Kristin; DuVail, Scott L.] Univ Utah, Coll Pharm, Salt Lake City, UT 84112 USA. [Kamauu, Aaron] Anolinx LLC, Salt Lake City, UT USA. [DuVail, Scott L.; Nelson, Richard E.] Univ Utah, Sch Med, Salt Lake City, UT 84112 USA. [Haselkorn, Jodie] Vet Affairs Puget Sound Hlth Care Syst, Seattle, WA USA. [Haselkorn, Jodie] Univ Washington, Sch Publ Hlth, Seattle, WA 98195 USA. RP Nelson, RE (reprint author), 500 Foothill Blvd, Salt Lake City, UT 84148 USA. EM richard.nelson@utah.edu NR 0 TC 0 Z9 0 U1 2 U2 2 PU SAGE PUBLICATIONS INC PI THOUSAND OAKS PA 2455 TELLER RD, THOUSAND OAKS, CA 91320 USA SN 8755-1225 EI 1549-4810 J9 J PHARM TECHNOL JI J. Pharm. Technol. PD AUG PY 2016 VL 32 IS 4 BP 143 EP 149 DI 10.1177/8755122516640297 PG 7 WC Pharmacology & Pharmacy SC Pharmacology & Pharmacy GA DQ5YZ UT WOS:000379282500002 ER PT J AU Kopacz, MS Morley, SW Wozniak, BM Simons, KV Bishop, TM Vance, CG AF Kopacz, Marek S. Morley, Sybil W. Wozniak, Barbara M. Simons, Kelsey V. Bishop, Todd M. Vance, C. Garland TI Religious Well-Being and Suicide Ideation in Veterans - An Exploratory Study SO PASTORAL PSYCHOLOGY LA English DT Article DE Veterans; Suicide ideation; Religious practice; Religious well-being ID POSTTRAUMATIC-STRESS-DISORDER; RISK-FACTORS; HEALTH; CARE; PREVALENCE; PTSD; ORIENTATION; PREVENTION; SEEKING; SAMPLE AB Religious well-being is a multi-faceted construct posited as a protective factor against suicidal thoughts and behaviors. This cross-sectional, exploratory study used religious practice data collected from n = 5378 U.S. military veterans to create composite measures of private and public religious practice. These composite measures were subsequently used to determine the probability of being identified with a history of suicide ideation. Data analysis was conducted using logistic regression. Veterans with a history of suicide ideation made up 10.2 % (n = 549) of the sample. Such veterans had significantly lower mean public and private religiosity scores compared to those without ideation. Differences between these two composite measures of religiosity were associated with a higher probability of being identified with a history of suicide ideation. The present study adds to the extant literature by presenting a framework for interpreting religious well-being in the context of religious practice. Quantitative differences in engagement between private and public practices may be indicative of a decreased sense of religious well-being, conferring less protection against suicidal behavior. C1 [Kopacz, Marek S.; Morley, Sybil W.; Simons, Kelsey V.; Bishop, Todd M.] VISN 2 Ctr Excellence Suicide Prevent, US Dept Vet Affairs, 400 Ft Hill Ave, Canandaigua, NY 14424 USA. [Wozniak, Barbara M.] Jagiellonian Univ, Coll Med, Dept Med Sociol, Kopernika 7a, PL-31034 Krakow, Poland. [Bishop, Todd M.] Univ Rochester, Med Ctr, Rochester, NY USA. [Vance, C. Garland] Charles George VA Med Ctr, US Dept Vet Affairs, Asheville, NC USA. RP Kopacz, MS (reprint author), VISN 2 Ctr Excellence Suicide Prevent, US Dept Vet Affairs, 400 Ft Hill Ave, Canandaigua, NY 14424 USA. EM marek.kopacz@va.gov NR 55 TC 1 Z9 1 U1 3 U2 5 PU SPRINGER PI NEW YORK PA 233 SPRING ST, NEW YORK, NY 10013 USA SN 0031-2789 EI 1573-6679 J9 PASTOR PSYCHOL JI Pastor. Psychol. PD AUG PY 2016 VL 65 IS 4 BP 481 EP 491 DI 10.1007/s11089-016-0699-z PG 11 WC Psychology, Clinical; Psychology, Multidisciplinary SC Psychology GA DQ0OP UT WOS:000378899600004 ER PT J AU Toro, JJ Gushiken, FC Schneider, D Lee, S Haile, DJ Freytes, CO AF Toro, Juan Jose Gushiken, Francisca Cecilia Schneider, Deanna Lee, Shuko Haile, David Johannes Freytes, Cesar Ovidio TI Edentulism and transplant-associated complications in patients with multiple myeloma undergoing autologous hematopoietic stem cell transplantation SO SUPPORTIVE CARE IN CANCER LA English DT Article DE Multiple myeloma; Autologous hematopoietic stem cell transplantation; Edentulous; Dentate; Oral complications; Post-transplant toxicities ID MARROW-TRANSPLANTATION; PERIODONTAL PATHOGENS; ORAL MUCOSITIS; MELPHALAN; RECIPIENTS; THERAPY; DISEASE; CANCER; CHEMOTHERAPY; GUIDELINES AB Patients undergoing autologous hematopoietic stem cell transplantation (HSCT) are at risk for oral complications which may cause significant morbidity. The aim of this study was to compare the incidence of toxicities and complications in edentulous and dentate patients undergoing autologous HSCT for multiple myeloma. We conducted a retrospective case-control study to analyze the incidence of bacteremia, fever, and oral mucositis, between edentulous and dentate patients. All patients underwent dental evaluation, received dental treatment if indicated, and were cleared before transplantation. The two groups were matched for age, gender, ethnicity, disease stage, time from diagnosis to transplant, performance status, and conditioning regimen. A total of 45 edentulous and 90 dentate patients were enrolled. All patients were male with a median age of 60 years and a mean performance status by Karnofsky score of 90 %. Two thirds had stage III MM with a median time from diagnosis to transplantation of 12 months, and all received melphalan as part of the conditioning regimen. The incidence of bacteremia (p = 0.553), fever (p = 0.245), severity of oral mucositis (p = 0.465), and other post-transplant toxicities were similar between both groups. There were no significant differences in the incidence of bacteremia, fever, severity of oral mucositis, or other complications between edentulous and dentate patients with multiple myeloma after autologous HSCT. C1 [Toro, Juan Jose; Gushiken, Francisca Cecilia; Schneider, Deanna; Lee, Shuko; Haile, David Johannes; Freytes, Cesar Ovidio] South Texas Vet Hlth Care Syst, Audie L Murphy Mem Vet Hosp, 7400 Merton Minter Blvd, San Antonio, TX 78229 USA. RP Toro, JJ (reprint author), South Texas Vet Hlth Care Syst, Audie L Murphy Mem Vet Hosp, 7400 Merton Minter Blvd, San Antonio, TX 78229 USA. EM Juan.toro2@va.gov NR 22 TC 0 Z9 0 U1 4 U2 5 PU SPRINGER PI NEW YORK PA 233 SPRING ST, NEW YORK, NY 10013 USA SN 0941-4355 EI 1433-7339 J9 SUPPORT CARE CANCER JI Support. Care Cancer PD AUG PY 2016 VL 24 IS 8 BP 3411 EP 3415 DI 10.1007/s00520-016-3168-4 PG 5 WC Oncology; Health Care Sciences & Services; Rehabilitation SC Oncology; Health Care Sciences & Services; Rehabilitation GA DQ0JE UT WOS:000378884400025 PM 26984247 ER PT J AU Yesavage, JA Taylor, JL Friedman, L Rosenberg, PB Lazzeroni, LC Leoutsakos, JMS Kinoshita, LM Perlow, MJ Munro, CA Devanand, DP Drye, LT Mintzer, JE Pollock, BG Porsteinsson, AP Schneider, LS Shade, DM Weintraub, D Lyketsos, CG Noda, A AF Yesavage, Jerome A. Taylor, Joy L. Friedman, Leah Rosenberg, Paul B. Lazzeroni, Laura C. Leoutsakos, Jeannie-Marie S. Kinoshita, Lisa M. Perlow, Mark J. Munro, Cynthia A. Devanand, D. P. Drye, Lea T. Mintzer, Jacobo E. Pollock, Bruce G. Porsteinsson, Anton P. Schneider, Lon S. Shade, David M. Weintraub, Daniel Lyketsos, Constantine G. Noda, Art CA CitAD Res Grp TI Principal components analysis of agitation outcomes in Alzheimer's disease SO JOURNAL OF PSYCHIATRIC RESEARCH LA English DT Article DE Agitation; Alzheimer's disease; Principal component analysis ID CITALOPRAM AB Background: We developed a composite measure of agitation as a secondary outcome of change over time in the Citalopram for Agitation in Alzheimer's disease study (CitAD). CitAD demonstrated a positive effect of citalopram on agitation on the Neurobehavioral Rating Scale agitation subscale (NBRS-A). CitAD included additional agitation measures such as the Cohen-Mansfield Agitation Inventory and the Neuropsychiatric Inventory. Methods: We performed principal components analyses on change in individual item of these scales for the same, original CitAD subjects. Results: The first principal component accounted for 12.6% of the observed variance and was composed of items that appear to reflect agitation. The effect size for citalopram calculated using this component was 0.53 (95% CI 0.22-0.83) versus 0.32 for the NBRS-A (95% CI 0.01-0.62). Conclusions: Results suggest that a composite measure of change in agitation might be more sensitive than change in a single primary agitation measure. Published by Elsevier Ltd. C1 [Yesavage, Jerome A.; Taylor, Joy L.; Kinoshita, Lisa M.; Perlow, Mark J.] Dept Vet Affairs Hlth Care Syst, Palo Alto, CA 94304 USA. [Yesavage, Jerome A.; Taylor, Joy L.; Friedman, Leah; Lazzeroni, Laura C.; Noda, Art] Stanford Univ, Sch Med, Dept Psychiat & Behav Sci, Stanford, CA 94305 USA. [Yesavage, Jerome A.] Stanford Univ, Sch Med, Dept Neurol & Neurol Sci, Stanford, CA 94305 USA. [Rosenberg, Paul B.; Leoutsakos, Jeannie-Marie S.; Munro, Cynthia A.; Lyketsos, Constantine G.] Johns Hopkins Sch Med, Johns Hopkins Bayview Med Ctr, Dept Psychiat & Behav Sci, Baltimore, MD 21205 USA. [Devanand, D. P.] New York State Psychiat Inst & Hosp, Div Geriatr Psychiat, New York, NY 10032 USA. [Devanand, D. P.] Columbia Univ, Coll Phys & Surg, New York, NY 10032 USA. [Drye, Lea T.; Shade, David M.] Johns Hopkins Bloomberg Sch Publ Hlth, Baltimore, MD 21205 USA. [Mintzer, Jacobo E.] Roper St Francis Healthcare, Clin Biotechnol Res Inst, Charleston, SC 29401 USA. [Mintzer, Jacobo E.] Ralph H Johnson VA Med Ctr, Charleston, SC 29401 USA. [Pollock, Bruce G.] Univ Toronto, CAMH, Campbell Inst, Toronto, ON M5S 2S1, Canada. [Porsteinsson, Anton P.] Univ Rochester, Sch Med & Dent, Rochester, NY 14642 USA. [Schneider, Lon S.] Univ So Calif, Keck Sch Med, Los Angeles, CA 90089 USA. [Weintraub, Daniel] Univ Penn, Perelman Sch Med, Philadelphia, PA 19104 USA. [Weintraub, Daniel] Dept Vet Affairs, Philadelphia, PA 19104 USA. RP Yesavage, JA (reprint author), Palo Alto VA Hlth Care Syst, 3801 Miranda Ave 151Y, Palo Alto, CA 94304 USA. EM yesavage@stanford.edu FU NIA; NIMH [R01AG031348]; NIH [P50, AG05142]; Sierra-Pacific Mental Illness Research, Education, and Clinical Center (MIRECC); Medical Research Service of the Department of Veterans Affairs FX This work was supported by NIA and NIMH, R01AG031348 and in part by NIH P50, AG05142 (USC, LSS). and by the Sierra-Pacific Mental Illness Research, Education, and Clinical Center (MIRECC) and the Medical Research Service of the Department of Veterans Affairs. The funding sources had a role in study design; in the collection, analysis and interpretation of data; in the writing of the report; and in the decision to submit the article for publication. NR 12 TC 0 Z9 0 U1 4 U2 9 PU PERGAMON-ELSEVIER SCIENCE LTD PI OXFORD PA THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, ENGLAND SN 0022-3956 EI 1879-1379 J9 J PSYCHIATR RES JI J. Psychiatr. Res. PD AUG PY 2016 VL 79 BP 4 EP 7 DI 10.1016/j.jpsychires.2016.04.004 PG 4 WC Psychiatry SC Psychiatry GA DP0KP UT WOS:000378179000002 PM 27115509 ER PT J AU Thames, AD Sayegh, P Terashima, K Foley, JM Cho, A Arentoft, A Hinkin, CH Bookheimer, SY AF Thames, April D. Sayegh, Philip Terashima, Kevin Foley, Jessica M. Cho, Andrew Arentoft, Alyssa Hinkin, Charles H. Bookheimer, Susan Y. TI Increased subcortical neural activity among HIV plus individuals during a lexical retrieval task SO NEUROBIOLOGY OF DISEASE LA English DT Article DE Lexical retrieval; Verbal fluency; HIV; Neuroimaging; Immunosuppression ID IMMUNODEFICIENCY-VIRUS TYPE-1; VERBAL FLUENCY EVIDENCE; NEUROCOGNITIVE IMPAIRMENT; ANTIRETROVIRAL THERAPY; FUNCTIONAL MRI; BASAL GANGLIA; CD4 NADIR; INFECTION; BRAIN; ADULTS AB Background: Deficits in lexical retrieval, present in approximately 40% of HIV + patients, are thought to reflect disruptions to frontal-striatal functions and may worsen with immunosuppression. Coupling frontal-striatal tasks such as lexical retrieval with functional neuroimaging may help delineate the pathophysiologic mechanisms underlying HIV-associated neurological dysfunction. Objective: We examined whether HIV infection confers brain functional changes during lexical access and retrieval. It was expected that HIV + individuals would demonstrate greater brain activity in frontal-subcortical regions despite minimal differences between groups on neuropsychological testing. Within the HIV + sample, we examined associations between indices of immunosuppression (recent and nadir CD4+ count) and task-related signal change in frontostriatal structures. Method 16 HIV+ participants and 12 HIV - controls underwent fMRI while engaged in phonemic/letter and semantic fluency tasks. Participants also completed standardized measures of verbal fluency Results: HIV status groups performed similarly on phonemic and semantic fluency tasks prior to being scanned. fMRI results demonstrated activation differences during the phonemic fluency task as a function of HIV status, with HIV + individuals demonstrating significantly greater activation in BG structures than HIV individuals. There were no significant differences in frontal brain activation between HIV status groups during the phonemic fluency task, nor were there significant brain activation differences during the semantic fluency task. Within the HIV+ group, current CD4+ count, though not nadir, was positively correlated with increased activity in the inferior frontal gyrus and basal ganglia. Conclusion: During phonemic fluency performance, HIV+ patients recruit subcortical structures to a greater degree than HIV controls despite similar task performances suggesting that fMRI may be sensitive to neurocompromise before overt cognitive declines can be detected. Among HIV + individuals, reduced activity in the frontal-subcortical structures was associated with lower CD4+ count. (C) 2015 Elsevier Inc. All rights reserved. C1 [Thames, April D.; Sayegh, Philip; Terashima, Kevin; Cho, Andrew; Arentoft, Alyssa; Hinkin, Charles H.; Bookheimer, Susan Y.] Univ Calif Los Angeles, Dept Psychiat & Biobehav Sci, 740 Westwood Plaza C8-746, Los Angeles, CA 90095 USA. [Foley, Jessica M.] Univ Calif San Francisco, Med Ctr, 505 Parnassus Ave, San Francisco, CA 94143 USA. [Arentoft, Alyssa] Calif State Univ Northridge, Dept Psychol, 18111 Nordhoff St, Northridge, CA 91330 USA. [Hinkin, Charles H.] VA Greater Los Angeles Healthcare Syst, 11301 Wilshire Blvd, Los Angeles, CA 90073 USA. RP Thames, AD (reprint author), Univ Calif Los Angeles, Dept Psychiat & Biobehav Sci, 740 Westwood Plaza, Los Angeles, CA 90095 USA. EM athames@mednet.ucla.edu FU UCLA Academic Senate Grant; National Institute of Health (NIH/NIMH) Career Development Award [K23 MH095661] FX We would like to thank Vanessa Streiff and Darryl Stallworth for assistance with MRI data collection. We would like to acknowledge the following funding sources: UCLA Academic Senate Grant (PI: S.Y. Bookheimer). Center For AIDS Research (CFAR) (AI28697; PI: A. Thames). Dr. Thames is supported by a National Institute of Health (NIH/NIMH) Career Development Award (K23 MH095661). NR 50 TC 0 Z9 0 U1 4 U2 4 PU ACADEMIC PRESS INC ELSEVIER SCIENCE PI SAN DIEGO PA 525 B ST, STE 1900, SAN DIEGO, CA 92101-4495 USA SN 0969-9961 EI 1095-953X J9 NEUROBIOL DIS JI Neurobiol. Dis. PD AUG PY 2016 VL 92 SI SI BP 175 EP 182 DI 10.1016/j.nbd.2015.10.017 PN B PG 8 WC Neurosciences SC Neurosciences & Neurology GA DP4IQ UT WOS:000378460000008 PM 26484382 ER PT J AU Warren, T Dickey, MW Lei, CM AF Warren, Tessa Dickey, Michael Walsh Lei, Chia-Ming TI Structural prediction in aphasia: Evidence from either SO JOURNAL OF NEUROLINGUISTICS LA English DT Article DE Sentence processing; Language comprehension; Prediction; Syntax; Reading; Aphasia; Aging ID LANGUAGE COMPREHENSION; SENTENCE PRODUCTION; SYNTACTIC COMPREHENSION; READING-COMPREHENSION; AGRAMMATIC APHASIA; BROCAS APHASIA; INTEGRATION; INFORMATION; IMPLICIT; ACTIVATION AB Young neurotypical adults engage in prediction during language comprehension (e.g., Altmann & Kamide, 1999; Staub & Clifton, 2006; Yoshida, Dickey & Sturt, 2013). The role of prediction in aphasic comprehension is less clear. Some evidence suggests that lexical prediction may be spared in aphasia (Dickey, Warren, Hayes, & Milburn, 2014; Love & Webb, 1977; cf. Mack, Ji, & Thompson, 2013), and there is even indication that structural prediction may be spared in some people with aphasia (PWA; e.g. Hanne, Burchert, De Bleser, & Vashishth, 2015). The current self-paced reading experiment manipulated the presence of either to examine structural prediction among PWA and a set of similar-aged neurotypical control participants. Consistent with intact structural prediction for both groups of participants, when either preceded a disjunction, reading times were faster on the or and second disjunct (cf. Staub & Clifton, 2006). For neurotypical controls, this effect of the presence vs. absence of either shrank reliably as more experimental items were encountered, whereas for PWA there was a non-significant trend for it to grow as more experimental items were encountered. These findings indicate that PWA and older neurotypical individuals can use a lexical cue to predict the structural form of upcoming material during comprehension, but that on-line adaptation to patterns in the local context may be different for the two groups. (C) 2016 Elsevier Ltd. All rights reserved. C1 [Warren, Tessa] Univ Pittsburgh, Learning Res & Dev Ctr, Pittsburgh, PA 15260 USA. [Warren, Tessa] Univ Pittsburgh, Dept Psychol, Pittsburgh, PA 15260 USA. [Dickey, Michael Walsh; Lei, Chia-Ming] Univ Pittsburgh, Dept Commun Sci & Disorders, Pittsburgh, PA 15260 USA. [Dickey, Michael Walsh] VA Pittsburgh Healthcare Syst, Pittsburgh, PA USA. RP Warren, T (reprint author), 635 LRDC,3939 OHara St, Pittsburgh, PA 15260 USA. EM tessa@pitt.edu OI Dickey, Michael Walsh/0000-0002-9068-3313 FU NIH [R01DC011520]; [UL1TR000005] FX This research was supported by NIH grant R01DC011520 to the first and second authors and by grant number UL1TR000005 to the Clinical and Translational Science Institute of the University of Pittsburgh. It is the result of work supported with resources and the use of facilities at the VA Pittsburgh Healthcare System. We thank Mandy Simons for helpful discussion and for her work helping develop the original set of stimuli from which the ones in the current study were adapted; Rebecca Hayes, Michelle Holcomb, Evelyn Milburn, and Teljer Liburd for help running participants; and Dominique Walker for help with language testing. NR 51 TC 1 Z9 1 U1 3 U2 6 PU PERGAMON-ELSEVIER SCIENCE LTD PI OXFORD PA THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, ENGLAND SN 0911-6044 J9 J NEUROLINGUIST JI J. Neurolinguist. PD AUG PY 2016 VL 39 BP 38 EP 48 DI 10.1016/j.jneuroling.2016.01.001 PG 11 WC Linguistics; Neurosciences; Psychology, Experimental SC Linguistics; Neurosciences & Neurology; Psychology GA DO5NL UT WOS:000377829700004 PM 27041821 ER PT J AU Ruben, MA Hall, JA AF Ruben, Mollie A. Hall, Judith A. TI A Lens Model Approach to the Communication of Pain SO HEALTH COMMUNICATION LA English DT Article ID FACIAL EXPRESSIONS; DETECTING DECEPTION; ACCURACY; EMPATHY; METAANALYSIS; PERCEPTION; FRAMEWORK; GENUINE AB Two studies examined the expression and detection of suppressed, genuine, and exaggerated pain. In Study 1, videotaped participants underwent an acute laboratory pain stressor and completed pain ratings. In Study 2, the lens model examined the cues encoders displayed while in pain (facial expressions of pain and viewers' global impressions), the cues decoders used to infer pain in the videotaped encoders, and decoders' accuracy in making judgments of pain. Results revealed expression differences between the suppressed, genuine, and exaggerated pain such that exaggerated expressions contained more tightened facial expressions while genuine expressions of pain contained more open facial expressions of pain. Decoders were accurate at detecting pain only in the exaggerated pain expressions. These results highlight the need for improving providers' accuracy in detecting pain intensity for suppressed, genuine, and exaggerated pain displays. Trainings should focus on teaching providers that patients who appear more agitated and less composed may be suppressing pain, while patients who appear more tense and determined may be exaggerating pain. Finally, patients who seem to not be in that much pain because they are not showing tightened facial expressions may actually be experiencing higher intensities of genuine pain. C1 [Ruben, Mollie A.] US Dept Vet Affairs, Ctr Healthcare Org & Implementat Res, 150 S Huntington Ave,Bdg 9, Boston, MA 02130 USA. [Hall, Judith A.] Northeastern Univ, Dept Psychol, Boston, MA USA. RP Ruben, MA (reprint author), US Dept Vet Affairs, Ctr Healthcare Org & Implementat Res, 150 S Huntington Ave,Bdg 9, Boston, MA 02130 USA. EM Mollie.Ruben@va.gov NR 49 TC 0 Z9 0 U1 4 U2 6 PU ROUTLEDGE JOURNALS, TAYLOR & FRANCIS LTD PI ABINGDON PA 4 PARK SQUARE, MILTON PARK, ABINGDON OX14 4RN, OXFORDSHIRE, ENGLAND SN 1041-0236 EI 1532-7027 J9 HEALTH COMMUN JI Health Commun. PD AUG PY 2016 VL 31 IS 8 BP 934 EP 945 DI 10.1080/10410236.2015.1020261 PG 12 WC Communication; Health Policy & Services SC Communication; Health Care Sciences & Services GA DN7YH UT WOS:000377295600003 PM 26752199 ER PT J AU Denny, BT Fan, J Liu, X Guerreri, S Mayson, SJ Rimsky, L McMaster, A Alexander, H New, AS Goodman, M Perez-Rodriguez, M Siever, LJ Koenigsberg, HW AF Denny, Bryan T. Fan, Jin Liu, Xun Guerreri, Stephanie Mayson, Sarah Jo Rimsky, Liza McMaster, Antonia Alexander, Heather New, Antonia S. Goodman, Marianne Perez-Rodriguez, Mercedes Siever, Larry J. Koenigsberg, Harold W. TI Brain structural anomalies in borderline and avoidant personality disorder patients and their associations with disorder-specific symptoms SO JOURNAL OF AFFECTIVE DISORDERS LA English DT Article DE Borderline personality disorder; Avoidant personality disorder; Voxel-based morphometry; Anxiety; Affective instability ID MAJOR DEPRESSIVE DISORDER; MEDIAL PREFRONTAL CORTEX; AMYGDALA; METAANALYSIS; MEMORY; VOLUME; ATLAS; SELF; HIPPOCAMPUS; COMORBIDITY AB Background: Borderline personality disorder (BPD) and avoidant personality disorder (AvPD) are characterized by hyper-reactivity to negatively-perceived interpersonal cues, yet they differ in degree of affective instability. Recent work has begun to elucidate the neural (structural and functional) and cognitive-behavioral underpinnings of BPD, although some initial studies of brain structure have reached divergent conclusions. AvPD, however, has been almost unexamined in the cognitive neuroscience literature. Methods: In the present study we investigated group differences among 29 BPD patients, 27 AvPD patients, and 29 healthy controls (HC) in structural brain volumes using voxel-based morphometry (VBM) in five anatomically-defined regions of interest: amygdala, hippocampus, medial prefrontal cortex (MPFC), dorsolateral prefrontal cortex (DLPFC), and anterior cingulate cortex (ACC). We also examined the relationship between individual differences in brain structure and self-reported anxiety and affective instability in each group. Results: We observed reductions in MPFC and ACC volume in BPD relative to HC, with no significant difference among patient groups. No group differences in amygdala volume were found. However, BPD and AvPD patients each showed a positive relationship between right amygdala volume and state-related anxiety. By contrast, in HC there was an inverse relationship between MPFC volume and state and trait related anxiety as well as between bilateral DLPFC volume and affective instability. Limitations: Current sample sizes did not permit examination of gender effects upon structure-symptom correlations. Conclusions: These results shed light on potentially protective, or compensatory, aspects of brain structure in these populations namely, relatively reduced amygdala volume or relatively enhanced MPFC and DLPFC volume. Published by Elsevier B.V. C1 [Denny, Bryan T.; Fan, Jin; Guerreri, Stephanie; Mayson, Sarah Jo; Rimsky, Liza; McMaster, Antonia; Alexander, Heather; New, Antonia S.; Goodman, Marianne; Perez-Rodriguez, Mercedes; Siever, Larry J.; Koenigsberg, Harold W.] Icahn Sch Med Mt Sinai, Dept Psychiat, New York, NY 10029 USA. [Fan, Jin] Icahn Sch Med Mt Sinai, Dept Neurosci, New York, NY 10029 USA. [Fan, Jin] CUNY Queens Coll, Dept Psychol, Flushing, NY 11367 USA. [Liu, Xun] Chinese Acad Sci, Inst Psychol, Beijing 100101, Peoples R China. [New, Antonia S.; Goodman, Marianne; Siever, Larry J.; Koenigsberg, Harold W.] James J Peters VA Med Ctr, Bronx, NY 10468 USA. RP Koenigsberg, HW (reprint author), James J Peters VA Med Ctr, Mental Hlth Patient Care Ctr, 130 West Kingsbridge Rd, Bronx, NY 10468 USA. EM HWarrenK@nyc.rr.com FU National Institute of Mental Health (NIH) [R01 MH077813]; NIH [F32 MH105119]; National Center for Advancing Translational Sciences (NCATS), a component of the National Institutes of Health (NIH) [UL1TR000067]; James J Peters Veterans Affairs Medical Center FX This work was supported by the National Institute of Mental Health (NIH grant R01 MH077813 to Dr. Koenigsberg and NIH grant F32 MH105119 to Dr. Denny), by the James J Peters Veterans Affairs Medical Center, and Grant UL1TR000067 from the National Center for Advancing Translational Sciences (NCATS), a component of the National Institutes of Health (NIH). NR 51 TC 0 Z9 0 U1 6 U2 14 PU ELSEVIER SCIENCE BV PI AMSTERDAM PA PO BOX 211, 1000 AE AMSTERDAM, NETHERLANDS SN 0165-0327 EI 1573-2517 J9 J AFFECT DISORDERS JI J. Affect. Disord. PD AUG PY 2016 VL 200 BP 266 EP 274 DI 10.1016/j.jad.2016.04.053 PG 9 WC Clinical Neurology; Psychiatry SC Neurosciences & Neurology; Psychiatry GA DN9IH UT WOS:000377392400036 PM 27155069 ER PT J AU Kopacz, MS Feldstein, BD Asekoff, CA Kaprow, MS Smith-Coggins, R Rasmussen, KA AF Kopacz, Marek S. Feldstein, Bruce D. Asekoff, Cecille Allman Kaprow, Maurice S. Smith-Coggins, Rebecca Rasmussen, Kathy A. TI How Involved are Non-VA Chaplains in Supporting Veterans? SO JOURNAL OF RELIGION & HEALTH LA English DT Article DE Veterans; Non-VA; Community health ID MENTAL-HEALTH-SERVICES AB In terms of supporting veteran populations, little is known of the experiences of chaplains professionally active outside of Department of Veterans Affairs (VA) healthcare settings. The present study looks to examine how involved non-VA chaplains are in supporting veterans as well as their familiarity with the VA. An online survey was distributed in a convenience sample of chaplains, of which n = 39 met the inclusion criterion for this study (i.e., no past or present VA affiliation). The results find that most of the non-VA chaplains encounter veteran service users either on a weekly or monthly basis. Though familiar with VA services, non-VA chaplains were not sure of their veteran service users' VA enrollment status nor did they feel able to adequately advise their veteran service users on VA enrollment. The results suggest that non-VA chaplains actively support veteran populations. Opportunities for enhancing chaplaincy services and VA outreach programs are discussed. C1 [Kopacz, Marek S.; Rasmussen, Kathy A.] US Dept Vet Affairs, VISN Ctr Excellence Suicide Prevent 2, 400 Ft Hill Ave, Canandaigua, NY 14424 USA. [Feldstein, Bruce D.; Smith-Coggins, Rebecca] Stanford Univ, Sch Med, Stanford, CA 94305 USA. [Feldstein, Bruce D.; Asekoff, Cecille Allman; Kaprow, Maurice S.] Neshama Assoc Jewish Chaplains, Whippany, NJ USA. [Rasmussen, Kathy A.] Univ Rochester, Med Ctr, Rochester, NY 14642 USA. RP Kopacz, MS (reprint author), US Dept Vet Affairs, VISN Ctr Excellence Suicide Prevent 2, 400 Ft Hill Ave, Canandaigua, NY 14424 USA. EM marek.kopacz@va.gov FU Office of Academic Affiliations, Advanced Fellowship Program in Mental Illness Research and Treatment, US Department of Veterans Affairs, VISN 2 Center of Excellence for Suicide Prevention FX Dr. Rasmussen was supported by the Office of Academic Affiliations, Advanced Fellowship Program in Mental Illness Research and Treatment, US Department of Veterans Affairs, VISN 2 Center of Excellence for Suicide Prevention. Institutional support for this study was provided by the VISN 2 Center of Excellence for Suicide Prevention (Canandaigua, NY) and Neshama: Association of Jewish Chaplains (Whippany, NJ). The views expressed are those of the authors and do not reflect the official policy or position of the Department of Veterans Affairs or the US Government. NR 13 TC 1 Z9 1 U1 2 U2 2 PU SPRINGER PI NEW YORK PA 233 SPRING ST, NEW YORK, NY 10013 USA SN 0022-4197 EI 1573-6571 J9 J RELIG HEALTH JI J. Relig. Health PD AUG PY 2016 VL 55 IS 4 BP 1206 EP 1214 DI 10.1007/s10943-016-0223-x PG 9 WC Public, Environmental & Occupational Health; Religion SC Public, Environmental & Occupational Health; Religion GA DN2FW UT WOS:000376880500008 PM 27023459 ER PT J AU Lingren, T Chen, P Bochenek, J Doshi-Velez, F Manning-Courtney, P Bickel, J Welchons, LW Reinhold, J Bing, N Ni, YZ Barbaresi, W Mentch, F Basford, M Denny, J Vazquez, L Perry, C Namjou, B Qiu, HJ Connolly, J Abrams, D Holm, IA Cobb, BA Lingren, N Solti, I Hakonarson, H Kohane, IS Harley, J Savova, G AF Lingren, Todd Chen, Pei Bochenek, Joseph Doshi-Velez, Finale Manning-Courtney, Patty Bickel, Julie Welchons, Leah Wildenger Reinhold, Judy Bing, Nicole Ni, Yizhao Barbaresi, William Mentch, Frank Basford, Melissa Denny, Joshua Vazquez, Lyam Perry, Cassandra Namjou, Bahram Qiu, Haijun Connolly, John Abrams, Debra Holm, Ingrid A. Cobb, Beth A. Lingren, Nataline Solti, Imre Hakonarson, Hakon Kohane, Isaac S. Harley, John Savova, Guergana TI Electronic Health Record Based Algorithm to Identify Patients with Autism Spectrum Disorder SO PLOS ONE LA English DT Article ID GENOME-WIDE ASSOCIATION; MEDICAL-RECORDS; DISEASE; CLASSIFICATION; INFORMATICS; COMORBIDITY; SELECTION; CHILDREN; CLUSTERS; TODDLERS AB Objective Cohort selection is challenging for large-scale electronic health record (EHR) analyses, as International Classification of Diseases 9th edition (ICD-9) diagnostic codes are notoriously unreliable disease predictors. Our objective was to develop, evaluate, and validate an automated algorithm for determining an Autism Spectrum Disorder (ASD) patient cohort from EHR. We demonstrate its utility via the largest investigation to date of the co-occurrence patterns of medical comorbidities in ASD. Methods We extracted ICD-9 codes and concepts derived from the clinical notes. A gold standard patient set was labeled by clinicians at Boston Children's Hospital (BCH) (N = 150) and Cincinnati Children's Hospital and Medical Center (CCHMC) (N = 152). Two algorithms were created: (1) rule-based implementing the ASD criteria from Diagnostic and Statistical Manual of Mental Diseases 4th edition, (2) predictive classifier. The positive predictive values (PPV) achieved by these algorithms were compared to an ICD-9 code baseline. We clustered the patients based on grouped ICD-9 codes and evaluated subgroups. Results The rule-based algorithm produced the best PPV: (a) BCH: 0.885 vs. 0.273 (baseline); (b) CCHMC: 0.840 vs. 0.645 (baseline); (c) combined: 0.864 vs. 0.460 (baseline). A validation at Children's Hospital of Philadelphia yielded 0.848 (PPV). Clustering analyses of comorbidities on the three-site large cohort (N = 20,658 ASD patients) identified psychiatric, developmental, and seizure disorder clusters. Conclusions In a large cross-institutional cohort, co-occurrence patterns of comorbidities in ASDs provide further hypothetical evidence for distinct courses in ASD. The proposed automated algorithms for cohort selection open avenues for other large-scale EHR studies and individualized treatment of ASD. C1 [Lingren, Todd; Ni, Yizhao; Solti, Imre] Cincinnati Childrens Hosp Med Ctr, Div Biomed Informat, Cincinnati, OH 45229 USA. [Chen, Pei] Boston Childrens Hosp, Ctr Syst Biol, Boston, MA USA. [Bochenek, Joseph; Denny, Joshua] Vanderbilt Univ, Sch Med, Biomed Informat, Nashville, TN 37212 USA. [Doshi-Velez, Finale] Harvard Med Sch, Ctr Biomed Informat, Boston, MA USA. [Manning-Courtney, Patty; Reinhold, Judy; Bing, Nicole; Harley, John] Univ Cincinnati, Dept Pediat, Cincinnati, OH USA. [Manning-Courtney, Patty; Reinhold, Judy; Bing, Nicole] Cincinnati Childrens Hosp Med Ctr, Div Dev & Behav Pediat, Cincinnati, OH 45229 USA. [Bickel, Julie; Welchons, Leah Wildenger] Boston Childrens Hosp, Pediat, Boston, MA USA. [Bickel, Julie; Welchons, Leah Wildenger] Boston Childrens Hosp, Dev Med, Boston, MA USA. [Welchons, Leah Wildenger] Boston Childrens Hosp, Neurol, Boston, MA USA. [Welchons, Leah Wildenger] Boston Childrens Hosp, Ctr Commun Enhancement, Boston, MA USA. [Barbaresi, William; Holm, Ingrid A.] Childrens Hosp, Div Med, 300 Longwood Ave, Boston, MA 02115 USA. [Mentch, Frank; Vazquez, Lyam; Qiu, Haijun; Connolly, John; Abrams, Debra; Hakonarson, Hakon] Childrens Hosp Philadelphia, Ctr Appl Genom, Philadelphia, PA 19104 USA. [Basford, Melissa] Vanderbilt Univ, Med Ctr, Vanderbilt Inst Clin & Translat Res, Nashville, TN USA. [Perry, Cassandra; Holm, Ingrid A.] Boston Childrens Hosp, Div Genet & Genom, Boston, MA USA. [Namjou, Bahram; Cobb, Beth A.; Harley, John] Cincinnati Childrens Hosp Med Ctr, Ctr Autoimmune Genom & Etiol, Cincinnati, OH 45229 USA. [Namjou, Bahram; Solti, Imre] Univ Cincinnati, Coll Med, Cincinnati, OH USA. [Holm, Ingrid A.; Kohane, Isaac S.; Savova, Guergana] Harvard Med Sch, Pediat, Boston, MA USA. [Holm, Ingrid A.] Boston Childrens Hosp, Manton Ctr Orphan Dis Res, Boston, MA USA. [Lingren, Nataline] Cincinnati Childrens Hosp Med Ctr, Emergency Med, Cincinnati, OH 45229 USA. [Hakonarson, Hakon] Perelman Sch Med, Pediat, Philadelphia, PA USA. [Kohane, Isaac S.; Savova, Guergana] Boston Childrens Hosp, Childrens Hosp Informat Program, Boston, MA USA. [Harley, John] US Dept Vet Affairs, Med Ctr, Med, Cincinnati, OH USA. RP Lingren, T (reprint author), Cincinnati Childrens Hosp Med Ctr, Div Biomed Informat, Cincinnati, OH 45229 USA. EM todd.lingren@cchmc.org OI Lingren, Todd/0000-0003-0311-7100 FU collaborative sites in the eMERGE Network; National Human Genome Research Institute (NHGRI) [U01HG006828, U01HG006830, U01HG006378, U01HG008666] FX This work was supported by collaborative sites in the eMERGE Network and funded by National Human Genome Research Institute (NHGRI) through the following grants: U01HG006828 (Cincinnati Children's Hospital Medical Center/Boston Children's Hospital); U01HG006830 (Children's Hospital of Philadelphia); U01HG006378 (Vanderbilt University Medical Center) and U01HG008666 (Cincinnati Children's Hospital Medical Center). NR 40 TC 1 Z9 1 U1 4 U2 5 PU PUBLIC LIBRARY SCIENCE PI SAN FRANCISCO PA 1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA SN 1932-6203 J9 PLOS ONE JI PLoS One PD JUL 29 PY 2016 VL 11 IS 7 AR e0159621 DI 10.1371/journal.pone.0159621 PG 16 WC Multidisciplinary Sciences SC Science & Technology - Other Topics GA DT5IM UT WOS:000381516300015 PM 27472449 ER PT J AU Fischer, MJ Stroupe, KT Kaufman, JS O'Hare, AM Browning, MM Sohn, MW Huo, ZP Hynes, DM AF Fischer, Michael J. Stroupe, Kevin T. Kaufman, James S. O'Hare, Ann M. Browning, Margaret M. Sohn, Min-Woong Huo, Zhiping Hynes, Denise M. TI Predialysis nephrology care and dialysis-related health outcomes among older adults initiating dialysis SO BMC NEPHROLOGY LA English DT Article DE Dialysis; Elderly; Nephrology care ID CHRONIC KIDNEY-DISEASE; OF-VETERANS-AFFAIRS; ELDERLY-PATIENTS; PERITONEAL-DIALYSIS; VASCULAR ACCESS; REFERRED LATE; MORTALITY; PATIENT; AGE; TRANSPLANTATION AB Background: Predialysis nephrology care is associated with lower mortality and rates of hospitalization following chronic dialysis initiation. Whether more frequent predialysis nephrology care is associated with other favorable outcomes for older adults is not known. Methods: Retrospective cohort study of patients >= 66 years who initiated chronic dialysis in 2000-2001 and were eligible for VA and/or Medicare-covered services. Nephrology visits in VA and/or Medicare during the 12-month predialysis period were identified and classified by low intensity (<3 visits), moderate intensity (3-6 visits), and high intensity (>6 visits). Outcome measures included very low estimated glomerular filtration rate, severe anemia, use of peritoneal dialysis, and receipt of permanent vascular access at dialysis initiation and death and kidney transplantation within two years of initiation. Generalized linear models with propensity score weighting were used to examine the association between nephrology care and outcomes. Results: Among 58,014 patients, 46 % had none, 22 % had low, 13 % had moderate, and 19 % had high intensity predialysis nephrology care. Patients with a greater intensity of predialysis nephrology care had more favorable outcomes (all p < 0.001). In adjusted models, patients with high intensity predialysis nephrology care were less likely to have severe anemia (RR = 0.70, 99 % CI: 0.65-0.74) and more likely to have permanent vascular access (RR = 3.60, 99 % CI: 3.42-3.79) at dialysis initiation, and less likely to die within two years of dialysis initiation (RR = 0.80, 99 % CI: 0.77-0.82). Conclusion: In a large cohort of older adults treated with chronic dialysis, greater intensity of predialysis nephrology care was associated with more favorable outcomes. C1 [Fischer, Michael J.] Univ Illinois, Med Ctr, Jesse Brown VA Med Ctr, Med Nephrol, Chicago, IL 60607 USA. [Fischer, Michael J.; Stroupe, Kevin T.; Browning, Margaret M.; Sohn, Min-Woong; Huo, Zhiping; Hynes, Denise M.] Edward Hines Jr VA Hosp, Ctr Innovat Complex Chron Care, Hines, IL 60141 USA. [Stroupe, Kevin T.] Loyola Univ Chicago, Dept Publ Hlth Sci, Maywood, IL USA. [Browning, Margaret M.; Hynes, Denise M.] Edward Hines Jr VA Hosp, VA Informat Resource Ctr, Hines, IL USA. [Kaufman, James S.] VA New York Harbor Healthcare Syst, Med Nephrol, New York, NY USA. [Kaufman, James S.] NYU, Sch Med, New York, NY USA. [O'Hare, Ann M.] VA Puget Sound Healthcare Syst, Med Nephrol, Seattle, WA USA. [O'Hare, Ann M.] Univ Washington, Grp Hlth Res Inst, Med Nephrol, Seattle, WA 98195 USA. [Sohn, Min-Woong] Univ Virginia, Dept Publ Hlth Sci, Charlottesville, VA USA. [Hynes, Denise M.] Univ Illinois, Sch Publ Hlth, Med Hlth Promot Res, Chicago, IL USA. RP Fischer, MJ (reprint author), Univ Illinois, Med Ctr, Jesse Brown VA Med Ctr, Med Nephrol, Chicago, IL 60607 USA.; Fischer, MJ (reprint author), Edward Hines Jr VA Hosp, Ctr Innovat Complex Chron Care, Hines, IL 60141 USA. EM fischerm@uic.edu FU Department of Veterans Affairs, Veterans Health Administration, Health Services Research and Development Service (VA HSRD) [IIR 02-244, IIR 20-016]; NIH [K23AG28980]; VA Information Resource Center (VA HSRD) [SDR 02-237] FX The authors received funding support for this research project from: Department of Veterans Affairs, Veterans Health Administration, Health Services Research and Development Service (VA HSR&D IIR 02-244 and IIR 20-016 - K. Stroupe, D. Hynes, M. Browning; VA HSR&D Research Career Scientist Award - D, Hynes; VA HSR&D Career Development Award - M. Fischer); NIH K23AG28980 - A. O'Hare. USRDS and Medicare data for this project were provided by the VA Information Resource Center (VA HSR&D SDR 02-237). NR 45 TC 1 Z9 1 U1 0 U2 0 PU BIOMED CENTRAL LTD PI LONDON PA 236 GRAYS INN RD, FLOOR 6, LONDON WC1X 8HL, ENGLAND SN 1471-2369 J9 BMC NEPHROL JI BMC Nephrol. PD JUL 29 PY 2016 VL 17 AR 103 DI 10.1186/s12882-016-0324-5 PG 10 WC Urology & Nephrology SC Urology & Nephrology GA DS5WP UT WOS:000380854000002 PM 27473684 ER PT J AU Vahidy, F Nguyen, C Albright, KC Boehme, AK Mir, O Sands, KA Savitz, SI AF Vahidy, Farhaan Nguyen, Claude Albright, Karen C. Boehme, Amelia K. Mir, Osman Sands, Kara A. Savitz, Sean I. TI Transferring Patients with Intracerebral Hemorrhage Does Not Increase In-Hospital Mortality SO PLOS ONE LA English DT Article ID ASSOCIATION/AMERICAN-STROKE-ASSOCIATION; INTENSIVE-CARE-UNIT; OUTCOMES; IMPACT; POPULATION; PREVENTION; GUIDELINES; ADMISSION; STATEMENT; REGISTRY AB Introduction Comprehensive stroke centers (CSCs) accept transferred patients from referring hospitals in a given regional area. The transfer process itself has not been studied as a potential factor that may impact outcome. We compared in-hospital mortality and severe disability or death at CSCs between transferred and directly admitted intracerebral hemorrhage (ICH) patients of matched severity. Materials and Methods We retrospectively reviewed all primary ICH patients from a prospectively-collected stroke registry and electronic medical records, at two tertiary care sites. Patients meeting inclusion criteria were divided into two groups: patients transferred in for a higher level of care and direct presenters. We used propensity scores (PS) to match 175 transfer patients to 175 direct presenters. These patients were taken from a pool of 530 eligible patients, 291 (54.9%) of whom were transferred in for a higher level of care. Severe disability or death was defined as a modified Rankin Scale (mRS) sore of 4-6. Mortality and morbidity were compared between the 2 groups using Pearson chi-squared test and Student t test. We fit logistic regression models to estimate odds ratios (OR) and 95% confidence intervals (CI) for association between transfer status and in-hospital mortality and severe disability or death in full and PS-matched patients. Results There were no significant differences in the PS-matched transfer and direct presentation groups. Patients transferred to a regional center were not at higher odds of in-hospital mortality (OR: 0.93, 95% CI: 0.50-1.71) and severe disability or death (OR: 0.77, 95% CI: 0.39-1.50), than direct presenters, even after adjustment for PS, age, baseline NIHSS score, and glucose on admission. Conclusion Our observation suggests that transfer patients of similar disease burden are not at higher risk of in-hospital mortality than direct presenters. C1 [Vahidy, Farhaan; Nguyen, Claude; Mir, Osman; Savitz, Sean I.] Univ Texas Hlth Sci Ctr Houston, McGovern Med Sch, Dept Neurol, Houston, TX USA. [Albright, Karen C.] Birmingham VA Med Ctr, Geriatr Res Educ & Clin Ctr, Birmingham, AL USA. [Albright, Karen C.] Univ Alabama Birmingham, Sch Publ Hlth, Dept Epidemiol, Birmingham, AL 35294 USA. [Boehme, Amelia K.] Columbia Univ, Gertrude H Sergievsky Ctr, Dept Neurol, New York, NY 10027 USA. [Sands, Kara A.] Univ Alabama Birmingham, Dept Neurol, UAB Stn, Birmingham, AL 35294 USA. RP Vahidy, F (reprint author), Univ Texas Hlth Sci Ctr Houston, McGovern Med Sch, Dept Neurol, Houston, TX USA. EM farhaan.vahidy@uth.tmc.edu FU National Institutes of Health Training Grant [5 T32 NS007412-12]; NINDS [T32 NS007153 31] FX Financial support for this study was provided in part by National Institutes of Health Training Grant 5 T32 NS007412-12. Dr. Boehme is supported by NINDS T32 NS007153 31. The funding agreement ensured the authors' independence in designing the study, interpreting the data, writing and publishing the report.; The authors acknowledge technical and infrastructural research supported provided by the Center for Clinical Research and Evidence Based Medicine at the McGovern Medical School at University of Texas in Houston for this work. This work was supported by National Institutes of Health Training Grant 5 T32 NS007412-12. Dr. Boehme is supported by NINDS T32 NS007153 31. NR 37 TC 0 Z9 0 U1 1 U2 1 PU PUBLIC LIBRARY SCIENCE PI SAN FRANCISCO PA 1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA SN 1932-6203 J9 PLOS ONE JI PLoS One PD JUL 28 PY 2016 VL 11 IS 7 AR e0159174 DI 10.1371/journal.pone.0159174 PG 12 WC Multidisciplinary Sciences SC Science & Technology - Other Topics GA DT5IL UT WOS:000381516100020 PM 27467594 ER PT J AU Marcum, ZA Bellon, JE Li, J Gellad, WF Donohue, JM AF Marcum, Zachary A. Bellon, Johanna E. Li, Jie Gellad, Walid F. Donohue, Julie M. TI New chronic disease medication prescribing by nurse practitioners, physician assistants, and primary care physicians: a cohort study SO BMC HEALTH SERVICES RESEARCH LA English DT Article DE Health services research; Pharmacoepidemiology; Primary care; Work force ID ATRIAL-FIBRILLATION; RISK-FACTORS; DABIGATRAN; INHIBITORS; MANAGEMENT; KNOWLEDGE; MORTALITY; WARFARIN; TRENDS; DRUGS AB Background: Medications to treat and prevent chronic disease have substantially reduced morbidity and mortality; however, their diffusion has been uneven. Little is known about prescribing of chronic disease medications by nurse practitioners (NPs) and physician assistants (PAs), despite their increasingly important role as primary care providers. Thus, we sought to conduct an exploratory analysis to examine prescribing of new chronic disease medications by NPs and PAs compared to primary care physicians (PCPs). Methods: We obtained prescribing data from IMS Health's Xponent (TM) on all NPs, PAs, and PCPs in Pennsylvania regularly prescribing anticoagulants, antihypertensives, oral hypoglycemics, and/or HMG-Co-A reductase inhibitors pre- and post-introduction of five new drugs in these classes that varied in novelty (i.e., dabigatran, aliskiren, sitagliptin or saxagliptin, and pitavastatin). We constructed three measures of prescriber adoption during the 15-month post-FDA approval period: 1) any prescription of the medication, 2) proportion of prescriptions in the class for the medication, and 3) time to adoption (first prescription) of the medication. Results: From 2007 to 2011, the proportion of antihypertensive prescriptions prescribed by NPs and PAs approximately doubled from 2.0 to 4.2 % and 2.2 to 4.9 %, respectively. Similar trends were found for anticoagulants, oral hypoglycemics, and HMG-Co-A reductase inhibitors. By 2011, more PCPs had prescribed each of the newly approved medications than NPs and PAs (e.g., 44.3 % vs. 18.5 % vs. 20 % for dabigatran among PCPs, NPs, and PAs). Across all medication classes, the newly approved drugs accounted for a larger share of prescriptions in the class for PCPs followed by PAs, followed by NPs (e.g., dabigatran: 4.9 % vs. 3.2 % vs. 2.8 %, respectively). Mean time-to-adoption for the newly approved medications was shorter for PCPs compared to NPs and PAs (e.g., dabigatran, 7.3 vs. 8.2 vs. 8.5 months; P all medications < 0.001). Conclusions: PCPs were more likely to prescribe each of the newly approved medications per each measure of drug adoption, regardless of drug novelty. Differences in the rate and speed of drug adoption between PCPs, NPs, and PAs may have important implications for care and overall costs at the population level as NPs and PAs continue taking on a larger role in prescribing. C1 [Marcum, Zachary A.] Univ Washington, Sch Pharm, Dept Pharm, 1959 NE Pacific St,Box 357630, Seattle, WA 98102 USA. [Bellon, Johanna E.] UPMC, Wolff Ctr, Ross Bldg,Room 219,4601 Baum Blvd, Pittsburgh, PA 15213 USA. [Li, Jie; Donohue, Julie M.] Univ Pittsburgh, Grad Sch Publ Hlth, Dept Hlth Policy & Management, 130 De Soto St, Pittsburgh, PA 15261 USA. [Gellad, Walid F.] Univ Pittsburgh, Sch Med, VA Pittsburgh Healthcare Syst, 200 Meyran Ave,Parkvale Bldg, Pittsburgh, PA 15213 USA. [Gellad, Walid F.] Univ Pittsburgh, Sch Med, Dept Gen Internal Med, 200 Meyran Ave,Parkvale Bldg, Pittsburgh, PA 15213 USA. RP Marcum, ZA (reprint author), Univ Washington, Sch Pharm, Dept Pharm, 1959 NE Pacific St,Box 357630, Seattle, WA 98102 USA. EM zmarcum@uw.edu FU NHLBI [R01HL119246]; VA HSR&D Career Development Award [CDA 09-207]; RAND-University of Pittsburgh Health Institute (RUPHI); National Center for Research Resources (NCRR), a component of the National Institutes of Health [UL1 RR024153] FX This work was supported by R01HL119246 from NHLBI (Drs. Donohue and Gellad). Dr. Gellad was also supported by a VA HSR&D Career Development Award (CDA 09-207). Drs. Donohue and Gellad were partially supported by a pilot grant from the RAND-University of Pittsburgh Health Institute (RUPHI) and Grant Number UL1 RR024153 from the National Center for Research Resources (NCRR), a component of the National Institutes of Health. NR 28 TC 0 Z9 0 U1 9 U2 10 PU BIOMED CENTRAL LTD PI LONDON PA 236 GRAYS INN RD, FLOOR 6, LONDON WC1X 8HL, ENGLAND SN 1472-6963 J9 BMC HEALTH SERV RES JI BMC Health Serv. Res. PD JUL 27 PY 2016 VL 16 AR 312 DI 10.1186/s12913-016-1569-1 PG 8 WC Health Care Sciences & Services SC Health Care Sciences & Services GA DS2WY UT WOS:000380645800005 PM 27464570 ER PT J AU Xiao, LJ Feng, Q Zhang, Z Wang, F Lydon, JP Ittmann, MM Xin, L Mitsiades, N He, B AF Xiao, Lijuan Feng, Qin Zhang, Zheng Wang, Fen Lydon, John P. Ittmann, Michael M. Xin, Li Mitsiades, Nicholas He, Bin TI The essential role of GATA transcription factors in adult murine prostate SO ONCOTARGET LA English DT Article DE GATA2; GATA3; FoxA1; androgen receptor; prostate cancer ID ACUTE MYELOID-LEUKEMIA; ANDROGEN RECEPTOR; CELL-DIFFERENTIATION; REGULATORY LOOP; GENE-EXPRESSION; MOUSE PROSTATE; MAMMARY-GLAND; BREAST-CANCER; STEM-CELLS; FOXA1 AB GATA transcription factors are essential in mammalian cell lineage determination and have a critical role in cancer development. In cultured prostate cancer cells, GATA2 coordinates with androgen receptor (AR) to regulate gene transcription. In the murine prostate, among six GATA members, GATA2 and GATA3 are expressed. Immunofluorescence staining revealed that both GATA factors predominantly localize in the nuclei of luminal epithelial cells. The pioneer factor FoxA1 is exclusively detected in the luminal cells, whereas AR is detected in both luminal and basal cells. Using genetic engineering, we generated prostate-specific GATA2 and GATA3 knockout (KO) mice. Ablation of single GATA gene had marginal effect on prostate morphology and AR target gene expression, likely due to their genetic compensation. Double KO mice exhibited PIN III to IV lesions, but decreased prostate to body weight ratio, altered AR target gene expression, and expansion of p63-positive basal cells. However, deletion of GATA2 and GATA3 did not reduce the mRNA or protein levels of AR or FoxA1, indicating that GATA factors are not required for AR or FoxA1 expression in adult prostate. Surprisingly, GATA2 and GATA3 exhibit minimal expression in the ventral prostatic (VP) lobe. In contrast, FoxA1 and AR expression levels in VP are at least as high as those in anterior prostatic (AP) and dorsal-lateral prostatic (DLP) lobes. Together, our results indicate that GATA2 and GATA3 are essential for adult murine prostate function and in vivo AR signaling, and the lack of the GATA factor expression in the VP suggests a fundamental difference between VP and other prostatic lobes. C1 [Xiao, Lijuan; Mitsiades, Nicholas; He, Bin] Baylor Coll Med, Dept Med Hematol & Oncol, Houston, TX 77030 USA. [Feng, Qin; Zhang, Zheng; Lydon, John P.; Xin, Li; Mitsiades, Nicholas; He, Bin] Baylor Coll Med, Dept Mol & Cellular Biol, Houston, TX 77030 USA. [Wang, Fen] Texas A&M Hlth Sci Ctr, Inst Biosci & Technol, Ctr Canc & Stem Cell Biol, Houston, TX USA. [Ittmann, Michael M.] Baylor Coll Med, Dept Pathol & Immunol, Houston, TX 77030 USA. [Ittmann, Michael M.] US Dept Vet Affairs, Michael E DeBakey Vet Affairs Med Ctr, Houston, TX USA. RP Mitsiades, N; He, B (reprint author), Baylor Coll Med, Dept Med Hematol & Oncol, Houston, TX 77030 USA.; Mitsiades, N; He, B (reprint author), Baylor Coll Med, Dept Mol & Cellular Biol, Houston, TX 77030 USA. EM mitsiade@bcm.edu; bhe@bcm.edu FU NIH [K01DK081446, R01HD042311, R21AI122418]; American Cancer Society [RSG-13-061-01-TBE]; Department of Defense [BC122115] FX We thank the Genetically Engineered Mouse Core for their assistance (P30CA125123). This work has been supported by NIH K01DK081446 (B.H.), American Cancer Society RSG-13-061-01-TBE (B.H.), NIH R01HD042311 (J.L.P.), Department of Defense BC122115 (Q.F.), and NIH R21AI122418 (Q.F.). NR 58 TC 0 Z9 0 U1 0 U2 0 PU IMPACT JOURNALS LLC PI ALBANY PA 6211 TIPTON HOUSE, STE 6, ALBANY, NY 12203 USA SN 1949-2553 J9 ONCOTARGET JI Oncotarget PD JUL 26 PY 2016 VL 7 IS 30 BP 47891 EP 47903 DI 10.18632/oncotarget.10294 PG 13 WC Oncology; Cell Biology SC Oncology; Cell Biology GA DY8WP UT WOS:000385413000082 PM 27374105 ER PT J AU Singh, JA Yu, SH AF Singh, Jasvinder A. Yu, Shaohua TI Emergency Department and Inpatient Healthcare utilization due to Hypertension SO BMC HEALTH SERVICES RESEARCH LA English DT Article DE Emergency department; Hospitalization; Health care utilization; Charges; Hypertension; Predictors; Hospital discharge; Predictors ID UNITED-STATES; HOSPITALIZATION; BURDEN; RISK AB Background: Hypertension is one of the commonest chronic diseases, yet limited data are available for related health care utilization. Our study objective was to describe the emergency department (ED) and subsequent hospitalization related health care utilization and charges due to hypertension in the U.S. Methods: We used the National ED sample (NEDS) to study hypertension-related utilization and charges. Multivariable-adjusted linear or logistic regression was used to assess hypertension-associated ED and hospitalization outcomes (disposition, length of stay, charges), adjusted for patient demographic, comorbidity and hospital characteristics. Results: There were 0.92, 0.97 and 1.04 million ED visits (0.71-0.77 % of all ED visits) with hypertension as the primary diagnosis in 2009, 2010 and 2012, respectively; 23 % resulted in hospitalization. ED charges were $2.00, $2.27 and $2.86 billion, and for those hospitalized, total charges (ED plus inpatient) were $6.62, $7.09 and $7.94 billion, in 2009, 2010 and 2012, respectively. Older age (50 to 65 years), female sex, metropolitan area residence, South or West U.S. hospital location, private insurance and the presence of congestive heart failure were each associated with higher charges for an ED visit with hypertension as the primary diagnosis. Younger age, metropolitan residence, Medicaid insurance, hospital location in the Northeast and co-existing diabetes, gout, coronary heart disease, chronic obstructive pulmonary disease, hyperlipidemia and osteoarthritis were associated with higher risk, whereas male sex was associated with lower risk of hospitalization after ED visit for hypertension. In 2012, 71.6 % of all patients hospitalized with hypertension as the primary diagnosis were discharged home. Older age, metropolitan residence and most comorbidities were associated with lower odds, whereas male sex, payer other than Medicare, South or West U.S. hospital location were associated with higher odds of discharge to home. Conclusions: Hypertension is associated with significant healthcare burden in the U.S. Future studies should assess strategies to reduce hypertension-associated cost and health care burden. C1 [Singh, Jasvinder A.] Birmingham VA Med Ctr, Med Serv, Birmingham, AL 35233 USA. [Singh, Jasvinder A.; Yu, Shaohua] Univ Alabama Birmingham, Dept Med, Sch Med, Birmingham, AL 35294 USA. [Singh, Jasvinder A.; Yu, Shaohua] Univ Alabama Birmingham, Sch Publ Hlth, Div Epidemiol, Birmingham, AL 35294 USA. [Singh, Jasvinder A.] Mayo Clin, Coll Med, Dept Orthoped Surg, Rochester, MN USA. RP Singh, JA (reprint author), Birmingham VA Med Ctr, Med Serv, Birmingham, AL 35233 USA.; Singh, JA (reprint author), Univ Alabama Birmingham, Dept Med, Sch Med, Birmingham, AL 35294 USA.; Singh, JA (reprint author), Univ Alabama Birmingham, Sch Publ Hlth, Div Epidemiol, Birmingham, AL 35294 USA. EM Jasvinder.md@gmail.com FU Division of Rheumatology at the University of Alabama at Birmingham FX This material is the result of work supported by research funds from the Division of Rheumatology at the University of Alabama at Birmingham and the resources and use of facilities at the Birmingham VA Medical Center, Birmingham, Alabama, USA. The funding body did not play any role in design, in the collection, analysis, and interpretation of data; in the writing of the manuscript; and in the decision to submit the manuscript for publication. NR 17 TC 0 Z9 0 U1 5 U2 5 PU BIOMED CENTRAL LTD PI LONDON PA 236 GRAYS INN RD, FLOOR 6, LONDON WC1X 8HL, ENGLAND SN 1472-6963 J9 BMC HEALTH SERV RES JI BMC Health Serv. Res. PD JUL 26 PY 2016 VL 16 AR 303 DI 10.1186/s12913-016-1563-7 PG 11 WC Health Care Sciences & Services SC Health Care Sciences & Services GA DS2WS UT WOS:000380645200005 PM 27461237 ER PT J AU Winslow, BD Chadderdon, GL Dechmerowski, SJ Jones, DL Kalkstein, S Greene, JL Gehrman, P AF Winslow, Brent D. Chadderdon, George L. Dechmerowski, Sara J. Jones, David L. Kalkstein, Solomon Greene, Jennifer L. Gehrman, Philip TI Development and Clinical Evaluation of an mHealth Application for Stress Management SO FRONTIERS IN PSYCHIATRY LA English DT Article DE stress; electrodermal response; heart rate; mobile applications; wearable devices; cognitive behavioral therapy; telemedicine ID COGNITIVE-BEHAVIORAL THERAPY; DEPRESSION; ANXIETY; METAANALYSIS; DISORDERS; IMPAIRMENT; PREVALENCE; RESPONSES; DROPOUT; CARE AB A large number of individuals experience mental health disorders, with cognitive behavioral therapy (CBT) emerging as a standard practice for reduction in psychiatric symptoms, including stress, anger, anxiety, and depression. However, CBT is associated with significant patient dropout and lacks the means to provide objective data regarding a patient's experience and symptoms between sessions. Emerging wearables and mobile health (mHealth) applications represent an approach that may provide objective data to the patient and provider between CBT sessions. Here, we describe the development of a classifier of real-time physiological stress in a healthy population (n = 35) and apply it in a controlled clinical evaluation for armed forces veterans undergoing CBT for stress and anger management (n = 16). Using cardiovascular and electrodermal inputs from a wearable device, the classifier was able to detect physiological stress in a non-clinical sample with accuracy greater than 90%. In a small clinical sample, patients who used the classifier and an associated mHealth application were less likely to discontinue therapy (p = 0.016, d = 1.34) and significantly improved on measures of stress (p = 0.032, d = 1.61), anxiety (p = 0.050, d = 1.26), and anger (p = 0.046, d = 1.41) compared to controls undergoing CBT alone. Given the large number of individuals that experience mental health disorders and the unmet need for treatment, especially in developing nations, such mHealth approaches have the potential to provide or augment treatment at low cost in the absence of in-person care. C1 [Winslow, Brent D.; Chadderdon, George L.; Dechmerowski, Sara J.] Design Interact Inc, Orlando, FL USA. [Jones, David L.] Quantified Design Solut LLC, Orlando, FL USA. [Kalkstein, Solomon; Greene, Jennifer L.; Gehrman, Philip] Univ Penn, Philadelphia VA Med Ctr, Philadelphia, PA 19104 USA. RP Winslow, BD (reprint author), Design Interact Inc, Orlando, FL USA. EM brent.winslow@designinteractive.net RI Emchi, Karma/Q-1952-2016 FU US Army Medical Research and Materiel Command (USA MRMC) [W81XWH-12-C-0071] FX Portions of the classifier study were reported at the 49th Annual Meeting of the Interservice/Industry Training, Simulation & Education Conference (I/ITSEC), as SD, BW, GC, T. Schmidt-Daly, DJ (2014) Classifying stress in a mobile environment (14.195). This work was funded by the US Army Medical Research and Materiel Command (USA MRMC) grant W81XWH-12-C-0071. NR 50 TC 0 Z9 0 U1 9 U2 19 PU FRONTIERS MEDIA SA PI LAUSANNE PA PO BOX 110, EPFL INNOVATION PARK, BUILDING I, LAUSANNE, 1015, SWITZERLAND SN 1664-0640 J9 FRONT PSYCHIATRY JI Front. Psychiatry PD JUL 26 PY 2016 VL 7 AR 130 DI 10.3389/fpsyt.2016.00130 PG 8 WC Psychiatry SC Psychiatry GA DS1KV UT WOS:000380355400001 PM 27507949 ER PT J AU Peralta, CA McClure, LA Scherzer, R Odden, MC White, CL Shlipak, M Benavente, O Pergola, PE AF Peralta, Carmen A. McClure, Leslie A. Scherzer, Rebecca Odden, Michelle C. White, Carole L. Shlipak, Michael Benavente, Oscar Pergola, Pablo E. TI Response by Peralta et al to Letter Regarding Article, "Effect of Intensive Versus Usual Blood Pressure Control on Kidney Function Among Individuals With Prior Lacunar Stroke: A Post Hoc Analysis of the Secondary Prevention of Small Subcortical Strokes (SPS3) Randomized Trial" SO CIRCULATION LA English DT Letter C1 [Peralta, Carmen A.; Scherzer, Rebecca; Shlipak, Michael] Univ Calif San Francisco, Kidney Hlth Res Collaborat, San Francisco, CA 94143 USA. [Peralta, Carmen A.; Scherzer, Rebecca; Shlipak, Michael] San Francisco VA Med Ctr, San Francisco, CA USA. [McClure, Leslie A.] Univ Alabama Birmingham, Birmingham, AL USA. [Odden, Michelle C.] Oregon State Univ, Corvallis, OR 97331 USA. [White, Carole L.; Pergola, Pablo E.] Univ Texas Hlth Sci Ctr San Antonio, San Antonio, TX 78229 USA. [Benavente, Oscar] Univ British Columbia, Vancouver, BC, Canada. RP Peralta, CA (reprint author), Univ Calif San Francisco, Kidney Hlth Res Collaborat, San Francisco, CA 94143 USA.; Peralta, CA (reprint author), San Francisco VA Med Ctr, San Francisco, CA USA. FU NIA NIH HHS [R01 AG046206] NR 3 TC 0 Z9 0 U1 1 U2 3 PU LIPPINCOTT WILLIAMS & WILKINS PI PHILADELPHIA PA TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA SN 0009-7322 EI 1524-4539 J9 CIRCULATION JI Circulation PD JUL 26 PY 2016 VL 134 IS 4 BP E26 EP E27 DI 10.1161/CIRCULATIONAHA.116.022942 PG 2 WC Cardiac & Cardiovascular Systems; Peripheral Vascular Disease SC Cardiovascular System & Cardiology GA DR8GP UT WOS:000380136700005 PM 27462061 ER PT J AU Bibbins-Domingo, K Grossman, DC Curry, SJ Davidson, KW Ebell, M Epling, JW Garcia, FAR Gillman, MW Kemper, AR Krist, AH Kurth, AE Landefeld, CS Mangione, CM Phillips, WR Phipps, MG Pignone, MP Siu, AL AF Bibbins-Domingo, Kirsten Grossman, David C. Curry, Susan J. Davidson, Karina W. Ebell, Mark Epling, John W., Jr. Garcia, Francisco A. R. Gillman, Matthew W. Kemper, Alex R. Krist, Alex H. Kurth, Ann E. Landefeld, C. Seth Mangione, Carol M. Phillips, William R. Phipps, Maureen G. Pignone, Michael P. Siu, Albert L. CA US Preventive Serv Task Force TI Screening for Skin Cancer US Preventive Services Task Force Recommendation Statement SO JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION LA English DT Review ID MELANOMA; DERMATOLOGISTS; PROGRAM AB IMPORTANCE Basal and squamous cell carcinoma are the most common types of cancer in the United States and represent the vast majority of all cases of skin cancer; however, they rarely result in death or substantial morbidity, whereas melanoma skin cancer has notably higher mortality rates. In 2016, an estimated 76 400 US men and women will develop melanoma and 10 100 will die from the disease. OBJECTIVE To update the 2009 US Preventive Services Task Force (USPSTF) recommendation on screening for skin cancer. EVIDENCE REVIEW The USPSTF reviewed the evidence on the effectiveness of screening for skin cancer with a clinical visual skin examination in reducing skin cancer morbidity and mortality and death from any cause; its potential harms, including any harms resulting from associated diagnostic follow-up; its test characteristics when performed by a primary care clinician vs a dermatologist; and whether its use leads to earlier detection of skin cancer compared with usual care. FINDINGS Evidence to assess the net benefit of screening for skin cancer with a clinical visual skin examination is limited. Direct evidence on the effectiveness of screening in reducing melanoma morbidity and mortality is limited to a single fair-quality ecologic study with important methodological limitations. Information on harms is similarly sparse. The potential for harm clearly exists, including a high rate of unnecessary biopsies, possibly resulting in cosmetic or, more rarely, functional adverse effects, and the risk of overdiagnosis and overtreatment. CONCLUSIONS AND RECOMMENDATION The USPSTF concludes that the current evidence is insufficient to assess the balance of benefits and harms of visual skin examination by a clinician to screen for skin cancer in adults (I statement). C1 [Bibbins-Domingo, Kirsten] Univ Calif San Francisco, San Francisco, CA 94143 USA. [Grossman, David C.] Grp Hlth Res Inst, Seattle, WA USA. [Curry, Susan J.] Univ Iowa, Iowa City, IA USA. [Davidson, Karina W.] Columbia Univ, New York, NY USA. [Ebell, Mark] Univ Georgia, Athens, GA 30602 USA. [Epling, John W., Jr.] SUNY Upstate Med Univ, Syracuse, NY 13210 USA. [Garcia, Francisco A. R.] Pima Cty Dept Hlth, Tucson, AZ USA. [Gillman, Matthew W.] Harvard Med Sch, Boston, MA USA. [Gillman, Matthew W.] Harvard Pilgrim Hlth Care Inst, Boston, MA USA. [Kemper, Alex R.] Duke Univ, Durham, NC USA. [Krist, Alex H.] Fairfax Family Practice Residency, Fairfax, VA USA. [Krist, Alex H.] Virginia Commonwealth Univ, Richmond, VA 23284 USA. [Kurth, Ann E.] Yale Univ, New Haven, CT USA. [Landefeld, C. Seth] Univ Alabama, Tuscaloosa, AL 35487 USA. [Mangione, Carol M.] Univ Calif Los Angeles, Los Angeles, CA USA. Univ Washington, Seattle, WA 98195 USA. Brown Univ, Providence, RI 02912 USA. [Pignone, Michael P.] Univ Texas Austin, Austin, TX 78712 USA. [Siu, Albert L.] Mt Sinai Sch Med, New York, NY USA. [Siu, Albert L.] James J Peters Vet Affairs Med Ctr, Bronx, NY USA. RP Bibbins-Domingo, K (reprint author), Univ Calif San Francisco, San Francisco, CA 94143 USA. EM chair@uspstf.net OI Epling, John W/0000-0001-9445-8669 NR 21 TC 8 Z9 8 U1 0 U2 0 PU AMER MEDICAL ASSOC PI CHICAGO PA 330 N WABASH AVE, STE 39300, CHICAGO, IL 60611-5885 USA SN 0098-7484 EI 1538-3598 J9 JAMA-J AM MED ASSOC JI JAMA-J. Am. Med. Assoc. PD JUL 26 PY 2016 VL 316 IS 4 BP 429 EP 435 DI 10.1001/jama.2016.8465 PG 7 WC Medicine, General & Internal SC General & Internal Medicine GA DR9MV UT WOS:000380221700021 ER PT J AU McMahan, RH Porsche, CE Edwards, MG Rosen, HR AF McMahan, Rachel H. Porsche, Cara E. Edwards, Michael G. Rosen, Hugo R. TI Free Fatty Acids Differentially Downregulate Chemokines in Liver Sinusoidal Endothelial Cells: Insights into Non-Alcoholic Fatty Liver Disease SO PLOS ONE LA English DT Article ID LIPID-ACCUMULATION; INSULIN-RESISTANCE; HEPATIC STEATOSIS; CXC CHEMOKINE; INJURY; MODEL; STEATOHEPATITIS; RECRUITMENT; ACTIVATION; LIPOTOXICITY AB Non-alcoholic fatty liver disease is a prevalent problem throughout the western world. Liver sinusoidal endothelial cells (LSEC) have been shown to play important roles in liver injury and repair, but their role in the underlying pathogenetic mechanisms of non-alcoholic fatty liver disease remains undefined. Here, we evaluated the effects of steatosis on LSEC gene expression in a murine model of non-alcoholic fatty liver disease and an immortalized LSEC line. Using microarray we identified distinct gene expression profiles following exposure to free fatty acids. Gene pathway analysis showed a number of differentially expressed genes including those involved in lipid metabolism and signaling and inflammation. Interestingly, in contrast to hepatocytes, fatty acids led to decreased expression of pro-inflammatory chemokines including CCL2 (MCP-1), CXCL10 and CXCL16 in both primary and LSEC cell lines. Chemokine downregulation translated into a significant inhibition of monocyte migration and LSECs isolated from steatotic livers demonstrated a similar shift towards an antiinflammatory phenotype. Overall, these pathways may represent a compensatory mechanism to reverse the liver damage associated with non-alcoholic fatty liver disease. C1 [McMahan, Rachel H.; Porsche, Cara E.; Rosen, Hugo R.] Univ Colorado Denver, Div Gastroenterol & Hepatol, Dept Med, Aurora, CO 80045 USA. [Edwards, Michael G.] Univ Colorado Denver, Div Pulm Sci & Crit Care Med, Dept Med, Aurora, CO USA. [Rosen, Hugo R.] Univ Colorado Denver, Dept Microbiol & Immunol, Aurora, CO 80045 USA. [Rosen, Hugo R.] Denver Vet Affairs Med Ctr, Denver, CO 80220 USA. RP Rosen, HR (reprint author), Univ Colorado Denver, Div Gastroenterol & Hepatol, Dept Med, Aurora, CO 80045 USA.; Rosen, HR (reprint author), Univ Colorado Denver, Dept Microbiol & Immunol, Aurora, CO 80045 USA.; Rosen, HR (reprint author), Denver Vet Affairs Med Ctr, Denver, CO 80220 USA. EM Hugo.Rosen@ucdenver.edu FU NIH/NIDDK [K01DKO96025]; VA Merit Review Grant FX RHM was funded by NIH/NIDDK K01DKO96025. HRR was funded by a VA Merit Review Grant. The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript. NR 40 TC 2 Z9 2 U1 1 U2 1 PU PUBLIC LIBRARY SCIENCE PI SAN FRANCISCO PA 1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA SN 1932-6203 J9 PLOS ONE JI PLoS One PD JUL 25 PY 2016 VL 11 IS 7 AR e0159217 DI 10.1371/journal.pone.0159217 PG 14 WC Multidisciplinary Sciences SC Science & Technology - Other Topics GA DT5ID UT WOS:000381515200013 PM 27454769 ER PT J AU Carmona-Moran, CA Zavgorodnya, O Penman, AD Kharlampieva, E Bridges, SL Hergenrother, RW Singh, JA Wick, TM AF Carmona-Moran, Carlos A. Zavgorodnya, Oleksandra Penman, Andrew D. Kharlampieva, Eugenia Bridges, S. Louis, Jr. Hergenrother, Robert W. Singh, Jasvinder A. Wick, Timothy M. TI Development of gellan gum containing formulations for transdermal drug delivery: Component evaluation and controlled drug release using temperature responsive nanogels SO INTERNATIONAL JOURNAL OF PHARMACEUTICS LA English DT Article DE Transdermal drug transport; Transdermal formulation development; Diclofenac; Semisolid gel; Hydrogel film; Nanogels; Synthetic membrane ID NONSTEROIDAL ANTIINFLAMMATORY DRUGS; VITRO PERCUTANEOUS PENETRATION; IN-VIVO EVALUATION; DICLOFENAC SODIUM; TOPICAL DELIVERY; PHARMACEUTICAL APPLICATIONS; ISOPROPYL MYRISTATE; PROPYLENE-GLYCOL; RAT SKIN; HYDROGELS AB Enhancing skin permeation is important for development of new transdermal drug delivery formulations. This is particularly relevant for non-steroidal anti-inflammatory drugs (NSAIDs). To address this, semisolid gel and solid hydrogel film formulations containing gellan gum as a gelling agent were developed and the effects of penetration enhancers (dimethyl sulfoxide, isopropyl alcohol and propylene glycol) on transport of the NSAID diclofenac sodium was quantified. A transwell diffusion system was used to accelerate formulation development. After 4 h, diclofenac flux from a superior formulation of the semisolid gel or the solid hydrogel film was 130 +/- 11 mu g/cm(2) h and 108 +/- 7 mu g/cm(2) h, respectively, and significantly greater than that measured for a currently available diclofenac sodium topical gel (30 +/- 4 mu g/cm(2) h, p < 0.05) or solution formulation (44 +/- 6 mu g/cm(2) h, p < 0.05) under identical conditions. Over 24 h diclofenac transport from the solid hydrogel film was greater than that measured for any new or commercial diclofenac formulation. Entrapment of temperature-responsive nanogels within the solid hydrogel film provides temperature-activated prolonged release of diclofenac. Diclofenac transport was minimal at 22 degrees C, when diclofenac is entrapped within temperature-responsive nanogels incorporated into the solid hydrogel film, but increased 6-fold when the temperature was increased to skin surface temperature of 32 degrees C. These results demonstrate the feasibility of the semisolid gel and solid hydrogel film formulations that can include thermo-responsive nanogels for development of transdermal drug formulations with adjustable drug transport kinetics. (C) 2016 Elsevier B.V. All rights reserved. C1 [Carmona-Moran, Carlos A.; Wick, Timothy M.] Univ Alabama Birmingham, Dept Biomed Engn, Birmingham, AL 35294 USA. [Zavgorodnya, Oleksandra; Kharlampieva, Eugenia] Univ Alabama Birmingham, Dept Chem, Birmingham, AL 35294 USA. [Bridges, S. Louis, Jr.; Singh, Jasvinder A.] Univ Alabama Birmingham, Dept Med, Div Clin Immunol & Rheumatol, Birmingham, AL 35294 USA. [Hergenrother, Robert W.] Southern Res, Birmingham, AL USA. [Singh, Jasvinder A.] Birmingham VA Med Ctr, Med Serv, Birmingham, AL USA. [Singh, Jasvinder A.] Mayo Clin, Coll Med, Dept Orthoped Surg, Rochester, MN USA. RP Wick, TM (reprint author), Univ Alabama Birmingham, Sch Engn, 115G Hoehn Engn Bldg,1075 13th St South, Birmingham, AL 35233 USA. EM tmwick@uab.edu OI Wick, Timothy/0000-0001-8922-0939; Zavgorodnya, Oleksandra/0000-0001-8296-6340 FU University of Alabama at Birmingham; Southern Research Institute; NSF CAREER [1350370] FX This research was supported by the University of Alabama at Birmingham and the Southern Research Institute, and by NSF CAREER 1350370 (EK). We thank Dr. Veronika Kozlovskaya (UAB) for SEM imaging and technical assistance. NR 82 TC 2 Z9 2 U1 9 U2 22 PU ELSEVIER SCIENCE BV PI AMSTERDAM PA PO BOX 211, 1000 AE AMSTERDAM, NETHERLANDS SN 0378-5173 EI 1873-3476 J9 INT J PHARMACEUT JI Int. J. Pharm. PD JUL 25 PY 2016 VL 509 IS 1-2 BP 465 EP 476 DI 10.1016/j.ijpharm.2016.05.062 PG 12 WC Pharmacology & Pharmacy SC Pharmacology & Pharmacy GA DQ1GP UT WOS:000378949800048 PM 27260133 ER PT J AU Safdar, N Musuuza, JS Xie, AP Hundt, AS Hall, M Wood, K Carayon, P AF Safdar, Nasia Musuuza, Jackson S. Xie, Anping Hundt, Ann Schoofs Hall, Matthew Wood, Kenneth Carayon, Pascale TI Management of ventilator-associated pneumonia in intensive care units: a mixed methods study assessing barriers and facilitators to guideline adherence SO BMC INFECTIOUS DISEASES LA English DT Article DE Ventilator-associated pneumonia; VAP; Guidelines; Systems Engineering Initiative for Patient Safety; Barriers and facilitators ID CLINICAL-PRACTICE GUIDELINES; HOSPITAL-ACQUIRED PNEUMONIA; CRITICALLY-ILL PATIENTS; ACUTE OTITIS-MEDIA; ANTIBIOTIC-THERAPY; IMPLEMENTATION; PHYSICIANS; IMPACT; MORTALITY; PATTERNS AB Background: Guidelines from the Infectious Diseases Society of America/The American Thoracic Society (IDSA/ATS) provide recommendations for diagnosis and treatment of ventilator-associated pneumonia (VAP). However, the mere presence of guidelines is rarely sufficient to promote widespread adoption and uptake. Using the Systems Engineering Initiative for Patient Safety (SEIPS) model framework, we undertook a study to understand barriers and facilitators to the adoption of the IDSA/ATS guidelines. Methods: We conducted surveys and focus group discussions of different health care providers involved in the management of VAP. The setting was medical-surgical ICUs at a tertiary academic hospital and a large multispecialty rural hospital in Wisconsin, USA. Results: Overall, we found that 55 % of participants indicated that they were aware of the IDSA/ATS guideline. The top ranked barriers to VAP management included: 1) having multiple physician groups managing VAP, 2) variation in VAP management by differing ICU services, 3) physicians and level of training, and 4) renal failure complicating doses of antibiotics. Facilitators to VAP management included presence of multidisciplinary rounds that include nurses, pharmacist and respiratory therapists, and awareness of the IDSA/ATS guideline. This awareness was associated with receiving effective training on management of VAP, keeping up to date on nosocomial infection literature, and belief that performing a bronchoscopy to diagnose VAP would help with expeditious diagnosis of VAP. Conclusions: Findings from our study complement existing studies by identifying perceptions of the many different types of healthcare workers in ICU settings. These findings have implications for antibiotic stewardship teams, clinicians, and organizational leaders. C1 [Safdar, Nasia] William S Middleton Mem Vet Adm Med Ctr, Madison, WI 53705 USA. [Safdar, Nasia] Univ Wisconsin, Sch Med & Publ Hlth, Dept Med, Madison, WI 53706 USA. [Safdar, Nasia] Univ Wisconsin Hosp & Clin, Dept Infect Dis, Madison, WI 53792 USA. [Musuuza, Jackson S.] Univ Wisconsin, Inst Clin & Translat Res, Madison, WI USA. [Xie, Anping] Johns Hopkins Univ, Sch Med, Armstrong Inst Patient Safety & Qual, Baltimore, MD USA. [Hundt, Ann Schoofs; Carayon, Pascale] Univ Wisconsin, Ctr Qual & Prod Improvement, Madison, WI USA. [Hall, Matthew] Marshfield Clin Fdn Med Res & Educ, Dept Infect Med, Marshfield, WI USA. [Wood, Kenneth] Univ Maryland, Sch Med, R Adams Cowley Shock Trauma Ctr, Baltimore, MD 21201 USA. RP Safdar, N (reprint author), William S Middleton Mem Vet Adm Med Ctr, Madison, WI 53705 USA.; Safdar, N (reprint author), Univ Wisconsin, Sch Med & Publ Hlth, Dept Med, Madison, WI 53706 USA. EM ns2@medicine.wisc.edu FU Clinical and Translational Science Award (CTSA) program, through the NIH National Center for Advancing Translational Sciences (NCATS) [UL1TR000427]; United States Department of Veterans Affairs MERIT award FX The project described was supported by the Clinical and Translational Science Award (CTSA) program, through the NIH National Center for Advancing Translational Sciences (NCATS), grant UL1TR000427. NS is supported by a United States Department of Veterans Affairs MERIT award. The content is solely the responsibility of the authors and does not necessarily represent the official views of the NIH or the Department of Veterans Affairs. There are no conflicts of interest for any of the authors. NR 46 TC 2 Z9 2 U1 7 U2 8 PU BIOMED CENTRAL LTD PI LONDON PA 236 GRAYS INN RD, FLOOR 6, LONDON WC1X 8HL, ENGLAND SN 1471-2334 J9 BMC INFECT DIS JI BMC Infect. Dis. PD JUL 22 PY 2016 VL 16 AR 349 DI 10.1186/s12879-016-1665-1 PG 9 WC Infectious Diseases SC Infectious Diseases GA DS7WW UT WOS:000380994700001 PM 27448800 ER PT J AU Sosa, MAG De Gasperi, R Hof, PR Elder, GA AF Sosa, Miguel A. Gama De Gasperi, Rita Hof, Patrick R. Elder, Gregory A. TI Fibroblast growth factor rescues brain endothelial cells lacking presenilin 1 from apoptotic cell death following serum starvation SO SCIENTIFIC REPORTS LA English DT Article ID AMYLOID BETA-PEPTIDE; ALZHEIMERS-DISEASE; PROGENITOR CELLS; PC12 CELLS; ACTIVATION; MICE; SURVIVAL; CATENIN; DIFFERENTIATION; CYTOPROTECTION AB Presenilin 1 (Psen1) is important for vascular brain development and is known to influence cellular stress responses. To understand the role of Psen1 in endothelial stress responses, we investigated the effects of serum withdrawal on wild type (wt) and Psen1-/- embryonic brain endothelial cells. Serum starvation induced apoptosis in Psen1-/- cells but did not affect wt cells. PI3K/AKT signaling was reduced in serum-starved Psen1-/- cells, and this was associated with elevated levels of phospho-p38 consistent with decreased pro-survival AKT signaling in the absence of Psen1. Fibroblast growth factor (FGF1 and FGF2), but not vascular endothelial growth factor (VEGF) rescued Psen1-/- cells from serum starvation induced apoptosis. Inhibition of FGF signaling induced apoptosis in wt cells under serum withdrawal, while blocking gamma-secretase activity had no effect. In the absence of serum, FGF2 immunoreactivity was distributed diffusely in cytoplasmic and nuclear vesicles of wt and Psen1-/- cells, as levels of FGF2 in nuclear and cytosolic fractions were not significantly different. Thus, sensitivity of Psen1-/- cells to serum starvation is not due to lack of FGF synthesis but likely to effects of Psen1 on FGF release onto the cell surface and impaired activation of the PI3K/AKT survival pathway. C1 [Sosa, Miguel A. Gama] James J Peters Dept Vet Affairs Med Ctr, Gen Med Res Serv, Bronx, NY 10468 USA. [Sosa, Miguel A. Gama; De Gasperi, Rita; Elder, Gregory A.] Icahn Sch Med Mt Sinai, Dept Psychiat, New York, NY 10029 USA. [Sosa, Miguel A. Gama; De Gasperi, Rita; Hof, Patrick R.; Elder, Gregory A.] Icahn Sch Med Mt Sinai, Friedman Brain Inst, New York, NY 10029 USA. [De Gasperi, Rita] James J Peters Dept Vet Affairs Med Ctr, Res & Dev Serv, Bronx, NY USA. [Hof, Patrick R.] Icahn Sch Med Mt Sinai, Fishberg Dept Neurosci, New York, NY 10029 USA. [Hof, Patrick R.] Icahn Sch Med Mt Sinai, Dept Geriatr & Palliat Care, New York, NY 10029 USA. [Elder, Gregory A.] James J Peters Dept Vet Affairs Med Ctr, Neurol Serv, Bronx, NY USA. [Elder, Gregory A.] Icahn Sch Med Mt Sinai, Dept Neurol, New York, NY 10029 USA. RP Sosa, MAG (reprint author), James J Peters Dept Vet Affairs Med Ctr, Gen Med Res Serv, Bronx, NY 10468 USA.; Sosa, MAG (reprint author), Icahn Sch Med Mt Sinai, Dept Psychiat, New York, NY 10029 USA.; Sosa, MAG (reprint author), Icahn Sch Med Mt Sinai, Friedman Brain Inst, New York, NY 10029 USA. EM miguel.gama-sosa@mssm.edu FU Department of Veterans Affairs [1I01BX000342-01, 1I01RX000996-01, I21RX002069]; General Medical Research Service of the James J. Peters Department of Veterans Affairs Medical Center FX This work was supported in part by funds from the Department of Veterans Affairs, Awards 1I01BX000342-01, 1I01RX000996-01 and I21RX002069. MAGS was supported in part by the General Medical Research Service of the James J. Peters Department of Veterans Affairs Medical Center. NR 49 TC 0 Z9 0 U1 1 U2 1 PU NATURE PUBLISHING GROUP PI LONDON PA MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND SN 2045-2322 J9 SCI REP-UK JI Sci Rep PD JUL 22 PY 2016 VL 6 AR 30267 DI 10.1038/srep30267 PG 12 WC Multidisciplinary Sciences SC Science & Technology - Other Topics GA DR9OO UT WOS:000380226200001 ER PT J AU Bawadekar, M Gendron-Fitzpatrick, A Rebernick, R Shim, D Warner, TF Nicholas, AP Lundblad, LKA Thompson, PR Shelef, MA AF Bawadekar, Mandar Gendron-Fitzpatrick, Annette Rebernick, Ryan Shim, Daeun Warner, Thomas F. Nicholas, Anthony P. Lundblad, Lennart K. A. Thompson, Paul R. Shelef, Miriam A. TI Tumor necrosis factor alpha, citrullination, and peptidylarginine deiminase 4 in lung and joint inflammation SO ARTHRITIS RESEARCH & THERAPY LA English DT Article DE Rheumatoid arthritis; Citrullination; Peptidylarginine deiminase 4; Lung; TNF-alpha; Experimental arthritis ID POSITIVE RHEUMATOID-ARTHRITIS; SYNOVIAL-FLUID; AUTOIMMUNE ARTHRITIS; DISEASE; MICE; EXPRESSION; MODEL; PROTEIN; ASSOCIATION; SELECTION AB Background: The relationship between lung and joint inflammation in rheumatoid arthritis is poorly understood. Lung inflammation with resultant protein citrullination may trigger anti-citrullinated protein antibodies, inflammation, and arthritis. Alternatively, lung and joint inflammation may be two manifestations of a single underlying pathology. The lung has increased citrullination and TNF-alpha levels are high in rheumatoid arthritis; however, it is unknown if TNF-alpha can induce lung protein citrullination. The citrullinating enzyme peptidylarginine deiminase 4 (PAD4) exacerbates TNF-alpha-induced arthritis, but a role for PAD4 in lung citrullination and TNF-alpha-induced lung inflammation has not been explored. Our aim was to use TNF-alpha-overexpressing mice to clarify the intersection of TNF-alpha, citrullination, PAD4, arthritis, and lung inflammation. Methods: Lung protein citrullination in wild-type mice, mice that overexpress TNF-alpha systemically (TNF+), TNF(+)PAD4(+/+), and TNF(+)PAD4(-/-) mice was quantified by both gel electrophoresis using a citrulline probe and western blot. Hematoxylin and eosin (H&E)-stained lung sections from TNF(+)PAD4(+/+) and TNF(+)PAD4(-/-) mice were scored for lung inflammation. H&E-stained ankle joint sections from mice that overexpress TNF-a only in the lungs were assessed for arthritis. Results: TNF+ mice have increased lung protein citrullination. TNF(+)PAD4(-/-) mice do not have significantly reduced lung protein citrullination, but do have decreased lung inflammation compared to TNF(+)PAD4(+/+) mice. Mice that overexpress TNF-alpha only in the lungs do not develop arthritis. Conclusions: PAD4 exacerbates lung inflammation downstream of TNF-alpha without having a major role in generalized protein citrullination in inflamed lungs. Also, TNF-alpha-induced lung inflammation is not sufficient to drive murine arthritis. C1 [Bawadekar, Mandar; Rebernick, Ryan; Shim, Daeun; Shelef, Miriam A.] Univ Wisconsin, Dept Med, Madison, WI 53706 USA. [Gendron-Fitzpatrick, Annette] Univ Wisconsin, Sch Vet Med, Res Anim Resource Ctr Comparat Pathol Lab, Madison, WI 53706 USA. [Gendron-Fitzpatrick, Annette] Univ Wisconsin, Sch Vet Med, Dept Pathobiol Sci, Madison, WI 53706 USA. [Warner, Thomas F.] Univ Wisconsin, Dept Pathol & Lab Med, Madison, WI USA. [Nicholas, Anthony P.] Univ Alabama Birmingham, Dept Neurol, UAB Stn, Birmingham, AL 35294 USA. [Nicholas, Anthony P.] Univ Alabama Birmingham, Ctr Neurodegenerat & Expt Therapeut, Birmingham, AL USA. [Nicholas, Anthony P.] Birmingham VA Med Ctr, Birmingham, AL USA. [Lundblad, Lennart K. A.] Univ Vermont, Dept Med, Burlington, VT USA. [Thompson, Paul R.] Univ Massachusetts, Sch Med, Dept Biochem, Worcester, MA 01655 USA. [Thompson, Paul R.] Univ Massachusetts, Sch Med, Dept Mol Pharmacol, Worcester, MA USA. [Shelef, Miriam A.] William S Middleton Mem Vet Adm Med Ctr, Madison, WI 53705 USA. RP Shelef, MA (reprint author), Univ Wisconsin, Dept Med, Madison, WI 53706 USA.; Shelef, MA (reprint author), William S Middleton Mem Vet Adm Med Ctr, Madison, WI 53705 USA. EM mshelef@medicine.wisc.edu FU Rheumatology Research Foundation via a Scientist Development Award; National Institutes of Health (NIH) [K08 AR065500]; NIH/National Center for Research Resources (NCRR) [P30 GM103532]; NIH [R01 GM079357] FX Funding for this research was made possible by the Rheumatology Research Foundation via a Scientist Development Award as well as awards from the National Institutes of Health (NIH) K08 AR065500 to MAS, NIH/National Center for Research Resources (NCRR) P30 GM103532 to LKAL, and NIH R01 GM079357 to PRT. NR 45 TC 1 Z9 1 U1 1 U2 4 PU BIOMED CENTRAL LTD PI LONDON PA 236 GRAYS INN RD, FLOOR 6, LONDON WC1X 8HL, ENGLAND SN 1478-6354 EI 1478-6362 J9 ARTHRITIS RES THER JI Arthritis Res. Ther. PD JUL 22 PY 2016 VL 18 AR 173 DI 10.1186/s13075-016-1068-0 PG 9 WC Rheumatology SC Rheumatology GA DR6EW UT WOS:000379996000001 PM 27450561 ER PT J AU Halbert, CH McDonald, J Vadaparampil, S Rice, L Jefferson, M AF Halbert, Chanita Hughes McDonald, Jasmine Vadaparampil, Susan Rice, LaShanta Jefferson, Melanie TI Conducting Precision Medicine Research with African Americans SO PLOS ONE LA English DT Article ID CANCER GENETICS RESEARCH; RESEARCH PARTICIPATION; DIETARY INTERVENTIONS; PHYSICAL-ACTIVITY; PROSTATE-CANCER; INCREASED RISK; RETENTION; RECRUITMENT; INTENTIONS; TRIAL AB Importance Precision medicine is an approach to detecting, treating, and managing disease that is based on individual variation in genetic, environmental, and lifestyle factors. Precision medicine is expected to reduce health disparities, but this will be possible only if studies have adequate representation of racial minorities. Objective It is critical to anticipate the rates at which individuals from diverse populations are likely to participate in precision medicine studies as research initiatives are being developed. We evaluated the likelihood of participating in a clinical study for precision medicine. Design, Setting, Participants Observational study conducted between October 2010 and February 2011 in a national sample of African Americans. Main Outcome Measure Intentions to participate in a government sponsored study that involves providing a biospecimen and generates data that could be shared with other researchers to conduct future studies. Results One third of respondents would participate in a clinical study for precision medicine. Only gender had a significant independent association with participation intentions. Men had a 1.86 (95% CI = 1.11, 3.12, p = 0.02) increased likelihood of participating in a precision medicine study compared to women in the model that included overall barriers and facilitators. In the model with specific participation barriers, distrust was associated with a reduced likelihood of participating in the research described in the vignette (OR = 0.57, 95% CI = 0.34, 0.96, p = 0.04). Conclusion and Relevance African Americans may have low enrollment in PMI research. As PMI research is implemented, extensive efforts will be needed to ensure adequate representation. Additional research is needed to identify optimal ways of ethically describing precision medicine studies to ensure sufficient recruitment of racial minorities. C1 [Halbert, Chanita Hughes; Rice, LaShanta] Med Univ South Carolina, Dept Psychiat & Behav Sci, 171 Ashley Ave, Charleston, SC 29425 USA. [Halbert, Chanita Hughes; Rice, LaShanta] Med Univ South Carolina, Hollings Canc Ctr, Charleston, SC 29425 USA. [Halbert, Chanita Hughes; Rice, LaShanta] Ralph H Johnson Vet Adm Med Ctr, Charleston, SC 29401 USA. [McDonald, Jasmine; Jefferson, Melanie] Columbia Univ, Dept Epidemiol, Mailman Sch Publ Hlth, New York, NY USA. [Vadaparampil, Susan] H Lee Moffitt Canc Ctr & Res Inst, Tampa, FL USA. RP Halbert, CH (reprint author), Med Univ South Carolina, Dept Psychiat & Behav Sci, 171 Ashley Ave, Charleston, SC 29425 USA.; Halbert, CH (reprint author), Med Univ South Carolina, Hollings Canc Ctr, Charleston, SC 29425 USA.; Halbert, CH (reprint author), Ralph H Johnson Vet Adm Med Ctr, Charleston, SC 29401 USA. EM hughesha@musc.edu FU National Human Genome Research Institute [R01HG004346]; American Cancer Society [RSG-11-268-01-CPPB]; National Cancer Institute [UG1CA189848]; National Center for Advancing Translational Science [UL1TR001450] FX This research was supported by National Human Genome Research Institute grant #R01HG004346, grant #RSG-11-268-01-CPPB from the American Cancer Society, grant #UG1CA189848 from the National Cancer Institute, and grant #UL1TR001450 from the National Center for Advancing Translational Science. The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript. NR 30 TC 0 Z9 0 U1 2 U2 2 PU PUBLIC LIBRARY SCIENCE PI SAN FRANCISCO PA 1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA SN 1932-6203 J9 PLOS ONE JI PLoS One PD JUL 21 PY 2016 VL 11 IS 7 AR e0154850 DI 10.1371/journal.pone.0154850 PG 10 WC Multidisciplinary Sciences SC Science & Technology - Other Topics GA DS5CG UT WOS:000380797500003 PM 27441706 ER PT J AU Ren, XY Weisgerber, DW Bischoff, D Lewis, MS Reid, RR He, TC Yamaguchi, DT Miller, TA Harley, BAC Lee, JC AF Ren, Xiaoyan Weisgerber, Daniel W. Bischoff, David Lewis, Michael S. Reid, Russell R. He, Tong-Chuan Yamaguchi, Dean T. Miller, Timothy A. Harley, Brendan A. C. Lee, Justine C. TI Nanoparticulate Mineralized Collagen Scaffolds and BMP-9 Induce a Long-Term Bone Cartilage Construct in Human Mesenchymal Stem Cells SO ADVANCED HEALTHCARE MATERIALS LA English DT Article ID BMP9-INDUCED OSTEOGENIC DIFFERENTIATION; MORPHOGENETIC PROTEIN-9; ACTIVATION; STIMULATION; DELIVERY; P38; REGENERATION; RECEPTORS; SYSTEMS; ERK1/2 AB Engineering the osteochondral junction requires fabrication of a micro-environment that supports both osteogenesis and chondrogenesis. Multiphasic scaffold strategies utilizing a combination of soluble factors and extracellular matrix components are ideally suited for such applications. In this work, the contribution of an osteogenic nanoparticulate mineralized glycosaminoglycan scaffold (MC-GAG) and a dually chondrogenic and osteogenic growth factor, BMP-9, in the differentiation of primary human mesenchymal stem cells (hMSCs) is evaluated. Although 2D cultures demonstrate alkaline phosphatase activity and mineralization of hMSCs induced by BMP-9, MC-GAG scaffolds do not demonstrate significant differences in the collagen I expression, osteopontin expression, or mineralization. Instead, BMP-9 increases expression of collagen II, Sox9, aggrecan (ACAN), and cartilage oligomeric protein. However, the hypertrophic chondrocyte marker, collagen X, is not elevated with BMP-9 treatment. In addition, histologic analyses demonstrate that while BMP-9 does not increase mineralization, BMP-9 treatment results in an increase of sulfated glycosaminoglycans. Thus, the combination of BMP-9 and MC-GAG stimulates chondrocytic and osteogenic differentiation of hMSCs. C1 [Ren, Xiaoyan; Miller, Timothy A.; Lee, Justine C.] Univ Calif Los Angeles, David Geffen Sch Med, Div Plast & Reconstruct Surg, Los Angeles, CA 90095 USA. [Ren, Xiaoyan; Bischoff, David; Yamaguchi, Dean T.; Miller, Timothy A.; Lee, Justine C.] Greater Los Angeles VA Healthcare Syst, Res Serv, Los Angeles, CA 90073 USA. [Weisgerber, Daniel W.; Harley, Brendan A. C.] Univ Illinois, Inst Genom Biol, Dept Chem & Biomol Engn, Urbana, IL 61801 USA. [Lewis, Michael S.] Greater Los Angeles VA Healthcare Syst, Dept Pathol, Los Angeles, CA 90073 USA. [Reid, Russell R.] Univ Chicago, Sect Plast & Reconstruct Surg, Chicago, IL 60637 USA. [He, Tong-Chuan] Univ Chicago, Dept Orthopaed Surg, Chicago, IL 60637 USA. RP Lee, JC (reprint author), Univ Calif Los Angeles, David Geffen Sch Med, Div Plast & Reconstruct Surg, Los Angeles, CA 90095 USA.; Lee, JC (reprint author), Greater Los Angeles VA Healthcare Syst, Res Serv, Los Angeles, CA 90073 USA. EM justine@ucla.edu OI Harley, Brendan/0000-0001-5458-154X FU US Department of Veterans Affairs [IK2 BX002442-01A2, 1I01BX001367-01A2]; Jean Perkins Foundation; Aramont Foundation; Bernard G. Sarnat Endowment for Craniofacial Biology; National Institute of Arthritis and Musculoskeletal and Skin Diseases of the National Institutes of Health [R21 AR063331]; UIUC from National Science Foundation (NSF) [0965918] FX This work was supported by the US Department of Veterans Affairs under award numbers IK2 BX002442-01A2 (JCL) and 1I01BX001367-01A2 (TAM), the Jean Perkins Foundation (JCL), the Aramont Foundation (TAM), and the Bernard G. Sarnat Endowment for Craniofacial Biology (JCL). Research reported in this publication was also supported by the National Institute of Arthritis and Musculoskeletal and Skin Diseases of the National Institutes of Health under award number R21 AR063331 (BACH). The content is solely the responsibility of the authors and does not necessarily represent the official views of the National Institutes of Health. D.W.W. was funded at UIUC from National Science Foundation (NSF) under Grant 0965918 IGERT: Training the Next Generation of Researchers in Cellular & Molecular Mechanics and BioNanotechnology. NR 35 TC 0 Z9 0 U1 10 U2 11 PU WILEY-BLACKWELL PI HOBOKEN PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA SN 2192-2640 EI 2192-2659 J9 ADV HEALTHC MATER JI Adv. Healthc. Mater. PD JUL 20 PY 2016 VL 5 IS 14 BP 1821 EP 1830 DI 10.1002/adhm.201600187 PG 10 WC Engineering, Biomedical; Nanoscience & Nanotechnology; Materials Science, Biomaterials SC Engineering; Science & Technology - Other Topics; Materials Science GA DV2RT UT WOS:000382769400011 PM 27275929 ER PT J AU VanEpps, EM Volpp, KG Halpern, SD AF VanEpps, Eric M. Volpp, Kevin G. Halpern, Scott D. TI A nudge toward participation: Improving clinical trial enrollment with behavioral economics SO SCIENCE TRANSLATIONAL MEDICINE LA English DT Editorial Material AB Interventions informed by behavioral economics can address barriers to patient enrollment in clinical trials and improve recruitment efforts. C1 [VanEpps, Eric M.; Volpp, Kevin G.] Corporal Michael J Crescenz Vet Affairs Med Ct, Ctr Hlth Equity Res & Promot, 3900 Woodland Ave, Philadelphia, PA 19104 USA. [VanEpps, Eric M.; Volpp, Kevin G.; Halpern, Scott D.] Univ Penn, Dept Med Eth & Hlth Policy, 3401 Market St, Philadelphia, PA 19104 USA. [Volpp, Kevin G.; Halpern, Scott D.] Univ Penn, Dept Med, 3400 Spruce St, Philadelphia, PA 19104 USA. [Volpp, Kevin G.] Univ Penn, Dept Hlth Care Management, 3641 Locust Walk, Philadelphia, PA 19104 USA. [Halpern, Scott D.] Univ Penn, Dept Biostat & Epidemiol, 423 Guardian Dr, Philadelphia, PA 19104 USA. RP VanEpps, EM (reprint author), Corporal Michael J Crescenz Vet Affairs Med Ct, Ctr Hlth Equity Res & Promot, 3900 Woodland Ave, Philadelphia, PA 19104 USA.; VanEpps, EM (reprint author), Univ Penn, Dept Med Eth & Hlth Policy, 3401 Market St, Philadelphia, PA 19104 USA. EM vanepps@mail.med.upenn.edu NR 8 TC 0 Z9 0 U1 0 U2 0 PU AMER ASSOC ADVANCEMENT SCIENCE PI WASHINGTON PA 1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA SN 1946-6234 EI 1946-6242 J9 SCI TRANSL MED JI Sci. Transl. Med. PD JUL 20 PY 2016 VL 8 IS 348 AR 348fs13 DI 10.1126/scitranslmed.aaf0946 PG 3 WC Cell Biology; Medicine, Research & Experimental SC Cell Biology; Research & Experimental Medicine GA DR6SC UT WOS:000380030600001 PM 27440726 ER PT J AU Pinilla-Vera, M Xiong, ZY Zhao, YT Zhao, J Donahoe, MP Barge, S Horne, WT Kolls, JK McVerry, BJ Birukova, A Tighe, RM Foster, WM Hollingsworth, J Ray, A Mallampalli, R Ray, P Lee, JS AF Pinilla-Vera, Miguel Xiong, Zeyu Zhao, Yutong Zhao, Jing Donahoe, Michael P. Barge, Suchitra Horne, William T. Kolls, Jay K. McVerry, Bryan J. Birukova, Anastasiya Tighe, Robert M. Foster, W. Michael Hollingsworth, John Ray, Anuradha Mallampalli, Rama Ray, Prabir Lee, Janet S. TI Full Spectrum of LPS Activation in Alveolar Macrophages of Healthy Volunteers by Whole Transcriptomic Profiling SO PLOS ONE LA English DT Article ID OBSTRUCTIVE PULMONARY-DISEASE; BACTERIAL PNEUMONIA; MYCOBACTERIUM-TUBERCULOSIS; ISOPEPTIDASE ACTIVITY; ENDOTOXIN TOLERANCE; SIGNALING PATHWAY; IL-10 PRODUCTION; I INTERFERONS; RECEPTOR; CELLS AB Despite recent advances in understanding macrophage activation, little is known regarding how human alveolar macrophages in health calibrate its transcriptional response to canonical TLR4 activation. In this study, we examined the full spectrum of LPS activation and determined whether the transcriptomic profile of human alveolar macrophages is distinguished by a TIR-domain-containing adapter-inducing interferon-beta (TRIF)-dominant type I interferon signature. Bronchoalveolar lavage macrophages were obtained from healthy volunteers, stimulated in the presence or absence of ultrapure LPS in vitro, and whole transcriptomic profiling was performed by RNA sequencing (RNA-Seq). LPS induced a robust type I interferon transcriptional response and Ingenuity Pathway Analysis predicted interferon regulatory factor (IRF) 7 as the top upstream regulator of 89 known gene targets. Ubiquitin-specific peptidase (USP)-18, a negative regulator of interferon alpha/beta responses, was among the top up-regulated genes in addition to IL10 and USP41, a novel gene with no known biological function but with high sequence homology to USP18. We determined whether IRF-7 and USP-18 can influence downstream macrophage effector cytokine production such as IL-10. We show that IRF-7 siRNA knockdown enhanced LPS-induced IL-10 production in human monocyte-derived macrophages, and USP-18 overexpression attenuated LPS-induced production of IL-10 in RAW264.7 cells. Quantitative PCR confirmed upregulation of USP18, USP41, IL10, and IRF7. An independent cohort confirmed LPS induction of USP41 and IL10 genes. These results suggest that IRF-7 and predicted downstream target USP18, both elements of a type I interferon gene signature identified by RNA-Seq, may serve to fine-tune early cytokine response by calibrating IL-10 production in human alveolar macrophages. C1 [Pinilla-Vera, Miguel; Xiong, Zeyu; Zhao, Yutong; Zhao, Jing; Donahoe, Michael P.; Barge, Suchitra; McVerry, Bryan J.; Ray, Anuradha; Ray, Prabir; Lee, Janet S.] Univ Pittsburgh, Dept Med, Div Pulm Allergy & Crit Care Med, Pittsburgh, PA 15260 USA. [Horne, William T.; Kolls, Jay K.] Univ Pittsburgh, Dept Pediat, Pittsburgh, PA USA. [Birukova, Anastasiya; Tighe, Robert M.; Foster, W. Michael; Hollingsworth, John] Duke Univ, Dept Med, Durham, NC USA. [Hollingsworth, John] Ohio State Univ, Dept Med, Div Pulm & Crit Care Med, Columbus, OH USA. [Mallampalli, Rama] Vet Affairs Pittsburgh Healthcare Syst, Med Specialty Serv Line, Pittsburgh, PA USA. [Zhao, Yutong; Zhao, Jing; Lee, Janet S.] Univ Pittsburgh, Vasc Med Inst, Pittsburgh, PA USA. RP Lee, JS (reprint author), Univ Pittsburgh, Dept Med, Div Pulm Allergy & Crit Care Med, Pittsburgh, PA 15260 USA.; Lee, JS (reprint author), Univ Pittsburgh, Vasc Med Inst, Pittsburgh, PA USA. EM leejs3@upmc.edu OI Tighe, Robert/0000-0002-3465-9861 FU Breathe Pennsylvania; National Institute of Health [R01 HL086884, R21AI119042, K08 HL105537, P01 HL114453]; Flight Attendant Medical Research Institute; Pilot Project Program in Hemostasis and Vascular Biology; Vascular Medicine Institute; Hemophilia Center of Western Pennsylvania; Institute for Transfusion Medicine FX This study was supported by Breathe Pennsylvania (JSL, MPD); National Institute of Health R01 HL086884 and R21AI119042 (JSL), K08 HL105537 (RMT), P01 HL114453 (RKM, PR); Flight Attendant Medical Research Institute (JSL); Pilot Project Program in Hemostasis and Vascular Biology, the Vascular Medicine Institute, the Hemophilia Center of Western Pennsylvania, Institute for Transfusion Medicine (JSL). The funders had no role in study design, data collection, decision to publish, or preparation of the manuscript. NR 59 TC 0 Z9 0 U1 1 U2 3 PU PUBLIC LIBRARY SCIENCE PI SAN FRANCISCO PA 1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA SN 1932-6203 J9 PLOS ONE JI PLoS One PD JUL 19 PY 2016 VL 11 IS 7 AR e0159329 DI 10.1371/journal.pone.0159329 PG 22 WC Multidisciplinary Sciences SC Science & Technology - Other Topics GA DR8TG UT WOS:000380169600047 PM 27434537 ER PT J AU Qaseem, A Kansagara, D Forciea, MA Cooke, M Denberg, TD AF Qaseem, Amir Kansagara, Devan Forciea, Mary Ann Cooke, Molly Denberg, Thomas D. CA Clinical Guidelines Comm Amer TI Management of Chronic Insomnia Disorder in Adults: A Clinical Practice Guideline From the American College of Physicians SO ANNALS OF INTERNAL MEDICINE LA English DT Article ID RANDOMIZED CONTROLLED-TRIAL; COGNITIVE-BEHAVIORAL THERAPY; SELF-HELP TREATMENT; LATE-LIFE INSOMNIA; GENERAL MEDICAL-PRACTICE; OLDER-ADULTS; DOUBLE-BLIND; LONG-TERM; PSYCHOLOGICAL TREATMENT; COMORBID INSOMNIA AB Description: The American College of Physicians (ACP) developed this guideline to present the evidence and provide clinical recommendations on the management of chronic insomnia disorder in adults. Methods: This guideline is based on a systematic review of randomized, controlled trials published in English from 2004 through September 2015. Evaluated outcomes included global outcomes assessed by questionnaires, patient-reported sleep outcomes, and harms. The target audience for this guideline includes all clinicians, and the target patient population includes adults with chronic insomnia disorder. This guideline grades the evidence and recommendations by using the ACP grading system, which is based on the GRADE (Grading of Recommendations Assessment, Development and Evaluation) approach. Recommendation 1: ACP recommends that all adult patients receive cognitive behavioral therapy for insomnia (CBT-I) as the initial treatment for chronic insomnia disorder. (Grade: strong recommendation, moderate-quality evidence) Recommendation 2: ACP recommends that clinicians use a shared decision-making approach, including a discussion of the benefits, harms, and costs of short-term use of medications, to decide whether to add pharmacological therapy in adults with chronic insomnia disorder in whom cognitive behavioral therapy for insomnia (CBT-I) alone was unsuccessful. (Grade: weak recommendation, low-quality evidence) C1 [Qaseem, Amir] Amer Coll Physicians, 190 N Independence Mall West, Philadelphia, PA 19106 USA. [Forciea, Mary Ann] Penn Hlth Syst, 3615 Chestnut St, Philadelphia, PA 19104 USA. [Kansagara, Devan] Portland VA Med Ctr, 3805 NE 34th Ave, Portland, OR 97212 USA. [Cooke, Molly] Univ Calif San Francisco, 550 16th St, San Francisco, CA 94158 USA. [Qaseem, Amir; Denberg, Thomas D.] Caril Clin, POB 13727, Roanoke, VA 24036 USA. RP Qaseem, A (reprint author), Amer Coll Physicians, 190 N Independence Mall West, Philadelphia, PA 19106 USA. EM aqaseem@acponline.org NR 78 TC 24 Z9 24 U1 7 U2 12 PU AMER COLL PHYSICIANS PI PHILADELPHIA PA INDEPENDENCE MALL WEST 6TH AND RACE ST, PHILADELPHIA, PA 19106-1572 USA SN 0003-4819 EI 1539-3704 J9 ANN INTERN MED JI Ann. Intern. Med. PD JUL 19 PY 2016 VL 165 IS 2 BP 125 EP + DI 10.7326/M15-2175 PG 15 WC Medicine, General & Internal SC General & Internal Medicine GA DS2GY UT WOS:000380583100019 PM 27136449 ER PT J AU Radomski, TR Fine, MJ Gellad, WF AF Radomski, Thomas R. Fine, Michael J. Gellad, Walid F. TI Outcome After Admission at Veterans Affairs vs Non-Veterans Affairs Hospitals SO JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION LA English DT Letter ID SYSTEM C1 [Radomski, Thomas R.] Univ Pittsburgh, Sch Med, Div Gen Internal Med, Pittsburgh, PA USA. [Fine, Michael J.; Gellad, Walid F.] VA Pittsburgh Healthcare Syst, Ctr Hlth Equity Res & Promot, Univ Dr,151C, Pittsburgh, PA 15240 USA. RP Radomski, TR (reprint author), VA Pittsburgh Healthcare Syst, Ctr Hlth Equity Res & Promot, Univ Dr,151C, Pittsburgh, PA 15240 USA. EM radomskitr@upmc.edu NR 4 TC 0 Z9 0 U1 1 U2 1 PU AMER MEDICAL ASSOC PI CHICAGO PA 330 N WABASH AVE, STE 39300, CHICAGO, IL 60611-5885 USA SN 0098-7484 EI 1538-3598 J9 JAMA-J AM MED ASSOC JI JAMA-J. Am. Med. Assoc. PD JUL 19 PY 2016 VL 316 IS 3 BP 345 EP 346 DI 10.1001/jama.2016.5391 PG 2 WC Medicine, General & Internal SC General & Internal Medicine GA DR3LN UT WOS:000379804800024 PM 27434448 ER PT J AU Park, LS Tate, JP Sigel, K Rimland, D Crothers, K Gibert, C Rodriguez-Barradas, MC Goetz, MB Bedimo, RJ Brown, ST Justice, AC Dubrow, R AF Park, Lesley S. Tate, Janet P. Sigel, Keith Rimland, David Crothers, Kristina Gibert, Cynthia Rodriguez-Barradas, Maria C. Goetz, Matthew Bidwell Bedimo, Roger J. Brown, Sheldon T. Justice, Amy C. Dubrow, Robert TI Time trends in cancer incidence in persons living with HIV/AIDS in the antiretroviral therapy era: 1997-2012 SO AIDS LA English DT Article DE AIDS; cancer; HIV infections; neoplasms; veterans ID HIV-INFECTED PATIENTS; AIDS-DEFINING CANCERS; FORCE RECOMMENDATION STATEMENT; HUMAN-PAPILLOMAVIRUS VACCINE; UNITED-STATES; NORTH-AMERICA; LUNG-CANCER; ANAL CANCER; HIV-1-INFECTED PATIENTS; CHANGING PATTERNS AB Objective: Utilizing the Veterans Aging Cohort Study, the largest HIV cohort in North America, we conducted one of the few comprehensive comparisons of cancer incidence time trends in HIV-infected (HIV+) versus uninfected persons during the antiretroviral therapy (ART) era. Design: Prospective cohort study. Methods: We followed 44 787 HIV+ and 96 852 demographically matched uninfected persons during 1997-2012. We calculated age-, sex-, and race/ethnicity-standardized incidence rates and incidence rate ratios (IRR, HIV+ versus uninfected) over four calendar periods with incidence rate and IRR period trend P values for cancer groupings and specific cancer types. Results: We observed 3714 incident cancer diagnoses in HIV+ and 5760 in uninfected persons. The HIV+ all-cancer crude incidence rate increased between 1997-2000 and 2009-2012 (P trend = 0.0019). However, after standardization, we observed highly significant HIV+ incidence rate declines for all cancer (25% decline; P trend <0.0001), AIDS-defining cancers (55% decline; P trend <0.0001), nonAIDS-defining cancers (NADC; 15% decline; P trend = 0.0003), and nonvirus-related NADC (20% decline; P trend<0.0001); significant IRRdeclines for all cancer (from 2.0 to 1.6; P trend<0.0001), AIDS-defining cancers (from 19 to 5.5; P trend <0.0001), and nonvirus-related NADC (from 1.4 to 1.2; P trend = 0.049); and borderline significant IRR declines for NADC(from 1.6 to 1.4; P trend = 0.078) and virus-related NADC (from 4.9 to 3.5; P trend = 0.071). Conclusion: Improved HIV care resulting in improved immune function most likely contributed to the HIV+ incidence rate and the IRR declines. Further promotion of early and sustained ART, improved ART regimens, reduction of traditional cancer risk factor (e.g. smoking) prevalence, and evidence-based screening could contribute to future cancer incidence declines among HIV+ persons. Copyright (C) 2016 Wolters Kluwer Health, Inc. All rights reserved. C1 [Park, Lesley S.] Stanford Univ, Sch Med, Stanford, CA 94305 USA. [Tate, Janet P.; Justice, Amy C.] Vet Affairs Connecticut Healthcare Syst, West Haven, CT USA. [Tate, Janet P.; Justice, Amy C.; Dubrow, Robert] Yale Sch Med, New Haven, CT USA. [Sigel, Keith; Brown, Sheldon T.] Icahn Sch Med Mt Sinai, New York, NY 10029 USA. [Rimland, David] Atlanta Vet Affairs Med Ctr, Atlanta, GA USA. [Rimland, David] Emory Univ, Sch Med, Atlanta, GA USA. [Crothers, Kristina] Univ Washington, Sch Med, Seattle, WA USA. [Gibert, Cynthia] Washington DC Vet Affairs Med Ctr, Washington, DC USA. [Gibert, Cynthia] George Washington Univ, Sch Med & Hlth Sci, Washington, DC 20052 USA. [Rodriguez-Barradas, Maria C.] Michael E DeBakey VA Med Ctr, Houston, TX USA. [Rodriguez-Barradas, Maria C.] Baylor Coll Med, Houston, TX 77030 USA. [Goetz, Matthew Bidwell] Vet Affairs Greater Los Angeles Healthcare Syst, Los Angeles, CA USA. [Goetz, Matthew Bidwell] Univ Calif Los Angeles, David Geffen Sch Med, Los Angeles, CA 90095 USA. [Bedimo, Roger J.] Vet Affairs North Texas Healthcare Syst, Dallas, TX USA. [Bedimo, Roger J.] Univ Texas Southwestern Med Ctr, Dallas, TX USA. [Brown, Sheldon T.] James J Peters Vet Affairs Med Ctr, New York, NY USA. [Dubrow, Robert] Yale Sch Publ Hlth, New Haven, CT USA. RP Park, LS (reprint author), Stanford Univ, Sch Med, Ctr Hlth Policy, Ctr Primary Care & Outcomes Res, 117 Encina Commons, Stanford, CA 94305 USA. EM lesley.park@stanford.edu OI Sigel, Keith/0000-0002-4051-4861 FU US Veterans Health Administration; National Institute on Alcohol Abuse and Alcoholism [U01-AA020790, U24-AA020794, U10-AA013566]; National Institute of Mental Health [T32-MH020031, P30-MH062294]; National Institute of Allergy and Infectious Diseases [U01-A1069918]; National Cancer Institute [F31-CA180775, R01-CA165937, R01-CA173754]; National Institute of Diabetes and Digestive and Kidney Diseases of the National Institutes of Health [3T32-DK007217] FX This research was supported by the US Veterans Health Administration and by grants from the National Institute on Alcohol Abuse and Alcoholism (U01-AA020790, U24-AA020794, U10-AA013566), National Institute of Mental Health (T32-MH020031, P30-MH062294), National Institute of Allergy and Infectious Diseases (U01-A1069918), National Cancer Institute (F31-CA180775, R01-CA165937, R01-CA173754), and National Institute of Diabetes and Digestive and Kidney Diseases (3T32-DK007217) of the National Institutes of Health. NR 67 TC 4 Z9 4 U1 2 U2 3 PU LIPPINCOTT WILLIAMS & WILKINS PI PHILADELPHIA PA TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA SN 0269-9370 EI 1473-5571 J9 AIDS JI Aids PD JUL 17 PY 2016 VL 30 IS 11 BP 1795 EP 1806 DI 10.1097/QAD.0000000000001112 PG 12 WC Immunology; Infectious Diseases; Virology SC Immunology; Infectious Diseases; Virology GA DR1KT UT WOS:000379665100014 PM 27064994 ER PT J AU Weygant, N Ge, Y Qu, DF Kaddis, JS Berry, WL May, R Chandrakesan, P Bannerman-Menson, E Vega, KJ Tomasek, JJ Bronze, MS An, GY Houchen, CW AF Weygant, Nathaniel Ge, Yang Qu, Dongfeng Kaddis, John S. Berry, William L. May, Randal Chandrakesan, Parthasarathy Bannerman-Menson, Edwin Vega, Kenneth J. Tomasek, James J. Bronze, Michael S. An, Guangyu Houchen, Courtney W. TI Survival of Patients with Gastrointestinal Cancers Can Be Predicted by a Surrogate microRNA Signature for Cancer Stem-like Cells Marked by DCLK1 Kinase SO CANCER RESEARCH LA English DT Article ID EPITHELIAL-MESENCHYMAL TRANSITION; GASTRIC-CANCER; COLORECTAL-CANCER; TUMOR-GROWTH; TUFT CELLS; DEPENDENT MECHANISM; RADIATION-INJURY; IDENTIFICATION; DOUBLECORTIN; EXPRESSION AB Doublecortin-like kinase 1 (DCLK1) is a gastrointestinal (GI) tuft cell kinase that has been investigated as a biomarker of cancer stem-like cells in colon and pancreatic cancers. However, its utility as a biomarker may be limited in principle by signal instability and dilution in heterogeneous tumors, where the proliferation of diverse tumor cell lineages obscures the direct measurement of DCLK1 activity. To address this issue, we explored the definition of a miRNA signature as a surrogate biomarker for DCLK1 in cancer stem-like cells. Utilizing RNA/miRNA-sequencing datasets from the Cancer Genome Atlas, we identified a surrogate 15-miRNA expression signature for DCLK1 activity across several GI cancers, including colon, pancreatic, and stomach cancers. Notably, Cox regression and Kaplan-Meier analysis demonstrated that this signature could predict the survival of patients with these cancers. Moreover, we identified patient subgroups that predicted the clinical utility of this DCLK1 surrogate biomarker. Our findings greatly strengthen the clinical significance for DCLK1 expression across GI cancers. Further, they provide an initial guidepost toward the development of improved prognostic biomarkers or companion biomarkers for DCLK1-targeted therapies to eradicate cancer stem-like cells in these malignancies. (C)2016 AACR. C1 [Weygant, Nathaniel; Qu, Dongfeng; May, Randal; Chandrakesan, Parthasarathy; Vega, Kenneth J.; Bronze, Michael S.; Houchen, Courtney W.] Univ Oklahoma, Hlth Sci Ctr, Dept Med, Oklahoma City, OK USA. [Ge, Yang; An, Guangyu] Capital Med Univ, Beijing Chao Yang Hosp, Dept Oncol, Beijing, Peoples R China. [Qu, Dongfeng; May, Randal; Chandrakesan, Parthasarathy; Vega, Kenneth J.; Houchen, Courtney W.] US Dept Vet Affairs, Med Ctr, Oklahoma City, OK USA. [Qu, Dongfeng; Chandrakesan, Parthasarathy; Houchen, Courtney W.] Peggy & Charles Stephenson Canc Ctr, Oklahoma City, OK USA. [Kaddis, John S.] City Hope Natl Med Ctr, 1500 E Duarte Rd, Duarte, CA 91010 USA. [Berry, William L.; Tomasek, James J.] Univ Oklahoma, Hlth Sci Ctr, Dept Cell Biol, Oklahoma City, OK USA. [Bannerman-Menson, Edwin; Houchen, Courtney W.] COARE Biotechnol Inc, Oklahoma City, OK USA. RP Houchen, CW (reprint author), 920 Stanton L Young Blvd,WP 1345, Oklahoma City, OK 73104 USA.; An, GY (reprint author), 8 Gongren Tiyuchang Nanlu Rd, Beijing 100020, Peoples R China. EM anguangyu@hotmail.com; courtney-houchen@ouhsc.edu OI Berry, William/0000-0002-1661-5443 FU BLRD VA [I01 BX001952]; NCI NIH HHS [R01 CA182869, R21 CA186175] NR 40 TC 1 Z9 1 U1 2 U2 4 PU AMER ASSOC CANCER RESEARCH PI PHILADELPHIA PA 615 CHESTNUT ST, 17TH FLOOR, PHILADELPHIA, PA 19106-4404 USA SN 0008-5472 EI 1538-7445 J9 CANCER RES JI Cancer Res. PD JUL 15 PY 2016 VL 76 IS 14 BP 4090 EP 4099 DI 10.1158/0008-5472.CAN-16-0029 PG 10 WC Oncology SC Oncology GA DS9NY UT WOS:000381111400008 PM 27287716 ER PT J AU Ebrahimi, R Uberoi, A Treadwell, M Rafie, AHS AF Ebrahimi, Ramin Uberoi, Abhimanyu Treadwell, Michelle Rafie, Amir H. Sadrzadeh TI Effect of Low-Frame Invasive Coronary Angiography on Radiation and Image Quality SO AMERICAN JOURNAL OF CARDIOLOGY LA English DT Article ID IONIZING-RADIATION; CATARACT FORMATION; EXPOSURE; LENS; FLUOROSCOPY; COHORT AB Invasive coronary angiography (ICA) uses harmful x-ray energy. To date, there are no studies evaluating the effect of performing ICA at lower than the standard 15 frames per second (f/s) on radiation dose and image quality. In this study, we investigated the effect of performing IC As at 7.5 f/s as opposed to the standard 15 f/s on radiation exposure and image quality. Thirty-nine patients referred for ICA for clinical indications were assigned to have their ICA performed at 7.5 f/s or 15 f/s in a 2:1 ratio, respectively. All studies were performed by one experienced operator in the same laboratory. Magnification, table height, collimation, number of images, and specific angles for image acquisition were kept constant to account for these variables that also effect radiation. Studies performed at 7.5 f/s had significantly less radiation exposure than those performed at 15 f/s (252.2 mGy vs 433.7 mGy, p < 0.01). In addition, radiation per unit time was also significantly reduced in the 7.5 f/s versus the 15 f/s group (140.0 mGy/min vs 254.7 mGy/min, p < 0.01). Image quality was evaluated by an experienced operator blinded to the goals of the study; all studies were graded as good to excellent. In conclusion, performing ICA at 7.5 f/s versus 15 f/s significantly reduces x-ray exposure without compromising image quality. The results of this single-center study warrant a larger randomized clinical trial. Published by Elsevier Inc. C1 [Ebrahimi, Ramin; Treadwell, Michelle] Vet Affairs Greater Los Angeles Healthcare Syst, Dept Med, Div Cardiol, Los Angeles, CA USA. [Ebrahimi, Ramin] Univ Calif Los Angeles, Dept Med, Div Cardiol, Los Angeles, CA 90024 USA. [Uberoi, Abhimanyu] Cedars Sinai Med Ctr, Dept Med, Div Cardiol, Los Angeles, CA 90048 USA. [Rafie, Amir H. Sadrzadeh] Glendale Heart Inst Med Grp Inc, Dept Med, Div Cardiol, Glendale, CA USA. RP Ebrahimi, R (reprint author), Vet Affairs Greater Los Angeles Healthcare Syst, Dept Med, Div Cardiol, Los Angeles, CA USA.; Ebrahimi, R (reprint author), Univ Calif Los Angeles, Dept Med, Div Cardiol, Los Angeles, CA 90024 USA. EM ebrahimi@ucla.edu NR 13 TC 1 Z9 1 U1 0 U2 1 PU EXCERPTA MEDICA INC-ELSEVIER SCIENCE INC PI BRIDGEWATER PA 685 ROUTE 202-206 STE 3, BRIDGEWATER, NJ 08807 USA SN 0002-9149 EI 1879-1913 J9 AM J CARDIOL JI Am. J. Cardiol. PD JUL 15 PY 2016 VL 118 IS 2 BP 195 EP 197 DI 10.1016/j.amjcard.2016.04.041 PG 3 WC Cardiac & Cardiovascular Systems SC Cardiovascular System & Cardiology GA DR8XA UT WOS:000380180500007 PM 27241835 ER PT J AU Bhatt, SP Soler, X Wang, X Murray, S Anzueto, AR Beaty, TH Boriek, AM Casaburi, R Criner, GJ Diaz, AA Dransfield, MT Curran-Everett, D Galban, CJ Hoffman, EA Hogg, JC Kazerooni, EA Kim, V Kinney, GL Lagstein, A Lynch, DA Make, BJ Martinez, FJ Ramsdell, JW Reddy, R Ross, BD Rossiter, HB Steiner, RM Strand, MJ van Beek, EJR Wan, ES Washko, GR Wells, JM Wendt, CH Wise, RA Silverman, EK Crapo, JD Bowler, RP Han, MLK AF Bhatt, Surya P. Soler, Xavier Wang, Xin Murray, Susan Anzueto, Antonio R. Beaty, Terri H. Boriek, Aladin M. Casaburi, Richard Criner, Gerard J. Diaz, Alejandro A. Dransfield, Mark T. Curran-Everett, Douglas Galban, Craig J. Hoffman, Eric A. Hogg, James C. Kazerooni, Ella A. Kim, Victor Kinney, Gregory L. Lagstein, Amir Lynch, David A. Make, Barry J. Martinez, Fernando J. Ramsdell, Joe W. Reddy, Rishindra Ross, Brian D. Rossiter, Harry B. Steiner, Robert M. Strand, Matthew J. van Beek, Edwin J. R. Wan, Emily S. Washko, George R. Wells, J. Michael Wendt, Chris H. Wise, Robert A. Silverman, Edwin K. Crapo, James D. Bowler, Russell P. Han, MeiLan K. CA COPDGene Investigators TI Association between Functional Small Airway Disease and FEV1 Decline in Chronic Obstructive Pulmonary Disease SO AMERICAN JOURNAL OF RESPIRATORY AND CRITICAL CARE MEDICINE LA English DT Article DE FEV1; lung function; parametric response mapping ID COPD; FLOW; EPIDEMIOLOGY; SPIROMETRY; SMOKERS; TIME; SITE AB Rationale: The small conducting airways are the major site of airflow obstruction in chronic obstructive pulmonary disease and may precede emphysema development. Objectives: We hypothesized a novel computed tomography (CT) biomarker of small airway disease predicts FEV1 decline. Methods: We analyzed 1,508 current and former smokers from COPDGene with linear regression to assess predictors of change in FEV1 (ml/yr) over 5 years. Separate models for subjects without and with airflow obstruction were generated using baseline clinical and physiologic predictors in addition to two novel CT metrics created by parametric response mapping (PRM), a technique pairing inspiratory and expiratory CT images to define emphysema (PRMemph) and functional small airways disease (PRMfSAD), a measure of nonemphysematous air trapping. Measurements and Main Results: Mean (SD) rate of FEV1 decline in ml/yr for GOLD (Global Initiative for Chronic Obstructive Lung Disease) 0-4 was as follows: 41.8 (47.7), 53.8 (57.1), 45.6 (61.1), 31.6 (43.6), and 5.1 (35.8), respectively (trend test for grades 1-4; P < 0.001). In multivariable linear regression, for participants without airflow obstruction, PRMfSAD but not PRMemph was associated with FEV1 decline (P < 0.001). In GOLD 1-4 participants, both PRMfSAD and PRMemph were associated with FEV1 decline (P, 0.001 and P = 0.001, respectively). Based on the model, the proportional contribution of the two CT metrics to FEV1 decline, relative to each other, was 87% versus 13% and 68% versus 32% for PRMfSAD and PRMemph in GOLD 1/2 and 3/4, respectively. Conclusions: CT-assessed functional small airway disease and emphysema are associated with FEV1 decline, but the association with functional small airway disease has greatest importance in mild-to-moderate stage chronic obstructive pulmonary disease where the rate of FEV1 decline is the greatest. C1 [Bhatt, Surya P.; Dransfield, Mark T.; Wells, J. Michael] Univ Alabama Birmingham, Div Pulm Allergy & Crit Care Med, Birmingham, AL USA. [Bhatt, Surya P.; Dransfield, Mark T.; Wells, J. Michael] Univ Alabama Birmingham, UAB Lung Hlth Ctr, Birmingham, AL USA. [Soler, Xavier; Ramsdell, Joe W.] Univ Calif San Diego, Div Pulm Crit Care & Sleep Med, San Diego, CA 92103 USA. [Wang, Xin; Murray, Susan] Univ Michigan, Sch Publ Hlth, Ann Arbor, MI 48109 USA. [Galban, Craig J.; Ross, Brian D.] Univ Michigan, Dept Radiol, Ctr Mol Imaging, Ann Arbor, MI 48109 USA. [Kazerooni, Ella A.] Univ Michigan, Dept Radiol, Ann Arbor, MI 48109 USA. [Lagstein, Amir] Univ Michigan, Dept Pathol, Ann Arbor, MI 48109 USA. [Martinez, Fernando J.; Han, MeiLan K.] Univ Michigan, Div Pulm & Crit Care Med, Ann Arbor, MI 48109 USA. [Reddy, Rishindra] Univ Michigan, Div Thorac Surg, Ann Arbor, MI 48109 USA. [Anzueto, Antonio R.] Univ Texas Hlth Sci Ctr San Antonio, Div Pulm & Crit Care Med, San Antonio, TX 78229 USA. [Anzueto, Antonio R.] South Texas Vet Hlth Care Syst, San Antonio, TX USA. [Beaty, Terri H.] Johns Hopkins Univ, Sch Publ Hlth, Dept Epidemiol, Baltimore, MD 21205 USA. [Wise, Robert A.] Johns Hopkins Univ, Div Pulm & Crit Care Med, Baltimore, MD USA. [Boriek, Aladin M.] Baylor Coll Med, Pulm Crit Care & Sleep Med, Houston, TX 77030 USA. [Casaburi, Richard; Rossiter, Harry B.] Harbor UCLA Med Ctr, Div Pulm & Crit Care Physiol & Med, Torrance, CA 90509 USA. [Anzueto, Antonio R.] Harbor UCLA Med Ctr, Rehabil Clin Trials Ctr, Los Angeles Biomed Res Inst, Torrance, CA 90509 USA. [Criner, Gerard J.; Kim, Victor] Temple Univ Hosp & Med Sch, Pulm & Crit Care Med, Philadelphia, PA 19140 USA. [Steiner, Robert M.] Temple Univ Hosp & Med Sch, Dept Radiol, Philadelphia, PA 19140 USA. [Diaz, Alejandro A.; Washko, George R.] Brigham & Womens Hosp, Div Pulm & Crit Care Med, 75 Francis St, Boston, MA 02115 USA. [Curran-Everett, Douglas; Strand, Matthew J.] Natl Jewish Hlth, Dept Biostat & Bioinformat, Denver, CO USA. [Lynch, David A.] Natl Jewish Hlth, Dept Radiol, Denver, CO USA. [Make, Barry J.; Crapo, James D.; Bowler, Russell P.] Natl Jewish Hlth, Div Pulm Crit Care & Sleep Med, Denver, CO USA. [Curran-Everett, Douglas; Strand, Matthew J.] Univ Colorado, Dept Biostat & Informat, Colorado Sch Publ Hlth, Denver, CO 80202 USA. [Kinney, Gregory L.] Univ Colorado, Dept Epidemiol, Colorado Sch Publ Hlth, Denver, CO 80202 USA. [Hoffman, Eric A.] Univ Iowa, Dept Radiol, Iowa City, IA 52242 USA. [Hoffman, Eric A.] Univ Iowa, Dept Med, Iowa City, IA 52242 USA. [Hoffman, Eric A.] Univ Iowa, Dept Biomed Engn, Iowa City, IA 52242 USA. [Hogg, James C.] Univ British Columbia, Dept Pathol & Lab Med, Vancouver, BC, Canada. [Hogg, James C.] St Pauls Hosp, James Hogg Res Ctr, Vancouver, BC, Canada. [van Beek, Edwin J. R.] Univ Edinburgh, Clin Res Imaging Ctr, Edinburgh, Midlothian, Scotland. [Wan, Emily S.; Silverman, Edwin K.] Harvard Med Sch, Brigham & Womens Hosp, Channing Div Network Med, Boston, MA USA. [Wendt, Chris H.] Univ Minnesota, Pulm Allergy Crit Care & Sleep Med Sect, Minneapolis VAMC, Minneapolis, MN USA. RP Han, MLK (reprint author), Univ Michigan, Div Pulm & Crit Care Med, Ann Arbor, MI 48109 USA. EM mrking@med.umich.edu FU NHLBI [R01 HL089897, R01 HL089856, R01 HL122438, R44 HL118837]; COPD Foundation FX Supported by Award R01 HL089897, R01 HL089856, R01 HL122438, and R44 HL118837 from the NHLBI. The COPDGene project is also supported by the COPD Foundation through contributions made to an Industry Advisory Board composed of AstraZeneca, Boehringer Ingelheim, Novartis, Pfizer, Siemens, Sunovion, and GlaxoSmithKline. NR 22 TC 17 Z9 17 U1 2 U2 7 PU AMER THORACIC SOC PI NEW YORK PA 25 BROADWAY, 18 FL, NEW YORK, NY 10004 USA SN 1073-449X EI 1535-4970 J9 AM J RESP CRIT CARE JI Am. J. Respir. Crit. Care Med. PD JUL 15 PY 2016 VL 194 IS 2 BP 178 EP 184 DI 10.1164/rccm.201511-2219OC PG 7 WC Critical Care Medicine; Respiratory System SC General & Internal Medicine; Respiratory System GA DT7VY UT WOS:000381697500015 PM 26808615 ER PT J AU Pagulayan, KF Temkin, NR Machamer, JE Dikmen, SS AF Pagulayan, Kathleen F. Temkin, Nancy R. Machamer, Joan E. Dikmen, Sureyya S. TI Patterns of Alcohol Use after Traumatic Brain Injury SO JOURNAL OF NEUROTRAUMA LA English DT Article DE alcohol; traumatic brain ID SPINAL-CORD-INJURY; SUBSTANCE-ABUSE; PSYCHIATRIC-DISORDERS; RANDOMIZED-TRIAL; HEAD-INJURY; FOLLOW-UP; DRUG-USE; AXIS-I; REHABILITATION; VALPROATE AB Alcohol misuse and traumatic brain injury (TBI) frequently co-occur. The negative consequences of this interaction are well documented, but the patterns of long-term post-injury alcohol consumption are less clear. This study examined patterns of alcohol use among 170 adults with a history of complicated mild to severe TBI. Participants were recruited from a Level 1 Trauma Center at the time of their injury and completed evaluations at 1 month, 6 months, 12 months, and 3-5 years post-injury. Pre-injury alcohol use was also assessed at the time of the 1-month assessment. A modified Quantity-Frequency Index of alcohol consumption was then calculated for each time point. The results revealed high levels of pre-injury alcohol consumption, followed by a reduction in consumption at 1-month post-injury. A significant increase in consumption was noted by 6 months post-injury, followed by more gradual increases in alcohol consumption at 1 year. Post-injury alcohol consumption was comparable to the general public at 6 months, 12 months, and 3-5 years post-injury. These results suggest that the first 6 months post-injury may be the critical window of opportunity for alcohol intervention. C1 [Pagulayan, Kathleen F.] VA Puget Sound Mental Illness Res Educ & Clin Ctr, Seattle, WA USA. [Pagulayan, Kathleen F.; Dikmen, Sureyya S.] Univ Washington, Dept Psychiat & Behav Med, Seattle, WA 98195 USA. [Temkin, Nancy R.; Machamer, Joan E.; Dikmen, Sureyya S.] Univ Washington, Dept Rehabil Med, Seattle, WA 98195 USA. [Temkin, Nancy R.; Dikmen, Sureyya S.] Univ Washington, Dept Neurol Surg, Seattle, WA 98195 USA. [Temkin, Nancy R.] Univ Washington, Dept Biostat, Seattle, WA 98195 USA. RP Pagulayan, KF (reprint author), VA Puget Sound Hlth Care Syst, 1660 S Columbian Way S-116-MIRECC, Seattle, WA 98108 USA. EM farkat@u.washington.edu FU CSRD VA [IK2 CX000516] NR 41 TC 0 Z9 0 U1 7 U2 9 PU MARY ANN LIEBERT, INC PI NEW ROCHELLE PA 140 HUGUENOT STREET, 3RD FL, NEW ROCHELLE, NY 10801 USA SN 0897-7151 EI 1557-9042 J9 J NEUROTRAUM JI J. Neurotrauma PD JUL 15 PY 2016 VL 33 IS 14 BP 1390 EP 1396 DI 10.1089/neu.2015.4071 PG 7 WC Critical Care Medicine; Clinical Neurology; Neurosciences SC General & Internal Medicine; Neurosciences & Neurology GA DQ5CX UT WOS:000379223100011 PM 26530335 ER PT J AU Sharma, A Sharma, SK Vallakati, A Garg, A Lavie, CJ Mukherjee, D Marmur, JD AF Sharma, Abhishek Sharma, Samin K. Vallakati, Ajay Garg, Akash Lavie, Carl J. Mukherjee, Debabrata Marmur, Jonathan D. TI Duration of dual antiplatelet therapy after various drug-eluting stent implantation SO INTERNATIONAL JOURNAL OF CARDIOLOGY LA English DT Article DE Dual anti-platelet therapy; Drug-eluting stents ID PERCUTANEOUS CORONARY INTERVENTION; RANDOMIZED CONTROLLED-TRIALS; NETWORK METAANALYSIS; THROMBOSIS; TERM; ENDOTHELIALIZATION; MULTICENTER; GUIDELINES; MORTALITY; PAIRWISE AB Objective: To evaluate efficacy and safety of long duration dual anti-platelet therapy i.e., >12 months (L-DAPT) and short duration DAPT i.e., <= 12 months (S-DAPT) after various drug-eluting stent (DES) implantation. Methods: We searched Medline, Embase, and Cochrane Central Register of Controlled Trials (CENTRAL) to identify randomized controlled trials (RCTs) assessing the effect of L-DAPT versus S-DAPT after sirolimus-eluting (Cypher (R)); paclitaxel-eluting stents (Taxus (R)); zotarolimus-eluting (Endeavor (R)) and everolimus-eluting stents (Xience V (R)) implantation. Odds ratio (OR) and 95% confidence intervals (CI) were calculated using random-effects models. Subgroup analyses were performed comparing two second generation DES and for RCTs comparing S-DAPT and L-DAPT. Results: We included six RCTs that randomized 19,012 patients to S-DAPT versus L-DAPT (4638 in first generation DES; 14,374 in second generation DES; 8099 EES; 4876 in ZES). Compared with L-DAPT, S-DAPT was associated with a higher rate of myocardial infarction (MI) and stent thrombosis (ST) after first [2.65 (1.88, 3.73) and 3.85 (2.14-6.93) respectively] and a higher rate of MI after second generation DES [1.33 (1.06, 1.67)]. There were no significant differences in the rates of all cause mortality, cardiovascular (CV) mortality and stroke with L-DAPT and S-DAPT after implantation of first [0.97 (0.52, 1.81); 1.19 (0.52-2.70); and 1.12 (0.36-3.52) respectively] and second generation DES [0.93 (0.69, 1.25); 0.93 (0.63, 1.36); and 0.58 (0.19, 1.75), respectively]. On further analysis of type of second generation DES, S-DAPT continues to show a higher rate of MI and ST after EES implantation [1.54 (1.11, 2.13) and 2.68 (1.20-5.94) respectively]; however there was no significant difference in the rate of MI and ST with S-DAPT and L-DAPT after ZES implantation [1.07 (0.44, 2.61) and 1.11(0.39, 3.13), respectively]. Conclusion: 1) Compared with L-DAPT, S-DAPT was associated with a higher rate of MI without any significant difference in the rate of all cause mortality, CV mortality and stroke after first and second generation DES. 2) Rate of ST was also higher with S-DAPT compared to L-DAPT after first generation DES implantation; however, it was not significantly different after second generation DES. 3) On further subgroup analysis of second generation stent there was no significant difference in the rate of all cause mortality, CV mortality, MI, ST and stroke with S-DAPT and L-DAPT after ZES implantation. S-DAPT may be optimal for newer generation stents particularly ZES. (C) 2016 Elsevier Ireland Ltd. All rights reserved. C1 [Sharma, Abhishek; Marmur, Jonathan D.] Suny Downstate Med Ctr, Div Cardiovasc Med, New York, NY USA. [Sharma, Samin K.] Mt Sinai Med Ctr, Icahn Sch Med Mt Sinai, Inst Heart & Vasc, Dept Cardiovasc Med, New York, NY 10029 USA. [Vallakati, Ajay] Case Western Reserve Univ, Metrohlth Med Ctr, Div Cardiol, Cleveland, OH USA. [Garg, Akash] James J Peters VA Med Ctr, Mt Sinai Sch Med, Dept Med, New York, NY USA. [Lavie, Carl J.] Univ Queensland, John Ochsner Heart & Vasc Inst, Ochsner Clin Sch, Dept Cardiovasc Dis,Sch Med, New Orleans, LA USA. [Mukherjee, Debabrata] Texas Tech Univ, Div Cardiol, El Paso, TX USA. RP Sharma, A (reprint author), Suny Downstate Med Ctr, Div Cardiovasc Med, 450 Clarkson Ave, Brooklyn, NY 11203 USA. EM abhisheksharma4mamc@gmail.com RI Lavie, Carl/A-6014-2011 NR 31 TC 0 Z9 0 U1 0 U2 9 PU ELSEVIER IRELAND LTD PI CLARE PA ELSEVIER HOUSE, BROOKVALE PLAZA, EAST PARK SHANNON, CO, CLARE, 00000, IRELAND SN 0167-5273 EI 1874-1754 J9 INT J CARDIOL JI Int. J. Cardiol. PD JUL 15 PY 2016 VL 215 BP 157 EP 166 DI 10.1016/j.ijcard.2016.04.118 PG 10 WC Cardiac & Cardiovascular Systems SC Cardiovascular System & Cardiology GA DM4DX UT WOS:000376297100040 PM 27116326 ER PT J AU Kalra, A Pokharel, Y Glusenkamp, N Wei, J Kerkar, PG Oetgen, WJ Virani, SS AF Kalra, Ankur Pokharel, Yashashwi Glusenkamp, Nathan Wei, Jessica Kerkar, Prafulla G. Oetgen, William J. Virani, Salim S. CA PINNACLE India Quality Improvement TI Gender disparities in cardiovascular care access and delivery in India: Insights from the American College of Cardiology's PINNACLE India Quality Improvement Program (PIQIP) SO INTERNATIONAL JOURNAL OF CARDIOLOGY LA English DT Article DE Gender disparity; Cardiovascular care; India; Quality improvement; American College of Cardiology ID HEART-DISEASE; DOUBLE BURDEN; WOMEN; MORTALITY; HEALTH; MEN AB Background: Limited data are available to assess whether access to and quality of cardiovascular disease (CVD) care are comparable among men and women in India. We analyzed data from the American College of Cardiology's PINNACLE (Practice Innovation and Clinical Excellence) India Quality Improvement Program (PIQIP) to evaluate gender disparities in CVD care delivery. Methods and results: Between 2011 and 2015, we collected data on performance measures for patients with coronary artery disease (CAD) (n = 14,010), heart failure (HF) (n = 11,965) and atrial fibrillation (AF) (n = 496) in PIQIP, among 17 participating practices. The total number of women was 31,796 (32.0%). Women had fewer total encounters compared to men during the study interval (mean number of encounters = 2.59 vs. 2.82 for women and men, respectively, p <= 0.001). Women were significantly younger (48.9 years vs. 51.5 years, p <= 0.01), but had a higher co-morbidity burden compared to men - hypertension (62.0% vs. 45.6%, p <= 0.01), diabetes (39.4% vs. 35%, p <= 0.01), and hyperlipidemia (3.7% vs. 3.1%, p = 0.19). On the contrary, the guideline-directed medication prescriptions were strikingly lower in women with CAD compared to men - aspirin (38% vs. 50.4%, p <= 0.001), aspirin or thienopyridine combination (46.9% vs. 57.2%, p <= 0.001), and beta-blockers (36.8% vs. 47.8%, p <= 0.001). Similarly, among women with ejection fraction <= 40%, the use of guideline-directed medical therapy was significantly lower compared to men for beta-blockers (30.8% vs. 37.0%, p <= 0.001), angiotensin-converting enzyme inhibitors (ACE-i) or angiotensin receptor blockers (ARBs) (29.3% vs. 34.9%, p <= 0.001), and beta-blockers/ACE-i or ARBs (24.6% vs. 31.0%, p <= 0.001). Among patients with atrial fibrillation and CHADS2 score >= 2, more women were on oral anticoagulation (19.6% vs. 14.6%, p = 0.34), although this was not significantly different, and the overall number of patients with atrial fibrillation was low. Conclusions: Despite a significantly higher co-morbidity burden in women, we found fewer women receiving guideline-directed medical therapy for CVD compared with men. If such disparities are confirmed in the larger Indian population, it is important to find potential causes for, and seek solutions to narrow this gap. Published by Elsevier Ireland Ltd. C1 [Kalra, Ankur] Kalra Hosp SRCNC Sri Ram Cardiothorac & Neurosci, Dept Med, Div Cardiol, New Delhi, India. [Kalra, Ankur] Harvard Univ, Beth Israel Deaconess Med Ctr, Sch Med, Div Intervent Cardiol, Boston, MA 02215 USA. [Kalra, Ankur] Harvard Univ, Sch Med, Safety Qual Informat & Leadership Program, Boston, MA USA. [Pokharel, Yashashwi] Univ Missouri, Dept Cardiovasc Res, St Lukes Mid Amer Heart Inst, Kansas City, MO 64110 USA. [Glusenkamp, Nathan; Wei, Jessica; Oetgen, William J.] Amer Coll Cardiol Fdn, Washington, DC USA. [Kerkar, Prafulla G.] King Edward VII Mem Hosp & Seth GS Med Coll, Bombay, Maharashtra, India. [Virani, Salim S.] Baylor Coll Med, Michael E DeBakey Vet Affairs Med Ctr, Hlth Policy Qual & Informat Program, Hlth Serv Res & Dev Ctr Innovat, Houston, TX 77030 USA. [Virani, Salim S.] Baylor Coll Med, Dept Med, Sect Cardiovasc Res, Houston, TX 77030 USA. RP Virani, SS (reprint author), Michael E DeBakey VA Med Ctr, Hlth Serv Res & Dev 152, 2002 Holcombe Blvd, Houston, TX 77030 USA. EM virani@bcm.edu OI Virani, Salim/0000-0001-9541-6954 FU American College of Cardiology Foundation, Washington, DC; Bristol Myers-Squibb; Pfizer, Inc. FX This work was supported by the American College of Cardiology Foundation, Washington, DC. Bristol Myers-Squibb and Pfizer, Inc. are Founding Sponsors of PIQIP. NR 10 TC 0 Z9 0 U1 1 U2 5 PU ELSEVIER IRELAND LTD PI CLARE PA ELSEVIER HOUSE, BROOKVALE PLAZA, EAST PARK SHANNON, CO, CLARE, 00000, IRELAND SN 0167-5273 EI 1874-1754 J9 INT J CARDIOL JI Int. J. Cardiol. PD JUL 15 PY 2016 VL 215 BP 248 EP 251 DI 10.1016/j.ijcard.2016.04.058 PG 4 WC Cardiac & Cardiovascular Systems SC Cardiovascular System & Cardiology GA DM4DX UT WOS:000376297100057 PM 27128540 ER PT J AU Krishnaswami, A Go, AS Forman, DE Leong, TK Lee, H Maurer, MS McCulloch, CE AF Krishnaswami, Ashok Go, Alan S. Forman, Daniel E. Leong, Thomas K. Lee, Hon Maurer, Mathew S. McCulloch, Charles E. TI Multimorbidity is strongly associated with long-term but not short-term mortality after cardiac valve replacement SO INTERNATIONAL JOURNAL OF CARDIOLOGY LA English DT Article DE Multiple chronic conditions; Multimorbidity; Valvular heart disease; Cardiac valve replacement; Mortality; Proportional hazards models ID HEART-FAILURE; DIALYSIS PATIENTS; OLDER-ADULTS; RISK; DISEASE; SURGERY; COMORBIDITY; SURVIVAL; HEALTH; CARE AB Background: The presence of multimorbidity is known to be related to adverse clinical outcomes. However, its association with mortality in patients undergoing cardiac valve replacement is not known. Methods: Multimorbidity (as a continuous variable) was characterized in adults receiving cardiac valve replacement surgery between 2008 and 2012 within Kaiser Permanente Northern California based on information from health plan electronic health records. Our primary outcome was 3-year all-causemortality after surgery. We used Cox proportional hazards regression to evaluate the independent association of each additional comorbidity with mortality. Results: Among 3686 eligible patients, mean age was 67.9 +/- 13.5 years and median comorbidity burden was 3 (IQR: 2). The presence of most individual comorbidities except hypertension and hyperlipidemia did not occur in isolation. The unadjusted annual incidence (per 100 person-years) of death increased with higher comorbidity burden: <= 1: 4.61 (95% CI: 3.29-6.45), 2-3: 13.7 (95% CI: 11.9-15.8), 4-5: 23.6 (95% CI: 20.6-26.9), and >= 6: 43.4(95% CI: 34.654.4). Advancing age, diabetes mellitus, cerebrovascular accident, heart failure, lung disease, urgent status and use of aldosterone-receptor antagonists were independently associated with an increased risk of mortality. Inmultivariable analyses, each additional comorbidity was significantly associated with an increased risk of long-term (adjusted hazard ratio (HR) 1.30, 95% CI: 1.22-1.39) but not short-term mortality (HR 0.92, 95% CI: 0.80-1.07). Conclusions: Our study demonstrated that multimorbidity in patients undergoing cardiac valve replacement is significantly associated with long-term but not short-term mortality. (C) 2016 Elsevier Ireland Ltd. All rights reserved. C1 [Krishnaswami, Ashok] Kaiser Permanente San Jose Med Ctr, Div Cardiol, San Jose, CA USA. [Go, Alan S.; Leong, Thomas K.] Kaiser Permanente Northern Calif, Div Res, Oakland, CA USA. [Go, Alan S.; McCulloch, Charles E.] Univ Calif San Francisco, Dept Epidemiol & Biostat, San Francisco, CA 94143 USA. [Go, Alan S.] Univ Calif San Francisco, Dept Med, San Francisco, CA USA. [Go, Alan S.] Stanford Univ, Dept Hlth Res & Policy, Stanford, CA 94305 USA. [Forman, Daniel E.] Univ Pittsburgh, Div Geriatr Cardiol, Pittsburgh, PA USA. [Forman, Daniel E.] VA Pittsburgh Healthcare Syst, Ctr Geriatr Res Educ & Clin, Pittsburgh, PA USA. [Lee, Hon] Kaiser Permanente Santa Clara Med Ctr, Dept Cardiovasc Surg, Santa Clara, CA USA. [Maurer, Mathew S.] Columbia Univ, Med Ctr, Div Cardiol, New York, NY USA. RP Krishnaswami, A (reprint author), Kaiser Permanente San Jose Med Ctr, 270 Int Circle,2nd Floor, San Jose, CA 95119 USA. EM ashok.krishnaswami@kp.org FU Kaiser Permanente Northern California Community Benefit grant [KR021350]; NIA grant [P30 AG024827]; VA Office of Rehabilitation Research and Development grant [F0834-R]; Mid-Career Mentoring Award in Geriatric Cardiology from NIA [K24-AG036778-06] FX Dr. Krishnaswami was supported by a Kaiser Permanente Northern California Community Benefit grant (KR021350). The funders had no role in the design and conduct of the study; collection, management, analysis, and interpretation of the data; preparation, review, or approval of themanuscript; and the decision to submit themanuscript for publication. No other disclosures are present.; Dr. Forman is supported in part by NIA grant P30 AG024827 and VA Office of Rehabilitation Research and Development grant F0834-R.; Dr. Maurer is supported by a Mid-Career Mentoring Award in Geriatric Cardiology from NIA (K24-AG036778-06). NR 37 TC 0 Z9 0 U1 0 U2 2 PU ELSEVIER IRELAND LTD PI CLARE PA ELSEVIER HOUSE, BROOKVALE PLAZA, EAST PARK SHANNON, CO, CLARE, 00000, IRELAND SN 0167-5273 EI 1874-1754 J9 INT J CARDIOL JI Int. J. Cardiol. PD JUL 15 PY 2016 VL 215 BP 417 EP 421 DI 10.1016/j.ijcard.2016.04.110 PG 5 WC Cardiac & Cardiovascular Systems SC Cardiovascular System & Cardiology GA DM4DX UT WOS:000376297100091 PM 27131261 ER PT J AU Vidadala, RSR Rivas, KL Ojo, KK HuIverson, MA Zambriski, JA Bruzual, I Schultz, TL Huang, WL Zhang, ZS Scheele, S DeRocher, AE Choi, R Barrett, LK Siddaramaiah, LK Hol, WGJ Fan, EK Merritt, EA Parsons, M Freiberg, G Marsh, K Kempf, DJ Carruthers, VB Isoherranen, N Doggett, JS Van Voorhis, WC Maly, DJ AF Vidadala, Rama Subba Rao Rivas, Kasey L. Ojo, Kayode K. HuIverson, Matthew A. Zambriski, Jennifer A. Bruzual, Igor Schultz, Tracey L. Huang, Wenlin Zhang, Zhongsheng Scheele, Suzanne DeRocher, Amy E. Choi, Ryan Barrett, Lynn K. Siddaramaiah, Latha Kallur Hol, Wim G. J. Fan, Erkang Merritt, Ethan A. Parsons, Marilyn Freiberg, Gail Marsh, Kennan Kempf, Dale J. Carruthers, Vern B. Isoherranen, Nina Doggett, J. Stone Van Voorhis, Wesley C. Maly, Dustin J. TI Development of an Orally Available and Central Nervous System (CNS) Penetrant Toxoplasma gondii Calcium-Dependent Protein Kinase 1 (TgCDPK1) Inhibitor with Minimal Human Ether-a-go-go-Related Gene (hERG) Activity for the Treatment of Toxoplasmosis SO JOURNAL OF MEDICINAL CHEMISTRY LA English DT Article ID SELECTIVE INHIBITORS; C. PARVUM; T. GONDII; IN-VITRO; POTENT; INFECTION; CDPK1; DRUG; TRANSMISSION; DISCOVERY AB New therapies are needed for the treatment of toxoplasmosis, which is a disease caused by the protozoan parasite Toxoplasma gondii. To this end, we previously developed a potent and selective inhibitor (compound 1) of Toxoplasma gondii calcium-dependent protein kinase 1 (TgCDPK1) that possesses antitoxoplasmosis activity in vitro and in vivo. Unfortunately, 1 has potent human ether-a-go-go-related gene (hERG) inhibitory activity, associated with long Q-T syndrome, and consequently presents a cardiotoxicity risk. Here, we describe the identification of an optimized TgCDPK1 inhibitor 32, which does not have a hERG liability and possesses a favorable pharmacokinetic profile in small and large animals. 32 is CNS-penetrant and highly effective in acute and latent mouse models of T. gondii infection, significantly reducing the amount of parasite in the brain, spleen, and peritoneal fluid and reducing brain cysts by >85%. These properties make 32 a promising lead for the development of a new antitoxoplasmosis therapy. C1 [Huang, Wenlin; Zhang, Zhongsheng; Siddaramaiah, Latha Kallur; Hol, Wim G. J.; Fan, Erkang; Merritt, Ethan A.; Maly, Dustin J.] Univ Washington, Dept Biochem, Seattle, WA 98195 USA. [Rivas, Kasey L.; Ojo, Kayode K.; HuIverson, Matthew A.; Choi, Ryan; Barrett, Lynn K.; Van Voorhis, Wesley C.] Univ Washington, Dept Med, Div Allergy & Infect Dis, Seattle, WA 98109 USA. [Rivas, Kasey L.; Ojo, Kayode K.; HuIverson, Matthew A.; Choi, Ryan; Barrett, Lynn K.; Van Voorhis, Wesley C.] Univ Washington, Ctr Emerging & Re Emerging Infect Dis CERID, Seattle, WA 98109 USA. [Vidadala, Rama Subba Rao; Parsons, Marilyn; Maly, Dustin J.] Univ Washington, Dept Chem, Seattle, WA 98195 USA. [Scheele, Suzanne; DeRocher, Amy E.; Parsons, Marilyn] Seattle Biomed Res Inst, Ctr Infect Dis Res, 4 Nickerson St, Seattle, WA 98109 USA. [Parsons, Marilyn; Van Voorhis, Wesley C.] Univ Washington, Dept Global Hlth, Seattle, WA 98195 USA. [Bruzual, Igor; Doggett, J. Stone] Portland VA Med Ctr, Portland, OR 97239 USA. [Zambriski, Jennifer A.] Washington State Univ, Paul G Allen Sch Global Anim Hlth, Coll Vet Med, Pullman, WA 99164 USA. [Schultz, Tracey L.; Carruthers, Vern B.] Univ Michigan, Dept Microbiol & Immunol, Sch Med, Ann Arbor, MI 48109 USA. [Isoherranen, Nina] Univ Washington, Dept Pharmaceut, Seattle, WA 98195 USA. [Freiberg, Gail; Marsh, Kennan; Kempf, Dale J.] AbbVie, N Chicago, IL 60064 USA. RP Maly, DJ (reprint author), Univ Washington, Dept Biochem, Seattle, WA 98195 USA.; Van Voorhis, WC (reprint author), Univ Washington, Dept Med, Div Allergy & Infect Dis, Seattle, WA 98109 USA.; Van Voorhis, WC (reprint author), Univ Washington, Ctr Emerging & Re Emerging Infect Dis CERID, Seattle, WA 98109 USA.; Maly, DJ (reprint author), Univ Washington, Dept Chem, Seattle, WA 98195 USA.; Van Voorhis, WC (reprint author), Univ Washington, Dept Global Hlth, Seattle, WA 98195 USA. EM wesley@uw.edu; maly@chem.washington.edu RI huang, wenlin/H-7572-2016 OI Parsons, Marilyn/0000-0003-3994-8096 FU National Institute of General Medical Sciences, National Institute of Allergy and Infectious Diseases; National Institute of Child Health and Human Development of the National Institutes of Health [R01GM086858, R01AI089441, R01AI111341, R01HD080670]; United States Department of Agriculture [2014-06183]; United States Department of Veterans Affairs Biomedical Laboratory Research and Development [BX002440]; Stanley Medical Research Institute [07R1857]; U.S. Department of Energy Office of Basic Energy Sciences [DE-AC02-76SF00515]; National Institutes of Health [P41GM103393] FX We thank DeAnne Stolarik (AbbVie) and Lance Heinle (AbbVie) for assistance with the dog and monkey PK studies. Research reported in this publication was supported by the National Institute of General Medical Sciences, National Institute of Allergy and Infectious Diseases, and National Institute of Child Health and Human Development of the National Institutes of Health under Awards R01GM086858, R01AI089441, R01AI111341, and R01HD080670. This work was also supported in part by Award 2014-06183 from the United States Department of Agriculture, by Career Development Award BX002440 from the United States Department of Veterans Affairs Biomedical Laboratory Research and Development, and by Award 07R1857 from the Stanley Medical Research Institute. Crystallography performed in support of the work benefitted from remote access to resources at the Stanford Synchrotron Radiation Lightsource supported by the U.S. Department of Energy Office of Basic Energy Sciences under Contract DE-AC02-76SF00515 and by the National Institutes of Health (Grant P41GM103393). The content is solely the responsibility of the authors and does not necessarily represent the official views of the National Institutes of Health. NR 36 TC 8 Z9 8 U1 4 U2 12 PU AMER CHEMICAL SOC PI WASHINGTON PA 1155 16TH ST, NW, WASHINGTON, DC 20036 USA SN 0022-2623 EI 1520-4804 J9 J MED CHEM JI J. Med. Chem. PD JUL 14 PY 2016 VL 59 IS 13 BP 6531 EP 6546 DI 10.1021/acs.jmedchem.6b00760 PG 16 WC Chemistry, Medicinal SC Pharmacology & Pharmacy GA DR6CN UT WOS:000379989800040 PM 27309760 ER PT J AU Fontana, L Cummings, NE Apelo, SIA Neuman, JC Kasza, I Schmidt, BA Cava, E Spelta, F Tosti, V Syed, FA Baar, EL Veronese, N Cottrell, SE Fenske, RJ Bertozzi, B Brar, HK Pietka, T Bullock, AD Figenshau, RS Andriole, GL Merrins, MJ Alexander, CM Kimple, ME Lamming, DW AF Fontana, Luigi Cummings, Nicole E. Apelo, Sebastian I. Arriola Neuman, Joshua C. Kasza, Ildiko Schmidt, Brian A. Cava, Edda Spelta, Francesco Tosti, Valeria Syed, Faizan A. Baar, Emma L. Veronese, Nicola Cottrell, Sara E. Fenske, Rachel J. Bertozzi, Beatrice Brar, Harpreet K. Pietka, Terri Bullock, Arnold D. Figenshau, Robert S. Andriole, Gerald L. Merrins, Matthew J. Alexander, Caroline M. Kimple, Michelle E. Lamming, Dudley W. TI Decreased Consumption of Branched-Chain Amino Acids Improves Metabolic Health SO CELL REPORTS LA English DT Article ID ISLET BETA-CELLS; CALORIC RESTRICTION; INSULIN-RESISTANCE; DIETARY-PROTEIN; LIFE-SPAN; METHIONINE RESTRICTION; GLUCOSE-METABOLISM; ADIPOSE-TISSUE; VISCERAL FAT; MICE AB Protein-restricted (PR), high-carbohydrate diets improve metabolic health in rodents, yet the precise dietary components that are responsible for these effects have not been identified. Furthermore, the applicability of these studies to humans is unclear. Here, we demonstrate in a randomized controlled trial that a moderate PR diet also improves markers of metabolic health in humans. Intriguingly, we find that feeding mice a diet specifically reduced in branched-chain amino acids (BCAAs) is sufficient to improve glucose tolerance and body composition equivalently to a PR diet via metabolically distinct pathways. Our results highlight a critical role for dietary quality at the level of amino acids in the maintenance of metabolic health and suggest that diets specifically reduced in BCAAs, or pharmacological interventions in this pathway, may offer a translatable way to achieve many of the metabolic benefits of a PR diet. C1 [Fontana, Luigi; Cava, Edda; Spelta, Francesco; Tosti, Valeria; Veronese, Nicola; Bertozzi, Beatrice; Pietka, Terri] Washington Univ, Div Geriatr & Nutr Sci, St Louis, MO 63130 USA. [Fontana, Luigi] Univ Brescia, Sch Med, Dept Clin & Expt Sci, I-25121 Brescia, Italy. [Fontana, Luigi] CEINGE Biotecnol Avanzate, I-80145 Naples, Italy. [Cummings, Nicole E.; Apelo, Sebastian I. Arriola; Neuman, Joshua C.; Schmidt, Brian A.; Syed, Faizan A.; Baar, Emma L.; Cottrell, Sara E.; Fenske, Rachel J.; Brar, Harpreet K.; Merrins, Matthew J.; Kimple, Michelle E.; Lamming, Dudley W.] Univ Wisconsin, Dept Med, Madison, WI 53705 USA. [Cummings, Nicole E.; Apelo, Sebastian I. Arriola; Neuman, Joshua C.; Schmidt, Brian A.; Syed, Faizan A.; Baar, Emma L.; Cottrell, Sara E.; Fenske, Rachel J.; Brar, Harpreet K.; Merrins, Matthew J.; Kimple, Michelle E.; Lamming, Dudley W.] William S Middleton Mem Vet Adm Med Ctr, Madison, WI 53705 USA. [Cummings, Nicole E.; Kimple, Michelle E.; Lamming, Dudley W.] Univ Wisconsin, Endocrinol & Reprod Physiol Grad Training Program, Madison, WI 53706 USA. [Neuman, Joshua C.; Fenske, Rachel J.; Kimple, Michelle E.; Lamming, Dudley W.] Univ Wisconsin, Interdisciplinary Grad Program Nutr Sci, Madison, WI 53706 USA. [Kasza, Ildiko; Alexander, Caroline M.] Univ Wisconsin, McArdle Lab Canc Res, Madison, WI 53705 USA. [Cava, Edda] Sapienza Univ Rome, Dept Expt Med, I-00185 Rome, Italy. [Spelta, Francesco; Tosti, Valeria] Univ Verona, Dept Med, I-37129 Verona, Italy. [Veronese, Nicola] Univ Padua, Dept Med, Div Geriatr, I-35122 Padua, Italy. [Cottrell, Sara E.; Lamming, Dudley W.] Univ Wisconsin, Rural & Urban Scholars Community Hlth Program, Madison, WI 53706 USA. [Bullock, Arnold D.; Figenshau, Robert S.; Andriole, Gerald L.] Washington Univ, Sch Med St Louis, Div Urol, St Louis, MO 63110 USA. [Merrins, Matthew J.] Univ Wisconsin, Dept Biomol Chem, Madison, WI 53706 USA. [Kimple, Michelle E.] Univ Wisconsin, Dept Cell & Regenerat Biol, Madison, WI 53705 USA. RP Fontana, L (reprint author), Washington Univ, Div Geriatr & Nutr Sci, St Louis, MO 63130 USA.; Fontana, L (reprint author), Univ Brescia, Sch Med, Dept Clin & Expt Sci, I-25121 Brescia, Italy.; Fontana, L (reprint author), CEINGE Biotecnol Avanzate, I-80145 Naples, Italy.; Lamming, DW (reprint author), Univ Wisconsin, Dept Med, Madison, WI 53705 USA.; Lamming, DW (reprint author), William S Middleton Mem Vet Adm Med Ctr, Madison, WI 53705 USA.; Lamming, DW (reprint author), Univ Wisconsin, Endocrinol & Reprod Physiol Grad Training Program, Madison, WI 53706 USA.; Lamming, DW (reprint author), Univ Wisconsin, Interdisciplinary Grad Program Nutr Sci, Madison, WI 53706 USA.; Lamming, DW (reprint author), Univ Wisconsin, Rural & Urban Scholars Community Hlth Program, Madison, WI 53706 USA. EM lfontana@dom.wustl.edu; dlamming@medicine.wisc.edu OI Lamming, Dudley/0000-0002-0079-4467 FU NIH/National Institute on Aging [K99/R00, AG041765]; Wisconsin Partnership Program; Glenn Foundation Award for Research in the Biological Mechanisms of Aging; UW-Madison School of Medicine and Public Health; UW-Madison Department of Medicine; American Federation for Aging Research; Bakewell Foundation; Longer Life Foundation (an RGA/Washington University Partnership); National Center for Research Resources [UL1 RR024992]; American Diabetes Association [1-14-BS-115, 1-16-IBS-212, 1-16-PMF-001]; NIH/NIDDK [R01 DK102598, K01 DK101683]; UW Institute on Aging (NIA) [T32 AG000213]; McArdle Departmental Funds; Rural and Urban Scholars in Community Health Program FX We would like to thank all the members of the D.W.L., L.F., C.M.A., M.E.K., and M.J.M. labs for their assistance and insight, and the Davis lab for their continual support. We would like to thank Dena Cohen for advice and consultation, Tina Herfel (Envigo) for assistance with the formulation of the amino-acid-defined diets, and the reviewers of this manuscript, who greatly aided us with their suggestions. We thank Kathleen Obert, MS, RD, LD for the photograph of a sample dinner used in the slider image accompanying this manuscript and Clint Thayer for assistance with preparation of the slider image. The D.W.L. lab is supported by a K99/R00 Pathway to Independence Award to D.W.L. from the NIH/National Institute on Aging (AG041765), a New Investigator Program Award from the Wisconsin Partnership Program, and a Glenn Foundation Award for Research in the Biological Mechanisms of Aging, as well as startup funds from the UW-Madison School of Medicine and Public Health and the UW-Madison Department of Medicine. This research was conducted while D.W.L. was an AFAR Research Grant recipient from the American Federation for Aging Research. The L.F. lab is supported by grants from the Bakewell Foundation, the Longer Life Foundation (an RGA/Washington University Partnership), and the National Center for Research Resources (UL1 RR024992). This work was also supported by grants from the American Diabetes Association (1-14-BS-115) and the NIH/NIDDK (R01 DK102598) to M.E.K. The M.J.M. lab is supported in part by a Research Scientist Development Award from the NIH/NIDDK (K01 DK101683) and an Innovative Basic Science Award from the American Diabetes Association (1-16-IBS-212) to M.J.M. S.I.A.A. is supported in part by a fellowship from the American Diabetes Association (1-16-PMF-001). J.C.N. is supported in part by a training grant from the UW Institute on Aging (NIA T32 AG000213). I.K. is supported in part by McArdle Departmental Funds. S.E.C. was supported by the Rural and Urban Scholars in Community Health Program. This work was supported using facilities and resources from the William S. Middleton Memorial Veterans Hospital. This work does not represent the views of the Department of Veterans Affairs or the United States Government. NR 47 TC 2 Z9 2 U1 8 U2 13 PU CELL PRESS PI CAMBRIDGE PA 600 TECHNOLOGY SQUARE, 5TH FLOOR, CAMBRIDGE, MA 02139 USA SN 2211-1247 J9 CELL REP JI Cell Reports PD JUL 12 PY 2016 VL 16 IS 2 BP 520 EP 530 DI 10.1016/j.celrep.2016.05.092 PG 11 WC Cell Biology SC Cell Biology GA DS0CG UT WOS:000380262300022 PM 27346343 ER PT J AU Joseph, TT Mincer, JS AF Joseph, Thomas T. Mincer, Joshua S. TI Common Internal Allosteric Network Links Anesthetic Binding Sites in a Pentameric Ligand-Gated Ion Channel SO PLOS ONE LA English DT Article ID GENERAL-ANESTHETICS; TRANSMEMBRANE DOMAIN; DYNAMICS; ACETYLCHOLINE; PROPOFOL; KETAMINE; RECEPTOR; MODULATION; MECHANISMS; SIMULATION AB General anesthetics bind reversibly to ion channels, modifying their global conformational distributions, but the underlying atomic mechanisms are not completely known. We examine this issue by way of the model protein Gloeobacter violaceous ligand-gated ion channel (GLIC) using computational molecular dynamics, with a coarse-grained model to enhance sampling. We find that in flooding simulations, both propofol and a generic particle localize to the crystallographic transmembrane anesthetic binding region, and that propofol also localizes to an extracellular region shared with the crystallographic ketamine binding site. Subsequent simulations to probe these binding modes in greater detail demonstrate that ligand binding induces structural asymmetry in GLIC. Consequently, we employ residue interaction correlation analysis to describe the internal allosteric network underlying the coupling of ligand and distant effector sites necessary for conformational change. Overall, the results suggest that the same allosteric network may underlie the actions of various anesthetics, regardless of binding site. C1 [Joseph, Thomas T.; Mincer, Joshua S.] Icahn Sch Med Mt Sinai, Dept Anesthesiol, New York, NY 10029 USA. [Mincer, Joshua S.] James J Peters Vet Affairs Med Ctr, Bronx, NY USA. RP Mincer, JS (reprint author), Icahn Sch Med Mt Sinai, Dept Anesthesiol, New York, NY 10029 USA.; Mincer, JS (reprint author), James J Peters Vet Affairs Med Ctr, Bronx, NY USA. EM joshua.mincer@mountsinai.org RI Mincer, Joshua/B-4785-2008 OI Mincer, Joshua/0000-0002-2482-3154 FU Eliasberg Clinical Scientist Training Program of the Department of Anesthesiology at Icahn School of Medicine at Mount Sinai; National Science Foundation's XSEDE program [TG-MCB140093]; Department of Scientific Computing at the Icahn School of Medicine at Mount Sinai FX Support to T.T.J. is acknowledged from the Eliasberg Clinical Scientist Training Program of the Department of Anesthesiology at Icahn School of Medicine at Mount Sinai. Computational resources on the Stampede computer cluster at the Texas Advanced Computing Center, University of Texas, were supplied through the National Science Foundation's XSEDE program (allocation TG-MCB140093). This work was supported in part through the computational resources and staff expertise provided by the Department of Scientific Computing at the Icahn School of Medicine at Mount Sinai. The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript. NR 43 TC 0 Z9 0 U1 0 U2 4 PU PUBLIC LIBRARY SCIENCE PI SAN FRANCISCO PA 1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA SN 1932-6203 J9 PLOS ONE JI PLoS One PD JUL 12 PY 2016 VL 11 IS 7 AR e0158795 DI 10.1371/journal.pone.0158795 PG 20 WC Multidisciplinary Sciences SC Science & Technology - Other Topics GA DQ9CO UT WOS:000379508200015 PM 27403526 ER PT J AU Lee, JS Giesler, DL Fine, MJ AF Lee, Jonathan S. Giesler, Daniel L. Fine, Michael J. TI Management of Community-Acquired Pneumonia Reply SO JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION LA English DT Letter C1 [Lee, Jonathan S.] Univ Calif San Francisco, Div Gen Internal Med, San Francisco, CA 94143 USA. [Giesler, Daniel L.] Univ Pittsburgh, Sch Med, Div Gen Internal Med, Pittsburgh, PA USA. [Fine, Michael J.] Vet Affairs Pittsburgh Healthcare Syst, Ctr Hlth Equ Res & Promot, Univ Dr 151C,Bldg 30, Pittsburgh, PA 15240 USA. RP Fine, MJ (reprint author), Vet Affairs Pittsburgh Healthcare Syst, Ctr Hlth Equ Res & Promot, Univ Dr 151C,Bldg 30, Pittsburgh, PA 15240 USA. EM michael.fine@va.gov NR 2 TC 0 Z9 0 U1 0 U2 0 PU AMER MEDICAL ASSOC PI CHICAGO PA 330 N WABASH AVE, STE 39300, CHICAGO, IL 60611-5885 USA SN 0098-7484 EI 1538-3598 J9 JAMA-J AM MED ASSOC JI JAMA-J. Am. Med. Assoc. PD JUL 12 PY 2016 VL 316 IS 2 BP 222 EP 223 DI 10.1001/jama.2016.5028 PG 2 WC Medicine, General & Internal SC General & Internal Medicine GA DQ9CW UT WOS:000379509000023 PM 27404195 ER PT J AU Singhal, S Bhojnagarwala, PS O'Brien, S Moon, EK Garfall, AL Rao, AS Quatromoni, JG Stephen, TL Litzky, L Deshpande, C Feldman, MD Hancock, WW Conejo-Garcia, JR Albelda, SM Eruslanov, EB AF Singhal, Sunil Bhojnagarwala, Pratik S. O'Brien, Shaun Moon, Edmund K. Garfall, Alfred L. Rao, Abhishek S. Quatromoni, Jon G. Stephen, Tom Li Litzky, Leslie Deshpande, Charuhas Feldman, Michael D. Hancock, Wayne W. Conejo-Garcia, Jose R. Albelda, Steven M. Eruslanov, Evgeniy B. TI Origin and Role of a Subset of Tumor-Associated Neutrophils with Antigen-Presenting Cell Features in Early-Stage Human Lung Cancer SO CANCER CELL LA English DT Article ID POLYMORPHONUCLEAR NEUTROPHILS; CLASS-II; T-CELLS; INDUCTION; GROWTH; TRANSDIFFERENTIATION; DIFFERENTIATION; PROLIFERATION; ACTIVATION; NY-ESO-1 AB Based on studies in mouse tumor models, granulocytes appear to play a tumor-promoting role. However, there are limited data about the phenotype and function of tumor-associated neutrophils (TANs) in humans. Here, we identify a subset of TANs that exhibited characteristics of both neutrophils and antigen-presenting cells (APCs) in early-stage human lung cancer. These APC-like "hybrid neutrophils," which originate from CD11b(+)CD15(hi)CD10(-)CD16(low) immature progenitors, are able to cross-present antigens, as well as trigger and augment anti-tumor T cell responses. Interferon-g and granulocyte-macrophage colony-stimulating factor are requisite factors in the tumor that, working through the Ikaros transcription factor, synergistically exert their APC-promoting effects on the progenitors. Overall, these data demonstrate the existence of a specialized TAN subset with anti-tumor capabilities in human cancer. C1 [Singhal, Sunil; Bhojnagarwala, Pratik S.; Rao, Abhishek S.; Quatromoni, Jon G.; Eruslanov, Evgeniy B.] Univ Penn, Perelman Sch Med, Dept Surg, Div Thorac Surg, Philadelphia, PA 19104 USA. [O'Brien, Shaun; Moon, Edmund K.; Albelda, Steven M.] Univ Penn, Perelman Sch Med, Div Pulm Allergy & Crit Care, Dept Med, Philadelphia, PA 19104 USA. [Garfall, Alfred L.] Univ Penn, Perelman Sch Med, Div Hematol Oncol, Dept Med, Philadelphia, PA 19104 USA. [Litzky, Leslie; Deshpande, Charuhas; Feldman, Michael D.; Hancock, Wayne W.] Univ Penn, Perelman Sch Med, Dept Pathol & Lab Med, Philadelphia, PA 19104 USA. [Singhal, Sunil] Philadelphia VA Med Ctr, Div Thorac Surg, Dept Surg, Philadelphia, PA 19104 USA. [Stephen, Tom Li; Conejo-Garcia, Jose R.] Wistar Inst Anat & Biol, Tumor Microenvironm & Metastasis Program, 3601 Spruce St, Philadelphia, PA 19104 USA. [Hancock, Wayne W.] Childrens Hosp Philadelphia, Dept Pathol & Lab Med, Philadelphia, PA 19104 USA. RP Eruslanov, EB (reprint author), Univ Penn, Perelman Sch Med, Dept Surg, Div Thorac Surg, Philadelphia, PA 19104 USA. EM evgeniy.eruslanov@uphs.upenn.edu FU Department of Defense [LC140199]; NIH [RO1 CA187392-01A1, R01 CA193556, K12CA076931]; Lung Cancer Translation Center of Excellence of the Abramson Cancer Center at the University of Pennsylvania FX This work was supported by the Department of Defense (LC140199 to E.E.), NIH (RO1 CA187392-01A1 to E.E.), NIH (R01 CA193556 to S.S.), NIH (K12CA076931 to A.G.), and the Lung Cancer Translation Center of Excellence of the Abramson Cancer Center at the University of Pennsylvania. NR 38 TC 11 Z9 12 U1 9 U2 15 PU CELL PRESS PI CAMBRIDGE PA 600 TECHNOLOGY SQUARE, 5TH FLOOR, CAMBRIDGE, MA 02139 USA SN 1535-6108 EI 1878-3686 J9 CANCER CELL JI Cancer Cell PD JUL 11 PY 2016 VL 30 IS 1 BP 120 EP 135 DI 10.1016/j.ccell.2016.06.001 PG 16 WC Oncology; Cell Biology SC Oncology; Cell Biology GA DR7JY UT WOS:000380077100016 PM 27374224 ER PT J AU Das, F Dey, N Bera, A Kasinath, BS Ghosh-Choudhury, N Choudhury, GG AF Das, Falguni Dey, Nirmalya Bera, Amit Kasinath, Balakuntalam S. Ghosh-Choudhury, Nandini Choudhury, Goutam Ghosh TI MicroRNA-214 Reduces Insulin-like Growth Factor-1 (IGF-1) Receptor Expression and Downstream mTORC1 Signaling in Renal Carcinoma Cells SO JOURNAL OF BIOLOGICAL CHEMISTRY LA English DT Article DE Akt PKB; cancer; cell signaling; microRNA (miRNA); mTOR complex (mTORC) ID PHASE-III TRIAL; MAMMALIAN TARGET; CLEAR-CELL; MESSENGER-RNA; TRANSLATION INITIATION; TUMOR PROGRESSION; PROMOTER ACTIVITY; MESANGIAL CELLS; CANCER; RAPAMYCIN AB Elevated IGF-1/insulin-like growth factor-1 receptor (IGF-1R) autocrine/paracrine signaling in patients with renal cell carcinoma is associated with poor prognosis of the disease independent of their von Hippel-Lindau (VHL) status. Increased expression of IGF-1R in renal cancer cells correlates with their potency of tumor development and progression. The mechanism by which expression of IGF-1R is increased in renal carcinoma is not known. We report that VHL-deficient and VHL-positive renal cancer cells possess significantly decreased levels of mature, pre-, and pri-miR-214 than normal proximal tubular epithelial cells. We identified an miR-214 recognition element in the 3UTR of IGF-1R mRNA and confirmed its responsiveness to miR-214. Overexpression of miR-214 decreased the IGF-1R protein levels, resulting in the inhibition of Akt kinase activity in both types of renal cancer cells. IGF-1 provoked phosphorylation and inactivation of PRAS40 in an Akt-dependent manner, leading to the activation of mTORC1 signal transduction to increase phosphorylation of S6 kinase and 4EBP-1. Phosphorylation-deficient mutants of PRAS40 and 4EBP-1 significantly inhibited IGF-1R-driven proliferation of renal cancer cells. Expression of miR-214 suppressed IGF-1R-induced phosphorylation of PRAS40, S6 kinase, and 4EBP-1, indicating inhibition of mTORC1 activity. Finally, miR-214 significantly blocked IGF-1R-forced renal cancer cell proliferation, which was reversed by expression of 3UTR-less IGF-1R and constitutively active mTORC1. Together, our results identify a reciprocal regulation of IGF-1R levels and miR-214 expression in renal cancer cells independent of VHL status. Our data provide evidence for a novel mechanism for IGF-1R-driven renal cancer cell proliferation involving miR-214 and mTORC1. C1 [Kasinath, Balakuntalam S.; Ghosh-Choudhury, Nandini; Choudhury, Goutam Ghosh] South Texas Vet Hlth Care Syst, Vet Affairs Res & Geriatr Res, San Antonio, TX 78229 USA. [Choudhury, Goutam Ghosh] South Texas Vet Hlth Care Syst, Educ & Clin Ctr, San Antonio, TX 78229 USA. [Das, Falguni; Dey, Nirmalya; Bera, Amit; Kasinath, Balakuntalam S.; Choudhury, Goutam Ghosh] Univ Texas Hlth Sci Ctr San Antonio, Dept Med, San Antonio, TX 78229 USA. [Ghosh-Choudhury, Nandini] Univ Texas Hlth Sci Ctr San Antonio, Dept Pathol, San Antonio, TX 78229 USA. RP Choudhury, GG (reprint author), South Texas Vet Hlth Care Syst, Vet Affairs Res & Geriatr Res, San Antonio, TX 78229 USA.; Choudhury, GG (reprint author), South Texas Vet Hlth Care Syst, Educ & Clin Ctr, San Antonio, TX 78229 USA.; Choudhury, GG (reprint author), Univ Texas Hlth Sci Ctr San Antonio, Dept Med, San Antonio, TX 78229 USA. EM choudhuryg@uthscsa.edu FU Veterans Affairs Research Service Merit Review Grant [2 I01 BX000926]; National Institutes of Health [RO1 DK50190]; Veterans Affairs Merit Review Grant [5I01BX001340, 5I01BX000150]; Veterans Affairs Senior Research Career Scientist Award FX This work was supported in part by the Veterans Affairs Research Service Merit Review Grant 2 I01 BX000926 and National Institutes of Health Grant RO1 DK50190 (to G. G. C.). The authors declare that they have no conflicts of interest with the contents of this article. The content is solely the responsibility of the authors and does not necessarily represent the official views of the National Institutes of Health.; Supported by Veterans Affairs Merit Review Grant 5I01BX001340.; Supported by Veterans Affairs Merit Review Grant 5I01BX000150.; Recipient of a Veterans Affairs Senior Research Career Scientist Award. To whom correspondence should be addressed. E-mail: choudhuryg@uthscsa.edu. NR 91 TC 2 Z9 2 U1 3 U2 4 PU AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC PI BETHESDA PA 9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA SN 0021-9258 EI 1083-351X J9 J BIOL CHEM JI J. Biol. Chem. PD JUL 8 PY 2016 VL 291 IS 28 BP 14662 EP 14676 DI 10.1074/jbc.M115.694331 PG 15 WC Biochemistry & Molecular Biology SC Biochemistry & Molecular Biology GA DS1OV UT WOS:000380366700021 PM 27226530 ER PT J AU Shergill, AK Farraye, FA AF Shergill, Amandeep K. Farraye, Francis A. TI Endoscopic evaluation for colon cancer and dysplasia in patients with inflammatory bowel disease SO TECHNIQUES IN GASTROINTESTINAL ENDOSCOPY LA English DT Article DE Inflammatory bowel disease; Dysplasia; Colon cancer; Surveillance; Image-enhanced endoscopy; Chromoendoscopy ID CONFOCAL LASER ENDOMICROSCOPY; RANDOMIZED CONTROLLED-TRIAL; ADENOMA DETECTION RATE; WHITE-LIGHT ENDOSCOPY; ULCERATIVE-COLITIS; COLORECTAL-CANCER; SURVEILLANCE COLONOSCOPY; IN-VIVO; CONVENTIONAL COLONOSCOPY; HIGH-DEFINITION AB Certain patients with inflammatory bowel disease (IBD) have an increased risk of developing colorectal cancer, and surveillance is recommended to detect dysplasia and early neoplasia. Endoscopic techniques that screen large mucosal surface areas for potential areas of interest that have been studied in IBD surveillance include dye-based surface chromoendoscopy with methylene blue or indigo carmine, dye-less chromoendoscopy including narrow-band imaging, i-scan, Fujinon intelligent chromoendoscopy, and autofluorescence imaging. Literature to date supports the use of surface chromoendoscopy with either methylene blue or indigo carmine to maximize dysplasia detection. Characterization of detected lesions may be further enhanced with optical biopsy technology, including confocal laser endomicroscopy and endocystoscopy, that allows in vivo histologic diagnosis that may guide both diagnosis and therapy of detected dysplastic lesions. Current and future endoscopic approaches for optimizing screening and surveillance of colon cancer and dysplasia in patients with IBD are reviewed. C1 [Shergill, Amandeep K.] Univ CA, San Francisco VA Med Ctr, Sect Gastroenterol, San Francisco, CA USA. [Farraye, Francis A.] Boston Med Ctr, Sect Gastroenterol, Boston, MA USA. RP Shergill, AK (reprint author), Univ CA, San Francisco VA Med Ctr, Sect Gastroenterol, San Francisco, CA USA. EM amandeep.shergill@ucsf.edu NR 85 TC 0 Z9 0 U1 0 U2 0 PU ELSEVIER SCIENCE INC PI NEW YORK PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA SN 1096-2883 EI 1558-5050 J9 TECH GASTROINTEST EN JI Tech. Gastrointest. Endosc. PD JUL PY 2016 VL 18 IS 3 BP 145 EP 151 DI 10.1016/j.tgie.2016.08.003 PG 7 WC Gastroenterology & Hepatology SC Gastroenterology & Hepatology GA ER8YX UT WOS:000399110600007 ER PT J AU Marshall, B Tate, J McGinnis, K Fiellin, D Bryant, K Justice, A AF Marshall, B. Tate, J. McGinnis, K. Fiellin, D. Bryant, K. Justice, A. TI Long-term alcohol use patterns and HIV disease severity typologies in US veterans: a joint trajectory analysis SO JOURNAL OF THE INTERNATIONAL AIDS SOCIETY LA English DT Meeting Abstract C1 [Marshall, B.] Brown Univ, Dept Epidemiol, Providence, RI 02912 USA. [Tate, J.; Fiellin, D.; Justice, A.] Yale Univ, Dept Internal Med, New Haven, CT USA. [Tate, J.; Fiellin, D.; Justice, A.] West Haven VA Healthcare Syst, Vet Aging Cohort Study Coordinating Ctr, West Haven, CT USA. [McGinnis, K.] VA Pittsburgh Healthcare Syst, Pittsburgh, PA USA. [Bryant, K.] Natl Inst Alcohol Abuse & Alcoholism, Bethesda, MD USA. EM brandon_marshall@brown.edu NR 0 TC 0 Z9 0 U1 0 U2 0 PU INT AIDS SOCIETY PI GENEVA PA AVENUE DE FRANCE 23, GENEVA, 1202, SWITZERLAND SN 1758-2652 J9 J INT AIDS SOC JI J. Int. AIDS Soc. PD JUL PY 2016 VL 19 SU 5 MA WEACO401 PG 2 WC Immunology; Infectious Diseases SC Immunology; Infectious Diseases GA EM6AD UT WOS:000395394300095 ER PT J AU Smith, AK Ritchie, CS Miao, YH Boscardin, WJ Wallhagen, ML AF Smith, Alexander K. Ritchie, Christine S. Miao, Yinghui Boscardin, W. John Wallhagen, Margaret L. TI Self-Reported Hearing in the Last 2 Years of Life in Older Adults SO JOURNAL OF THE AMERICAN GERIATRICS SOCIETY LA English DT Article DE hearing loss; end of life; population-based studies ID LONGITUDINAL ANALYSIS; UNITED-STATES; AID USE; CARE; IMPAIRMENT; PREVALENCE; COMMUNICATION; EPIDEMIOLOGY; QUALITY; PATIENT AB OBJECTIVES: To assess the prevalence and correlates of self-reported hearing loss during the last 2 years of life. DESIGN: Observational cohort study. SETTING: The Health and Retirement Study (HRS), a longitudinal nationally representative cohort of adults aged 50 and older (2000-13). PARTICIPANTS: Older adults (N = 5,895, mean age at death 78, 53% female, 20% nonwhite). MEASUREMENTS: The HRS interview closest to death was used (mean 12.2 months before death). Participants rated their hearing (excellent, very good, good, fair, poor) and indicated whether they used hearing aids. The prevalence and correlates of fair and poor ratings are described, adjusted for age and sex. RESULTS: Thirty-two percent (95% confidence interval (CI) = 31-34%) of all participants and 60% (95% CI = 57-64%) of the 7% of participants who used hearing aids rated their hearing as fair or poor. The prevalence of fair or poor hearing was highest in participants interviewed closest to death (29% 19-24 months before death, 36% 1-6 months before death, P for trend = .01). Correlates of fair or poor hearing during the last 2 years of life included age at death (50-59, 22%; 60-69, 21%; 70-79, 26%; 80-89, 38%; >= 90, 50%), sex (men 35%, women 30%), race and ethnicity (Hispanic 42%, white 33%), wealth (lowest quartile 38%, highest quartile 27%), history of heart disease (yes 38%, no 27%), activity of daily living dependence (yes 42%, no 26%), difficulty taking medications (yes 46%, no 29%), and probable dementia (yes 44%, no 24%). CONCLUSION: Self-reported hearing loss increases during the last 2 years of life and is associated with physical and social vulnerability. C1 [Smith, Alexander K.; Ritchie, Christine S.; Boscardin, W. John] Univ Calif San Francisco, Div Geriatr, San Francisco, CA 94143 USA. [Smith, Alexander K.; Miao, Yinghui; Boscardin, W. John] Univ Calif San Francisco, Vet Affairs Med Ctr, Geriatr Palliat & Extended Care, San Francisco, CA 94143 USA. [Ritchie, Christine S.] Univ Calif San Francisco, Jewish Home San Francisco, San Francisco, CA 94143 USA. [Miao, Yinghui; Boscardin, W. John] Univ Calif San Francisco, Dept Epidemiol & Biostat, San Francisco, CA 94143 USA. [Wallhagen, Margaret L.] Univ Calif San Francisco, Dept Physiol Nursing, San Francisco, CA USA. RP Smith, AK (reprint author), UCSF, Div Geriatr, San Francisco VA Med Ctr, Med, 4150 Clement St 181G, San Francisco, CA 94121 USA. EM aksmith@ucsf.edu FU National Institute on Aging [1K23AG040772]; American Federation for Aging Research FX Dr. Wallhagen serves on the board of the Hearing Loss Association of America. Dr. Smith was funded by a K23 Beeson award from the National Institute on Aging (1K23AG040772) and the American Federation for Aging Research. NR 23 TC 1 Z9 1 U1 0 U2 0 PU WILEY-BLACKWELL PI HOBOKEN PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA SN 0002-8614 EI 1532-5415 J9 J AM GERIATR SOC JI J. Am. Geriatr. Soc. PD JUL PY 2016 VL 64 IS 7 BP 1486 EP 1491 DI 10.1111/jgs.14145 PG 6 WC Geriatrics & Gerontology; Gerontology SC Geriatrics & Gerontology GA DW3NN UT WOS:000383548400015 PM 27341383 ER PT J AU Furie, R Merrill, J Werth, V Khamashta, M Kalunian, K Brohawn, P Illei, G Drappa, J Wang, L Yoo, S AF Furie, R. Merrill, J. Werth, V. Khamashta, M. Kalunian, K. Brohawn, P. Illei, G. Drappa, J. Wang, L. Yoo, S. TI ANIFROLUMAB, AN ANTI-INTERFERON-ALPHA RECEPTOR MONOCLONAL ANTIBODY, IN MODERATE TO SEVERE SYSTEMIC LUPUS ERYTHEMATOSUS (SLE) SO CLINICAL AND EXPERIMENTAL RHEUMATOLOGY LA English DT Meeting Abstract DE Efficacy; Clinical trial; Low disease activity C1 [Furie, R.] Northwell Hlth, Great Neck, NY USA. [Merrill, J.] Oklahoma Med Res Fdn, 825 NE 13th St, Oklahoma City, OK 73104 USA. [Werth, V.] Philadelphia VA Med Ctr, Philadelphia, PA USA. [Werth, V.] Univ Penn, Philadelphia, PA 19104 USA. [Khamashta, M.] Graham Hughes Lupus Res Lab, Div Womens Hlth, London, England. [Kalunian, K.] UCSD Sch Med, La Jolla, CA USA. [Brohawn, P.; Illei, G.; Drappa, J.; Wang, L.] MedImmune, Gaithersburg, MD USA. [Yoo, S.] Regenxbio, Rockville, MD USA. NR 0 TC 0 Z9 0 U1 1 U2 1 PU CLINICAL & EXPER RHEUMATOLOGY PI PISA PA VIA SANTA MARIA 31, 56126 PISA, ITALY SN 0392-856X EI 1593-098X J9 CLIN EXP RHEUMATOL JI Clin. Exp. Rheumatol. PD JUL-AUG PY 2016 VL 34 IS 4 SU 99 MA S2:03 BP S4 EP S4 PG 1 WC Rheumatology SC Rheumatology GA EF4IT UT WOS:000390289700005 ER PT J AU Merrill, J Furie, R Werth, V Khamashta, M Drappa, J Wang, L Illei, G AF Merrill, J. Furie, R. Werth, V. Khamashta, M. Drappa, J. Wang, L. Illei, G. TI ANIFROLUMAB REDUCES DISEASE ACTIVITY IN MULTIPLE ORGAN DOMAINS IN MODERATE TO SEVERE SYSTEMIC LUPUS ERYTHEMATOSUS (SLE) SO CLINICAL AND EXPERIMENTAL RHEUMATOLOGY LA English DT Meeting Abstract DE novel therapy; interferon; efficacy C1 [Merrill, J.] Oklahoma Med Res Fdn, 825 NE 13th St, Oklahoma City, OK 73104 USA. [Furie, R.] Northwell Hlth, Great Neck, NY USA. [Werth, V.] Philadelphia VA Med Ctr, Philadelphia, PA USA. [Werth, V.] Univ Penn, Philadelphia, PA 19104 USA. [Khamashta, M.] Graham Hughes Lupus Res Lab, Div Womens Hlth, London, England. [Drappa, J.; Wang, L.; Illei, G.] MedImmune, Gaithersburg, MD USA. NR 0 TC 0 Z9 0 U1 1 U2 1 PU CLINICAL & EXPER RHEUMATOLOGY PI PISA PA VIA SANTA MARIA 31, 56126 PISA, ITALY SN 0392-856X EI 1593-098X J9 CLIN EXP RHEUMATOL JI Clin. Exp. Rheumatol. PD JUL-AUG PY 2016 VL 34 IS 4 SU 99 MA S2:04 BP S4 EP S4 PG 1 WC Rheumatology SC Rheumatology GA EF4IT UT WOS:000390289700006 ER PT J AU Ruderman, L Ehrlich, DB Roy, A Pietrzak, RH Harpaz-Rotem, I Levy, I AF Ruderman, Lital Ehrlich, Daniel B. Roy, Alicia Pietrzak, Robert H. Harpaz-Rotem, Ilan Levy, Ifat TI POSTTRAUMATIC STRESS SYMPTOMS AND AVERSION TO AMBIGUOUS LOSSES IN COMBAT VETERANS SO DEPRESSION AND ANXIETY LA English DT Article DE PTSD; decision making; uncertainty; ambiguity; aversion; anxious arousal ID DECISION-MAKING; PSYCHOLOGICAL DISTRESS; PREFRONTAL CORTEX; UNCERTAINTY; DISORDER; RISK; RDOC; HYPERAROUSAL; FRAMEWORK; BEHAVIOR AB Background: Psychiatric symptoms typically cut across traditional diagnostic categories. In order to devise individually tailored treatments, there is a need to identify the basic mechanisms that underlie these symptoms. Behavioral economics provides a framework for studying these mechanisms at the behavioral level. Here, we utilized this framework to examine a widely ignored aspect of trauma-related symptomatology-individual uncertainty attitudes-in combat veterans with and without posttraumatic stress disorder (PTSD). Methods: Fifty-seven combat veterans, including 30 with PTSD and 27 without PTSD, completed a risk and ambiguity decision-making task that characterizes individual uncertainty attitudes, distinguishing between attitudes toward uncertain outcomes with known ("risk") and unknown ("ambiguity") probabilities, and between attitudes toward uncertain gains and uncertain losses. Participants' choices were used to estimate risk and ambiguity attitudes in the gain and loss domains. Results: Veterans with PTSD were more averse to ambiguity, but not risk, compared to veterans without PTSD, when making choices between possible losses, but not gains. The degree of aversion was associated with anxious arousal (e.g., hypervigilance) symptoms, as well as with the degree of combat exposure. Moreover, ambiguity attitudes fully mediated the association between combat exposure and anxious arousal symptoms. Conclusions: These results provide a foundation for prospective studies of the causal association between ambiguity attitudes and trauma-related symptoms, as well as etiologic studies of the neural underpinnings of these behavioral outcomes. More generally, these results demonstrate the potential of neuroeconomic and behavioral economic techniques for devising objective and incentive-compatible diagnostic tools, and investigating the etiology of psychiatric disorders. (C) 2016 Wiley Periodicals, Inc. C1 [Ruderman, Lital; Ehrlich, Daniel B.; Levy, Ifat] Yale Sch Med, Sect Comparat Med, POB 208016, New Haven, CT 06520 USA. [Roy, Alicia; Pietrzak, Robert H.; Harpaz-Rotem, Ilan; Levy, Ifat] US Dept Vet Affairs, Natl Ctr PTSD, New Haven, CT USA. [Roy, Alicia; Pietrzak, Robert H.; Harpaz-Rotem, Ilan] Yale Sch Med, Dept Psychiat, New Haven, CT USA. [Levy, Ifat] Yale Sch Med, Dept Neurosci, New Haven, CT USA. RP Levy, I (reprint author), Yale Sch Med, Sect Comparat Med, POB 208016, New Haven, CT 06520 USA. EM ifat.levy@yale.edu FU National Institute of Mental Health [R21MH102634]; Clinical Neurosciences Division of the U.S. Department of Veterans Affairs National Center for PTSD FX Contract grant sponsor: National Institute of Mental Health (to I. L. and I. H.-R.); Contract grant number: R21MH102634; Contract grant sponsor: Clinical Neurosciences Division of the U.S. Department of Veterans Affairs National Center for PTSD. NR 39 TC 0 Z9 0 U1 3 U2 4 PU WILEY-BLACKWELL PI HOBOKEN PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA SN 1091-4269 EI 1520-6394 J9 DEPRESS ANXIETY JI Depress. Anxiety PD JUL PY 2016 VL 33 IS 7 BP 606 EP 613 DI 10.1002/da.22494 PG 8 WC Psychology, Clinical; Psychiatry; Psychology SC Psychology; Psychiatry GA DW5TD UT WOS:000383708900005 PM 27000639 ER PT J AU Petrillo, LA Ritchie, CS AF Petrillo, Laura A. Ritchie, Christine S. TI The challenges of symptom management for patients with multimorbidity in research and practice: A thematic review SO PROGRESS IN PALLIATIVE CARE LA English DT Review DE Multimorbidity; Symptom management; Palliative care ID MULTIPLE CHRONIC CONDITIONS; QUALITY-OF-LIFE; OLDER-ADULTS; PALLIATIVE CARE; PHYSICAL FUNCTION; COMORBIDITY; PREVALENCE AB Introduction: Multimorbidity, the presence of multiple coexisting diseases or conditions, afflicts the majority of older adults, and is associated with increased mortality and healthcare utilization. In addition, multimorbidity negatively impacts quality of life and increases symptom burden. Yet, there is a dearth of evidence on how to best manage symptoms in patients with multimorbidity. Methods: We conducted a thematic review of approaches to symptom management in multimorbidity. Results: Research in this area has been hampered by inconsistent definitions of multimorbidity and challenges in outcome measurement. Investigations of symptom management strategies in specific disease states, like cancer, typically exclude medically complex patients. In the absence of evidence, the American Geriatrics Society's recommendations for the care of adults with multimorbidity provide a useful starting point for clinicians. We present a case to demonstrate how the AGS recommendations can be tailored to the situation of symptom management in patients with multimorbidity. We also present suggestions for future research directions. Discussion: Multimorbidity is an incredibly common and overlooked problem in our healthcare system, and only stands to increase in relevance as patients live longer and have the opportunity to accrue a greater burden of chronic illness. A comprehensive approach to patients with multimorbidity includes focusing on patient preferences, carefully interpreting the available evidence (including both the benefits and potential harms), and thinking critically about the burden of any treatment. Taking time to elicit patient goals and preferences, and apprise patients of their prognosis if they want to know, are especially important in symptom management discussions with patients with multimorbidity. C1 [Petrillo, Laura A.] San Francisco VA Med Ctr, San Francisco, CA 94121 USA. [Ritchie, Christine S.] Univ Calif San Francisco, Div Geriatr, San Francisco, CA 94143 USA. RP Petrillo, LA (reprint author), San Francisco VA Med Ctr, San Francisco, CA 94121 USA. EM laura.petrillo@ucsf.edu NR 37 TC 0 Z9 0 U1 2 U2 2 PU ROUTLEDGE JOURNALS, TAYLOR & FRANCIS LTD PI ABINGDON PA 2-4 PARK SQUARE, MILTON PARK, ABINGDON OX14 4RN, OXON, ENGLAND SN 0969-9260 EI 1743-291X J9 PROG PALLIAT CARE JI Prog. Palliat. Care PD JUL PY 2016 VL 24 IS 5 BP 262 EP 267 DI 10.1080/09699260.2016.1192320 PG 6 WC Public, Environmental & Occupational Health SC Public, Environmental & Occupational Health GA DW4AE UT WOS:000383583400002 ER PT J AU Yeomans, PD Ross, RJ AF Yeomans, Peter D. Ross, Richard J. TI Removing Barriers in the Assessment of Combat-Related Post-traumatic Stress Disorder SO MILITARY MEDICINE LA English DT Editorial Material ID VETERANS AB While the Veterans Health Administration continues to treat Vietnam War Veterans, approximately two million service men and women have returned from Iraq and Afghanistan. However, our treatments can only be as effective as the quality of our clinical assessment. Disclosure of trauma is facilitated when the type of trauma is present in the sociocultural environment of patient and clinician. Topics that once were deemed too shameful for inquiry, specifically, childhood abuse, domestic violence, sexual abuse, and military sexual trauma are now part of a standard assessment. Similarly, the standard clinical assessment of combat Veterans should include specific queries that address the darkest underside of wartime experiences. C1 [Yeomans, Peter D.; Ross, Richard J.] Philadelphia Vet Affairs Med, Behav Hlth Serv, 3900 Woodland Ave, Philadelphia, PA 19104 USA. [Ross, Richard J.] Univ Penn, Perelman Sch Med, Dept Psychiat, 3535 Market St, Philadelphia, PA 19104 USA. RP Yeomans, PD (reprint author), Philadelphia Vet Affairs Med, Behav Hlth Serv, 3900 Woodland Ave, Philadelphia, PA 19104 USA. NR 8 TC 0 Z9 0 U1 1 U2 1 PU ASSOC MILITARY SURG US PI BETHESDA PA 9320 OLD GEORGETOWN RD, BETHESDA, MD 20814 USA SN 0026-4075 EI 1930-613X J9 MIL MED JI Milit. Med. PD JUL PY 2016 VL 181 IS 7 BP 625 EP 626 DI 10.7205/MILMED-D-15-00182 PG 2 WC Medicine, General & Internal SC General & Internal Medicine GA DW5LT UT WOS:000383687400006 PM 27391614 ER PT J AU Heinz, AJ Pennington, DL Cohen, N Schmeling, B Lasher, BA Schrodek, E Batki, SL AF Heinz, Adrienne J. Pennington, David L. Cohen, Nicole Schmeling, Brandi Lasher, Brooke A. Schrodek, Emily Batki, Steven L. TI Relations Between Cognitive Functioning and Alcohol Use, Craving, and Post-Traumatic Stress: An Examination Among Trauma-Exposed Military Veterans With Alcohol Use Disorder SO MILITARY MEDICINE LA English DT Article ID SUBSTANCE USE DISORDERS; COMPULSIVE DRINKING SCALE; RANDOMIZED CLINICAL-TRIAL; RISK TASK BART; EXECUTIVE FUNCTION; PREFRONTAL CORTEX; PSYCHOMETRIC PROPERTIES; TREATMENT OUTCOMES; TREATMENT RESPONSE; WORKING-MEMORY AB Cognitive dysfunction is commonly observed among individuals with alcohol use disorder (AUD) and trauma exposure and is, in turn, associated with worse clinical outcomes. Accordingly, disruptions in cognitive functioning may be conceptualized as a trans-disease phenomenon representing a potential high-yield target for intervention. Less is known though about how different cognitive functions covary with alcohol use, craving, and post-traumatic stress symptom severity among trauma-exposed individuals with AUD. Sixty-eight male and female trauma-exposed military veterans with AUD, entering treatment trials to reduce alcohol use, completed measures assessing alcohol use and craving, post-traumatic stress symptom severity, and cognitive functioning. In multivariate models, after controlling for post-traumatic stress symptom severity, poorer learning and memory was associated with higher alcohol consumption and higher risk taking/impulsivity was associated with stronger preoccupations with alcohol and compulsions to drink. Alcohol consumption and craving, but not performance on cognitive tests, were positively associated with post-traumatic stress symptom severity. Findings suggest that interventions to strengthen cognitive functioning might be used as a preparatory step to augment treatments for AUD. Clinicians are encouraged to consider a standard assessment of cognitive functioning, in addition to post-traumatic stress symptom severity, in treatment planning and delivery for this vulnerable and high-risk population. C1 [Heinz, Adrienne J.; Cohen, Nicole] Palo Alto Vet Affairs Hlth Care Syst, Ctr Innovat Implementat, Natl Ctr Posttraumat Stress Disorder, 795 Willow Rd, Menlo Pk, CA 94025 USA. [Pennington, David L.; Lasher, Brooke A.; Schrodek, Emily; Batki, Steven L.] San Francisco VA Med Ctr, 4150 Clement St, San Francisco, CA 94121 USA. [Pennington, David L.; Lasher, Brooke A.; Schrodek, Emily; Batki, Steven L.] Univ Calif San Francisco, Dept Psychiat, 500 Parnassus Ave, San Francisco, CA 94143 USA. [Pennington, David L.] Northern Calif Inst Res & Educ, 4150 Clement St 151NC, San Francisco, CA 94121 USA. [Schmeling, Brandi] Palo Alto Univ, 1791 Arastradero Rd, Palo Alto, CA 94304 USA. RP Heinz, AJ (reprint author), Palo Alto Vet Affairs Hlth Care Syst, Ctr Innovat Implementat, Natl Ctr Posttraumat Stress Disorder, 795 Willow Rd, Menlo Pk, CA 94025 USA. FU Department of Defense [W81XWH-05-2-0094, W81XWH-12-2-0137, W81XWH-11-2-0245]; National Center for Research Resources; National Center for Advancing Translational Sciences, National Institutes of Health [UCSF-CTSI UL1 RR024131]; VA Rehabilitation Research and Development (RR&D) Career Development Award-2 [1IK2RX001492-01A1] FX This project was supported by Department of Defense W81XWH-05-2-0094, W81XWH-12-2-0137, and W81XWH-11-2-0245 (SLB), the National Center for Research Resources and the National Center for Advancing Translational Sciences, National Institutes of Health UCSF-CTSI UL1 RR024131, which were administered by the Northern California Institute for Research and Education, and with resources of the Veterans Affairs Medical Center, San Francisco, California. Support was also provided by a VA Rehabilitation Research and Development (RR&D) Career Development Award-2 (1IK2RX001492-01A1) granted to Dr. Heinz. NR 97 TC 0 Z9 0 U1 10 U2 10 PU ASSOC MILITARY SURG US PI BETHESDA PA 9320 OLD GEORGETOWN RD, BETHESDA, MD 20814 USA SN 0026-4075 EI 1930-613X J9 MIL MED JI Milit. Med. PD JUL PY 2016 VL 181 IS 7 BP 663 EP 671 DI 10.7205/MILMED-D-15-00228 PG 9 WC Medicine, General & Internal SC General & Internal Medicine GA DW5LT UT WOS:000383687400012 PM 27391620 ER PT J AU Edwards-Stewart, A Smolenski, DJ Reger, GM Bush, N Workman, DE AF Edwards-Stewart, Amanda Smolenski, Derek J. Reger, Greg M. Bush, Nigel Workman, Don E. TI An Analysis of Personal Technology Use by Service Members and Military Behavioral Health Providers SO MILITARY MEDICINE LA English DT Article ID SMARTPHONE; SOLDIERS; IPHONE AB Personal technology use is ubiquitous in the United States today and technology, in general, continues to change the face of health care. However, little is known about the personal technology use of military service members and the behavioral health care providers that treat them. This study reports the technology use of 1,101 active duty service members and 45 behavioral health care providers at a large military installation. Participants reported Internet usage; ownership of smartphones, tablets, and e-readers; usage of mobile applications (apps); and basic demographic information. Compared with providers, service members reported higher rates of smartphone ownership, were more likely to own Android smartphones than iPhones, and spent more time gaming. Both groups spent a comparable amount of time using social media. With the exception of gaming, however, differences between service members and providers were not statistically significant when demographics were matched and controlled. Among service members, younger respondents (18-34) were statistically more likely than older respondents (35-58) to own smartphones, spend time gaming, and engage in social media. Our findings can help inform provider's technology-based education and intervention of their patients and guide the development of new technologies to support the psychological health of service members. C1 [Edwards-Stewart, Amanda; Smolenski, Derek J.; Bush, Nigel; Workman, Don E.] Natl Ctr Telehlth & Technol T2, 9933 West Hayes St, Tacoma, WA 98431 USA. [Reger, Greg M.] VA Puget Sound, Dept Vet Affairs, 9600 Vet Dr, Tacoma, WA 98493 USA. RP Edwards-Stewart, A (reprint author), Natl Ctr Telehlth & Technol T2, 9933 West Hayes St, Tacoma, WA 98431 USA. NR 28 TC 1 Z9 1 U1 2 U2 2 PU ASSOC MILITARY SURG US PI BETHESDA PA 9320 OLD GEORGETOWN RD, BETHESDA, MD 20814 USA SN 0026-4075 EI 1930-613X J9 MIL MED JI Milit. Med. PD JUL PY 2016 VL 181 IS 7 BP 701 EP 709 DI 10.7205/MILMED-D-15-00041 PG 9 WC Medicine, General & Internal SC General & Internal Medicine GA DW5LT UT WOS:000383687400017 PM 27391625 ER PT J AU Guo, FJ Garvey, WT AF Guo, Fangjian Garvey, W. Timothy TI Trends in Cardiovascular Health Metrics in Obese Adults: National Health and Nutrition Examination Survey (NHANES), 1988-2014 SO JOURNAL OF THE AMERICAN HEART ASSOCIATION LA English DT Article DE blood pressure; glucose; lipids; obesity; risk factor ID BODY-MASS INDEX; WEIGHT-LOSS THERAPY; METABOLIC SYNDROME; INSULIN-RESISTANCE; UNITED-STATES; US ADULTS; MYOCARDIAL-INFARCTION; DISEASE RISK; PREVALENCE; OVERWEIGHT AB Background-No study has quantified trends in the prevalence of cardiovascular disease risk factors and cardiovascular health metrics among obese people in the United States in recent years. Methods and Results-We examined the secular changes in cardiovascular health metrics and key cardiovascular disease risk factors among obese adults (aged >= 20 years) in the United States. We included 18 626 obese adults (body mass index >= 30) from the National Health and Nutrition Examination Survey (NHANES) III and NHANES 1999-2014. Among those obese adults, there were decreases in mean systolic blood pressure, diastolic blood pressure, and total cholesterol levels and increases in mean high-density lipoprotein cholesterol levels and mean hemoglobin A1c levels. Prevalence of blood pressure health and lipid health remained stable during the period 1988-2014, whereas prevalence of blood glucose health decreased significantly during this period. Prevalence of freedom from cardiovascular disease risk factors remained stable at approximate to 15% among the adult obese population during the period 1988-2014, whereas prevalence of presence of all 3 risk factors increased from 16.4% to 22.4% during this period, commensurate with a decline in those with 1 to 2 risk factors (from 69.6% to 62.4%). Conclusions-During the past 3 decades, blood pressure health and blood lipid health remained stable or improved, whereas blood glucose health deteriorated among adult obese population. This resulted in an overall decrease in cardiovascular health status among obese adults and greater risk of type 2 diabetes mellitus. The data argue for interventions targeted to those obese persons who are metabolically unhealthy to stem rising rates of diabetes mellitus. C1 [Guo, Fangjian] Univ Texas Med Branch, Dept Obstet & Gynecol, Galveston, TX 77555 USA. [Guo, Fangjian] Univ Texas Med Branch, Ctr Interdisciplinary Res Womens Hlth, Galveston, TX 77555 USA. [Garvey, W. Timothy] Univ Alabama Birmingham, Dept Nutr Sci, Birmingham, AL 35294 USA. [Garvey, W. Timothy] Birmingham Vet Affairs Med Ctr, Birmingham, AL USA. RP Guo, FJ (reprint author), Univ Texas Med Branch, Ctr Interdisciplinary Res Womens Hlth, Dept Obstet & Gynecol, 301 Univ Blvd, Galveston, TX 77555 USA. EM guofangjian@gmail.com; garveyt@uab.edu OI Guo, Fangjian/0000-0003-3729-2724 FU Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD) at the National Institutes of Health (NIH) [T32HD055163]; Merit Review program of the Department of Veterans Affairs, National Institutes of Health [DK-038765, DK-083562]; UAB Diabetes Research Center [P60-DK079626]; National Center for Health Statistics Centers for Disease Control and Prevention FX Dr Guo is currently a postdoctoral fellow supported by an institutional training grant (National Research Service Award T32HD055163) from the Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD) at the National Institutes of Health (NIH). This study is supported by the Merit Review program of the Department of Veterans Affairs, National Institutes of Health (DK-038765 and DK-083562), and the UAB Diabetes Research Center (P60-DK079626). Role of the Sponsors: All data from NHANES used in this study were collected by the National Center for Health Statistics Centers for Disease Control and Prevention. NR 47 TC 0 Z9 0 U1 2 U2 2 PU WILEY-BLACKWELL PI HOBOKEN PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA SN 2047-9980 J9 J AM HEART ASSOC JI J. Am. Heart Assoc. PD JUL PY 2016 VL 5 IS 7 AR e003619 DI 10.1161/JAHA.116.003619 PG 20 WC Cardiac & Cardiovascular Systems SC Cardiovascular System & Cardiology GA EA6CT UT WOS:000386713800050 ER PT J AU Elgin, C Nuhi, V Johnson, RH AF Elgin, Cristina Nuhi, Veldana Johnson, Ralph H. TI Comparison of decentralized versus centralized pharmacist management of patients with atrial fibrillation treated with direct oral anticoagulants (DOACs). SO PHARMACOTHERAPY LA English DT Meeting Abstract CT American-College-of-Clinical-Pharmacy (ACCP) Virtual Poster Symposium CY MAY 18-19, 2016 CL ELECTR NETWORK SP Amer Coll Clin Pharm C1 [Elgin, Cristina; Nuhi, Veldana; Johnson, Ralph H.] Ralph H Johnson VA Med Ctr, Dept Pharm, Charleston, SC USA. NR 0 TC 0 Z9 0 U1 0 U2 0 PU WILEY-BLACKWELL PI HOBOKEN PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA SN 0277-0008 EI 1875-9114 J9 PHARMACOTHERAPY JI Pharmacotherapy PD JUL PY 2016 VL 36 IS 7 MA 5 BP E85 EP E85 PG 1 WC Pharmacology & Pharmacy SC Pharmacology & Pharmacy GA DW4EP UT WOS:000383595600008 ER PT J AU Gauthier, J Griffith, J AF Gauthier, Joshua Griffith, June TI Implementation and evaluation of an overdose education and naloxone distribution (OEND) program. SO PHARMACOTHERAPY LA English DT Meeting Abstract CT American-College-of-Clinical-Pharmacy (ACCP) Virtual Poster Symposium CY MAY 18-19, 2016 CL ELECTR NETWORK SP Amer Coll Clin Pharm C1 [Gauthier, Joshua] Tuscaloosa VA Med Ctr, Tuscaloosa, AL USA. [Griffith, June] Tuscaloosa VA Med Ctr, US Dept Vet Affairs, Tuscaloosa, AL USA. NR 0 TC 0 Z9 0 U1 1 U2 1 PU WILEY-BLACKWELL PI HOBOKEN PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA SN 0277-0008 EI 1875-9114 J9 PHARMACOTHERAPY JI Pharmacotherapy PD JUL PY 2016 VL 36 IS 7 MA 148 BP E126 EP E126 PG 1 WC Pharmacology & Pharmacy SC Pharmacology & Pharmacy GA DW4EP UT WOS:000383595600145 ER PT J AU Im, EP Griffith, J Hamilton, D AF Im, Eun Pyung Griffith, June Hamilton, Debora TI Opioid safety initiative: clinical pharmacy intervention. SO PHARMACOTHERAPY LA English DT Meeting Abstract CT American-College-of-Clinical-Pharmacy (ACCP) Virtual Poster Symposium CY MAY 18-19, 2016 CL ELECTR NETWORK SP Amer Coll Clin Pharm C1 [Im, Eun Pyung; Griffith, June; Hamilton, Debora] US Dept Vet Affairs, Tuscaloosa VA Med Ctr, Tuscaloosa, AL USA. NR 0 TC 0 Z9 0 U1 0 U2 0 PU WILEY-BLACKWELL PI HOBOKEN PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA SN 0277-0008 EI 1875-9114 J9 PHARMACOTHERAPY JI Pharmacotherapy PD JUL PY 2016 VL 36 IS 7 MA 138 BP E123 EP E124 PG 2 WC Pharmacology & Pharmacy SC Pharmacology & Pharmacy GA DW4EP UT WOS:000383595600136 ER PT J AU Morgan, J Griffith, J AF Morgan, Joni Griffith, June TI Quality improvement project regarding posttraumatic stress disorder (PTSD) and benzodiazepines as part of the Psychotropic Drug Safety Initiative ( PDSI). SO PHARMACOTHERAPY LA English DT Meeting Abstract CT American-College-of-Clinical-Pharmacy (ACCP) Virtual Poster Symposium CY MAY 18-19, 2016 CL ELECTR NETWORK SP Amer Coll Clin Pharm C1 [Morgan, Joni; Griffith, June] Tuscaloosa VA Med Ctr, US Dept Vet Affairs, Tuscaloosa, AL USA. NR 0 TC 0 Z9 0 U1 0 U2 0 PU WILEY-BLACKWELL PI HOBOKEN PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA SN 0277-0008 EI 1875-9114 J9 PHARMACOTHERAPY JI Pharmacotherapy PD JUL PY 2016 VL 36 IS 7 MA 147 BP E126 EP E126 PG 1 WC Pharmacology & Pharmacy SC Pharmacology & Pharmacy GA DW4EP UT WOS:000383595600144 ER PT J AU Effing, TW Vercoulen, JH Bourbeau, J Trappenburg, J Lenferink, A Cafarella, P Coultas, D Meek, P van der Valk, P Bischoff, EWMA Bucknall, C Dewan, NA Early, F Fan, V Frith, P Janssen, DJA Mitchell, K Morgan, M Nici, L Patel, I Walters, H Rice, KL Singh, S Zuwallack, R Benzo, R Goldstein, R Partridge, MR van der Palen, J AF Effing, Tanja W. Vercoulen, Jan H. Bourbeau, Jean Trappenburg, Jaap Lenferink, Anke Cafarella, Paul Coultas, David Meek, Paula van der Valk, Paul Bischoff, Erik W. M. A. Bucknall, Christine Dewan, Naresh A. Early, Frances Fan, Vincent Frith, Peter Janssen, Daisy J. A. Mitchell, Katy Morgan, Mike Nici, Linda Patel, Irem Walters, Haydn Rice, Kathryn L. Singh, Sally Zuwallack, Richard Benzo, Roberto Goldstein, Roger Partridge, Martyn R. van der Palen, Job TI Definition of a COPD self-management intervention: International Expert Group consensus SO EUROPEAN RESPIRATORY JOURNAL LA English DT Article ID OBSTRUCTIVE PULMONARY-DISEASE; MOTIVATION AB There is an urgent need for consensus on what defines a chronic obstructive pulmonary disease (COPD) self-management intervention. We aimed to obtain consensus regarding the conceptual definition of a COPD self-management intervention by engaging an international panel of COPD self-management experts using Delphi technique features and an additional group meeting. In each consensus round the experts were asked to provide feedback on the proposed definition and to score their level of agreement (1=totally disagree; 5=totally agree). The information provided was used to modify the definition for the next consensus round. Thematic analysis was used for free text responses and descriptive statistics were used for agreement scores. In total, 28 experts participated. The consensus round response rate varied randomly over the five rounds (ranging from 48% (n=13) to 85% (n=23)), and mean definition agreement scores increased from 3.8 (round 1) to 4.8 (round 5) with an increasing percentage of experts allocating the highest score of 5 (round 1: 14% (n=3); round 5: 83% (n=19)). In this study we reached consensus regarding a conceptual definition of what should be a COPD self-management intervention, clarifying the requisites for such an intervention. Operationalisation of this conceptual definition in the near future will be an essential next step. C1 [Effing, Tanja W.; Cafarella, Paul; Frith, Peter] Southern Adelaide Local Hlth Network, Dept Resp Med, Adelaide, SA, Australia. [Effing, Tanja W.; Cafarella, Paul; Frith, Peter] Flinders Univ S Australia, Sch Med, Adelaide, SA 5001, Australia. [Vercoulen, Jan H.] Radboud Univ Nijmegen, Med Ctr, Dept Med Psychol, NL-6525 ED Nijmegen, Netherlands. [Vercoulen, Jan H.] Radboud Univ Nijmegen, Med Ctr, Dept Pulm Dis, NL-6525 ED Nijmegen, Netherlands. [Bourbeau, Jean] McGill Univ, McGill Univ Hlth Ctr, Res Inst, Resp Epidemiol & Clin Res Unit, Montreal, PQ, Canada. [Trappenburg, Jaap] Univ Med Ctr Utrecht, Dept Rehabil Nursing Sci & Sports, Utrecht, Netherlands. [Lenferink, Anke; van der Valk, Paul; van der Palen, Job] Med Spectrum Twente, Dept Pulm Med, Enschede, Netherlands. [Coultas, David] Oregon Hlth & Sci Univ, VA Portland Hlth Care Syst, Portland, OR 97201 USA. [Coultas, David] Oregon Hlth & Sci Univ, Dept Med, Portland, OR 97201 USA. [Meek, Paula] Univ Colorado, Coll Nursing, Aurora, CO USA. [Bischoff, Erik W. M. A.] Radboud Univ Nijmegen, Med Ctr, Dept Primary & Community Care, Nijmegen, Netherlands. [Bucknall, Christine] Glasgow Royal Infirm, Dept Resp Med, Glasgow G4 0SF, Lanark, Scotland. [Dewan, Naresh A.] Creighton Univ, Div Pulm Crit Care & Sleep Med, Omaha, NE 68178 USA. [Dewan, Naresh A.] Omaha Vet Affairs Med Ctr, Omaha, NE USA. [Early, Frances] Cambridge Univ Hosp NHS Fdn Trust, Addenbrookes Hosp, Ctr Self Management Support, Cambridge, England. [Fan, Vincent] VA Puget Sound Hlth Care Syst, Seattle, WA USA. [Fan, Vincent] Univ Washington, Dept Med, Seattle, WA 98195 USA. [Janssen, Daisy J. A.] CIRO, Ctr Expertise Chron Organ Failure, Dept Res & Educ, Horn, Netherlands. [Mitchell, Katy; Singh, Sally] Univ Hosp Leicester, Ctr Exercise & Rehabil Sci, Leicester, Leics, England. [Morgan, Mike] Univ Hosp Leicester NHS Trust, Glenfield Hosp, Dept Resp Med, Leicester, Leics, England. [Nici, Linda] Providence Vet Adm Med Ctr, Dept Pulm & Crit Care, Providence, RI USA. [Patel, Irem] Kings Coll Hosp NHS Trust, Dept Resp Med, London, England. [Walters, Haydn] Univ Tasmania, Sch Med, CRE Chron Resp Dis, Hobart, Tas, Australia. [Rice, Kathryn L.] VA Med Ctr, Dept Med, Pulm Sect, Minneapolis, MN USA. [Rice, Kathryn L.] Univ Minnesota, Dept Med, Minneapolis, MN 55455 USA. [Zuwallack, Richard] St Francis Hosp & Med Ctr, Dept Pulm & Crit Care, Hartford, CT USA. [Benzo, Roberto] Mayo Clin, Mindful Breathing Lab, Rochester, MN USA. [Goldstein, Roger] Univ Toronto, West Pk Healthcare, Toronto, ON, Canada. [Partridge, Martyn R.] Imperial Coll, Natl Heart & Lung Inst, London, England. [van der Palen, Job] Univ Twente, Dept Res Methodol Measurement & Data Anal, POB 217, NL-7500 AE Enschede, Netherlands. RP Effing, TW (reprint author), Repatriat Gen Hosp, Dept Resp Med, Daws Rd, Daw Pk, SA 5041, Australia. EM tanja.effing@health.sa.gov.au NR 23 TC 6 Z9 6 U1 2 U2 2 PU EUROPEAN RESPIRATORY SOC JOURNALS LTD PI SHEFFIELD PA 442 GLOSSOP RD, SHEFFIELD S10 2PX, ENGLAND SN 0903-1936 EI 1399-3003 J9 EUR RESPIR J JI Eur. Resp. J. PD JUL PY 2016 VL 48 IS 1 BP 46 EP 54 DI 10.1183/13993003.00025-2016 PG 9 WC Respiratory System SC Respiratory System GA DZ6FK UT WOS:000385956800011 PM 27076595 ER PT J AU Sheehan, SE Coburn, JA Singh, H Vanness, DJ Sittig, DF Moberg, DP Safdar, N Lee, KS Brunner, MC AF Sheehan, Scott E. Coburn, John A. Singh, Hardeep Vanness, David J. Sittig, Dean F. Moberg, D. Paul Safdar, Nasia Lee, Kenneth S. Brunner, Michael C. TI Reducing Unnecessary Shoulder MRI Examinations Within a Capitated Health Care System: A Potential Role for Shoulder Ultrasound SO JOURNAL OF THE AMERICAN COLLEGE OF RADIOLOGY LA English DT Article DE Shoulder; MRI; ultrasound; utilization; costs ID CLINICAL DECISION-SUPPORT; ROTATOR CUFF TEARS; PHYSICIAN ORDER ENTRY; LONG HEAD; UTILIZATION MANAGEMENT; METAANALYSIS; RADIOLOGY; ACCURACY; JOINT; PAIN AB Purpose: MRI is frequently overused. The aim of this study was to analyze shoulder MRI ordering practices within a capitated health care system and explore the potential effects of shoulder ultrasound substitution. Methods: We reviewed medical records of 237 consecutive shoulder MRI examinations performed in 2013 at a Department of Veterans Affairs tertiary care hospital. Using advanced imaging guidelines, we assessed ordering appropriateness of shoulder MRI and estimated the proportion of examinations for which musculoskeletal ultrasound could have been an acceptable substitute, had it been available. We then reviewed MRI findings and assessed if ultrasound with preceding radiograph would have been adequate for diagnosis, based on literature reports of shoulder ultrasound diagnostic performance. Results: Of the 237 examinations reviewed, 106 (45%) were deemed to be inappropriately ordered, most commonly because of an absent preceding radiograph (n = 98; 92%). Nonorthopedic providers had a higher frequency of inappropriate ordering (44%) relative to orthopedic specialists (17%) (P = .016; odds ratio = 3.15, 95% confidence interval = 1.24-8.01). In the 237 examinations, ultrasound could have been the indicated advanced imaging modality for 157 (66%), and most of these (133/157; 85%) could have had all relevant pathologies characterized when combined with radiographs. Regardless of indicated modality, ultrasound could have characterized 80% of all cases ordered by nonorthopedic providers and 50% of cases ordered by orthopedic specialists (P = .007). Conclusions: Advanced shoulder imaging is often not ordered according to published appropriateness criteria. While nonorthopedic provider orders were more likely to be inappropriate, inappropriateness persisted among orthopedic providers. A combined ultrasound and radiograph evaluation strategy could accurately characterize shoulder pathologies for most cases. C1 [Sheehan, Scott E.; Coburn, John A.; Vanness, David J.; Moberg, D. Paul; Safdar, Nasia; Lee, Kenneth S.; Brunner, Michael C.] William S Middleton Mem Vet Adm Med Ctr, Madison, WI 53705 USA. [Coburn, John A.; Vanness, David J.; Moberg, D. Paul; Lee, Kenneth S.] Univ Wisconsin, Sch Med & Publ Hlth, Madison, WI USA. [Singh, Hardeep] Michael E DeBakey VA Med Ctr, Houston VA Ctr Innovat Qual Effectiveness & Safet, Houston, TX USA. [Singh, Hardeep] Baylor Coll Med, Houston, TX 77030 USA. [Sittig, Dean F.] Univ Texas Hlth Sci Ctr Houston, Houston, TX 77030 USA. RP Sheehan, SE (reprint author), William S Middleton Mem Vet Adm Med Ctr, Dept Radiol 114, 2500 Overlook Terrace, Madison, WI 53705 USA. EM ssheehan@uwhealth.org NR 52 TC 1 Z9 1 U1 0 U2 0 PU ELSEVIER SCIENCE INC PI NEW YORK PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA SN 1546-1440 J9 J AM COLL RADIOL JI J. Am. Coll. Radiol. PD JUL PY 2016 VL 13 IS 7 BP 780 EP 787 DI 10.1016/j.jacr.2016.03.015 PG 8 WC Radiology, Nuclear Medicine & Medical Imaging SC Radiology, Nuclear Medicine & Medical Imaging GA DZ6SF UT WOS:000385991500009 PM 27162045 ER EF